詳細

工藤　正俊 （クドウ　マサトシ）

  • 医学科　教授/主任
Last Updated :2024/05/01

コミュニケーション情報 byコメンテータガイド

  • コメント

    （１）肝細胞癌の診断と治療。（２） 肝臓の画像診断。（３） 腹部超音波診断。（４） 消化器癌全般。（５） 胆道・膵臓癌の診断治療。

  • 報道関連出演・掲載一覧

    ＜報道関連出演・掲載一覧＞ ●2023/7/28 　読売新聞 　肝細胞がんにおける新たな治療法について ●2019/12/10 　日経産業新聞 　肝細胞がんにおける新たな治療法として、「肝動脈塞栓療法」（TACE）と、分⼦標的薬「ソラフェニブ」を併⽤することについて ●2019/7/31、8/1、8/10 　関西テレビ「報道ランナー」 　共同通信・朝日新聞・日刊工業新聞 　読売新聞 　難治性の肝細胞がんに対して世界初の画期的な根治治療法を開発 ●2017/12/12 　日経産業新聞 　がんの免疫治療について ●2017/8/31 　産経新聞（関東版） 　進行肝臓がんについて ●2017/1/23 朝日放送「キャスト」 患者様との問診の様子 ●2017/2/2 日本テレビ系列「NEWS ZERO」 患者様との問診の様子 ●2016/6/1 　日本テレビ「news every.」 　医学部附属病院患者様の密着取材で主治医として ●2016/5/4 　日本テレビ「NEWS ZERO」 　診療、検査の様子について

研究者情報

学位

  • 医学博士（1986年11月）

ホームページURL

科研費研究者番号

  • 10298953

J-Global ID

プロフィール

  • 1978年　京都大学医学部卒業


    1999年　近畿大学医学部消化器内科教授


    2008年　近畿大学医学部附属病院病院長


    2015年　学校法人近畿大学理事

研究キーワード

  • 肝細胞癌   肝腫瘍の画像診断   造影エコー法   EOB-MRI   ラジオ波治療   肝動注塞栓療法（TACE）   肝動注化学療法   分子標的治療   血管新生阻害治療   免疫療法   免疫チェックポイント阻害剤   

現在の研究分野（キーワード）

    （１）肝細胞癌の診断と治療。（２） 肝臓の画像診断。（３） 腹部超音波診断。（４） 消化器癌全般。（５） 胆道・膵臓癌の診断治療。

研究分野

  • ライフサイエンス / 医用システム
  • ライフサイエンス / 消化器内科学 / 肝細胞癌
  • ライフサイエンス / 腫瘍診断、治療学

経歴

  • 1999年04月 - 現在  近畿大学医学部教授

研究活動情報

論文

  • Andreas Teufel; Masatoshi Kudo; Yuquan Qian; Jimmy Daza; Isaac Rodriguez; Christoph Reissfelder; Ezequiel Ridruejo; Matthias P Ebert
    Digestive diseases (Basel, Switzerland) 2024年04月 
    Hepatocellular Carcinoma (HCC) remains a significant global health burden with a high mortality rate. Over the past 40 years, significant progress has been achieved in the prevention and management of HCC. Hepatitis B vaccination programs, the development of direct acting antiviral drugs for Hepatitis C and effective surveillance strategies provide a profound basis for prevention for HCC. Advanced surgery and liver transplantation along with local ablation techniques potentially offer cure for the disease, Also just recently, the introduction of immunotherapy opened a new chapter in systemic treatment. Finally, the introduction of the BCLC classification system for HCC, clearly defining patient groups and assigning reasonable treatment options, has standardized treatment and become the basis of almost all clinical trials for HCC. With this review, we provide a comprehensive overview of the evolving landscape of HCC management but also touch on current challenges. A comprehensive and multidisciplinary approach is crucial for effective HCC management. Continued research and clinical trials are imperative to further enhance treatment options and will ultimately reduce the global burden of this devastating disease.
  • Margherita Rimini; Bernardo Stefanini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Fabian Finkelmeier; Changhoon Yoo; José Presa; Elisabeth Amadeo; Virginia Genovesi; Maria Caterina De Grandis; Massimo Iavarone; Fabio Marra; Francesco Foschi; Emiliano Tamburini; Federico Rossari; Francesco Vitiello; Linda Bartalini; Caterina Soldà; Francesco Tovoli; Caterina Vivaldi; Sara Lonardi; Marianna Silletta; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Vera Himmelsbach; Margarida Montes; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Camera; Silvia Foti; Luca Aldrighetti; Stefano Cascinu; Andrea Casadei-Gardini; Fabio Piscaglia
    Liver international : official journal of the International Association for the Study of the Liver 2024年03月 
    INTRODUCTION: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first-line treatment. METHODS AND MATERIAL: The cohort included consecutive patients affected by BCLC-c and BCLC-B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first-line therapy. Population was stratified according to the BMI in under-, over- and normal-weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analysed with log-rank tests. RESULTS: 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal-weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal-weight patients, whereas no differences were found between normal-weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal-weight patients (HR: 1.7; 95% CI: 1.0-2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal-weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal-weight versus underweight and between normal-weight versus overweight, which was confirmed at multivariate analysis. CONCLUSION: Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
  • Satoru Hagiwara; Toru Takase; Itsuki Oda; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi Kudo
    Clinical Journal of Gastroenterology 2024年03月 
    Abstract A 53-year-old woman was diagnosed with liver dysfunction in August 20XX. Computed tomography (CT) revealed multiple hepatic AV shunts, and she was placed under observation. In March 20XX + 3, she developed back pain, and CT performed during an emergency hospital visit showed evidence of intrahepatic bile duct dilatation. She was referred to our gastroenterology department in May 20XX + 3. We conducted investigations on suspicion of hereditary hemorrhagic telangiectasia (HHT) with hepatic AV shunting based on contrast-enhanced CT performed at another hospital. HHT is generally discovered due to epistaxis, but there are also cases where it is diagnosed during examination of liver damage.
  • Ken Kamata; Masatoshi Kudo; Tomohiro Watanabe
    Pancreatology 2024年03月
  • Josep M Llovet; Roser Pinyol; Mark Yarchoan; Amit G Singal; Thomas U Marron; Myron Schwartz; Eli Pikarsky; Masatoshi Kudo; Richard S Finn
    Nature reviews. Clinical oncology 2024年02月 
    Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer mortality worldwide. The development of effective systemic therapies, particularly those involving immune-checkpoint inhibitors (ICIs), has substantially improved the outcomes of patients with advanced-stage HCC. Approximately 30% of patients are diagnosed with early stage disease and currently receive potentially curative therapies, such as resection, liver transplantation or local ablation, which result in median overall survival durations beyond 60 months. Nonetheless, up to 70% of these patients will have disease recurrence within 5 years of resection or local ablation. To date, the results of randomized clinical trials testing adjuvant therapy in patients with HCC have been negative. This major unmet need has been addressed with the IMbrave 050 trial, demonstrating a recurrence-free survival benefit in patients with a high risk of relapse after resection or local ablation who received adjuvant atezolizumab plus bevacizumab. In parallel, studies testing neoadjuvant ICIs alone or in combination in patients with early stage disease have also reported efficacy. In this Review, we provide a comprehensive overview of the current approaches to manage patients with early stage HCC. We also describe the tumour immune microenvironment and the mechanisms of action of ICIs and cancer vaccines in this setting. Finally, we summarize the available evidence from phase II/III trials of neoadjuvant and adjuvant approaches and discuss emerging clinical trials, identification of biomarkers and clinical trial design considerations for future studies.
  • Yasuo Otsuka; Kosuke Minaga; Masatoshi Kudo; Tomohiro Watanabe
    Frontiers in Immunology 15 1364839 - 1364839 2024年02月 
    Introduction Intrapancreatic activation of trypsinogen caused by alcohol or high-fat intake and the subsequent autodigestion of the pancreas tissues by trypsin are indispensable events in the development of acute pancreatitis. In addition to this trypsin-centered paradigm, recent studies provide evidence that innate immune responses triggered by translocation of intestinal bacteria to the pancreas due to intestinal barrier dysfunction underlie the immunopathogenesis of acute pancreatitis. Although severe acute pancreatitis is often associated with pancreatic colonization by fungi, the molecular mechanisms linking fungus-induced immune responses to the development of severe acute pancreatitis are poorly understood. Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that mediates innate immune responses to fungi and bacteria. Mutations in Lrrk2 is a risk factor for Parkinson’s disease and Crohn’s disease, both of which are driven by innate immune responses to gut organisms. Discussion In this Minireview article, we discuss how activation of LRRK2 by the recognition of fungi induces severe acute pancreatitis.
  • Masatoshi Kudo
    Liver cancer 13 1 1 - 5 2024年02月
  • Akane Hara; Kosuke Minaga; Yasuo Otsuka; Hidekazu Tanaka; Mamoru Takenaka; Masatoshi Kudo
    Endoscopy international open 12 2 E271-E273  2024年02月
  • Lorenz Balcar; Bernhard Scheiner; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Katharina Pomej; Marta Bofill Roig; Elias Laurin Meyer; Jaekyung Che; Naoshi Nishida; Pei-Chang Lee; Linda Wu; Celina Ang; Anja Krall; Anwaar Saeed; Bernardo Stefanini; Antonella Cammarota; Tiziana Pressiani; Yehia I Abugabal; Shadi Chamseddine; Brooke Wietharn; Alessandro Parisi; Yi-Hsiang Huang; Samuel Phen; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Johann von Felden; Kornelius Schulze; Marianna Silletta; Michael Trauner; Adel Samson; Henning Wege; Fabio Piscaglia; Peter R Galle; Rudolf Stauber; Masatoshi Kudo; Amit G Singal; Aleena Itani; Susanna V Ulahannan; Neehar D Parikh; Alessio Cortellini; Ahmed Kaseb; Lorenza Rimassa; Hong Jae Chon; David J Pinato; Matthias Pinter
    JHEP reports : innovation in hepatology 6 2 100982 - 100982 2024年02月 
    BACKGROUND & AIMS: Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic cytokines, are well-known. Whether sex influences the efficacy and safety of immunotherapy is not known. METHODS: We performed a restricted maximum likelihood random effects meta-analysis of five phase III trials that evaluated immune checkpoint inhibitors (ICIs) in advanced HCC and reported overall survival (OS) hazard ratios (HRs) stratified by sex to evaluate sex-related differences in OS. In a real-world cohort of 840 patients with HCC from 22 centres included between 2018 and 2023, we directly compared the efficacy and safety of atezolizumab + bevacizumab (A+B) between sexes. Radiological response was reported according to RECIST v1.1. Uni- and multivariable Cox regression analyses were performed for OS and progression-free survival (PFS). RESULTS: In the meta-analysis, immunotherapy was associated with a significant OS benefit only in male (pooled HR 0.79; 95% CI 0.73-0.86) but not in female (pooled HR 0.85; 95% CI 0.70-1.03) patients with HCC. When directly comparing model estimates, no differences in the treatment effect between sexes were observed. Among 840 patients, 677 (81%) were male (mean age 66 ± 11 years), and 163 (19%) were female (mean age 67 ± 12 years). Type and severity of adverse events were similar between the two groups. OS and PFS were comparable between males and females upon uni- and multivariable analyses (aHR for OS and PFS: 0.79, 95% CI 0.59-1.04; 1.02, 95% CI 0.80-1.30, respectively). Objective response rates (24%/22%) and disease control rates (59%/59%) were also similar between sexes. CONCLUSION: Female phase III trial participants experienced smaller OS benefit following ICI therapy for advanced HCC, while outcomes following A+B treatment were comparable between sexes in a large real-world database. Based on the ambiguous sex-related differences in survival observed here, further investigation of sex-specific clinical and biologic determinants of responsiveness and survival following ICIs are warranted. IMPACT AND IMPLICATIONS: While immune checkpoint inhibitors have emerged as standard of care for the treatment of hepatocellular carcinoma, there are conflicting reports on whether the efficacy of cancer immunotherapy differs between females and males. Our study suggests ambiguous sex-related differences in outcomes from immunotherapy in hepatocellular carcinoma. Further investigation of sex-specific clustering in clinicopathologic and immunologic determinants of responsiveness to immune checkpoint inhibitor therapy should be prioritised. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023429625.
  • Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi Nishida
    Liver cancer 13 1 56 - 69 2024年02月 
    INTRODUCTION: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (HCC). While immune checkpoint inhibitor has revolutionized the concept of cancer treatment, it has also led to unexpected tumor growth. Regulatory T cells express PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptors, which are proliferated and activated by antibody binding, and their ratio to CD8+ T cells is altered, which is one of the causes for hyper progressive disease (HPD). We examined the frequency of HPD in anti-PD-1/PD-L1 monotherapy and combination therapy with vascular endothelial growth factor (VEGF) antibody and anti-CTLA-4 antibodies. METHODS: This was a prospective and retrospective cohort study which enrolled 198 patients with unresectable HCC from January 2015 to December 2021 at the Kindai University Hospital. Fifty-eight patients received anti-PD-1/PD-L1 monotherapy, 119 patients combination with VEGF antibody, and 21 patients combination with anti-CTLA-4 antibody. We defined HPD as tumor growth rate (TGR) ratio ≥4, ΔTGR ≥40%, and tumor growth kinetics ratio ≥4. RESULTS: The HPD rate was 10.3% (6/58) in anti-PD-1/PD-L1 monotherapy, 1.7% (2/119) in combination with VEGF antibody, and 4.8% (1/21) in combination with anti-CTLA-4 antibody (p = 0.034). The odds ratio for HPD in the combined anti-CTLA-4 antibody group was 0.433 (95% confidence interval [CI]: 0.05-3.83) when compared to the anti-PD-1/PD-L1 monotherapy group and 2.93 (95% CI: 0.25-33.79) when compared to the combined VEGF antibody group. CONCLUSION: The frequency of HPD in unresectable HCC compared to anti-PD-1/PD-L1 monotherapy was decreased with the combination with anti-VEGF antibody and not increased with anti-CTLA-4 antibody. Anti-PD-1/PD-L1 combined with anti-CTLA-4 antibody is now available in real-world and needs to be further validated with accumulated clinical practice.
  • Silvia Camera; Margherita Rimini; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Francesca Salani; Mariarosaria Marseglia; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Sara Lonardi; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Targeted oncology 2024年01月 
    BACKGROUND: Data concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing. OBJECTIVE: This analysis aimed to evaluate the efficacy and safety of lenvatinib in a large cohort of very old patients (≥ 80 years) with unresectable HCC. PATIENTS AND METHODS: The study was conducted on a cohort of 1325 patients from 46 centers in four Western and Eastern countries (Italy, Germany, Japan, and the Republic of Korea) who were undergoing first-line treatment with lenvatinib between July 2010 and February 2022. Patients were stratified according to age as very old (≥ 80 years) and not very old (< 80 years). RESULTS: The median overall survival (OS) was 15.7 months for patients < 80 years old and 18.4 months for patients ≥ 80 years old [hazard ratio (HR) = 1.02, 95% confidence interval (CI) 0.84-1.25, p = 0.8281]. Median progression free survival (PFS) was 6.3 months for patients < 80 years old and 6.5 months for patients ≥ 80 years old (HR = 1.07, 95% CI 0.91-1.25, p = 0.3954). No differences between the two study groups were found in terms of disease control rate (DCR; 80.8% versus 78.8%; p = 0.44) and response rate (RR; 38.2% versus 37.9%; p = 0.88). Patients < 80 years old experienced significantly more hand-foot skin reaction (HFSR) grade ≥ 2 and decreased appetite grade ≥ 2. Conversely, patients ≥ 80 years old experienced significantly more fatigue grade ≥ 2. In the very old group, parameters associated with prognosis were AFP, albumin-bilirubin (ALBI) grade, Barcelona Clinic Liver Cancer (BCLC), and Child-Pugh score. BCLC stage was the only independent predictor of overall survival (OS; HR = 1.59, 95% CI 1.11-2.29, p = 0.01115). CONCLUSIONS: Our study highlights the same efficacy and safety of lenvatinib between very old and not very old patients.
  • Satoru Hagiwara; Junko Tanizaki; Hidetoshi Hayashi; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi Kudo
    Cancer reports (Hoboken, N.J.) e1960  2024年01月 
    BACKGROUND: Immune checkpoint inhibitors have been reported to have excellent therapeutic effects on various malignant tumors. However, immune-related adverse events can occur, targeting various organs. CASE PRESENTATION: A 49-year-old male with lung carcinoma was started on carboplatin + pemetrexed + nivolumab (every 3 weeks) + ipilimumab (every 6 weeks), and nivolumab/ipilimumab was administered in the 3rd course. Subsequently, fever and fatigue developed, and grade 3 liver damage was also noted, so he was admitted to Kindai University Hospital. A bone marrow aspirate examination was performed on the third day of illness, and a definitive diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made. It was determined that immediate therapeutic intervention was necessary, and pulse therapy with methylprednisolone was started on the third day of illness. After 3 days of pulse treatment, a rapid recovery of platelet values, a decrease in ferritin levels, and a decrease in lactate dehydrogenase were observed. Subjective symptoms such as fever and fatigue also quickly improved. CONCLUSION: Early diagnosis and treatment for HLH resulted in a positive response. The number of HLH cases may increase in the future due to the expansion of immune checkpoint inhibitor indications.
  • Satoru Hagiwara; Koichi Nakagawa; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi Kudo
    Internal Medicine 2024年 
    In October 2021, a 51-year-old woman developed a skin rash. Abdominal computed tomography revealed a large splenic artery aneurysm and an intrahepatic portovenous shunt. As her splenic artery aneurysm was at risk of rupture, she was referred to the Kindai University Hospital and underwent coiling surgery. In October 2023, approximately two years after she had been initially referred, contrast-enhanced ultrasound revealed findings suggestive of focal nodular hyperplasia. No reports have confirmed the occurrence of liver masses in patients with hereditary hemorrhagic telangiectasia, which is considered to be an interesting finding when investigating the mechanism of tumor development.
  • Bachir Taouli; Ahmed Ba-Ssalamah; Julius Chapiro; Jagpreet Chhatwal; Kathryn Fowler; Tae Wook Kang; Gesine Knobloch; Dow-Mu Koh; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; David J Pinato; Kristina I Ringe; Bin Song; Parissa Tabrizian; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Valérie Vilgrain
    European radiology 2023年12月
  • 【肝細胞癌治療のパラダイムチェンジ】Wnt/βカテニン経路活性化と肝癌免疫療法の効果
    盛田 真弘; 青木 智子; 西田 直生志; 工藤 正俊
    消化器内科 5 2 70 - 79 (株)医学出版 2023年12月 
    HCCにおける抗PD-1抗体単剤療法に対する奏効率は20%前後であり,ICIが奏功するサブグループを特定することは臨床的に重要である.ICIの効果と腫瘍免疫微小環境は密接な関係があると考えられている.腫瘍免疫微小環境にはさまざまな分類が提唱されているが,過去の検討からICIの効果を得るためには腫瘍へのリンパ球浸潤や免疫チェックポイントの発現状況も重要な因子の1つである.そのなかで,Wnt/βカテニン経路活性化は腫瘍内へのリンパ球浸潤に乏しい"immune exclusion"をきたすことが基礎的検討で示されている.少数例ながら,Wnt/βカテニン経路活性化をきたしたHCCはICIの奏功が得られづらいことが臨床データにおいても示されている.HCCの診療においてもICIが広く使用されるようになっており,Wnt/βカテニン経路活性化と臨床的意義について,これまでの報告を基に解説する.(著者抄録)
  • Arndt Vogel; Richard S Finn; Marie-Hélène Blanchet Zumofen; Carolina Heuser; Javier Sanchez Alvarez; Michael Leibfried; Catherine R Mitchell; Sarah Batson; Gabrielle Redhead; Vincent E Gaillard; Masatoshi Kudo
    Liver cancer 12 6 510 - 520 2023年12月 
    BACKGROUND: In 2020, atezolizumab-bevacizumab became the new standard of care (SOC) for first-line unresectable hepatocellular carcinoma (HCC) patients, following a decade where sorafenib was the preferred first-line treatment. In the last few years, a number of novel systemic treatments with non-inferiority and superiority to sorafenib have been approved as first-line treatments. OBJECTIVES: The objective of this systematic literature review (SLR) and network meta-analysis (NMA) was to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line treatment of patients with unresectable HCC. METHODS: Randomised controlled trials investigating first-line treatment of HCC in adults with no prior systemic treatment were eligible for inclusion into the SLR and were retrieved from Embase, MEDLINE, and Evidence-Based Medicine (EBM) Reviews. Interventions of interest for the NMA included atezolizumab-bevacizumab, sorafenib, lenvatinib, durvalumab (including in combination with tremelimumab), cabozantinib (including in combination with atezolizumab), camrelizumab (including in combination with rivoceranib), pembrolizumab (including in combination with lenvatinib), and tislelizumab. Random effects NMA was conducted for survival endpoints within a Bayesian framework with an informative prior distribution for between-study heterogeneity. The hazard ratios for relative treatment effect were estimated with 95% credible intervals (CrIs). RESULTS: The SLR identified 49 studies, of which eight formed a connected evidence network permitting the indirect treatment comparison of atezolizumab-bevacizumab with comparators of interest. The indirect comparisons suggested an improved overall survival (OS) with atezolizumab-bevacizumab versus most comparators. All indirect treatment comparison results for atezolizumab-bevacizumab included the null value within the 95% CrI (n = 1) for OS and progression-free survival (PFS). CONCLUSIONS: The results of the NMA indicate atezolizumab-bevacizumab is associated with superior or comparable OS and PFS together with a manageable safety profile compared with globally relevant comparators in the unresected HCC indication. The findings support that atezolizumab-bevacizumab remains SOC for the management of first-line unresectable HCC patients.
  • Masatoshi Kudo
    Liver cancer 12 6 497 - 509 2023年12月
  • Naoshi Nishida; Masatoshi Kudo
    Liver Cancer (in press) 1 - 14 2023年12月 [査読有り]
     
    <b><i>Background:</i></b> Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cisplatin. However, recent advancements in the understanding of the molecular characteristics of iCCA have opened new possibilities for molecular-targeted therapies and immunotherapy. <b><i>Summary:</i></b> Reportedly, 9–36% of iCCA cases have an inflamed tumor immune microenvironment (TME) based on the immune gene expression signature, which is characterized by the presence of immune cells involved in anti-tumor immune responses. The majority of iCCA cases have a non-inflamed TME with a lack of effector T cells, rendering immune checkpoint inhibitors (ICIs) ineffective in these cases. Interestingly, alterations in the fibroblast growth factor receptor (<i>FGFR2</i>) gene and <i>IDH1/2</i> gene mutations are often observed in the non-inflamed TME in iCCA. Several mechanisms have been reported for the role of driver mutations on the establishment of TME unique for iCCA. For example, <i>IDH1/2</i> mutations, which cause an increase in DNA methylation, are associated with the downregulation and hypermethylation of antigen processing and presentation machinery, which may contribute to the establishment of a non-inflamed TME. Therefore, inhibitors targeting <i>IDH1/2</i> may restore the DNA methylation and expression status of molecules involved in antigen presentation, potentially improving the efficacy of ICIs. FGFR inhibitors may also have the potential to modulate immunosuppressive TME by inhibitingthe suppressor of cytokine signaling 1 and activating the interferon-γ signaling as a consequence of inhibition of the <i>FGFR</i> signal. From this perspective, understanding the molecular characteristics of iCCA, including the TME and driver mutations, is essential for the effective application of ICIs and molecular-targeted therapies. <b><i>Key Messages:</i></b> Combination approaches that target both the tumor and immune system hold promise for improving the outcomes of patients with iCCA. Further research and clinical trials are needed to validate these approaches and optimize the treatment strategies for iCCA.
  • Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Valentina Burgio; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
    International journal of cancer 2023年11月 
    Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first-line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison of the two regimens has been performed in randomized clinical trials, making the identification of baseline differential predictors of response of major relevance to tailor the best therapeutic option to each patient. Baseline clinical and laboratory characteristics of real-world AB-treated HCC patients were analyzed in uni- and multivariate analyses to find potential prognostic factors of overall survival (OS). Significant variables were incorporated in a composite score (α-FAtE) and it was tested for specificity and sensitivity in receiver operating characteristic (ROC) curve and in multivariate analysis for OS. The score was applied in uni- and multivariate analyses for OS of a comparable lenvatinib-treated HCC population. Finally, comparison between treatments was performed in patients with low and high α-FAtE scores and predictivity estimated by interaction analysis. Time-to-progression (TTP) was a secondary endpoint. OS of AB-treated HCC patients was statistically longer in those with α-fetoprotein <400 ng/mL (HR 0.62, p = .0407), alkaline phosphatase (ALP) <125 IU/L (HR 0.52, p = .0189) and eosinophil count ≥70/μL (HR 0.46, p = .0013). The α-FAtE score was generated by the sum of single points attributed to each variable among the above reported. In ROC curve analysis, superior sensitivity and specificity were achieved by the score compared to individual variables (AUC 0.794, p < .02). Patients with high score had longer OS (HR 0.44, p = .0009) and TTP (HR 0.34, p < .0001) compared to low score if treated with AB, but not with lenvatinib. Overall, AB was superior to lenvatinib in high score patients (HR 0.55, p = .0043) and inferior in low score ones (HR 1.75, p = .0227). At interaction test, low α-FAtE score resulted as negative predictive factor of response to AB (p = .0004). In conclusion, α-FAtE is a novel prognostic and predictive score of response to first-line AB for HCC patients that, if validated in prospective studies, could drive therapeutic choice between lenvatinib and AB.
  • Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Keisuke Yokohama; Hiroki Nishikawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Atsushi Naganuma; Yutaka Yata; Hideko Ohama; Hidekatsu Kuroda; Kazunari Tanaka; Takaaki Tanaka; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
    Cancer medicine 2023年11月 
    AIM: This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. METHODS: We included 526 patients who received Atez/Bev and 731 who received LEN March 2018 and July 2022 in this study. We conducted a 1:1 propensity-score-matched analysis and identified 324 patients in each group for inclusion in the present analysis. Nonlinear mixed-effects regression models were employed, allowing for the evaluation and inclusion of cases where treatment was interrupted due to disease progression, adverse events, or loss to follow-up. These models were used to compare the ALBI score between the Atez/Bev and LEN groups. RESULTS: Following propensity score matching, the mean ALBI scores in the Atez/Bev and LEN groups were -2.41 ± 0.40 and -2.44 ± 0.42 at baseline, and -2.17 ± 0.56 and -2.19 ± 0.58 at 12 weeks, respectively. Although the ALBI score significantly worsened during treatment in both groups (p < 0.001), there was no significant difference in the rate of ALBI score deterioration between the groups (p = 0.06). Subgroup analyses showed that LEN-treated patients with BCLC advanced stage (p = 0.02) and those who initially received the full dose (p < 0.001) had a significantly greater worsening of ALBI score compared to Atez/Bev. CONCLUSIONS: Using a nonlinear mixed-effects regression approach, which allowed for the inclusion of cases with treatment interruption, we found no significant difference in the trend of liver function deterioration between the Atez/Bev and LEN groups. Caution should be exercised for LEN-treated patients with BCLC advanced stage or those receiving the full dose of LEN.
  • Hironobu Sugimori; Sho Masaki; Hajime Honjo; Masatoshi Kudo; Tomohiro Watanabe
    Cureus 15 11 e49133  2023年11月 
    Although delayed gastric emptying promotes gastrointestinal bezoar formation in patients with diabetes mellitus (DM), the association between movement of gastrointestinal bezoars and glycemic status remains unclear. We report a case of small bowel obstruction (SBO) caused by impaction of the migrated gastric bezoar into the small bowel in a patient with DM. Correction of hyperglycemia and lactic acidosis led to normalization of gastrointestinal motility, followed by expulsion of the impacted bezoar and resolution of SBO. This case suggests a link between hyperglycemia, metabolic acidosis, and gastrointestinal motility based on visualization of gastrointestinal bezoar movement in the gastrointestinal tract using computed tomography.
  • Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Keisuke Yokohama; Hiroki Nishikawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Atsushi Naganuma; Yutaka Yata; Hideko Ohama; Hidekatsu Kuroda; Tomoko Aoki; Kazunari Tanaka; Takaaki Tanaka; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
    Hepatology research : the official journal of the Japan Society of Hepatology 2023年11月 
    AIM: Elderly patients are believed to have a reduced immune capacity, which may make immunotherapy less effective. The aim of this study was to compare the therapeutic outcome of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) for advanced hepatocellular carcinoma (HCC) in patients aged 80 years and older. METHODS: From March 2018 to July 2022, 170 and 92 elderly patients who received LEN and Atez/Bev as first-line treatment, respectively, were retrospectively analyzed. RESULTS: The median ages of the Atez/Bev and LEN groups were 83.0 (8.01-86.0) and 83.0 (82.0-86.0) years (p=0.3), respectively. Males accounted for approximately 70% of the patients in both groups. The objective response rate was 35.9% in the LEN group and 33.7% in the Atez/Bev group (p=0.8), whereas the disease control rates in the LEN and Atez/Bev groups were 62.9% and 63.0%, respectively (p=1.0). The median PFS in the LEN and Atez/Bev groups was 6.3 months and 7.2 months, respectively, which were not significantly different (p=0.2). The median OS was 17.9 months in the LEN group and 14.0 months in the Atez/Bev group. This difference was not statistically significant (p=0.7). In multivariate analyses, the choice of treatment (LEN vs. Atez/Bev) showed no association with PFS or OS. The Atez/Bev group had a significantly higher rate of post-progression treatment (59.0% vs. 35.7%, p=0.01) and a lower rate of discontinuation due to adverse events (69 [40.6%] vs. 19 [20.7%], p<0.001) compared to the LEN group. CONCLUSIONS: Atez/Bev showed comparable effectiveness to LEN in HCC patients aged 80 years and older. Given the results of post-progression treatment and discontinuation due to adverse events, Atez/Bev could serve as a first-line treatment even for elderly HCC patients. This article is protected by copyright. All rights reserved.
  • Sirish Dharmapuri; Umut Özbek; Hiren Jethra; Tomi Jun; Thomas U Marron; Anwaar Saeed; Yi-Hsiang Huang; Mahvish Muzaffar; Matthias Pinter; Lorenz Balcar; Claudia Fulgenzi; Suneetha Amara; Arndt Weinmann; Nicola Personeni; Bernhard Scheiner; Tiziana Pressiani; Musharraf Navaid; Bertram Bengsch; Sonal Paul; Uqba Khan; Dominik Bettinger; Naoshi Nishida; Yehia Ibrahim Mohamed; Arndt Vogel; Anuhya Gampa; James Korolewicz; Antonella Cammarota; Ahmed Kaseb; Peter R Galle; Anjana Pillai; Ying-Hong Wang; Alessio Cortellini; Masatoshi Kudo; Antonio D'Alessio; Lorenza Rimassa; David James Pinato; Celina Ang
    World journal of gastrointestinal oncology 15 11 1900 - 1912 2023年11月 
    BACKGROUND: A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI. Deaths are reported in < 5% of patients treated with ICI. There are, however, no reliable markers to predict the onset and severity of IrAEs. We tested the association between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at baseline with development of clinically significant IrAEs (grade ≥ 2) in hepatocellular carcinoma (HCC) patients treated with ICI. AIM: To test the association between NLR and PLR at baseline with development of clinically significant IrAEs (grade ≥ 2) in HCC patients treated with ICI. METHODS: Data was extracted from an international database from a consortium of 11 tertiary-care referral centers. NLR = absolute neutrophil count/absolute lymphocyte count (ALC) and PLR = platelet count/ALC. Cutoff of 5 was used for NLR and 300 for PLR based on literature. We also tested the association between antibiotic and steroid exposure to IrAEs. RESULTS: Data was collected from 361 patients treated between 2016-2020 across the United States (67%), Asia (14%) and Europe (19%). Most patients received Nivolumab (n = 255, 71%). One hundred sixty-seven (46%) patients developed at least one IrAE, highest grade 1 in 80 (48%), grade ≥ 2 in 87 (52%) patients. In a univariable regression model PLR > 300 was significantly associated with a lower incidence of grade ≥ 2 IrAEs (OR = 0.40; P = 0.044). Similarly, a trend was observed between NLR > 5 and lower incidence of grade ≥ 2 IrAEs (OR = 0.58; P = 0.097). Multivariate analyses confirmed PLR > 300 as an independent predictive marker of grade ≥ 2 IrAEs (OR = 0.26; P = 0.011), in addition to treatment with programmed cell death ligand 1 (PD-1)/cytotoxic T lymphocyte-associated protein-4 (OR = 2.57; P = 0.037) and PD-1/tyrosine kinase inhibitor (OR = 3.39; P = 0.01) combinations. Antibiotic use was not associated with IrAE incidence (OR = 1.02; P = 0.954). Patients treated with steroids had a > 2-fold higher incidence of grade ≥ 2 IrAEs (OR = 2.74; P < 0.001), although 74% were prescribed steroids for the treatment of IrAEs. CONCLUSION: Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs, lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI. This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs.
  • Ciro Celsa; Giuseppe Cabibbo; Claudia Am Fulgenzi; Bernhard Scheiner; Antonio d'Alessio; Giulia F Manfredi; Naoshi Nishida; Celina Ang; Thomas U Marron; Anwaar Saeed; Brooke Wietharn; Matthias Pinter; Jaekyung Cheon; Yi-Hsiang Huang; Pei-Chang Lee; Samuel Phen; Anuhya Gampa; Anjana Pillai; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Natascha Roehlen; Robert Thimme; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Paul El Tomb; Susanna Ulahannan; Alessandro Parisi; Hong Jae Chon; Wei-Fan Hsu; Bernardo Stefanini; Elena Verzoni; Raffaele Giusti; Antonello Veccia; Annamaria Catino; Giuseppe Aprile; Pamela Francesca Guglielmini; Marilena Di Napoli; Paola Ermacora; Lorenzo Antonuzzo; Ernesto Rossi; Francesco Verderame; Fable Zustovich; Corrado Ficorella; Francesca Romana Di Pietro; Nicola Battelli; Giorgia Negrini; Francesco Grossi; Roberto Bordonaro; Stefania Pipitone; Maria Banzi; Serena Ricciardi; Letizia Laera; Antonio Russo; Ugo De Giorgi; Luigi Cavanna; Mariella Sorarù; Vincenzo Montesarchio; Paola Bordi; Leonardo Brunetti; Carmine Pinto; Melissa Bersanelli; Calogero Cammà; Alessio Cortellini; David J Pinato
    Journal of hepatology 2023年11月 
    BACKGROUND&AIMS: Immune-related liver injury(irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors(ICIs). We aimed to compare incidence, clinical characteristics and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma(HCC) versus other solid tumours. METHODS: Two separate cohorts were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with first-line Atezolizumab+Bevacizumab from AB-real study and a non-HCC cohort, including 459 patients treated with first-line ICI therapy from INVIDIa-2 multicentre study. IrLI was defined as treatment-related increase of transaminases levels after exclusion of alternative aetiologies of liver injury. Incidence of irLI was adjusted for the duration of treatment exposure. RESULTS: In HCC patients, incidence of any-grade irLI was 11.4% over a median treatment exposure of 4.4 months(95%CI 3.7-5.2), compared to 2.6% in INVIDIa-2 cohort over a median treatment exposure of 12.4 months(95%CI 11.1-14.0). Exposure-adjusted-incidence of any-grade irLI was 22.1 per 100-Patient-years(PY) in HCC patients and 2.1 per 100-PY in non-HCC patients(p<0.001), with median time to irLI of 1.4 and 4.7 months, respectively. Among patients who developed irLI, systemic corticosteroids were administered in 16.3% of HCC and 75.0% of non-HCC patients(p<0.001) and irLI resolution was observed in 72.1% and 58.3%, respectively(p=0.362). In HCC patients, rates of hepatic decompensation and treatment discontinuation due to irLI were 7%. Grade 1-2 irLI was associated with improved overall survival in HCC patients only(HR 0.53, 95%CI 0.29-0.96). CONCLUSIONS: Despite higher incidence and earlier onset in patients with HCC, IrLI is characterised by high rates of remission, low requirement for corticosteroid therapy and low risk of decompensation compared to other solid tumours. Hepatotoxicity leads to discontinuation in 7% of patients with HCC and does not negatively affect oncological outcomes. IMPACT AND IMPLICATIONS: Immune-related liver injury (irLI) is common in patients with cancer receiving immune checkpoint inhibitors (ICI), but whether irLI is more frequent or it is associated with a worse clinical course in patients with hepatocellular carcinoma (HCC), compared to other tumours, is not known. Herein, we compared characteristics and outcomes of irLI in two prospective cohorts including patients treated with ICIs for HCC or for other oncological indications. irLI is significantly more common and it occurs earlier in patients with HCC, also after adjustment for duration of treatment exposure. However, outcomes of patients with HCC who developed irLI are not negatively affected in terms of requirement of corticosteroid therapy, hepatic decompensation, treatment discontinuation and overall survival.
  • Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Toru Ishikawa; Takeshi Hatanaka; Ei Itobayashi; Koichi Takaguchi; Akemi Tsutsui; Atsushi Naganuma; Satoshi Yasuda; Satoru Kakizaki; Akiko Wakuta; Shohei Shiota; Masatoshi Kudo; Takashi Kumada
    Journal of liver cancer 2023年11月 
    INTRODUCTION: The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary Hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database. METHODS: The study included consecutive 2067 patients with solitary HCC who were treated with either ablation (N=1248) or surgery (N=819). The patients were divided into three groups based on the tumor size and compared the outcomes of the two therapies using propensity score matching. RESULTS: No significant difference in recurrence-free survival (RFS) or overall survival (OS) was found between surgery and ablation groups for tumors measuring ≤2 cm or >2 cm but ≤3 cm. For tumors measuring >3 cm but ≤5 cm, RFS was significantly better with surgery than with ablation (3.6 and 2.0 years, respectively, p = 0.0297). However, no significant difference in OS was found between surgery and ablation in this group (6.7 and 6.0 years, respectively, p = 0.668). DISCUSSION/CONCLUSION: The study suggests that surgery and ablation can be equally used as a treatment for solitary HCC no more than 3 cm in diameter. For HCCs measuring 3-5 cm, the OS was not different between therapies; thus, ablation and less invasive therapy can be considered a treatment option; however, special caution should be taken to prevent recurrence.
  • Bachir Taouli; Ahmed Ba-Ssalamah; Julius Chapiro; Jagpreet Chhatwal; Kathryn Fowler; Tae Wook Kang; Gesine Knobloch; Dow-Mu Koh; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; David J Pinato; Kristina I Ringe; Bin Song; Parissa Tabrizian; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Valérie Vilgrain
    European radiology 2023年11月
  • 萩原 智; 上嶋 一臣; 西田 直生志; 依田 広; 三長 孝輔; 南 康範; 田北 雅弘; 青木 智子; 盛田 真弘; 千品 寛和; 松原 卓哉; 大丸 直哉; 稲村 昇; 工藤 正俊
    肝臓 64 11 567 - 574 (一社)日本肝臓学会 2023年11月 
    症例は30代男性.幼少期に完全大血管転位III型に対してFontan手術が施行され,近医に定期的に通院していた.20XX年7月腹部USで多発肝腫瘤を指摘され当院紹介受診となった.造影CTにて最大13cmの多発肝細胞癌と判明した(BCLC stage B).画像上は門脈圧亢進所見や明らかな肝形態異常を認めなかったが,肝生検でCongestive Hepatic Fibrosis Score 3であり,実際には線維化の進展を認めていた.肝内多発のため外科手術やRFAの適応外であった.また最大径の腫瘍は肝外に突出しており,腹腔内破裂の危険性もあることから,まずTACEを施行した.再発に応じて各種抗癌剤治療を行い,生存中である.画像上は肝線維化を示唆する所見はなかったが,Fontan術後の特殊な循環動態では,肝線維化が進展している可能性があり,本症例を通して肝癌サーベイランスの重要性を再考する.(著者抄録)
  • 萩原 智; 上嶋 一臣; 西田 直生志; 依田 広; 三長 孝輔; 南 康範; 田北 雅弘; 青木 智子; 盛田 真弘; 千品 寛和; 松原 卓哉; 大丸 直哉; 稲村 昇; 工藤 正俊
    肝臓 64 11 567 - 574 (一社)日本肝臓学会 2023年11月 
    症例は30代男性.幼少期に完全大血管転位III型に対してFontan手術が施行され,近医に定期的に通院していた.20XX年7月腹部USで多発肝腫瘤を指摘され当院紹介受診となった.造影CTにて最大13cmの多発肝細胞癌と判明した(BCLC stage B).画像上は門脈圧亢進所見や明らかな肝形態異常を認めなかったが,肝生検でCongestive Hepatic Fibrosis Score 3であり,実際には線維化の進展を認めていた.肝内多発のため外科手術やRFAの適応外であった.また最大径の腫瘍は肝外に突出しており,腹腔内破裂の危険性もあることから,まずTACEを施行した.再発に応じて各種抗癌剤治療を行い,生存中である.画像上は肝線維化を示唆する所見はなかったが,Fontan術後の特殊な循環動態では,肝線維化が進展している可能性があり,本症例を通して肝癌サーベイランスの重要性を再考する.(著者抄録)
  • Teerha Piratvisuth; Jinlin Hou; Tawesak Tanwandee; Thomas Berg; Arndt Vogel; Jörg Trojan; Enrico N De Toni; Masatoshi Kudo; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Kairat Madin; Konstantin Kroeniger; Ashish Sharma; Henry L Y Chan
    Hepatology communications 7 11 2023年11月 
    BACKGROUND: Alpha-fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP), also known as protein induced by vitamin K absence-II (PIVKA-II [DCP]) are biomarkers for HCC with limited diagnostic value when used in isolation. The novel GAAD algorithm is an in vitro diagnostic combining PIVKA-II (DCP) and AFP measurements, age, and gender (biological sex) to generate a semi-quantitative result. We conducted prospective studies to develop, implement, and clinically validate the GAAD algorithm for differentiating HCC (early and all-stage) and benign chronic liver disease (CLD), across disease stages and etiologies. METHODS: Patients aged ≥18 years with HCC or CLD were prospectively enrolled internationally into algorithm development [n = 1084; 309 HCC cases (40.7% early-stage) and 736 controls] and clinical validation studies [n = 877; 366 HCC cases (47.6% early-stage) and 303 controls]. Serum samples were analyzed on a cobas® e 601 analyzer. Performance was assessed using receiver operating characteristic curve analyses to calculate AUC. RESULTS: For algorithm development, AUC for differentiation between early-stage HCC and CLD was 90.7%, 84.4%, and 77.2% for GAAD, AFP, and PIVKA-II, respectively. The sensitivity of GAAD for the detection of early-stage HCC was 71.8% with 90.0% specificity. Similar results were shown in the clinical validation study; AUC for differentiation between early-stage HCC and CLD was 91.4% with 70.1% sensitivity and 93.7% specificity. GAAD also showed strong specificity, with a lower rate of false positives regardless of disease stage, etiology, or region. CONCLUSIONS: The GAAD algorithm significantly improves early-stage HCC detection for patients with CLD undergoing HCC surveillance. Further phase III and IV studies are warranted to assess the utility of incorporating the algorithm into clinical practice.
  • Shukui Qin; Minshan Chen; Ann-Lii Cheng; Ahmed O Kaseb; Masatoshi Kudo; Han Chu Lee; Adam C Yopp; Jian Zhou; Lu Wang; Xiaoyu Wen; Jeong Heo; Won Young Tak; Shinichiro Nakamura; Kazushi Numata; Thomas Uguen; David Hsiehchen; Edward Cha; Stephen P Hack; Qinshu Lian; Ning Ma; Jessica H Spahn; Yulei Wang; Chun Wu; Pierce K H Chow
    Lancet (London, England) 2023年10月 
    BACKGROUND: No adjuvant treatment has been established for patients who remain at high risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We aimed to assess the efficacy of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with high-risk hepatocellular carcinoma. METHODS: In the global, open-label, phase 3 IMbrave050 study, adult patients with high-risk surgically resected or ablated hepatocellular carcinoma were recruited from 134 hospitals and medical centres in 26 countries in four WHO regions (European region, region of the Americas, South-East Asia region, and Western Pacific region). Patients were randomly assigned in a 1:1 ratio via an interactive voice-web response system using permuted blocks, using a block size of 4, to receive intravenous 1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles (12 months) or to active surveillance. The primary endpoint was recurrence-free survival by independent review facility assessment in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT04102098. FINDINGS: The intention-to-treat population included 668 patients randomly assigned between Dec 31, 2019, and Nov 25, 2021, to either atezolizumab plus bevacizumab (n=334) or to active surveillance (n=334). At the prespecified interim analysis (Oct 21, 2022), median duration of follow-up was 17·4 months (IQR 13·9-22·1). Adjuvant atezolizumab plus bevacizumab was associated with significantly improved recurrence-free survival (median, not evaluable [NE]; [95% CI 22·1-NE]) compared with active surveillance (median, NE [21·4-NE]; hazard ratio, 0·72 [adjusted 95% CI 0·53-0·98]; p=0·012). Grade 3 or 4 adverse events occurred in 136 (41%) of 332 patients who received atezolizumab plus bevacizumab and 44 (13%) of 330 patients in the active surveillance group. Grade 5 adverse events occurred in six patients (2%, two of which were treatment related) in the atezolizumab plus bevacizumab group, and one patient (<1%) in the active surveillance group. Both atezolizumab and bevacizumab were discontinued because of adverse events in 29 patients (9%) who received atezolizumab plus bevacizumab. INTERPRETATION: Among patients at high risk of hepatocellular carcinoma recurrence following curative-intent resection or ablation, recurrence-free survival was improved in those who received atezolizumab plus bevacizumab versus active surveillance. To our knowledge, IMbrave050 is the first phase 3 study of adjuvant treatment for hepatocellular carcinoma to report positive results. However, longer follow-up for both recurrence-free and overall survival is needed to assess the benefit-risk profile more fully. FUNDING: F Hoffmann-La Roche/Genentech.
  • Yasuo Otsuka; Akane Hara; Kosuke Minaga; Ikue Sekai; Masayuki Kurimoto; Yasuhiro Masuta; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo; Tomohiro Watanabe
    Clinical and Experimental Immunology 2023年10月 
    Abstract Translocation of gut bacteria into the pancreas promotes the development of severe acute pancreatitis (SAP). Recent clinical studies have also highlighted the association between fungal infections and SAP. The sensing of gut bacteria by pattern recognition receptors promotes the development of SAP via the production of proinflammatory cytokines; however, the mechanism by which gut fungi mediate SAP remains largely unknown. Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that regulates innate immunity against fungi via Dectin-1 activation. Here, we investigated the role of LRRK2 in SAP development and observed that administration of LRRK2 inhibitors attenuated SAP development. The degree of SAP was greater in Lrrk2 transgenic (Tg) mice than in control mice and was accompanied by an increased production of nuclear factor-kappaB-dependent proinflammatory cytokines. Ablation of the fungal mycobiome by anti-fungal drugs inhibited SAP development in Lrrk2 Tg mice, whereas the degree of SAP was comparable in Lrrk2 Tg mice with or without gut sterilization by a broad range of antibiotics. Pancreatic mononuclear cells from Lrrk2 Tg mice produced large amounts of IL-6 and TNF-α upon stimulation with Dectin-1 ligands, and inhibition of the Dectin-1 pathway by a spleen tyrosine kinase inhibitor protected Lrrk2 Tg mice from SAP. These data indicate that LRRK2 activation is involved in the development of SAP through proinflammatory cytokine responses upon fungal exposure.
  • Yoriaki Komeda; George Tribonias; Masashi Kono; Kohei Handa; Shunsuke Omoto; Mamoru Takenaka; Satoru Hagiwara; Naoko Tsuji; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Inflammatory Intestinal Diseases 8 4 161 - 166 2023年10月 
    Introduction: Ustekinumab is an IgG1 kappa monoclonal antibody directed against the common p40 subunit of interleukin-12 and interleukin-23, which activate Th1- and Th17-mediated immune responses, respectively. It has proven efficacy for the treatment of moderate to severe ulcerative colitis (UC) in the UNIFI Phase III clinical trial; however, data on its efficacy in the real world is limited. In this study, we aimed to assess the real-world efficacy of ustekinumab.Methods: This observational study included 30 patients with UC who received ustekinumab from April 2020 to April 2022. We examined demographic information, disease type and activity (Mayo score, partial Mayo score [PMS]), use of biologics, concomitant use of predonisolone (PSL), 8-week ustekinumab clinical response rate, remission induction rate, 44- and 152-week remission maintenance rate, continuation rate, and 44-week steroid-free remission rate. The primary outcomes were the short- and long-term efficacy of ustekinumab.Results: Included patients (53% women; mean age: 41.2 years [16–80 years]) had an average disease duration of 86 weeks. Mayo’s score (median) was 7.4 and the PMS was 5.4. Two (7%), 24 (80%), and four (13%) patients had a Mayo endoscopic sub-score (MES) of MES1, MES2, and MES3, respectively. The median serum CRP was 1.0 mg/dL. Five patients had no history of biotherapy (naive), while 8 and 17 had a history of one and two or more biologic agents, respectively. Eight patients were PSL-resistant and 22 were PSL-dependent. The 8-week clinical response rate was 73%, and the clinical remission induction rate was 70%. The remission maintenance rates at 44 and 152 weeks were 67% and 63%, respectively. The ustekinumab retention rate was 67% (86-week mean follow-up period). Regarding biologic failure cases, the clinical response rate in the failure group with up to one biologic agent (including naive cases) was 84.6%, which was higher than the 58.0% rate in the failure group with two or more biologic agents (p=0.06). Steroid-free remission rates at 44 and 152 weeks were 63% each. In the logistic regression analysis parameters for discontinuation of ustekinumab, only PMS remained significant after multivariate analysis (p=0.018).Conclusion: Our study showed short-term and long-term ustekinumab effectiveness, especially with comparative low disease activity.
  • Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Tomomitsu Matono; Tomoko Aoki; Hidekatsu Kuroda; Yutaka Yata; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo
    Liver international : official journal of the International Association for the Study of the Liver 2023年10月 
    BACKGROUND & AIMS: The study goal was to compare the outcomes of patients with intermediate-stage (Barcelona Clinic Liver Cancer [BCLC]-B) hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first-line systemic therapy. METHODS: A total of 358 patients with BCLC-B HCC treated with Atezo/Bev (n = 177) or LEN (n = 181) as first-line systemic therapy were included. RESULTS: The median progression-free survival (PFS) times in the Atezo/Bev and LEN groups were 10.8 months (95% confidence interval [CI], 7.8-12.6) and 7.3 months (95% CI, 6.3-8.5), respectively (p = .019). In the propensity score-matched cohort, the median PFS times in the Atezo/Bev (n = 151) and LEN (n = 151) groups were 10.2 months (95% CI, 7.0-12.3) and 6.9 months (95% CI, 5.9-8.1), respectively (p = .020). Restricted mean survival times of PFS were significantly higher in the Atezo/Bev group than in the LEN group at landmarks of 12 and 18 months (p = .031 and .012, respectively). In a subgroup analysis of patients with HCC beyond the up-to-seven criteria, the median PFS times in the Atezo/Bev (n = 134) and LEN (n = 117) groups were 10.5 months (95% CI, 7.0-11.8) and 6.3 months (95% CI, 5.5-7.3), respectively (p = .044). CONCLUSIONS: The use of Atezo/Bev as first-line systemic therapy in patients with BCLC-B HCC is expected to result in good PFS.
  • 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Early stage肝細胞癌 肝細胞癌での腫瘍免疫微小環境とアジュバント療法における免疫チェックポイント阻害剤の役割
    西田 直生志; 工藤 正俊
    肝胆膵 87 4 381 - 387 (株)アークメディア 2023年10月
  • 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 64 10 514 - 516 (一社)日本肝臓学会 2023年10月 
    カボザンチニブは血管内皮増殖因子受容体や肝細胞増殖因子受容体(MET)を標的とする分子標的薬であり、主に腫瘍増殖抑制を期待する薬剤として使用されている。今回、肺転移により症状増悪した肝細胞癌患者(50歳代男性)に対して、FoundationOne CDxがん遺伝子パネル検査によりMET遺伝子増幅を確認したうえでカボザンチニブを投与し、著明な腫瘍縮小が認められたので報告した。
  • 肝がん局所治療の多様性とその到達点 切除不能HCCに対するABC conversion療法とclinical CRの現状
    青木 智子; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.3 A773 - A773 (一社)日本肝臓学会 2023年10月
  • 予後改善に向けた胆道癌の集学的治療 "non-inflamed type"の胆管癌における抗原提示分子のメチル化と発現低下
    西田 直生志; 工藤 正俊
    肝臓 64 Suppl.3 A786 - A786 (一社)日本肝臓学会 2023年10月
  • 【Stenting Bible～Renewal～ステントと挿入・留置手技にこだわる!!】ステント治療のトラブルシューティングおよび偶発症マネージメント SEMS迷入に対するトラブルシューティング
    竹中 完; 大塚 康生; 益田 康弘; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊
    胆と膵 44 臨増特大 1337 - 1341 医学図書出版(株) 2023年10月 
    遠位悪性胆管狭窄に対する経乳頭的胆道ドレナージにおいて自己拡張型メタリックステント(self-expandable metallic stent:SEMS)の中でもポリウレタンやPTFEなどの膜で被覆されたcovered SEMS(CSEMS)は腫瘍増殖を防ぐことができるとされる一方でさまざまな要因によりCSEMSは逸脱・迷入を起こし,閉塞性黄疸,閉塞性胆管炎の再燃を引き起こす。CSEMS迷入に対する最大のトラブルシューティングは「迷入させないこと」であり,事前議論,胆管造影,適切なデバイス選択がまず行われなくてはならない。迷入に対しては「乳頭拡張をしておく」,「カバーの腐食・ingrowthの可能性を確認する」,「迷入したCSEMSのカバーが外巻きか内巻きかを確認しておく」,「迷入したCSEMSと胆管狭窄部との位置関係を確認する」といったtipsを理解し,引き抜き法か翻転抜去法を選択する対応が求められる。ただしまずはドレナージ不良に対する治療を最優先すべきであり,無理な迷入SEMSの抜去は決して行ってはならない。(著者抄録)
  • Masatoshi Kudo; Richard S Finn; Ann-Lii Cheng; Andrew X Zhu; Michel Ducreux; Peter R Galle; Naoya Sakamoto; Naoya Kato; Michitaka Nakano; Jing Jia; Arndt Vogel
    Liver cancer 12 5 479 - 493 2023年10月 
    INTRODUCTION: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score. METHODS: Patients with treatment-naïve unresectable HCC, ≥1 measurable untreated lesion, and Child-Pugh class A liver function were randomized 2:1 to receive atezolizumab 1,200 mg + bevacizumab 15 mg/kg every 3 weeks or sorafenib 400 mg twice daily. Overall survival (OS) and progression-free survival (PFS) were assessed in the intention-to-treat population by ALBI/modified (m)ALBI grade. Time to deterioration (TTD; defined as time to 0.5-point increase from the baseline ALBI score over 2 visits or death) of liver function and safety were investigated. RESULTS: Of 501 enrolled patients, 336 were randomized to receive atezolizumab + bevacizumab (ALBI grade [G] 1: n = 191; G2: n = 144 [mALBI G2a: n = 72, G2b: n = 72]; missing ALBI grade: n = 1) and 165 to sorafenib (ALBI G1: n = 87; G2: n = 78 [mALBI G2a: n = 37; G2b: n = 41]). Median follow-up was 15.6 months. OS and PFS improved with atezolizumab + bevacizumab versus sorafenib in patients with ALBI G1 (OS HR: 0.50 [95% CI: 0.35, 0.72]; PFS HR: 0.61 [95% CI: 0.45, 0.82]). In patients with ALBI G2 or mALBI G2a or G2b, PFS was numerically longer with atezolizumab + bevacizumab versus sorafenib, but no OS benefit was seen. Median TTD in the intention-to-treat population was 10.2 months (95% CI: 8.0, 11.0) with atezolizumab + bevacizumab versus 8.6 months (95% CI: 6.2, 11.8) with sorafenib (HR: 0.82 [95% CI: 0.65, 1.03]). Safety profiles of atezolizumab and bevacizumab were consistent with previous analyses, regardless of ALBI grade. CONCLUSION: ALBI grade appeared to be prognostic for outcomes with both atezolizumab + bevacizumab and sorafenib treatment in patients with HCC. Atezolizumab + bevacizumab preserved liver function for a numerically longer duration than sorafenib.
  • Masatoshi Kudo
    Liver cancer 12 5 395 - 404 2023年10月
  • Ken Kamata; Hajime Imai; Hisakazu Matsumoto; Yukitaka Yamashita; Takao Kato; Katsuhisa Nishi; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Tomoko Hyodo; Sung‐Woon Im; Akane Hara; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Kazuomi Ueshima; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Watanabe; Masayuki Kitano; Masatoshi Kudo
    JGH Open 7 9 659 - 666 2023年09月 
    Abstract Background and Aim A multicenter, open‐label randomized Phase II trial was conducted to determine whether low‐dose gemcitabine plus nab‐paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard‐dose GnP for elderly patients with metastatic pancreatic cancer. Methods Consecutive patients aged ≥65 years with metastatic pancreatic cancer who presented at one of four Japanese referral centers between November 2016 and January 2021 were enrolled. The 60 patients were randomly assigned to low‐ or standard‐dose groups with a 1:1 ratio. Patients in the low‐dose GnP group received gemcitabine at a dose of 250 mg/m2 and nab‐paclitaxel at 125 mg/m2. Results Low‐dose GnP significantly decreased the rate of cases requiring dose reduction (16.7% vs 63.3%). The response rate (36.7% vs 33.3%) and progression‐free survival (7.3 vs 8 months) were comparable between the low‐ and standard‐dose groups as determined by independent review. The difference in the median overall survival between the two groups was not significant (7.9 vs 12 months). The proportion of patients with hematologic and non‐hematologic treatment‐related adverse events was comparable between the two groups. Conclusion Low‐dose GnP had an equivalent efficacy to conventional therapy; however, it did not reduce adverse events.
  • Ghassan K Abou-Alfa; George Lau; Masatoshi Kudo; Stephen L Chan; Robin Kate Kelley; Junji Furuse; Wattana Sukeepaisarnjaroen; Yoon Koo Kang; Tu Van Dao; Enrico N De Toni; Lorenza Rimassa; Valeriy Breder; Alexander Vasilyev; Alexandra Heurgué; Vincent C Tam; Kabir Mody; Satheesh Chiradoni Thungappa; Yurii Ostapenko; Thomas Yau; Sergio Azevedo; María Varela; Ann-Lii Cheng; Shukui Qin; Peter R Galle; Sajid Ali; Charu Gupta; Mallory Makowsky; John F Kurland; Alejandra Negro; Bruno Sangro
    Future oncology (London, England) 2023年09月 
    WHAT IS THIS SUMMARY ABOUT?: This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC). HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body's immune system fight cancer. WHAT WERE THE RESULTS OF THE STUDY?: Participants who took STRIDE lived longer than participants who took sorafenib, whilst participants who took durvalumab alone lived a similar length of time as participants who took sorafenib. Participants who took STRIDE or durvalumab had a lower relative risk of experiencing worsening in their quality of life than participants who took sorafenib. The side effects that participants who received STRIDE or durvalumab experienced were expected for these types of treatments and could mostly be managed. WHAT DO THE RESULTS OF THE STUDY MEAN?: Overall, STRIDE is more effective than sorafenib for people with unresectable HCC. Clinical Trial Registration: NCT03298451 (HIMALAYA) (ClinicalTrials.gov).
  • カボザンチニブ投与による腫瘍の著明な縮小、腫瘍マーカーの低下を認めたMET遺伝子増幅を伴う肝細胞癌の1例
    八田 寛朗; 萩原 智; 上嶋 一臣; 大丸 直哉; 松原 卓哉; 盛田 真弘; 千品 寛和; 田北 雅弘; 南 康範; 依田 広; 渡邉 智裕; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 119回 99 - 99 日本消化器病学会-近畿支部 2023年09月
  • 新型コロナワクチン接種後にIgA血管炎を発症し、コロナ感染を契機に再燃を繰り返した1例
    勝部 滉平; 永井 知行; 駒谷 真; 有山 武尊; 栗本 真之; 岡井 夏輝; 吉田 早希; 半田 康平; 正木 翔; 河野 匡志; 米田 頼晃; 本庶 元; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 119回 91 - 91 日本消化器病学会-近畿支部 2023年09月
  • Masatoshi Kudo
    Liver cancer 12 4 289 - 296 2023年09月
  • Philippe Merle; Masatoshi Kudo; Julien Edeline; Mohamed Bouattour; Ann-Lii Cheng; Stephen L Chan; Thomas Yau; Marcelo Garrido; Jennifer Knox; Bruno Daniele; Valeriy Breder; Ho Yeong Lim; Sadahisa Ogasawara; Stéphane Cattan; Yee Chao; Abby B Siegel; Iván Martinez-Forero; Ziwen Wei; Chih-Chin Liu; Richard S Finn
    Liver cancer 12 4 309 - 320 2023年09月 
    INTRODUCTION: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported. METHODS: Adults with sorafenib-treated advanced HCC were randomized 2:1 to pembrolizumab 200 mg intravenously every 3 weeks or placebo. Dual primary endpoints were OS and PFS assessed per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included objective response rate (ORR), assessed per RECIST v1.1 by BICR, and safety. RESULTS: 413 patients were randomized (pembrolizumab, n = 278; placebo, n = 135). As of July 13, 2020, median (range) time from randomization to data cutoff was 39.6 (31.7-48.8) months for pembrolizumab and 39.8 (31.7-47.8) months for placebo. Estimated OS rates (95% CI) were 17.7% (13.4-22.5%) for pembrolizumab and 11.7% (6.8-17.9%) for placebo at 36 months. The estimated PFS rate (95% CI) for pembrolizumab was 8.9% (5.3-13.6%) and 0% for placebo at 36 months. ORR (95% CI) was 18.3% (14.0-23.4%) for pembrolizumab and 4.4% (1.6-9.4%) for placebo. Immune-mediated hepatitis events did not increase with follow-up. No viral hepatitis flare events were reported. CONCLUSION: With extended follow-up, pembrolizumab continued to maintain improvement in OS and PFS and was associated with a consistent adverse event profile compared with placebo in patients with sorafenib-treated advanced HCC. Although KEYNOTE-240 did not meet prespecified statistical significance criteria at the final analysis, these results together with the antitumor activity of second-line pembrolizumab observed in KEYNOTE-224 and the statistically significant and clinically meaningful OS and PFS benefits of second-line pembrolizumab in patients from Asia observed in KEYNOTE-394 reinforce the clinical activity of pembrolizumab in previously treated patients with advanced HCC.
  • 【早わかり消化器内視鏡関連ガイドライン2023】胆膵 IPMN国際診療ガイドライン
    山崎 友裕; 鎌田 研; 大本 俊介; 三長 孝輔; 竹中 完; 樫田 博史; 工藤 正俊
    消化器内視鏡 35 9 1310 - 1316 (株)東京医学社 2023年09月
  • Yasuo Otsuka; Kosuke Minaga; Akane Hara; Yasuhiro Masuta; Mamoru Takenaka; Masatoshi Kudo
    Endoscopy international open 11 9 E811-E813  2023年09月
  • Mamoru Takenaka; Tae Hoon Lee; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2023年08月
  • Laurent Peyrin-Biroulet; Jessica R Allegretti; David T Rubin; Brian Bressler; Matthew Germinaro; Kuan-Hsiang Gary Huang; Nicole Shipitofsky; Hongyan Zhang; Rebbecca Wilson; Chenglong Han; Brian G Feagan; William J Sandborn; Julian Panés; Tadakazu Hisamatsu; Gary R Lichtenstein; Bruce E Sands; Axel Dignass; Orest Abrahamovych; Halyna Afanasieva; Lilia Aitova; Engin Altintas; Romain Altwegg; Pavel Andreev; Kazuki Aomatsu; Monika Augustyn; Paola Balestrieri; Jakob Begun; Luciana Brunatto; Diego Bulgheroni; Elena Bunkova; Mercedes Cabello; Qian Cao; Flavio Caprioli; Rute Cerqueira; Baili Chen; Chou-Chen Chen; Chou-Pin Chen; Cheng-Tang Chiu; Chang Hwan Choi; Michele Cicala; Olena Datsenko; Pieter Dewint; Eugeni Domenech; Joris Dutré; George Duvall; Juan Fernandez; Rafal Filip; Ronald Fogel; Sharyle Fowler; Toshimitsu Fujii; Masayuki Fukata; Yohei Furumoto; Antonio Gasbarrini; Beata Gawdis-Wojnarska; Cyrielle Gilletta; Paolo Gionchetti; Eran Goldin; Oleksandr Golovchenko; Maciej Gonciarz; Can Gonen; Gaston Gonzalez Segura; Oleksii Gridnyev; Tibor Gyokeres; Xavier Hébuterne; Charlotte Hedin; Per Hellström; Ida Normiha Hilmi; Ivo Horný; Gyula Horvat; Namiko Hoshi; Ludek Hrdlicka; Shunji Ishihara; Olha Ivanishyn; Byung Ik Jang; Odery Junior; Takashi Kagaya; Shuji Kanmura; Marina Karakina; Nakai Katsuhiko; Jaroslaw Kierkus; Hyo Jong Kim; Tae-Oh Kim; Young-Ho Kim; Gyula G Kiss; Jochen Klaus; Dariusz Kleczkowski; Maria Klopocka; Taku Kobayashi; Iwona Kobielusz-Gembala; Ja Seol Koo; Adam Kopon; Tetiana Kravchenko; Masatoshi Kudo; Kwang An Kwon; Paula Lago; David Laharie; Ian Lawrance; Jaroslaw Leszczyszyn; Yan Li; Milan Lukas; Christian Maaser; Atsuo Maemoto; Hiroyuki Marusawa; Matthew McBride; Shoba Mendu; Pal Miheller; Hideharu Miyabayashi; Wolfgang Mohl; Gregory Moore; Satoshi Motoya; Narayanachar Murali; Mohammed Naem; Koichi Nakajima; Yasunari Nakamoto; Stéphane Nancey; Joaquim Neto; Michio Onizawa; Yohei Ono; Yohei Ono; Taro Osada; Marina Osipenko; Danuta Owczarek; Bhaktasharan Patel; Kamal Patel; Elina Petrova; Elena Poroshina; Francisco Portela; Lyudmyla Prystupa; Monserrat Rivero; Xavier Roblin; Jacek Romatowski; Grazyna Rydzewska; Simone Saibeni; Hirotake Sakuraba; Mark Samaan; Michael Schultz; Joerg Schulze; Shahriar Sedghi; Ursula Seidler; Sung Jae Shin; Mykola Stanislavchuk; David Stokesberry; Takayoshi Suzuki; Hiroki Taguchi; Lyudmila Tankova; Lena Thin; Alexander Tkachev; Leyanira Torrealba; Nataliia Tsarynna; Zsolt Tulassay; Tetsuya Ueo; Ekaterina Valuyskikh; Olga Vasilevskaya; Manuel Viamonte; Shu-Chen Wei; Roni Weisshof; Katarzyna Wojcik; Byong Duk Ye; Hsu-Heng Yen; Hyuk Yoon; Kosuke Yoshida; Andriy Yurkiv; Osamu Zaha; Qiang Zhan
    Gastroenterology 2023年08月 
    BACKGROUND & AIMS: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, or advanced therapy. METHODS: In this double-blind, placebo-controlled, dose-ranging, induction study, patients were randomized (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0/4/8. The primary endpoint was clinical response (compared with baseline, modified Mayo score decrease ≥30% and ≥2 points, rectal bleeding subscore ≥1-point decrease or subscore of 0/1) at week 12. Guselkumab and placebo week-12 clinical nonresponders received subcutaneous or intravenous guselkumab 200 mg, respectively, at weeks 12/16/20 (uncontrolled study period). RESULTS: The primary analysis population included patients with baseline modified Mayo scores ≥5 and ≤9 (intravenous guselkumab 200 mg, N=101; 400 mg, N=107; placebo, N=105). Week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) versus placebo (27.6%; both P<.001). Greater proportions of guselkumab-treated versus placebo-treated patients achieved all major secondary endpoints (clinical remission, symptomatic remission, endoscopic improvement, histo-endoscopic mucosal improvement, and endoscopic normalization) at week 12. Among guselkumab week-12 clinical nonresponders, 54.3% and 50.0% of patients in the 200 and 400 mg groups, respectively, achieved clinical response at week 24. Safety was similar among guselkumab and placebo groups. CONCLUSIONS: Guselkumab intravenous induction was effective versus placebo in patients with moderately to severely active UC. Guselkumab was safe, and efficacy and safety were similar between guselkumab dose groups.
  • Shunsuke Omoto; Mamoru Takenaka; Tomohiro Fukunaga; Ayana Okamoto; Yoriaki Komeda; Seok Jeong; Masatoshi Kudo
    Endoscopy 55 S 01 E1012 - E1014 2023年08月
  • Enrui Xie; Yee Hui Yeo; Bernhard Scheiner; Yue Zhang; Atsushi Hiraoka; Xinxing Tantai; Petros Fessas; Tiago de Castro; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Shuo Xu; Hong-Ming Tsai; Swetha Kambhampati; Wenjun Wang; Bridget P Keenan; Xu Gao; Zixuan Xing; Matthias Pinter; Yih-Jyh Lin; Zhanjun Guo; Arndt Vogel; Takaaki Tanaka; Hsin-Yu Kuo; Robin K Kelley; Masatoshi Kudo; Ju Dong Yang; David J Pinato; Fanpu Ji
    JAMA oncology 2023年08月 
    IMPORTANCE: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with advanced HCC and impaired liver function are scarce. OBJECTIVE: To conduct a systematic review and meta-analysis to determine the efficacy and safety of ICI treatment for advanced HCC with Child-Pugh B liver function. DATA SOURCES: PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant studies from inception through June 15, 2022. STUDY SELECTION: Randomized clinical trials, cohort studies, or single-group studies that investigated the efficacy or safety of ICI therapy for Child-Pugh B advanced HCC were included. DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline was followed to extract data. A random-effects model was adopted if the heterogeneity was significant (I2 > 50%); otherwise, a fixed-effect model was used. MAIN OUTCOMES AND MEASURES: The objective response rate (ORR) and overall survival (OS) were considered to be the primary efficacy outcomes of ICI treatment for Child-Pugh B advanced HCC, and the incidence of treatment-related adverse events (trAEs) was set as the primary measure for the safety outcome. RESULTS: A total of 22 studies including 699 patients with Child-Pugh B and 2114 with Child-Pugh A advanced HCC comprised the analytic sample (median age range, 53-73 years). Upon pooled analysis, patients treated with ICIs in the Child-Pugh B group had an ORR of 14% (95% CI, 11%-17%) and disease control rate (DCR) of 46% (95% CI, 36%-56%), with a median OS of 5.49 (95% CI, 3.57-7.42) months and median progression-free survival of 2.68 (95% CI, 1.85-3.52) months. The rate of any grade trAEs in the Child-Pugh B group was 40% (95% CI, 34%-47%) and of grade 3 or higher trAEs was 12% (95% CI, 6%-23%). Compared with the Child-Pugh A group, the ORR (odds ratio, 0.59; 95% CI, 0.43-0.81; P < .001) and DCR (odds ratio, 0.64; 95% CI, 0.50-0.81; P < .001) were lower in the Child-Pugh B group. Child-Pugh B was independently associated with worse OS in patients with advanced HCC treated with ICIs (hazard ratio, 2.72 [95% CI, 2.34-3.16]; adjusted hazard ratio, 2.33 [95% CI, 1.81-2.99]). However, ICIs were not associated with increased trAEs in the Child-Pugh B group. CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis suggest that although the safety of ICI treatment was comparable between patients with HCC with vs without advanced liver disease and the treatment resulted in a significant number of radiologic responses, survival outcomes are still inferior in patients with worse liver function. More study is needed to determine the effectiveness of ICI treatment in this population.
  • Ken Kamata; Mamoru Takenaka; Naoshi Nishida; Akane Hara; Yasuo Otsuka; Hidekazu Tanaka; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Yasutaka Chiba; Kazuko Sakai; Kazuto Nishio; Tomohiro Watanabe; Masatoshi Kudo
    International journal of clinical oncology 28 11 1511 - 1519 2023年08月 
    BACKGROUND: This prospective cohort study evaluated the feasibility of using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) samples for comprehensive mutational analysis of cancer-related genes using microtissues. METHODS: Fifty patients with suspected pancreatic cancer presenting consecutively at the Kindai University Hospital between January 2018 and January 2019 were enrolled. Cancerous tissues from EUS-FNB were obtained from each tumor and subjected to histological examination and mutational analysis. The primary endpoint was the collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing. Clinical history and genetic variations between the disease control and progressive disease groups of patients on chemotherapy were evaluated as secondary endpoints. RESULTS: The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. The cancer panel was sequenced for 25 patients with pancreatic cancer treated initially with systemic chemotherapy. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020). CONCLUSIONS: Tissue samples from EUS-FNB were suitable for mutational analysis. Pancreatic cancers with p53 and without Smad4 mutations responded better to chemotherapy and had a better prognosis than those others.
  • Hiroko Iijima; Masatoshi Kudo; Shoji Kubo; Masayuki Kurosaki; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Osamu Nakashima; Takumi Fukumoto; Yutaka Matsuyama; Takamichi Murakami; Arata Takahashi; Hiroaki Miyata; Norihiro Kokudo
    Hepatology research : the official journal of the Japan Society of Hepatology 53 10 895 - 959 2023年08月 
    In the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20,889 newly registered patients and 42,274 previously registered follow-up patients were compiled from 516 institutions over a 2-year period from 1 January 2014 to 31 December 2015. Basic statistics compiled for patients newly registered in the 23rd survey was cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 22nd survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular cholangiocarcinoma (combined HCC and ICC) by treatment type and background characteristics for patients newly registered between 2004 and 2015 whose final outcome was survival or death. Median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, Child-Pugh grade, or ALBI grade) and by treatment type (hepatectomy, radiofrequency ablation therapy [RFA], transcatheter arterial chemoembolization [TACE], hepatic arterial infusion chemotherapy [HAIC] and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2015 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world. This article is protected by copyright. All rights reserved.
  • Hideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hiroshi Shibata; Tomoko Aoki; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
    Oncology 101 9 1 - 11 2023年08月 
    INTRODUCTION: Systemic treatment is generally recommended for Child-Pugh (CP) A status patients with an unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate differences regarding therapeutic efficacy between lenvatinib (LEN), a multi-molecular target agent, and atezolizumab plus bevacizumab (Atez/Bev), a newly developed immune-combined therapeutic regimen for CP-B patients affected by uHCC. METHODS: From April 2018 to July 2022, 128 patients with uHCC treated with Atez/Bev (n = 29) or LEN (n = 99) as the initial systemic treatment were enrolled (median age 71 years; males 97; CP score 7:8:9 = 94:28:6; median albumin-bilirubin score -1.71). Therapeutic response was evaluated using RECIST, version 1.1. Clinical features and prognosis were retrospectively examined. RESULTS: There were no significant differences between the Atez/Bev and LEN groups in regard to best response (CR:PR:SD:PD = 0:5:12:7 vs. 5:22:25:20, p = 0.415), progression-free survival (PFS) (median 5.0 [95% CI: 2.4-7] vs. 5.5 [95% CI: 3.4-7.9] months, p = 0.332), or overall survival (OS) (5.8 [95% CI: 4.3-11] vs. 8.8 [95% CI: 6.1-12.9] months, p = 0.178). Adverse events (any grade/≥ grade 3) were observed in 72.4%/17.2% (n = 21/5) of patients treated with Atez/Bev and 78.8%/25.3% (n = 78/25) of those treated with LEN (p = 0.46/0.46). DISCUSSION: This retrospective study found no significant differences regarding PFS or OS between CP-B patients given Atez/Bev or LEN as initial systemic treatment for uHCC.
  • Masashi Kono; Yoriaki Komeda; George Tribonias; Saki Yoshida; Kenji Nomura; Kohei Handa; Tomoyuki Nagai; Satoru Hagiwara; Shunsuke Omoto; Mamoru Takenaka; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi Kudo
    JGH Open 7 8 579 - 583 2023年08月 
    Abstract Background and Aim Serum leucine‐rich alpha‐2 glycoprotein level has been reported to be a useful biomarker in assessing mucosal healing in patients undergoing biotherapy, where mucosal lesions caused by ulcerative colitis are difficult to assess endoscopically. However, no such reports have been reported in biotherapy‐naïve cases. Methods Sixty‐eight patients with ulcerative colitis (UC) who were biotherapy‐naïve at Kindai University Hospital between October 2021 and October 2022 were enrolled. We prospectively examined the correlation between leucine‐rich alpha‐2 glycoprotein (LRG), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Geboes scores with clinical endoscopic activity using the Mayo endoscopic subscore (MES). Results Mucosal healing was achieved in 39 (57%) patients. Univariate analysis revealed that the factors associated with mucosal healing were LRG (P = 0.0024), CRP (P = 0.1078), ESR (P = 0.0372), and Geboes scores (P = 0.0075). Logistic regression analysis identified LRG and Geboes scores as independent factors associated with mucosal healing assessed using MES (P = 0.0431 for LRG and P = 0.0166 for Geboes scores). Conclusion LRG was found to be the easiest marker to monitor disease activity and mucosal inflammation in UC patients with biotherapy‐naïve cases, with a performance equivalent to that of Geboes scores.
  • 異所性静脈瘤の治療戦略 異所性静脈瘤に対する内視鏡治療の検討
    松井 繁長; 樫田 博史; 工藤 正俊
    日本門脈圧亢進症学会雑誌 29 3 71 - 71 (一社)日本門脈圧亢進症学会 2023年08月
  • 異所性静脈瘤の治療戦略 十二指腸静脈瘤の血行動態とIVR治療
    鶴崎 正勝; 小寺 卓; 上月 瞭平; 浦瀬 篤史; 逢坂 友也; 松井 繁長; 杉本 幸司; 石井 一成; 工藤 正俊
    日本門脈圧亢進症学会雑誌 29 3 73 - 73 (一社)日本門脈圧亢進症学会 2023年08月
  • 異所性静脈瘤の治療戦略 異所性静脈瘤に対する内視鏡治療の検討
    松井 繁長; 樫田 博史; 工藤 正俊
    日本門脈圧亢進症学会雑誌 29 3 71 - 71 (一社)日本門脈圧亢進症学会 2023年08月
  • 異所性静脈瘤の治療戦略 十二指腸静脈瘤の血行動態とIVR治療
    鶴崎 正勝; 小寺 卓; 上月 瞭平; 浦瀬 篤史; 逢坂 友也; 松井 繁長; 杉本 幸司; 石井 一成; 工藤 正俊
    日本門脈圧亢進症学会雑誌 29 3 73 - 73 (一社)日本門脈圧亢進症学会 2023年08月
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Masaki Kaibori; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Hisashi Kosaka; Yoichi Hiasa; Masatoshi Kudo
    Liver cancer 12 3 209 - 217 2023年08月 
    BACKGROUND/AIM: There is no known report regarding the relationship of atezolizumab plus bevacizumab (Atez/Bev) treatment with muscle volume loss (MVL) in unresectable hepatocellular carcinoma (u-HCC) patients. This study aimed to elucidate the clinical relationship between MVL and Atez/Bev. MATERIALS/METHODS: From September 2020 to December 2021, 229 u-HCC patients treated with Atez/Bev and with muscle volume data obtained by computed tomography at the baseline available were analyzed (median age, 74 years; males, 186 (81.2%); ECOG PS 0/1, 221 (96.5%); HCV:HBV:alcohol:others = 81:33:40:75; Child-Pugh A, 212 (92.6%); modified albumin-bilirubin (mALBI) grade 1:2a:2b = 79:60:90; BCLC 0:A:B:C = 1:24:87:117; median observation period, 6.8 months). Japan Society of Hepatology criteria were used for definition of MVL and prognostic factors were retrospectively evaluated. RESULTS: Multivariate Cox-hazard analysis of prognostic factors for progression-free survival (PFS) showed elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 1.848, 95% CI 1.264-2.702, p = 0.002), mALBI grade (≥2a) (HR 1.563, 95% CI 1.035-2.359, p = 0.034), and MVL (HR 1.479, 95% CI 1.020-2.144, p = 0.039) as significant factors. For overall survival (OS), significant factors included elevated AFP (≥100 ng/mL) (HR 3.564, 95% CI 1.856-6.844, p < 0.001), mALBI grade (≥2a) (HR 3.451, 95% CI 1.580-7.538, p = 0.002), and MVL (HR 2.119, 95% CI 1.150-3.904, p = 0.016). Patients with MVL (MVL group, n = 91) showed worse PFS than those without (non-MVL group, n = 138) (median PFS 5.3 vs. 7.6 months, p = 0.025), while the MVL group showed worse OS (p = 0.038), though neither reached the median survival time. CONCLUSION: MVL may be a clinical factor related to poor prognosis in patients receiving Atez/Bev treatment for u-HCC.
  • Masatoshi Kudo; Richard S Finn; Peter R Galle; Andrew X Zhu; Michel Ducreux; Ann-Lii Cheng; Masafumi Ikeda; Kaoru Tsuchiya; Ken-Ichi Aoki; Jing Jia; Riccardo Lencioni
    Liver cancer 12 3 238 - 250 2023年08月 
    INTRODUCTION: The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease. METHODS: Patients with systemic treatment-naive unresectable HCC and Child-Pugh class A liver function were randomized 2:1 to receive 1,200 mg of atezolizumab plus 15 mg/kg of bevacizumab or 400 mg of sorafenib. Co-primary endpoints were overall survival (OS) and progression-free survival (PFS) per independent review facility (IRF)-assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in the BCLC stage B subgroup. Patients in this analysis had BCLC stage B disease at baseline per electronic case report form. Secondary efficacy endpoints included the objective response rate (ORR) and change in the sum of longest diameters (SLD) of target lesions from baseline per IRF RECIST 1.1 and modified RECIST (mRECIST) for HCC. RESULTS: Of 501 enrolled patients, 74 (15%) had BCLC stage B disease at baseline (atezolizumab + bevacizumab, n = 49; sorafenib, n = 24). For this group, median follow-up was 19.7 months. A trend toward improved OS and PFS per IRF RECIST 1.1 was observed with atezolizumab + bevacizumab versus sorafenib (OS: hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.29, 1.34; PFS: HR: 0.64; 95% CI: 0.36, 1.12). ORRs per IRF RECIST 1.1 and HCC mRECIST were 43% and 50% with atezolizumab + bevacizumab and 26% and 30% with sorafenib, respectively. Percentage change in SLD of target lesions from baseline per IRF RECIST 1.1 and HCC mRECIST showed durable responses with atezolizumab + bevacizumab treatment. Safety data were consistent with known profiles of atezolizumab and bevacizumab, as seen in the overall study population. DISCUSSION/CONCLUSION: Efficacy benefits were observed with atezolizumab + bevacizumab in patients with baseline BCLC stage B disease, consistent with the intention-to-treat population.
  • Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Takashi Niizeki; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Bernardo Stefanini; Atsushi Hiraoka; Takuya Sho; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Claudia Campani; Elisabeth Amadeo; Federico Rossari; Valentina Burgio; Stefano Cascinu; Mario Scartozzi; Andrea Casadei-Gardini
    European journal of cancer (Oxford, England : 1990) 189 112933 - 112933 2023年08月 
    INTRODUCTION: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab. MATERIALS AND METHODS: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line. RESULTS: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6months) and atezolizumab plus bevacizumab first-line (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who underwent trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8months, p < 0.01; HR=0.64). After atezolizumab plus bevacizumab first-line, there was a statistical difference between second-line therapy subgroups (p < 0.01; sorafenib HR: 1; lenvatinib HR: 0.50; cabozantinib HR: 1.29; other therapies HR: 0.54). Patients who received lenvatinib (17.0months) and those who underwent TACE (15.9months) had a significative longer OS than patients treated with sorafenib (14.2months; respectively, p = 0.01; HR=0.45, and p < 0.05; HR=0.46). CONCLUSION: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy.
  • Bachir Taouli; Ahmed Ba-Ssalamah; Julius Chapiro; Jagpreet Chhatwal; Kathryn Fowler; Tae Wook Kang; Gesine Knobloch; Dow-Mu Koh; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; David J Pinato; Kristina I Ringe; Bin Song; Parissa Tabrizian; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Valérie Vilgrain
    European radiology 2023年07月 
    The 10th Global Forum for Liver Magnetic Resonance Imaging was held in October 2021. The themes of the presentations and discussions at this Forum are described in detail in the review by Taouli et al (2023). The focus of this second manuscript developed from the Forum is on multidisciplinary tumor board perspectives in hepatocellular carcinoma (HCC) management: how to approach early-, mid-, and late-stage management from the perspectives of a liver surgeon, an interventional radiologist, and an oncologist. The manuscript also includes a panel discussion by multidisciplinary experts on three selected cases that explore challenging aspects of HCC management. CLINICAL RELEVANCE STATEMENT: This review highlights the importance of a multidisciplinary team approach in liver cancer patients and includes the perspectives of a liver surgeon, an interventional radiologist, and an oncologist, including illustrative case studies. KEY POINTS: • A liver surgeon, interventional radiologist, and oncologist presented their perspectives on the treatment of early-, mid-, and late-stage HCC. • Different perspectives on HCC management between specialties emphasize the importance of multidisciplinary tumor boards. • A multidisciplinary faculty discussed challenging aspects of HCC management, as highlighted by three case studies.
  • 急性膵炎の致命率改善への集学的治療 地域連携モデル構築による重症急性膵炎死亡率低減への取り組み
    竹中 完; 大本 俊介; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 38 3 A169 - A169 (一社)日本膵臓学会 2023年07月
  • 地域連携システムを用いた南大阪地区早期膵癌発見・診断プロジェクト
    吉田 晃浩; 竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 38 3 A370 - A370 (一社)日本膵臓学会 2023年07月
  • 急性膵炎の致命率改善への集学的治療 地域連携モデル構築による重症急性膵炎死亡率低減への取り組み
    竹中 完; 大本 俊介; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 38 3 A169 - A169 (一社)日本膵臓学会 2023年07月
  • 地域連携システムを用いた南大阪地区早期膵癌発見・診断プロジェクト
    吉田 晃浩; 竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 38 3 A370 - A370 (一社)日本膵臓学会 2023年07月
  • Yasuhiro Masuta; Kosuke Minaga; Yasuo Otsuka; Mamoru Takenaka; Masatoshi Kudo
    Endoscopy international open 11 7 E651-E652  2023年07月
  • Daizen Hirata; Hiroshi Kashida; Tsuguhiro Matsumoto; Chikara Ebisutani; Akira Teramoto; Mineo Iwatate; Santa Hattori; Mikio Fujita; Wataru Sano; Yoriaki Komeda; Yasushi Sano; Yoshitaka Murakami; Masatoshi Kudo
    Gastrointestinal Endoscopy 97 6 AB447 - AB448 2023年06月
  • Masatoshi Kudo; Kazuomi Ueshima; Issei Saeki; Toru Ishikawa; Yoshitaka Inaba; Naoki Morimoto; Hiroshi Aikata; Nobukazu Tanabe; Yoshiyuki Wada; Yasuteru Kondo; Masahiro Tsuda; Kazuhiko Nakao; Takanori Ito; Tetsuya Hosaka; Yusuke Kawamura; Teiji Kuzuya; Shunsuke Nojiri; Chikara Ogawa; Hironori Koga; Keisuke Hino; Masafumi Ikeda; Michihisa Moriguchi; Takashi Hisai; Kenichi Yoshimura; Junji Furuse; Yasuaki Arai
    LIVER CANCER 13 1 99 - 112 2023年06月 
    Background:Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better ORR than sorafenib (jRCTs031180074). Patients and Methods:Participants were patients with HCC who had not previously received systemic therapy, hepatic arterial infusion chemotherapy, or immunotherapy, and who were ineligible for resection or percutaneous ablation therapy. LEN was to be administered 14-21 days before the first TACE, stopped 2 days before TACE, and resumed 3 days after TACE. Key inclusion criteria were unresectable HCC, Child-Pugh A liver function, 0-2 prior TACE sessions, tumor size <= 10 cm, number of tumors <= 10, and ECOG performance status 0-1. Key exclusion criteria were vascular invasion and extrahepatic spread. The primary endpoint was PFS by RECICL, and secondary endpoints were time to untreatable progression, objective response rate (ORR), OS, and safety. Results:A total of 62 HCC patients were enrolled in this trial. The median age was 72 years, 77.4% of patients were men, and 95.2% had PS 0. The primary endpoint of median PFS was 28.0 months (95% CI 25.1-31.0) after a minimum 24 months of follow-up. The secondary endpoint of median OS was not reached (95% CI 35.5 months-NR). LEN-TACE achieved a high response rate and high CR rate (4 weeks after the first TACE: ORR 79.0%, CR rate 53.2%; best response: ORR 88.7%, CR rate 67.7%) by RECICL. Exploratory subgroup analyses showed that the characteristics of responders/nonresponders (ORR and CR) were similar, and that LEN-TACE would be effective in all subgroups, including the population in whom TACE alone would be less likely to be curative (e.g., patients with the nonsimple nodular type or a high tumor burden). The relative dose intensity of LEN before the first TACE was important for achieving higher CR/ORR by LEN-TACE. No new safety concerns were observed. Conclusion:The results of this trial provide encouraging evidence supporting the efficacy and favorable safety profile of LEN-TACE in patients who are ineligible for locoregional therapy.
  • Masatoshi Kudo
    Hepatobiliary surgery and nutrition 12 3 435 - 439 2023年06月
  • Tomohiro Watanabe; Kosuke Minaga; Hajime Honjo; Masatoshi Kudo
    Biochemical and Biophysical Research Communications 674 117 - 123 2023年06月 
    The liver is a tolerogenic organ that exhibits hypo-responsiveness to antigens circulating in the portal vein. Antigens that are orally administered at high doses reach the liver. In our previous study, we demonstrated that administering ovalbumin (OVA) orally at high doses generates unique CD4+ T cells and tolerogenic dendritic cells, both of which can suppress T helper type 1 (Th1) responses, in the livers of two groups of mice: DO11.10 mice with transgenic CD4+ T cell receptors for OVA and BALB/c mice that received OVA-specific CD4+ T cells through adoptive transfer. This study aimed to investigate whether oral administration of OVA at high doses inhibits the development of hepatitis in the presence of OVA-specific CD4+ T cells. Oral administration of OVA at high doses inhibited the development of OVA-specific and concanavalin A (Con A)-induced hepatitis in DO11.10 mice, and these effects were associated with the downregulation of Th1 responses. Furthermore, the adoptive transfer of CD4+ T cells from the liver of OVA-fed DO11.10 mice inhibited the development of Con A-induced hepatitis in recipient BALB/c mice through the downregulation of Th1 responses. Finally, oral administration of OVA at high doses inhibited the development of Con A-induced hepatitis in BALB/c mice bearing naïve OVA-specific CD4+ T cells. These results suggest that the oral administration of antigens at high doses suppresses Th1-mediated hepatitis in an antigen-non-specific manner in the presence of antigen-specific CD4+ T cells.
  • Philippe Merle; Masatoshi Kudo; Stanimira Krotneva; Kirhan Ozgurdal; Yun Su; Irina Proskorovsky
    Liver cancer 12 2 145 - 155 2023年06月 
    INTRODUCTION: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or safety to guide choice between the two treatments. METHODS: We conducted an anchored matching-adjusted indirect comparison using individual patient data from the RESORCE trial of regorafenib and published aggregate data from the CELESTIAL trial of cabozantinib. Second-line HCC patients with prior sorafenib exposure of ≥3 months were included in the analyses. Hazard ratios (HRs) and restricted mean survival time (RMST) were estimated to quantify differences in overall survival (OS) and progression-free survival (PFS). Safety outcomes compared were rates of grade 3 or 4 adverse events (AEs), occurring in >10% of patients, and discontinuation or dose reduction due to treatment-related AEs. RESULTS: After matching adjustment for differences in baseline patient characteristics, regorafenib showed a favorable OS (HR, 0.80; 95% CI: 0.54, 1.20) and ∼3-month-longer RMST over cabozantinib (RMST difference, 2.76 months; 95% CI: -1.03, 6.54), although not statistically significant. For PFS, there was no numerical difference in HR (HR, 1.00; 95% CI: 0.68, 1.49) and no clinically meaningful difference based on RMST analyses (RMST difference, -0.59 months; 95% CI: -1.83, 0.65). Regorafenib showed a significantly lower incidence of discontinuation (risk difference, -9.2%; 95% CI: -17.7%, -0.6%) and dose reductions (-15.2%; 95% CI: -29.0%, -1.5%) due to treatment-related AEs (any grade). Regorafenib was also associated with a lower incidence (not statistically significant) of grade 3 or 4 diarrhea (risk difference, -7.1%; 95% CI: -14.7%, 0.4%) and fatigue (-6.3%; 95% CI: -14.6%, 2.0%). CONCLUSION: This indirect treatment comparison suggests, relative to cabozantinib, that regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and discontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue.
  • Masatoshi Kudo
    Liver cancer 12 2 95 - 102 2023年06月
  • Bruno Sangro; Thomas Yau; Anthony B El-Khoueiry; Masatoshi Kudo; Yun Shen; Marina Tschaika; Amit Roy; Yan Feng; Ling Gao; Urvi Aras
    Clinical and translational science 2023年05月 
    This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib-experienced patients with hepatocellular carcinoma. CheckMate 040 is an open-label, multicohort, phase I/II trial in adults with advanced hepatocellular carcinoma that evaluated nivolumab monotherapy (0.1 to 10 mg/kg once every 2 weeks [Q2W]) and the following three combinations of nivolumab plus ipilimumab: (1) nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks (Q3W) for four doses, followed by nivolumab monotherapy 240 mg Q2W (arm A); (2) nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for four doses, followed by nivolumab monotherapy 240 mg Q2W (arm B); and (3) nivolumab 3 mg/kg Q2W plus ipilimumab 1 mg/kg every 6 weeks continuously (arm C). Exposure-response relationships (efficacy and safety) were characterized using nivolumab and ipilimumab concentrations after the first dose (Cavg1) as the exposure measure. Objective tumor response (OTR) and overall survival (OS) improvements were associated with increased ipilimumab exposure (OTR: odds ratio 1.45 [95% CI, 1.13-1.86]; OS: hazard ratio 0.86 [0.75-0.98]), but not nivolumab exposure (OTR: odds ratio 0.99 [0.97-1.02]; OS: hazard ratio 1.08 [0.89-1.32]). Hepatic treatment-related and immune-mediated adverse events were more common in arm A than in arms B or C. Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W for four doses, followed by nivolumab monotherapy 240 mg Q2W had the most favorable benefit:risk profile in patients with advanced hepatocellular carcinoma.
  • Ken Kamata; Akane Hara; Kosuke Minaga; Tomoe Yoshikawa; Masayuki Kurimoto; Ikue Sekai; Natsuki Okai; Naoya Omaru; Yasuhiro Masuta; Yasuo Otsuka; Ryutaro Takada; Shiki Takamura; Masatoshi Kudo; Warren Strober; Tomohiro Watanabe
    Clinical and Experimental Immunology 2023年05月 
    Abstract The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor expressed in hematopoietic and non-hematopoietic cells. Activation of the AhR by xenobiotics, microbial metabolites, and natural substances induces immunoregulatory responses. Autoimmune pancreatitis (AIP) is a chronic fibroinflammatory disorder of the pancreas driven by autoimmunity. Although AhR activation generally suppresses pathogenic autoimmune responses, the roles played by the AhR in AIP have been poorly defined. In this study, we examined how AhR activation affected the development of experimental AIP caused by the activation of plasmacytoid dendritic cells producing IFN-α and IL-33. Experimental AIP was induced in MRL/MpJ mice by repeated injections of polyinosinic-polycytidylic acid. Activation of the AhR by indole-3-pyruvic acid and indigo naturalis, which were supplemented in the diet, inhibited the development of experimental AIP, and these effects were independent of the activation of plasmacytoid dendritic cells producing IFN-α and IL-33. Interaction of indole-3-pyruvic acid and indigo naturalis with AhRs robustly augmented the production of IL-22 by pancreatic islet α cells. The blockade of IL-22 signaling pathways completely canceled the beneficial effects of AhR ligands on experimental AIP. Serum IL-22 concentrations were elevated in patients with type 1 AIP after the induction of remission with prednisolone. These data suggest that AhR activation suppresses chronic fibroinflammatory reactions that characterize AIP via IL-22 produced by pancreatic islet α cells.
  • Hajime Honjo; Yasuhiro Masuta; Yasuo Otsuka; Sho Masaki; Kosuke Minaga; Masatoshi Kudo; Tomohiro Watanabe
    DEN Open 4 1 e222  2023年05月 [査読有り]
     
    Although prednisolone treatment is effective in Cronkhite-Canada syndrome (CCS), its mechanisms of action are poorly understood. We performed analyses of cytokine expression and fecal microbiota in a patient with the concurrent occurrence of CCS and rectal cancer, in whom regression of polyposis was achieved by prednisolone. Regression of CCS polyps was accompanied by downregulation of proinflammatory cytokine expression and alterations in microbiota composition; a decrease in Bacteroides fragilis and Peptostreptococcus anaerobius with the promotion of inflammation. We could not completely exclude the possibility that alterations in fecal microbiota composition might be influenced by the presence of advanced cancer. However, this case suggests that the administration of PSL might lead to the regression of CCS polyps through alterations in gut microbiota composition and suppression of proinflammatory cytokine responses.
  • Shunsuke Omoto; Mamoru Takenaka; Tomohiro Fukunaga; Kota Takashima; Yoriaki Komeda; Seok Jeong; Masatoshi Kudo
    Endoscopy 55 S 01 E698 - E699 2023年05月
  • Naoshi Nishida; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo
    Cancers 15 8 2023年04月 
    Cholangiocarcinoma (CCA) is a refractory cancer; a majority of CCAs represents a non-inflamed tumor phenotype that should be resistant to treatment, including immune checkpoint inhibitors (ICIs). In this study, we aimed to understand the molecular characteristics associated with non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was obtained from the Cancer Genome Atlas (PanCancerAtlas). CCAs were classified based on immune class using hierarchical clustering analysis of gene expressions related to tumor-infiltrating lymphocytes. The associations between immune class and genetic/epigenetic events were analyzed. We found that the tumors with alterations in FGFR2 and IDH1/2 had a "non-inflamed" tumor phenotype. A significant association was observed between the non-inflamed group and the downregulation of genes involved in antigen presentation (p = 0.0015). The expression of antigen-presenting machineries was inversely correlated with their DNA methylation levels, where 33.3% of tumors had an upregulation/low-methylation pattern, and 66.7% of tumors had a downregulation/high-methylation pattern. All tumors in the "inflamed" group exhibited an upregulation/low-methylation pattern. In contrast, 24 of 30 tumors in the non-inflamed group represent the downregulation/high-methylation pattern (p = 0.0005). Methylation with downregulation of antigen-presenting machineries is associated with the "non-inflamed" tumor phenotype of CCAs. This evidence provides important insights for developing new strategies for treating CCA.
  • Masahiro Morita; Naoshi Nishida; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo
    Cancers 15 8 2023年04月 
    Recently, the therapeutic combination of atezolizumab and bevacizumab was widely used to treat advanced hepatocellular carcinoma (HCC). According to recent clinical trials, immune checkpoint inhibitors (ICIs) and molecular target agents are expected to be key therapeutic strategies in the future. Nonetheless, the mechanisms underlying molecular immune responses and immune evasion remain unclear. The tumor immune microenvironment plays a vital role in HCC progression. The infiltration of CD8-positive cells into tumors and the expression of immune checkpoint molecules are key factors in this immune microenvironment. Specifically, Wnt/β catenin pathway activation causes "immune exclusion", associated with poor infiltration of CD8-positive cells. Some clinical studies suggested an association between ICI resistance and β-catenin activation in HCC. Additionally, several subclassifications of the tumor immune microenvironment were proposed. The HCC immune microenvironment can be broadly divided into inflamed class and non-inflamed class, with several subclasses. β-catenin mutations are important factors in immune subclasses; this may be useful when considering therapeutic strategies as β-catenin activation may serve as a biomarker for ICI. Various types of β-catenin modulators were developed. Several kinases may also be involved in the β-catenin pathway. Therefore, combinations of β-catenin modulators, kinase inhibitors, and ICIs may exert synergistic effects.
  • Masatoshi Kudo
    Hepatobiliary surgery and nutrition 12 2 256 - 260 2023年04月
  • 当院における難治性腹水に対するデンバーシャントの有用性
    浦瀬 篤史; 鶴崎 正勝; 小寺 卓; 上月 暸平; 平山 歩; 石井 一成; 青木 智子; 工藤 正俊
    日本インターベンショナルラジオロジー学会雑誌 38 Suppl. 143 - 143 (一社)日本インターベンショナルラジオロジー学会 2023年04月
  • 胃静脈瘤に対するCANDISを用いたB-RTOの中期成績と肝予備能温存における効果
    小寺 卓; 鶴崎 正勝; 浦瀬 篤史; 上月 瞭平; 平山 歩; 石井 一成; 青木 智子; 工藤 正俊
    日本インターベンショナルラジオロジー学会雑誌 38 Suppl. 216 - 216 (一社)日本インターベンショナルラジオロジー学会 2023年04月
  • 消化管がんに対する超音波診断(EUS含む) 当院におけるスキルス胃癌および下部消化管粘膜下腫瘍に対するEUS精査症例の検討
    田中 秀和; 鎌田 研; 高田 隆太郎; 三長 孝輔; 竹中 完; 松井 繁長; 樫田 博史; 工藤 正俊
    超音波医学 50 Suppl. S211 - S211 (公社)日本超音波医学会 2023年04月
  • 外科医療におけるビッグデータの有効活用 術後死亡予測率を指標とした肝細胞癌切除基準の確立 日本肝癌研究会全国集計データ解析
    荒牧 修; 松山 裕; 久保 正二; 國土 典宏; 黒崎 雅之; 村上 卓道; 椎名 秀一朗; 工藤 正俊; 坂元 亨宇; 中島 収; 福本 巧; 飯島 尋子; 江口 晋; 副島 雄二; 幕内 雅敏; 高山 忠利; 岡村 行泰
    日本外科学会定期学術集会抄録集 123回 PD - 4 (一社)日本外科学会 2023年04月
  • B型肝炎診療の未来予想図(現状と課題) 免疫チェックポイント阻害剤投与に伴うHBV再活性化および抗ウイルス効果についての検討
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.1 A51 - A51 (一社)日本肝臓学会 2023年04月
  • 遺伝・代謝性肝疾患の未来予想図(現状と課題) Erythropoietic porphyria(EPP)関連肝障害における瀉血治療の有効性
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.1 A111 - A111 (一社)日本肝臓学会 2023年04月
  • NASH/ASHの病態解明とTransrational Research 非アルコール性脂肪肝疾患におけるDNAメチル化に関連する臨床的・病理学的特徴
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.1 A208 - A208 (一社)日本肝臓学会 2023年04月
  • 非硬変肝から発生したFontan術後HCCの1例
    有山 武尊; 萩原 智; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.1 A324 - A324 (一社)日本肝臓学会 2023年04月
  • B型慢性肝炎患者に対するTAFの効果および安全性の検討
    萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.1 A425 - A425 (一社)日本肝臓学会 2023年04月
  • 高アンモニア血症に対するレボカルニチン自体の効果について
    萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 64 Suppl.1 A432 - A432 (一社)日本肝臓学会 2023年04月
  • 切除不能HCCに対するABC conversion療法と造影超音波によるclinical CRの補助診断
    青木 智子; 南 康範; 依田 広; 千品 寛和; 田北 雅弘; 萩原 智; 上嶋 一臣; 鶴崎 正勝; 西田 直生志; 工藤 正俊
    超音波医学 50 Suppl. S598 - S598 (公社)日本超音波医学会 2023年04月
  • 診断の鍵となる所見 膵・胆管合流異常の診断におけるEUS・造影ハーモニックEUSの意義の検討
    山崎 友裕; 鎌田 研; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 大本 俊介; 三長 孝輔; 竹中 完; 工藤 正俊
    超音波医学 50 Suppl. S200 - S200 (公社)日本超音波医学会 2023年04月
  • 膵腫瘍(嚢胞性疾患も)の超音波およびEUS診断 膵腫瘍の造影ハーモニックEUS診断
    鎌田 研; 大塚 康生; 田中 秀和; 中井 敦; 山崎 友裕; 大本 俊介; 三長 孝輔; 竹中 完; 北野 雅之; 工藤 正俊
    超音波医学 50 Suppl. S230 - S230 (公社)日本超音波医学会 2023年04月
  • 胆管病変に対するDetective flow imaging(DFI)の有用性について
    大本 俊介; 竹中 完; 吉田 晃浩; 福永 朋洋; 田中 秀和; 高島 耕太; 山崎 友裕; 三長 孝輔; 鎌田 研; 工藤 正俊
    超音波医学 50 Suppl. S586 - S586 (公社)日本超音波医学会 2023年04月
  • 消化管がんに対する超音波診断(EUS含む) 当院におけるスキルス胃癌および下部消化管粘膜下腫瘍に対するEUS精査症例の検討
    田中 秀和; 鎌田 研; 高田 隆太郎; 三長 孝輔; 竹中 完; 松井 繁長; 樫田 博史; 工藤 正俊
    超音波医学 50 Suppl. S211 - S211 (公社)日本超音波医学会 2023年04月
  • 希少疾患の内視鏡診断(全体) 弾性線維性仮性黄色腫に合併する消化管病変の内視鏡所見
    三長 孝輔; 山下 幸孝; 工藤 正俊
    Gastroenterological Endoscopy 65 Suppl.1 823 - 823 (一社)日本消化器内視鏡学会 2023年04月
  • 【US Today 2023 超音波検査・診断最前線 腹部領域の最新動向を中心に】腹部領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望
    西田 直生志; 工藤 正俊
    INNERVISION 38 5 40 - 43 (株)インナービジョン 2023年04月 
    医療ではリアルタイムの対応が必要な場合が多く,厳しい時間的制約の下でのタスクはヒューマンエラーにつながりやすい。一方,人工知能(AI)の導入により,医療関係者は多様なデータから適切に処理された必要な情報をわかりやすい形で得ることができるようになり,医療の効率化とヒューマンエラーの防止が期待できる。加えて,疾患診断のみならず,予後予測や最適な治療アプローチの提案など,超音波診断の分野でも,さまざまなタスクを行うAIモデルが報告されている。本稿では,腹部超音波診断をサポートするAIにフォーカスして,その開発状況を概説する。(著者抄録)
  • Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Tiziana Pressiani; Fabio Piscaglia; Takashi Kumada; Lorenza Rimassa; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Anticancer research 43 4 1599 - 1610 2023年04月 
    BACKGROUND/AIM: The purpose of this study was to ascertain a novel prognostic index via recursive partitioning analysis (RPA) in hepatocellular carcinoma (HCC) patients being treated with the combination of atezolizumab plus bevacizumab (ABE) in first-line setting. PATIENTS AND METHODS: A total of 784 patients with HCC were included in the analysis. RESULTS: RPA identified three groups of patients: high-risk [Child-Pugh B (CP-B) patients; CP-A and Albumin-Bilirubin (ALBI)-2 patients; CP-A and ALBI-1 patients with macrovascular invasion (MVI), and alpha-fetoprotein (α-FP) ≥400 ng/ml]; intermediate-risk [CP-A and ALBI-1 patients with aspartate aminotransferase (AST) normal value (NV), and αFP ≥400 ng/ml, but without MVI; CP-A and ALBI-1 patients with AST increased value (IV), and neutrophil-lymphocyte ratio (NLR) ≥3, but without MVI]; low-risk (CP-A and ALBI-1 patients with AST NV, and αFP <400 ng/ml, but without MVI; CP-A and ALBI-1 patients with AST IV, and NLR <3, but without MVI; CP-A and ALBI-1 patients with MVI, and αFP <400 ng/ml). Overall survival was 7.0 months in high-risk patients (20.8%), 14.2 months in intermediate-risk patients (19.1%), and 22.5 months in low-risk patients (60.1%). CONCLUSION: The ABE index allows for easy stratification of HCC patients treated with the combination of ABE in first-line setting.
  • Mathew Vithayathil; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Valentina Zanuso; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato; Rohini Sharma
    Hepatology international 2023年04月 
    BACKGROUND: Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC. METHODS: 191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated. RESULTS: Patients in the overweight cohort (n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort (n = 97). Baseline Child-Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2% vs. 22.0%; p = 0.44) and DCR (74.1% vs. 71.9%; p = 0.46). There were higher rates of atezolizumab-related fatigue (22.3% vs. 10.3%; p = 0.02) and bevacizumab-related thrombosis (8.5% vs. 2.1%; p = 0.045) in the overweight patients, but overall trAEs and treatment discontinuation were comparable between cohorts. CONCLUSION: Atezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD.
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    Cancers 15 7 2023年03月 
    Immune checkpoint inhibitors (ICIs) aim to induce immune responses against tumors and are less likely to develop drug resistance than molecularly targeted drugs. In addition, they are characterized by a long-lasting antitumor effect. However, since its effectiveness depends on the tumor's immune environment, it is essential to understand the immune environment of hepatocellular carcinoma to select ICI therapeutic indications and develop biomarkers. A network of diverse cellular and humoral factors establishes cancer immunity. By analyzing individual cases and classifying them from the viewpoint of tumor immunity, attempts have been made to select the optimal therapeutic drug for immunotherapy, including ICIs. ICI treatment is discussed from the viewpoints of immune subclass of HCC, Wnt/β-catenin mutation, immunotherapy in NASH-related HCC, the mechanism of HPD onset, and HBV reactivation.
  • Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Francesca Salani; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Marta Schirripa; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Journal of cancer research and clinical oncology 149 10 7565 - 7577 2023年03月 
    INTRODUCTION: The best first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B remains unknown. The aim of the present study was to perform a real-world analysis on a large sample of patients with unresectable HCC with CP B treated with atezolizumab plus bevacizumab Vs Lenvatinib. METHODS: The study population included patients affected by advanced (BCLC-C) or intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from both the Western and Eastern world (Italy, Germany, Republic of Korea and Japan), who received atezolizumab plus bevacizumab or Lenvatinib as first-line treatment. All the study population presented a CP class of B. The primary endpoint of the study was the overall survival (OS) of CP B patients treated with Lenvatinib compared to atezolizumab plus bevacizumab. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analyzed with log-rank tests. Finally, an interaction test was performed for the main baseline clinical characteristics. RESULTS: 217 CP B HCC patients were enrolled in the study: 65 (30%) received atezolizumab plus bevacizumab, and 152 (70%) received lenvatinib. The mOS for patients receiving Lenvatinib was 13.8 months (95% CI: 11.6-16.0), compared to 8.2 months (95% CI 6.3-10.2) for patients receiving atezolizumab plus bevacizumab as first-line treatment (atezolizumab plus bevacizumab Vs Lenvatinib: HR 1.9, 95% CI 1.2-3.0, p = 0.0050). No statistically significant differences were highlighted in terms of mPFS. The multivariate analysis confirmed that patients receiving Lenvatinib as first-line treatment have a significantly longer OS compared to patients receiving atezolizumab plus bevacizumab (HR 2.01; 95% CI 1.29-3.25, p = 0.0023). By evaluating the cohort of patients who received atezolizumab plus bevacizumab, we found that Child B patients with ECOG PS 0, or BCLC B stage or ALBI grade 1 were those who had benefited from the treatment thus showing survival outcomes no significantly different compared to those receiving Lenvatinib. CONCLUSION: The present study suggests for the first time a major benefit from Lenvatinib compared to atezolizumab plus bevacizumab in a large cohort of patients with CP B class HCC.
  • Takushi Manabe; Chikara Ogawa; Kei Takuma; Mai Nakahara; Kyoko Oura; Tomoko Tadokoro; Koji Fujita; Joji Tani; Mitsushige Shibatoge; Asahiro Morishita; Masatoshi Kudo; Tsutomu Masaki
    Diagnostics (Basel, Switzerland) 13 7 2023年03月 
    Computed tomography (CT) is often used in the diagnosis of sarcopenia. In this study, we validated the assessment of sarcopenia by the psoas muscle volume using versatile software. The study involved a retrospective analysis of data from 190 patients with liver disease who underwent grip-strength testing and abdominal pelvic computed tomography. To assess sarcopenia, SYNAPSE 3D was used to obtain the skeletal muscle index, the psoas muscle index (PMI), and the simple method. We also used the recently proposed PMI cutoff values, for which the usefulness has been evaluated (O-PMI). The cutoff value of the psoas muscle volume index (PMVI) was determined using one of the diagnostic methods as the gold standard. All diagnostic methods showed that patients with sarcopenia had shorter survival, with O-PMI having the highest hazard ratio (HR) (HR, 6.12; 95% confidence interval [CI], 2.6-14.41; p < 0.001). Even when sarcopenia could not be diagnosed by O-PMI, low PMVI was associated with shorter survival (HR, 3.53; 95% CI, 1.34-9.32; p = 0.01). PMVI may be useful in the evaluation of sarcopenia, including the identification of poor overall survival in cases that cannot be diagnosed by O-PMI, which is considered more useful than PMI.
  • Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Lorenza Rimassa; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Targeted oncology 18 2 221 - 233 2023年03月 
    BACKGROUND: Atezolizumab plus bevacizumab has recently been approved as a new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). OBJECTIVE: We performed a real-world study to evaluate the impact of the IMbrave150 trial inclusion criteria on the safety and efficacy of treatment outside of clinical trials. METHODS: We analyzed patients treated with atezolizumab plus bevacizumab for unresectable HCC from four different countries. No specific inclusion and exclusion criteria were applied, except for the absence of previous systemic therapies for HCC. The entire population was split into two groups according to concordance with the inclusion criteria as reported in the IMbrave150 trial in 'IMbrave150-in' and 'IMbrave150-out' patients, and safety and efficacy in the two groups of patients were evaluated. RESULTS: Overall, 766 patients were included in the analysis: 561/766 (73%) in the 'IMbrave150-in' group and 205/766 (27%) in the 'IMbrave150-out' group. Median overall survival (OS) and median progression-free survival (PFS) were 16.3 versus 14.3 months (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.35-0.65; p < 0.0001] and 8.3 versus 6.0 months (HR 0.79, 95% CI 0.63-0.99; p = 0.0431) in 'IMbrave150-in' and 'IMbrave150-out' patients, respectively. Multivariate analysis confirmed that patients included in the 'IMbrave150-in' group had significantly longer OS compared with patients included in the 'IMbrave150-out' group (HR 0.76, 95% CI 0.47-0.97; p = 0.0195). In 'IMbrave150-in' patients, the albumin-bilirubin (ALBI) grade was not associated with OS, whereas in 'IMbrave150-out' patients, those with ALBI grade 1 reported a significant benefit in terms of OS compared with those with ALBI grade 2 (16.7 vs. 5.9 months; HR 4.40, 95% CI 2.40-8.08; p > 0.0001). No statistically significant differences were reported in the 'IMbrave150-in' and 'IMbrave150-out' groups in terms of safety profile. CONCLUSION: Adherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment.
  • Yasuo Otsuka; Ken Kamata; Masatoshi Kudo
    Diagnostics (Basel, Switzerland) 13 6 2023年03月 
    Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is useful for the diagnosis of pancreatic masses. According to three meta-analyses, the sensitivity, specificity, and accuracy of EUS-FNA are 84-92%, 96-98%, and 86-91%, respectively. However, the occurrence of false-negative and false-positive results indicates that the diagnostic performance of EUS-FNA needs to be improved. Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is used for the characterization of pancreatic masses and can be applied to improve the performance of EUS-FNA. When CH-EUS is used to evaluate intratumor blood flow, an avascular area inside the pancreatic mass that is considered to be fibrosis is often detected. This area can be avoided by performing EUS-FNA under CH-EUS guidance. In this review, we summarize the data on contrast-enhanced harmonic endoscopic ultrasound-guided fine-needle aspiration (CH-EUS-FNA), which suggest that its benefit is still a matter of debate. Of eight studies analyzed, only one showed that CH-EUS improved the sensitivity of EUS-FNA. The future challenge is to determine under what circumstances CH-EUS-FNA is useful.
  • 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 120 臨増総会 A36 - A36 (一財)日本消化器病学会 2023年03月
  • 青木 智子; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 120 臨増総会 A85 - A85 (一財)日本消化器病学会 2023年03月
  • 【マイクロバイオームが切り拓く肝胆膵の新未来】膵疾患 マイクロバイオームと自己免疫性膵炎
    三長 孝輔; 吉川 智恵; 原 茜; 瀬海 郁衣; 栗本 真之; 大塚 康生; 益田 康弘; 鎌田 研; 工藤 正俊; 渡邉 智裕
    肝胆膵 86 3 377 - 385 (株)アークメディア 2023年03月
  • 福永 朋洋; 大本 俊介; 竹中 完; 工藤 正俊; 栗本 真之; 大塚 康生; 田中 秀和; 高島 耕太; 吉田 晃浩; 山崎 友裕; 三長 孝輔; 鎌田 研
    日本消化器病学会雑誌 120 臨増総会 A283 - A283 (一財)日本消化器病学会 2023年03月
  • 三長 孝輔; 原 茜; 瀬海 郁衣; 栗本 真之; 大塚 康生; 益田 康弘; 吉川 智恵; 鎌田 研; 工藤 正俊; 渡邉 智裕
    胆と膵 44 3 235 - 241 医学図書出版(株) 2023年03月 
    膵臓に慢性炎症性変化をきたす疾患は慢性膵炎と自己免疫性膵炎に大別される。これらの慢性炎症性膵疾患の病態生理は十分に解明されておらず,病態生理の理解に基づいた根治療法は開発されていない。近年,膵臓の慢性炎症性疾患である慢性膵炎と自己免疫性膵炎の病態形成における腸内細菌の関与を示唆する報告が相次ぎ,注目を浴びている。われわれは主に自然免疫反応の観点から,これらの慢性炎症性膵疾患の病態生理の解明に取り組む過程で,それぞれの病態形成に炎症性サイトカインであるI型IFN・IL-33が重要な役割を果たしていることを見出した。さらに,これらのサイトカインの産生には腸内細菌が深く関与しており,病的な膵臓・腸管間免疫ネットワーク機構が膵臓の慢性炎症や線維化に関与していることを明らかにした。腸内細菌は,根治療法が存在しない慢性膵炎および自己免疫性膵炎の新たな治療標的として有望である可能性があり,今後の研究が期待される。(著者抄録)
  • 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 120 臨増総会 A36 - A36 (一財)日本消化器病学会 2023年03月
  • 青木 智子; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 120 臨増総会 A85 - A85 (一財)日本消化器病学会 2023年03月
  • 吉田 早希; 米田 頼晃; 杉森 啓伸; 大丸 直哉; 松原 卓哉; 吉川 馨介; 野村 健司; 半田 康平; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器病学会雑誌 120 臨増総会 A357 - A357 (一財)日本消化器病学会 2023年03月
  • Yasuo Otsuka; Yoriaki Komeda; Masayuki Takeda; Takayuki Takahama; Masashi Kono; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Case Reports in Medicine 2023 1 - 4 2023年02月 
    A 76-year-old woman presented with lower abdominal pain and nausea and was referred to the gastroenterology department in our institution. Previous contrast-enhanced computed tomography (CE-CT) for follow-up after breast cancer surgery had indicated a soft tissue mass below the right diaphragm, which was considered a benign change. CE-CT performed at the first visit to our department revealed further thickening of the soft tissue mass with extension to the liver surface. In addition, ascites and nodules were observed in the abdominal cavity. Histopathological examination of a biopsy specimen revealed peritoneal invasion of atypical epithelioid cells with trabecular and glandular patterns. The tumor cells were positive for AE1/AE2, calretinin, WT-1, D2-40, HEG1, EMA, BAP1, and MTAP and negative for carcinoembryonic antigen, MOC-31, Ber-Ep4, ER, PgR, TTF-1, claudin 4, and desmin. A diagnosis of epithelioid mesothelioma was made. The patient received chemotherapy with cisplatin (75 mg/m2) and pemetrexed (500 mg/m2). After six courses of combined chemotherapy, pemetrexed was administered as a single agent. At the time of writing this report, she was undergoing over the 30th course of chemotherapy without any significant side effects. Diffuse malignant peritoneal mesothelioma is a rare, fatal, and progressive disease. Our patient achieved long-term survival of more than 5 years with maintenance therapy using single-agent pemetrexed.
  • Kiyoshi Hasegawa; Nobuyuki Takemura; Tatsuya Yamashita; Takeyuki Watadani; Masaki Kaibori; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Hiroshi Aikata; Hiroko Iijima; Kazuomi Ueshima; Kazuyoshi Ohkawa; Takuya Genda; Kaoru Tsuchiya; Takuji Torimura; Masafumi Ikeda; Junji Furuse; Masaaki Akahane; Satoshi Kobayashi; Hideyuki Sakurai; Atsuya Takeda; Takamichi Murakami; Utaroh Motosugi; Yutaka Matsuyama; Masatoshi Kudo; Ryosuke Tateishi
    Hepatology research : the official journal of the Japan Society of Hepatology 53 5 383 - 390 2023年02月 
    The 5th version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance-diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Herein, new or revised algorithms and evidence on which the recommendations are based are described. This article is protected by copyright. All rights reserved.
  • Amit G Singal; Masatoshi Kudo; Jordi Bruix
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2023年02月 
    ▪▪▪.
  • Hiroki Kato; Satoru Hagiwara; Naoshi Nishida; Yoriaki Komeda; Akihiro Yoshida; Masatoshi Kudo
    Clinical Journal of Gastroenterology 2023年02月 
    This study aimed to demonstrate the effect of transcatheter arterial embolization (TAE) on hepatic segmental arterial mediolysis (SAM). The patient, a 68-year-old female, suddenly developed right upper abdominal pain in October 2021, which was initially relieved. However, she was rushed to a local hospital the next day when her abdominal pain recurred. An abdominal computed tomography scan suggested a ruptured hepatic aneurysm; therefore, she was transferred to our hospital and admitted on the same day. On the first day after admission, she underwent emergency catheterization and N-butyl-2-cyanoacrylate (NBCA)/lipiodol embolization for an aneurysm in the hepatic S6. A multi-detector computed tomography on hospital day 8 to probe for extrahepatic lesions revealed multiple beaded irregularities in the superior mesenteric and bilateral renal arteries. A head magnetic resonance angiography performed on the ninth day showed no aneurysms or irregularities. She did well after TAE, did not have rebleeding, and was discharged on hospital day 16. Rupture of an aneurysm associated with SAM occurs frequently in the colonic and gastroepiploic arteries, and rupture of a hepatic aneurysm is relatively rare. TAE hemostasis was able to save the patient by preventing intraperitoneal bleeding caused by hepatic segmental arterial mediolysis.
  • Yoshinari Asaoka; Ryosuke Tateishi; Yasuhide Yamada; Hiroko Iijima; Naoya Kato; Mitsuo Shimada; Etsuro Hatano; Takumi Fukumoto; Takamichi Murakami; Hirohisa Yano; Kengo Yoshimitsu; Masayuki Kurosaki; Michiie Sakamoto; Yutaka Matsuyama; Masatoshi Kudo; Norihiro Kokudo
    Journal of Clinical Oncology 41 4_suppl 510 - 510 2023年02月 
    510 Background: Currently 6 regimens are available for advanced hepatocellular carcinoma (HCC) in Japan, including atezolizumab plus bevacizumab (AB), sorafenib (S), and lenvatinib (L) for first-line treatment and regorafenib (R), ramucirumab (RAM), and cabozantinib (C) for the second-line treatment. In real-world clinical practice, the number of combinations of treatment sequences is enormous. We have launched a nationwide registry of systemic therapy for HCC named Hepatoma Registry of Integrating and Aggregating Electric Health Records (HERITAGE). Methods: The HERITAGE is linked to the nationwide follow-up survey of the Japan Liver Cancer Association; cases treated with systemic therapy between 2015 and 2022 were included in the current study. Information on treatment efficacy and duration was collected and registered on each treatment regimen. Results: As of June 2022, 6,400 treatment lines (S 2,319, L 2559, AB 768, R 406, RAM 251, C 71) in 4,307 cases were enrolled. The response rates, disease control rates, and median treatment duration of each sequence of regimens are shown in the table. The 1st line regimen, S, L, and AB, were also used as the second and later lines in Japan and found as effective as if used as the 1st line treatment. Limitation: No adjustments for clinical conditions were performed. Conclusions: We have demonstrated the efficacy of various treatment sequences in a sufficient number of cases. Clinical trial information: UMIN000046567 . [Table: see text]
  • 【上部消化管内視鏡のトラブルシューティング】静脈瘤に対する内視鏡治療 十二指腸静脈瘤の内視鏡治療(EVL,clipping)後に出血をきたした
    松井 繁長; 樫田 博史; 米田 頼晃; 辻 直子; 工藤 正俊
    消化器内視鏡 35 2 202 - 203 (株)東京医学社 2023年02月
  • Masatoshi Kudo; Tomoko Aoki; Kazuomi Ueshima; Kaoru Tsuchiya; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Naoshi Nishida; Chikara Ogawa; Tetsu Tomonari; Noriaki Nakamura; Hidekatsu Kuroda; Atsushi Takebe; Yoshifumi Takeyama; Masaaki Hidaka; Susumu Eguchi; Stephen L. Chan; Masayuki Kurosaki; Namiki Izumi
    LIVER CANCER 12 4 321 - 338 2023年02月 
    Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or super selective transarterial chemoembolization (TACE) with curative intent. This concept, i.e., curative conversion by combining systemic therapy and locoregional therapy, has not been reported before. This multicenter proof-of-concept study was conducted to show the value of curative conversion in immunotherapy-treated intermediate-stage HCC meeting TACE-unsuitable criteria.Methods: This study included 110 consecutive Child-Pugh A patients who received atezolizumab plus bevacizumab as first-line treatment for unresectable and TACE-unsuitable intermediate-stage HCC at seven centers in Japan. CR rate, drug-free rate, time to CR, change in liver function, efficacy in positron emission tomography (PET)-positive HCC, progression-free survival (PFS), and overall survival (OS) were assessed in patients who achieved CR using resection, ablation, super selective TACE with curative intent following atezolizumab plus bevacizumab or atezolizumab plus bevacizumab alone.Results: Clinical or pathological CR was achieved in 38 patients (35%) (median observation period: 21.2 months). The modalities of curative conversion in 35 patients were as follows: resection, 7; ablation, 13; and superselective TACE, 15. Three patients achieved clinical CR with atezolizumab plus bevacizumab therapy alone. Among the 38 CR patients, 25 achieved drug-free status. PFS was not reached, and three patients experienced recurrence after reaching CR. Regarding OS, there were no deaths in any of the CR patients. The albumin-bilirubin score did not deteriorate after locoregional therapy or resection. Of seven PET-positive patients who achieved CR with atezolizumab plus bevacizumab followed by curative conversion, five achieved drug-free status.Discussion/Conclusion: The achievement of CR rate by curative conversion in patients treated with atezolizumab plus bevacizumab as the preceding therapy for unresectable and TACE-unsuitable intermediate-stage HCC was 35%. Overall, 23% of patients achieved drug-free status and no recurrence was observed from this patient subgroup with CR and drug free status. Thus, achieving CR and/or drug-free status should be a therapeutic goal for patients with intermediate-stage HCC without vascular invasion or extrahepatic spread.
  • Masatoshi Kudo
    Liver cancer 12 1 1 - 6 2023年02月
  • Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa Ramos; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Bernardo Stefanini; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Oncology 101 5 283 - 291 2023年01月 
    INTRODUCTION: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab. METHODS: The overall cohort of this multicentric study included 871 consecutive HCC patients from 4 countries treated with atezolizumab plus bevacizumab in first-line therapy. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm3). RESULTS: For only 773 patients, data regarding lymphocyte counts and albumin levels were available, so only these patients were included in the final analysis. The cut-off point of the PNI was determined to be 41 by receiver operating characteristic (ROC) analysis. 268 patients (34.7%) were categorized as the PNI-low group, while the remaining 505 (65.3%) patients as the PNI-high group. At the univariate analysis, high PNI was associated with longer overall survival (OS) (22.5 vs. 10.1 months, HR 0.34, p < 0.01) and progression-free survival (PFS) (8.7 vs. 5.8 months, HR 0.63, p < 0.01) compared to patients with low PNI. At the multivariate analysis, high versus low PNI resulted as an independent prognostic factor for OS (HR 0.49 , p < 0.01) and PFS (HR 0.82, p = 0.01). There was no difference in objective response rate (ORR) between the two groups (high 26.1% vs. low 19.8%, p = 0.09), while disease control rate (DCR) was significantly higher in the PNI-high group (76.8% vs. 66.4%, p = 0.01). CONCLUSION: PNI is an independent prognostic factor for OS and PFS in HCC patients on first-line treatment with atezolizumab plus bevacizumab.
  • Daizen Hirata; Hiroshi Kashida; Tsuguhiro Matsumoto; Chikara Ebisutani; Akira Teramoto; Mineo Iwatate; Santa Hattori; Mikio Fujita; Wataru Sano; Yoriaki Komeda; Yasushi Sano; Yoshitaka Murakami; Masatoshi Kudo
    Digestion 1 - 8 2023年01月 
    <b><i>Introduction:</i></b> Sessile serrated lesions (SSLs) have malignant potential for colorectal cancer in the serrated pathway. Selective endoscopic resection of SSLs would reduce medical costs and procedure-related accidents, but the accurate endoscopic differentiation of SSLs from hyperplastic polyps (HPs) is challenging. To explore the differential diagnostic performance of magnifying colonoscopy in distinguishing SSLs from HPs, we conducted a multicenter prospective validation study in clinical practice. <b><i>Methods:</i></b> Considering the rarity of diminutive SSLs, all lesions ≥6 mm that were detected during colonoscopy and diagnosed as type 1 based on the Japan narrow-band imaging expert team (JNET) classification were included in this study. Twenty expert endoscopists were asked to differentiate between SSLs and HPs with high or low confidence level after conventional and magnifying NBI observation. To examine the validity of selective endoscopic resection of SSLs using magnifying colonoscopy in clinical practice, we calculated the sensitivity of endoscopic diagnosis of SSLs with histopathological findings as comparable reference. <b><i>Results:</i></b> A total of 217 JNET type 1 lesions from 162 patients were analyzed, and 114 lesions were diagnosed with high confidence. The sensitivity of magnifying colonoscopy in detecting SSLs was 79.8% (95% confidence interval [CI]: 74.7–84.4%) overall, and 82.4% (95% CI: 76.1–87.7%) in the high-confidence group. These results showed that the sensitivity of this study was not high enough, even limited in the high-confidence group. <b><i>Conclusions:</i></b> Accurate differential diagnosis of SSLs and HPs using magnifying colonoscopy was challenging even for experts. JNET type 1 lesions ≥6 mm are recommended to be resected because selective endoscopic resection has a disadvantage of leaving approximately 20% of SSLs on site.
  • Naoya Kato; Masatoshi Kudo; Kaoru Tsuchiya; Atsushi Hagihara; Kazushi Numata; Hiroshi Aikata; Yoshitaka Inaba; Shunsuke Kondo; Kenta Motomura; Naohiro Okano; Masafumi Ikeda; Manabu Morimoto; Shingo Kuroda; Akiko Kimura
    Hepatology research : the official journal of the Japan Society of Hepatology 2023年01月 
    AIM: Cabozantinib showed a favorable benefit-risk profile in Japanese patients with advanced hepatocellular carcinoma (HCC) in an open-label, phase 2 study (NCT03586973). This analysis presents cumulative data to final database lock. METHODS: Patients with previously treated, advanced HCC received cabozantinib 60 mg/day. Progression-free survival (PFS) and tumor response rates in prior-sorafenib and sorafenib-naïve cohorts were assessed by independent radiology committee (IRC) and an investigator. Liver function was evaluated by albumin-bilirubin (ALBI) score. RESULTS: Median cabozantinib exposure was 5.6 months. In the prior-sorafenib cohort (n = 20), median PFS was 7.4 months per IRC assessment and 5.6 months per investigator assessment. In the sorafenib-naïve cohort (n = 14), median PFS was 3.6 months and 4.4 months per IRC and investigator assessment, respectively. Six-month PFS rate per IRC and investigator assessment in the prior-sorafenib cohort was 59.8% and 49.5%, respectively, and in the sorafenib-naïve cohort was 16.7% and 35.7%, respectively. Disease control rate by both IRC and investigator assessment was 85.0% in the prior-sorafenib cohort and 64.3% in the sorafenib-naïve cohort. Median overall survival (Kaplan-Meier estimate) was 19.3 months and 9.9 months in the prior-sorafenib and sorafenib-naïve cohort, respectively. Mean ALBI score remained relatively constant in patients able to continue treatment. The most frequent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified. CONCLUSIONS: Cabozantinib showed efficacy and a manageable safety profile in Japanese patients with advanced HCC. This article is protected by copyright. All rights reserved.
  • Junji Furuse; Namiki Izumi; Kenta Motomura; Yoshitaka Inaba; Yoshio Katamura; Yasuteru Kondo; Kazuhisa Yabushita; Katsuaki Motoyoshi; Masatoshi Kudo
    Drugs - real world outcomes 2023年01月 
    BACKGROUND: Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate the safety and effectiveness of lenvatinib in real-world clinical settings. OBJECTIVE: This study aimed to evaluate the real-world safety and effectiveness of lenvatinib for uHCC in clinical practice in Japan. PATIENTS AND METHODS: Between July 2018 and January 2019, patients with uHCC who were administered lenvatinib for the first time were enrolled in this prospective, multicenter, observational post-marketing study (NCT03663114). Patients were orally administered lenvatinib and followed up for 12 months. For safety, adverse drug reactions (ADRs) were evaluated. For effectiveness, the objective response rate (ORR) was calculated to evaluate tumor response. Overall survival (OS) was estimated using the Kaplan-Meier method. RESULTS: Data of 703 patients (median age, 73 years; 80.2% males) were analyzed. The median (range) treatment duration was 25.3 (0.3-68.9) weeks. The mean ± standard deviation initial dose was 7.37 ± 1.65 mg in patients with body weight < 60 kg and 10.43 ± 2.49 mg in those with body weight ≥ 60 kg. ADRs (any grade) were reported in 84.9% of the patients, with Grade ≥ 3 ADRs reported in 42.5% of the patients. The most common ADRs (> 10%) were decreased appetite, fatigue, hypertension, proteinuria, palmar-plantar erythrodysesthesia, hypothyroidism, and diarrhea. The median OS of the 703 patients was 498.0 days. In 494 patients assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST), the ORR was 39.5% (95% confidence interval: 35.1-43.9%). Patients with better liver or renal function at baseline achieved significantly higher ORR than those with worse liver or renal function. CONCLUSIONS: In patients with uHCC in real-world clinical practice in Japan, treatment with lenvatinib was generally well tolerated, and no new safety concerns were identified. The ORR and median OS were similar to or better than the results of the Japanese subset of the global Phase III REFLECT trial. Our results demonstrated that clinically meaningful treatment responses were achieved with lenvatinib in real-world clinical practice.
  • Natsuki Okai; Yasuhiro Masuta; Yasuo Otsuka; Akane Hara; Sho Masaki; Ken Kamata; Kosuke Minaga; Hajime Honjo; Masatoshi Kudo; Tomohiro Watanabe
    Journal of Clinical Biochemistry and Nutrition 74 2 146 - 153 2023年 
    Nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for muramyl dipeptide (MDP), a degradation product of bacterial cell wall peptidoglycan (PGN). PGN stimulates cell-surface Toll-like receptor 2 (TLR2) independently of NOD2, indicating the presence of crosstalk between extracellular TLR2 and intracellular NOD2 upon exposure to PGN. NOD2-deficient mice were sensitive, while TLR2-deficient mice were resistant to experimental colitis induced by intrarectal administration of PGN. Severe colitis in NOD2-deficient mice was accompanied by increased expression of nuclear factor-kappa B-dependent cytokines and decreased expression of autophagy-related 16-like 1 (ATG16L1). MDP activation of NOD2 enhanced autophagy mediated by TLR2 in human dendritic cells. mRNA expression of TLR2 tended to be higher in the colonic mucosa of patients with active ulcerative colitis compared to that of those in remission. Induction of remission was associated with increased mRNA expression of ATG16L1 in both ulcerative colitis and Crohn's disease patients. Conversely, mRNA expression of receptor-interacting serine/threonine-protein kinase 2 was higher in the inflammatory colonic mucosa of patients with active disease than in the non-inflamed mucosa of patients in remission, in both ulcerative colitis and Crohn's disease. These findings highlight the role of NOD2-TLR2 crosstalk in the immunopathogenesis of colitis.
  • Yasuo Otsuka; Yasuhiro Masuta; Kosuke Minaga; Natsuki Okai; Akane Hara; Ryutaro Takada; Sho Masaki; Ken Kamata; Hajime Honjo; Kouhei Yamashita; Masatoshi Kudo; Tomohiro Watanabe
    Journal of Clinical Biochemistry and Nutrition 2023年
  • Yasuhiro Masuta; Kosuke Minaga; Yasuo Otsuka; Natsuki Okai; Akane Hara; Sho Masaki; Tomoyuki Nagai; Hajime Honjo; Masatoshi Kudo; Tomohiro Watanabe
    Journal of Clinical Biochemistry and Nutrition 74 2 127 - 135 2023年 
    Coronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine responses that differ from those of UC not associated with vaccination. mRNAs derived from COVID-19 vaccines are potent inducers of type I IFN response. We encountered three cases of UC relapse after COVID-19 vaccination. mRNA expressions of IFN-α, IFN-β, IL-1β, and IL-12/23p40 showed higher tendency in the colonic mucosa of patients with UC associated with vaccination compared with those not associated with vaccination. In contrast, the expressions of C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 were comparable. Immunofluorescence analyses also showed higher expression of IFN-α in the colonic mucosa of patients with UC associated with COVID-19 vaccination than in those not associated with vaccination. Taken together, these data suggest that the colonic mucosa of patients with UC who relapsed after COVID-19 vaccination was characterized by enhanced type I IFN responses.
  • Naoshi Nishida; Masatoshi Kudo; Takafumi Nishimura; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naosuke Yokomichi; Takeshi Nagasaka; Ajay Goel
    PLOS ONE 18 1 2023年01月
  • Hajime Honjo; Kosuke Minaga; Akane Hara; Ryutaro Takada; Yasuo Otsuka; Yasuhiro Masuta; Sho Masaki; Shigenaga Matsui; Masatoshi Kudo; Tomohiro Watanabe
    Internal Medicine 2023年 
    Isolated eosinophilic gastroenteritis (EGE) of the second part of the duodenum is rare. We herein report a case of EGE limited to the second part of the duodenum that caused circumferential stenosis due to massive wall thickening. A boring biopsy was useful to verify the accumulation of eosinophils. Induction of remission by prednisolone was accompanied by a marked reduction in the mRNA expression of IL-6, C-C motif chemokine ligand 17 (CCL17), and CCL26 without any reduction in prototypical EGE-associated T helper type 2 cytokines (IL-5, IL-13). Thus, the enhanced expression of IL-6, CCL17, and CCL26 might be involved in the development of EGE in this case.
  • Yoriaki Komeda; Hideki Ishikawa; Teruhiko Yoshida; Mineko Ushiama; Saki Yoshida; Kenji Nomura; Masashi Kono; Shunsuke Omoto; Mamoru Takenaka; Satoru Hagiwara; Hiroshi Kashida; Masatoshi Kudo
    Internal Medicine 2023年 
    Familial adenomatous polyposis (FAP) is caused by pathogenic variants of the APC gene on the long arm of chromosome 5. An analysis showed an association between germline APC gene variants and clinical signs of FAP; however, attenuated FAP has also been reported in cases with pathogenic variants. In contrast, a phenotype of FAP with no APC germline pathogenic variant and with few signs has been reported. We herein report a 16-year-old girl in whom the presence of multiple large bowel cancers from a young age and several small bowel cancers reflected a carcinogenic tendency higher than that typical for FAP.
  • 吉田 晃浩; 鎌田 研; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊
    臨床消化器内科 38 2 178 - 182 (株)日本メディカルセンター 2023年01月 
    ＜文献概要＞Stage 0,IA(腫瘍径20mm以下)膵癌の診断において,空間分解能に優れる超音波内視鏡(EUS)は膵癌の直接あるいは間接所見の検出に有用である.また,コンベックス型EUSを用いることで病理診断を目的としたEUS下穿刺吸引法(EUS-FNA)も実施可能である.EUSは膵癌診療において,診断や治療方針決定のためには欠かせない検査法といえる.近年,膵癌診断において,造影ハーモニックEUSの有用性が報告されている.EUSとそれに続くEUS-FNAや造影ハーモニックEUS等を駆使してもStage 0,IA膵癌の診断には苦慮することが多く,内視鏡的逆行性胆管膵管造影をはじめとするその他の画像診断を併用し,総合的な診断を行うことが望ましいと考えられる.
  • IL-6応答亢進を伴う潰瘍性大腸炎関連脊椎関節炎の一例
    藤田 峻輔; 本庶 元; 高田 隆太郎; 原 茜; 益田 康弘; 半田 康平; 三長 孝輔; 渡邉 智裕; 工藤 正俊; 辻 成佳
    日本消化器病学会近畿支部例会プログラム・抄録集 118回 88 - 88 日本消化器病学会-近畿支部 2023年01月
  • Yasuhiro Masuta; Yasuo Otsuka; Kosuke Minaga; Hajime Honjo; Masatoshi Kudo; Tomohiro Watanabe
    Journal of Clinical Biochemistry and Nutrition 73 2 103 - 107 2023年 
    The development of Inflammatory bowel disease (IBD) is driven by excessive production of pro-inflammatory cytokines including TNF-α, IL-12, and IL-23. This notion is supported by the remarkable clinical success of biologics targeting these cytokines. Recognition of cell wall components derived from intestinal bacteria by Toll-like receptors (TLRs) induces the production of these pro-inflammatory cytokines by macrophages and dendritic cells in human IBD and experimental colitis model. Although sensing of bacterial nucleic acids by endosomal TLRs, specifically TLR3, TLR7, and TLR9 leads to robust production of type I IFNs, it remains debatable whether TLR-mediated type I IFN responses are pathogenic or protective in IBD patients. Additionally, recent studies identified deubiquitinating enzyme A (DUBA) as a novel negative regulator of TLR-mediated type I IFN responses. In light of these observations and their potential applications, in this review, we summarize recent findings on the roles of type I IFN responses and DUBA-mediated negative regulation of these responses in human IBD and experimental colitis model.
  • Y Linda Wu; Grace van Hyfte; Umut Özbek; Marlene Reincke; Anuhya Gampa; Yehia I Mohamed; Naoshi Nishida; Brooke Wietharn; Suneetha Amara; Pei-Chang Lee; Bernhard Scheiner; Lorenz Balcar; Matthias Pinter; Arndt Vogel; Arndt Weinmann; Anwaar Saeed; Anjana Pillai; Lorenza Rimassa; Abdul Rafeh Naqash; Mahvish Muzaffar; Yi-Hsiang Huang; Ahmed O Kaseb; Masatoshi Kudo; David J Pinato; Celina Ang
    Frontiers in oncology 13 1128569 - 1128569 2023年 
    BACKGROUND: In patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC). We aimed to investigate whether beta blockers (BBs), which can mediate portal hypertension, conferred survival benefits in patients treated with immune checkpoint inhibitors (ICIs). METHODS: We conducted a retrospective, observational study of 578 patients with unresectable HCC treated with ICI from 2017 to 2019 at 13 institutions across three continents. BB use was defined as exposure to BBs at any time during ICI therapy. The primary objective was to assess the association of BB exposure with overall survival (OS). Secondary objectives were to evaluate the association of BB use with progression-free survival (PFS) and objective response rate (ORR) according to RECIST 1.1 criteria. RESULTS: In our study cohort, 203 (35%) patients used BBs at any point during ICI therapy. Of these, 51% were taking a nonselective BB. BB use was not significantly correlated with OS (hazard ratio [HR] 1.12, 95% CI 0.9-1.39, P = 0.298), PFS (HR 1.02, 95% CI 0.83-1.26, P = 0.844) or ORR (odds ratio [OR] 0.84, 95% CI 0.54-1.31, P = 0.451) in univariate or multivariate analyses. BB use was also not associated with incidence of adverse events (OR 1.38, 95% CI 0.96-1.97, P = 0.079). Specifically, nonselective BB use was not correlated with OS (HR 0.94, 95% CI 0.66-1.33, P = 0.721), PFS (HR 0.92, 0.66-1.29, P = 0.629), ORR (OR 1.20, 95% CI 0.58-2.49, P = 0.623), or rate of adverse events (OR 0.82, 95% CI 0.46-1.47, P = 0.510). CONCLUSION: In this real-world population of patients with unresectable HCC treated with immunotherapy, BB use was not associated with OS, PFS or ORR.
  • Yoriaki Komeda; Masashi Kono; Hiroshi Kashida; George Tribonias; Sho Masaki; Ryutaro Takada; Tomoyuki Nagai; Satoru Hagiwara; Naoshi Nishida; Mamoru Takenaka; Hajime Honjo; Shigenaga Matsui; Naoko Tsuji; Masatoshi Kudo
    Annals of gastroenterology 36 1 97 - 102 2023年 
    BACKGROUND: The standard therapy for acute severe ulcerative colitis (ASUC) is intravenous corticosteroids; however, 30% of ulcerative colitis (UC) patients do not recover with corticosteroids alone. Few studies have reported the efficacy and safety of tofacitinib for ASUC with steroid resistance. We report a case series of successful first-line treatment consisting of tofacitinib (20 mg/day) administered to ASUC patients with steroid resistance. METHODS: Patients diagnosed with ASUC at our institution between October 2018 and February 2020 were retrospectively evaluated. They were administered a high dose of tofacitinib (20 mg) after showing no response to steroid therapy in a dose of 1-1.5 mg/kg/day. RESULTS: Eight patients with ASUC, 4 (50%) men, median age 47.1 (range 19-65) years, were included. Four patients were newly diagnosed, and the median UC duration was 4 (range 0-20) years. Six of the 8 patients were able to avoid colectomy. One patient (patient 2) had no response; however, remission was achieved after switching from tofacitinib to infliximab. One patient (patient 6) with no response to tofacitinib underwent total colectomy. Only one patient (patient 4) experienced an adverse event, local herpes zoster, treated with acyclovir without tofacitinib discontinuation. CONCLUSIONS: Clinical remission without serious adverse events can be achieved with high probability and colectomy can be avoided by first administering high-dose tofacitinib to steroid-resistant ASUC patients. Tofacitinib may be one of the first-line treatment options for steroid-resistant ASUC.
  • Shunsuke Fujita; Hajime Honjo; Ryutaro Takada; Akane Hara; Yasuhiro Masuta; Yasuo Otsuka; Kohei Handa; Kosuke Minaga; Shigeyoshi Tsuji; Masatoshi Kudo; Tomohiro Watanabe
    Internal Medicine 2023年 
    Although concurrent occurrence of spondyloarthritis (SpA) and ulcerative colitis (UC) is sometimes seen, the profiles of cytokines have been poorly understood in UC-associated SpA. We herein report a case of UC-associated SpA successfully treated with infliximab. Profiles of cytokines in the serum and colonic mucosa were characterized by an enhanced expression of IL-6 but not TNF-α. Successful induction of remission by infliximab was associated with the downregulation of IL-6 expression but no significant alteration in TNF-α expression. These findings suggest that some cases of UC-associated SpA might be driven by IL-6, and infliximab might be effective in cases lacking enhanced TNF-α responses.
  • Thomas Talbot; Antonio D'Alessio; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas U Marron; Tomi Jun; Sirish Dharmapuri; Celina Ang; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Claudia A M Fulgenzi; Suneetha Amara; Abdul Rafeh Naqash; Anuhya Gampa; Anjana Pillai; Yinghong Wang; Uqba Khan; Pei-Chang Lee; Yi-Hsiang Huang; Bertram Bengsch; Dominik Bettinger; Yehia I Mohamed; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Masatoshi Kudo; Arndt Weinmann; Peter R Galle; Ambreen Muhammed; Alessio Cortellini; Arndt Vogel; David J Pinato
    Liver international : official journal of the International Association for the Study of the Liver 43 3 695 - 707 2022年12月 [査読有り]
     
    BACKGROUND & AIMS: Different approaches are available after progression of disease (PD) to immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC), including continuation of ICI, treatment switching to tyrosine kinase inhibitors (TKIs) and cessation of anticancer therapy. We sought to characterise the relationship between radiologic patterns of progression and survival post-ICI, also appraising treatment strategies. METHODS: We screened 604 HCC patients treated with ICIs, including only those who experienced PD by data cut-off. We evaluated post-progression survival (PPS) according to treatment strategy at PD and verified its relationship with radiologic patterns of progression: intrahepatic growth (IHG), new intrahepatic lesion (NIH), extrahepatic growth (EHG), new extrahepatic lesion (NEH) and new vascular invasion (nVI). RESULTS: Of 604 patients, 364 (60.3%) experienced PD during observation. Median PPS was 5.3 months (95%CI: 4.4-6.9; 271 events). At data cut-off, 165 patients (45%) received no post-progression anticancer therapy; 64 patients (17.6%) continued ICI beyond PD. IHG (HR 1.64 [95%CI:1.21-2.22]; p=0.0013) and nVI (HR 2.15 [95%CI:1.38-3.35]; p=0.0007) were associated with shorter PPS. Multivariate models adjusted for progression patterns, treatment line, and ALBI grade and ECOG-PS at PD confirmed receipt of ICI beyond PD with (HR 0.17, 95%CI 0.09-0.32; p<0.0001), or without subsequent TKI (HR 0.39, 95%CI 0.26-0.58; p<0.0001) as predictors of prolonged PPS versus no anticancer therapy. CONCLUSIONS: ICI-TKI sequencing is a consolidated option in advanced HCC. nVI and IHG predict poorer prognosis. Despite lack of recommendation, continuation of ICI beyond progression in HCC is adopted clinically: future efforts should appraise which patients benefit from this approach.
  • Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Takumi Kawaguchi; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Antonella Cammarota; Valentina Burgio; Stefano Cascinu; Andrea Casadei-Gardini
    Journal of cancer research and clinical oncology 149 9 5591 - 5602 2022年12月 
    PURPOSE: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. METHODS: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). RESULTS: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not reached in both arms, but the result from univariate Cox regression model showed 62% reduction of death risk for patients treated with atezolizumab plus bevacizumab (p = 0.05). In all multivariate analyses, treatment arm was not found to be an independent factor conditioning OS. Comparing ORR achieved in the two arms, there was a statistically significant difference in favor of lenvatinib compared to atezolizumab plus bevacizumab in all subgroups except for Eastern patients, Child-Pugh B patients, presence of portal vein thrombosis, α-feto-protein ≥ 400 ng/mL, presence of extrahepatic disease, albumin-bilirubin (ALBI) grade 2, and no previous locoregional procedures. CONCLUSION: Lenvatinib achieves higher ORR in all patient subgroups. Patients who achieve CR with atezolizumab plus bevacizumab can achieve OS so far never recorded in HCC patients. This study did not highlight any factors that could identify patient subgroups capable of obtaining CR.
  • Kosuke Minaga; Masayuki Kitano; Yoshito Uenoyama; Keiichi Hatamaru; Hideyuki Shiomi; Kenji Ikezawa; Tsukasa Miyagahara; Hajime Imai; Nao Fujimori; Hisakazu Matsumoto; Yuzo Shimokawa; Atsuhiro Masuda; Mamoru Takenaka; Masatoshi Kudo; Yasutaka Chiba
    Endoscopic ultrasound 2022年12月 
    BACKGROUND AND OBJECTIVES: Although the use of a long metal stent is favored for EUS-guided hepaticogastrostomy (EUS-HGS) for the relief of malignant biliary obstruction (MBO), endoscopic reintervention (E-RI) at the time of recurrent biliary obstruction (RBO) is challenging due to a long intragastric portion. This study evaluated the feasibility and safety of E-RI after a long partially covered metal stent (L-PCMS) placement during EUS-HGS. MATERIALS AND METHODS: We performed a multicenter retrospective study between January 2015 and December 2019 examining patients with MBO who underwent E-RI for RBO through the EUS-HGS route after the L-PCMS placement. Technical and clinical success rates, details of E-RI, adverse events (AEs), stent patency, and survival time were evaluated. RESULTS: Thirty-three patients at eight referral centers in Japan who underwent E-RI through the EUS-HGS route were enrolled. The location of MBO was distal in 54.5%. The median intragastric length of the L-PCMS was 5 cm. As the first E-RI attempt, E-RI via the distal end of the existing L-PCMS was successful in 60.6%. The overall technical and clinical success rates of E-RI were 100% and 81.8%, respectively. Liver abscess was noted in one patient. A proximal biliary stricture was associated with the clinical ineffectiveness of E-RI in multivariable analysis (odds ratio, 12.5, P = 0.04). The median survival and stent patency duration after E-RI were 140 and 394 days, respectively. CONCLUSIONS: Our study findings suggest that E-RI for RBO after EUS-HGS with a L-PCMS is technically feasible and clinically effective, without any severe AEs, especially for patients with distal MBO.
  • S Yoshida; K Minaga; T Watanabe; M Kudo
    Journal of Gastroenterology and Hepatology 38 10  2022年12月
  • 三長 孝輔; 大塚 康生; 益田 康弘; 竹中 完; 工藤 正俊
    消化器内視鏡 34 12 1971 - 1975 (株)東京医学社 2022年12月
  • Daneng Li; Han Chong Toh; Philippe Merle; Kaoru Tsuchiya; Sairy Hernandez; Wendy Verret; Alan Nicholas; Masatoshi Kudo
    Liver cancer 11 6 558 - 571 2022年12月 
    INTRODUCTION: The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab versus sorafenib as a first-line treatment in younger versus older patients with unresectable HCC. METHODS: This global, phase 3, open-label, randomized clinical trial (IMbrave150) recruited patients aged ≥18 years with locally advanced metastatic or unresectable HCC, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and Child-Pugh class A liver function who had not previously received systemic therapy for liver cancer. Patients received either 1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily until loss of clinical benefit or unacceptable toxicity. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were the incidence of adverse events and time to deterioration of patient-reported outcomes (PROs). This subgroup analysis evaluated safety and efficacy endpoints in patients <65 years, ≥65 to <75 years, and ≥75 years. RESULTS: Of 501 patients, 165 patients were randomized to sorafenib and 336 were randomized to atezolizumab plus bevacizumab (175 patients <65 years; 106 patients ≥65 to <75 years; 55 patients ≥75 years). Across all age groups, patients receiving atezolizumab plus bevacizumab had longer median OS (<65: 18.0 vs. 12.2 months [HR, 0.57; 95% CI: 0.40-0.82]; ≥65 to <75: 19.4 vs. 14.9 months [HR, 0.80; 95% CI: 0.52-1.23]; ≥75: 24.0 vs. 18.0 months [HR, 0.72, 95% CI: 0.37-1.41]) and PFS than those receiving sorafenib. Time to deterioration for multiple PROs was delayed for patients receiving atezolizumab plus bevacizumab, including older adults. There were no clinically meaningful differences in toxicity between age groups. CONCLUSION: Atezolizumab plus bevacizumab is safe and effective in adults <65, ≥65 to <75, and ≥75. Treatment was well-tolerated even in elderly patients.
  • Andrea Casadei-Gardini; Margherita Rimini; Masatoshi Kudo; Shigeo Shimose; Toshifumi Tada; Goki Suda; Myung Ji Goh; Andre Jefremow; Mario Scartozzi; Giuseppe Cabibbo; Claudia Campani; Emiliano Tamburini; Francesco Tovoli; Kazuomi Ueshima; Tomoko Aoki; Hideki Iwamoto; Takuji Torimura; Takashi Kumada; Atsushi Hiraoka; Masanori Atsukawa; Ei Itobayashi; Hidenori Toyoda; Naoya Sakamoto; Takuya Sho; Wonseok Kang; Jürgen Siebler; Markus Friedrich Neurath; Valentina Burgio; Stefano Cascinu
    Liver cancer 11 6 527 - 539 2022年12月 
    INTRODUCTION: In the REFLECT trial, lenvatinib was found to be noninferior compared to sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world and identify clinical factors that could be significantly associated with survival outcomes. METHODS: The study population was derived from retrospectively collected data of HCC patients treated with lenvatinib. The overall cohort included western and eastern populations from 23 center in five countries. RESULTS: We included 1,325 patients with HCC and treated with lenvatinib in our analysis. Median OS was 16.1 months. Overall response rate was 38.5%. Multivariate analysis for OS highlighted that HBsAg positive, NLR >3, and AST >38 were independently associated with poor prognosis in all models. Conversely, NAFLD/NASH-related etiology was independently associated with good prognosis. Median progression-free survival was 6.3 months. Multivariate analysis for progression-free survival revealed that NAFLD/NASH, BCLC, NLR, and AST were independent prognostic factors for progression-free survival. A proportion of 75.2% of patients suffered from at least one adverse effect during the study period. Multivariate analysis exhibited the appearance of decreased appetite grade ≥2 versus grade 0-1 as an independent prognostic factor for worse progression-free survival. 924 patients of 1,325 progressed during lenvatinib (69.7%), and 827 of them had a follow-up over 2 months from the beginning of second-line treatment. From first-line therapy, the longest median OS was obtained with the sequence lenvatinib and immunotherapy (47.0 months), followed by TACE (24.7 months), ramucirumab (21.2 months), sorafenib (15.7 months), regorafenib (12.7 months), and best supportive care (10.8 months). CONCLUSIONS: Our study confirms in a large and global population of patients with advanced HCC, not candidates for locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib.
  • Masatoshi Kudo
    Liver cancer 11 6 487 - 496 2022年12月
  • Soo Ki Kim; Takako Fujii; Soo Ryang Kim; Atsushi Nakai; Young-Suk Lim; Satoru Hagiwara; Masatoshi Kudo
    Liver cancer 11 6 497 - 510 2022年12月 
    BACKGROUND: Long-term therapy with nucleos(t)ide analogs (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular carcinoma (HCC) on the basis of data from randomized or matched control studies. Recent data suggest a lower HCC incidence after 5 years of ETV or TDF therapy in chronic hepatitis B (CHB) patients, especially those with baseline cirrhosis. SUMMARY: Three controversial issues remain to be resolved regarding hepatitis B virus (HBV) treatment and HCC. (1) The efficacy of antiviral treatment for the prevention of HCC is not established. The guidelines of the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APASL), and the European Association for the Study of the Liver (EASL) for the management of HBV infection state that antiviral treatment of HBV with interferon and NAs prevents the development of HCC. Among experts in CHB treatment, however, there is disagreement on the HCC prevention effects of antiviral treatment. (2) The rationale for antiviral management in patients with high HBV DNA and normal levels of alanine aminotransferase is unclear. The AASLD, EASL, and APASL guidelines do not recommend antiviral treatment for immune-tolerant CHB patients, and the terms and methods of treating such patients remain to be clarified. (3) The efficacy of first-line treatment with NAs, including ETV, TDF, and tenofovir alafenamide fumarate (TAF), to prevent HCC in CHB patients remains unknown. Several studies have produced controversial results regarding the effects of NAs on the risk and prevention of HCC. In the present review, we discuss these 3 issues, citing recent studies and clinical management guidelines from major international associations. KEY MESSAGES: Suggested approaches for reaching a consensus including applying the propensity score matching method, performing randomized controlled studies, and performing clinical studies with larger numbers of subjects and longer follow-up.
  • Dominique Thabut; Masatoshi Kudo
    Journal of hepatology 2022年11月 
    Portal hypertension (PHT) and hepatocellular carcinoma (HCC) often coexist, and their association impairs the prognosis of patients with cirrhosis. The interplay between those two complications is of major importance to propose adequate therapeutic options to patients with HCC, as well as to prevent and manage complications of portal hypertension. Recommendations on management of PHT have been deeply revised in last Baveno VII conference, redefining screening and extending indications of prophylaxis. PHT can preclude locoregional therapies, and TIPS placement can be discussed in HCC patients. New systemic therapies of HCC can influence the level of PHT and favor bleeding. In all patients, PHT complications should be prevented and treated adequately, especially if they present with advanced HCC. Those specific aspects will be discussed in the present review, taking into account the very recent data in HCC field.
  • Yue Linda Wu; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Jaekyung Cheon; Naoshi Nishida; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Yi-Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Rohini Sharma; Alessio Cortellini; Vincent E Gaillard; Hong Jae Chon; David J Pinato; Celina Ang
    Cancers 14 23 2022年11月 
    Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic value in HCC treated with standard of care atezolizumab plus bevacizumab (Atezo-Bev). We conducted a multicenter, international retrospective cohort study of patients with unresectable HCC treated with Atezo-Bev to assess the association of NLR and PLR with overall survival (OS), progression-free survival (PFS), and objective response rates. Patients with NLR ≥ 5 had a significantly shorter OS (9.38 vs. 16.79 months, p < 0.001) and PFS (4.90 vs. 7.58 months, p = 0.03) compared to patients with NLR < 5. NLR ≥ 5 was an independent prognosticator of worse OS (HR 2.01, 95% CI 1.22-3.56, p = 0.007) but not PFS. PLR ≥ 300 was also significantly associated with decreased OS (9.38 vs. 15.72 months, p = 0.007) and PFS (3.45 vs. 7.11 months, p = 0.04) compared to PLR < 300, but it was not an independent prognosticator of OS or PFS. NLR and PLR were not associated with objective response or disease control rates. NLR ≥ 5 independently prognosticated worse survival outcomes and is worthy of further study and validation.
  • Andrea Casadei-Gardini; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mara Persano; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Stefano Cascinu; Alessandro Cucchetti
    European journal of cancer (Oxford, England : 1990) 180 9 - 20 2022年11月 
    BACKGROUND AND AIMS: Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario. METHODS: Clinical features of lenvatinib and atezolizumab plus bevacizumab patients were balanced through inverse probability of treatment weighting (IPTW) methodology, which weights patients' characteristics and measured outcomes of each patient in both treatment arms. Overall survival (OS) was the primary end-point. RESULTS: The analysis included 1341 patients who received lenvatinib, and 864 patients who received atezolizumab plus bevacizumab. After IPTW adjustment, atezolizumab plus bevacizumab did not show a survival advantage over lenvatinib HR 0.97 (p = 0.739). OS was prolonged by atezolizumab plus bevacizumab over lenvatinib in viral patients (HR: 0.76; p = 0.024). Conversely, OS was prolonged by lenvatinib in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (HR: 1.88; p = 0.014). In the IPTW-adjusted population, atezolizumab plus bevacizumab provided better safety profile for most of the recorded adverse events. CONCLUSION: Our study did not identify any meaningful difference in OS between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease might benefit more from lenvatinib therapy and patients with viral aetiology more from atezolizumab plus bevacizumab.
  • 西田 直生志; 工藤 正俊
    臨床消化器内科 37 13 1653 - 1661 (株)日本メディカルセンター 2022年11月 
    ＜文献概要＞超音波検査(US)は非侵襲的であり,頻用される画像検査法であるが,非専門領域の臓器の検査を行うことも多く,初学者ではしばしば診断に苦慮する場面が少なくない.また多くの症例を短時間で検査する場合,微小病変の見逃しのリスクが増える.今日までに多くのUSを支援する人工知能(AI)の報告があるが,USは反射波を利用した検査であるため,表示画像が体格や体位の影響を受け,またパラメーターの設定が複雑であるため,AIによる診断支援モデルの開発が困難であった.さらに肝臓領域のUSは正常構造物が複雑であり,多くの画像を学習させる必要があった.われわれは,日本超音波医学会の事業として肝腫瘤の検出と鑑別をBモード超音波で行うAIを開発している.本稿では,肝臓領域のUSを支援するAIの報告を概説し,またわれわれが開発している肝腫瘤診断支援AIについて紹介する.
  • Mamoru Takenaka; Masatoshi Kudo
    Clinical endoscopy 55 6 757 - 759 2022年11月
  • Claudia Angela Maria Fulgenzi; Jaekyung Cheon; Antonio D'Alessio; Naoshi Nishida; Celina Ang; Thomas U Marron; Linda Wu; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Andrea Napolitano; Yi-Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Rohini Sharma; Alessio Cortellini; Vincent E Gaillard; Hong Jae Chon; David James Pinato
    European journal of cancer (Oxford, England : 1990) 175 204 - 213 2022年11月 
    BACKGROUND: IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). METHODS: We generated a prospectively maintained database including patients treated with atezolizumab plus bevacizumab for unresectable HCC across Europe, Asia and USA. Clinico-pathologic characteristics were assessed for their prognostic influence on overall survival (OS) and progression-free survival (PFS) in univariable and multivariate analyses. Overall response rate by RECIST v1.1 and treatment-related adverse events (TRAEs) per CTCAE v.5.0 were reported. RESULTS: Out of 433 patients, 296 Child-Pugh A and ECOG performance status01 patients received atezolizumab plus bevacizumab in first line and were included. Patients were mostly male (82.7%), cirrhotic (75%) with history of viral hepatitis (65.9%). Overall, 68.9% had Barcelona Clinic Liver Cancer C-stage HCC with portal vein tumour thrombosis (PVTT, 35%) and extrahepatic spread (EHS, 51.7%). After a median follow-up of 10.0 months (95% confidence interval (CI): 9.4-10.4), median OS and PFS were 15.7 (95% CI: 14.5-NE) and 6.9 months (95% CI: 6.1-8.3), respectively. In the response-evaluable patients (n = 273), overall response rate was 30.8%. Overall, 221 patients (74.6%) developed TRAEs, with 70 (23.6%) reporting grade 3 or higher TRAEs; 25 (8.4%) patients had bleeding events. OS was independently associated with baseline Albumin-bilirubin (ALBI) grade and PVTT. Shorter PFS was associated with AFP≥ 400 ng/ml, worse ALBI and presence of EHS. CONCLUSION: This global observational study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice. Within Child-Pugh-A criteria, the presence of PVTT and higher ALBI grade identify patients with poorer survival.
  • Ikue Sekai; Kosuke Minaga; Akane Hara; Yasuo Otsuka; Masayuki Kurimoto; Naoya Omaru; Natsuki Okai; Yasuhiro Masuta; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo; Tomohiro Watanabe
    Biochemical and Biophysical Research Communications 2022年11月
  • Kayo Miyawaki; Takaya Komori; Yoshihiro Ishida; Yuri Sakaguchi; Hajime Honjo; Masatoshi Kudo; Atsushi Otsuka
    Acta dermato-venereologica 2022年10月
  • Naoshi Nishida; Masatoshi Kudo
    Ultrasonography (Seoul, Korea) 42 1 10 - 19 2022年10月 
    With the development of more advanced methods for the diagnosis and treatment of diseases, the data required for medical care are becoming complex, and misinterpretation of information due to human error may result in serious consequences. Human error can be avoided with the support of artificial intelligence (AI). AI models trained with various medical data for diagnosis and management of liver diseases have been applied to hepatitis, fatty liver disease, liver cirrhosis, and liver cancer. Some of these models have been reported to outperform human experts in terms of performance, indicating their potential for supporting clinical practice given their high-speed output. This paper summarizes the recent advances in AI for liver disease and introduces the AI-aided diagnosis of liver tumors using B-mode ultrasonography.
  • Satoru Hagiwara; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Masatoshi Kudo
    Cancer reports (Hoboken, N.J.) 5 11 e1721  2022年10月 
    BACKGROUND: Although reports of gastrointestinal perforation after immune-related adverse events (irAE) enteritis are rare, the anti- vascular endothelial growth factor (VEGF) effect of bevacizumab may be involved in gastrointestinal perforation. We report a rare case of gastrointestinal perforation in a patient with hepatocellular carcinoma treated with atezolizumab/bevacizumab combination therapy and infliximab before steroid use. CASE: A 72-year-old man, who received seven courses of atezolizumab/bevacizumab for hepatocellular carcinoma due to hepatitis B, was admitted to our department with idiopathic abdominal pain and diarrhea (grade 2 [G2]). Computed tomography (CT) and colonoscopy confirmed edema in the gastrointestinal tract. Perforation of the jejunum was observed in a CT performed on the third day and an emergency operation was performed. Intraoperative findings showed severe edema of the jejunum and leakage of feces into the abdominal cavity. The patient was diagnosed with irAE enteritis comprehensively with severe wall thickening on CT and colonoscopy, negative stool culture, and pathological findings of CD8-positive cells. Infliximab was administered before initiating steroids, to prevent reperforation. The enteritis improved by the 22nd day; however, CT performed on the 35th day of illness showed relapse of gastrointestinal wall thickening and G2 diarrhea symptoms; therefore, prednisolone (PSL) 60 mg/day was started on the 36th day of illness. After introducing PSL, enteritis did not reoccur, and the patient was discharged on the 63rd day of illness after admission. CONCLUSION: There are no reports of gastrointestinal perforation by atezolizumab/bevacizumab for hepatocellular carcinoma, and prior administration of infliximab. We therefore report the clinical course and management.
  • Yasunori Minami; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    Cancers 14 19 2022年10月 
    BACKGROUND: The treatment of the hepatitis C virus (HCV) has reduced the risk of hepatocellular carcinoma (HCC)-related mortality. Many patients with advanced HCC have achieved longer survival through systemic chemotherapy. However, survivors of HCC may develop liver cancer during and after treatment. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC in the new era of molecular targeted therapy. METHODS: A total of 359 patients with HCV-related HCC treated with first-line chemotherapy were reviewed. A Cox proportional hazards model and Kaplan-Meier curve were used to identify prognostic factors associated with survival outcomes. RESULTS: The median follow-up duration was 16.0 months (range, 1.0-115.7) and the median duration of first-line systemic therapy was 3.73 months (range, 0.7-86.9). The achievement of a sustained virological response (SVR) (p  <  0.001), albumin-bilirubin (ALBI) grade II/III (p  <  0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p  =  0.005), extrahepatic spread (p < 0.001), baseline AFP (alpha-fetoprotein) level ≥ 90 (p = 0.038), baseline DCP (des-γ-carboxy prothrombin) level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p  =  0.003) were identified as prognostic factors for overall survival. CONCLUSIONS: The achievement of SVR was most strongly associated with overall survival. Other factors, such as the BCLC stage, extrahepatic spread, baseline tumor marker (AFP/DCP) levels, ALBI grade, and FIB-4 index need to be considered in the management of patients with HCV-related HCC.
  • Naoya Omaru; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
    Frontiers in Immunology 13 1004439 - 1004439 2022年10月 
    Hepatocytes and liver-resident antigen-presenting cells are exposed to microbe-associated molecular patterns (MAMPs) and microbial metabolites, which reach the liver from the gut via the portal vein. MAMPs induce innate immune responses via the activation of pattern recognition receptors (PRRs), such as toll-like receptors (TLRs), nucleotide-binding oligomerization domain 1 (NOD1), and NOD2. Such proinflammatory cytokine responses mediated by PRRs likely contribute to the development of chronic liver diseases and hepatocellular carcinoma (HCC), as shown by the fact that activation of TLRs and subsequent production of IL-6 and TNF-α is required for the generation of chronic fibroinflammatory responses and hepatocarcinogenesis. Similar to TLRs, NOD1 and NOD2 recognize MAMPs derived from the intestinal bacteria. The association between the activation of NOD1/NOD2 and chronic liver diseases is poorly understood. Given that NOD1 and NOD2 can regulate proinflammatory cytokine responses mediated by TLRs both positively and negatively, it is likely that sensing of MAMPs by NOD1 and NOD2 affects the development of chronic liver diseases, including HCC. Indeed, recent studies have highlighted the importance of NOD1 and NOD2 activation in chronic liver disorders. Here, we summarize the roles of NOD1 and NOD2 in hepatocarcinogenesis and liver injury.
  • 急激な経過を辿ったClostridium perfringens肝膿瘍・多臓器ガス壊疽の1例
    原 茜; 大塚 康生; 三長 孝輔; 渡邉 智裕; 工藤 正俊; 梶山 博
    日本消化器病学会近畿支部例会プログラム・抄録集 117回 91 - 91 日本消化器病学会-近畿支部 2022年10月
  • COVID-19ワクチン接種後のI型インターフェロン反応を特徴とする潰瘍性大腸炎再発の一例
    益田 康弘; 三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 117回 102 - 102 日本消化器病学会-近畿支部 2022年10月
  • 空腸瀘胞性リンパ腫から形質転換した腹部Double Expressor Lymphoma(DEL)の1例
    高田 隆太郎; 三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 117回 103 - 103 日本消化器病学会-近畿支部 2022年10月
  • 胆膵内視鏡施行時のプロポフォールを用いた鎮静における当院での取り組み 胆膵
    田中 秀和; 竹中 完; 高島 耕太; 福永 朋洋; 吉田 晃浩; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊
    Gastroenterological Endoscopy 64 Suppl.2 2188 - 2188 (一社)日本消化器内視鏡学会 2022年10月
  • 代謝性肝疾患の標準治療確立のためのエビデンス構築 NAFLD関連肝癌における背景肝のエピゲノム変異の蓄積
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.3 A654 - A654 (一社)日本肝臓学会 2022年10月
  • B型慢性肝炎患者におけるETVとTAFの効果・安全性の比較
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.3 A768 - A768 (一社)日本肝臓学会 2022年10月
  • 発症早期から進行期までを観察しえたirAE胆管炎の1例
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.3 A793 - A793 (一社)日本肝臓学会 2022年10月
  • irAE腸炎による消化管穿孔に対してステロイド前のinfliximab先行投与により救命できた1例
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.3 A794 - A794 (一社)日本肝臓学会 2022年10月
  • Osamu Aramaki; Tadatoshi Takayama; Yutaka Matsuyama; Shoji Kubo; Norihiro Kokudo; Masayuki Kurosaki; Takamichi Murakami; Shuichiro Shiina; Masatoshi Kudo; Michiie Sakamoto; Osamu Nakashima; Takumi Fukumoto; Hiroko Iijima; Susumu Eguchi; Yuji Soejima; Masatoshi Makuuchi
    Hepatology research : the official journal of the Japan Society of Hepatology 53 2 127 - 134 2022年10月 
    AIM: Although Makuuchi's criteria are widely used to determine the cut-off for safe liver resection, there have been few reports of concrete data supporting their validity. Here, we verified the utility of Makuuchi's criteria by comparing the operative mortality rates associated with liver resection between hepatocellular carcinoma (HCC) patients meeting or exceeding the criteria. METHODS: A database was built using data from 15 597 patients treated between 2000 and 2007 for whom values for all three variables included in Makuuchi's criteria for liver resection (clinical ascites, serum bilirubin, and indocyanine green clearance) were available. The patients were divided into those fulfilling (n = 12 175) or exceeding (n = 3422) the criteria. The postoperative mortality (death for any reason within 30 days) and long-term survival were compared between the two groups. RESULTS: The operative mortality rate was significantly lower in patients meeting the criteria than in those exceeding the criteria (1.07% vs. 2.01%, respectively; p < 0.001). On multivariate analysis, exceeded the criteria was significantly associated with the risk for operative mortality (relative risk 2.08; 95% confidence interval (CI), 1.23-3.52; p = 0.007). Surgical indication meeting or exceeding the criteria was an independent factor for overall survival (hazard ratio 1.27; 95% CI, 1.18-1.36; p < 0.001). CONCLUSION: Makuuchi's criteria are suitable for determining the indication for resection of HCC due to the reduction in risk of operative mortality.
  • Yasuhiro Masuta; Kosuke Minaga; Masayuki Kurimoto; Ikue Sekai; Akane Hara; Naoya Omaru; Natsuki Okai; Yasuo Otsuka; Ryutaro Takada; Tomoe Yoshikawa; Sho Masaki; Ken Kamata; Hajime Honjo; Yasuyuki Arai; Kouhei Yamashita; Masatoshi Kudo; Tomohiro Watanabe
    International Immunology 2022年09月 
    Abstract Mutations in nucleotide-binding oligomerization domain 2 (NOD2) are associated with Crohn’s disease (CD). Although NOD2 activation contributes to the maintenance of intestinal homeostasis through the negative regulation of pro-inflammatory cytokine responses mediated by Toll-like receptors (TLRs), the effects of NOD2 activation on interferon (IFN)-α responses induced by TLR9 have been poorly defined. To explore the cross-talk between NOD2 and TLR9, human monocytes or dendritic cells (DCs) were stimulated with NOD2 and/or TLR9 ligands to measure IFN-α production. The severity of dextran sodium sulfate (DSS)-induced colitis was compared in mice treated with NOD2 and/or TLR9 ligands. Expression of IFN-α and IFN-stimulated genes (ISGs) was examined in the colonic mucosa of patients with inflammatory bowel disease (IBD). NOD2 activation reduced TLR9-induced IFN-α production by monocytes and DCs in a deubiquitinating enzyme A (DUBA)-dependent manner. Activation of DUBA induced by the co-stimulation of TLR9 and NOD2 inhibited Lys63-linked polyubiquitination of TRAF3 and suppressed TLR9-mediated IFN-α production. NOD2 activation in hematopoietic cells protected mice from TLR9-induced exacerbation of DSS-induced colitis by down-regulating IFN-α responses and up-regulating DUBA expression. Colonic mucosa of patients with active and remitted IBD phases was characterized by the enhanced and reduced expression of ISGs, respectively. Expression levels of IFN-α and IL-6 positively correlated in the active colonic mucosa of patients with ulcerative colitis and CD, whereas DUBA expression inversely correlated with that of IFN-α in patients with CD. Collectively, these data suggest that DUBA-dependent negative effect of NOD2 on TLR9-mediated IFN-α responses contributes to the maintenance of intestinal homeostasis.
  • Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Ann-Lii Cheng; Arndt Vogel; Francesco Tovoli; Kazuomi Ueshima; Hiroshi Aikata; Carlos López López; Marc Pracht; Zhiqiang Meng; Bruno Daniele; Joong-Won Park; Daniel Palmer; Toshiyuki Tamai; Kenichi Saito; Corina E Dutcus; Riccardo Lencioni
    Journal of hepatology 78 1 133 - 141 2022年09月 
    BACKGROUND & AIMS: Validated surrogate endpoints for overall survival (OS) are important for expediting the clinical study and drug-development processes. Herein, we aimed to validate objective response as an independent predictor of OS in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. METHODS: We investigated the association between objective response (investigator-assessed mRECIST, independent radiologic review [IRR] mRECIST and RECIST v1.1) and OS in REFLECT, a phase III study of lenvatinib vs. sorafenib. We conducted landmark analyses (Simon-Makuch) of OS by objective response at 2, 4, and 6 months after randomization. RESULTS: Median OS was 21.6 months (95% CI 18.6-24.5) for responders (investigator-assessed mRECIST) vs. 11.9 months (95% CI 10.7-12.8) for non-responders (hazard ratio [HR] 0.61; 95% CI 0.49-0.76; p <0.001). Objective response by IRR per mRECIST and RECIST v1.1 supported the association with OS (HR 0.61; 95% CI 0.51-0.72; p <0.001 and HR 0.50; 95% CI 0.39-0.65; p <0.001, respectively). OS was significantly prolonged for responders vs. non-responders (investigator-assessed mRECIST) at the 2-month (HR 0.61; 95% CI 0.49-0.76; p <0.001), 4-month (HR 0.63; 95% CI 0.51-0.80; p <0.001), and 6-month (HR 0.68; 95% CI 0.54-0.86; p <0.001) landmarks. Results were similar when assessed by IRR, with both mRECIST and RECIST v1.1. An exploratory multivariate Cox regression analysis identified objective response by investigator-assessed mRECIST (HR 0.55; 95% CI 0.44-0.68; p <0.0001) and IRR-assessed RECIST v1.1 (HR 0.49; 95% CI, 0.38-0.64; p <0.0001) as independent predictors of OS in individuals with unresectable HCC. CONCLUSIONS: Objective response was an independent predictor of OS in individuals with unresectable HCC in REFLECT; additional studies are needed to confirm surrogacy. Participants achieving a complete or partial response by mRECIST or RECIST v1.1 had significantly longer survival vs. those with stable/progressive/non-evaluable disease. GOV NUMBER: NCT01761266. IMPACT AND IMPLICATIONS: This analysis of data taken from a completed clinical trial (REFLECT) looked for any link between objective response and overall survival time in individuals with unresectable HCC receiving anti-angiogenic treatments. Significantly longer median overall survival was found for responders (21.6 months) vs. non-responders (11.9 months). Overall survival was also significantly longer for responders vs. non-responders (based on objective response status at 2, 4, and 6 months) in the landmark analysis. Our results indicate that objective response is an independent predictor of overall survival in this setting, confirming its validity as a rapid marker of efficacy that can be applied in phase II trials; however, further validation is required to determine is validity for other systemic treatments (e.g. immunotherapies), or as a surrogate of overall survival.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo
    Oncology 100 12 645 - 654 2022年09月 
    BACKGROUND/AIM: Adverse events (AEs) of urinary protein from monoclonal antibodies against vascular endothelial growth factor (VEGF) are factors that often inhibit systemic therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate risk factors of urinary protein in the early period (<12 weeks) of atezolizumab plus bevacizumab treatment (Atez/Bev). MATERIALS/METHODS: From 2020 to June 2022, 193 uHCC patients treated with Atez/Bev at our affiliated hospitals were enrolled (median 73 years, 158 males, 183 Child-Pugh A, BCLC-0: A: B: C=1: 7: 73: 112). AEs related to urinary protein (≥G2) within 12 weeks were defined as significant and related clinical features were analyzed retrospectively. RESULTS: In analyses of risk factors of urinary protein-related AEs during the first 12 weeks after starting Atez/Bev using a logistic regression method, univariate analysis showed positive for hypertension [odds ratio (OR) 3.54, 95%CI: 1.28-9.80, P=0.015] and baseline urinary protein urine creatinine ratio (UPC: ≥0.16) (OR 2.52, 95%CI: 1.09-5.83, P=0.031) as pre-treatment clinical factors, while elevation of urinary protein in the early period (baseline to three weeks) with delta UPC per three weeks (ΔUPC/3W) (≥0.23) (OR 15.80, 95%CI: 6.15-40.50, P<0.001) was a clinical factor after starting treatment. Multivariate analysis of only baseline clinical factors revealed positive for history of hypertension as the only predictive factor (OR 3.20, 95%CI: 1.14-8.95, P=0.027), while only ΔUPC/3W (≥0.23) (OR 14.40, 95%CI: 4.91-42.00, P<0.001) were noted in multivariate analysis including ΔUPC/3W. Predictive factors for ΔUPC/3W (≥0.23) (OR 3.50, 95%CI: 1.23-99.90, P=0.019) were hypertension and UPC (≥0.16) (OR 6.12, 95%CI 2.61-14.30, P<0.001) in multiple analysis. CONCLUSION: Urinary protein-related AEs are frequently observed during Atez/Bev treatment in uHCC patients with elevated ΔUPC/3W (≥0.23), and ΔUPC/3W (≥0.23) is often seen in patients with hypertension and/or UPC (≥0.16).
  • Mamoru Takenaka; Shunsuke Omoto; Tomohiro Fukunaga; Masatoshi Kudo
    Gastrointestinal endoscopy 97 1 146 - 147 2022年09月
  • 肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果
    西田 直生志; 上嶋 一臣; 工藤 正俊
    肝臓 63 Suppl.2 A465 - A465 (一社)日本肝臓学会 2022年09月
  • 腹部超音波動画からの肝腫瘍検出AIシステムの開発
    目加田 慶人; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.2 A467 - A467 (一社)日本肝臓学会 2022年09月
  • 進行肝癌の薬物治療の課題と展望 切除不能肝細胞癌におけるhyper progressive disease(HPD)の頻度と有効な後治療
    青木 智子; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.2 A537 - A537 (一社)日本肝臓学会 2022年09月
  • 肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果
    西田 直生志; 上嶋 一臣; 工藤 正俊
    肝臓 63 Suppl.2 A465 - A465 (一社)日本肝臓学会 2022年09月
  • 腹部超音波動画からの肝腫瘍検出AIシステムの開発
    目加田 慶人; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.2 A467 - A467 (一社)日本肝臓学会 2022年09月
  • 進行肝癌の薬物治療の課題と展望 切除不能肝細胞癌におけるhyper progressive disease(HPD)の頻度と有効な後治療
    青木 智子; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.2 A537 - A537 (一社)日本肝臓学会 2022年09月
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 肝細胞癌の新たな免疫クラス分類
    盛田 真弘; 西田 直生志; 工藤 正俊
    肝胆膵 85 3 345 - 353 (株)アークメディア 2022年09月
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 Wnt/β-catenin変異を有するHCCの二面性(Inflamed and non-inflamed)
    青木 智子; 西田 直生志; 工藤 正俊
    肝胆膵 85 3 369 - 374 (株)アークメディア 2022年09月
  • Kazuomi Ueshima; Atsushi Komemushi; Takeshi Aramaki; Hideki Iwamoto; Shuntaro Obi; Yozo Sato; Toshihiro Tanaka; Kiyoshi Matsueda; Michihisa Moriguchi; Hiroya Saito; Miyuki Sone; Takuji Yamagami; Yoshitaka Inaba; Masatoshi Kudo; Yasuaki Arai
    Liver cancer 11 5 407 - 425 2022年09月 
    Hepatocellular carcinoma is one of the leading causes of cancer-related death both in Japan and globally. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is one of the most commonly used treatment options for liver cancer in Japan, and implantation of a catheter system (called a port system) in the body is a treatment method that has evolved mainly in Japan. The Guideline Committee of the Japanese Society of Interventional Radiology and the Japanese Society of Implantable Port Assisted Treatment jointly published clinical practice guidelines for HAIC with a port system to ensure its appropriate and safe performance in Japanese in 2018. We have written an updated English version of the guidelines with the aim of making this treatment widely known to experts globally. In this article, the evidence, method, indication, treatment regimen, and maintenance of the system are summarized.
  • Sho Masaki; Yoriaki Komeda; Yasumasa Yoshioka; Mamoru Takenaka; Masatoshi Kudo
    VideoGIE 2022年09月
  • Mamoru Takenaka; Tomohiro Fukunaga; Akihiro Yoshida; Shunsuke Omoto; Masatoshi Kudo
    Endoscopy 54 S 02 E1083-E1085  2022年09月
  • Mamoru Takenaka; Kae Fukunishi; Kota Takashima; Tomohiro Yamazaki; Masatoshi Kudo
    Endoscopy 2022年09月
  • Shohei Komatsu; Kazuomi Ueshima; Masahiro Kido; Kaori Kuramitsu; Daisuke Tsugawa; Hiroaki Yanagimoto; Hirochika Toyama; Yonson Ku; Masatoshi Kudo; Takumi Fukumoto
    Journal of hepato-biliary-pancreatic sciences 30 3 303 - 314 2022年09月 
    AIM: Sorafenib was previously considered a first-line treatment for hepatocellular carcinoma (HCC) patients with macroscopic portal vein tumor thrombus (PVTT). This case-matched analysis was performed to evaluate the best first-line treatment for HCC in patients with macroscopic PVTT. METHODS: The HCC patients with Vp2 (PVTT invaded into a second-order portal branch), Vp3 (first-order portal branch), and Vp4 (main trunk or contralateral portal vein) PVTT who underwent hepatectomy and those treated with sorafenib were included. Treatment results were compared between the two modalities for each PVTT category, and a propensity analysis was performed for patients with Vp3 and Vp4 (Vp3/4). RESULTS: The median survival times (MSTs) of patients with Vp2, Vp3, and Vp4 PVTT who underwent hepatectomy were 21.4, 13.6, and 14.9 months, respectively; the MSTs for those with Vp2, Vp3, and Vp4 PVTT who received sorafenib treatment were 6.9, 5.5, and 3.6 months, respectively, with a significant difference. In a propensity-matched cohort of patients with Vp3/4 PVTT (36 patients in each), the MST of patients who underwent hepatectomy (15.1 months) was significantly better than the patients treated with sorafenib (4.5 months). CONCLUSION: Hepatectomy can be associated with prolonged survival in HCC patients with macroscopic PVTT.
  • Tomoe Yoshikawa; Kosuke Minaga; Akane Hara; Ikue Sekai; Masayuki Kurimoto; Yasuhiro Masuta; Yasuo Otsuka; Ryutaro Takada; Ken Kamata; Ah-Mee Park; Shiki Takamura; Masatoshi Kudo; Tomohiro Watanabe
    International Immunology 2022年09月 
    Abstract Autoimmune pancreatitis (AIP) and IgG4-related disease (IgG4-RD) are new disease entities characterized by enhanced IgG4 antibody responses and involvement of multiple organs, including the pancreas and salivary glands. Although the immunopathogenesis of AIP and IgG4-RD is poorly understood, we previously reported that intestinal dysbiosis mediates experimental AIP through the activation of IFN-α- and IL-33-producing plasmacytoid dendritic cells (pDCs). Because intestinal dysbiosis is linked to intestinal barrier dysfunction, we explored whether the latter affects the development of AIP and autoimmune sialadenitis in MRL/MpJ mice treated with repeated injections of polyinosinic–polycytidylic acid [poly (I:C)]. Epithelial barrier disruption was induced by the administration of dextran sodium sulfate (DSS) in the drinking water. Mice co-treated with poly (I:C) and DSS, but not those treated with either agent alone, developed severe AIP, but not autoimmune sialadenitis, which was accompanied by the increased accumulation of IFN-α- and IL-33-producing pDCs. Sequencing of 16S ribosomal RNA revealed that Staphylococcus sciuri translocation from the gut to the pancreas was preferentially observed in mice with severe AIP co-treated with DSS and poly (I:C). The degree of experimental AIP, but not of autoimmune sialadenitis, was greater in germ-free mice mono-colonized with S. sciuri and treated with poly (I:C) than in germ-free mice treated with poly (I:C) alone, which was accompanied by the increased accumulation of IFN-α- and IL-33-producing pDCs. Taken together, these data suggest that intestinal barrier dysfunction exacerbates AIP through the activation of pDCs and translocation of S. sciuri into the pancreas.
  • Mamoru Takenaka; Masatoshi Kudo
    Clinical endoscopy 2022年08月 
    The double-guidewire method has been increasingly used in endoscopic procedures for biliary and pancreatic diseases in recent years, including endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography-related procedures. In addition, double-lumen catheters with uneven distal and proximal lumen openings have been introduced, making it possible to easily create a double-guidewire situation, and the usefulness of the double-guidewire technique using uneven double-lumen cannulas has been widely reported. Although the advantages of using two guidewires depend on the particular situation and the appropriate use of the two guidewires, deepening the knowledge of the double-guidewire method will contribute greatly to troubleshooting in daily practice. In this review, the usefulness of the double-guidewire technique is discussed with respect to two main areas: selective insertion of guidewires and devices and biliary cannulation.
  • Mathew Vithayathil; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato; Rohini Sharma
    Liver international : official journal of the International Association for the Study of the Liver 42 11 2538 - 2547 2022年08月 
    BACKGROUND AND AIMS: Combination atezolizumab/bevacizumab is the gold standard for first line-treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. METHODS: 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age≥65 years) and younger (age<65 years) age patients. Treatment-related adverse events (trAEs) were evaluated. RESULTS: The elderly (n=116) had higher rates of non-alcoholic fatty liver disease (19.8% vs. 2.7%; p<0.001), presenting with smaller tumours (6.2cm vs 7.9cm, p=0.02) with less portal vein thrombosis (31.9 vs. 54.7%, p=0.002), with fewer patients presenting with BCLC-C stage disease (50.9 vs. 74.3%, p=0.002). There was no significant difference in OS (median 14.9 vs. 15.1 months; HR 1.15, 95% CI 0.65-2.02 p=0.63) and PFS (median 7.1 vs. 5.5 months; HR 1.11, 95% CI 0.54-1.92; p=0.72) between older age and younger age. Older patients had similar ORR (27.6% vs. 20.0%; p=0.27) and DCR (77.5% vs. 66.1%; p=0.11) compared to younger patients. Atezolizumab-related (40.5% vs. 48.0%; p=0.31) and bevacizumab-related (44.8% vs. 41.3%; p=0.63) trAEs were comparable between groups. Rates of grade ≥3 trAEs and toxicity-related treatment discontinuation were similar between older and younger age patients. Patients 75 years and older had similar survival and safety outcomes compared to younger patients. CONCLUSIONS: Atezolizumab and bevacizumab therapy is associated with comparable efficacy and tolerability in older age patients with unresectable HCC.
  • Margherita Rimini; Wonseok Kang; Valentina Burgio; Mara Persano; Tamoko Aoki; Shigeo Shimose; Toshifumi Tada; Takashi Kumada; Takuya Sho; Eleonora Lai; Ciro Celsa; Claudia Campani; Matteo Tonnini; Emiliano Tamburini; Atsushi Hiraoka; Koichi Takaguchi; Naoshi Nishida; Hideki Iwamoto; Ei Itobayashi; Kunihiko Tsuji; Naoya Sakamoto; Toru Ishikawa; Hidenori Toyoda; Masatoshi Kudo; Takumi Kawaguchi; Takeshi Hatanaka; Kazugiro Nouso; Goki Suda; Giuseppe Cabibbo; Fabio Marra; Angelo Della Corte; Francesca Ratti; Federica Pedica; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Hepatology research : the official journal of the Japan Society of Hepatology 2022年08月 
    BACKGROUND: The identification of new prognostic factors able to stratify HCC patients candidate to first line therapy is an urgent. In the present work we validated the prognostic value of the LEP index. MATHERIALS AND METHODS: Data of Eastern and Western patients treated with lenvatinib as first-line for BCLC stage B or C HCC were recollected. LEP index was composed by three class of risk according with our previously study. The 'low risk'group includes patients with PNI >43.3 and with previous TACE. The 'medium risk' group includes patients with PNI >43.3 but without previous TACE and patients with PNI <43.3, ALBI grade 1 and BCLC-B. The 'high risk'group includes patients with PNI <43.3, ALBI grade 2 and patients with PNI <43.3, ALBI grade 1 and BCLC-C. RESULTS: 717 patients were included. Median OS was 20.7 months (95% CI 16.1-51.6) in patients with low risk (n = 223), 16.7 months (95% CI 13.3-47.0) in medium risk (n = 264) and 10.7 months (95% CI 9.3-12.2) in high risk (n = 230) [HR 1, 1.29 and 1.92 respectively; p < 0.0001]. Median PFS was 7.3 months (95% CI 6.3-46.5) in patients with low risk, 6.4 months (95% CI 5.3-8.0) in medium and 4.9 months (95% CI 4.3-5.5) in high risk [HR 1, 1.07, 1.47 respectively; p = 0.0009]. CONCLUSION: The LEP index confirms its prognostic value on an external cohort of HCC patients treated with Lenvatinib. This article is protected by copyright. All rights reserved.
  • 急性膵炎後のWONに対する画像診断および経皮的ドレナージの役割
    上月 瞭平; 鶴崎 正勝; 浦瀬 篤史; 小寺 卓; 平山 歩; 石井 一成; 大本 俊介; 竹中 完; 工藤 正俊
    日本医学放射線学会秋季臨床大会抄録集 58回 S439 - S440 (公社)日本医学放射線学会 2022年08月
  • 【肝疾患における画像診断の進歩-腹部超音波、CT、MRI-】人工知能を応用した超音波画像診断
    西田 直生志; 工藤 正俊
    消化器内科 4 8 36 - 43 (株)医学出版 2022年08月 
    超音波検査は肝疾患スクリーニングの画像検査として頻用されるが、リアルタイムの判断が必要であり、初学者では診断に迷う状況が起こりうる。また、短時間で多くの検査を行うことが多く、見逃しなどのヒューマンエラーのリスクがある。近年、医用AIの開発が進められており、AIによるヒューマンエラーの回避が期待されている。超音波診断領域では、AIによる肝線維化や脂肪肝などのびまん性肝疾患のステージング、肝腫瘤の検出と鑑別支援に関する報告が多く、さらに肝細胞癌の超音波画像による治療後の予後推定など、疾患マネージメントに関わる報告も散見される。一方、超音波検査では、音響的に異なる境界面から戻ってくる反射波を基に生体構造を画像化するため画像の視認性が悪い状況があり、また機種の違いによる画像の多様性がAI学習の際に問題となる。さらに、医用画像AIの社会実装には、AIのブラックボックスとしての性質、学習に伴う性能変化、責任の所在に関する考え方など、多くの課題が残されている。本稿では、肝疾患領域の超音波検査に関連するAIの開発動向を概説し、AIによる超音波診断支援の課題について言及する。(著者抄録)
  • 【肝疾患における画像診断の進歩-腹部超音波、CT、MRI-】人工知能を応用した超音波画像診断
    西田 直生志; 工藤 正俊
    消化器内科 4 8 36 - 43 (株)医学出版 2022年08月 
    超音波検査は肝疾患スクリーニングの画像検査として頻用されるが、リアルタイムの判断が必要であり、初学者では診断に迷う状況が起こりうる。また、短時間で多くの検査を行うことが多く、見逃しなどのヒューマンエラーのリスクがある。近年、医用AIの開発が進められており、AIによるヒューマンエラーの回避が期待されている。超音波診断領域では、AIによる肝線維化や脂肪肝などのびまん性肝疾患のステージング、肝腫瘤の検出と鑑別支援に関する報告が多く、さらに肝細胞癌の超音波画像による治療後の予後推定など、疾患マネージメントに関わる報告も散見される。一方、超音波検査では、音響的に異なる境界面から戻ってくる反射波を基に生体構造を画像化するため画像の視認性が悪い状況があり、また機種の違いによる画像の多様性がAI学習の際に問題となる。さらに、医用画像AIの社会実装には、AIのブラックボックスとしての性質、学習に伴う性能変化、責任の所在に関する考え方など、多くの課題が残されている。本稿では、肝疾患領域の超音波検査に関連するAIの開発動向を概説し、AIによる超音波診断支援の課題について言及する。(著者抄録)
  • 【肝胆膵疾患とサルコペニア】胆道・膵疾患 急性膵炎とサルコペニア
    竹中 完; 田中 隆光; 山崎 友祐; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊
    肝胆膵 85 2 229 - 238 (株)アークメディア 2022年08月
  • Masatoshi Kudo
    Hepatobiliary surgery and nutrition 11 4 592 - 596 2022年08月
  • Kazuya Okushin; Ryosuke Tateishi; Arata Takahashi; Koji Uchino; Ryo Nakagomi; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Mitsuhiro Fujishiro; Kiyoshi Hasegawa; Yuichiro Eguchi; Tatsuya Kanto; Shoji Kubo; Hitoshi Yoshiji; Hiroaki Miyata; Namiki Izumi; Masatoshi Kudo; Kazuhiko Koike
    Journal of gastroenterology 57 8 587 - 597 2022年08月 
    BACKGROUND: We developed a nationwide database that stores data of patients with primary liver cancer (PLC) and decompensated cirrhosis (DC) on an admission basis. METHODS: A database was constructed using the National Clinical Database, a nationwide registry platform for various diseases in Japan. Mutual data exchange was possible with the Nationwide Follow-up Survey of Primary Liver Cancer in Japan by the Liver Cancer Study Group of Japan. The stored data on the admission of patients with PLC, DC, or both, included treatment details as well as patient characteristics. RESULTS: A total of 37,705 admissions (29,489 PLC, 10,077 DC, and 1862 for both) in 21,376 patients from 224 hospitals were analyzed. The proportions of patients with hepatitis B, hepatitis C, and non-viral etiology were 11.9%, 36.2%, and 42.6%, respectively, in PLC, and 7.5%, 23.8%, and 55.0%, respectively, in DC. The mean ages (± standard deviation) on admission with PLC and DC were 73 ± 10 and 68 ± 13 years, respectively. The Barcelona Clinic Liver Cancer (BCLC) stage for PLC was 0, A, B, C, and D in 22.0%, 17.1%, 29.6%, 15.1%, and 5.1%, respectively. Treatment modalities for PLC were resection, ablation, transarterial chemoembolization, and systemic therapy in 18.4%, 22.8%, 33.7%, and 11.4%, respectively. A vasopressin receptor V2 antagonist was used in 38.2% in addition to conventionally used loop diuretics and aldosterone antagonists for DC. CONCLUSIONS: The distribution of treatment options for PLC on admission differed from that of the initial treatment. Newly introduced drugs are widely used in patients with DC.
  • Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Tomoko Aoki; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Yoichi Hiasa; Masatoshi Kudo
    European journal of gastroenterology & hepatology 34 8 857 - 864 2022年08月 
    OBJECTIVE: The use of Glasgow prognostic score (GPS), calculated using the serum C-reactive protein and albumin levels, to predict the outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib was investigated in this study. METHODS: A total of 508 patients with Child-Pugh class A HCC treated with lenvatinib were included in this study. RESULTS: The median overall and progression-free survivals were 20.4 months [95% confidence interval (CI), 17.7-23.2 months] and 7.5 months (95% CI, 6.8-8.5 months), respectively. The median overall survivals of patients with a GPS of 0, 1, and 2 were 28.5, 16.0, and 9.1 months, respectively (P < 0.001). When adjusted for age, sex, performance status, etiology, α-fetoprotein, macroscopic vascular invasion, extrahepatic spread, history of sorafenib therapy, and GPS, a GPS of 1 [hazard ratio (HR), 1.664; 95% CI, 1.258-2.201; P < 0.001] and a GPS of 2 (HR, 2.664; 95% CI, 1.861-3.813; P < 0.001) were found to be independently associated with overall survival. The median progression-free survivals of patients with a GPS of 0, 1, and 2 were 8.8, 6.8, and 3.8 months, respectively (P < 0.001). When adjusted for the same factors of overall survival, a GPS of 2 (HR, 2.010; 95% CI, 1.452-2.784; P < 0.001) was found to be independently associated with progression-free survival. As the albumin-bilirubin with tumor node metastasis score increased, the proportion of patients with a GPS of 1 or 2 increased (P < 0.001). CONCLUSIONS: GPS can be used to predict survival in patients with unresectable HCC who were treated with lenvatinib.
  • Yasuo Otsuka; Ken Kamata; Kosuke Minaga; Tomohiro Watanabe; Masatoshi Kudo
    Frontiers in Cellular and Infection Microbiology 12 940532 - 940532 2022年07月 
    Acute pancreatitis is a common emergent disorder, a significant population of which develops the life-threatening condition, called severe acute pancreatitis (SAP). It is generally accepted that bacterial infection is associated with the development and persistence of SAP. In addition to bacterial infection, recent clinical studies disclosed a high incidence of fungal infection in patients with SAP. Moreover, SAP patients with fungal infection exhibit a higher mortality rate than those without infection. Although these clinical studies support pathogenic roles played by fungal infection in SAP, beneficial effects of prophylactic anti-fungal therapy on SAP have not been proved. Here we summarize recent clinical findings as to the relationship between fungal infection and the development of SAP. In addition, we discuss molecular mechanisms accounting for the development of SAP in the presence of fungal infection.
  • Satoru Hagiwara; Takeshi Yoshida; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Cishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 52 10 888 - 892 2022年07月 
    AIM: We report a rare case of immune-related cholangitis in which the natural course could be demonstrated. CASE PRESENTATION: Eight courses of pembrolizumab maintenance therapy were given as first-line treatment for squamous cell lung cancer; however, the patient was subsequently hospitalized due to a rapid increase in hepatobiliary enzymes. On endoscopic ultrasound, the common bile duct was dilated to 11 mm, and the wall, throughout its length from the papilla, was thickened. Endoscopic retrograde cholangiopancreatography showed no obvious stenosis in the lower bile duct; however, a parapapillary diverticulum was found, and papillary incision and bile duct plastic stent insertion were carried out. However, the liver disorder did not improve and overt jaundice appeared subsequently; therefore, an immune-related cholangitis was suspected, and prednisolone (PSL) 35 mg/day was introduced from day 59 of admission. Following PSL initiation, a decrease in serum bilirubin level was observed; however, significant decrease was not observed in alkaline phosphatase. Given the history of recurrent infectious cholangitis, magnetic resonance cholangiopancreatography was carried out on day 70 of admission. The intrahepatic bile duct showed stenosis and dilated findings, which was considered to be a factor for repeated infectious cholangitis. CONCLUSION: No previous case reports have described the changes and progression in bile duct images in immune-related adverse events. Therefore, this case is noteworthy for considering the progression of immune-related cholangitis.
  • Natsuki Okai; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Hajime Honjo; Masatoshi Kudo
    World Journal of Gastroenterology 28 26 3063 - 3070 2022年07月 
    Crohn's disease (CD) is driven by the loss of tolerance to intestinal microbiota and excessive production of pro-inflammatory cytokines. These pro-inflammatory cytokines are produced by macrophages and dendritic cells (DCs) upon sensing the intestinal microbiota by the pattern recognition receptors (PRRs). Impaired activation of PRR-mediated signaling pathways is associated with chronic gastrointestinal inflammation, as shown by the fact that loss-of-function mutations in the nucleotide-binding oligomerization domain 2 gene increase the risk of CD development. Autophagy is an intracellular degradation process, during which cytoplasmic nutrients and intracellular pathogens are digested. Given that impaired reaction to intestinal microbiota alters signaling pathways mediated by PRRs, it is likely that dysfunction of the autophagic machinery is involved in the development of CD. Indeed, the loss-of-function mutation T300A in the autophagy related 16 like 1 (ATG16L1) protein, a critical regulator of autophagy, increases susceptibility to CD. Recent studies have provided evidence that ATG16L1 is involved not only in autophagy, but also in PRR-mediated signaling pathways. ATG16L1 negatively regulates pro-inflammatory cytokine responses of macrophages and DCs after these cells sense the intestinal microbiota by PRRs. Here, we discuss the molecular mechanisms underlying the development of CD in the T300A ATG16L1 mutation by focusing on PRR-mediated signaling pathways.
  • Hidekazu Tanaka; Kosuke Minaga; Yasuo Otsuka; Yasuhiro Masuta; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Tomoko Hyodo; Masatomo Kimura; Tomohiro Watanabe; Masatoshi Kudo
    Frontiers in Medicine 9 2022年07月 
    Background Pancreatic neuroendocrine carcinoma (PanNEC) is a rare disease entity with rapid progression and poor prognosis. Here, we report a PanNEC case with unique morphological features mimicking intraductal papillary mucinous carcinoma. Case presentation A 69-year-old Japanese man was referred to our hospital for further evaluation of weight loss and deterioration of diabetes mellitus. Contrast-enhanced computed tomography showed a solid and cystic mass with hypo-enhancement at the tail of the pancreas. The main pancreatic duct (MPD) was diffusely dilated without obstruction, accompanied by marked parenchymal atrophy. Multiple peritoneal and omental nodules were observed, suggesting tumor dissemination. Endoscopic retrograde cholangiopancreatography revealed that the mass correlated with the dilated MPD. During pancreatography, a large amount of mucus was extruded from the pancreatic orifice of the ampulla. Based on these imaging findings, intraductal papillary mucinous carcinoma was suspected. Per-oral pancreatoscopy (POPS)-guided tumor biopsies were conducted for the lesion's solid components. Histopathological examination of the biopsied material confirmed small-cell-type PanNEC with a Ki-67 labeling index of 90%. Due to his condition's rapid decline, the patient was given the best supportive care and died 28 days after diagnosis. Conclusion Although rare, PanNEC, which correlates with the MPD and is accompanied by marked dilation of the MPD, does exist as one phenotype. In such cases, POPS-guided biopsy could be a useful diagnostic modality.
  • Ayana Okamoto; Ken Kamata; Takeshi Miyata; Tomoe Yoshikawa; Rei Ishikawa; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Toshiharu Sakurai; Naoshi Nishida; Masayuki Kitano; Masatoshi Kudo
    Clinical endoscopy 55 4 558 - 563 2022年07月 
    Background/Aims: Bispectral index (BIS) monitors process and display electroencephalographic data and are used to assess the depth of anesthesia. This study retrospectively evaluated the usefulness of BIS monitoring during endoscopic ultrasonography (EUS). Methods: This study included 725 consecutive patients who underwent EUS under sedation with propofol. BIS monitoring was used in 364 patients and was not used in 361. The following parameters were evaluated: (1) median dose of propofol; (2) respiratory and circulatory depression; (3) occurrence of body movements; (4) awakening score >8 at the time; and (5) awakening score 2 hours after leaving the endoscopy room. Results: The BIS group received a significantly lower median dose of propofol than the non-BIS group (159.2 mg vs. 167.5 mg; p=0.015) in all age groups. For patients aged ≥75 years, the reduction in heart rate was significantly lower in the BIS group than in the non-BIS group (1.2% vs. 9.1%; p=0.023). Moreover, the occurrence of body movements was markedly lower in the BIS group than in the non-BIS group (8.5% vs. 39.4%; p<0.001). Conclusions: During EUS examination, BIS monitoring is useful for maintaining a constant depth of anesthesia, especially in patients 75 years of age or older.
  • Atsushi Nakai; Ken Kamata; Tomoko Hyodo; Takaaki Chikugo; Akane Hara; Yasuo Otsuka; Hidekazu Tanaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Tomohiro Watanabe; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    Endoscopic ultrasound 11 5 401 - 406 2022年07月 
    Background: The value of contrast-enhanced harmonic EUS (CH-EUS) for diagnosis of portal vein invasion in patients with pancreatic cancer was evaluated. Patients and Methods: This single-center, retrospective study included consecutive patients with pancreatic cancer who underwent both surgical resection after preoperative EUS, CH-EUS, and contrast-enhanced computed tomography (CE-CT) examinations between April 2015 and August 2017. CH-EUS evaluation was performed during the late phase. Portal vein invasion on EUS and CH-EUS was defined as no continuity in the line of the vessel wall. Definition of portal vein invasion on CE-CT was based on the Loyer's criteria. The accuracy of three modalities for diagnosis of invasion into the portal vein was compared using the McNemar's test. Results: Eighty-eight patients (mean age: 71.0 years, ratio of male to female: 48:40) were eligible. Postoperative pathological results were as follows: seven cases of portal vein invasion; 81 cases without. Diagnostic accuracy of EUS, CH-EUS, and CE-CT for diagnosing invasion into the portal vein was 72.7%, 93.2%, and 81.8%, respectively. The differences between CH-EUS and CE-CT (P = 0.0094) and CH-EUS and EUS (P = 0.0022) were significant. EUS and CE-CT were comparable. Conclusion: CH-EUS is useful for diagnosis of portal vein invasion by pancreatic cancer.
  • アノテーションが不完全な教師データを用いた腹部超音波画像からの肝腫瘍検出
    池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊
    日本医用画像工学会大会予稿集 41回 192 - 193 (一社)日本医用画像工学会 2022年07月 
    腹部超音波検査の支援を目的として,機械学習を用いた超音波画像からの肝腫瘍検出に関する研究がおこなわれている.中島らの研究ではYOLOv3を用いて検出を行っていた.しかし,学習データには画像1枚に1つの腫瘍のアノテーションしか付与されていなかった.転移性肝がんは1枚の超音波画像に複数箇所写っている場合があり,アノテーションのない腫瘍は学習に悪影響を与えている.そのため,アノテーションの不完全性を考慮した肝腫瘍検出手法が必要であった.これに対して本研究では,YOLOv3の損失関数に腫瘍の種類に応じた重みを加えることで,アノテーションがない腫瘍に対する検出および検出精度の改善を試みた.実験の結果,転移性肝がんに対する再現率の向上が確認された.また,適合率は低下したものの,転移性肝がんにおいてはアノテーションが入力されていない腫瘍部分を検出できていることが確認でき,提案手法の有効性が示唆された.(著者抄録)
  • アノテーションが不完全な教師データを用いた腹部超音波画像からの肝腫瘍検出
    池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊
    日本医用画像工学会大会予稿集 41回 192 - 193 (一社)日本医用画像工学会 2022年07月 
    腹部超音波検査の支援を目的として,機械学習を用いた超音波画像からの肝腫瘍検出に関する研究がおこなわれている.中島らの研究ではYOLOv3を用いて検出を行っていた.しかし,学習データには画像1枚に1つの腫瘍のアノテーションしか付与されていなかった.転移性肝がんは1枚の超音波画像に複数箇所写っている場合があり,アノテーションのない腫瘍は学習に悪影響を与えている.そのため,アノテーションの不完全性を考慮した肝腫瘍検出手法が必要であった.これに対して本研究では,YOLOv3の損失関数に腫瘍の種類に応じた重みを加えることで,アノテーションがない腫瘍に対する検出および検出精度の改善を試みた.実験の結果,転移性肝がんに対する再現率の向上が確認された.また,適合率は低下したものの,転移性肝がんにおいてはアノテーションが入力されていない腫瘍部分を検出できていることが確認でき,提案手法の有効性が示唆された.(著者抄録)
  • 竹中 完; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊
    内科 130 1 13 - 19 (株)南江堂 2022年07月 
    ＜文献概要＞▼急性膵炎と診断した後はまず重症化のリスクを判断し,重症化した場合,もしくは重症化が高率に予想される場合には適切な施設への搬送と適切な治療をシステマティックに行うことが求められ,「Pancreatitis Bundles 2021」の積極的活用が望まれる.▼「Pancreatitis Bundles 2021」で改訂された内容として,軽症急性膵炎には予防的抗菌薬は使用しないこと,経腸栄養は経胃でも可であること,感染性膵壊死に対するステップアップ・アプローチ,などがあげられる.▼急性膵炎診療における地域連携ネットワークの重要性は「急性膵炎診療ガイドライン2021」でも強調されており,各地域それぞれのネットワークづくりが求められる.▼急性胆管炎の診断には長らくCharcot 3徴(発熱・黄疸・腹痛)が用いられてきたが,実際にはCharcot 3徴をきたさない急性胆管炎が多く経験され,「急性胆管炎・胆嚢炎診療ガイドライン2018」では急性胆管炎の診断は「全身の炎症」「胆汁うっ滞」「胆管病変」の3因子を用いて行われている.▼急性膵炎・胆管炎,いずれの病態も重症度評価は頻回に行い,当初は軽症の症例でも重症化する可能性を常に念頭に置き,重症化のタイミングを逃さないようにすることが肝要である.
  • 山雄 健太郎; 竹中 完; 鎌田 研; 三長 孝輔; 工藤 正俊
    内科 130 1 69 - 71 (株)南江堂 2022年07月 
    ＜文献概要＞▼膵がんは予後不良ながん腫であり,その改善のためには早期診断・早期治療が必須である.▼早期膵がんを疑う画像所見としては「尾側膵管拡張を伴う限局性主膵管狭窄」がその代表である.しかしながらこの所見は慢性膵炎などの良性膵疾患でも認められる.▼近年,早期膵がん症例のCTにおける「主膵管狭窄部周囲の限局性膵実質萎縮」が良悪性診断に有用との報告が散見される.この所見を認めた場合は早期膵がんの可能性を考慮し,胆膵専門医へ紹介することが推奨される.
  • Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
    Liver cancer 11 4 290 - 314 2022年07月 
    This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These guidelines consist of 1 treatment algorithm, 5 background statements, 16 clinical questions, and 1 clinical topic, including etiology, staging, pathology, diagnosis, and treatments. Globally, a high incidence of ICC has been reported in East and Southeast Asian countries, and the incidence has been gradually increasing in Japan and also in Western countries. Reported risk factors for ICC include cirrhosis, hepatitis B/C, alcohol consumption, diabetes, obesity, smoking, nonalcoholic steatohepatitis, and liver fluke infestation, as well as biliary diseases, such as primary sclerosing cholangitis, hepatolithiasis, congenital cholangiectasis, and Caroli disease. Chemical risk factors include thorium-232, 1,2-dichloropropane, and dichloromethane. CA19-9 and CEA are recommended as tumor markers for early detection and diagnostic of ICC. Abdominal ultrasonography, CT, and MRI are effective imaging modalities for diagnosing ICC. If bile duct invasion is suspected, imaging modalities for examining the bile ducts may be useful. In unresectable cases, tumor biopsy should be considered when deemed necessary for the differential diagnosis and drug therapy selection. The mainstay of treatment for patients with Child-Pugh class A or B liver function is surgical resection and drug therapy. If the patient has no regional lymph node metastasis (LNM) and has a single tumor, resection is the treatment of choice. If both regional LNM and multiple tumors are present, drug therapy is the first treatment of choice. If the patient has either regional LNM or multiple tumors, resection or drug therapy is selected, depending on the extent of metastasis or the number of tumors. If distant metastasis is present, drug therapy is the treatment of choice. Percutaneous ablation therapy may be considered for patients who are ineligible for surgical resection or drug therapy due to decreased hepatic functional reserve or comorbidities. For unresectable ICC without extrahepatic metastasis, stereotactic radiotherapy (tumor size ≤5 cm) or particle radiotherapy (no size restriction) may be considered. ICC is generally not indicated for liver transplantation, and palliative care is recommended for patients with Child-Pugh class C liver function.
  • Masatoshi Kudo
    Liver cancer 11 4 283 - 289 2022年07月
  • Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Michihisa Moriguchi; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Sadahisa Ogasawara; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
    Liver cancer 11 4 354 - 367 2022年07月 
    Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). Methods: Patients with unresectable HCC were randomized to a TACE plus sorafenib group (N = 80) or a TACE alone group (N = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. Results: At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607-1.223; p = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466-0.938; p = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (p = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. Conclusions: In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hiroshi Shibata; Tomoko Aoki; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo
    Cancer medicine 12 1 325 - 334 2022年06月 
    BACKGROUND/AIM: A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line therapy for unresectable hepatocellular carcinoma (u-HCC) in regard to progression-free survival (PFS) overall survival (OS) has not been reported. We aimed to elucidate which of those given as initial treatment for u-HCC has greater prognostic impact on PFS and OS of affected patients, retrospectively. MATERIALS/METHODS: From 2020 to January 2022, 251 u-HCC (Child-Pugh A, ECOG PS 0/1, BCLC-B/C) treated were enrolled (Atez/Bev-group, n = 194; lenvatinib-group, n = 57). PFS and OS were analyzed following adjustment based on inverse probability weighting (IPW). RESULTS: There was a greater number of patients with macro-vascular invasion in Atez/Bev-group (22.7% vs. 8.8%, p = 0.022). In lenvatinib-group, the frequencies of appetite loss (38.6% vs. 19.6%, p = 0.002), hypothyroidism (21.1% vs. 6.7%, p = 0.004), hand foot skin reaction (19.3% vs. 1.0%, p < 0.001), and diarrhea (10.5% vs. 4.6%, p = 0.012) were greater, while that of general fatigue was lower (22.8% vs. 26.3%, p = 0.008). Comparisons of therapeutic best response using modified response evaluation criteria in solid tumors (mRECIST) did not show significant differences between the present groups (Atez/Bev vs. lenvatinib: CR/PR/SD/PD = 6.1%/39.1%/39.1%/15.6% vs. 0%/48.0%/38.0%/14.0%, p = 0.285). In patients of discontinuation of treatments, 48.2% switched to lenvatinib, 10.6% continued beyond PD, 8.2% received another systemic treatment, 5.9% underwent transcatheter arterial chemoembolization (TACE), 3.5% received hepatic arterial infusion chemotherapy (HAIC), and 1.2% underwent surgical resection in Atez/Bev-group, while 42.2% switched to Atez/Bev, 4.4% continued beyond PD, 4.4% received another systemic treatment, 2.2% nivolumab, 6.7% received TACE, and 2.2% received HAIC in lenvatinib-group. Following adjustment with inverse probability weighting (IPW), Atez/Bev-group showed better PFS (0.5-/1-/1.5-years: 56.6%/31.6%/non-estimable vs. 48.6%/20.4%/11.2%, p < 0.0001) and OS rates (0.5-/1-/1.5-years: 89.6%/67.2%/58.1% vs. 77.8%/66.2%/52.7%, p = 0.002). CONCLUSION: The present study showed that u-HCC patients who received Atez/Bev as a first-line treatment may have a better prognosis than those who received lenvatinib.
  • 胆膵内視鏡治療の工夫とリスクマネージメント 胆嚢結石を合併した総胆管結石に対する内視鏡治療戦略の検討 術前にとるか術後にとるか
    高島 耕太; 三長 孝輔; 鎌田 研; 竹中 完; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 49 - 49 日本消化器内視鏡学会-近畿支部 2022年06月
  • 非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例
    加藤 弘樹; 松井 繁長; 田北 雅弘; 上中 大地; 今村 瑞貴; 原 茜; 野村 健司; 瀬海 郁衣; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 本庶 元; 米田 頼晃; 上嶋 一臣; 渡邉 智裕; 西田 直生志; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 89 - 89 日本消化器内視鏡学会-近畿支部 2022年06月
  • 胆膵内視鏡治療の工夫とリスクマネージメント 胆嚢結石を合併した総胆管結石に対する内視鏡治療戦略の検討 術前にとるか術後にとるか
    高島 耕太; 三長 孝輔; 鎌田 研; 竹中 完; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 49 - 49 日本消化器内視鏡学会-近畿支部 2022年06月
  • 【膵神経内分泌腫瘍-新たなる胎動2022-】画像診断 膵神経内分泌腫瘍の内視鏡診断
    大塚 康生; 鎌田 研; 山崎 友裕; 大本 俊介; 三長 孝輔; 竹中 完; 樫田 博史; 工藤 正俊
    肝胆膵 84 6 783 - 788 (株)アークメディア 2022年06月
  • 安全に内視鏡治療できた小腸pyogenic granuloma(化膿性肉芽腫)の一例
    有山 武尊; 米田 頼晃; 加藤 弘樹; 瀬海 郁衣; 原 茜; 野村 健司; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 82 - 82 日本消化器内視鏡学会-近畿支部 2022年06月
  • Tadatoshi Takayama; Kiyoshi Hasegawa; Namiki Izumi; Masatoshi Kudo; Mitsuo Shimada; Naoki Yamanaka; Masafumi Inomata; Shuichi Kaneko; Hisashi Nakayama; Yoshikuni Kawaguchi; Kosuke Kashiwabara; Ryosuke Tateishi; Shuichiro Shiina; Kazuhiko Koike; Yutaka Matsuyama; Masao Omata; Masatoshi Makuuchi; Norihiro Kokudo
    Liver cancer 11 3 209 - 218 2022年06月 
    Introduction: It remains unclear which surgery or radiofrequency ablation (RFA) is the more effective treatment for small hepatocellular carcinoma (HCC). We aimed to compare survival between patients undergoing surgery (surgery group) and patients undergoing RFA (RFA group). Methods: We conducted a randomized controlled trial involving 49 institutions in Japan. Patients with Child-Pugh scores ≤7, largest HCC diameter ≤3 cm, and ≤3 HCC nodules were considered eligible. The co-primary endpoints were recurrence-free survival (RFS) and overall survival (OS). The current study reports the final result of RFS, and the follow-up of OS is still ongoing. Results: During 2009-2015, 308 patients were registered. After excluding ineligible patients, the surgery and RFA groups included 150 and 151 patients, respectively. Baseline factors did not differ significantly between the groups. In both groups, 90% of patients had solitary HCC. The median largest HCC diameter was 1.8 cm (interquartile range [IQR], 1.5-2.2 cm) in the surgery group and 1.8 cm (IQR, 1.5-2.3 cm) in the RFA group. The median procedure duration (274 vs. 40 min, p < 0.01) and the median duration of hospital stay (17 days vs. 10 days, p < 0.01) were longer in the surgery group than in the RFA group. RFS did not differ significantly between the groups as the median RFS was 3.5 (95% confidence interval [CI], 2.6-5.1) years in the surgery group and 3.0 (95% CI, 2.4-5.6) years in the RFA group (hazard ratio, 0.92; 95% CI, 0.67-1.25; p = 0.58). Discussion/Conclusion: Our study did not show which surgery or RFA is the better treatment option for small HCC.
  • Masatoshi Kudo
    Liver cancer 11 3 185 - 191 2022年06月
  • 非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例
    加藤 弘樹; 松井 繁長; 田北 雅弘; 上中 大地; 今村 瑞貴; 原 茜; 野村 健司; 瀬海 郁衣; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 本庶 元; 米田 頼晃; 上嶋 一臣; 渡邉 智裕; 西田 直生志; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 89 - 89 日本消化器内視鏡学会-近畿支部 2022年06月
  • Brett Marinelli; Edward Kim; Antonio D'Alessio; Mario Cedillo; Ishan Sinha; Neha Debnath; Masatoshi Kudo; Naoshi Nishida; Anwaar Saeed; Hannah Hildebrand; Ahmed O Kaseb; Yehia I Abugabal; Anjana Pillai; Yi-Hsiang Huang; Uqba Khan; Mahvish Muzaffar; Abdul Rafeh Naqash; Rahul Patel; Aaron Fischman; Vivian Bishay; Dominik Bettinger; Max Sung; Celina Ang; Myron Schwartz; David J Pinato; Thomas Marron
    Journal for immunotherapy of cancer 10 6 2022年06月 
    BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes. METHODS: From a retrospective multicenter dataset of 323 patients treated with ICI, we identified 31 patients who underwent >1 TACE 60 days before or concurrently, with nivolumab at a single center. We derived a propensity score-matched cohort of 104 patients based on Child-Pugh Score, portal vein thrombosis, extrahepatic metastasis and alpha fetoprotein (AFP) who received nivolumab monotherapy. We described overall survival (OS), progression-free survival (PFS), objective responses according to modified RECIST criteria and safety in the multimodal arm in comparison to monotherapy. RESULTS: Over a median follow-up of 9.3 (IQR 4.0-16.4) months, patients undergoing multimodal immunotherapy with TACE achieved a significantly longer median (95% CI) PFS of 8.8 (6.2-23.2) vs 3.7 (2.7-5.4) months (log-rank 0.15, p<0.01) in the monotherapy group. Multimodal immunotherapy with TACE demonstrated a numerically longer OS compared with ICI monotherapy with a median 35.1 (16.1-Not Evaluable) vs 16.6 (15.7-32.6) months (log-rank 0.41, p=0.12). In the multimodal treatment group, there were three (10%) grade 3 or higher adverse events (AEs) attributed to immunotherapy compared with seven (6.7%) in the matched ICI monotherapy arm. There were no AEs grade 3 or higher attributed to TACE in the multimodal treatment arm. At 3 months following each TACE in the multimodal arm, there was an overall objective response rate of 84%. There were no significant changes in liver functional reserve 1 month following each TACE. Four patients undergoing multimodal treatment were successfully bridged to transplant. CONCLUSIONS: TACE can be safely integrated with programmed cell death 1 blockade and may lead to a significant delay in tumor progression and disease downstaging in selected patients.
  • Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Cishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo
    Hepatology Research 2022年05月
  • Kosuke Minaga; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2022年05月
  • Takaaki Tanaka; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
    Hepatology research : the official journal of the Japan Society of Hepatology 52 9 773 - 783 2022年05月 
    BACKGROUND/AIM: Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP-A and -B cases. MATERIALS/METHODS: From September 2020 to March 2022, 457 u-HCC patients treated with Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B = 427:30, Child-Pugh score [CPS] 5:6:7:8:9 = 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features and prognosis were retrospectively evaluated. RESULTS: There were no significant differences between CP-A and -B patients in regard to best response (CR:PR:SD:PD = 16:91:194:81 vs. 0:7:13:8, p = 0.739; objective response rate/disease control rate = 28.0%/78.8% vs. 25.0%/71.4%). Analysis performed using inverse probability weighting adjustments of clinical factors other than those related to hepatic reserve function with a p value < 0.10 for comparisons between patients with CP-A and -B showed that the progression-free survival (PFS) rate for CP-A cases was better (6-/12-/18-month: 58.2%/36.1%/27.8% vs. 49.6%/8.7%/non-estimable [NE], p < 0.001), as was overall survival (OS) rate (6-/12-/18-month: 89.9%/71.7%/51.4% versus 63.6%/18.4%/NE; p < 0.001). Median PFS (mPFS) and median OS (mOS) for the CPS-5 were 9.5 months/NE, and 5.1/14.0 months for the CPS-6 (both p < 0.001). Furthermore, for modified albumin-bilirubin grade (mALBI)-1/2a/2b, mPFS was 9.4/8.5/5.3 months (p < 0.001) and mOS was NE/17.8/13.4 months (p < 0.001). CONCLUSION: Better hepatic function, such as mALBI grade 1 or 2a are thought to indicate a better condition for obtaining sufficient prognosis with Atez/Bev treatment for u-HCC patients, whereas for CP-B patients, who mainly shown an mALBI grade of 2b or 3, Atez/Bev might have less therapeutic efficacy.
  • Tomohiro Watanabe; Kosuke Minaga; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo
    Frontiers in Immunology 13 2022年05月 
    Efficient protection against coronavirus disease 2019 (COVID-19) has been achieved by immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, efficient immune responses against this novel virus by vaccination are accompanied by a wide variety of side effects. Indeed, flares or new-onset of autoimmune disorders have been reported soon after the COVID-19 vaccination. Although pro-inflammatory cytokine responses play pathogenic roles in the development of autoimmunity, cytokines charactering COVID-19 vaccination-related autoimmune responses have been poorly understood. Given that mRNA derived from COVID-19 vaccine is a potent inducer for pro-inflammatory cytokine responses, these cytokines might mediate autoimmune responses after COVID-19 vaccination. Here we report a case with new-onset rheumatoid arthritis (RA) following COVID-19 vaccination. Serum concentrations not only of arthrogenic cytokines, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), but also of type I interferon (IFN) were elevated at the active phase in this case. Induction of remission by methotrexate and tocilizumab was accompanied by a marked reduction in serum concentrations of type I IFN, IL-6, and TNF-α. These results suggest that production of type I IFN, IL-6, and TNF-α induced by COVID-19 vaccination might be involved in this case with new-onset RA.
  • Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Tomoko Aoki; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Yoichi Hiasa; Masatoshi Kudo
    Scientific reports 12 1 8421 - 8421 2022年05月 
    We investigated the impact of C-reactive protein to albumin ratio (CAR) on predicting outcomes in 522 patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib. We determined the optimal CAR cutoff value with time-dependent receiver operating characteristic curve analysis. Additionally, we clarified the relationship between CAR and liver function or HCC progression. Median overall survival was 20.0 (95% confidence interval (CI), 17.2-22.6) months. The optimal CAR cutoff value was determined to be 0.108. Multivariate analysis showed that high CAR (≥ 0.108) (hazard ratio (HR), 1.915; 95% CI, 1.495-2.452), Eastern Cooperative Oncology Group performance status ≥ 1 (HR, 1.429), and α-fetoprotein ≥ 400 ng/mL (HR, 1.604) were independently associated with overall survival. Cumulative overall survival differed significantly between patients with low versus high CAR (p < 0.001). Median progression-free survival was 7.5 (95% CI, 6.7-8.1) months. Multivariate analysis showed that age, CAR ≥ 0.108 (HR, 1.644; 95% CI, 1.324-2.043), and non-hepatitis B, non-hepatitis C etiology (HR, 0.726) were independently associated with progression-free survival. Cumulative progression-free survival differed significantly between patients with low versus high CAR (p < 0.001). CAR values were significantly higher as Japan Integrated Staging score increased (p < 0.001). In conclusion, CAR can predict outcomes in patients with unresectable HCC treated with lenvatinib.
  • Mamoru Takenaka; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2022年05月
  • Sho Masaki; Tomohiro Watanabe; Yasuyuki Arai; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Yasuo Otsuka; Yasuhiro Masuta; Tomoe Yoshikawa; Ryutaro Takada; Ken Kamata; Kosuke Minaga; Kouhei Yamashita; Masatoshi Kudo
    Clinical and experimental immunology 207 3 340 - 350 2022年05月 
    Cellular inhibitors of apoptosis proteins 1 (cIAP1) and 2 (cIAP2) are involved in signaling pathways mediated by Toll-like receptors (TLRs) and tumor necrosis factor (TNF)-α. Excessive activation of TLRs and TNF-α underlies the immunopathogenesis of Crohn's disease (CD) and ulcerative colitis (UC). However, the roles played by cIAP1 and cIAP2 in the development of CD and UC remain poorly understood. In this study, we attempted to clarify the molecular link between cIAP1/cIAP2 and colonic inflammation. Human monocyte-derived dendritic cells (DCs) treated with siRNAs specific for cIAP1 or cIAP2 exhibited reduced pro-inflammatory cytokine responses upon stimulation with TLR ligands. Expression of cIAP1 and cIAP2 in human DCs was suppressed in the presence of interferon regulatory factor 4 (IRF4). This effect was associated with inhibition of cIAP1 and cIAP2 polyubiquitination. To verify these in vitro findings, we created mice overexpressing IRF4 in DCs and showed that these mice were resistant to trinitrobenzene sulfonic acid-induced colitis as compared with wild-type mice; these effects were accompanied by reduced expression levels of cIAP1 and cIAP2. Pro-inflammatory cytokine production by mesenteric lymph node cells upon stimulation with TLR ligands was reduced in mice with DC-specific IRF4 overexpression as compared with that in wild-type mice. Finally, in clinical samples of the colonic mucosa from patients with CD, there was a negative relationship between the percentage of IRF4+ DCs and percentages of cIAP1+ or cIAP2+ lamina propria mononuclear cells. These data suggest that the colitogenic roles of cIAP1 and cIAP2 are negatively regulated by IRF4.
  • Masatoshi Kudo
    International journal of clinical oncology 2022年05月 
    Since the approval of sorafenib for the treatment of unresectable hepatocellular carcinoma in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and atezolizumab plus bevacizumab for first-line treatment, and regorafenib, cabozantinib, and ramucirumab for second-line treatment, which are currently available for clinical use. The positive results of durvalumab, a programmed cell death ligand 1 antibody, plus tremelimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, were also presented at the 2022 American Society Clinical Oncology Gastrointestinal Cancers Symposium as superior to sorafenib in prolonging the overall survival; this combination is expected to be approved by the end of 2022. These systemic therapies are changing the treatment paradigm not only for advanced hepatocellular carcinoma but also for intermediate-stage hepatocellular carcinoma. This review focuses on the role of systemic therapy in intermediate-stage hepatocellular carcinoma.
  • Mamoru Takenaka; Shunsuke Omoto; Masatoshi Kudo
    Endoscopic ultrasound 2022年05月
  • Shunsuke Omoto; Mamoru Takenaka; Fauze Maluf-Filho; Masatoshi Kudo
    VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy 7 5 165 - 168 2022年05月 
    Video 1A novel training method for endoscopic ultrasound operators, the Educational Program of Kindai system enables visualization of a trainee's learning curve and difficult-to-learn areas. This visualization helps both the trainer and the trainee to structure learning and teaching methods in real time.
  • Henry L Y Chan; Arndt Vogel; Thomas Berg; Enrico N De Toni; Masatoshi Kudo; Jörg Trojan; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Ashish Sharma; Kairat Madin; Vinzent Rolny; Marcus-Rene Lisy; Teerha Piratvisuth
    JGH open : an open access journal of gastroenterology and hepatology 6 5 292 - 300 2022年05月 
    Background and Aims: Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. We aimed to assess the clinical and analytical performance of the Elecsys® PIVKA-II immunoassay in diagnosing HCC and evaluate PIVKA-II's technical performance. Methods: Serum samples from adult cases (i.e. patients with a first-time HCC diagnosis; n = 168) and disease controls (i.e. patients without HCC with an at-risk condition; n = 208) were assessed. An AFP cut-off of 20 ng/mL was used to differentiate between HCC cases and disease controls. Clinical performance of the Elecsys PIVKA-II assay was compared with that of comparator assays (Lumipulse G PIVKA-II, μTASWako DCP, ARCHITECT PIVKA-II) using receiver operating characteristic curve analysis to determine the area under the curve (AUC) values. Results: The Elecsys PIVKA-II assay compared favorably with comparator assays. Using a 28.4 ng/mL cut-off, the Elecsys PIVKA-II assay detected HCC with 86.9% sensitivity and 83.7% specificity. Clinical performance of the Elecsys PIVKA-II assay (AUC: 90.8%) was equivalent to that of comparator assays (AUC: 88.3-89.6%). Relatively high PIVKA-II concentrations were observed for cholangiocarcinoma and pancreatic cancer with the Elecsys assay in specificity panel analyses, indicating that high PIVKA-II concentrations should not be used alone in the absence of other clinical data. Conclusions: The Elecsys PIVKA-II assay showed good analytical performance under routine laboratory conditions, comparing favorably with comparator assays. These findings support the suitability of the Elecsys PIVKA-II assay as an aid in HCC diagnosis.
  • Daisuke Morimoto-Ishikawa; Tomoko Hyodo; Mamoru Takenaka; Yuko Matsukubo; Isao Numoto; Makoto Itoh; Masato Ohmi; Ken Kamata; Yu Ueda; Miyuki Wakana; Masatoshi Kudo; Shigeyoshi Saito; Kazunari Ishii
    European journal of radiology 150 110279 - 110279 2022年05月 
    PURPOSE: To compare image quality and the detectability of gallstones in patients with T1 hyperintense bile between single breath-hold three-dimensional (3D) magnetic resonance cholangiopancreatography (MRCP) with gradient and spin-echo (GRASE) and with compressed sensing (CS). METHODS: We retrospectively evaluated patients who underwent MRCP using GRASE and CS and had hyperintense bile on T1-weighted fat-suppressed images. The relative duct-to-periductal contrast ratios (RCs) of each bile duct segment were calculated. Pancreaticobiliary duct visibility, motion artifacts, background suppression, and overall image quality were scored on a 5-point scale. The Wilcoxon signed-rank test was used to analyze differences in qualitative and quantitative results. Diagnostic performance in detecting common bile duct (CBD) and gallbladder stones was assessed using receiver operating characteristic (ROC) curves. RESULTS: In total, 96 patients were included in the study. RCs of all bile duct segments in GRASE MRCP were significantly lower than those in CS MRCP (p < 0.001). All biliary duct visibility and overall image quality had significantly higher scores in GRASE MRCP than in CS MRCP (p < 0.001-0.003). Area under ROC curves of GRASE MRCP and CS MRCP were 1.00 and 0.88 for CBD stone (p = 0.14) and 0.93 and 0.82 for gallbladder stone (p = 0.08), respectively. CONCLUSIONS: GRASE MRCP provides better image quality than CS MRCP in patients with hyperintense bile on T1-weighted images. The detectability of biliary stones was also higher in GRASE MRCP than in CS MRCP, although not significantly.
  • Rohini Sharma; Anjana Pillai; Thomas Urban Marron; Petros Fessas; Anwaar Saeed; Tomi Jun; Sirish Dharmapuri; David Szafron; Abdul Rafeh Naqash; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Chieh-Ju Lee; Pei-Chang Lee; Anushi Bulumulle; Sonal Paul; Dominic Bettinger; Hannah Hildebrand; Mohammed Yehia; Tiziana Pressiani; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Masatoshi Kudo; Naoshi Nishida; Nicola Personeni; Lorenza Rimassa; David James Pinato
    Hepatology communications 6 7 1776 - 1785 2022年04月 
    The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary aim of this retrospective, multicenter study was to examine the types of anticancer treatment received after ICIs and to assess the impact on post-ICI survival. We established an international consortium of 11 tertiary-care referral centers located in the USA (n = 249), Europe (n = 74), and Asia (n = 97), and described patterns of care following ICI therapy. The impact of subsequent therapy on overall survival (OS) was estimated using the Kaplan-Meier method and presented with a 95% confidence interval (CI). A total of 420 patients were treated with ICIs for advanced HCC after one line of systemic therapy (n = 371, 88.8%): 31 (8.8%) had died, 152 (36.2%) received best supportive care (BSC) following ICIs, and 163 patients (38.8%) received subsequent anticancer therapy. Tyrosine kinase inhibitors (TKIs, n = 132, 80.9%), in particular sorafenib (n = 49, 30.0%), were the most common post-ICI therapy followed by external beam radiotherapy (n = 28, 17.2%), further immunotherapy (n = 21, 12.9%), locoregional therapy (n = 23, 14.1%), chemotherapy (n = 9, 5.5%), and surgery (n = 6, 3.6%). Receipt of post-ICI therapy was associated with longer median OS compared with those who had received BSC (12.1 vs. 3.3 months; hazard ratio [HR]: 0.4 (95% CI: 2.7-5.0). No difference in OS was noted in those patients who received TKI before ICIs compared with those who received ICIs followed by TKI. Conclusion: Post-ICI therapy is associated with OS in excess of 12 months, suggesting a role for therapeutic sequencing. OS from TKI therapy was similar to that reported in registration studies, suggesting preserved efficacy following ICIs.
  • Yasunori Minami; Haruyuki Takaki; Koichiro Yamakado; Masatoshi Kudo
    Cancers 14 9 2022年04月 
    Cancer immunotherapy, which reactivates the weakened immune cells of cancer patients, has achieved great success, and several immune checkpoint inhibitors (ICIs) are now available in clinical practice. Despite promising clinical outcomes, favorable responses are only observed in a fraction of patients, and resistance mechanisms, including the absence of tumor antigens, have been reported. Thermal ablation involves the induction of irreversible damage to cancer cells by localized heat and may result in the release of tumor antigens. The combination of immunotherapy and thermal ablation is an emerging therapeutic option with enhanced efficacy. Since thermal ablation-induced inflammation and increases in tumor antigens have been suggested to promote the cancer-immunity cycle, the combination of immuno-oncology (IO) therapy and thermal ablation may be mutually beneficial. In preclinical and clinical studies, the combination of ICI and thermal ablation significantly inhibited tumor growth, and synergistic antitumor effects appeared to prolong the survival of patients with secondary liver cancer. However, evidence for the efficacy of ICI monotherapy combined with thermal ablation is currently insufficient. Therefore, the clinical feasibility of immune response activation by ICI monotherapy combined with thermal ablation may be limited, and thermal ablation may be more compatible with dual ICIs (the IO-IO combination) to induce strong immune responses.
  • Gontran Verset; Ivan Borbath; Mark Karwal; Chris Verslype; Hans Van Vlierberghe; Adel Kardosh; Vittorina Zagonel; Per Stal; Debashis Sarker; Daniel H Palmer; Arndt Vogel; Julien Edeline; Stephane Cattan; Masatoshi Kudo; Ann-Lii Cheng; Sadahisa Ogasawara; Bruno Daniele; Stephen L Chan; Jennifer J Knox; Shu-Kui Qin; Abby B Siegel; Michael Chisamore; Ken Hatogai; Anran Wang; Richard S Finn; Andrew X Zhu
    Clinical cancer research : an official journal of the American Association for Cancer Research 2022年04月 
    PURPOSE: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with aHCC and no prior systemic therapy. EXPERIMENTAL DESIGN: KEYNOTE-224 was an open-label, multi-country phase 2 trial. Eligible patients in cohort 2 had aHCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every three weeks for {less than or equal to}2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease control rate (DCR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety/tolerability. RESULTS: Between Sept 4, 2018 and Feb 20, 2019, 51 patients were allocated in cohort 2. The median time from the first dose to data cutoff (Jan 19, 2021) was 27 months (range, 23-29). ORR was 16% (95% CI, 7-29) and was similar across key subgroups. Median DOR was 16 months (range, 3-24+), and DCR was 57%. The median PFS was 4 months (95% CI, 2-8), and median TTP was 4 months (95% CI, 3-9). Median OS was 17 months (95% CI, 8-23). Grade {greater than or equal to}3 treatment-related adverse events occurred in 16% of patients. CONCLUSIONS: In patients with aHCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC.
  • Ken Kamata; Makiko Kinoshita; Ikuharu Kinoshita; Hajime Imai; Takeshi Ogura; Hisakazu Matsumoto; Kosuke Minaga; Yasutaka Chiba; Mamoru Takenaka; Masatoshi Kudo; Masayuki Kitano
    International journal of clinical oncology 2022年04月 
    OBJECTIVES: This study evaluated the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) in combination with EUS-guided celiac ganglia neurolysis (EUS-CGN) for pancreatic cancer-associated pain. METHODS: This multicenter prospective trial was registered in the University Hospital Medical Information Network (UMIN000031228). Fifty-one consecutive patients with pancreatic cancer-associated pain who presented at one of five Japanese referral centers between February 2018 and March 2021 were enrolled. EUS-CGN was added in cases of visible celiac ganglia. The primary endpoint was effectiveness, defined as a decrease in the numerical rating scale (NRS) by ≥ 3 points. NRS data were prospectively acquired at 1 week after the procedure to evaluate its effectiveness and the extent of pain relief. RESULTS: The technical success rates of EUS-CPN and EUS-CGN were 100% and 80.4%, respectively. The overall efficacy rate was 82.4% [90% confidence interval (CI) 71.2-90.5, P < 0.0001]. The complete pain relief rate was 27.4%. The adverse events rate was 15.7%. The average pain relief period was 72 days. The efficacy rate was higher in the EUS-CPN plus EUS-CGN group than in the EUS-CPN alone group. EUS-CPN plus EUS-CGN was superior to EUS-CPN alone for achieving complete pain relief (P = 0.045). EUS-CGN did not improve the average length of the pain relief period. CONCLUSIONS: EUS-CPN combined with EUS-CGN is safe, feasible, and effective for pain relief in patients with pancreatic cancer. The patients who received additional EUS-CGN had a better short-term response. CLINICAL TRIAL NUMBER: UMIN000031228.
  • Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Yoriaki Komeda; Akihiro Yoshida; Ah-Mee Park; Masako Sato; Akira Kawada; Hajime Nakano; Hiroshi Nakagawa; Masatoshi Kudo
    Scientific reports 12 1 6100 - 6100 2022年04月 
    Liver damage affects the prognosis of patients with erythropoietic protoporphyria (EPP). However, there is no radical cure for EPP patients with severe liver damage. This study aims to investigate the effectiveness of phlebotomy in patients with severe liver damage. We examined seven patients diagnosed with EPP and liver damage between 2010 and 2020. Of the 7 cases, phlebotomy was performed in 3 cases with severe hepatic disorder, and the improvement effect of hepatic disorder was observed in all cases. In addition, as an additional study, we also investigated the mechanism by which liver damage becomes more severe. Liver biopsy samples were stained with hematoxylin and eosin and immunohistochemistry was used to examine the expression of adenosine triphosphate-binding transporter G2 (ABCG2). Liver biopsies were performed in 3 of 7 patients with EPP. Of these three patients, ABCG2 expression was low in two patients, especially in the protoporphyrin (PP) deposition area. Two patients with reduced ABCG2 expression subsequently developed severe liver damage. However, the causal relationship between the decreased expression of ABCG2 and the exacerbation of liver damage has not been directly proved, and further investigation is required in the future. This study demonstrated the effectiveness of phlebotomy in EPP patients with severe liver damage.
  • Yasuhiro Masuta; Tomohiro Watanabe; Kosuke Minaga; Masatoshi Kudo
    Inflammatory bowel diseases 28 8 e113  2022年04月
  • 小型肝細胞癌に対する腹腔鏡下肝切除、開腹肝切除と経皮的ラジオ波焼灼療法の治療成績の比較 SURF trial付随研究
    増田 崇; 遠藤 裕一; 長谷川 潔; 河口 義邦; 高山 忠利; 泉 並木; 山中 若樹; 工藤 正俊; 島田 光生; 金子 周一; 馬場 秀夫; 小池 和彦; 小俣 政男; 幕内 雅敏; 松山 裕; 猪股 雅史; 國土 典宏
    日本外科学会定期学術集会抄録集 122回 SF - 8 (一社)日本外科学会 2022年04月
  • 肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 Phase 2根治後NIVOLVE試験における奏効症例の特徴
    青木 智子; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.1 A35 - A35 (一社)日本肝臓学会 2022年04月
  • 治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 免疫チェックポイント阻害剤投与に伴うirAE肝障害・HBV再活性化についての検討
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.1 A95 - A95 (一社)日本肝臓学会 2022年04月
  • 竹中 完; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊
    臨床消化器内科 37 5 571 - 575 (株)日本メディカルセンター 2022年04月 
    ＜文献概要＞胆道ジスキネジアは胆嚢,総胆管,十二指腸乳頭部に至る胆道系に器質的な病変が認められないにもかかわらず,右季肋部痛を主体とする胆石症様の腹部症状を呈する病態であり,Rome IV診断基準における機能性消化管障害の病型分類の"機能性胆嚢・Oddi乳頭括約筋障害(gallbladder and sphincter of Oddi disorder)"にあたる.問診により胆道痛の定義を満たすが,胆石,総胆管結石や他の器質的疾患を認めない症例のなかで,胆嚢がある症例にgallbladder disorderを疑い,胆嚢摘出後で血液検査にて肝酵素逸脱,もしくは画像検査にて胆管拡張を認める症例に胆道型乳頭括約筋機能異常(SOD)が疑われる.食事療法や生活習慣改善でも症状の改善が認められない場合に薬剤投与治療が施行され,薬物療法が無効な症例には内視鏡的乳頭切開術がおもに行われる.本病態は疑わなければ絶対に診断できない病態であるため,まず疑うことができるか,が最も重要なポイントとなる.
  • 潰瘍性大腸炎関連腫瘍の臨床学的特徴と内視鏡治療時の取り組み
    米田 頼晃; 樫田 博史; 工藤 正俊; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 辻 直子
    Gastroenterological Endoscopy 64 Suppl.1 828 - 828 (一社)日本消化器内視鏡学会 2022年04月
  • 【革新的技術が変える肝疾患診療】AIによる超音波診断
    西田 直生志; 工藤 正俊
    消化器・肝臓内科 11 4 465 - 474 (有)科学評論社 2022年04月
  • 肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 Phase 2根治後NIVOLVE試験における奏効症例の特徴
    青木 智子; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.1 A35 - A35 (一社)日本肝臓学会 2022年04月
  • 治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 免疫チェックポイント阻害剤投与に伴うirAE肝障害・HBV再活性化についての検討
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 63 Suppl.1 A95 - A95 (一社)日本肝臓学会 2022年04月
  • Kosuke Minaga; Tomohiro Watanabe; Ken Kamata; Masatoshi Kudo; Warren Strober
    Current protocols 2 4 e422  2022年04月 
    Pancreatitis occurs in two forms defined by its chronicity. Acute pancreatitis (AP) occurs suddenly and only lasts for several days. Consequently, most patients with AP recover without permanent damage to the pancreas, and about 20% of patients with AP have severe disease. In contrast, chronic pancreatitis (CP) is a long-lasting inflammation that causes permanent damage to pancreatic tissue; consequently, this form is marked by the emergence of persistent endocrine and exocrine pancreatic insufficiency. Despite these differences, AP and CP share central mechanisms of disease: in both forms, inflammation is initiated and/or sustained by the intrapancreatic activation of pancreatic digestive enzymes followed by the autodigestion of pancreatic tissues. In addition, in both forms enzymatic damage is accompanied by changes in intestinal permeability and entry of commensal organisms into the pancreas where they elicit innate immune responses that ultimately dominate and define pancreatic inflammation. In the murine models of AP and CP described here, both of these elements of pancreatitis pathogenesis are taken into account. Thus, in one approach mice are administered high doses of cerulein, a cholecystokinin analog with the ability at this dose to induce excessive activation of the cholecystokinin receptor expressed in pancreatic acinar cells and the release of active trypsin that causes both direct and indirect acinar damages due to entry of commensal organisms and stimulation of innate immune responses. In a second approach mice are administered low doses of cerulein, which causes little or no damage to the pancreas unless given along with nucleotide-binding oligomerization domain 1 (NOD1) ligand, which in the presence of low-dose cerulein administration induces a pathologic innate immune response mediated by NOD1. These approaches are adopted to produce AP when cerulein or cerulein plus NOD1 ligand is applied only once or to produce CP when a similar regimen is applied multiple times. © 2022 Wiley Periodicals LLC. Basic Protocol 1: Cerulein-induced acute pancreatitis Alternate Protocol 1: Acute pancreatitis induced by cerulein and NOD1 ligand Basic Protocol 2: Cerulein-induced chronic pancreatitis Alternate Protocol 2: Chronic pancreatitis induced by cerulein and NOD1 ligand Support Protocol: Isolation of pancreatic mononuclear cells.
  • Naoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Yoshito Mekada; Mutsumi Nishida; Naoya Sakamoto; Takashi Nishimura; Hiroko Iijima; Toshiko Hirai; Ken Takahashi; Masaya Sato; Ryosuke Tateishi; Masahiro Ogawa; Hideaki Mori; Masayuki Kitano; Hidenori Toyoda; Chikara Ogawa; Masatoshi Kudo
    Journal of gastroenterology 57 4 309 - 321 2022年04月 
    BACKGROUND: Ultrasonography (US) is widely used for the diagnosis of liver tumors. However, the accuracy of the diagnosis largely depends on the visual perception of humans. Hence, we aimed to construct artificial intelligence (AI) models for the diagnosis of liver tumors in US. METHODS: We constructed three AI models based on still B-mode images: model-1 using 24,675 images, model-2 using 57,145 images, and model-3 using 70,950 images. A convolutional neural network was used to train the US images. The four-class liver tumor discrimination by AI, namely, cysts, hemangiomas, hepatocellular carcinoma, and metastatic tumors, was examined. The accuracy of the AI diagnosis was evaluated using tenfold cross-validation. The diagnostic performances of the AI models and human experts were also compared using an independent test cohort of video images. RESULTS: The diagnostic accuracies of model-1, model-2, and model-3 in the four tumor types are 86.8%, 91.0%, and 91.1%, whereas those for malignant tumor are 91.3%, 94.3%, and 94.3%, respectively. In the independent comparison of the AIs and physicians, the percentages of correct diagnoses (accuracies) by the AIs are 80.0%, 81.8%, and 89.1% in model-1, model-2, and model-3, respectively. Meanwhile, the median percentages of correct diagnoses are 67.3% (range 63.6%-69.1%) and 47.3% (45.5%-47.3%) by human experts and non-experts, respectively. CONCLUSION:  The performance of the AI models surpassed that of human experts in the four-class discrimination and benign and malignant discrimination of liver tumors. Thus, the AI models can help prevent human errors in US diagnosis.
  • Kentaro Yamao; Takeshi Ogura; Hideyuki Shiomi; Takaaki Eguchi; Hisakazu Matsumoto; Zhao Liang Li; Hiroaki Hashimoto; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Watanabe; Masatoshi Kudo; Tsuyoshi Sanuki
    DEN Open 2 1 e20  2022年04月 
    Objectives: The endoscopic bilateral stent-in-stent (SIS) deployment is a challenging procedure. Such difficulty is mainly caused by sticking of the tip of the delivery sheath into the self-expandable metal stents (SEMSs) mesh, requiring an additional dilating procedure. Herein, we assessed the clinical results of using cross-wired metal stent for endoscopic bilateral SIS deployment (BONASTENT M-Hilar) in patients with malignant hilar biliary obstruction (MHBO) in both high-volume and non-high-volume centers. Methods: We prospectively enrolled consecutive patients with MHBO between February 2016 and December 2018 at eight centers. Results: Forty-six patients were enrolled during the study period. The proportions of technical success were 93.5% (43/46) and clinical success (CS) on intention-to-treat and per-protocol analyses were 91.3% (42/46) and 93.0% (40/43), respectively. The proportion of an additional dilating procedure during the primary procedure was 50.0% (23/46). Recurrent biliary obstruction (RBO) on intention-to-treat analysis occurred in 32.6% (15/46) of cases. Almost all of the events were caused by stent ingrowth (14/15). The median survival time and time to RBO were 255 and 349 days, respectively. The probability of stent patency at 3, 6, and 12 months was 86.5%, 63.9%, and 47.6%, respectively. Conclusions: The cross-wired metal stent had excellent technical and CS, although non-high-volume centers were included in this study (UMIN000021441).
  • Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Vincent E Gaillard; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Rohini Sharma; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato
    Hepatology (Baltimore, Md.) 76 4 1000 - 1012 2022年03月 
    BACKGROUND & AIMS: Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable hepatocellular carcinoma (HCC). No evidence exists as to its use in routine clinical practice in patients with impaired liver function. APPROACH & RESULTS: In 216 HCC patients consecutively treated with AtezoBev across 11 tertiary centres we retrospectively evaluated treatment-related adverse events (trAEs) graded (G) according to CTCAE v5.0, including in the analysis all patients treated according to label (n=202, 94%). We also assessed overall survival (OS), progression-free survival (PFS), overall response (ORR) and disease control rates (DCR) defined by RECIST v1.1. Disease was mostly secondary to viral hepatitis, namely Hepatitis C (n=72; 36%) and Hepatitis B infection (n=35, 17%). Liver function was graded as Child-Pugh (CP)-A in 154 patients (76%) and CP-B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared to CP-A, CP-B patients showed comparable rates of trAEs. Presence and grade of varices at pre-treatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow-up of 9.0 months (95%CI, 7.8-10.1), median OS was 14.9 months (95%CI, 13.6-16.3), while median PFS was 6.8 months (95%CI, 5.2-8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes. CONCLUSIONS: This study confirms reproducible safety and efficacy of AtezoBev in routine practice. CP-B patients reported similar tolerability compared to CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.
  • Mamoru Takenaka; Madan M Rehani; Makoto Hosono; Tomohiro Yamazaki; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi Kudo
    Journal of clinical medicine 11 6 2022年03月 
    Fluoroscopy forms an essential part of endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) and hepaticogastrostomy with antegrade stenting (EUS-HGAS). To date, no study has assessed and compared radiation exposure between EUS-HGS and EUS-HGAS. This study aimed to compare the radiation exposure parameters between EUS-HGS and EUS-HGAS. This retrospective single-center cohort study included consecutive patients who underwent EUS-HGS or EUS-HGAS from October 2017 to March 2019. The air kerma (AK: mGy), kerma-area product (KAP: Gycm2), fluoroscopy time (FT: min), and procedure time (PT: min) were assessed and compared between the two procedures. Altogether, 45 and 24 patients underwent EUS-HGS and EUS-HGAS, respectively. The median AK, KAP, FT, and PT were higher in the EUS-HGAS group than in the EUS-HGS group. A comparison revealed no difference in the technical success rate, complications rate, adverse event occurrence rate, and re-intervention rate between both procedures. This is the first report in which radiation exposure was used as a comparative parameter between EUS-HGS and EUS-HGAS. This study revealed that radiation exposure is significantly higher in EUS-HGAS than in EUS-HGS. Increased awareness on radiation exposure is warranted among gastroenterologists so that they choose the procedure with lower radiation exposure in cases where both procedures are indicated.
  • Josep M Llovet; Amit G Singal; Augusto Villanueva; Richard S Finn; Masatoshi Kudo; Peter R Galle; Masafumi Ikeda; Sophie Callies; Louise M McGrath; Chunxiao Wang; Paolo Abada; Ryan C Widau; Elena Gonzalez-Gugel; Andrew X Zhu
    Clinical cancer research : an official journal of the American Association for Cancer Research 2022年03月 
    PURPOSE: Ramucirumab is an effective treatment for patients with advanced HCC (aHCC) and baseline AFP {greater than or equal to}400 ng/mL. We aimed to identify prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP {greater than or equal to}400 ng/mL from the Phase III REACH and REACH-2 randomized trials. EXPERIMENTAL DESIGN: Patients with aHCC, Child-Pugh class A with prior sorafenib treatment were randomized in REACH and REACH-2 (ramucirumab 8 mg/kg or placebo, biweekly). Meta-analysis of individual patient-level data (pooled population) from REACH (AFP {greater than or equal to}400 ng/mL) and REACH-2 was performed. A drug exposure analysis was conducted for those with evaluable pharmacokinetics data. To identify potential prognostic factors for overall survival (OS), multivariate analyzes were performed using a Cox proportional hazard regression model. To define predictors of ramucirumab benefit, subgroup-by-treatment interactions terms were evaluated. RESULTS: Of 542 patients (316 ramucirumab, 226 placebo) analyzed, 8 variables had independent prognostic value associated with poor outcome (geographical region, ECOG PS {greater than or equal to}1, AFP >1000 ng/mL, Child-Pugh >A5, extrahepatic spread, high neutrophil-to-lymphocyte, high alkaline phosphatase and aspartate aminotransferase). Ramucirumab benefit was present across all subgroups, including patients with very aggressive HCC (above median AFP; HR: 0.64; 95%CI:0.49-0.84) and non-viral aHCC (HR: 0.56; 95%CI:0.40-0.79). While no baseline factor was predictive of a differential OS benefit with ramucirumab, analyzes demonstrated an association between high drug exposure, treatment-emergent hypertension (Grade {greater than or equal to}3) and increased ramucirumab benefit. CONCLUSIONS: Ramucirumab provided a survival benefit irrespective of baseline prognostic covariates, and this benefit was greatest in patients with high ramucirumab drug exposure and/or those with treatment-related hypertension.
  • 齊藤 郁美; 多田 俊史; 熊田 卓; 平岡 淳; 厚川 正則; 青木 智子; 谷 丈二; 豊田 秀徳; 柿崎 暁; 糸林 詠; 能祖 一裕; 畑中 健; 高口 浩一; 石川 達; 福西 新弥; 川田 一仁; 田尻 和人; 島田 紀朋; 日浅 陽一; 工藤 正俊
    日本消化器病学会雑誌 119 臨増総会 A332 - A332 (一財)日本消化器病学会 2022年03月
  • 萩原 智; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 119 臨増総会 A214 - A214 (一財)日本消化器病学会 2022年03月
  • 西田 直生志; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 119 臨増総会 A41 - A41 (一財)日本消化器病学会 2022年03月
  • 上嶋 一臣; 田北 雅弘; 工藤 正俊
    日本消化器病学会雑誌 119 臨増総会 A79 - A79 (一財)日本消化器病学会 2022年03月
  • 西田 直生志; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 119 臨増総会 A41 - A41 (一財)日本消化器病学会 2022年03月
  • 萩原 智; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 119 臨増総会 A214 - A214 (一財)日本消化器病学会 2022年03月
  • Yasuhiro Masuta; Tomohiro Watanabe; Kosuke Minaga; Masatoshi Kudo
    Inflammatory bowel diseases 28 8 e110-e111  2022年02月
  • Mamoru Takenaka; Masatoshi Kudo
    Gut and liver 2022年02月 
    Drainage therapy for malignant biliary obstruction (MBO) includes trans-papillary endoscopic retrograde biliary drainage (ERBD), percutaneous transhepatic biliary drainage (PTBD), and trans-gastrointestinal endoscopic ultrasound-guided biliary drainage (EUS-BD). With the development of chemotherapy, many MBO cases end up needing endoscopic reintervention (E-RI) for recurrent biliary obstruction. To achieve a successful E-RI, it is necessary to understand the various findings regarding E-RI in MBO cases reported to date. Therefore, in this review, we focus on E-RI for ERBD of distal MBO, ERBD of hilar MBO, and EUS-BD. To plan an appropriate E-RI strategy for biliary stent occlusion for MBO, the following must be considered on a case-by-case basis: the urgency of the drainage, the cause of the occlusion, the original route of drainage (PTBD/ERBD/EUS-BD), the initial stent used (plastic stent or self-expandable metallic stent), and in the case of self-expandable metallic stents, the type used (fully covered or uncovered). Regardless of the original method of stent placement, if the inflammation caused by obstructive cholangitis is severe and/or the patient is in shock, PTBD should be considered as the first choice. Finally, it is important to keep in mind that in many cases, performing E-RI will be difficult.
  • Josep M Llovet; Arndt Vogel; David C Madoff; Richard S Finn; Sadahisa Ogasawara; Zhenggang Ren; Kalgi Mody; Jerry J Li; Abby B Siegel; Leonid Dubrovsky; Masatoshi Kudo
    Cardiovascular and interventional radiology 45 4 405 - 412 2022年02月 
    PURPOSE: Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC). Lenvatinib, a multikinase inhibitor, and pembrolizumab, a PD-1 inhibitor, have shown efficacy and tolerability in patients with HCC, and adding this combination to TACE may enhance clinical benefit. PROTOCOL: LEAP-012 is a prospective, double-blind randomized phase 3 study. Adults with confirmed HCC localized to the liver without portal vein thrombosis and not amenable to curative treatment, ≥ 1 measurable tumor per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1), Eastern Cooperative Oncology Group performance status 0 or 1, Child-Pugh class A and no previous systemic treatment for HCC are eligible. Patients will be randomly assigned to lenvatinib once daily plus pembrolizumab every 6 weeks plus TACE or placebos plus TACE. Dual primary endpoints are overall survival and progression-free survival per RECIST 1.1 by blinded independent central review (BICR). Secondary endpoints are progression-free survival, objective response rate, disease control rate, duration of response and time to progression per modified RECIST by BICR; objective response rate, disease control rate, duration of response and time to progression per RECIST 1.1 by BICR; and safety. STATISTICS: The planned sample size, 950 patients, was calculated to permit accumulation of sufficient overall survival events in 5 years to achieve 90% power for the overall survival primary endpoint. DISCUSSION: LEAP-012 will evaluate the clinical benefit of adding lenvatinib plus pembrolizumab to TACE in patients with intermediate-stage HCC not amenable to curative treatment. ClinicalTrials.gov NCT04246177.
  • 腸内細菌に対する炎症性サイトカイン応答の増強を示すクローン病関連脊椎関節炎の一例
    福西 香栄; 本庶 元; 岡井 夏輝; 河野 匡志; 鎌田 研; 三長 孝輔; 米田 頼晃; 辻 成佳; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 108 - 108 日本消化器病学会-近畿支部 2022年02月
  • 浸潤性膵管癌、腺扁平上皮癌が重複膵管に同時発生した1例
    加藤 弘樹; 大本 俊介; 原 茜; 大塚 康夫; 益田 康弘; 高島 耕太; 吉田 晃浩; 福永 朋洋; 岡本 彩那; 山崎 友裕; 鎌田 研; 三長 孝輔; 竹中 完; 筑後 孝章; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 111 - 111 日本消化器病学会-近畿支部 2022年02月
  • 制御性T細胞に依存性しない寛解導入が得られたCollagenous Colitisの一例
    瀬海 郁衣; 本庶 元; 今村 瑞貴; 松原 卓哉; 河野 匡志; 原 茜; 栗本 真之; 吉川 馨介; 益田 康弘; 大塚 康生; 高田 隆太郎; 吉川 智恵; 鎌田 研; 三長 孝輔; 松井 繁長; 木村 雅友; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 117 - 117 日本消化器病学会-近畿支部 2022年02月
  • EUS-FNAにより診断が可能であった、後腹膜DLBCLの1例
    大丸 直哉; 松原 卓哉; 今村 瑞貴; 田中 秀和; 半田 康平; 河野 辰哉; 木下 大輔; 川崎 俊彦; 水野 成人; 若狭 朋子; 大谷 知之; 山田 薫; 花本 仁; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 113 - 113 日本消化器病学会-近畿支部 2022年02月
  • 肝炎ウイルスコントロール下における課題へのアプローチ ICI投与とHBVフォローにおける問題点
    盛田 真弘; 萩原 智; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 73 - 73 日本消化器病学会-近畿支部 2022年02月
  • 免疫チェックポイント阻害剤をめぐる諸問題 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討
    萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 79 - 79 日本消化器病学会-近畿支部 2022年02月
  • 上・下腸間膜動静脈奇形に伴う門脈圧亢進からの難治性腹水及び循環血液量低下に伴う血圧低下に対し血管内治療(IVR)にて改善しえた1例
    上原 広樹; 田北 雅弘; 杉森 啓伸; 岡井 夏輝; 野村 健司; 盛田 真弘; 千品 寛和; 青木 智子; 萩原 智; 依田 広; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 88 - 88 日本消化器病学会-近畿支部 2022年02月
  • 腸内細菌に対する炎症性サイトカイン応答の増強を示すクローン病関連脊椎関節炎の一例
    福西 香栄; 本庶 元; 岡井 夏輝; 河野 匡志; 鎌田 研; 三長 孝輔; 米田 頼晃; 辻 成佳; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 108 - 108 日本消化器病学会-近畿支部 2022年02月
  • 浸潤性膵管癌、腺扁平上皮癌が重複膵管に同時発生した1例
    加藤 弘樹; 大本 俊介; 原 茜; 大塚 康夫; 益田 康弘; 高島 耕太; 吉田 晃浩; 福永 朋洋; 岡本 彩那; 山崎 友裕; 鎌田 研; 三長 孝輔; 竹中 完; 筑後 孝章; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 111 - 111 日本消化器病学会-近畿支部 2022年02月
  • 膵癌診療の進歩と今後の展望 地域連携システムを用いた膵癌早期診断 MAGURO projectの成績
    益田 康弘; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 57 - 57 日本消化器病学会-近畿支部 2022年02月
  • 制御性T細胞に依存性しない寛解導入が得られたCollagenous Colitisの一例
    瀬海 郁衣; 本庶 元; 今村 瑞貴; 松原 卓哉; 河野 匡志; 原 茜; 栗本 真之; 吉川 馨介; 益田 康弘; 大塚 康生; 高田 隆太郎; 吉川 智恵; 鎌田 研; 三長 孝輔; 松井 繁長; 木村 雅友; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 116回 117 - 117 日本消化器病学会-近畿支部 2022年02月
  • Masatoshi Kudo; Masafumi Ikeda; Kazuomi Ueshima; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Kazuhiro Nouso; Kiyoshi Hasegawa; Junji Furuse; Shiro Miyayama; Takamichi Murakami; Tatsuya Yamashita; Norihiro Kokudo
    Hepatology research : the official journal of the Japan Society of Hepatology 52 4 329 - 336 2022年01月 
    Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation or transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2021 by the Liver Cancer Study Group of Japan based on the 2019 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2021 is inclusion of RECIST 1.1 and modified RECIST as response evaluation criteria in systemic therapy for HCC. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally This article is protected by copyright. All rights reserved.
  • Hidekazu Tanaka; Ken Kamata; Rika Ishihara; Hisashi Handa; Yasuo Otsuka; Akihiro Yoshida; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Journal of gastroenterology and hepatology 37 5 841 - 846 2022年01月 
    BACKGROUND AND AIM: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is useful for the diagnosis of lesions inside and outside the digestive tract. This study evaluated the value of artificial intelligence (AI) in the diagnosis of gastric submucosal tumors by CH-EUS. METHODS: This retrospective study included 53 patients with gastrointestinal stromal tumors (GISTs) and leiomyomas, all of whom underwent CH-EUS between June 2015 and February 2020. A novel technology, SiamMask, was used to track and trim the lesions in CH-EUS videos. CH-EUS was evaluated by AI using deep learning involving a residual neural network and leave-one-out cross-validation. The diagnostic accuracy of AI in discriminating between GISTs and leiomyomas was assessed and compared with that of blind reading by two expert endosonographers. RESULTS: Of the 53 patients, 42 had GISTs and 11 had leiomyomas. Mean tumor size was 26.4 mm. The consistency rate of the segment range of the tumor image extracted by SiamMask and marked by the endosonographer was 96% with a Dice coefficient. The sensitivity, specificity, and accuracy of AI in diagnosing GIST were 90.5%, 90.9%, and 90.6%, respectively, whereas those of blind reading were 90.5%, 81.8%, and 88.7%, respectively (P = 0.683). The κ coefficient between the two reviewers was 0.713. CONCLUSIONS: The diagnostic ability of CH-EUS results evaluated by AI to distinguish between GISTs and leiomyomas was comparable with that of blind reading by expert endosonographers.
  • Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
    Cancers 14 2 2022年01月 
    Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor inhibitors has been approved as a first-line treatment for unresectable hepatocellular carcinoma (HCC), indicating a critical role of ICIs in the treatment of HCC. However, 20% of patients do not respond effectively to ICIs; mutations in the activation of the Wnt/β-catenin pathway are known to contribute to primary resistance to ICIs. From this point of view, non-invasive detection of Wnt/β-catenin activation should be informative for the management of advanced HCC. Wnt/β-catenin mutations in HCC have a dual aspect, which results in two distinct tumor phenotypes. HCC with minimal vascular invasion, metastasis, and good prognosis is named the "Jekyll phenotype", while the poorly differentiated HCC subset with frequent vascular invasion and metastasis, cancer stem cell features, and high serum Alpha fetoprotein levels, is named the "Hyde phenotype". To differentiate these two HCC phenotypes, a combination of the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and fluoro-2-deoxy-D-glucose-PET/CT may be useful. The former is applicable for the detection of the Jekyll phenotype, as nodules present higher enhancement on the hepatobiliary phase, while the latter is likely to be informative for the detection of the Hyde phenotype by showing an increased glucose uptake.
  • Kosuke Minaga; Masayuki Kitano; Yoshito Uenoyama; Keiichi Hatamaru; Hideyuki Shiomi; Kenji Ikezawa; Tsukasa Miyagahara; Hajime Imai; Nao Fujimori; Hisakazu Matsumoto; Yuzo Shimokawa; Atsuhiro Masuda; Mamoru Takenaka; Masatoshi Kudo; Yasutaka Chiba
    Endoscopic ultrasound 11 6 478 - 486 2022年 
    BACKGROUND AND OBJECTIVES: Although the use of a long metal stent is favored for EUS-guided hepaticogastrostomy (EUS-HGS) for the relief of malignant biliary obstruction (MBO), endoscopic reintervention (E-RI) at the time of recurrent biliary obstruction (RBO) is challenging due to a long intragastric portion. This study evaluated the feasibility and safety of E-RI after a long partially covered metal stent (L-PCMS) placement during EUS-HGS. MATERIALS AND METHODS: We performed a multicenter retrospective study between January 2015 and December 2019 examining patients with MBO who underwent E-RI for RBO through the EUS-HGS route after the L-PCMS placement. Technical and clinical success rates, details of E-RI, adverse events (AEs), stent patency, and survival time were evaluated. RESULTS: Thirty-three patients at eight referral centers in Japan who underwent E-RI through the EUS-HGS route were enrolled. The location of MBO was distal in 54.5%. The median intragastric length of the L-PCMS was 5 cm. As the first E-RI attempt, E-RI via the distal end of the existing L-PCMS was successful in 60.6%. The overall technical and clinical success rates of E-RI were 100% and 81.8%, respectively. Liver abscess was noted in one patient. A proximal biliary stricture was associated with the clinical ineffectiveness of E-RI in multivariable analysis (odds ratio, 12.5, P = 0.04). The median survival and stent patency duration after E-RI were 140 and 394 days, respectively. CONCLUSIONS: Our study findings suggest that E-RI for RBO after EUS-HGS with a L-PCMS is technically feasible and clinically effective, without any severe AEs, especially for patients with distal MBO.
  • Mamoru Takenaka; Shunsuke Omoto; Masatoshi Kudo
    Endoscopic ultrasound 11 6 520 - 521 2022年
  • 【AIの足音は肝胆膵診療に聞こえてきたか!】肝臓学とAI 超音波画像でのAIを用いた肝腫瘤検出と鑑別診断
    西田 直生志; 山川 誠; 目加田 慶人; 椎名 毅; 工藤 正俊
    肝胆膵 84 1 37 - 45 (株)アークメディア 2022年01月
  • 【AIの足音は肝胆膵診療に聞こえてきたか!】肝臓学とAI AIを用いたHCCに対するTKIの効果予測
    池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊
    肝胆膵 84 1 63 - 68 (株)アークメディア 2022年01月
  • Mamoru Takenaka; Masatoshi Kudo
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 119 4 285 - 294 2022年
  • Masatoshi Kudo
    Liver cancer 11 1 1 - 8 2022年01月
  • Ambreen Muhammed; Claudia Angela Maria Fulgenzi; Sirish Dharmapuri; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas U Marron; Tomi Jun; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Musharraf Navaid; Abdul Rafeh Naqash; Anuhya Gampa; Umut Ozbek; Junk-Yi Lin; Ylenia Perone; Bruno Vincenzi; Marianna Silletta; Anjana Pillai; Yinghong Wang; Uqba Khan; Yi-Hsiang Huang; Dominik Bettinger; Yehia I Abugabal; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Luca Di Tommaso; Masatoshi Kudo; Arndt Vogel; Francesco A Mauri; Alessio Cortellini; Rohini Sharma; Antonio D'Alessio; Celina Ang; David J Pinato
    Cancers 14 1 2021年12月 
    Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), and prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), and radiologic responses. In our 362 patients treated with immunotherapy, median OS and PFS were 9 and 3.5 months, respectively. Amongst tested inflammatory biomarkers, patients with NLR ≥ 5 had shorter OS (7.7 vs. 17.6 months, p < 0.0001), PFS (2.1 vs. 3.8 months, p = 0.025), and lower objective response rate (ORR) (12% vs. 22%, p = 0.034); similarly, patients with PLR ≥ 300 reported shorter OS (6.4 vs. 16.5 months, p < 0.0001) and PFS (1.8 vs. 3.7 months, p = 0.0006). NLR emerged as independent prognostic factors for OS in univariate and multivariate analysis (HR 1.95, 95%CI 1.45-2.64, p < 0.001; HR 1.73, 95%CI 1.23-2.42, p = 0.002) and PLR remained an independent prognostic factor for both OS and PFS in multivariate analysis (HR 1.60, 95%CI 1.6-2.40, p = 0.020; HR 1.99, 95%CI 1.11-3.49, p = 0.021). Systemic inflammation measured by NLR and PLR is an independent negative prognostic factor in HCC patients undergoing ICI therapy. Further studies are required to understand the biological mechanisms underlying this association and to investigate the predictive significance of circulating inflammatory biomarkers in HCC patients treated with ICIs.
  • Fumitaka Suzuki; Yoshiyuki Suzuki; Yoshiyasu Karino; Yasuhito Tanaka; Masayuki Kurosaki; Hiroshi Yatsuhashi; Tomofumi Atarashi; Masanori Atsukawa; Tsunamasa Watanabe; Masaru Enomoto; Masatoshi Kudo; Naoto Maeda; Hiroshi Kohno; Kouji Joko; Kojiro Michitaka; Koichiro Miki; Kazuhiro Takahashi; Tatsuya Ide; Shigetoshi Fujiyama; Tomoko Kohno; Hiroshi Itoh; Sakiyo Tsukamoto; Yuko Suzuki; Yoshiaki Kawano; Wataru Sugiura; Hiromitsu Kumada
    BMC gastroenterology 21 1 489 - 489 2021年12月 
    BACKGROUND: Tenofovir disoproxil fumarate (TDF) is widely used and recommended as first-line treatment for patients infected with the hepatitis B virus (HBV). However, current data are limited regarding the efficacy and safety of switching to TDF for the treatment of chronic hepatitis B in hepatitis B e-antigen (HBeAg)-positive patients who are virologically suppressed with another nucleos(t)ide analogue. The primary objective of this study was to evaluate the hepatitis B surface antigen (HBsAg) reduction potential of switching from entecavir (ETV) to TDF at week 48 in HBeAg-positive chronic hepatitis B patients with undetectable serum HBV-DNA. METHODS: In this multicenter, single-arm, open-label, phase 4 clinical study, 75 participants currently treated with ETV 0.5 mg once daily were switched to TDF 300 mg once daily for 96 weeks. RESULTS: At week 48, 3/74 participants (4%) achieved 0.25 log10 reduction of HBsAg levels from baseline (the primary endpoint). Mean HBsAg reduction was -0.14 log10 IU/mL and 12% (9/74) achieved 0.25 log10 reduction by 96 weeks. No participants achieved HBsAg seroclearance. HBsAg reduction at weeks 48 and 96 was numerically greater in participants with higher alanine aminotransferase levels (≥ 60 U/L). Seventeen participants (25%) achieved HBeAg seroclearance up to week 96. No participants experienced viral breakthrough. All drug-related adverse events (18 participants [24%]) were mild in intensity, including an increase in urine beta-2-microglobulin (15 participants [20%]). CONCLUSIONS: In conclusion, HBsAg reduction was limited after switching from ETV to TDF in this study population. Further investigation is warranted to better understand the clinical impact of switching from ETV to TDF. ClinicalTrials.gov: NCT03258710 registered August 21, 2017. https://clinicaltrials.gov/ct2/show/NCT03258710?term=NCT03258710&draw=2&rank=1.
  • Masatoshi Kudo; Robert Montal; Richard S Finn; Florian Castet; Kazuomi Ueshima; Naoshi Nishida; Philipp K Haber; Youyou Hu; Yasutaka Chiba; Myron Schwartz; Tim Meyer; Riccardo Lencioni; Josep M Llovet
    Clinical cancer research : an official journal of the American Association for Cancer Research 28 16 3443 - 3451 2021年12月 
    PURPOSE: Due to the increased number of sequential treatments used for advanced HCC, there is a need for surrogate endpoints of overall survival (OS). We analyze if objective response (OR) is an independent predictor and surrogate endpoint of OS. EXPERIMENTAL DESIGN: A systematic review of randomized clinical trials (RCTs) in advanced HCC published between 2010 and 2020 was conducted to explore OS surrogacy of OR by RECIST and mRECIST. In parallel, RCTs exploring the impact of OR on OS in a time-dependent multivariate analysis were integrated in a meta-analysis. RESULTS: Out of 65 RCTs identified in advanced HCC, we analyzed 34 studies including 14,056 patients that reported OS and OR by either RECIST (n=23), mRECIST (n=5) or both (n=6). When exploring surrogacy, the trial-level correlation between OR odds ratio and OS hazard ratio was R=0.677 by mRECIST and R=0.532 by RECIST. Meta-analysis of five RCT assessing predictors of survival in multivariate analysis found that patients with OR by mRECIST presented a pooled HR for OS of 0.44 (95% CI, 0.27-0.70, p<0.001) compared with non-responders. Responses to atezolizumab-bevacizumab had a greater impact on OS than tyrosine-kinase inhibitor responses. CONCLUSIONS: OR-mRECIST is an independent predictor of OS in patients with advanced HCC. Although correlation of OR-mRECIST and OS is better than with OR-RECIST, the level of surrogacy is modest. Thus, it can be used as endpoint in proof-of-concept phase II trials, but the data does not support its use as a primary endpoint of phase III investigations assessing systemic therapies.
  • 胆膵内視鏡 治療困難症例を克服するための工夫 当院における胆管ステント迷入に対する経乳頭的re-interventionへの取り組み
    大塚 康生; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 107回 76 - 76 日本消化器内視鏡学会-近畿支部 2021年12月
  • 小腸ポリープからの出血によると思われる黒色便の1例
    大丸 直哉; 松原 卓哉; 今村 瑞貴; 河野 辰哉; 半田 康平; 田中 秀和; 木下 大輔; 川崎 俊彦; 水野 成人; 若狭 朋子; 大谷 知之; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 107回 108 - 108 日本消化器内視鏡学会-近畿支部 2021年12月
  • 【膵Interventionの最前線】悪性胃十二指腸閉塞に対する内視鏡的消化管ステンティング
    山雄 健太郎; 竹中 完; 高島 耕太; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 工藤 正俊
    肝胆膵 83 6 899 - 904 (株)アークメディア 2021年12月
  • 【胆膵疾患、一歩進んだ診断のコツ】早期膵癌発見における膵実質萎縮の意義と検出方法
    山雄 健太郎; 竹中 完; 高島 耕太; 田中 秀和; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 工藤 正俊
    消化器・肝臓内科 10 6 655 - 660 (有)科学評論社 2021年12月
  • 難治性胆膵疾患に対する内視鏡診療の取り組み 膵上皮内癌および良性膵管狭窄症例に特徴的なEUS所見の検討 多施設共同後ろ向き研究
    山雄 健太郎; 竹中 完; 南 竜城; 大花 正也; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 107回 53 - 53 日本消化器内視鏡学会-近畿支部 2021年12月
  • 胆膵内視鏡 治療困難症例を克服するための工夫 当院における胆管ステント迷入に対する経乳頭的re-interventionへの取り組み
    大塚 康生; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 107回 76 - 76 日本消化器内視鏡学会-近畿支部 2021年12月
  • 診断に難渋した小腸GISTの一例
    福西 香栄; 永井 知行; 杉森 啓伸; 岡井 夏輝; 高田 隆太郎; 河野 匡志; 正木 翔; 米田 頼晃; 本庶 元; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 107回 127 - 127 日本消化器内視鏡学会-近畿支部 2021年12月
  • 工藤 正俊; 池田 公史; 上嶋 一臣; 坂元 亨宇; 椎名 秀一朗; 建石 良介; 能祖 一裕; 長谷川 潔; 古瀬 純司; 宮山 士朗; 村上 卓道; 山下 竜也; 國土 典宏; 日本肝癌研究会肝癌治療効果判定基準作成委員会
    肝臓 62 12 823 - 829 (一社)日本肝臓学会 2021年12月
  • Mamoru Takenaka; Makoto Hosono; Shiro Hayashi; Tsutomu Nishida; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2021年11月 
    Fluoroscopy-guided endoscopic procedures (FGEPs) are rapidly gaining popularity in the field of gastroenterology. Radiation is a well-known health hazard. Gastroenterologists who perform FGEPs are required to protect themselves, patients, as well as nurses and radiologists engaged in examinations from radiation exposure. To achieve this, all gastroenterologists must first understand and adhere to the International Commission on Radiological Protection Publication. In particular, it is necessary to understand the three principles of radiation protection (Justification, Optimization, and Dose Limits), the As Low As Reasonably Achievable principle, and the Diagnostic Reference Levels (DRLs) according to them. This review will mainly explain the three principles of radiation exposure protection, DRLs, and occupational radiological protection in interventional procedures while introducing related findings. Gastroenterologists must gain knowledge of radiation exposure protection and keep it updated.
  • Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Yasunori Minami; Yoriaki Komeda; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Chishina; Akihiro Yoshida; Hiroshi Ida; Masatoshi Kudo
    Cells 10 11 3257 - 3257 2021年11月 
    The incidence of hepatocellular carcinoma (HCC) related to non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. We analyzed 16 surgically resected HCC cases in which the background liver was pathologically diagnosed as NAFLD. Specimens with Brunt classification grade 3 or higher were assigned as the fibrotic progression group (n = 8), and those with grade 1 or lower were classified as the non-fibrosis progression group (n = 8). Comprehensive mutational and methylome analysis was performed in cancerous and noncancerous tissues. The target gene mutation analysis with deep sequencing revealed that CTNNB1 and TP53 mutation was observed in 37.5% and TERT promoter mutation was detected in 50% of cancerous samples. Furthermore, somatic mutations in non-cancerous samples were less frequent, but were observed regardless of the progression of fibrosis. Similarly, on cluster analysis of methylome data, status for methylation events involving non-cancerous liver was similar regardless of the progression of fibrosis. It was found that, even in cases of non-progressive fibrosis, accumulation of gene mutations and abnormal methylation within non-cancerous areas were observed. Patients with NAFLD require a rigorous liver cancer surveillance due to the high risk of HCC emergence based on the accumulation of genetic and epigenetic abnormalities, even when fibrosis is not advanced.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 52 3 308 - 316 2021年11月 
    BACKGROUND/AIM: Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u-HCC) classified as beyond the up-to-7 criteria (UT-7 out/multiple) as a transcatheter arterial chemoembolization (TACE) unsuitable condition, few reports have examined the therapeutic efficacy of atezolizumab plus bevacizumab combination therapy (Atez/Bev) in such cases. This study aimed to elucidate the therapeutic response of Atez/Bev in u-HCC patients classified as UT-7 out/multiple. MATERIAL/METHODS: From September 2020 to September 2021, 95 u-HCC Japanese patients classified as UT-7 out/multiple/Child-Pugh A were enrolled from 21 institutions (median age 76 years, males 73, Child-Pugh 5:6 = 68:27, TNM stage II:III = 17:78). Therapeutic response was retrospectively evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), ver. 1.1 and modified RECIST (mRECIST). RESULTS: Atez/Bev was given as first-line treatment to 52 (54.7%). Objective response rate (ORR)/disease control rate (DCR) at six weeks of RECIST and mRECIST were 17.7%/84.7% and 42.5%/86.2%, respectively. Median PFS was 8.0 months (median observation period: 6.0 months). Child-Pugh A/modified Albumin-bilirubin grade (mALBI) 1 and 2a at baseline, 3, 6, and 9 weeks, were 100%/69.4%, 89.8%/57.3%, 94.8%/65.3%, and 91.4%/60.0%, respectively. Among adverse events (any-grade, >10%) during the present observation period, general fatigue was most frequent (23.2%), followed by urine protein (21.1%), appetite loss (20.0%), and hypertension (13.7%). CONCLUSION: Atez/Bev treatment showed favorable therapeutic response with less influence on hepatic function, suggesting it as a useful therapeutic option for patients with such condition.
  • Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 70 1 221554211056853 - 221554211056853 2021年11月 
    Immune checkpoint inhibitors have become the mainstay of treatment for hepatocellular carcinoma (HCC). However, they are ineffective in some cases. Previous studies have reported that genetic alterations in oncogenic pathways such as Wnt/β-catenin are the important triggers in HCC for primary refractoriness. T-cell exhaustion has been reported in various tumors and is likely to play a prominent role in the emergence of HCC due to chronic inflammation and cirrhosis-associated immune dysfunction. Immunosuppressive cells including regulatory T-cells and tumor-associated macrophages infiltrating the tumor are associated with hyperprogressive disease in the early stages of immune checkpoint inhibitor treatment. In addition, stellate cells and tumor-associated fibroblasts create an abundant desmoplastic environment by producing extracellular matrix. This strongly contributes to epithelial to mesenchymal transition via signaling activities including transforming growth factor beta, Wnt/β-catenin, and Hippo pathway. The abundant desmoplastic environment has been demonstrated in pancreatic ductal adenocarcinoma and cholangiocarcinoma to suppress cytotoxic T-cell infiltration, PD-L1 expression, and neoantigen expression, resulting in a highly immunosuppressive niche. It is possible that a similar immunosuppressive environment is created in HCC with advanced fibrosis in the background liver. Although sufficient understanding is required for the establishment of immune therapies of HCC, further investigations are still required in this field.
  • ATP-binding cassette transporter G2(ABCG2)の発現低下はerythropoietic porphyria(EPP)における肝障害の重症化と関連する
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.3 A737 - A737 (一社)日本肝臓学会 2021年11月
  • Segmental arterial mediolysis(SAM)に伴う肝動脈瘤破裂に対して肝動脈塞栓術を施行した1例
    加藤 弘樹; 千品 寛和; 瀬海 郁衣; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.3 A824 - A824 (一社)日本肝臓学会 2021年11月
  • 超音波画像ナショナルデータベース構築とAI支援による次世代超音波診断システムの実用化
    工藤 正俊; 西田 直生志; 椎名 毅
    医療情報学連合大会論文集 41回 176 - 180 (一社)日本医療情報学会 2021年11月
  • Masatoshi Kudo
    Liver cancer 10 6 539 - 544 2021年11月
  • Petros Fessas; Muntaha Naeem; Matthias Pinter; Thomas U Marron; David Szafron; Lorenz Balcar; Anwaar Saeed; Tomi Jun; Sirish Dharmapuri; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Musharraf Navaid; Pei-Chang Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Yehia I Abugabal; Tiziana Pressiani; Nicola Personeni; Naoshi Nishida; Masatoshi Kudo; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Anjana Pillai; Lorenza Rimassa; Abdul Rafeh Naqash; Elad Sharon; Alessio Cortellini; David J Pinato
    Liver cancer 10 6 583 - 592 2021年11月 
    Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indications; however, the effect of ATB is undefined in HCC. Methods: In a large international cohort of 450 ICI recipients from Europe, North America, and Asia, we categorized patients according to timing of ATB focusing on exposure within -30 to +30 days from ICI (early immunotherapy period [EIOP]). EIOP was evaluated in association with overall survival (OS), progression-free survival (PFS), and best radiologic response using RECIST 1.1 criteria. Results: Our study comprised mostly cirrhotic (329, 73.3%) males (355, 79.1%) with a Child-Turcotte Pugh class of A (332, 73.9%), receiving ICI after 1 therapy line (251, 55.9%) for HCC of Barcelona clinic liver cancer stage C (325, 72.4%). EIOP (n = 170, 37.9%) was independent of baseline clinicopathologic features of HCC and correlated with longer PFS (6.1 vs. 3.7 months, log-rank p = 0.0135). EIOP+ patients had similar OS, overall response, and disease control rates (DCRs) compared to EIOP. The effect of EIOP persisted in landmark time analyses and in multivariable models, confirming the independent predictive role of EIOP in influencing PFS following adjustment for covariates reflective of tumor burden, liver function, and ICI regimen administered. In patients receiving programmed cell death-1 receptor/ligand inhibitors monotherapy, EIOP was also associated with higher DCRs (61.4% vs. 50.9%, p = 0.0494). Conclusions: Unlike other oncological indications, ATB in the 30 days before or after ICI initiation is associated with improved benefit from immunotherapy, independent of disease and treatment-related features. Evaluation of the immune microbiologic determinants of response to ICI in HCC warrants further investigation.
  • Tomoko Aoki; Naoshi Nishida; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Akira Yamada; Keitaro Sofue; Masakatsu Tsurusaki; Masatoshi Kudo
    Liver cancer 10 6 615 - 628 2021年11月 
    Introduction: Immune checkpoint inhibitors (ICIs) are promising agents for the treatment of hepatocellular carcinoma (HCC). However, the establishment of noninvasive measure that could predict the response to ICIs is challenging. This study aimed to evaluate tumor responses to ICIs using the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), which was shown to reflect Wnt/β-catenin activating mutation. Methods: A total of 68 intrahepatic HCC nodules from 18 patients with unresectable HCC and Child-Pugh class A liver function who received anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy were enrolled in this study. All patients had viable intrahepatic lesions evaluable using the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI within the 6 months prior to the treatment. The relative enhancement ratio was calculated, and the time to nodular progression (TTnP) defined as 20% or more increase in each nodule was compared between higher or hypo-enhancement HCC nodules. Then, the progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) were compared between patients with and without HCC nodules with higher enhancement on hepatobiliary phase images. Results: The median PFS was 2.7 (95% confidence interval [CI]: 1.4-4.0) months in patients with HCC nodules with higher enhancement (n = 8) and 5.8 (95% CI: 0.0-18.9) months in patients with hypointense HCC nodules (n = 10) (p = 0.007). The median TTnP of HCC nodules with higher enhancement (n = 23) was 1.97 (95% CI: 1.86-2.07) months and that of hypointense HCC nodules (n = 45) was not reached (p = 0.003). The ORR was 12.5% (1/8) versus 30.0% (3/10); the disease control rate was 37.5% (3/8) versus 70.0% (7/10), respectively, in patients with or without higher enhancement intrahepatic HCC nodules. Conclusion: The TTnP on HCC nodules with higher enhancement and the median PFS in patients who carried higher enhancement intrahepatic HCC nodules were significantly shorter than those in hypointense HCC nodules with anti-PD-1/PD-L1 monotherapy. The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC.
  • Masatoshi Kudo
    Cancers 13 21 2021年10月 
    Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/β-catenin mutations to a certain degree.
  • Kosuke Minaga; Mamoru Takenaka; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 1 79 - 81 2021年10月
  • Kentaro Yamao; Masakatsu Tsurusaki; Kota Takashima; Hidekazu Tanaka; Akihiro Yoshida; Ayana Okamoto; Tomohiro Yamazaki; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Mamoru Takenaka; Takaaki Chikugo; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi Kudo
    Diagnostics (Basel, Switzerland) 11 10 2021年10月 
    BACKGROUND: Pancreatic cancer (PC) exhibits extremely rapid growth; however, it remains largely unknown whether the early stages of PC also exhibit rapid growth speed equivalent to advanced PC. This study aimed to investigate the natural history of early PCs through retrospectively assessing pre-diagnostic images. METHODS: We examined the data of nine patients, including three patients with carcinoma in situ (CIS), who had undergone magnetic resonance cholangiopancreatography (MRCP) to detect solitary main pancreatic duct (MPD) stenosis >1 year before definitive PC diagnosis. We retrospectively analyzed the time to diagnosis and first-time tumor detection from the estimated time point of first-time MPD stenosis detection without tumor lesion. RESULTS: The median tumor size at diagnosis and the first-time tumor detection size were 14 and 7.5 mm, respectively. The median time to diagnosis and first-time tumor detection were 26 and 49 months, respectively. CONCLUSIONS: No studies have investigated the PC history, especially that of early PCs, including CIS, based on the initial detection of MPD stenosis using MRCP. Assessment of a small number of patients showed that the time to progression can take several years in the early PC stages. Understanding this natural history is very important in the clinical setting.
  • ここまで進んだEUSとその関連手技 超音波内視鏡ガイド下腹腔神経叢ブロック(EUS-guided celiac plexus neurolysis:EUS-CPN)関連手技の現状
    竹中 完; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    日本超音波医学会関西地方会学術集会 48回 64 - 64 (公社)日本超音波医学会-関西地方会 2021年10月
  • IPMNの壁在結節におけるDetective flow imaging(DFI)の有用性について
    高島 耕太; 大本 俊介; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本超音波医学会関西地方会学術集会 48回 83 - 83 (公社)日本超音波医学会-関西地方会 2021年10月
  • 腹部超音波スクリーニング支援のための深層学習による撮影断面推定に関する初期検討
    目加田 慶人; 道満 恵介; 小川 眞広; 西田 直生志; 工藤 正俊
    日本医用画像工学会大会予稿集 40回 301 - 303 (一社)日本医用画像工学会 2021年10月 
    本稿では,腹部超音波スクリーニングにおいて撮影された画像に対して,それが25断面撮影法のどの断面に対応しているかを推定する深層学習手法の初期的検討について述べる.25断面撮影法は腹部スクリーニングにおける診断の網羅性を保証するものであり,画像から撮影された断面が推定できることで腫瘍等が腹部のどの位置に存在しているのかを把握できる.25の断面画像には比較的類似した見えの画像も含まれているため,画像特徴の類似した断面をまとめたクラスとして扱う分類器に加えて,同一クラスと判定された画像をいずれかの断面に分類する分類器を利用する2段階の分類アルゴリズムを開発した.25断面を記録した267例の検査データセットを対象とした評価実験の結果,25クラス分類を単純に適用した場合の正解率が0.790であったのに対して,2段階の分類をする本手法により正解率が0.836に向上したことを確認した.(著者抄録)
  • 盛田 真弘; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 118 臨増大会 A535 - A535 (一財)日本消化器病学会 2021年10月
  • 盛田 真弘; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 118 臨増大会 A535 - A535 (一財)日本消化器病学会 2021年10月
  • 腹部超音波スクリーニング支援のための深層学習による撮影断面推定に関する初期検討
    目加田 慶人; 道満 恵介; 小川 眞広; 西田 直生志; 工藤 正俊
    日本医用画像工学会大会予稿集 40回 301 - 303 (一社)日本医用画像工学会 2021年10月 
    本稿では,腹部超音波スクリーニングにおいて撮影された画像に対して,それが25断面撮影法のどの断面に対応しているかを推定する深層学習手法の初期的検討について述べる.25断面撮影法は腹部スクリーニングにおける診断の網羅性を保証するものであり,画像から撮影された断面が推定できることで腫瘍等が腹部のどの位置に存在しているのかを把握できる.25の断面画像には比較的類似した見えの画像も含まれているため,画像特徴の類似した断面をまとめたクラスとして扱う分類器に加えて,同一クラスと判定された画像をいずれかの断面に分類する分類器を利用する2段階の分類アルゴリズムを開発した.25断面を記録した267例の検査データセットを対象とした評価実験の結果,25クラス分類を単純に適用した場合の正解率が0.790であったのに対して,2段階の分類をする本手法により正解率が0.836に向上したことを確認した.(著者抄録)
  • 【肝胆膵疾患におけるバイオマーカーの意義を探る】膵疾患のバイオマーカー 自然免疫反応からみた自己免疫性膵炎・IgG4関連疾患の血清バイオマーカー IFN-α・IL-33
    原 茜; 三長 孝輔; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊
    肝胆膵 83 4 617 - 623 (株)アークメディア 2021年10月
  • 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会雑誌 118 臨増大会 A760 - A760 (一財)日本消化器病学会 2021年10月
  • Mamoru Takenaka; Makoto Hosono; Shiro Hayashi; Tsutomu Nishida; Masatoshi Kudo
    The British journal of radiology 94 1126 20210399 - 20210399 2021年10月 
    Although many interventions involving radiation exposure have been replaced to endoscopic procedure in the gastrointestinal and hepatobiliary fields, there remains no alternative for enteroscopy and endoscopic retrograde cholangiopancreatography (ERCP), which requires the use of radiation. In this review, we discuss the radiation doses and protective measures of endoscopic procedures, especially for ERCP. For the patient radiation dose, the average dose area product for diagnostic ERCP was 14-26 Gy.cm², while it increased to as high as 67-89 Gy.cm² for therapeutic ERCP. The corresponding entrance skin doses for diagnostic and therapeutic ERCP were 90 and 250 mGy, respectively. The mean effective doses were 3- 6 mSv for diagnostic ERCP and 12-20 mSv for therapeutic ERCP. For the occupational radiation dose, the typical doses were 94 μGy and 75 μGy for the eye and neck, respectively. However, with an over-couch-type X-ray unit, the eye and neck doses reached as high as 550 and 450 μGy, with maximal doses of up to 2.8 and 2.4 mGy/procedure, respectively.A protective lead shield was effective for an over couch X-ray tube unit. It lowered scattered radiation by up to 89.1% in a phantom study. In actual measurements, the radiation exposure of the endoscopist closest to the unit was reduced to approximately 12%. In conclusion, there is a clear need for raising awareness among medical personnel involved endoscopic procedures to minimise radiation risks to both the patients and staff.
  • TNF-αおよびIL-6の関与が考えられた好酸球性胃腸炎の1例
    瀬海 郁衣; 吉川 馨介; 高田 隆太郎; 原 茜; 吉川 智恵; 鎌田 研; 三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 115回 81 - 81 日本消化器病学会-近畿支部 2021年09月
  • Detective flow imaging(DFI)にて特徴的な血流血管を観察し得たIntraductal papillary neoplasm of bile duct(IPNB)の2例
    上中 大地; 岡本 彩那; 大本 俊介; 原 茜; 大塚 康生; 益田 康弘; 高島 耕太; 吉田 晃浩; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 115回 98 - 98 日本消化器病学会-近畿支部 2021年09月
  • 【TACE再考】Intermediate stage肝癌の新たな治療戦略 薬剤先行投与によるconversion治療
    工藤 正俊; 青木 智子; 上嶋 一臣; 西田 直生志
    肝胆膵 83 3 475 - 483 (株)アークメディア 2021年09月
  • B-mode超音波検査による肝腫瘍検出・診断を支援するAIモデルの開発
    西田 直生志; 工藤 正俊
    肝臓 62 Suppl.2 A457 - A457 (一社)日本肝臓学会 2021年09月
  • 薬物性肝障害の実態 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.2 A515 - A515 (一社)日本肝臓学会 2021年09月
  • Gd-EOB-DTPA-enhanced MRI肝細胞相で高信号の肝細胞癌は、PD-1/PD-L1療法への一次耐性を反映し予後不良である
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.2 A552 - A552 (一社)日本肝臓学会 2021年09月
  • 竹中 完; 福永 朋洋; 高島 耕太; 田中 秀和; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    消化器内視鏡 33 9 1459 - 1466 (株)東京医学社 2021年09月 
    近年膵管内圧上昇による病態の治療として、外科的減圧治療、内視鏡的逆行性膵管ドレナージに加え、新たなドレナージ方法としてEUS下経消化管的膵管ドレナージ(EUS-PD)が報告されその有用性が報告されている。EUS-PDとは「胃や十二指腸から、EUSを用いて拡張膵管を描出し、EUS-FNAの要領で膵管にアクセスして内視鏡的にドレナージを行う手法」であるが、治療成績に関してはおおむね80%以上と高いものの手技成功率は63〜100%とばらつきがあり、最新のメタ解析では手技成功率は81.4%、臨床改善率は84.6%とされ、偶発症発症率は21.3%とされている。偶発症には出血や穿孔、頻度は低いながら重症膵炎なども報告されており、EUS-PDは同じEUS下ドレナージ治療であるEUS-BDと比較すると依然確立されていない適応を、慎重に検討する必要がある手技であると考えられる。本稿ではその適応と手技の実際について解説を行う。(著者抄録)
  • EUS-FNAにて術前診断できた食道schwannomaの1例
    福西 香栄; 松井 繁長; 杉森 啓伸; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 米田 頼晃; 山崎 友裕; 山雄 健太郎; 竹中 完; 本庶 元; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊; 白石 治; 安田 卓司
    日本消化器病学会近畿支部例会プログラム・抄録集 115回 79 - 79 日本消化器病学会-近畿支部 2021年09月
  • Masatoshi Kudo
    Liver cancer 10 5 399 - 403 2021年09月
  • Masatoshi Kudo; Richard S Finn; Manabu Morimoto; Kun-Ming Rau; Masafumi Ikeda; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Bruno Daniele; Ho Yeong Lim; David W McIlwain; Reigetsu Yoshikawa; Kenichi Nakamura; Kun Liang; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X Zhu
    Liver cancer 10 5 451 - 460 2021年09月 
    Background: Intermediate-stage hepatocellular carcinoma (HCC), as defined by Barcelona Clinic Liver Cancer (BCLC) stage B, is heterogeneous in terms of liver function and tumor burden. REACH and REACH-2 investigated ramucirumab in patients with HCC after prior sorafenib, with REACH-2 enrolling only patients with baseline α-fetoprotein (AFP) ≥400 ng/mL. An exploratory analysis of outcomes by BCLC stage was performed. Methods: A pooled meta-analysis of independent patient data (stratified by study) from REACH (AFP ≥ 400 ng/mL) and REACH-2 was performed. All patients had Child-Pugh A, Eastern Cooperative Oncology Group performance status 0-1, prior sorafenib treatment, and either HCC BCLC stage B (refractory/not amenable to locoregional therapy) or BCLC stage C. Patients were randomized to ramucirumab 8 mg/kg or placebo every 2 weeks. Median overall survival (OS) and progression-free survival were estimated by the Kaplan-Meier method. Treatment effects in BCLC stage B and C were evaluated by Cox proportional-hazards model; prognosis of BCLC staging for OS was evaluated by multivariate Cox proportional-hazards model. Tumor responses were evaluated according to Response Evaluation in Solid Tumors v1.1. Liver function was assessed with albumin-bilirubin score. Results: Baseline characteristics were generally balanced between treatment arms in each BCLC stage. BCLC staging trended as an independent prognostic factor for OS (B vs. C; hazard ratio [HR] 0.756 [95% CI 0.546-1.046]). Consistent treatment benefit was observed for ramucirumab versus placebo across BCLC stages. Median OS for ramucirumab versus placebo was 13.7 versus 8.2 months; HR (95%): 0.43 (0.23-0.83) and 7.7 versus 4.8 months; HR (95%): 0.72 (0.59-0.89) for BCLC stage B and C, respectively. Adverse events (AEs) were consistent with observations from both studies; hypertension was the most frequent grade ≥3 AE. Liver function was preserved throughout the study and similar between treatment arms in both BCLC stages. Conclusions: Ramucirumab provided a better survival benefit irrespective of BCLC stage and was well tolerated without compromising liver function during treatment.
  • Arndt Vogel; Catherine Frenette; Max Sung; Bruno Daniele; Ari Baron; Stephen L Chan; Jean Frédéric Blanc; Toshiyuki Tamai; Min Ren; Howard J Lim; Daniel H Palmer; Yuko Takami; Masatoshi Kudo
    Liver cancer 10 5 510 - 521 2021年09月 
    Introduction: Baseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact efficacy outcomes and safety profiles of treatments. This post hoc analysis of the phase 3 REFLECT study examined the efficacy and safety outcomes for lenvatinib and for sorafenib in patients with uHCC, assessed by Child-Pugh score (CPS) and albumin-bilirubin (ALBI) grade. Methods: Efficacy and safety were assessed in patient cohorts from REFLECT according to study entry baseline ALBI grade and CPS. Results: Lenvatinib treatment generally provided survival benefits in all groups. Median overall survival (OS) among patients with an ALBI grade of 1 was consistently higher than among patients with an ALBI grade of 2 for both the lenvatinib and sorafenib arms (lenvatinib: 17.4 vs. 8.6 months; sorafenib: 14.6 vs. 7.7 months, respectively). Median OS among patients with a CPS of 5 was consistently higher than among patients with a CPS of 6 (lenvatinib: 15.3 vs. 9.4 months; sorafenib: 14.2 vs. 7.9 months, respectively). Progression-free survival and objective response rates for these ALBI grades and CPS demonstrated similar patterns. Among patients who received lenvatinib and experienced a treatment-related treatment-emergent adverse event leading to withdrawal, 6.6% had an ALBI grade of 1, while 13.3% had an ALBI grade of 2, and 7.9% had a CPS of 5, while 12.1% had a CPS of 6. Conclusions: Better liver function at baseline, as measured by ALBI grade or CPS, may be prognostic for better survival outcomes in patients with uHCC undergoing treatment with lenvatinib or sorafenib.
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    Liver cancer 10 5 535 - 538 2021年09月
  • Yasuo Otsuka; Ken Kamata; Tomoko Hyodo; Takaaki Chikugo; Akane Hara; Hidekazu Tanaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Tomohiro Watanabe; Takuya Nakai; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    Surgical Endoscopy 36 5 3254 - 3260 2021年08月 
    BACKGROUND: The value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for T-staging in patients with extrahepatic bile duct cancer was evaluated. METHODS: This single-center, retrospective study included consecutive patients with extrahepatic bile duct cancer who underwent surgical resection after preoperative EUS, CH-EUS, and contrast-enhanced CT (CE-CT) examinations between June 2014 and August 2017. The capacity of these modalities for T-staging of extrahepatic bile duct cancer was evaluated by assessing invasion beyond the biliary wall into the surrounding tissue, gallbladder, liver, pancreas, duodenum, portal vein system (portal vein and/or superior mesenteric vein), inferior vena cava, and hepatic arteries (proper hepatic artery, right. and/or left. hepatic artery). Blind reading of EUS, CH-EUS, and CE-CT images was performed by two expert reviewers each. RESULTS: 38 patients were eligible for analysis, of which eight had perihilar bile duct cancer and 30 had distal bile duct cancer. Postoperative T-staging was T1 in 6, T2 in 16, and T3 in 16 cases. CH-EUS was superior to CE-CT for diagnosing invasion beyond the biliary wall into surrounding tissue (92.1% vs. 45.9%, P = 0.0002); the ability to detect invasion to other organs did not differ significantly between the two modalities. The accuracy of CH-EUS for T-staging of tumors was better than that of CE-CT (73.7% vs. 39.5%, P = 0.0059). CH-EUS tended to have a better accuracy than EUS for the diagnosis of invasion beyond the biliary wall into the surrounding tissue (92.1% vs. 78.9%, P = 0.074) and T-staging (73.7% vs. 60.5%, P = 0.074). CONCLUSION: CH-EUS is useful for T-staging of extra hepatic bile duct cancer, especially in terms of invasion beyond the biliary wall into the surrounding tissue.
  • Yasunobu Yamashita; Toshio Shimokawa; Reiko Ashida; Christoph F Dietrich; Mirko D'Onofrio; Yoshiki Hirooka; Masatoshi Kudo; Hideaki Mori; Atsushi Sofuni; Masayuki Kitano
    Ultrasound in medicine & biology 47 12 3315 - 3322 2021年08月 
    The incidence and mortality rates of pancreatic cancer (PC) are increasing. It is important to discriminate PC from the other pancreatic lesions; however, differential diagnosis based on conventional transabdominal ultrasound (US) remains challenging even though US is often the first examination performed. Transabdominal contrast-enhanced ultrasound (CEUS) has high diagnostic accuracy for PC. This meta-analysis aimed to examine the utility of low-mechanical-index CEUS with enhancement for PC diagnosis. A systematic meta-analysis of all potentially relevant articles was performed. Fixed-effects or random-effects models were used to investigate pooled sensitivity, specificity, positive likelihood ratio (LR) and negative LR. The study enrolled 983 patients from nine eligible studies. The pooled estimates of sensitivity and specificity were 92% (95% confidence interval [CI]: 0.89-0.94) and 76% (95% CI: 0.71-0.81), respectively. The diagnostic odds ratio (DOR) for CEUS was high (53.62). The area under the summary receiver operating characteristic curve was 0.95. Funnel plots revealed no publication bias, and there was no significant relationship between the DORs and study characteristics, including continent, type of contrast agent, contrast agent dosage and scan phase. Only number of patients affected diagnostic ability. This meta-analysis indicates that CEUS with enhancement pattern is useful for diagnosis of PC.
  • Ryutaro Takada; Kosuke Minaga; Akane Hara; Yasuo Otsuka; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Hajime Honjo; Shigenaga Matsui; Takaaki Chikugo; Tomohiro Watanabe; Masatoshi Kudo
    Journal of Clinical Medicine 10 16 3716 - 3716 2021年08月 
    Due to the tendency of gastric linitis plastica (GLP) to cause extensive submucosal infiltration, a superficial endoscopic biopsy sometimes yields no evidence of malignancy, hindering definite diagnosis. The present study was a single-center retrospective analysis of 54 consecutive patients diagnosed with GLP between 2016 and 2020 to evaluate EUS-guided fine-needle aspiration (EUS-FNA) biopsy outcomes in patients with negative endoscopic biopsy findings. A pathological GLP diagnosis was achieved by endoscopic biopsy in 40 patients (74.1%). EUS-FNA biopsy with a 22-gauge needle was performed in 13 of the remaining 14 patients, and GLP diagnosis was confirmed in 10 patients, with a median of three needle passes. The remaining four patients were laparoscopically diagnosed with GLP. The diagnostic ability of EUS-FNA biopsy for GLP was 76.9%, and EUS-FNA biopsy contributed to GLP diagnosis in 18.5% (10/54) of all cases. None of the 13 patients exhibited EUS-FNA biopsy-related adverse events. Univariable and multivariable analyses revealed an absence of superficial ulcerations as a predictor of false-negative endoscopic biopsy findings in patients with GLP. These results suggest EUS-FNA biopsy as a minimally invasive and safe alternative diagnostic modality for GLP in cases where conventional endoscopic biopsy fails to verify malignancy, although prospective studies with larger cohorts are warranted to confirm these findings.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Joji Tani; Kazuya Kariyama; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Tomoko Aoki; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Taeang Arai; Tomomi Okubo; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Koji Joko; Yoichi Hiasa; Masatoshi Kudo
    Scientific reports 11 1 16663 - 16663 2021年08月 
    It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC patients with Child-Pugh A were enrolled, and divided into the NAFLD/NASH (n = 103) and Viral/Alcohol (n = 427) groups. Clinical features were compared in a retrospective manner. Progression-free survival (PFS) was better in the NAFLD/NASH than the Viral/Alcohol group (median 9.3 vs. 7.5 months, P = 0.012), while there was no significant difference in overall survival (OS) (20.5 vs. 16.9 months, P = 0.057). In Cox-hazard analysis of prognostic factors for PFS, elevated ALT (≥ 30 U/L) (HR 1.247, P = 0.029), modified ALBI grade 2b (HR 1.236, P = 0.047), elevated AFP (≥ 400 ng/mL) (HR 1.294, P = 0.014), and NAFLD/NASH etiology (HR 0.763, P = 0.036) were significant prognostic factors. NAFLD/NASH etiology was not a significant prognostic factor in Cox-hazard analysis for OS (HR0.758, P = 0.092), whereas AFP (≥ 400 ng/mL) (HR 1.402, P = 0.009), BCLC C stage (HR 1.297, P = 0.035), later line use (HR 0.737, P = 0.014), and modified ALBI grade 2b (HR 1.875, P < 0.001) were significant. Lenvatinib can improve the prognosis of patients affected by u-HCC irrespective of HCC etiology or its line of treatment.
  • 高島 耕太; 大本 俊介; 大塚 康生; 吉田 晃浩; 吉川 智恵; 岡本 彩那; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太朗; 竹中 完; 工藤 正俊
    胆道 35 3 519 - 519 (一社)日本胆道学会 2021年08月
  • 特別鼎談 最新の肝癌薬物療法を語る
    工藤正俊; 土谷 薫; 長谷川 潔
    肝胆膵 163 179 2021年08月 [査読有り]
  • 田中 秀和; 水野 成人; 橋本 和彦; 大谷 知之; 若狹 朋子; 福永 朋洋; 工藤 正俊
    胆道 35 3 425 - 425 (一社)日本胆道学会 2021年08月
  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 WNT/β-catenin経路の活性化と免疫療法の効果
    盛田 真弘; 西田 直生志; 工藤 正俊
    肝胆膵 83 2 197 - 207 (株)アークメディア 2021年08月
  • 竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    膵臓 36 3 A200 - A200 (一社)日本膵臓学会 2021年08月
  • 胆嚢病変に対するDetective flow imaging(DFI)の有用性について
    高島 耕太; 大本 俊介; 大塚 康生; 吉田 晃浩; 吉川 智恵; 岡本 彩那; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太朗; 竹中 完; 工藤 正俊
    胆道 35 3 519 - 519 日本胆道学会 2021年08月
  • X線透視下胆管擦過細胞診・胆管生検の診断能についての検討
    田中 秀和; 水野 成人; 橋本 和彦; 大谷 知之; 若狹 朋子; 福永 朋洋; 工藤 正俊
    胆道 35 3 425 - 425 日本胆道学会 2021年08月
  • 膵疾患におけるinterventional endoscopyの進歩 Walled-off necrosisに対するContrast enhanced EUS-guided cyst drainageの有用性
    竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    膵臓 36 3 A200 - A200 (一社)日本膵臓学会 2021年08月
  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 WNT/β-catenin経路の活性化と免疫療法の効果
    盛田 真弘; 西田 直生志; 工藤 正俊
    肝胆膵 83 2 197 - 207 (株)アークメディア 2021年08月
  • Kosuke Minaga; Tomohiro Watanabe; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo
    Frontiers in Immunology 12 2021年07月 
    Although plasmacytoid dendritic cells (pDCs) able to produce large amounts of type 1 interferons (IFN-I) play beneficial roles in host defense against viral infections, excessive activation of pDCs, followed by robust production of IFN-I, causes autoimmune disorders including systemic lupus erythematosus (SLE) and psoriasis. Autoimmune pancreatitis (AIP), which is recognized as a pancreatic manifestation of systemic immunoglobulin G4-related disease (IgG4-RD), is a chronic fibroinflammatory disorder driven by autoimmunity. IgG4-RD is a multi-organ autoimmune disorder characterized by elevated serum concentrations of IgG4 antibody and infiltration of IgG4-expressing plasmacytes in the affected organs. Although the immunopathogenesis of IgG4-RD and AIP has been poorly elucidated, recently, we found that activation of pDCs mediates the development of murine experimental AIP and human AIP/IgG4-RD via the production of IFN-I and interleukin-33 (IL-33). Depletion of pDCs or neutralization of signaling pathways mediated by IFN-I and IL-33 efficiently inhibited the development of experimental AIP. Furthermore, enhanced expression of IFN-I and IL-33 was observed in the pancreas and serum of human AIP/IgG4-RD. Thus, AIP and IgG4-RD share their immunopathogenesis with SLE and psoriasis because in all these conditions, IFN-I production by pDCs contributes to the pathogenesis. Because the enhanced production of IFN-I and IL-33 by pDCs promotes chronic inflammation and fibrosis characteristic for AIP and IgG4-RD, neutralization of IFN-I and IL-33 could be a new therapeutic option for these disorders. In this Mini Review, we discuss the pathogenic roles played by the pDC-IFN-I-IL-33 axis and the development of a new treatment targeting this axis in AIP and IgG4-RD.
  • Robin Kate Kelley; Bruno Sangro; William Harris; Masafumi Ikeda; Takuji Okusaka; Yoon-Koo Kang; Shukui Qin; David W-M Tai; Ho Yeong Lim; Thomas Yau; Wei-Peng Yong; Ann-Lii Cheng; Antonio Gasbarrini; Silvia Damian; Jordi Bruix; Mitesh Borad; Johanna Bendell; Tae-You Kim; Nathan Standifer; Philip He; Mallory Makowsky; Alejandra Negro; Masatoshi Kudo; Ghassan K Abou-Alfa
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology JCO2003555  2021年07月 
    PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348). PATIENTS AND METHODS: Patients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles. RESULTS: A total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively. CONCLUSION: All regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.
  • Hajime Honjo; Tomohiro Watanabe; Mizuki Tomooka; Takuya Matsubara; Masashi Kono; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Keisuke Yoshikawa; Yasuhiro Masuta; Yasuo Otsuka; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Shigenaga Matsui; Masatomo Kimura; Masatoshi Kudo
    Frontiers in Medicine 8 2021年07月 
    Collagenous colitis (CC), a prototypical microscopic colitis, is a chronic inflammatory disorder of the colon. The diagnosis of CC depends on the pathological examination. The colonic mucosa of patients with CC is characterized by the presence of a substantially thickened collagen band (&gt;10μm) under the surface epithelium. In addition, intraepithelial and lamina propria lymphocytes are markedly increased in patients with CC. However, the roles played by the lymphocytes accumulating in the colonic mucosa of patients with CC are poorly defined. Recent studies indicate that T cells infiltrating the colonic mucosa of patients with CC are mainly represented by CD4+ T cells, CD8+ T cells, and forkhead box P3 (FOXP3)+ regulatory T cells (Tregs). Given that activation of CD4+/CD8+ T cells and FOXP3+ Tregs usually mediates pro-inflammatory and anti-inflammatory responses, respectively, alterations in the colonic numbers of these adaptive T cells might be related to the resolution of colitis in patients with CC. We determined alterations in the composition of colonic T cells by extensive immunohistochemical (IHC) analyses in a case of CC successfully treated with budesonide and metronidazole. Colonic lamina propria immune cells mainly comprised CD3+ T cells, CD4+ T cells, CD8+ T cells, CD68+ macrophages, and FOXP3+ Tregs, but not CD20+ B cells or myeloperoxidase (MPO)+ granulocytes in the active phase. During remission, the numbers of CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD68+ macrophages did not change significantly in the colonic lamina propria, whereas FOXP3+ Tregs were markedly decreased, suggesting that induction of remission was achieved in a Treg-independent manner. Thus, our study indicates that accumulation of FOXP3+ Tregs in the colonic mucosa of patients with CC might be a counter-regulatory mechanism reflecting persistent inflammation and that induction of remission might be achieved without activation of Tregs.
  • Toshiharu Sakurai; Marco A De Velasco; Kazuko Sakai; Tomoyuki Nagai; Hiroki Nishiyama; Kentaro Hashimoto; Hirotsugu Uemura; Hisato Kawakami; Kazuhiko Nakagawa; Hiroyuki Ogata; Kazuto Nishio; Masatoshi Kudo
    Molecular oncology 2021年07月 
    Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies. Although the gut microbiome is known to influence the efficacy of ICIs on epithelial tumors, the functional interactions between gut taxa and colonic mucosa remain poorly understood. Here we performed transcriptomic profiling and 16S rRNA sequencing to investigate the relationships between mucosal gene expression and microbial composition with ICI responses and gastrointestinal immune-related adverse events (GI irAEs). In responders, genes related to DNA repair and cell cycle signatures were enriched in responders whereas signatures related to innate immune response, NFAT and IFN-γ signaling pathways were enriched in nonresponders. Gut microbial composition revealed an association between moderate GI irAE and favorable response to ICI therapy. Favorable therapeutic responses to ICI and GI irAE treatments were associated with taxa classified as Enterobacteriaceae and were related to ribonucleoprotein complex biogenesis, cytokine-mediated signaling pathway, tRNA metabolic process, and ribonucleoprotein complex assembly in the colon. These findings open new perspectives for improving the efficacy and safety of cancer immunotherapy.
  • Yasunori Minami; Masahiro Morita; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    Ultrasound in medicine & biology 47 10 2930 - 2935 2021年07月 
    Developments in image fusion technology made it possible to visualize the ablative margin on ultrasound (US). The purpose of the present study was to assess the ablative area of radiofrequency ablation for hepatocellular carcinoma and compare it with the ablative hyperechoic zone with a non-enhanced area on contrast-enhanced US/contrast-enhanced computed tomography (CEUS/CECT) in the same cross-section. This retrospective study included 25 patients with 27 hepatocellular carcinomas. The long and short dimensions of the ablative hyperechoic zone were measured using B-mode US, and those of the non-enhanced area were assessed with CEUS/CECT on the same cross-section measured with B-mode US, using image fusion techniques. The technical effectiveness of ablation with an adequate ablative margin in a single session was determined in all patients. The long and short dimensions of the ablative hyperechoic zone ranged between 15.0 and 40.7 mm (mean: 27.3 ± 6.9 mm) and between 14.0 and 33.0 mm (mean: 23.3 ± 5.8 mm), respectively. R values for the long and short dimensions were 0.99 and 0.98, respectively, between B-mode US and CEUS, and 0.96 and 0.92, respectively, between B-mode US and CECT. The ablative hyperechoic zone may be regarded as a necrotic lesion after radiofrequency ablation.
  • Yasuhiro Masuta; Yoriaki Komeda; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Keisuke Yoshikawa; Yasuo Otsuka; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Osamu Maenishi; Tomohiro Watanabe; Masatoshi Kudo
    Asian Pacific journal of allergy and immunology 2021年07月 
    BACKGROUND: Granulomatosis with polyangiitis (GPA) is characterized by granulomatous inflammation, vasculitis, and elevated levels of serum proteinase 3 (PR3)-anti-neutrophil cytoplasmic antibody (PR3-ANCA). OBJECTIVE: We tried to characterize immune cells accumulated into the lung lesions of a GPA patient exhibiting spontaneous regression. METHODS: Transbronchial lung biopsy (TBLB) samples were subjected to immunohistochemical analyses. RESULTS: Multiple lung nodules were detected by CT. TBLB showed granulomatous inflammation and small vessel vasculitis. This case was diagnosed as GPA based on pathological findings and elevation of PR-3 ANCA levels. Spontaneous disappearance of multiple lung nodules was observed in CT. CD3+ T cells and CD20+ B cells accumulated in the inflammatory lesions surrounding the vessels whereas granulomatous inflammation was mainly comprised of CD3+ T cells and CD68+ macrophages, but not B cells or myeloperoxidase+ neutrophils. CONCLUSIONS: We characterized immune cell compositions of the lung lesions of a patient with GPA exhibiting spontaneous regression.
  • Kota Takashima; Yoriaki Komeda; Toshiharu Sakurai; Sho Masaki; Tomoyuki Nagai; Shigenaga Matsui; Satoru Hagiwara; Mamoru Takenaka; Naoshi Nishida; Hiroshi Kashida; Konosuke Nakaji; Tomohiro Watanabe; Masatoshi Kudo
    World journal of gastrointestinal pharmacology and therapeutics 12 4 79 - 89 2021年07月 
    BACKGROUND: Preparation for colon capsule endoscopy (CCE) requires a large liquid laxative volume for capsule excretion, which compromises the procedure's tolerability. AIM: To assess the safety and utility of castor oil-boosted bowel preparation. METHODS: This prospective cohort study including 20 patients (age range, 16-80 years; six men and 14 women) suspected of having colorectal disease was conducted at Kindai University Hospital from September 2017 to August 2019. All patients underwent CCE because of the following inclusion criteria: previous incomplete colonoscopy in other facility (n = 20), history of abdominal surgery (n = 7), or organ abnormalities such as multiple diverticulum (n = 4) and adhesion after surgery (n = 6). The exclusion criteria were as follows: Dysphagia, history of allergic reactions to the drugs used in this study (magnesium citrate, polyethylene glycol, metoclopramide, and castor oil), possibility of pregnancy, possibility of bowel obstruction or stenosis based on symptoms, or scheduled magnetic resonance imaging within 2 wk after CCE. The primary outcome was the capsule excretion rate within the battery life, as evaluated by the total large bowel observation rate, large bowel transit time, and bowel creasing level using a five-grade scale in different colorectal segments. The secondary outcomes were complications, colorectal lesion detection rates, and patients' tolerability. RESULTS: The castor oil-based regimen was implemented in 17 patients. Three patients cancelled CCE because they could tolerate castor oil, but not liquid laxatives. The capsule excretion rate within the battery life was 88% (15/17). The mean large bowel transit time was 236 min. Approximately 70% of patients had satisfactory colon cleansing levels. CCE detected colon polyps (14/17, 82%) and colonic diverticulum (4/12, 33%). The sensitivity, specificity, and diagnostic accuracy rates for detecting colorectal polyps (size ≥ 6 mm) were 76.9%, 75.0%, and 76.4%, respectively. The sensitivity, specificity, and diagnostic accuracy rates for detection of diverticulum were 100% each. Twelve patients (71%) rated CCE as more than "good", confirming the new regimen's tolerability. No serious adverse events occurred during this study. CONCLUSION: The castor oil-based regimen could reduce bowel preparation dose and improve CCE tolerability.
  • 胆膵疾患に対する内視鏡診断・治療の工夫 膵上皮内癌におけるEUS所見の検討 多施設共同後ろ向き研究
    山雄 健太郎; 竹中 完; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 106回 59 - 59 日本消化器内視鏡学会-近畿支部 2021年07月
  • 胆膵内視鏡のトラブルマネジメント 胆道Plastic StentドレナージのRe-interventionにおけるSnare Over The Guidewire法の有用性
    吉田 晃浩; 竹中 完; 山雄 健太郎; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 106回 77 - 77 日本消化器内視鏡学会-近畿支部 2021年07月
  • 内視鏡で保存的に回収できた胃石の1例
    杉森 啓伸; 本庶 元; 原 茜; 益田 康弘; 吉田 早希; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 106回 98 - 98 日本消化器内視鏡学会-近畿支部 2021年07月
  • カプセルおよびバルーン小腸内視鏡で比較的早期に発見し根治手術を行った原発性小腸癌の1例
    吉田 早希; 米田 頼晃; 原 茜; 益田 康弘; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 106回 100 - 100 日本消化器内視鏡学会-近畿支部 2021年07月
  • 内視鏡で保存的に回収できた胃石の1例
    杉森 啓伸; 本庶 元; 原 茜; 益田 康弘; 吉田 早希; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 106回 98 - 98 日本消化器内視鏡学会-近畿支部 2021年07月
  • カプセルおよびバルーン小腸内視鏡で比較的早期に発見し根治手術を行った原発性小腸癌の1例
    吉田 早希; 米田 頼晃; 原 茜; 益田 康弘; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 106回 100 - 100 日本消化器内視鏡学会-近畿支部 2021年07月
  • Masahiro Morita; Naoshi Nishida; Kazuko Sakai; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Kazuto Nishio; Yukari Kobayashi; Kazuhiro Kakimi; Masatoshi Kudo
    Liver Cancer 10 4 380 - 393 2021年07月 
    Introduction: Although immune checkpoint inhibitors (ICIs) have been considered as promising agents for the treatment of advanced hepatocellular carcinoma (HCC), previous clinical trials revealed that the response to anti-programmed cell death protein 1 (anti-PD-1) monotherapy was as low as 20%. Identifying subgroups that respond well to ICIs is clinically important. Here, we studied the prognostic factors for anti-PD-1 antibody treatment based on the molecular and immunological features of HCC. Methods: Patients who were administered anti-PD1 antibody for advanced HCC at Kindai University Hospital were included. Clinicopathological backgrounds and antitumor responses were examined in 34 cases where tumor tissues before treatment were available. Transcriptome analysis was performed using 40 HCC samples obtained from surgical resection, and immune status was compared between 20 HCCs with activating mutations in β-catenin and those without the mutations using transcriptome-based immunogram. Results: Univariate analysis showed that the disease control rate was significantly better in patients with α-fetoprotein < 400 ng/mL, negative for β-catenin/glutamate synthetase (GS) staining, high combined positive score (CPS) of programmed death-ligand 1 (PD-L1), and increased infiltration of CD8+ cells in tumor tissues. Among them, negative staining of β-catenin/GS, CPS of PD-L1 ≥ 1, and high degree of CD8+ tumor-infiltrating lymphocytes (TILs) were significantly associated with longer survival in both progression-free survival (PFS) and overall survival (OS). The combination of these factors well stratified the survival of the patients on anti-PD-1 antibody in both PFS and OS (p < 0.0001 and p = 0.0048 for PFS and OS, respectively). In addition, the immunogram revealed that tumor-carrying mutations in β-catenin showed downregulation of immune-related genes, especially in those related to priming and activation by dendritic cells, interferon-γresponse, inhibitory molecules, and regulatory T cells. Discussion/Conclusion: The combined score including Wnt/β-catenin activation, CPS of PD-L1, and degree of CD8+ TILs in HCC is informative for predicting the response to ICI in HCC cases. Constitutive activation of β-catenin can induce an immune cold phenotype with downregulation of immune-related genes, and immunohistochemistry-based evaluation is beneficial for identifying the subgroup that shows a good response to ICI.
  • Koichiro Kawano; Mamoru Takenaka; Reiko Kawano; Daisuke Kagoshige; Yuta Kawase; Tomonori Moriguchi; Hiroshi Tanabe; Takao Katoh; Katsuhisa Nishi; Masatoshi Kudo
    Journal of clinical medicine 10 13 2021年06月 
    Colonic diverticular could bleed recurrently, and, sometimes, fatal massive bleeding could occur. However, the choice of endoscopic hemostasis remains controversial. Although the over-the-scope clip (OTSC) method has been reported to be effective, it has not been fully evaluated due to the small number of cases. This study aimed to evaluate the efficacy of the OTSC method for colonic diverticular bleeding. Between August 2017 and December 2020, 36 consecutive patients, including those who could not be treated using endoscopic band ligation (EBL) and those in whom re-bleeding had occurred after EBL, underwent the OTSC method for hemostasis of colonic diverticular bleeding at Hyogo Prefectural Awaji Medical Center. The procedure success rate, adverse events rate, early phase re-bleeding rate (within 30 days following primary hemostasis), and the requirement rate for additional transcatheter arterial embolization (TAE) or surgery were the outcomes assessed. The outcomes were procedure success rate 100%, adverse events rate 0%, early phase re-bleeding rate 8.3%, and additional TAE or surgery rate 0%. These results suggest that the OTSC method is a safe and effective treatment for managing colonic diverticular bleeding.
  • Akihiro Yoshida; Mamoru Takenaka; Kota Takashima; Hidekazu Tanaka; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Yoriaki Komeda; Naoshi Nishida; Masatoshi Kudo
    Journal of clinical medicine 10 13 2021年06月 
    Unsuccessful stent replacement in transpapillary biliary drainage with plastic stents (PSs) has a significant impact on patient prognosis; thus, a safe and reliable replacement method is required. We aimed to compare the snare-over-the-guidewire (SOG) method, wherein the PS lumen is used as an access route to the biliary tract and the PS is removed with a snare inserted via the inserted guidewire, with the conventional side-of-stent (SOS) method, wherein the biliary approach is performed from the side of the PS. This retrospective single-center study included 244 consecutive patients who underwent biliary PS replacement between January 2018 and July 2020. The procedural success rates were compared between the two methods. A predictive analysis of unsuccessful PS replacement was also performed. The procedural success rate in the SOG group was significantly higher than that in the SOS group (p = 0.026). In the proximal biliary stenosis lesion, the same trend was observed (p = 0.025). Multivariate analysis also showed that the SOS method (p = 0.0038), the presence of proximal biliary stenosis (p < 0.0001), and parapapillary diverticulum (p = 0.0007) were predictors of unsuccessful PS replacement. The SOG method may be useful for biliary PS replacement, especially in cases of proximal hilar bile duct stenosis.
  • Peter R Galle; Masatoshi Kudo; Josep M Llovet; Richard S Finn; Mark Karwal; Denis Pezet; Tae-You Kim; Tsai-Sheng Yang; Sara Lonardi; Jiri Tomasek; Jean-Marc Phelip; Yann Touchefeu; Su-Jin Koh; Guido Stirnimann; Kun Liang; Kenyon D Ogburn; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X Zhu
    Liver international : official journal of the International Association for the Study of the Liver 2021年06月 
    BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying etiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease etiology and baseline serum viral load. METHODS: Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N=542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by etiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pretreatment serum HBV-DNA and HCV-RNA were quantified using Roche COBAS AmpliPrep/COBAS TaqMan. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method and Cox proportional hazard model (stratified by study). RESULTS: Baseline characteristics were generally balanced between arms in each subgroup (HBV: N=225, HCV: N=127, Other: N=190). No significant difference in treatment effect by etiology subgroup was detected (OS interaction p-value= 0.23). Median OS (ramucirumab vs placebo) in months was 7.7 versus 4.5 (HR 0.74; 95% CI 0.55-0.99) for HBV, 8.2 versus 5.5 (HR 0.82; 95% CI 0.55-1.23) for HCV, and 8.5 versus 5.4 (HR 0.56; 95% CI 0.40-0.79) for Other. Ramucirumab showed similar overall safety profiles across subgroups. Worst outcomes were noted in patients with a detectable HBV load. Use of HBV antiviral therapy, irrespective of viral load, was beneficial for survival, liver function, and liver-specific adverse events. CONCLUSIONS: Ramucirumab improved survival across etiology subgroups with a tolerable safety profile, supporting its use in patients with aHCC and elevated AFP.
  • Ryutaro Takada; Tomohiro Watanabe; Akane Hara; Ikue Sekai; Masayuki Kurimoto; Yasuo Otsuka; Yasuhiro Masuta; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
    Biochemical and biophysical research communications 568 55 - 61 2021年06月 
    Nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular receptor for muramyl dipeptide derived from the intestinal microbiota. Loss-of-function mutations in Nod2 are associated with the development of Crohn's disease, suggesting that NOD2 signaling plays critical roles in the maintenance of intestinal immune homeostasis. Although NOD2 activation prevents the development of short-term experimental colitis, it remains unknown whether the sensitivity to long-term experimental colitis is influenced by NOD2. In this study, we explored the roles played by NOD2 in the development of long-term adoptive transfer colitis. Unexpectedly, we found that Rag1-/-Nod2-/- mice were more resistant to adoptive transfer colitis than Rag1-/- mice and had reduced proinflammatory cytokine responses and enhanced accumulation of regulatory T cells (Tregs) expressing forkhead box P3 in the colonic mucosa. Prevention of colitis in Rag1-/-Nod2-/- mice was mediated by TGF-β1 because neutralization of TGF-β1 resulted in the development of more severe colitis due to reduced accumulation of Tregs. Such paradoxical Treg responses in the absence of NOD2 could explain why Nod2 mutations in humans are not sufficient to cause Crohn's disease.
  • Mamoru Takenaka; Atsushi Nakai; Masatoshi Kudo
    Journal of hepato-biliary-pancreatic sciences 2021年06月 
    Plastic stents (PSs) are commonly used to for obstructive jaundice (1, 2), but there are difficulties associated with removing migrated PSs. (3-5) A 75-year-old woman presented with obstructive jaundice due to hilar cholangiocarcinoma, and two PSs were inserted. After two years, re-intervention for the occlusion of PSs was performed. However, the right PS was migrated in the common bile duct above the papilla.
  • Makoto Hosono; Mamoru Takenaka; Hajime Monzen; Mikoto Tamura; Masatoshi Kudo; Yasumasa Nishimura
    The British journal of radiology 94 1126 20210388 - 20210388 2021年06月 
    Positron emission tomography (PET)/computed tomography (CT) is an essential imaging modality for the management of various diseases. Increasing numbers of PET/CT examinations are carried out across the world and deliver benefits to patients; however, there are concerns about the cumulative radiation doses from these examinations in patients. Compared to the radiation exposure delivered by CT, there have been few reports on the frequency of patients with a cumulative effective radiation dose of ≥100 mSv from repeated PET/CT examinations. The emerging dose tracking system facilitates surveys on patient cumulative doses by PET/CT because it can easily wrap up exposure doses of PET radiopharmaceuticals and CT. Regardless of the use of a dose tracking system, implementation of justification for PET/CT examinations and utilisation of dose reduction measures are key issues in coping with the cumulative dose in patients. Despite all the advantages of PET/MRI such as eliminating radiation exposure from CT and providing good tissue contrast in MRI, it is expensive and cannot be introduced at every facility; thus, it is still necessary to utilise PET/CT with radiation reduction measures in most clinical situations.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo
    Cancer reports (Hoboken, N.J.) 5 2 e1464  2021年06月 
    BACKGROUND: Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u-HCC), changes in hepatic function during therapy have yet to be reported. AIM: This retrospective clinical study aimed to elucidate early responses to Atez/Bev. METHODS: From September 2020 to April 2021, 171 u-HCC patients undergoing Atez/Bev treatment were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative changes in hepatic function and therapeutic response were assessed using albumin-bilirubin (ALBI) score and Response Evaluation Criteria in Solid Tumors (RECIST), ver. 1.1, respectively. RESULTS: In initial imaging examination findings, objective response rates for early tumor shrinkage and disease control after 6 weeks (ORR-6W/DCR-6W) were 10.6%/79.6%. Similar response results were observed in patients with and without a past history of systemic treatment (ORR-6W/DCR-6W = 9.7%/77.8% and 12.2%/82.9%), as well as patients in whom Atez/Bev was used as post-progression treatment following lenvatinib (ORR-6W/DCR-6W = 7.7%/79.5%), for which no known effective post-progression treatment has been established. In 111 patients who underwent a 6-week observation period, ALBI score was significantly worsened at 3 weeks after introducing Atez/Bev (-2.525 ± 0.419 vs -2.323 ± 0.445, p < .001), but then recovered at 6-weeks (-2.403 ± 0.452) as compared to 3-weeks (p = .001). During the observation period, the most common adverse events were appetite loss (all grades) (12.3%), general fatigue/hypertension (all grades) (11.1%, respectively), and urine protein (all grades) (10.5%). CONCLUSION: Atez/Bev might have therapeutic potential not only as first but also later-line treatment of existing molecular target agents. In addition, this drug combination may have less influence on hepatic function during the early period, as the present patients showed a good initial therapeutic response.
  • Mamoru Takenaka; Makoto Hosono; Madan M Rehani; Yasutaka Chiba; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 3 579 - 586 2021年06月 
    OBJECTIVES: The transpapillary drainage by endoscopic retrograde cholangiopancreatography (ERCP-D) cannot be performed without fluoroscopy, and there are many situations in which fluoroscopy is required even in endoscopic ultrasound-guided drainage (EUS-D). Previous studies have compared the efficacy, but not the radiation exposure of EUS-D and ERCP-D. While radiation exposure in ERCP-D has been previously evaluated, there is a paucity of information regarding radiation doses in EUS-D. This study aimed to assess radiation exposure in EUS-D compared with that in ERCP-D. METHODS: This retrospective single-center cohort study included consecutive patients who underwent EUS-D and ERCP-D between October 2017 and March 2019. The air kerma (AK: mGy), kerma-area product (KAP: Gycm2 ), fluoroscopy time (FT: min), and procedure time (PT: min) were assessed. The invasive probability weighting method was used to qualify the comparisons. RESULTS: We enrolled 372 and 105 patients who underwent ERCP-D and EUS-D, respectively. The mean AK, KAP, and FT in the EUS-D group were higher by 53%, 28%, and 27%, respectively, than those in the ERCP-D group, whereas PT was shorter by approximately 11% (AK; 135.0 vs. 88.4, KAP; 28.1 vs. 21.9, FT; 20.4 vs. 16.0, PT; 38.7 vs. 43.5). The sub-analysis limited to biliary drainage cases showed the same trend (AK; 128.3 vs. 90.9, KAP; 27.0 vs. 22.2, FT; 16.4 vs. 16.1, PT; 32.5 vs. 44.4). CONCLUSIONS: This is the first study to assess radiation exposure in EUS-D compared with that in ERCP-D. Radiation exposure was significantly higher in EUS-D than in ERCP-D, despite the shorter procedure time.
  • Richard S Finn; Masatoshi Kudo; Ann-Lii Cheng; Lucjan Wyrwicz; Roger Kai-Cheong Ngan; Jean-Frederic Blanc; Ari D Baron; Arndt Vogel; Masafumi Ikeda; Fabio Piscaglia; Kwang-Hyub Han; Shu-Kui Qin; Yukinori Minoshima; Michio Kanekiyo; Min Ren; Ryo Dairiki; Toshiyuki Tamai; Corina E Dutcus; Hiroki Ikezawa; Yasuhiro Funahashi; Thomas R Jeffry Evans
    Clinical cancer research : an official journal of the American Association for Cancer Research 2021年06月 
    PURPOSE: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and efficacy outcomes from REFLECT. EXPERIMENTAL DESIGN: Serum biomarkers (VEGF, ANG2, FGF19, FGF21, and FGF23) were measured by ELISA. Gene expression in tumor tissues was measured by the nCounter PanCancer Pathways Panel. Pharmacodynamic changes in serum biomarker levels from baseline, and associations of clinical outcomes with baseline biomarker levels were evaluated. RESULTS: 407 patients were included in the serum analysis set (lenvatinib n=279, sorafenib n=128); 58 patients were included in the gene-expression analysis set (lenvatinib n=34, sorafenib n=24). Both treatments were associated with increases in VEGF; only lenvatinib was associated with increases in FGF19 and FGF23 at all timepoints. Lenvatinib-treated responders had greater increases in FGF19 and FGF23 versus non-responders at C4D1 (FGF19: 55.2% vs 18.3%, P=0.014; FGF23: 48.4% vs 16.4%, P=0.0022, respectively). Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups. OS was longer for lenvatinib than sorafenib (median, 10.9 vs 6.8 months, respectively; HR, 0.53; 95% CI, 0.33-0.85; P=0.0075; P-interaction=0.0397) with higher baseline FGF21. In tumor tissue biomarker analysis, VEGF/FGF enriched groups showed improved OS with lenvatinib versus the intermediate VEGF/FGF group (HR 0.39; 95% CI 0.16-0.91; P=0.0253). CONCLUSIONS: Higher baseline levels of VEGF, FGF21, and ANG2 may be prognostic for shorter OS. Higher baseline FGF21 may be predictive for longer OS with lenvatinib compared with sorafenib, but this needs confirmation.
  • Koichiro Kawano; Mamoru Takenaka; Reiko Kawano; Daisuke Kagoshige; Takao Kato; Katsuhisa Nishi; Masatoshi Kudo
    Endoscopy 54 5 E240-E241  2021年06月
  • β-カテニン陽性の肝細胞癌に対してアテゾリズマブ+ベバシズマブ療法が奏効した1例
    喜田 行洋; 小川 力; 金澤 秀晃; 坂上 純也; 真鍋 卓嗣; 松浦 賢史; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 辻 晃仁; 工藤 正俊
    日本消化器病学会四国支部例会プログラム・抄録集 115回 57 - 57 日本消化器病学会-四国支部 2021年06月
  • Masatoshi Kudo
    Liver cancer 10 3 167 - 180 2021年06月
  • Masatoshi Kudo; Yusuke Kawamura; Kiyoshi Hasegawa; Ryosuke Tateishi; Kazuya Kariyama; Shuichiro Shiina; Hidenori Toyoda; Yasuharu Imai; Atsushi Hiraoka; Masafumi Ikeda; Namiki Izumi; Michihisa Moriguchi; Sadahisa Ogasawara; Yasunori Minami; Kazuomi Ueshima; Takamichi Murakami; Shiro Miyayama; Osamu Nakashima; Hirohisa Yano; Michiie Sakamoto; Etsuro Hatano; Mitsuo Shimada; Norihiro Kokudo; Satoshi Mochida; Tetsuo Takehara
    Liver cancer 10 3 181 - 223 2021年06月 
    The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
  • Masatoshi Kudo; Kenta Motomura; Yoshiyuki Wada; Yoshitaka Inaba; Yasunari Sakamoto; Masayuki Kurosaki; Yoshiko Umeyama; Yoichi Kamei; Junichiro Yoshimitsu; Yosuke Fujii; Mana Aizawa; Paul B Robbins; Junji Furuse
    Liver cancer 10 3 249 - 259 2021年06月 
    Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity in various tumor types; axitinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. We report the final analysis from VEGF Liver 100 (NCT03289533), a phase 1b study evaluating safety and efficacy of avelumab plus axitinib in treatment-naive patients with aHCC. Methods: Eligible patients had confirmed aHCC, no prior systemic therapy, ≥1 measurable lesion, Eastern Cooperative Oncology Group performance status ≤1, and Child-Pugh class A disease. Patients received avelumab 10 mg/kg intravenously every 2 weeks plus axitinib 5 mg orally twice daily until progression, unacceptable toxicity, or withdrawal. Endpoints included safety and investigator-assessed objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) for HCC. Results: Twenty-two Japanese patients were enrolled and treated with avelumab plus axitinib. The minimum follow-up was 18 months as of October 25, 2019 (data cutoff). Grade 3 treatment-related adverse events (TRAEs) occurred in 16 patients (72.7%); the most common (≥3 patients) were hypertension (n = 11 [50.0%]), palmar-plantar erythrodysesthesia syndrome (n = 5 [22.7%]), and decreased appetite (n = 3 [13.6%]). No grade 4 TRAEs or treatment-related deaths occurred. Ten patients (45.5%) had an immune-related AE (irAE) of any grade; 3 patients (13.6%) had an infusion-related reaction (IRR) of any grade, and no grade ≥3 irAE and IRR were observed. The objective response rate was 13.6% (95% CI: 2.9-34.9%) per RECIST 1.1 and 31.8% (95% CI: 13.9-54.9%) per mRECIST for HCC. Conclusion: Treatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.
  • Masatoshi Kudo; Ho Yeong Lim; Ann-Lii Cheng; Yee Chao; Thomas Yau; Sadahisa Ogasawara; Masayuki Kurosaki; Naoki Morimoto; Kazuyoshi Ohkawa; Tatsuya Yamashita; Kyung-Hun Lee; Erluo Chen; Abby B Siegel; Baek-Yeol Ryoo
    Liver cancer 10 3 275 - 284 2021年06月 
    Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia are described. Methods: Adults with advanced HCC previously treated with sorafenib were randomized 2:1 to pembrolizumab or placebo plus BSC. Here, the Asian subgroup comprised patients enrolled in Hong Kong, Japan, Korea, the Philippines, Taiwan, and Thailand. Primary endpoints were progression-free survival (PFS) per blinded central imaging review and overall survival (OS). Secondary endpoints included objective response rate (ORR) per blinded central imaging review, duration of response (DOR), and safety. Results: The Asian subgroup included 157 patients. As of January 2, 2019, the median follow-up in this subgroup was 13.8 months for pembrolizumab and 8.3 months for placebo. The median PFS was 2.8 months for pembrolizumab (95% confidence interval [CI] 2.6-4.1) versus 1.4 months (95% CI 1.4-2.4) for placebo (hazard ratio [HR] 0.48; 95% CI 0.32-0.70). The median OS was 13.8 months (95% CI 10.1-16.9) for pembrolizumab versus 8.3 months (95% CI 6.3-11.8) for placebo (HR 0.55; 95% CI 0.37-0.80). ORR was 20.6% (95% CI 13.4-29.5) for pembrolizumab versus 2.0% (95% CI 0.1-10.6) for placebo (difference: 18.5%; 95% CI 8.3-27.6). The median DOR was 8.6 and 2.8 months for pembrolizumab and placebo, respectively. Any grade treatment-related adverse events (TRAEs) occurred in 63 patients (58.9%) receiving pembrolizumab and 24 patients (48.0%) receiving placebo; 14 (13.1%) and 2 (4.0%) patients experienced grade 3-5 TRAEs, respectively. No treatment-related deaths occurred. Conclusion: Pembrolizumab demonstrated antitumor activity and was well tolerated in the Asian subgroup of KEYNOTE-240. A trend toward greater benefit with pembrolizumab in the Asian subgroup was observed compared with the overall cohort, supporting further evaluation of pembrolizumab treatment in this population.
  • Arndt Vogel; Shukui Qin; Masatoshi Kudo; Yun Su; Stacie Hudgens; Tatsuya Yamashita; Jung-Hwan Yoon; Laetitia Fartoux; Krzysztof Simon; Carlos López; Max Sung; Kalgi Mody; Tatsuroh Ohtsuka; Toshiyuki Tamai; Lee Bennett; Genevieve Meier; Valery Breder
    The lancet. Gastroenterology & hepatology 6 8 649 - 658 2021年06月 
    BACKGROUND: Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The aim of this study was to evaluate the effect of treatment with lenvatinib versus sorafenib on HRQOL. METHODS: REFLECT was a previously published multicentre, randomised, open-label, non-inferiority phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment for unresectable hepatocellular carcinoma. Eligible patients were aged 18 years or older with unresectable hepatocellular carcinoma and one or more measurable target lesion per modified Response Evaluation Criteria in Solid Tumors criteria, Barcelona Clinic Liver Cancer stage B or C categorisation, Child-Pugh class A, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or lower, and adequate organ function. Patients were randomly assigned (1:1) via an interactive voice-web response system; stratification factors for treatment allocation included region; macroscopic portal vein invasion, extrahepatic spread, or both; ECOG performance status; and bodyweight. Patient-reported outcomes (PROs), collected at baseline, on day 1 of each subsequent cycle, and at the end of treatment, were evaluated in post-hoc analyses of secondary and exploratory endpoints in the analysis population, which was the subpopulation of patients with a PRO assessment at baseline. A linear mixed-effects model evaluated change from baseline in PROs, including European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and hepatocellular carcinoma-specific QLQ-HCC18 scales (both secondary endpoints of the REFLECT trial). Time-to-definitive-deterioration analyses were done based on established thresholds for minimum differences for worsening in PROs. Responder analyses explored associations between HRQOL and clinical response. This study is registered with ClinicalTrials.gov, NCT01761266. FINDINGS: Of 954 eligible patients randomly assigned to lenvatinib (n=478) or sorafenib (n=476) between March 14, 2013, and July 30, 2015, 931 patients (n=468 for lenvatinib; n=463 for sorafenib) were included in this analysis. Baseline PRO scores reflected impaired HRQOL and functioning and considerable symptom burden relative to full HRQOL. Differences in overall mean change from baseline estimates in most PRO scales generally favoured the lenvatinib over the sorafenib group, although the differences were not nominally statistically or clinically significant. Patients treated with lenvatinib experienced nominally statistically significant delays in definitive, meaningful deterioration on the QLQ-C30 fatigue (hazard ratio [HR] 0·83, 95% CI 0·69-0·99), pain (0·80, 0·66-0·96), and diarrhoea (0·52, 0·42-0·65) domains versus patients treated with sorafenib. Significant differences in time to definitive deterioration were not observed for other QLQ-C30 domains, and there was no difference in time to definitive deterioration on the global health status/QOL score (0·89, 0·73-1·09). For most PRO scales, differences in overall mean change from baseline estimates favoured responders versus non-responders. Across all scales, HRs for time to definitive deterioration were in favour of responders; median time to definitive deterioration for responders exceeded those for non-responders by a range of 4·8 to 14·6 months. INTERPRETATION: HRQOL for patients undergoing treatment for unresectable hepatocellular carcinoma is an important therapeutic consideration. The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with sorafenib to delay functional deterioration in advanced hepatocellular carcinoma. FUNDING: Eisai and Merck Sharp & Dohme.
  • Takuji Okusaka; Kenji Ikeda; Masatoshi Kudo; Richard Finn; Shukui Qin; Kwang-Hyub Han; Ann-Lii Cheng; Fabio Piscaglia; Masahiro Kobayashi; Max Sung; Minshan Chen; Lucjan Wyrwicz; Jung-Hwan Yoon; Zhenggang Ren; Kalgi Mody; Corina Dutcus; Toshiyuki Tamai; Min Ren; Seiichi Hayato; Hiromitsu Kumada
    Journal of gastroenterology 56 6 570 - 580 2021年06月 
    BACKGROUND: REFLECT was an open-label, phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC). Based on phase 2 study (Study 202) results, body weight-based dosing for lenvatinib was used in REFLECT to minimize dose disruptions and modifications needed to address dose-related adverse events. This post hoc analysis of REFLECT data assessed lenvatinib efficacy and safety by body weight group. METHODS: The study randomly administered lenvatinib (n = 476) or sorafenib (n = 475) to patients with untreated (no prior systemic therapy) uHCC. Lenvatinib starting-dose data were stratified by body weight: patients weighing < 60 kg received 8 mg/day; patients weighing ≥ 60 kg received 12 mg/day. Overall survival (OS), progression-free survival (PFS), objective response rate, and safety were assessed. RESULTS: Survival outcomes and safety profiles appeared similar between the two body-weight-based lenvatinib starting-dose groups. Median OS for patients in the < 60 kg body weight group (n = 153) was 13.4 months [95% confidence interval (CI) 10.5-15.7] compared to 13.7 months (95% CI 12.0-15.6) in the ≥ 60 kg body weight group (n = 325). In both lenvatinib groups, PFS was 7.4 months (< 60 kg group: 95% CI 5.4-9.2; ≥ 60 kg group: 95% CI 6.9-9.0). Treatment-emergent adverse events (TEAEs) required dose modifications in 43.0% in the < 60 kg body weight group and 57.5% in the ≥ 60 kg body weight group. CONCLUSIONS: This exploratory analysis of data from REFLECT indicated that body weight-based lenvatinib dosing in patients with uHCC was successful in maintaining efficacy, with comparable rates of TEAEs and dose modifications in the two body weight groups. CLININCAL TRIAL: Trial registration ID: ClinicalTrials.gov # NCT01761266.
  • Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Shoji Kubo
    Hepatology research : the official journal of the Japan Society of Hepatology 52 1 5 - 66 2021年05月 
    In the 22nd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21,155 newly registered patients and 43,041 previously registered follow-up patients were compiled from 538 institutions over a 2-year period from 1 January 2012 to 31 December 2013. Basic statistics compiled for patients newly registered in the 22nd survey was cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 21st survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2002 and 2013 whose final outcome was survival or death. Median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, or Child-Pugh grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2013 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world. This article is protected by copyright. All rights reserved.
  • Peter R Galle; Richard S Finn; Shukui Qin; Masafumi Ikeda; Andrew X Zhu; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed Kaseb; Daneng Li; Sohail Mulla; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Beiying Ding; Juan Liu; Chen Huang; Ho Yeong Lim; Ann-Lii Cheng; Michel Ducreux
    The Lancet. Oncology 2021年05月 
    BACKGROUND: Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already shown significant overall survival and progression-free survival benefits with this combination therapy. METHODS: We did an open-label, randomised, phase 3 trial in 111 hospitals and cancer centres across 17 countries or regions. We included patients aged 18 years or older with systemic, treatment-naive, histologically, cytologically, or clinically confirmed unresectable hepatocellular carcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with disease that was not amenable to curative surgical or locoregional therapies, or progressive disease after surgical or locoregional therapies. Participants were randomly assigned (2:1; using permuted block randomisation [blocks of six], stratified by geographical region; macrovascular invasion, extrahepatic spread, or both; baseline alpha-fetoprotein concentration; and ECOG performance status) to receive 1200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously once every 3 weeks or 400 mg sorafenib orally twice a day, until loss of clinical benefit or unacceptable toxicity. The independent review facility for tumour assessment was masked to the treatment allocation. Previously reported coprimary endpoints were overall survival and independently assessed progression-free survival per Response Evaluation Criteria in Solid Tumors 1.1. Prespecified secondary and exploratory analyses descriptively evaluated treatment effects on patient-reported quality of life, functioning, and disease symptoms per the European Organisation for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire for cancer (QLQ-C30) and quality-of-life questionnaire for hepatocellular carcinoma (QLQ-HCC18). Time to confirmed deterioration of PROs was analysed in the intention-to-treat population; all other analyses were done in the PRO-evaluable population (patients who had a baseline PRO assessment and at least one assessment after baseline). The trial is ongoing; enrolment is closed. This trial is registered with ClinicalTrials.gov, NCT03434379. FINDINGS: Between March 15, 2018, and Jan 30, 2019, 725 patients were screened and 501 patients were enrolled and randomly assigned to atezolizumab plus bevacizumab (n=336) or sorafenib (n=165). 309 patients in the atezolizumab plus bevacizumab group and 145 patients in the sorafenib group were included in the PRO-evaluable population. At data cutoff (Aug 29, 2019) the median follow-up was 8·6 months (IQR 6·2-10·8). EORTC QLQ-C30 completion rates were 90% or greater for 23 of 24 treatment cycles in both groups (range 88-100% in the atezolizumab plus bevacizumab group and 80-100% in the sorafenib group). EORTC QLQ-HCC18 completion rates were 90% or greater for 20 of 24 cycles in the atezolizumab plus bevacizumab group (range 88-100%) and 21 of 24 cycles in the sorafenib group (range 89-100%). Compared with sorafenib, atezolizumab plus bevacizumab reduced the risk of deterioration on all EORTC QLQ-C30 generic cancer symptom scales that were prespecified for analysis (appetite loss [hazard ratio (HR) 0·57, 95% CI 0·40-0·81], diarrhoea [0·23, 0·16-0·34], fatigue [0·61, 0·46-0·81], pain [0·46, 0·34-0·62]), and two of three EORTC QLQ-HCC18 disease-specific symptom scales that were prespecified for analysis (fatigue [0·60, 0·45-0·80] and pain [0·65, 0·46-0·92], but not jaundice [0·76, 0·55-1·07]). At day 1 of treatment cycle five (after which attrition in the sorafenib group was more than 50%), the mean EORTC QLQ-C30 score changes from baseline in the atezolizumab plus bevacizumab versus sorafenib groups were: -3·29 (SD 17·56) versus -5·83 (20·63) for quality of life, -4·02 (19·42) versus -9·76 (21·33) for role functioning, and -3·77 (12·82) versus -7·60 (15·54) for physical functioning. INTERPRETATION: Prespecified analyses of PRO data showed clinically meaningful benefits in terms of patient-reported quality of life, functioning, and disease symptoms with atezolizumab plus bevacizumab compared with sorafenib, strengthening the combination therapy's positive benefit-risk profile versus that of sorafenib in patients with unresectable hepatocellular carcinoma. FUNDING: F Hoffmann-La Roche and Genentech.
  • Masaki Kaibori; Kengo Yoshii; Kosuke Kashiwabara; Takashi Kokudo; Kiyoshi Hasegawa; Namiki Izumi; Takamichi Murakami; Masatoshi Kudo; Shuichiro Shiina; Michiie Sakamoto; Osamu Nakashima; Yutaka Matsuyama; Susumu Eguchi; Md; Tatsuya Yamashita; Md; Tadatoshi Takayama; Norihiro Kokudo; Shoji Kubo
    Hepatology research : the official journal of the Japan Society of Hepatology 51 8 890 - 901 2021年05月 
    AIM: We reviewed the data of a nationwide follow-up survey to determine the impact of hepatitis C virus (HCV) infection on the outcomes of hepatectomy for intrahepatic cholangiocarcinoma (ICC) of the mass-forming (MF) type and combined mass-forming and periductal infiltrating (MF+PI) types. METHODS: In total, 956 patients with ICC who underwent curative hepatic resection were included in this cohort study, and patients were classified according to virus status. Patients were classified according to virus status as follows: HCV-related ICC (n=138, 14.4%), hepatitis B virus (HBV)-related ICC (n=43, 4.5%), and non-virus-related ICC (n=775, 81.1%). To control for variables, we used 1-to-1 propensity score matching to compare outcomes after surgery between the HCV-related (n=102) and the non-virus-related ICC cases (n=102). RESULTS: We successfully matched HCV-related and non-virus-related ICC cases with similar liver function and tumor characteristics. Patients with HCV-related ICC had significantly shorter recurrence-free survival (RFS; hazard ratio [HR] 0.62, 95% confidence interval [Cl] 0.42-0.92, P=.016) and overall survival (OS; HR: 0.57, 95% Cl: 0.37-0.88, P=.011) than patients with non-virus-related ICC. Cox proportional hazard analysis demonstrated that HCV-related ICC offered a worse prognosis than non-virus-related ICC. CONCLUSIONS: HCV infection increases the risk of recurrence and worsens OS in patients after curative resection for MF and combined MF+PI type ICC. This article is protected by copyright. All rights reserved.
  • Akane Hara; Tomohiro Watanabe; Kosuke Minaga; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo
    World journal of gastroenterology 27 19 2257 - 2269 2021年05月 
    Solitary organ autoimmune disorders, formerly known as autoimmune pancreatitis (AIP), autoimmune sialadenitis, and autoimmune sclerosing cholangitis, are now considered organ-specific manifestations of systemic immunoglobulin G4-related disease (IgG4-RD). AIP and IgG4-RD are characterized by elevated serum concentration of IgG4 antibody (Ab), accumulation of IgG4-expressing plasmacytes in the affected organs, and involvement of multiple organs. It is well established that enhanced IgG4 Ab responses are a hallmark of AIP and IgG4-RD for diagnosis and monitoring disease activity. However, a significant fraction of patients with AIP and IgG4-RD who develop chronic fibroinflammatory responses have normal serum concentrations of this IgG subtype. In addition, disease flare-up is sometimes seen even in the presence of normalized serum concentrations of IgG4 Ab after successful induction of remission by prednisolone. Therefore, it is necessary to identify new biomarkers based on the understanding of the pathophysiology of AIP and IgG4-RD. Recently, we found that activation of plasmacytoid dendritic cells producing both interferon-α (IFN-α) and interleukin-33 (IL-33) mediate murine AIP and human IgG4-RD. More importantly, we provided evidence that serum concentrations of IFN-α and IL-33 could be useful biomarkers for the diagnosis and monitoring of AIP and IgG4-RD activity after induction of remission in these autoimmune disorders. In this Frontier article, we have summarized and discussed biomarkers of AIP and IgG4-RD, including Igs, autoAbs, and cytokines to provide useful information not only for clinicians but also for researchers.
  • Masatoshi Kudo; Ana Matilla; Armando Santoro; Ignacio Melero; Antonio Cubillo Gracián; Mirelis Acosta-Rivera; Su-Pin Choo; Anthony B El-Khoueiry; Ryoko Kuromatsu; Bassel El-Rayes; Kazushi Numata; Yoshito Itoh; Francesco Di Costanzo; Oxana Crysler; Maria Reig; Yun Shen; Jaclyn Neely; Marina Tschaika; Tami Wisniewski; Bruno Sangro
    Journal of hepatology 2021年05月 
    BACKGROUND & AIMS: Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3-5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ipilimumab, is conditionally approved in the United States to treat patients with aHCC who previously received sorafenib. We describe nivolumab monotherapy outcomes in patients with Child-Pugh B status. METHODS: This phase 1/2, open-label, non-comparative, multicentre trial (27 centres) included patients with Child-Pugh B (B7-B8) aHCC. Patients received intravenous nivolumab 240 mg every 2 weeks until unacceptable toxicity or disease progression. Primary endpoints were objective response rate (ORR) by investigator assessment (using Response Evaluation Criteria in Solid Tumors v1.1) and duration of response (DOR). Safety was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. RESULTS: Twenty-five sorafenib-naive and 24 sorafenib-treated patients began treatment between November 2016 and October 2017 (median follow-up, 16.3 months). Investigator-assessed ORR was 12% (95% CI 5-25%) with six patients responding; disease control rate was 55% (95% CI 40-69%). Median time to response was 2.7 months (interquartile range, 1.4-4.2), and median DOR was 9.9 months (95% CI 9.7-9.9). Treatment-related adverse events (TRAEs) were reported in 25 patients (51%) and led to discontinuation in two patients (4%). The most frequent grade 3/4 TRAEs were hypertransaminasemia (n=2), and amylase increase and aspartate aminotransferase increase (n=2 each). The safety of nivolumab was comparable to that of patients with Child-Pugh A aHCC. CONCLUSIONS: Nivolumab showed clinical activity and favourable safety with manageable toxicities, suggesting it could be suitable for patients with Child-Pugh B aHCC. LAY SUMMARY: In patients with advanced HCC, almost all systemic therapies require very good liver function, i.e. Child-Pugh A liver function. The evidence from this study suggests that nivolumab shows clinical activity and an acceptable safety profile in patients with HCC with Child-Pugh B status who have mild to moderate impairment of liver function or liver decompensation that might rule out other therapies, so should be further studied. CLINICAL TRIAL NUMBER: NCT01658878.
  • Mamoru Takenaka; Tomohiro Yamazaki; Yasuo Otsuka; Rei Ishikawa; Masatoshi Kudo
    Endoscopy 54 5 E190-E192  2021年05月
  • 当院における大腸ESDの工夫
    正木 翔; 櫻井 俊治; 高島 耕太; 山田 光成; 永井 知行; 米田 頼晃; 樫田 博史; 工藤 正俊
    日本大腸肛門病学会雑誌 74 5 326 - 326 (一社)日本大腸肛門病学会 2021年05月
  • 工藤 正俊; 泉 並木; 久保 正二; 國土 典宏; 坂元 亨宇; 椎名 秀一朗; 高山 忠利; 建石 良介; 中島 収; 村上 卓道; 松山 裕; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会
    肝臓 62 5 251 - 299 (一社)日本肝臓学会 2021年05月 
    第22回全国原発性肝癌追跡調査においては,2012年1月1日から2013年12月31日までの2年間の21,155例の新規症例と43,041例の追跡症例が538施設から集計された.基礎統計は,第22回新規登録症例を対象として死因,既往歴,臨床診断,画像診断,治療法別の各因子,病理診断,再発,剖検についてまとめた.第21回調査と比較し,肝細胞癌における臨床診断時の高齢化,女性の増加,非B非C肝癌の増加,腫瘍径の縮小の傾向が,治療においては切除の割合の増加,局所療法におけるラジオ波焼灼療法の増加が認められた.2002年から2013年まで新規登録症例の中で最終予後が生存または死亡となった症例(追跡不能症例を除く)について肝細胞癌,肝内胆管癌,混合型肝癌の治療法別,背景因子別生存中央値・累積生存率を算出した.肝細胞癌については腫瘍個数,腫瘍径,肝障害度,Child-Pugh分類を組み合わせることにより背景因子を揃えて,治療法別(肝切除,局所療法,肝動脈塞栓療法(TACE)),肝動注化学療法・全身薬物療法(分子標的治療)の累積生存率を算出し,また,1978年から2013年までの新規登録症例を5期に分け,累積生存率を算出した.新規登録症例数は経時的に増加し,肝細胞癌,肝内胆管癌,混合型肝癌ともに予後の改善が著しいことが明らかとなった.本追跡調査が原発性肝癌の研究および診療の進歩に役立つことを期待する.(著者抄録)
  • 【消化器癌;診断と治療のすべて】消化器癌の診断・病期分類・治療・成績 肝細胞癌 集学的治療
    青木 智子; 上嶋 一臣; 工藤 正俊
    消化器外科 44 6 855 - 861 (株)へるす出版 2021年05月
  • Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo; Kosuke Minaga; Yoriaki Komeda; Ken Kamata; Masatomo Kimura; Hidetoshi Hayashi; Kazuhiko Nakagawa; Kazuomi Ueshima; Yasunori Minami; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Cishina; Hiroshi Ida; Ah-Mee Park; Naoshi Nishida
    Scientific reports 11 1 9242 - 9242 2021年04月 
    Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers. Neutralisation of PD-1 or CTLA-4 by ICIs results in immune-related adverse events (irAEs). The clinicopathological features of twelve patients with hepatic irAEs were evaluated and compared to those of ten patients with autoimmune hepatitis (AIH) or graft-versus-host disease (GVHD). No significant difference was seen in serum levels of transaminases, whereas serum levels of IgG and anti-nuclear antibody were higher in patients with AIH than in those with GVHD or hepatic irAEs. Inflammation was limited to the liver lobes in patients with GVHD or hepatic irAEs, whereas patients with AIH exhibited both portal and lobular inflammation. Immunohistochemical analyses revealed a predominant infiltration of CD8+ T cells and defective accumulation of regulatory T cells (Tregs) expressing forkhead box p3 (FOXP3) in the lobular areas of patients with hepatic irAEs and GVHD. In contrast, periportal lesions of patients with AIH were characterised by an infiltration of CD4+ T cells, CD8+ T cells, CD20+ B cells, and FOXP3+ Tregs. Overall, the activation of CD8+ T cells in the absence of activation of Tregs potentially underlies the immunopathogenesis of hepatic irAEs.
  • Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Akihiro Yoshida; Yasunori Minami; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 51 7 767 - 774 2021年04月 
    AIM: Both entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are widely used to treat chronic hepatitis B (CHB) in Japan. However, it remains unclear whether the efficacy of TAF in decreasing the hepatitis B surface antigen (HBsAg) level, and its safety, are superior to those of ETV. This study aimed to report the long-term effects and safety of 96-week ETV and TAF treatment in patients with CHB. METHODS: A prospective comparative observational study was undertaken on the following two groups: patients with CHB who received continuous ETV (n = 32) and patients with CHB who were switched from ETV to TAF upon request (n = 48). The HBsAg, urinary β2-microglobulin (β2MG)/creatinine (Cr), urinary N-acetyl-β-D-glucosaminidase (NAG)/Cr, and serum alanine aminotransferase (ALT) levels, estimated glomerular filtration rate (eGFR), and bone mineral density (lumbar spine and femur) at 96 weeks were compared. RESULTS: The two groups did not significantly differ with respect to mean age, male / female patient ratio, or rate of hepatitis B e antigen-positive status. The mean changes in serum HBsAg level and eGFR at 96 weeks were not significantly different between the two groups. The β2MG/Cr and NAG/Cr levels at 96 weeks were similar between the two groups. Additionally, the bone mineral density of the lumbar spine and femur as well as the serum ALT did not significantly differ. CONCLUSIONS: When compared with patients who received continuous ETV, those who were introduced to TAF after ETV showed similar effects in terms of the decrease in HBsAg level and safety.
  • Tomohiro Yamazaki; Mamoru Takenaka; Shunsuke Omoto; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Atsushi Nakai; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Yoriaki Komeda; Tomohiro Watanabe; Naoshi Nishida; Keiko Kamei; Ippei Matsumoto; Yoshifumi Takeyama; Takaaki Chikugo; Yasutaka Chiba; Masatoshi Kudo
    Journal of clinical medicine 10 9 2021年04月 
    This study aimed to investigate whether the incorporation of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) into the international consensus guidelines (ICG) for the management of intraductal papillary mucinous neoplasm (IPMN) could improve its malignancy diagnostic value. In this single-center retrospective study, 109 patients diagnosed with IPMN who underwent preoperative CH-EUS between March 2010 and December 2018 were enrolled. We analyzed each malignancy diagnostic value (sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV)) by replacing fundamental B-mode EUS with CH-EUS as the recommended test for patients with worrisome features (WF) (the CH-EUS incorporation ICG) and comparing the results to those obtained using the 2017 ICG. The malignancy diagnostic values as per the 2017 ICG were 78.9%, 42.3%, 60.0%, and 64.7% for Se, Sp, PPV, and NPV, respectively. The CH-EUS incorporation ICG plan improved the malignancy diagnostic values (Se 78.9%/Sp, 53.8%/PPV, 65.2%/NPV 70.0%). CH-EUS may be useful in determining the appropriate treatment strategies for IPMN.
  • Yoshikuni Kawaguchi; Kiyoshi Hasegawa; Yasuhiro Hagiwara; Mario De Bellis; Simone Famularo; Elena Panettieri; Yutaka Matsuyama; Ryosuke Tateishi; Tomoaki Ichikawa; Takashi Kokudo; Namiki Izumi; Shoji Kubo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Osamu Nakashima; Takamichi Murakami; Jean-Nicolas Vauthey; Felice Giuliante; Luciano De Carlis; Fabrizio Romano; Andrea Ruzzenente; Alfredo Guglielmi; Masatoshi Kudo; Norihiro Kokudo
    The American journal of gastroenterology 116 8 1698 - 1708 2021年04月 
    INTRODUCTION: Most studies predicting survival after resection, transarterial chemoembolization (TACE), and ablation analyzed diameter and number of hepatocellular carcinomas (HCCs) as dichotomous variables, resulting in an underestimation of risk variation. We aimed to develop and validate a new prognostic model for patients with HCC using largest diameter and number of HCCs as continuous variables. METHODS: The prognostic model was developed using data from patients undergoing resection, TACE, and ablation in 645 Japanese institutions. The model results were shown after balanced using the inverse probability of treatment-weighted analysis and were externally validated in an international multi-institution cohort. RESULTS: Of 77,268 patients, 43,904 patients, including 15,313 (34.9%) undergoing liver resection, 13,375 (30.5%) undergoing TACE, and 15,216 (34.7%) undergoing ablation, met the inclusion criteria. Our model (http://www.u-tokyo-hbp-transplant-surgery.jp/about/calculation.html) showed that the 5-year overall survival (OS) in patients with HCC undergoing these procedures decreased with progressive incremental increases in diameter and number of HCCs. For patients undergoing resection, the inverse probability of treatment-weighted-adjusted 5-year OS probabilities were 10%-20% higher compared with patients undergoing TACE for 1-6 HCC lesions <10 cm and were also 10%-20% higher compared with patients undergoing ablation when the HCC diameter was 2-3 cm. For patients undergoing resection and TACE, the model performed well in the external cohort. DISCUSSION: Our novel prognostic model performed well in predicting OS after resection and TACE for HCC and demonstrated that resection may have a survival benefit over TACE and ablation based on the diameter and number of HCCs.
  • Hajime Honjo; Tomohiro Watanabe; Natsuki Okai; Masashi Kono; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Shigeyoshi Tsuji; Masatoshi Kudo
    Asian Pacific journal of allergy and immunology 2021年04月 
    BACKGROUND: Despite the high incidence of spondyloarthritis (SpA) as an extra-intestinal manifestation of Crohn's disease (CD), the immunopathogenesis of CD-associated SpA remains largely unknown. OBJECTIVE: We tried to explore molecular mechanisms accounting for the development of CD-associated SpA in a patient successfully treated with infliximab. METHODS: Peripheral blood mononuclear cells (PBMCs) before infliximab treatment were stimulated with Toll-like receptor (TLR) ligands to measure pro-inflammatory cytokine responses. Endoscopic biopsy samples before and after infliximab treatment were subjected to quantitative polymerase chain reaction. RESULTS: PBMCs from this CD-associated SpA patient exhibited higher production of pro-inflammatory cytokines upon stimulation with TLR ligands than PBMCs from healthy controls. Induction of remission by infliximab was associated with the downregulation of pro-inflammatory cytokine responses in the small intestinal mucosa, which is continually exposed to TLR ligands. CONCLUSIONS: Excessive pro-inflammatory cytokine responses to TLR ligands might underlie the immunopathogenesis of CD-associated SpA.
  • Atsushi Hiraoka; Takashi Kumada; Takeshi Hatanaka; Toshifumi Tada; Kazuya Kariyama; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Ogawa Chikara; Tsutomu Tamai; Satoru Kakizaki; Hiroki Tojima; Tamon Nagashima; Takashi Ueno; Daichi Takizawa; Atsushi Naganuma; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 51 8 880 - 889 2021年04月 
    AIM: Multiple molecular agents have been developed for treating unresectable hepatocellular carcinoma. This study aimed to elucidate the clinical efficacy of sequential treatment with lenvatinib after regorafenib failure. METHODS: From June 2017 to October 2020, 63 patients with Child-Pugh A and treated with regorafenib followed by sorafenib were enrolled (median age 71 years, 52 men, Barcelona Clinic Liver Cancer B:C = 23:40). They were divided into two groups, those treated with lenvatinib after regorafenib treatment (R-L group, n = 47) and those who did not receive lenvatinib after regorafenib (non-R-L group, n = 16). Prognostic factors were retrospectively analyzed after adjustment with inverse probability weighting. RESULTS: Serum albumin level at the start of regorafenib and reasons for discontinuation of regorafenib were significantly different between the R-L and non-R-L groups, whereas the albumin-bilirubin score, Child-Pugh class, and tumor burden were not. Progression-free survival was also not significantly different (median 4.1 vs. 3.8 months, p = 0.586). As for overall survival, the R-L group showed better prognosis after introducing regorafenib and after introducing sorafenib, following inverse probability weighting adjustment (MST 19.7 vs. 10.3 months, 33.8 vs. 15.3 months, p < 0.001 and p = 0.022, respectively). Modified albumin-bilirubin grade 2b (score >-2.27) at the start of regorafenib (HR 2.074, p = 0.041) and the presence of lenvatinib treatment after regorafenib failure (HR 0.355, p = 0.004) were found to be significant prognostic factors in Cox proportional hazards multivariate analysis, after inverse probability weighting adjustment. CONCLUSION: These results show that lenvatinib is a good sequential treatment option after progression under regorafenib therapy in unresectable hepatocellular carcinoma patients with better hepatic reserve function.
  • 肝癌に対する局所療法(肝切除、アブレーション、TACE、他)の最前線 US-US overlay fusionガイドを用いたラジオ波焼灼術の最前線
    南 康範; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.1 A179 - A179 (一社)日本肝臓学会 2021年04月
  • 肝癌の基礎研究と臨床応用 Gd-EOB-DTPA-enhanced MRI肝細胞相はPD-1/PD-L1抗体単独療法の非侵襲的なバイオマーカーである
    青木 智子; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.1 A187 - A187 (一社)日本肝臓学会 2021年04月
  • 肝疾患におけるビックデータとAI(人工知能)の臨床応用 超音波画像ビッグデータベース構築と腹部超音波B-mode検査における肝腫瘍検出のAI支援
    西田 直生志; 目加田 慶人; 工藤 正俊
    肝臓 62 Suppl.1 A203 - A203 (一社)日本肝臓学会 2021年04月
  • 進行肝癌に対する薬物治療法の新たな展開 肝細胞癌における腫瘍免疫環境と抗PD-1抗体有効群の選別
    盛田 真弘; 西田 直生志; 工藤 正俊
    肝臓 62 Suppl.1 A20 - A20 (一社)日本肝臓学会 2021年04月
  • Masatoshi Kudo
    Liver cancer 10 2 85 - 93 2021年04月
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Kazuya Kariyama; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
    Liver cancer 10 2 115 - 125 2021年04月 
    Background/Aim: An effective postprogression treatment of lenvatinib (LEN) against unresectable hepatocellular carcinoma (u-HCC) has not been established. We aimed to elucidate the clinical role of continuing LEN beyond progression of disease (PD). Methods: From March 2018 to October 2020, 99 u-HCC patients, in whom PD was confirmed (male:female = 78:21, median age 72 years, Child-Pugh A = 99, Barcelona Clinic Liver Cancer stage A:B:C = 2:43:54, LEN as first-line = 55), were enrolled (stopped LEN at PD [A group], n = 26; continued LEN beyond PD [B group], n = 73). Radiological response was evaluated with RECIST 1.1. Clinical features and prognostic factors for overall survival (OS) were retrospectively investigated using inverse probability weighting (IPW) calculated by propensity score. Results: Median time to progression, best response, and modified albumin-bilirubin grade (mALBI) at both baseline and PD did not show significant difference between the groups. Postprogression treatment in the A group was best supportive care in 17, sorafenib in 4, regorafenib in 3, ramucirumab in 1, and hepatic arterial infusion chemotherapy in 1. After adjusting with IPW, the B group showed better prognosis in regard to OS after PD and OS after introducing LEN than the A group (10.8/19.6 vs. 5.8/11.2 months, p < 0.001, respectively). In IPW-adjusted Cox hazard multivariate analysis, significant prognostic factors for OS after PD were mALBI 2b/3 at PD (HR 1.983, p = 0.021), decline of Eastern Cooperative Oncology Group performance status (ECOG PS) from baseline at PD (HR 3.180, p < 0.001), elevated alpha-fetoprotein (≥100 ng/mL) at introducing LEN (HR 2.511, p = 0.004), appearance of new extrahepatic metastasis (HR 2.396, p = 0.006), positive for hand-foot skin reaction (HFSR) before PD (any grade) (HR 0.292, p < 0.001), and continuing LEN beyond PD (HR 0.297, p < 0.001). Conclusion: When ECOG PS and hepatic reserve function permit, continuing LEN treatment beyond PD, especially in u-HCC patients showed HFSR during LEN treatment, might be a good therapeutic option, at least until a more effective drug as a postprogression treatment after LEN failure is developed.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Chikara Ogawa; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
    Gastroenterology report 9 2 133 - 138 2021年04月 
    Background: Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment. Methods: Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020, 28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective manner. Results: The median age of the 28 patients given ramucirumab was 70 years and the median albumin-bilirubin score was -2.19. Of the 28 patients, 23 were male, 21 were classified as Child-Pugh A and 7 as Child-Pugh B, and 25 were Barcelona Clinic Liver Cancer Stage C. Ramucirumab was given as second-line therapy in 14, third-line in 9, and fourth-line in 5. Therapeutic response was obtained in only 26 patients; the objective response rate was 3.8% (1/26) and the disease-control rate was 42.3% (11/26), with a median period to progression of 2.0 months. The reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events (gastrointestinal bleeding, ascites) in 2. Conclusions: The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.
  • Masatoshi Kudo
    Hepatobiliary surgery and nutrition 10 2 241 - 245 2021年04月
  • Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
    Hepatobiliary surgery and nutrition 10 2 180 - 192 2021年04月 
    Importance: Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma (HCC), and consistently it is the hotspot in clinical studies. Objective: To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies. Evidence Review: We searched PubMed, MEDLINE, Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC. Findings: Several clinical issues are worth reconsidering, such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems, the translation of surrogate endpoint objective response rate (ORR) benefits into overall survival (OS) benefits, and whether conversion surgery contributes to initial expectations of long-term survival or not. New concepts in novel immunotherapy and targeted therapy in combination with loco-regional therapies may improve overall survival for HCC. Conclusions and Relevance for Reviews: Comprehensive understanding of the mechanism of immunotherapy and targeted therapy contributes to better prognosis of advanced HCC and more explorative combination therapies are needed.
  • Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Shoji Kubo
    Hepatology research : the official journal of the Japan Society of Hepatology 51 4 355 - 405 2021年04月 
    In the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 22,134 new patients and 41,956 previously followed patients were compiled from 546 institutions over a 2-year period from 1 January 2010 to 31 December 2011. Basic statistics compiled for patients newly registered in the 21st survey were cause of death, medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 20th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy and with radiofrequency ablation. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 1998 and 2011 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment type (hepatectomy, local ablation therapy, transcatheter arterial chemoembolization, and hepatic arterial infusion chemotherapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2011 into four time-period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer.
  • Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias Heikenwalder
    Nature 592 7854 450 - 456 2021年04月 
    Hepatocellular carcinoma (HCC) can have viral or non-viral causes1-5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+ T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH-HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+ T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+ T cells or TNF neutralization, suggesting that CD8+ T cells help to induce NASH-HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+ T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH-HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
  • Andrew X Zhu; Richard S Finn; Yoon-Koo Kang; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Kenta Motomura; Izumi Ohno; Bruno Daniele; Arndt Vogel; Tatsuya Yamashita; Chih-Hung Hsu; Guido Gerken; John Bilbruck; Yanzhi Hsu; Kun Liang; Ryan C Widau; Chunxiao Wang; Paolo Abada; Masatoshi Kudo
    British journal of cancer 124 8 1388 - 1397 2021年04月 
    BACKGROUND: Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or progression, during treatment in two placebo-controlled trials (REACH, REACH-2). METHODS: Serum AFP was measured at baseline and every three cycles. The prognostic and predictive value of baseline AFP was assessed by Cox regression models and Subpopulation Treatment Effect Pattern Plot method. Associations between AFP (≥ 20% increase) and radiographic progression and efficacy were assessed. RESULTS: Baseline AFP was confirmed as a continuous (REACH, REACH-2; p < 0.0001) and dichotomous (≥400 vs. <400 ng/ml; REACH, p < 0.01) prognostic factor, and was predictive for ramucirumab survival benefit in REACH (p = 0.0042 continuous; p < 0.0001 dichotomous). Time to AFP (hazard ratio [HR] 0.513; p < 0.0001) and radiographic (HR 0.549; p < 0.0001) progression favoured ramucirumab. Association between AFP and radiographic progression was shown for up to 6 (odds ratio [OR] 5.1; p < 0.0001) and 6-12 weeks (OR 1.8; p = 0.0065). AFP response was higher with ramucirumab vs. placebo (p < 0.0001). Survival was longer in patients with an AFP response than patients without (13.6 vs. 5.6 months, HR 0.451; 95% confidence interval, 0.354-0.574; p < 0.0001). CONCLUSIONS: AFP is an important prognostic factor and a predictive biomarker for ramucirumab survival benefit. AFP ≥ 400 ng/ml is an appropriate selection criterion for ramucirumab. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, REACH (NCT01140347) and REACH-2 (NCT02435433).
  • Masatoshi Kudo; Peter R Galle; Giovanni Brandi; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Josep M Llovet; Eric Assenat; Philippe Merle; Stephen L Chan; Daniel H Palmer; Masafumi Ikeda; Tatsuya Yamashita; Arndt Vogel; Yi-Hsiang Huang; Paolo B Abada; Reigetsu Yoshikawa; Kenta Shinozaki; Chunxiao Wang; Ryan C Widau; Andrew X Zhu
    JHEP reports : innovation in hepatology 3 2 100215 - 100215 2021年04月 
    Background & Aims: The albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc analysis, we assessed prognosis in terms of survival by baseline ALBI grade and monitored liver function during treatment with ramucirumab or placebo using the ALBI score in patients with advanced HCC. Methods: Patients with advanced HCC, Child-Pugh class A with prior sorafenib treatment were randomised in REACH trials to receive ramucirumab 8 mg/kg or placebo every 2 weeks. Data were analysed by trial and as a meta-analysis of individual patient-level data (pooled population) from REACH (alpha-fetoprotein ≥400 ng/ml) and REACH-2. Patients from REACH with Child-Pugh class B were analysed as a separate cohort. The ALBI grades and scores were calculated at baseline and before each treatment cycle. Results: Baseline characteristics by ALBI grade were balanced between treatment arms among patients in the pooled population (ALBI-1, n = 231; ALBI-2, n = 296; ALBI-3, n = 7). Baseline ALBI grade was prognostic for overall survival (OS; ALBI grade 2 vs. 1; hazard ratio [HR]: 1.38 [1.13-1.69]), after adjusting for other significant prognostic factors. Mean ALBI scores remained stable in both treatment arms compared with baseline and were unaffected by baseline ALBI grade, macrovascular invasion, tumour response, geographical region, or prior locoregional therapy. Baseline ALBI grades 2 and 3 were associated with increased incidence of liver-specific adverse events and discontinuation rates in both treatments. Ramucirumab improved OS in patients with baseline ALBI grade 1 (HR 0.605 [0.445-0.824]) and ALBI grade 2 (HR 0.814 [0.630-1.051]). Conclusions: Compared with placebo, ramucirumab did not negatively impact liver function and improved survival irrespective of baseline ALBI grade. Lay summary: Hepatocellular carcinoma is the third leading cause of cancer-related death worldwide. Prognosis is affected by many clinical factors including liver function both before and during anticancer treatment. Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies. We confirm the practicality of using this more simplistic approach in assessing liver function prior to and during anticancer therapy, and demonstrate ramucirumab did not impair liver function when compared with placebo.
  • Mamoru Takenaka; Tomohiro Yamazaki; Yasuo Otsuka; Kota Takashima; Rei Ishikawa; Masatoshi Kudo
    Endoscopy 54 3 E102-E105  2021年03月
  • Yasunori Minami; Tomohiro Minami; Kazuomi Ueshima; Yukinobu Yagyu; Masakatsu Tsurusaki; Takuya Okada; Masatoshi Hori; Masatoshi Kudo; Takamichi Murakami
    Cancers 13 6 2021年03月 
    BACKGROUND: We investigate the feasibility of image fusion application for ablative margin assessment in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) and possible causes for a wrong initial evaluation of technical success through a side-by-side comparison. METHODS: A total of 467 patients with 1100 HCCs who underwent RFA were reviewed retrospectively. Seventeen patients developed local tumor progressions (LTPs) (median size, 1.0 cm) despite initial judgments of successful ablation referring to contrast-enhanced images obtained in the 24 h after ablation. The ablative margins were reevaluated radiologically by overlaying fused images pre- and post-ablation. RESULTS: The initial categorizations of the 17 LTPs had been grade A (absolutely curative) (n = 5) and grade B (relatively curative) (n = 12); however, the reevaluation altered the response categories to eight grade C (margin-zero ablation) and nine grade D (existence of residual HCC). LTP occurred in eight patients re-graded as C within 4 to 30.3 months (median, 14.3) and in nine patients re-graded as D within 2.4 to 6.7 months (median, 4.2) (p = 0.006). Periablational hyperemia enhancements concealed all nine HCCs reevaluated as grade D. CONCLUSION: Side-by-side comparisons carry a risk of misleading diagnoses for LTP of HCC. Overlay fused imaging technology can be used to evaluate HCC ablative margin with high accuracy.
  • Masatoshi Kudo; Masafumi Ikeda; Peter R Galle; Tatsuya Yamashita; Richard S Finn; Kun Liang; Chunxiao Wang; Sachi Sakaguchi; Paolo Abada; Ryan C Widau; Andrew X Zhu
    Hepatology research : the official journal of the Japan Society of Hepatology 51 6 715 - 721 2021年03月 
    AIM: The REACH and REACH-2 trials investigated ramucirumab versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ascites is common in HCC and is associated with poorer outcomes. This exploratory, pooled meta-analysis of patients with baseline α-fetoprotein (AFP) ≥400 ng/ml investigated outcomes by treatment-emergent (TE) ascites in REACH and REACH-2. METHODS: A pooled meta-analysis of independent patient data for participants (N = 542) with baseline AFP ≥400 ng/ml (stratified by study) from REACH and REACH-2 was carried out. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier estimator, and OS further assessed by Cox models. The effect of TE ascites on OS was evaluated by multivariate Cox models. RESULTS: Treatment-emergent ascites developed in 66 patients (20.9%) in the ramucirumab group and 33 patients (14.8%) in the placebo group. When adjusted for treatment duration, the incidence rates per 100 patient-years of any grade TE ascites were 59.1 and 71.9 for the ramucirumab and placebo groups, respectively, and the incidence of grade ≥3 TE ascites were 13.4 and 19.6, respectively. Treatment-emergent ascites was associated with TE hypoalbuminemia (odds ratio 4.9; 95% confidence interval 2.5-9.3), but not TE proteinuria or hypertension. One patient discontinued ramucirumab treatment due to TE ascites. Ramucirumab treatment improved OS and PFS compared with placebo, irrespective of TE ascites. CONCLUSIONS: When adjusted for treatment duration, the incidence of TE ascites was no higher in patients who received ramucirumab than in those who received placebo. Ramucirumab was well tolerated and provided a survival benefit irrespective of the development of TE ascites.
  • Ikue Sekai; Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo
    Clinical journal of gastroenterology 14 4 1191 - 1196 2021年03月 
    Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Although the liver is a preferential organ for irAEs, the immuno-pathogenesis underlying hepatic irAEs has been poorly understood. We describe a 57-year-old man with Stage IV lung cancer who underwent the first-line regimen composed of carboplatin and paclitaxel. Nivolumab treatment (3.2 mg/kg, every 3 weeks) was initiated when the disease progressed after the first chemotherapy. Sequential occurrence of irAEs involving the multiorgan systems was observed. He developed hepatic irAEs (Grade 3) after endocrine, lung, and cutaneous irAEs. Lobular hepatitis characterized by predominant infiltration of CD8+ T cells was seen in the liver biopsy specimens. Interestingly, defective accumulation of regulatory T cells (Tregs) expressing forkhead box protein P3 (FOXP3) was evident in this case with hepatic irAEs as compared with typical cases with autoimmune hepatitis. This case suggests that hepatic irAEs are characterized not only by lobular infiltration of CD8+ T cells but also by defective accumulation of FOXP3+ Tregs.
  • Mamoru Takenaka; Koichiro Kawano; Reiko Kawano; Takao Katoh; Katsuhisa Nishi; Masatoshi Kudo
    Endoscopy 54 1 101 - 102 2021年03月
  • 急性膵炎からアプローチする膵癌早期診断
    山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会雑誌 118 臨増総会 A397 - A397 (一財)日本消化器病学会 2021年03月
  • 肝癌における薬物療法の診療体系 切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の経験(IMbrave150試験より)
    青木 智子; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 118 臨増総会 A114 - A114 (一財)日本消化器病学会 2021年03月
  • 肝予備能の評価法:検体検査と画像検査 切除不能肝細胞癌へのレンバチニブ療法におけるFIB-4 index、ALBI scoreの有用性
    青木 智子; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 118 臨増総会 A118 - A118 (一財)日本消化器病学会 2021年03月
  • 消化器領域におけるAI研究の進歩 腹部超音波B-modeでの肝腫瘤検出・診断支援システムの開発
    西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 118 臨増総会 A28 - A28 (一財)日本消化器病学会 2021年03月
  • 胆膵の内視鏡診断と治療 膵腫瘤におけるDetective flow imaging(DFI)の有用性の検討
    大本 俊介; 竹中 完; 工藤 正俊
    日本消化器病学会雑誌 118 臨増総会 A90 - A90 (一財)日本消化器病学会 2021年03月
  • 消化器領域におけるAI研究の進歩 腹部超音波B-modeでの肝腫瘤検出・診断支援システムの開発
    西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 118 臨増総会 A28 - A28 (一財)日本消化器病学会 2021年03月
  • Masayuki Kitano; Yasunobu Yamashita; Ken Kamata; Tiing Leong Ang; Hiroo Imazu; Eizaburo Ohno; Yoshiki Hirooka; Pietro Fusaroli; Dong-Wan Seo; Bertrand Napoléon; Anthony Yuen Bun Teoh; Tae Hyeon Kim; Christoph F Dietrich; Hsiu-Po Wang; Masatoshi Kudo
    Ultrasound in medicine & biology 47 6 1433 - 1447 2021年02月 
    The Asian Federation of Societies for Ultrasound in Medicine and Biology aimed to provide information on techniques and indications for contrast-enhanced harmonic endoscopic ultrasound (CH-EUS), and to create statements including the level of recommendation. These statements are based on current scientific evidence reviewed by a Consensus Panel of 15 internationally renowned experts. The reliability of clinical questions was measured by agreement rates after voting. Six statements were made on techniques, including suitable contrast agents for CH-EUS, differences between contrast agents, setting of mechanical index, dual imaging and duration and phases for observation. Thirteen statements were made on indications, including pancreatic solid masses, pancreatic cancer staging, pancreatic cystic lesions and mural nodules, detection of subtle pancreatic lesions, gallbladder sludge and polyps, hepatic lesions, lymph nodes, subepithelial lesions, visceral vascular diseases, guidance of fine needle aspiration and evaluation for local therapy. These international expert consensus guidelines will assist endosonographers in conducting CH-EUS according to evidence-based information.
  • Tomoe Yoshikawa; Kosuke Minaga; Akane Hara; Ikue Sekai; Yasuo Otsuka; Ryutaro Takada; Ken Kamata; Tomohiro Watanabe; Masatoshi Kudo
    Asian Pacific journal of allergy and immunology 2021年02月 
    BACKGROUND: Type 1 autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4-related disease (IgG4-RD). Although AIP and IgG4-RD are characterized by multiple organ involvement including salivary glands, lung, and kidney, co-occurrence of chronic rhinosinusitis (CRS) and AIP/IgG4-RD has been poorly defined. OBJECTIVE: We explored molecular mechanism accounting for the co-occurrence of CRS and AIP/IgG4-RD. METHODS: Serum concentrations of IFN-α and IL-33 were measured by enzyme-linked immune-sorbent assay. RESULTS: We encountered a patient with concurrent type 1 AIP/IgG4-RD and CRS. Induction of remission by prednisolone (PSL) for type 1 AIP/IgG4-RD led to a marked improvement of CRS. Serum cytokine analysis after PSL treatment revealed a marked reduction in serum concentrations of IFN-α and IL-33, both of which are candidate pathogenic cytokines for AIP/IgG4-RD. CONCLUSIONS: Given that IL-33 is shared as one of pathogenic cytokines by type 1 AIP/IgG4-RD and CRS, enhanced IL33 responses may cause concurrent type 1 AIP/IgG4-RD and CRS.
  • Mamoru Takenaka; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 6 924 - 926 2021年02月
  • Ken Kamata; Akira Kurita; Satoru Yasukawa; Yasutaka Chiba; Hiroko Nebiki; Masanori Asada; Hiroaki Yasuda; Hideyuki Shiomi; Takeshi Ogura; Makoto Takaoka; Noriyuki Hoki; Reiko Ashida; Minoru Shigekawa; Akio Yanagisawa; Masatoshi Kudo; Masayuki Kitano
    Endoscopic ultrasound 2021年02月 
    Background and Objectives: Differential diagnosis to estimate the malignant potential of gastric submucosal tumor (g-SMT) is important for decision-making. This study evaluated the use of a 20G needle with a core trap for EUS-guided fine-needle biopsy (EUS-FNB) for g-SMT. Methods: This multicentric prospective trial was registered in the University Hospital Medical Information Network (UMIN000021410). Consecutive patients with g-SMT who presented at one of the nine Japanese Referral Centers between June 2017 and November 2018 were enrolled. All patients underwent EUS-FNB using a 20G needle with a core trap. Samples obtained with the first-needle pass were used for central pathological review. EUS-FNB was evaluated in terms of (i) technical success rate, (ii) adequacy for histological evaluation, (iii) rate of complications, (iv) accuracy for histological diagnosis of gastrointestinal stromal tumor (GIST), and (v) concordance between GIST mitotic index determined by EUS-FNB and after tumor resection. Results: The study included 52 patients. The technical success rate of EUS-FNB was 100%. The adequacy rate for histological evaluation was 90.4% (P < 0.001). There were no complications related to EUS-FNB. Of the 38/52 patients who underwent surgical resection, 36 were finally diagnosed with GIST. The sensitivity, specificity, and accuracy of EUS-FNB for the histological diagnosis of g-SMT were 80.6%, 100%, and 81.6%, respectively. The concordance rate between the mitotic index on EUS-FNB and that after analysis of the resected tumor was 89.7%. Conclusions: EUS-FNB using a 20G needle with a core trap is feasible, providing histological samples of sufficient quality for diagnosing g-SMT.
  • Shunsuke Omoto; Masayuki Kitano; Mitsuharu Fukasawa; Reiko Ashida; Hironari Kato; Hideyuki Shiomi; Kazuya Sugimori; Atsushi Kanno; Yasutaka Chiba; Shinichi Takano; Naoki Yamamoto; Takeshi Ezaki; Haruo Miwa; Akitaka Yokomura; Masato Hoshikawa; Takamitsu Tanaka; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 1 198 - 206 2021年02月 
    OBJECTIVES: This prospective multicenter study aimed to assess and compare the accuracy of tissue harmonic endoscopic ultrasonography (TH-EUS) and contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for differentiating pancreatic carcinoma from other pancreatic tumors. METHODS: Consecutive patients with solid pancreatic tumors were prospectively enrolled between August 2013 and December 2014. To assess the accuracy of TH-EUS and CH-EUS, we compared four parameters of TH-EUS (fuzzy edge, irregular periphery, hypoechogenicity, and heterogeneous internal echogenicity) and four parameters of CH-EUS (hypoenhancement and heterogeneous enhancement in early and late phases, respectively) to investigate which parameter of each method was most suitable to diagnose pancreatic carcinomas. Inter-observer agreement and the diagnostic ability of pancreatic carcinoma using TH-EUS and CH-EUS were assessed and compared. RESULTS: A total of 204 patients were enrolled. For the diagnosis of pancreatic carcinoma, inter-observer agreement by experts and non-experts was 0.33-0.50 and 0.35-0.50 for TH-EUS, respectively, and 0.72-0.74 and 0.20-0.54 for CH-EUS, respectively. Irregular periphery was the most accurate diagnostic parameter among TH-EUS findings for differentiating pancreatic carcinomas, with sensitivity, specificity, and accuracy of 95.0%, 42.9%, and 77.5%, respectively. Late phase hypoenhancement was the most accurate diagnostic parameter among CH-EUS findings for differentiating pancreatic carcinomas, with sensitivity, specificity, and accuracy of 90.8%, 74.6%, and 84.8%, respectively. The accuracy of CH-EUS (late phase hypoenhancement) for diagnosis of pancreatic carcinoma was significantly higher than that of TH-EUS (irregular periphery) (P<0.001). CONCLUSIONS: In comparison with TH-EUS, CH-EUS increased the diagnostic ability and reproducibility for the diagnosis of pancreatic carcinoma. UMIN (000011124).
  • Saur Hajiev; Elias Allara; Leila Motedayеn Aval; Tadaaki Arizumi; Dominik Bettinger; Mario Pirisi; Lorenza Rimassa; Tiziana Pressiani; Nicola Personeni; Laura Giordano; Masatoshi Kudo; Robert Thimme; Joong-Won Park; Tamar H Taddei; David E Kaplan; Ramya Ramaswami; David J Pinato; Rohini Sharma
    British journal of cancer 2021年02月
  • Masatoshi Kudo
    Liver cancer 10 1 1 - 9 2021年02月
  • Mingyu Chen; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Jian Lin; Chenhao Tong; Jiliang Shen; Bin Zhang; Jennifer Wu; Christine Pocha; Masatoshi Kudo; Amedeo Amedei; Franco Trevisani; Pil Soo Sung; Victor M Zaydfudim; Tatsuo Kanda; Xiujun Cai
    Liver cancer 10 1 38 - 51 2021年02月 
    Background: The preoperative selection of patients with intermediate-stage hepatocellular carcinoma (HCC) who are likely to have an objective response to first transarterial chemoembolization (TACE) remains challenging. Objective: To develop and validate a clinical-radiomic model (CR model) for preoperatively predicting treatment response to first TACE in patients with intermediate-stage HCC. Methods: A total of 595 patients with intermediate-stage HCC were included in this retrospective study. A tumoral and peritumoral (10 mm) radiomic signature (TPR-signature) was constructed based on 3,404 radiomic features from 4 regions of interest. A predictive CR model based on TPR-signature and clinical factors was developed using multivariate logistic regression. Calibration curves and area under the receiver operating characteristic curves (AUCs) were used to evaluate the model's performance. Results: The final CR model consisted of 5 independent predictors, including TPR-signature (p < 0.001), AFP (p = 0.004), Barcelona Clinic Liver Cancer System Stage B (BCLC B) subclassification (p = 0.01), tumor location (p = 0.039), and arterial hyperenhancement (p = 0.050). The internal and external validation results demonstrated the high-performance level of this model, with internal and external AUCs of 0.94 and 0.90, respectively. In addition, the predicted objective response via the CR model was associated with improved survival in the external validation cohort (hazard ratio: 2.43; 95% confidence interval: 1.60-3.69; p < 0.001). The predicted treatment response also allowed for significant discrimination between the Kaplan-Meier curves of each BCLC B subclassification. Conclusions: The CR model had an excellent performance in predicting the first TACE response in patients with intermediate-stage HCC and could provide a robust predictive tool to assist with the selection of patients for TACE.
  • Dow-Mu Koh; Ahmed Ba-Ssalamah; Giuseppe Brancatelli; Ghaneh Fananapazir; M Isabel Fiel; Satoshi Goshima; Sheng-Hong Ju; Nikolaos Kartalis; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; Max Seidensticker; Claude B Sirlin; Cher Heng Tan; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Bachir Taouli
    European radiology 2021年02月 
    OBJECTIVES: The 9th International Forum for Liver Magnetic Resonance Imaging (MRI) was held in Singapore in September 2019, bringing together radiologists and allied specialists to discuss the latest developments in and formulate consensus statements for liver MRI, including the applications of gadoxetic acid-enhanced imaging. METHODS: As at previous Liver Forums, the meeting was held over 2 days. Presentations by the faculty on days 1 and 2 and breakout group discussions on day 1 were followed by delegate voting on consensus statements presented on day 2. Presentations and discussions centered on two main meeting themes relating to the use of gadoxetic acid-enhanced MRI in primary liver cancer and metastatic liver disease. RESULTS AND CONCLUSIONS: Gadoxetic acid-enhanced MRI offers the ability to monitor response to systemic therapy and to assist in pre-surgical/pre-interventional planning in liver metastases. In hepatocellular carcinoma, gadoxetic acid-enhanced MRI provides precise staging information for accurate treatment decision-making and follow-up post therapy. Gadoxetic acid-enhanced MRI also has potential, currently investigational, indications for the functional assessment of the liver and the biliary system. Additional voting sessions at the Liver Forum debated the role of multidisciplinary care in the management of patients with liver disease, evidence to support the use of abbreviated imaging protocols, and the importance of standardizing nomenclature in international guidelines in order to increase the sharing of scientific data and improve the communication between centers. KEY POINTS: • Gadoxetic acid-enhanced MRI is the preferred imaging method for pre-surgical or pre-interventional planning for liver metastases after systemic therapy. • Gadoxetic acid-enhanced MRI provides accurate staging of HCC before and after treatment with locoregional/biologic therapies. • Abbreviated protocols for gadoxetic acid-enhanced MRI offer potential time and cost savings, but more evidence is necessary. The use of gadoxetic acid-enhanced MRI for the assessment of liver and biliary function is under active investigation.
  • Mamoru Takenaka; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 5 746 - 748 2021年02月
  • Shunya Ikeda; Masatoshi Kudo; Namiki Izumi; Masahiro Kobayashi; Mie Azuma; Genevieve Meier; Janice Pan; Mika Ishii; Shuichi Kaneko
    Value in health regional issues 24 82 - 89 2021年01月 
    BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Japan. Prognosis is poor, and until recently sorafenib was the only treatment option available for patients with unresectable disease. Lenvatinib is the first therapy to demonstrate noninferiority to sorafenib. An analysis was conducted using clinical data from Japanese patients in the phase III REFLECT trial to assess the cost-effectiveness of lenvatinib versus sorafenib for first-line treatment of unresectable HCC in Japan. METHODS: A partitioned survival model was implemented adopting the perspective of the Japanese healthcare system, with costs and outcomes modeled over a lifetime horizon and using a discount rate of 2%, as per Japanese guidelines. Population data from the Japanese subpopulation of REFLECT were used to extrapolate outcomes, and costs and resource use were based on Japanese sources. The Japanese tariff was applied to EQ-5D data collected during the REFLECT clinical trial to obtain utility values reflecting the preferences of the Japanese population. RESULTS: Compared with sorafenib, lenvatinib is dominant because it is associated with a reduction in incremental costs of \156 799 and incremental quality-adjusted life-years of 0.31. These results were robust to changes in key assumptions, and probabilistic outcomes aligned with deterministic outcomes. CONCLUSION: Given the use of Japan-specific data in the cost-effectiveness model, it is expected that the use of lenvatinib as a first-line treatment in Japan will be associated with cost savings and improved clinical outcomes versus sorafenib for patients with unresectable HCC.
  • Kosuke Minaga; Tomohiro Watanabe; Masatoshi Kudo
    Digestive diseases and sciences 2021年01月
  • Masakatsu Tsurusaki; Keitaro Sofue; Masatoshi Hori; Kosuke Sasaki; Kazunari Ishii; Takamichi Murakami; Masatoshi Kudo
    Diagnostics (Basel, Switzerland) 11 2 2021年01月 
    Dual-energy computed tomography (DECT) is an imaging technique based on data acquisition at two different energy settings. Recent advances in CT have allowed data acquisitions and simultaneous analyses of X-rays at two energy levels, and have resulted in novel developments in the field of abdominal imaging. The use of low and high X-ray tube voltages in DECT provide fused images that improve the detection of liver tumors owing to the higher contrast-to-noise ratio (CNR) of the tumor compared with the liver. The use of contrast agents in CT scanning improves image quality by enhancing the CNR and signal-to-noise ratio while reducing beam-hardening artifacts. DECT can improve detection and characterization of hepatic abnormalities, including mass lesions. The technique can also be used for the diagnosis of steatosis and iron overload. This article reviews and illustrates the different applications of DECT in liver imaging.
  • Akihiro Yoshida; Yasutake Uchima; Naoki Hosaka; Kosuke Minaga; Masatoshi Kudo
    BMC gastroenterology 21 1 11 - 11 2021年01月 
    BACKGROUND: Colonic volvulus, a condition in which a colonic segment partially twists around its base, is the third leading cause of large bowel obstruction after colonic neoplasms and diverticular disease. However, volvulus of the transverse colon is the rarest type of large intestinal volvulus. Moreover, the occurrence of transverse colonic volvulus secondary to a benign tumor originating from outside the intestine has never been reported. We hereby report a case of transverse colonic volvulus caused by mesenteric fibromatosis. CASE PRESENTATION: A 53-year-old female with a history of rheumatoid arthritis and thyroid tumor presented with abdominal pain for 1 day. Abdominal computed tomography revealed intestinal torsion at the hepatic flexure. Twisted and obstructed mucosa of the transverse colon was observed during colonoscopy, but no tumor invasion of the mucosal surface was detected. A solid mass of a mesenteric origin with involvement of the transverse colon was observed during surgery. The mass was diagnosed surgically as transverse colonic volvulus induced by a mesenteric tumor. Hence, the patient underwent a right hemicolectomy. Histopathological results indicated mesenteric desmoid-type fibromatosis. The postoperative recovery was uneventful, and the patient was discharged 8 days after surgery. CONCLUSIONS: Although mesenteric fibromatosis is rare, this disease should be considered when managing transverse colonic volvulus resulting from nonmucosal tumors.
  • Ikue Sekai; Tomohiro Watanabe; Keisuke Yoshikawa; Ryutaro Takada; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
    Clinical journal of gastroenterology 2021年01月 
    Eosinophilic gastroenteritis (EGE) is a chronic allergic disorder characterized by infiltration of eosinophils in the gastrointestinal (GI) tract and hypereosinophilia. Although T helper type 2 (Th2) responses play pathogenic roles in EGE, roles of innate immunity cytokines including IL-6 and TNF-α have been poorly defined. Here, we describe a case of EGE exhibiting accumulation of eosinophils in the upper GI mucosa and hypereosinophilia. Induction of remission by prednisolone reduced expression levels not only of Th2 cytokines but also of IL-6 and TNF-α in the GI mucosa. Moreover, induction of remission was accompanied by a marked reduction in serum levels of chemokine C-C motif ligand 17 (CCL17, TARC), IL-6 and TNF-α, implicating that both Th2 and innate immune responses were involved in the development of EGE in this case. Collectively, this case suggests possible involvement of IL-6 and TNF-α in the development of EGE.
  • Masatoshi Kudo; Kaoru Tsuchiya; Naoya Kato; Atsushi Hagihara; Kazushi Numata; Hiroshi Aikata; Yoshitaka Inaba; Shunsuke Kondo; Kenta Motomura; Junji Furuse; Masafumi Ikeda; Manabu Morimoto; Meguru Achira; Shingo Kuroda; Akiko Kimura
    Journal of gastroenterology 2021年01月 
    BACKGROUND: To evaluate the efficacy and safety of cabozantinib in Japanese patients with advanced hepatocellular carcinoma (HCC) who had progressed following one or two lines of systemic therapy including sorafenib. An exploratory evaluation in sorafenib-naïve patients was performed. METHODS: In this open-label, single-arm, phase 2 trial, patients received oral cabozantinib 60 mg once daily. The primary endpoint was progression-free survival (PFS) rate at Week 24. Secondary endpoints included PFS, overall survival (OS), objective response rate (ORR, best response of complete/partial response), disease control rate (DCR, objective response or stable disease) and safety. RESULTS: Thirty-four patients received cabozantinib across 17 centers (prior sorafenib cohort, n = 20; sorafenib-naïve cohort, n = 14). PFS rate at 24 weeks was 59.8% [90% confidence interval (CI) 36.1-77.2%] in the prior sorafenib cohort, 16.7% (90% CI 4.0-36.8%) in the sorafenib-naïve cohort and 40.1% (90% CI 24.8-55.0%) overall. Median PFS was 7.4 months for the prior sorafenib cohort, 3.6 months for the sorafenib-naïve cohort, and 5.6 months overall. OS rate at 6 months was 100.0%, 78.6% and 91.1%, respectively; DCR was 85.0%, 64.3% and 76.5%, respectively. The ORR was 0.0% for both cohorts. All patients required dose modifications due to adverse events, the most common of these were palmar-plantar erythrodysesthesia syndrome and diarrhea. Three patients (8.8%) discontinued due to adverse events other than disease progression. CONCLUSIONS: Cabozantinib 60 mg/day has a favorable benefit/risk profile for Japanese patients with advanced HCC who have previously received one or two lines of systemic anticancer therapy including sorafenib. (Clinical trial registration: NCT03586973).
  • Makoto Yamakawa; Tsuyoshi Shiina; Koichiro Tsugawa; Naoshi Nishida; Masatoshi Kudo
    INTERNATIONAL ULTRASONICS SYMPOSIUM (IEEE IUS 2021) 2021年 
    The quality and quantity of training data is vital for computer-aided diagnosis (CADx) based on deep learning. However, the biomedical industry lacks large database of ultrasound images. Therefore, The Japan Society of Ultrasonics in Medicine (JSUM) is currently constructing an ultrasound image database for liver tumors, breast tumors, and heart diseases. As of August 2021, the project has collected more than 140,000 ultrasound images and videos. This database contains ultrasound images, their corresponding labels, and annotation information. That is, the ultrasound image data contains information related to the size and location of the tumor. In this study, we developed a CADx to classify liver tumors and breast tumors by utilizing approximately 71,000 liver tumor and 14,000 breast tumor ultrasound images from the abovementioned database. We classified liver tumors into four classes: cysts, hemangiomas, hepatocellular carcinomas, and metastatic liver cancers. Similarly, we classified breast tumors into four classes: breast cancer, fibroadenoma, cysts, and others. We used a convolutional neural network based on VGG19 for these classifications, and evaluated the accuracy of each case unit by k-fold cross-validation, thereby achieving an accuracy of 91.1% and 85.2% for four-class classification of liver tumor and breast tumor, respectively. In addition, the accuracy, sensitivity, and specificity of the benign/malignant classification based on this result was, respectively, 94.3%, 82.8%, and 96.7% for liver tumors and 89.9% 92.6% and 86.6% for breast tumors. Furthermore, when compared with the results obtained in a previous study that utilized a small database, using a large database provided a higher accuracy for both liver and breast tumors.
  • Shigenaga Matsui; Tomohiro Yamazaki; Osamu Shiraishi; Masatoshi Kudo
    Annals of gastroenterology 34 4 597 - 597 2021年
  • Mihir Gandhi; Wen-Huan Ling; Chien-Hung Chen; Joon Hyeok Lee; Masatoshi Kudo; Rawisak Chanwat; Simone I Strasser; Zhu Xu; Soh-Han Lai; Pierce Kah-Hoe Chow
    Journal of hepatocellular carcinoma 8 1159 - 1167 2021年 
    Purpose: The COVID-19 pandemic has altered healthcare priorities which may adversely impact cancer management. We aimed to evaluate the impact of the pandemic on the diagnosis, treatment, and consultation methods for patients with hepatocellular carcinoma (HCC). Patients and Methods: We conducted a survey among 27 hospitals from 14 Asia-Pacific countries, collecting hospital-level information on the number of newly diagnosed HCC cases during a pre-pandemic period (February to May 2019) and for the same period during the pandemic (February to May 2020). Information was also collected on delays in diagnosis and treatment, changes in treatment modalities and complication rates, changes in patient enrollment in clinical trials, and modes of patient consultation. The information was stratified by the Barcelona Clinic Liver Cancer (BCLC) stage. Results: The survey included cohorts of 2789 and 2045 patients newly diagnosed with HCC during the pre- and pandemic period, respectively. A decline of 26.7% in new HCC cases was reported during the pandemic compared to the pre-pandemic. A sizable proportion of institutions reported delays in diagnosis (48.2% in BCLC 0/A/B and 51.9% in BCLC C), delays in treatment (66.7% in BCLC 0/A/B and 63.0% in BCLC C), changes in treatment modality (33.3% in BCLC 0/A/B and 18.5% in BCLC C), an increase in treatment complications (about 15% across all BCLC stages), and no growth in clinical trial enrollments during the pandemic. Furthermore, there was a decline of 27.3% in face-to-face patient consultations and an increase of 18.3% in video/telephonic consultations during the pandemic. A considerable variation in changes in HCC management was observed among countries. Conclusion: The COVID-19 pandemic has significantly impacted the management of HCC among Asia-Pacific countries. The impact varies according to the disease stage and country. Well thought-through long-term strategies are required to ameliorate the negative impact of the pandemic on HCC patients.
  • Arndt Vogel; Philippe Merle; Chris Verslype; Richard S Finn; Andrew X Zhu; Ann-Lii Cheng; Stephen Lam Chan; Thomas Yau; Baek-Yeol Ryoo; Jennifer Knox; Bruno Daniele; Shukui Qin; Ziwen Wei; Yanna Miteva; Usha Malhotra; Abby B Siegel; Masatoshi Kudo
    Therapeutic advances in medical oncology 13 17588359211039928 - 17588359211039928 2021年 
    Aims: This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study. Methods: Patients with confirmed hepatocellular carcinoma (HCC) and progression after/intolerance to sorafenib, Child-Pugh class A liver function, and Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned 2:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks plus BSC for ⩽35 cycles or until confirmed progression/unacceptable toxicity. Outcomes were assessed by ALBI grade. Results: Of 413 patients, at baseline 116 had an ALBI grade 1 score (pembrolizumab, n = 74; placebo, n = 42) and 279 had an ALBI grade 2 score (n = 193; n = 86). Change from baseline in ALBI score to the end of treatment was similar in both arms [difference in least squares mean, -0.039; 95% confidence interval (CI): -0.169 to 0.091]. Time to ALBI grade increase was similar in both arms [median for pembrolizumab versus placebo: 7.8 versus 6.9 months; hazard ratio (HR) = 0.863 (95% CI: 0.625-1.192)]. Regardless of baseline ALBI grade, a trend toward improved overall survival was observed with pembrolizumab [grade 1: HR = 0.725 (95% CI: 0.454-1.158); grade 2: HR = 0.827 (95% CI: 0.612-1.119)]. Conclusion: Pembrolizumab did not adversely impact liver function compared with placebo in patients with HCC, as measured by changes in ALBI scores. A trend toward improved overall survival was observed with pembrolizumab in both ALBI grade groups. ClinicalTrials.gov identifier: NCT02702401.
  • Masayuki Kurimoto; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
    Frontiers in physiology 12 781012 - 781012 2021年 
    IL-33 is a pleiotropic cytokine that promotes inflammation and fibrosis. IL-33 is produced by a broad range of cells, including antigen-presenting cells (APCs), epithelial cells, and fibroblasts. IL-33 produced by the innate immune cells has been shown to activate pro-inflammatory T helper type 1 (Th1) and T helper type 2 (Th2) responses. The intestinal barrier and tolerogenic immune responses against commensal microbiota contribute to the maintenance of gut immune homeostasis. Breakdown of tolerogenic responses against commensal microbiota as a result of intestinal barrier dysfunction underlies the immunopathogenesis of inflammatory bowel diseases (IBD) and pancreatitis. Recent studies have provided evidence that IL-33 is an innate immune cytokine that bridges adaptive Th1 and Th2 responses associated with IBD and pancreatitis. In this Mini Review, we discuss the pathogenic roles played by IL-33 in the development of IBD and pancreatitis and consider the potential of this cytokine to be a new therapeutic target.
  • Kazuko Sakai; Toshiharu Sakurai; Marco A De Velasco; Tomoyuki Nagai; Takaaki Chikugo; Kazuomi Ueshima; Yurie Kura; Takayuki Takahama; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo; Kazuto Nishio
    Frontiers in oncology 11 763468 - 763468 2021年 
    Immune checkpoint inhibitors (ICIs) have become the standard of care for several cancers. However, ICI therapy has also been associated with various immune-related adverse events (irAEs). Clinical manifestations of immune-related colitis resemble those of inflammatory bowel diseases such as ulcerative colitis (UC). The composition of the bowel microflora is thought to influence the development of inflammatory bowel disease and irAE colitis. We profiled the gene expressions and microbe compositions of colonic mucosa from patients with solid cancers receiving anti-PD-L1 antibody treatment; we then compared the expression profiles associated with irAE colitis with those associated with UC. The pathway enrichment analysis revealed functional similarities between inflamed regions of irAE colitis and UC. The common enriched pathways included leukocyte extravasation and immune responses, whereas non-inflamed mucosa from patients with irAE colitis was distinct from patients with UC and was characterized by the recruitment of immune cells. A similarity between the microbiota profiles was also identified. A decreased abundance of Bacteroides species was observed in inflamed regions from both irAE colitis and UC based on a microbiota composition analysis of 16S rDNA sequencing. Pathways associated with molecule transport systems, including fatty acids, were enriched in inflamed and non-inflamed irAE colitis and inflamed UC, similar to Piphillin-inferred KEGG pathways. While UC is characterized by local regions of inflammation, ICI treatment extends to non-inflammatory regions of the colonial mucosa where immune cells are reconstituted. This analysis of the similarity and heterogeneity of irAE colitis and UC provides important information for the management of irAE colitis.
  • 異所性静脈瘤の診断と治療
    松井繁長; 樫田博史; 工藤正俊
    食道・胃静脈瘤 改訂第4版 313 - 318 2021年
  • 食道・胃静脈瘤
    松井繁長; 工藤正俊
    消化器疾患 最新の治療2021-2022 77 - 80 2021年
  • Masatoshi Kudo
    Hepatobil Surg Nutr 10 4 522 - 525 2021年 [査読有り]
  • Ryutaro Takada; Tomohiro Watanabe; Ikue Sekai; Keisuke Yoshikawa; Akane Hara; Yasuo Otsuka; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Takaaki Chikugo; Yasuyuki Arai; Kohei Yamashita; Masatoshi Kudo
    Frontiers in oncology 11 656219 - 656219 2021年 
    Double expressor lymphoma (DEL), defined as overexpression of BCL2 and MYC, is an aggressive subtype of diffuse large B cell lymphoma (DLBCL). Here we report a case of a 64-year-old female diagnosed with abdominal DEL transformed from jejunum follicular lymphoma (FL). 18F-fluorodeoxyglucose (FDG)-positron emission tomography showed diffuse accumulation of FDG into the peritoneum and small bowel wall. Double balloon-assisted enteroscopy revealed whitish submucosal tumors in the proximal jejunum. Aggregation of atypical lymphocytes positive for CD20, CD79a, and BCL2 was seen in the jejunal biopsy samples. These atypical lymphocytes were monoclonal since cell surface expression of Ig light chains was limited to κ chain by flow-cytometry. Thus, immunohistochemical and flowcytometric analyses data were consistent with FL of the jejunum. Neoplastic lymphocytes obtained from ascites were positive for CD10, CD20, CD79a, BCL2, and BCL6. Fluorescence in situ hybridization (FISH) showed formation of BCL2/IgH fusion gene and extra copies of MYC, the former of which is a characteristic chromosomal abnormality of FL. These genetic alterations and protein expression profiles of ascitic fluid cells were consistent with those of DEL transformed from FL. Given that a significant population of patients with indolent FL of the gastrointestinal tract developed into aggressive DLBCL, it is likely that primary FL of the jejunum transformed into the abdominal aggressive DEL in this case. This case is unique in that concurrent occurrence of FL and DEL was confirmed by immunohistochemical and FISH analyses and that abdominal DEL transformed from jejunal FL was highly suspected.
  • Yoriaki Komeda; Hisashi Handa; Ryoma Matsui; Shohei Hatori; Riku Yamamoto; Toshiharu Sakurai; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Tomohiro Watanabe; Masatoshi Kudo
    PloS one 16 6 e0253585  2021年 
    Convolutional neural networks (CNNs) are widely used for artificial intelligence (AI)-based image classification. Residual network (ResNet) is a new technology that facilitates the accuracy of image classification by CNN-based AI. In this study, we developed a novel AI model combined with ResNet to diagnose colorectal polyps. In total, 127,610 images consisting of 62,510 images with adenomatous polyps, 30,443 with non-adenomatous hyperplastic polyps, and 34,657 with healthy colorectal normal mucosa were subjected to deep learning after annotation. Each validation process was performed using 12,761 stored images of colorectal polyps by a 10-fold cross validation. The efficacy of the ResNet system was evaluated by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy. The sensitivity, specificity, PPV, NPV, and diagnostic accuracy for adenomatous polyps at WLIs were 98.8%, 94.3%, 90.5%, 87.4%, and 92.8%, respectively. Similar results were obtained for adenomatous polyps at narrow-band imagings (NBIs) and chromoendoscopy images (CEIs) (NBIs vs. CEIs: sensitivity, 94.9% vs. 98.2%; specificity, 93.9% vs. 85.8%; PPV, 92.5% vs. 81.7%; NPV, 93.5% vs. 99.9%; and overall accuracy, 91.5% vs. 90.1%). The ResNet model is a powerful tool that can be used for AI-based accurate diagnosis of colorectal polyps.
  • Keisuke Yoshikawa; Tomohiro Watanabe; Ikue Sekai; Ryutaro Takada; Akane Hara; Masayuki Kurimoto; Yasuhiro Masuta; Yasuo Otsuka; Tomoe Yoshikawa; Sho Masaki; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Takaaki Chikugo; Masatoshi Kudo
    Frontiers in medicine 8 679237 - 679237 2021年 
    Behçet's disease (BD) is a rare inflammatory condition characterized by oral and genital ulcers, skin lesions, as well as ophthalmological, neurological, and gastrointestinal manifestations. BD involving the gastrointestinal tract is known as intestinal BD. The mucosa of the gastrointestinal tract of patients with intestinal BD exhibits enhanced levels of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α. These proinflammatory cytokines play pathogenic roles in the development of BD, as evidenced by the fact that biologics targeting these cytokines effectively induce BD remission. It should be noted, however, that the molecular mechanisms by which the blockade of these cytokines suppresses chronic inflammatory responses in BD are poorly understood. Herein, we report a case of intestinal BD resistant to prednisolone that was successfully treated with infliximab (IFX). The induction of remission by IFX was accompanied by a marked elevation of IL-6 and forkhead box P3 (FOXP3) at mRNA level. This case suggests that induction of remission by IFX is mediated not only by the suppression of TNF-α-mediated signaling pathways, but also by the promotion of IL-6 expression and accumulation of regulatory T cells expressing FOXP3.
  • Tomi Jun; Umut Ozbek; Sirish Dharmapuri; Camille Hardy-Abeloos; Huili Zhu; Jung-Yi Lin; Nicola Personeni; Tiziana Pressiani; Naoshi Nishida; Pei-Chang Lee; Chieh-Ju Lee; Hannah Hildebrand; Neil Nimkar; Sonal Paul; Petros Fessas; Muntaha Naeem; Dominik Bettinger; Uqba Khan; Anwaar Saeed; Yi-Hsiang Huang; Masatoshi Kudo; Lorenza Rimassa; Thomas U Marron; David J Pinato; Celina Ang
    Therapeutic advances in medical oncology 13 17588359211010937 - 17588359211010937 2021年 
    Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs), are also known to disrupt the microbiome, but data on their association with ICI outcomes are conflicting. Methods: We conducted a retrospective, multicenter, international cohort study including 314 hepatocellular carcinoma (HCC) patients treated with ICIs from 2017 to 2019 to assess the association between PPI or H2RA exposure (up to 30 days before ICI) and overall survival. Secondary outcomes included overall response rate (ORR) and development of any treatment-related adverse events (AEs). Results: Baseline PPI/H2RA exposure was not associated with overall survival in univariable (HR 1.01, 95% CI 0.75-1.35) or multivariable analysis (HR 0.98, 95% CI 0.71-1.36). Baseline PPI/H2RA exposure was not associated with either ORR (OR 1.32, 95% CI 0.66-2.65) or AEs (OR 1.07, 95% CI 0.54-2.12) in multivariable analysis. Conclusions: Our results suggest that exposure to PPI/H2RA prior to ICIs does not adversely affect outcomes in HCC patients.
  • Hajime Honjo; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
    Frontiers in pharmacology 12 650403 - 650403 2021年 
    Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/threonine kinase 2 (RIPK2), also known as receptor-interacting protein 2 (RIP2), is a downstream signaling molecule for nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs). RIPK2 is expressed in antigen-presenting cells, such as dendritic cells and macrophages. Recognition of microbe-associated molecular patterns by NOD1, NOD2, and TLRs leads to the interaction between RIPK2 and these innate immune receptors, followed by the release of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12/23p40 through the activation of nuclear factor kappa B and mitogen-activated protein kinases. Thus, activation of RIPK2 plays a critical role in host defense against microbial infections. Recent experimental and clinical studies have provided evidence that activation of RIPK2 is involved in the development of autoimmune diseases, especially IBDs. In addition, the colonic mucosa of patients with IBD exhibits enhanced expression of RIPK2 and associated signaling molecules. Furthermore, the blockage of RIPK2 activation ameliorates the development of experimental murine colitis. Thus, activation of RIPK2 underlies IBD immunopathogenesis. In this review, we attempt to clarify the roles played by RIPK2 in the development of IBD by focusing on its associated signaling pathways. We also discuss the possibility of using RIPK2 as a new therapeutic target in IBD.
  • Tomoe Yoshikawa; Tomohiro Watanabe; Ken Kamata; Akane Hara; Kosuke Minaga; Masatoshi Kudo
    Frontiers in immunology 12 621532 - 621532 2021年 
    Autoimmune pancreatitis (AIP) is a chronic fibro-inflammatory disorder of the pancreas. Recent clinicopathological analysis revealed that most cases of AIP are pancreatic manifestations of systemic IgG4-related disease (IgG4-RD), a newly established disease characterized by enhanced IgG4 antibody responses and the involvement of multiple organs. Although the immuno-pathogenesis of AIP and IgG4-RD has been poorly defined, we recently showed that activation of plasmacytoid dendritic cells (pDCs) with the ability to produce large amounts of IFN-α and IL-33 mediates chronic fibro-inflammatory responses in experimental and human AIP. Moreover, M2 macrophages producing a large amount of IL-33 play pathogenic roles in the development of human IgG4-RD. Interestingly, recent studies including ours provide evidence that compositional alterations of gut microbiota are associated with the development of human AIP and IgG4-RD. In addition, intestinal dysbiosis plays pathological roles in the development of chronic pancreatic inflammation as dysbiosis mediates the activation of pDCs producing IFN-α and IL-33, thereby causing experimental AIP. In this Mini Review, we focus on compositional alterations of gut microbiota in AIP and IgG4-RD to clarify the mechanisms by which intestinal dysbiosis contributes to the development of these disorders.
  • Yasunori Minami; Masatoshi Kudo
    Frontiers in oncology 11 593636 - 593636 2021年 
    The ultrasound (US) imaging technology, including contrast-enhanced US (CEUS) and fusion imaging, has experienced radical improvement, and advancement in technology thus overcoming the problem of poor conspicuous hepatocellular carcinoma (HCC). On CEUS, the presence or absence of enhancement distinguishes the viable portion from the ablative necrotic portion. Using volume data of computed tomography (CT) or magnetic resonance imaging (MRI), fusion imaging enhances the three-dimensional relationship between the liver vasculature and HCC. Therefore, CT/MR-US fusion imaging provides synchronous images of CT/MRI with real-time US, and US-US fusion imaging provides synchronous US images before and after ablation. Moreover, US-US overlay fusion can visualize the ablative margin because it focuses the tumor image onto the ablation zone. Consequently, CEUS and fusion imaging are helpful to identify HCC with little conspicuity, and with more confidence, we can perform ablation therapy. CEUS/fusion imaging guidance has improved the clinical effectiveness of ablation therapy in patients with poor conspicuous HCCs. Therefore; this manuscript reviews the status of CEUS/fusion imaging guidance in ablation therapy of poor conspicuous HCC.
  • Yoriaki Komeda; Toshiharu Sakurai; Kazuko Sakai; Yasuyoshi Morita; Arito Hashimoto; Tomoyuki Nagai; Satoru Hagiwara; Itaru Matsumura; Kazuto Nishio; Masatoshi Kudo
    World journal of clinical cases 8 24 6389 - 6395 2020年12月 
    BACKGROUND: Concomitant ulcerative colitis (UC) and idiopathic thrombocytopenic purpura (ITP) is a rare phenomenon. The management of UC with ITP can be challenging, since a decreased platelet count augments UC. CASE SUMMARY: A 24-year-old man with UC and steroid-resistant ITP experienced UC flare. Although continuous infusion of cyclosporine was initiated, UC did not improve. The administration of tofacitinib subsequently led to the induction of remission. The patient has maintained remission of UC and ITP for over one year on tofacitinib treatment. Whole transcriptomic sequencing was performed for inflamed rectal mucosae obtained before and after the initiation of Janus kinase (JAK) inhibitor, suggesting that distinct molecular signatures seemed to be regulated by JAK inhibitors and other conventional therapies including tumor necrosis factor lockers. CONCLUSION: Tofacitinib should be considered in refractory cases of UC with ITP.
  • 工藤 正俊; 泉 並木; 久保 正二; 國土 典宏; 坂元 亨宇; 椎名 秀一朗; 高山 忠利; 建石 良介; 中島 収; 村上 卓道; 松山 裕; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会
    肝臓 61 12 645 - 691 (一社)日本肝臓学会 2020年12月 
    第21回全国原発性肝癌追跡調査においては、546施設から2010年1月1日から2011年12月31日までの2年間の22,134例の新規症例と41,956例の追跡症例が集計された。基礎統計は、第21回新規登録症例を対象として死因、既往歴、臨床診断、画像診断、治療法別の各因子、病理診断、再発、剖検についてまとめた。第20回調査と比較し、肝細胞癌における臨床診断時の高齢化、女性の増加、非B非C肝癌の増加、腫瘍径の縮小の傾向が、治療においては切除の割合の増加、局所療法におけるラジオ波焼灼療法の増加が認められた。1998年から2011年まで新規登録症例の中で最終予後が生存または死亡となった症例(不明を除く)について肝細胞癌、肝内胆管癌、混合型肝癌の治療法別、背景因子別累積生存率を算出した。肝細胞癌については腫瘍個数、腫瘍径、肝障害度、Child-Pugh分類を組み合わせることにより背景因子を揃えて、治療法別(肝切除、局所療法、肝動脈塞栓療法(TACE))、肝動注化学療法の累積生存率を算出し、また、1978年から2011年までの新規登録症例を4期に分け、累積生存率を算出した。新規登録症例数は経時的に増加し、肝細胞癌の予後の改善が著しいことが明らかとなった。本追跡調査が原発性肝癌の研究および診療の進歩に役立つことを期待する。(著者抄録)
  • 西田 直生志; 工藤 正俊
    肝臓 61 12 623 - 636 (一社)日本肝臓学会 2020年12月 
    近年、社会機能の種々の場面で人工知能(artificial intelligence:AI)を導入する試みがなされている。医療においても、医療従事者の負担軽減や見逃し防止を目的としてAI診断の導入が始まっており、内視鏡検査のAI診断補助、胸部レントゲンの病変スクリーニング、病理検査のAI遠隔診断など、既に実用化、あるいは実用化が近いものが出てきている。加えて、病変検出や診断のみならず、治療法選択などの疾患マネージメントを視野に入れた報告もなされている。画像診断支援はAIに親和性の高い分野であり、本邦でも重点的にAI開発がなされるべき分野として、日本医療研究開発機構の臨床研究等ICT基盤構築・人工知能実装研究事業の枠組みでの大規模なデータベース構築とAI開発が進んでいる。一方、超音波分野のAI開発に関しては、画像データの取得に際して術者依存性が高いこと、機器ベンダーや機種が多く、さらに画質パラメータが複数あるなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっている。本稿では、医療分野での画像診断領域AIの現状を概説し、特に超音波AIにフォーカスして、その特有の問題点を取り上げ、近未来の超音波AI支援システム展開において取り組むべき課題を述べる。(著者抄録)
  • 消化器早期がん内視鏡スクリーニング〜検診も含めて〜 微小膵癌診断のためのスクリーニングEUSの意義と位置づけ
    山雄 健太郎; 竹中 完; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 105回 45 - 45 日本消化器内視鏡学会-近畿支部 2020年12月
  • 食道平滑筋腫上に発生した表在癌に対して内視鏡的粘膜下層剥離術を施行した1例
    吉田 早希; 松井 繁長; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 本庶 元; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 105回 66 - 66 日本消化器内視鏡学会-近畿支部 2020年12月
  • Naoshi Nishida; Masatoshi Kudo
    Kanzo 61 12 623 - 636 2020年12月
  • 消化管止血に対する工夫〜こういうときどうする〜 胆管空腸吻合部静脈瘤出血に対する小腸内視鏡による内視鏡的静脈瘤硬化療法
    高島 耕太; 松井 繁長; 米田 頼晃; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 105回 54 - 54 日本消化器内視鏡学会-近畿支部 2020年12月
  • 食道平滑筋腫上に発生した表在癌に対して内視鏡的粘膜下層剥離術を施行した1例
    吉田 早希; 松井 繁長; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 本庶 元; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 105回 66 - 66 日本消化器内視鏡学会-近畿支部 2020年12月
  • K. Kamata; T. Watanabe; K. Minaga; A. Hara; I. Sekai; Y. Otsuka; T. Yoshikawa; A.‐M. Park; M. Kudo
    Clinical & Experimental Immunology 202 3 308 - 320 2020年12月
  • Masatoshi Kudo
    Liver cancer 9 6 629 - 639 2020年12月
  • Masatoshi Kudo
    Liver cancer 9 6 640 - 662 2020年12月 
    Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the available treatment options for patients with extrahepatic spread and vascular invasion and improved survival in patients with advanced HCC; however, various shortcomings such as low response rates and relatively high toxicity (e.g., hand-foot skin reaction) prompted concerted efforts aimed at developing new molecular targeted agents to provide more treatment options and second-line agents for patients with disease progression or intolerance to sorafenib. Despite many attempts to develop new drugs between 2007 and 2016, all first-line and second-line clinical trials conducted during this period failed. However, between 2017 and 2019, 4 drugs (lenvatinib as a first-line agent and regorafenib, cabozantinib, and ramucirumab as second-line agents) emerged in quick succession from clinical trials and became available for clinical use. In addition, nivolumab and pembrolizumab were approved as second-line agents after sorafenib. A recent phase III trial (IMbrave150) showed that combination immunotherapy with atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected soon. This review describes the recent advances in systemic therapy and the use of tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib, and cabozantinib), monoclonal antibodies (ramucirumab and bevacizumab), and immune checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) in elderly patients and the similarity of their efficacy and safety profiles to those in the general population.
  • Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Akiko Wakuta; Ayano Oonishi; Teiji Kuzuya; Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Masatoshi Kudo; Takashi Kumada
    Liver cancer 9 6 734 - 743 2020年12月 
    Introduction: The ALBI score is acknowledged as the gold standard for the assessment of liver function in patients with hepatocellular carcinoma (HCC). Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation. However, the complex calculation of the ALBI score limits its applicability. Therefore, we developed a simplified ALBI score, based on data from a large-scale HCC database. We used the data of 5,249 naïve HCC cases registered in eight collaborating hospitals. Methods: We developed a new score, the EZ (Easy)-ALBI score, based on regression coefficients of Alb and T.Bil for survival risk in a multivariate Cox proportional hazard model. We also developed the EZ-ALBI grade and EZ-ALBI-T grade as alternative options for the ALBI grade and ALBI-T grade and evaluated their stratifying ability. Results: The equation used to calculate the EZ-ALBI score was simple {[T.Bil (mg/dL)] - [9 × Alb (g/dL)]}; this value highly correlated with the ALBI score (correlation coefficient, 0.981; p < 0.0001). The correlation was preserved across different Barcelona clinic liver cancer grade scores (regression coefficient, 0.93-0.98) and across different hospitals (regression coefficient, 0.98-0.99), indicating good generalizability. Although a good agreement was observed between ALBI and EZ-ALBI, discrepancies were observed in patients with poor liver function (T.Bil, ≥3 mg/dL; regression coefficient, 0.877). The stratifying ability of EZ-ALBI grade and EZ-ALBI-T grade were good and their Akaike's information criterion values (35,897 and 34,812, respectively) were comparable with those of ALBI grade and ALBI-T grade (35,914 and 34,816, respectively). Conclusions: The EZ-ALBI score, EZ-ALBI grade, and EZ-ALBI-T grade are useful, simple scores, which might replace the conventional ALBI score in the future.
  • Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Hepatobiliary surgery and nutrition 9 6 777 - 779 2020年12月 [査読有り][招待有り]
  • Baek-Yeol Ryoo; Philippe Merle; Amit S Kulkarni; Ann-Lii Cheng; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Bruno Daniele; Josephine M Norquist; Erluo Chen; Abby B Siegel; Andrew X Zhu; Richard S Finn; Masatoshi Kudo
    Cancer 127 6 865 - 874 2020年11月 
    BACKGROUND: Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) versus placebo plus BSC in patients with HCC who previously received sorafenib. This study presents the results of a prespecified exploratory analysis of patient-reported outcomes. METHODS: Patients completed the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) and its HCC supplement (EORTC QLQ-HCC18) electronically at baseline; at weeks 2, 3, 4, 6, 9, 12, and 18; and then every 9 weeks until 1 year or end of treatment, and at the 30-day safety follow-up visit. RESULTS: The HRQoL population included 271 and 127 patients randomly assigned to pembrolizumab and placebo, respectively. From baseline to week 12, changes in both scores were similar between pembrolizumab and placebo; global health status/QoL scores were stable. The proportions of patients who improved, remained stable, or deteriorated across all functional domain and symptom scores were generally similar between pembrolizumab and placebo. Time to deterioration was similar between the 2 arms based on the prespecified analysis of EORTC QLQ-HCC18 domains of abdominal swelling, fatigue, and pain. CONCLUSION: Pembrolizumab preserved HRQoL during treatment for advanced HCC. Combined with efficacy and safety results from KEYNOTE-240, these findings support a positive benefit/risk profile for pembrolizumab in a second-line treatment setting for patients with HCC who previously received sorafenib.
  • Maria Reig; Peter R Galle; Masatoshi Kudo; Richard Finn; Josep M Llovet; Andrea L Metti; William R Schelman; Kun Liang; Chunxiao Wang; Ryan C Widau; Paolo Abada; Andrew X Zhu
    Liver international : official journal of the International Association for the Study of the Liver 2020年11月 
    BACKGROUND & AIMS: Radiological progression patterns to first-line sorafenib have been associated with post-progression and overall survival in advanced hepatocellular carcinoma, but these associations remain unknown for therapies in second- and later-line settings. This post hoc analysis of REACH and REACH-2 examined outcomes by radiological progression patterns in the second-line setting of patients with advanced hepatocellular carcinoma treated with ramucirumab or placebo. METHODS: Patients with advanced hepatocellular carcinoma, Child-Pugh A and Eastern Cooperative Oncology Group Performance Status 0 or 1 with prior sorafenib were randomized to receive ramucirumab 8mg/kg or placebo every 2 weeks. Among 625 patients with ≥1 progression pattern (new extrahepatic lesion [including new macrovascular invasion], new intrahepatic lesion, extrahepatic growth or intrahepatic growth), data were analysed by trial and for pooled individual patient data for REACH-2 and REACH (alpha-fetoprotein ≥400 ng/mL). Cox models evaluated prognostic implications of progression patterns on overall and post-progression survival. RESULTS: Post-progression survival was worse among those with new extrahepatic lesions in REACH (HR 2.33, 95% CI 1.51-3.60), REACH-2 (HR 1.49, 95% CI 0.72-3.08) and the pooled population (HR 1.75, 95% CI 1.12-2.74) compared to other progression patterns. Overall survival was also significantly reduced in those with new extrahepatic lesions across studies. Ramucirumab provided an overall survival benefit across progression patterns, including patients with new extrahepatic lesions (HR 0.56, 95% CI 0.39-0.80) in the pooled population. CONCLUSIONS: The emergence of new extrahepatic lesions in the second-line setting is a poor prognostic factor for post-progression survival. The benefit of ramucirumab for overall survival was consistent across progression patterns.
  • Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Toshifumi Tada; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
    Journal of gastroenterology and hepatology 36 7 1812 - 1819 2020年11月 
    BACKGROUND AND AIM: This study aimed to elucidate the clinical importance of muscle volume loss (pre-sarcopenia) in patients receiving lenvatinib as treatment for unresectable hepatocellular carcinoma (u-HCC). METHODS: Of 437 u-HCC patients treated with lenvatinib at specific institutions in Japan between March 2018 and May 2020, 151 with available computed tomography imaging data from the time of lenvatinib introduction were enrolled. Pre-sarcopenia was diagnosed based on a previously reported cut-off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm2 )/height (m)2 ]. Clinical features and prognostic factors for overall survival (OS) with inverse probability weighting were investigated retrospectively for their relationship with pre-sarcopenia. RESULTS: Cox hazard multivariate analysis showed alpha-fetoprotein (≥400 ng/mL) (hazard ratio [HR] 2.271, P < 0.001), Barcelona Clinic Liver Cancer stage (C and D) (HR 1.625, P = 0.018), and positive for pre-sarcopenia (HR 1.652, P = 0.042) to be significant prognostic factors. OS rates for the pre-sarcopenia group (n = 41) were worse than those for the non-pre-sarcopenia group (n = 110) (0.5-, 1-, and 1.5-year OS: 72.5%, 27.9%, and 7.0% vs 80.7%, 56.7%, and 46.1%, respectively; P < 0.001), as was progression-free survival (P = 0.025). Time to stopping lenvatinib or disease progression was better in the non-pre-sarcopenia group (0.5-, 1-, and 1.5-year OS: 48.0%, 24.5%, and 8.4% vs 20.0%, 10.3%, and 4.2%, respectively; P < 0.001). Also, the frequency of the adverse event appetite loss (any grade) was greater in the pre-sarcopenia group (43.9% vs 18.2%, P = 0.003). CONCLUSION: Pre-sarcopenia was shown to be a significant prognostic factor in patients treated with lenvatinib for u-HCC.
  • Toshiharu Sakurai; Hiroki Nishiyama; Kazuko Sakai; Marco A De Velasco; Tomoyuki Nagai; Yoriaki Komeda; Hiroshi Kashida; Akiyoshi Okada; Isao Kawai; Kazuto Nishio; Hiroyuki Ogata; Masatoshi Kudo
    Scientific reports 10 1 19186 - 19186 2020年11月 
    Given that sustained remission is the ultimate treatment goal in the management of patients with ulcerative colitis (UC), the decision to stop anti-tumor necrosis factor (anti-TNF) treatment in UC patients is difficult. The aim of this study was to evaluate mucosal microbiota and gene expression profiles associated with long-term remission after discontinuation of anti-TNF therapy. In nine UC patients who received anti-TNF therapy for 6 months, microbiota isolated from uninflamed mucosae and gene expression in inflamed and uninflamed mucosae were investigated at week 0 and at week 24. At treatment initiation, Fusobacterium sp. and Veillonella dispar were over-represented in the relapse group compared with the non-relapse group. After treatment, Dorea sp. and Lachnospira sp. were over-represented in the non-relapse group. In the relapse group only, a significant shift in gut bacterial community composition was found between week 0 and week 24. Gene expression of ALIX (PDCD6IP) and SLC9A3 was significantly higher in the non-relapse group than in the relapse group. Lastly, we used machine learning methods to identify relevant gene signatures associated with sustained remission. Statistical analyses of microbiota and expression profiles revealed differences between UC patients who did or did not keep remission after the discontinuation of TNF inhibitors.Trial registration: UMIN000020785: Evaluation of adalimumab therapy in mesalazine-resistant or -intolerant ulcerative colitis; an observational study (EARLY study).
  • 超音波画像ビッグデータベース構築とAI支援肝腫瘍検出・診断システムの開発 AMED臨床研究等ICT基盤構築・人工知能実装研究事業での取り組み
    西田 直生志; 山川 誠; 椎名 毅; 目加田 慶人; 工藤 正俊
    超音波医学 47 Suppl. S544 - S544 (公社)日本超音波医学会 2020年11月
  • 進行肝癌に対する免疫チェックポイント阻害薬後レンバチニブ療法の画像評価
    青木 智子; 依田 広; 盛田 真弘; 南 知宏; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    超音波医学 47 Suppl. S167 - S167 (公社)日本超音波医学会 2020年11月
  • 鑑別診断において造影超音波が有用であった多血性の肝内胆管癌の1例
    盛田 真弘; 南 康範; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    超音波医学 47 Suppl. S275 - S275 (公社)日本超音波医学会 2020年11月
  • トルバプタン不応の難治性腹水に対する腹腔-静脈シャント(デンバーシャント)の有用性
    青木 智子; 南 康範; 鶴崎 正勝; 盛田 真弘; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊
    日本門脈圧亢進症学会雑誌 26 4 244 - 248 (一社)日本門脈圧亢進症学会 2020年11月 
    デンバーシャント術は難治性腹水症に対して行われる腹腔-静脈シャント術である。2014〜2018年にデンバーシャント術を施行した7例を対象とし、非代償性肝硬変に伴うトルバプタン不応腹水への有効性と安全性を検討した。奏効の内訳は、(1)腹満感など自覚症状の改善:57%、(2)体重・画像など他覚的所見の改善:71%、(3)治療内容の改善:腹水穿刺の中止29%、利尿薬減量71%であった。総合評価からデンバーシャント術の奏効率は86%であった。術後合併症は、播種性血管内凝固症候群(n=3)、創部し開(n=1)、特発性細菌性腹膜炎(n=1)、肝性脳症(n=1)、右心不全(n=1)を認め、保存的治療で軽快した。腹水コントロール不良で基礎疾患の病勢進行により術後30日目に永眠した症例が1例いた。デンバーシャント術は非代償性肝硬変症に伴うトルバプタン不応の難治性腹水に対して施行可能で有効な治療法と考える。(著者抄録)
  • 【進化するEUS】診断的EUS 造影ハーモニックEUS
    三長 孝輔; 原 茜; 田中 秀和; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊
    消化器内視鏡 32 11 1641 - 1649 (株)東京医学社 2020年11月
  • 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】レンバチニブ REFLECT試験のサブ解析
    上嶋 一臣; 工藤 正俊
    肝・胆・膵 81 5 835 - 840 (株)アークメディア 2020年11月
  • 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】レンバチニブ 切除不能肝細胞癌へのPD-1/PD-L1療法不応後二次治療として投与したレンバチニブ逐次治療の有効性
    青木 智子; 上嶋 一臣; 鶴崎 正勝; 工藤 正俊
    肝・胆・膵 81 5 874 - 880 (株)アークメディア 2020年11月
  • 進歩する化学療法時代に注意すべき肝細胞癌の遠隔転移
    吉田 早希; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊
    肝臓 61 Suppl.3 A924 - A924 (一社)日本肝臓学会 2020年11月
  • 難治性腹水に対するデンバーシャント術の試み
    家村 郁衣; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊
    肝臓 61 Suppl.3 A946 - A946 (一社)日本肝臓学会 2020年11月
  • 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】免疫療法時代における分子標的治療の今後を考える
    工藤 正俊; 古瀬 純司; 山下 竜也; 森口 理久
    肝・胆・膵 81 5 761 - 779 (株)アークメディア 2020年11月
  • Taku Aoki; Keiichi Kubota; Shoji Kubo; Susumu Eguchi; Namiki Izumi; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Osamu Nakashima; Yutaka Matsuyama; Takamichi Murakami; Masatoshi Kudo
    World journal of surgery 45 2 607 - 614 2020年10月 
    BACKGROUND: Non-curative (debulking) hepatic resection for hepatocellular carcinoma (HCC) is occasionally applied for selected cases with bulky tumors or for oncologic emergency cases; however, the clinical usefulness of this procedure has not yet been fully evaluated. The aim of the present study was to evaluate the patient outcomes of non-curative hepatic resections for HCC using data from bi-annual nationwide surveys conducted in Japan. METHOD: Data of 1084 non-curative hepatic resections for HCC were collected. The patient outcomes were compared with those of curative resections, transcatheter arterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). RESULTS: Patient survival after the non-curative resection was poorer than that after curative resection (P < 0.001) and was especially dismal in cases with extrahepatic tumor spread (lymph node metastasis, peritoneal seeding, or distant metastasis). As compared to cases receiving TACE without surgery, non-curative resections for multiple intrahepatic tumors were applied to cases with advanced tumors with good liver functional reserve. The survival outcomes were significantly more favorable in the TACE group, but the results became similar after propensity score matching of the patients. The survival outcome of patients receiving non-curative resections was better than that of cases treated by HAIC, with median survival times of 26.0 months and 10.0 months, respectively. CONCLUSION: The indications for non-curative hepatic resection in patients with HCC should be judged cautiously, especially in patients with extrahepatic tumor spread. This treatment approach may be beneficial for selected patients with intermediate- or advanced-stage HCC limited in liver and with good liver functional reserve.
  • Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi Nishida
    Cancers 12 10 2020年10月 
    Although programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) blockade is effective in a subset of patients with hepatocellular carcinoma (HCC), its therapeutic response is still unsatisfactory. Alternatively, the potential impact of the lenvatinib in patients who showed tumor progression on PD-1/PD-L1 blockade is unknown. In this work, we evaluated the safety and efficacy of lenvatinib administration after PD-1/PD-L1 checkpoint blockade. The outcome and safety of lenvatinib administered after PD-1/PD-L1 blockade failure was analyzed retrospectively in 36 patients. Tumor growth was assessed every 4-8 weeks using modified Response Evaluation Criteria in Solid Tumors. The mean relative dose intensity of lenvatinib was 87.6% and 77.8% in patients receiving a starting dose of 8 (interquartile range (IQR), 77.5-100.0) mg and 12 (IQR, 64.4-100.0) mg, respectively. Since lenvatinib therapy initiation, the median progression-free survival was 10 months (95% confidence interval (CI): 8.3-11.8) and the median overall survival was 15.8 months (95% CI: 8.5-23.2). The objective response rate was 55.6%, and the disease control rate was 86.1%. No particular safety concerns were observed. Lenvatinib demonstrated considerable antitumor effects with acceptable safety in patients with progressive and unresectable HCC when administered right after PD-1/PD-L1 blockade failure.
  • Saur Hajiev; Elias Allara; Leila Motedayеn-Aval; Tadaaki Arizumi; Dominik Bettinger; Mario Pirisi; Lorenza Rimassa; Tiziana Pressiani; Nicola Personeni; Laura Giordano; Masatoshi Kudo; Robert Thimme; Joong-Won Park; Tamar H Taddei; David E Kaplan; Ramya Ramaswami; David J Pinato; Rohini Sharma
    British journal of cancer 2020年10月 [査読有り]
     
    BACKGROUND: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly. METHODS: In an international, multicentre cohort study, outcomes for those aged <75 or ≥75 years were determined while accounting for common prognostic factors and demographic characteristics in univariable and multivariable models. RESULTS: Five thousand five hundred and ninety-eight patients were recruited; 792 (14.1%) were aged ≥75 years. The elderly were more likely to have larger tumours (>7 cm) (39 vs 33%, p < 0.01) with preserved liver function (67 vs 57.7%) (p < 0.01). No difference in the median OS of those aged ≥75 years and <75 was noted (7.3 months vs 7.2 months; HR 1.00 (95% CI 0.93-1.08), p = 0.97). There was no relationship between starting dose of sorafenib 800 mg vs 400 mg/200 mg and OS between those <75 and ≥75 years. The elderly experienced a similar overall incidence of grade 2-4 sorafenib-related toxicity compared to <75 years (63.5 vs 56.7%, p = 0.11). However, the elderly were more likely to discontinue sorafenib due to toxicity (27.0 vs 21.6%, p < 0.01). This did not vary between different starting doses of sorafenib. CONCLUSIONS: Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib prescribed.
  • Rei Ishikawa; Ken Kamata; Akane Hara; Hidekazu Tanaka; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Yasutaka Chiba; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Yuko Matsukubo; Tomoko Hyodo; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 5 829 - 839 2020年10月 [査読有り]
     
    BACKGROUND AND AIMS: Pancreatic neuroendocrine neoplasms (PanNENs), including Grade 1 (G1) or G2 tumors, can have a poor prognosis. This study investigated the value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for predicting the prognosis of PanNENs. METHODS: This single-center, retrospective study included 47 consecutive patients who underwent CH-EUS and were diagnosed with PanNEN by surgical resection or EUS-guided fine needle aspiration between December 2011 and February 2016. Patients were divided into aggressive and non-aggressive groups according to the degree of clinical malignancy. CH-EUS was assessed regarding its capacity for diagnosing aggressive PanNEN, the correspondence between contrast patterns and pathological features, and its ability to predict the prognosis of PanNEN. RESULTS: There were 19 cases of aggressive PanNEN and 28 cases of non-aggressive PanNEN. The aggressive group included three G1, four G2, three G3 tumors, three mixed neuroendocrine non-neuroendocrine neoplasms, and six neuroendocrine carcinomas. CH-EUS was superior to contrast-enhanced computed tomography for the diagnosis of aggressive PanNEN (P < 0.001): hypo-enhancement on CH-EUS was an indicator of aggressive PanNEN, with sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 94.7%, 100%, 100%, 96.6%, and 97.9%, respectively. Among G1/G2 PanNENs, cases with hypo-enhancement on CH-EUS had a poorer prognosis than those with hyper/iso-enhancement (P = 0.0009). Assessment of 36 resected specimens showed that hypo-enhancement on CH-EUS was associated with smaller and fewer vessels and greater degree of fibrosis. CONCLUSION: CH-EUS may be useful for predicting the prognosis of PanNENs.
  • 田中 隆光; 竹中 完; 吉田 晃弘; 田中 秀和; 吉川 智恵; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊輔; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A789 - A789 (一財)日本消化器病学会 2020年10月
  • 山雄 健太郎; 竹中 完; 石川 嶺; 沼本 勲; 鶴崎 正勝; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A721 - A721 (一財)日本消化器病学会 2020年10月
  • 三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A678 - A678 (一財)日本消化器病学会 2020年10月
  • 西田 直生志; 盛田 真弘; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A513 - A513 (一財)日本消化器病学会 2020年10月
  • 早期胃胎児消化管上皮類似癌の1例
    岡井 夏輝; 松井 繁長; 正木 翔; 栗本 真之; 大丸 直哉; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 永井 知行; 米田 頼晃; 本庶 元; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 94 - 94 日本消化器病学会-近畿支部 2020年10月
  • 拡大観察から見たPPI関連胃底腺ポリープの特徴
    友岡 瑞貴; 辻 直子; 高島 耕太; 正木 翔; 河野 匡志; 永井 知之; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 樫田 博史; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2088 - 2088 (一社)日本消化器内視鏡学会 2020年10月
  • 小腸内視鏡診療ガイドラインでのカプセル内視鏡検査の運用の実際
    米田 頼晃; 樫田 博史; 櫻井 俊治; 松村 まり子; 高島 耕太; 正木 翔; 河野 匡志; 山田 光成; 本庶 元; 永井 知行; 松井 繁長; 辻 直子; 渡邉 智裕; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2113 - 2113 (一社)日本消化器内視鏡学会 2020年10月
  • 膵神経内分泌腫瘍治癒切除後の肝転移再発を認め切除された一例
    杉崎 俊亮; 川崎 俊彦; 福永 朋洋; 野村 健司; 米澤 真衣; 半田 康平; 河野 辰也; 橋本 有人; 木下 大輔; 水野 成人; 若狭 朋子; 太田 善夫; 辻本 智之; 橋本 和彦; 石川 原; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 83 - 83 日本消化器病学会-近畿支部 2020年10月
  • 内視鏡的乳頭切除術後胆管狭窄に対する予防的金属ステント留置の有用性
    岡本 彩那; 竹中 完; 田中 隆光; 田中 秀和; 吉田 晃浩; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2136 - 2136 (一社)日本消化器内視鏡学会 2020年10月
  • KINDAI20を用いたコンベックスEUSの教育について
    大本 俊介; 竹中 完; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2164 - 2164 (一社)日本消化器内視鏡学会 2020年10月
  • 西田 直生志; 工藤 正俊
    肝・胆・膵 81 4 643 - 650 (株)アークメディア 2020年10月
  • 消化器領域から見たIgG4関連疾患研究の進歩 IRF7-I型IFN-IL-33経路がIgG4関連疾患の病態に果たす役割とバイオマーカーとしての有用性
    三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A678 - A678 (一財)日本消化器病学会 2020年10月
  • 急性膵炎におけるプレサルコペニアの臨床的意義に関しての検討
    田中 隆光; 竹中 完; 吉田 晃弘; 田中 秀和; 吉川 智恵; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊輔; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A789 - A789 (一財)日本消化器病学会 2020年10月
  • 消化器癌化学療法の進歩と課題 切除不能進行肝癌に対する免疫チェックポイント阻害薬不応後の二次治療を見据えて
    青木 智子; 萩原 智; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 54 - 54 日本消化器病学会-近畿支部 2020年10月
  • 鑑別診断に造影超音波が有用であった多血性の肝内胆管癌の1例
    吉田 早希; 南 康範; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 103 - 103 日本消化器病学会-近畿支部 2020年10月
  • 肝癌診療の現状と未来 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異
    西田 直生志; 盛田 真弘; 工藤 正俊
    日本消化器病学会雑誌 117 臨増大会 A513 - A513 (一財)日本消化器病学会 2020年10月
  • 内視鏡的乳頭切除術後胆管狭窄に対する予防的金属ステント留置の有用性
    岡本 彩那; 竹中 完; 田中 隆光; 田中 秀和; 吉田 晃浩; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2136 - 2136 (一社)日本消化器内視鏡学会 2020年10月
  • KINDAI20を用いたコンベックスEUSの教育について
    大本 俊介; 竹中 完; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2164 - 2164 (一社)日本消化器内視鏡学会 2020年10月
  • 胆膵領域癌に対する診断の取り組み 膵腫瘤性病変におけるDetective flow imaging(DFI)の有用性について
    田中 隆光; 大本 俊介; 竹中 完; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 60 - 60 日本消化器病学会-近畿支部 2020年10月
  • Detective flow imaging(DFI)にて特徴的な腫瘍内血流を観察し得たIntraductal papillary neoplasm of the bile duct(IPNB)の1例
    尼崎 雅也; 大本 俊介; 吉田 晃浩; 田中 秀和; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 三長 孝輔; 鎌田 研; 竹中 完; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 85 - 85 日本消化器病学会-近畿支部 2020年10月
  • 拡大観察から見たPPI関連胃底腺ポリープの特徴
    友岡 瑞貴; 辻 直子; 高島 耕太; 正木 翔; 河野 匡志; 永井 知之; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 樫田 博史; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2088 - 2088 (一社)日本消化器内視鏡学会 2020年10月
  • 小腸内視鏡診療ガイドラインでのカプセル内視鏡検査の運用の実際
    米田 頼晃; 樫田 博史; 櫻井 俊治; 松村 まり子; 高島 耕太; 正木 翔; 河野 匡志; 山田 光成; 本庶 元; 永井 知行; 松井 繁長; 辻 直子; 渡邉 智裕; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.2 2113 - 2113 (一社)日本消化器内視鏡学会 2020年10月
  • 消化管腫瘍の診断と治療における工夫 胃底腺型胃癌の内視鏡診断と治療
    益田 康弘; 松井 繁長; 櫻井 俊治; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 67 - 67 日本消化器病学会-近畿支部 2020年10月
  • 早期胃胎児消化管上皮類似癌の1例
    岡井 夏輝; 松井 繁長; 正木 翔; 栗本 真之; 大丸 直哉; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 永井 知行; 米田 頼晃; 本庶 元; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 113回 94 - 94 日本消化器病学会-近畿支部 2020年10月
  • 工藤 正俊; 黒崎 雅之; 森口 理久; 小笠原 定久; 寺島 健志
    肝臓クリニカルアップデート 6 2 227 - 236 医学図書出版(株) 2020年10月
  • Thomas Yau; Yoon-Koo Kang; Tae-You Kim; Anthony B El-Khoueiry; Armando Santoro; Bruno Sangro; Ignacio Melero; Masatoshi Kudo; Ming-Mo Hou; Ana Matilla; Francesco Tovoli; Jennifer J Knox; Aiwu Ruth He; Bassel F El-Rayes; Mirelis Acosta-Rivera; Ho-Yeong Lim; Jaclyn Neely; Yun Shen; Tami Wisniewski; Jeffrey Anderson; Chiun Hsu
    JAMA oncology 2020年10月 [査読有り]
     
    Importance: Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. Objective: To assess efficacy and safety of nivolumab plus ipilimumab in patients with advanced HCC who were previously treated with sorafenib. Design, Setting, and Participants: CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were randomized between January 4 and September 26, 2016. Treatment group information was blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia, Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A and 49 each to arms B and C). Interventions: Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C). Main Outcomes and Measures: Coprimary end points were safety, tolerability, and objective response rate. Duration of response was also measured (investigator assessed with the Response Evaluation Criteria in Solid Tumors v1.1). Results: Of 148 total participants, 120 were male (81%). Median (IQR) age was 60 (52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR, 29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median (range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months (4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A; grade 5 pneumonitis). Conclusions and Relevance: In this randomized clinical trial, nivolumab plus ipilimumab had manageable safety, promising objective response rate, and durable responses. The arm A regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab 240 mg every 2 weeks) received accelerated approval in the US based on the results of this study. Trial Registration: ClinicalTrials.gov Identifier: NCT01658878.
  • Ken Kamata; Reiko Ashida; Satoru Yasukawa; Yasutaka Chiba; Nobuyasu Fukutake; Hiroko Nebiki; Akira Kurita; Makoto Takaoka; Takeshi Ogura; Hideyuki Shiomi; Masanori Asada; Hiroaki Yasuda; Minoru Shigekawa; Akio Yanagisawa; Masatoshi Kudo; Masayuki Kitano
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20 7 1428 - 1433 2020年10月 [査読有り]
     
    OBJECTIVES: Preoperative grading of pancreatic neuroendocrine tumors (PanNET) is challenging. The aim of this study was to prospectively evaluate the use of a 25-gauge needle with a core trap for diagnosis and grading of PanNET. METHODS: This multicenter prospective trial was registered with the University Hospital Medical Information Network (UMIN000021409). Consecutive patients with suspected PanNET between June 2016 and November 2017 were enrolled. All patients underwent endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) using a 25-gauge needle with a core trap. Samples obtained after the first needle pass were used for central pathological review. EUS-FNB was evaluated in terms of (i) technical success rate, (ii) adequacy for histological evaluation, (iii) complication rate during the procedure, and (iv) concordance between PanNET grading on EUS-FNB and that after analysis of the resected tumor. RESULTS: Fifty-two patients were enrolled. Of the 36/52 patients who underwent surgical resection, 31 were finally diagnosed with PanNET and were eligible for analysis. The technical success rate of EUS-FNB was 100%. The rate of adequacy for histological evaluation was 90.3%. There were no complications related to EUS-FNB. The concordance rate between PanNET grading on EUS-FNB and that after analysis of the resected tumor was 82.6% (95% confidence interval = 61.22-95.05, P = 0.579). CONCLUSIONS: EUS-FNB using a 25-gauge needle with a core trap is feasible, providing histological samples are of sufficient quality for diagnosis and grading of PanNET.
  • Christoph F Dietrich; Christian Pállson Nolsøe; Richard G Barr; Annalisa Berzigotti; Peter N Burns; Vito Cantisani; Maria Cristina Chammas; Nitin Chaubal; Byung Ihn Choi; Dirk-André Clevert; Xinwu Cui; Yi Dong; Mirko D'Onofrio; J Brian Fowlkes; Odd Helge Gilja; Pintong Huang; Andre Ignee; Christian Jenssen; Yuko Kono; Masatoshi Kudo; Nathalie Lassau; Won Jae Lee; Jae Young Lee; Ping Liang; Adrian Lim; Andrej Lyshchik; Maria Franca Meloni; Jean Michel Correas; Yasunori Minami; Fuminori Moriyasu; Carlos Nicolau; Fabio Piscaglia; Adrian Saftoiu; Paul S Sidhu; Ioan Sporea; Guido Torzilli; Xiaoyan Xie; Rongqin Zheng
    Ultrasound in medicine & biology 46 10 2579 - 2604 2020年10月 [査読有り]
     
    The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
  • Daisuke Morimoto; Tomoko Hyodo; Ken Kamata; Tomoya Kadoba; Makoto Itoh; Hiroyuki Fukushima; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Mochizuki; Yu Ueda; Keizou Miyagoshi; Masatoshi Kudo; Kazunari Ishii
    Abdominal radiology (New York) 45 10 3081 - 3091 2020年10月 [査読有り]
     
    PURPOSE: To examine whether MRCP using a combination of compressed sensing and sensitivity encoding with navigator-triggered and breath-hold techniques (NT C-SENSE and BH C-SENSE, respectively) have comparable image quality to that of navigator-triggered MRCP using only sensitivity encoding (NT SENSE) at 1.5-T. METHODS: Fifty-one participants were enrolled in this prospective study between July and October 2018 and underwent the three 3D MRCP sequences each. The acquisition time and relative duct-to-periductal contrast ratios (RC values) of each bile duct segment were obtained. Visualization of the bile and main pancreatic ducts, background suppression, artifacts, and overall image quality were scored on 5-point scales. Mean and median differences in RC values and qualitative scores of NT C-SENSE and BH C-SENSE relative to NT SENSE were calculated with 95% confidence intervals (CIs). RESULTS: Acquisition time of NT SENSE, NT C-SENSE, and BH C-SENSE were 348, 143 (mean for both), and 18 s (for all participants), respectively. The RC value of each bile duct segment was inferior, but the lower limits of the 95% CIs of the mean differences were ≥ - 0.10, for both NT C-SENSE and BH C-SENSE. The visualization score of the intrahepatic duct in BH C-SENSE was inferior to that in NT SENSE (lower 95% CI limit, - 1.5). In both NT C-SENSE and BH C-SENSE, the 95% CIs of the median differences in the other qualitative scores were from - 1.0 to 0.0. CONCLUSION: NT C-SENSE and BH C-SENSE have comparable image quality to NT SENSE at 1.5-T.
  • Kosuke Minaga; Tomohiro Watanabe; Akane Hara; Ken Kamata; Shunsuke Omoto; Atsushi Nakai; Yasuo Otsuka; Ikue Sekai; Tomoe Yoshikawa; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Masatoshi Kudo
    Scientific reports 10 1 14879 - 14879 2020年09月 [査読有り]
     
    IgG4-related disease (IgG4-RD) is a multi-organ autoimmune disease characterized by elevated serum IgG4 concentration. Although serum IgG4 concentration is widely used as a biomarker for IgG4-RD and type 1 autoimmune pancreatitis (AIP), a pancreatic manifestation of IgG4-RD, a significant number of patients have normal serum IgG4 levels, even in the active phase of the disease. Recently, we reported that the development of experimental AIP and human type 1 AIP is associated with increased expression of IFN-α and IL-33 in the pancreas. In this study, we assessed the utility of serum IFN-α and IL-33 levels as biomarkers for type 1 AIP and IgG4-RD. Serum IFN-α and IL-33 concentrations in patients who met the diagnostic criteria for definite type 1 AIP and/or IgG4-RD were significantly higher than in those with chronic pancreatitis or in healthy controls. Strong correlations between serum IFN-α, IL-33, and IgG4 concentrations were observed. Diagnostic performance of serum IFN-α and IL-33 concentrations as markers of type 1 AIP and/or IgG4-RD was comparable to that of serum IgG4 concentration, as calculated by the receiver operating characteristic curve analysis. Induction of remission by prednisolone treatment markedly decreased the serum concentration of these cytokines. We conclude that serum IFN-α and IL-33 concentrations can be useful as biomarkers for type 1 AIP and IgG4-RD.
  • Hajime Honjo; Tomohiro Watanabe; Yasuyuki Arai; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Kouhei Yamashita; Masatoshi Kudo
    International immunology 33 2 91 - 105 2020年09月 [査読有り]
     
    Polymorphisms in the autophagy-related protein 16 like 1 (ATG16L1) and nucleotide-binding oligomerization domain 2 (NOD2) genes are associated with Crohn's disease (CD). Impaired interaction between ATG16L1 and NOD2 underlies CD immunopathogenesis. Although activation of the receptor-interacting serine/threonine kinase (RICK, also known as RIP2), a downstream signaling molecule for NOD2 and multiple toll-like receptors (TLRs), plays a pathogenic role in the development of inflammatory bowel disease, the molecular interaction between ATG16L1 and RICK/RIP2 remains poorly understood. In this study, we examined the physical interaction between ATG16L1 and RICK/RIP2 in human embryonic kidney 293 (HEK293) cells and human monocyte-derived dendritic cells (DCs) expressing excessive and endogenous levels of these proteins, respectively. We established that ATG16L1 binds to RICK/RIP2 kinase domain and negatively regulates TLR2-mediated nuclear factor-kappa B (NF-κB) activation and proinflammatory cytokine responses by inhibiting the interaction between TLR2 and RICK/RIP2. Binding of ATG16L1 to RICK/RIP2 suppressed NF-κB activation by downregulating RICK/RIP2 polyubiquitination. Notably, the percentage of colonic DCs expressing ATG16L1 inversely correlated with IL-6 and TNF-α expression levels in the colon of CD patients. These data suggest that the interaction between ATG16L1 and RICK/RIP2 maintains intestinal homeostasis via the downregulation of TLR-mediated proinflammatory cytokine responses.
  • Richard S Finn; Masafumi Ikeda; Andrew X Zhu; Max W Sung; Ari D Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Konstantin Mamontov; Tim Meyer; Tomoki Kubota; Corina E Dutcus; Kenichi Saito; Abby B Siegel; Leonid Dubrovsky; Kalgi Mody; Josep M Llovet
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 26 2960 - 2970 2020年09月 [査読有り]
     
    PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvatinib plus pembrolizumab (an anti-PD-1 antibody) in unresectable HCC (uHCC). PATIENTS AND METHODS: In this open-label multicenter study, patients with uHCC received lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily and pembrolizumab 200 mg intravenously on day 1 of a 21-day cycle. The study included a dose-limiting toxicity (DLT) phase and an expansion phase (first-line patients). Primary objectives were safety/tolerability (DLT phase), and objective response rate (ORR) and duration of response (DOR) by modified RECIST (mRECIST) and RECIST version 1.1 (v1.1) per independent imaging review (IIR; expansion phase). RESULTS: A total of 104 patients were enrolled. No DLTs were reported (n = 6) in the DLT phase; 100 patients (expansion phase; included n = 2 from DLT phase) had received no prior systemic therapy and had Barcelona Clinic Liver Cancer stage B (n = 29) or C disease (n = 71). At data cutoff, 37% of patients remained on treatment. Median duration of follow-up was 10.6 months (95% CI, 9.2 to 11.5 months). Confirmed ORRs by IIR were 46.0% (95% CI, 36.0% to 56.3%) per mRECIST and 36.0% (95% CI, 26.6% to 46.2%) per RECIST v1.1. Median DORs by IIR were 8.6 months (95% CI, 6.9 months to not estimable [NE]) per mRECIST and 12.6 months (95% CI, 6.9 months to NE) per RECIST v1.1. Median progression-free survival by IIR was 9.3 months per mRECIST and 8.6 months per RECIST v1.1. Median overall survival was 22 months. Grade ≥ 3 treatment-related adverse events occurred in 67% (grade 5, 3%) of patients. No new safety signals were identified. CONCLUSION: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.
  • 直腸NENに対する治療の適応と工夫 当院での直腸NENの治療成績からみた治療方法の検討
    永井 知行; 樫田 博史; 益田 康弘; 友岡 瑞貴; 高島 耕太; 高田 隆太郎; 正木 翔; 河野 匡志; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 工藤 正俊
    日本大腸肛門病学会雑誌 73 9 A70 - A70 (一社)日本大腸肛門病学会 2020年09月
  • 直腸NENに対する治療の適応と工夫 当院での直腸NENの治療成績からみた治療方法の検討
    永井 知行; 樫田 博史; 益田 康弘; 友岡 瑞貴; 高島 耕太; 高田 隆太郎; 正木 翔; 河野 匡志; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 工藤 正俊
    日本大腸肛門病学会雑誌 73 9 A70 - A70 (一社)日本大腸肛門病学会 2020年09月
  • 全身化学療法により生存利益を得られる切除不能C型肝細胞癌の特徴
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊
    肝臓 61 Suppl.2 A647 - A647 (一社)日本肝臓学会 2020年09月
  • 切除不能肝細胞癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ二次療法
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊
    肝臓 61 Suppl.2 A654 - A654 (一社)日本肝臓学会 2020年09月
  • Stephen Lam Chan; Masatoshi Kudo
    Liver cancer 9 5 491 - 502 2020年09月 
    Background: The pandemic of coronavirus disease 2019 (COVID-19) has diverted resources from healthcare services for patients with chronic medical illness such as cancer. COVID-19 also causes organ dysfunction, complicating cancer treatment. In most countries with an outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patients to the infection. In countries where COVID-19 numbers are subsiding, medical teams should also be prepared to resume normal practices gradually. Here, we aim to review the literature on the impact of COVID-19 on patients with hepatocellular carcinoma (HCC) as well as discuss modifications to the management of HCC during and after recovery from the pandemic. Summary: Based on current data, 10-40% of patients with COVID-19 have hepatic injury characterized by an elevation of transaminases and/or hyperbilirubinemia. Multiple mechanisms contribute to the hepatic injury, including direct viral entry to hepatocytes/cholangiocytes, immune-mediated hepatitis, hypoxia, and drug-related hepatotoxicity. In patients with HCC, COVID-19 may exacerbate existing chronic liver disease and complicate the management of cancer. Cancer patients generally have a higher risk of infection and worse outcome, especially those who have recently undergone cancer treatment. Although HCC is under-represented in COVID-19 series, mitigation measures should be implemented to minimize the exposure of patients to the virus. A decision on the treatment of HCC should be balanced with consideration of the availability of medical resources, the level of infection risk of COVID-19, and the risk-benefit ratio of the individual patient. In areas where the COVID-19 outbreak is subsiding, clinicians should be prepared to manage a surge of HCC patients with higher disease burdens and complications. Key Messages: Mitigation measures to protect at-risk patients, such as those with cancers, from SARS-CoV-2 infection should be exercised and the impact of COVID-19 on this group of patients should be thoroughly studied.
  • Masatoshi Kudo
    Liver cancer 9 5 479 - 490 2020年09月
  • Mamoru Takenaka; Shunsuke Omoto; Masatoshi Kudo
    Clinical endoscopy 53 5 508 - 509 2020年09月 [査読有り]
  • Mamoru Takenaka; Tomoe Yoshikawa; Kosuke Minaga; Kentaro Yamao; Masatoshi Kudo
    VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy 5 9 389 - 394 2020年09月 [査読有り]
  • Kazuomi Ueshima; Sadahisa Ogasawara; Masafumi Ikeda; Yutaka Yasui; Takeshi Terashima; Tatsuya Yamashita; Shuntaro Obi; Shinpei Sato; Hiroshi Aikata; Takumi Ohmura; Hidekatsu Kuroda; Takamasa Ohki; Kengo Nagashima; Yoshihiko Ooka; Masahiro Takita; Masayuki Kurosaki; Kazuaki Chayama; Shuichi Kaneko; Namiki Izumi; Naoya Kato; Masatoshi Kudo; Masao Omata
    Liver cancer 9 5 583 - 595 2020年09月 [査読有り]
     
    Background: Prior to the approval of sorafenib, hepatic arterial infusion chemotherapy (HAIC) was offered to patients with advanced hepatocellular carcinoma (HCC) in East Asia, particularly Japan. According to the Japanese guidelines, HAIC is recommended as one of the treatment options in patients without extrahepatic metastasis (EHM). Methods: The present cohort study compared the use of HAIC and sorafenib on outcomes of patients with advanced HCC. Consecutive patients with advanced HCC who received HAIC or sorafenib as a first-line systemic therapy were enrolled from 10 Japanese institutions. The primary outcomes were overall survival (OS) in patients with macrovascular invasion (MVI), but without EHM, and OS in patients without both MVI and EHM. Results: Between 2009 and 2016, 2,006 patients were enrolled (541 HAIC patients, 1,465 sorafenib patients). After propensity score matching, the OS of patients with MVI but without EHM was significantly longer in the HAIC group compared with the sorafenib group (10.1 vs. 9.1 months for the HAIC and sorafenib groups, respectively; n = 170 for each group; hazard ratio [HR] 0.668; 95% confidence interval [95% CI] 0.475-0.935; p = 0.018). There was no significant difference in OS between patients without both MVI and EHM (12.2 vs. 15.4 months for the HAIC and sorafenib groups, respectively; n = 76 in each cohort after propensity score matching; HR 1.227; 95% CI 0.699-2.155; p = 0.475). Conclusion: HAIC is a potential front-line treatment choice in a subpopulation of patients with advanced HCC with MVI but without EHM.
  • Akihiro Yoshida; Kosuke Minaga; Osami Takeda; Hajime Hanno; Shigenori Takayanagi; Toshio Dozaiku; Masatoshi Kudo
    Endoscopy 52 9 E333-E334  2020年09月 [査読有り]
  • Laura L de Guevara; Lucy Dagher; Vanessa Mv Arruda; Keiko Nakajima; Masatoshi Kudo
    Future oncology (London, England) 2020年08月 [査読有り]
     
    Aim: To evaluate sorafenib treatment in Latin American patients with unresectable hepatocellular carcinoma in the real-world GIDEON study. Patients and methods: Sorafenib administration, safety and efficacy were analyzed by Child-Pugh status. Results: Of 90 evaluable patients (37% Child-Pugh A, 46% Child-Pugh B and 3% Child-Pugh C at study entry), 97% started sorafenib at 800 mg/day. Patients with Child-Pugh B7 had the longest median treatment duration of sorafenib (33.1 weeks). Sorafenib-related adverse events occurred in 58% of patients with Child-Pugh A (21% grade 3/4) and 46% with Child-Pugh B (7% grade 3/4). Conclusion: Sorafenib had a similar safety profile across patients with Child-Pugh A and B and is a treatment option for both groups.
  • 炎症性疾患における最先端の内視鏡診療 下部 UC/CD以外のIBD MDS関連IBDに対する治療方法の検討
    河野 匡志; 櫻井 俊治; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.1 1047 - 1047 (一社)日本消化器内視鏡学会 2020年08月
  • 福永 朋洋; 水野 成人; 松村 まり子; 高田 竜太郎; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 野村 健司; 米澤 真衣; 河野 辰哉; 半田 康平; 石川 原; 橋本 和彦; 工藤 正俊
    胆道 34 3 601 - 601 日本胆道学会 2020年08月
  • 急性膵炎局所合併症に対する内視鏡治療 当院におけるwalled-off necrosisに対するstep-up approachの成績と内視鏡治療不成功の要因解析
    大本 俊介; 竹中 完; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.1 1091 - 1091 (一社)日本消化器内視鏡学会 2020年08月
  • 山雄 健太郎; 竹中 完; 田中 秀和; 田中 隆光; 吉田 晃浩; 石川 嶺; 岡本 彩那; 中井 敦; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 渡邉 智裕; 工藤 正俊
    胆と膵 41 8 713 - 718 医学図書出版(株) 2020年08月 
    膵癌は予後不良な癌腫であり、予後改善が急務である。小膵癌の場合、CTやMRIでの直接指摘が困難であるため、尾側膵管拡張を伴う主膵管狭窄などの間接所見が診断の契機となる。しかしながら主膵管狭窄は慢性膵炎などの良性疾患でも認められる。近年、上皮内癌を含む腫瘍径10mm以下の微小膵癌において膵実質の部分萎縮(やせ)が診断の指標になるとの報告が散見される。ただし膵臓は膵頭部が膨大している、門脈から腹側へ圧排を受けるなどの構造をしているため、通常のCTでは萎縮がやや評価しにくい。3D-CTは本来立体構造をした膵臓をそのまま3D画像として可視化できるため、この技術を用いて膵臓を抽出することで膵実質の萎縮を直感的かつ簡便に評価できる。3D-CTによる膵実質の萎縮評価は膵癌の早期診断および予後改善に寄与すると考える。(著者抄録)
  • 急性膵炎局所合併症に対する内視鏡治療 当院におけるwalled-off necrosisに対するstep-up approachの成績と内視鏡治療不成功の要因解析
    大本 俊介; 竹中 完; 工藤 正俊
    Gastroenterological Endoscopy 62 Suppl.1 1091 - 1091 (一社)日本消化器内視鏡学会 2020年08月
  • 西田 直生志; 山川 誠; 椎名 毅; 工藤 正俊
    臨床消化器内科 35 9 1166 - 1174 (株)日本メディカルセンター 2020年08月
  • EPLBD後にfood impactionによる胆管炎を繰り返した一例
    福永 朋洋; 水野 成人; 松村 まり子; 高田 竜太郎; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 野村 健司; 米澤 真衣; 河野 辰哉; 半田 康平; 石川 原; 橋本 和彦; 工藤 正俊
    胆道 34 3 601 - 601 日本胆道学会 2020年08月
  • 【肝胆膵における結石診療のベストプラクティス】胆嚢結石症 Confluence stoneとMirizzi症候群はどう違うのか Biliobiliary fistulaと合わせて
    竹中 完; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    肝・胆・膵 81 2 305 - 312 (株)アークメディア 2020年08月
  • Masatoshi Kudo
    Liver cancer 9 4 367 - 377 2020年08月 [査読有り]
  • Chia-Jui Yen; Masatoshi Kudo; Ho-Yeong Lim; Chih-Hung Hsu; Arndt Vogel; Giovanni Brandi; Rebecca Cheng; Ioana Simona Nitu; Paolo Abada; Yanzhi Hsu; Andrew X Zhu; Yoon-Koo Kang
    Liver cancer 9 4 440 - 454 2020年08月 [査読有り]
     
    Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). We evaluated the efficacy and safety of ramucirumab in Asian and non-Asian patients with AFP ≥400 ng/mL from REACH-2 and REACH. Methods: We pooled Asian and non-Asian patients from the REACH-2 and REACH trials and performed an individual patient data meta-analysis. Overall survival (OS) and progression-free survival were evaluated using the Kaplan-Meier method. Hazard ratios (HRs) were estimated with a stratified Cox regression model. Results: In the pooled REACH-2 and REACH patient population, 291 Asian patients were randomly assigned to receive ramucirumab (n = 168) or placebo (n = 123), and 251 non-Asian patients received ramucirumab (n = 148) or placebo (n = 103). The median OS was significantly longer in the ramucirumab arm in comparison to the placebo arm for Asian patients (8.08 vs. 4.76 months, stratified HR 0.73 [95% CI 0.56-0.95], p = 0.0189) and non-Asian patients (7.98 vs. 5.22 months, stratified HR 0.65 [95% CI 0.49-0.86], p = 0.0028). The overall response rate (ORR) and disease control rate (DCR) were significantly higher in the ramucirumab arm compared to the placebo arm for Asian patients (ORR: 4.2 vs. 0.8%; DCR: 53.6 vs. 33.3%) and non-Asian patients (ORR: 6.8 vs. 1.0%; DCR: 59.5 vs. 41.7%). The most common grade ≥3 treatment-emergent adverse events reported in the ramucirumab arm were hypertension (7.7%), decreased appetite (1.2%), and ascites (1.2%) for Asian patients and hypertension (16.9%), ascites (8.8%), asthenia (4.7%), and fatigue (5.4%) for non-Asian patients. Discussion and Conclusion: This pooled analysis of the REACH-2/REACH trials demonstrates significant benefits, with a manageable safety profile, of ramucirumab treatment in Asian and non-Asian patients with advanced HCC and baseline AFP ≥400 ng/mL.
  • Andrew X Zhu; Ryan D Nipp; Richard S Finn; Peter R Galle; Josep M Llovet; Jean-Frederic Blanc; Takuji Okusaka; Ian Chau; David Cella; Allicia Girvan; Jonathon Gable; Lee Bowman; Chunxiao Wang; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
    ESMO open 5 4 2020年08月 [査読有り]
     
    BACKGROUND: Symptoms of advanced hepatocellular carcinoma (HCC) represent a substantial burden for the patient and are important endpoints to assess when evaluating treatment. Patient-reported outcomes were evaluated in subjects with advanced HCC and baseline alpha-fetoprotein (AFP) ≥400 ng/mL treated with second-line ramucirumab. PATIENTS AND METHODS: Patients with AFP≥400 ng/mL enrolled in the REACH or REACH-2 phase 3 studies were used in this analysis. Eligible patients had advanced HCC, Child-Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and prior sorafenib. Patients received ramucirumab 8 mg/kg or placebo once every 2 weeks. Disease-related symptoms and health-related quality of life (HRQoL) were assessed with the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index (FHSI)-8 and EuroQoL-5-Dimensions (EQ-5D) instruments, respectively. Time to deterioration (TTD) (≥3-point decrease in FHSI-8 total score;≥0.06-point decrease in EQ-5D score, from randomisation to first date of deterioration) was determined using Kaplan-Meier estimation and the Cox proportional hazards model. Both separate and pooled analyses for REACH AFP≥400 ng/mL and REACH-2 patients were conducted. RESULTS: In the pooled population with AFP ≥400 ng/mL (n=542; ramucirumab, n=316; placebo, n=226), median TTD in FHSI-8 total score was prolonged with ramucirumab relative to placebo (3.3 vs 1.9 months; HR 0.725; (95% CI 0.559 to 0.941); p=0.0152), including significant differences in back pain (0.668; (0.497 to 0.899); p=0.0044), weight loss (0.699; (0.505 to 0.969); p=0.0231) and pain (0.769; (0.588 to 1.005); p=0.0248) symptoms. TTD in EQ-5D score was not significantly different between ramucirumab and placebo groups (median 2.9 vs 1.9 months). Results in the individual trials were consistent with these findings. CONCLUSIONS: Ramucirumab in second-line treatment of advanced HCC demonstrates consistent benefit in the delay of deterioration in disease-related symptoms with no worsening of HRQoL. Taken with previously demonstrated ramucirumab-driven survival benefits in this setting, these data may inform patient-clinician discussions about the benefit-risk profile of this therapy. TRIAL REGISTRATION NUMBER: NCT01140347; NCT02435433, NCT02435433.
  • Masatoshi Kudo
    Hepatobiliary surgery and nutrition 9 4 530 - 533 2020年08月 [査読有り]
  • Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi Kudo
    Liver cancer 9 4 426 - 439 2020年08月 [査読有り]
     
    Background and Aim: Immune checkpoint inhibitors are promising agents for the treatment of hepatocellular carcinomas (HCC) refractory to conventional therapies. To enhance the efficacy of this treatment, immunological and molecular characteristics of HCC with programmed cell death ligand 1 (PD-L1) should be explored. Methods: Clinical backgrounds, PD-L1 expression, and the amount of CD8+ tumor-infiltrating mononuclear cells (TIMCs) were analyzed in 154 HCCs. The expression of 3 stem cell markers and co-inhibitory receptors on tumor cells and TIMCs, respectively, were examined by immunohistochemical analysis. Somatic mutations in the 409 cancer-associated genes and TERT promoter were determined; HCCs were classified based on the presence of gene alterations affecting the 8 oncogenic pathways. The results were validated using the dataset from the Cancer Genome Atlas. Results: The expression of PD-L1 in the HCCs was positively correlated with progressive tumor features, the presence of cytokeratin 19 (CK19), Sal-like protein 4 (SALL4), and the mutations of genes involving the phosphatidyl inositol 3-kinase (PI3K)-Akt pathway. Although CD8+ cells were densely infiltrated in PD-L1-positive tumors, these TIMCs frequently expressed multiple co-inhibitory receptors. However, a subset of PD-L1-positive tumors characterized by activating mutations of the PI3K-Akt pathway showed a low degree of TIMCs. Conversely, PD-L1-negative HCCs were associated with mutations in the β-catenin pathway and a small number of TIMCs, although the expression of co-inhibitory receptors was rare. Conclusions: PD-L1-positive HCCs frequently showed an inflamed phenotype with stem cell features; a subset of PD-L1-positive HCCs with mutations in the PI3K-Akt pathway showed a non-inflamed phenotype. In HCCs with dense infiltration of TIMCs, CD8+ cells expressed multiple co-inhibitory receptors, suggesting T cell exhaustion. On the other hand, PD-L1-negative HCCs showed mutations leading to β-catenin activation and exhibited a non-inflamed background. These characteristics should be taken into consideration for developing novel combination therapies using immune checkpoint inhibitors.
  • Naoko Tsuji; Yasuko Umehara; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Gastroenterology report 8 4 293 - 298 2020年08月 [査読有り]
     
    Background: There have been few studies in the English literature regarding verrucous gastritis (VG). The present study investigated the clinical and endoscopic features of verrucous antral gastritis, especially focusing on Helicobacter pylori infection, nutrition, and gastric atrophy. Methods: We performed a retrospective study of patients who underwent routine endoscopy with indigo carmine chromoendoscopy and a comparative study was conducted between VG-positive and VG-negative groups. VG was subdivided into classical and numerous types based on the number and distribution of verrucous lesions. Demographic, clinical, and endoscopic data including body mass index (BMI), serum albumin and cholesterol, gastric atrophy, reflux oesophagitis, Barrett's oesophagus, and H. pylori status were collected. Univariate and multivariable analyses were performed to identify factors associated with VG. Results: We analysed the data of 621 patients undergoing routine endoscopy and found that VG (n = 352) was significantly associated with increased BMI (1.12 [1.05-1.18], P < 0.01), reflux esophagitis (1.96 [1.10-3.28], P < 0.01), and H. pylori negativity with or without a history of eradication (9.94 [6.00-16.47] and 6.12 [3.51-10.68], P < 0.001, respectively). Numerous-type (n = 163) VG was associated with both closed- and open-type gastric atrophy (9.9 [4.04-21.37] and 8.10 [3.41-19.24], P < 0.001, respectively). There were no statistical differences between groups regarding age, sex, total cholesterol, albumin, and bile-colored gastric juice. Conclusions: Verrucous antral gastritis was related to increased BMI, reflux esophagitis, and H. pylori negativity. Numerous-type verrucous lesions were associated with gastric atrophy. These indicate that VG may be a physiological phenomenon due to high gastric acidity, mechanical overload, and vulnerability of background mucosa.
  • Saki Yoshida; Mariko Matsumura; Kiyoshi Maekawa; Kosuke Minaga; Ken Kamata; Masahiro Nozawa; Tomohiro Watanabe; Masatoshi Kudo
    Clinical journal of gastroenterology 13 4 621 - 625 2020年08月 [査読有り]
     
    Nephroptosis is a benign disorder defined as a significant descent of the affected kidney as the patient moves from supine to erect. Patients with nephroptosis sometimes manifest symptoms including abdominal pain, back pain, nausea and hematuria, while the majority of those are asymptomatic. Downward migration of the affected kidney induced by a postural change from the supine to the upright position underlies the pathophysiology of nephroptosis. The diagnosis of nephroptosis is difficult since routine imaging examinations are conducted in the supine position alone. Here, we report a case presenting recurrent abdominal pain due to unknown causes. This patient was successfully diagnosed as nephroptosis by ultrasonography and drip infusion pyelography, both of which were performed in both supine and upright positions. This case report strongly suggests that we need to take into consideration a possibility of nephroptosis when we encounter with patients complaining abdominal and/or back pain due to unknown causes.
  • Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
    Gut 69 8 1492 - 1501 2020年08月 [査読有り]
     
    OBJECTIVE: This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE. DESIGN: Patients with unresectable hepatocellular carcinoma (HCC) were randomised to TACE plus sorafenib (n=80) or TACE alone (n=76). Patients in the combination group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable (unTACEable) progression (TTUP), defined as untreatable tumour progression, transient deterioration to Child-Pugh C or appearance of vascular invasion/extrahepatic spread. Co-primary endpoints were progression-free survival (PFS), which is not a conventional one but defined as TTUP, or time to any cause of death plus overall survival (OS). Multiplicity was adjusted by gatekeeping hierarchical testing. RESULTS: Median PFS was significantly longer in the TACE plus sorafenib than in the TACE alone group (25.2 vs 13.5 months; p=0.006). OS was not analysed because only 73.6% of OS events were reached. Median TTUP (26.7 vs 20.6 months; p=0.02) was also significantly longer in the TACE plus sorafenib group. OS at 1 year and 2 years in TACE plus sorafenib group and TACE alone group were 96.2% and 82.7% and 77.2% and 64.6%, respectively. There were no unexpected toxicities. CONCLUSION: TACE plus sorafenib significantly improved PFS over TACE alone in patients with unresectable HCC. Adverse events were consistent with those of previous TACE combination trials. TRIAL REGISTRATION NUMBER: NCT01217034.
  • Sho Masaki; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Masatomo Kimura; Masatoshi Kudo
    Clinical journal of gastroenterology 13 4 473 - 476 2020年08月 [査読有り]
     
    Although patients with anorexia nervosa (AN) present with various gastrointestinal disorders, little has been understood regarding the incidence and pathophysiology of gastrointestinal ulcers related to AN. A 20-year-old woman with a past history of AN was hospitalized for further examination of dysphagia and chest pain. Her nutritional status was very poor as evidenced by very low body mass index. Esophagogastroduodenoscopy detected longitudinal and geographical ulcers in the entire circumference of the cervical and upper esophagus. Enhanced expression of autophagy-related proteins, LC3B and p62, was seen in the esophageal epithelium surrounding the active ulcers. Expression of these autophagy markers disappeared from the esophageal epithelium soon after the nutritional rehabilitation. Given the fact that starvation and malnutrition are potent inducers for autophagy, these findings suggest that autophagy might be involved in the development of gastrointestinal ulcers in patients with AN.
  • Masatoshi Kudo; Manabu Morimoto; Michihisa Moriguchi; Namiki Izumi; Tetsuji Takayama; Hitoshi Yoshiji; Keisuke Hino; Takayoshi Oikawa; Tetsuhiro Chiba; Kenta Motomura; Junko Kato; Kentaro Yasuchika; Akio Ido; Takashi Sato; Daisuke Nakashima; Kazuomi Ueshima; Masafumi Ikeda; Takuji Okusaka; Kazuo Tamura; Junji Furuse
    Cancer science 111 10 3759 - 3769 2020年07月 [査読有り]
     
    A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c-Met inhibitor tivantinib as second-line treatment significantly prolonged progression-free survival in a subpopulation whose tumor samples highly expressed c-Met (MET-high). Accordingly, this phase 3 study was conducted to evaluate the efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. This randomized, double-blind, placebo-controlled study was conducted at 60 centers in Japan. Hepatocellular carcinoma patients with one prior sorafenib treatment and those with MET-high tumor samples were eligible for inclusion. Registered patients were randomly assigned to either the tivantinib or placebo group at a 2:1 ratio and were treated with twice-a-day oral tivantinib (120 mg bid) or placebo until the discontinuation criteria were met. The primary endpoint was progression-free survival while the secondary endpoints included overall survival and safety. Between January 2014 and June 2016, 386 patients provided consent, and 195 patients were randomized to the tivantinib (n = 134) or placebo (n = 61) group. Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) mo in the tivantinib and placebo groups, respectively (hazard ratio = 0.74, 95% confidence interval: 0.52-1.04, P = .082). Median overall survival was 10.3 (95% confidence interval: 8.1-11.6) and 8.5 (6.2-11.4) mo in the tivantinib and placebo group, respectively (hazard ratio = 0.82, 95% confidence interval: 0.58-1.15). The most common tivantinib-related grade ≥3 adverse events were neutropenia (31.6%), leukocytopenia (24.8%), and anemia (12.0%). This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. (NCT02029157).
  • Christoph F Dietrich; Christian Pállson Nolsøe; Richard G Barr; Annalisa Berzigotti; Peter N Burns; Vito Cantisani; Maria Cristina Chammas; Nitin Chaubal; Byung Ihn Choi; Dirk-André Clevert; Xinwu Cui; Yi Dong; Mirko D'Onofrio; J Brian Fowlkes; Odd Helge Gilja; Pintong Huang; Andre Ignee; Christian Jenssen; Yuko Kono; Masatoshi Kudo; Nathalie Lassau; Won Jae Lee; Jae Young Lee; Ping Liang; Adrian Lim; Andrej Lyshchik; Maria Franca Meloni; Jean Michel Correas; Yasunori Minami; Fuminori Moriyasu; Carlos Nicolau; Fabio Piscaglia; Adrian Saftoiu; Paul S Sidhu; Ioan Sporea; Guido Torzilli; Xiaoyan Xie; Rongqin Zheng
    Ultraschall in der Medizin (Stuttgart, Germany : 1980) 41 1 - 24 2020年07月 [査読有り]
     
    The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications.The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including the United States Food and Drug Administration (FDA) approval as well as the extensive Asian experience, to produce a truly international perspective.These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCA) and are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis to improve the management of patients.
  • Mariko Matsumura; Yoriaki Komeda; Tomohiro Watanabe; Masatoshi Kudo
    BMJ case reports 13 7 2020年07月 [査読有り]
     
    IgA vasculitis (Henoch-Schönlein purpura) affects various organs, including the skin, gastrointestinal (GI) tract, joints and kidneys. Its clinical course typically consists of two phases: initial appearance of purpura and delayed onset of arthralgia, GI symptoms and haematuria. We report the case of an adult patient with IgA vasculitis of the small bowel, without skin involvement, complicated by cytomegalovirus (CMV) enteritis following prednisolone administration. Single-balloon enteroscopy revealed mucosal oedema, redness, erosions and transverse ulcers of the duodenum and jejunum. Jejunal biopsy specimens showed IgA deposition in the capillary walls. CMV reactivation was confirmed by PCR and immunostaining using jejunal biopsy specimens. This case report strongly suggests that adult patients with IgA vasculitis can present with isolated GI involvement, without characteristic skin purpura. Furthermore, CMV reactivation needs to be considered in patients with IgA vasculitis showing poor response to glucocorticoids.
  • Guohong Han; Sarah Berhane; Hidenori Toyoda; Dominik Bettinger; Omar Elshaarawy; Anthony W H Chan; Martha Kirstein; Cristina Mosconi; Florian Hucke; Daniel Palmer; David J Pinato; Rohini Sharma; Diego Ottaviani; Jeong W Jang; Tim A Labeur; Otto M van Delden; Mario Pirisi; Nick Stern; Bruno Sangro; Tim Meyer; Waleed Fateen; Marta García-Fiñana; Asmaa Gomaa; Imam Waked; Eman Rewisha; Guru P Aithal; Simon Travis; Masatoshi Kudo; Alessandro Cucchetti; Markus Peck-Radosavljevic; R B Takkenberg; Stephen L Chan; Arndt Vogel; Philip J Johnson
    Hepatology (Baltimore, Md.) 72 1 198 - 212 2020年07月 [査読有り]
     
    BACKGROUND AND AIMS: The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use of transarterial chemoembolization (TACE) outside recommended guidelines have encouraged the development of scoring systems that predict patient survival. The aim of this study was to build and validate statistical models that offer individualized patient survival prediction using response to TACE as a variable. APPROACH AND RESULTS: Clinically relevant baseline parameters were collected for 4,621 patients with HCC treated with TACE at 19 centers in 11 countries. In some of the centers, radiological responses (as assessed by modified Response Evaluation Criteria in Solid Tumors [mRECIST]) were also accrued. The data set was divided into a training set, an internal validation set, and two external validation sets. A pre-TACE model ("Pre-TACE-Predict") and a post-TACE model ("Post-TACE-Predict") that included response were built. The performance of the models in predicting overall survival (OS) was compared with existing ones. The median OS was 19.9 months. The factors influencing survival were tumor number and size, alpha-fetoprotein, albumin, bilirubin, vascular invasion, cause, and response as assessed by mRECIST. The proposed models showed superior predictive accuracy compared with existing models (the hepatoma arterial embolization prognostic score and its various modifications) and allowed for patient stratification into four distinct risk categories whose median OS ranged from 7 months to more than 4 years. CONCLUSIONS: A TACE-specific and extensively validated model based on routinely available clinical features and response after first TACE permitted patient-level prognostication.
  • 山雄 健太郎; 竹中 完; 松本 逸平; 竹山 宜典; 沼本 勲男; 鶴崎 正勝; 工藤 正俊
    膵臓 35 3 A345 - A345 (一社)日本膵臓学会 2020年07月
  • 三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A200 - A200 (一財)日本消化器病学会 2020年07月
  • 原 茜; 三長 孝輔; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A299 - A299 (一財)日本消化器病学会 2020年07月
  • 竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 35 3 A209 - A209 (一社)日本膵臓学会 2020年07月
  • 「KINDAI20」を用いたコンベックスEUSの教育について
    大本 俊介; 竹中 完; 工藤 正俊
    膵臓 35 3 A330 - A330 (一社)日本膵臓学会 2020年07月
  • 石川 嶺; 鎌田 研; 田中 秀和; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 竹中 完; 工藤 正俊
    膵臓 35 3 A367 - A367 (一社)日本膵臓学会 2020年07月
  • 岡本 彩那; 鎌田 研; 河野 辰哉; 田中 秀和; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A389 - A389 (一財)日本消化器病学会 2020年07月
  • 青木 智子; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A52 - A52 (一財)日本消化器病学会 2020年07月
  • 大塚 康生; 青木 智子; 南 知宏; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A291 - A291 (一財)日本消化器病学会 2020年07月
  • 三長 孝輔; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A200 - A200 (一財)日本消化器病学会 2020年07月
  • 原 茜; 三長 孝輔; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A299 - A299 (一財)日本消化器病学会 2020年07月
  • 岡本 彩那; 鎌田 研; 河野 辰哉; 田中 秀和; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会雑誌 117 臨増総会 A389 - A389 (一財)日本消化器病学会 2020年07月
  • 急性膵炎に対する局所合併症治療 Walled-off necrosisに対するLAMS with 10 FrENCD持続洗浄治療の有用性について
    竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 35 3 A209 - A209 (一社)日本膵臓学会 2020年07月
  • PanNETG1/G2における造影ハーモニックEUSの悪性度評価の有用性に関する検討
    石川 嶺; 鎌田 研; 田中 秀和; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 竹中 完; 工藤 正俊
    膵臓 35 3 A367 - A367 (一社)日本膵臓学会 2020年07月
  • 膵管狭窄症例におけるCT間接所見の検討 微小膵癌と良性膵管狭窄症例の比較
    山雄 健太郎; 竹中 完; 松本 逸平; 竹山 宜典; 沼本 勲男; 鶴崎 正勝; 工藤 正俊
    膵臓 35 3 A345 - A345 (一社)日本膵臓学会 2020年07月
  • Kentaro Yamao; Mamoru Takenaka; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Ippei Matsumoto; Yoshifumi Takeyama; Isao Numoto; Masakatsu Tsurusaki; Takaaki Chikugo; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi Kudo
    Diagnostics (Basel, Switzerland) 10 7 2020年07月 [査読有り]
     
    BACKGROUND: This study aimed to evaluate and identify the specific CT findings by focusing on abnormalities in the main pancreatic duct (MPD) and pancreatic parenchyma in patients with small pancreatic cancer (PC) including carcinoma in situ (CIS). METHODS: Nine CT findings indicating abnormalities of MPD and pancreatic parenchyma were selected as candidate findings for the presence of small PC ≤ 10 mm. The proportions of patients positive for each finding were compared between small PC and benign MPD stenosis groups. Interobserver agreement between two independent image reviewers was evaluated using kappa statistics. RESULTS: The final analysis included 24 patients with small PC (including 11 CIS patients) and 28 patients with benign MPD stenosis. The proportion of patients exhibiting partial pancreatic parenchymal atrophy (PPA) corresponding to the distribution of MPD stenosis (45.8% vs. 7.1%, p < 0.01), upstream PPA arising from the site of MPD stenosis (33.3% vs. 3.6%, p = 0.01), and MPD abrupt stenosis (45.8% vs. 14.3%, p = 0.03) was significantly higher in the small PC group than in the benign MPD stenosis group. CONCLUSIONS: The presence of partial PPA, upstream PPA, and MPD abrupt stenosis on a CT image was highly suggestive of the presence of small PCs including CIS.
  • Jae Young Lee; Yasunori Minami; Byung Ihn Choi; Won Jae Lee; Yi-Hong Chou; Woo Kyoung Jeong; Mi-Suk Park; Nobuki Kudo; Min Woo Lee; Ken Kamata; Hiroko Iijima; So Yeon Kim; Kazushi Numata; Katsutoshi Sugimoto; Hitoshi Maruyama; Yasukiyo Sumino; Chikara Ogawa; Masayuki Kitano; Ijin Joo; Junichi Arita; Ja-Der Liang; Hsi-Ming Lin; Christian Nolsoe; Odd Helge Gilja; Masatoshi Kudo
    Ultrasonography (Seoul, Korea) 39 3 191 - 220 2020年07月 [査読有り]
     
    The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management.
  • Shuya Maeshima; Yoshiyuki Ida; Ryo Shimizu; Yuki Kawaji; Takashi Tamura; Junya Nuta; Keiichi Hatamaru; Masahiro Itonaga; Masatoshi Kudo; Masayuki Kitano
    Journal of medical ultrasonics (2001) 47 3 435 - 443 2020年07月 [査読有り]
     
    PURPOSE: Animal studies of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) of the liver have rarely been reported. We assessed the effectiveness and safety of EUS-RFA in pigs. METHODS: We conducted four experiments using newly designed RFA electrodes. In the first experiment, we ablated excised liver using 19 G electrodes with active electrode tips with lengths of 1, 1.5, and 2 cm. The second experiment was performed with the same electrodes as those used in the first experiment, but with the electrodes inserted into the livers of live pigs under EUS. In the third experiment, we tested the electrodes for water permeability. In the fourth experiment, we performed EUS-RFA on live pigs, using 19 G electrodes in 7/12 pigs and 18 G electrodes in 5/12 pigs. Complications were evaluated after 7 days of survival. RESULTS: The newly designed RFA electrodes achieved ablation of the liver. In the first experiment, the maximal sizes of the ablation areas were 27, 26, 24, and 25 mm at 10, 20, 30, and 40 W, respectively, with the 2-cm electrode. In the second experiment, the maximal vertical sizes were 22, 23, 22, and 23 mm at 10, 20, 30, and 40 W, respectively, with the 2-cm electrode. In the third experiment, the 18 G electrode had better water permeability than the 19 G electrode. In the fourth experiment, all pigs survived. Complications occurred in 1/5 (18 G electrode) and 4/7 (19 G electrode) pigs. CONCLUSION: We performed EUS-RFA in pigs and concluded that it may be feasible to perform RFA of lesions near the stomach.
  • Yasuyuki Fukami; Yuji Kaneoka; Atsuyuki Maeda; Takashi Kumada; Junko Tanaka; Tomoyuki Akita; Shoji Kubo; Namiki Izumi; Masumi Kadoya; Michiie Sakamoto; Osamu Nakashima; Yutaka Matsuyama; Takashi Kokudo; Kiyoshi Hasegawa; Tatsuya Yamashita; Kosuke Kashiwabara; Tadatoshi Takayama; Norihiro Kokudo; Masatoshi Kudo
    Annals of surgery 272 1 145 - 154 2020年07月 [査読有り]
     
    OBJECTIVE: The aim of the study was to evaluate the survival benefits of liver resection (LR) compared with transarterial chemoembolization (TACE) for patients with multiple hepatocellular carcinomas (HCCs). BACKGROUND: Despite significant improvements in diagnostic imaging and the widespread application of screening programs, some patients with HCC continue to present with multiple tumors. The surgical indications for multiple HCCs remain controversial. METHODS: Among 77,268 patients with HCC reported in a Japanese nationwide survey, 27,164 patients had multiple HCCs. The exclusion criteria were Child-Pugh B/C, treatment other than LR and TACE, >3 tumors, and insufficient available data. Ultimately, 3246 patients (LR: n = 1944, TACE: n = 1302) were included. The survival benefit of LR for patients multiple HCCs was evaluated by using propensity score matching analysis. RESULTS: The study group of 2178 patients (LR: n = 1089, TACE: n = 1089) seemed to be well matched. The overall survival rate in the LR group was 60.0% at 5 years, which was higher than that in the TACE group (41.6%, P < 0.001). Among patients with a tumor size of 30 mm or more, LR showed a survival benefit over TACE at 5 years (53.0% vs 32.7%, P < 0.001). The multivariate analysis indicated that age, serum albumin level, serum alpha-fetoprotein (AFP) level, macrovascular invasion, tumor size, and TACE were independent predictors of poor prognosis in multiple HCCs. CONCLUSIONS: LR could offer better long-term survival than TACE for patients with multiple HCCs (up to 3 tumors). If patients have good liver function (Child-Pugh A), LR is recommended, even for those with multiple HCCs with tumor sizes of 30 mm or more.
  • Masatoshi Kudo; Masayuki Kurosaki; Masafumi Ikeda; Hiroshi Aikata; Atsushi Hiraoka; Takuji Torimura; Naoya Sakamoto
    Hepatology research : the official journal of the Japan Society of Hepatology 50 9 1004 - 1014 2020年06月 [査読有り]
     
    This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the COVID-19 pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). Also, models suggest that second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.
  • Kosuke Minaga; Masayuki Kitano; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Masakatsu Tsurusaki; Takaaki Chikugo; Ippei Matsumoto; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi Kudo
    Gastrointestinal endoscopy 93 2 433 - 441 2020年06月 [査読有り]
     
    BACKGROUND AND AIMS: Kupffer-phase imaging visualized by Sonazoid distribution into normal liver tissues upon phagocytosis by Kupffer cells, potentially aids in improving liver metastasis detection compared with fundamental B-mode EUS (FB-EUS). However, the diagnostic performance of Kupffer-phase imaging in contrast-enhanced harmonic EUS (CH-EUS) remains unclear. Hence, this study aimed to evaluate the usefulness of CH-EUS-based Kupffer-phase imaging for diagnosing liver metastasis from pancreatic cancer. METHODS: We retrospectively analyzed consecutive patients with pancreatic cancer who underwent contrast-enhanced CT (CE-CT) and FB-EUS, followed by CH-EUS, from 2011 to 2017. The diagnostic ability of CH-EUS against that of CE-CT and FB-EUS for left-lobe liver metastasis was compared. Subsequently, the influences of CH-EUS on the determination of clinical stage and patient management for pancreatic cancer were assessed. RESULTS: We enrolled 426 patients with pancreatic cancer. The left-lobe liver metastasis was present in 27.2% of patients. The diagnostic accuracy of CE-CT, FB-EUS, and CH-EUS was 90.6%, 93.4%, and 98.4%, respectively. The sensitivity and diagnostic accuracy of CH-EUS for left-lobe liver metastasis were significantly higher than those of FB-EUS or CE-CT. The sensitivity of CH-EUS for detecting small liver metastasis (<10 mm) was considerably higher than that of CE-CT or FB-EUS (P < 0.001). In 2.1% patients, only CH-EUS could detect a single distant metastasis of the left-lobe liver, thereby upgrading the tumor staging and altering the clinical management. CONCLUSIONS: CH-EUS-based Kupffer-phase imaging increased the detectability of left-lobe liver metastasis. This technique could be a reliable pretreatment imaging modality for clinical decision-making in pancreatic cancer patients.
  • 全身疾患/薬物副作用と消化器内視鏡 ダビガトランによる食道粘膜傷害の検討
    益田 康弘; 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部例会プログラム・抄録集 104回 39 - 39 日本消化器内視鏡学会-近畿支部 2020年06月
  • 竹中 完; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    消化器内視鏡 32 6 862 - 864 (株)東京医学社 2020年06月
  • 渡邉 智裕; 吉川 智恵; 原 茜; 鎌田 研; 三長 孝輔; 工藤 正俊
    炎症と免疫 28 4 310 - 314 (株)先端医学社 2020年06月 
    IgG4関連疾患の病態生理については明らかになっていないものの、研究者らは自己抗原の同定・獲得免疫反応の解明・自然免疫反応の解明の3つのアプローチから病態に迫っている。IgG4関連疾患の病態にかかわる自然免疫担当細胞として、形質細胞様樹状細胞・M2マクロファージ・好塩基球が同定されている。さらに、IFN-α・IL-33などのサイトカインが慢性炎症や線維化を誘導すると考えられている。IgG4関連疾患の発症にかかわる自然免疫反応の解明は、病態生理の解明のみならず新規治療法の開発にもつながる可能性がある。(著者抄録)
  • Masatoshi Kudo
    Liver cancer 9 3 232 - 244 2020年06月 [査読有り]
  • Masatoshi Kudo; Kwang-Hyub Han; Sheng-Long Ye; Jian Zhou; Yi-Hsiang Huang; Shi-Ming Lin; Chung-Kwe Wang; Masafumi Ikeda; Stephen Lam Chan; Su Pin Choo; Shiro Miyayama; Ann Lii Cheng
    Liver cancer 9 3 245 - 260 2020年06月 [査読有り]
     
    The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APPLE Meeting. This manuscript summarizes the international consensus statements developed at APPLE 2019. Transarterial chemoembolization (TACE) is the only guideline-recommended global standard of care for intermediate-stage HCC. However, not all patients benefit from TACE because intermediate-stage HCC is a heterogeneous disease in terms of tumor burden and liver function. Ten important clinical questions regarding this stage of HCC were raised, and consensus statements were generated based on high-quality evidence. In intermediate-stage HCC, preservation of liver function is as important as achieving a high objective response (OR) because the treatment goal is to prolong overall survival. Superselective conventional TACE (cTACE) is recommended as the first choice of treatment in patients eligible for effective (curative) TACE, whereas in patients who are not eligible, systemic therapy is recommended as the first choice of treatment. TACE is not indicated as the first-line therapy in TACE-unsuitable patients. Another important statement is that TACE should not be continued in patients who develop TACE failure/refractoriness in order to preserve liver function. Targeted therapy is the recommended first-line treatment for TACE-unsuitable patients. Especially, the drug, which can have higher OR rate, is preferred. Immunotherapy, transarterial radioembolization, TACE + targeted therapy or other modalities may be considered alternative options in TACE-unsuitable patients who are not candidates for targeted therapy. Better liver function, such as albumin-bilirubin grade 1, is an important factor for maximizing the therapeutic effect of systemic therapy.
  • Fabio Piscaglia; Federico Stefanini; Vito Cantisani; Paul S Sidhu; Richard Barr; Annalisa Berzigotti; Maria Cristina Chammas; Jean-Michel Correas; Christoph Frank Dietrich; Steven Feinstein; Pintong Huang; Christian Jenssen; Yuko Kono; Masatoshi Kudo; Ping Liang; Andrej Lyshchik; Christian Nolsøe; Xyaoyan Xie; Francesco Tovoli
    Ultraschall in der Medizin (Stuttgart, Germany : 1980) 41 3 228 - 236 2020年06月 [査読有り]
  • Masatoshi Kudo; Takuji Okusaka; Kenta Motomura; Izumi Ohno; Manabu Morimoto; Satoru Seo; Yoshiyuki Wada; Shinpei Sato; Tatsuya Yamashita; Masayuki Furukawa; Takeshi Aramaki; Seijin Nadano; Kazuyoshi Ohkawa; Hirofumi Fujii; Toshihiro Kudo; Junji Furuse; Hiroki Takai; Gosuke Homma; Reigetsu Yoshikawa; Andrew X Zhu
    Journal of gastroenterology 55 6 627 - 639 2020年06月 [査読有り]
     
    BACKGROUND: The global, randomized, phase 3 REACH-2 study (ClinicalTrials.gov identifier: NCT02435433) found significantly longer overall survival (OS) for second-line ramucirumab versus placebo (hazard ratio [HR]: 0.710, 95% confidence interval [CI] 0.531-0.949, P = 0.0199) in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥ 400 ng/mL. This prespecified subgroup analysis evaluated the efficacy and safety of ramucirumab in the Japanese patients enrolled in the study. METHODS: Patients with advanced HCC and AFP ≥ 400 ng/mL after first-line sorafenib were randomized 2:1 to ramucirumab (8 mg/kg intravenously) or placebo every 2 weeks. Hazard ratios for progression-free survival (PFS) and OS (primary endpoint of the overall study) were estimated using the stratified Cox regression model. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with AFP ≥ 400 ng/mL. RESULTS: In the Japanese REACH-2 subpopulation, there were improvements for ramucirumab (n = 41) versus placebo (n = 18) in PFS (HR 0.282, 95% CI 0.144-0.553) and OS was numerically prolonged (HR 0.599, 95% CI 0.303-1.187), consistent with the significant benefit seen in the overall REACH-2 study population. In the ramucirumab and placebo arms, respectively, the objective response rate was 7.3% and 0%, and the disease control rate was 70.7% and 33.3%. The most frequently reported grade ≥ 3 treatment-emergent adverse event was hypertension (ramucirumab: 15%; placebo: 11%). CONCLUSIONS: Ramucirumab after prior sorafenib improved PFS and OS compared with placebo, with a manageable safety profile, in the Japanese REACH-2 subpopulation, consistent with the overall REACH-2 study results. Ramucirumab is the first agent to demonstrate clinical benefit for Japanese patients with HCC in the second-line setting.
  • Josep M Llovet; Augusto Villanueva; Jorge A Marrero; Myron Schwartz; Tim Meyer; Peter R Galle; Riccardo Lencioni; Tim F Greten; Masatoshi Kudo; Sumithra J Mandrekar; Andrew X Zhu; Richard S Finn; Lewis R Roberts
    Hepatology (Baltimore, Md.) 2020年05月 [査読有り]
     
    Proper trial design is critical for the success of clinical investigations. Hepatocellular carcinoma (HCC) is a complex disease that has several unique properties. In 2008, after the approval of sorafenib, a panel of experts proposed guidelines for trial design and endpoints in HCC that have been instrumental during the last decade and provided a framework to allow an homogeneous analysis of reported investigations. Since then, several phase III studies have been reported and novel challenges have emerged. A panel of experts conveyed by AASLD organized a Special Topic Conference on trial design and endpoints to address those emerging challenges. This review summarizes the analysis and conclusions of those discussions and provides novel recommendations on the selection endpoints, stratification variables and targeted populations in the complex arena of HCC. We have covered the full spectrum of the disease, from surveillance/ chemoprevention, to neoadjuvant and adjuvant trials after curative therapies, and trials in intermediate and advanced stages of HCC. We explore the prospects for incorporating biomarkers and liquid biopsy into conventional clinical trials. In addition, we address the need for obtaining tissue and blood samples in all investigations and propose novel primary endpoints such as progression free survival with restrictive rules and patient reported outcomes. This up-dated set of recommendations is timely considering the advent of more potent combination therapies in all areas of HCC management, the increase in adverse events associated with those combinations, and the evidence that several lines of effective treatments will benefit a given patient. We herein articulate a framework to facilitate capturing the efficacy of novel therapeutic strategies with the goal of improving the outcomes of patients suffering from this disease.
  • Naoshi Nishida; Masatoshi Kudo
    Cancers 12 5 2020年05月 [査読有り]
     
    Immunotherapies are promising approaches for treating hepatocellular carcinomas (HCCs) refractory to conventional therapies. However, a recent clinical trial of immune checkpoint inhibitors (ICIs) revealed that anti-tumor responses to ICIs are not satisfactory in HCC cases. Therefore, it is critical to identify molecular markers to predict outcome and develop novel combination therapies that enhance the efficacy of ICIs. Recently, several attempts have been made to classify HCC based on genome, epigenome, and transcriptome analyses. These molecular classifications are characterized by unique clinical and histological features of HCC, as well immune phenotype. For example, HCCs exhibiting gene expression patterns with proliferation signals and stem cell markers are associated with the enrichment of immune infiltrates in tumors, suggesting immune-proficient characteristics for this type of HCC. However, the presence of activating mutations in β-catenin represents a lack of immune infiltrates and refractoriness to ICIs. Although the precise mechanism that links the immunological phenotype with molecular features remains controversial, it is conceivable that alterations of oncogenic cellular signaling in cancer may lead to the expression of immune-regulatory molecules and result in the acquisition of specific immunological microenvironments for each case of HCC. Therefore, these molecular and immune characteristics should be considered for the management of HCC using immunotherapy.
  • Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
    The New England journal of medicine 382 20 1894 - 1905 2020年05月 [査読有り]
     
    BACKGROUND: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RESULTS: The intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab-bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab-bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab-bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab-bevacizumab group; however, other high-grade toxic effects were infrequent. CONCLUSIONS: In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).
  • David M Hughes; Sarah Berhane; C A Emily de Groot; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Shinji Satomura; Naoshi Nishida; Masatoshi Kudo; Toru Kimura; Yukio Osaki; Ruwanthi Kolamunage-Dona; Ruben Amoros Salvador; Tom Bird; Marta Garcίa-Fiñana; Philip Johnson
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 19 1 162 - 170 2020年05月 [査読有り]
     
    BACKGROUND & AIMS: Ultrasound (US)-based screening has been recommended for patients with an increased risk of hepatocellular carcinoma (HCC). US analysis, however, is limited in patients who are obese or have small tumors. The addition of serum level of α-fetoprotein (AFP) measurements to US analysis can increase detection of HCC. We analyzed data from patients with chronic liver disease, collected over 15 years in an HCC surveillance program, to develop a model to assess risk of HCC. METHODS: We collected data from 3450 patients with chronic liver disease undergoing US surveillance in Japan from March 1998 through April 2014, and followed them up for a median of 8.83 years. We performed longitudinal discriminant analysis of serial AFP measurements (median number of observations/patient, 56; approximately every 3 months) to develop a model to determine the risk of HCC. We validated the model using data from 2 cohorts of patients with chronic liver disease in Japan (404 and 2754 patients) and 1 cohort in Scotland (1596 patients). RESULTS: HCC was detected in 413 patients (median tumor diameter, 1.8 cm), during a median follow-up time of 6.60 years. In the development data set, the model identified patients who developed HCC with an area under the curve of 0.78; it correctly identified 74.3% of patients who did develop HCC, and 72.9% of patients who did not. Overall, 73.1% of patients were classified correctly. The model could be used to assign patients to a high-risk group (27.5 HCCs/1000 patient-years) vs a low-risk group (4.9 HCCs/1000 patient-years). A similar performance was observed when the model was used to assess patients with cirrhosis. Analysis of the validation cohorts produced similar results. CONCLUSIONS: We developed and validated a model to identify patients with chronic liver disease who are at risk for HCC based on change in serum AFP level over time. The model could be used to assign patients to high-risk vs low-risk groups, and might be used to select patients for surveillance.
  • Mamoru Takenaka; Atsushi Nakai; Masatoshi Kudo
    Journal of hepato-biliary-pancreatic sciences 27 5 282 - 283 2020年05月 [査読有り]
     
    Highlight Takenaka and colleagues report on a novel bare uncovered self-expandable metal stent developed to be compatible with only 0.025-inch guide wires. This unprecedented feature makes the delivery tip thinner and more flexible than the conventional type and useful for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction.
  • Kosuke Minaga; Mamoru Takenaka; Ayana Okamoto; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Masatoshi Kudo
    Endoscopy 52 5 E152-E153  2020年05月 [査読有り]
  • 椎名 毅; 山川 誠; 西田 直生志; 工藤 正俊; 津川 浩一郎; 中島 康雄
    INNERVISION 35 6 47 - 49 (株)インナービジョン 2020年05月 
    人工知能(AI)による医療画像診断の研究は、かつては医師の思考過程をいかにまねるかに注力していた。すなわち、画像から所見(特徴量)を抽出し、疾患と特徴量との関係性について医師の専門知識と経験をモデル化する必要があったが、いずれも容易ではなかった。しかし、近年のビックデータ時代の到来と、深層学習(deep learning)を中心とする機械学習の進歩により、特徴抽出やモデル化の処理が不要となり、さらにAI画像診断の精度が飛躍的に向上したことで、実用化が一気に加速化した。実際、眼底写真、病理標本、皮膚病変、胸部X線、内視鏡などのAI診断で、すでに専門医と同等レベルか、それを凌駕する結果が報告されている。ここで重要なのは、AIに対して大量かつ良質な教師データを与えることであるが、超音波画像データの取得に際しては、術者依存性、機種依存性、多くの画質パラメータなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっていた。このため、日本超音波医学会(以下、JSUM)は、2018年から日本医療研究開発機構(以下、AMED)の「臨床研究等ICT基盤構築・人工知能実装研究事業」で、超音波画像の大規模なデータベースの構築とAI診断システムの開発に取り組んでいる。本稿では、このプロジェクトの試みの一例として超音波画像から肝腫瘤および乳腺腫瘤タイプを推定するAI診断技術の開発の現状を紹介したい。(著者抄録)
  • Changhoon Yoo; Do-Youn Oh; Hye Jin Choi; Masatoshi Kudo; Makoto Ueno; Shunsuke Kondo; Li-Tzong Chen; Motonobu Osada; Christoph Helwig; Isabelle Dussault; Masafumi Ikeda
    Journal for immunotherapy of cancer 8 1 2020年05月 [査読有り]
     
    BACKGROUND: Patients with biliary tract cancer (BTC) have poor prognosis with few treatment options. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor (TGF)-βRII receptor (a TGF-β 'trap') fused to a human IgG1 antibody blocking programmed death ligand 1 (PD-L1), has shown clinical efficacy in multiple solid tumors. METHODS: In this phase I, open-label trial expansion cohort, Asian patients with BTC whose disease progressed after first-line chemotherapy received bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint is safety/tolerability, while the secondary endpoints include best overall response per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: As of August 24, 2018, 30 patients have received bintrafusp alfa for a median of 8.9 (IQR 5.7-32.1) weeks; 3 patients remained on treatment for >59.7 weeks. Nineteen (63%) patients experienced treatment-related adverse events (TRAEs), most commonly rash (17%), maculopapular rash and fever (13% each), and increased lipase (10%). Eleven (37%) patients had grade ≥3 TRAEs; three patients had grade 5 events (septic shock due to bacteremia, n=1; interstitial lung disease (reported term: interstitial pneumonitis), n=2). The objective response rate was 20% (95% CI 8 to 39) per independent review committee (IRC), with five of six responses ongoing (12.5+ to 14.5+ months) at data cut-off. Two additional patients with durable stable disease had a partial response per investigator. Median progression-free survival assessed by IRC and overall survival were 2.5 months (95% CI 1.3 to 5.6) and 12.7 months (95% CI 6.7 to 15.7), respectively. Clinical activity was observed irrespective of PD-L1 expression and microsatellite instability-high status. CONCLUSIONS: Bintrafusp alfa had clinical activity in Asian patients with pretreated BTC, with durable responses. Based on these results, bintrafusp alfa is under further investigation in patients with BTC (NCT03833661 and NCT04066491). TRIAL REGISTRATION NUMBER: NCT02699515.
  • 【US Today 2020 超音波検査・診断最前線-表在(乳腺・甲状腺)領域の最新動向を中心に】表在(乳腺・甲状腺)領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望
    椎名 毅; 山川 誠; 西田 直生志; 工藤 正俊; 津川 浩一郎; 中島 康雄
    INNERVISION 35 6 47 - 49 (株)インナービジョン 2020年05月 [査読有り]
     
    人工知能(AI)による医療画像診断の研究は、かつては医師の思考過程をいかにまねるかに注力していた。すなわち、画像から所見(特徴量)を抽出し、疾患と特徴量との関係性について医師の専門知識と経験をモデル化する必要があったが、いずれも容易ではなかった。しかし、近年のビックデータ時代の到来と、深層学習(deep learning)を中心とする機械学習の進歩により、特徴抽出やモデル化の処理が不要となり、さらにAI画像診断の精度が飛躍的に向上したことで、実用化が一気に加速化した。実際、眼底写真、病理標本、皮膚病変、胸部X線、内視鏡などのAI診断で、すでに専門医と同等レベルか、それを凌駕する結果が報告されている。ここで重要なのは、AIに対して大量かつ良質な教師データを与えることであるが、超音波画像データの取得に際しては、術者依存性、機種依存性、多くの画質パラメータなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっていた。このため、日本超音波医学会(以下、JSUM)は、2018年から日本医療研究開発機構(以下、AMED)の「臨床研究等ICT基盤構築・人工知能実装研究事業」で、超音波画像の大規模なデータベースの構築とAI診断システムの開発に取り組んでいる。本稿では、このプロジェクトの試みの一例として超音波画像から肝腫瘤および乳腺腫瘤タイプを推定するAI診断技術の開発の現状を紹介したい。(著者抄録)
  • Stephen P Hack; Jessica Spahn; Minshan Chen; Ann-Lii Cheng; Ahmed Kaseb; Masatoshi Kudo; Han Chu Lee; Adam Yopp; Pierce Chow; Shukui Qin
    Future oncology (London, England) 16 15 975 - 989 2020年05月 [査読有り]
     
    Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT04102098.
  • Kosuke Minaga; Tomohiro Watanabe; Yasuyuki Arai; Masahiro Shiokawa; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Kouhei Yamashita; Masatoshi Kudo
    Journal of gastroenterology 55 5 565 - 576 2020年05月 [査読有り]
     
    BACKGROUND: Excessive type I IFN (IFN-I) production by plasmacytoid dendritic cells (pDCs) promotes autoimmunity. Recently, we reported that a prominent feature of both experimental autoimmune pancreatitis (AIP) and human type 1 AIP is pDC activation followed by enhanced production of IFN-I and IL-33. However, the roles played by interferon regulatory factor 7 (IRF7), a critical transcription factor for IFN-I production in pDCs, in these disorders have not been clarified. METHODS: Whole and nuclear extracts were isolated from pancreatic mononuclear cells (PMNCs) from MRL/MpJ mice exhibiting AIP. Expression of phospho-IRF7 and nuclear translocation of IRF7 was examined in these extracts by immunoblotting. Pancreatic expression of IRF7 was assessed by immunofluorescence analysis in experimental AIP. Nuclear translocation of IRF7 upon exposure to neutrophil extracellular traps (NETs) was assessed in peripheral blood pDCs from type 1 AIP patients. Pancreatic IRF7 expression was examined in surgically operated specimens from type 1 AIP patients. RESULTS: IRF7 activation was induced in pancreatic pDCs in experimental AIP. siRNA-mediated knockdown of IRF7 expression prevented AIP development, which was accompanied by a marked reduction in both pancreatic accumulation of pDCs and production of IFN-α and IL-33. Notably, in peripheral blood pDCs isolated from patients with type 1 AIP, nuclear translocation of IRF7 was enhanced as compared with the translocation in pDCs from healthy controls. Furthermore, IRF7-expressing pDCs were detected in the pancreas of patients with type 1 AIP. CONCLUSIONS: These findings suggest that the IRF7-IFN-I-IL-33 axis activated in pDCs drives pathogenic innate immune responses associated with type 1 AIP.
  • Yukihiro Watanabe; Yutaka Matsuyama; Namiki Izumi; Shoji Kubo; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Osamu Nakashima; Masatoshi Kudo
    Surgery 167 5 793 - 802 2020年05月 [査読有り]
     
    BACKGROUND: Data are inconsistent regarding the effects of a wide surgical margin for intrahepatic cholangiocarcinoma on recurrence-free survival and overall survival. This study was performed to investigate the effect of surgical margin width in patients undergoing R0 resection for intrahepatic cholangiocarcinoma, using a nationwide database in Japan. METHODS: In total, 635 patients with intrahepatic cholangiocarcinoma who were treated by an R0 resection from 2000 to 2007 were identified from the database of a Japanese nationwide survey. Patients were divided into quartiles of the surgical margin width as follows: marginal (<1 mm), narrow (1-4 mm), intermediate (5-9 mm), and wide groups (≥10 mm). Multivariable Cox regression models for recurrence-free survival and overall survival were constructed with adjustment for preoperative and postoperative clinicopathologic factors. RESULTS: Compared with the marginal group, the risk-adjusted hazard ratios (95% confidence intervals) in the narrow, intermediate, and wide groups for recurrence-free survival were 0.92 (0.62-1.37), 0.91 (0.61-1.37), and 0.81 (0.56-1.17), and those for overall survival were 0.79 (0.51-1.24), 0.93 (0.59-1.47), and 0.70 (0.46-1.08), respectively. In 398 patients without lymph node metastasis, the hazard ratios for overall survival were 0.62 (0.34-1.11), 0.63 (0.34-1.17), and 0.51 (0.29-0.90), and those of mass-forming type intrahepatic cholangiocarcinoma were 0.48 (0.21-1.08), 0.43 (0.19-0.96), and 0.40 (0.19-0.82), respectively. CONCLUSION: Surgical margin width appears to have a limited effect on the prognosis of intrahepatic cholangiocarcinoma except in patients without lymph node metastasis, where a wide surgical margin is associated with favorable outcomes. This survival benefit of a wide surgical margin is especially apparent for the mass-forming type intrahepatic cholangiocarcinoma.
  • Masatoshi Kudo
    Cancers 12 5 2020年04月 [査読有り]
     
    A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is groundbreaking because nivolumab and pembrolizumab, both programmed cell death-1 (PD-1) antibodies, have failed to show efficacy as first- and second-line therapeutics, respectively, in phase III clinical trials. Immunotherapy with a combination of atezolizumab and bevacizumab resulted in better survival than treatment with sorafenib for the first time since sorafenib was approved in 2007. The high efficacy of the combination of PD-1/programmed death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) antibodies is not only due to their additive effects on tumor growth, but also to their reprogramming of the immunosuppressive microenvironment into an immunostimulatory microenvironment. These results were confirmed in a phase Ib trial that showed significantly longer progression-free survival in the atezolizumab plus bevacizumab group than in patients that received atezolizumab alone. These results demonstrate that immunotherapy with a combination of PD-1/PD-L1 and VEGF inhibitors is effective and may result in a reprogramming of the tumor microenvironment. The results of an ongoing phase III trial of a PD-1 antibody in combination with the VEGF receptor tyrosine kinase inhibitor (TKI) are highly anticipated.
  • Toshihiko Doi; Yutaka Fujiwara; Takafumi Koyama; Masafumi Ikeda; Christoph Helwig; Morihiro Watanabe; Yulia Vugmeyster; Masatoshi Kudo
    The oncologist 25 e1292 - 1302 2020年04月 [査読有り]
     
    LESSONS LEARNED: Bintrafusp alfa had a manageable safety profile and demonstrated preliminary clinical activity in heavily pretreated patients with solid tumors (including hepatocellular carcinoma) with no or limited treatment options. Findings from this study suggest bintrafusp alfa may be a novel therapeutic approach for patients with advanced solid tumors. Additional trials are needed to further explore safety and efficacy of bintrafusp alfa in specific tumor types. BACKGROUND: Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor-β (TGF-β) RII receptor (a TGF-β "trap") fused to a human immunoglobulin (Ig) G1 antibody blocking programmed death-ligand 1 (PD-L1). Bintrafusp alfa is designed to neutralize TGF-β signaling by "trapping" and sequestering all TGF-β isoforms, and this trap function is physically linked to PD-L1 blockade in the tumor microenvironment. METHODS: NCT02699515 was a phase I, open-label, dose-escalation study of bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks) in Asian patients with advanced solid tumors, including a hepatocellular carcinoma (HCC) safety-assessment cohort. The primary objective was safety and tolerability; the secondary objective is best overall response. RESULTS: As of August 24, 2018, 23 patients (including 9 in the HCC cohort) received bintrafusp alfa. Eight patients experienced treatment-related adverse events (TRAEs). Three patients had grade 3 TRAEs (13.0%; hypoacusis, hyponatremia, hypopituitarism, increased blood creatine phosphokinase, and intracranial tumor hemorrhage); one had grade 4 hyponatremia (4.3%). No treatment-related deaths occurred. In the dose-escalation cohort, two patients had a confirmed partial response, and 3 had stable disease (SD), for an overall response rate of 14.3% and a disease control rate (DCR) of 35.7%. In the HCC cohort, one patient had SD (DCR, 11.1%). A dose-proportional pharmacokinetics profile was observed at doses of >3 mg/kg. CONCLUSION: Bintrafusp alfa had a manageable safety profile and preliminary efficacy in heavily pretreated patients with advanced solid tumors, including HCC.
  • Masatoshi Kudo; Peter R Galle; Josep M Llovet; Richard S Finn; Arndt Vogel; Kenta Motomura; Eric Assenat; Philippe Merle; Giovanni Brandi; Bruno Daniele; Takuji Okusaka; Jiří Tomášek; Christophe Borg; Vincenzo Dadduzio; Manabu Morimoto; Marc Pracht; Min-Hua Jen; Nora Drove Ubreva; Ryan C Widau; Kenta Shinozaki; Reigetsu Yoshikawa; Andrew X Zhu
    Liver international : official journal of the International Association for the Study of the Liver 2020年04月 [査読有り]
     
    BACKGROUND & AIMS: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years). METHODS: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods (stratified by study) assessed OS, progression-free survival (PFS), time to progression (TTP) and patient-reported outcomes (Functional Hepatobiliary System Index-8 [FHSI-8] score). RESULTS: A total of 542 patients (<65 years: n = 302; ≥65 to <75 years: n = 160; ≥75 years: n = 80) showed similar baseline characteristics between ramucirumab and placebo. Older subgroups had higher hepatitis C and steatohepatitis incidences, and lower AFP levels, than the <65 years subgroup. Ramucirumab prolonged OS in patients <65 years (hazard ratio [HR], 0.753; 95% CI 0.581-0.975), ≥65 to <75 years (0.602; 0.419-0.866) and ≥75 years (0.709; 0.420-1.199), PFS and TTP irrespective of age. Ramucirumab showed similar overall safety profiles across subgroups, with a consistent median relative dose intensity ≥97.8%. A trend towards a delay in symptom deterioration in FHSI-8 with ramucirumab was observed in all subgroups. CONCLUSIONS: In this post-hoc analysis, ramucirumab showed a survival benefit across age subgroups with a tolerable safety profile, supporting its use in advanced HCC with elevated AFP, irrespective of age, including ≥75 years.
  • Keitaro Sofue; Minori Onoda; Masakatsu Tsurusaki; Daisuke Morimoto; Norihisa Yada; Masatoshi Kudo; Takamichi Murakami
    Journal of magnetic resonance imaging : JMRI 51 4 1053 - 1064 2020年04月 [査読有り]
     
    BACKGROUND: Differentiation between inflammation and fibrosis is an important clinical distinction in patients with chronic liver disease, which has been difficult so far with MR elastography. PURPOSE: To investigate whether dual-frequency MR elastography can estimate necroinflammation of the liver and improve diagnostic performance for the staging of liver fibrosis. STUDY TYPE: Retrospective. SUBJECTS: In all, 30 patients (14 males, 16 females) with chronic liver disease. FIELD STRENGTH/SEQUENCE: 1.5T/dual-frequency MR elastography at 60-Hz and 80-Hz vibration frequencies. [Correction added on November 12, 2019, after first online publication: The field strength in the preceding sentence was corrected.] ASSESSMENT: Necroinflammation activity and fibrosis were assessed using the METAVIR scoring system. Stiffness values at 60-Hz (G60-Hz ) and 80-Hz (G80-Hz ) were obtained with an MR elastogram. The difference value between G80-Hz and G60-Hz (ΔG) was calculated. Four values (G60-Hz , G80-Hz , G60-Hz - ΔG, and G80-Hz  + ΔG) were generated to estimate necroinflammation and fibrosis. STATISTICAL TESTS: The ΔG were correlated with necroinflammation activity grade and fibrosis stage using Spearman's rank correlation. Diagnostic performance of the four values for necroinflammation activity grade and fibrous stage was assessed by using area under the receiver operating characteristic curve (AUC). RESULTS: The mean value of G80-Hz (6.23 ± 3.67 kPa) was significantly higher than that of G60-Hz (5.27 ± 3.14 kPa) (P < 0.0001). The ΔG demonstrated a strong correlation with necroinflammation grade (ρ = 0.625, P < 0.001) and no correlation with fibrosis stage (ρ = 0.306, P = 0.113). The AUC of the G80-Hz and G80-Hz  + ΔG showed higher accuracy for necroinflammation, and optimal cutoff values yielded better discrimination of ≥A1, ≥A2, and = A3. The AUC demonstrated that all the generated values had high diagnostic performance (≥0.87 for all) for fibrosis. DATA CONCLUSION: Dual-frequency MR elastography shows potential in estimating necroinflammation of the liver and may improve diagnostic performance for staging liver fibrosis. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:1053-1064.
  • 金村 宙昌; 林 秀敏; 原谷 浩司; 米阪 仁雄; 中川 和彦; 萩原 智; 工藤 正俊; 大谷 知之; 伊藤 彰彦
    肺癌 60 2 149 - 150 (NPO)日本肺癌学会 2020年04月
  • 画像診断の新展開 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援
    西田 直生志; 工藤 正俊
    肝臓 61 Suppl.1 A203 - A203 (一社)日本肝臓学会 2020年04月
  • 肝癌に対する分子標的治療および免疫治療 進行肝癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ療法の有効性の検討
    青木 智子; 上嶋 一臣; 工藤 正俊
    肝臓 61 Suppl.1 A85 - A85 (一社)日本肝臓学会 2020年04月
  • B型慢性肝炎患者(CH-B)に対する,ETVとTAFの前向き比較観察研究
    萩原 智; 盛田 真弘; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 61 Suppl.1 A423 - A423 (一社)日本肝臓学会 2020年04月
  • 超音波及びワークステーションを用いた新しいレンバチニブの治療効果判定の試み
    野村 貴子; 小川 力; 柴峠 光成; 正木 勉; 工藤 正俊
    肝臓 61 Suppl.1 A374 - A374 (一社)日本肝臓学会 2020年04月
  • Noboru Yamamoto; Baek-Yeol Ryoo; Bhumsuk Keam; Masatoshi Kudo; Chia-Chi Lin; Futoshi Kunieda; Howard A Ball; Diarmuid Moran; Kanji Komatsu; Kentaro Takeda; Musashi Fukuda; Junji Furuse; Satoshi Morita; Toshihiko Doi
    Investigational new drugs 38 2 445 - 456 2020年04月 [査読有り]
     
    ASP5878 is a selective small-molecule inhibitor of fibroblast growth factor receptors (FGFRs). This study investigated safety, tolerability, and antitumor effect of single and multiple oral doses of ASP5878 in patients with solid tumors. This phase 1, open label, first-in-human study comprised dose-escalation and dose-expansion parts. Primary objectives of the dose-escalation part were to identify the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended dose of ASP5878 for the dose-expansion part. Nine dose cohorts of ASP5878 were evaluated (0.5─2 mg once daily; 2─40 mg twice daily [BID]). A single dose of ASP5878 was followed by a 2-day pharmacokinetic collection, and then either 28-day cycles of daily dosing (ASP5878 ≤ 10 mg BID) or 5-day dosing/2-day interruption (ASP5878 ≥ 20 mg BID). The primary objective of the dose-expansion part was to determine the safety of ASP5878 (16 mg BID) administered in 28-day cycles of 5-day dosing/2-day interruption in patients with urothelial carcinoma, hepatocellular carcinoma, or squamous cell lung carcinoma with FGFR genetic alterations. Safety was assessed by monitoring adverse events (AEs). Thirty-five patients were enrolled and 31 discontinued in the dose-escalation part; 51 patients were enrolled and 51 discontinued in the dose-expansion part. In the dose-escalation part, 66.7% of patients in the 20 mg BID 5-day dosing/2-day interruption group reported DLTs of hyperphosphatemia. The recommended dose for the dose-expansion part was 16 mg BID. Common AEs included retinal detachment, diarrhea, and increased alanine aminotransferase. One death occurred that was not related to ASP5878. ASP5878 was well tolerated with manageable toxicities including hyperphosphatemia.
  • 画像診断の新展開 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援
    西田 直生志; 工藤 正俊
    肝臓 61 Suppl.1 A203 - A203 (一社)日本肝臓学会 2020年04月 [査読有り]
  • B型慢性肝炎患者(CH-B)に対する,ETVとTAFの前向き比較観察研究
    萩原 智; 盛田 真弘; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 61 Suppl.1 A423 - A423 (一社)日本肝臓学会 2020年04月 [査読有り]
  • Masatoshi Kudo
    Liver cancer 9 2 119 - 137 2020年04月 [査読有り]
  • Yasunori Minami; Masatoshi Kudo
    Journal of medical ultrasonics (2001) 47 2 257 - 263 2020年04月 [査読有り]
     
    With advances in imaging technology, images from ultrasound (US) and computed tomography (CT) or magnetic resonance imaging (MRI) can be displayed simultaneously and in real time, according to the angle of the transducer. CT/MR-US fusion imaging improves the visualization of inconspicuous hepatocellular carcinoma (HCC) and helps us to understand the three-dimensional relationship between the liver vasculature and HCC. US fusion imaging guidance facilitates improvement in the treatment response for HCC with poor conspicuity, and the rates of technical success of ablation and local tumor progression for inconspicuous HCC range from 94.4 to 100% and 0 to 8.3%, respectively. Moreover, the development of image fusion has made it possible to compare and overlay pre- and post-ablation US images. This US-US fusion imaging allows side-by-side comparison of the ablative margin, while US-US overlay fusion can visualize the ablative margin because the tumor image is projected onto the ablative hyperechoic zone. Thus, US-US overlay fusion guidance is highly effective for safety margin achievement in local ablation therapy for HCC, providing a lower risk of local tumor progression. This manuscript reviews the current status of ultrasound fusion imaging for percutaneous ablation therapy of HCC.
  • Alessandro Cucchetti; Jianhong Zhong; Sarah Berhane; Hidenori Toyoda; KeQing Shi; Toshifumi Tada; Charing C N Chong; Bang-De Xiang; Le-Qun Li; Paul B S Lai; Giorgio Ercolani; Vincenzo Mazzaferro; Masatoshi Kudo; Matteo Cescon; Antonio Daniele Pinna; Takashi Kumada; Philip J Johnson
    Journal of hepatology 72 4 711 - 717 2020年04月 [査読有り]
     
    BACKGROUND & AIMS: The popular sense of the word "cure" implies that a patient treated for a specific disease will return to have the same life expectancy as if he/she had never had the disease. In analytic terms, it translates into the concept of statistical cure which occurs when a group of patients returns to having similar mortality to a reference population. The aim of this study was to assess the probability of being cured from hepatocellular carcinoma (HCC) by hepatic resection. METHODS: Data from 2,523 patients undergoing resection for HCC were used to fit statistical cure models, to compare disease-free survival (DFS) after surgery to the survival expected for patients with chronic hepatitis and/or cirrhosis and the general population, matched by sex, age, race/ethnicity and year of diagnosis. RESULTS: The probability of resection enabling patients with HCC to achieve the same life expectancy as those with chronic hepatitis and/or cirrhosis was 26.3%. The conditional probability of achieving this result was time-dependent, requiring about 8.9 years to be accomplished with 95% certainty. Considering the general population as a reference, the cure fraction decreased to 17.1%. Uncured patients had a median DFS of 1.5 years. In multivariable analysis, patient's age and the risk of early HCC recurrence (within 2 years) were independent determinants of the chance of cure (p <0.001). The chances of being cured ranged between 36.0% for individuals at low risk of early recurrence to approximately 3.6% for those at high risk. CONCLUSION: Estimates of the chance of being cured of HCC by resection showed that cure is achievable, and its likelihood increases with the passing of recurrence-free time. The data presented herein can be used to inform decision making and to provide patients with accurate information. LAY SUMMARY: Data from 2,523 patients who underwent resection for hepatocellular carcinoma were used to estimate the probability that resection would enable treated patients to achieve the same life expectancy as patients with chronic hepatitis and/or cirrhosis, and the general population. Herein, the cure model suggests that in patients with hepatocellular carcinoma, resection can enable patients to achieve the same life expectancy as those with chronic liver disease in 26.3% of cases and as the general population in 17.1% of cases.
  • Kentaro Yamao; Tomohiro Watanabe; Masatoshi Kudo
    Internal medicine (Tokyo, Japan) 59 6 879 - 879 2020年03月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Kentaro Yamao; Ken Kamata; Shunsuke Omoto; Atsushi Nakai; Tomohiro Yamazaki; Ayana Okamoto; Rei Ishikawa; Tomoe Yoshikawa; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi Kudo
    World journal of gastroenterology 26 9 947 - 959 2020年03月 [査読有り]
     
    BACKGROUND: Although several techniques for endoscopic ultrasound-guided biliary drainage (EUS-BD) are available at present, an optimal treatment algorithm of EUS-BD has not yet been established. AIM: To evaluate the clinical utility of treatment method conversion during single endoscopic sessions for difficult cases in initially planned EUS-BD. METHODS: This was a single-center retrospective analysis using a prospectively accumulated database. Patients with biliary obstruction undergoing EUS-BD between May 2008 and April 2016 were included. The primary outcome was to evaluate the improvement in EUS-BD success rates by converting the treatment methods during a single endoscopic session. Secondary outcomes were clarification of the factors leading to the conversion from the initial EUS-BD and the assessment of efficacy and safety of the conversion as judged by technical success, clinical success, and adverse events (AEs). RESULTS: A total of 208 patients underwent EUS-BD during the study period. For 18.8% (39/208) of the patients, the treatment methods were converted to another EUS-BD technique from the initial plan. Biliary obstruction was caused by pancreatobiliary malignancies, other malignant lesions, biliary stones, and other benign lesions in 22, 11, 4, and 2 patients, respectively. The reasons for the difficulty with the initial EUS-BD were classified into the following 3 procedures: Target puncture (n = 13), guidewire manipulation (n = 18), and puncture tract dilation (n = 8). Technical success was achieved in 97.4% (38/39) of the cases and clinical success was achieved in 89.5% of patients (34/38). AEs occurred in 10.3% of patients, including bile leakage (n = 2), bleeding (n = 1), and cholecystitis (n = 1). The puncture target and drainage technique were altered in subsequent EUS-BD procedures in 25 and 14 patients, respectively. The final technical success rate with 95%CI for all 208 cases was 97.1% (95%CI: 93.8%-98.9%), while that of the initially planned EUS-BD was 78.8% (95%CI: 72.6%-84.2%). CONCLUSION: Among multi-step procedures in EUS-BD, guidewire manipulation appeared to be the most technically challenging. When initially planned EUS-BD is technically difficult, treatment method conversion in a single endoscopic session may result in successful EUS-BD without leading to severe AEs.
  • Mamoru Takenaka; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Yoriaki Komeda; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yasutaka Chiba; Chang-Il Kwon; Seok Jeong; Tae Hoon Lee; Masatoshi Kudo
    Surgical endoscopy 34 3 1432 - 1441 2020年03月 [査読有り]
     
    BACKGROUND: Balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (BE-ERCP) has been reported to be effective for patients with surgically altered gastrointestinal anatomy. However, selective biliary cannulation remains difficult in BE-ERCP. We examined the usefulness of a modified double-guidewire technique using an uneven double lumen cannula (the uneven method) for BE-ERCP in patients with surgically altered gastrointestinal anatomy. METHODS: To clarify the usefulness of the uneven method for selective biliary cannulation in BE-ERCP in comparison to the pancreatic guidewire (PGW) method, 40 patients with surgically altered gastrointestinal anatomy who underwent BE-ERCP with successful placement of a guidewire in the pancreatic duct were evaluated. The uneven method was used in 18 cases (uneven group) and the PGW method was used in the remaining 22 cases (PGW group). RESULTS: The technical success rate of biliary cannulation was higher in the uneven group than in the PGW group (83.3 vs. 59.0%; P = 0.165). In addition, the time to biliary cannulation were significantly shorter in the uneven group than in the PGW group (6 vs. 18 min; P = 0.004; respectively). In the PGW group, post-ERCP pancreatitis (PEP) occurred in 3 of 22 cases (13.6%). No adverse events, including PEP, occurred in the uneven group. CONCLUSIONS: The uneven method may be a useful option of selective biliary cannulation in BE-ERCP for the patients with surgically altered gastrointestinal anatomy.
  • 竹中 完; 中井 敦史; 大本 俊輔; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊
    消化器内視鏡 32 3 358 - 364 (株)東京医学社 2020年03月 [査読有り]
  • 【EUSの現状と将来】診断 造影ハーモニック超音波内視鏡の実際と将来展望
    鎌田 研; 原 茜; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊
    肝・胆・膵 80 3 403 - 411 (株)アークメディア 2020年03月 [査読有り]
  • Hiroaki Kanemura; Hidetoshi Hayashi; Satoru Hagiwara; Tomoyuki Otani; Koji Haratani; Kimio Yonesaka; Akihiko Ito; Masatoshi Kudo; Kazuhiko Nakagawa
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 15 3 e39-e42  2020年03月 [査読有り]
  • Kentaro Yamao; Mamoru Takenaka; Takeshi Ogura; Hiroaki Hashimoto; Hisakazu Matsumoto; Masashi Yamamoto; Tsukasa Ikeura; Akira Kurita; Zhao Liang Li; Hideyuki Shiomi; Yasutaka Chiba; Masatoshi Kudo; Tsuyoshi Sanuki
    Digestive diseases and sciences 65 12 3702 - 3709 2020年02月 [査読有り]
     
    BACKGROUND: Self-expandable metal stents (SEMSs) are widely used in patients with distal malignant biliary obstruction. A SEMS that can avoid occlusion as much as possible is desirable. AIMS: The aim of this multicenter single-arm prospective study was to assess the clinical effectiveness and safety of a novel fully covered braided SEMS. METHODS: We enrolled consecutive patients with distal malignant biliary obstruction between February 2016 and November 2017 at ten tertiary-care medical centers. RESULTS: We included 79 patients with a median age of 76 years; 47 (59.5%) patients were men. The technical and clinical success rate was 98.7% and 93.6%, respectively. Recurrent biliary obstruction occurred in 14 patients (17.9%); stent ingrowth, overgrowth, migration, and other occurred in five (6.4%), four (5.1%), four (5.1%), and one (1.3%) patients, respectively. All reinterventions in patients with recurrent biliary obstruction were successful via the transpapillary approach. Adverse events occurred in 15 patients (19.2%); cholangitis, pancreatitis, and others occurred in ten (12.8%), three (3.8%), and two (2.6%) patients, respectively. The stent patency probability at 6 months was 48.5%. Median time to stent patency was 171 days, median time to recurrent biliary obstruction was 536 days, and median survival time was 195 days. CONCLUSIONS: We confirmed the utility and safety of a novel fully covered braided SEMS with low axial force and high radial force in patients with malignance biliary obstruction. This novel SEMS is recommended in patients with distal malignant biliary obstruction.
  • 上嶋 一臣; 工藤 正俊
    臨床消化器内科 35 3 333 - 336 (株)日本メディカルセンター 2020年02月 
    ＜文献概要＞はじめに 分子標的薬の登場により,肝細胞癌診療は大きく変化した.肝細胞癌に対する二次治療薬としてレゴラフェニブに続き,ラムシルマブが使用可能となった.ラムシルマブは肝細胞癌に対するはじめての点滴静注製剤であり,ほかのキナーゼ阻害薬と比較して副作用がマイルドであることが特徴である.本稿ではラムシルマブについて,臨床成績およびその使用の実際について概説する.
  • 術前診断が困難であった肝多血性腫瘍の1例
    大丸 直哉; 川崎 俊彦; 高田 隆太郎; 福永 朋洋; 橋本 有人; 秦 康倫; 木下 大輔; 水野 成人; 橋本 和彦; 石川 原; 若狭 朋子; 太田 善夫; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 112回 93 - 93 日本消化器病学会-近畿支部 2020年02月
  • 【慢性膵炎診療2020】基礎研究・病態 腸内細菌は慢性膵炎発症に関連するのか
    渡邉 智裕; 三長 孝輔; 原 茜; 鎌田 研; 工藤 正俊
    肝・胆・膵 80 2 241 - 246 (株)アークメディア 2020年02月 [査読有り]
  • 【慢性膵炎診療2020】診断 早期慢性膵炎のEUS所見は特異的か 加齢や他疾患の影響は
    竹中 完; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 渡邉 智裕; 松本 逸平; 竹山 宜典; 工藤 正俊
    肝・胆・膵 80 2 295 - 302 (株)アークメディア 2020年02月 [査読有り]
  • Kota Takashima; Shigenaga Matsui; Yoriaki Komeda; Tomoyuki Nagai; Sakurai Toshiharu; Hiroshi Kashida; Masatoshi Kudo
    Endoscopy 52 2 E41-E42  2020年02月 [査読有り]
  • Ann-Lii Cheng; Chiun Hsu; Stephen L Chan; Su-Pin Choo; Masatoshi Kudo
    Journal of hepatology 72 2 307 - 319 2020年02月 [査読有り]
     
    Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at improving the objective response and survival of patients with hepatocellular carcinoma (HCC). Clinical trials of immuno-oncology regimens in other cancer types have shed light on issues of study design, including how to choose candidate regimens based on early-phase trial results, statistical considerations in trials with multiple primary endpoints, and the importance of predictive biomarkers. In this review, the updated data from early-phase trials of combination immunotherapy for HCC are summarised. Since the most extensively tested combination regimens for advanced HCC comprise anti-PD-1/anti-PD-L1 agents plus antiangiogenic agents, the relative benefit and antitumor mechanism of antiangiogenic multikinase inhibitors versus specific VEGF/VEGFR inhibitors are discussed. Other critical issues in the development of combination immunotherapy, including optimal management of immune-related adverse events and the value of ICI therapy in combination with locoregional treatment for HCC, are also explored.
  • Yoriaki Komeda; Tomohiro Watanabe; Masatoshi Kudo
    Journal of investigative surgery : the official journal of the Academy of Surgical Research 1 - 2 2020年01月 [査読有り]
  • Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii Cheng
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 3 193 - 202 2020年01月 [査読有り]
     
    PURPOSE: Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this population. PATIENTS AND METHODS: This randomized, double-blind, phase III study was conducted at 119 medical centers in 27 countries. Eligible patients with advanced HCC, previously treated with sorafenib, were randomly assigned at a two-to-one ratio to receive pembrolizumab plus best supportive care (BSC) or placebo plus BSC. Primary end points were overall survival (OS) and progression-free survival (PFS; one-sided significance thresholds, P = .0174 [final analysis] and P = .002 [first interim analysis], respectively). Safety was assessed in all patients who received ≥ 1 dose of study drug. RESULTS: Between May 31, 2016, and November 23, 2017, 413 patients were randomly assigned. As of January 2, 2019, median follow-up was 13.8 months for pembrolizumab and 10.6 months for placebo. Median OS was 13.9 months (95% CI, 11.6 to 16.0 months) for pembrolizumab versus 10.6 months (95% CI, 8.3 to 13.5 months) for placebo (hazard ratio [HR], 0.781; 95% CI, 0.611 to 0.998; P = .0238). Median PFS for pembrolizumab was 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 2.5 to 4.1 months) for placebo at the first interim analysis (HR, 0.775; 95% CI, 0.609 to 0.987; P = .0186) and 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 1.6 to 3.0 months) at final analysis (HR, 0.718; 95% CI, 0.570 to 0.904; P = .0022). Grade 3 or higher adverse events occurred in 147 (52.7%) and 62 patients (46.3%) for pembrolizumab versus placebo; those that were treatment related occurred in 52 (18.6%) and 10 patients (7.5%), respectively. No hepatitis C or B flares were identified. CONCLUSION: In this study, OS and PFS did not reach statistical significance per specified criteria. The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population.
  • Toshiharu Sakurai; Hiroki Nishiyama; Tomoyuki Nagai; Susumu Goto; Hiroyuki Ogata; Masatoshi Kudo
    BMC gastroenterology 20 1 12 - 12 2020年01月 [査読有り]
     
    BACKGROUND: Gankyrin (GK) is an oncoprotein which regulates inflammatory responses and its inhibition is considered as a possible anti-inflammatory therapy for inflammatory bowel disease (IBD). METHODS: In this study, we investigated the role of GK in epithelial cells using mice with intestinal epithelial cell-specific GK deletion in (i) the entire small intestine and colon (Villin-Cre;Gankyrinf/f) and (ii) the distal intestine and colon (Cdx2-Cre;Gankyrinf/f). RESULT: Unexpectedly, GK-deficiency in the upper small bowel augmented inflammatory activity compared with control mice when colitis was induced with dextran sodium sulfate. Biochemical analyses have revealed GK-deficiency to have caused reduction in the expression of antimicrobial peptides, α-Defensin-5 and -6, in the upper small bowel. Examination of human samples have further confirmed that the reduction of GK expression in the small bowel is associated with colonic involvement in human Crohn's disease. Through the sequencing of bacterial 16S rRNA gene amplicons, bacteria potentially deleterious to intestinal homeostasis such as Helicobacter japonicum and Bilophila were found to be over-represented in colitis induced Villin-Cre;Gankyrinf/f mice when compared to Gankyrinf/f control mice under the same condition. CONCLUSION: These results highlight the distinct site dependence of the pro- and anti-inflammatory functions of GK and provide important insights into the pathogenesis of IBD.
  • Daisuke Morimoto; Tomoko Hyodo; Ken Kamata; Tomoya Kadoba; Makoto Itoh; Hiroyuki Fukushima; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Mochizuki; Yu Ueda; Keizou Miyagoshi; Masatoshi Kudo; Kazunari Ishii
    Abdominal radiology (New York) 45 10 3081 - 3091 2020年01月 [査読有り]
     
    PURPOSE: To examine whether MRCP using a combination of compressed sensing and sensitivity encoding with navigator-triggered and breath-hold techniques (NT C-SENSE and BH C-SENSE, respectively) have comparable image quality to that of navigator-triggered MRCP using only sensitivity encoding (NT SENSE) at 1.5-T. METHODS: Fifty-one participants were enrolled in this prospective study between July and October 2018 and underwent the three 3D MRCP sequences each. The acquisition time and relative duct-to-periductal contrast ratios (RC values) of each bile duct segment were obtained. Visualization of the bile and main pancreatic ducts, background suppression, artifacts, and overall image quality were scored on 5-point scales. Mean and median differences in RC values and qualitative scores of NT C-SENSE and BH C-SENSE relative to NT SENSE were calculated with 95% confidence intervals (CIs). RESULTS: Acquisition time of NT SENSE, NT C-SENSE, and BH C-SENSE were 348, 143 (mean for both), and 18 s (for all participants), respectively. The RC value of each bile duct segment was inferior, but the lower limits of the 95% CIs of the mean differences were ≥ - 0.10, for both NT C-SENSE and BH C-SENSE. The visualization score of the intrahepatic duct in BH C-SENSE was inferior to that in NT SENSE (lower 95% CI limit, - 1.5). In both NT C-SENSE and BH C-SENSE, the 95% CIs of the median differences in the other qualitative scores were from - 1.0 to 0.0. CONCLUSION: NT C-SENSE and BH C-SENSE have comparable image quality to NT SENSE at 1.5-T.
  • Masatoshi Kudo; Namiki Izumi; Shoji Kubo; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Tadatoshi Takayama
    Hepatology research : the official journal of the Japan Society of Hepatology 50 1 15 - 46 2020年01月 [査読有り]
     
    In the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21 075 new patients and 40 769 previously followed patients were compiled from 544 institutions over a 2-year period from 1 January 2008 to 31 December 2009. Compared with the previous 19th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, included more female patients, included more patients with non-B non-C HCC, had smaller tumor diameters and more frequently received radiofrequency ablation as local ablation therapy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and by background characteristics for patients newly registered between 1998 and 2009 whose final outcome was survival or death. Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment types (hepatectomy, local ablation therapy, and transcatheter arterial chemoembolization). Cumulative survival rates and median overall survival in patients treated by resection, transcatheter arterial chemoembolization, and local ablation therapy were calculated. The same values were also calculated by the registration date by dividing patients newly registered between 1978 and 2009 into four time period groups . The results of the analysis show that the prognosis of HCC is improving dramatically. It is expected that the data obtained from this nationwide follow-up survey will contribute to advancing clinical research, including the design of clinical trials, as well as the treatment strategy of primary liver cancer in the clinical practice setting.
  • Tatsuya Yamashita; Masatoshi Kudo; Kenji Ikeda; Namiki Izumi; Ryosuke Tateishi; Masafumi Ikeda; Hiroshi Aikata; Yasunori Kawaguchi; Yoshiyuki Wada; Kazushi Numata; Yoshitaka Inaba; Ryoko Kuromatsu; Masahiro Kobayashi; Takuji Okusaka; Toshiyuki Tamai; Chifumi Kitamura; Kenichi Saito; Katsuya Haruna; Kiwamu Okita; Hiromitsu Kumada
    Journal of gastroenterology 55 1 113 - 122 2020年01月 [査読有り]
     
    BACKGROUND: A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC). LEN had an effect on overall survival (OS) compared to SOR, statistically confirmed by non-inferiority [OS: median = 13.6 months vs. 12.3 months; hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.79-1.06], and demonstrated statistically significant improvements in progression-free survival (PFS) and the objective response rate (ORR) in the overall population. The results of a subset analysis that evaluated the efficacy and safety of LEN and SOR in the Japanese population are reported. METHODS: The intent-to-treat population enrolled in Japan was analyzed. RESULTS: Of 954 patients in the overall population, 168 Japanese patients were assigned to the LEN arm (N = 81) or the SOR arm (N = 87). Median OS was 17.6 months for LEN vs. 17.8 months for SOR (HR 0.90; 95% CI 0.62-1.29). LEN showed statistically significant improvements over SOR in PFS (7.2 months vs. 4.6 months) and ORR (29.6% vs. 6.9%). The relative dose intensity of LEN and SOR in the Japanese population was lower than in the overall population. Frequently observed, related adverse events included palmar-plantar erythrodysaesthesia syndrome (PPES), hypertension, decreased appetite, and proteinuria in the LEN arm, and PPES, hypertension, diarrhea, and alopecia in the SOR arm. CONCLUSIONS: The efficacy and safety of LEN in the Japanese population were similar to those in the overall population of REFLECT. With manageable adverse events, LEN is a new treatment option for Japanese patients with uHCC. TRIAL REGISTRATION ID: ClinicalTrials.gov. No. NCT01761266.
  • Takahiro Nakashima; Issei Tsutsumi; Hiroki Takami; Keisuke Doman; Yoshito Mekada; Naoshi Nishida; Masatoshi Kudo
    INTERNATIONAL WORKSHOP ON ADVANCED IMAGING TECHNOLOGY (IWAIT) 2020 11515 2020年 
    The ultrasound examination is a difficult operation because a doctor not only operates an ultrasound scanner but also interprets images in rea time, which may increase the risk of overlooking tumors. To prevent that, we study a liver tumor detection method using convolutional neural networks toward realizing computer-assisted diagnosis systems. In this paper, we propose a liver tumor detection method within a false positive reduction framework. The proposed method uses YOLOv3 [1] in order to find tumor candidate regions in real-time, and also uses VGG16 [2] to reduce false positives. The proposed method using YOLOv3 [1] and VGG16 [2] achieved an F-measure of 0.837, which showed the effectiveness of the proposed method for liver tumor detection. Future work includes the collection of training data from more hospitals and their effective use for improving the detection accuracy.
  • 【ここがキモ!いまはこうする 肝疾患vs.薬物療法 肝機能評価&薬物性肝障害マネジメントに強くなる】(第8章)肝硬変と肝腫瘍 肝細胞がん患者へのアプローチ(手術療法と薬物治療)
    上嶋 一臣; 工藤 正俊
    薬事 62 2 448 - 455 (株)じほう 2020年01月 
    ＜Key Points＞・肝細胞がんは、慢性B型肝炎(肝硬変)や慢性C型肝炎(肝硬変)などの慢性肝疾患を背景に発症する悪性腫瘍であり、その治療にあたっては、肝予備能を最大限に考慮することが重要である。・肝予備能が良好で、腫瘍が限局している場合には手術療法(肝切除)が選択される。・切除困難な場合には、RFA(ラジオ波焼灼療法)、TACE(肝動脈化学塞栓療法)などの局所療法が選択される。・腫瘍量が多い場合(両葉多発など)や、脈管浸潤、遠隔転移症例には分子標的薬による化学療法が選択される。・いずれの治療を選択した場合でも、肝予備能に留意することが重要であり、予備能を低下させるような治療は避けるべきである。(著者抄録)
  • Naoshi Nishida; Masatoshi Kudo
    Frontiers in oncology 10 594580 - 594580 2020年 
    Recent advancement in artificial intelligence (AI) facilitate the development of AI-powered medical imaging including ultrasonography (US). However, overlooking or misdiagnosis of malignant lesions may result in serious consequences; the introduction of AI to the imaging modalities may be an ideal solution to prevent human error. For the development of AI for medical imaging, it is necessary to understand the characteristics of modalities on the context of task setting, required data sets, suitable AI algorism, and expected performance with clinical impact. Regarding the AI-aided US diagnosis, several attempts have been made to construct an image database and develop an AI-aided diagnosis system in the field of oncology. Regarding the diagnosis of liver tumors using US images, 4- or 5-class classifications, including the discrimination of hepatocellular carcinoma (HCC), metastatic tumors, hemangiomas, liver cysts, and focal nodular hyperplasia, have been reported using AI. Combination of radiomic approach with AI is also becoming a powerful tool for predicting the outcome in patients with HCC after treatment, indicating the potential of AI for applying personalized medical care. However, US images show high heterogeneity because of differences in conditions during the examination, and a variety of imaging parameters may affect the quality of images; such conditions may hamper the development of US-based AI. In this review, we summarized the development of AI in medical images with challenges to task setting, data curation, and focus on the application of AI for the managements of liver tumor, especially for US diagnosis.
  • 抗PD-1/PD-L1抗体や抗CTLA-4抗体併用のRationale. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）”
    南 康範; 工藤正俊
    肝胆膵 81 703 - 708 2020年
  • ICI-Anti-VEGF/TKI併用療法のrationale. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）”
    盛田真弘; 工藤正俊
    肝胆膵 81 4 677 - 683 (株)アークメディア 2020年
  • 肝細胞癌における微小免疫環境と免疫チェックポイント阻害剤. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）”
    西田直生志; 工藤正俊
    肝胆膵 81 643 - 650 2020年
  • アテゾリズマブ+ベバシズマブ併用療法登場後の進行肝細胞癌に対するシークエンシャル治療の今後. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）”
    工藤正俊
    肝胆膵 81 625 - 633 2020年
  • WNT/β-catenin変異と免疫チェックポイント阻害剤の治療抵抗性—EOB-MRIのbiomarkerとしての可能性-. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）
    工藤正俊
    肝胆膵 81 613 - 624 2020年
  • 免疫チェックポイント阻害剤の単剤治療はなぜ限界があるのか. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）”
    工藤正俊
    肝胆膵 81 603 - 612 2020年
  • 特別座談会「免疫療法の登場により肝細胞癌の治療は新たなステージに」, 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—（免疫療法）”
    工藤正俊; 池田公史; 小笠原定久; 坂元亨宇
    肝胆膵 81 585 - 601 2020年
  • 超音波デジタル画像とAI診断
    西田直生志; 工藤正俊
    臨牀検査 64 850 - 857 2020年
  • Contrast-enhanced ultrasonography with sonazoid in hepatocellular carcinoma diagnosis
    Minami Y; Kudo M
    Hepatoma Research 6 46  2020年 [査読有り]
  • The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid
    Lee JY; Minami Y; Choi BI; Lee WJ; Chou YH; Jeong WK; Park MS; Kudo N; Lee MW; Kamata K; Iijima H; Kim SY; Numata K; Sugimoto K; Maruyama H; Sumino Y; Ogawa C; Kitano M; Joo I; Arita J; Liang JD; Lin HM; Nolsoe C; Gilja OH; Kudo M
    J Med Ultrasound 28 59 - 82 2020年 [査読有り]
  • Optimal corpping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumor
    Yamakawa M; Shiina T; Nishida N; Kudo M
    Jpn J Appl Phys 59 SKKE09  2020年 [査読有り]
  • Author response to: comment on: “Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma”
    Aoki T; Kubota K; Kubo S; Kudo M
    Br J Surg 107 470  2020年 [査読有り]
  • Aoki T, Kubota K, Kubo S, Kudo M
    Author response to; comment on; “Significance of; the surgical hepatic resection margin; in; atients with; a single hepatocellular carcinoma”
    Br J Surg 107 465  2020年 [査読有り]
  • Masatoshi Kudo
    Liver cancer 9 1 1 - 5 2020年01月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Takeshi Ogura; Takashi Tamura; Taira Kuroda; Toyoma Kaku; Yoshito Uenoyama; Chishio Noguchi; Hidefumi Nishikiori; Hajime Imai; Ryota Sagami; Nao Fujimori; Kazuhide Higuchi; Masatoshi Kudo; Yasutaka Chiba; Masayuki Kitano
    Therapeutic advances in gastroenterology 13 1756284820930964 - 1756284820930964 2020年 [査読有り]
     
    Background: Endoscopic treatment for malignant biliary obstruction (MBO) in patients bearing surgically altered anatomy (SAA) is not well-established. Although endoscopic ultrasound-guided biliary drainage (EUS-BD) has emerged as a new treatment option for MBO, limited data are available regarding the efficacy and safety of EUS-BD in patients with SAA. We conducted a multicenter prospective registration study to evaluate the efficacy and safety of EUS-BD in this population. Methods: This study involved 10 referral centers in Japan. Patients with SAA who were scheduled to receive EUS-BD for unresectable MBO between May 2016 and September 2018 were prospectively registered. The primary endpoint was technical success and the secondary outcomes were clinical success, procedure time, procedure-related adverse events (AEs), stent patency, and overall survival. Results: In total, 40 patients were prospectively enrolled. The surgical reconstruction methods were gastrectomy with Roux-en-Y reconstruction (47.5%), gastrectomy with Billroth-II reconstruction (15%), pancreaticoduodenectomy (27.5%), and hepaticojejunostomy with Roux-en-Y reconstruction (10%). EUS-BD was performed for primary biliary drainage in 31 patients and for rescue biliary drainage in nine patients. Transmural stenting alone (60%), antegrade stenting alone (5%), and a combination of the two techniques (35%) were selected for patients treated with EUS-BD. Technical and clinical success rates were 100% (95% confidence interval, 91.2-100.0%) and 95% (95% confidence interval, 83.1-99.4%), respectively. Mean procedure time was 36.5 min. Early AEs were noted in six patients (15%): three self-limited bile leak, one bile peritonitis, and two pneumoperitonea. Late AEs occurred in six patients (15%): one jejunal ulcer and five stent occlusions. Stent patency rate after 3 months of survival was 95.7% (22/23). Median overall survival was 96 days. Conclusion: EUS-BD for MBO in patients with SAA appears to be effective and safe not only as a rescue drainage technique after failed endoscopic retrograde cholangiography but also as a primary drainage technique. Clinical Trial Registration: UMIN000022101.
  • 三長 孝輔; 加藤 博也; 鎌田 英紀; 奥田 篤; 佐上 亮太; 橋本 宏明; 樋口 和秀; 千葉 康敬; 工藤 正俊; 北野 雅之; 小倉 健; 塩見 英之; 今井 元; 伯耆 徳之; 竹中 完; 錦織 英史; 山下 幸孝; 比佐 岳史
    日本消化器内視鏡学会雑誌 62 7 817 - 826 一般社団法人 日本消化器内視鏡学会 2020年 [査読有り]
     

    【背景と目的】超音波内視鏡下胆道ドレナージ術（Endoscopic ultrasound-guided biliary drainage；EUS-BD）には，endoscopic ultrasound-guided choledochoduodenostomy（EUS-CDS）およびendoscopic ultrasound-guided hepaticogastrostomy（EUS-HGS）の２つのアプローチ方法が存在する．本研究は，悪性胆道閉塞に対するこれらの２つの手技の有効性と安全性を比較検討した前向き無作為化試験である．

    【方法】ERCPが不成功であった悪性遠位胆道閉塞を有する患者を対象とし，EUS-CDS群およびEUS-HGS群に無作為に割り付けた．本研究は，2013年９月から2016年３月の期間に国内の高次医療機関９施設で行われた．主要評価項目は手技成功率とし，片側有意水準５％，非劣性マージンを15％と設定し，EUS-HGSのEUS-CDSに対する非劣性を検討した．副次的評価項目は，臨床的成功率，偶発症発生率，ステント開存期間，生存時間，および初期治療，二次治療を含めたEUS-BDの手技成功率とした．

    【結果】EUS-HGS群：24例，EUS-CDS群：23例の計47症例が登録された．手技成功率は，EUS-HGS群およびEUS-CDS群で，各々87.5％，82.6％であり，リスク差の90％信頼区間の下限は12.2％であった（P値＝0.0278）．臨床的成功率は，EUS-HGS群およびEUS-CDS群で，各々100％，94.7％であった（P値＝0.475）．偶発症発生率，ステント開存期間，生存期間には両群で差がなかった．EUS-BDの二次治療を含めた全体での手技成功率は，EUS-HGS群およびEUS-CDS群で各々100％，95.7％であった（P値＝0.983）．

    【結語】本研究により手技成功に関してEUS-HGSのEUS-CDSに対する非劣性が示された．いずれかの手技が困難な場合，他のEUS-BD手技に切り替えることが手技成功を高めることにつながる可能性がある．

  • Angel Alsina; Masatoshi Kudo; Arndt Vogel; Ann-Lii Cheng; Won Young Tak; Baek-Yeol Ryoo; Thomas R Jeffry Evans; Carlos López López; Bruno Daniele; Soamnauth Misir; Min Ren; Namiki Izumi; Shukui Qin; Richard S Finn
    Liver cancer 9 1 93 - 104 2020年01月 [査読有り]
     
    Introduction: Understanding the relationship between subsequent-line therapies and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Objective: In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up period. Methods: The follow-up period commenced at the first off-treatment visit after stopping the study medication and continued until study termination, withdrawal of consent, or death. OS and objective response rate were calculated for patients who did or did not receive poststudy anticancer medication for both treatment arms, as well as for the overall cohort. We investigated the subset of patients who responded to first-line treatment and subsequently received anticancer medication. Results: The OS for patients initially randomized to first-line lenvatinib (versus first-line sorafenib) and who then received any subsequent anticancer medication was 20.8 vs. 17.0 months (hazard ratio [HR] 0.87; 95% CI 0.67-1.14). The OS for patients who initially received first-line lenvatinib (versus first-line sorafenib) and who did not receive any subsequent anticancer medication was 11.5 vs. 9.1 months (HR 0.90; 95% CI 0.75-1.09). Responders to first-line lenvatinib who received subsequent medication had a median OS of 25.7 months (95% CI 18.5-34.6); responders to first line-sorafenib who received subsequent medication had a median OS of 22.3 months (95% CI 14.6-not evaluable). Conclusions: In this post hoc analysis of all patients in the REFLECT study who received subsequent anticancer medication, OS was increased compared with patients who did not receive any subsequent anticancer medication. In a subset analysis of responders who had received subsequent anticancer medication, use of first-line lenvatinib led to a slightly longer median OS; more research is needed on the benefits of using first-line lenvatinib compared with sorafenib.
  • Atsushi Hiraoka; Takashi Kumada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Keisuke Yokohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
    Liver cancer 9 1 73 - 83 2020年01月 [査読有り]
     
    Background/Aim: Post-progression treatment following tyrosine-kinase inhibitor (TKI) failure in patients with unresectable hepatocellular carcinoma (u-HCC) is important to prolong post-progression survival (PPS), which has a good correlation with overall survival (OS). This study aimed to elucidate the clinical features of progressive disease (PD) in patients treated with lenvatinib (LEN). Materials/Methods: From March 2018 to June 2019, 156 u-HCC patients with Child-Pugh A were enrolled (median age: 71 years, Child-Pugh score 5:6 = 105:51, BCLC A:B:C = 8:56:92, modified albumin-bilirubin grade (mALBI) 1:2a:2b = 59:42:55, past history of sorafenib:regorafenib = 57:17). Clinical features were retrospectively evaluated. Results: The median observation period was 8.5 months. Median OS was not obtained, while median time to decline to Child-Pugh B (CPB) was 11.4 months, median time to progression (TTP) was 8.4 months, and the period of LEN administration was 7.3 months. When we compared predictive values for time to decline to CPB based on Child-Pugh score and mALBI, values for Akaike information criterion (AIC) score and c-index of mALBI were superior as compared to Child-Pugh score (AIC: 592.3 vs. 599.7) (c-index: 0.655 vs. 0.597). Of the 73 patients with PD, 32 (43.8%) showed no decline to CPB or death. After excluding 3 without alpha-fetoprotein data at PD determination, only 14 (20.0%) of 70 showed REACH-2 eligibility. Non-mALBI 1/2a at the start of LEN was a significant risk factor for decline to CPB during LEN treatment (HR 2.552, 95% CI: 1.577-4.129; p < 0.001). Conclusion: Introduction of TKI therapy including LEN for u-HCC patients with better hepatic function (mALBI 1/2a: ALBI score ≤-2.27), when possible, increases the chance of undergoing post-progression treatment, which can improve PPS.
  • Shigenaga Matsui; Hiroshi Kashida; Kenji Nomura; Yoriaki Komeda; Masatoshi Kudo
    Adv Res Gastroentero Hepatol Volume 14 Issue 3 - January 2020 2020年01月 [査読有り]
  • Aoki T; Kubota K; Hasegawa K; Kubo S; Izumi N; Kokudo N; Sakamoto M; Shiina S; Takayama T; Nakashima O; Matsuyama Y; Murakami T; Kudo M
    Br J Surg 107 1 113 - 120 2020年01月 [査読有り]
     
    BACKGROUND: The impact of a wide surgical margin on the outcome of patients with hepatocellular carcinoma (HCC) has not been evaluated in relation to the type of liver resection performed, anatomical or non-anatomical. The aim of this study was to evaluate the impact of surgical margin status on outcomes in patients undergoing anatomical or non-anatomical resection for solitary HCC. METHODS: Data from patients with solitary HCC who had undergone non-anatomical partial resection (Hr0 group) or anatomical resection of one Couinaud segment (HrS group) between 2000 and 2007 were extracted from a nationwide survey database in Japan. Overall and recurrence-free survival associated with the surgical margin status and width were evaluated in the two groups. RESULTS: A total of 4457 patients were included in the Hr0 group and 3507 in the HrS group. A microscopically positive surgical margin was associated with poor overall survival in both groups. A negative but 0-mm surgical margin was associated with poorer overall and recurrence-free survival than a wider margin only in the Hr0 group. In the HrS group, the width of the surgical margin was not associated with patient outcome. CONCLUSION: Anatomical resection with a negative 0-mm surgical margin may be acceptable. Non-anatomical resection with a negative 0-mm margin was associated with a less favourable survival outcome.
  • Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Hidenori Toyoda; Hideko Ohama; Akemi Tsutsui; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Shinichiro Nakamura; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
    Oncology 98 5 295 - 302 2020年 [査読有り]
     
    BACKGROUND/AIM: Few studies have examined the details of nutritional status in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing systemic chemotherapy with lenvatinib. We evaluated the prognostic/predictive value of nutritional status using Onodera's prognostic nutritional index (O-PNI) for overall survival among patients with u-HCC treated with lenvatinib. METHODS: Three-hundred and seventy-five u-HCC patients treated with lenvatinib were enrolled (median age 72 years; Child-Pugh class A/B/C: n = 312/60/3; BCLC stage A/B/C/D: n = 2/159/212/2). We examined median survival time (MST) and time to progression (TTP) in all patients (n = 375), prognosis according to the O-PNI (high/low: >40/≤40) in 298 patients with lymphocyte findings, and the prognostic/predictive values of Child-Pugh stage, albumin-bilirubin (ALBI)/modified ALBI (mALBI) grade, and O-PNI for Chemotherapy grade (OPNIC grade 1/2/3: O-PNI >40/≤40 to >36/≤36). RESULTS: The MST and TTP were 16.6 and 8.0 months, respectively. The MST and TTP according to the O-PNI (>40/≤40) were "not reached" (NR)/12.4 months (p < 0.001) and 10.0/6.1 months (p = 0.012), respectively. There was a good correlation noted between ALBI score and O-PNI (r = -0.939, p < 0.001). The predictive value of the O-PNI for mALBI grade 2a was 36.0 (specificity/sensitivity = 0.894/0.942; area under the curve [AUC] = 0.978), while that for mALBI grade 1 was 39 (specificity/sensitivity = 0.920/0.929; AUC = 0.972), which was very similar to a high O-PNI. The MST analyzed with the OPNIC in the 298 patients was NR/16.2/10.4 months for OPNIC grade 1/2/3 (p < 0.001), respectively, and the c-index was 0.632, the same as that for mALBI grade (0.632), while that for Child-Pugh class was 0.571. CONCLUSIONS: OPNIC grading might have a potential for easy substitution of mALBI grading. A good nutritional status (OPNIC grade 1) or mALBI grade 1 is the best indication for lenvatinib use, while with an OPNIC grade 3, lenvatinib might be not suitable.
  • Masahiro Morita; Chikara Ogawa; Akina Omura; Teruyo Noda; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Hiroshi Seno; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Internal medicine (Tokyo, Japan) 59 4 471 - 477 2020年 [査読有り]
     
    Objective The usefulness of contrast-enhanced ultrasonography (CEUS) for making decisions in the treatment of liver abscess is unknown. Methods We evaluated the internal blood flow in the arterial-predominant phase by CEUS using Sonazoid® in 21 patients. The stain area rate was evaluated in maximum parting plane of abscess in CEUS. Patients were divided into two groups: the vascular phase enhancement (VE) group, in which ≥50% of the abscess cavity was enhanced (12 patients), and the vascular phase non-enhancement (VNE) group, in which <50% of the abscess cavity was enhanced (9 patients). The rate of patients who were cured by conservative treatment alone was examined in both groups. The defect rate of all liver abscesses in the post-vascular phase was also evaluated. Results In the VE group, improvement by conservative treatment alone was obtained in 11 out of 12 patients (91.7%), while in the VNE group, improvement by conservative treatment alone was obtained in only 1 out of 9 patients (11.1%), a significant difference (p<0.001). In the VE group, one patient did not improve with conservative treatment alone because the abscess ruptured near the liver surface. In the VE group, the abscess size was smaller than in the VNE group. By examining the defect rate in the post-vascular phase, it was found that 16 out of 21 patients (76.2%) showed 71% or more defects. Conclusion The enhancement rate in the arterial-predominant phase of CEUS was considered useful for determining the treatment approach for liver abscess.
  • Yasunori Minami; Tomohiro Minami; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 50 1 67 - 74 2020年01月 [査読有り]
     
    AIM: To retrospectively investigate the potential benefit of ultrasound-ultrasound (US-US) overlay fusion guidance for local controllability of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). METHODS: Patients (n = 101) with 121 HCCs (mean ± SD, 1.8 ± 0.7 cm) who underwent RFA guided by US-US overlay fusion were included in the retrospective study. By overlaying pre/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. The ablative margin could thereby be evaluated three-dimensionally during the RFA procedure. As a control group, all 325 patients with 453 HCCs who underwent conventional RFA during the same study period were selected. RESULTS: The total number of RF needle insertions per tumor for ablation was significantly more in the US overlay fusion group (mean 1.9 vs. 1.2; P < 0.01). The technical success rates of ablation after a single session were 100% (101/101) and 96.6% (314/325) for the US overlay fusion group and the control group, respectively. For early assessment of RFA response, 5-mm safety margins were achieved in 89.3% (108/121) and 47.0% (213/453) of nodules in the US overlay fusion group and the control group, respectively (P < 0.01). During the follow-up period (median 19 months), the 2-year local tumor progression rates were 0.8% (1/121) and 6.0% (27/453) in the US overlay fusion group and the control group, respectively (P = 0.022, log-rank test). CONCLUSIONS: US-US overlay fusion guidance can be highly effective for safety margin achievement in RFA for HCC, providing a lower risk of local tumor progression.
  • Thomas Yau; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Yoon-Koo Kang; Ming-Mo Hou; Kazushi Numata; Winnie Yeo; Akhil Chopra; Masafumi Ikeda; Ryoko Kuromatsu; Michihisa Moriguchi; Yee Chao; Huanyu Zhao; Jeffrey Anderson; Christine Dela Cruz; Masatoshi Kudo
    Journal of hepatology 71 6 1278 - 1278 2019年12月 [査読有り]
  • 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊
    日本臨床 別冊 消化管症候群I 152 - 155 (株)日本臨床社 2019年12月
  • Peter R Galle; Friedrich Foerster; Masatoshi Kudo; Stephen L Chan; Josep M Llovet; Shukui Qin; William R Schelman; Sudhakar Chintharlapalli; Paolo B Abada; Morris Sherman; Andrew X Zhu
    Liver international : official journal of the International Association for the Study of the Liver 39 12 2214 - 2229 2019年12月 [査読有り]
     
    Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths globally due, in part, to the majority of patients being diagnosed with intermediate or advanced stage disease. Our increased understanding of the heterogeneous molecular pathogenesis of HCC has led to significant developments in novel targeted therapies. Despite these advances, there remains a high unmet need for new treatment options. HCC is a complex disease with multiple pathogenic mechanisms caused by a variety of risk factors, making it difficult to characterize with a single biomarker. In fact, numerous biomarkers have been studied in HCC, but alpha-fetoprotein (AFP) remains the most widely used and accepted serum marker since its discovery over 60 years ago. This review summarizes the most relevant studies associated with the regulation of AFP at the gene and protein levels; the pathophysiology of AFP as a pro-proliferative protein; and the correlation of AFP with molecular HCC subclasses, the vascular endothelial growth factor pathway and angiogenesis. Also described are the historical and current uses of AFP for screening and surveillance, diagnosis, its utility as a prognostic and predictive biomarker and its role as a tumour antigen in HCC. Taken together, these data demonstrate the relevance of AFP for patients with HCC and identify several remaining questions that will benefit from future research.
  • Mamoru Takenaka; Kosuke Minaga; Tomoe Yoshikawa; Ayana Okamoto; Atsushi Nakai; Shunsuke Omoto; Masatoshi Kudo
    Endoscopy 51 12 E362-E363  2019年12月 [査読有り]
  • Ken Kamata; Tomohiro Watanabe; Kosuke Minaga; Akane Hara; Tomoe Yoshikawa; Ayana Okamoto; Kentaro Yamao; Mamoru Takenaka; Ah-Mee Park; Masatoshi Kudo
    International immunology 31 12 795 - 809 2019年11月 [査読有り]
     
    Autoimmune pancreatitis (AIP) is a pancreatic manifestation of a newly proposed disease entity, IgG4-related disease (IgG4-RD), characterized by enhanced IgG4 antibody responses and involvement of multiple organs. We have previously reported that innate immune activation contributes to the development of AIP and IgG4-RD, as these diseases are characterized by the production of IFN-α and IL-33 by plasmacytoid dendritic cells (pDCs) that mediate chronic fibroinflammatory responses. In this study, we investigated the roles played by innate immunity against intestinal microflora in experimental AIP induced in MRL/MpJ mice by repeated administrations of 100 µg of polyinosinic-polycytidylic acid [poly (I:C)]. Bowel sterilization with a broad spectrum of antibiotics inhibited pancreatic accumulation of pDCs producing IFN-α and IL-33, and thereby suppressed the development of AIP. Mice treated with 10 µg of poly (I:C) developed severe AIP equivalent to that induced by 100 µg of poly (I:C) upon co-housing with mice treated with 100 µg of poly (I:C). Fecal microbiota transplantation (FMT) from donor mice treated with 100 µg of poly (I:C) led to the development of severe AIP in the recipient mice upon injection with 10 µg of poly (I:C). Induction of severe AIP in mice with 10 µg of poly (I:C) was associated with pancreatic accumulation of pDCs producing IFN-α and IL-33 in the co-housing and FMT experiments. These data collectively suggest that innate immune responses against intestinal microflora are involved in the development of experimental AIP, and that intestinal dysbiosis increases sensitivity to experimental AIP via activation of pDCs.
  • 【超音波TOPICS2019〜第45回超音波ドプラ・新技術研究会報告集〜】eFLOWを用いた後血管相のdefectの評価の初期経験
    小川 力; 盛田 真弘; 野村 貴子; 工藤 正俊
    Rad Fan 17 15 24 - 26 (株)メディカルアイ 2019年11月 
    今回日立製作所のARIETTA850の新しいversionで搭載された、eFLOWを用いた後血管相の評価の初期経験を報告する。同テクノロジーは容易な操作で、明瞭な後血管でのdefectの評価が可能であり、また分化度の違いによりdefectの程度に違いが認められる可能性も示唆された。(著者抄録)
  • 大本 俊介; 竹中 完; 工藤 正俊
    胆と膵 40 臨増特大 1163 - 1168 医学図書出版(株) 2019年11月 
    重症急性膵炎の死亡率は10.1%と高率であり、基本的治療のみならず集中治療やOption(特殊治療)の実施を検討する必要がある。集中治療には、臓器不全対策、輸液管理、栄養管理、早期経腸栄養、感染予防、abdominal compartment syndrome(ACS)対策があげられ、Optionとしては、動注治療や血液浄化があげられる。臓器不全対策は、発症早期の高度の全身性炎症反応症候群(systemic inflammatory response syndrome:SIRS)と発症後期のbacterial translocationが播種性血管内凝固症(disseminated intravascular coagulation:DIC)、臓器不全の誘引となることが知られており、この両者の病態を検討することが重要である。SIRS対策としては血液浄化と動注治療があり、感染対策として、重症例に対する予防的抗菌薬投与、早期経腸栄養が実施される。腹腔内圧を測定し、ACSを予防し適切な加療を行うことが膵炎の予後改善に寄与する可能性がある。DIC合併膵炎の治療として遺伝子組み換え型ヒト可溶性トロンボモジュリン(recombinant human soluble thrombomodulin:rTM)が有用である可能性が示唆されており今後のさらなる検討が期待される。(著者抄録)
  • 山雄 健太郎; 竹中 完; 工藤 正俊
    日本消化器病学会雑誌 116 臨増大会 A573 - A573 (一財)日本消化器病学会 2019年11月
  • 鑑別診断において造影超音波が有用であった多血性の肝内胆管癌(腫瘤形成型)の1例
    友岡 瑞樹; 盛田 真弘; 南 康範; 依田 広; 南 知宏; 青木 智子; 田北 雅弘; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 60 Suppl.3 A926 - A926 (一社)日本肝臓学会 2019年11月 [査読有り]
  • Masatoshi Kudo
    Liver cancer 8 6 413 - 426 2019年11月 [査読有り]
  • Mamoru Takenaka; Ken Kamata; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 6 718 - 718 2019年11月 [査読有り]
  • Masatoshi Kudo; Kazuomi Ueshima; Yasutaka Chiba; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Yasuaki Arai
    Liver cancer 8 6 505 - 519 2019年11月 [査読有り]
     
    Objective: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective response by mRECIST and OS in the sorafenib group, in the combination group, and in all patients in the SILIUS trial. Methods: Association between objective response and OS in patients treated with sorafenib (n = 103) or combination (n = 102) and all patients (n = 205) were analyzed. The median OS of responders was compared with that of non-responders. Landmark analyses were performed according to objective response at several fixed time points, as sensitivity analyses, and the effect on OS was evaluated by Cox regression analysis with objective response as a time-dependent covariate, with other prognostic factors. Results: In the sorafenib group, OS of responders (n = 18) was significantly better than that of non-responders (n = 78) (p < 0.0001), where median OS was 27.2 (95% CI, 16.0-not reached) months for responders and 8.9 (95% CI, 6.5-12.6) months for non-responders. HRs from landmark analyses at 4, 6, and 8 months were 0.45 (p = 0.0330), 0.37 (p = 0.0053), and 0.36 (p = 0.0083), respectively. Objective response was an independent predictor of OS based on unstratified Cox regression analyses. In the all patients and the combination group, similar results were obtained. Conclusions: In the SILIUS trial, objective response by sorafenib assessed by mRECIST is an independent prognostic factor for OS in patients with HCC.
  • Mamoru Takenaka; Kentaro Yamao; Masatoshi Kudo
    Clinical endoscopy 52 6 523 - 524 2019年11月 [査読有り]
  • Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka Matsuyama
    Hepatology research : the official journal of the Japan Society of Hepatology 49 10 1109 - 1113 2019年10月 [査読有り]
     
    The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development, and Evaluation system, which was published in October 2017 in Japanese. New or revised recommendations were described, herein, with a special reference to the surveillance, diagnostic, and treatment algorithms.
  • Thomas R Jeffry Evans; Masatoshi Kudo; Richard S Finn; Kwang-Hyub Han; Ann-Lii Cheng; Masafumi Ikeda; Silvija Kraljevic; Min Ren; Corina E Dutcus; Fabio Piscaglia; Max W Sung
    British journal of cancer 121 7 625 - 625 2019年10月 [査読有り]
     
    This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly.An amendment to this paper has been published and can be accessed via a link at the top of the paper.
  • DLBCLに発症したリンパ管拡張症に対してステロイド投与、食事療法が奏効した1症例
    大塚 康生; 米田 頼晃; 正木 翔; 筑後 孝章; 吉川 馨介; 高島 耕太; 橋本 有人; 山田 光成; 本庶 元; 永井 知行; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 111回 91 - 91 日本消化器病学会-近畿支部 2019年10月
  • 福永 朋洋; 水野 成人; 松村 まり子; 高田 隆太郎; 河野 匡志; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 工藤 正俊
    胆道 33 3 636 - 636 日本胆道学会 2019年10月
  • 肝細胞腺腫の1例
    山根 雅智; 秦 康倫; 松村 まり子; 福永 朋洋; 高田 隆太郎; 河野 匡志; 木下 大輔; 奥田 英之; 川崎 俊彦; 水野 成人; 日向 聖; 石川 原; 井上 雅智; 若狭 朋子; 太田 善夫; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 111回 76 - 76 日本消化器病学会-近畿支部 2019年10月
  • Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み
    西田 直生志; 工藤 正俊
    肝臓 60 Suppl.2 A566 - A566 (一社)日本肝臓学会 2019年10月 [査読有り]
  • EUS施行時のプロポフォール持続注入による鎮静の有用性の検討
    岡本 彩那; 鎌田 研; 竹中 完; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 工藤 正俊
    Gastroenterological Endoscopy 61 Suppl.2 2182 - 2182 (一社)日本消化器内視鏡学会 2019年10月 [査読有り]
  • Kudo Masatoshi; Ueshima Kazuomi; Chan Stephen L; Minami Tomohiro; Chishina Hirokazu; Aoki Tomoko; Takita Masahiro; Hagiwara Satoru; Minami Yasunori; Ida Hiroshi; Takenaka Mamoru; Sakurai Toshiharu; Watanabe Tomohiro; Morita Masahiro; Ogawa Chikara; Wada Yoshiyuki; Ikeda Masafumi; Ishii Hiroshi; Izumi Namiki; Nishida Naoshi
    HEPATOLOGY 70 133A - 134A 2019年10月 [査読有り]
  • Kosuke Minaga; Tomoe Yoshikawa; Yukitaka Yamashita; Hiroko Akamatsu; Maiko Ikenouchi; Tatsuya Ishii; Hisakazu Matsumoto; Hiroyoshi Iwagami; Yasuki Nakatani; Keiichi Hatamaru; Mamoru Takenaka; Takuji Akamatsu; Yoshito Uenoyama; Tomohiro Watanabe; Kazuo Ono; Yasutaka Chiba; Masatoshi Kudo
    Digestive Diseases and Sciences 64 10 2982 - 2991 2019年10月 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Yoriaki Komeda; Masatoshi Kudo
    Journal of medical virology 91 10 1804 - 1810 2019年10月 [査読有り]
     
    Tenofovir alafenamide (TAF) is a newly developed prodrug of tenofovir (TFV). We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study. There were no significant differences in the alterations in the serum levels of HBs antigen (HBsAg) level between the ETV continuation and the TAF switching groups at 24 or 48 weeks. We also examined the effect of baseline HBsAg level on the decrease of HBsAg during the treatment; in the TAF switching group, the decrease of HBsAg level at 48 weeks was more significant in patients with low baseline HBsAg (<800 IU/mL) than those with high baseline HBsAg ( >800 IU/mL) (change of HBsAg; - 0.029 vs - 0.132 for high and low baseline HBsAg, respectively, P = .007). Also, the effect on renal function was found to be comparable between the TAF switch group and the ETV continuation group. In this study, switching from ETV to TAF may represent higher efficacy for a decrease of HBsAg than a continuation of ETV among the patients with low baseline HBsAg level.
  • Masatoshi Kudo
    Liver cancer 8 5 299 - 311 2019年10月 [査読有り]
  • Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
    Liver cancer 8 5 312 - 325 2019年10月 [査読有り]
     
    Background: Because of the rapid progression of antiviral treatment options and the increasing frequency of nonviral-related hepatocellular carcinoma (HCC) due to the aging of society, the number of HCC patients with good hepatic function has been increasing and a more detailed method of assessment of hepatic function is needed. The Child-Pugh classification (CP) is used worldwide as an assessment tool for hepatic reserve function, even though it has some weaknesses. Recently, the albumin-bilirubin (ALBI) grade, calculated based on only albumin and total bilirubin, was proposed, and recent investigations have suggested that ALBI grade instead of CP can be used as an assessment tool for hepatic function as part of therapeutic strategies such as Barcelona Clinic Liver Cancer staging and a practical guideline presented by the Japan Society of Hepatology as well for total staging scoring systems. There has been an increasing number of reports showing that it has better capability than CP for HCC patients who undergo not only curative but also palliative treatments. Transcatheter arterial chemoembolization (TACE) is a major palliative treatment used for unresectable HCC, and the idea of TACE-refractory status has been proposed to indicate the possibility of switching to a tyrosine kinase inhibitor (TKI). However, TKI administration requires a maintained hepatic reserve function, thus the importance of assessment of hepatic function in patients undergoing TACE treatments has increased. We consider that ALBI grade might also play a significant role as part of a detailed assessment of relative changes in hepatic function during treatment. In this review, we evaluate the practical usefulness of ALBI grade for assessing hepatic function and HCC prognosis. Key Message: A detailed assessment of hepatic function is required for recent HCC therapeutic strategies. ALBI grade may be a powerful tool to improve treatment options for affected patients.
  • Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Susumu Eguchi; Tatsuya Yamashita; Masatoshi Kudo
    Liver cancer 8 5 403 - 411 2019年10月 [査読有り]
     
    Background/Aim: Adequate assessment of transcatheter arterial chemoembolization (TACE)-refractory status has become more important for switching treatment in intermediate-stage (BCLC-B) hepatocellular carcinoma (HCC) patients treated with TACE. The usefulness of a previously proposed tumor marker score for predicting prognosis of BCLC-B HCC patients treated with TACE was investigated. Methods: Using a nationwide database, we examined the records of 1,306 naïve BCLC-B HCC with Child-Pugh A who were treated from 2001 to 2007, after excluding those with missing data (hepatic function or tumor markers) or cases with a single large tumor. Alpha-fetoprotein (AFP) ≥100 ng/mL, fucosylated AFP (AFP-L3) ≥10%, and des-gamma-carboxy prothrombin ≥100 mAU/mL were markers used to define positive cases. The number of positive tumor markers was used as a prognostic score, and its predictive value was evaluated in a retrospective manner. Results: Median survival time became shorter along with increased score (0, 1, ≥2 = 4.8, 3.8, 3.2 years, respectively; p < 0.01). Tumor marker score (≥2; hazard ratio [HR] 1.675, 95% confidence interval [CI] 1.372-2.044, p < 0.001), serum levels of albumin (≥3.5 g/dL; HR 0.726, 95% CI 0.528-0.997, p = 0.048), and up-to-7 criteria (HR 1.673, 95% CI 1.400-2.000, p < 0.001) were significant prognostic factors for death in the Cox hazard multivariate analysis. Conclusion: Tumor marker score had a useful predictive prognostic value in BCLC-B HCC treated with TACE. Especially in patients with a tumor marker score of 2 or greater, a poor therapeutic response should be expected, and appropriate judgement of TACE-refractory status is necessary.
  • Daizen Hirata; Hiroshi Kashida; Mineo Iwatate; Tomomasa Tochio; Akira Teramoto; Yasushi Sano; Masatoshi Kudo
    World journal of clinical cases 7 18 2658 - 2665 2019年09月 [査読有り]
     
    Five years have passed since the Japan Narrow Band Imaging Expert Team (JNET) classification was proposed in 2014. However, the diagnostic performance of this classification has not yet been established. We conducted a retrospective study and a systematic search of Medical Literature Analysis and Retrieval System On-Line. There were three retrospective single center studies about the diagnostic performance of this classification. In order to clarify this issue, we reviewed our study and three previous studies. This review revealed the diagnostic performance in regards to three important differentiations. (1) Neoplasia from non-neoplasia; (2) malignant neoplasia from benign neoplasia; and (3) deep submucosal invasive cancer (D-SMC) from other neoplasia. The sensitivity in differentiating neoplasia from non-neoplasia was 98.1%-99.8%. The specificity in differentiating malignant neoplasia from benign neoplasia was 84.7%-98.2% and the specificity in the differentiation D-SMC from other neoplasia was 99.8%-100.0%. This classification would enable endoscopists to identify almost all neoplasia, to appropriately determine whether to perform en bloc resection or not, and to avoid unnecessary surgery. This article is the first review about the diagnostic performance of the JNET classification. Previous reports about the diagnostic performance have all been retrospective single center studies. A large-scale prospective multicenter evaluation study is awaited for the validation.
  • Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Atsushi Kitani; Masaki Tajima; Ivan J Fuss; Masatoshi Kudo; Warren Strober
    International immunology 31 10 669 - 683 2019年09月 [査読有り]
     
    Previous studies have shown that inhibition of receptor-interacting serine/threonine kinase (RICK) (also known as RIP2) results in amelioration of experimental colitis. This role has largely been attributed to nucleotide-binding oligomerization domain 2 (NOD2) signaling since the latter is considered a major inducer of RICK activation. In this study, we explored the molecular mechanisms accounting for RICK-mediated inhibition of inflammatory bowel disease (IBD). In an initial series of studies focused on trinitrobenzene sulfonic acid (TNBS)-colitis and dextran sodium sulfate (DSS)-colitis we showed that down-regulation of intestinal RICK expression in NOD2-intact mice by intra-rectal administration of a plasmid expressing RICK-specific siRNA was accompanied by down-regulation of pro-inflammatory cytokine responses in the colon and protection of the mice from experimental colitis. Somewhat surprisingly, intra-rectal administration of RICK-siRNA also inhibited TNBS-colitis and DSS-colitis in NOD2-deficient and in NOD1/NOD2-double deficient mice. In complementary studies of humans with IBD we found that expression of RICK, cellular inhibitor of apoptosis protein 2 (cIAP2) and downstream signaling partners were markedly increased in inflamed tissue of IBD compared to controls without marked elevations of NOD1 or NOD2 expression. In addition, the increase in RICK expression correlated with disease activity and pro-inflammatory cytokine responses. These studies thus suggest that NOD1- or NOD2-independenent activation of RICK plays a major role in both murine experimental colitis and human IBD.
  • 潰瘍性大腸炎関連大腸癌の予防における内視鏡的粘膜下層剥離術の役割(Role of endoscopic submucosal dissection for ulcerative colitis-associated cancer prevention)
    櫻井 俊治; 坂井 和子; 永井 知行; 樫田 博史; 筑後 孝章; 根津 理一郎; 西尾 和人; 工藤 正俊
    日本癌学会総会記事 78回 P - 3296 2019年09月
  • Ogura T; Takenaka M; Shiomi H; Goto D; Tamura T; Hisa T; Kato H; Nishioka N; Minaga K; Masuda A; Onoyama T; Kudo M; Higuchi K; Kitano M
    Endoscopic ultrasound 8 6 398 - 403 2019年09月 [査読有り]
  • Thomas Yau; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Yoon-Koo Kang; Ming-Mo Hou; Kazushi Numata; Winnie Yeo; Akhil Chopra; Masafumi Ikeda; Ryoko Kuromatsu; Michihisa Moriguchi; Yee Chao; Huanyu Zhao; Jeffrey Anderson; Christine Dela Cruz; Masatoshi Kudo
    Journal of hepatology 71 3 543 - 552 2019年09月 [査読有り]
     
    BACKGROUND & AIMS: Nivolumab, an immune checkpoint inhibitor, is approved in several countries to treat sorafenib-experienced patients with HCC, based on results from the CheckMate 040 study (NCT01658878). Marked differences exist in HCC clinical presentation, aetiology, treatment patterns and outcomes across regions. This analysis assessed the safety and efficacy of nivolumab in the Asian cohort of CheckMate 040. METHODS: CheckMate 040 is an international, multicentre, open-label, phase I/II study of nivolumab in adults with advanced HCC, regardless of aetiology, not amenable to curative resection or local treatment and with/without previous sorafenib treatment. This analysis included all sorafenib-experienced patients in the intent-to-treat (ITT) overall population and Asian cohort. The analysis cut-off date was March 2018. RESULTS: There were 182 and 85 patients in the ITT population and Asian cohort, respectively. In both populations, most patients were older than 60 years, had BCLC (Barcelona Clinic Liver Cancer) Stage C disease, and had received previous systemic therapy. A higher percentage of Asian patients had HBV infections, extrahepatic metastases and prior therapies. Median follow-up was 31.6 and 31.3 months for the ITT and Asian patients, respectively. Objective response rates were 14% and 15% in the ITT population and Asian cohort, respectively. In the Asian cohort, patients with HBV, HCV or those who were uninfected had objective response rates of 13%, 14% and 21%, respectively. The median duration of response was longer in the ITT (19.4 months) vs. Asian patients (9.7 months). Median overall survival was similar between the ITT (15.1 months) and Asian patients (14.9 months), and unaffected by aetiology in Asian patients. The nivolumab safety profile was similar and manageable across both populations. CONCLUSION: Nivolumab safety and efficacy are comparable between sorafenib-experienced ITT and Asian patients. LAY SUMMARY: The CheckMate 040 study evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy. This subanalysis of the data showed that treatment responses and safety in patients in Asia were similar to those of the overall treatment population, providing support for nivolumab as a treatment option for these patients. Clinical trial number: NCT01658878.
  • 難治性腹水に対して行われたデンバーシャント術の報告
    青木 智子; 田北 雅弘; 大塚 康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 鶴崎 正勝; 工藤 正俊
    日本門脈圧亢進症学会雑誌 25 3 146 - 146 (一社)日本門脈圧亢進症学会 2019年09月 [査読有り]
  • Ayana Okamoto; Kosuke Minaga; Mamoru Takenaka; Tomoe Yoshikawa; Ken Kamata; Kentaro Yamao; Masatoshi Kudo
    Endoscopy 51 9 E255-E256  2019年09月 [査読有り]
  • Masatoshi Kudo; Masafumi Ikeda; Kazuomi Ueshima; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Kiyoshi Hasegawa; Junji Furuse; Shiro Miyayama; Takamichi Murakami; Tatsuya Yamashita; Norihiro Kokudo
    Hepatology research : the official journal of the Japan Society of Hepatology 49 9 981 - 989 2019年09月 [査読有り]
     
    Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19-9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non-target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.
  • Mamoru Takenaka; Atsushi Nakai; Masatoshi Kudo
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 5 e99-e100 - e100 2019年09月 [査読有り]
  • Kosuke Minaga; Takeshi Ogura; Hideyuki Shiomi; Hajime Imai; Noriyuki Hoki; Mamoru Takenaka; Hidefumi Nishikiori; Yukitaka Yamashita; Takeshi Hisa; Hironari Kato; Hideki Kamada; Atsushi Okuda; Ryota Sagami; Hiroaki Hashimoto; Kazuhide Higuchi; Yasutaka Chiba; Masatoshi Kudo; Masayuki Kitano
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 5 575 - 582 2019年09月 [査読有り]
     
    BACKGROUND AND AIM: Endoscopic ultrasound-guided biliary drainage (EUS-BD) can be carried out by two different approaches: choledochoduodenostomy (CDS) and hepaticogastrostomy (HGS). We compared the efficacy and safety of these approaches in malignant distal biliary obstruction (MDBO) patients using a prospective, randomized clinical trial. METHODS: Patients with malignant distal biliary obstruction after failed endoscopic retrograde cholangiopancreatography were randomly selected for either CDS or HGS. The procedures were carried out at nine tertiary centers from September 2013 to March 2016. Primary endpoint was technical success rate, and the noninferiority of HGS to CDS was examined with a one-sided significance level of 5%, where the noninferiority margin was set at 15%. Secondary endpoints were clinical success, adverse events (AE), stent patency, survival time, and overall technical success including alternative EUS-BD procedures. RESULTS: Forty-seven patients (HGS, 24; CDS, 23) were enrolled. Technical success rates were 87.5% and 82.6% in the HGS and CDS groups, respectively, where the lower limit of the 90% confidence interval of the risk difference was -12.2% (P = 0.0278). Clinical success rates were 100% and 94.7% in the HGS and CDS groups, respectively (P = 0.475). Overall AE rate, stent patency, and survival time did not differ between the groups. Overall technical success rates were 100% and 95.7% in the HGS and CDS groups, respectively (P = 0.983). CONCLUSIONS: This study suggests that HGS is not inferior to CDS in terms of technical success. When one procedure is particularly challenging, readily switching to the other could increase technical success.
  • 上嶋 一臣; 工藤 正俊
    肝・胆・膵 79 2 227 - 231 (株)アークメディア 2019年08月
  • Yasunori Minami; Masatoshi Kudo
    Hepatobiliary surgery and nutrition 8 4 414 - 416 2019年08月 [査読有り]
  • Takaguchi, Koichi; Toyoda, Hidenori; Tsutsui, Akemi; Suzuki, Yoshiyuki; Nakamuta, Makoto; Imamura, Michio; Senoh, Tomonori; Nagano, Takuya; Tada, Toshifumi; Tachi, Yoshihiko; Hiraoka, Atsushi; Michitaka, Kojiro; Shibata, Hiroshi; Joko, Kouji; Okubo, Hironao; Tsuji, Kunihiko; Takaki, Shintaro; Watanabe, Tsunamasa; Ogawa, Chikara; Chayama, Kazuaki; Kumada, Takashi; Kudo, Masatoshi; Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY 54 8 742 - 751 SPRINGER JAPAN KK 2019年08月 [査読有り]
     
    BackgroundThe virological efficacy and safety of the direct-acting antiviral (DAA) regimen consisting of daclatasvir, asunaprevir, and beclabuvir (DCV/ASV/BCV) for patients chronically infected with hepatitis C virus (HCV) genotype 1 have not been previously evaluated in Japanese real-world settings.MethodsIn a Japanese nationwide multicenter study, the rate of sustained virologic response (SVR) and safety were analyzed in 91 patients who started the DCV/ASV/BCV regimen between November 2016 and July 2017. SVR rates were compared based on baseline patient characteristics.ResultsMore than 60% of patients had a history of failure to achieve SVR with interferon (IFN)-free DAA therapy. Overall, 50 of 91 patients (54.9%) achieved SVR. Multivariate analysis identified a history of failure with IFN-free DAA therapy and pretreatment HCV RNA levels as factors significantly associated with treatment failure. Whereas the SVR rate in patients without a history of IFN-free DAA therapy was 91.7% (33 of 36 patients), it was only 30.9% (17 of 55 patients) among patients with a history of IFN-free DAA therapy. The rate of discontinuation due to an adverse event was 4.4%.ConclusionsMany patients tre
  • Hidekazu Tanaka; Tomohiro Watanabe; Tomoyuki Nagai; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Masatoshi Kudo
    Clinical Journal of Gastroenterology 12 4 316 - 319 2019年08月 [査読有り]
  • Hidekazu Tanaka; Ken Kamata; Mamoru Takenaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yasutaka Chiba; Masayuki Kitano; Masatoshi Kudo
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 51 8 1130 - 1134 2019年08月 [査読有り]
     
    BACKGROUND AND AIMS: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is used for the diagnosis of pancreatic cancer (PC). Here, we examined the usefulness of CH-EUS for evaluating therapeutic responses in PC. METHODS: The study included 23 patients with PC who received chemotherapy. Patients underwent contrast-enhanced computed tomography (CE-CT) and CH-EUS before chemotherapy and at the time of evaluation of the therapeutic response. Patients with a ≧50% reduction in serum carbohydrate antigen 19-9 levels after chemotherapy were defined as "super responders". The incidence of an avascular area in the tumor on CH-EUS after chemotherapy was compared between "super responders" and non-super responders. RESULTS: Nine patients were included in the "super responders" group.Tumor reduction rates did not differ significantly between CE-CT and CH-EUS in the "super responders". The appearance of an avascular area was detected in 7 of 9 super responders (77.8%) and in 4 of 14 non-super responders (28.6%), and the difference was significant (P = 0.036). The mean survival time of patients with an avascular area after chemotherapy was longer than that of without an avascular area. CONCLUSIONS: Detection of avascular areas by CH-EUS after chemotherapy may predict long-term survival of patients with PC.
  • Shusuke Uchida; Naoki Oiso; Yoriaki Komeda; Masatoshi Kudo; Akira Kawada
    European journal of dermatology : EJD 29 4 444 - 445 2019年08月 [査読有り]
  • Masatoshi Kudo; Kazuomi Ueshima; Stephan Chan; Tomohiro Minami; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Naoshi Nishida
    Cancers 11 8 2019年07月 [査読有り]
     
    Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients currently remains an unmet need in clinical practice. Here, we performed a proof-of-concept study that lenvatinib may be a more favorable treatment option over TACE as an initial treatment in intermediate-stage HCC patients with large or multinodular tumours exceeding the up-to-seven criteria. This proof-of-concept study included 642 consecutive patients with HCC initially treated with lenvatinib or conventional TACE (cTACE) between January 2006 and December 2018. Of these patients, 176 who received lenvatinib or cTACE as an initial treatment and met the eligibility criteria (unresectable, beyond the up-to-seven criteria, no prior TACE/systemic therapy, no vascular invasion, no extrahepatic spread and Child-Pugh A liver function) were selected for the study. Propensity score matching was used to adjust for patient demographics. After propensity-score matching, the outcome of 30 patients prospectively treated with lenvatinib (14 in clinical trials, one in an early access program and 15 in real world settings) and 60 patients treated with cTACE as the initial treatment was compared. The change of albumin-bilirubin (ALBI) score from baseline to the end of treatment were -2.61 to -2.61 for 30 patients in the lenvatinib group (p = 0.254) and -2.66 to -2.09 in the cTACE group (p < 0.01), respectively. The lenvatinib group showed a significantly higher objective response rate (73.3% vs. 33.3%; p < 0.001) and significantly longer median progression-free survival than the cTACE group (16.0 vs. 3.0 months; p < 0.001). Overall survival was significantly longer in the lenvatinib group than in the cTACE group (37.9 vs. 21.3 months; hazard ratio: 0.48, p < 0.01). In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child-Pugh A liver function, who usually do not benefit from TACE, lenvatinib provides a more favorable outcome than TACE.
  • Kentaro Yamao; Mamoru Takenaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Satoru Hagiwara; Toshiharu Sakurai; Naoshi Nishida; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi Kudo
    Internal medicine (Tokyo, Japan) 58 14 1993 - 2002 2019年07月 [査読有り]
     
    Objective Although modified FOLFIRINOX (mFOLFIRINOX, mFFX) is widely used for patients with advanced pancreatic ductal adenocarcinoma (PDAC), maintenance of the standard dose intensity is often difficult due to the high incidence of neutropenic events. Pegylated granulocyte colony-stimulating factor (G-CSF) (Peg G) is a long-lasting G-CSF agent that is applicable for prophylaxis against neutropenic complications. The aim of this study was to assess the clinical safety and efficacy of mFFX combined with secondary prophylaxis using Peg G in advanced PDAC patients. Methods Advanced PDAC patients who had received more than two cycles of mFFX were analyzed. The clinical safety and efficacy were compared between patients in the Peg G group and those in the non-Peg G group in a retrospective manner. Results Among 45 patients treated with mFFX, 28 exhibited grade 3-4 neutropenia or febrile neutropenia. Among these 28 patients, 4 who received only 1 or 2 mFFX cycles were excluded from this study. Finally, 11 patients in the Peg G group and 13 in the non-Peg G group were enrolled. The combination therapy with Peg G and mFFX markedly prolonged the progression-free survival compared with the non-Peg G group, and its effects were associated with a reduced incidence of neutropenic events as well as lower rates of dosage reduction, delayed chemotherapy due to neutropenic events and altered blood cell counts after chemotherapy. Conclusion The scheduled administration of secondary prophylactic Peg G prolonged the progression-free survival in patients treated with mFFX. The combination therapy of Peg G and mFFX may be recommended in patients who exhibit grade 3-4 neutropenic events after prior mFFX cycles.
  • Masashi Kono; Toshiharu Sakurai; Kazuki Okamoto; Tomoyuki Nagai; Yoriaki Komeda; Hiroshi Kashida; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Eisuke Enoki; Hiroaki Inoue; Itaru Matsumura; Masatoshi Kudo
    Internal medicine (Tokyo, Japan) 58 14 2029 - 2033 2019年07月 [査読有り]
     
    Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. A 63-year-old man with a 7-year history of MDS was referred for examination of diarrhea, abdominal pain and fever. A blood examination revealed a marked elevation of C-reactive protein. Colonoscopy showed multiple ulcers in the terminal ileum. He was resistant to anti-tumor necrosis factor (TNF)-α antibody and azacitidine. Subsequently, UST treatment reduced colonic IL-17 and IL-6 expression and the patient currently maintains a state of remission.
  • Kazuomi Ueshima; Naoshi Nishida; Satoru Hagiwara; Tomoko Aoki; Tomohiro Minami; Hirokazu Chishina; Masahiro Takita; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Atsushi Hiraoka; Philip Johnson; Masatoshi Kudo
    Cancers 11 7 2019年07月 [査読有り]
     
    BACKGROUND: This study investigated the impact of baseline liver function according to the Child-Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with unresectable hepatocellular carcinoma treated with lenvatinib. METHODS: A total of 82 lenvatinib treated patients were included. The correlations of baseline liver function according to the Child-Pugh score and ALBI grade with treatment outcomes, including objective response rate per mRECIST (modified Response Evaluation Criteria in the Solid Tumor), time to treatment failure, treatment duration, and likelihood of treatment discontinuation due to adverse events, were assessed in patients with hepatocellular carcinoma treated with lenvatinib. Patients were divided into four groups: (1) Child-Pugh score 5 and ALBI grade 1 (group 1), (2) Child-Pugh score 5 and ALBI grade 2 (group 2), (3) Child-Pugh score 6 (group 3), and (4) Child-Pugh score ≥7 (group 4). Univariate and multivariate analyses were performed to identify the factors contributing to the objective response rate and likelihood of discontinuation due to adverse events. Results: Among the 82 patients analyzed, group 1 had the highest objective response rate (57.1%) and the lowest likelihood of treatment discontinuation because of adverse events (11.1%) among the four groups (p < 0.05 and p < 0.05). Multivariate analysis identified ALBI grade 1 and baseline AFP level <200 ng/mL as the significant predictors of a high objective response rate (p < 0.05 and p < 0.01), and confirmed that patients with ALBI grade 1 had the lowest probability of treatment discontinuation due to adverse events (p < 0.01). Conclusions: Patients with Child-Pugh score of 5 and ALBI grade 1 predicted a higher response rate and lower treatment discontinuation due to adverse events by lenvatinib treatment.
  • Naosuke Yokomichi; Naoshi Nishida; Yuzo Umeda; Fumitaka Taniguchi; Kazuya Yasui; Toshiaki Toshima; Yoshiko Mori; Akihiro Nyuya; Takehiro Tanaka; Takeshi Yamada; Takahito Yagi; Toshiyoshi Fujiwara; Yoshiyuki Yamaguchi; Ajay Goel; Masatoshi Kudo; Takeshi Nagasaka
    Liver cancer 8 4 239 - 254 2019年07月 [査読有り]
     
    Objective: Keratin 19 (K19) expression is a potential predictor of poor prognosis in patients with hepatocellular carcinoma (HCC). To clarify the feature of K19-proficient HCC, we traced epigenetic footprints in cultured cells and clinical materials. Patients and Methods: In vitro, KRT19 promoter methylation was analyzed and 5-aza-2'-deoxycytidine with trichostatin A (TSA) treatment was performed. Among 564 surgically resected HCCs, the clinicopathological relevance of K19-proficent HCCs was performed in comparison with hepatocytic (HepPar-1 and arginase-1), epithelial-mesenchymal transition (E-cadherin and vimentin), biliary differentiation-associated (K7 and NOTCH-1) markers, and epigenetic markers (KRT19 promoter/long interspersed nucleotide element-1 [LINE-1] methylation status). Results: KRT19 promoter methylation was clearly associated with K19 deficiency and 5-aza-2'-deoxycytidine with TSA treatment-stimulated K19 re-expression, implicating DNA methylation as a potential epigenetic process for K19 expression. After excluding HCCs with recurrence, TNM stage as IIIB or greater, preoperative therapy, transplantation, and combined hepatocellular cholangiocarcinoma, we assessed 125 of 564 HCC cases. In this cohort, K19 expression was found in 29 HCCs (23.2%) and corresponded with poor survival following surgery (p = 0.025) and extrahepatic recurrence-free survival (p = 0.017). Compared with K19-deficient HCCs, lower KRT19 promoter methylation level was observed in K19-proficient HCCs (p < 0.0001). Conversely, HCC with genome-wide LINE-1 hypermethylation was frequently observed in K19-proficient HCCs (p = 0.0079). Additionally, K19 proficiency was associated with K7 proficiency (p = 0.043), and reduced E-cadherin and HepPar-1 expression (p = 0.043 and p < 0.0001, respectively). Conclusions: K19-proficient HCC exhibited poor prognosis owing to extrahepatic recurrence, with molecular signatures differing from those in conventional cancer stem cells, providing novel insights of the heterogeneity underlying tumor development.
  • Masatoshi Kudo
    Liver cancer 8 4 221 - 238 2019年07月 [査読有り]
  • Masatoshi Kudo; Kazuomi Ueshima; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masayuki Kitano; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Chikara Ogawa; Kohei Akazawa
    Liver cancer 8 4 271 - 280 2019年07月 [査読有り]
     
    Background: Current practice guidelines recommend the use of ultrasound (US) as an initial surveillance tool for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Patients with liver cirrhosis, however, frequently have coarse liver parenchyma, masking the presence of tiny nodules during B-mode US. Contrast-enhanced US (CEUS) with Sonazoid has a long-lasting, stable Kupffer phase, which makes it possible to scan the entire liver to depict small lesions. In addition, defect reperfusion imaging (reinjection imaging) enables to determine whether the detected nodule is HCC or not. This prospective, multicenter, randomized, controlled trial was conducted to demonstrate the usefulness of Kupffer phase surveillance in the detection of small HCC compared to B-mode US. Methods: A total of 23 institutions joined this study. In total, 656 patients with hepatitis B- or C-related liver cirrhosis were randomized either to the B-mode US surveillance group (n = 313) or the Kupffer phase CEUS with Sonazoid surveillance group (n = 309). The primary endpoint was the maximum size of HCC at the time of the first detection. Secondary endpoints included time to HCC detection, number of tumors, and Barcelona Clinic Liver Cancer stage at the first detection, and sensitivity, specificity, and accuracy of each method in the diagnosis, and the cumulative detection rate of HCC. Results: The mean HCC size at the first detection was significantly smaller in the CEUS (13.0 ± 4.1 mm; n = 28) than in the B-mode US group (16.7 ± 4.1 mm; n = 26) (p = 0.011). Of the 38 patients with HCV cirrhosis diagnosed with HCC by US alone, mean tumor size at the first detection was significantly smaller in the 20 patients diagnosed by CEUS alone than in the 18 diagnosed by B-mode US alone (12.7 ± 3.1 vs. 17.6 ± 7.0 mm, p = 0.012). In contrast, among the 16 patients with HBV cirrhosis diagnosed by US alone, mean tumor size at the first detection was similar in the 8 patients diagnosed by CEUS alone and the 8 diagnosed by B-mode US (13.6 ± 6.0 vs. 14.5 ± 2.7 mm, p = 0.715). Conclusion: Kupffer phase CEUS surveillance with Sonazoid is extremely useful for the early detection and confirmation of HCC using a reinjection technique. Kupffer phase CEUS with Sonazoid contrast combined with the reinjection technique is, therefore, recommended as first-line screening tool for HCC in patients with liver cirrhosis, especially those with very coarse liver parenchyma.
  • Dominik Bettinger; David J Pinato; Michael Schultheiss; Rohini Sharma; Lorenza Rimassa; Tiziana Pressiani; Michela E Burlone; Mario Pirisi; Masatoshi Kudo; Joong Won Park; Nico Buettner; Christoph Neumann-Haefelin; Tobias Boettler; Nasrin Abbasi-Senger; Horst Alheit; Wolfgang Baus; Oliver Blanck; Sabine Gerum; Mathias Guckenberger; Daniel Habermehl; Christian Ostheimer; Oliver Riesterer; Jörg Tamihardja; Anca-Ligia Grosu; Robert Thimme; Thomas Baptist Brunner; Eleni Gkika
    Liver cancer 8 4 281 - 294 2019年07月 [査読有り]
     
    Background and Aims: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. Methods: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. Results: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. Conclusions: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.
  • 深層学習による超音波画像からの肝腫瘍検出に関する初期的検討
    堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊
    日本医用画像工学会大会予稿集 38回 48 - 48 日本医用画像工学会 2019年07月 [査読有り]
  • Atsushi Hiraoka; Takashi Kumada; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
    Cancer medicine 8 8 3719 - 3728 2019年07月 [査読有り]
     
    BACKGROUND/AIM: We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u-HCC) by investigating real-world clinical features of patients. MATERIALS/METHODS: One hundred fifty two u-HCC patients, who receive LEN treatment from March to December 2018, were enrolled. (Child-Pugh score [CPS] 5/6/7/8 = 76/61/13/2, modified albumin-bilirubin grade [mALBI] 1/2a/2b/3 = 53/35/60/4). Clinical features were evaluated retrospectively. RESULTS: Overall-response rate (ORR)/disease control rate (DCR) at 1 month after starting LEN were 38.7%/86.0%, respectively. Estimated median time to progression (TTP) was 7.0 months, while median survival time was not reached within the observation period. CPS (≥7) and past history of tyrosine-kinase inhibitor (TKI) were not significant prognostic factors. mALBI ≥2b was an only significant prognostic factor (HR 4.632, 95%CI 1.649-13.02, P = 0.004) in Cox-hazard multivariate analysis. In patients with Child-Pugh A, c-index/Akaike's information criterion (AIC) of prognostic predictive value of mALBI were superior to CPS (0.682/135.6 vs 0.652/138.7), while those of stopping LEN also showed that mALBI was better (0.575/447.3 vs 0.562/447.8). Additional analysis of patients with good mALBI (1/2a) revealed that time to stopping LEN was significantly shorter in those with the adverse event (AE) of appetite loss (any grade) than those without (P = 0.006) and body mass index (BMI) was also lower in patients with that AE (20.3 ± 3.0 vs 23.6 ± 4.0kg/m2 , P < 0.001), while patients with a hand-foot skin reaction (any grade) showed good ORR/DCR (59.1%/86.4%) and longer TTP as compared to patients without (P = 0.007). CONCLUSION: Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.
  • Thomas R Jeffry Evans; Masatoshi Kudo; Richard S Finn; Kwang-Hyub Han; Ann-Lii Cheng; Masafumi Ikeda; Silvija Kraljevic; Min Ren; Corina E Dutcus; Fabio Piscaglia; Max W Sung
    British journal of cancer 121 3 218 - 221 2019年07月 [査読有り]
     
    BACKGROUND: Proteinuria monitoring is required in patients receiving lenvatinib, however, current methodology involves burdensome overnight urine collection. METHODS: To determine whether the simpler urine protein:creatinine ratio (UPCR) calculated from spot urine samples could be accurately used for proteinuria monitoring in patients receiving lenvatinib, we evaluated the correlation between UPCR and 24-hour urine protein results from the phase 3 REFLECT study. Paired data (323 tests, 154 patients) were analysed. RESULTS: Regression analysis showed a statistically significant correlation between UPCR and 24-hour urine protein (R2: 0.75; P < 2 × 10-16). A UPCR cut-off value of 2.4 had 96.9% sensitivity, 82.5% specificity for delineating between grade 2 and 3 proteinuria. Using this UPCR cut-off value to determine the need for further testing could reduce the need for 24-hour urine collection in ~74% of patients. CONCLUSION: Incorporation of UPCR into the current algorithm for proteinuria management can enable optimisation of lenvatinib treatment, while minimising patient inconvenience. CLINICAL TRIAL REGISTRATION: NCT01761266.
  • Yoriaki Komeda; Hisashi Handa; Ryoma Matsui; Toshiharu Sakurai; Tomohiro Watanabe; Hiroshi Kashida; Masatoshi Kudo
    Gastrointestinal Endoscopy 89 6 AB631 - AB631 2019年06月
  • Minaga Kosuke; Takenaka Mamoru; Yoshikawa Tomoe; Okamoto Ayana; Ishikawa Rei; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Kamata Ken; Yamao Kentaro; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 89 6 AB299  2019年06月 [査読有り]
  • Itonaga Masahiro; Kitano Masayuki; Hatamaru Keiichi; Tamura Takashi; Nuta Junya; Kawaji Yuki; Takenaka Mamoru; Minaga Kosuke; Kudo Masatoshi; Ogura Takeshi; Higuchi Kazuhide; Chiba Yasutaka
    GASTROINTESTINAL ENDOSCOPY 89 6 AB315  2019年06月 [査読有り]
  • Ogura Takeshi; Takenaka Mamoru; Shiomi Hideyuki; Goto Daisuke; Hisa Takeshi; Tamura Takashi; Kato Hironari; Nishioka Nobu; Minaga Kosuke; Kudo Masatoshi; Higuchi Kazuhide; Kitano Masayuki
    GASTROINTESTINAL ENDOSCOPY 89 6 AB297  2019年06月 [査読有り]
  • Okamoto Ayana; Kamata Ken; Takenaka Mamoru; Yoshikawa Tomoe; Ishikawa Rei; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Minaga Kosuke; Yamao Kentaro; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 89 6 AB602 - AB603 2019年06月 [査読有り]
  • Omoto Shunsuke; Takenaka Mamoru; Ishikawa Rei; Okamoto Ayana; Nakai Atsushi; Yamazaki Tomohiro; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 89 6 AB584  2019年06月 [査読有り]
  • Takenaka Mamoru; Yoshikawa Tomoe; Ishikawa Rei; Okamoto Ayana; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 89 6 AB223  2019年06月 [査読有り]
  • Takenaka Mamoru; Hayashi Shiro; Nishida Tsutomu; Hosono Makoto; Yoshikawa Tomoe; Ishikawa Rei; Okamoto Ayana; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 89 6 AB444 - AB445 2019年06月 [査読有り]
  • Ayana Okamoto; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
    Internal Medicine 58 11 1533 - 1539 2019年06月 [査読有り]
  • Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
    Journal of gastroenterology 54 6 558 - 570 2019年06月 [査読有り]
  • Akane Hara; Ken Kamata; Mamoru Takenaka; Takaaki Chikugo; Masatoshi Kudo
    Gastrointestinal endoscopy 89 6 1257 - 1259 2019年06月 [査読有り]
  • Takenaka M; Yoshikawa T; Okamoto A; Nakai A; Minaga K; Yamao K; Kudo M
    Endoscopy 51 6 E132 - E134 2019年06月 [査読有り]
  • Minaga K; Watanabe T; Kamata K; Takenaka M; Yasukawa S; Kudo M
    The American journal of gastroenterology 114 6 1002 - 1003 2019年06月 [査読有り]
  • Kosuke Minaga; Tomohiro Watanabe; Hobyung Chung; Masatoshi Kudo
    World journal of gastroenterology 25 19 2308 - 2314 2019年05月 [査読有り]
     
    IgG4-related disease (IgG4-RD) is a chronic-fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease. Although common organ involvement of IgG4-RD includes the salivary glands, pancreas, and bile duct, hepatic involvement is less well established. Recently, five studies identified a subtype of autoimmune hepatitis (AIH), called IgG4-associated AIH (IgG4-AIH). IgG4-AIH is diagnosed based on significant accumulation of IgG4-expressing plasmacytes in the liver in patients who met the diagnostic criteria for classical AIH. Although four of the five reports regarded IgG4-AIH based on hepatic accumulation of IgG4-positive cells alone, one report diagnosed IgG4-AIH based on both hepatic accumulation of IgG4-positive cells and elevated serum concentrations of IgG4. IgG4-AIH diagnosed based on the latter criteria may be a hepatic manifestation of IgG4-RD whereas IgG4-AIH diagnosed based on the former criteria may be a subtype of AIH. In this review article, we summarize and discuss clinicopathological features of IgG4-AIH.
  • Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki Arai
    Medical oncology (Northwood, London, England) 36 6 52 - 52 2019年05月 [査読有り]
     
    A randomized, phase III trial of orantinib in combination with transcatheter arterial chemoembolization (TACE) did not prolong overall survival (OS) over placebo (ORIENTAL study). A subgroup analysis was conducted to evaluate the efficacy and safety of orantinib in Japanese patients enrolled in the ORIENTAL study. The data of Japanese patients from this study were analyzed. The overall survival (OS), time to progression (TTP), and time to TACE failure (TTTF) were compared between orantinib and placebo arms using stratified log-rank test. Since TTTF in patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) showed favor outcome in this study, the OS and TTTF according to BCLC staging system were also analyzed. The subgroup analysis consisted of 219 and 213 patients in the orantinib and placebo arms. Median OS was 32.5 vs 33.0 months (p = 0.906), median TTP was 4.7 vs 3.1 months (p = 0.011), and median TTTF was 25.3 vs 18.2 months (p = 0.160) in the orantinib and placebo groups, respectively. Patients with BCLC-B in the orantinib and placebo groups showed a median OS of 33.7 and 30.1 months, respectively (p = 0.260), while the corresponding median TTTF were 25.3 and 14.0 months (p = 0.125). The Japanese population safety profile was similar to all over population in the ORIENTAL study. No significant differences were observed in the OS and TTTF though the TTP was significantly improved in the orantinib arm. The OS and TTTF showed a tendency to be prolonged following orantinib treatment of Japanese HCC patients with BCLC-B in the ORIENTAL study.
  • 好酸球性食道炎の臨床的特徴の検討
    正木 翔; 松井 繁長; 工藤 正俊; 大塚 康生; 松村 まり子; 高島 耕太; 河野 辰哉; 岡元 寿樹; 河野 匡志; 山田 光成; 永井 知行; 米田 頼晃; 櫻井 俊治; 渡邉 智裕; 辻 直子; 樫田 博史
    Gastroenterological Endoscopy 61 Suppl.1 963 - 963 (一社)日本消化器内視鏡学会 2019年05月
  • Soo Ki Kim; Soo Ryang Kim; Susumu Imoto; Naomi Shida; Yumi Fujii; Takako Fujii; Masahiro Kido; Hisoka Kinoshita; Yu-Ichiro Koma; Yoshitake Hayashi; Toshiyuki Matsuoka; Masatoshi Kudo
    Pathology international 69 5 306 - 308 2019年05月 [査読有り]
  • 南 康範; 南 知宏; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓クリニカルアップデート 5 1 39 - 42 医学図書出版(株) 2019年05月 [査読有り]
     
    ラジオ波焼灼術(RFA)で良好な局所制御を得るには十分なablative marginが必要であるが、超音波(US)観察の制限のためablative marginをRFA治療中に評価することは困難である。しかし、新たなフュージョン画像技術である「US-US fusion imaging」では治療前後のUS画像の対比、「US-US overlay fusion」では治療前後のUS画像の重ね合わせによってablative marginについてUS画像の客観性ある画像情報が得られるようになった。とくに、US-US overlay fusionによるablative marginの可視化はRFA治療における局所制御の向上がもたらされ、より精度の高いRFA治療(precision RFA)に貢献する有用な画像技術である。(著者抄録)
  • Tanaka H; Matsui S; Kashida H; Kudo M
    Annals of gastroenterology 32 3 316  2019年05月 [査読有り]
  • Masashi Kono; Toshiharu Sakurai; Kazuki Okamoto; Shou Masaki; Tomoyuki Nagai; Yoriaki Komeda; Ken Kamata; Kosuke Minaga; Kentarou Yamao; Mamoru Takenaka; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Internal Medicine 58 9 1263 - 1266 2019年05月 [査読有り]
  • Takenaka M; Okabe Y; Kudo M
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 51 5 743 - 743 2019年05月 [査読有り]
  • Masatoshi Kudo
    Liver cancer 8 3 143 - 154 2019年05月 [査読有り]
  • 青木 武士; 古泉 友丈; 藤森 聡; 草野 智一; 野垣 航二; 田代 良彦; 箱崎 智樹; 富岡 幸大; 平井 隆仁; 山崎 達哉; 村上 雅彦
    外科 81 6 673 - 680 (株)南江堂 2019年05月 [査読有り][招待有り]
     
    ＜文献概要＞光力学診断法は,消化器外科領域のみならず各外科領域において横断的に臨床応用され,その手術支援の有用性は高く評価され,近年大きな注目を集めている.光力学診断法は肝胆膵外科領域においては,インドシアニングリーン(ICG)蛍光法を中心に解剖学的・腫瘍学的に精緻な手術を実現するnavigation surgeryの役割を担い,さまざまな手術支援に応用されている.光力学診断法のさらなる発展は,術中診断・治療成績を向上させ安全・確実な手術に寄与する大きな可能性を有している.
  • Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 17 6 1192 - 1200 2019年05月 [査読有り]
  • Itonaga M; Kitano M; Hatamaru K; Tamura T; Nuta J; Kawaji Y; Takenaka M; Minaga K; Kudo M; Ogura T; Higuchi K; Chiba Y
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 3 291 - 298 2019年05月 [査読有り]
     
    BACKGROUND AND AIM: When endoscopic retrograde cholangiopancreatography (ERCP) fails in patients with malignant distal biliary obstruction, endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) is an alternative. It has high technical and clinical success rates, but also has high adverse event rates. This prospective cohort study was aimed to evaluate the clinical efficacy and safety of EUS-CDS with our newly developed partially covered self-expandable metal stent with a thin delivery system. METHODS: Patients consisted of all consecutive patients in three tertiary referral centers with unresectable malignant distal obstruction in whom ERCP failed and in whom EUS-CDS with the thin delivery system was selected as the second-line approach. Rates of clinical success, technical success, technical success in cases not requiring fistulous tract dilation, adverse events, and stent dysfunction were determined. RESULTS: In the 20 patients, technical and clinical success rates were 95.0% (19/20) and 100% (19/19), respectively. In 31.6% (6/19), the delivery system was successfully inserted into the bile duct without requiring a fistulous-tract dilatation device. These patients had significantly shorter procedure times than patients requiring fistulous-tract dilatation (12.7 ± 3.1 vs 23.2 ± 2.1 min; P < 0.01). One patient (5.0%) who required fistulous dilation had an adverse event, which was managed conservatively. There were no procedure-related deaths. During follow up, four patients (21.1%) developed stent dysfunction. Reintervention was successful in all cases. CONCLUSIONS: The EUS-CDS approach had 95% technical and 100% clinical success rates, with adverse events reported in 5% of cases. EUS-CDS may become safer if efforts are made to avoid the dilation step (UMIN 000023938).
  • レンバチニブ著効症例の残存病変評価に造影エコーが有用であった一例
    盛田 真弘; 小川 力; 重福 亜紀奈; 野田 晃世; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊
    超音波医学 46 Suppl. S662 - S662 (公社)日本超音波医学会 2019年04月
  • Minami Y; Nishida N; Kudo M
    European radiology 29 9 5045 - 5051 2019年04月 [査読有り]
     
    Percutaneous radiofrequency ablation (RFA), a generally accepted alternative therapy for patients with liver metastases, is a minimally invasive approach with a favorable safety profile and a lower rate of major complications. The use of RFA or combined RFA plus resection can produce total tumor clearance in patients with unresectable liver metastases. However, the relatively high rate of local tumor progression has prevented the widespread use of RFA. Furthermore, its efficacy is controversial because there have been no comparisons for its effect on overall survival compared with standard options such as systemic chemotherapy. Meanwhile, immunotherapy has become a major research focus for oncology based on the recent successes reported for immune checkpoint inhibitors for melanoma, non-small cell lung cancer, gastric cancer, and other cancers. Immune checkpoints negatively regulate T cell function, and inhibition prevents the blockade of the immune system by cancer cells to prevent their destruction. Unfortunately, only some patients (< 25%) respond to immuno-oncology drugs, whereas other patients acquire resistance. However, RFA can induce massive necrotic cell death which might activate immunity and the presentation of cryptic antigens to induce tumor-specific T cell response. Because RFA can induce the rapid release of large amounts of tumor antigens, it can potentially stimulate transient immune responses to much tumor antigens. Combination therapies have induced synergistic enhancement of anticancer immune response in preclinical studies, indicating great promise for the future of oncologic treatment. Key Points center dot Only some patients respond to immuno-oncology drugs. center dot RFA causes the release of large amounts of cellular debris, a source of tumor antigens that elicit immune responses against tumors. center dot Combination RFA for liver metastases and immune checkpoint inhibitor therapies might synergistically enhance antitumor immunity.
  • Masatoshi Kudo
    Hepatobiliary surgery and nutrition 8 2 153 - 156 2019年04月 [査読有り]
  • Yoriaki Komeda; Tomohiro Watanabe; Toshiharu Sakurai; Masashi Kono; Kazuki Okamoto; Tomoyuki Nagai; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi Kudo
    World Journal of Gastroenterology 25 12 1502 - 1512 2019年03月 [査読有り]
  • Tomoe Yoshikawa; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Masatoshi Kudo
    Modern Rheumatology 29 2 219 - 225 2019年03月 [査読有り]
  • 平岡 淳; 道堯 浩二郎; 熊田 卓; 泉本 並木; 角谷 眞澄; 國土 典宏; 久保 正二; 松山 裕; 中島 収; 坂元 亨宇; 高山 忠利; 國土 貴嗣; 柏原 康佑; 江口 晋; 山下 達也; 工藤 正俊
    日本消化器病学会雑誌 116 臨増総会 A286 - A286 (一財)日本消化器病学会 2019年03月 [査読有り]
  • Atsushi Hiraoka; Takashi Kumada; Kunihiko Tsuji; Koichi Takaguchi; Ei Itobayashi; Kazuya Kariyama; Hironori Ochi; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Toru Ishikawa; Yoshihiko Tachi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
    Liver cancer 8 2 121 - 129 2019年03月 [査読有り]
     
    Background/Aim: The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing in Japan along with the progression of antiviral therapies and aging of the society. We evaluated the usefulness of modified albumin-bilirubin (ALBI) grade as a tool for assessment of hepatic reserve function. Materials/Methods: We enrolled 6,649 naïve HCC patients treated from 2000 to 2017 and divided them into training (Ehime Prefecture group: E group, n = 2,357) and validation (validation group: V group, n = 4,292) cohorts. Child-Pugh classification and ALBI and modified ALBI (mALBI) grading were compared using with Japan Integrated Staging (JIS), ALBI-TNM (ALBI-T), and mALBI-T scores, which were calculated based on TNM stage and each assessment tool, retrospectively. Results: In the E group, Akaike's Information Criterion (AIC) and c-index values for mALBI-T (13,725.2/0.744) were better as compared to those of ALBI-T (13,772.6/0.733) and JIS score (13,874.7/0.720), with similar results observed in the V group (mALBI-T: 27,727.4/0.760; ALBI-T: 27,817.8/0.750; JIS: 27,807.5/0.748). Although there were some significant differences between the groups with regard to clinical background factors (age, etiology, tumor size, tumor number, treatment modalities), for all patients the AIC and c-index values of mALBI-T (45,327.1/0.755) were also better than those of ALBI-T (45,467.7/0.744) and JIS scores (45,555.8/0.739), indicating its superior stratification ability and prognostic predictive value in patients with HCC. Conclusion: The detailed stratification ability of mALBI grade for hepatic reserve function is suitable for the recent trend of HCC patients, while mALBI-T may provide a more accurate predictive value than existing total staging scoring systems.
  • Ayana Okamoto; Kosuke Minaga; Mamoru Takenaka; Tomoe Yoshikawa; Toshimitsu Iwasaki; Masakatsu Tsurusaki; Masatoshi Kudo
    Endoscopy 51 03 E42 - E44 2019年03月 [査読有り]
  • Kosuke Minaga; Yukitaka Yamashita; Takeshi Ogura; Mamoru Takenaka; Yuzo Shimokawa; Takeshi Hisa; Masahiro Itonaga; Hironari Kato; Hidefumi Nishikiori; Atsushi Okuda; Hisakazu Matsumoto; Yoshito Uenoyama; Tomohiro Watanabe; Yasutaka Chiba; Kazuhide Higuchi; Masatoshi Kudo; Masayuki Kitano
    Digestive Endoscopy 31 2 180 - 187 2019年03月 [査読有り]
  • 炎症性腸疾患治療の最前線 ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験
    河野 匡志; 櫻井 俊治; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 110回 66 - 66 日本消化器病学会-近畿支部 2019年02月
  • ピロリ陰性時代の上部消化管診療 胃底腺型胃癌の臨床的特徴の検討
    河野 辰哉; 松井 繁長; 櫻井 俊治; 工藤 正俊
    日本消化器病学会近畿支部例会プログラム・抄録集 110回 57 - 57 日本消化器病学会-近畿支部 2019年02月
  • 【自己免疫性膵炎2019】AIPの病因・病態 腸内細菌叢からみた発症機序
    渡邉 智裕; 鎌田 研; 吉川 智恵; 三長 孝輔; 工藤 正俊
    肝・胆・膵 78 2 189 - 195 (株)アークメディア 2019年02月 [査読有り]
  • Nishida N; Yamakawa M; Shiina T; Kudo M
    Hepatol Int Feb 21. doi: 10.1007/s12072-01 4 416 - 421 2019年02月 [査読有り]
     
    An ultrasound (US) examination is a common noninvasive technique widely applied for diagnosis of a variety of diseases. Based on the rapid development of US equipment, many US images have been accumulated and are now available and ready for the preparation of a database for the development of computer-aided US diagnosis with deep learning technology. On the contrary, because of the unique characteristics of the US image, there could be some issues that need to be resolved for the establishment of computer-aided diagnosis (CAD) system in this field. For example, compared to the other modalities, the quality of a US image is, currently, highly operator dependent; the conditions of examination should also directly affect the quality of US images. So far, these factors have hampered the application of deep learning-based technology in the field of US diagnosis. However, the development of CAD and US technologies will contribute to an increase in diagnostic quality, facilitate the development of remote medicine, and reduce the costs in the national health care through the early diagnosis of diseases. From this point of view, it may have a large enough potential to induce a paradigm shift in the field of US imaging and diagnosis of liver diseases.
  • Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M; REACH; study investigators
    The Lancet. Oncology 20 2 282 - 296 2019年02月 [査読有り]
     
    BACKGROUND: Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. METHODS: REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433. FINDINGS: Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0-12·5), median overall survival (8·5 months [95% CI 7·0-10·6] vs 7·3 months [5·4-9·1]; hazard ratio [HR] 0·710 [95% CI 0·531-0·949]; p=0·0199) and progression-free survival (2·8 months [2·8-4·1] vs 1·6 months [1·5-2·7]; 0·452 [0·339-0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8-4·4] vs 2·8 months [1·6-2·9]; HR 0·799 [95% CI 0·545-1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639-1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure). INTERPRETATION: REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma. FUNDING: Eli Lilly.
  • Yohei Koizumi; Masashi Hirooka; Nobuharu Tamaki; Norihisa Yada; Osamu Nakashima; Namiki Izumi; Masatoshi Kudo; Yoichi Hiasa
    PloS one 14 8 e0221548  2019年 [査読有り]
     
    PURPOSE: We have developed a diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient (ATT) in ultrasound B mode imaging. A controlled attenuation parameter (CAP) by vibration-controlled transient elastography (VCTE) has also been used to evaluate hepatic steatosis. As that method uses ultrasound A mode, visualizing the liver in real time is difficult. We designed this clinical study to evaluate the diagnostic advantage of our technique using ATT compared to CAP. MATERIALS AND METHODS: The study group included 94 patients with chronic liver disease who had undergone both ATT and CAP assessment at the time of liver biopsy. The M-probe and XL-probe were used for CAP measurement. Data for ATT and CAP were compared as a function of the steatosis grade. RESULTS: The area under the receiver operating characteristic curve (AUC-ROCs) for ATT and PAC as a function of the steatosis grade were as follows: grade 1, 0.74 and 0.81; grade 2, 0.80 and 0.85; and grade 3, 0.96 and 0.98, respectively. CONCLUSION: The accuracy of steatosis grade diagnosis using ATT was the same as that using CAP, with no significant differences and with the added advantage of B mode ultrasound being more convenient and rapid, compared to A mode ultrasound, particularly for patients with subcutaneous fat thickness ≥2 cm.
  • Makoto Yamakawa; Tsuyoshi Shiina; Naoshi Nishida; Masatoshi Kudo
    2019 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS) 2330 - 2333 2019年 
    The Japan Society of Ultrasonics in Medicine (JSUM) is currently constructing an ultrasound image database. This database collects B-mode images of liver tumors and breast tumors, and B-mode videos of heart disease. In the past year, 31,000 liver tumor images have been collected from 11 institutions and 14,000 breast tumor images have been collected from 5 institutions. We are developing computer-aided detection (CADe) and computer-aided diagnosis ( CADx) systems for liver and breast tumors based on deep learning using this database. In this paper, we report on CADx to estimate liver tumor types as a first trial. The data used in this study are 159 cyst cases (338 images), 68 hemangioma cases (279 images), 73 hepatocellular carcinoma (HCC) cases (241 images), and 24 metastatic liver cancer cases (122 images), collected at one facility. We developed the CADx system that estimates four types of liver tumor using a convolutional neural network based on VGGNet. The accuracy of the developed 4-class classification CADx was 88.0%. The accuracy by tumor type was 98.1% for cysts, 86.8% for hemangiomas, 86.3% for HCC, and 29.2% for metastatic liver cancer, with increasing accuracy observed for larger data sets. We also developed CADx to estimate whether a liver tumor is benign or malignant. The accuracy of this 2-class classification CADx was 94.8%, the sensitivity was 93.8%, and the specificity was 95.2%. Both 4-class classification and 2-class classification CADx had relatively high accuracy. However, in this study, we used only a small amount data collected from a single facility. In the future, we plan to verify our results using a larger amount of data collected from multiple facilities. In addition, we prototyped CAD software and are currently developing it with feedback from doctors.
  • Non-B Non-C related hepatocellular carcinoma with sarcomatous change due to epithelial mesenchymal transition
    Kim SK; Fujii T; Kim SR; Imoto S; Fujii Y; Yuasa K; Ohtani A; Kobayashi H; Yamamoto M; Koma Y; Kumabe T; Nakashima O; Kudo M
    Ann Case Reports 5 2019年 [査読有り]
  • Multiple HNF-1α inactivated type hepatocellular adenoma due to intrahepatic portosystemic venous shunt
    Hayakumo T; Kobayashi H; Ohtani A; Hayashi Y; Koma Y; Kumabe T; Nakashima O; Kudo M
    Ann Case Reports 5 2019年 [査読有り]
  • Differential diagnosis of small HCC focusing on pseudolymphoma and bile duct adenoma
    Kim SK; Fujii T; Kim SR; Imoto S; Fujii Y; Yuasa K; Kobayashi H; Ohtni A; Koma Y; Kudo M
    Ann Case Reports 21 2019年 [査読有り]
  • Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein
    Zhu AX; Finn RS; Galle PR; Llovet JM; Kudo M
    Lancet Oncol 20 e191  2019年 [査読有り]
  • Rationale 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
    Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX
    Future Oncol 15 1811 - 1822 2019年 [査読有り]
  • Takeda H; Nishijima N; Nasu A; Komekado H; Kita R; Kimura T; Osaki Y; Kudo M
    Hepatol Res 49 5 594 - 599 2019年 [査読有り]
     
    Lenvatinib is a novel multikinase inhibitor that has recently shown antitumor activity against hepatocellular carcinoma (HCC) in a phase III trial. We report the case of a woman in whom lenvatinib showed long-term antitumor activity, and in whom computed tomography (CT) scans revealed a series of suggestive radiological changes on the intratumor vascularity. A 68-year-old woman with hepatitis C virus-related liver disease presented with multiple HCCs. Following previous therapy, including six sessions of transcatheter arterial chemoembolization, we introduced lenvatinib monotherapy. Lenvatinib could rapidly cause hypovascularity in the main hypervascular target lesion, and portal vein tumor thrombosis also became undetectable 11 months after the initiation of lenvatinib. These radiological changes suggested that lenvatinib could exert not only anti-angiogenic activity but also direct antitumoral effect. Of note, CT scans during lenvatinib treatment revealed the target lesion as a low-density area in the early arterial phase, whereas scans during drug interruption due to proteinuria showed that the lesion was enhanced in the arterial phase. Finally, near-complete response could be achieved as the best response. We successfully managed various adverse events including proteinuria and hypertension, and the patient was able to continue this lenvatinib therapy for more than 4 years with well-controlled general condition. We report the first case of a patient with HCC in whom lenvatinib monotherapy demonstrated long-term antitumor activity. Suggestive radiological changes reflecting intratumor vascularity as presented here should be considered in patients receiving lenvatinib for HCC.
  • Objective response by mRECIST is an independent prognostic factor of overall survival in systemic therapy for hepatocellular carcinoma
    Kudo M
    Liver Cancer 8 73 - 77 2019年 [査読有り]
  • Efficacy and safety of elbasvir/grazoprevir combination therapy for chronic hepatitis C
    Hagiwara S; Kudo M
    Biomedical Journal of Scientific & Technical Research 2019年 [査読有り]
  • Utility of FIB4-T as a prognostic factor for hepatocellular carcinoma
    Kariyama K; Nouso K; Toyoda H; Tada T; Hiraoka A; Tsuji K; Itobayashi E; Ishikawa T; Wakuta A; Oonishi A; Kumada T; Kudo M
    Cancers 11 2019年 [査読有り]
  • Combination cancer immunotherapy with molecular targeted agents/anti-CTLA-4 antibody for hepatocellular carcinoma
    Kudo M
    Liver Cancer 8 1 - 11 2019年 [査読有り]
  • Sorafenib: Key lessons from over 10 years of experience
    Escudier B; Worden F; Kudo M
    Expert Rev Anticancer Ther 19 177 - 189 2019年 [査読有り]
  • Case of endoscopic ultrasonography-guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second puncture
    Omoto S; Takenaka M; Kudo M
    Dig Endosc 31 e20 - e21 2019年 [査読有り]
  • 鎌田 研; 千葉 康敬; 渡邉 智裕; 櫻井 俊治; 西田 直生志; 筑後 考章; 松本 逸平; 竹山 宜典; 北野 雅之; 工藤 正俊; 竹中 完; 三長 孝輔; 大本 俊介; 宮田 剛; 山雄 健太郎; 今井 元; 中井 敦史; 田中 秀和
    日本消化器内視鏡学会雑誌 61 4 417 - 426 一般社団法人 日本消化器内視鏡学会 2019年 [査読有り]
     

    【背景と目的】本研究では，造影ハーモニック超音波内視鏡（contrast-enhanced harmonic EUS：CH-EUS）を併用した超音波内視鏡（endoscopic ultrasonography：EUS）による精査が膵管内乳頭粘液性腫瘍（intraductal papillary mucinous neoplasm：IPMN）に対する外科的切除後の残膵フォローアップに有用であるかを検討した．

    【方法】本研究は，単一施設で行われたレトロスペクティブな研究である．2009年４月から2015年３月までにIPMNに対して外科的切除が施行された計134人の患者を対象とした．フォローアップ中における再発率とIPMN併存膵癌の発生率を検討した．また，それらの患者の臨床所見についても検討した．

    【結果】134例のIPMNのうち56例（41.8％）が良性，78例（58.2％）が悪性であった．経過観察期間中央値は29カ月であった．33例（24.6％）に対して，造影剤増強コンピュータ断層撮影法（contrast-enhanced computed tomography：CE-CT）にEUSを併用しフォローアップを行った．一方，101例（75.4％）はCE-CTのみによりフォローアップを行った．再発は13例（9.7％）に認め，うち５例が膵内再発，８例が膵外転移であった．１例において，拡張した主膵管内における造影効果のある壁在結節がEUSのみで描出された．２例において，フォローアップ中にIPMN併存膵癌が発生した．それらは小病変であり，CH-EUSでは検出されたが，CE-CTでは検出されなかった．うち１例においては，EUSでは腫瘍が不明瞭であり，CH-EUSが腫瘍の描出に有用であった．

    【結語】IPMN切除後フォローアップにEUSを加えることが有用であることが示唆された．

  • 慢性膵炎と自己免疫性膵炎の発症に関わる自然免疫反応
    渡邉 智裕; 工藤 正俊
    近畿大学医学雑誌 44 1・2 3 - 7 2019年 [招待有り]
  • 第20回全国原発性肝癌追跡調査報告(2008〜2009)
    工藤正俊; 泉 並木; 久保正二; 國土典宏; 坂元享宇; 椎名秀一朗; 高山忠利; 建石良介; 中島 収; 村上卓道; 松山 裕
    肝臓 60 258 - 293 2019年 [査読有り]
  • Atsushi Hiraoka; Takashi Kumada; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Michitaka Imai; Kouji Joko; Hironori Tanaka; Tsutomu Tamai; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
    Oncology 97 5 277 - 285 2019年 [査読有り]
     
    BACKGROUND/AIM: We evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN). MATERIALS/METHODS: We enrolled 84 u-HCC cases treated with TKIs including LEN from March 2018 to January 2019 (median age 71 years, 63 males, Child-Pugh score (CPS) 5/6/7 = 62/21/1, tumor-node-metastasis stage of Liver Cancer Study Group of Japan 6th (TNM-LCSGJ) II/III/IVa/IVb = 12/30/5/37, Barcelona Clinic Liver Cancer stage B/C = 33:51). Clinical findings at introduction of the initial TKI were retrospectively evaluated. RESULTS: The median albumin-bilirubin (ALBI) score at introduction of the initial TKI (sorafenib [SOR]/LEN = 80/4) was -2.56, and the past number of transarterial catheter chemoembolization was 3 (IQR: 2-5) (second-line: regorafenib [REG]/LEN/SOR = 31/49/4, third-line: LEN/REG = 31:1). The total period of administration with TKIs showed a good relationship with overall survival (OS) (r = 0.946, 95% confidence interval [CI]: 0.918-0.965, p < 0.001). The prognosis of the entire cohort was good (estimated median survival time: 46.4 months, 1-/2-/3-year OS rate [OSR] = 87.7/63.0/57.2%). A modified-ALBI grade (mALBI) of 2b (ALBI score >-2.27) was the only significant factor at the start of the initial TKI for poor prognosis (hazard ratio 2.319, 95% CI: 1.064-5.052, p = 0.034), while CPS (≥6) was not. Although there was no significant difference in TNM-LCSGJ (p = 0.213), the prognosis of patients with mALBI 1/2a (n = 66) showed better prognosis as compared to those with mALBI 2b (n = 18) (1-year/2-year/3-year OSR = 89.1/69.8/66% vs. 82.4/47.1/23.5%, p = 0.029). CONCLUSION: Good hepatic function (mALBI 1/2a) at introduction of the initial TKI is a requirement for improved prognosis of u-HCC undergoing TKI sequential therapy.
  • Targeted and immune therapy for hepatocellular carcinoma: predictions for 2019 and beyond
    工藤正俊
    World J Gastroenterol 25 789 - 807 2019年 [査読有り]
  • Kudo M
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 116 1 8 - 17 2019年 [査読有り]
  • Nishida N; Kudo M
    Hepatology international 13 3 248 - 252 2019年01月 [査読有り]
     
    Recently, immune checkpoint inhibitors are becoming one of the key agents of systemic treatment of cancer. The anti-cancer mechanism of this type of agent is totally different from that of conventional therapies; blockade of regulatory receptors and ligand of immune checkpoint molecules arose anti-tumor immunity with durable response. However, owing to its unique action to host immune system, immune checkpoint inhibitors sometimes induce immune-related adverse events (irAEs) which has not been observed for conventional chemotherapies. It has been reported that irAEs are manageable by discontinuation of immune checkpoint inhibitors and corticosteroid. However, severe irAEs might lead to the unsuccessful management of cancer treatment. It is conceivable that irAEs during the treatment of immune checkpoint blockade might mimic the autoimmune disease of the specific organ, such as autoimmune hepatitis (AIH). However, detail of the pathogenesis of irAEs has not been well estimated. In this review, we specially focused on this important issue and discussed the liver toxicity of this type of agent in the context of comparison of clinical and pathological findings of liver damage related to irAEs and AIH.
  • Mamoru Takenaka; Makoto Hosono; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi Kudo
    Journal of Japanese Society of Gastroenterology 116 12 1053 - 1055 2019年 [査読有り]
  • Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Ken Kamata; Kosuke Minaga; Kentarou Yamao; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Kazuhiko Nakagawa; Masatoshi Kudo
    Digestion 100 3 1 - 9 2018年12月 [査読有り]
  • Kato R; Hayashi H; Sano K; Handa K; Kumode T; Ueda H; Okuno T; Kawakami H; Matsumura I; Kudo M; Nakagawa K
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 13 12 e239 - e241 2018年12月 [査読有り]
  • Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
    Investigational new drugs 36 6 1072 - 1084 2018年12月 [査読有り]
     
    PURPOSE: Resminostat is an oral inhibitor of class I, IIB, and IV histone deacetylases. This phase I/II study compared the safety and efficacy of resminostat plus sorafenib versus sorafenib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: In phase I, resminostat (400 mg or 600 mg/day on days 1 to 5 every 14 days) was administered with sorafenib (800 mg/day for 14 days) to determine the recommended dose for phase II. In phase II, patients were randomized (1:1) to sorafenib monotherapy or resminostat plus sorafenib. The primary endpoint was time-to-progression (TTP). RESULTS: Nine patients (3: 400 mg, 6: 600 mg) were enrolled in phase I, and the recommended dose of resminostat was determined to be 400 mg/day. Then 170 patients were enrolled in phase II. Median TTP/overall survival (OS) were 2.8/14.1 months with monotherapy versus 2.8/11.8 months with combination therapy (Hazard Ratio [HR]: 0.984, p = 0.925/HR: 1.046, p = 0.824). The overall incidence of adverse events was similar in both groups (98.8% versus 100.0%). However, thrombocytopenia ≥ Grade 3 was significantly more frequent in the combination therapy group (34.5% versus 2.4%, p < 0.001). Subgroup analysis revealed that median TTP/OS was 1.5/6.9 months for monotherapy versus 2.8/13.1 months for combination therapy (HR: 0.795, p = 0.392/HR: 0.567, p = 0.065) among patients with a normal-to-high baseline platelet count (≥ 150 × 103/mm3). CONCLUSIONS: In patients with advanced HCC, first-line therapy with resminostat at the recommended dose plus sorafenib showed no significant efficacy advantage over sorafenib monotherapy.
  • Ferraioli G; Wong VW; Castera L; Berzigotti A; Sporea I; Dietrich CF; Choi BI; Wilson SR; Kudo M; Barr RG
    Ultrasound in medicine & biology 44 12 2419 - 2440 2018年12月 [査読有り]
  • 肝門部胆管癌における胆道再建後の吻合部再発に対し胆管および門脈にステント留置術を行った2例
    門場 智也; 鶴崎 正勝; 小田 晃義; 沼本 勲男; 柳生 行伸; 柏木 伸夫; 石井 一成; 鎌田 研; 工藤 正俊
    IVR: Interventional Radiology 33 3 318 - 318 (一社)日本インターベンショナルラジオロジー学会 2018年11月
  • Sofue K; Tsurusaki M; Mileto A; Hyodo T; Sasaki K; Nishii T; Chikugo T; Yada N; Kudo M; Sugimura K; Murakami T
    Hepatology research : the official journal of the Japan Society of Hepatology 48 12 1008 - 1019 2018年11月 [査読有り]
     
    AIM: To investigate whether iodine density measurements from contrast-enhanced dual-energy computed tomography (CT) data can non-invasively stage liver fibrosis. METHODS: This single-center, prospective study was approved by our IRB with written informed consent. Forty-seven consecutive patients (26 men and 21 women; mean age, 63.1 years) with chronic liver disease underwent contrast-enhanced dual-energy CT of the liver (non-contrast, arterial, portal venous, and equilibrium phase images), followed by liver biopsy. Iodine density of liver and aorta were obtained by two independent observers. Iodine uptake of the liver (Δ Liver), representing the difference in iodine density between equilibrium phase and non-contrast images, was calculated and normalized by aorta (Δ Liver/Aorta). We accounted for contrast agent distribution volume by using hematocrit level. Accuracy of iodine density measurements for staging liver fibrosis was assessed by using receiver operating characteristic (ROC) curves. Multivariate linear regression analysis was used to assess the impact of independent variables (liver fibrosis stage and patient-related confounders) on iodine uptake. RESULTS: The Δ Liver/Aorta significantly increased and moderately correlated with METAVIR liver fibrosis stage (ρ = 0.645, P < 0.001). Areas under the ROC curve ranged from 0.795 to 0.855 for discriminating each liver fibrosis score (≥F1-F4). METAVIR fibrosis stage was the most significant independent factor associated with Δ Liver (P = 0.005) and Δ Liver/Aorta (P < 0.001). CONCLUSION: Hepatic extracellular volume fraction with contrast-enhanced dual-energy CT can non-invasively stage liver fibrosis in chronic liver diseases. This technique could prove useful for monitoring disease progression and treatment response, potentially reducing the need for liver biopsy.
  • Yasuo Otsuka; Ken Kamata; Kosuke Minaga; Mamoru Takenaka; Tomohiro Watanabe; Masatoshi Kudo
    Internal Medicine 57 21 3075 - 3078 2018年11月 [査読有り]
  • 工藤 正俊
    肝臓 59 11 587 - 603 (一社)日本肝臓学会 2018年11月 
    2007年に分子標的薬ソラフェニブがSHARP試験とAsia Pacific試験において肝細胞癌に対する予後延長効果が示されて以来、肝細胞癌の薬物療法は大きく変化した。遠隔転移、脈管浸潤に対する治療選択肢が増え、進行性肝癌でもある程度長期生存が得られるようになったが、ソラフェニブは腫瘍縮小効果が乏しいことや手足症候群などの比較的強い副作用から、ソラフェニブに代わる新規分子標的薬やソラフェニブ治療で病勢が進行した後の2次治療薬の開発が望まれてきた。ただし2007〜2016年までの10年間、多数の薬剤の開発が試みられたものの、その全ての臨床試験がことごとく失敗に終わった。しかしながら、2017年と2018年の2年間で立て続けに4剤(レゴラフェニブ、レンバチニブ、カボザンチニブ、ラムシルマブ)が臨床試験に成功し、臨床現場で使用可能となりつつある。また免疫チェックポイント阻害剤の治験や免疫チェックポイント阻害剤と分子標的薬との併用の治験も進行中であり肝細胞癌の薬物治療は今後も大きく変化し肝細胞癌治療のパラダイムシフトが起こりつつある。(著者抄録)
  • Takenaka M; Yamao K; Minaga K; Nakai A; Omoto S; Kamata K; Kudo M
    Endoscopy 51 2 E30-E31  2018年11月 [査読有り]
  • Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Masatoshi Kudo; Warren Strober
    Trends in Immunology 39 11 874 - 889 2018年11月 [査読有り]
  • Innovative therapeutic endoscopy良性胆管・膵管狭窄に対する内視鏡治療 良性胆道狭窄(慢性膵炎)に対するfully covered metallic stentの有用性
    竹中 完; 山雄 健太郎; 工藤 正俊
    Gastroenterological Endoscopy 60 Suppl.2 2010 - 2010 (一社)日本消化器内視鏡学会 2018年10月
  • 良性胆管・膵管狭窄に対する内視鏡治療 良性胆道狭窄(慢性膵炎)に対するfully covered metallic stentの有用性
    竹中 完; 山雄 健太郎; 工藤 正俊
    日本消化器病学会雑誌 115 臨増大会 A630 - A630 (一財)日本消化器病学会 2018年10月
  • 当院でのirAE大腸炎の臨床的特徴
    櫻井 俊治; 川上 尚人; 工藤 正俊
    日本消化器病学会雑誌 115 臨増大会 A441 - A441 (一財)日本消化器病学会 2018年10月
  • 膵癌の門脈浸潤診断における造影ハーモニックEUSと造影CTの診断能の比較検討
    中井 敦史; 鎌田 研; 竹中 完; 石川 嶺; 岡本 彩那; 大本 俊介; 三長 孝輔; 山雄 健太郎; 兵頭 朋子; 松本 逸平; 竹山 宜典; 工藤 正俊
    Gastroenterological Endoscopy 60 Suppl.2 2126 - 2126 (一社)日本消化器内視鏡学会 2018年10月
  • EUS施行時の鎮静に対するBISモニターの有用性の検討
    岡本 彩那; 鎌田 研; 竹中 完; 石川 嶺; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 工藤 正俊
    Gastroenterological Endoscopy 60 Suppl.2 2126 - 2126 (一社)日本消化器内視鏡学会 2018年10月
  • 術前水平方向進展度診断にSpyGlass DSが有用であった遠位胆管癌の2例
    東原 久美; 三長 孝輔; 岡本 彩那; 榎木 英介; 石川 嶺; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊
    Gastroenterological Endoscopy 60 Suppl.2 2153 - 2153 (一社)日本消化器内視鏡学会 2018年10月
  • Koizumi Yohei; Hirooka Masashi; Yada Norihisa; Tamaki Nobuharu; Izumi Namiki; Kudo Masatoshi; Hiasa Yoichi
    HEPATOLOGY 68 1311A  2018年10月 [査読有り]
  • Kudo M
    Cancers 10 11 2018年10月 [査読有り]
  • Kudo M
    Liver cancer 7 4 305 - 311 2018年10月 [査読有り]
  • Omoto S; Takenaka M; Kudo M
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 1 e20 - e21 2018年10月 [査読有り]
  • Yamashita Y; Shimokawa T; Napoléon B; Fusaroli P; Gincul R; Kudo M; Kitano M
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 2 125 - 133 2018年10月 [査読有り]
     
    BACKGROUND: Current imaging modalities are limited in their ability to distinguish pancreatic cancer (PC) from non-neoplastic pancreatic lesions. The diagnostic use of contrast-enhanced endoscopic ultrasonography (CE-EUS) has increased, and its utility has been reported. Recently, contrast-enhanced harmonic EUS (CH-EUS) was reported to facilitate imaging of parenchymal perfusion and microvessels in pancreatobiliary diseases, leading to a high diagnostic accuracy for PC. The present meta-analysis aims to investigate the usefulness of CH-EUS with enhancement pattern for PC diagnosis. METHODS: A systematic meta-analysis of all potentially relevant articles identified in PubMed, the Cochrane library, and Medline was carried out. Fixed-effects or random-effects models were used to investigate pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio with 95% confidence interval (CI). RESULTS: The study enrolled 887 patients from nine eligible studies. Pooled estimates of sensitivity and specificity were 93% (95% CI, 0.91-0.95) and 80% (95% CI, 0.75-0.85), respectively. Subgroup analyses were carried out on the main results after excluding two outliers. Area under summary receiver operating characteristics curve was 0.97. No publication bias was found using funnel plots. No significant relationship was found between the diagnostic odds ratios and the characteristics of the studies including continent and contrast agent. CONCLUSIONS: This meta-analysis showed that CH-EUS with qualitative analysis of enhancement pattern is useful for the diagnosis of PC, and has high sensitivity and accuracy, regardless of the type of contrast agent used. This modality may provide improved diagnostic accuracy for PC in clinical practice.
  • Naoshi Nishida; Takafumi Nishimura; Toshimi Kaido; Kosuke Minaga; Kentaro Yamao; Ken Kamata; Mamoru Takenaka; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi Kudo
    Cancers 10 10 367 - 367 2018年09月 [査読有り]
     
    Hepatocellular carcinoma (HCC) causes one of the most frequent cancer-related deaths; an HCC subset shows rapid progression that affects survival. We clarify molecular features of aggressive HCC, and establish a molecular scoring system that predicts metastasis after curative treatment. In total, 125 HCCs were examined for TP53, CTNNB1, and TERT promoter mutation, methylation of 8 tumor suppressor genes, and 3 repetitive DNA sequences to estimate promoter hypermethylation and global hypomethylation. A fractional allelic loss (FAL) was calculated to represent chromosomal instability through microsatellite analysis. Molecular subclasses were determined using corresponding and hierarchical clustering analyses. Next, twenty-five HCC patients who underwent liver transplantation were analyzed for associations between molecular characteristics and metastatic recurrence; survival analyses were validated using a publicly available dataset of 376 HCC cases from the Cancer Genome Atlas (TCGA). An HCC subtype characterized by TP53 mutation, high FAL, and global hypomethylation was associated with aggressive tumor characteristics, like vascular invasion; CTNNB1 mutation was a feature of the less-progressive phenotype. A number of molecular risk factors, including TP53 mutation, high FAL, significant global hypomethylation, and absence of CTNNB1 mutation, were noted to predict shorter recurrence-free survival in patients who underwent liver transplantation (p = 0.0090 by log-rank test). These findings were validated in a cohort of resected HCC cases from TCGA (p = 0.0076). We concluded that molecular risks determined by common genetic and epigenetic alterations could predict metastatic recurrence after curative treatments, and could be a marker for considering systemic therapy for HCC patients.
  • Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
    European journal of cancer (Oxford, England : 1990) 100 135 - 136 2018年09月 [査読有り]
  • Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Atsushi Nakai; Hidekazu Tanaka; Yasutaka Chiba; Tomohiro Watanabe; Toshiharu Sakurai; Naoshi Nishida; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Masayuki Kitano; Masatoshi Kudo
    Digestive Endoscopy 30 5 659 - 666 2018年09月 [査読有り]
  • Nobuharu Tamaki; Yohei Koizumi; Masashi Hirooka; Norihisa Yada; Hitomi Takada; Osamu Nakashima; Masatoshi Kudo; Yoichi Hiasa; Namiki Izumi
    Hepatology research : the official journal of the Japan Society of Hepatology 48 10 821 - 828 2018年09月 [査読有り]
     
    AIM: The present study has developed and evaluated the effectiveness of a new echo attenuation measurement function combined with an ultrasonic diagnostic system for the accurate diagnosis of liver steatosis. METHODS: A multicenter prospective study involving patients with chronic hepatitis was carried out. All patients underwent liver biopsy, and attenuation coefficient (ATT) was measured on the same day. The fat area (%) of biopsy specimens was quantitatively evaluated. Correlations between ATT, steatosis grade, and fat area were evaluated. RESULTS: A total of 351 patients were enrolled in this study. The median values of fat area for steatosis grades S0, S1, S2, and S3 were 0.6%, 3.2%, 6.4%, and 15.5%, respectively. A significant correlation was found between fat area and steatosis grade (P < 0.001). Similarly, the median values of ATT for steatosis grades S0, S1, S2, and S3 were 0.55, 0.63, 0.69, and 0.85 dB/cm/MHz, respectively, and ATT increased with an increase in the steatosis grade (P < 0.001). Attenuation coefficient was significantly correlated with fat area (r = 0.50, P < 0.001). The area under the receiver operating characteristic curve corresponding to S ≥ 1, S ≥ 2, and S ≥ 3 were 0.79, 0.87, and 0.96, respectively. Similarly, the sensitivity and specificity of S ≥ 1, S ≥ 2, and S ≥ 3 were 72%, 82%, and 87% and 72%, 82%, and 89%, respectively. CONCLUSIONS: The newly developed ATT measurement for evaluation of liver steatosis was closely correlated with steatosis grade and automated quantification of fat area, and it provides clinically relevant information.
  • Takenaka M; Minaga K; Kudo M
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 30 5 700 - 701 2018年09月 [査読有り]
  • Chan AWH; Zhong J; Berhane S; Toyoda H; Cucchetti A; Shi K; Tada T; Chong CCN; Xiang BD; Li LQ; Lai PBS; Mazzaferro V; García-Fiñana M; Kudo M; Kumada T; Roayaie S; Johnson PJ
    Journal of hepatology 2018年09月 [査読有り]
  • Kudo M
    Liver cancer 7 3 215 - 224 2018年09月 [査読有り]
  • Kudo M
    Liver cancer 7 3 225 - 234 2018年09月 [査読有り]
  • Yoshida Akihiro; Hagiwara Satoru; Watanabe Tomohiro; Nishida Naosihi; Ida Hiroshi; Sakurai Toshiharu; Komeda Yoriaki; Yamao Kentaro; Takenaka Mamoru; Enoki Eisuke; Kimura Masatomo; Miyake Masako; Kawada Akira; Kudo Masatoshi
    Internal Medicine 57 17 2505 - 2509 2018年09月 [査読有り]
     
    症例は27歳男性で、小児期から光線性皮膚症に罹患しており、約1年前に全身性エリテマトーデスと診断されていた。この時点で肝胆道酵素値などが著明に上昇しており、最終的に骨髄性プロトポルフィリン症(EPP)関連肝障害と診断された。今回、全身疲労と血清中のAST、ALT、GGT、総ビリルビン値が再び上昇した。肝生検により、EPP関連肝障害の増悪であると診断した。血漿交換を計5回施行したが血中のAST、ALT、プロトポルフィリン値が低下しなかったため、200〜400mLの瀉血を毎週行ったところ、血清中の肝酵素値、AST、ALT、プロトポルフィリン値は著明に減少し、症状も軽減した。
  • Takenaka M; Minaga K; Kudo M
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 1 e1 - e2 2018年08月 [査読有り]
  • 大塚 康生; 鎌田 研; 竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 筑後 孝章; 兵頭 朋子; 中居 卓也; 竹山 宜典; 工藤 正俊
    胆道 32 3 567 - 567 日本胆道学会 2018年08月
  • Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency
    Naosuke Yokomichi; Naoshi Nishida; Yuzo Umeda; Fumitaka Taniguchi; Kazuya Yasui; Toshiaki Toshima; Yoshiko Mori; Akihiro Nyuya; Takehiro Tanaka; Takeshi Yamada; Takahito Yagi; Toshiyoshi Fujiwara; Yoshiyuki Yamaguchi; Ajay Goel; Masatoshi Kudo; Takeshi Nagasaka
    Liver Cancer 2018年08月 [査読有り]
  • Takenaka M; Yamao K; Kudo M
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 30 6 808 - 809 2018年08月 [査読有り]
  • Yoshida A; Yamao K; Takenaka M; Nakai A; Omoto S; Kamata K; Minaga K; Miyata T; Imai H; Matsumoto I; Takeyama Y; Chikugo T; Kudo M
    Internal medicine (Tokyo, Japan) 57 23 3377 - 3380 2018年08月 [査読有り]
     
    Neurilemmomas are benign tumors arising from the sheaths of peripheral nerves. They appear rarely in the abdominal cavity. We herein report an 80-year-old man with a multilocular cystic neurilemmoma mimicking a liver lesion. Preoperative images showed a lesion in the porta hepatis. Although a preoperative diagnosis was difficult, surgery was undertaken because of the possibility of malignancy. Histologically, the tumor consisted of spindle-shaped cells with positivity for S-100 protein. The final diagnosis was a neurilemmoma. Porta hepatic neurilemmomas are rare. When we encounter a multilocular cystic lesion of the liver, neurilemmoma should be considered in the differential diagnosis.
  • Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Journal of gastroenterology 54 2 171 - 181 2018年08月 [査読有り]
  • 【急速に変貌する肝細胞癌の薬物療法2018 Update】ほかの分子標的薬の動向 ラムシルマブの第III相臨床試験結果
    小川 力; 工藤 正俊
    肝・胆・膵 77 2 398 - 408 (株)アークメディア 2018年08月
  • Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo; Angela Alistar; Jamil Asselah; Jean-Frederic Blanc; Ivan Borbath; Timothy Cannon; Ki Chung; Allen Cohn; David P Cosgrove; Nevena Damjanov; Mukul Gupta; Yoshivasu Karino; Mark Karwal; Andreas Kaubisch; Robin Kelley; Jena-Luc Van Laethem; Timothy Larson; James Lee; Daneng Li; Atisha Manhas; Gulam Abbas Manji; Kazushi Numata; Benjamin Parsons; Andrew S. Paulson; Carmine Pinto; Robert Ramirez; Suresh Ratnam; Magnus Rizell; Olivier Rosmorduc; Yvonne Sada; Yutaka Sasaki; Per I Stal; Simone Strasser; Joerg Trojan; Gina Vaccaro; Hans Van Vlierberghe; Alan Weiss; Karl-Heinz Weiss; Tatsuya Yamashita; KEYNOTE-224 investigators
    The Lancet Oncology 19 7 940 - 952 2018年07月 [査読有り]
     
    Background: Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Methods: KEYNOTE-224 is a non-randomised, multicentre, open-label, phase 2 trial that is set in 47 medical centres and hospitals across ten countries. Eligible patients had pathologically confirmed hepatocellular carcinoma had previously been treated with sorafenib and were either intolerant to this treatment or showed radiographic progression of their disease after treatment an Eastern Cooperative Oncology Group performance status of 0–1 adequate organ function, and were Child-Pugh class A. Participants received 200 mg pembrolizumab intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision. The primary endpoint was objective response, defined as the proportion of patients with complete or partial response in all patients who received at least one dose of pembrolizumab, which was radiologically confirmed by use of the Response Evaluation Criteria in Solid Tumors version 1.1 by central review. Safety was also assessed in all treated patients. This trial is ongoing but closed to enrolment and is registered with ClinicalTrials.gov number NCT02702414. Findings: Between June 7, 2016, and Feb 9, 2017, we screened 169 patients with advanced hepatocellular carcinoma, of whom 104 eligible patients were enrolled and treated. As of data cutoff on Feb 13, 2018, 17 (16%) patients were still receiving pembrolizumab. We recorded an objective response in 18 (17% 95% CI 11–26) of 104 patients. The best overall responses were one (1%) complete and 17 (16%) partial responses meanwhile, 46 (44%) patients had stable disease, 34 (33%) had progressive disease, and six (6%) patients who did not have a post-baseline assessment on the cutoff date were considered not to be assessable. Treatment-related adverse events occurred in 76 (73%) of 104 patients, which were serious in 16 (15%) patients. Grade 3 treatment-related events were reported in 25 (24%) of the 104 patients the most common were increased aspartate aminotransferase concentration in seven (7%) patients, increased alanine aminotransferase concentration in four (4%) patients, and fatigue in four (4%) patients. One (1%) grade 4 treatment-related event of hyperbilirubinaemia occurred. One death associated with ulcerative oesophagitis was attributed to treatment. Immune-mediated hepatitis occurred in three (3%) patients, but there were no reported cases of viral flares. Interpretation: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib. These results indicate that pembrolizumab might be a treatment option for these patients. This drug is undergoing further assessment in two phase 3, randomised trials as a second-line treatment in patients with hepatocellular carcinoma. Funding: Merck & Co, Inc.
  • Yen CJ; Muro K; Kim TW; Kudo M; Shih JY; Lee KW; Chao Y; Kim SW; Yamazaki K; Sohn J; Cheng R; Zhang Y; Binder P; Mi G; Orlando M; Chung HC
    Journal of global oncology 4 1 - 12 2018年07月 [査読有り]
  • Jean-Luc Raoul; Masatoshi Kudo; Richard S. Finn; Julien Edeline; Maria Reig; Peter R. Galle
    Cancer Treatment Reviews 68 16 - 24 2018年07月 [査読有り]
     
    The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC. More recently, regorafenib and nivolumab have received approval in the second-line setting after sorafenib, with further positive phase 3 studies emerging in the first line (lenvatinib non-inferior to sorafenib) and second line versus placebo (cabozantinib and ramucirumab). A key recommendation in the management of patients receiving sorafenib is to promote close communication between the patient and the physician so that adverse events (AEs) are detected early and severe AEs can be prevented. Sorafenib-related AEs have been identified as clinical biomarkers for sorafenib efficacy. Healthcare professionals have become more efficient in managing AEs, identifying patients who are likely to benefit from treatment, and assessing response to treatment, resulting in a trend towards increased overall survival in the sorafenib arms of clinical studies. The rapidly changing treatment landscape due to the emergence of new treatment options (sorafenib and lenvatinib equally effective in first line regorafenib, cabozantinib, and ramucirumab showing OS benefit in second line with nivolumab approved by the FDA based on response rate) underscores the importance of re-assessing the role of the first approved systemic agent in HCC, sorafenib.
  • Kosuke Minaga; Mamoru Takenaka; Ayana Okamoto; Shunsuke Omoto; Takeshi Miyata; Hajime Imai; Masatoshi Kudo
    Endoscopy 50 7 E153 - E154 2018年07月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Masahiro Itonaga; Hajime Imai; Takeshi Miyata; Kentaro Yamao; Takashi Tamura; Junya Nuta; Kenji Warigaya; Masatoshi Kudo
    Journal of Medical Ultrasonics 45 3 391 - 397 2018年07月 [査読有り]
     
    Purpose: This study was designed to evaluate the feasibility and safety of a newly designed self-expandable metal stent for endoscopic ultrasound-guided biliary drainage (EUS-BD) when it was delivered via three different stent delivery systems: a 7.5Fr delivery catheter with a bullet-shaped tip (7.5Fr-bullet), a 7Fr catheter with a bullet-shaped tip (7Fr-bullet), or a 7Fr catheter with a tee-shaped tip (7Fr-tee). Methods: This experimental study utilized a porcine model of biliary dilatation involving ten pigs. In the animal study, technical feasibility and clinical outcomes of the stent when placed with each of the delivery systems were examined. In addition, a phantom model was used to measure the resistance of these delivery systems to advancement. Results: Phantom experiments showed that, compared with 7Fr-bullet, 7Fr-tee had less resistance force to the advancement of the stent delivery system. EUS-BD was technically successful in all ten pigs. Fistulous tract dilation was necessary in 100% (2/2), 75% (3/4), and 0% (0/4) of the pigs that underwent EUS-BD using 7.5Fr-bullet, 7Fr-bullet, and 7Fr-tee, respectively. There were no procedure-related complications. Conclusion: Our newly designed metal stent may be feasible and safe for EUS-BD, particularly when delivered by 7Fr-tee, because it eliminates the need for fistulous tract dilation.
  • Kentaro Yamao; Masayuki Kitano; Mamoru Takenaka; Kosuke Minaga; Toshiharu Sakurai; Tomohiro Watanabe; Takahisa Kayahara; Tomoe Yoshikawa; Yukitaka Yamashita; Masanori Asada; Yoshihiro Okabe; Keiji Hanada; Yasutaka Chiba; Masatoshi Kudo
    Gastrointestinal Endoscopy 88 1 66 - 75.e2 2018年07月 [査読有り]
  • Takenaka M; Arisaka Y; Sakai A; Kobayashi T; Shiomi H; Masuda A; Kudo M
    Endoscopy 50 8 E229 - E230 2018年06月 [査読有り]
  • Minaga Kosuke; Kitano Masayuki; Ogura Takeshi; Shiomi Hideyuki; Hoki Noriyuki; Nishikiori Hidefumi; Yamashita Yukitaka; Hisa Takeshi; Kato Hironari; Kamada Hideki; Takenaka Mamoru; Higuchi Kazuhide; Chiba Yasutaka; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 87 6 AB147  2018年06月 [査読有り]
  • Takenaka Mamoru; Nakai Atsushi; Omoto Shunsuke; Miyata Takeshi; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Imai Hajime; Kudo Masatoshi
    GASTROINTESTINAL ENDOSCOPY 87 6 AB209 - AB210 2018年06月 [査読有り]
  • Masatoshi Kudo; Kazuomi Ueshima; Osamu Yokosuka; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Kohei Akazawa; Ken-Ichi Yoshimura; Philip Johnson; Yasuaki Arai
    The lancet. Gastroenterology & hepatology 3 6 424 - 432 2018年06月 [査読有り]
     
    BACKGROUND: Hepatic arterial infusion chemotherapy plus sorafenib in phase 2 trials has shown favourable tumour control and a manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma. However, no randomised phase 3 trial has tested the combination of sorafenib with continuous arterial infusion chemotherapy. We aimed to compare continuous hepatic arterial infusion chemotherapy plus sorafenib with sorafenib alone in patients with advanced, unresectable hepatocellular carcinoma. METHODS: We did an open-label, randomised, phase 3 trial (SILIUS) at 31 sites in Japan. Eligible patients were aged 20 years or older, with advanced hepatocellular carcinoma not suitable for resection, local ablation, or transarterial chemoembolisation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Child-Pugh score 7 or lower; and adequate bone marrow, liver, and renal function. Patients were randomly assigned (1:1) via an interactive web response system with a computer-generated sequence to receive 400 mg sorafenib orally twice daily or 400 mg sorafenib orally twice daily plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle via an implanted catheter system). The primary endpoint was overall survival. The primary efficacy analysis comprised all randomised patients (the intention-to-treat population), and the safety analysis comprised all randomised patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01214343. FINDINGS: Between Nov 4, 2010, and June 10, 2014, 206 patients were randomly assigned (103 to the sorafenib group, 103 to the sorafenib plus hepatic arterial infusion chemotherapy group). One patient in the sorafenib plus hepatic arterial infusion chemotherapy group withdrew after randomisation. Median overall survival was similar in the sorafenib plus hepatic arterial infusion chemotherapy (n=102) and sorafenib monotherapy (n=103) groups (11·8 months [95% CI 9·1-14·5] vs 11·5 months [8·2-14·8]; hazard ratio 1·009 [95% CI 0·743-1·371]; p=0·955). Grade 3-4 adverse events that were more frequent in the sorafenib plus hepatic arterial infusion chemotherapy group than in the sorafenib monotherapy group included anaemia (15 [17%] of 88 vs six [6%] of 102), neutropenia (15 [17%] vs one [1%]), thrombocytopenia (30 [34%] vs 12 [12%]), and anorexia (12 [14%] vs six [6%]). INTERPRETATION: Addition of hepatic arterial infusion chemotherapy to sorafenib did not significantly improve overall survival in patients with advanced hepatocellular carcinoma. FUNDING: Japanese Ministry of Health, Labour and Welfare.
  • Ian Chau; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frédéric Blanc; Masatoshi Kudo; Tulio Pfiffer; Etsuro Hatano; Hyun Cheol Chung; Katerina Kopeckova; Jean-Marc Phelip; Giovanni Brandi; Shinichi Ohkawa; Chung-Pin Li; Takuji Okusaka; Yanzhi Hsu; Paolo B. Abada; Andrew X. Zhu
    British Journal of Cancer 119 1 1 - 8 2018年05月 [査読有り]
     
    Background: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. Methods: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. Results: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621 P < 0.0001) and to radiographic progression (HR 0.613 P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29 P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53 P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001). Conclusions: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
  • Kazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Ayana Okamoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Toshiharu Sakurai; Tomonori Tanaka; Hiroki Sakamoto; Kiyoshige Fujimoto; Naoshi Nishida; Masatoshi Kudo
    Frontiers in Immunology 9 918  2018年05月 [査読有り]
  • 石川 嶺; 鎌田 研; 竹中 完; 田中 秀和; 中井 敦史; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 工藤 正俊
    膵臓 33 3 346 - 346 (一社)日本膵臓学会 2018年05月
  • 大本 俊介; 竹中 完; 松本 逸平; 竹山 宜典; 工藤 正俊
    膵臓 33 3 410 - 410 (一社)日本膵臓学会 2018年05月
  • 田中 秀和; 鎌田 研; 竹中 完; 石川 嶺; 中井 敦史; 大本 俊介; 三長 孝輔; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊
    膵臓 33 3 505 - 505 (一社)日本膵臓学会 2018年05月
  • Masatoshi Kudo; Yoon-Koo Kang; Joong-Won Park; Shukui Qin; Yoshitaka Inaba; Eric Assenat; Yoshiko Umeyama; Maria José Lechuga; Olga Valota; Yosuke Fujii; Jean-Francois Martini; J Andrew Williams; Shuntaro Obi
    Liver cancer 7 2 148 - 164 2018年05月 [査読有り]
     
    Background: An unmet need exists for treatment of patients with advanced hepatocellular carcinoma (HCC) who progress on or are intolerant to sorafenib. A global randomized phase II trial (ClinicalTrial.gov No. NCT01210495) of axitinib, a vascular endothelial growth factor receptor 1-3 inhibitor, in combination with best supportive care (BSC) did not prolong overall survival (OS) over placebo/BSC, but showed improved progression-free survival in some patients. Subgroup analyses were conducted to identify potential predictive/prognostic factors. Methods: The data from this phase II study were analyzed for the efficacy and safety of axitinib/BSC in patients from Asia versus non-Asia versus Asian subgroups (Japan, Korea, or mainland China/Hong Kong/Taiwan) and predictive/prognostic values of baseline microRNAs and serum soluble proteins, using the Cox proportional hazards model. Results: Of 202 patients, 78 were from non-Asia and 124 from Asia (37 Japanese, 36 Korean, and 51 Chinese). No significant differences in OS were found between axitinib/BSC and placebo/BSC in non-Asians, Asians, or Asian subgroups. However, in an exploratory analysis, axitinib/BSC showed favorable OS in Asians, especially Japanese, when patients intolerant to prior antiangiogenic therapy were excluded from the data set. Axitinib/BSC was well tolerated by non-Asians and Asians alike. The presence of 4 circulating microRNAs, including miR-5684 and miR-1224-5p, or a level lower than or equal to the median protein level of stromal cell-derived factor 1 at baseline was significantly associated with longer OS in axitinib/BSC-treated Asians or non-Asians. Conclusions: Axitinib/BSC did not prolong survival over placebo/BSC in non-Asians, Asians, or Asian subgroups, but favorable OS with axitinib/BSC was observed in a subset of Japanese patients. A patient population that excludes sorafenib-intolerant patients might potentially be more suitable for clinical trials of new agents in advanced HCC. Since these results are very preliminary, further investigation is warranted. The potential predictive/prognostic value of several baseline microRNAs and soluble proteins identified in this study would require validation in prospective studies on a large cohort of patients.
  • Yasunori Minami; Tomohiro Minami; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
    European Radiology 28 5 1986 - 1993 2018年05月 [査読有り]
     
    Objectives: To assess the clinical feasibility of US-US image overlay fusion with evaluation of the ablative margin in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods: Fifty-three patients with 68 HCCs measuring 0.9–4.0 cm who underwent RFA guided by US-US overlay image fusion were included in this retrospective study. By an overlay of pre-/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. Therefore, the ablative margin three-dimensionally could be shown during the RFA procedure. US-US image overlay was compared to dynamic CT a few days after RFA for assessment of early treatment response. Accuracy of graded response was calculated, and the performance of US-US image overlay fusion was compared with that of CT using a Kappa agreement test. Results: Technically effective ablation was achieved in a single session, and 59 HCCs (86.8 %) succeeded in obtaining a 5-mm margin on CT. The response with US-US image overlay correctly predicted early CT evaluation with an accuracy of 92.6 % (63/68) (k = 0.67 95 % CI: 0.39–0.95). Conclusion: US-US image overlay fusion can be proposed as a feasible guidance in RFA with a safety margin and predicts early response of treatment assessment with high accuracy. Key points: • US-US image overlay fusion visualizes the ablative margin during RFA procedure. • Visualizing the margin during the procedure can prompt immediate complementary treatment. • US image fusion correlates with the results of early evaluation CT.
  • Nishida N; Kudo M
    Hepatology research : the official journal of the Japan Society of Hepatology 48 8 622 - 634 2018年05月 [査読有り]
     
    Hepatocellular carcinoma (HCC) is one of the most common cancers with a high recurrence rate. Currently, tyrosine kinase inhibitors (TKIs) are the first-line treatment for cases refractory to conventional therapies. However, the acquisition of somatic mutations can result in TKI resistance. Clinical evidence suggests that acquired immunity contributes to the suppression of tumor recurrence, indicating the potential of induced antitumor immune reaction for the treatment of HCC. Recently, immune checkpoint inhibitors have become available for the treatment of malignancies. They are effective regardless of the response to prior therapies and a durable effect can be expected, which should be attributed to an adaptive immunity to HCC components. The results of phase I/II trials of nivolumab, an anti-programmed cell death-1 antibody, showed that 20% of patients showed objective response and that nivolumab was effective regardless of prior sorafenib treatment and viral status. Nivolumab received expedited Food and Drug Administration approval in 2017 for the treatment of advanced HCC after failure or intolerance to sorafenib. However, the majority of the patients remain refractory, likely due to the solid immune suppressive status, which involves many stromal cells, humoral mediators, and suppressive checkpoint molecules. Therefore, current clinical trials are focusing on how immunosuppressive conditions in HCC might be overcome using immune checkpoint inhibitors in combination with different types of immune checkpoint blockades, TKIs, and other conventional treatments. The development of immune checkpoint inhibitors is rapidly progressing and these inhibitors are likely to be key agents for HCC treatment in the near feature.
  • Tanaka H; Kamata K; Takenaka M; Kudo M
    Internal medicine (Tokyo, Japan) 57 20 3051 - 3052 2018年05月 [査読有り]
  • Kosuke Minaga; Tomohiro Watanabe; Ken Kamata; Naoki Asano; Masatoshi Kudo
    World Journal of Gastroenterology 24 16 1725 - 1733 2018年04月 [査読有り]
  • 肝臓 診断 肝腫瘍の悪性度診断〜Bモード・エラスト・Sonazoid造影〜 肝膿瘍治療指針におけるソナゾイド造影の有用性
    盛田 真弘; 小川 力; 大村 亜紀奈; 野田 晃世; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 大西 宏明; 工藤 正俊
    超音波医学 45 Suppl. S308 - S308 (公社)日本超音波医学会 2018年04月
  • 肝臓 診断 肝腫瘤の診療ガイドラインを考える 新しい造影法導入後の問題点
    小川 力; 盛田 真弘; 野田 晃世; 大村 亜紀奈; 久保 敦司; 石川 哲朗; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊
    超音波医学 45 Suppl. S313 - S313 (公社)日本超音波医学会 2018年04月
  • 肝臓 診断 肝腫瘤の診療ガイドラインを考える 肝腫瘍の視認性に関する低音圧造影tissue harmonic imagingの有用性
    南 康範; 河野 匡志; 工藤 正俊
    超音波医学 45 Suppl. S314 - S314 (公社)日本超音波医学会 2018年04月
  • 肝癌研究会追跡調査よりみた高齢肝細胞癌に対する外科的切除の意義 Annals of Surgery
    海堀 昌樹; 吉井 健悟; 横田 勲; 長谷川 潔; 高山 忠利; 久保 正二; 權 雅憲; 泉 並木; 角谷 眞澄; 工藤 正俊; 熊田 卓; 坂元 亨宇; 中島 収; 松山 裕; 國土 典宏
    日本外科学会定期学術集会抄録集 118回 773 - 773 (一社)日本外科学会 2018年04月
  • Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    American Journal of Gastroenterology 113 4 462  2018年04月 [査読有り]
  • Masashi Kono; Yoriaki Komeda; Toshiharu Sakurai; Ayana Okamoto; Kosuke Minaga; Ken Kamata; Satoru Hagiwara; Hiroaki Inoue; Eisuke Enoki; Itaru Matsumura; Tomohiro Watanabe; Masatoshi Kudo
    Journal of Crohn's and Colitis 12 4 499 - 502 2018年03月 [査読有り]
  • Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
    The Lancet 391 10126 1163 - 1173 2018年03月 [査読有り]
     
    Background: In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, PDGF receptor α RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Methods: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice–web response system—with region macroscopic portal vein invasion, extrahepatic spread, or both Eastern Cooperative Oncology Group performance status and bodyweight as stratification factors—to receive oral lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight < 60 kg) or sorafenib 400 mg twice-daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The non-inferiority margin was set at 1·08. The trial is registered with ClinicalTrials.gov, number NCT01761266. Findings: Between March 1, 2013 and July 30, 2015, 1492 patients were recruited. 954 eligible patients were randomly assigned to lenvatinib (n=478) or sorafenib (n=476). Median survival time for lenvatinib of 13·6 months (95% CI 12·1–14·9) was non-inferior to sorafenib (12·3 months, 10·4–13·9 hazard ratio 0·92, 95% CI 0·79–1·06), meeting criteria for non-inferiority. The most common any-grade adverse events were hypertension (201 [42%]), diarrhoea (184 [39%]), decreased appetite (162 [34%]), and decreased weight (147 [31%]) for lenvatinib, and palmar-plantar erythrodysaesthesia (249 [52%]), diarrhoea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]) for sorafenib. Interpretation: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed. Funding: Eisai Inc.
  • パンクレリパーゼ摂取による腸管内および便の腸内細菌叢に対する影響の検討
    永井 知行; 櫻井 俊治; 工藤 正俊; 西山 拓輝; 岡崎 能久; 東 慶直; 渡邉 智裕; 五斗 進; 緒方 博之
    日本消化器病学会雑誌 115 臨増総会 A335 - A335 (一財)日本消化器病学会 2018年03月
  • 汎用性の画像ソフトを用いた自動抽出機能による大腰筋測定法の有用性
    盛田 真弘; 小川 力; 工藤 正俊; 大村 亜紀奈; 野田 晃世; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成
    日本消化器病学会雑誌 115 臨増総会 A344 - A344 (一財)日本消化器病学会 2018年03月
  • 画像支援ソフトを用いたHCC診療に対する当院の取り組み
    小川 力; 盛田 真弘; 大村 亜紀奈; 野田 晃世; 久保 敦司; 石川 哲朗; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊
    日本消化器病学会雑誌 115 臨増総会 A388 - A388 (一財)日本消化器病学会 2018年03月
  • 膵体部の膵神経内分泌腫瘍に合併した膵性胸水の一例
    河野 辰哉; 山雄 健太郎; 中井 敦史; 大本 俊介; 鎌田 研; 三長 孝輔; 宮田 剛; 今井 元; 松本 逸平; 竹山 宜典; 田中 伴典; 筑後 孝章; 林 暁洋; 工藤 正俊
    日本消化器病学会雑誌 115 臨増総会 A395 - A395 (一財)日本消化器病学会 2018年03月
  • 十二指腸穿破をきたした正中球状靱帯症候群による膵十二指腸動脈瘤の一例
    高島 耕太; 大本 俊介; 三長 孝輔; 竹中 完; 中井 敦史; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 米田 頼晃; 松井 繁長; 工藤 正俊
    日本消化器病学会雑誌 115 臨増総会 A355 - A355 (一財)日本消化器病学会 2018年03月
  • Masatoshi Kudo
    Liver Cancer 7 1 1 - 19 2018年03月 [査読有り]
  • Masatoshi Kudo
    Liver Cancer 7 1 20 - 27 2018年03月 [査読有り]
  • Kaibori M; Yoshii K; Hasegawa K; Ogawa A; Kubo S; Tateishi R; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo N; Liver Cancer Study; Group of Japan
    Annals of surgery 270 121 - 130 2018年03月 [査読有り]
  • Takayasu K; Arii S; Sakamoto M; Matsuyama Y; Kudo M; Kaneko S; Nakashima O; Kadoya M; Izumi N; Takayama T; Ku Y; Kumada T; Kubo S; Kokudo T; Hagiwara Y; Kokudo N; Liver Cancer Study; Group of Japan
    Liver international : official journal of the International Association for the Study of the Liver 38 3 484 - 493 2018年03月 [査読有り]
     
    BACKGROUND AND AIMS: Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined. The efficacy of surgical resection (SR), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) was evaluated. METHODS: The 853 (SR, 176; RFA, 491; PEI, 186) patients were enrolled who met Child-Pugh A/B, single hypovascular HCC ≤2 cm pathologically proven, available tumour differentiation and absence of macrovascular invasion and extrahepatic metastasis. Overall and recurrence-free survivals were compared in original and a propensity score weighted pseudo-population with 732 patients. RESULTS: The median follow-up time and tumour size were 2.8 years and 1.47 cm respectively. In original population, multivariate Cox regression showed no significant difference for overall survival among three groups. In pseudo-population, Cox regression also revealed no significant difference for overall survival among them, although SR (HR, 0.56; 95% CI, 0.36-0.86) and RFA (HR, 0.75; 95% CI, 0.57-1.00) groups had significantly lower recurrence than PEI group. The overall survival rates at 3 and 5 years for the SR, RFA and PEI groups were 94%/70%, 90%/75% and 94%/73% respectively. Corresponding recurrence-free survival rates were 64%/54%, 59%/41% 48%/33% respectively. Subgroup analysis revealed no significant survival benefit of SR compared with non-SR. No treatment-related death occurred. CONCLUSIONS: For patients with single hypovascular HCC ≤2 cm, no significant difference for overall survival was first identified among 3 treatment groups. The SR or RFA could be recommended, and PEI would be alternative to RFA.
  • Kosuke Minaga; Mamoru Takenaka; Ken Kamata; Masatoshi Kudo
    Digestive and Liver Disease 50 3 311  2018年03月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Ken Kamata; Tomoe Yoshikawa; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Masayuki Kitano; Masatoshi Kudo
    Cancers 10 2 2018年02月 [査読有り]
     
    The most common symptom in patients with advanced pancreatic cancer is abdominal pain. This has traditionally been treated with nonsteroidal anti-inflammatory drugs and opioid analgesics. However, these treatments result in inadequate pain control or drug-related adverse effects in some patients. An alternative pain-relief modality is celiac plexus neurolysis, in which the celiac plexus is chemically ablated. This procedure was performed percutaneously or intraoperatively until 1996, when endoscopic ultrasound (EUS)-guided celiac plexus neurolysis was first described. In this transgastric anterior approach, a neurolytic agent is injected around the celiac trunk under EUS guidance. The procedure gained popularity as a minimally invasive approach and is currently widely used to treat pancreatic cancer-associated pain. We focus on two relatively new techniques of EUS-guided neurolysis: EUS-guided celiac ganglia neurolysis and EUS-guided broad plexus neurolysis, which have been developed to improve efficacy. Although the techniques are safe and effective in general, some serious adverse events including ischemic and infectious complications have been reported as the procedure has gained widespread popularity. We summarize reported clinical outcomes of EUS-guided neurolysis in pancreatic cancer (from the PubMed and Embase databases) with a goal of providing information useful in developing strategies for pancreatic cancer-associated pain alleviation.
  • 幕谷 悠介; 松本 逸平; 大本 俊介; 筑後 孝章; 川口 晃平; 松本 正孝; 村瀬 貴昭; 亀井 敬子; 里井 俊平; 中居 卓也; 竹中 完; 工藤 正俊; 竹山 宜典
    日本消化器外科学会雑誌 51 2 114 - 121 (一社)日本消化器外科学会 2018年02月 [査読有り]
     
    膵・胆管合流異常に合併した共通管内乳頭状腫瘍の1例を報告する.症例は75歳の男性で,6ヵ月間に2度の急性膵炎を発症し保存的加療で軽快した.急性膵炎の原因精査および加療目的で当院へ紹介となった.ERCPでは膵・胆管合流異常を認め,共通管内に7mmの結節様陰影欠損像を認めた.上部内視鏡検査では乳頭部からの粘液排出は認めず,超音波内視鏡検査では共通管内に乳頭状の腫瘍が描出された.造影CTでは膵頭部に拡張した共通管と内部に増強効果を持つ8mmの腫瘤を認めた.尾側の主膵管の拡張は認めなかった.膵・胆管合流異常に合併した共通管内乳頭状腫瘍と診断し,亜全胃温存膵頭十二指腸切除術を施行した.病理肉眼所見では共通管内に発育する有茎性の乳頭状腫瘍で,組織像は管状構造増生を主体とする腺腫であった.免疫組織学的染色ではMUC1,MUC2陰性,MUC5AC陽性で胃型腺腫と最終診断した.(著者抄録)
  • Minami Y; Kudo M
    Brain and nerve = Shinkei kenkyu no shinpo 70 2 133 - 137 2018年02月 [査読有り]
  • Masafumi Ikeda; Masatoshi Kudo; Hiroshi Aikata; Hiroaki Nagamatsu; Hiroshi Ishii; Osamu Yokosuka; Takuji Torimura; Manabu Morimoto; Kenji Ikeda; Hiromitsu Kumada; Tosiya Sato; Ikuko Kawai; Toru Yamashita; Hiroshi Horio; Takuji Okusaka
    Journal of gastroenterology 53 2 281 - 290 2018年02月 [査読有り]
     
    BACKGROUND: This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: Patients with unresectable HCC were randomized 1:1 to receive TACE with miriplatin or epirubicin in lipiodol. The primary endpoint was OS; secondary endpoints were percentages of patients who achieved treatment effect (TE) 4 (100% necrotizing effect or tumor reduction), duration of time to TACE failure, and adverse events (AEs). OS was compared using a stratified log-rank test adjusted for clinical stage, Child-Pugh class, and institution. RESULTS: Of 257 patients enrolled from August 2008 to August 2010, 247 were analyzed for efficacy and toxicity (miriplatin, n = 124; epirubicin, n = 123). Baseline characteristics were well balanced between the two groups. Median OS times were 1111 days for miriplatin and 1127 days for epirubicin (adjusted hazard ratio 1.01, 95% confidence interval 0.73-1.40, P = 0.946). TE4 rates were 44.4% for miriplatin and 37.4% for epirubicin. Median times to TACE failure were 365.5 days for miriplatin and 414.0 days for epirubicin. AEs of grade 3 or higher, including elevated aspartate aminotransferase (miriplatin, 39.5%; epirubicin, 57.7%) and elevated alanine aminotransferase (miriplatin, 31.5%; epirubicin, 53.7%), were less frequent in the miriplatin than the epirubicin group. CONCLUSIONS: OS after TACE with miriplatin was not superior to that after TACE with epirubicin; however, hepatic AEs were less frequent with miriplatin. CLINICAL TRIAL REGISTRATION: JapicCTI-080632.
  • 肝がんの新しい薬「消化器病の薬」
    工藤正俊
    消化器のひろば 13 8  2018年 [査読有り][招待有り]
  • 鎌田 研; 西田 直生志; 樫田 博史; 筑後 孝章; 千葉 康敬; 中居 卓也; 竹山 宜典; Andrea Lisotti; Pietro Fusaroli; 工藤 正俊; 竹中 完; 北野 雅之; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 櫻井 俊治
    日本消化器内視鏡学会雑誌 60 9 1611 - 1620 一般社団法人 日本消化器内視鏡学会 2018年 

    【背景と目的】孤立性胆嚢病変の鑑別診断は課題が残されている．本研究の目的は，胆嚢孤立性病変に対する造影ハーモニックEUS（CH-EUS）の有用性を評価すること．

    【方法】2007年３月から2014年２月までの間に，孤立性胆嚢病変を有する125人の患者に対してCH-EUSを施行し，レトロスペクティブにCH-EUSの有用性を検討した．はじめに，胆嚢病変と胆泥の鑑別診断能に関して，通常のBモードEUS（FB-EUS）とCH-EUSを比較検討した．その後，良悪性鑑別に対する診断能を両検査間で比較検討した．CH-EUSのVascular imageおよびPerfusion imageにおける血流パターンを５人の医師によるブラインドリーディングにて評価した．

    【結果】胆嚢病変と胆泥の鑑別診断能に関して，FB-EUSの感度は82％，特異度は100％，正診率は95％であった．一方，CH-EUSの感度は100％，特異度は99％，正診率は99％であった．良悪性鑑別に関して，腫瘍の大きさあるいは形状に基づいて診断した場合のFB-EUSの診断感度は61-87％，特異度は71-88％，正診率は74-86％であった．CH-EUSにてVascular imageにおけるirregular vessel patternあるいはPerfusion imageにおけるheterogeneous enhancementを悪性所見とした場合の診断感度は90％，特異度は98％，正診率は96％であり，FB-EUSの診断能と比較し有意に良好であった．

    【結語】CH-EUSは，孤立性胆嚢病変の鑑別診断において有用である．

  • IgG4
    渡邉 智裕; 工藤正俊
    消化器病学サイエンス 2 3 41 - 41 2018年 [招待有り]
  • 自然免疫反応が膵臓の慢性炎症に果たす役割
    渡邉 智裕; 三長 孝輔; 鎌田 研; 工藤 正俊
    膵臓 33 4 737 - 741 2018年 [査読有り][招待有り]
  • 学会レポート「第54回米国臨床腫瘍学会（ASCO）」
    工藤正俊
    肝胆膵 77 522 - 532 2018年 [査読有り]
  • 肝細胞癌の切除・RFA後のアジュバント・ネオアジュバント療法
    工藤正俊
    肝胆膵 77 506 - 511 2018年 [査読有り]
  • 西田直生志; 工藤正俊
    肝胆膵 77 2 499 - 505 (株)アークメディア 2018年 [査読有り]
  • どのようにしてcold tumorをhot tumorに変えるか
    工藤正俊
    肝胆膵 77 449 - 455 2018年 [査読有り]
  • ニボルマブの臨床試験のアップデート
    平岡 淳; 道堯浩二郎; 工藤正俊
    肝胆膵 77 419 - 424 2018年 [査読有り]
  • レンバチニブのQOLと費用対効果
    上嶋一臣; 工藤正俊
    肝胆膵 77 306 - 309 2018年 [査読有り]
  • レンバチニブとソラフェニブの有効性および肝機能の変化－REFLECT試験への登録症例の経験から－
    上嶋一臣; 工藤正俊
    肝胆膵 77 278 - 283 2018年 [査読有り]
  • REFLECT試験の結果を振り返る、レンバチニブの高い奏効率の臨床的意義
    工藤正俊
    肝胆膵 77 263 - 270 2018年 [査読有り]
  • TACEとソラフェニブ併用試験（TACTICS）の概要と成功要因－過去の失敗試験との比較からTACE併用試験のendpointを考える－
    工藤正俊
    肝胆膵 77 231 - 240 2018年 [査読有り]
  • TACEによる肝予備能低下‐ALBI score/gradeによる評価－
    平岡 淳; 道堯浩二郎; 熊田 卓; 工藤正俊
    肝胆膵 77 224 - 230 2018年 [査読有り]
  • 特別座談会「肝細胞癌薬物療法のパラダイムシフトを語る」
    工藤正俊; 池田公史; 古瀬純司; 北野滋久
    肝胆膵 77 183 - 210 2018年 [査読有り][招待有り]
  • Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varices
    Matsui S; Kashida H; Kudo M
    Ann Gastroenterol 31 636  2018年 [査読有り]
  • Management of hepatocellular carcinoma in Japan as a world-leading model
    工藤正俊
    Liver Cancer 7 134 - 147 2018年 [査読有り]
  • Cabozantinib as a second-line agent in advanced hepatocellular carcinoma
    工藤正俊
    Liver Cancer 7 123 - 133 2018年 [査読有り]
  • Mamoru Takenaka; Ken Kamata; Kosuke Minaga; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Endoscopic Ultrasound 7 5 349 - 349 2018年 [査読有り]
  • 肝癌診療の最前線
    工藤正俊
    日本内科学会雑誌 107 9 1934 - 1943 2018年 [査読有り]
  • 切除不能な肝細胞癌に対するスチバーガの位置づけと適正使用のポイント―ネクサバールとスチバーガによるsequential therapy を視野に入れた治療戦略―
    工藤正俊; Josep M. Llovet; Ann-Lii Cheng; 泉 並木; 古瀬純司; 山下太郎
    医学書院 Cancer Board Square 4 2018年 [査読有り]
  • 開発中の肝癌治療薬 特集：肝癌―診断・治療の最新知見― V.特論
    工藤正俊
    日本臨床 76 343 - 352 2018年
  • Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review.
    Minaga K; Watanabe T; Kamata K; Asano N; Kudo M
    World J Gastroenterol 2018年 [査読有り]
  • Dietrich CF; Averkiou M; Nielsen MB; Barr RG; Burns PN; Calliada F; Cantisani V; Choi B; Chammas MC; Clevert DA; Claudon M; Correas JM; Cui XW; Cosgrove D; D'Onofrio M; Dong Y; Eisenbrey J; Fontanilla T; Gilja OH; Ignee A; Jenssen C; Kono Y; Kudo M; Lassau N; Lyshchik A; Franca Meloni M; Moriyasu F; Nolsøe C; Piscaglia F; Radzina M; Saftoiu A; Sidhu PS; Sporea I; Schreiber-Dietrich D; Sirlin CB; Stanczak M; Weskott HP; Wilson SR; Willmann JK; Kim TK; Jang HJ; Vezeridis A; Westerway S
    Ultrasound international open 4 1 E2 - E15 2018年01月 [査読有り]
  • Ken Kamata; Tomohiro Watanabe; Kosuke Minaga; Warren Strober; Masatoshi Kudo
    Current Protocols in Immunology 120 1 15.31.1 - 15.31.8 2018年01月 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Hiroshi Ida; Toshiharu Sakurai; Kazuomi Ueshima; Masahiro Takita; Yoriaki Komeda; Norihiro Nishijima; Yukio Osaki; Masatoshi Kudo
    Antiviral Therapy 23 6 513 - 521 2018年 [査読有り]
  • Hiroki Nishiyama; Tomoyuki Nagai; Masatoshi Kudo; Yoshihisa Okazaki; Yoshinao Azuma; Tomohiro Watanabe; Susumu Goto; Hiroyuki Ogata; Toshiharu Sakurai
    Biochemical and Biophysical Research Communications 495 1 273 - 279 2018年01月 [査読有り]
  • Masatoshi Kudo; Ann-Lii Cheng; Joong-Won Park; Jae Hyung Park; Po-Chin Liang; Hisashi Hidaka; Namiki Izumi; Jeong Heo; Youn Jae Lee; I-Shyan Sheen; Chang-Fang Chiu; Hitoshi Arioka; Satoshi Morita; Yasuaki Arai
    The Lancet Gastroenterology and Hepatology 3 1 37 - 46 2018年01月 [査読有り]
     
    Background Orantinib is an oral multi-kinase inhibitor. This study was done to evaluate the efficacy of orantinib combined with conventional transcatheter arterial chemoembolisation (cTACE) in patients with unresectable hepatocellular carcinoma. Methods This randomised, double-blind, placebo-controlled, phase 3 study was done at 75 sites in Japan, South Korea, and Taiwan. Patients with unresectable hepatocellular carcinoma, no extra-hepatic tumour spread, and Child-Pugh score of 6 or less were randomly assigned (1:1) by interactive web response system using a computer-generated sequence to receive orantinib or placebo, within 28 days of cTACE. Randomisation was stratified by region, Child-Pugh score (5 vs 6), alpha fetoprotein concentrations (< 400 ng/mL vs ≥400 ng/mL), and size of the largest lesion (≤50 mm vs > 50 mm). Orantinib at 200 mg, twice per day, or placebo was given orally until TACE failure or unacceptable toxicity. The patients, investigators, and study personnel were masked to treatment assignment. The primary endpoint was overall survival, analysed in the full analysis set (patients who had received at least one dose of study drug). This study is registered at ClinicalTrials.gov, number NCT01465464, and has been terminated. Findings Between Dec 10, 2010, and Nov 21, 2013, 889 patients were randomly assigned to receive either orantinib (445 patients 444 treated) or placebo (444 patients all treated). The study was ended at interim analysis for futility evaluation. Median follow-up was 17·3 months (IQR 11·3–26·4). There was no improvement in overall survival with orantinib compared with placebo (median 31·1 months [95% CI 26·5–34·5] vs 32·3 months [28·4–not reached] hazard ratio 1·090, 95% CI 0·878–1·352 p=0·435). The main adverse events in the orantinib group were oedema, ascites, and elevation of aspartate and alanine aminotransferases. The most frequent adverse events of grade 3 or worse in the orantinib group included elevated aspartate aminotransferase (189 [43%] patients in the oratinib group, 161 [36%] patients in the placebo group), elevated alanine aminotransferase (150 [34%] patients in the oratinib group, 132 (30%) patients in the placebo group), and hypertension (47 [11%] patients in the oratinib group, 39 [9%] patients in the placebo group). Serious adverse events were reported in 200 (45%) patients in the orantinib group and 134 (30%) patients in the placebo group. Interpretation Orantinib combined with cTACE did not improve overall survival in patients with unresectable hepatocellular carcinoma. Funding Taiho Pharmaceutical.
  • Meeting Report; 第54回米国臨床腫瘍学会（ASCO 2018）
    工藤正俊
    The Liver Cancer Journal 10 54 - 61 2018年 [査読有り][招待有り]
  • Ken Kamata; Mamoru Takenaka; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 87 1 158 - 163 2018年01月 [査読有り]
     
    Background and Aims: EUS-guided FNA (EUS-FNA) is used for the diagnosis of pancreatic adenocarcinoma, but sometimes the method results in a false negative. Occasionally, an avascular area may be observed within the pancreatic adenocarcinoma tumor during contrast-enhanced harmonic EUS (CH-EUS). The aim of this study was to evaluate whether the diagnostic sensitivity of EUS-FNA for pancreatic adenocarcinoma was affected by the presence of avascularity on CH-EUS. Methods: Two hundred ninety-two patients with pancreatic adenocarcinoma who presented at Kindai University Hospital for EUS-FNA and CH-EUS between June 2009 and August 2013 were retrospectively evaluated. This was a single-center retrospective analysis of prospectively collected data held in a registry. The overall sensitivity of EUS-FNA for the diagnosis of pancreatic adenocarcinoma was calculated. The sensitivities of cytology, histology, and the combination of cytology and histology were also evaluated. These variables were individually evaluated according to the presence or absence of an avascular area on CH-EUS to assess whether the diagnostic sensitivity of EUS-FNA for pancreatic adenocarcinoma was related to the presence of an avascular area within the tumors. Results: The overall sensitivity of EUS-FNA was 90.8% (265/292). The sensitivities of EUS-FNA for lesions with and without an avascular area were 72.9% (35/48) and 94.3% (230/244), respectively, with the difference being statistically significant (P <.001). Conclusions: EUS-FNA has lower sensitivity for pancreatic adenocarcinoma with avascular areas on CH-EUS.
  • Ken Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Tosiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Yasutaka Chiba; Takuya Nakai; Yoshifumi Takeyama; Andrea Lisotti; Pietro Fusaroli; Masatoshi Kudo
    Digestive Endoscopy 30 1 98 - 106 2018年01月 [査読有り]
     
    Background and Aim: Differential diagnosis of localized gallbladder lesions is challenging. The aim of the present study was to evaluate the utility of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for diagnosis of localized gallbladder lesions. Methods: One hundred and twenty-five patients with localized gallbladder lesions were evaluated by CH-EUS between March 2007 and February 2014. This was a single-center retrospective study. Utilities of fundamental B-mode EUS (FB-EUS) and CH-EUS in the differentiation of gallbladder lesions and sludge plug were initially compared. Thereafter, these two examinations were compared with respect to their accuracy in the diagnosis of malignant lesions. Five reviewers blinded to the clinicopathological results evaluated microcirculation patterns in the vascular and perfusion images. Results: In the differentiation between gallbladder lesions and sludge plug, FB-EUS had a sensitivity, specificity, and accuracy of 82%, 100%, and 95%, respectively, whereas CH-EUS had a sensitivity, specificity, and accuracy of 100%, 99%, and 99%, respectively. FB-EUS-based diagnosis of carcinomas based on tumor size and/or shape had a sensitivity, specificity, and accuracy of 61–87%, 71–88%, and 74–86%, respectively. Additional information regarding irregular vessel patterns in the vascular image and/or heterogeneous enhancement in the perfusion image on CH-EUS increased the sensitivity, specificity, and accuracy for the diagnosis of carcinomas to 90%, 98%, and 96%, respectively. There was a significant difference between FB-EUS and CH-EUS in terms of carcinoma diagnosis. Conclusion: CH-EUS was useful for the evaluation of localized gallbladder lesions.
  • Kosuke Minaga; Mamoru Takenaka; Shunsuke Omoto; Takeshi Miyata; Ken Kamata; Kentaro Yamao; Hajime Imai; Tomohiro Watanabe; Masayuki Kitano; Masatoshi Kudo
    Journal of Medical Ultrasonics 45 1 161 - 165 2018年01月 [査読有り]
  • 編集; 消化器内科診療レジデントマニュアル
    工藤正俊
    2 - 431 2018年 [査読有り]
  • 座談会「肝癌治療のシミュレーション・ナビゲーションを語る」. 特集「肝癌治療のイノベーション-シミュレーション・ナビゲーション技術の新展開-」
    工藤正俊; 大城幸雄; 小川 力; 宮山士朗
    肝胆膵 77 1241 - 1263 2018年 [査読有り][招待有り]
  • Hepatic Guideの有用性. 特集「肝癌治療のイノベーション-シミュレーション・ナビゲーション技術の新展開-」
    南 知宏; 南 康範; 工藤正俊; 鶴﨑正勝; 柳生行伸; 村上卓道
    肝胆膵 77 1161 - 1165 2018年 [査読有り]
  • 南 康範; 南 知宏; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    肝胆膵 77 6 1139 - 1144 (株)アークメディア 2018年 [査読有り]
  • 座談会; 肝細胞癌の薬物療法の最先端
    工藤正俊; 山下竜也; 森口理久; 池田公史; 上嶋一臣; 鳥村拓司
    肝臓 59 517 - 544 2018年 [査読有り][招待有り]
  • 香川県下におけるSorafenibの使用とその傾向
    小川 力; 筒井 朱美; 妹尾 知典; 永野 拓也; 高口 浩一; 谷 丈二; 森下 朝洋; 米山 弘人; 正木 勉; 守屋 昭男; 安東 正晴; 出口 章広; 國土 泰孝; 工藤 正俊
    The Liver Cancer Journal 9 2 160 - 161 (株)メディカルレビュー社 2017年12月
  • Masatoshi Kudo; Tadaaki Arizumi
    Oncology (Switzerland) 93 1 127 - 134 2017年12月 [査読有り]
     
    The multikinase inhibitor sorafenib is the first oral molecular targeted agent with proven prognostic benefit in unresectable advanced hepatocellular carcinoma (HCC). However, as with other drugs, sorafenib has its limitations, and various clinical trials have been conducted to develop novel molecular targeted agents for use alone or in combination with existing locoregional therapies. Despite this, clinical trials of molecular targeted agents combined with transarterial chemoembolization (TACE) have not reported major treatment outcomes to date. In this review, we describe previous clinical trials of combination therapy with TACE and a molecular targeted agent in patients with unresectable HCC.
  • Masatoshi Kudo
    Oncology (Switzerland) 93 1 1 - 8 2017年12月 [査読有り]
  • Hiroki Sakamoto; Satoshi Harada; Nobu Nishioka; Kazuo Maeda; Takamasa Kurihara; Tateki Sakamoto; Kazuhide Higuchi; Masayuki Kitano; Yoshifumi Takeyama; Masafumi Kogire; Masatoshi Kudo
    Oncology (Switzerland) 93 1 89 - 97 2017年12月 [査読有り]
     
    Objectives: The early-stage pancreatic cancer (e-PC stage I/II) detection rate is quite low at approximately 25%. The aim of this study was to evaluate the feasibility of a social program (the Kishiwada Katsuragi project) wherein our hospital, which specializes in PC, and primary care medical offices (PMOs) used clinical findings to detect e-PC. Methods: Patients with a score of ≥2 points on clinical findings were enrolled: symptoms of abdominal pain/back pain (1 point), new-onset diabetes (1 point), high amylase (AMY) and/or pancreaitc AMY (P-AMY) (1 point), high carbohydrate antigen 19-9 (1 point), and ultrasonography (US) findings including direct (e.g., a solid pancreatic tumor) and/or indirect findings (e.g., dilatation of a pancreatic diameter of ≥2.5 mm and/or cystic lesions) (2 points) were evaluated using the protocol for social programs. Results: Between November 2014 and December 2016, 244 patients were enrolled by 41 PMOs as cooperative facilities, and 15 e-PC cases (53.6%) of the 28 PC patients were detected. The mean clinical finding score of the e-PC group (3.13 ± 1.9) was significantly higher than that of the overall non-PC group (2.1 ± 0.4) (p < 0.05). "High AMY/P-AMY" and "symptoms" were significantly more frequent in the e-PC group than in the non-PC group (p < 0.05). Although the sensitivity of direct findings by US was 40.0%, that of indirect-findings was 93.3% in the e-PC group. Nine and 6 of the 15 patients with e-PC were enrolled via general internal medicine offices (GIMs) and other PMOs without GIMs (general surgery, n = 3 urology, n = 2 otolaryngology, n = 1). Conclusion: This social program with collaborations between medical centers that specialize in PC and PMOs used clinical findings, suggesting that not only GIMs but also other PMOs and indirect findings by US may play an important role in improving the e-PC detection rate.
  • Yasuo Otsuka; Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Hidekazu Tanaka; Masatoshi Kudo
    ENDOSCOPY 49 12 E316 - E318 2017年12月 [査読有り]
  • Kamata K; Takenaka M; Minaga K; Kudo M
    Gastrointestinal endoscopy 86 6 1177 - 1179 2017年12月 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo
    Oncology (Switzerland) 93 1 160 - 164 2017年12月 [査読有り]
     
    During tumor development, several immunosuppressive molecules are released from cancer cells and contribute to the establishment of immunosuppressive tumor environment. In tumor tissues, cytokines, chemokines, growth factors, and metabolites are present and could counter the effects of immune checkpoint inhibitors. From this point of view, monotherapy of anti-PD-1/PD-L1 antibody might not be enough to exert a sufficient antitumor effect additional blockade of immunosuppressive molecules in tumor microenvironment could enhance the antitumor effect of anti-PD-1/PD-L1 antibody. Importantly, the production of immunosuppressive molecules in cancer cells is attributed to the activation of cellular signaling through genetic and epigenetic alterations and environmental stimulation, such as inflammation and hypoxia. In this review, we focus on the establishment of immunosuppressive microenvironment of hepatocellular carcinoma in the context of activation of oncogenic signals, and discuss how the immunosuppressive condition could be overcome using tyrosine kinase inhibitors.
  • Masatoshi Kudo
    Oncology (Switzerland) 93 1 147 - 159 2017年12月 [査読有り]
     
    Clinical trials are currently ongoing to evaluate the utility of antibodies against programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) as monotherapy or combination therapy in patients with hepatocellular carcinoma (HCC). Results of combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab in HCC were presented at the 2017 annual meeting of the ASCO (American Society of Clinical Oncology). Response rates were 25% in all 40 patients and 40% in the 20 uninfected patients, both of which are encouraging. Transcatheter arterial chemoembolization and radiofrequency ablation can activate tumor immunogenicity by releasing tumor-associated antigen and by inducing the migration of cytotoxic T lymphocytes to small intrahepatic metastatic nodules. Subsequent administration of anti-PD-1 antibody could control these small intrahepatic metastatic nodules. In a nonclinical study, the combination of pembrolizumab and lenvatinib inhibited the cancer immunosuppressive environments induced by tumor-associated macrophages and regulatory T cells. This, in turn, decreased the levels of TGF-β and IL-10, the expression of PD-1, and the inhibition of Tim-3, triggering anticancer immunity mediated by immunostimulatory cytokines such as IL-12. Studies such as these may provide insight into the appropriate molecular targeted agents to be used with immune checkpoint inhibitors.
  • Masatoshi Kudo
    Oncology (Switzerland) 93 1 135 - 146 2017年12月 [査読有り]
     
    Systemic therapy for hepatocellular carcinoma (HCC) changed drastically after the introduction of the molecular targeted agent sorafenib in 2007. Sorafenib provides an additional therapeutic option for patients with extrahepatic spread or vascular invasion, resulting in improved survival even among patients with advanced HCC however, the toxicity of sorafenib and its unsatisfactory antitumor effects remain unsolved issues. The development of novel molecular targeted agents as alternatives to sorafenib has been limited by difficulties unique to HCC. Recent studies have demonstrated the efficacy of two molecular targeted agents, the second-line agent regorafenib, which is used after sorafenib failure, and the first-line agent lenvatinib, which has been shown to be noninferior to sorafenib. Another category of agents that are attracting considerable interest are immune checkpoint inhibitors such as anti-PD-1/PD-L1 or CTLA-4 antibodies, which kill cancer cells via a unique mechanism. The therapeutic effects of some of these agents are currently under investigation in phase III studies. The most recent topics of interest are the combination of anti-PD-1/PD-L1 therapies with other immune checkpoint inhibitors, such as anti-CTLA-4 antibodies, or with a tyrosine kinase inhibitor, or with locoregional therapies such as resection, ablation, or transarterial chemoembolization.
  • Takeshi Miyata; Mamoru Takenaka; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Masatoshi Kudo
    Oncology (Switzerland) 93 1 98 - 101 2017年12月 [査読有り]
     
    Repeated pancreatic juice cytology via endoscopic nasopancreatic drainage (ENPD) has a high diagnostic yield and might be useful for the diagnosis of early-stage pancreatic cancer. A 67-year-old man presented with a pancreatic cyst occasionally detectable in the body of the pancreas by ultrasonography (US). No obvious pancreatic tumor was detected by US, computed tomography (CT), magnetic resonance cholangiopancreatography, and endoscopic ultrasound (EUS) (although the latter did reveal a weak, low echoic area). Endoscopic retrograde pancreatography showed irregular narrowing of the main pancreatic duct (MPD) at the pancreatic body. Pancreatic juice cytology was also performed, but did not give evidence of a malignancy. Therefore, the patient was followed up. CT and EUS performed after 3 months showed the same findings as did endoscopic retrograde pancreatography however, the results of repeated pancreatic juice cytology performed via ENPD tube revealed a suspected malignancy on 2 of 6 occasions. Therefore, we performed a central pancreatectomy. Histopathological examination of a resected specimen revealed carcinoma in situ in the narrow MPD at the body of the pancreas. In the current case, repeated pancreatic juice cytology via ENPD was effective. A weak low echoic area around the MPD stricture on EUS might be related to the inflammatory change accompanying carcinoma in situ of the pancreas.
  • Satoshi Ogawa; Tatsuya Ishii; Kosuke Minaga; Yasuki Nakatani; Keiichi Hatamaru; Takuji Akamatsu; Takeshi Seta; Shunji Urai; Yoshito Uenoyama; Yukitaka Yamashita; Masatoshi Kudo
    Oncology (Switzerland) 93 1 43 - 48 2017年12月 [査読有り]
     
    Objectives: This study aimed to evaluate the characteristics and the feasibility of 18-mm-diameter stents for obstructive colorectal cancer, comparing the clinical courses with 22-mm-diameter stents. Methods: We retrospectively compared 33 consecutive cases treated with 18-mm-diameter stents (bridge to surgery [BTS] in 25, palliative therapy [PAL] in 8) with 27 consecutive cases treated with 22-mm-diameter stents (BTS in 21, PAL in 6) for obstructive colorectal cancer between May 2013 and November 2015 in our institution. Results: There were no significant differences between the 18-mm and 22-mm groups in technical success rates (97 and 96%, respectively) and clinical success rates (100 and 100%, respectively). As a BTS, the rates of complications and stoma formation were not significantly different between groups. For PAL, although the rates of complications and stent patency were similar, stent occlusion occurred in 1 patient (12.5%) in the 18-mm group. Conclusions: The 18-mm-diameter stents were similarly effective when compared with 22-mm-diameter stents. Because 18-mm-diameter stents are easy to handle and produce less mechanical stress, they have the potential to decrease the perforation rate and mitigate the stent's impact on the tumors. 18-mm-diameter stents can be useful and safe, especially as a BTS.
  • Ken Kamata; Mamoru Takenaka; Masakatsu Tsurusaki; Masatoshi Kudo
    DIGESTIVE AND LIVER DISEASE 49 11 1282 - 1282 2017年11月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Ken Kamata; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Masatoshi Kudo
    ENDOSCOPY 49 11 E281 - E282 2017年11月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Yasutaka Chiba; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES 31 11 4764 - 4772 2017年11月 [査読有り]
     
    Treatment of unresectable malignant hilar biliary stricture (UMHBS) is challenging, especially after failure of repeated transpapillary endoscopic stenting. Endoscopic ultrasonography-guided intrahepatic biliary drainage (EUS-IBD) is a recent technique for intrahepatic biliary decompression, but indications for its use for complex hilar strictures have not been well studied. The aim of this study was to assess the feasibility and safety of EUS-IBD for UMHBS after failed transpapillary re-intervention. Retrospective analysis of all consecutive patients with UMHBS of Bismuth II grade or higher who, between December 2008 and May 2016, underwent EUS-IBD after failed repeated transpapillary interventions. The technical success, clinical success, and complication rates were evaluated. Factors associated with clinical ineffectiveness of EUS-IBD were explored. A total of 30 patients (19 women, median age 66 years [range 52-87]) underwent EUS-IBD for UMHBS during the study period. Hilar biliary stricture morphology was classified as Bismuth II, III, or IV in 5, 13, and 12 patients, respectively. The median number of preceding endoscopic interventions was 4 (range 2-14). EUS-IBD was required because the following procedures failed: duodenal scope insertion (n = 4), accessing the papilla after duodenal stent insertion (n = 5), or achieving desired intrahepatic biliary drainage (n = 21). Technical success with EUS-IBD was achieved in 29 of 30 patients (96.7%) and clinical success was attained in 22 of these 29 (75.9%). Mild peritonitis occurred in three of 30 (10%) and was managed conservatively. Stent dysfunction occurred in 23.3% (7/30). There was no procedure-related mortality. On multivariable analysis, Bismuth IV stricture predicted clinical ineffectiveness (odds ratio = 12.7, 95% CI 1.18-135.4, P = 0.035). EUS-IBD may be a feasible and effective rescue alternative with few major complications after failed transpapillary endoscopic re-intervention in patients with UMHBS, particularly for Bismuth II or III strictures.
  • Toshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    CANCER SCIENCE 108 10 1996 - 2003 2017年10月 [査読有り]
     
    Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the invitro function of gankyrin is well known, its role invivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f)) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f)). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
  • Yoriaki Komeda; Tomohiro Watanabe; Shigenaga Matsui; Hiroshi Kashida; Toshiharu Sakurai; Masashi Kono; Kosuke Minaga; Tomoyuki Nagai; Satoru Hagiwara; Eisuke Enoki; Masatoshi Kudo
    JGH Open 1 2 74 - 75 2017年10月 [査読有り]
  • 肝細胞癌に対する分子標的治療. 特集「肝癌診療A to Z」.
    工藤正俊
    肝臓クリニカルアップデート 3 6 155 - 163 2017年10月 [査読有り]
  • Toshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Cancer Science 108 10 1996 - 2003 2017年10月 [査読有り]
     
    Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the in vitro function of gankyrin is well known, its role in vivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre gankyrinf/f) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre gankyrinf/f). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
  • Tomohiro Watanabe; Naoki Asano; Masatoshi Kudo; Warren Strober
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES 93 8 578 - 599 2017年10月 [査読有り]
     
    Nucleotide-binding oligomerization domain 1 (NOD1) is an intracellular sensor that detects small peptides derived from the cell wall component of intestinal microflora. NOD1 is expressed in both non-hematopoietic cells such as epithelial cells and hematopoietic cells such as antigen-presenting cells. Detection of its ligand by NOD1 leads to innate immune responses through activation of nuclear factor kappa B and type I interferon as well as induction of autophagy. Innate immune responses through NOD1 activation play an indispensable role both in host defense against microbial infection and in the development of gastrointestinal disorders. Of particular importance, NOD1-mediated innate immune responses are associated with mucosal host defenses against Helicobacter pylori (H. pylori) infection of the stomach and with the development of pancreatitis. In this review, we discuss the molecular mechanisms by which NOD1 activation leads to the development of H. pylori-related gastric diseases and pancreatitis.
  • Ken Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Haruhiko Imamoto; Takushi Yasuda; Andrea Lisotti; Pietro Fusaroli; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 32 10 1686 - 1692 2017年10月 [査読有り]
     
    Background and Aim: The study aims to evaluate contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for the differential diagnosis of submucosal tumors (SMT) of the upper gastrointestinal tract. Methods: Between June 2008 and May 2015, 157 consecutive patients with submucosal lesions of the upper gastrointestinal tract were evaluated by CH-EUS. This was a single-center retrospective analysis of prospectively collected data in a registry. The data from 73 patients who later underwent surgical resection were analyzed in this study. Surgical specimens served as the final diagnoses. The two CH-EUS variables of blood flow (hyper-enhancement vs hypo-enhancement) and homogeneity of enhancement pattern were evaluated. Results: The final diagnoses were 58 gastrointestinal stromal tumors (GISTs) and 15 benign SMTs (two lipomas, five leiomyomas, five schwannomas, two glomus tumors, and one ectopic pancreas). On CH-EUS, 49 of 58 (84.5%) GISTs presented with hyper-enhancement, whereas 4 of 15 (26.7%) benign SMTs showed hyper-enhancement; 21 of 58 (36.2%) GISTs showed inhomogeneous contrast enhancement, while only 2 of 15 (13.3%) benign SMTs demonstrated inhomogeneous contrast enhancement. If hyper-enhancement was considered to indicate GISTs, the sensitivity, specificity, and accuracy were 84.5%, 73.3%, and 82.2%, respectively. If inhomogeneous enhancement was considered to indicate GISTs, the sensitivity, specificity, and accuracy were 36.2%, 86.7%, and 46.6%, respectively. In lesions of less than 2cm, hyper-enhancement was a more sensitive indicator of GISTs than inhomogeneous enhancement. Conclusions: Hyper-enhancement and inhomogeneous enhancement were found to be a characteristic of GISTs. CH-EUS was useful for discrimination of benign SMTs from GISTs.
  • Hienori Toyoda; Toshifumi Tada; Philip J. Johnson; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Norihiro Kokudo; Yonson Ku; Shoji Kubo; Takashi Kumada; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY 52 10 1112 - 1121 2017年10月 [査読有り]
     
    Background Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. Methods BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. Results There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child-Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. Conclusions Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.
  • Minaga Kosuke; Takenaka Mamoru; Kamata Ken; Miyata Takeshi; Yamao Kentaro; Imai Hajime; Omoto Shunsuke; Nakai Atsushi; Yoshikawa Tomoe; Watanabe Tomohiro; Kudo Masatoshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 32 240  2017年09月 [査読有り]
  • 上嶋一臣; 工藤正俊
    日本消化器病学会雑誌 114 1621 - 1628 2017年09月 [査読有り]
  • 肝動脈化学塞栓療法(TACE)の適応の再考①BCLC-Bの亜分類とTACEの適応
    有住忠明; 工藤正俊
    The Liver Cancer Journal 6 26 - 29 2017年09月 [査読有り]
  • Yanagihara K; Watanabe A; Aoki N; Matsumoto T; Yoshida M; Sato J; Wakamura T; Sunakawa K; Kadota J; Kiyota H; Iwata S; Kaku M; Hanaki H; Ohsaki Y; Fujiuchi S; Takahashi M; Takeuchi K; Takeda H; Ikeda H; Miki M; Nakanowatari S; Takahashi H; Utagawa M; Nishiya H; Kawakami S; Morino E; Takasaki J; Mezaki K; Chonabayashi N; Tanaka C; Sugiura H; Goto H; Saraya T; Kurai D; Katono Y; Inose R; Niki Y; Takuma T; Kudo M; Ehara S; Sato Y; Tsukada H; Watabe N; Honma Y; Mikamo H; Yamagishi Y; Nakamura A; Ohashi M; Seki M; Hamaguchi S; Toyokawa M; Fujikawa Y; Mitsuno N; Ukimura A; Miyara T; Nakamura T; Mikasa K; Kasahara K; Ui K; Fukuda S; Nakamura A; Morimura M; Yamashita M; Takesue Y; Wada Y; Sugimoto K; Kusano N; Nose M; Mihara E; Kuwabara M; Doi M; Watanabe Y; Tokuyasu H; Hino S; Negayama K; Mukae H; Kawanami T; Ota T; Fujita M; Honda J; Hiramatsu K; Aoki Y; Fukuoka M; Magarifuchi H; Nagasawa Z; Kaku N; Fujita J; Higa F; Tateyama M
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 23 9 587 - 597 2017年09月 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Ah-Mee Park; Yoriaki Komeda; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi Kudo
    SCIENTIFIC REPORTS 7 1 10440  2017年09月 [査読有り]
     
    Although Hepatitis B virus (HBV) X gene mutations are frequently detected in HBV-related human hepatocellular carcinoma (HCC) patients, causative HBx mutations in the development of HCC have not yet been determined. We herein identified C1485T and C1653T mutations in the HBx gene as independent risk of HCC for HBV through the analysis using serum from chronic hepatitis B patients. We generated transgenic mice expressing wild-type (WT-HBxTg) and mutant (C1485T-HBxTg) HBx to assess the carcinogenic potential of mutated HBx. C1485T-HBxTg mice were more susceptible to diethylnitrosamine-induced hepatocarcinogenesis than WT-HBxTg mice and control non-Tg mice. The promotion of hepatocarcinogenesis in C1485T-HBxTg mice was accompanied by the activation of beta-catenin and Jun N-terminal kinase (JNK) signaling pathways as well as the production of reactive oxygen species, whereas the activation of nuclear factor-kappa B in the livers of C1485T-HBxTg mice was attenuated. These results demonstrate that the HBx C1485T mutation contributes to human and murine hepatocarcinogenesis.
  • Shimada H; Kogure N; Noro E; Kudo M; Sugawara K; Sato I; Shimizu K; Kobayashi M; Suzuki D; Parvin R; Saito-Ito T; Uruno A; Saito-Hakoda A; Rainey WE; Ito S; Yokoyama A; Sugawara A
    FEBS open bio 7 9 1410 - 1421 2017年09月 [査読有り]
     
    Aldosterone synthase is the key rate-limiting enzyme in adrenal aldosterone production, and induction of its gene (CYP11B2) results in the progression of hypertension. As hypertension is a frequent complication among patients with diabetes, we set out to elucidate the link between diabetes mellitus and hypertension. We examined the effects of high glucose on CYP11B2 expression and aldosterone production using human adrenal H295R cells and a stable H295R cell line expressing a CYP11B2 5'-flanking region/luciferase cDNA chimeric construct. d-glucose (d-glu), but not its enantiomer l-glucose, dose dependently induced CYP11B2 transcription and mRNA expression. A high concentration (450 mg·dL-1) of d-glu time dependently induced CYP11B2 transcription and mRNA expression. Moreover, high glucose stimulated secretion of aldosterone into the media. Transient transfection studies using deletion mutants/nerve growth factor-induced clone B (NGFIB) response element 1 (NBRE-1) point mutant of CYP11B2 5'-flanking region revealed that the NBRE-1 element, known to be activated by transcription factors NGFIB and NURR1, was responsible for the high glucose-mediated effect. High glucose also induced the mRNA expression of these transcription factors, especially that of NURR1, but NURR1 knockdown using its siRNA did not affect high glucose-induced CYP11B2 mRNA expression. Taken together, it is speculated that high glucose may induce CYP11B2 transcription via the NBRE-1 element in its 5'-flanking region, resulting in the increase in aldosterone production although high glucose-induced NURR1 is not directly involved in the effect. Additionally, glucose metabolism and calcium channels were found to be involved in the high glucose effect. Our observations suggest one possible explanation for the high incidence of hypertension in patients with diabetes.
  • Kaibori M; Yoshii K; Yokota I; Hasegawa K; Nagashima F; Kubo S; Kon M; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo N; Liver Cancer Study; Group of Japan
    Annals of surgery 269 4 692 - 699 2017年09月 [査読有り]
  • 免疫チェックポイント阻害薬の役割, 肝がん. 特集「なぜ免疫チェックポイント阻害薬はがんに効くのか」
    工藤正俊
    消化器病学サイエンス 1 2 35 - 41 2017年09月 [査読有り][招待有り]
  • 山雄 健太郎; 竹中 完; 工藤 正俊
    胆道 31 3 427 - 427 日本胆道学会 2017年08月
  • 肝癌における免疫チェックポイント阻害剤と既存治療との組み合わせ治療 (根治後アジュバント・TACE併用・ほかの免疫療法) 開発の現状と今後の展望. 特集「肝細胞癌の化学療法が変わる」.
    工藤正俊
    肝胆膵 75 2 522 - 528 2017年08月 [査読有り]
  • レンバチニブ第III相試験 (REFLECT試験)からみえてきたもの―いかに効果を引き出すか―. 特集「肝細胞癌の化学療法が変わる」.
    工藤正俊
    肝胆膵 75 2 466 - 471 2017年08月 [査読有り]
  • ソラフェニブ・レゴラフェニブ sequential療法の効果を考察する. 特集「肝細胞癌の化学療法が変わる」.
    上嶋一臣; 工藤正俊
    肝胆膵 75 2 437 - 439 2017年08月 [査読有り]
  • TACE併用 (Post TACE, BRISK-TA, SPACE, ORIENTAL, TACE-2) ―標的分子と結果の概要・失敗原因の考察―. 特集「肝細胞癌の化学療法が変わる」.
    有住忠晃; 工藤正俊
    肝胆膵 75 2 398 - 406 2017年08月 [査読有り]
  • 動注化学療法は生き残れるか―エビデンスからみた動注化学療法の今後―. 特集「肝細胞癌の化学療法が変わる」.
    上嶋一臣; 工藤正俊
    肝胆膵 75 2 363 - 367 2017年08月 [査読有り]
  • 分子標的治療時代におけるIntermediate stage肝癌の亜分類の重要性を考える.
    有住忠晃; 工藤正俊
    肝胆膵 75 2 253 - 256 2017年08月 [査読有り]
  • 特別座談会「急激に変貌する肝細胞癌の薬物療法を語る」, 特集 肝細胞癌の化学療法が変わる.
    工藤正俊; 池田公史; 古瀬純司; 小笠原定久
    肝胆膵 75 2 187 - 208 2017年08月 [査読有り]
  • Morimoto R; Ono Y; Tezuka Y; Kudo M; Yamamoto S; Arai T; Gomez-Sanchez CE; Sasano H; Ito S; Satoh F
    Hypertension (Dallas, Tex. : 1979) 70 2 334 - 341 2017年08月 [査読有り]
     
    Measurement of plasma aldosterone and renin concentration, or activity, is useful for selecting antihypertensive agents and detecting hyperaldosteronism in hypertensive patients. However, it takes several days to get results when measured by radioimmunoassay and development of more rapid assays has been long expected. We have developed chemiluminescent enzyme immunoassays enabling the simultaneous measurement of both aldosterone and renin concentrations in 10 minutes by a fully automated assay using antibody-immobilized magnetic particles with quick aggregation and dispersion. We performed clinical validation of diagnostic ability of this newly developed assay-based screening of 125 patients with primary aldosteronism from 97 patients with essential hypertension. Results of this novel assay significantly correlated with the results of radioimmunoassay (aldosterone, active renin concentration, and renin activity) and liquid chromatography-tandem mass spectrometry (aldosterone). The analytic sensitivity of this particularly novel active renin assay was 0.1 pg/mL, which was better than that of radioimmunoassay (2.0 pg/mL). The ratio of aldosterone-to-renin concentrations of 6.0 (ng/dL per pg/mL) provided 92.0% sensitivity and 76.3% specificity as a cutoff for differentiating primary aldosteronism from essential hypertension. This novel measurement is expected to be a clinically reliable alternative for conventional radioimmunoassay and to provide better throughput and cost effectiveness in diagnosis of hyperaldosteronism from larger numbers of hypertensive patients in clinical settings.
  • Takashi Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Tadatoshi Takayama; Namiki Izumi; Masumi Kadoya; Masatoshi Kudo; Shoji Kubo; Michiie Sakamoto; Osamu Nakashima; Takashi Kumada; Norihiro Kokudo
    HEPATOLOGY 66 2 510 - 517 2017年08月 [査読有り]
     
    Because of the rarity of hepatic vein tumor thrombus (HVTT) compared with portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma, little is known about this disease entity. The aim of this study was to evaluate the prognosis of each treatment modality for HVTT through an analysis of data collected in a Japanese nationwide survey. We analyzed data for 1,021 Child-Pugh A hepatocellular carcinoma patients with HVTT without inferior vena cava invasion registered between 2000 and 2007. Of these patients, 540 who underwent liver resection (LR) and 481 who received other treatments were compared. Propensity scores were calculated, and we successfully matched 223 patients (49.0% of the LR group). The median survival time in the LR group was 2.89 years longer than that in the non-LR group (4.47 versus 1.58 years, P < 0.001) and 1.61 years longer than that in the non-LR group (3.42 versus 1.81 years, P = 0.023) in a propensity score-matched cohort. After curative resection, median survival times were similar between patients with HVTT in the peripheral hepatic vein and those with HVTT in the major hepatic vein (4.85 versus 4.67 years, P = 0.974). In the LR group, the postoperative 90-day mortality rate was 3.4% (16 patients). In patients without PVTT, the median survival time was significantly better than that in patients with PVTT (5.67 versus 1.88 years, P < 0.001). Conclusion: LR is associated with a good prognosis in hepatocellular carcinoma patients with HVTT, especially in patients without PVTT.
  • Hisato Kawakami; Junko Tanizaki; Kaoru Tanaka; Koji Haratani; Hidetoshi Hayashi; Masayuki Takeda; Ken Kamata; Mamoru Takenaka; Masatomo Kimura; Takaaki Chikugo; Takao Sato; Masatoshi Kudo; Akihiko Ito; Kazuhiko Nakagawa
    INVESTIGATIONAL NEW DRUGS 35 4 529 - 536 2017年08月 [査読有り]
     
    Background Nivolumab demonstrates promising efficacy for the treatment of non-small cell lung cancer and other malignancies. The clinical benefit of nivolumab, however, may be hampered by specific immune-related adverse events (irAEs), and little is known regarding nivolumab-related cholangitis. Methods A computerized search of our clinical database identified 3 metastatic non-small cell lung cancer patients with nivolumab-related cholangitis. All patients were treated with in-travenous nivolumab monotherapy (3.0 mg/kg) every 2 weeks until disease progression or irAEs occurred. Clinical data regarding the duration of nivolumab treatment, symptoms, laboratory abnormalities, pathological findings of liver parenchyma biopsy specimens, and management of nivolumab-related cholangitis were analyzed. Results Our analysis revealed that nivolumab-related cholangitis was characterized by (1) localized extrahepatic bile duct dilation without obstruction; (2) diffuse hypertrophy of the extrahepatic bile duct wall; (3) a dominant increase in the biliary tract enzymes alkaline phosphatase and gamma-glutamyl transpeptidase relative to the hepatic enzymes aspartate and alanine aminotransferase; (4) normal or reduced levels of the serum immunological markers antinuclear antibody, antimitochondrial antibody, smooth muscle antibody, and immunoglobulin G4; (5) the pathological finding of biliary tract cluster of differentiation 8-positive T cell infiltration from liver biopsy; and (6) amoderate to poor response to steroid therapy. Conclusions Nivolumab-related cholangitis is associated with distinct imaging and clinicopathological features that distinguish it from acute cholangitis of common etiologies and other immune-related cholangitis. Further studies are warranted to establish the optimal management of patients with this irAE.
  • Ian Chau; Markus Peck-Radosavljevic; Christophe Borg; Peter Malfertheiner; Jean Francois Seitz; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D. Baron; Takuji Okusaka; L. Bowman; Zhanglin Lin Cui; Allicia C. Girvan; Paolo B. Abada; Ling Yang; Andrew X. Zhu
    EUROPEAN JOURNAL OF CANCER 81 17 - 25 2017年08月 [査読有り]
     
    Purpose: To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled randomised study, assessing ramucirumab in advanced hepatocellular carcinoma (HCC) patients who received prior sorafenib. Methods: Eligible patients had advanced HCC, Child-Pugh A, PS 0 or 1 and prior sorafenib. Patients received ramucirumab (8 mg/kg) or placebo (1:1) on day 1 of a 2-week cycle. QoL was assessed by FACT Hepatobiliary Symptom Index (FHSI)-8 and EuroQoL (EQ-5D) at baseline; cycles 4, 10, and 16; and end of treatment. PS was assessed at baseline, each cycle, and end of treatment. Deterioration in FHSI-8 was defined as a >= 3-point decrease from baseline and PS deterioration was defined as a change of >= 2. Both intention-to-treat and pre-specified subgroup of patients with baseline serum alpha-fetoprotein (AFP) >= 400 ng/mL were assessed. Results: There were 565 patients randomised to ramucirumab and placebo. Compliance with FHSI and EQ-5D was high and similar between groups. In the ITT population, deterioration in FHSI-8, EQ-5D, and PS was similar between ramucirumab and placebo. In patients with baseline AFP >= 400 ng/mL, ramucirumab significantly reduced deterioration in FHSI-8 at the end of treatment compared with placebo (P = 0.0381), and there was a trend towards a delay in the deterioration of symptoms in FHSI-8 (HR 0.690; P = 0.054) and PS (HR 0.642; P = 0.057) in favour of ramucirumab. Conclusions: We report one of the most comprehensive data sets of QoL and symptom burden in patients undergoing systemic therapy for advanced HCC. Ramucirumab was associated with no worsening of QoL. In patients with baseline AFP >= 400 ng/mL, the significant survival benefit observed in patients treated with ramucirumab was coupled with a trend in patientfocused outcome benefits. Clinical trial registration: NCT01140347. (C) 2017 Elsevier Ltd. All rights reserved.
  • 企画: 肝胆 特集「肝細胞癌の化学療法が変わる」
    工藤正俊
    肝胆膵 75 2 2017年08月 [査読有り][招待有り]
  • 上嶋 一臣; 工藤 正俊
    消化器・肝臓内科 2 1 92 - 98 (有)科学評論社 2017年07月
  • 松井繁長; 樫田博史; 田中梨絵; 高山政樹; 峯 宏昌; 足立哲平; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 工藤正俊; 筑後孝章; 月山雅之
    胃と腸 52 8 1098 - 1106 2017年07月 [査読有り]
  • Miyata Y; Kashiwagi H; Koizumi K; Kawachi J; Kudo M; Teshima S; Isogai N; Miyake K; Shimoyama R; Fukai R; Ogino H
    International journal of surgery case reports 39 5 - 8 2017年07月 [査読有り]
  • Minaga K; Takenaka M; Miyata T; Yamao K; Kamata K; Kitano M; Kudo M
    Endosc Ultrasound in press 2017年07月 [査読有り]
  • Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K. Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A. Lesmana; Laurentius A. Lesmana; Rino A. Gani; Shuntaro Obi; A. Kadir Dokmeci; Shiv Kumar Sarin
    HEPATOLOGY INTERNATIONAL 11 4 317 - 370 2017年07月 [査読有り]
     
    There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.
  • 肝動脈化学塞栓療法(TACE)の適応の再考 (1)BCLC-Bの亜分類とTACEの適応
    有住忠明; 工藤正俊
    The Liver Cancer Journal 9 1 26 - 29 2017年06月 [査読有り]
  • Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Masatoshi Kudo
    ARAB JOURNAL OF GASTROENTEROLOGY 18 2 120 - 121 2017年06月 [査読有り]
     
    EUS-guided hepaticogastrostomy (EUS-HGS) is useful for treating obstructive jaundice. However, stent migration may sometimes occur both during and after the procedure. This report describes a patient with pancreatic cancer and massive ascites who underwent EUS-HGS combined with EUS-guided antegrade stenting (EUS-AS), with additional EUS-AS playing a role in troubleshooting for stent migration during EUS-HGS. (C) 2017 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.
  • Riccardo Lencioni; Robert Montal; Ferran Torre; Joong-Won Park; Thomas Decaens; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; Jose Rios; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Josep M. Llovet
    JOURNAL OF HEPATOLOGY 66 6 1166 - 1172 2017年06月 [査読有り]
     
    Background & Aims: The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether objective response by mRECIST accurately predicted overall survival (OS) in patients with advanced HCC treated with systemic targeted therapies and also to preliminarily assess this endpoint as a potential surrogate of OS. Methods: Individual patient data from the BRISK-PS randomized phase III trial comparing brivanib vs. placebo (the first to prospectively incorporate mRECIST) were used to analyze objective response as a predictor of OS in a time-dependent covariate analysis. Patients with available imaging scans during follow-up were included (n = 334; 85% of those randomized). Moreover, a correlation of the survival probability in deciles vs. the observed objective response was performed to evaluate its suitability as a surrogate end-point. Results: Objective response was observed in 11.5% and 1.9% of patients treated with brivanib and placebo respectively, and was associated with a better survival (median OS 15.0 vs. 9.4 months, p < 0.001). In addition, objective response had an independent prognostic value (HR = 0.48; 95% confidence interval [CI], 0.26-0.91, p = 0.025) along with known prognostic factors. Finally, objective response showed promising results as a surrogate of OS in this trial (R = -0.92; 95% CI, -1 to -0.73, p < 0.001). It was an early indicator of the treatment effect (median time to objective response was 1.4 months). Conclusions: Objective response by mRECIST in advanced HCC predicts OS and thus can be considered as a candidate surrogate end-point. Further studies are needed to support this finding. Lay summary: There is a need to identify surrogate end-points for overall survival in advanced hepatocellular carcinoma. We studied patients from the phase III BRISK trial, comparing brivanib treatment with placebo after sorafenib progression. We demonstrate that objective response is an independent predictor of survival and qualifies as a potential surrogate end-point for overall survival in this patient population. Clinical trial number: NCT00825955. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • Masatoshi Kudo; Michihisa Moriguchi; Kazushi Numata; Hisashi Hidaka; Hironori Tanaka; Masafumi Ikeda; Seiji Kawazoe; Shinichi Ohkawa; Yozo Sato; Shuichi Kaneko; Junji Furuse; Madoka Takeuchi; Xuemin Fang; Yoshito Date; Masahiro Takeuchi; Takuji Okusaka
    The Lancet Gastroenterology and Hepatology 2 6 407 - 417 2017年06月 [査読有り]
     
    Background Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited. We assessed the efficacy and safety of S-1, a chemotherapeutic agent based on fluorouracil, in patients with sorafenib-refractory advanced hepatocellular carcinoma. Methods We did a randomised, double-blind, placebo-controlled, phase 3 study done at 57 sites in Japan. Patients with advanced hepatocellular carcinoma who were ineligible for surgical or local-regional therapy and judged refractory to sorafenib (ie, had progressed on sorafenib or had discontinued sorafenib because of adverse events) were randomly assigned (2:1) to receive oral S-1 (weight-banded 80 mg/m2 [80–120 mg per day]), or placebo, twice per day for 28 days consecutively, followed by a minimum 14 day drug-free period. This cycle was repeated until disease progression or the patient became intolerant to the study treatment. Patients were stratified by site and presence or absence of extrahepatic metastasis or vascular invasion. The primary endpoint was overall survival, assessed in the full analysis set (ie, all patients who were treated with study drug except any individuals who were found not to have hepatocellular carcinoma or who were found to have active double cancer). Patients, medical staff, investigators, and the sponsor were masked to treatment assignment. Blinding was maintained even after study treatment concluded. This study is registered with JapicCTI, number JapicCTI-090920, and has been completed. Findings Between Oct 26, 2009, and Aug 22, 2012, we screened 399 patients. 65 patients were excluded due to not meeting criteria (n=61), declining to participate (n=3), or other reasons (n=1). 334 patients were randomly assigned to receive either S-1 (n=223) or placebo (n=111). One patient in the S-1 group did not receive treatment, and was thus excluded from analyses. At data cutoff, median follow-up was 32·4 months (IQR 24·0–34·7) in the S-1 group and 32·9 months (23·7–39·5) in the placebo group. Median overall survival was 11·1 months (95% CI 9·7–13·1) in the S-1 group and 11·2 months (9·2–12·8) in the placebo group (hazard ratio 0·86, 95% CI 0·67–1·10 p=0·220). The most frequently reported adverse events were skin hyperpigmentation (123 [55%] of 222 patients in the S-1 group vs nine [8%] of 111 patients in the placebo group), decreased appetite (104 [47%] vs 21 [19%]), fatigue (102 [46%] vs 20 [18%]), diarrhoea (77 [35%] vs 14 [13%]), and increased blood bilirubin (77 [35%] vs 14 [13%]). Serious adverse events were reported in 90 (41%) of 222 patients in the S-1 group and 24 (22%) of 111 patients in the placebo group. Five treatment-related deaths were reported in the S-1 group. Interpretation S-1 did not prolong overall survival in patients with sorafenib-refractory advanced hepatocellular carcinoma. Further research is needed to identify subgroups of patients who might benefit from S-1. Funding Taiho Pharmaceuticals.
  • Masafumi Toguchi; Masakatsu Tsurusaki; Norihisa Yada; Keitaro Sofue; Tomoko Hyodo; Minori Onoda; Isao Numoto; Mitsuru Matsuki; Izumi Imaoka; Masatoshi Kudo; Takamichi Murakami
    ABDOMINAL RADIOLOGY 42 6 1659 - 1666 2017年06月 [査読有り]
     
    Purpose: To evaluate the quantitative measurement of liver stiffness (LS), compare the diagnostic performance of magnetic resonance elastography (MRE) and ultrasound-based transient elastography (TE), and evaluate two different MRE-based LS measurement methods. Methods: Between October 2013 and January 2015, 116 consecutive patients with chronic liver disease underwent MRE to measure LS (kilopascals; kPa). Of the 116 patients, 51 patients underwent both TE and liver biopsy, and the interval between the liver biopsy and both the MRE and TE was less than 90 days. MRE-derived LS values were measured on the anterior segment of the right lobe (single small round regions of interest per slice; srROIs) and whole right lobe of the liver (free hand region of interest; fhROI), and these values were correlated with pathological fibrosis grades and diagnostic performance. Results: Pathological fibrosis stage was significantly correlated with srROIs (r = 0.87, p < 0.001), fhROI (r = 0.80, p < 0.001), and TE (r = 0.73, p < 0.001). For detection of significant fibrosis (>= F2), advanced fibrosis (>= F3), and cirrhosis, the area under the curve (AUC) associated with the srROIs was largest, and there was a significant difference between srROIs and TE (0.93 vs. 0.82, p = 0.006), srROIs and fhROI (0.93 vs. 0.89, p = 0.04) for detection of >= F2. For advanced fibrosis and cirrhosis detection, AUCs were not significant (0.92-0.96). Conclusions: MRE and TE detected liver fibrosis with comparable accuracy. In particular, the srROIs method was effective for detecting of significant fibrosis.
  • Anthony B. El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S. Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jorg Trojan; Theodore H. Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B. Dastani; Ignacio Melero
    LANCET 389 10088 2492 - 2502 2017年06月 [査読有り]
     
    Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis. Methods We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (>= 18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load < 100 IU/mL); antiviral therapy was not required for patients with HCV infection. We excluded patients previously treated with an agent targeting T-cell costimulation or checkpoint pathways. Patients received intravenous nivolumab 0.1-10 mg/kg every 2 weeks in the dose-escalation phase (3+ 3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose-expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected. Primary endpoints were safety and tolerability for the escalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1) for the expansion phase. This study is registered with ClinicalTrials.gov, number NCT01658878. Findings Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed treatment and follow-up is ongoing. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progression. Incidence of treatment-related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached. 12 (25%) of 48 patients had grade 3/4 treatment-related adverse events. Three (6%) patients had treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder). 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy). Nivolumab 3 mg/kg was chosen for dose expansion. The objective response rate was 20% (95% CI 15-26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6-28) in the dose-escalation phase. Interpretation Nivolumab had a manageable safety profile and no new signals were observed in patients with advanced hepatocellular carcinoma. Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma.
  • Eri Banno; Yosuke Togashi; Marco A. De Velasco; Takuro Mizukami; Yu Nakamura; Masato Terashima; Kazuko Sakai; Yoshihiko Fujita; Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Kazuto Nishio
    INTERNATIONAL JOURNAL OF ONCOLOGY 50 6 2049 - 2058 2017年06月 [査読有り]
     
    Akt2 is an isoform of Akt, and an association between Akt2 and resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been suggested in pancreatic cancer (PC) in vitro. In this study, we investigated the association between Akt2 expression as evaluated using immunohistochemistry and the outcome of patients with advanced PC who had received treatment with erlotinib (an EGFR-TKI). Although the difference was not significant, patients with high levels of Akt2 expression tended to have a poorer response and a shorter progression-free survival period after treatment with erlotinib plus gemcitabine than those with low expression levels (P=0.16 and 0.19, respectively). In vitro, an Akt2-amplified PC cell line and Akt2-overexpressed cell lines exhibited resistance to anti-EGFR therapies, including erlotinib, but combined treatment with BYL719 (a PI3K inhibitor) cancelled this resistance. Our findings suggest that Akt2 might be associated with the resistance to anti-EGFR therapies, especially the use of erlotinib against PC, and that this resistance can be overcome by combined treatment with a PI3K inhibitor. Akt2 expression could become a predictive biomarker for erlotinib resistance in PC.
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Masashi Kono; Tomoyuki Nagai; Yutaka Asakuma; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Takaaki Chikugo; Masatoshi Kudo
    AMERICAN JOURNAL OF GASTROENTEROLOGY 112 6 833 - 833 2017年06月 [査読有り]
  • 三長 孝輔; 竹中 完; 宮田 剛; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 今井 元; 渡邉 智裕; 工藤 正俊
    膵臓 32 3 329 - 329 (一社)日本膵臓学会 2017年05月
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Tomoyuki Nagai; Shigenaga Matsui; Tomohiro Watanabe; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 85 5 AB392 - AB392 2017年05月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Tomoe Yoshikawa; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 85 5 AB493 - AB493 2017年05月 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Tomoe Yoshikawa; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 85 5 AB53 - AB53 2017年05月 [査読有り]
  • Kentaro Yamao; Masayuki Kitano; Takahisa Kayahara; Etsuji Ishida; Hiroshi Yamamoto; Tomoe Yoshikawa; Kosuke Minaga; Yukitaka Yamashita; Masanori Asada; Yoshihiro Okabe; Yukio Osaki; Juri Ikemoto; Keiji Hanada; Mamoru Takenaka; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 85 5 AB327 - AB328 2017年05月 [査読有り]
  • Jessica A. Howell; David J. Pinato; Ramya Ramaswami; Tadaaki Arizumi; Carlotta Ferrari; Antonello Gibbin; Michela E. Burlone; Giulia Guaschino; Pierluigi Toniutto; James Black; Laura Sellers; Masatoshi Kudo; Mario Pirisi; Rohini Sharma
    ONCOTARGET 8 22 36161 - 36170 2017年05月 [査読有り]
     
    Background and Aims: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. Results: 442 patients with advanced stage HCC on sorafenib were recruited (follow-up 5096 person-months at risk). 88% had BCLC stage B or greater HCC and 72.3% had Child-Pugh A cirrhosis. On Cox multivariate regression, previously-treated HCC (HR 0.579, 95% CI 0.385-0.872, p=0.009), Cancer of Liver Italian Program (CLIP) score (HR 1.723, 95% CI 1.462-2.047, p < 0.0001), baseline red cell distribution width (RDW; HR 1.234, 95% CI 1.115-1.290, p < 0.0001) and neutrophil to lymphocyte ratio (NLR; HR 1.218, 95% CI 1.108-1.322, p < 0.0001) were significant independent risks for shorter survival, whilst sorafenib-related diarrhoea was associated with prolonged survival (HR 0.533, 95% CI 0.373-0.763, p=0.001). The combination of RDCLIP score (CLIP score multiplied by RDW) >= 70 and no treatment-related diarrhoea had good utility for predicting 3-month survival (AUC of 0.808 (95% CI 0.734-0.882), positive predictive value of 86.4% and negative predictive value of 83.3%), compared with CLIP (AUC=0.642) or BCLC score alone (AUC=0.579). RD-CLIP score >= 35 and no treatment-related diarrhoea had an AUC of 0.787 for predicting 12-month survival. Methods: Patients with HCC were consecutively recruited from three tertiary centres (Japan, Italy and UK) and clinical data were prospectively collected. The primary study endpoint was overall survival (OS) after commencing sorafenib. Conclusion: The novel prognostic index of CLIP score combined with inflammatory marker RDW and treatment-related diarrhoea has good accuracy for predicting overall, 3 month and 12 month survival in patients on sorafenib.
  • Watanabe T; Yamashita K; Arai Y; Minaga K; Kamata K; Nagai T; Komeda Y; Takenaka M; Hagiwara S; Ida H; Sakurai T; Nishida N; Strober W; Kudo M
    Journal of immunology (Baltimore, Md. : 1950) 198 10 3886 - 3896 2017年05月 [査読有り]
     
    In previous studies, we found that human IgG4-related autoimmune pancreatitis (AIP) and murine AIP are driven by activation of plasmacytoid dendritic cells (pDCs) producing IFN-alpha. In the present studies we examined additional roles of pDC-related mechanisms in AIP pathogenesis, particularly those responsible for induction of fibrosis. We found that in murine AIP (MRL/Mp mice treated with polyinosinic-polycytidylic acid) not only the pancreatic infiltration of immune cells but also the development of fibrosis were markedly reduced by the depletion of pDCs or blockade of type I IFN signaling; moreover, such treatment was accompanied by a marked reduction of pancreatic expression of IL-33. Conversely, polyinosinic-polycytidylic acid-induced inflamed pancreatic tissue in murine AIP exhibited increased expression of type I IFNs and IL-33 (and downstream IL-33 cytokines such as IL-13 and TGF-beta 1). pDCs stimulated by type I IFN were the source of the IL-33 because purified populations of these cells isolated from the inflamed pancreas produced a large amount of IL-33 upon activation by TLR9 ligands, and such production was abrogated by the neutralization of type I IFN. The role of IL-33 in murine AIP pathogenesis was surprisingly important because blockade of IL-33 signaling by anti-ST2 Ab attenuated both pancreatic inflammation and accompanying fibrosis. Finally, whereas patients with both conventional pancreatitis and IgG4-related AIP exhibited increased numbers of acinar cells expressing IL-33, only the latter also exhibited pDCs producing this cytokine. These data thus suggest that pDCs producing IFN-alpha and IL-33 play a pivotal role in the chronic fibro-inflammatory responses underlying murine AIP and human IgG4-related AIP.
  • 緩和医療における内視鏡の役割 切除不能悪性胃十二指腸狭窄症例に対する胃十二指腸ステント留置の予後予測因子の検討
    山雄 健太郎; 竹中 完; 工藤 正俊
    Gastroenterological Endoscopy 59 Suppl.1 858 - 858 (一社)日本消化器内視鏡学会 2017年04月
  • J. Howell; D. J. Pinato; R. Ramaswami; D. Bettinger; T. Arizumi; C. Ferrari; C. Yen; A. Gibbin; M. E. Burlone; G. Guaschino; L. Sellers; J. Black; M. Pirisi; M. Kudo; R. Thimme; J. -W. Park; R. Sharma
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS 45 8 1146 - 1155 2017年04月 [査読有り]
     
    Background Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mortality despite treatment. While sorafenib has a survival benefit for patients with advanced HCC, clinical response is highly variable. Aim To determine whether development of sorafenib toxicity is a prognostic marker of survival in HCC. Methods In this prospective multicentre cohort study, patients with advanced-stage HCC receiving sorafenib were recruited from five international specialist centres. Demographic and clinical data including development and grade of sorafenib toxicity during treatment, radiological response to sorafenib and survival time (months) were recorded prospectively. Results A total of 634 patients with advanced-stage HCC receiving sorafenib were recruited to the study, with a median follow-up of 6692.3 person-months at risk. The majority of patients were male (81%) with Child-Pugh A stage liver disease (74%) and Barcelona Clinic Liver Cancer stage C HCC (64%). Median survival time was 8.1 months (IQR 3.8-18.6 months). 94% experienced at least one sorafenib-related toxicity: 34% diarrhoea, 16% hypertension and 37% hand-foot syndrome (HFS). Twenty-one per cent ceased sorafenib due to toxicity and 59% ceased treatment due to progressive disease or death. On multivariate analysis, sorafenib-related diarrhoea (HR 0.76, 95% CI 0.61-0.95, P = 0.017), hypertension (HR 0.531, 95% CI 0.37-0.76, P < 0.0001) and HFS (HR 0.65, 95% CI 0.51-0.81, P < 0.0001) were all significant independent predictors of overall survival after adjusting for age, severity of liver disease, tumour stage and sorafenib dose. Conclusion Development of sorafenib-related toxicity including diarrhoea, hypertension and hand-foot syndrome is associated with prolonged overall survival in patients with advanced-stage HCC on sorafenib.
  • M. Ikeda; S. Shimizu; T. Sato; M. Morimoto; Y. Kojima; Y. Inaba; A. Hagihara; M. Kudo; S. Nakamori; S. Kaneko; R. Sugimoto; T. Tahara; T. Ohmura; K. Yasui; K. Sato; H. Ishii; J. Furuse; T. Okusaka
    ANNALS OF ONCOLOGY 28 4 903 - 904 2017年04月 [査読有り]
  • Masatoshi Kudo; Etsuro Hatano; Shinichi Ohkawa; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Shuichi Kaneko; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Akihito Tsuji; Toshihiro Kudo; Mitsuo Shimada; Yukio Osaki; Ryosuke Tateishi; Gen Sugiyama; Paolo Benjamin Abada; Ling Yang; Takuji Okusaka; Andrew Xiuxuan Zhu
    JOURNAL OF GASTROENTEROLOGY 52 4 494 - 503 2017年04月 [査読有り]
     
    Bckground REACH evaluated ramucirumab in the second-line treatment of patients with advanced hepatocellular carcinoma. In the intent-to-treat population (n = 565), a significant improvement in overall survival (OS) was not observed. In patients with an elevated baseline alpha-fetoprotein (AFP) level (400 ng/mL or greater), an improvement in OS was demonstrated. An analysis of the Japanese patients in REACH was performed. Methods An analysis was performed with the subset of the intent-to-treat population enrolled in Japan (n = 93). Results The median OS was 12.9 months for the ramucirumab arm (n = 45) and 8.0 months for the placebo arm (n = 48) [hazard ratio (HR) 0.621 (95 % confidence interval (CI) 0.391-0.986); P = 0.0416]. The median progression-free survival was 4.1 months for the ramucirumab arm and 1.7 months for the placebo arm [HR 0.449 (95 % CI 0.285-0.706); P = 0.0004]. The objective response rates were 11 % for the ramucirumab arm and 2 % for the placebo arm (P = 0.0817). The grade 3 or higher treatment-emergent adverse events occurring in more than 5 % of patients with a higher incidence for the ramucirumab arm (n = 44) than for the placebo arm (n = 47) were ascites (7% vs 2 %), hypertension (7 % vs 2 %), and cholangitis (7 % vs 0 %). In patients with a baseline AFP level of 400 ng/mL or greater, the median OS was 12.9 months for the ramucirumab arm (n = 20) and 4.3 months for the placebo arm (n = 22) [HR 0.464 (95 % CI 0.232-0.926); P = 0.0263]. Conclusion In the Japanese patients in REACH, ramucirumab treatment improved OS, including in patients with a baseline AFP level of 400 ng/mL or greater; improvements in progression-free survival and objective response rate were also demonstrated. The safety profile of ramucirumab was acceptable and well tolerated in Japanese patients.
  • Kenji Ikeda; Masatoshi Kudo; Seiji Kawazoe; Yukio Osaki; Masafumi Ikeda; Takuji Okusaka; Toshiyuki Tamai; Takuya Suzuki; Takashi Hisai; Seiichi Hayato; Kiwamu Okita; Hiromitsu Kumada
    JOURNAL OF GASTROENTEROLOGY 52 4 512 - 519 2017年04月 [査読有り]
     
    Background Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular carcinoma (HCC). Methods Patients with histologically/clinically confirmed advanced HCC who did not qualify for surgical resection or local therapies received lenvatinib at a dosage of 12 mg once daily (QD) in 28-day cycles. The primary efficacy endpoint was time to progression (TTP) per modified Response Evaluation Criteria in Solid Tumors v1.1; secondary efficacy endpoints included objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results Between July 2010 and June 2011, 46 patients received lenvatinib at sites across Japan and Korea. The median TTP, as determined by independent radiological review, was 7.4 months [95 % confidence interval (CI): 5.5-9.4]. Seventeen patients (37 %) had partial response and 19 patients (41 %) had stable disease (ORR: 37 %; DCR: 78 %). Median OS was 18.7 months (95 % CI: 12.7-25.1). The most common any-grade adverse events (AEs) were hypertension (76 %), palmar-plantar erythrodysesthesia syndrome (65 %), decreased appetite (61 %), and proteinuria (61 %). Dose reductions and discontinuations due to AEs occurred in 34 (74 %) and 10 patients (22 %), respectively. Median body weight was lower in patients with an early (< 30 days) dose withdrawal or reduction than in those without. Conclusion Lenvatinib 12-mg QD showed clinical activity and acceptable toxicity profiles in patients with advanced HCC, but early dose modification was necessary in patients with lower body weight. Further development of lenvatinib in HCC should consider dose modification by body weight.
  • Tomoko Hyodo; Norihisa Yada; Masatoshi Hori; Osamu Maenishi; Peter Lamb; Kosuke Sasaki; Minori Onoda; Masatoshi Kudo; Teruhito Mochizuki; Takamichi Murakami
    RADIOLOGY 283 1 108 - 118 2017年04月 [査読有り]
     
    Purpose: To assess the clinical accuracy and reproducibility of liver fat quantification with the multimaterial decomposition (MMD) algorithm, comparing the performance of MMD with that of magnetic resonance (MR) spectroscopy by using liver biopsy as the reference standard. Materials and Methods: This prospective study was approved by the institutional ethics committee, and patients provided written informed consent. Thirty-three patients suspected of having hepatic steatosis underwent non-contrast material-enhanced and triple-phase dynamic contrast-enhanced dual-energy computed tomography (CT) (80 and 140 kVp) and single-voxel proton MR spectroscopy within 30 days before liver biopsy. Percentage fat volume fraction (FVF) images were generated by using the MMD algorithm on dual-energy CT data to measure hepatic fat content. FVFs determined by using dual-energy CT and percentage fat fractions (FFs) determined by using MR spectroscopy were compared with histologic steatosis grade (0-3, as defined by the nonalcoholic fatty liver disease activity score system) by using Jonck-heere-Terpstra trend tests and were compared with each other by using Bland-Altman analysis. Real non-contrast-enhanced FVFs were compared with triple-phase contrast-enhanced FVFs to determine the reproducibility of MMD by using Bland-Altman analyses. Results: Both dual-energy CT FVF and MR spectroscopy FF increased with increasing histologic steatosis grade (trend test, P <.001 for each). The Bland-Altman plot of dual-energy CT FVF and MR spectroscopy FF revealed a proportional bias, as indicated by the significant positive slope of the line regressing the difference on the average (P < .001). The 95% limits of agreement for the differences between real non-contrast- enhanced and contrast-enhanced FVFs were not greater than about 2%. Conclusion: The MMD algorithm quantifying hepatic fat in dual-energy CT images is accurate and reproducible across imaging phases. (C) RSNA, 2017
  • Toshiharu Sakurai; Hiroaki Higashitsuji; Hiroshi Kashida; Tomohiro Watanabe; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Masayuki Kitano; Naoshi Nishida; Takaya Abe; Hiroshi Kiyonari; Katsuhiko Itoh; Jun Fujita; Masatoshi Kudo
    ONCOTARGET 8 15 24762 - 24776 2017年04月 [査読有り]
     
    Although long-standing colonic inflammation due to refractory inflammatory bowel disease (IBD) promotes the development of colitis-associated cancer (CAC), the molecular mechanisms accounting for the development of CAC remains largely unknown. In this study, we investigated the role of gankyrin in the development of CAC since gankyrin is overexpressed in sporadic colorectal cancers. We analyzed gene expression of colon tissues obtained from 344 patients with IBD and CAC and found that expression of gankyrin was much higher in colonic mucosa of patients with refractory IBD than in those with IBD in remission. Expression of gankyrin was upregulated in inflammatory cells as well as tumor cells in colonic mucosa of patients with CAC. Over-expressing studies utilizing tagged ganlyrin-cDNA identified physical interaction between ganlyrin and Src homology 2-containing protein tyrosine phosphatase-1 (SHP-1). Importantly, the interaction between ganlyrin and SHP1 leads to inhibition of STAT3 activation and to enhancement of TNF-alpha and IL-17 in inflammatory cells. To further address the role of gankyrin in the development of CAC, we created mice with intestinal epithelial cell-specific gankyrin ablation (Vil-Cre; Gankyrin(f/f)) and deletion of gankyrin in myeloid and epithelial cells (Mx1Cre; Gankyrin(f/f)). Gankyrin deficiency in myeloid cells, but not in epithelial cells, reduced the activity of mitogen activated protein kinase and the expression of stem cell markers, leading to attenuated tumorigenic potential. These findings provide important insights into the pathogenesis of CAC and suggest that gankyrin is a promising target for developing therapeutic and preventive strategies against CAC.
  • Akihiro Nishie; Satoshi Goshima; Hiroki Haradome; Etsuro Hatano; Yasuharu Imai; Masatoshi Kudo; Masanori Matsuda; Utaroh Motosugi; Satoshi Saitoh; Kengo Yoshimitsu; Bruce Crawford; Eliza Kruger; Graeme Ball; Hiroshi Honda
    CLINICAL THERAPEUTICS 39 4 738 - 750 2017年04月 [査読有り]
     
    Purpose: The objective of the study was to evaluate the cost-effectiveness of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the diagnosis and treatment of hepatocellular carcinoma (HCC) in Japan compared with extracellular contrast media-enhanced MRI (ECCM-MRI) and contrast media-enhanced computed tomography (CE-CT) scanning. Methods: A 6-stage Markov model was developed to estimate lifetime direct costs and clinical outcomes associated with EOB-MRI. Diagnostic sensitivity and specificity, along with clinical data on HCC survival, recurrence, treatment patterns, costs, and health state utility values, were derived from predominantly Japanese publications. Parameters unavailable from publications were estimated in a Delphi panel of Japanese clinical experts who also confirmed the structure and overall approach of the model. Sensitivity analyses, including one-way, probabilistic, and scenario analyses, were conducted to account for uncertainty in the results. Findings: Over a lifetime horizon, EOB-MRI was associated with lower direct costs ((sic)2,174,869) and generated a greater number of quality-adjusted life years (QALYs) (9.502) than either ECCM-MRI ((sic)2,365,421, 9.303 QALYs) or CE-CT ((sic)2,482,608, 9.215 QALYs). EOB-MRI was superior to the other diagnostic strategies considered, and this finding was robust over sensitivity and scenario analyses. A majority of the direct costs associated with HCC in Japan were found to be costs of treatment. The model results revealed the superior cost-effectiveness of the EOB-MRI diagnostic strategy compared with ECCM-MRI and CE-CT. Implications: EOB-MRI could be the first-choice imaging modality for medical care of HCC among patients with hepatitis or liver cirrhosis in Japan. Widespread implementation of EOB-MRI could reduce health care expenditures, particularly downstream treatment costs, associated with HCC. (C) 2017 Elsevier HS Journals, Inc. All rights reserved.
  • T. Watanabe; M. Kudo; W. Strober
    MUCOSAL IMMUNOLOGY 10 2 283 - 298 2017年03月 [査読有り]
     
    The conventional view of the pathogenesis of acute and chronic pancreatitis is that it is due to a genetic-or environment-based abnormality of intracellular acinar trypsinogen activation and thus to the induction of acinar cell injury that, in turn, sets in motion an intra-pancreatic inflammatory process. More recent studies, reviewed here, present strong evidence that while such trypsinogen activation is likely a necessary first step in the inflammatory cascade underlying pancreatitis, sustained pancreatic inflammation is dependent on damage-associated molecular patterns-mediated cytokine activation causing the translocation of commensal (gut) organisms into the circulation and their induction of innate immune responses in acinar cells. Quite unexpectedly, these recent studies reveal that the innate responses involve activation of responses by an innate factor, nucleotide-binding oligomerization domain 1 (NOD1), and that such NOD1 responses have a critical role in the activation/production of nuclear factor-kappa B and type I interferon. In addition, they reveal that chronic inflammation and its accompanying fibrosis are dependent on the generation of IL-33 by injured acinar cells and its downstreaminduction of Tcells producing IL-13. These recent studies thus establish that pancreatitis is quite a unique form of inflammation and one susceptible to newer, more innovative therapy.
  • Yasunori Minami; Masahiro Takita; Masakatsu Tsurusaki; Yukinobu Yagyu; Kazuomi Ueshima; Takamichi Murakami; Masatoshi Kudo
    HEPATOLOGY RESEARCH 47 3 E113 - E119 2017年03月 [査読有り]
     
    AimTo investigate whether plain cone-beam computed tomography (CT) immediately after conventional transcatheter arterial chemoembolization (c-TACE) can help to predict tumor response semiquantitatively in patients with hepatocellular carcinoma (HCC). MethodsAnalysis was carried out retrospectively on 262 targeted HCCs in 169 patients treated with c-TACE. Dynamic CT was performed at baseline and 1-4months after c-TACE. Receiver-operating characteristic curve analysis was undertaken to evaluate whether voxel values of cone-beam CT could predict a complete response and to identify the cut-off value. Final tumor response assessment and early prediction using the retention pattern of iodized oil, the cut-off value of the density, and the combination of the cut-off density value and retention pattern of iodized oil in HCCs on postprocedural cone-beam CT were compared. ResultsComplete response was obtained in 72.9% of lesions. According to the pattern of iodized oil uptake, the sensitivity, specificity, and accuracy for predicting complete response were 85.9%, 70.4%, and 81.7%, respectively by excellent uptake on cone-beam CT. The area under the curve was 0.86 with the optimal cut-off at a voxel value of 200.13. According to not only the density but also the homogeneity of iodized oil retention, the sensitivity, specificity, and accuracy values for predicting complete response were 86.4%, 95.8%, and 88.9%, respectively. The predictive accuracy was significantly better than that of the pattern of iodized oil retention only (P=0.019). ConclusionThe combination of density and visual estimate of homogeneity is superior to either alone in predicting tumor response of c-TACE in HCC patients.
  • Kosuke Minaga; Masayuki Kitano; Chimyon Gon; Kentaro Yamao; Hajime Imai; Takeshi Miyata; Ken Kamata; Shunsuke Omoto; Mamoru Takenaka; Masatoshi Kudo
    DIGESTIVE ENDOSCOPY 29 2 211 - 217 2017年03月 [査読有り]
     
    Background and AimEndoscopic ultrasonography (EUS)-guided choledochoduodenostomy (EUS-CDS) is increasingly used in the treatment of malignant distal biliary obstruction. Standardized use of this technique requires improvements in instruments, including more convenient and safer devices. The present study was designed to evaluate the resistance force to migration (RFM) of a newly designed laser-cut metal stent and the feasibility of EUS-CDS using this stent. MethodsThis experimental study used a porcine model of biliary dilatation involving five male pigs. The new stent is a fully covered laser-cut stent with anti-migration anchoring hooks. The RFM of the new stents was compared with those of three commercially available covered metal stents using a phantom model. In the animal study, after ligation of Vater's ampulla with endoscopic clips, the dilated common bile duct was punctured under EUS guidance, followed by EUS-CDS using the new stent. One week after the procedure, the stents were removed endoscopically and the fistulas were assessed after the pigs were killed. Technical feasibility and clinical outcomes were evaluated. ResultsAmong the four stents, the new stent had the highest RFM. Metal stent placement was successful in all five pigs, with no procedure-related complications occurring during and 1 week after endoscopic intervention. All stents remained in place without migration and were removed easily using a snare. At necropsy, fistulas were created between the bile duct and duodenum in all pigs. ConclusionEUS-CDS using a newly designed metal stent was feasible and effective in this porcine model of biliary dilatation.
  • D. J. Pinato; C. Yen; D. Bettinger; R. Ramaswami; T. Arizumi; C. Ward; M. Pirisi; M. E. Burlone; R. Thimme; M. Kudo; R. Sharma
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS 45 5 714 - 722 2017年03月 [査読有り]
     
    Background Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes. The albumin-bilirubin (ALBI) grade is a validated index of liver function in patients with HCC. Aim To test the accuracy of the ALBI grade in predicting post-sorafenib overall survival (PSOS) in patients who permanently discontinued treatment. Methods From a prospectively maintained international database of 447 consecutive referrals, we derived 386 eligible patients treated with sorafenib within Barcelona Clinic Liver Cancer C stage (62%), 75% of whom were of Child class A at initiation. Clinical variables at sorafenib discontinuation were analysed for their impact on post-sorafenib overall survival using uni- and multivariable analyses. Results Median post-sorafenib overall survival of the 386 eligible patients was 3.4 months and median sorafenib duration was 2.9 months, with commonest causes of cessation being disease progression (68%) and toxicity (24%). At discontinuation, 92 patients (24%) progressed to terminal stage, due to worsening Child class to C in 40 (10%). Median post-sorafenib overall survival in patients eligible for second-line therapies (n = 294) was 17.5, 7.5 and 1.9 months according respectively to ALBI grade 1, 2 and 3 (P < 0.001). Conclusions The ALBI grade at sorafenib discontinuation identifies a subset of patients with prolonged stability of hepatic reserve and superior survival. This may allow improved patient selection for second-line therapies in advanced HCC.
  • 鎌田 研; 竹中 完; 北野 雅之; 大本 俊介; 三長 孝輔; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊
    膵臓 32 1 38 - 44 (一社)日本膵臓学会 2017年02月 
    膵癌早期診断におけるEUSの果たす役割は近年大きくなりつつある。リスクファクターを有する症例や膵管内乳頭粘液性腫瘍の精査あるいは経過観察にEUSを用いることによって実際に早期膵癌が発見されたとする報告が数多くみられる。EUS機器の進歩、EUS-FNAの普及によって膵癌の存在診断・質的診断能は確実に向上してきている。本稿では、膵癌、特に小膵癌の存在診断におけるEUSの役割について解説する。(著者抄録)
  • Andrew X. Zhu; Ari David Baron; Peter Malfertheiner; Masatoshi Kudo; Seiji Kawazoe; Denis Pezet; Florian Weissinger; Giovanni Brandi; Carlo A. Barone; Takuji Okusaka; Yoshiyuki Wada; Joon Oh Park; Baek-Yeol Ryoo; Jae Yong Cho; Hyun Cheol Chung; Chung-Pin Li; Chia-Jui Yen; Kuan-Der Lee; Shao-Chun Chang; Ling Yang; Paolo B. Abada; Ian Chau
    JAMA ONCOLOGY 3 2 235 - 243 2017年02月 [査読有り]
     
    IMPORTANCE REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab survival benefit, severity of liver disease, and baseline a-fetoprotein (aFP). OBJECTIVE To assess treatment effects and tolerability of ramucirumab by Child-Pugh score in patients with HCC enrolled in the REACH trial. DESIGN, SETTINGS, AND PARTICIPANTS Randomized, double-blind, phase 3 trial of ramucirumab and best supportive care vs placebo and best supportive care as second-line treatment in patients with HCC enrolled between November 4, 2010 and April 18, 2013, from 154 global sites. Overall, 643 patients were randomized and included in this analysis; 565 patients considered Child-Pugh class A (Child-Pugh scores 5 and 6) and 78 patients considered class B (Child-Pugh scores 7 and 8). INTERVENTIONS Ramucirumab (8mg/kg) or placebo intravenously plus best supportive care every 2 weeks. MAIN OUTCOMES AND MEASURES Overall survival (OS), defined as time from randomization to death from any cause. RESULTS In the randomized population of 643 patients (mean [SD] age, 62.8 [11.1] years) in this analysis, a potential ramucirumab OS benefit was observed for patients with a Child-Pugh score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P =.06) but no apparent benefit for patients with Child-Pugh scores of 6 or 7 and 8. In patients with baseline aFP levels of 400 ng/mL (to convert ng/mL to mu g/L, multiply by 1.0) or more, a ramucirumab OS benefit was significant for a score of Child-Pugh 5 9HR, 0.61; 95% CI, 0.43-0.87; P =.01) and Child-Pugh 6 (HR, 0.64; 95% CI, 0.42-0.98; P =.04), but was not significant for Child-Pugh 7 and 8. The overall safety profile of ramucirumab, regardless of Child-Pugh score, was considered manageable. Regardless of treatment arm, patients with Child-Pugh scores of 7 and 8 experienced a higher incidence of grade 3 or higher treatment-emergent adverse events, including ascites and asthenia, and special-interest events, including liver injury and/or failure and bleeding, compared with patients with Child-Pugh scores of 5 or 6. CONCLUSIONS AND RELEVANCE In unselected patients, a trend for ramucirumab survival benefit was observed only for patients with a Child-Pugh score of 5. In patients with baseline aFP levels of 400 ng/mL or more, a ramucirumab survival benefit was observed for Child-Pugh scores of 5 and 6. Ramucirumab had a manageable toxic effect profile. These results support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC with underlying Child-Pugh A cirrhosis and baseline aFP levels of 400 ng/mL or more.
  • David J. Pinato; Rohini Sharma; Elias Allara; Clarence Yen; Tadaaki Arizumi; Keiichi Kubota; Dominik Bettinger; Jeong Won Jang; Carlo Smirne; Young Woon Kim; Masatoshi Kudo; Jessica Howell; Ramya Ramaswami; Michela E. Burlone; Vito Guerra; Robert Thimme; Mitsuru Ishizuka; Justin Stebbing; Mario Pirisi; Brian I. Carr
    JOURNAL OF HEPATOLOGY 66 2 338 - 346 2017年02月 [査読有り]
     
    Background & Aims: Overall survival (OS) is a composite clinical endpoint in hepatocellular carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating patient's mortality. The ALBI grade is a recently described index of liver dysfunction in hepatocellular carcinoma, based solely on albumin and bilirubin levels. Whilst accurate, this score lacks cross validation, especially in intermediate stage HCC, where OS is highly heterogeneous. Methods: We evaluated the prognostic accuracy of the ALBI grade in estimating OS in a large, multi-centre study of 2426 patients, including a large proportion of intermediate stage patients treated with chemoembolization (n = 1461) accrued from Europe, the United States and Asia. Results: Analysis of survival by primary treatment modality confirmed the ALBI grade as a significant predictor of patient OS after surgical resection (p <0.001), transarterial chemoembolization (p <0.001) and sorafenib (p <0.001). Stratification by Barcelona Clinic Liver Cancer stage confirmed the independent prognostic value of the ALBI across the diverse stages of the disease, geographical regions of origin and time of recruitment to the study (p <0.001). Conclusions: In this large, multi-centre retrospective study, the ALBI grade satisfied the criteria for accuracy and reproducibility following statistical validation in Eastern and Western HCC patients, including those treated with chemoembolization. Consideration should be given to the ALBI grade as a stratifying biomarker of liver reserve in routine clinical practice. Lay summary: Liver failure is a key determinant influencing the natural history of hepatocellular carcinoma (HCC). In this large multi-centre study we externally validate a novel biomarker of liver functional reserve, the ALBI grade, across all the stages of HCC. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • 造影超音波検査でのnodule in nodule type HCCの評価
    三野 智; 小川 力; 盛田 真弘; 野田 晃世; 出田 雅子; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊
    超音波医学 44 1 71 - 71 (公社)日本超音波医学会 2017年01月
  • 3D-GPS markerを用いたRFA治療の試み
    盛田 真弘; 小川 力; 三野 智; 野田 晃世; 出田 雅子; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊
    超音波医学 44 1 73 - 73 (公社)日本超音波医学会 2017年01月
  • Toshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 23 1 66 - 74 2017年01月 [査読有り]
     
    Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and heat shock protein A4 are involved in the refractory clinical course and development of CAC. RNAbinding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, heat shock protein A4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.
  • Serum microRNA profile that predict initial effect of sorafenib in patients with advanced hepatocellular carcinoma
    Nishida N; Arizumi T; Hagiwara S; Ida H; Sakurai T; Kudo M
    Liver Cancer 6 113 - 125 2017年 [査読有り]
  • Mamoru Takenaka; Masayuki Kitano; Masatoshi Kudo
    Gastroenterological Endoscopy 59 255 - 264 2017年01月 
    Chronic pancreatitis is one of the risk factors for pancreatic cancer and is considered to be an irreversible and progressive disease. However, the conventional diagnostic criteria of chronic pancreatitis had the problem of being able to diagnose only advanced chronic pancreatitis. Based on the hypothesis that the early stage of chronic pancreatitis is a reversible disease, the diagnostic criteria of "early-stage" chronic pancreatitis were developed in Japan for early detection and early treatment of chronic pancreatitis. Endoscopic ultrasonography (EUS) plays an important role in detecting "early-stage" chronic pancreatitis. Many EUS image findings of "early-stage" chronic pancreatitis are mentioned in the Rosemont criteria for the EUS diagnosis of chronic pancreatitis.
  • Shiori Fujii; Makoto Yamakawa; Kengo Kondo; Takeshi Namita; Masatoshi kudo; Tsuyoshi Shiina
    2017 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS) 2017年 [査読有り]
     
    Shear wave elasticity imaging has been utilized for chronic hepatitis diagnosis. The relationship between hepatic fibrosis and elasticity or viscosity has been described recently. Therefore, it is expected that viscosity analysis will improve the accuracy of staging fibrosis, in addition to elasticity measuring. However, fibrous structures affect dispersion slope analysis, so it is necessary to investigate the effect of fibrous structure on dispersion slope analysis. In order to simulate shear wave propagation in liver tissue, we use two types of models representing fibrosis progression. One is created using a potential function, and the other is created from hepatic histological sections. Simulating shear wave propagation in these models without viscosity in order to examine the effect of fibrous structure alone, dispersion analysis was applied to the particle velocity data. We evaluated the dispersion slope and shear wave phase velocity at 200 Hz (c (200 Hz)). In both models, the dispersion slope increased significantly with fibrosis progression. The resulting dispersion slope is about 30% of the dispersion slope in in vivo measurements, indicating that the effect of fibrous structure is large enough for viscosity analysis.
  • Kwok WY; Hagiwara S; Nishida N; Watanabe T; Sakurai T; Ida H; Minami Y; Takita M; Minami T; Iwanishi M; Chishina H; Kono M; Ueshima K; Komeda Y; Arizumi T; Enoki E; Nakai T; Kumabe T; Nakashima O; Kondo F; Kudo M
    Oncology 92 Suppl 1 16 - 28 2017年
  • 座談会; 切除不能な肝細胞癌に対するスチバーガ治療～2nd line治療における世界初のエビデンス創出およびネクサバールとのsequential therapyへの期待～
    工藤正俊; 黒崎雅之; 池田公史; 小笠原定久
    Medical Tribune Web 2017年 [査読有り]
  • 肝生検での診断が可能であった、AFP-L3陽性の細胆管細胞癌（CoCC）の一例
    小川 力; 工藤正俊
    第17回肝血流動態イメージ研究会記録集 93 - 96 2017年 [査読有り]
  • 膵炎における腸管免疫機構破綻と重症化機序
    渡邉智裕; 三長孝輔; 鎌田研; 山雄健太郎; 竹中完; 工藤正俊
    肝胆膵 75 991 - 996 2017年 [査読有り]
  • 肝癌診療のブレイクスルー―世界に誇る肝癌診療の構築. 特集: ターニングポイントを迎えた肝癌診療
    工藤正俊
    クリニシアン 659 712 - 715 2017年
  • 日本における新薬開発と今後の展望
    上嶋一臣; 工藤正俊
    消化器・肝臓内科 2 1 1 - 7 2017年
  • Clarence Yen; Rohini Sharma; Lorenza Rimassa; Tadaaki Arizumi; Dominik Bettinger; Huay Yee Choo; Tiziana Pressiani; Michela E. Burlone; Mario Pirisi; Laura Giordano; Anisa Abdulrahman; Masatoshi Kudo; Robert Thimme; Joong Won Park; David James Pinato
    LIVER CANCER 6 4 313 - 324 2017年 [査読有り]
     
    Background: Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease. Aim: We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival. Methods: From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment naive (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization (n = 413; 79%). The primary endpoint was overall survival (OS) from sorafenib initiation with prognostic factors tested on uni- and multivariate analyses. Results: Median OS for the entire cohort was 9 months; the median sorafenib duration was 2.8 months, with discontinuation being secondary to progression (n = 454; 58%) or toxicity (n = 149; 19%). PT patients had significantly longer OS than TN patients (10.5 vs. 6.6 months; p < 0.001). Compared to TN patients, PT patients had a better Child-Pugh (CP) class (CP A: 57 vs. 47%; p < 0.001) and a lower BCLC stage (BCLC A-B, 40 vs. 30%; p = 0.007). PT status preserved an independent prognostic role (p = 0.002) following adjustment for BCLC stage, a-fetoprotein, CP class, aetiology, and post-sorafenib treatment status. PT patients were more likely to receive further anticancer treatment after sorafenib (31 vs. 9%; p < 0.001). Conclusion: Patients receiving sorafenib after having failed curative or locoregional therapies survive longer and are more likely to receive further treatment after sorafenib. This suggests an incremental benefit to OS from sequential exposure to multiple lines of therapy, justifying treatment stage migration in eligible patients. (C) 2017 S. Karger AG, Basel
  • Shunsuke Omoto; Mamoru Takenaka; Masayuki Kitano; Takeshi Miyata; Ken Kamata; Kosuke Minaga; Tadaaki Arizumi; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi Kudo
    Oncology 93 1 55 - 60 2017年 [査読有り]
  • Kazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Tatsuya Kono; Kouta Takashima; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Tomoyuki Nagai; Yutaka Asakuma; Mamoru Takenaka; Toshiharu Sakurai; Shigenaga Matsui; Naoshi Nishida; Takaaki Chikugo; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 35 - 42 2017年 [査読有り]
  • Kentaro Yamao; Mamoru Takenaka; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 81 - 86 2017年 [査読有り]
  • Yoriaki Komeda; Hisashi Handa; Tomohiro Watanabe; Takanobu Nomura; Misaki Kitahashi; Toshiharu Sakurai; Ayana Okamoto; Tomohiro Minami; Masashi Kono; Tadaaki Arizumi; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 30 - 34 2017年 [査読有り]
  • Takenaka M; Masuda A; Shiomi H; Yagi Y; Zen Y; Sakai A; Kobayashi T; Arisaka Y; Okabe Y; Kutsumi H; Toyama H; Fukumoto T; Ku Y; Kudo M; Azuma T
    Oncology 93 Suppl 1 61 - 68 2017年 [査読有り]
  • Kazuki Okamoto; Shigenaga Matsui; Tomohiro Watanabe; Yutaka Asakuma; Yoriaki Komeda; Ayana Okamoto; Ishikawa Rei; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 9 - 14 2017年 [査読有り]
  • Hirofumi Izumoto; Atsushi Hiraoka; Yoshihiro Ishimaru; Tadashi Murakami; Shogo Kitahata; Hidetaro Ueki; Toshihiko Aibiki; Tomonari Okudaira; Yuji Miyamoto; Hiroka Yamago; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Masato Kishida; Eiji Tsubouchi; Hideki Miyata; Tomoyuki Ninomiya; Hideki Kawasaki; Masashi Hirooka; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
    Oncology 93 Suppl 1 120 - 126 2017年 [査読有り]
     
    BACKGROUND/AIM: Determination of failure of transarterial chemoembolization (TACE) for treatment of Barcelona Clinic Liver Cancer stage B (BCLC-B) hepatocellular carcinoma (HCC) has become important because of the development of tyrosine kinase inhibitor (TKI) treatment. We evaluated the usefulness and efficacy of the newly proposed time to TACE progression (TTTP). PATIENTS AND METHODS: From 2006 to 2016, 192 BCLC-B HCC patients [median age 72 years, male/female ratio = 149/43, Child-Pugh score 5/6/7 = 106/56/30, albumin-bilirubin (ALBI) grade 1/2 = 64/128, Kinki criteria B1/B2 = 64/128] were enrolled. TTTP was defined based on a previous report and first imaging performed 3 months after initial TACE had been used to obtain baseline images. The patients were divided into three groups according to TTTP (<5, 5-10, and ≥10 months; group I, II, and III, respectively). We evaluated the relationship between TTTP and overall survival (OS) as well as the prognostic factors for death. RESULTS: The median number of TACE procedures was 4 (interquartile range 3-7). There was a moderate correlation between TTTP and OS (r = 0.527, 95% CI 0.416-0.622, p < 0.001). The median survival for group I (n = 78), II (n = 49), and III (n = 65) was 24.6, 34.7, and 49.5 months, respectively (group I vs. group II, p = 0.023; group I vs. group III, p < 0.001; group II vs. group III, p = 0.037; Holm's method). ALBI grade 2 (HR 1.548, 95% CI 1.004-2.388, p = 0.048), alpha-fetoprotein (>100 ng/mL) (HR 1.540, 95% CI 1.035-2.291, p = 0.033), and TTTP (<5 months) (HR 2.157, 95% CI 1.447-3.215, p < 0.001) were significant prognostic factors for death in multivariate Cox hazard analysis. CONCLUSION: In patients with reduced TTTP, especially <5 months, it might be difficult to improve prognosis with a repeated TACE procedures. In such cases, reconsideration of the therapeutic strategy might be needed when possible.
  • Teppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Kazuki Okamoto; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Yoriaki Komeda; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Yutaka Asakuma; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 15 - 19 2017年 [査読有り]
  • Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Masashi Kudo
    LIVER CANCER 6 4 377 - 379 2017年 [査読有り]
  • Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Masatoshi Kudo
    LIVER CANCER 6 4 325 - 336 2017年 [査読有り]
     
    Background/Aim: Recently, albumin-bilirubin (ALBI) scoring/grading, consisting of only albumin and total bilirubin, has been proposed. We examined the efficacy of this grading system for determining hepatic function in patients with hepatocellular carcinoma (HCC). Methods/Materials: The prognoses of 46,681 HCC patients based on results obtained from a nationwide survey conducted in Japan from 2001 to 2007 were evaluated using (1) Japan Integrated Staging (JIS), consisting of Child-Pugh classification and TNM staging (TNM), (2) modified JIS (m-JIS), consisting of liver damage grading and TNM, and (3) ALBI-TNM (ALBI-T), consisting of ALBI grading and TNM, and the results were compared. A subanalysis was also performed to define a cutoff value for ALBI scores for a more detailed stratification of hepatic function. Results: ALBI-T, JIS, and m-JIS each showed good capacity for the stratification of prognoses. Although the Akaike information criterion for ALBI-T was nearly equal to that for JIS and m-JIS, the Kaplan-Meier curves and median survival times obtained with ALBI-T were always superior to the corresponding scores. When the indocyanine green retention test (<30%) was used as an additional cutoff value for ALBI score (-2.270, area under the curve 0.828) to divide ALBI grade into 4 levels (modified ALBI [mALBI] grade), mALBI grade was able to stratify the prognosis of patients at any TNM stage in order of grade. Modified ALBI-T (mALBI-T), using mALBI grading and TNM, produced a more detailed stratification for prognosis. Conclusion: The predictive value for prognosis of ALBI-T was found to be equal to that of JIS and m-JIS. In addition, mALBI grading and mALBI-T, as proposed in the present study, might provide a more detailed assessment of the hepatic function and prognosis of HCC patients. (C) 2017 S. Karger AG, Basel
  • Masatoshi Kudo
    LIVER CANCER 6 4 253 - 263 2017年 [査読有り]
  • Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 493 - 497 2017年 [査読有り]
  • Imoto S; Kim SR; Amano K; Iio E; Yoon S; Hirohata S; Yano Y; Ishikawa T; Katsushima S; Komeda T; Fukunaga T; Chung H; Kokuryu H; Horie Y; Hatae T; Fujinami A; Kim SK; Kudo M; Tanaka Y
    Digestive diseases (Basel, Switzerland) 35 6 531 - 540 2017年 [査読有り]
     
    Background: Recent genome-wide association studies demonstrated that 2 single nucleotide polymorphisms (SNPs), upstream of the interferon-lambda (IFNL) 3 gene, are associated with the spontaneous clearance of hepatitis C virus (HCV) in symptomatic patients with acute hepatitis C (AHC). Although these 2 SNPs, rs8099917 and rs12979860, have established their significant roles in the innate immunity response to spontaneously clear HCV in patients with AHC, the detailed mechanisms of their roles remain largely unknown. Aim: This study is aimed at clarifying the factors affecting IFNL3 production and assessing the roles of IFNL3 in AHC. Materials and Methods: A total of 21 AHC patients who visited the hospital within 10 days after symptom onset were assessed. As controls, 23 healthy volunteers (HVs) were examined. Serum IFNL3 levels were quantified using an inhouse, IFNL3-specific chemiluminescence enzyme immunoassay (CLEIA) kit. Serum IFNL1, IFN-alpha, IFN-alpha, and IFN-beta induced protein-10 (IP-10) levels were assayed using commercial enzyme-linked immunosorbent assay (ELISA) kits. Results: At baseline, serum IFNL3 levels were higher in AHC patients than in HVs (p < 0.0001). The higher levels in AHC patients did not differ between patients with the rs8099917 TT genotype and those with the non-TT (TG/GG) genotype (p = 0.546). Serial measurement of serum IFNL3 levels did not predict the outcome of conventional AHC. However, serum IFNL3 levels at baseline correlated positively with the HCV RNA levels (p = 0.005). Following HCV eradication, serum IFNL3 levels reduced to within the range obtained for HVs. Baseline serum IFNL1 levels did not differ significantly between AHC patients and HVs (p = 0.284). Serum levels of IFNL1 and IFNL3 at baseline also showed no correlative power (p = 0.288). Serum IFN-alpha and IFN-beta were detected together with remarkably high serum IFNL3 levels in only one patient who progressed to acute liver failure (ALF). Conclusion: These findings indicate that serum IFNL3 levels at baseline are higher in AHC patients regardless of the rs8099917 polymorphism, and primary HCV infection triggers the production of IFNL3. As a first line of defense in the innate immune system against invading HCV, increased IFNL3 levels play an important role, but serum IFNL3 levels are not the principal determinant of the clinical course of conventional AHC. (C) 2017 S. Karger AG, Basel
  • Takayuki Iwamoto; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Yoshitaka Yamaguchi; Yasushi Matsumoto; Masanori Nakahara; Osakuni Morimoto; Hiroshi Ohashi; Norihiko Fujita; Masatoshi Kudo; Tetsuo Takehara
    DIGESTIVE DISEASES 35 6 574 - 582 2017年 [査読有り]
     
    Background: Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI have been reported to be associated with intrahepatic distant recurrence (IDR) after hepatectomy or radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). IDR is categorized into hypervascular transformation of non-hypervascular hypointense hepatic nodules and new intrahepatic recurrence. The aim of this study was to evaluate the relationship between non-hypervascular hypointense hepatic nodules on Gd-EOB-DTPA-enhanced MRI and IDR after RFA, focusing on new intrahepatic recurrence. Methods: Ninety-one consecutive patients with 115 HCCs undergoing pretreatment Gd-EOB-DTPA-enhanced MRI and RFA for treatment of HCC were enrolled. Results: Of the 91 patients who underwent RFA for HCC, 24 had non-hypervascular hypointense hepatic nodules on pretreatment Gd-EOB-DTPA-enhanced MRI. Recurrences were observed in 15 and 19 patients with and without non-hypervascular hypointense hepatic nodules, respectively. Of the 15 recurrences in patients with non-hypervascular hypointense hepatic nodules, 10 patients had new intrahepatic recurrences. The cumulative incidence of new intrahepatic recurrence was significantly higher in patients with non-hypervascular hypointense hepatic nodules than in those without non-hypervascular hypointense hepatic nodules (p < 0.0001). Multivariate analysis revealed that the presence of non-hypervascular hypointense hepatic nodules and Child-Pugh score were independent risk factors for new intrahepatic recurrence. Conclusions: Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI were a useful predictive factor for IDR, particularly for new intrahepatic recurrence, after RFA. (C) 2017 S. Karger AG, Basel
  • Kudo M
    Arerugi = [Allergy] 66 6 798 - 803 2017年 [査読有り]
  • Yoshitomi H; Tsuru R; Li L; Zhou J; Kudo M; Liu T; Gao M
    PloS one 12 8 e0183988  2017年 [査読有り]
  • Kazuomi Ueshima; Masatoshi Kudo
    Journal of Japanese Society of Gastroenterology 114 9 1621 - 1628 2017年 [査読有り]
  • Wada K; Kanazawa H; Kudo M; Kindaichi J; Miyashin M
    Journal of oral science 59 3 457 - 460 日本大学歯学部 2017年 [査読有り]
     

    This study attempted to identify appropriate materials for restoration of enamel defects in the primary dentition, which were classified by severity and region with the modified developmental defects of enamel index. To identify the most appropriate materials, we used restorative materials to protect teeth and evaluated clinical outcomes of restoration. Three materials were used for restoration or repair after dislodgement of restorations. Our findings in this case suggest that, because of its durability and esthetic advantages, adhesive resin is beneficial for patients with enamel defects, particularly for restorations of less than two-thirds of the extent of the defect.

  • Transarterial Chemoembolization in Combination with Molecular Targeted Agent: Lessons from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)
    Masatoshi Kudo; Tadaaki Arizumi
    Oncology Suppl in press 2017年 [査読有り]
  • Hirofumi Izumoto; Atsushi Hiraoka; Yoshihiro Ishimaru; Tadashi Murakami; Shogo Kitahata; Hidetaro Ueki; Toshihiko Aibiki; Tomonari Okudaira; Yuji Miyamoto; Hiroka Yamago; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Masato Kishida; Eiji Tsubouchi; Hideki Miyata; Tomoyuki Ninomiya; Hideki Kawasaki; Masashi Hirooka; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
    Oncology 93 Suppl 1 in press 120 - 126 2017年 [査読有り]
     
    BACKGROUND/AIM: Determination of failure of transarterial chemoembolization (TACE) for treatment of Barcelona Clinic Liver Cancer stage B (BCLC-B) hepatocellular carcinoma (HCC) has become important because of the development of tyrosine kinase inhibitor (TKI) treatment. We evaluated the usefulness and efficacy of the newly proposed time to TACE progression (TTTP). PATIENTS AND METHODS: From 2006 to 2016, 192 BCLC-B HCC patients [median age 72 years, male/female ratio = 149/43, Child-Pugh score 5/6/7 = 106/56/30, albumin-bilirubin (ALBI) grade 1/2 = 64/128, Kinki criteria B1/B2 = 64/128] were enrolled. TTTP was defined based on a previous report and first imaging performed 3 months after initial TACE had been used to obtain baseline images. The patients were divided into three groups according to TTTP (<5, 5-10, and ≥10 months; group I, II, and III, respectively). We evaluated the relationship between TTTP and overall survival (OS) as well as the prognostic factors for death. RESULTS: The median number of TACE procedures was 4 (interquartile range 3-7). There was a moderate correlation between TTTP and OS (r = 0.527, 95% CI 0.416-0.622, p < 0.001). The median survival for group I (n = 78), II (n = 49), and III (n = 65) was 24.6, 34.7, and 49.5 months, respectively (group I vs. group II, p = 0.023; group I vs. group III, p < 0.001; group II vs. group III, p = 0.037; Holm's method). ALBI grade 2 (HR 1.548, 95% CI 1.004-2.388, p = 0.048), alpha-fetoprotein (>100 ng/mL) (HR 1.540, 95% CI 1.035-2.291, p = 0.033), and TTTP (<5 months) (HR 2.157, 95% CI 1.447-3.215, p < 0.001) were significant prognostic factors for death in multivariate Cox hazard analysis. CONCLUSION: In patients with reduced TTTP, especially <5 months, it might be difficult to improve prognosis with a repeated TACE procedures. In such cases, reconsideration of the therapeutic strategy might be needed when possible.
  • A social program for the early detection of pancreatic cancer, the Kishiwada project: A multi-center study
    Hiroki Sakamoto; Satoshi Harada; Nobu Nishioka; Kazuo Maeda; Takamasa Kurihara; Tateki Sakamoto; Kazuhide Higuchi; Masayuki Kitano; Yoshifumi Takeyama; Masafumi Kogire; Masatoshi Kudo
    Oncology Suppl in press 2017年 [査読有り]
  • Chikara Ogawa; Masahiro Morita; Akina Omura; Teruyo Noda; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Akemi Tsutsui; Tomonori Senoh; Takuya Nagano; Kouichi Takaguchi; Joji Tani; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki; Akio Moriya; Masaharu Ando; Akihiro Deguchi; Yasutaka Kokudo; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Oncology 93 Suppl 1 in press 113 - 119 2017年 [査読有り]
     
    OBJECTIVE: To determine the relationship between treatment outcomes and hand-foot syndrome (HFS), and the relationship between survival rate and post-progression treatment after sorafenib therapy. METHODS: The study assessed 314 patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib at 5 general hospitals in Kagawa Prefecture, Japan. RESULTS: At the start of sorafenib therapy, 23.6% of the patients had HCC of a Child-Pugh class other than A. The initial sorafenib dose was 800 mg in 9.2% of the patients and 400 mg in 64.3%. Time to progression was 129 days (95% CI: 87.3-170.7) and the median overall survival (OS) was 392 days (95% CI: 316.0-468.0). The OS of the patients with Child-Pugh class A HCC was significantly better than that of the patients with Child-Pugh class B HCC (p < 0.0001). The survival curves for Child-Pugh class A-5 points and class A-6 points were significantly different, with that for class A-5 points being better (p < 0.0001). A significant difference was observed between the patients who exhibited HFS and those who did not, with the former exhibiting a better survival rate (p < 0.001). In addition, the survival rate of the patients who received post-progression treatment after sorafenib therapy was significantly better than that of the patients who did not (p < 0.001). CONCLUSION: In sorafenib therapy, patients with HFS and those who received post-progression treatment exhibited good OS.
  • Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Oncology 93 1 87 - 88 2017年 [査読有り]
  • Kentaro Yamao; Mamoru Takenaka; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 81 - 86 2017年 [査読有り]
  • Kentaro Yamao; Mamoru Takenaka; Hajime Imai; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 76 - 80 2017年 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Akio Katanuma; Masayuki Kitano; Yukitaka Yamashita; Ken Kamata; Kentaro Yamao; Tomohiro Watanabe; Hiroyuki Maguchi; Masatoshi Kudo
    Oncology 93 1 107 - 112 2017年 [査読有り]
  • Ken Kamata; Mamoru Takenaka; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Tomohiro Matsuda; Kentaro Yamao; Hajime Imai; Yasutaka Chiba; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    Oncology 93 1 102 - 106 2017年 [査読有り]
  • Hajime Imai; Mamoru Takenaka; Shunsuke Omoto; Ken Kamata; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Toshiharu Sakurai; Naoshi Nishida; Tomohiro Watanabe; Masayuki Kitano; Masatoshi Kudo
    Oncology 93 1 69 - 75 2017年 [査読有り]
  • Chronic Pancreatitis finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of IPMNs is Associated with Invasive IPMC
    Mamoru Takenaka; Atsuhiro Masuda; Hideyuki Shiomi; Yosuke Yagi; Yoh Zen; Arata Sakai; Takashi Kobayashi; Yoshifumi Arisaka; Yoshihiro Okabe; Hiromu Kutsumi; Hirochika Toyama; Takumi Fukumoto; Yonson Ku; Masatoshi Kudo; Takeshi Azuma
    Oncology Supple in press 2017年 [査読有り]
  • Shunsuke Omoto; Mamoru Takenaka; Masayuki Kitano; Takeshi Miyata; Ken Kamata; Kosuke Minaga; Tadaaki Arizumi; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi Kudo
    Oncology 93 1 55 - 60 2017年 [査読有り]
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; George Tribonias; Tomoyuki Nagai; Masashi Kono; Kosuke Minaga; Mamoru Takenaka; Tadaaki Arizumi; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Masatoshi Kudo
    Oncology 93 1 49 - 54 2017年 [査読有り]
  • Kazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Tatsuya Kono; Kouta Takashima; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Tomoyuki Nagai; Yutaka Asakuma; Mamoru Takenaka; Toshiharu Sakurai; Shigenaga Matsui; Naoshi Nishida; Takaaki Chikugo; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 35 - 42 2017年 [査読有り]
  • Yoriaki Komeda; Hisashi Handa; Tomohiro Watanabe; Takanobu Nomura; Misaki Kitahashi; Toshiharu Sakurai; Ayana Okamoto; Tomohiro Minami; Masashi Kono; Tadaaki Arizumi; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 30 - 34 2017年 [査読有り]
  • Toshiharu Sakurai; Teppei Adachi; Masashi Kono; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Yoriaki Komeda; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 27 - 29 2017年 [査読有り]
  • Mitsunari Yamada; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 20 - 26 2017年 [査読有り]
  • Teppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Kazuki Okamoto; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Yoriaki Komeda; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Yutaka Asakuma; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 15 - 19 2017年 [査読有り]
  • Kazuki Okamoto; Shigenaga Matsui; Tomohiro Watanabe; Yutaka Asakuma; Yoriaki Komeda; Ayana Okamoto; Ishikawa Rei; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 9 - 14 2017年 [査読有り]
  • Preface: New Paradigm in Gastrointestinal Cancer Treatment
    工藤正俊
    Oncology Supple in press 2017年 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 618 - 622 2017年 [査読有り]
     
    With the development of molecular targeting therapy, several treatment options for advanced hepatocellular carcinoma (HCC) have become available in cases where curative and other palliative treatments, such as radiofrequency ablation, surgical resection, and transarterial chemoembolization, are not applicable. However, with the detection of a variety of mutations in cancer-related genes in a single tumor, molecular heterogeneity is commonly observed in HCC. Therefore, mutations in the major cellular signaling pathways underlie the development of resistance to molecular targeting agents. On the contrary, immune checkpoint inhibitors have proven effective in patients who are refractory to conventional treatments and molecular targeting therapy. Several clinical trials are currently investigating the efficacy of immune checkpoint inhibitors both individually and in combination with other types of anticancer agents. In this review, we focus on the potential of immune checkpoint blockade in the treatment of human HCC. (C) 2017 S. Karger AG, Basel
  • Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 611 - 617 2017年 [査読有り]
     
    Objectives: Previously, no therapeutic agent has been known to improve the overall survival compared with placebo in patients with hepatocellular carcinoma (HCC), who have progressed after sorafenib. In this patient population, regorafenib was first demonstrated to confer a survival benefit in the RESORCE trial, and subsequently it was approved as a second-line treatment for patients with advanced HCC. An open-label expanded access program (EAP) of regorafenib was implemented for compassionate use. We investigated the efficacy and safety of regorafenib based on our experience of the RESORCE trial and the EAP. Methods: Data from 5 patients from the RESORCE trial and 6 from the EAP were analyzed retrospectively. All patients had tolerated prior sorafenib and were progressing during sorafenib treatment. Results: The median progression-free survival was 9.2 months (95% CI 2.3-16.1). One patient achieved a partial response and 7 achieved stable disease. The objective response rate was 9.1%, and the disease control rate was 72.7%. No treatment-associated mortalities were observed. Grade 3 hypophosphatemia was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively. All treatment-related adverse events were improved by reduction or interruption of regorafenib. Five patients showed decreased serum albumin levels. Conclusion: Sorafenib and regorafenib sequential therapy presents a safe and effective treatment option for patients with advanced HCC. (C) 2017 S. Karger AG, Basel
  • Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Yohei Koizumi; Yoichi Hiasa; Kazuto Tajiri; Hidenori Toyoda; Toshifumi Tada; Hironori Ochi; Koji Joko; Noritomo Shimada; Akihiro Deguchi; Toru Ishikawa; Michitaka Imai; Kunihiko Tsuji; Kojiro Michitaka
    DIGESTIVE DISEASES 35 6 602 - 610 2017年 [査読有り]
     
    Background/Aim: We evaluated the relationship of hepatic function with repeated transarterial catheter chemoembolization (TACE) and prognosis after sorafenib treatment in various patient cohorts. Methods: Study 1 comprised of 212 Barcelona clinic liver cancer stage-B (BCLC-B) HCC patients classified as Child-Pugh A (CP-A) and who had received repeated TACE treatments (r-TACE) (naive: recurrence = 66: 146). Study 2 comprised of 435 patients with unresectable HCC classified as CP-A in who sorafenib was introduced (naive: recurrence = 37: 398; CP score 5: 6 = 282: 153; macrovessel invasion [MVI]+: extrahepatic metastasis [EHM]+ both negative = 124: 226: 143). Changes in hepatic function along with CP and albumin-bilirubin (ALBI) score/grade during r-TACE in Study 1, and prognosis after introducing sorafenib in Study 2 were evaluated. Results: Hepatic function worsened to CP-B in 9-14% with each TACE procedure, while 18-21% had a change of classification from ALBI-1 to ALBI-2. When the prognosis of patients with the best CP score of 5 was analyzed, those with ALBI-1 (n = 154) had a better outcome than those with ALBI-2 (n = 128) (MST 17.5 vs. 9.9 months; p = 0.01), while ALBI-1 (n = 43) patients also showed a better outcome than ALBI-2 (n = 34) patients with a CP score of 5 without MVI/EHM (MST: 17.5 vs. 10.0 months; p = 0.029). The Akaike's Information criterion for ALBI-grade (MST: grade 1 vs. 2 = 16.9 vs. 10.4 months; p = 0.001) was also better than that for CP (MST: score 5 vs. 6 = 14.4 vs. 10.5 months; p = 0.003) (3195.6 vs. 3197.5) in all 435 patients. Conclusion: The rate of patients with downgraded hepatic function during r-TACE, especially with regard to ALBI-grade, was not low. ALBI-grade was shown to be a better hepatic function assessment tool than CP in patients receiving sorafenib treatment. Strict judgment of TACE-refractory status in patients with unresectable HCC is needed to improve prognosis before downgrading the hepatic function. (C) 2017 S. Karger AG, Basel
  • Toru Ishikawa; Michitaka Imai; Takashi Owaki; Hiroki Sato; Yujiro Nozawa; Tomoe Sano; Akito Iwanaga; Keiichi Seki; Terasu Honma; Toshiaki Yoshida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 598 - 601 2017年 [査読有り]
     
    Background/Aim: Balloon-occluded transcatheter arterial chemoembolization (B-TACE) using miriplatin (MPT) is anticipated as a new strategy for hepatocellular carcinoma (HCC). This study was aimed at evaluating the hemodynamic changes with/without balloon occlusion of the hepatic artery, correlation of cone-beam CT (CBCT) pixels, and CT value after B-TACE for HCC. Methods: A total of 52 patients with HCC, who underwent B-TACE using MPT in addition to the balloon-occluded CBCT hepatic arteriography, were studied. Results: After balloon occlusion, CBCT pixel values increased in 37 lesions, whereas it decreased in 15 lesions. Intratumoral CT values after B-TACE were lower with decreased CBCT pixel values than with increased CBCT pixel values. Conclusion: Hemodynamic changes on CBCT during balloon occlusion can be used to predict the efficacy of B-TACE using MPT. (C) 2017 S. Karger AG, Basel
  • Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 589 - 597 2017年 [査読有り]
     
    Background: Transarterial chemoembolization (TACE) is recommended for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B. However, because of the heterogeneity of HCC in BCLC stage B; various subclassification systems have been proposed to predict the prognosis of patients. Previously, we proposed the Kinki criteria for precise classification of HCC cases in BCLC stage B. In this study, we compared the time to TACE refractoriness in HCC patients with Kinki criteria substages B1 and B2-HCC. Summary: Between January 2006 and December 2013, 592 HCC patients (substage B1, n = 118; substage B2, n = 170) underwent TACE. Time to progression under TACE treatment was defined as the time to untreatable progression (TTUP). TTUP and changes in liver function were analyzed in patients with substages B1 and B2-HCC. The median TTUP was 25.7 months (95% CI 19.3-37.3) and 16.4 months (95% CI 13.1-20.2) in patients with substage B1-HCC and substage B2-HCC, respectively (p = 0.0050). In patients with substage B2-HCC, median Child-Pugh scores after the first TACE session was significantly different from those after third and fifth TACE sessions (first-third, p = 0.0020; first-fifth, p = 0.0008). Key Message: TACE refractoriness occurred earlier in patients with substage B2-HCC than those with substage B1-HCC; deterioration of liver function with repeated TACE was more obvious in HCC cases with stage-B1 tumor. Shorter TTUP and impaired liver function due to repeated TACE could be responsible for the shorter survival in patients with substage B2-HCC. (C) 2017 S. Karger AG, Basel
  • Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 583 - 588 2017年 [査読有り]
     
    Background: Tumors classified based on the Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are heterogeneous in nature. Previously, the Kinki criterion was proposed for a more precise subclassification of tumors in BCLC-stage B. However, tumors in sub-stage B2 include various size and number of HCCs even with the Kinki criteria, which could lead to heterogeneity for overall survival (OS). In this study, we assessed how the size and number of tumors affect the OS and time to progression (TTP) in patients with Kinki criteria stage B2 tumors and treated with transarterial chemoembolization (TACE). Methods: Of 906 HCC patients treated with TACE at Kindai University Hospital, 236 patients with HCC considered as Kinki criteria stage B2 were examined. They were classified into the following 4 groups according to the maximum tumor diameter and number of tumors: B2a group, tumor size <= 6 cm and total number of tumors <= 6; B2b group, size <= 6 cm and number >6; B2c group, size >6 cm and number <= 6; and B2d group, size >6 cm and number >6. The OS and TTP of patients in each group were compared. Results: There were 131 patients (55.5%) in the B2a group, 58 (24.6%) in the B2b group, 41 (17.4%) in the B2c group, and 6 (0.03%) in the B2d group. Comparison of the survivals revealed that the median OS was 2.8 years (95% CI 2.0-3.5) in the B2a group, 2.8 years (95% CI 2.0-3.3) in the B2b group, 1.9 years (95% CI 0.8-4.0) in the B2c group, and 2.3 years (95% CI 1.2-ND [no data]) in the B2d group, respectively (p = 0.896). The median TTP in B2a, B2b, B2c, and B2d sub-substage HCC were13.2, 12.1, 13.8, and 11.5 months, respectively (p = 0.047). The median TTP in B2a + B2c sub-substage patients was longer than that in B2b + B2d sub-substage HCC patients (14.0 months and 10.4 months; p = 0.002). Conclusion: No significant differences were observed in the OS among HCC patients subclassified based on the maximum tumor diameter and tumor number in Kinki criteria stage B2. Consequently, Kinki criteria stage B2 HCC is a homogeneous subgroup in terms of OS prediction. However, shorter TTP in B2b + B2c sub-substage HCC patients than that in B2a + B2c sub-substage HCC patients suggests that different treatment strategy, such as systemic therapy with targeted agents instead of TACE, may be suitable to preserve the liver function. (C) 2017 S. Karger AG, Basel
  • Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma.
    Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara T
    Digest Dis 35 6 574 - 582 2017年 [査読有り]
  • Hiroshi Ida; Satoru Hagiwara; Masashi Kono; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Yasunori Minami; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 565 - 573 2017年 [査読有り]
     
    Background: Interferon-based antiviral therapies against hepatitis C virus (HCV) infection have been shown to reduce the incidence of hepatocellular carcinoma (HCC) in patients with sustained viral response (SVR). Recently, direct-acting antivirals (DAAs) have been proven to be much more effective in achieving SVR than interferon-based therapies. However, whether DAAs can efficiently prevent the occurrence of HCC after SVR remains controversial. To clarify this issue, we analyzed the clinical features of patients in whom HCC developed after achievement of SVR with DAAs for chronic HCV infection. Summary: Among patients who achieved SVR with daclatasvir and asunaprevir (n = 100), HCC developed in 17 patients (HCC group; n = 17) and did not develop in 83 patients (non-HCC group; n = 83) during a mean observation period of 15 months. A multivariate Cox proportional hazards analysis identified past history of HCC and male sex as significant risk factors for the emergence of HCC after DAAs. Sixteen cases with HCC after DAAs were in the very early or early stage (16/ 17, 94.1%), and one case was in the advanced stage (1/17, 5.9%) with portal venous tumor thrombus. Radiofrequency ablation and/or transarterial chemoembolization were performed in most cases as curative therapy (16/17, 94.1%). Key Messages: SVR by DAAs did not completely prevent the occurrence of HCC. However, even if HCC did develop after SVR, curative anticancer therapy was applicable in most cases. (C) 2017 S. Karger AG, Basel
  • Masashi Kono; Naoshi Nishida; Satoru Hagiwara; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Toshiharu Sakurai; Mamoru Takenaka; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Yasunori Minami; Kazuomi Ueshima; Tomohiro Watanabe; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 556 - 564 2017年 [査読有り]
     
    Background and Aims: Direct-acting antivirals (DAAs) dramatically improve the sustained virological response (SVR) of chronic hepatitis C (CHC) patients. However, continuous liver damage after SVR may be a risk of hepatocellular carcinoma (HCC). We clarified pretreatment characteristics related to sustained liver damage after SVR. Methods: A total of 286 CHC patients were treated with an interferon-free DAA regimen. Among them, 250 patients achieved SVR for 12 weeks after the end of treatment (SVR12); these individuals were classified based on a-fetoprotein (AFP) and alanine transaminase (ALT) levels posttreatment. Baseline characteristics significantly associated with AFP > 5 ng/mL and ALT level >= 20 IU/L after SVR were clarified using multivariate analyses. Results: Among the pretreatment factors examined, serum AFP values and the presence of fatty liver (FL) were significantly associated with abnormal AFP (p < 0.0001) and ALT levels 12 weeks after SVR12 (SVR24; p = 0.0109). For 126 patients who showed an increase in baseline AFP level, FL, fibrosis-4 (FIB-4) index, and albumin levels before treatment were related to abnormal AFP at SVR24 (p = 0.0005, 0.0232, and 0.0400 for FL, FIB-4 index, and albumin, respectively). Similarly, for 150 patients with abnormal baseline ALT levels, FL was associated with an ALT level = 30 IU/L after SVR (p = 0.0430). Conclusions: High FIB-4 index, low albumin level, and FL before DAA treatment were associated with a risk of sustained liver damage with AFP and ALT elevation after SVR; patients with these factors should be carefully monitored for emergence of HCC. (C) 2017 S. Karger AG, Basel
  • Yasuko Umehara; Satoru Hagiwara; Naoshi Nishida; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Tomohiro Watanabe; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 548 - 555 2017年 [査読有り]
     
    Objective: It is a generally accepted fact that eradication of hepatitis virus C inhibits the subsequent development of hepatocellular carcinoma (HCC). On the contrary, a significant population of patients developed HCC despite sustained virological responses (SVRs) to interferon (IFN) therapy. Methods: A total of 415 patients with chronic hepatitis C, who were treated at our hospital between 2004 and 2014, were enrolled for this study. We examined the risk factors for HCC development after IFN therapy. Results: After analyzing various clinical parameters, it was concluded that a serum albumin (ALB) level <4.0 g/dL and the presence or absence of SVR achievement were risk factors for the development of HCC. When analyzing pre-and posttreatment factors, only a serum ALB level <4.0 g/dL was considered a significant risk factor. The presence or absence of liver fibrosis progression was not identified as a risk factor. Conclusions: In patients with a serum ALB level <4.0 g/dL before IFN therapy, hepatic carcinogenesis after SVR achievement need to be considered. Furthermore, the serum ALB level may be more useful than the degree of fibrosis for the prediction of HCC after SVR in chronic hepatitis C. (C) 2017 S. Karger AG, Basel
  • Kayo Seo; Soo Ki Kim; Soo Ryang Kim; Aya Ohtani; Mana Kobayashi; Airi Kato; Eri Morimoto; Yuka Saijo; Ke Ih Kim; Susumu Imoto; Chi Wan Kim; Yoshihiko Yano; Masatoshi Kudo; Yoshitake Hayashi
    DIGESTIVE DISEASES 35 6 541 - 547 2017年 [査読有り]
     
    Background: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far. Summary: Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and alpha-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12. Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group. In both groups, while the reduction in ALT levels was significant that of AFP was not. Compared with the baseline, although serum PLT count at the end of treatment (EOT) was significantly higher in the Sofosbuvir plus RBV group, it was significantly lower in the peg-IFN plus RBV group. Although a significant decline in fibrosis markers such as FIB-4 and APRI was observed between the baseline and at EOT in the Sofosbuvir plus RBV group, no significant change of these markers was observed in the pegIFN plus RBV group. Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Key Message: The treatment with Sofosbuvir plus RBV results in not only a higher SVR, but also improves the liver function and the degree of fibrosis. (C) 2017 S. Karger AG, Basel
  • Imoto S; Kim SR; Amano K; Iio E; Yoon S; Hirohata S; Yano Y; Ishikawa T; Katsushima S; Komeda T; Fukunaga T; Chung H; Kokuryu H; Horie Y; Hatae T; Fujinami A; Kim SK; Kudo M; Tanaka Y
    Digest Dis 35 6 531 - 540 2017年 [査読有り]
     
    Background: Recent genome-wide association studies demonstrated that 2 single nucleotide polymorphisms (SNPs), upstream of the interferon-lambda (IFNL) 3 gene, are associated with the spontaneous clearance of hepatitis C virus (HCV) in symptomatic patients with acute hepatitis C (AHC). Although these 2 SNPs, rs8099917 and rs12979860, have established their significant roles in the innate immunity response to spontaneously clear HCV in patients with AHC, the detailed mechanisms of their roles remain largely unknown. Aim: This study is aimed at clarifying the factors affecting IFNL3 production and assessing the roles of IFNL3 in AHC. Materials and Methods: A total of 21 AHC patients who visited the hospital within 10 days after symptom onset were assessed. As controls, 23 healthy volunteers (HVs) were examined. Serum IFNL3 levels were quantified using an inhouse, IFNL3-specific chemiluminescence enzyme immunoassay (CLEIA) kit. Serum IFNL1, IFN-alpha, IFN-alpha, and IFN-beta induced protein-10 (IP-10) levels were assayed using commercial enzyme-linked immunosorbent assay (ELISA) kits. Results: At baseline, serum IFNL3 levels were higher in AHC patients than in HVs (p < 0.0001). The higher levels in AHC patients did not differ between patients with the rs8099917 TT genotype and those with the non-TT (TG/GG) genotype (p = 0.546). Serial measurement of serum IFNL3 levels did not predict the outcome of conventional AHC. However, serum IFNL3 levels at baseline correlated positively with the HCV RNA levels (p = 0.005). Following HCV eradication, serum IFNL3 levels reduced to within the range obtained for HVs. Baseline serum IFNL1 levels did not differ significantly between AHC patients and HVs (p = 0.284). Serum levels of IFNL1 and IFNL3 at baseline also showed no correlative power (p = 0.288). Serum IFN-alpha and IFN-beta were detected together with remarkably high serum IFNL3 levels in only one patient who progressed to acute liver failure (ALF). Conclusion: These findings indicate that serum IFNL3 levels at baseline are higher in AHC patients regardless of the rs8099917 polymorphism, and primary HCV infection triggers the production of IFNL3. As a first line of defense in the innate immune system against invading HCV, increased IFNL3 levels play an important role, but serum IFNL3 levels are not the principal determinant of the clinical course of conventional AHC. (C) 2017 S. Karger AG, Basel
  • Natsuko Kobayashi; Takashi Kumada; Hidenori Toyoda; Toshifumi Tada; Takanori Ito; Masayoshi Kage; Takeshi Okanoue; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 521 - 530 2017年 [査読有り]
     
    Background: Several laboratory markers used in lieu of liver biopsy are reportedly useful in the diagnosis of nonalcoholic steatohepatitis (NASH). In the present study, we investigated the diagnostic impact of various non-invasive markers for predicting NASH. Methods: A total of 229 nonalcoholic fatty liver disease (NAFLD) patients who underwent liver biopsy were enrolled for the study. The diagnostic ability of various markers to diagnose NASH from NAFLD was investigated. Results: A total of 140 patients were histologically diagnosed with NASH. Of these, 104 had degree 0-2 fibrosis (F0-2), and 36 had degree 3-4 fibrosis (F3-4). Multiple logistic regression analysis identified hyaluronic acid (HA) (OR 1.014; 95% CI 1.002-1.026; p = 0.024), FIB-4 index (OR 2.097; 95% CI 1.177-3.735; p = 0.012), and cytokeratin-18 fragments (CK-18F) (OR 1.002; 95% CI 1.001-1.002; p < 0.001) as factors independently associated with the diagnosis of NASH. The areas under the receiver operating characteristic curves (AUROCs) of HA, FIB-4 index, and CK-18F for the diagnosis of NASH were 0.77, 0.76, and 0.72, respectively. In addition, FIB-4 index (OR 1.907; 95% CI 1.063-3.419; p = 0.03) and CK-18F (OR 1.002; 95% CI 1.001-1.002; p < 0.001) could differentiate between NASH and NAFL, even when NASH patients with advanced fibrosis (F3-4) were excluded. AUROCs of FIB-4 index and CK-18F for the diagnosis of NASH with mild fibrosis (F0-2) from NAFLD were 0.70 and 0.70, respectively. Conclusions: FIB-4 index and CK-18F have good diagnostic abilities not only for NASH overall, but also for NASH with mild fibrosis. (C) 2017 S. Karger AG, Basel
  • Norihisa Yada; Nobuhura Tamaki; Yohei Koizumi; Masashi Hirooka; Osamu Nakashima; Yoichi Hiasa; Namiki Izumi; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 515 - 520 2017年 [査読有り]
     
    Objective: Performing shear wave imaging is simple, but can be difficult when inflammation, jaundice, and congestion are present. Therefore, the correct diagnosis of liver fibrosis using shear wave imaging alone might be difficult in mild-to-moderate fibrosis cases. Strain imaging can diagnose liver fibrosis without the influence of inflammation. Therefore, the combined use of strain and shear wave imaging (combinational elastography) for cases without jaundice and congestion might be useful for evaluating fibrosis and inflammation. Methods: We enrolled consecutive patients with liver disease, without jaundice or liver congestion. Strain and shear wave imaging, blood tests, and liver biopsy were performed on the same day. The liver fibrosis index (LF index) was calculated by strain imaging; real-time tissue elastography, and the shear wave velocity (V-s) was calculated by shear wave imaging. Fibrosis index (F index) and activity index (A index) were calculated as a multiple regression equation for determining hepatic fibrosis and inflammation using histopathological diagnosis as the gold standard. The diagnostic ability of F index for fibrosis and A index for inflammation were compared using LF index and V-s. Results: The total number of enrolled cases was 388. The area under the receiver operating characteristic (AUROC) was 0.87, 0.80, 0.83, and 0.80, at diagnosis of fibrosis stage with an F index of F1 or higher, F2 or higher, F3 or higher, and F4, respectively. The AUROC was 0.94, 0.74, and 0.76 at diagnosis of activity grade with an A index of A1 or higher, A2 or higher, and A3, respectively. The diagnostic ability of F index for liver fibrosis and A index for inflammation was higher than for other conventional diagnostic values. Conclusions: The combined use of strain and shear wave imaging (combinational elastography) might increase the positive diagnosis of liver fibrosis and inflammation. (C) 2017 S. Karger AG, Basel
  • Akemi Tsutsui; Kenichi Harada; Koichi Tsuneyama; Tomonori Senoh; Takuya Nagano; Koichi Takaguchi; Midori Ando; Satoko Nakamura; Koichi Mizobuchi; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 506 - 514 2017年 [査読有り]
     
    Aim: Acute-onset autoimmune hepatitis (AIH) histopathologically presents with features of acute hepatitis and lacks a specific diagnostic method. Also, AIH is often difficult to differentiate from drug-induced liver injury (DILI). We aimed to investigate the final clinical diagnosis of these cases, and compare the clinical, biochemical, and histological characteristics of AIH vs. DILI. Methods: We examined the Digestive Disease Week Japan 2004 (DDW-J) scale scores, AIH scores, clinical data, and pathological findings in 20 patients in whom it was difficult to differentiate autoimmune liver disease from DILI. Results: In cases with a DDW-J scale score of >= 5, there was a good correlation between the final diagnosis and DDW-J scale assessments, but in cases with a DDW-J scale score of <= 4 they did not correlate well. The scores for pathological findings, such as cobblestone hepatocellular change (p = 0.015), interface hepatitis (p = 0.012), and prominent plasma cells in portal areas (p = 0.011), were higher in the AIH group than in the DILI group. Conclusion: This study showed that DDW-J scale was useful for differentiating AIH from DILI in cases with a DDW-J scale score of >= 5. The histologic features of AIH were characterized by cobblestone hepatocellular change, interface hepatitis, and plasma cell infiltration of the portal region. (C) 2017 S. Karger AG, Basel
  • Shogo Kitahata; Atsushi Hiraoka; Masatoshi Kudo; Taisei Murakami; Marie Ochi; Hirofumi Izumoto; Hidetaro Ueki; Miho Kaneto; Toshihiko Aibiki; Tomonari Okudaira; Hiroka Yamago; Yuji Miyamoto; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Masato Kishida; Hideki Miyata; Eiji Tsubouchi; Masashi Hirooka; Yohei Koizumi; Tomoyuki Ninomiya; Yoichi Hiasa; Kojiro Michitaka
    DIGESTIVE DISEASES 35 6 498 - 505 2017年 [査読有り]
     
    Aim/Background: Evaluations of abdominal ultrasonography (US) findings of primary and secondary tumor-forming hepatic malignant lymphoma (HML) have not been adequately reported. In this study, we elucidated US and contrast-enhanced US (CEUS) findings in patients with HML. Materials/Methods: From January 2006 to March 2017, 25 patients with HML were enrolled (primary 7, secondary 18), each of whom was diagnosed pathologically. They were divided into 2 groups based on tumor diameter (cutoff, 30 mm). US imaging findings were retrospectively analyzed. Results: All tumors in patients with a small HML (<30 mm in diameter, small group, n = 14) were revealed as homogeneous hypo-echoic type (100%), with penetrating sign observed in only 1 patient. Tumors in 11 patients in the small group, examined with CEUS, showed homogeneous enhancement in the early vascular phase (91%) and a washout pattern in the portal phase (100%), and they were revealed as defective in the post-vascular phase (100%). In the large group (>= 30 mm; n = 11), tumors were revealed as a heterogeneous hypo-echoic lesion in 10 (91%) and penetrating sign was observed in 8 (73%). Dilatation of the distal intrahepatic bile duct by the tumor was observed in 4 patients in the large group. In 7 large group patients examined with CEUS, imaging findings in the early vascular phase varied, with 5 (71%) showing a washout pattern in the portal phase and 5 (71%) revealed as defective in the post-vascular phase. Conclusion: We found that US imaging features of HML differ depending on the tumor diameter. (C) 2017 S. Karger AG, Basel
  • Impact of age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey.
    Kaibori M; Yoshii K; Yokota I; Hasegwa K; Nagashima F; Kubo S; Kon M; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo N
    J Hepatol in press 2017年 [査読有り]
  • Identification of a HBx mutation that enhances human hepatocarcinogenesis through the activation of the JNK and Wnt pathways.
    Hagiwara S; Nishida N; Sakurai T; Park AM; Komeda Y; Kitano M; Kudo M
    BMC Cancer in press 2017年 [査読有り]
  • Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study.
    Nishikawa H; Enomoto H; Saito M; Aizawa N; Tsuda Y; Higuchi K; Okazaki K; Seki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M; Osaki Y; Nishiguchi S
    Acta Gastro-Ent Belg in press 2017年 [査読有り]
  • Second IA of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) non-interventional study
    Lencioni R; Kudo M; Venook A; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Marrero JA
    Liver Int in press 2017年 [査読有り]
  • New Era in the Treatment of Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2017
    Masatoshi Kudo
    Digest Dis 35 6 493 - 497 2017年 [査読有り]
  • Shigenaga Matsui; Hiroshi Kashida; Yutaka Asakuma; Masatoshi Kudo
    Annals of Gastroenterology 30 5 578 - 578 2017年 [査読有り]
  • Mayumi Imoto; Koji Yoshida; Yasuhiro Maeda; Ken-Ichi Nakae; Masatoshi Kudo; Ikunosuke Sakurabayashi; Toshiyuki Yamada; Toshinori Kamisako
    CLINICAL LABORATORY 63 5-6 983 - 989 2017年 [査読有り]
     
    Background: We encountered a rare case of Waldenstrom macroglobulinemia with temporary appearance of 7S IgM half molecule and with monoclonal proteins binding to agarose gel. Methods: The patient's serum and urine were analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting. The N-terminal amino acid sequences of the IgM with abnormal mass (68 kDa) were determined and compared with those of known immunoglobulin. Results: The 68 kDa IgM consisted of a defective Et chain (36 kDa) and an intact kappa chain. N-terminal amino acid sequence analysis demonstrated that the defective It chain had the variable region of IgM. The agarose gel-binding ability of the IgM-w M-protein was lost after reduction or alkaline treatment of serum. Conclusions: The 7S half molecule IgM in the present case may miss a large part of the constant region of the mu chain.
  • アミロイドーシスを疑う胃病変.
    松井繁長; 樫田博史; 河野匡史; 岡元寿樹; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 渡邉智裕; 工藤正俊
    消化器内視鏡 29 4 756 - 758 2017年 [査読有り]
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    LIVER CANCER 6 3 227 - 235 2017年 [査読有り]
     
    Aim/Background: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. This retrospective study examined the association between OS and the newly defined time to TACE progression (TTTP) to assess whether TTTP can be an alternative to OS in HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B. Methods: Between January 2006 and December 2013, 592 patients with HCC (BCLC B1, n = 118; BCLC B2, n = 170) underwent TACE. TTTP was then redefined as time to progression from the first image taken after TACE. The relationship between TTTP and OS was then examined based on survival time. Results: Survival analysis revealed significant differences in the OS of patients with BCLC B1 and those with BCLC B2 (median OS: 42.3 months, 95% confidence interval [CI] 34.4-50.7; and 29.3 months, 95% CI 26.1-37.6, respectively, p = 0.0348). The median TTTP values were 9.5 months (95% CI 7.0-10.9) and 5.3 months (95% CI 4.6-6.7), respectively (p = 0.0078). There was a moderate positive correlation between OS and TTTP for both B1 (R-2 = 0.6563, p = 0.0045) and B2 (R-2 = 0.6433, p = 0.0052) substages. There was also a positive correlation between OS and TTTP for the combined B1 and B2 substages (R-2 = 0.6590, p = 0.0024). Conclusions: There was a moderate correlation between the TTTP and OS of patients with HCC after TACE therapy, where the patients with short TTTP represented short OS, indicating that TTTP is an alternative parameter for survival analysis of HCC patients with BCLC stage B tumors who undergo TACE. (C) 2017 S. Karger AG, Basel
  • M. Kudo
    LIVER CANCER 6 1 1 - 12 2017年 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Yukitaka Yamashita; Yasuki Nakatani; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 85 1 263 - 264 2017年01月 [査読有り]
  • Tomohiro Watanabe; Kouhei Yamashita; Masatoshi Kudo
    IGG4-RELATED DISEASE 401 115 - 128 2017年 [査読有り]
     
    An increased number of clinicopathological studies on autoimmune pancreatitis, cholangitis, and sialoadenitis have led to the recognition of immunoglobulin G4-related disease (IgG4-RD) as a novel disorder, characterized by elevated levels of serum IgG4 and infiltration of IgG4-expressing plasma cells in the affected organs. Although the immunological background associated with the development of IgG4-RD remains poorly understood, recent studies have suggested involvement of the innate immune response in its pathogenesis. Peripheral blood innate immune cells, such as plasmacytoid dendritic cells and monocytes isolated from patients with IgG4-RD, promote IgG4 production by B cells. Activation of the innate immune response by microbe-and/or damage-associated molecular patterns stimulates production of type I interferon and B cell-activating factor by innate immune cells and results in IgG4 production by B cells. Elucidation of the innate immune response associated with IgG4-RD may help identify a new therapeutic target for this immune disorder.
  • Toshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 23 1 57 - 65 2017年01月 [査読有り]
     
    Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and HSPA4 are involved in the refractory clinical course and development of CAC. RNA-binding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, HSPA4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.
  • Masatoshi Kudo
    ONCOLOGY 92 50 - 62 2017年 [査読有り]
     
    Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-Iymphocyte-associated protein 4 (CTLA-4) for the treatment of advanced hepatocellular carcinoma (HCC) are ongoing. Expansion cohorts of a phase I/II trial of the anti-PD-1 antibody nivolumab in advanced HCC showed favorable results. Two phase III studies are currently ongoing: a comparison of nivolumab and sorafenib in the first-line setting for advanced HCC, and a comparison of the anti-PD-1 antibody pembrolizumab and a placebo in the second-line setting for patients with advanced HCC who progressed on sorafenib therapy. The combination of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies is being evaluated in other phase I/II trials, and the results suggest that an anti-PD-1 antibody combined with locoregional therapy or other molecular targeted agents is an effective treatment strategy for HCC. Immune checkpoint inhibitors may therefore open new doors to the treatment of HCC. (C) 2017 S. Karger AG, Basel
  • Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
    LIVER CANCER 6 3 204 - 215 2017年 [査読有り]
     
    Aim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. Methods: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group). ALBI score used for grading (<= -2.60 = grade 1, greater than -2.60 to <= -1.39 = grade 2, greater than -1.39 = grade 3) as well as clinical features and prognosis (Japan Integrated Staging [JIS], modified JIS, ALBI-TNM [ALBI-T] score) were retrospectively investigated. Results: For prediction of liver damage A, the values for sensitivity and specificity, positive predictive and negative predictive values, and positive and negative likelihood ratios of ALBI-1 and Child-Pugh A were similar among the 2 groups. Akaike information criterion results showed that prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score (22,291.8/21,989.4, 22,379.6/22,076.0, 22,392.1/22,075.1, respectively). The cutoff values for ALBI score for indocyanine green retention rate at 15 min (ICG-R15) < 10, < 20, and < 30% were -2.623 (area under the curve [AUC]: 0.798), -2.470 (AUC: 0.791), and -2.222 (AUC: 0.843), respectively. The distribution of ICG-R15 (< 10%, 10 to < 20%, 20 to < 30%, and >= 30%) for ALBI grade 1 was similar to that for liver damage A. There were only small differences with regard to therapeutic selection with the Japanese HCC treatment algorithm between liver damage and ALBI grade. Conclusion: ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making. (C) 2017 S. Karger AG, Basel
  • Ken Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 23 4 661 - 667 2017年01月 [査読有り]
     
    AIM To assess the long-term outcomes of this procedure after removal of self-expandable metal stent (SEMS). The efficacy and safety of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with SEMS were also assessed. METHODS Between January 2010 and April 2015, 12 patients with acute calculous cholecystitis, who were deemed unsuitable for cholecystectomy, underwent EUS-GBD with a SEMS. EUS-GBD was performed under the guidance of EUS and fluoroscopy, by puncturing the gallbladder with a needle, inserting a guidewire, dilating the puncture hole, and placing a SEMS. The SEMS was removed and/or replaced with a 7-Fr plastic pigtail stent after cholecystitis improved. The technical and clinical success rates, adverse event rate, and recurrence rate were all measured. RESULTS The rates of technical success, clinical success, and adverse events were 100%, 100%, and 0%, respectively. After cholecystitis improved, the SEMS was removed without replacement in eight patients, whereas it was replaced with a 7-Fr pigtail stent in four patients. Recurrence was seen in one patient (8.3%) who did not receive a replacement pigtail stent. The median follow-up period after EUS-GBD was 304 d (78-1492). CONCLUSION EUS-GBD with a SEMS is a possible alternative treatment for acute cholecystitis. Long-term outcomes after removal of the SEMS were excellent. Removal of the SEMS at 4-wk after SEMS placement and improvement of symptoms might avoid migration of the stent and recurrence of cholecystitis due to food impaction.
  • 鎌田 研; 竹中 完; 北野 雅之; 大本 俊介; 三長 孝輔; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊
    膵臓 32 1 38 - 44 日本膵臓学会 2017年 [査読有り]
     

    膵癌早期診断におけるEUSの果たす役割は近年大きくなりつつある．リスクファクターを有する症例や膵管内乳頭粘液性腫瘍の精査あるいは経過観察にEUSを用いることによって実際に早期膵癌が発見されたとする報告が数多くみられる．EUS機器の進歩，EUS-FNAの普及によって膵癌の存在診断・質的診断能は確実に向上してきている．本稿では，膵癌，特に小膵癌の存在診断におけるEUSの役割について解説する．

  • IPMN経過観察におけるEUSの有用性. 特集「今IPMNをどう診るか」
    鎌田 研; 竹中 完; 北野雅之; 工藤正俊
    肝胆膵 74 583 - 586 2017年 [査読有り]
  • Masatoshi kudo
    LIVER CANCER 6 3 185 - 188 2017年 [査読有り][招待有り]
  • M. Kudo
    LIVER CANCER 6 3 177 - 184 2017年 [査読有り][招待有り]
  • Hitoshi Tochio; Eriko Tamaki; Yukihiro Imai; Nobuhiro Iwasaki; Kazushi Minowa; Hobyung Chung; Yoshiki Suginoshita; Tetsurou Inokuma; Masatoshi Kudo
    ONCOLOGY 92 35 - 39 2017年 [査読有り]
     
    Four resected specimens of hepatic angiomyolipoma in which uptake of Sonazoid was observed in the postvascular phase of Sonazoid-enhanced ultrasonography were analyzed. Macrophage localization in the tumor was revealed pathologically by immunohistochemical staining for CD68. CD68-positive cells were observed in the tumor in all cases. The density of CD68-positive cells was 100/mm(2), and the ratio of CD68-positive cell density in the tumor to that in the surrounding parenchyma was 32-171%. These results suggested that the uptake of the contrast agent Sonazoid was related to the density of CD68-positive cells. (C) 2016 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 92 40 - 49 2017年 [査読有り]
     
    Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of patients with advanced stage of disease remains unfavorable. Several immune therapies have been applied to HCC, and their responses have not been satisfactory. The immune response to cancer is determined by the balance between the antigenicity of the tumor and the microenvironment of cancer tissues. Generally, accumulated genetic mutations are observed in HCC, which may lead to increased neoantigens on cancer cells with high antigenicity. However, cancer cells may evade the immune system because of alterations in molecules and cellular pathways involved in antigen processing and presentation. In addition, hypoxia in tissue induces several cytokines, chemokines, and immunosuppressive molecules from HCC cells and stromal cells. These cells also produce cytokines that attract regulatory T cells infiltrating tumor tissues and contribute to establishing an immunosuppressive microenvironment. Some cancers show a good response to immune checkpoint therapy. However, prolonged stabilization of disease for this treatment is reportedly 12-41% in patients with advanced cancer. Therefore, immunosuppressive forces in the microenvironment of HCC may cause resistance to immune therapy, and modification of the tumor microenvironment may restore normal anticancer immunity. In this review, we focus on the immunological microenvironment of HCC tissues and discuss how the immunosuppressive environment of HCC should be modulated to achieve a favorable response to immune therapy, such as immune checkpoint therapy, in HCC. (C) 2016 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 92 10 - 15 2017年 [査読有り]
     
    Objective: In order to evaluate the influence of liver inflammation on liver stiffness measurement (LSM) by the simultaneous use of shear wave and strain imaging (combinational elastography), shear wave and strain imaging were compared before and after initial therapy for autoimmune hepatitis (AIH). Methods: Nine AIH patients initially treated with steroid were enrolled. Transient elastography and real-time tissue elastography were performed just before and 1 month after the start of initial steroid treatment. Blood samples, LSM, and the liver fibrosis index (LFI) were compared. Results: Aspartate aminotransferase (p = 0.002) and alanine aminotransferase (ALT) (p = 0.015) were significantly decreased after initial treatment. The LSM was 15.5 +/- 9.6 kPa at baseline, decreasing to 7.2 +/- 2.3 kPa after initial treatment p = 0.034). The LFI was 1.67 +/- 0.67 at baseline and 1.61 +/- 0.66 after initial treatment; no significant change in LFI was recognized (p = 0.842). Between Delta ALT and Delta LSM, a significant regression equation could be calculated as follows: Delta ALT = -0.55 + 0.654 x Delta LSM. Conclusions: Combinational elastography was useful in evaluating not only the degree of liver fibrosis, but also the degree of liver inflammation in AIH. (C) 2017 S. Karger AG, Basel
  • Masatoshi Kudo
    ONCOLOGY 92 1 - 2 2017年 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi Kudo
    ONCOLOGY 92 3 - 9 2017年 [査読有り]
     
    Introduction: Recently, the treatment of chronic hepatitis C has markedly advanced. A phase III clinical study of combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) was conducted in Japan, and the additive therapeutic effects were reported. In this study, we report the results of treatment in our hospital. Methods: Of 147 patients with chronic type C liver disease who had consulted our hospital since September 2015 and received SOF/LDV therapy, in 91 subjects a sustained virological response of 12 weeks (SVR12) could be evaluated. Results: In all 91 patients, end treatment response was achieved. Subsequently, recrudescence was noted in 1 before the completion of treatment (week 12); an SVR12 was achieved in 90 patients (99%). The following adverse reactions were observed in 3 patients (3.3%): bradycardia, paroxysmal atrial fibrillation, and heart failure with QT prolongation, which were associated with heart disease. Conclusion: A favorable SVR was achieved by SOF/LDV therapy even in elderly patients, those with liver cirrhosis, or those having undergone radical treatment of liver cancer. Furthermore, a high tolerance was demonstrated, but adverse reactions associated with the heart may appear in patients with heart disease as an underlying disease; strict management during treatment is necessary. (C) 2016 S. KargerAG, Basel
  • Wing Yee Kwok; Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Lda; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Lwanishi; Hirokazu Chishina; Masashi Kono; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Eisuke Enoki; Takuya Nakai; Tsutomu Kumabe; Osamu Nakashima; Fukuo Kondo; Masatoshi Kudo
    ONCOLOGY 92 16 - 28 2017年 [査読有り]
     
    The patient was a 20-year-old male in whom a hepatic hyper vascular mass accompanied by intratumoral hemorrhage was detected on examination for epigastric pain. Based on the enlargement of the mass and diagnostic imaging, hepatocellular adenoma (HCA) was suspected and hepatectomy was performed. The lesion was diagnosed as malignant transformation of P-catenin-activated HCA. There are only few reports of cases with malignant transformation of HCA in Japan; it is necessary to accumulate cases to investigate it. (C) 2016 S. Karger AG, Basel
  • Masashi Kono; Yasunori Minami; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Yoriaki Komeda; Toshiharu Sakurai; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 92 29 - 34 2017年 [査読有り]
     
    Objective: To compare contrast tissue harmonic imaging (THI) with low mechanical index (MI) and conventional contrast harmonic imaging (CHI) with respect to lesion visibility of hepatocellular carcinoma (HCC). Methods: One hundred and twenty-five patients (84 men and 41 women, age range 39-94 years, mean age 74 years) with 100 naive HCCs and 30 lesions after radiofrequency ablation (RFA) for HCC were evaluated. One hundred and four patients had liver cirrhosis of Child-Pugh class A, and the remaining 21 had Child-Pugh class B cirrhosis. The lesion conspicuity and intratumoral echogenicity during the postvascular phase were compared using conventional CHI and contrast THI with low MI. Results:The MI values ranged from 0.20 to 0.30 on conventional CHI and from 0.30 to 0.35 on contrast THI. Regarding HCC lesion conspicuity, contrast THI with low MI was clearer in 79 lesions (60.8%), equal in 34 lesions (26.2%), and less clear in 17 lesions (13.1%) when compared with conventional CHI. The lesion conspicuity with contrast THI was significantly better than that with conventional CHI (p < 0.01). All of the postablative lesions were well delineated in patients who received RFA. Conclusion: Low-MI contrast THI was superior to conventional CHI with respect to lesion visibility of HCCs and might offer good imaging for the guiding of RFA. (C) 2016 S. Karger AG, Basel
  • Fabio Piscaglia; Masatoshi Kudo; Kwang-Hyub Han; Claude Sirlin
    ULTRASCHALL IN DER MEDIZIN 38 1 9 - 11 2017年01月 [査読有り]
  • Toshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 23 1 57 - 65 2017年01月 [査読有り]
     
    Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and HSPA4 are involved in the refractory clinical course and development of CAC. RNA-binding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, HSPA4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.
  • Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; Gyrogy Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; Rene Gerolami; Gianluca Masi; Paul J. Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M. Llovet; Richard S. Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
    LANCET 389 10064 56 - 66 2017年01月 [査読有り]
     
    Background There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment. Methods In this randomised, double-blind, parallel-group, phase 3 trial done at 152 sites in 21 countries, adults with HCC who tolerated sorafenib (>= 400 mg/day for >= 20 of last 28 days of treatment), progressed on sorafenib, and had Child-Pugh A liver function were enrolled. Participants were randomly assigned (2: 1) by a computer-generated randomisation list and interactive voice response system and stratified by geographical region, Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic disease, and a-fetoprotein level to best supportive care plus oral regorafenib 160 mg or placebo once daily during weeks 1-3 of each 4-week cycle. Investigators, patients, and the funder were masked to treatment assignment. The primary endpoint was overall survival (defined as time from randomisation to death due to any cause) and analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01774344. Findings Between May 14, 2013, and Dec 31, 2015, 843 patients were screened, of whom 573 were enrolled and randomised (379 to regorafenib and 194 to placebo; population for efficacy analyses), and 567 initiated treatment (374 received regorafenib and 193 received placebo; population for safety analyses). Regorafenib improved overall survival with a hazard ratio of 0.63 (95% CI 0.50-0.79; one-sided p<0.0001); median survival was 10.6 months (95% CI 9.1-12.1) for regorafenib versus 7.8 months (6.3-8.8) for placebo. Adverse events were reported in all regorafenib recipients (374 [100%] of 374) and 179 (93%) of 193 placebo recipients. The most common clinically relevant grade 3 or 4 treatment-emergent events were hypertension (57 patients [15%] in the regorafenib group vs nine patients [5%] in the placebo group), hand-foot skin reaction (47 patients [13%] vs one [1%]), fatigue (34 patients [9%] vs nine patients [5%]), and diarrhoea (12 patients [3%] vs no patients). Of the 88 deaths (grade 5 adverse events) reported during the study (50 patients [13%] assigned to regorafenib and 38 [20%] assigned to placebo), seven (2%) were considered by the investigator to be related to study drug in the regorafenib group and two (1%) in the placebo group, including two patients (1%) with hepatic failure in the placebo group. Interpretation Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenib treatment. Future trials should explore combinations of regorafenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafenib and regorafenib. Funding Bayer.
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; George Tribonias; Kazuki Okamoto; Masashi Kono; Mitsunari Yamada; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yutaka Asakuma; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Masayuki Kitano; Takaaki Chikugo; Yasutaka Chiba; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 23 2 328 - 335 2017年01月 [査読有り]
     
    AIM To compare the efficacy and safety of cold snare polypectomy (CSP) and hot forceps biopsy (HFB) for diminutive colorectal polyps. METHODS This prospective, randomized single-center clinical trial included consecutive patients >= 20 years of age with diminutive colorectal polyps 3-5 mm from December 2014 to October 2015. The primary outcome measures were en-bloc resection (endoscopic evaluation) and complete resection rates (pathological evaluation). The secondary outcome measures were the immediate bleeding or immediate perforation rate after polypectomy, delayed bleeding or delayed perforation rate after polypectomy, use of clipping for bleeding or perforation, and polyp retrieval rate. Prophylactic clipping after polyp removal wasn't routinely performed. RESULTS Two hundred eight patients were randomized into the CSP (102), HFB (106) and 283 polyps were evaluated (CSP: 148, HFB: 135). The en-bloc resection rate was significantly higher with CSP than with HFB [99.3% (147/148) vs 80.0% (108/135), P < 0.0001]. The complete resection rate was significantly higher with CSP than with HFB [80.4% (119/148) vs 47.4% (64/135), P < 0.0001]. The immediate bleeding rate was similar between the groups [8.6% (13/148) vs 8.1% (11/135), P = 1.000], and endoscopic hemostasis with hemoclips was successful in all cases. No cases of perforation or delayed bleeding occurred. The rate of severe tissue injury to the pathological specimen was higher HFB than CSP [52.6% (71/135) vs 1.3% (2/148), P < 0.0001]. Polyp retrieval failure was encountered CSP (7), HFB (2). CONCLUSION CSP is more effective than HFB for resecting diminutive polyps. Further long-term follow-up study is required.
  • Naoshi Nishida; Tadaaki Arizumi; Satoru Hagiwara; Hiroshi Ida; Toshiharu Sakurai; Masatoshi Kudo
    LIVER CANCER 6 2 113 - 125 2017年 [査読有り]
     
    Background: Several studies suggest the role of circulating microRNAs (miRNAs) as biomarkers of hepatocellular carcinoma (HCC). However, the serum miRNA profile associated with the response to sorafenib remains to be elucidated. The aim of this study was to clarify the specific miRNAs in serum that could predict the early response of HCC to sorafenib treatment. Summary: Analyzing the sera from 16 HCC patients, we selected five miRNAs that showed differences in serum levels between patients with and without tumor responses among 179 known secretory miRNAs by using locked nucleic acid probe -based quantitative PCR. Through further analysis using a validation cohort that included 53 HCC patients who underwent sorafenib treatment and 8 healthy control subjects, we found that miR-181a-5p and miR-3395p showed significant differences in serum levels among patients with partial response (PR), stable disease (SD), and progressive disease (PD), where PR patients showed the highest and PD the lowest levels. We also analyzed the factors associated with disease control (DC; PR or SD) 3 months after the initiation of sorafenib treatment; patients with DC showed a significantly higher level of serum miR-181a-5p than non -DC patients or healthy control subjects (p = 0.0349 and 0.0180 for DC vs. non -DC and control vs. non -DC by Tukey-Kramer test, respectively). We further conducted multivariate analysis among HCC patients with Barcelona Clinic Liver Cancer stage C using extrahepatic metastasis, serum decarboxyprothrombin, and miR-181a-5p levels as covariables; serum miR-181a-5p was the only independent factor for achieving DC (p = 0.0092, odds ratio 0.139, and 95% confidence interval 0.011-0.658). In addition, miR-181a-5p level was also the only independent factor affecting overall survival (p = 0.0194, hazard ratio 0.267, and 95% confidence interval 0.070-0.818). Key Messages: A high serum level of miR-181a-5p before treatment is associated with DC after the initiation of sorafenib. (C) 2016 S. Karger AG, Basel
  • M. Kudo
    LIVER CANCER 6 2 101 - 112 2017年 [査読有り][招待有り]
  • Masatoshi Kudo; Franco Trevisani; Ghassan K. Abou-Alfa; Lorenza Rimassa
    LIVER CANCER 6 1 16 - 26 2017年 [査読有り]
     
    Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have many commonalities but may also differ in certain aspects, as described in this article. In view of the limited therapeutic options for advanced HCC, evidence-based therapies are few, and thus there is a dependence on consensus-based guidelines. This article focuses on the Italian Association for the Study of the Liver guidelines and the Japanese approaches to therapy, while drawing attention to certain controversies from other academic bodies where applicable and appropriate. Copyright (C) 2016 S. Karger AG, Basel
  • Jorge A. Marrero; Masatoshi Kudo; Alan P. Venook; Sheng-Long Ye; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Tadatoshi Takayama; Arun J. Sanyal; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni
    JOURNAL OF HEPATOLOGY 65 6 1140 - 1147 2016年12月 [査読有り]
     
    Background & Aims: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction. Methods: Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up. Results: In the overall safety population (n = 3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800 mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n = 3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8-14.7]) compared with Child-Pugh B patients (5.2 [4.6-6.3]). Conclusions: In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions. Lay summary: The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • Masatoshi Kudo; Masafumi Ikeda; Tadatoshi Takayama; Kazushi Numata; Namiki Izumi; Junji Furuse; Takuji Okusaka; Masumi Kadoya; Satoshi Yamashita; Yuichiro Ito; Norihiro Kokudo
    JOURNAL OF GASTROENTEROLOGY 51 12 1150 - 1160 2016年12月 [査読有り]
     
    GIDEON was a prospective, global, non-interventional study evaluating the safety of sorafenib in patients with unresectable hepatocellular carcinoma in real-world practice. The aim of this subgroup analysis was to assess the safety and efficacy of sorafenib as used by Japanese patients. In Japan, 508 patients were valid for safety analysis. Efficacy and safety were evaluated by the Child-Pugh score. The number of patients with Child-Pugh A and B was 432 (85.0 %) and 58 (11.4 %), respectively. The median overall survival time and time to progression in patients with Child-Pugh A and Child-Pugh B were 17.4 and 4.9 months, 3.7 and 2.3 months, respectively. The most common drug-related adverse events (AEs) included hand-foot skin reaction (47.8 %), diarrhea (35.8 %) and hypertension (24.2 %). The incidences of all or drug-related AEs were similar between patients with Child-Pugh A and B. However, all or drug-related serious AEs, AEs resulting in permanent discontinuation of sorafenib and deaths were observed more frequently in patients with Child-Pugh B compared with Child-Pugh A. Duration of treatment tended to be shorter as the Child-Pugh score worsened. Sorafenib was well tolerated by Japanese HCC patients in clinical settings. Patients with Child-Pugh B had shorter duration of treatment and higher incidence of SAEs. It is important to carefully evaluate patients' conditions and assess the benefit and risk before making a decision to treat patients with sorafenib.
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yutaka Asakuma; Shigenaga Matsui; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 268 - 268 2016年11月 [査読有り]
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Tomoyuki Nagai; Hiromasa Mine; Teppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 307 - 308 2016年11月 [査読有り]
  • Toshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Shigenaga Matsui; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 136 - 136 2016年11月 [査読有り]
  • Takeshi Miyata; Mamoru Takenaka; Masayuki Kitano; Tomohiko Matsuda; Syunsuke Omoto; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 248 - 248 2016年11月 [査読有り]
  • Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ling Yang; Paolo B. Abada; Rebecca Cheng; Mauro Orlando; Andrew X. Zhu; Takuji Okusaka
    ONCOTARGET 7 46 75482 - 75491 2016年11月 [査読有り]
     
    Purpose: REACH investigated second-line ramucirumab therapy for advanced hepatocellular carcinoma. Results: Median overall survival was 8.2 months for ramucirumab and 6.9 months for placebo (HR, 0.835; 95% CI, 0.634-1.100; p = 0.2046) for East Asians, and 10.1 months for ramucirumab and 8.0 months for placebo (HR, 0.895; 95% CI, 0.690-1.161; p = 0.4023) for non-East Asians. Median overall survival in patients with baseline alpha-fetoprotein >= 400 ng/mL was 7.8 months for ramucirumab and 4.2 months for placebo (HR, 0.749; 95% CI, 0.519-1.082; p = 0.1213) for East Asians (n = 139), and 8.2 months for ramucirumab and 4.5 months for placebo (HR, 0.579; 95% CI, 0.371-0.904; p = 0.0149) for non-East Asians (n = 111). The most common grade >= 3 treatment-emergent adverse events in East Asians and non-East Asians included hypertension and malignant neoplasm progression. Materials and methods: A post-hoc analysis of East Asians (N = 252) and non-East Asians (N = 313) in the intent-to-treat population was performed. Conclusions: In East Asians and non-East Asians, ramucirumab did not significantly prolong overall survival. In patients with baseline alpha-fetoprotein >= 400 ng/mL, a potentially larger survival benefit was observed in both subgroups. Safety for East Asians was similar to non-East Asians.
  • Kentaro Yamao; Masayuki Kitano; Takahisa Kayahara; Etsuji Ishida; Hiroshi Yamamoto; Kosuke Minaga; Yukitaka Yamashita; Jun Nakajima; Masanori Asada; Yoshihiro Okabe; Yukio Osaki; Yasutaka Chiba; Hajime Imai; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 84 5 757 - + 2016年11月 [査読有り]
     
    Background and Aims: Endoscopic gastroduodenal stenting for malignant gastric outlet obstruction recently has become more effective, but the factors that predict gastroduodenal stenting outcomes are poorly defined. This multicenter retrospective cohort study evaluated the clinical outcomes of gastroduodenal stenting in malignant gastroduodenal obstruction and identified factors predicting clinical ineffectiveness, stent dysfunction, and adverse events. Methods: All consecutive patients with malignant gastroduodenal obstruction who underwent through-the-scope gastroduodenal stenting from 2009 to 2014 at 4 tertiary-care medical centers were identified. Clinically ineffective stenting was defined as symptom recurrence and a gastric outlet obstruction scoring system (GOOSS) score < 2. Results: Of the 278 patients (mean age +/- standard deviation [SD] 71.7 +/- 11.4 years), 121 (43.5%) and 87 (31.3%) had pancreatic and gastric cancer, respectively. Technical success was achieved in 277 patients (99.6%). GOOSS scores rose from 0.5 +/- 0.6 to 2.6 +/- 0.8. Stenting was ineffective in 32 patients (12.6%). Stent dysfunction that caused symptom recurrence during follow-up developed in 46 patients (16.6%). Adverse events occurred in 49 patients (17.7%). Three or more stenosis sites (odds ratio [OR] = 6.11; P < .01) and Karnofsky performance scores <= 50 (OR Z 6.63; P < .01) predicted clinical ineffectiveness. Karnofsky performance scores <= 50 predicted stent dysfunction (hazard ratio [HR] = 3.63; P < .01). Bile duct stenosis (HR = 9.55; P =. 02) and liver metastasis (HR = 9.42; P <.01) predicted stent overgrowth. Covered stent predicted stent migration (HR = 12.63; P < .01). Deployment of 2 stents predicted perforation (HR Z 854.88; P < .01). Conclusions: Through-the-scope gastroduodenal stenting tended to be ineffective in patients with poor performance status and long stenosis sites. Stent dysfunction occurred more frequently in patients with poorer performance status. Deployment of 2 stents was a risk factor for perforation. Identification of these risk variables may help yield better gastroduodenal stenting outcomes.
  • Takashi Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Tadatoshi Takayama; Namiki Izumi; Masumi Kadoya; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Shuichi Kaneko; Norihiro Kokudo
    JOURNAL OF HEPATOLOGY 65 5 938 - 943 2016年11月 [査読有り]
     
    Background & Aims: The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is regarded as indicating an advanced stage, and liver resection (LR) is not recommended. The aim of this study was to evaluate the survival benefit of LR for HCC patients with PVTT through the analysis of the data from a Japanese nationwide survey. Methods: We analyzed data for 6474 HCC patients with PVTT registered between 2000 and 2007. Of these patients, 2093 patients who underwent LR and 4381 patients who received other treatments were compared. The propensity scores were calculated and we successfully matched 1058 patients (66.1% of the LR group). Results: In the Child-Pugh A patients, the median survival time (MST) in the LR group was 1.77 years longer than that in the non-LR group (2.87 years vs. 1.10 years; p <0.001) and 0.88 years longer than that in the non-LR group (2.45 years vs. 1.57 years; p <0.001) in a propensity score-matched cohort. A subgroup analysis revealed that LR provides a survival benefit regardless of age, etiology of HCC, tumor marker elevation, and tumor number. The survival benefit was not statistically significant only in patients with PVTT invading the main trunk or contralateral branch. In the LR group, the postoperative 90-day mortality rate was 3.7% (68 patients). Conclusions: As long as the PVTT is limited to the first-order branch, LR is associated with a longer survival outcome than non-surgical treatment. Lay summary: The presence of portal vein tumor thrombosis in patients with hepatocellular carcinoma is regarded as indicating an advanced stage, and liver resection is not recommended. We performed a multicenter, nationwide study to assess the survival benefit of liver resection in hepatocellular carcinoma patients with portal vein tumor thrombosis using propensity score based matching. As long as the portal vein tumor thrombosis is limited to the first-order branch, liver resection is associated with a longer survival outcome than non-surgical treatment. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • Soo Ki Kim; Soo Ryang Kim; Susumu Imoto; Chi Wan Kim; Toshiyuki Matsuoka; Osamu Nakashima; Motoko Sasaki; Tsutomu Kumabe; Masatoshi Kudo; Toshio Fukusato; Fukuo Kondo
    PATHOLOGY INTERNATIONAL 66 11 640 - 642 2016年11月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Eisuke Enoki; Hiroshi Kashida; Masatoshi Kudo
    AMERICAN JOURNAL OF GASTROENTEROLOGY 111 11 1515 - 1515 2016年11月 [査読有り]
  • M. Ikeda; S. Shimizu; T. Sato; M. Morimoto; Y. Kojima; Y. Inaba; A. Hagihara; M. Kudo; S. Nakamori; S. Kaneko; R. Sugimoto; T. Tahara; T. Ohmura; K. Yasui; K. Sato; H. Ishii; J. Furuse; T. Okusaka
    ANNALS OF ONCOLOGY 27 11 2090 - 2096 2016年11月 [査読有り]
     
    Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. We conducted a multicenter open-labeled randomized phase II trial in chemo-na < ve patients with advanced HCC with Child-Pugh scores of 5-7. Eligible patients were randomly assigned 2:1 to receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m(2), day 1, every 4-6 weeks) or Sor (400 mg bid). The primary end point was overall survival. A total of 108 patients were randomized (Sor, n = 42; SorCDDP, n = 66). The median survival in the Sor and SorCDDP arms were 8.7 and 10.6 months, respectively [stratified hazard ratio (95% confidence interval), 0.60 (0.38-0.96), P = 0.031]. The median time to progression and the response rate were, respectively, 2.8 months and 7.3% in the Sor arm and 3.1 months and 21.7% in the SorCDDP arm. The adverse events were more frequent in the SorCDDP arm than in the Sor arm, but well-tolerated. SorCDDP yielded favorable overall survival when compared with Sor in patients with advanced HCC. UMIN-CTR (), identification number: UMIN000005703.
  • 膵・胆道癌の早期発見における内視鏡の役割 pTis/pT1a膵癌の診断における内視鏡の役割
    山雄 健太郎; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 58 Suppl.2 1819 - 1819 (一社)日本消化器内視鏡学会 2016年10月
  • Ramya Ramaswami; David J. Pinato; Keiichi Kubota; Mitsuru Ishizuka; Tadaaki Arizumi; Masatoshi Kudo; Jeong Won Jang; Young Woon Kim; Mario Pirisi; Elias Allara; Rohini Sharma
    MEDICAL ONCOLOGY 33 10 114 - 121 2016年10月 [査読有り]
     
    There is significant heterogeneity in the clinicopathological characteristics of intermediate hepatocellular carcinoma (IHCC). This also translates to treatment as transarterial chemoembolization (TACE) is used as firstline therapy for patients with IHCC; however, in Asia liver resection (LR) is preferred. Prognostic tools are required to help guide clinicians in deciding treatment options. This study evaluates the prognostic impact of the Intermediate Stage Score (ISS) on overall survival (OS) in a large, multicenter cohort study of patients with IHCC treated with TACE or surgery LR. Consecutive patients from centers in Japan, Korea, Italy and the United Kingdom who underwent TACE or LR between 2001 and 2015 were enrolled. Propensity score (PS) adjustment was used to remove residual confounding and applied to LR (n = 162) and TACE (n = 449) to determine the prognostic significance of ISS. Among 611 patients, 75 % were men and 25 % women, with a mean age of 70 years. ISS is a valid prognostic tool in the BCLC-B population with a median OS ISS 1-51, 2-38.3, 3-24.3, 4-15.6, 5-16 months (p < 0.0001). ISS was analyzed within each treatment modality, and this was a valid prognostic score among those treated with TACE and LR (p < 0.001 vs. p = 0.008). In the PS-adjusted model, ISS retained its prognostic utility in TACE and LR groups (p < 0.001 vs. p = 0.007). ISS optimizes prognostic prediction in IHCC, reducing clinical heterogeneity, and is a useful tool for patients treated for TACE or LR.
  • T. Watanabe; Y. Sadakane; N. Yagama; T. Sakurai; H. Ezoe; M. Kudo; T. Chiba; W. Strober
    MUCOSAL IMMUNOLOGY 9 5 1234 - 1249 2016年09月 [査読有り]
     
    Nucleotide-binding oligomerization domain 1 (NOD1) fulfills important host-defense functions via its responses to a variety of gut pathogens. Recently, however, we showed that in acute pancreatitis caused by administration of cholecystokinin receptor (CCKR) agonist ( cerulein) NOD1 also has a role in inflammation via its responses to gut commensal organisms. In the present study, we explored the long-term outcome of such NOD1 responsiveness in a new model of chronic pancreatitis induced by repeated administration of low doses of cerulein in combination with NOD1 ligand. We found that the development of chronic pancreatitis in this model requires intact NOD1 and type I IFN signaling and that such signaling mediates a macrophage-mediated inflammatory response that supports interleukin (IL)-33 production by acinar cells. The IL-33, in turn, has a necessary role in the induction of IL-13 and TGF-beta 1, factors causing the fibrotic reaction characteristic of chronic pancreatitis. Interestingly, the Th2 effects of IL-33 were attenuated by the concomitant type I IFN response since the inflammation was marked by clear increases in IFN-gamma and TNF-alpha production but only marginal increases in IL-4 production. These studies establish chronic pancreatitis as an IL-33-dependent inflammation resulting from synergistic interactions between the NOD1 and CCKR signaling pathways.
  • Naoshi Nishida; Norihisa Yada; Satoru Hagiwara; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 9 1646 - 1653 2016年09月 [査読有り]
     
    Background and AimNon-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC). Previously, we reported that DNA oxidation induced epigenetic alteration of tumor suppressor genes (TSGs) and contributed to HCC emergence. Here, we examine the associations between clinicopathological characteristics of NAFLD and advanced oxidative DNA damage that is associated with TSG methylation in the NAFLD liver. MethodsLiver biopsies from 65 NAFLD patients were analyzed for clinicopathological features and oxidative DNA damage using immunohistochemistry of 8-hydroxydeoxyguanosine (8-OHdG). Abnormal DNA methylation in the promoters of 6 TSGs, HIC1, GSTP1, SOCS1, RASSF1, CDKN2A, and APC, was examined using MethyLight. Associations between clinicopathological characteristics, methylation of TSGs, and accumulation of 8-OHdG were analyzed. ResultsWe found that aspartate aminotransferase/alanine aminotransferase ratio, the fibrosis-4 index, and serum -fetoprotein (AFP) level were associated with degree of 8-OHdG, and AFP was an independent factor among them (P=0.0271). Regarding pathological findings, hepatocellular ballooning and stage of fibrosis were also associated with oxidative DNA damage (P=0.0021 and 0.0054); ballooning was an independent risk for detecting high degree of 8-OHdG in hepatocytes (odds ratio 7.38, 95% confidence interval 1.41-49.13, P=0.0171). Accumulation of methylated TSGs was significantly associated with deposition of 8-OHdG (P=0.0362). ConclusionsPatients with high serum AFP and high degree of ballooning showed accumulation of oxidative DNA damage that could be a seed of DNA methylation responsible for hepatocarcinogenesis. These characteristics could be risk of HCC; such patients require urgent intervention such as lifestyle modification.
  • Ann-Lii Cheng; Sumitra Thongprasert; Ho Yeong Lim; Wattana Sukeepaisarnjaroen; Tsai-Shen Yang; Cheng-Chung Wu; Yee Chao; Stephen L. Chan; Masatoshi Kudo; Masafumi Ikeda; Yoon-Koo Kang; Hongming Pan; Kazushi Numata; Guohong Han; Binaifer Balsara; Yong Zhang; Ana-Marie Rodriguez; Yi Zhang; Yongyu Wang; Ronnie T. P. Poon
    HEPATOLOGY 64 3 774 - 784 2016年09月 [査読有り]
     
    Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogenic escape from sorafenib may occur due to angiogenesis-associated fibroblast growth factor receptor (FGFR) pathway activation. In addition to VEGFR and PDGFR, dovitinib inhibits FGFR. Frontline oral dovitinib (500 mg/day, 5 days on, 2 days off; n = 82) versus sorafenib (400 mg twice daily; n = 83) was evaluated in an open-label, randomized phase 2 study of Asian-Pacific patients with advanced HCC. The primary and key secondary endpoints were overall survival (OS) and time to tumor progression (TTP) as determined by a local investigator, respectively. Patients included in the study were ineligible for surgical and/or locoregional therapies or had disease progression after receiving these therapies. The median OS (95% confidence interval [CI]) was 8.0 (6.6-9.1) months for dovitinib and 8.4 (5.4-11.3) months for sorafenib. The median TTP (95% CI) per investigator assessment was 4.1 (2.8-4.2) months and 4.1 (2.8-4.3) months for dovitinib and sorafenib, respectively. Common any-cause adverse events included diarrhea (62%), decreased appetite (43%), nausea (41%), vomiting (41%), fatigue (35%), rash (34%), and pyrexia (30%) for dovitinib and palmar-plantar erythrodysesthesia syndrome (66%) and decreased appetite (31%) for sorafenib. Subgroup analysis revealed a significantly higher median OS for patients in the dovitinib arm who had baseline plasma soluble VEGFR1 (sVEGFR1) and hepatocyte growth factor (HGF) below median levels versus at or above the median levels (median OS [95% CI]: sVEGFR1, 11.2 [9.0-13.8] and 5.7 [4.3-7.0] months, respectively [P = .0002]; HGF, 11.2 [8.9-13.8] and 5.9 [5.0-7.6] months, respectively [P = 0.0002]). Conclusion: Dovitinib was well tolerated, but activity was not greater than sorafenib as a frontline systemic therapy for HCC. Based on these data, no subsequent phase 3 study has been planned. (Hepatology 2016;64:774-784)
  • 山雄 健太郎; 北野 雅之; 工藤 正俊
    胆道 30 3 403 - 403 日本胆道学会 2016年08月
  • Kosuke Minaga; Masayuki Kitano; Hajime Imai; Yogesh Harwani; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Kumpei Kadosaka; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 22 30 6917 - 6924 2016年08月 [査読有り]
     
    AIM: To assess anti-migration potential of six biliary covered self-expandable metal stents (C-SEMSs) by using a newly designed phantom model. METHODS: In the phantom model, the stent was placed in differently sized holes in a silicone wall and retracted with a retraction robot. Resistance force to migration (RFM) was measured by a force gauge on the stent end. Radial force (RF) was measured with a RF measurement machine. Measured flare structure variables were the outer diameter, height, and taper angle of the flare (ODF, HF, and TAF, respectively). Correlations between RFM and RF or flare variables were analyzed using a linear correlated model. RESULTS: Out of the six stents, five stents were braided, the other was laser-cut. The RF and RFM of each stent were expressed as the average of five replicate measurements. For all six stents, RFM and RF decreased as the hole diameter increased. For all six stents, RFM and RF correlated strongly when the stent had not fully expanded. This correlation was not observed in the five braided stents excluding the laser cut stent. For all six stents, there was a strong correlation between RFM and TAF when the stent fully expanded. For the five braided stents, RFM after full stent expansion correlated strongly with all three stent flare structure variables (ODF, HF, and TAF). The laser-cut C-SEMS had higher RFMs than the braided C-SEMSs regardless of expansion state. CONCLUSION: RF was an important anti-migration property when the C-SEMS did not fully expand. Once fully expanded, stent flare structure variables plays an important role in anti-migration.
  • Masatoshi Kudo; Riccardo Lencioni; Jorge A. Marrero; Alan P. Venook; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Sheng-Long Ye
    LIVER INTERNATIONAL 36 8 1196 - 1205 2016年08月 [査読有り]
     
    Background & AimsTreatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. MethodsGIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1-24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8-25.0 months). ConclusionsData from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.
  • Ghassan K. Abou-Alfa; Oscar Puig; Bruno Daniele; Masatoshi Kudo; Philippe Merle; Joong-Won Park; Paul Ross; Jean-Marie Peron; Oliver Ebert; Stephen Chan; Tung Ping Poon; Massimo Colombo; Takuji Okusaka; Baek-Yeol Ryoo; Beatriz Minguez; Takayoshi Tanaka; Toshihiko Ohtomo; Stacey Ukrainskyj; Frederic Boisserie; Olga Rutman; Ya-Chi Chen; Chao Xu; Eliezer Shochat; Lori Jukofsky; Bernhard Reis; Gong Chen; Laura Di Laurenzio; Ray Lee; Chia-Jui Yen
    JOURNAL OF HEPATOLOGY 65 2 289 - 295 2016年08月 [査読有り]
     
    Background & Aims: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in hepatocellular carcinoma (HCC), interacts with CD16/FccRIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied vs. placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Methods: Patients with advanced HCC who had failed prior systemic therapy, >= 18 years, Eastern cooperative oncology group (ECOG) 0-1, Child-Pugh A were randomized 2: 1 to biweekly codrituzumab 1600 mg vs. placebo. Patients were stratified based on GPC3 immunohistochemical expression: 2+/3+, 1+, and 0. Primary endpoint was progression free survival. Secondary endpoints include overall survival (OS), tolerability, pharmacokinetics, and an exploratory endpoint in biomarkers analysis. Results: 185 patients were enrolled: 125 received codrituzumab and 60 placebo: Median age 64/63, 85/75% male, 46/42% Asian, ECOG 0 65/63%, 74/77% having vascular invasion and/or extrahepatic metastasis. 84%/70% had prior sorafenib. Drug exposure was 98.4% of planned dose, with an identical adverse events profile between the 2 groups. The median progression free survival and overall survival in the codrituzumab vs. placebo groups in months were: 2.6 vs. 1.5 (hazard ratios 0.97, p = 0.87), and 8.7 vs. 10 (hazard ratios 0.96, p = 0.82). Projected Ctrough at cycle 3 day 1 based exposure, high CD16/FccRIIIa on peripheral immune cells, and GPC3 expression in the tumor, were all associated with prolonged progression free survival and overall survival. Conclusions: Codrituzumab did not show clinical benefit in this previously treated HCC population. Whether higher codrituzumab drug exposure or the use of CD16 and GPC3 as potential biomarkers would improve outcome remain unanswered questions. Lay summary: Codrituzumab is a manufactured antibody against a liver cancer protein called glypican-3. In this clinical trial, codrituzumab was not found be effective against liver cancer. It was suggested though that a higher dose of codrituzumab or selecting patients with high level of glypican-3 or its mediator CD16 might improve outcome. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • Masatoshi Kudo
    Liver Cancer 5 3 2016年07月 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    HEPATOLOGY 64 1 306 - 306 2016年07月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Hiroki Sakamoto; Takeshi Miyata; Hajime Imai; Kentaro Yamao; Ken Kamata; Shunsuke Omoto; Kumpei Kadosaka; Toshiharu Sakurai; Naoshi Nishida; Yasutaka Chiba; Masatoshi Kudo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 9 4 483 - 494 2016年07月 [査読有り]
     
    Background: Interventional endoscopic ultrasound (EUS)-guided procedures such as EUS-guided celiac ganglia neurolysis (EUS-CGN) and EUS-guided broad plexus neurolysis (EUS-BPN) were developed to treat abdominal cancer-associated pain; however, these procedures are not always effective. The aim of this study was to explore predictors of pain response in EUS-guided neurolysis for pancreatic cancer-associated pain. Methods: This was a retrospective analysis of prospectively collected data of 112 consecutive patients who underwent EUS-BPN in our institution. EUS-CGN was added in cases of visible celiac ganglia. The neurolytic-spread area was divided into six sections and evaluated by post-procedural computed tomography scanning. Pain intensity was assessed using a visual analog scale (VAS), and a decrease in VAS scores by 3 points after neurolysis was considered a good pain response. Univariable and multivariable logistic regression analyses were performed to explore predictors of pain response at 1 and 4 weeks, and complications. Results: A good pain response was obtained in 77.7% and 67.9% of patients at 1 and 4 weeks, respectively. In the multivariable analysis of these patients, the combination method (EUS-BPN plus CGN) was a significant positive predictive factor at 1 week (odds ratio = 3.69, p = 0.017) and 4 weeks (odds ratio = 6.37, p = 0.043). The numbers of neurolytic/contrast spread areas (mean SD) were 4.98 +/- 1.08 and 4.15 +/- 1.12 in patients treated with the combination method and single method, respectively (p < 0.001). There was no significant predictor of complications. Conclusions: EUS-BPN in combination with EUS-CGN was a predictor of a good pain response in EUS-guided neurolysis for pancreatic cancer-related pain. The larger number of neurolytic/contrast spread areas may lead to better outcomes in patients receiving combination treatment.
  • David J. Pinato; Tadaaki Arizumi; Jeong Won Jang; Elias Allara; Puvan I. Suppiah; Carlo Smirne; Paul Tait; Madhava Pai; Glenda Grossi; Young Woon Kim; Mario Pirisi; Masatoshi Kudo; Rohini Sharma
    ONCOTARGET 7 28 44705 - 44718 2016年07月 [査読有り]
     
    Background: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is variable, despite a myriad of prognostic markers. We compared and integrated the established prognostic models, HAP and ART scores, for their accuracy of overall survival (OS) prediction. Results: In both training and validation sets, HAP and ART scores emerged as independent predictors of OS (p<0.01) with HAP achieving better prognostic accuracy (c-index: 0.68) over ART (0.57). We tested both scores in combination to evaluate their combined ability to predict OS. Subgroup analysis of BCLC-C patients revealed favorable HAP stage (p<0.001) and radiological response after initial TACE (p<0.001) as positive prognostic factors. Patients and Methods: Prognostic scores were studied using multivariable Cox regression and c-index analysis in 83 subjects with Barcelona Clinic Liver Cancer (BCLC) A/B stage from UK and Italy (training set), and 660 from Korea and Japan (validation set), all treated with conventional TACE. Scores were further validated in an separate analysis of patients with BCLC-C stage disease (n=63) receiving initial TACE. Conclusion: ART and HAP scores are validated indices in patients with intermediate stage HCC undergoing TACE. The HAP score is best suited for screening patients prior to initial TACE, whilst sequential ART assessment improves early detection of chemoembolization failure. BCLC-C patients with low HAP stage may be a subgroup where TACE should be explored in clinical studies.
  • Hajime Imai; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Ken Kamata; Takeshi Miyata; Kentaro Yamao; Hiroki Sakamoto; Yogesh Harwani; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 84 1 147 - 151 2016年07月 [査読有り]
     
    Background and Aims: EUS-guided bile duct drainage (EUS-BD) is a well-recognized rescue biliary drainage method after unsuccessful ERCP. EUS-guided gallbladder drainage (EUS-GBD) was recently used to treat acute cholecystitis. The aim of this study was to assess the efficacy and safety of EUS-GBD for malignant biliary stricture-induced obstructive jaundice after unsuccessful ERCP as well as unsuccessful or impractical EUS-BD. Methods: Between January 2006 and October 2014, 12 patients with obstructive jaundice due to unresectable malignant distal biliary stricture underwent EUS-GBD after ERCP failed. EUS-GBD was performed under the guidance of EUS and fluoroscopy by puncturing the gallbladder with a needle, inserting a guidewire, dilating the puncture hole, and placing a stent. The technical and functional success rates, adverse events rate, overall patient survival time, and stent dysfunction rate during patient survival were measured. Results: The rates of technical success, functional success, adverse events, and stent dysfunction were 100%, 91.7%, 16.7%, and 8.3%, respectively. The median survival time after EUS-GBD was 105 days (range 15 - 236 days). Conclusions: EUS-GBD is a possible alternative route for decompression of the biliary system when ERCP is unsuccessful.
  • Ken Kamata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Masatoshi Kudo
    Ultrasonography 35 3 169 - 179 2016年07月 [査読有り]
     
    Endoscopic ultrasonography (EUS) is widely used to evaluate pancreaticobiliary diseases, especially pancreatic masses. EUS has a good ability to detect pancreatic masses, but it is not sufficient for the differential diagnosis of various types of lesions. In order to address the limitations of EUS, new techniques have been developed to improve the characterization of the lesions detected by EUS. EUS-guided fine needle aspiration (EUS-FNA) has been used for diagnosing pancreatic tumors. In order to improve the histological diagnostic yield, a EUS-FNA needle with a core trap has recently been developed. Contrast-enhanced harmonic EUS is a new imaging modality that uses an ultrasonographic contrast agent to visualize blood flow in fine vessels. This technique is useful in the diagnosis of pancreatic solid lesions and in confirming the presence of vascularity in mural nodules for cystic lesions. EUS elastography analyzes several different variables to measure tissue elasticity, color patterns, and strain ratio, using analytical techniques such as hue-histogram analysis, and artificial neural networks, which are useful for the diagnosis of chronic pancreatitis and pancreatic cancer.
  • Ken Kamata; Masayuki Kitano; Satoru Yasukawa; Masatoshi Kudo; Yasutaka Chiba; Takeshi Ogura; Kazuhide Higuchi; Nobuyasu Fukutake; Reiko Ashida; Tomoaki Yamasaki; Hiroko Nebiki; Satoru Hirose; Noriyuki Hoki; Masanori Asada; Shujiro Yazumi; Makoto Takaoka; Kazuichi Okazaki; Fumihiro Matsuda; Yoshihiro Okabe; Akio Yanagisawa
    ENDOSCOPY 48 7 632 - 638 2016年07月 [査読有り]
     
    Background and study aims: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) with 25-gauge needles yields small volume samples that are mainly processed for cytology. Using 25-gauge needles with a core trap may overcome this limitation. This trial compared 25-gauge needles with and without a core trap in terms of their ability to obtain histologic samples from solid pancreatic masses. Patients and methods: Consecutive patients with solid pancreatic masses who presented to eight Japanese referral centers for EUS-FNA in April-September 2013 were randomized to undergo sampling with a 25-gauge needle with a core trap (ProCore) or a standard 25-gauge needle. Tissue samples were fixed in formalin and processed for histologic evaluation. For the purpose of this study only samples obtained with the first needle pass were used for comparison of: (i) accuracy for the diagnosis of malignancy, (ii) rate of samples with preserved tissue architecture adequate for histologic evaluation, and (iii) sample cellularity. Results: A total of 214 patients were enrolled. Compared to the first pass with a standard needle (n=108), the first pass with the ProCore needle (n=106) provided samples that were more often adequate for histologic evaluation (81.1% vs. 69.4 %; P=0.048) and had superior cellularity (rich/moderate/poor, 36%/27%/37% vs. 19%/26%/ 55%; P=0.003). There were no significant differences between the two needles in sensitivity (75.6% vs. 69.0 %, P=0.337) and accuracy (79.2% vs. 75.9 %, P=0.561) for the diagnosis of malignancy. Conclusions: In patients with solid pancreatic masses, a 25-gauge EUS-FNA needle with a core trap provides histologic samples of better quality than a standard 25-gauge needle. There was no difference in accuracy for the diagnosis of malignancy between the needles. Clinical trial number: UMIN000010021.
  • Masayuki Kitano; Hajime Imai; Ken Kamata; Masatoshi Kudo
    Gastrointestinal Endoscopy 83 6 1303  2016年06月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Tomohiko Matsuda; Shunsuke Omoto; Kumpei Kadosaka; Tomoe Yoshikawa; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 22 21 5132 - 5136 2016年06月 [査読有り]
     
    We report a successful endoscopic ultrasonography-guided drainage of a huge infected multilocular walled-off necrosis (WON) that was treated by a modified single transluminal gateway transcystic multiple drainage (SGTMD) technique. After placing a wide-caliber fully covered metal stent, follow-up computed tomography revealed an undrained subcavity of WON. A large fistula that was created by the wide-caliber metal stent enabled the insertion of a forward-viewing upper endoscope directly into the main cavity, and the narrow connection route within the main cavity to the subcavity was identified with a direct view, leading to the successful drainage of the subcavity. This modified SGTMD technique appears to be useful for seeking connection routes between subcavities of WON in some cases.
  • 上嶋 一臣; 工藤 正俊
    救急・集中治療 28 5-6 431 - 435 (株)総合医学社 2016年05月 
    ＜Point＞肝癌は肝硬変をベースに発症することが多いため、その治療にあたっては肝予備能の評価が最も重要である。肝癌・肝硬変ともに最終転帰は肝不全であり、いずれの治療においても肝機能温存を目指すことが重要である。(著者抄録)
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Yoshihisa Okazaki; Tomoyuki Nagai; Hiromasa Mine; Teppei Adachi; Rie Tanaka; Mitsunari Yamada; Masashi Kono; Toshiki Okamoto; Shigenaga Matsui; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 83 5 AB392 - AB392 2016年05月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Tomohiko Matsuda; Shunsuke Omoto; Kumpei Kadosaka; Tomoe Yoshikawa; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 83 5 AB521 - AB521 2016年05月 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    HEPATOLOGY 63 5 1744 - 1745 2016年05月 [査読有り]
  • Jean-Francois Geschwind; Masatoshi Kudo; Jorge A. Marrero; Alan P. Venook; Xiao-Ping Chen; Jean-Pierre Bronowicki; Lucy Dagher; Junji Furuse; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Sheng-Long Ye; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo Lencioni
    RADIOLOGY 279 2 630 - 640 2016年05月 [査読有り]
     
    Purpose: To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions. Materials and Methods: GIDEON is an observational registry study of more than 3000 HCC patients. Patients with histologically, cytologically, or radiographically diagnosed HCC, and for whom a decision had been made to treat with sorafenib, were eligible. Patients were enrolled into the registry from 39 countries beginning in January 2009, with the last patient follow-up in April 2012. Detailed data on treatment history, treatment patterns, adverse events, and outcomes were collected. All treatment decisions were at the discretion of the treating physicians. Documented approval from local ethics committees was obtained, and all patients provided signed informed consent. Descriptive statistics, including minimum, median, and maximum, were calculated for metric data, and frequency tables for categorical data. Kaplan-Meier estimates with 95% confidence intervals were calculated for survival end points. Results: A total of 3202 patients were eligible for safety analysis, of whom 2631 (82.2%) were male. Median age was 62 years (range, 15-98 years). A total of 1511 (47.2%) patients underwent TACE prior to sorafenib; 325 (10.1%) underwent TACE concomitantly. TACE prior to sorafenib was more common in Japan and Asia- Pacific compared with all other regions (362 [71.3%] and 560 [60.3%] vs 12-209 [13.3%-37.1%]). Adverse events were reported in 2732 (85.3%) patients overall, with no notable differences in the incidence of adverse events, regardless of TACE treatment history. Overall survival was 12.7 months in prior-TACE patients, 9.2 months in non-prior-TACE patients, 21.6 months in concomitant-TACE patients, and 9.7 months in non-concomitant-TACE patients. Conclusion: Global variation exists in TACE use in sorafenib-treated HCC patients. The combination of TACE with sorafenib appears to be a well-tolerated and viable therapeutic approach. (C) RSNA, 2016
  • Naoshi Nishida; Masatoshi Kudo
    Journal of Japanese Society of Gastroenterology 113 5 775 - 784 2016年05月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Hajime Imai; Takeshi Miyata; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 83 5 1039 - 1040 2016年05月 [査読有り]
  • 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 113 5 775 - 784 (一財)日本消化器病学会 2016年05月 [査読有り]
     
    細胞形質の多様性はゲノムのみならずエピゲノム情報によっても規定され、後者はゲノム情報読み取りの制御機構といえる。肝細胞癌において、エピゲノム変異を示す遺伝子はゲノム変異よりも遥かに多様である。またエピゲノム制御機構の破綻は、癌の発生のみならず幹細胞様形質の獲得にも重要であると想定される。近年の高速シークエンス技術の発達により、肝細胞癌でもエピゲノム情報の維持に関わる種々の遺伝子の変異が明らかとなり、さらに環境因子のエピゲノム情報に及ぼす影響やその機序も解明されつつある。今後は、肝細胞癌のマネージメントにおいて、ゲノム・エピゲノム変異の包括的な情報が重要になると予想される。(著者抄録)
  • 自己免疫性膵炎の診断・治療におけるEUSの役割
    大本 俊介; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 58 Suppl.1 706 - 706 (一社)日本消化器内視鏡学会 2016年04月
  • 胆膵疾患の造影エコー診断up-to-date 造影ハーモニックEUSの定量的血流評価による膵腫瘍診断
    大本 俊介; 北野 雅之; 工藤 正俊
    超音波医学 43 Suppl. S318 - S318 (公社)日本超音波医学会 2016年04月
  • 消化器疾患の診断と治療におけるEUSの役割 EUSガイド下ドレナージを中心としたWONの治療成績及び内視鏡治療不成功因子の解析(Role of EUS in Diagnosis and Treatment of Digestive Diseases EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment)
    三長 孝輔; 北野 雅之; 今井 元; 山雄 健太郎; 鎌田 研; 宮田 剛; 松田 友彦; 大本 俊介; 門阪 薫平; 工藤 正俊
    超音波医学 43 Suppl. S322 - S322 2016年04月
  • Toshiharu Sakurai; Hiroshi Kashida; Rie Tanaka; Toshiki Okamoto; Mitsunari Yamada; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yutaka Asakuma; Yoriaki Komeda; Yoshihisa Okazaki; Shigenaga Matsui; Masatoshi Kudo
    GASTROENTEROLOGY 150 4 S83 - S83 2016年04月 [査読有り]
  • Teppei Adachi; Shigenaga Matsui; Rie Tanaka; Mitsunari Yamada; Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yutaka Asakuma; Yoriaki Komeda; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 150 4 S881 - S881 2016年04月 [査読有り]
  • Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    AMERICAN JOURNAL OF GASTROENTEROLOGY 111 4 453 - 453 2016年04月 [査読有り]
  • Masatoshi Kudo; Namiki Izumi; Takafumi Ichida; Yonson Ku; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
    HEPATOLOGY RESEARCH 46 5 372 - 390 2016年04月 [査読有り]
     
    The 19th Nationwide Follow-up Survey of Primary Liver Cancer in Japan comprised 20 850 primary liver cancer patients newly registered at 482 medical institutions over a period of 2 years (from 1 January 2006 to 31 December 2007). Of these, 94.7% had hepatocellular carcinoma (HCC) and 4.4% had intrahepatic cholangiocarcinoma (ICC). In addition, follow-up data were obtained regarding 34 752 patients who were registered in the previous survey. Epidemiological and clinicopathological factors, diagnosis, and treatment were examined in newly registered patients. Compared with the 18th follow-up survey, the present follow-up survey suggested an increase in the number of elderly and female patients, a reduction in the number of hepatitis B surface antigen-and anti-hepatitis C virus antibody-positive patients, and a reduction in tumor size at the time of clinical diagnosis. In terms of local ablation therapy, the number of patients receiving radiofrequency ablation therapy increased. The cumulative survival rates for newly registered patients between 1996 and 2007 were calculated for each histological type (HCC, ICC, and combined HCC and ICC) and stratified according to background factors and treatments. The cumulative survival rates of newly registered patients between 1978 and 2007 were calculated after dividing individuals into groups according to registration date (1978-1987, 1988-1997, and 1998-2007). The data obtained from this follow-up survey will contribute to the medical management of primary liver cancer and facilitate future research.
  • Kosuke Minaga; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Kumpei Kadosaka; Tomoe Yoshikawa; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 22 16 4264 - 4269 2016年04月 [査読有り]
     
    Acute obstructive suppurative cholangitis (AOSC) due to biliary lithiasis is a life-threatening condition that requires urgent biliary decompression. Although endoscopic retrograde cholangiopancreatography (ERCP) with stent placement is the current gold standard for biliary decompression, it can sometimes be difficult because of failed biliary cannulation. In this retrospective case series, we describe three cases of successful biliary drainage with recovery from septic shock after urgent endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) was performed for AOSC due to biliary lithiasis. In all three cases, technical success in inserting the stents was achieved and the patients completely recovered from AOSC with sepsis in a few days after EUS-CDS. There were no procedure-related complications. When initial ERCP fails, EUS-CDS can be an effective life-saving endoscopic biliary decompression procedure that shortens the procedure time and prevents post-ERCP pancreatitis, particularly in patients with AOSC-induced sepsis.
  • 【肝臓治療の最前線-最善の医療を目指す取り組み-】Intermediate Stageの肝癌治療を考える TACEから分子標的薬への切り替えのポイント
    上嶋 一臣; 工藤 正俊
    クリニシアン 63 3 335 - 342 エーザイ(株) 2016年03月
  • Intermediateから進行肝細胞癌治療の最前線 BCLC Bの細分類と治療選択
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 113 臨増総会 A107 - A107 (一財)日本消化器病学会 2016年03月
  • Takeshi Miyata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Ken Kamata; Hajime Imai; Hiroki Sakamoto; Naoshi Nisida; Yogesh Harwani; Takamichi Murakami; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 22 12 3381 - 3391 2016年03月 [査読有り]
     
    AIM: To assess the usefulness of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for lymph node metastasis in pancreatobiliary carcinoma. METHODS: All patients suspected of pancreatobiliary carcinoma with visible lymph nodes after standard EUS between June, 2009 and January, 2012 were enrolled. In the primary analysis, patients with successful EUS-fine needle aspiration (FNA) were included. The lymph nodes were assessed by several standard EUS variables (short and long axis lengths, shape, edge characteristic and echogenicity), color Doppler EUS variable [central intranodal blood vessel (CIV) presence] and CH-EUS variable (heterogeneous/homogeneous enhancement patterns). The diagnostic accuracy relative to EUS-FNA was calculated. In the second analysis, N-stage diagnostic accuracy of CH-EUS was compared with EUS-FNA in patients who underwent surgical resection. RESULTS: One hundred and nine patients (143 lymph nodes) fulfilled the criteria. The short axis cutoff >= 13 mm predicted malignancy with a sensitivity and specificity of 72% and 85%, respectively. These values were 72% and 63% for the long axis cut-off >= 20 mm, 62% and 75% for the round shape variable, 81% and 30% for the sharp edge variable, 66% and 61% for the hypoechogenicity variable, 70% and 72% for the CIV-absent variable, and 83% and 91% for the heterogeneous CH-EUS-enhancement variable, respectively. CH-EUS was more accurate than standard and color Doppler EUS, except the short axis cut-off. Notably, three patients excluded because of EUS-FNA failure were correctly N-staged by CH-EUS. CONCLUSION: CH-EUS complements standard and color Doppler EUS and EUS-FNA for assessment of lymph node metastases.
  • Tatsuo Inoue; Tomoko Hyodo; Keiko Korenaga; Takamichi Murakami; Yasuharu Imai; Atsushi Higaki; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Kazushi Numata; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY 51 2 144 - 152 2016年02月 [査読有り]
     
    Background It remains unknown whether Kupffer-phase images in Sonazoid-enhanced ultrasonography (US) can be used to predict hypervascularization of borderline lesions. Therefore, we aimed to clarify whether Kupffer-phase images in Sonazoid-enhanced ultrasonography can predict subsequent hypervascularization in hypovascular borderline lesions detected on hepatobiliary-phase gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (GdEOB-DTPA)-enhanced magnetic resonance imaging. Methods From January 2008 to March 2012, 616 low-intensity hypovascular nodules were detected in hepatobiliary-phase images of Gd-EOB-DTPA-enhanced MRI at nine institutions. Among these, 167 nodules, which were confirmed as hypovascular by Gd-EOB-DTPA-enhanced MRI and Sonazoid-enhanced US, were evaluated in this study. Potential hypervascularization factors were selected based on their clinical significance and the results of previous reports. The Kaplan-Meier model and log-rank test were used for univariate analysis and the Cox regression model was used for multivariate analysis. Results The cumulative incidence of hypervascularization of borderline lesions was 18, 37, and 43 % at 1, 2, and 3 years, respectively. Univariate analyses showed that tumor size (p = 0.0012) and hypoperfusion on Kupffer-phase images in Sonazoid-enhanced US (p = 0.004) were associated with hypervascularization of the tumor. Multivariate analysis showed that tumor size [HR: 1.086, 95 % confidence interval = 1.027-1.148, p = 0.004] and hypo perfusion on Kupffer-phase images [HR: 3.684, 95 % confidence interval = 1.798-7.546, p = 0.0004] were significantly different. Conclusions Kupffer-phase images in Sonazoid-enhanced US and tumor diameter can predict hypervascularization of hypointense borderline lesions detected on hepatobiliary-phase Gd-EOB-DTPA-enhanced MRI.
  • 河野匡志; 辻 直子; 尾崎信人; 松本 望; 高場雄久; 奥村直己; 川崎正憲; 冨田崇文; 梅原康湖; 谷池聡子; 遠藤英樹; 落合 健; 前倉利治; 工藤正俊
    肝臓 56 12 655 - 660 2016年01月 [査読有り]
     
    A 51-year-old man with psoriasis vulgaris presented general malaise and liver dysfunction after 9 months of infliximab therapy. Viral blood tests (HBs antigen, anti-HBc antibody, anti-HCV antibody) were negative, while antimitochondrial M2 antibody titer was high, His autoantibody status before the therapy was unknown. His liver function normalized after stopping infliximab and starting the administration of ursodeoxycholic acid and bezafibrate. A liver biopsy specimen showed non-specific inflammatory change without chronic nonsuppurative destructive cholangitis. Several cases of infliximab-related hepatitis have been reported, and many of them were antinuclear antibody-positive, resembling autoimmune hepatitis. Only one case of primary biliary cirrhosis (PBC) after infliximab therapy has been reported, while a high ratio of PBC-psoriasis overlap was reported in England. Infliximab-immunomediated liver dysfunction is a novel disease group, and the further accumulation of cases is needed.
  • 工藤 正俊; 泉 並木; 市田 隆文; 具 英成; 國土 典宏; 坂元 亨宇; 高山 忠利; 中島 収; 松井 修; 松山 裕; 田村 利恵; 前原 なつみ; 上妻 智子
    肝臓 57 1 45 - 73 一般社団法人 日本肝臓学会 2016年 
    第19回全国原発性肝癌追跡調査においては，482施設から2006年1月1日から2007年12月31日までの2年間の20,850例の新規症例と34,752例の追跡症例が集計された．追跡症例の有効回答率は60.0％であった．基礎統計は，第19回新規登録症例を対象として死因，既往歴，臨床診断，画像診断，治療法別の各因子，病理診断，再発，剖検についてまとめた．第18回調査と比較し，肝細胞癌における臨床診断時の高齢化，女性の増加，非B非C肝癌の増加，腫瘍径の縮小の傾向が，治療においては局所療法におけるラジオ波焼灼療法の増加が認められた．1996年から2007年まで新規登録症例の中で最終予後が生存または死亡となった症例（不明を除く）について肝細胞癌，肝内胆管癌，混合型肝癌の治療法別，背景因子別累積生存率を算出した．肝細胞癌については腫瘍個数，腫瘍径，肝障害度を組み合わせることにより背景因子を揃えて，治療法別（肝切除，局所療法，肝動脈塞栓療法）の累積生存率を算出し，また，1980年から2007年までの新規登録症例を3期に分け，累積生存率を算出した．新規登録症例数は経時的に増加し，肝細胞癌の予後の改善が著しいことが明らかとなった．本追跡調査が原発性肝癌の研究および診療の進歩に役立つことを期待する．
  • Masayuki Kitano; Kosuke Minaga; Masatoshi Kudo
    Endoscopic Imaging Techniques and Tools 187 - 208 2016年01月 [査読有り]
     
    Recent advances in endoscopic ultrasonography (EUS) imaging technology has led to the evolution of the image-enhanced EUS modalities called contrast-enhanced EUS and EUS elastography. These modalities can depict tissue structure in detail and thus are clinically useful for diagnosing pancreatobiliary and upper gastrointestinal diseases. Moreover, they complement EUS-guided fine-needle aspiration (EUS-FNA) by correctly diagnosing lesions with EUS-FNA false-negative findings and by identifying the most appropriate target site of EUS-FNA. This chapter focuses on the upcoming techniques of imaging in the field of EUS and how these techniques improve the diagnostic ability of EUS, particularly in terms of characterizing conventional EUS-detected lesions.
  • Reply: Hepatocyte damage due to protoporphyrin deposition
    Hagiwara S; Nishida N; Kudo M
    Hepatology 64 306  2016年 [査読有り]
  • 切除不能肝がん、レゴラフェニブ投与でOS延長～約7年ぶりの有望な結果～
    工藤正俊
    Medical Tribune Web 2016年 [査読有り]
  • 座談会; 肝癌に対する肝動注化学療法のエビデンスと今後
    工藤正俊; 山下竜也; 池田公史; 上嶋一臣
    The Liver Cancer Journal 8 13 - 19 2016年 [査読有り][招待有り]
  • M. Kudo
    LIVER CANCER 5 3 155 - 161 2016年 [査読有り]
  • M. Kudo
    LIVER CANCER 5 1 47 - 54 2016年 [査読有り]
  • Kudo M
    Liver cancer 5 1 1 - 7 2016年 [査読有り]
  • Yoshihiro Sakamoto; Norihiro Kokudo; Yutaka Matsuyama; Michiie Sakamoto; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Yonson Ku; Masatoshi Kudo; Tadatoshi Takayama; Osamu Nakashima
    CANCER 122 1 61 - 70 2016年01月 [査読有り]
     
    BACKGROUNDIn the current American Joint Committee on Cancer/International Union Against Cancer staging system (seventh edition) for intrahepatic cholangiocarcinoma (ICC), tumor size was excluded, and periductal invasion was added as a new tumor classification-defining factor. The objective of the current report was to propose a new staging system for ICC that would be better for stratifying the survival of patients based on data from the nationwide Liver Cancer Study Group of Japan database.METHODSOf 756 patients who underwent surgical resection for ICC between 2000 and 2005, multivariate analyses of the clinicopathologic factors of 419 patients who had complete data sets were performed to elucidate relevant factors for inclusion in a new tumor classification and staging system.RESULTSOverall survival data were best stratified using a cutoff value of 2cm using a minimal P value approach to discriminate patient survival. The 5-year survival rate of 15 patients who had ICC measuring 2cm in greatest dimension without lymph node metastasis or vascular invasion was 100%, and this cohort was defined as T1. Multivariate analysis of prognostic factors for 267 patients with lymph node-negative and metastasis-negative (N0M0) disease indicated that the number of tumors, the presence arterial invasion, and the presence major biliary invasion were independent and significant prognostic factors. The proposed new system, which included tumor number, tumor size, arterial invasion, and major biliary invasion for tumor classification, provided good stratification of overall patient survival according to disease stage. Macroscopic periductal invasion was associated with major biliary invasion and an inferior prognosis.CONCLUSIONSThe proposed new staging system, which includes a tumor cutoff size of 2cm and major biliary invasion, may be useful for assigning patients to surgery. Cancer 2016;122:61-70. (c) 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
  • Ken Kamata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Takaaki Chikugo; Yasutaka Chiba; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    ENDOSCOPY 48 1 35 - 41 2016年01月 [査読有り]
     
    Background and study aim: Comparison of fundamental B-mode endoscopic ultrasonography (FB-EUS) and contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) in the differential diagnosis of pancreatic cysts according to presence of mural nodules. Patients and methods: Between April 2007 and April 2012, FB-EUS and CH-EUS data were prospectively collected from 581 consecutive patients with pancreatic cysts, and were retrospectively analyzed from 70 with subsequent cyst resection. Presence and height of mural nodules as detected on FB-EUS and CH-EUS were evaluated, and thence accuracies of both methods for diagnosing mucinous versus nonmucinous and malignant versus benign cysts. Results: On pathological examination 48 cysts were mucinous and 22 were nonmucinous; 30 cysts were malignant (high grade dysplasia or invasive carcinoma) and 40 were benign. If presence of a mural nodule was considered to indicate a mucinous cyst, FB-EUS and CH-EUS accuracies did not differ significantly (respectively: sensitivity 85% vs. 79%; specificity 46% vs. 96%; accuracy 73% vs. 84%, P=0.057). If presence of mural nodule was considered to indicate malignancy, CH-EUS was significantly more accurate than FB-EUS (respectively: sensitivity 97% vs. 97%; specificity 75% vs. 40%; accuracy 84% vs. 64%, P=0.0001). For diagnosing malignancy by evaluating mural nodule height, the area under the receiver operating characteristic (AUROC) was 0.84 and 0.93 for FB-EUS and CH-EUS, respectively (P=0.028). Presence of a mural nodule of height >= 4mm on CH-EUS was a sign of malignancy (false-positive fraction 0.2; true-positive fraction 0.93; odds ratio 56.0). Conclusions: CH-EUS is more accurate than FB-EUS for diagnosing malignant pancreatic cysts.
  • Kudo M; Kanai H
    Journal of medical ultrasonics (2001) 43 1 163  2016年01月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Tomoe Yoshikawa; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Masatoshi Kudo
    ENDOSCOPY 48 E228 - E229 2016年 [査読有り]
  • Satoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
    LIVER CANCER 5 3 175 - 189 2016年 [査読有り]
     
    Background & Aims: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC. Methods: Of the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000-December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study. Among the patients analyzed, 108 underwent LT, 273 were treated by local ablation therapy (LAT), 370 were treated by transarterial chemoembolization (TACE), and 593 received best supportive care (BSC). The effect of LT, LAT, and TACE on overall survival (OS) was analyzed using multivariate and propensity score analyses. Results: Patient characteristics did not differ significantly between each treatment group and the BSC group, after propensity score matching. LAT (hazard ratio [HR]) = 0.568; 95% confidence interval [CI], 0.40-0.80) and TACE (HR = 0.691; 95% CI, 0.50-0.96) were identified as significant contributors to OS if the C-P score was less than 11 and tumor conditions met the Milan criteria. Conclusions: For patients with HCC within the Milan criteria and with a C-P score of 10 or 11, locoregional treatment can be used as a salvage treatment if LT is not feasible. Copyright (C) 2016 S. Karger AG, Basel
  • Naoshi Nishida; Masashi Kono; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Tashiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 632 - 639 2016年 [査読有り]
     
    Background: An interferon-free regimen including sofosbuvir and ribavirin (RBV) for patients with hepatitis C virus (HCV) genotype 2 (G2) infection leads to a drastic improvement of sustained virological response (SVR). However, the safety, tolerability, and efficacy in patients aged 75 or older have not been completely understood. Summary: Fifty-six patients with HCV G2 infection who were treated with sofosbuvir and weight-based dose of RBV were enrolled. Thirty-seven patients aged and 19 patients aged were classified as the aged and non-aged groups, respectively. The aged group was characterized by significantly more number of women, history of hepatocellular carcinoma, low serum albumin (ALB) level, low hemoglobin (Hb) concentration, low estimated glomerular filtration rate (eGFR), and high fibrosis-4 index (p = 0.0029). Forty-one patients were evaluated for SVR at 12 weeks after the end of therapy (SVR12); of them, all but one completed the treatment scheduled for 12 weeks. The aged group showed lower SVR12 rate than the non aged group (81.3%for aged and 96.0%for non-aged groups). Although the Hb concentration and eGFR are significantly lower in the aged group throughout the clinical course, all patients in the aged group completed the 12-week treatment with a gradual increase of serum ALB level. Key Messages: The combination of sofosbuvir plus RBV is tolerable and beneficial in patients aged >75. However, intensive management of anemia by dose reduction of RBV is necessary, which could lead to a low SVR12 rate compared to that observed in patients younger than 75 years. (C) 2016 S. Karger AG, Basel
  • Satoru Hagiwara; Naoshi Nishida; Hirokazu Chishina; Hiroshi Ida; Toshiharu Sakurai; Yoriaki Komeda; Masayuki Kitano; Masatoshi Kudo
    INTERNAL MEDICINE 55 22 3273 - 3277 2016年 [査読有り]
     
    The patient was a 67-year-old female with liver cirrhosis due to hepatitis C. She was administered furosemide at 20 mg/day and spironolactone at 25 mg/day, but the ascites did not improve. Despite the additional administration of tolvaptan at 3.75 mg/day, the response to ascites was still poor. While the dose of tolvaptan was thereafter increased to 7.5 mg/day on the 7th hospital day, the ascites still persisted. However, she continued to receive tolvaptan (7.5 mg/day) because the worsening of her subjective symptoms was mild and she wished to do so. The ascites was later found to have almost completely disappeared on computed tomography (CT) at 6 months.
  • 抗血栓薬服用患者における検査・治療について
    青山真吾; 足立哲平; 松井繁長; 樫田博史; 工藤正俊
    近畿大学医学雑誌 41 129 - 134 2016年 [査読有り]
  • EUSガイド下胆嚢ドレナージ術
    竹中 完; 北野雅之; 鎌田 研; 三長孝輔; 大本俊介; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    消化器内視鏡 28 1669 - 1678 2016年 [査読有り]
  • 北野 雅之; 三長 孝輔; 今井 元; 工藤 正俊
    胆道 30 4 689 - 698 日本胆道学会 2016年 [査読有り]
     

    超音波内視鏡下胆管ドレナージ術は，ERCPが困難な胆道閉塞症例における代替の胆管減圧法として近年，大きな注目が集まっており，ここ数年の間に多数の論文が発表されている．様々な手技の方法が報告されているが，主な穿刺ルートとして，胃から経肝的に肝内胆管にアプローチする方法及び十二指腸から肝外胆管にアプローチする方法に大別され，ステンティングの方法では，経消化管的ドレナージ術，ランデブー法および順行性ステンティング術の3通りの留置法がある．閉塞部位やスコープの乳頭部到達可否等の状態に応じて，穿刺ルート，ステント留置法を決定する必要がある．手技成功率および偶発症発生率は手技の方法や報告により異なるが，最近の1192例のメタ解析では，手技成功率94.7%，偶発症発生率23.3%と報告されている．今後の専用処置具の開発により，近未来には，より安全で確立した治療法となり得る可能性がある．

  • WONに対する内視鏡的ドレナージ
    三長孝輔; 北野雅之; 竹山宜典; 大本俊介; 宮田 剛; 鎌田 研; 山雄健太郎; 工藤正俊
    肝胆膵 73 41 - 51 2016年 [査読有り]
  • 急性膵炎診療における地域連携モデルの構築
    大本俊介; 北野雅之; 工藤正俊; 松本逸平; 竹山宜典
    肝胆膵 72 1003 - 1007 2016年 [査読有り]
  • Kosuke Minaga; Mamoru Takenaka; Takeshi Miyata; Yasuhiro Ueda; Masayuki Kitano; Masatoshi Kudo
    ENDOSCOPY 48 S 01 E369 - E370 2016年 [査読有り]
  • M. Kudo
    LIVER CANCER 5 4 235 - 244 2016年 [査読有り][招待有り]
  • Yuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Takayuki Iwamoto; Junya Okabe; Manabu Takamura; Norihiko Fujita; Masatoshi Hori; Tetsuo Takehara; Masatoshi Kudo; Takamichi Murakami
    LIVER CANCER 5 4 269 - 279 2016年 [査読有り]
     
    Background and Aims: Extracted-overlay fusion imaging is a novel computed tomography/magnetic resonance-ultrasonography (CT/MR-US) imaging technique in which a target tumor with a virtual ablative margin is extracted from CT/MR volume data and synchronously overlaid on US images. We investigated the applicability of the technique to intraoperative evaluation of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods: This retrospective study analyzed 85 HCCs treated with RFA using extracted-overlay fusion imaging for guidance and evaluation. To perform RFA, an electrode was inserted targeting the tumor and a virtual 5-mm ablative margin overlaid on the US image. Following ablation, contrast-enhanced US (CEUS) was performed to assess the ablative margin, and the minimal ablative margins were categorized into three groups: (I) margin <0 mm (protrusion), (II) margin 0 to <5 mm, and (III) margin >= 5 mm. Margin assessment was based on the positional relationship between the overlaid tumor plus margin and the perfusion defect of the ablation zone. Tumors in group I underwent repeat ablation until they were in groups II or III. The final classifications were compared with those obtained by retrospectively created fusion images of pre- and post-RFA CT or MR imaging (CT-CT/MR-MR fusion imaging). Results: Treatment evaluation was impossible using CEUS in six HCCs because the tumors were located far below the body surface. Of the remaining 79 HCCs, the categorizations of minimal ablative margins between CEUS extracted-overlay fusion imaging and CT-CT/MR-MR fusion imaging were in agreement for 72 tumors (91.1%) (Cohen's quadratic-weighted kappa coefficient 0.66, good agreement, p<0.01). Conclusions: Extracted-overlay fusion imaging combined with CEUS is feasible for the evaluation of RFA and enables intraoperative treatment evaluation without the need to perform contrast-enhanced CT. Copyright (C) 2016 S. Karger AG, Basel
  • 肝細胞癌に対する分子標的治療薬開発の現状と将来展望
    工藤正俊
    医学あゆみ 258 537 - 543 2016年 [査読有り][招待有り]
  • Masatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
    LIVER CANCER 5 3 190 - 197 2016年 [査読有り]
     
    Background: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. Methods: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry. Patients were grouped by years of diagnosis, with OS and 5-year OS rates being calculated. We also assessed OS and 5-year OS rates in patients who underwent resection, local ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC) and in those with baseline serum alpha-fetoprotein (AFP) levels >= 400 ng/ml. Results: The 5- and 10-year OS rates in the cohort of 173,378 patients were 37.9% and 16.5%, respectively. However, over time, the mean maximum tumor size decreased significantly, whereas 5-year OS rates and median survival time increased significantly. Similar findings were observed separately in patients who underwent resection, local ablation, TACE, and HAIC, as well as in patients with AFP levels >= 400 ng/ml. Conclusion: The establishment of a nationwide HCC surveillance program in Japan has contributed to longer median OS and increased OS rates in patients diagnosed with this disease. These findings suggest that the establishment of a surveillance program in other countries with patients at risk for HCC may provide significant survival benefits. Copyright (C) 2016 S. Karger AG, Basel
  • Tomoyuki Nagai; Tokuzo Arao; Kazuto Nishio; Kazuko Matsumoto; Satoru Hagiwara; Toshiharu Sakurai; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Kazuko Sakai; Nagahiro Saijo; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Seiji Haji; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 702 - 707 2016年 [査読有り]
     
    Background: Epithelial-mesenchymal transition (EMT) is considered to play a critical role in cancer progression and metastasis. However, the impact of EMT on the prognosis of hepatocellular carcinoma (HCC) is still elusive. In this study, we examined the relationship between the expression of EMT markers and recurrence-free survival (RFS) and overall survival (OS) in HCC patients after hepatic resection. Summary:The mRNA expression of 15 genes related to EMT was assessed by quantitative real-time polymerase chain reaction in cancerous tissues from 72 patients who underwent hepatic resection of HCC between January 2005 and December 2010 at our hospital. The upregulation of TWIST and the downregulation of tight junction protein ZO-1 (TJP1) were significantly associated with shorter RFS as well as OS. Increased levels of TWIST and decreased levels of TJP1 should be predictive markers for poor prognosis in patients with HCC after hepatectomy; those could serve as potential biomarkers for the treatment of HCC. Key Messages: A low level of TJP1 and high level of TWIST expression were prognostic factors predicting HCC after hepatic resection. (C) 2016 S. Karger AG, Basel
  • Tao Wu; Ping Wang; Ting Zhang; Jian Zheng; Shuoyang Li; Jie Zeng; Masatoshi Kudo; Rongqin Zheng
    DIGESTIVE DISEASES 34 6 640 - 649 2016年 [査読有り]
     
    Background: Noninvasive assessment of liver fibrosis has important clinical significance. Different techniques including two-dimensional shear-wave elastography (2D SWE) and real-time tissue elastography (RTE) are reported to be useful for the noninvasive diagnosis of hepatic fibrosis. All these techniques are affected by many factors. How to choose a reasonable method needs further studies. Purpose: This study was conducted to comparatively assess the diagnostic performance of 2D SWE and RTE in patients with Chronic Hepatitis B (CHB) and influence of inflammation on the stiffness values obtained by both techniques, so as to objectively assess the reasonable choice between these 2 elastography techniques for noninvasive assessment of hepatic fibrosis in clinical practice. Materials and Methods: Four hundred and thirty-seven patients with CHB meeting the inclusion criteria were enrolled in the study. All patients underwent liver stiffness measurements by using 2D SWE and RTE on the same day. Histologic fibrosis was staged and inflammation activity was graded based on the METAVIR scoring system on liver biopsy specimens. Results: The liver stiffness values by using 2D SWE and RTE both increased in parallel with the degree of liver fibrosis and the grade of inflammation. However, the diagnostic efficacy of significant fibrosis and cirrhosis using 2D SWE was significantly higher than that of RTE. The 2D SWE measurement values were statistically different in different alanine aminotransferase (ALT) levels and METAVIR activity grades; however, no statistically significant differences were observed by using RTE. The diagnostic efficacy of 2D SWE significantly varied with elevated ALT levels compared with RTE. Conclusion: 2D SWE was more accurate than RTE in the assessment of significant fibrosis and cirrhosis in patients with CHB. Compared with RTE, the measurement values and diagnostic performance obtained by 2D SWE were prone to be more easily affected by the inflammation fluctuations. (C) 2016 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 671 - 678 2016年 [査読有り]
     
    Background: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the patients with BCLC stage B disease is heterogeneous showing different tumor statuses and Child Pugh scores; treatment strategies other than TACE are frequently employed for the patients in this stage. Based on the subclassification system proposed by Bolondi et al. [Semin Liver Dis 2012;32:348-359], we developed the Kinki criteria focusing on a substaging for BCLC stage B disease, which is simpler and should be more suitable in actual clinical setting in Japan. In this study, we evaluated the performance of Kinki criteria. Summary: This study included 1,633 HCC patients who received first line treatment at the Kindai University Hospital. Patients were classified into subgroups based on the Kinki criteria and the survival time was estimated for each group. There were 156 (33.3%) patients in subclass B1, 278 (59.3%) in B2, and 35 (7.4%) in B3. The median overall survival times and 95% CI for BCLC B subclasses B1, B2, and B3 were 4.3 years (3.7-4.9), 2.9 years (2.2-3.4), and 1.1 years (0.5-1.8), respectively (p < 0.001). Key Messages: Classification of HCC patients in BCLC stage B based on the Kinki criteria showed statistically significant differences in survival, indicating the performance of Kinki criteria, which takes Child Pugh score and tumor status into account for determining treatment options for HCC in BCLC stage B. (C) 2016 S. Karger AG, Basel
  • Takayuki Iwamoto; Yasuharu Imai; Sachiyo Kogita; Takumi Igura; Yoshiyuki Sawai; Kazuto Fukuda; Yoshitaka Yamaguchi; Yasushi Matsumoto; Masanori Nakahara; Osakuni Morimoto; Yasushi Seki; Hiroshi Ohashi; Norihiko Fujita; Masatoshi Kudo; Tetsuo Takehara
    DIGESTIVE DISEASES 34 6 679 - 686 2016年 [査読有り]
     
    Objective: We compared the efficacy of contrast-enhanced ultrasound sonography (CEUS) with sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (GdEOB-DTPA)-enhanced MRI for the assessment of macroscopic classification of nodular hepatocellular carcinoma (HCC). Methods: Seventy-seven consecutive patients with 79 surgically resected HCCs who underwent both preoperative CEUS and Gd-EOB-DTPA-enhanced MRI were enrolled in this retrospective study. Based on the macroscopic diagnosis of resected specimens, nodules were categorized into the simple nodular (SN) and non-SN type HCC. Two hepatologists independently assessed image datasets of the post-vascular phase of CEUS and hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to compare their diagnostic performance. Results: Gd-EOB-DTPA-enhanced MRI enabled the evaluation of macroscopic classification in a significantly larger number of nodules than CEUS (78/79 (98.7%) vs. 70/79 (88.6%), p < 0.05). Of 70 nodules that could be evaluated by both modalities, 41 and 29 nodules were pathologically categorized as SN and non-SN, respectively. The areas under the receiver operating characteristic curve (AUC) for non-SN did not differ between CEUS and Gd-EOB-DTPA-enhanced MRI (reader 1: 0.748 for CEUS, 0.808 for MRI; reader 2: 0.759 for CEUS, 0.787 for MRI). The AUC of combined CEUS and Gd-EOB-DTPA-enhanced MRI for SN HCC was 0.855 (reader 1) and 0.824 (reader 2), indicating higher AUC values for the combined modalities. Conclusions: The diagnostic performance for macroscopic classification of nodular HCC of CEUS was comparable with that of Gd-EOB-DTPA-enhanced MRI, although some HCCs could not be evaluated by CEUS owing to lower detectability. The combination of the 2 modalities had a more accurate diagnostic performance. (C) 2016 S. Karger AG, Basel
  • Toshihiko Kawasaki; Kan-yun Hata; Daisuke Kinoshita; Masaki Takayama; Hideyuki Okuda; Shigeto Mizuno; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 692 - 695 2016年 [査読有り]
     
    Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC after TACE. Methods: After TACE was performed, 18 nodules in 12 patients were treated by B mode sonography guided RFA, while 22 nodules in 18 patients were treated by contrast-enhanced sonography-guided RFA. Results: The success rate of initial RFA was 83.3% (15/18 nodules) in the B-mode sonography group. On the other hand, the success rate was 100% (22/22 nodules) in the contrast-enhanced sonography group and the difference was significant (p = 0.046). Conclusion: These findings suggest that RFA guided by Kupffer phase contrast-enhanced sonography after TACE is a promising therapeutic option for curing HCC. (C) 2016 S. Karger AG, Basel
  • Kayo Sugimoto; Soo Ki Kim; Soo Ryang Kim; Mana Kobayashi; Airi Kato; Eri Morimoto; Susumu Imoto; Chi Wan Kim; Yasuhito Tanaka; Masatoshi Kudo; Yoshihiko Yano; Yoshitake Hayashi
    DIGESTIVE DISEASES 34 6 627 - 631 2016年 [査読有り]
     
    Objectives: The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA). Methods: Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed. Results: Rapid virological response was attained with sofosbuvir plus RBV treatment compared with peg-IFN plus RBV treatment. All patients under sofosbuvir plus RBV treatment achieved end-of-treatment response compared with 70% who sustained viral response under the peg-IFN plus RBV treatment, with the former demonstrating greater virological response. The decline in hemoglobin levels under the former treatment was greater than that under the latter and in patients over 65 years of age with ITPA gene major. Conclusion: Efficacy and safety of sofosbuvir plus RBV treatment were clearly demonstrated compared with those of peg-IFN plus RBV treatment. The decline in hemoglobin levels was not related to the discontinuation of the former treatment, irrespective of age or the effect of the ITPA gene. (C) 2016 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 650 - 653 2016年 [査読有り]
     
    Objective: We have reported about real-time tissue elastography (RTE), which displays relative strain by measuring the relative distortion of the tissue, and found this information to be useful for diagnosing liver fibrosis. However, its use in predicting hepatocellular carcinoma has not been reported as yet. Here, we investigated RTE to predict liver carcinogenesis in patients with chronic hepatitis C virus (HCV) infection. Methods: We enrolled 160 patients with chronic HCV, who were followed up for 39.9 +/- 22.9 weeks (median). They underwent RTE and then ultrasounds every 3-6 months. Results: Respective cumulative liver cancer incidences for years 1, 2, 3, 4, and 5 were, for the entire cohort: 2.0, 5.6, 8.8, 13.1, and 23.9%; for those whose liver fibrosis index (LFI) was <= 2.0: 0.0, 0.0, 0.0, 0.0, and 0.0%; for those whose LFI was 2-2.8:0.0, 7.4, 7.4, 13.2 and 19.9%; and for those whose LFI was >2.8: 12.9, 12.9, 21.7, 31.4, and 31.4% (p = 0.011; log-rank test). Conclusions: Measurements of LFI by strain imaging can effectively predict liver cancer risk in patients with chronic HCV infection. (C) 2016 S. Karger AG, Basel
  • Soo Ki Kim; Myung-Hee Shin; Kayo Sugimoto; Soo Ryang Kim; Susumu Imoto; Ke Ih Kim; Miyuki Taniguchi; Hyun-Kyung Oh; Yoshihiko Yano; Yoshitake Hayashi; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 665 - 670 2016年 [査読有り]
     
    Objectives: Significant inverse association between coffee intake and the levels of liver enzymes has been reported. We demonstrated higher prevalence of metabolic syndrome in Korean immigrants (KIs) than in indigenous Japanese (Us). The aim of this study was to investigate whether the association between coffee intake and liver enzyme levels was different between the 2 ethnic groups. Methods: This study is a cross-sectional study including a total of 966 subjects comprising KIs and Us. The association between the quintiles of coffee intake and dichotomous values of liver enzymes was evaluated by logistic regression analysis in KIs, Us, a high-risk group (current smokers or alcohol drinkers >= 45 g/day), and a low-risk group (non-smokers and alcohol drinkers <45 g/day). Results: In KIs, a significant inverse association between coffee intake and serum aspartate aminotransferase (AST) levels was observed. In the Us, a significant inverse association between coffee intake and serum alanine aminotransferase levels was observed. In the high-risk-group, a significant inverse association between coffee intake and serum AST and gamma-glutamyltransferase levels was observed. Conclusion: No difference was observed between KIs and Us regarding the association between coffee and liver enzymes. Coffee might inhibit hepatic damage by alcohol drinking and smoking. (C) 2016 S. Karger AG, Basel
  • Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 714 - 730 2016年 [査読有り][招待有り]
     
    Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Sonazoid-enhanced ultrasound and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI are the most important imaging modalities in diagnosing HCC. There are 2 non-contradictory HCC treatment algorithms in Japan. Hepatic arterial infusion chemotherapy plays an important role in the treatment of advanced HCC with main or branch portal vein invasion. Regorafenib, as a second-line systemic treatment, prolongs survival in patients with intermediate and advanced HCC who progressed on sorafenib. In recent clinical trials, immune check point inhibitors show promising results for the treatment of HCC. This review describes recent trends in the management of HCC. (C) 2016 S. Karger AG, Basel
  • Chikara Ogawa; Yasunori Minami; Masahiro Morita; Teruyo Noda; Soichi Arasawa; Masako Izuta; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 696 - 701 2016年 [査読有り]
     
    Purpose: Transcatheter arterial chemoembolization (TACE) is one of the most effective therapeutic options for hepatocellular carcinoma (HCC) and it is important to protect residual liver function after treatment as well as the effect. To reduce the liver function deterioration, we evaluated the automatic software to predict the embolization area of TACE in 3 dimensions. Materials and Methods: Automatic prediction software of embolization area was used in chemoembolization of 7 HCCs. Embolization area of chemoembolization was evaluated within 1 week CT findings after TACE and compared simulated area using automatic prediction software. Results: The maximal diameter of these tumors is in the range 12-42 mm (24.6 +/- 9.5 mm). The average time for detecting tumor-feeding branches was 242 s. The total time to detect tumor-feeding branches and simulate the embolization area was 384 s. All cases could detect all tumor-feeding branches of HCC, and the expected embolization area of simulation with automatic prediction software was almost the same as the actual areas, as shown by CT after TACE. Conclusion: This new technology has possibilities to reduce the amount of contrast medium used, protect kidney function, decrease radiation exposure, and improve the therapeutic effect of TACE. (C) 2016 S. Karger AG, Basel
  • Yasunori Minami; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 687 - 691 2016年 [査読有り]
     
    Objective: Radiofrequency ablation (RFA) induces gas bubbles in ablation zones, and the ablative margin cannot be evaluated accurately on ultrasound (US) during and immediately after RFA. This study assessed the usefulness of US-US fusion imaging to visualize the ablative margin of RFA for liver metastasis. Methods: RFA guided by US-US fusion imaging was performed on 12 targeted tumors in 10 patients. Secondary hepatic malignancies included patients with colorectal cancer (n = 4), breast cancer (n = 2), lung cancer (n = 1), gastrointestinal stromal tumor (n = 1), pancreatic neuroendocrine tumor (n = 1), and adrenocortical carcinoma (n = 1). The maximal diameter of the tumors ranged from 0.8 to 4.0 cm (mean SD 1.6 +/- 0.9 cm). Results: The mean number of electrode insertions was 1.6 per session (range 1-3). Technically, effective ablation was achieved in a single session in all patients, and safety ablative margins were confirmed on contrast-enhanced CT for early assessment of tumor response. There were no serious adverse events or procedure-related complications. During the follow-up period (median 220 days, range 31-417 days), none of the patients showed local tumor progression. Conclusion: US-US fusion imaging could show the tumor images before ablation and the ablative area on US in real time. The image overlay of US-US fusion imaging made it possible to evaluate the ablative margin three dimensionally according to the US probe action. Therefore, US-US fusion imaging can contribute to RFA therapy with a safety margin, that is, the so-called precise RFA. (C) 2016 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 708 - 713 2016年 [査読有り]
     
    Accumulation of genetic and epigenetic alterations is a hallmark of cancer genomes, including those in hepatocellular carcinoma (HCC). Particularly, in human HCC, epigenetic changes are more frequently observed than genetic changes in a variety of cancer-related genes, suggesting a potential role for epigenetic alterations during hepatocarcinogenesis. Several environmental factors, such as inflammation, obesity, and steatosis, are reported to affect the epigenetic status in hepatocytes, which could play a role in HCC development. In addition, genetic mutations in histone modulators and chromatin regulators would be critical for the acceleration of epigenetic alteration. It is also possible that major genetic mutations of HCC, such as TP53 and CNTTB1 mutations, are associated with the disturbance of epigenetic integrity. For example, specific TP53 mutations frequently induced by aflatoxin B1 exposure might affect histone modifiers and nucleosome remodelers. Generally, epigenetic alteration is reversible, because of which dysregulation of transcription takes place, without affecting protein structure. Therefore, differentiation therapy is one of the potential approaches for HCC with advanced epigenetic alterations. On the other hand, a tumor carrying an accumulation of genetic mutations would result in many abnormal proteins that could be recognized as non-self and could be targets for immune reactions; thus, immune-checkpoint blockers should be effective for HCCs with genetic hypermutation. Although the emergence of genetic and epigenetic alterations could be linked to each other and there could be some crossover or convergence between these cancer pathways, characterization of the mutation spectrum of genetic and epigenetic alterations could influence future HCC treatment. (C) 2016 S. Karger AG, Basel
  • Hirokazu Chishina; Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Masashi Kono; Tomohiro Minami; Mina Iwanishi; Yasuko Umehara; Tomohiro Watanabe; Yoriaki Komeda; Tadaaki Arizumi; Masotoshi Kudo
    DIGESTIVE DISEASES 34 6 659 - 664 2016年 [査読有り]
     
    Objective: Refractory ascites reduces the quality of life of liver cirrhosis patients. Albumin preparation and diuretics, such as furosemide, have been used to treat refractory ascites, but the effect was poor in many patients. In this study, we analyzed patients treated with tolvaptan (TLV) at our hospital and investigated predictors of the effect. Methods: The subjects were 70 patients for whom TLV was introduced to treat refractory ascites who could be analyzed between November 2013 and March 2015 at our hospital. Patient background before initiation of oral TLV treatment, the dose of diuretics, and each item of biochemical tests of blood and urine were investigated, and factors correlated with the treatment effect were analyzed. An increase of >= 1,000 ml in the daily urine volume from the day before oral treatment or a decrease of kg in the body weight within 7 days as an early effect was observed in 33 patients and not observed in 37 patients. TLV treatment was continued for 60 days or longer in 12 of the 37 patients in whom no early effect was observed, and the presence or absence of a delayed effect and predictors of the effect were investigated. A decrease in as cites on abdominal CT with improvement of subjective symptoms at 60 days was defined as a delayed effect. Results: When early predictors of the effect were investigated by univariate analysis, serum blood urea nitrogen (BUN) and serum creatinine (Cr) were significantly higher in the non responder group (BUN: p = 0.03, Cr: p = 0.04), but no factor independently associated with the treatment effect was extracted on multivariate analysis. The delayed effect was noted in 4 (33.3%) of the 12 patients, but no predictor of the effect before treatment was identified. However, reactions, such as an increase in serum Na and reduction of urinary osmotic pressure, were observed early after TLV administration in some patients in whom the delayed effect was observed. Conclusions: The diuretic effect of TLV may decrease in renal hypofunction patients. Since the delayed effect was noted in a specific ratio of patients, continuation of TLV administration is an option even though the early treatment effect is poor unless ascites aggravates or adverse effects develop. (C) 2016 S. Karger AG, Basel
  • Masahiro Takita; Mina Iwanishi; Tomohiro Minami; Masashi Kono; Hirokazo Chishina; Tadaaki Arizumi; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Nishida Naoshi; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 654 - 658 2016年 [査読有り]
     
    Objective: The objective of treatment for polycystic liver disease is to reduce the liver volume and reduce or resolve compression symptoms such as abdominal fullness and abdominal pain due to hepatomegaly. Liver cysts are treated internally by puncture and aspiration of the cyst contents or hepatic artery embolization and surgically by cyst fenestration or hepatectomy, but no clear consensus has been reached concerning their selection. We introduced monoethanolamine oleate (EO) sclerotherapy therapy for liver cysts in 1999 and reported its effectiveness. In this study, cases were added, and the results including those of long-term follow-up were evaluated. Subjects: Twenty-two patients (5 males and 17 females, mean age 65.2) who underwent EO infusion therapy for liver cysts between January 1999 and June 2011 were evaluated. Methods: Liver cysts were punctured under ultrasound guidance, and a 7Fr pigtail catheter was inserted. After aspirating the cyst contents, EO was infused, and a clamp was applied for 24 h. Then, the catheter was declamped, cyst contents were aspirated again, and the catheter was removed. After the treatment, the cyst size was measured, and the patients were followed up. Results: Eight simple cysts in 8 patients (simple cyst group) and 21 cysts in 14 patients with multiple cysts (polycystic liver disease group) were treated and followed up over a median of 78 months (0-203 months). The mean volume reduction rate was 99% in the simple cyst group and 91% in the polycystic liver disease group (p = 0.04). One procedural accident resulting in liver abscess formation was observed in 1 patient 1 week after discharge, and it required drain placement and antibiotic administration. While mild abdominal pain was observed in a few patients, it was resolved spontaneously under observation. Conclusion: EO infusion therapy achieves fairly high treatment response in the volume reduction (99%) and sustained shrinkage over long-term follow-up. Therefore, this is a breakthrough technique in the treatment of polycystic liver disease as well as simple cyst and should be a standard of care in the treatment of this disease. (C) 2016 S. Karger AG, Basel
  • Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 620 - 626 2016年 [査読有り]
     
    Objective: Treatment for chronic hepatitis C has recently developed in a very rapid manner. In Japan, in September 2014, IFN-free asunaprevir (ASV) and daclatasvir (DCV) became available for combination therapy. We report the treatment outcomes achieved at our hospital using this combination therapy. Methods: Sustained virological response (SVR) 24 could be evaluated in 120 of 125 patients with chronic liver disease type C who visited our hospital and were treated with ASV/DCV after September 2014, and these patients were analyzed. Results: SVR24 was achieved in 106 patients (88%). End-of-treatment response was not achieved in 10 patients (8.3%). Five of them carried multiple-resistant NS3/4A or NS5A region, and administration was discontinued early in 4 patients due to adverse effects. After ASV/DCV treatment, hepatocellular carcinoma (HCC) developed in 2 patients (1.7%) and recurred in 5 (4.2%). Conclusions: ASV/DCV treatment achieved favorable SVR in elderly and hepatic cirrhosis patients and patients in whom HCC was cured. However, an increase in the incidence of HCC development in patients who markedly respond to direct-acting antivirals treatment is expected and surveillance of HCC becomes more important. (C) 2016 S. Karger AG, Basel
  • Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 617 - 619 2016年 [査読有り][招待有り]
  • 座談会「“免疫チェックポイント阻害剤“の基礎から臨床成績および開発動向」
    工藤正俊; 石田靖雅; 池田公史; 田中真二
    肝胆膵 73 429 - 443 2016年 [査読有り][招待有り]
  • 免疫チェックポイント阻害剤の限界と課題. 特集「がん治療が変わる-免疫チェックポイント阻害剤の与えるインパクト-」
    工藤正俊
    肝胆膵 9 423 - 427 2016年 [査読有り][招待有り]
  • 肝細胞癌における免疫チェックポイント阻害剤の開発. 特集「癌治療が変わる-免疫チェックポイント阻害剤の与えるインパクト-」
    工藤正俊
    肝胆膵 9 401 - 412 2016年 [査読有り][招待有り]
  • 医用画像における超音波画像の今日的座標を説く-最新技術がもたらす新しい展開
    工藤正俊
    月刊新医療 8 80 - 82 2016年 [査読有り][招待有り]
  • 生検で胃癌が疑われたinflammatory fibroid polyp. 特集「粘膜下腫瘍のすべて」
    松井繁長; 樫田博史; 工藤正俊
    消化器内視鏡 28 302 - 303 2016年 [査読有り]
  • M. Kudo
    LIVER CANCER 5 2 91 - 96 2016年 [査読有り][招待有り]
  • Masatoshi Kudo; Kazuomi Ueshima; Shoji Kubo; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Takamichi Murakami; Masumi Kadoya; Norihiro Kokudo
    HEPATOLOGY RESEARCH 46 1 3 - 9 2016年01月 [査読有り]
     
    The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST ormodified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.
  • Y. Komeda; H. Kashida; T. Sakurai; Y. Asakuma; Y. Okazaki; T. Nagai; H. Mine; T. Adachi; R. Tanaka; M. Yamada; M. Kono; K. Okamoto; S. Matsui; M. Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30 191 - 191 2015年12月 [査読有り]
  • 山雄 健太郎; 北野 雅之; 工藤 正俊
    胆と膵 36 12 1325 - 1330 医学図書出版(株) 2015年12月 
    膵癌は予後不良な疾患であり、UICC Stage I aでの5年生存率は68.7%と決して満足できるものではない。一方で上皮内癌を意味するStage 0の場合には5年生存率は85.8%と比較的良好である。予後改善のためにはできるだけ早期に膵癌を発見し、治療を行うことが重要である。上皮内癌の主病変は膵管内腔側に突出する丈の低い乳頭状の病変であり、空間分解能に優れるEUSでも上皮内癌自体を直接的に画像所見として捉えることは困難である。上皮内癌を診断するためには主膵管狭窄および尾側膵管の拡張や膵嚢胞、主膵管狭窄部周囲の"淡い低エコー領域"などの間接所見に着目し剥離した上皮細胞を効率よく採取・回収できる膵液細胞診が有用と考えられ、とくに複数回の検体採取をすることができるENPD留置下の連続膵液細胞診を行うことが重要である。(著者抄録)
  • Masatoshi Kudo
    Liver Cancer 4 4 274  2015年12月 [査読有り]
  • Akiko Saito-Hakoda; Akira Uruno; Atsushi Yokoyama; Kyoko Shimizu; Rehana Parvin; Masataka Kudo; Takako Saito-Ito; Ikuko Sato; Naotaka Kogure; Dai Suzuki; Hiroki Shimada; Takeo Yoshikawa; Ikuma Fujiwara; Hiroyuki Kagechika; Yasumasa Iwasaki; Shigeo Kure; Sadayoshi Ito; Akira Sugawara
    PLOS ONE 10 12 2015年12月 [査読有り]
     
    Various retinoid X receptor (RXR) agonists have recently been developed, and some of them have shown anti-tumor effects both in vivo and in vitro. However, there has been no report showing the effects of RXR agonists on Cushing's disease, which is caused by excessive ACTH secretion in a corticotroph tumor of the pituitary gland. Therefore, we examined the effects of synthetic RXR pan-agonists HX630 and PA024 on the proliferation, apoptosis, ACTH secretion, and pro-opiomelanocortin (Pomc) gene expression of murine pituitary corticotroph tumor AtT20 cells. We demonstrated that both RXR agonists induced apoptosis dose-dependently in AtT20 cells, and inhibited their proliferation at their higher doses. Microarray analysis identified a significant gene network associated with caspase 3 induced by high dose HX630. On the other hand, HX630, but not PA024, inhibited Pomc transcription, Pomc mRNA expression, and ACTH secretion dose-dependently. Furthermore, we provide new evidence that HX630 negatively regulates the Pomc promoter activity at the transcriptional level due to the suppression of the transcription factor Nur77 and Nurr1 mRNA expression and the reduction of Nur77/Nurr1 heterodimer recruiting to the Pomc promoter region. We also demonstrated that the HX630-mediated suppression of the Pomc gene expression was exerted via RXR alpha. Furthermore, HX630 inhibited tumor growth and decreased Pomc mRNA expression in corticotroph tumor cells in female nude mice in vivo. Thus, these results indicate that RXR agonists, especially HX630, could be a new therapeutic candidate for Cushing's disease.
  • Masashi Kono; Shigenaga Matsui; Kazuki Okamoto; Mitsunari Yamada; Rie Tanaka; Teppeiadachi Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yoriakikomeda; Yutaka Asakuma; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30 103 - 103 2015年12月 [査読有り]
  • Mitsunari Yamada; Hiroshi Kashida; Yoriaki Komeda; Kazuki Okamoto; Masashi Kono; Rie Tanaka; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Matsui; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30 18 - 18 2015年12月 [査読有り]
  • Shunsuke Omoto; Masayuki Kitano; Hiroki Sakamoto; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Kosuke Minaga; Kumpei Kadosaka; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30 141 - 141 2015年12月 [査読有り]
  • Y. -K. Kang; T. Yau; J. -W. Park; H. Y. Lim; T. -Y. Lee; S. Obi; S. L. Chan; S. K. Qin; R. D. Kim; M. Casey; C. Chen; H. Bhattacharyya; J. A. Williams; O. Valota; D. Chakrabarti; M. Kudo
    ANNALS OF ONCOLOGY 26 12 2457 - 2463 2015年12月 [査読有り]
     
    Axitinib plus best supportive care failed to meet the primary end point of overall survival in second-line treatment of advanced hepatocellular carcinoma in a randomized phase II study. However, the axitinib arm showed substantially improved progression-free survival, time to tumour progression, and clinical benefit rate compared with the placebo arm, with acceptable safety profile. Background: The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Patients and methods: Patients with HCC and Child-Pugh Class A who progressed on or were intolerant to one prior antiangiogenic therapy were stratified by tumour invasion (presence/absence of extrahepatic spread and/or vascular invasion) and region (Asian/non-Asian) and randomized (2:1) to axitinib/BSC (starting dose 5 mg twice-daily) or placebo/BSC. The primary end point was overall survival (OS). Results: The estimated hazard ratio for OS was 0.907 [95% confidence interval (CI) 0.646-1.274; one-sided stratified P = 0.287] for axitinib/BSC (n = 134) versus placebo/BSC (n = 68), with the median (95% CI) of 12.7 (10.2-14.9) versus 9.7 (5.9-11.8) months, respectively. Results of prespecified subgroup analyses in Asian versus non-Asian patients or presence versus absence of tumour invasion were consistent with the overall population. Improvements favouring axitinib/BSC (P < 0.01) were observed in secondary efficacy end point analyses [progression-free survival (PFS), time to tumour progression (TTP), and clinical benefit rate (CBR)], and were retained among Asian patients in the prespecified subgroup analyses. Overall response rate did not differ significantly between treatments and patient-reported outcomes favoured placebo/BSC. Most common all-causality adverse events with axitinib/BSC were diarrhoea (54%), hypertension (54%), and decreased appetite (47%). Baseline serum analyses identified potential new prognostic (interleukin-6, E-selectin, interleukin-8, angiopoietin-2, migration inhibitory factor, and c-MET) or predictive (E-selectin and stromal-derived factor-1) factors for survival. Conclusions: Axitinib/BSC did not improve OS over placebo/BSC in the overall population or in stratification subgroups. However, axitinib/BSC resulted in significantly longer PFS and TTP and higher CBR, with acceptable toxicity in patients with advanced HCC. Trial Registration: ClinicalTrials.gov, NCT01210495.
  • Hideaki Takahashi; Masafumi Ikeda; Takashi Kumada; Yukio Osaki; Shunsuke Kondo; Shigeru Kusumoto; Kazuyoshi Ohkawa; Seijin Nadano; Junji Furuse; Masatoshi Kudo; Kiyoaki Ito; Masahiro Yokoyama; Takuji Okusaka; Masanori Shimoyama; Masashi Mizokami
    HEPATOLOGY RESEARCH 45 12 1220 - 1227 2015年12月 [査読有り]
     
    Aim: The purpose of this multicenter cooperative study was to elucidate the clinical features of hepatitis B virus (HBV) reactivation by chemotherapeutic agents and the patient outcomes after HBV reactivation by a retrospective review of accumulated patients' medical records. Methods: Records of a total of 27 patients (hematological malignancy, 14 patients; solid tumor, 13 patients) from 11 institutions who were diagnosed between June 2005 and October 2010 as having HBV reactivation following chemotherapy were reviewed. Results: Of the 27 patients with reactivation, 16 patients were hepatitis B surface antigen (HBsAg) positive and 11 were HBsAg negative prior to the commencement of chemotherapy. Of the 11 patients who were HBsAg negative prior to the chemotherapy, 10 had hematological malignancies and one had a solid tumor. Of the 14 patients with hematological malignancies with HBV reactivation enrolled in the study, the reactivation occurred more than 12 months after the completion of chemotherapy in five patients (36%); on the other hand, none of the patients (0%) with solid tumors developed HBV reactivation more than 12 months after the completion of chemotherapy. Of the 24 patients who had acute liver dysfunction at the diagnosis of HBV reactivation, nine (38%) had severe hepatitis and seven (29%) died of liver failure. Conclusion: Most of the patients with HBV reactivation who were HBsAg negative prior to the chemotherapy had underlying hematological malignancies. Furthermore, patients with hematological malignancies often developed late-onset HBV reactivation. The prognosis of patients who develop acute liver dysfunction as a complication of HBV reactivation is extremely dismal.
  • Satoru Hagiwara; Naoshi Nishida; Ah-Mee Park; Toshiharu Sakurai; Akira Kawada; Masatoshi Kudo
    HEPATOLOGY 62 5 1638 - 1639 2015年11月 [査読有り]
  • Naoshi Nishida; Toshimi Kaido; Masatoshi Kudo
    HEPATOLOGY 62 1151A - 1152A 2015年10月 [査読有り]
  • Arai Y; Yamashita K; Kuriyama K; Shiokawa M; Kodama Y; Sakurai T; Mizugishi K; Uchida K; Kadowaki N; Takaori-Kondo A; Kudo M; Okazaki K; Strober W; Chiba T; Watanabe T
    Journal of immunology (Baltimore, Md. : 1950) 195 7 3033 - 3044 2015年10月 [査読有り]
     
    The abnormal immune response accompanying IgG4-related autoimmune pancreatitis (AIP) is presently unclear. In this study, we examined the role of plasmacytoid dendritic cell (pDC) activation and IFN-alpha production in this disease as well as in a murine model of AIP (MRL/Mp mice treated with polyinosinic-polycytidylic acid). We found that the development of AIP in treated MRL/Mp mice occurred in parallel with pancreatic accumulation of pDCs producing IFN-alpha, and with pDC depletion and IFN-alpha-blocking studies, we showed that such accumulation was necessary for AIP induction. In addition, we found that the pancreas of treated MRL/Mp mice contained neutrophil extracellular traps (NETs) shown previously to stimulate pDCs to produce IFN-alpha. Consistent with these findings, we found that patients with IgG4-related AIP also exhibited pancreatic tissue localization of IFN-alpha-expressing pDCs and had significantly higher serum IFN-alpha levels than healthy controls. In addition, the inflamed pancreas of these patients but not controls also contained NETs that were shown to be capable of pDC activation. More importantly, patient pDCs cultured in the presence of NETs produced greatly increased levels of IFN-alpha and induced control B cells to produce IgG4 (but not IgG1) as compared with control pDCs. These data suggest that pDC activation and production of IFN-alpha is a major cause of murine AIP; in addition, the increased pDC production of IFN-alpha and its relation to IgG4 production observed in IgG4-related AIP suggest that this mechanism also plays a role in the human disease.
  • Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T. Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M. Llovet
    LANCET ONCOLOGY 16 13 1344 - 1354 2015年10月 [査読有り]
     
    Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. Methods We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries. Patients were randomly assigned (1: 1) to receive 400 mg oral sorafenib or placebo twice a day, for a maximum of 4 years, according to a block randomisation scheme (block size of four) using an interactive voice-response system. Patients were stratified by curative treatment, geography, Child-Pugh status, and recurrence risk. The primary outcome was recurrence-free survival assessed after database cut-off on Nov 29, 2013. We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered with ClinicalTrials.gov, number NCT00692770. Findings We screened 1602 patients between Aug 15, 2008, and Nov 17, 2010, and randomly assigned 1114 patients. Of 556 patients in the sorafenib group, 553 (> 99%) received the study treatment and 471 (85%) terminated treatment. Of 558 patients in the placebo group, 554 (99%) received the study treatment and 447 (80%) terminated treatment. Median duration of treatment and mean daily dose were 12.5 months (IQR 2.6-35.8) and 577 mg per day (SD 212.8) for sorafenib, compared with 22.2 months (8.1-38.8) and 778.0 mg per day (79.8) for placebo. Dose modification was reported for 497 (89%) of 559 patients in the sorafenib group and 206 (38%) of 548 patients in the placebo group. At final analysis, 464 recurrence-free survival events had occurred (270 in the placebo group and 194 in the sorafenib group). Median follow-up for recurrence-free survival was 8.5 months (IQR 2.9-19.5) in the sorafenib group and 8.4 months (2.9-19.8) in the placebo group. We noted no difference in median recurrence-free survival between the two groups (33.3 months in the sorafenib group vs 33.7 months in the placebo group; hazard ratio [HR] 0.940; 95% CI 0.780-1.134; one-sided p=0.26). The most common grade 3 or 4 adverse events were hand-foot skin reaction (154 [28%] of 559 patients in the sorafenib group vs four [<1%] of 548 patients in the placebo group) and diarrhoea (36 [6%] vs five [< 1%] in the placebo group). Sorafenib-related serious adverse events included hand-foot skin reaction (ten [2%]), abnormal hepatic function (four [< 1%]), and fatigue (three [< 1%]). There were four (< 1%) drug-related deaths in the sorafenib group and two (< 1%) in the placebo group. Interpretation Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
  • Ann-Lii Cheng; Yoon-Koo Kang; Aiwu Ruth He; Ho Yeong Lim; Baek-Yeol Ryoo; Chao-Hung Hung; I-Shyan Sheen; Namiki Izumi; TaShara Austin; Qiang Wang; Jonathan Greenberg; Shinichi Shiratori; Robert A. Beckman; Masatoshi Kudo
    JOURNAL OF HEPATOLOGY 63 4 896 - 904 2015年10月 [査読有り]
     
    Background & Aims: Tigatuzumab is a humanized monoclonal antibody that acts as a death receptor-5 agonist and exerts tumour necrosis factor-related apoptosis-inducing ligand-like activity. In this phase II study, safety and tolerability of the combination of tigatuzumab and sorafenib was evaluated in patients with advanced hepatocellular carcinoma. Methods: Adults with advanced hepatocellular carcinoma, measurable disease, and an Eastern Cooperative Oncology Group performance score <= 1 were enrolled. Eligible subjects were randomly assigned 1: 1: 1 to tigatuzumab (6 mg/kg loading, 2 mg/kg/week maintenance) plus sorafenib 400 mg twice daily; tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib 400 mg twice daily; or sorafenib 400 mg twice daily. The primary end point was time to progression. Secondary end points included overall survival and safety. Results: 163 subjects were randomized to treatment. Median time to progression was 3.0 months in the tigatuzumab 6/2 mg/kg combination group (p = 0.988 vs. sorafenib), 3.9 months in the tigatuzumab 6/6 mg/kg combination group (p = 0.586 vs. sorafenib), and 2.8 months in the sorafenib alone group. Median overall survival was 12.2 months in the tigatuzumab 6/6 mg/kg combination group (p = 0.659 vs. sorafenib), vs. 8.2 months in both other treatment groups (p = 0.303, tigatuzumab 6/2 mg/kg combination vs. sorafenib). The most common treatment-emergent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, and decreased appetite. Conclusions: Tigatuzumab combined with sorafenib vs. sorafenib alone in adults with advanced hepatocellular carcinoma did not meet its primary efficacy end point, although tigatuzumab plus sorafenib is well tolerated in hepatocellular carcinoma. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • 機能性上部消化管疾患の病態と新規治療 機能性ディスペプシアに早期慢性膵炎が含まれている
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 112 臨増大会 A761 - A761 (一財)日本消化器病学会 2015年09月
  • SSA/Pの内視鏡診断
    岡崎 能久; 樫田 博史; 櫻井 俊治; 朝隈 豊; 米田 頼晃; 高山 政樹; 峯 宏昌; 足立 哲平; 田中 梨絵; 山田 光成; 岡元 寿樹; 榎本 英介; 前西 修; 筑後 孝章; 木村 雅友; 佐藤 隆夫; 工藤 正俊
    Gastroenterological Endoscopy 57 Suppl.2 2145 - 2145 (一社)日本消化器内視鏡学会 2015年09月
  • 上腸間膜静脈血栓症による急性腸管虚血に対しTIPSを施行した1例
    沼本 勲男; 鶴崎 正勝; 柳生 行伸; 渡口 真史; 山川 美帆; 任 誠雲; 松木 充; 村上 卓道; 萩原 智; 工藤 正俊; 吉藤 竹仁; 船内 正憲
    IVR: Interventional Radiology 30 3 283 - 283 (一社)日本インターベンショナルラジオロジー学会 2015年09月
  • Joong-Won Park; Minshan Chen; Massimo Colombo; Lewis R. Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S. Orsini; Morris Sherman
    LIVER INTERNATIONAL 35 9 2155 - 2166 2015年09月 [査読有り]
     
    Background & AimsHepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. MethodsData were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. ResultsForty-two sites in 14 countries contributed final data for 18031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23months for Japan, North America, South Korea, Europe and China respectively (P<0.0001). ConclusionsInitial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.
  • Masashi Kono; Naoko Tsuji; Nobuto Ozaki; Nozomu Matsumoto; Takehisa Takaba; Naoki Okumura; Masanori Kawasaki; Takafumi Tomita; Yasuko Umehara; Satoko Taniike; Shigeru Hatabe; Sadao Funai; Yukihhiko Ono; Ken Ochiai; Shunji Maekura; Masatoshi Kudo
    Clinical Journal of Gastroenterology 8 4 217 - 222 2015年08月 [査読有り]
     
    Primary leiomyosarcomas of the gastrointestinal (GI) tract are extremely rare and highly aggressive neoplasms, and only a small number of true cases have been reported since the concept of GI stromal tumors was established. Here, we report a case of a primary leiomyosarcoma of the transverse colon. A 46-year-old Japanese male with a large mass in the right upper abdomen was admitted to our hospital. Computed tomography and magnetic resonance imaging revealed long segments of wall thickening of the transverse colon with large consecutive tumors measuring 12 cm in diameter. A projecting irregular mass with marked mucosal necrosis was found on colonoscopy. Pathological examination revealed a spindle cell tumor growing circumferentially and transmurally to replace the muscularis propria in the transverse colon. The spindle cells were positive for smooth muscle actin, and negative for KIT, CD34, DOG-1, and S-100 protein. The patient has shown repeat recurrence in spite of sufficient surgical excision being promptly performed.
  • 山雄 健太郎; 北野 雅之; 工藤 正俊
    胆道 29 3 551 - 551 日本胆道学会 2015年08月
  • Sasan Roayaie; Ghalib Jibara; Parissa Tabrizian; Joong-Won Park; Jijin Yang; Lunan Yan; Myron Schwartz; Guohong Han; Francesco Izzo; Mishan Chen; Jean-Frederic Blanc; Philip Johnson; Masatoshi Kudo; Lewis R. Roberts; Morris Sherman
    HEPATOLOGY 62 2 440 - 451 2015年08月 [査読有り]
     
    Current guidelines recommend surgical resection as the primary treatment for a single hepatocellular cancer (HCC) with Child's A cirrhosis, normal serum bilirubin, and no clinically significant portal hypertension. We determined how frequently guidelines were followed and whether straying from them impacted survival. BRIDGE is a multiregional cohort study including HCC patients diagnosed between January 1, 2005 and June 30, 2011. A total of 8,656 patients from 20 sites were classified into four groups: (A) 718 ideal resection candidates who were resected; (B) 144 ideal resection candidates who were not resected; (C) 1,624 nonideal resection candidates who were resected; and (D) 6,170 nonideal resection candidates who were not resected. Median follow-up was 27 months. Log-rank and Cox's regression analyses were conducted to determine differences between groups and variables associated with survival. Multivariate analysis of all ideal candidates for resection (A+B) revealed a higher risk of mortality with treatments other than resection. For all resected patients (A+C), portal hypertension and bilirubin >1 mg/dL were not associated with mortality. For all patients who were not ideal candidates for resection (C+D), resection was associated with better survival, compared to embolization and other treatments, but was inferior to ablation and transplantation. Conclusions: The majority of patients undergoing resection would not be considered ideal candidates based on current guidelines. Not resecting ideal candidates was associated with higher mortality. The study suggests that selection criteria for resection may be modestly expanded without compromising outcomes, and that some nonideal candidates may still potentially benefit from resection over other treatment modalities. (Hepatology 2015;62:440-451
  • Andrew X. Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D. Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B. Abada; Ling Yang; Jonathan D. Schwartz; Masatoshi Kudo
    LANCET ONCOLOGY 16 7 859 - 870 2015年07月 [査読有り]
     
    Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. Findings Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9.2 months (95% CI 8.0-10.6) versus 7.6 months (6.0-9.3) for the placebo group (HR 0.87 [95% CI 0.72-1.05]; p=0.14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]). The most frequently reported (>= 1%) treatment-emergent serious adverse event of any grade or grade 3 or more was malignant neoplasm progression. Interpretation Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma. No new safety signals were noted in eligible patients and the safety profile is manageable.
  • Matsui S; Kashida H; Asakuma Y; Sakurai T; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 73 7 1116 - 1122 2015年07月 [査読有り]
  • 胃潰瘍・十二指腸潰瘍
    松井繁長; 樫田博史; 朝隈 豊; 櫻井俊治; 工藤正俊
    日本臨床 73 7 1116 - 1122 2015年07月 [査読有り][招待有り]
  • David J. Pinato; Tadaaki Arizumi; Elias Allara; Jeong Won Jang; Carlo Smirne; Young Woon Kim; Masatoshi Kudo; Mario Pirisi; Rohini Sharma
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 13 6 1204 - + 2015年06月 [査読有り]
     
    BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is used to treat hepatocellular carcinoma (HCC), but it is a challenge to predict patient survival. The hepatic arterial embolization prognostic (HAP) score has been shown to predict which patients will have shorter survival times and should not undergo TACE. We aimed to validate this scoring system in a prospective study of patients in Europe and Asia. METHODS: We evaluated the prognostic accuracy of the HAP score in estimating overall survival (OS) of 126 patients with HCC who received TACE in the United Kingdom or Italy (training set) from 2001 through 2013. We also analyzed data from 723 patients treated in Korea and Japan (validation set), including 79 with newly diagnosed HCC, who underwent TACE in Korea or Japan from 2004 through 2013. Response to TACE was determined based on computed tomography analysis. OS was calculated from the time of the first TACE until death or the last follow-up evaluation. RESULTS: OS was associated with hypoalbuminemia, a-fetoprotein level greater than 400 ng/mL, and tumor size greater than 7 cm at diagnosis (P<.01), but not a bilirubin level greater than 17 umol/L (P>.05), in both data sets. The lack of association between OS and bilirubin level was confirmed using receiver operating characteristic analysis. We developed a modified version of the HAP score, based on the level of albumin and a-fetoprotein and tumor size, which predicted OS with increased accuracy in the training and validation cohorts. CONCLUSIONS: In a multicenter validation study, we developed a modified version of the HAP that predicts survival of patients with HCC treated with TACE in Europe and Asia. This system might be used to identify patients with HCC most likely to benefit from TACE in clinical practice.
  • 食道・胃静脈瘤
    松井繁長; 樫田博史; 工藤正俊
    内科 115 6 939 - 943 2015年06月 [査読有り]
  • Kiwamu Okita; Namiki Izumi; Kenji Ikeda; Yukio Osaki; Kazushi Numata; Masafumi Ikeda; Norihiro Kokudo; Kazuho Imanaka; Shuhei Nishiguchi; Shunsuke Kondo; Yoichi Nishigaki; Susumu Shiomi; Kazuomi Ueshima; Norio Isoda; Yoshiyasu Karino; Masatoshi Kudo; Katsuaki Tanaka; Shuichi Kaneko; Hisataka Moriwaki; Masatoshi Makuuchi; Takuji Okusaka; Norio Hayashi; Yasuo Ohashi; Hiromitsu Kumada
    JOURNAL OF GASTROENTEROLOGY 50 6 667 - 674 2015年06月 [査読有り]
     
    This study examined the effects of peretinoin, an acyclic retinoid, on the survival of patients with hepatitis C virus-related hepatocellular carcinoma (HCC) who had completed curative therapy and participated in a randomized, placebo-controlled trial. This study was an investigator-initiated retrospective cohort study. Subjects were all patients who were administered the investigational drug (peretinoin 600 mg/day, peretinoin 300 mg/day, or placebo) in the randomized trial. Survivals between the groups were compared using the log-rank test, and hazard ratios were estimated by Cox regression. Survey data were collected from all patients (n = 392) who participated in the randomized trial, all of whom were then divided into the peretinoin 600 mg/day (n = 132), peretinoin 300 mg/day (n = 131), and placebo (n = 129) groups. At the median follow-up of 4.9 years, 5-year cumulative survival rates for patients in the 600 mg/day, 300 mg/day, and placebo groups were 73.9, 56.8, and 64.3 %, respectively. Comparison of overall survival among patients classified as Child-Pugh A revealed that survival of the 600 mg/day group (n = 105) was significantly longer than that of the placebo group (n = 108) (hazard ratio 0.575, 95 % CI 0.341-0.967; P = 0.0347). Administration of 600 mg/day peretinoin to patients with hepatitis C virus-related HCC who have completed curative therapy may improve survival for those classified as Child-Pugh A, for whom liver function is relatively stable.
  • 大本 俊介; 北野 雅之; 工藤 正俊
    膵臓 30 3 326 - 326 (一社)日本膵臓学会 2015年05月
  • 山雄 健太郎; 北野 雅之; 工藤 正俊; 中島 潤; 岡部 純弘; 大崎 往夫; 萱原 隆久; 石田 悦嗣; 山本 博; 三長 孝輔; 山下 幸孝
    膵臓 30 3 307 - 307 日本膵臓学会 2015年05月
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Yoshihisa Okazaki; Toshiki Okamoto; Mitsunari Yamada; Rie Tanaka; Teppei Adachi; Hiromasa Mine; Masaki Takayama; Tomoyuki Nagai; Masanori Kawasaki; Shigenaga Matsui; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 81 5 AB219 - AB219 2015年05月 [査読有り]
  • Masatoshi Kudo
    ULTRASOUND IN MEDICINE AND BIOLOGY 41 5 1125 - 1125 2015年05月 [査読有り]
  • Shigenaga Matsui; Masatoshi Kudo; Masayuki Kitano; Yutaka Asakuma
    HEPATO-GASTROENTEROLOGY 62 139 595 - 598 2015年05月 [査読有り]
     
    Background/Aims: In advanced gastric cancers, a significant correlation exists between the response to chemotherapy in primary gastric cancers and patient prognosis. Therefore, accurate evaluation of the response to chemotherapy in primary gastric cancers is important. We examined the response to chemotherapy in primary gastric cancers by contrast enhanced harmonic endoscopic ultrasonography (CEH-EUS). Methodology: Thirty-five patients with advanced gastric cancer underwent CEH-EUS. Among these patients, 19 patients with stage IV advanced gastric cancer who received chemotherapy and CEH-EUS more than twice were enrolled, and evaluated the response to chemotherapy in primary gastric cancers by CEH-EUS and endoscopy. Results: In PRs evaluated by endoscopic findings, echo intensity ratio (EIR) was decreased, and in PDs EIR was increased significantly by CEH-EUS. Five cases had difficulty in evaluating the response of primary gastric cancers to chemotherapy by endoscopy, while evaluation was possible in those 5 cases by CEH-EUS. Conclusions: CEH-EUS is a new method to evaluate responses to chemotherapy in primary gastric cancers not only by a change in size but also in tumor vascularity. Correct evaluation of primary gastric cancers by CEH-EUS help predicting prognosis of patients.
  • Richard G. Barr; Kazutaka Nakashima; Dominique Amy; David Cosgrove; Andre Farrokh; Fritz Schafer; Jeffrey C. Bamber; Laurent Castera; Byung Ihn Choi; Yi-Hong Chou; Christoph F. Dietrich; Hong Ding; Giovanna Ferraioli; Carlo Filice; Mireen Friedrich-Rust; Timothy J. Hall; Kathryn R. Nightingale; Mark L. Palmeri; Tsuyoshi Shiina; Shinichi Suzuki; Ioan Sporea; Stephanie Wilson; Masatoshi Kudo
    ULTRASOUND IN MEDICINE AND BIOLOGY 41 5 1148 - 1160 2015年05月 [査読有り]
     
    The breast section of these Guidelines and Recommendations for Elastography produced under the auspices of the World Federation of Ultrasound in Medicine and Biology (WFUMB) assesses the clinically used applications of all forms of elastography used in breast imaging. The literature on various breast elastography techniques is reviewed, and recommendations are made on evidence-based results. Practical advice is given on how to perform and interpret breast elastography for optimal results, with emphasis placed on avoiding pitfalls. Artifacts are reviewed, and the clinical utility of some artifacts is discussed. Both strain and shear wave techniques have been shown to be highly accurate in characterizing breast lesions as benign or malignant. The relationship between the various techniques is discussed, and recommended interpretation based on a BI-RADS-like malignancy probability scale is provided. This document is intended to be used as a reference and to guide clinical users in a practical way. (C) 2015 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
  • Giovanna Ferraioli; Carlo Filice; Laurent Castera; Byung Ihn Choi; Ioan Sporea; Stephanie R. Wilson; David Cosgrove; Christoph F. Dietrich; Dominique Amy; Jeffrey C. Bamber; Richard Barr; Yi-Hong Chou; Hong Ding; Andre Farrokh; Mireen Friedrich-Rust; Timothy J. Hall; Kazutaka Nakashima; Kathryn R. Nightingale; Mark L. Palmeri; Fritz Schafer; Tsuyoshi Shiina; Shinichi Suzuki; Masatoshi Kudo
    ULTRASOUND IN MEDICINE AND BIOLOGY 41 5 1161 - 1179 2015年05月 [査読有り]
     
    The World Federation for Ultrasound in Medicine and Biology (WFUMB) has produced these guidelines for the use of elastography techniques in liver disease. For each available technique, the reproducibility, results, and limitations are analyzed, and recommendations are given. Finally, recommendations based on the international literature and the findings of the WFUMB expert group are established as answers to common questions. The document has a clinical perspective and is aimed at assessing the usefulness of elastography in the management of liver diseases. (C) 2015 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
  • Tsuyoshi Shiina; Kathryn R. Nightingale; Mark L. Palmeri; Timothy J. Hall; Jeffrey C. Bamber; Richard G. Barr; Laurent Castera; Byung Ihn Choi; Yi-Hong Chou; David Cosgrove; Christoph F. Dietrich; Hong Ding; Dominique Amy; Andre Farrokh; Giovanna Ferraioli; Carlo Filice; Mireen Friedrich-Rust; Kazutaka Nakashima; Fritz Schafer; Ioan Sporea; Shinichi Suzuki; Stephanie Wilson; Masatoshi Kudo
    ULTRASOUND IN MEDICINE AND BIOLOGY 41 5 1126 - 1147 2015年05月 [査読有り]
     
    Conventional diagnostic ultrasound images of the anatomy (as opposed to blood flow) reveal differences in the acoustic properties of soft tissues (mainly echogenicity but also, to some extent, attenuation), whereas ultrasound-based elasticity images are able to reveal the differences in the elastic properties of soft tissues (e.g., elasticity and viscosity). The benefit of elasticity imaging lies in the fact that many soft tissues can share similar ultrasonic echogenicities but may have different mechanical properties that can be used to clearly visualize normal anatomy and delineate pathologic lesions. Typically, all elasticity measurement and imaging methods introduce a mechanical excitation and monitor the resulting tissue response. Some of the most widely available commercial elasticity imaging methods are 'quasi-static' and use external tissue compression to generate images of the resulting tissue strain (or deformation). In addition, many manufacturers now provide shear wave imaging and measurement methods, which deliver stiffness images based upon the shear wave propagation speed. The goal of this review is to describe the fundamental physics and the associated terminology underlying these technologies. We have included a questions and answers section, an extensive appendix, and a glossary of terms in this manuscript. We have also endeavored to ensure that the terminology and descriptions, although not identical, are broadly compatible across the WFUMB and EFSUMB sets of guidelines on elastography (Bamber et al. 2013; Cosgrove et al. 2013). (C) 2015 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
  • 消化管機能異常に対する内視鏡の役割 早期慢性膵炎が機能性ディスペプシアとして診断される可能性について
    門阪 薫平; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 57 Suppl.1 653 - 653 (一社)日本消化器内視鏡学会 2015年04月
  • 大腸鋸歯状病変の内視鏡診断について
    岡崎 能久; 樫田 博史; 櫻井 俊治; 朝隈 豊; 米田 頼晃; 高山 政樹; 峯 宏昌; 足立 哲平; 田中 梨絵; 山田 光成; 岡元 寿樹; 榎本 英介; 前西 修; 筑後 孝章; 木村 雅友; 佐藤 隆夫; 工藤 正俊
    Gastroenterological Endoscopy 57 Suppl.1 829 - 829 (一社)日本消化器内視鏡学会 2015年04月
  • IgG4関連膵胆管病変における内視鏡の役割 自己免疫性膵炎の診断および治療におけるEUSの役割
    大本 俊介; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 57 Suppl.1 706 - 706 (一社)日本消化器内視鏡学会 2015年04月
  • Toshiharu Sakurai; Yoshihisa Okazaki; Yoriaki Komeda; Teppei Adachi; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 148 4 S141 - S141 2015年04月 [査読有り]
  • Toshiharu Sakurai; Norihisa Yada; Tomohiro Watanabe; Tadaaki Arizumi; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    CANCER SCIENCE 106 4 352 - 358 2015年04月 [査読有り]
     
    Most hepatocellular carcinomas (HCCs) develop in the context of chronic liver inflammation. Oxidative stress is thought to play a major role in the pathogenesis of HCC development. In this study, we examined whether cold-inducible RNA-binding protein (Cirp) controls reactive oxygen species (ROS) accumulation and development of HCC by using murine models of hepatocarcinogenesis and human liver samples. Cirp expression, ROS accumulation, and CD133 expression were increased in the liver of tumor-harboring mice. Cirp deficiency reduced production of interleukin-1 and interleukin-6 in Kupffer cells, ROS accumulation, and CD133 expression, leading to attenuated hepatocarcinogenesis. Thioacetamide treatment enhanced hepatic expression of CD133 and phosphorylated signal transducer and activator of transcription 3 (STAT3), which was prevented by treatment with the antioxidant butylated hydroxyanisole. Intriguingly, the risk of human HCC recurrence is positively correlated with Cirp expression in liver. Cirp appears to play a critical carcinogenic function and its expression might be a useful biomarker for HCC risk prediction.
  • Masayuki Kitano; Ken Kamata; Hajime Imai; Takeshi Miyata; Satoru Yasukawa; Akio Yanagisawa; Masatoshi Kudo
    DIGESTIVE ENDOSCOPY 27 60 - 67 2015年04月 [査読有り]
     
    The combination of second-generation ultrasound contrast agents and an endoscopic ultrasonography (EUS) system with a broad-band transducer has allowed contrast-enhanced harmonic imaging in the field of EUS. In contrast-enhanced harmonic EUS (CH-EUS), diffuse homogeneous enhancement is obtained in normal parenchyma of the pancreas. The bile duct and pancreatic duct are depicted as non-enhanced ductal structures with strong contrast in comparison to the surrounding parenchyma. CH-EUS identifies pancreatic adenocarcinomas as solid lesions exhibiting hypo-enhancement with a sensitivity and specificity of 88-96% and 88-94%, respectively. In particular, 80-100% of false-negative cases in endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) are correctly classified by CH-EUS, suggesting CH-EUS complements EUS-FNA. Moreover, CH-EUS improves depiction of some subtle lesions in conventional EUS, thus facilitating EUS-FNA. For quantitative perfusion analysis, a time-intensity curve (TIC) for the region of interest can be generated during CH-EUS. The maximum intensity gain and the echo intensity reduction rate from the peak at 1min obtained by TIC can be used for differentiation of pancreatic adenocarcinoma from other tumors. CH-EUS is also useful for differentiation of invasive intraductal papillary mucinous neoplasms (IPMN) from non-invasive IPMN, identification of malignant lesions in the gallbladder, and T- and N-staging of pancreatobiliary tumors.
  • Toshiharu Sakurai; Hiroshi Kashida; Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Jun Fujita; Masatoshi Kudo
    DIGESTIVE DISEASES AND SCIENCES 60 4 850 - 857 2015年04月 [査読有り]
     
    Aims and Methods Heat shock protein A4 (HSPA4, also called Apg-2), a member of the HSP110 family, regulates the immune response in the gut. Here, we assessed the involvement of HSPA4 in gastric ulcer healing by using fibroblasts from wild-type and HSPA4-deficient mice, a murine gastric ulcer model, and samples from 65 patients with gastric cancer. Results HSPA4 expression was inversely correlated with gastric ulcer healing following endoscopic resection of gastric cancer. In the human gastric mucosa, the expression of HSPA4 was inversely correlated with the expression of stromal cell-derived factor 1 (SDF-1), its cognate receptor CXC chemokine receptor 4(CXCR4), the stromal cell marker vimentin, and the epithelial-mesenchymal transition regulator Twist. HSPA4 was overexpressed in stromal cells as well as in human gastric cancer cells. HSPA4 deficiency increased the expression of SDF-1 and CXCR4, as well as the number of fibroblast-specific protein 1-positive cells, leading to accelerated ulcer healing in the murine gastric ulcer model. Deletion of HSPA4 promoted cell migration in mouse fibroblasts through increased expression of SDF-1 and Twist. Conclusion HSPA4 regulates the expression of SDF-1 and Twist in fibroblasts, thereby controlling gastric ulcer healing.
  • Masatoshi Kudo
    HEPATOLOGY INTERNATIONAL 9 2 155 - 156 2015年04月 [査読有り]
  • 工藤正俊; 上嶋一臣; 久保正二; 坂元亨宇; 田中正俊; 猪飼伊和夫; 古瀬純司; 村上卓道; 角谷眞澄; 國土典宏
    肝臓 56 3 116 - 121 2015年03月 [査読有り][招待有り]
  • 早期慢性膵炎の病態と予後 早期慢性膵炎の診断基準と臨床的意義
    北野 雅之; 門阪 薫平; 工藤 正俊
    日本消化器病学会雑誌 112 臨増総会 A164 - A164 (一財)日本消化器病学会 2015年03月
  • 機能性ディスペプシア診療の現状と将来 機能性ディスペプシア患者における早期慢性膵炎所見について
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 112 臨増総会 A197 - A197 (一財)日本消化器病学会 2015年03月
  • 壊死性膵炎の予後改善を目指した治療の新展開 当院におけるPancreatic fluid collectionに対する治療成績
    山雄 健太郎; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 112 臨増総会 A84 - A84 (一財)日本消化器病学会 2015年03月
  • Tohru Utsunomiya; Mitsuo Shimada; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Tadatoshi Takayama; Norihiro Kokudo
    ANNALS OF SURGERY 261 3 513 - 520 2015年03月 [査読有り]
     
    Objective: To compare the prognostic factors and outcomes after hepatic resection among patients with hepatitis B virus (HBV)-positive, hepatitis C virus (HCV)-positive, and negative for hepatitis B surface antigen and hepatitis Cantibody, so-called "NBNC"-hepatocellular carcinoma (HCC) using the data from a nationwide survey. Background: The incidence of NBNC-HCC is rapidly increasing in Japan. Methods: A total of 11,950 patients with HBV-HCC (n = 2194), HCV-HCC (n = 7018), or NBNC-HCC (n = 2738) who underwent a curative hepatic resection were enrolled in this study. The clinicopathological features were compared among the groups. The significant prognostic variables determined by univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. Results: Liver function in the HCV-HCC group was significantly worse than that in the HBV-HCC and NBNC-HCC groups. The NBNC-HCC group had significantly more advanced HCC than the HCV-HCC group. The 5-year overall survival rates after hepatectomy in the HBV-HCC, HCV-HCC, and NBNC-HCC groups were 65%, 59%, and 68%, respectively. The 5-year recurrence-free survival (RFS) rates in these 3 groups were 41%, 31%, and 47%, respectively. Stratifying the RFS rates according to the TNM stage showed that the NBNC-HCC group had a significantly better prognosis than the HBV-HCC group in stages II, III, and IVA, and a significantly better prognosis than the HCV-HCC group in stages I and II. Multivariate analysis revealed a significantly better RFS rate in the NBNC-HCC group. Conclusions: The findings of this nationwide survey indicated that patients with NBNC-HCC had a significantly lower risk of HCC recurrence than those with HBV-HCC and HCV-HCC.
  • Kitano M; Imai H; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 73 Suppl 3 50 - 54 2015年03月 [査読有り]
  • Kitano M; Kamata K; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 73 Suppl 3 491 - 494 2015年03月 [査読有り]
  • 胆道癌の画像診断: US
    北野雅之; 鎌田 研; 工藤正俊
    日本臨床 73 491 - 494 2015年03月 [査読有り][招待有り]
  • Masahiro Okada; Takamichi Murakami; Norihisa Yada; Kazushi Numata; Minori Onoda; Tomoko Hyodo; Tatsuo Inoue; Kazunari Ishii; Masatoshi Kudo
    JOURNAL OF MAGNETIC RESONANCE IMAGING 41 2 329 - 338 2015年02月 [査読有り]
     
    PurposeTo compare four imaging approaches in cirrhotic estimation; pre-enhancement T1 relaxation time (T1RT), reduction rate (RR) of T1RT, signal-based liver-to-muscle ratio (L/M ratio) on gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), and liver stiffness measurement (LSM) of US elastography. Materials and MethodsConsecutive 58 patients with chronic liver diseases who underwent both Gd-EOB-DTPA-enhanced MRI and FibroScan were analyzed. Four imaging approaches were evaluated by fibrosis score from liver biopsy and receiver operating characteristic (ROC) analysis. ResultsRR was found to be inversely correlated with LSM (r=-0.65). RR decreased with degree of fibrosis (F0-F1, 58.56.2%, versus F2-F3-F4, 48.8 +/- 11.7%, P=0.010, F0-F1-F2, 58.2 +/- 6.2% versus F3-F4, 45.5 +/- 12.3%, P=0.010 and F0-F1, 58.5 +/- 6.2%, versus F2-F3, 52.1 +/- 12.0%, P=0.0038). LSM increased with degree of fibrosis (F0-F1, 5.4 +/- 2.2 kPa versus F2-F3-F3, 19.3 +/- 15.5 kPa, P=0.0011 and F0-F1-F2, 6.8 +/- 3.6 kPa versus F3-F4, 23.8 +/- 17.1 kPa, P=0.0029 and F0-F1, 5.4 +/- 2.2 kPa, versus F2-F3, 11.4 +/- 7.2 kPa, P=0.0098). Area under ROC curves were 0.83 (F3-F4), 0.72 (F2-F3-F4), 0.68 (F2-F3) for RR and 0.83 (F3-F4), 0.88 (F2-F3-F4), 0.81 (F2-F3) for LSM in discriminating between patients with fibrosis. ConclusionThe capability by LSM was better than those by RR of T1RT, pre-enhancement T1RT, and L/M ratio to differentiate F2, but LSM and RR of T1RT showed the same value to differentiate F3. J. Magn. Reson. Imaging 2015;41:329-338.(c) 2013 Wiley Periodicals, Inc.
  • Kiwamu Okita; Namiki Izumi; Osamu Matsui; Katsuaki Tanaka; Shuichi Kaneko; Hisataka Moriwaki; Kenji Ikeda; Yukio Osaki; Kazushi Numata; Kohei Nakachi; Norihiro Kokudo; Kazuho Imanaka; Shuhei Nishiguchi; Takuji Okusaka; Yoichi Nishigaki; Susumu Shiomi; Masatoshi Kudo; Kenichi Ido; Yoshiyasu Karino; Norio Hayashi; Yasuo Ohashi; Masatoshi Makuuchi; Hiromitsu Kumada
    JOURNAL OF GASTROENTEROLOGY 50 2 191 - 202 2015年02月 [査読有り]
     
    Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo-controlled study. Patients with curative therapy were assigned to one of the following regimens: peretinoin 600, 300 mg/day, or placebo for up to 96 weeks. The primary outcome was recurrence-free survival (RFS). Of the 401 patients initially enrolled, 377 patients were analyzed for efficacy. The RFS rates in the 600-mg group, the 300-mg group, and the placebo group were 71.9, 63.6, and 66.0 % at 1 year, and 43.7, 24.9, and 29.3 % at 3 years, respectively. The primary comparison of peretinoin (300 and 600-mg) with placebo was not significant (P = 0.434). The dose-response relationship based on the hypothesis that "efficacy begins to increase at 600 mg/day" was significant (P = 0.023, multiplicity-adjusted P = 0.048). The hazard ratios for RFS in the 600-mg group vs. the placebo group were 0.73 [95 % confidence interval (CI) 0.51-1.03] for the entire study period and 0.27 (95 % CI 0.07-0.96) after 2 years of the randomization. Common adverse events included ascites, increased blood pressure, headache, presence of urine albumin, and increased transaminases. Although the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.
  • Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
    HEPATOLOGY RESEARCH 45 2 123 - 127 2015年02月 [査読有り]
     
    The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine, which was published in October 2013 in Japanese. Here, we briefly describe new or changed recommendations with a special reference to the two algorithms for surveillance, diagnosis, and treatment.
  • Naoki Okumura; Naoko Tsuji; Nobuto Ozaki; Nozomu Matsumoto; Takehisa Takaba; Masanori Kawasaki; Takafumi Tomita; Yasuko Umehara; Satoko Taniike; Masashi Kono; Masatoshi Kudo
    GASTROENTEROLOGY REPORT 3 1 69 - 74 2015年02月 [査読有り]
     
    Background and aims: Peristomal wound infections are common complications of percutaneous endoscopic gastrostomy (PEG). The Funada-style gastropexy device has two parallel needles with a wire loop and suture thread, and was developed about 20 years ago in Japan. This kit has allowed us to perform dual gastropexy very easily; PEG with gastropexy has become a very popular technique in Japan. The present study aimed to compare the advantages and disadvantages of PEG with the gastropexy technique with the standard 'pull' method. Methods: We retrospectively reviewed 182 consecutive, non-randomized patients undergoing PEG in our hospital, and a comparative analysis was made between the gastropexy (87 patients) and non-gastropexy (95 patients) groups. Results: The rates of patients having erythema (11.6% vs. 47.9%; P<0.001), exudates (2.3% vs. 14.9%; P<0.01) and infection (0% vs. 6.4%; P=0.01) in the peristomal area were lower in the gastropexy than in the non-gastropexy group. The rate of minor bleeding from the peristomal area was higher in the gastropexy than in the non-gastropexy group (12.8% vs. 2.1%; P<0.01), but no patient required a blood transfusion. Mean procedure time was longer in the gastropexy group than in the non-gastropexy group (31 vs. 24 min; P<0.001). The 30-day mortality rates were 4.7% and 5.3% respectively, and these deaths were not related to the gastrostomy procedure. Conclusion: PEG with gastropexy markedly reduces peristomal inflammation. Although minor bleeding and a longer procedure time were disadvantages, there were no severe complications. The findings suggested that PEG with Funada-style gastropexy was a safe and feasible method for reducing early complications of PEG.
  • 上嶋 一臣; 工藤 正俊
    日本臨床 73 増刊1 最新肝癌学 737 - 742 (株)日本臨床社 2015年01月
  • Flight Plan for Liverを用いたTACE
    柳生行伸; 鶴﨑正勝; 南 康範; 工藤正俊; 村上卓道
    肝胆膵 70 1 15 - 23 2015年01月 [査読有り]
  • Meeting Report; 第9回国際肝癌学会（ILCA）
    工藤正俊
    The Liver Cancer Journal 7 56 - 59 2015年 [査読有り][招待有り]
  • M. Kudo
    LIVER CANCER 4 4 201 - 207 2015年 [査読有り]
  • M. Kudo
    LIVER CANCER 4 3 I - VII 2015年 [査読有り]
  • M. Kudo
    LIVER CANCER 4 3 163 - 164 2015年 [査読有り]
  • M. Kudo
    LIVER CANCER 4 2 85 - 95 2015年 [査読有り]
  • Yosuke Togashi; Akihiro Kogita; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A. de Velasco; Kazuko Sakai; Yoshihiko Fujita; Shuta Tomida; Masayuki Kitano; Kiyotaka Okuno; Masatoshi Kudo; Kazuto Nishio
    CANCER LETTERS 356 2 819 - 827 2015年01月 [査読有り]
     
    We previously reported that activin produces a signal with a tumor suppressive role in pancreatic cancer (PC). Here, the association between plasma activin A and survival in patients with advanced PC was investigated. Contrary to our expectations, however, patients with high plasma activin A levels had a significantly shorter survival period than those with low levels (median survival, 314 days vs. 482 days, P = 0.034). The cellular growth of the MIA PaCa-2 cell line was greatly enhanced by activin A via non-SMAD pathways. The cellular growth and colony formation of an INHBA (beta subunit of inhibin)overexpressed cell line were also enhanced. In a xenograft study, INHBA-overexpressed cells tended to result in a larger tumor volume, compared with a control. The bodyweights of mice inoculated with INHBA-overexpressed cells decreased dramatically, and these mice all died at an early stage, suggesting the occurrence of activin-induced cachexia. Our findings indicated that the activin signal can promote cancer progression in a subset of PC and might be involved in cachexia. The activin signal might be a novel target for the treatment of PC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
  • Masatoshi Kudo
    LIVER CANCER 4 1 39 - 50 2015年 [査読有り]
     
    Background: Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the third leading cause of cancer-related death worldwide. HCC is most common in Asia, but its prevalence is rapidly increasing in Western countries; consequently, HCC is a global medical issue that urgently needs to be addressed. Japan is the only developed country that has experienced both hepatitis B-related and hepatitis C-related HCC and has a long history of innovation when it comes to new diagnostic and therapeutic modalities, such as computed tomography angiography, anatomical resection, ablation, and transarterial chemoembolization. Among these innovations, a nationwide surveillance program was well established by the 1980s, and such a long-term national program does not exist anywhere else in the world. Summary: More than 60% of the initially detected HCCs in Japan are Barcelona Clinic Liver Cancer stage 0 or A, which can undergo curative therapies such as resection, ablation, or transplantation. The recent 5-year survival rate of HCC patients in Japan was 43% and the median survival time was 50 months. In addition, both incidence and mortality rates are drastically declining as a result of the successful surveillance program, careful diagnostic flow, and extensive repeated treatments. Key Message: Japan's successful model in the surveillance, diagnosis, and treatment of HCC should be adopted as widely as possible to improve the survival of HCC patients worldwide. Copyright (C) 2015 S. Karger AG, Basel
  • Masatoshi Kudo; Tadaaki Arizumi; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida
    DIGESTIVE DISEASES 33 6 751 - 758 2015年 [査読有り]
     
    Intermediate stage hepatocellular carcinoma (HCC) is a very heterogeneous tumor in terms of tumor size (>3 cm similar to over 10 cm), tumor number (4 similar to over 20) and liver function (Child-Pugh score 5-9). However, transarterial chemoembolization is the only recommended treatment option according to the Barcelona Clinic Liver Cancer (BCLC) staging. Bolondi's subclassification of BCLC B stage is feasible; however, there are several weak points. Therefore, by modifying Bolondi's subclassification, we have proposed a more simplified subclassification, Kinki criteria. The Kinki criteria consist of 2 factors: liver function (Child-Pugh score 5-7 or 8, 9) and tumor status (Beyond Milan and within up-to-7 criteria; IN and OUT). The Kinki criteria classifies BCLC B stage from B1 (Child-Pugh score 5-7 and within up-to-7), B2 (Child-Pugh score 5-7 and beyond up-to-7) and B3 (Child-Pugh score 8, 9 and any tumor status). These criteria are simple and easy to apply to clinical practice. Therefore, these criteria will stratify the heterogeneous population of BCLC B group patient well and give the treatment indication according to each substage. These criteria should be further validated both retrospectively and prospectively. (C) 2015 S. Karger AG, Basel
  • Shigeru Yutani; Kazuomi Ueshima; Kazumichi Abe; Atsushi Ishiguro; Junichi Eguchi; Satoko Matsueda; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh; Tetsuro Sasada; Masatoshi Kudo; Masanori Noguchi
    JOURNAL OF IMMUNOLOGY RESEARCH 2015 473909  2015年 [査読有り]
     
    Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus-(HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35-44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination. Results. Forty-two patients were enrolled. Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival. Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction.
  • Masatoshi Kudo
    ONCOLOGY 89 1 - 3 2015年 [査読有り]
  • Yasunori Minami; Masatoshi Kudo
    LIVER CANCER 4 2 106 - 114 2015年 [査読有り]
     
    Tumor response and time to progression have been considered pivotal for surrogate assessment of treatment efficacy for patients with hepatocellular carcinoma (HCC). Recent advancements in imaging modalities such as contrast-enhanced ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) are playing an important role in assessing the therapeutic effects of HCC treatments. According to some HCC clinical guidelines, post-therapeutic evaluation of HCC patients is based exclusively on contrast-enhanced dynamic imaging criteria. The recommended techniques are contrast-enhanced CT or contrastenhanced MRI. Contrast-enhanced US is employed more in the positive diagnosis of HCC than in post-therapeutic monitoring. Although contrast enhancement is an important finding on imaging, enhancement does not necessarily depict the same phenomenon across modalities. We need to become well acquainted with the characteristics of each modality, including not only contrast-enhanced CT and MRI but also contrast-enhanced US. Many nonsurgical treatment options are now available for unresectable HCC, and accurate assessment of tumor response is essential to achieve favorable outcomes. For the assessment of successful radiofrequency ablation (RFA), the achievement of a sufficient ablation margin as well the absence of tumor vascular enhancement is essential. To evaluate the response to transcatheter arterial chemoembolization (TACE), enhanced tumor shrinkage is relied on as a measure of antitumor activity. Here, we give an overview of the current status of imaging assessment of HCC response to nonsurgical treatments including RFA and TACE. Copyright (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Tomohiro Minami; Masashi Kono; Hirokazu Chishina; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    LIVER CANCER 4 4 253 - 262 2015年 [査読有り]
     
    Background and Aims: Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. The aim of this study was to evaluate the superiority of conversion of treatment to sorafenib on overall survival (OS) for cases refractory to TACE. Methods: This was a retrospective cohort study carried out on 497 patients with HCC who were treated with TACE therapy at our hospital between January 2008 and December 2013. Fifty-six patients were diagnosed as refractory to TACE during their clinical course and they were divided into two cohorts, (1) those who switched from TACE to sorafenib and (2) those who continued TACE. The overall survival (OS) after the time of being refractory to TACE was evaluated between the two groups. Results: After refractoriness to TACE therapy was confirmed, 24 patients continued with TACE (TACE-group) and 32 patients underwent treatment conversion to sorafenib (sorafenib-group). The median OS was 24.7 months in the sorafenib-group and 13.6 months in the TACE-group ( p=0.002). Conclusions: Conversion to sorafenib significantly improves the OS in patients refractory to TACE therapy with intermediate-stage HCC. Administration of sorafenib is therefore recommended in such circumstances of TACE treatment failure. Copyright (C) 2015 S. Karger AG, Basel
  • Kazuomi Ueshima; Masatoshi Kudo; Masatoshi Tanaka; Takashi Kumada; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Norihisa Yada; Satoshi Kitai
    LIVER CANCER 4 4 263 - 273 2015年 [査読有り]
     
    We conducted a phase I/II study in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose, as well as the safety and efficacy, of combination therapy of sorafenib with hepatic arterial infusion chemotherapy (HAIC) using low dose cisplatin (CDDP) and 5-fluorouracil (5FU). Cohorts consisting of 3-6 patients with HCC received an escalated dose of CDDP and 5-FU until a maximum-tolerated dose was achieved. The treatment regimen was as follows: oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (14-20 mg/m(2), on days 1 and 8) and 5-FU (170-330 mg/m(2), continuously on days 1-5 and 8-12) via an implanted catheter system). Each treatment cycle consisted of 28 days and three cycles of combination therapy. At the end of the first cycle, adverse events were evaluated and future dose escalation was determined. Eighteen patients with advanced HCC were enrolled. Dose-limiting toxicity was observed in two patients from cohort 1 (erythema multiforme and grade 4 thrombocytopenia) and in one patient from cohort 2 (erythema multiforme). Seven of the 18 patients achieved a partial response, seven showed stable disease, two were diagnosed as progressive disease, and two were not assessable. The response rate was 38.9% and the disease control rate was 77.8%. The time-to-progression was 9.7 months and the 1-year survival rate was 88.2%. Oral administration of 400 mg of sorafenib twice daily, 20 mg/m(2) of intra-arterial infusion of CDDP, and 5-FU at 330 mg/m(2) are the recommended doses for combination therapy, which was well tolerated and efficacious. This combination therapy may be a promising treatment for patients with advanced HCC. Copyright (C) 2015 S. Karger AG, Basel
  • 上嶋一臣; 工藤正俊
    腫瘍内科 15 6 603 - 607 (有)科学評論社 2015年 [査読有り]
  • 肝細胞癌ステージングシステムと進行肝癌診療. 特集「進行肝細胞癌の治療戦略」
    北井 聡; 上嶋一臣; 工藤正俊
    臨床消化器内科 30 1019 - 1026 2015年 [査読有り]
  • Kentaro Yamao; Masayuki Kitano; Masatoshi Kudo; Osamu Maenishi
    ENDOSCOPY 47 E596 - E597 2015年 [査読有り]
  • 胆管ドレナージ（MS）. 特集「ERCPマスターへのロードマップ」
    北野雅之; 今井 元; 山雄健太郎; 鎌田 研; 宮田 剛; 三長孝輔; 大本俊介; 門阪薫平; 松田友彦; 工藤正俊
    胆と膵 36 969 - 974 2015年 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    World Journal of Hepatology 7 23 2427 - 2431 2015年 [査読有り]
     
    The ideal goal of chronic hepatitis B (CHB) treatment should be suppression of emergence of hepatocellular carcinoma through the disappearance of hepatitis B s antigen (HBsAg) rather than the control of serum hepatitis B virus-DNA level. For this purpose, various types of combination therapies using nucleoside analogs (NAs) and interferon (IFN) have been conducted. The therapeutic effects of combination of two different kinds of agents are better than those of the monotherapy using NAs or IFN alone, probably because different pharmaceutical properties might act in a coordinated manner. Recently, combination therapies with NAs and IFN and sequential therapies with NAs administration followed by IFN therapy have been routinely employed. We previously reported that combination therapy using entecavir (ETV) and pegylated (PEG)-IFN showed antiviral effects in 71% of CHB patients the effect of this combination was better than that using lamivudine (LAM) and PEG-IFN. This is partially explained by the better antiviral effects of ETV than those of LAM. In our analysis, the cohort of CHB consisted of the patients who showed a flare-up of hepatitis before antiviral therapy, and their baseline HBsAg levels were relatively low. Therefore, in addition to the combination of the agents, the appropriate selection of patients is critical to achieve a good viral response.
  • Soo Ki Kim; Soo Ryang Kim; Susumu Imoto; Madoka Tohyama; Yumi Otono; Tomoko Tamura; Ke Ih Kim; Mana Kobayashi; Aya Ohtani; Kayo Sugimoto; Aya Mizuguchi; Yukiko Hiramatsu; Masatoshi Kudo
    ONCOLOGY 89 60 - 69 2015年 [査読有り]
     
    At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (Asian Pacific Association for the Study of the Liver) guidelines. The use of pegylated interferon-alpha (PEG IFN-alpha) is recommended as the first-line therapy instead of standard IFN-alpha according to the above 3 guidelines. In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-alpha; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by EN and IFN treatment. The results are as follows: (1) both EN and TDF showed long-term efficacy and safety; (2) PEG IFN-alpha resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion;(3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (EN especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by EN and IFN. (C) 2015 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Kazuomi Ueshima; Hiroshi Ida; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 89 53 - 59 2015年 [査読有り]
     
    Objective: The aim of this study was to prospectively assess the usefulness of the reliability index, namely the percentage of the net amount of effective shear wave velocity (VsN). Methods: One hundred and sixty-eight patients with chronic liver disease, who underwent ultrasound elastography, were consecutively enrolled. Shear wave measurement (SWM), FibroScan, virtual touch quantification, and shear wave elastography were performed for all patients, and the variations in the measurement results were compared with VsN. The absolute average value of the difference between SWM_Vs and Vs measured using other elastography devices is termed vertical bar Delta Vs vertical bar. VsN was classified into three groups: 50, <50, and 0 (failure measurement). In these groups, there was a significant difference in abdominal circumference, body mass index, the distance between the ultrasound probe surface and the liver, and vertical bar Delta Vs vertical bar. When the distance between the ultrasound probe surface and the liver was >2cm, VsN tended to be significantly lower (p < 0.001). Results: When VsN was <50, bVsI became high, and there was variation in the results between each device. Conclusions:The results of this study show that VsN is a useful value to decide whether Vs is appropriate or not. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 89 47 - 52 2015年 [査読有り]
     
    Introduction: Barcelona Clinic Liver Cancer (BCLC) stage B, an intermediate stage, includes various conditions of hepatocellular carcinoma (HCC). This heterogeneity of the patients with intermediate-stage HCC makes it difficult to predict their survival rates. In the present study, we examined the validity of the modified Bolondi classification (Kinki criteria) as a subclassification of patients with BCLC stage B HCC. Methods: Of 906 patients who underwent conventional transarterial chemoembolization at Kinki University Hospital, 753, who met the inclusion criteria, were examined. Of these 753 patients, 425 (56.4%) with BCLC stage B were subclassified using the Kinki criteria to examine the survival rate. Results: According to the Kinki criteria, 158 (37.2%) were subclassified into subclass B1,236 (55.53) into B2, and 31(7.3%) into B3. The comparison of the survival rates showed that the median overall survival was 3.9 years (95% CI, 3.2-4.6) in the BCLC subclass B1 group, 2.5 years (95% Cl, 2.2-3.1) in the B2 group, and 1.1 years (95% Cl, 0.6-1.5) in the B3 group (p < 0.001). Conclusion: When the BCLC stage B patients were subclassified according to the Kinki criteria, survival curves were stratified with significant differences, suggesting that the Kinki criteria were suitable for the subclassification of the intermediate-stage HCC patients. (C) 2015 S. Karger AG, Basel
  • Kayo Sugimoto; Soo Ryang Kim; Soo Ki Kim; Susumu Imoto; Madoka Tohyama; Ke Ih Kim; Aya Ohtani; Takashi Hatae; Yoshihiko Yano; Masatoshi Kudo; Yoshitake Hayashi
    ONCOLOGY 89 42 - 46 2015年 [査読有り]
     
    Objectives:The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC). The levels of alanine aminotransferase (ALT) and a-fetoprotein (AFP) as suppressive markers of HCC were also measured. Methods: Patients received daclatasvir and asunaprevir (n = 17), simeprevir plus PEG-IFN/RBV (n = 15) and telaprevir plus PEG-IFN/RBV (n = 25). Sustained virological response (SVR) and the mean change in the level of serum ALT, AFP and platelet (PLT) count were compared among the three groups. Results: No difference in SVR was observed in patients given daclatasvir with asunaprevir (SVR4), telaprevir plus PEGIFN/RBV or simeprevir plus PEG-IFN/RBV (SVR24). Also, no significant difference was observed in the mean change of serum ALT, AFP or PLT count among the three groups. Conclusion: The preventive effect of the IFN-free,all-oral regimen of daclatasvir and asunaprevir was observed with a focus on the occurrence and recurrence of HCC, as was IFN-based treatment with telaprevir or simeprevir plus PEG-IFN/RBV. (C) 2015 S. Karger AG, Basel
  • Hitoshi Tochio; Masafumi Sugahara; Yukihiro Imai; Hiroshi Tei; Yoshiyuki Suginoshita; Nobuhiro Imawsaki; Ichiro Sasaki; Michio Hamada; Kazushi Minowa; Tetsuo Inokuma; Masatoshi Kudo
    ONCOLOGY 89 33 - 41 2015年 [査読有り]
     
    Aim: A hyperenhanced rim (termed 'HER') in the postvascular phase is detected in some cases of liver metastasis by Sonazoid-enhanced ultrasonography (US). Here, the association of the HER with histological features was investigated to clarify the cause of this characteristic imaging pattern. Subjects and Methods: A total of 13 hepatic nodules obtained from 11 patients with metastatic liver cancer who underwent Sonazoid-enhanced US followed by surgical resection were analyzed. The distribution density of CD68-positive cells in the tumor rim and the nontumor area was calculated and compared between the HER-positive and HER-negative groups. The relation between the pathological features of the tumor rim and the rate of necrosis within the tumor was also investigated. Results: In the HER-positive group (n = 8), the distribution density of CD68-positive cells was 2.9 +/- 0.9, which was significantly higher than that (1.0 +/- 0.3) in the HER-negative group (p < 0.05). Inflammatory cell infiltrates, including CD8-positive lymphocytes, were detected in all the HER-positive cases in the area surrounding the tumor, while fibrosis was observed in all the HER-negative cases. The necrotic area within the tumor was significantly larger in the HER-negative group. Conclusion: The HER-positive sign in liver metastases could reflect an increase in Kupifer cells in the tumor rim. The presence of the HER was associated with inflammatory cell infiltrates including CD8-positive lymphocytes surrounding the metastatic liver tumor. (C) 2015 S. Karger AG, Basel
  • Yasunori Minami; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Masakatsu Tsurusaki; Yukinobu Yagyu; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
    ONCOLOGY 89 27 - 32 2015年 [査読有り]
     
    Objective: To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to overcome inferior local control. Materials and Methods: We studied 27 patients with HCC, including single to uncountable multiple lesions, who underwent b-TACE between August 2013 and April 2015. Dynamic CT was performed at baseline and 1-3 months after b-TACE. The treatment effect (TE) after b-TACE was evaluated using the Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan. Results: In the countable HCC group, contrast-enhanced CT demonstrated RECICL TE4 in 43.8% (14/32), TE3 in 12.5% (4/32), TE2 in 37.5% (12/32), and TEl in 6.3% (2/32) of patients. For the TACE-naive cohort, the objective response rate was 52.9%. The objective response rate was 60% for the previously lACE-treated cohort. In the uncountable multiple HCC group, the objective response rate was 0% (0/10), with progressive disease in 90% (9/10) of patients. Conclusion: Our observations suggested that b-TACE did not reduce the efficacy of retreatment for HCC with an insufficient outcome from conventional TACE, but it could not improve the efficacy of treatment for uncountable multiple HCCs. (C) 2015 S. Karger AG, Basel
  • Kazuya Kariyama; Akiko Wakuta; Mamoru Nishimura; Masayuki Kishida; Ayano Oonishi; Atsushi Ohyama; Kazuhiro Nouso; Masatoshi Kudo
    ONCOLOGY 89 19 - 26 2015年 [査読有り]
     
    Objectives: Radiofrequency ablation plays a key role in the treatment of early-stage hepatocellular carcinoma. However, it is not recommended for intermediate-stage hepatocellular carcinoma. The objective of this study was to clarify the efficacy and safety of radiofrequency ablation for treating intermediate-stage hepatocellular carcinoma. Methods: We examined the outcome of 65 consecutive patients who were treated with radiofrequency ablation with or without transarterial chemoembolization for intermediate-stage hepatocellular carcinoma. Results: With a median follow-up of 37 months, overall survival rates of 65 cases at 1,3,5, and 7 years were 90, 70,51, and 36%, respectively. Multivariate analysis of clinical parameters revealed that the multicentric occurrence (MC)/intrahepatic metastasis (IM) was the only significant prognostic factor for overall survival (hazard ratio, 4.9; 95% confidence intervals, 2.1-11.4). Tumor size and tumor number were not significant factors for survival. The overall survival rates of patients with MC (n = 33) at 1, 3, 5, and 7 years were 97, 90, 80, and 59%, respectively; those for patients with IM (n = 32) were 86, 55, 14, and 8%, respectively (p < 0.0001). Two cases (4.9%) had complications of hemothorax and diaphragmatic burn; however, no major complications were observed. Conclusion: Radiofrequency ablation is safe and effective for the treatment of intermediate-stage hepatocellular carcinoma, especially for patients with MC. (C) 2015 S. Karger AG, Basel
  • Chikara Ogawa; Yasunori Minami; Turuyo Noda; Soichi Arasawa; Masako Izuta; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsunari Shibatoge; Masatoshi Kudo
    ONCOLOGY 89 11 - 18 2015年 [査読有り]
     
    Purpose: We report the efficacy of percutaneous ultrasound (US) examination using a novel real-time virtual sonography (RVS) method that collates multiple Digital Imaging and Communications in Medicine (DICOM) data sources and displays reference images in color. Materials and Methods: A total of 7 patients with 9 hepatocellular carcinomas were evaluated. Using the SYNAPSE VINCENT volume analyzer, DICOM data of the portal vein, hepatic vein, tumor, and hepatic segment were isolated from contrast-enhanced computed tomography DICOM data. Each portion of DICOM data was uploaded into an US scanner (HI VISION Ascendus, Hitachi Aloka Medical Ltd., Tokyo, Japan) and unified on a US platform to create a single reference image. Each uploaded portion of DICOM data was assigned a different color. Further, conventional RVS was performed using this information. Results: The maximal tumoral diameter ranged from 6.4 to 15 mm (mean +/- SD, 11.0 +/- 2.8). DICOM data could be isolated, enabling the display of color RVS in all patients. Color RVS facilitated superior visibility compared with conventional grayscale RVS and facilitated the comprehension of spatial positioning. Conclusion: RVS with color display demonstrates utility in increasing operator comprehension of spatial and positional relationships during percutaneous US examination. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakural; Naoshi Nishida; Masayuki Kitano; Masatoshi Kudo
    ONCOLOGY 89 4 - 10 2015年 [査読有り]
     
    Objective: Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. The Assessment for Retreatment with TACE (ART) scoring system was recently proposed for identifying patients who would not show sufficient survival benefit from repeated TACE. We reevaluated the performance of ART in HCC patients treated in Japan, where selective TACE is commonly used. Methods: Between 2000 and 2013, 988 patients with HCC underwent TACE at Kinki University Hospital, and 627 received >= 2 sessions of TACE. Seventy-six patients who underwent >= 2 TACE sessions within 90 days were investigated for their performance of the ART score in the context of overall survival (OS). Results: Only 12% (76/627) of patients underwent >= 2 TACE sessions within 90 days. Of those, 52 patients showed a low ART score (0-1.5), and 24 had a high ARTscore (>= 2.5); the median OS was 20.2 and 37.6 months, respectively (p = 0.8207). Conclusion:The ART scoring system did not demonstrate a sufficiently predictive impact on OS among the patients who underwent 2 TACE sessions within 90 days. Application of the ART score should be carefully considered because differences in TACE procedures and post-TACE treatment can affect the results while evaluating OS. (C) 2015 S. Karger AG, Basel
  • Masatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida
    DIGESTIVE DISEASES 33 6 780 - 790 2015年 [査読有り]
     
    Challenges of clinical practice and research on hepatocellular carcinoma (HCC) were reviewed. There are several differences in clinical practice between Japan and the Western countries such as tumor markers, understanding of pathological early HCC, imaging diagnosis, treatment strategy, staging system and subclassification of HCC. Further studies are warranted for the clinical practices of Japan to be adopted in the rest of the world. (C) 2015 5. Karger AG, Basel
  • Naoshi Nishida; Masayuki Kitano; Toshiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 771 - 779 2015年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage. Many molecular targeted agents are being developed for the treatment of advanced HCC; however, the only promising drug to have been developed is sorafenib, which acts as a multi-kinase inhibitor. Unfortunately, a subgroup of HCC is resistant to sorafenib, and the majority of these HCC patients show disease progression even after an initial satisfactory response. To date, a number of studies have examined the underlying mechanisms involved in the response to sorafenib, and trials have been performed to overcome the acquisition of drug resistance. The anti-tumor activity of sorafenib is largely attributed to the blockade of the signals from growth factors, such as vascular endothelial growth factor receptor and platelet-derived growth factor receptor, and the downstream RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade. The activation of an escape pathway from RAF/MEK/ERK possibly results in chemoresistance. In addition, there are several features of HCCs indicating sorafenib resistance, such as epithelial-mesenchymal transition and positive stem cell markers. Here, we review the recent reports and focus on the mechanism and prediction of chemoresistance to sorafenib in HCC. (C) 2015 S. Karger AG, Basel
  • Masatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida
    DIGESTIVE DISEASES 33 6 765 - 770 2015年 [査読有り]
     
    This review outlines the significance of establishing general rules, a nationwide follow-up survey, and clinical practice guidelines for liver cancer in Japan. The general rules are an essential part of hepatocellular carcinoma (HCC) treatment, enabling a 'common language' to be used in daily clinical practice and for the nationwide follow-up survey. The Japanese General Rules for the Clinical and Pathological Study of Primary Liver Cancer, which provide detailed descriptions of HCC, are excellent and are unique to Japan. Items in the General Rules for the Clinical and Pathological Study of Primary Liver Cancer are used substantially in another important project, the Nationwide Follow-Up Survey of Primary Liver Cancer, which has been rigorously undertaken with great effort by the Liver Cancer Study Group of Japan biannually since 1969. Both evidence-based and consensus-based treatment algorithms for HCC are used to complement each other in clinical practice in Japan. (C) 2015 S. Karger AG, Basel
  • Yasunori Minami; Takamichi Murakami; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 759 - 764 2015年 [査読有り]
     
    Cone-beam CT (CBCT) is generated during a rotational sweep of the C-arm around the patient, and can be a valuable imaging technique, providing in situ cross-sectional imaging. It is easy to evaluate the morphologic characteristics of hepatic arteries from multiple views with the use of various reconstruction techniques, such as maximum intensity projection (MIP) and volume rendering. CBCTangiography is capable of providing more information than the standard 2-dimensional angiography in visualizing hepatocellular carcinomas (HCCs) and targeting tumors though precise microcatheter placement in close proximity to HCCs. It can also be useful in evaluating treatment success at the time of the procedure. It is anticipated that CBCT could reduce radiation exposure, the overall procedure time and contrast material use because it allows immediate feedback for an efficient angiographic procedure. Therefore, CBCT angiography is an exciting technology with the potential to significantly impact the practice of interventional radiology. The purpose of this article is to provide a review of the principles, clinical applications and technique of CBCT angiography for HCC treatment. (C) 2015 S. Karger AG, Basel
  • Naoshi Nishida; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshirna; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 745 - 750 2015年 [査読有り]
     
    Objectives: Several studies revealed that the proportion of hepatocellular carcinoma (HCC) without hepatitis virus infection (NBNC-HCC) is increasing. On the other hand, epigenetic alterations are reportedly responsible for HCC development. Here, we identified HCC risk factors that are associated with DNA methylation in the background liver tissue of NBNC-HCC patients. Methods: We performed methylation analysis in 37 pairs of virus-positive and 22 pairs of NBNC-HCC and non-cancerous livers using a HumanMethylation450 BeadChip array. After the selection of differentially methylated CpGs (DM-CpGs) in cancerous and non-cancerous livers, we analyzed DNA methylation of DM-CpGs within the adjacent non-cancerous liver tissue that is affected by specific HCC risk factors. Results: A total of 38,331 CpGs were selected as DM-CpGs using the following criteria: difference of beta-value between HCC and non-cancerous liver and false discovery rate (FDR) q < 1.0E-12. We subsequently selected the DM-CpGs that had methylation differences with the background liver tissue (that has FDR q < 0.35). Among the virus-positive patients, the type of hepatitis virus was mostly associated with differences in methylation within the background liver tissues. However, we found that background methylation patterns were most significantly associated with aging in NBNC patients. Interestingly, age-related methylation differences in DM-CpGs were also observed in NBNC-HCC tissues. Conclusions: Hepatitis viruses affect the methylation profiles within background liver tissues. However, difference in background methylation was mostly associated with age in NCBC-HCC patients; some age-related methylation events could contribute to emergence of NBNC-HCC in elderly individuals. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masayuki Kitano; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 728 - 734 2015年 [査読有り]
     
    Objectives: Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III trials. We examined efficacy and adverse events (AEs) in patients treated with sorafenib over a 6-year period since approval in Japan. Methods: Two hundred and forty-one patients treated with sorafenib at the Kinki University Hospital were retrospectively analyzed clinically for the factors related to survival periods, tumor response evaluated by the Response Evaluation Criteria In Cancer of the Liver (RECICL) and AEs. Results: OS was 14.3 months. According to the RECICL, the objective response and disease control rates were 18.6% (43 of 241) and 61.1% (137 of 241), respectively. AEs were seen in 77.3% (187 of 241), with Grade 3 or higher in 23.6% (57 of 241). The most frequent AE was hand-foot skin reaction in 109 patients (45.0%), and 28 patients (11.8%) showed Grade 3 or higher. Significant factors contributing to the OS were treatment duration (p = 0.0204), up-to-7 criteria (p = 0.0400), increase of Child-Pugh score (p = 0.0008) and tumor response determined by the RECICL (p = 0.0007). Conclusion: Based on the analysis, using many cases at a single center, we concluded that continuation of treatment with sorafenib for >= 90 days without decrease of liver function was critical if tumor response was determined as stable disease or higher. (C) 2015 S. Karger AG, Basel
  • Kayo Sugimoto; Soo Ryang Kim; Susumu Imoto; Madoka Tohyama; Soo Ki Kim; Toshiyuki Matsuoka; Yoshihiko Yano; Masatoshi Kudo; Yoshitake Hayashi
    DIGESTIVE DISEASES 33 6 721 - 727 2015年 [査読有り]
     
    Objectives: The characteristics of hypovascular and hypervascular well-differentiated hepatocellular carcinomas (HCCs) were compared in terms of tumor size, tumor markers and detectability by imaging modalities. Methods: Well-differentiated HCC nodules that are smaller than 2 cm (n = 27) were evaluated in 27 patients using histopathology and divided into 2 groups: hypovascular (n = 10) and hypervascular (n = 17). The diagnostic sensitivity of imaging modalities was then evaluated for efficiency in disclosing tumor size and tumor markers in the 2 types. Results: No difference was observed in tumor size and tumor markers between the 2 types; however, the sensitivity of contrast-enhanced CT, contrast-enhanced ultrasonography and arterioportal angiography was significantly different between the 2 types, whereas that by Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging (Gd-EOB-DTPA MRI) demonstrated no difference. Conclusion: Hypovascular HCC could be diagnosed by Gd-EOB-DTPA MRI in the hepatobiliary phase. (C) 2015 S. Karger AG, Basel
  • Yutaka Hasegawa; Soo Ryang Kim; Takashi Hatae; Mitsuhiro Ohta; Aya Fujinami; Kayo Sugimoto; Ke Ih Kim; Susumu Imoto; Madoka Tohyama; Soo Ki Kim; Yoshihiro Ikura; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 715 - 720 2015年 [査読有り]
     
    Objective:The aim of this study was to evaluate cytokeratin-18M65 (CK-18M65) for distinguishing between simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) against healthy individuals (HIs) in Japanese population. Methods: The serum from 24 HIs, 21 patients with SS and 20 patients with NASH were examined. Serum CK-18M65 was measured by enzyme-linked immunosorbent assay. Results: Aspartate aminotransferase was significantly different between NASH patients and HIs with p < 0.0001 (SS patients and HIs: p < 0.0001), as was alanine aminotransferase between NASH patients and HIs with p < 0.0001 (SS patients and HIs: p < 0.0001). Serum CK-18M65 increased in a stepwise fashion in HIs and also in SS and NASH patients. Multivariate logistic regression analysis revealed that NASH could be diagnosed with the use of CK-18M65 alone (p = 0.0285, OR 1.0038, 95% CI 1.0004-1.0073). At the optimal cut-off level of 548 U/I, CK-18M65 had an AUC value of 0.7369,60.00% sensitivity and 85.70% specificity. In patients with NASH, no significant difference was observed between low fibrosis (Stage 0-1, 794.30 +/- 454.41, n = 10) and high fibrosis (Stage 2-3, 809.70 +/- 641.43, n = 10; p = 0.5967) and between slight steatosis (<33%, 512.89 +/- 229.65, n = 9) and moderate steatosis (>= 33%,655.13 +/- 480.78, n = 32) in patients with non-alcoholic fatty liver disease (NAFLD; p = 0.7647) with the use of CK-18M65. Conclusion: Serum CK-18M65 distinguished NASH from SS, but could not assess the severity of steatosis in NAFLD patients or the grade of fibrosis in NASH patients in Japanese population. (C) 2015 S. Karger AG, Basel
  • Naoshi Nishida; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 708 - 714 2015年 [査読有り]
     
    Objectives: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naive cases and relapsers to prior PEG-IFN/RBV therapy. Here, we retrospectively analyzed the antiviral response associated with a triple regimen, in the context of early reduction of viral load during treatment. Methods: Forty-six CHC patients with HCV genotype 1b were treated with PEG-IFN/RBV/SMV triple therapy: 20 were naive cases, 12 were relapsers and 14 were non-responders to prior PEG-IFN/RBV therapy. We evaluated rapid virological response (RVR), complete early virological response (EVR), viral clearance at the end of the treatment (EOT) and at 12 weeks after the EOT (SVR12). In addition, we quantified the serum HCV-RNA on the 1st day and the 7th day after initiating treatment. Results: Multivariate analysis revealed that response to prior treatment was identified as an independent factor for achieving SVR12 after triple therapy (p = 0.0005). The achievement of serum HCV-RNA <2 log(10) IU/ml on day 7, RVR, EVR and EOT were associated with SVR12 (p = 0.0050, p = 0.0002, p = 0.0009 and p = 0.0002, respectively). Conclusions: Rapid decline of HCV is a predictive factor for the achievement of SVR12, even in antiviral triple therapy with PEG-IFN/RBV/SMV. An extended treatment period should be applied for patients who show detectable serum HCV-RNA at week 4. (C) 2015 S. Karger AG, Basel
  • Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 705 - 707 2015年 [査読有り]
  • 膵嚢胞性疾患と膵癌. 特集「消化器癌予防up-to-date」
    鎌田 研; 北野雅之; 工藤正俊
    臨床消化器内科 30 1451 - 1456 2015年 [査読有り][招待有り]
  • 今井 元; 北野雅之; 大本俊介; 門阪薫平; 宮田 剛; 鎌田 研; 三長孝輔; 松田友彦; 山雄健太郎; 工藤正俊
    胆と膵 36 8 779 - 783 医学図書出版(株) 2015年 [査読有り][招待有り]
     
    「急性胆管炎・胆嚢炎診療ガイドライン2013」において急性胆嚢炎に対するドレナージ治療の一つとして、EUS下吸引生検術を応用したEUS下胆嚢ドレナージ術(EUS-GBD)がある。胃前庭部もしくは十二指腸球部より胆嚢を穿刺し、穿刺後に胆嚢内を生理食塩水にて洗浄する。続いてガイドワイヤーを留置し穿刺孔を拡張する。最後に両端ピッグテイルステントもしくは金属カバーステントを留置する。症例報告ではあるが、手技成功率は97〜100%、臨床症状改善率は100%と概ね良好な結果が得られており、今後、経皮的経肝胆嚢ドレナージ術、経乳頭的胆嚢ドレナージ術と同等の治療効果が期待できる方法として注目される手技である。(著者抄録)
  • 肝癌根治的治療後の再発の早期発見
    工藤正俊; 泉 並木; 金子周一
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 168 - 170 2015年 [査読有り][招待有り]
  • 肝癌治療後の再発抑制治療
    泉 並木; 工藤正俊; 金子周一
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 166 - 167 2015年 [査読有り][招待有り]
  • 肝癌全体の治療アルゴリズム
    工藤正俊; 國土典宏; 川崎誠治; 松井 修; 泉 並木
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 146 - 150 2015年 [査読有り][招待有り]
  • 肝動注化学療法と分子標的治療をどう使い分けるか
    工藤正俊; 小尾俊太郎; 山下竜也
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 144 - 146 2015年 [査読有り][招待有り]
  • TACE不応例に対する治療指針
    工藤正俊; 松井 修; 角谷眞澄
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 140 - 143 2015年 [査読有り][招待有り]
  • 全身化学療法と分子標的治療
    上嶋一臣; 工藤正俊
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 132 - 135 2015年 [査読有り][招待有り]
  • 造影超音波下RFA
    南 康範; 工藤正俊
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 91 - 93 2015年 [査読有り][招待有り]
  • 肝癌診療のためのステージングシステム
    工藤正俊
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 74 - 77 2015年 [査読有り][招待有り]
  • 乏血性肝細胞癌性結節（境界病変, 異型結節, 早期肝癌）はどのような場合に治療すべきか
    工藤正俊; 泉 並木; 角谷眞澄; 松井 修
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 66  2015年 [査読有り][招待有り]
  • 肝細胞癌の診断アルゴリズム
    工藤正俊; 泉 並木; 角谷眞澄; 松井 修
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 62 - 66 2015年 [査読有り][招待有り]
  • 早期肝癌の画像的特徴
    松井 修; 工藤正俊; 今井康陽; 中島 収; 坂元亨宇
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 58 - 61 2015年 [査読有り][招待有り]
  • どのようなときに造影超音波を行うか
    工藤正俊
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 52 - 58 2015年 [査読有り][招待有り]
  • どのようなときにGd-EOB-DTPA造影MRIを行うか
    工藤正俊; 今井康陽; 村上卓道
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 47 - 50 2015年 [査読有り][招待有り]
  • 肝癌早期発見のためのスクリーニング法
    建石良介; 泉 並木; 金子周一; 工藤正俊
    肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 35 - 37 2015年 [査読有り][招待有り]
  • BCLC Stage B (Intermediate stage) の細分類と治療選択. 特集「肝がん診療ガイドライン: どうする治療選択」
    工藤正俊
    肝胆膵 71 321 - 327 2015年 [査読有り][招待有り]
  • 鼎談「肝細胞癌に対するTACE再考」
    工藤正俊; 松井 修; 田中正俊
    肝胆膵 70 141 - 158 2015年 [査読有り][招待有り]
  • Intermediate stagの多様性. 特集「肝細胞癌に対するTACE再考」
    南 康範; 工藤正俊
    肝胆膵 70 33 - 38 2015年 [査読有り]
  • TACE不応基準をめぐって（日本肝癌研究会2014年改訂版）. 特集「肝細胞癌に対するTACE再考」
    工藤正俊
    肝胆膵 70 81 - 88 2015年 [査読有り][招待有り]
  • 膵腫瘍性病変における造影US（体外式）による鑑別診断
    大本俊介; 北野雅之; 前川 清; 工藤正俊
    胆と膵 36 685 - 389 2015年 [査読有り]
  • 第5章 肝がん診療ガイドライン
    工藤正俊
    最新医学別冊「診断と治療のABC 103 肝がん」 186 - 194 2015年 [査読有り][招待有り]
  • 眼で見る肝がん
    工藤正俊
    最新医学別冊「診断と治療のABC 103 肝がん MAP」 7 - 10 2015年 [査読有り][招待有り]
  • 肝癌に対する分子標的治療: 期待と展望. 特集「消化器癌の分子標的治療」
    上嶋一臣; 工藤正俊
    細胞 47 9 14 - 17 2015年 [査読有り][招待有り]
  • EUS-FNAによる膵嚢胞性腫瘍診断. 特集「胆膵EUS-FNAのエビデンス2015-この5年間の進歩-」
    鎌田 研; 北野雅之; 安川 覚; 柳澤昭夫; Bertrand Napoleon; 工藤正俊
    胆と膵 36 315 - 318 2015年 [査読有り]
  • 座談会 肝胆膵イメージング: 画像が映す分子病理
    全 陽; 角谷眞澄; 工藤正俊; 多田 稔
    肝臓 70 629 - 642 2015年 [査読有り][招待有り]
  • 早期慢性膵炎のEUSが反映する微細所見. 特集「肝胆膵イメージング: 画像が映す分子病理」
    門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    肝胆膵 70 601 - 608 2015年 [査読有り]
  • 松井繁長; 樫田博史; 工藤正俊
    日本門脈圧亢進症学会雑誌 21 19 - 25 2015年 [査読有り][招待有り]
  • 膵腫瘍の画像診断: US
    北野雅之; 今井 元; 工藤正俊
    日本臨床 73 50 - 54 2015年 [査読有り][招待有り]
  • Naoshi Nishida; Masatoshi Kudo
    Annals of Translational Medicine 3 1 1  2015年01月 [査読有り]
  • Calin Cainap; Shukui Qin; Wen-Tsung Huang; Ik Joo Chung; Hongming Pan; Ying Cheng; Masatoshi Kudo; Yoon-Koo Kang; Pei-Jer Chen; Han-Chong Toh; Vera Gorbunova; Ferry A. L. M. Eskens; Jiang Qian; Mark D. McKee; Justin L. Ricker; Dawn M. Carlson; Saied El-Nowiem
    JOURNAL OF CLINICAL ONCOLOGY 33 2 172 - U77 2015年01月 [査読有り]
     
    Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. Patients and Methods Patients were randomly assigned in a 1: 1 ratio to linifanib 17.5 mg once daily or sorafenib 400 mg twice daily. Patients were stratified by region (Outside Asia, Japan, and rest of Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 or 1), vascular invasion or extrahepatic spread (yes or no), and hepatitis B virus (HBV) infection (yes or no). The primary end point of the study was overall survival (OS). Secondary end points were time to progression (TTP) and objective response rate (ORR) per RECIST v1.1. Results We randomly assigned 1,035 patients (median age, 60 years; Asian, 66.6%; ECOG PS 0, 65.2%; HBV, 49.1%; vascular invasion or extrahepatic spread, 70.1%). Median OS was 9.1 months on the linifanib arm (95% CI, 8.1 to 10.2) and 9.8 months on the sorafenib arm (95% CI, 8.3 to 11.0; hazard ratio [HR], 1.046; 95% CI, 0.896 to 1.221). For prespecified stratification subgroups, OS HRs ranged from 0.793 to 1.119 and the 95% CI contained 1.0. Median TTP was 5.4 months on the linifanib arm (95% CI, 4.2 to 5.6) and 4.0 months on the sorafenib arm (95% CI, 2.8 to 4.2; HR, 0.759; 95% CI, 0.643 to 0.895; P = .001). Best response rate was 13.0% on the linifanib arm versus 6.9% on the sorafenib arm. Grade 3/4 adverse events (AEs); serious AEs; and AEs leading to discontinuation, dose interruption, and reduction were more frequent with linifanib (all P = .001). Conclusion Linifanib and sorafenib had similar OS in advanced HCC. Predefined superiority and non-inferiority OS boundaries were not met for linifanib and the study failed to meet the primary end point. TTP and ORR favored linifanib; safety results favored sorafenib. (C) 2014 by American Society of Clinical Oncology
  • 上嶋一臣; 工藤正俊
    Pharma Medica 33 1 21 - 23 (株)メディカルレビュー社 2015年 [査読有り][招待有り]
  • M. Kudo
    LIVER CANCER 4 1 1 - 5 2015年 [査読有り]
  • 編集: 日本臨床増刊号 最新肝癌学
    工藤正俊
    2015年 [査読有り]
  • Cone-beam CT angiography（tracking navitation imagingも含めて）
    南 康範; 村上卓道; 工藤正俊
    最新肝癌学 73 579 - 581 2015年 [査読有り]
  • 肝細胞癌の治療アルゴリズム
    井上達夫; 工藤正俊
    最新肝癌学 73 457 - 463 2015年 [査読有り]
  • 取扱い規約・診療ガイドラインを作成する意義
    工藤正俊
    最新肝癌学 73 443 - 446 2015年 [査読有り]
  • 発癌予測バイオマーカーとしてのエピゲノム変化
    萩原 智; 西田直生志; 工藤正俊
    最新肝癌学 73 403 - 407 2015年 [査読有り]
  • 超音波elastography（strain法）
    矢田典久; 工藤正俊
    最新肝癌学 73 367 - 371 2015年 [査読有り]
  • TNM stage、統合ステージングシステム
    北井 聡; 工藤正俊
    最新肝癌学 73 328 - 333 2015年 [査読有り]
  • 癌遺伝子と癌抑制遺伝子
    西田直生志; 工藤正俊
    最新肝癌学 73 164 - 169 2015年 [査読有り]
  • 肝細胞癌臨床研究の課題と展望
    工藤正俊
    最新肝癌学 73 33 - 41 2015年 [査読有り]
  • 序文
    工藤正俊
    最新肝癌学 73 1 - 14 2015年 [査読有り]
  • Teppei Adachi; Toshiharu Sakurai; Hiroshi Kashida; Hiromasa Mine; Satoru Hagiwara; Shigenaga Matsui; Koji Yoshida; Naoshi Nishida; Tomohiro Watanabe; Katsuhiko Itoh; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 21 1 31 - 39 2015年01月 [査読有り]
     
    Background: Expression of heat shock protein A4 (HSPA4, also called Apg-2), a member of the HSP110 family, is induced by several forms of stress. The physiological and pathological functions of HSPA4 in the intestine remain to be elucidated. Methods: We assessed HSPA4 expression and function by generating HSPA4-deficient mice and using 214 human intestinal mucosa samples from patients with inflammatory bowel disease (IBD). Results: In the colonic mucosa of patients with IBD, a significant correlation was observed between the expression of HSPA4 and antiapoptotic protein Bcl-2, a T-cell-derived cytokine IL-17 or stem cell markers, such as Sox2. In refractory ulcerative colitis, a condition associated with increased cancer risk, expression of HSPA4 and Bcl-2 was increased in inflammatory cells of colonic mucosae. HSPA4 was overexpressed both in cancer cells and immune cells of human colorectal cancers. Patients with high expression of HSPA4 or Bmi1 showed significantly lower response rates upon subsequent steroid therapy as compared with patients with low expression of each gene. HSPA4-deficient mice exhibit more apoptosis and less expression of IL-17/IL-23 in inflammatory cells and less number of Sox(2+) cells after administration of dextran sodium sulfate than control mice. Transduction of HspaA4(+/-) bone marrow into wild-type mice reduced the immune response. Conclusions: Upregulation of Bcl-2 and IL-17 by HSPA4 would control apoptosis of inflammatory cells and immune response in the gut, which might develop treatment resistance in IBD. HSPA4 and Bmi1 would be a useful biomarker for refractory clinical course and a promising approach for a therapeutic strategy in patients with IBD.
  • D. J. Pinato; G. Karamanakos; T. Arizumi; D. Adjogatse; Y. W. Kim; J. Stebbing; M. Kudo; J. W. Jang; R. Sharma
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS 40 11-12 1270 - 1281 2014年12月 [査読有り]
     
    BackgroundTransarterial chemoembolisation (TACE) is a standard treatment for unresectable, intermediate stage hepatocellular carcinoma (HCC). Survival after TACE, however, can be highly variable, with no suitable biomarker predicting therapeutic outcome. The inflammation-based index (IBI) has previously been shown to independently predict overall survival (OS) in all stages of HCC. AimTo explore the prognostic ability of IBI as a predictor of survival after TACE. MethodsBaseline staging, biochemical and clinicopathological features including IBI were studied in a derivation set of 64 patients undergoing TACE for intermediate stage HCC. Dynamic changes in IBI before and after TACE were studied as predictors of survival using both a univariate and multivariate Cox regression model and further validated in two independent patient cohorts from Korea (n=76) and Japan (n=577). ResultsPre-treatment IBI predicted for OS in the derivation set (P=0.001). Other univariate predictors of OS included radiological response to TACE (P<0.001), pre-TACE CLIP score (P<0.01), tumour diameter >5cm (P=0.05) and AFP 400 (P<0.001). Normalisation of IBI post-TACE was associated with radiological response by mRECIST criteria and improved OS (P<0.001). Normalisation of IBI remained a significant multivariate predictor of OS in both the derivation and validation sets (P<0.001). ConclusionsNormalisation of IBI after TACE is shown to be an independent predictor of survival and may be integrated into the retreatment criteria for repeat TACE in intermediate stage HCC. IBI and its dynamic changes after treatment are validated as a biomarker allowing the stratification of patients with a significant survival advantage following initial TACE.
  • Tadaaki Arizumi; Kazuomi Ueshima; Haruhiko Takeda; Yukio Osaki; Masahiro Takita; Tatsuo Inoue; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY 49 12 1578 - 1587 2014年12月 [査読有り]
     
    To test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS). The therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1 month was evaluated using the RECIST1.1, mRECIST, and RECICL. After categorization as showing progressive disease (PD), stable disease (SD), or objective response, the association between OS and categorization was examined using the Kaplan-Meier method to develop survival curves. The 141 cases categorized as PD or SD by the RECIST1.1, but objective response by the mRECIST and RECICL, were further analyzed for determination of the association between OS and categorization. Only categorization using the RECICL was found to be significantly correlated with OS (p = 0.0033). Among the patients categorized as SD or PD by the RECIST1.1, reclassification by the RECICL but not the mRECIST was found to be significantly associated with OS and allowed for precise prediction of prognosis (p = 0.0066). Only the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response.
  • Tomoyuki Nagai; Rie Tanaka; Mitsunari Yamada; Teppei Adachi; Masaki Takayama; Hiromasa Mine; Yoshihisa Okazaki; Yoriaki Komeda; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Mastui; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 168 - 168 2014年11月 [査読有り]
  • Teppei Adachi; Rie Tanaka; Mitsunari Yamada; Masaki Takayama; Hiromasa Mine; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Yoshihisa Okazaki; Yoriaki Komeda; Toshiharu Sakurai; Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 3 - 4 2014年11月 [査読有り]
  • Mitsunari Yamada; Hiroshi Kashida; Rie Tanaka; Teppei Adachi; Hiromasa Mine; Masaki Takayama; Yoshihiro Okazaki; Yoshiaki Nagata; Tomoyuki Nagai; Masanori Kawasaki; Noriaki Komeda; Yutaka Asakuma; Yoshiharu Sakurai; Shigenaga Matsui; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 265 - 266 2014年11月 [査読有り]
  • Teppei Adachi; Rie Tanaka; Mitsunari Yamada; Masaki Takayama; Hiromasa Mine; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Yoshihisa Okazaki; Yoriaki Komeda; Toshiharu Sakurai; Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 22 - 22 2014年11月 [査読有り]
  • Shigenaga Matsui; Hiroshi Kashida; Kazuki Okamoto; Yutaka Asakuma; Toshiharu Sakurai; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 114 - 114 2014年11月 [査読有り]
  • Shigenaga Matsui; Hiroshi Kashida; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29 114 - 115 2014年11月 [査読有り]
  • Masatoshi Kudo; Guohong Han; Richard S. Finn; Ronnie T. P. Poon; Jean-Frederic Blanc; Lunan Yan; Jijin Yang; Ligong Lu; Won-Young Tak; Xiaoping Yu; Joon-Hyeok Lee; Shi-Ming Lin; Changping Wu; Tawesak Tanwandee; Guoliang Shao; Ian B. Walters; Christine Dela Cruz; Valerie Poulart; Jian-Hua Wang
    HEPATOLOGY 60 5 1697 - 1707 2014年11月 [査読有り]
     
    Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, may improve the effectiveness of TACE when given as an adjuvant to TACE. In this multinational, randomized, double-blind, placebo-controlled, phase III study, 870 patients with TACE-eligible HCC were planned to be randomly assigned (1: 1) after the first TACE to receive either brivanib 800 mg or placebo orally once-daily. The primary endpoint was overall survival (OS). Secondary endpoints included time to disease progression (TTDP; a composite endpoint based on development of extrahepatic spread or vascular invasion, deterioration of liver function or performance status, or death), time to extrahepatic spread or vascular invasion (TTES/VI), rate of TACE, and safety. Time to radiographic progression (TTP) and objective response rate were exploratory endpoints. The trial was terminated after randomization of 502 patients (brivanib, 249; placebo, 253) when two other phase III studies of brivanib in advanced HCC patients failed to meet OS objectives. At termination, median follow-up was approximately 16 months. Intention-to-treat analysis showed no improvement in OS with brivanib versus placebo (median, 26.4 [95% confidence interval {CI}: 19.1 to not reached] vs. 26.1 months [19.0-30.9]; hazard ratio [HR]: 0.90 [95% CI: 0.66-1.23]; log-rank P50.5280). Brivanib improved TTES/VI (HR, 0.64 [95% CI: 0.45-0.90]), TTP (0.61 [0.48-0.77]), and rate of TACE (0.72 [0.61-0.86]), but not TTDP (0.94 [0.72-1.22]) versus placebo. Most frequent grade 3-4 adverse events included hyponatremia (brivanib, 18% vs. placebo, 5%) and hypertension (13% vs. 3%). Conclusions: In this study, brivanib as adjuvant therapy to TACE did not improve OS.
  • T. Watanabe; N. Asano; G. Meng; K. Yamashita; Y. Arai; T. Sakurai; M. Kudo; I. J. Fuss; A. Kitani; T. Shimosegawa; T. Chiba; W. Strober
    MUCOSAL IMMUNOLOGY 7 6 1312 - 1325 2014年11月 [査読有り]
     
    It is well established that polymorphisms of the caspase activation and recruitment domain 15 (CARD15) gene, a major risk factor in Crohn's disease (CD), lead to loss of nucleotide-binding oligomerization domain 2 (NOD2) function. However, a molecular explanation of how such loss of function leads to increased susceptibility to CD has remained unclear. In a previous study exploring this question, we reported that activation of NOD2 in human dendritic cells by its ligand, muramyl dipeptide (MDP), negatively regulates Toll-like receptor (TLR)-mediated inflammatory responses. Here we show that NOD2 activation results in increased interferon regulatory factor 4 (IRF4) expression and binding to tumor necrosis factor receptor associated factor 6 (TRAF6) and RICK (receptor interacting serine-threonine kinase). We then show that such binding leads to IRF4-mediated inhibition of Lys63-linked polyubiquitination of TRAF6 and RICK and thus to downregulation of nuclear factor (NF)-kappa B activation. Finally, we demonstrate that protection of mice from the development of experimental colitis by MDP or IRF4 administration is accompanied by similar IRF4-mediated effects on polyubiquitination of TRAF6 and RICK in colonic lamina propria mononuclear cells. These findings thus define a mechanism of NOD2-mediated regulation of innate immune responses to intestinal microflora that could explain the relation of CARD15 polymorphisms and resultant NOD2 dysfunction to CD.
  • Toshiharu Sakurai; Hiroshi Kashida; Tomohiro Watanabe; Satoru Hagiwara; Tsunekazu Mizushima; Hideki Iijima; Naoshi Nishida; Hiroaki Higashitsuji; Jun Fujita; Masatoshi Kudo
    CANCER RESEARCH 74 21 6119 - 6128 2014年11月 [査読有り]
     
    Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and is reported to be associated with refractory inflammatory bowel disease (IBD). Defective apoptosis of inflammatory cell populations seems to be a relevant pathogenetic mechanism in refractory IBD. We assessed the involvement of stress response protein cold-inducible RNA-binding protein (Cirp) in the development of intestinal inflammation and CAC. In the colonic mucosa of patients with ulcerative colitis, expression of Cirp correlated significantly with the expression of TNF alpha, IL23/IL17, antiapoptotic proteins Bcl-2 and Bcl-xL, and stem cell markers such as Sox2, Bmi1, and Lgr5. The expression of Cirp and Sox2 was enhanced in the colonic mucosae of refractory ulcerative colitis, suggesting that Cirp expression might be related to increased cancer risk. In human CAC specimens, inflammatory cells expressed Cirp protein. Cirp(-/-) mice given dextran sodium sulfate exhibited decreased susceptibility to colonic inflammation through decreased expression of TNF alpha, IL23, Bcl-2, and Bcl-xL in colonic lamina propria cells compared with similarly treated wild-type (WT) mice. In the murine CAC model, Cirp deficiency decreased the expression of TNF alpha, IL23/IL17, Bcl-2, Bcl-xL, and Sox2 and the number of Dclk1(+) cells, leading to attenuated tumorigenic potential. Transplantation of Cirp(-/-) bone marrow into WT mice reduced tumorigenesis, indicating the importance of Cirp in hematopoietic cells. Cirp promotes the development of intestinal inflammation and colorectal tumors through regulating apoptosis and production of TNF alpha and IL23 in inflammatory cells. (C) 2014 AACR.
  • Koichi Ogawa; Kiyoshi Fukunaga; Tomoyo Takeuchi; Naoki Kawagishi; Yoshifumi Ubara; Masatoshi Kudo; Nobuhiro Ohkohchi
    HEPATOLOGY RESEARCH 44 11 1110 - 1118 2014年10月 [査読有り]
     
    AimPolycystic liver disease (PLD) is a genetic disorder characterized by the progressive development of multiple liver cysts. No standardized criteria for the selection of treatment exist because PLD is a rare condition and most patients are asymptomatic. We here aimed to clarify the status of treatment and to present a therapeutic strategy for PLD in Japan. MethodsFrom 1 June 2011 to 20 December 2011, we administered a questionnaire to 202 PLD patients from 86 medical institutions nationwide. ResultsThe patients included 45 men and 155 women, and the median age was 63 years. Two hundred and eighty-one treatments were performed for these patients, as follows: cyst aspiration sclerotherapy (AS) in 152 cases, cyst fenestration (FN) in 53, liver resection (LR) in 44, liver transplantation (LT) in 13 and other treatments in 19. For cases of type I PLD (mild form) according to Gigot's classification, the therapeutic effects of AS, FN and LR were similar. For type II (moderate form), LT demonstrated the best therapeutic effects, followed by LR and FN. For type III (severe form), the effects of LT were the best. The incidences of complications were 23.0% in AS, 28.4% in FN, 31.8% in LR and 61.5% in LT. ConclusionConsidering the therapeutic effects and complications, AS, LR and LT showed good results for type I, type II and type III PLD, respectively. However, LT for PLD was performed in a small number of patients. In Japan, the transplantation therapy is expected to be common in the future.
  • 慢性膵炎とその進展予防 早期慢性膵炎におけるEUS画像所見と臨床的意義の検討
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 111 臨増大会 A794 - A794 (一財)日本消化器病学会 2014年09月
  • 重症急性膵炎の病態と有効な初期治療をめざして 急性膵炎の病態把握におけるプロカルシトニンの有用性について
    大本 俊介; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 111 臨増大会 A598 - A598 (一財)日本消化器病学会 2014年09月
  • Life saving endoscopy 胆膵良性疾患の救命救急におけるEUS下ドレナージ術の位置づけ
    山雄 健太郎; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 56 Suppl.2 2973 - 2973 (一社)日本消化器内視鏡学会 2014年09月
  • 胆管結石治療困難例への戦略 経乳頭処置困難総胆管結石に対するrendezvous法の手技と成績
    山雄 健太郎; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 56 Suppl.2 3007 - 3007 (一社)日本消化器内視鏡学会 2014年09月
  • Masayuki Kitano; Ken Kamata; Masatoshi Kudo
    DIGESTIVE ENDOSCOPY 26 5 636 - 637 2014年09月 [査読有り]
  • Naoto Ikeda; Hiroyasu Imanishi; Nobuhiro Aizawa; Hironori Tanaka; Yoshinori Iwata; Hirayuki Enomoto; Masaki Saito; Hiroko Iijima; Yuji Iimuro; Jiro Fujimoto; Satoshi Yamamoto; Shozo Hirota; Masatoshi Kudo; Shigeki Arii; Shuhei Nishiguchi
    HEPATOLOGY RESEARCH 44 8 829 - 836 2014年08月 [査読有り]
     
    Aim: In chronic liver disease associated with hepatitis C virus (HCV), a low platelet count is a major obstacle in carrying out interferon (IFN) treatment. We used a questionnaire to clarify the extent to which splenectomy/partial splenic embolization (PSE) is performed before IFN treatment, as well as the efficacy and complications thereof. Methods: Two questionnaires were distributed to 413 medical institutes in Japan specializing in the treatment of liver diseases, and responses were obtained from 204 institutes. Furthermore, a more detailed questionnaire was completed by 10 institutes that experienced cases of death. Results: In patients with HCV genotype 1b and a high viral load (HCV1b/High), the sustained viral response (SVR) rate was 28% for the splenectomy group and 22% for the PSE group, with no significant difference between these groups. In patients that were not HCV1b/High, the SVR rate was higher in those that underwent splenectomy (71%) compared to the PSE group (56%; P = 0.025). There were cases of death in seven of 799 splenectomy cases (0.89%) and four of 474 PSE cases (0.84%). Infectious diseases were involved in nine of 11 cases of death, with a peculiar patient background of Child-Pugh B (6/10) and an age of 60 years or greater (7/11). Conclusion: The application of splenectomy/PSE before IFN treatment should be avoided in patients with poor residual hepatic function and/or elderly patients. In HCV1b/High patients, splenectomy/PSE should be performed only after selecting those in which IFN treatment should be highly effective.
  • Andrew X. Zhu; Masatoshi Kudo; Eric Assenat; Stephane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T. P. Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B. Sellami; Li-Tzong Chen
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 312 1 57 - 67 2014年07月 [査読有り]
     
    IMPORTANCE Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma. OBJECTIVE To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. DESIGN, SETTING, AND PARTICIPANTS EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib. Patients were enrolled from 17 countries between May 2010 and March 2012. Randomization was stratified by region (Asia vs rest of world) and macrovascular invasion (present vs absent). INTERVENTIONS Everolimus, 7.5 mg/d, or matching placebo, both given in combination with best supportive care and continued until disease progression or intolerable toxicity. Per the 2: 1 randomization scheme, 362 patients were randomized to the everolimus group and 184 patients to the placebo group. MAIN OUTCOMES AND MEASURES The primary end point was overall survival. Secondary end points included time to progression and the disease control rate (the percentage of patients with a best overall response of complete or partial response or stable disease). RESULTS No significant difference in overall survival was seen between treatment groups, with 303 deaths (83.7%) in the everolimus group and 151 deaths (82.1%) in the placebo group (hazard ratio [HR], 1.05; 95% CI, 0.86-1.27; P=.68; median overall survival, 7.6 months with everolimus, 7.3 months with placebo). Median time to progression with everolimus and placebo was 3.0 months and 2.6 months, respectively (HR, 0.93; 95% CI, 0.75-1.15), and disease control rate was 56.1% and 45.1%, respectively (P=.01). The most common grade 3/4 adverse events for everolimus vs placebo were anemia (7.8% vs 3.3%, respectively), asthenia (7.8% vs 5.5%, respectively), and decreased appetite (6.1% vs 0.5%, respectively). No patients experienced hepatitis C viral flare. Based on central laboratory results, hepatitis B viral reactivation was experienced by 39 patients (29 everolimus, 10 placebo); all cases were asymptomatic, but 3 everolimus recipients discontinued therapy. CONCLUSIONS AND RELEVANCE Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib.
  • 尿タンパク試験紙にBence Jonesタンパクが反応することの検証
    井本真由美; 松村 到; 船内正憲; 中川和彦; 鮫島謙一; 前田裕弘; 森嶋祥之; 中江健市; 上硲俊法; 工藤正俊; 櫻林郁之助
    臨床化学 43 3 217 - 225 (一社)日本臨床化学会 2014年07月 
    Bence Jonesタンパク(BJP)は尿タンパク試験紙(以下、試験紙)にはほとんど反応しないことが定説となっている。我々はこの説に疑問を持ち、過去約6年間におけるBJP定性試験(Putnam法)陽性で、免疫電気泳動法(IEP)あるいは免疫固定法(IFE)においてBJP陽性が確認されている患者尿の試験紙反応性について調査した結果、BJP含有尿352検体(66症例)中、試験紙陰性はわずかに10検体(2.8%)で、342検体(97.2%)が±以上の反応(±〜4+)であった。試験紙法陰性検体は経過観察中の多発性骨髄腫患者3例のみであった。しかも、尿総タンパク量は、15mg/dL未満であり、試験紙法の検出限界濃度以下であった。またIgGおよびアルブミンが出現していないBJP陽性尿を用い、試験紙が±以上に反応する濃度(検出限界)を求めた結果、アルブミンの検出感度と同等で15mg/dLであった。さらにIgGが試験紙に反応しがたいことを再確認したうえで、IgGを還元処理してL鎖を遊離させた後は、試験紙の反応性が強くなることを確認した。したがって、尿タンパク試験紙がBJPに反応しない(反応しがたい)という説は見直されるべきであると考える。(著者抄録)
  • 井上達夫; 前川 清; 工藤正俊
    画像診断 34 7 761 - 770 2014年07月 [査読有り][招待有り]
  • 門阪 薫平; 北野 雅之; 工藤 正俊
    膵臓 29 3 473 - 473 (一社)日本膵臓学会 2014年06月
  • 大本 俊介; 北野 雅之; 門坂 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 坂本 洋城; 工藤 正俊
    膵臓 29 3 545 - 545 (一社)日本膵臓学会 2014年06月
  • 山雄 健太郎; 北野 雅之; 工藤 正俊; 竹山 宜典
    膵臓 29 3 442 - 442 日本膵臓学会 2014年06月
  • Masatoshi Kudo; Tadaaki Arizumi; Kazuomi Ueshima
    HEPATOLOGY 59 6 2424 - 2425 2014年06月 [査読有り]
  • 岡田 真広; 兵頭 朋子; 矢田 典久; 安座間 喜明; 伊良波 裕子; 村山 貞之; 工藤 正俊; 村上 卓道
    画像診断 34 7 753 - 759 学研メディカル秀潤社 2014年05月
  • Soo Ryang Kim; Fukuo Kondo; Yumi Otono; Susumu Imoto; Kenji Ando; Makoto Hirakawa; Katsumi Fukuda; Madoka Sasaki; Soo Ki Kim; Takamitsu Komaki; Shinobu Tsuchida; Sawako Kobayashi; Toshiyuki Matsuoka; Masatoshi Kudo
    HEPATOLOGY RESEARCH 44 5 584 - 590 2014年05月 [査読有り]
     
    We describe a case of serum amyloid A (SAA) and C-reactive protein (CRP) positive nodule detected by immunohistochemical analysis in a 37-year-old woman with alcohol-related cirrhosis. Imaging studies at first admission pointed to hepatocellular carcinoma (HCC), a dysplastic nodule, an inflammatory pseudotumor or focal nodular hyperplasia (FNH). Ultrasonography-guided biopsy in Segment 2 showed minimal atypical changes, except for a slight increase in cell density and micronodular cirrhosis in the non-nodular portion. gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging carried out after a year and a half revealed hypervascularity in the arterial phase and isointensity in the hepatobiliary phase. Three years thereafter, however, the imaging displayed a change from isointensity to a defect in the hepatobiliary phase, and the nodule demonstrated minimal histological atypia. Immunohistochemical staining of the nodule was positive for SAA, CRP, liver fatty acid-binding protein and glutamine synthetase, but negative for beta-catenin, heat shock protein 70 and Glypican 3. Organic anion transporter (OATP)8 staining was weaker in the nodule than in the non-nodular portion of the alcohol-related micronodular cirrhosis. The nodule was diagnosed as an SAA and CRP positive nodule, and HCC was ruled out. Despite the change from isointensity to a defect in the hepatobiliary phase, no evidence of HCC was found in the biopsy specimen. The change may be explained more by the weak OATP8 staining compared with that of alcohol-related liver cirrhosis than by malignant transformation into HCC.
  • R. Lencioni; M. Kudo; S. -L. Ye; J. -P. Bronowicki; X. -P. Chen; L. Dagher; J. Furuse; J. F. Geschwind; L. Ladron de Guevara; C. Papandreou; T. Takayama; S. K. Yoon; K. Nakajima; R. Lehr; S. Heldner; A. J. Sanyal
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 68 5 609 - 617 2014年05月 [査読有り]
     
    BackgroundGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials. MethodsPatients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow-up visits. The second interim analysis was undertaken when similar to 1500 treated patients were followed up for 4months. ResultsOf the 1571 patients evaluable for safety, 61% had Child-Pugh A status and 23% Child-Pugh B. The majority of patients (74%) received the approved 800mg initial sorafenib dose, regardless of Child-Pugh status; however, median duration of therapy was shorter in Child-Pugh B patients. The majority of drug-related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug-related AEs were broadly similar across Child-Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population. ConclusionsConsistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in >3000 patients are ongoing.
  • 胆膵疾患におけるInterventional EUS
    北野雅之; 工藤正俊
    最新医学 69 5 130 - 138 2014年05月 [査読有り][招待有り]
  • 上嶋 一臣; 工藤 正俊
    腫瘍内科 13 5 637 - 641 (有)科学評論社 2014年05月
  • Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic Masses
    Ashida R; Yasukawa S; Yanagisawa A; Kamata K; Kudo M; Ogura T; Higuchi K; Fukutake N; Nebiki H; Hirose S; Hoki N; Asada M; Yazumi S; Takaoka M; Okazaki K; Matsuda F; Okabe Y; Kitano M
    Gastrointest Endosc 79 AB111  2014年05月 [査読有り]
  • Yosuke Togashi; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A. de Velasco; Yoshihiko Fujita; Yasuo Kodera; Kazuko Sakai; Shuta Tomida; Masayuki Kitano; Akihiko Ito; Masatoshi Kudo; Kazuto Nishio
    MOLECULAR CANCER 13 126 - 136 2014年05月 [査読有り]
     
    Background: Transforming growth factor, beta (TGFB) signal is considered to be a tumor suppressive pathway based on the frequent genomic deletion of the SMAD4 gene in pancreatic cancer (PC); however; the role of the activin signal, which also belongs to the TGFB superfamily, remains largely unclear. Methods and results: We found a homozygous deletion of the activin A receptor, type IB (ACVR1B) gene in 2 out of 8 PC cell lines using array-comparative genomic hybridization, and the absence of ACVR1B mRNA and protein expression was confirmed in these 2 cell lines. Activin A stimulation inhibited cellular growth and increased the phosphorylation level of SMAD2 and the expression level of p21(CIP1/WAF1) in the Sui66 cell line (wild-type ACVR1B and SMAD4 genes) but not in the Sui68 cell line (homozygous deletion of ACVR1B gene). Stable ACVR1B-knockdown using short hairpin RNA cancelled the effects of activin A on the cellular growth of the PC cell lines. In addition, ACVR1B-knockdown significantly enhanced the cellular growth and colony formation abilities, compared with controls. In a xenograft study, ACVR1B-knockdown resulted in a significantly elevated level of tumorigenesis and a larger tumor volume, compared with the control. Furthermore, in clinical samples, 6 of the 29 PC samples (20.7%) carried a deletion of the ACVR1B gene, while 10 of the 29 samples (34.5%) carried a deletion of the SMAD4 gene. Of note, 5 of the 6 samples with a deletion of the ACVR1B gene also had a deletion of the SMAD4 gene. Conclusion: We identified a homozygous deletion of the ACVR1B gene in PC cell lines and clinical samples and proposed that the deletion of the ACVR1B gene may mediate an aggressive cancer phenotype in PC. Our findings provide novel insight into the role of the activin signal in PC.
  • Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 20 15 4160 - 4166 2014年04月 [査読有り]
     
    Radiofrequency ablation (RFA) is commonly applied for the treatment of hepatocellular carcinoma (HCC) because of the facile procedure, and the safety and effectiveness for the treatment of this type of tumor. On the other hand, it is believed that HCC cells should spread predominantly through the blood flow of the portal vein, which could lead to the formation of intrahepatic micrometastases. Therefore, monitoring tumor response after the treatment is quite important and accurate assessment of treatment response is critical to obtain the most favorable outcome after the RFA. Indeed, several reports suggested that even small HCCs of <= 3 cm in diameter might carry intrahepatic micrometastases and/or microvascular invasion. From this point of view, for preventing local recurrences, RFA should be performed ablating a main tumor as well as its surrounding non-tumorous liver tissue where micrometastases and microvascular invasion might exist. Recent advancement of imaging modalities such as contrast-enhanced ultrasonic, computed tomography, and magnetic resonance imaging are playing an important role on assessing the therapeutic effects of RFA. The local recurrence rate tends to be low in HCC patients who were proven to have adequate ablation margin after RFA; namely, not only disappearance of vascular enhancement of main tumor, but also an adequate ablation margin. Therefore, contrast enhancement gives important findings for the diagnosis of recurrent HCCs on each imaging. However, hyperemia of non-tumorous liver surrounding the ablated lesion, which could be attributed to an inflammation after RFA, may well obscure the findings of local recurrence of HCCs after RFA. Therefore, we need to carefully address to these imaging findings given the fact that diagnostic difficulties of local recurrence of HCC. Here, we give an overview of the current status of the imaging assessment of HCC response to RFA. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
  • 急性胆嚢炎および胆管炎例に対するEUS下胆嚢ドレナージ術の有用性
    門阪 薫平; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 56 Suppl.1 1061 - 1061 (一社)日本消化器内視鏡学会 2014年04月
  • 造影ハーモニックEUS(CH-EUS)における膵腫瘍の血流評価の有用性について
    大本 俊介; 田中 梨絵; 門阪 薫平; 鎌田 研; 宮田 剛; 山雄 健太郎; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊
    超音波医学 41 Suppl. S580 - S580 (公社)日本超音波医学会 2014年04月
  • 膵神経内分泌腫瘍に対するEUSの有用性
    今井 元; 北野 雅之; 工藤 正俊; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 坂本 洋城
    Gastroenterological Endoscopy 56 Suppl.1 1132 - 1132 (一社)日本消化器内視鏡学会 2014年04月
  • 消化管狭窄の内視鏡治療 上部 悪性胃十二指腸狭窄に対する治療戦略 胆道狭窄合併例に対するEUS下胆道ドレナージ術も含めて
    山雄 健太郎; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 56 Suppl.1 1033 - 1033 (一社)日本消化器内視鏡学会 2014年04月
  • Taku Aoki; Norihiro Kokudo; Yutaka Matsuyama; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Masatoshi Makuuchi
    ANNALS OF SURGERY 259 3 532 - 542 2014年03月 [査読有り]
     
    Objective: The aim of the present study was to investigate the background characteriscs of ruptured hepatocellular carcinoma (HCC) and to clarify the true impact of tumor rupture on patient prognosis in a large patient cohort. Background: Spontaneous tumor rupture of HCC has been associated with a very poor patient prognosis and the current TNM staging systems classify ruptured HCC as T4 based on insufficient evidence. Methods: In total, 1106 patients with ruptured HCC were extracted from the database of a nationwide survey conducted in Japan from 2000 to 2005. The clinicopathological parameters associated with HCC rupture were investigated using univariate and multivariate logistic regression models. The survival curves for ruptured and nonruptured HCC were generated and compared to evaluate the impact of the event (rupture) itself on patient prognosis and the TNM staging systems. Results: The multivariate analyses showed that tumor rupture was associated with both a poor liver functional reserve and an advanced tumor status. Analyses of the survival curves stratified according to the baseline TNM staging showed that tumor rupture had an additional impact on the baseline survival curves without rupture, and the impact corresponded to the addition of 0.5 to 2 stages to the baseline tumor staging. Conclusions: The present study suggested that tumor rupture itself had a negative impact on patient survival. However, its impact was not strong enough to cancel the effects of the other tumor-related parameters. Therefore, it may be appropriate to give additional stages to the baseline tumor staging in cases of ruptured HCC.
  • Nishiguchi S; Enomoto H; Aizawa N; Nishikawa H; Osaki Y; Tsuda Y; Higuchi K; Okazaki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M
    Journal of gastroenterology 49 3 492 - 501 2014年03月 [査読有り]
     
    We conducted a multicenter randomized clinical trial to determine the optimal treatment strategy against chronic hepatitis C virus (HCV) with genotype 1b and a high viral load (G1b/high). The study subjects included 153 patients with G1b/high. Patients were initially treated with PEG-IFN alpha-2a alone and then randomly assigned to receive different treatment regimens. Ribavirin (RBV) was administered to all patients with HCV RNA at week 4. Patients negative for HCV RNA at week 4 were randomly assigned to receive PEG-IFN alpha-2a (group A) or PEG-IFN alpha-2a/RBV (group B). Patients who showed HCV RNA at week 4 but were negative at week 12 were randomly assigned to receive weekly PEG-IFN alpha-2a (group C) or biweekly therapy (group D). Patients who showed HCV RNA at week 12 but were negative at week 24 were randomly assigned to receive PEG-IFN alpha-2a/RBV (group E) or PEG-IFN alpha-2a/RBV/fluvastatin (group F). Overall, the rate of sustained virological response (SVR) was 46 % (70/153). The total SVR rate in the group (A, D, and F) of response-guided therapy was significantly higher than that in the group (B, C, and E) of conventional therapy [70 % (38/54) versus 52 % (32/61), p = 0.049]. Although IL28-B polymorphism and Core 70 mutation were significantly associated with efficacy, patients with rapid virological response (RVR) and complete early virological response (cEVR) achieved high SVR rates regardless of their status of IL-28B polymorphism and Core 70 mutation. In addition to knowing the IL-28B polymorphism and Core 70 mutation status, understanding the likelihood of virological response during treatment is critical in determining the appropriate treatment strategy.
  • FDの亜分類と治療選択 機能性ディスペプシアと早期慢性膵炎との関係性について
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 111 臨増総会 A117 - A117 (一財)日本消化器病学会 2014年03月
  • 消化器領域超音波の最前線 診断からインターベンションまで 当院におけるEUS下胆管および膵管ドレナージの工夫と成績
    大本 俊介; 北野 雅之; 工藤 正俊
    超音波医学 41 2 241 - 241 (公社)日本超音波医学会 2014年03月
  • 造影ハーモニックEUS(CH-EUS)における膵腫瘍の血流評価の有用性について
    大本 俊介; 田中 梨絵; 門阪 薫平; 鎌田 研; 宮田 剛; 山雄 健太郎; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊
    超音波医学 41 2 245 - 245 (公社)日本超音波医学会 2014年03月
  • 造影ハーモニックEUSにおける消化器系疾患の鑑別および悪性度診断
    大本 俊介; 北野 雅之; 工藤 正俊
    超音波医学 41 2 256 - 256 (公社)日本超音波医学会 2014年03月
  • Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.
    Kawanaka Miwa; Nishino Ken; Nakamura Jun; Oka Takahito; Urata Noriyo; Goto Daisuke; Suehiro Mitsuhiko; Kawamoto Hirofumi; Kudo Masatoshi; Yamada Gotaro
    Liver Cancer 3 1 41 - 52 KARGER 2014年03月
  • Taku Aoki; Norihiro Kokudo; Yutaka Matsuyama; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Masatoshi Makuuchi
    ANNALS OF SURGERY 259 3 532 - 542 2014年03月 [査読有り]
     
    Objective: The aim of the present study was to investigate the background characteriscs of ruptured hepatocellular carcinoma (HCC) and to clarify the true impact of tumor rupture on patient prognosis in a large patient cohort. Background: Spontaneous tumor rupture of HCC has been associated with a very poor patient prognosis and the current TNM staging systems classify ruptured HCC as T4 based on insufficient evidence. Methods: In total, 1106 patients with ruptured HCC were extracted from the database of a nationwide survey conducted in Japan from 2000 to 2005. The clinicopathological parameters associated with HCC rupture were investigated using univariate and multivariate logistic regression models. The survival curves for ruptured and nonruptured HCC were generated and compared to evaluate the impact of the event (rupture) itself on patient prognosis and the TNM staging systems. Results: The multivariate analyses showed that tumor rupture was associated with both a poor liver functional reserve and an advanced tumor status. Analyses of the survival curves stratified according to the baseline TNM staging showed that tumor rupture had an additional impact on the baseline survival curves without rupture, and the impact corresponded to the addition of 0.5 to 2 stages to the baseline tumor staging. Conclusions: The present study suggested that tumor rupture itself had a negative impact on patient survival. However, its impact was not strong enough to cancel the effects of the other tumor-related parameters. Therefore, it may be appropriate to give additional stages to the baseline tumor staging in cases of ruptured HCC.
  • Ann Lii Cheng; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-Francois Geschwind; Khean L. Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A. Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T. Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Joong-Won Park
    LIVER INTERNATIONAL 34 2 174 - 183 2014年02月 [査読有り]
     
    Patients with unresectable hepatocellular carcinoma (HCC) usually receive transarterial chemoembolization (TACE) or systemic therapies with intermediate and advanced-stage disease. However, intermediate-stage HCC patients often have unsatisfactory clinical outcomes with repeated TACE and there is considerable uncertainty surrounding the criteria for repeating or stopping TACE treatment. In July 2012, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was re-convened in Shanghai in an attempt to provide a consensus on the practice of TACE, particularly in regard to evaluating TACE failure'. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies for intermediate HCC. This review summarizes the evidence discussed at the meeting and provides expert recommendations regarding the use of TACE for unresectable intermediate-stage HCC. A key consensus of the Expert Panel was that the current definitions of TACE failure are not useful in differentiating between situations where TACE is no longer effective in controlling disease locally vs. systemically. By redefining these concepts, it may be possible to provide a clearer indication of when TACE should be repeated and more importantly, when TACE should be discontinued.
  • Tohru Utsunomiya; Mitsuo Shimada; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
    ANNALS OF SURGERY 259 2 336 - 345 2014年02月 [査読有り]
     
    Objective: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called non-B non-C HCC using the data of a nationwide survey. Background: The proportion of non-B non-C HCC is rapidly increasing in Japan. Methods: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. Results: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores 1 and 2. The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA. Conclusions: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores 1 and 2 of non-B non-C HCC.
  • 上嶋 一臣; 工藤 正俊
    日本臨床 72 増刊2 最新がん薬物療法学 391 - 396 (株)日本臨床社 2014年02月
  • 北野雅之; 坂本洋城; 工藤正俊
    Gastroenterol Endosc 56 2 296 - 308 Japan Gastroenterological Endoscopy Society 2014年02月 
    胆膵疾患に対するコンベックス型超音波内視鏡検査は，主に経胃，経十二指腸球部および経十二指腸下行部の3ステーションから観察を行う．周辺臓器・大血管との位置関係を把握した上で，内視鏡の進行方向移動，捻り回転，アップ・ダウンアングルを組み合わせて，連続的に膵実質・膵管・胆道を観察する．血管と胆管・膵管の識別には，ドプラモードを使用する．胃からは，主に肝臓，膵頭部の一部，膵体尾部を描出する．門脈の走行に沿って内視鏡を進めると膵頭体移行部が描出され，時計回転により膵尾部側へ撮像を行う．十二指腸球部からは，主に胆道，膵頭部を観察する．コンフルエンス部から反時計および時計回転行うことにより，それぞれ膵頭体移行部および膵頭部が描出される．内視鏡を押し進めるとスキャンが胆管の肝側へ移動する．下行部からは主に膵頭部，乳頭部が観察される．内視鏡のストレッチ後，大動脈の画面右上方で膵頭下部を描出し，少しずつ引き戻すことにより，乳頭部が描出される．
  • Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kumpei Kadosaka; Takeshi Miyata; Hajime Imai; Kiyoshi Maekawa; Takaaki Chikugo; Masashi Kumano; Tomoko Hyodo; Takamichi Murakami; Yasutaka Chiba; Yoshifumi Takeyama
    ENDOSCOPY 46 1 22 - 29 2014年01月 [査読有り]
     
    Background and study aims: Pancreatic ductal adenocarcinomas (PDAC) sometimes arise in patients with intraductal papillary mucinous neoplasms (IPMNs). This study examined the incidence of PDACs concomitant to or derived from branch duct IPMNs. The usefulness of endoscopic ultrasonography (EUS) relative to other imaging methods for detecting these tumors was also assessed. Patients and methods: This retrospective study used data from clinical records and imaging studies that were collected prospectively. During 2001-2009, 167 consecutive patients with IPMNs underwent EUS, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). The 102 patients whose branch duct IPMNs lacked mural nodules/symptoms and thus did not qualify for resection were followed up by semiannual EUS and annual ultrasonography, CT, and MRI. The sensitivity and specificity with which the four modalities detected IPMN-derived and -concomitant PDACs at the first examination and throughout the study period were evaluated. The rate of PDAC development during follow-up was analyzed by the Kaplan-Meier method. Results: A total of 17 IPMN-derived and 11 IPMN-concomitant PDACs were diagnosed at the first examination. Lesions that did not qualify for resection or chemotherapy were followed up for a median of 42 months. Seven IPMN-concomitant PDACs and no IPMN-derived PDACs were detected during follow-up. The 3- and 5-year rates of IPMN-concomitant PDAC development were 4.0% and 8.8%, respectively. At the first examination, EUS was superior to other imaging modalities in terms of IPMN-derived and -concomitant PDAC detection. Throughout the study period, including follow-up, EUS was significantly better at detecting IPMN-concomitant PDACs than the other modalities. Conclusions: IPMN-concomitant PDACs are quite often found at diagnosis and during follow-up.EUS examination of the whole pancreas plays an important role in the management of IPMNs as it allows the early detection of these small invasive carcinomas.
  • Kinuyo Hatanaka; Yasunori Minami; Masatoshi Kudo; Tatsuo Inoue; Hobyung Chung; Seiji Haji
    JOURNAL OF CLINICAL ULTRASOUND 42 1 1 - 8 2014年01月 [査読有り]
     
    BackgroundThis study investigated the usefulness of postvascular images of contrast-enhanced ultrasonography (CE-US) in the gross classification of hepatocellular carcinoma (HCC) in comparison with contrast-enhanced CT (CE-CT) findings. MethodsThis is a prospective study with consecutive HCC patients who had both CE-US and CE-CT prior to surgical resection. Fifty-one patients (32 men, 19 women; mean age, 68.9 years) with 61 HCCs were enrolled. The maximal diameters of all tumors ranged from 1.0 to 5.0 cm (meanSD, 2.5 cm1.1). Weighted kappa statistics were used to assess the agreement of the sonographic or CT findings versus the results of macroscopic configurations. ResultsThirty-nine tumors were macroscopically diagnosed as simple nodule type; 19 tumors were macroscopically diagnosed as simple nodular type with extranodular growth, and 3 were macroscopically diagnosed as confluent multinodular type from the resected specimen. The diagnostic accuracy was 86.9% (53/61) for CE-US and 65.6% (40/61) for CE-CT. The differences in accuracy between CE-US and CE-CT were statistically significant (McNemar; p=0.007). Agreement analysis between gross classification using CE-US and final macroscopic results gave a kappa value of 0.74 (95% CI: 0.65-0.82), which was considered a good agreement. On the other hand, kappa coefficient value was 0.38 (95% CI: 0.28-0.48) between gross classification using CE-CT and final macroscopic results. ConclusionsCE-US is a more reliable tool than CE-CT to evaluate the gross type of HCC than CE-CT. Accurate gross classification using imaging is considered to be essential for the determination of the correct treatment strategy and the estimates of the patients' prognosis. (c) 2013 Wiley Periodicals, Inc. J Clin Ultrasound42:1-8, 2014
  • Miwa Kawanaka; Ken Nishino; Jun Nakamura; Takahito Oka; Noriyo Urata; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Masatoshi Kudo; Gotaro Yamada
    LIVER CANCER 3 1 41 - 52 2014年 [査読有り]
     
    Background: Serum levels of hepatitis B virus (HBV) DNA are an important predictor of the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. However, little is known about whether high levels of hepatitis B surface antigen (HBsAg) increase the risk for HCC. Methods: We investigated 167 patients who were treated with nucleos(t)ide analogues (NA) for at least 2 years (median: 5.8 years, range: 2-13.1 years). Relationships between reduced levels of HBsAg and various factors were evaluated. In addition, we evaluated the usefulness of quantitative serum levels of HBV DNA and HBsAg as predictors of HCC development in patients receiving long-term NA therapy. Results: HCC developed in 9 of the 167 NA-treated patients. In the 9 patients with HCC, HBV DNA was undetectable (<2.1 log copies/ mL), but HBsAg levels were >= 2000 degrees C.O.I. in 7 patients. No maternal transmission, long NA treatment period, HBV DNA levels <3.0 log copies/mL, and reduced hepatitis B e antigen levels during the first 24 weeks of treatment were a significant factor of HBsAg levels <2000 C.O.I.. Conclusions: Hepatocarcinogenesis was observed in patients with high HBsAg levels, despite the negative conversion of HBV DNA as a result of long-term NA therapy. Therefore, to suppress hepatocarcinogenesis, it is important to control not only HBV DNA levels but also HBsAg levels. Copyright (C) 2014 S. Karger AG, Basel
  • Yasunori Minami; Yukinobu Yagyu; Takamichi Murakami; Masatoshi Kudo
    LIVER CANCER 3 1 53 - 61 2014年 [査読有り]
     
    Purpose: New tracking navigation imaging software was used to evaluate the usefulness of three dimensional (3D) CT angiography for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Materials and Methods: Fifty-two patients with 73 HCCs were enrolled in this study retrospectively. Rotational angiography was performed from the hepatic artery for evaluation of the tumor feeding vessels. Arteries feeding the tumor were traced automatically by adjusting the region of interest around the targeted tumor on axial and coronal images using tracking navigation imaging with 3D cone-beam CT angiography. Results: Using final selective angiographic findings as the gold standard, the detection of feeding vessels was 90.4% (66/73) for tracking navigation imaging and 50.7% (37/73) for celiac trunk angiography. This difference was statistically significant (Wilcoxon rank sum test, p < 0.001). The sensitivity, specificity, positive predictive value, and negative predictive value for the detection of feeding arteries were 97.1% (66/68), 80.0% (4/5), 98.5% (66/67), and 66.7% (4/6), respectively. The kappa coefficient had a value of 0.638 (95% CI: 0.471-0.805), which is considered to indicate a good degree of agreement. With the as-sistance of tracking navigation imaging, the disease control rate of TACE for HCC was 67.3% (35/52) according to the modified Response Evaluation Criteria in Solid Tumors. During follow- up periods of 1-11 months, 10 patients (19.2%) remained cancer-free after TACE. Conclusion: Tracking navigation imaging with 3D cone-beam CT angiography should be useful for TACE in HCC patients with complicated feeding arteries. Copyright (C) 2014 S. Karger AG, Basel
  • Prediction of incidence risk of hepatocellular carcinoma by ultrasound elastography
    Kudo M
    Liver Cancer 3 1 - 5 2014年
  • Masayuki Kitano; Ken Kamata; Masatoshi Kudo
    Endoscopy 46 4 358 - 358 2014年 [査読有り]
  • Kiyoshi Hasegawa; Masatoshi Makuuchi; Norihiro Kokudo; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
    ANNALS OF SURGERY 259 1 166 - 170 2014年01月 [査読有り]
     
    Objective: To clarify the clinical significance of resection of lymph node metastases in patients' hepatocellular carcinoma (HCC). Background: Although the presence of lymph node metastasis form HCC has been considered as a systemic disease, prognosis after resection of them remains unknown. Methods: From the database of a Japanese nationwide survey, 14,872 patients of HCC treated by surgical resection between 2000 and 2005 were enrolled. We modified the current Japanese staging system for HCC, by further dividing stage IVA into stage IVAnon-n1 and stage n1, according to the absence or presence of pathologically proven lymph node metastasis. Thus, the patients classified into 6 disease stages, that is, I (n = 1494), II (n = 8056), III (n = 4243), IVAnon-n1 (n = 701), n1 (n = 112), and IVB (n = 266), and their long-term outcomes were compared. Results: The median follow-up period was 20.6 months. The 3-year overall survival rates of the patients with stage IVAnon-n1, stage n1, and stage IVB were 51.6%, 38.9% and 27.2%, respectively. A multivariate analysis showed that stage IVAnon-n1 would have a similar impact on the survival as stage n1 (hazard ratio: 0.88, 95% confidence interval: 0.59-1.33, P = 0.555), and that stage n1 still represented one class less advanced than stage IVB (hazard ratio: 0.52, 95% confidence interval: 0.34-0.80, P = 0.003). Conclusions: The prognosis of patients with histologically node-positive HCC was similar to that of patients with locally advanced HCC (stage IVA), which supports the validity of the current Japanese staging system and also partially validates the system proposed by the UICC/AJCC.
  • 膵充実性腫瘤の造影超音波内視鏡分類. 特集「内視鏡分類update」
    北野雅之; 坂本洋城; 工藤正俊
    消化器内視鏡 26 1 145 - 147 2014年01月
  • Kudo M; Matsuda K; Sugawara K; Iki Y; Kogure N; Saito-Ito T; Shimizu K; Sato I; Yoshikawa T; Uruno A; Yokoyama A; Saito-Hakoda A; Ito S; Sugawara A
    World Journal of Hypertension 4 1 7 - 14 2014年 [査読有り]
  • Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kumpei Kadosaka; Takeshi Miyata; Hajime Imai; Kiyoshi Maekawa; Takaaki Chikugo; Masashi Kumano; Tomoko Hyodo; Takamichi Murakami; Yasutaka Chiba; Yoshifumi Takeyama
    Endoscopy 46 4 358  2014年 [査読有り]
  • Naoshi Nishida; Norihisa Yada; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    HEPATOLOGY 60 758A - 758A 2014年 [査読有り]
  • Meeting Report: ILCA2013
    工藤正俊
    The Liver Cancer Journal 6 48 - 50 2014年 [査読有り][招待有り]
  • M. Kudo
    LIVER CANCER 3 2 68 - 70 2014年 [査読有り]
  • M. Kudo
    LIVER CANCER 3 1 1 - 5 2014年 [査読有り]
  • Kiyoshi Hasegawa; Masatoshi Makuuchi; Norihiro Kokudo; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
    ANNALS OF SURGERY 259 1 166 - 170 2014年01月 [査読有り]
     
    Objective: To clarify the clinical significance of resection of lymph node metastases in patients' hepatocellular carcinoma (HCC). Background: Although the presence of lymph node metastasis form HCC has been considered as a systemic disease, prognosis after resection of them remains unknown. Methods: From the database of a Japanese nationwide survey, 14,872 patients of HCC treated by surgical resection between 2000 and 2005 were enrolled. We modified the current Japanese staging system for HCC, by further dividing stage IVA into stage IVAnon-n1 and stage n1, according to the absence or presence of pathologically proven lymph node metastasis. Thus, the patients classified into 6 disease stages, that is, I (n = 1494), II (n = 8056), III (n = 4243), IVAnon-n1 (n = 701), n1 (n = 112), and IVB (n = 266), and their long-term outcomes were compared. Results: The median follow-up period was 20.6 months. The 3-year overall survival rates of the patients with stage IVAnon-n1, stage n1, and stage IVB were 51.6%, 38.9% and 27.2%, respectively. A multivariate analysis showed that stage IVAnon-n1 would have a similar impact on the survival as stage n1 (hazard ratio: 0.88, 95% confidence interval: 0.59-1.33, P = 0.555), and that stage n1 still represented one class less advanced than stage IVB (hazard ratio: 0.52, 95% confidence interval: 0.34-0.80, P = 0.003). Conclusions: The prognosis of patients with histologically node-positive HCC was similar to that of patients with locally advanced HCC (stage IVA), which supports the validity of the current Japanese staging system and also partially validates the system proposed by the UICC/AJCC.
  • Masatoshi Kudo
    ONCOLOGY 87 1 - 6 2014年 [査読有り]
  • Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai
    ONCOLOGY 87 7 - 21 2014年 [査読有り]
     
    Surveillance and diagnostic algorithms for hepatocellular carcinoma (HCC) have already been described in guidelines published by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer (EASL-EORTC), and the Japan Society of Hepatology (JSH), but the content of these algorithms differs slightly. The JSH algorithm mainly differs from the other two algorithms in that it is highly sophisticated and considers the functional imaging techniques of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI (EOB-MRI) and Sonazoid contrast-enhanced ultrasound (CEUS) to be very important diagnostic modalities. In contrast, the AASLD and EASL-EORTC algorithms are less advanced and suggest that a diagnosis be made based solely on hemodynamic findings using dynamic CT/MRI and biopsy findings. A consensus meeting regarding the JSH surveillance and diagnostic algorithm was held at the 50th Liver Cancer Study Group of Japan Congress, and a 2014 update of the algorithm was completed. The new algorithm reaffirms the very important role of EOB-MRI and Sonazoid CEUS in the surveillance and diagnosis of liver cancer and is more sophisticated than those currently used in the United States and Europe. This is now an optimized algorithm that can be used to diagnose early-stage to classical HCC easily and highly accurately. (C) 2014 S. Karger AG, Basel
  • Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Masumi Kadoya; Takuji Okusaka; Shiro Miyayama; Koichiro Yamakado; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami
    ONCOLOGY 87 22 - 31 2014年 [査読有り]
     
    In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and particularly in Japan, and areas with lipiodol deposition were considered to be necrotic. However, this concept is not well accepted internationally. Furthermore, following the approval of microspheres, an embolic material that does not use lipiodol, in February 2014 in Japan, the phrase 'lipiodol deposition' needed to be changed to 'necrotic lesion or viable lesion'. Accordingly, the respective section in the JSH guidelines was revised to define TACE failure as an insufficient response after >= 2 consecutive TACE procedures that is evident on response evaluation computed tomography or magnetic resonance imaging after 1-3 months, even after chemotherapeutic agents have been changed and/or the feeding artery has been reanalyzed. In addition, the appearance of a higher number of lesions in the liver than that recorded at the previous TACE procedure (other than the nodule being treated) was added to the definition of TACE failure/refractoriness. Following the discussion of other issues concerning the continuous elevation of tumor markers, vascular invasion, and extrahepatic spread, descriptions similar to those in the previous version were approved. The revision of these TACE failure definitions was approved by over 85% of HCC experts. (C) 2014 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 87 32 - 36 2014年 [査読有り]
     
    Background: Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. The study evaluated the validity of the definition of TACE failure or refractoriness as proposed by the Liver Cancer Study Group of Japan (LCSGJ) through a retrospective analysis of sorafenib treatment. Methods: Out of 265 patients with advanced hepatocellular carcinoma who were treated with sorafenib at our hospital, 45 experienced TACE failure or refractoriness and were included in this study and retrospectively analyzed. Results: Multivariate analysis only identified the number of ineffective TACE procedures performed before starting sorafenib treatment as significant factors. Overall survival (OS) after starting sorafenib was statistically longer in patients treated with <= 2 consecutive ineffective TACE procedures before sorafenib administration than in patients treated with >= 3 consecutive ineffective TACE procedures (p < 0.005). This result matched the LCSGJ criteria. Conclusion: In patients treated with sorafenib, OS was extended with <= 2 consecutive ineffective TACE procedures compared to that with >= 3 consecutive ineffective TACE procedures. Thus, if tumors are uncontrolled, TACE should not be repeated. The result of this study supports the definition of TACE failure or refractoriness proposed by the LCSGJ. (C) 2014 S. Karger AG, Basel
  • Fukuo Kondo; Toshio Fukusato; Masatoshi Kudo
    ONCOLOGY 87 37 - 49 2014年 [査読有り]
     
    There are various types of benign hepatocellular nodular lesions, and their diagnostic criteria were formulated in detail. However, in 2010, the new World Health Organization (WHO) classification introduced immunohistochemical diagnostic criteria for hepatocellular adenoma (HCA) reflecting molecular pathological properties, and HCA was classified into 4 subtypes. These criteria were useful for its differential diagnosis from focal nodular hyperplasia (FNH). They were also useful for the diagnosis of HCA, its subtyping, and differentiation from FNH in Japan. However, the new WHO classification is based on principles that differ from those of conventional definitions of disease concepts and methods for the differential diagnosis. Therefore, it has caused disagreements in the diagnosis in some cases. Based on this background, we present a new perspective on the diagnosis of benign hepatocellular nodular lesions. (C) 2014 S. Karger AG, Basel
  • Ogawa C; Minami Y; Morioka Y; Noda A; Arasawa S; Izuta M; Kubo A; Matsunaka T; Tamaki N; Shibatouge M; Kudo M
    Oncology 87 50 - 54 2014年 [査読有り]
     
    Purpose: To evaluate the usefulness of a virtual ultrasound (US) imaging device as a tool to assist novice sonographers. Materials and Methods: A prospective blinded pilot study was conducted involving patients with liver lesions. Two sonographers and 2 medical doctors with less than 5 years of experience performed US examinations. The time needed to detect liver lesions on US and the success rate for detecting liver lesions with and without using the virtual US imaging device SYNAPSE VINCENT (R) (Fujifilm Medical Co., Tokyo, Japan) before US examination were evaluated. Results: Thirty-two patients with the following 42 liver lesions were included: liver cyst (n = 24), hemangioma (n = 8), hepatocellular carcinoma (n = 6), and liver metastasis (n = 4). The maximal diameter of these lesions ranged from 0.3 to 1.5 cm (mean +/- SD, 0.8 +/- 0.4). The average time for detecting liver lesions on US was 47.8 s (range, 7-113) with VINCENT and 112.9 s (range, 14-313) without VINCENT before US examination. There were significant differences in the duration of US examination with and without VINCENT (p = 0.0002, Student's t test). The rates for accurately detecting liver lesions were 100 and 76.2% (16/21) in US beginners with and without VINCENT, respectively. Significantly higher detection rates were found in the US beginners who used VINCENT compared to those who did not use VINCENT (p = 0.047, Fisher's exact test). Conclusion: Before US examination, a reference with VINCENT could contribute to the successful detection of liver lesions and could be time-saving for US beginners. (C) 2014 S. Karger AG, Basel
  • Tomohiro Minami; Yasunori Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 87 55 - 62 2014年 [査読有り]
     
    Purpose: The purpose of this study was to evaluate the usefulness of the combination guidance of contrast-enhanced US (CEUS) and fusion imaging in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) with poor conspicuity on B-mode US and CEUS/fusion imaging. Materials and Methods: We conducted a retrospective cohort study, which included 356 patients with 556 HCCs that were inconspicuous on B-mode US. A total of 192 patients with 344 HCCs, 123 patients with 155 HCCs, and 37 patients with 57 HCCs underwent RFA under CEUS guidance, fusion imaging guidance, and the combination of CEUS and fusion imaging guidance. Results: The average number of treatment sessions was 1.1 (range: 1-2) in the CEUS guidance group, 1.1 (range: 1-2) in the fusion imaging guidance group, and 1.1 (range: 1-3) in the combination of CEUS and fusion imaging guidance group. Treatment analysis did not reveal significantly more RFA treatment sessions in the combination guidance group than in the other groups (p = 0.97, Student's t test). During the follow-up period (1.1-85.3 months, mean +/- SD, 43.2 +/- 59.5), the 3-year local tumor progression rates were 4.9, 7.2, and 5.9% in the CEUS guidance group, the fusion imaging guidance group, and the combination guidance group, respectively (p = 0.84, log-rank test). Conclusion: In spite of selection bias, session frequency and local tumor progression were not different under the combination guidance with CEUS and fusion imaging in RFA. The combination of fusion imaging and CEUS guidance in RFA therapy is an effective treatment for HCC with poor conspicuity on B-mode US and CEUS/fusion imaging. (C) 2014 S. Karger AG, Basel
  • Norihisa Yada; Masatoshi Kudo; Norifumi Kawada; Shuichi Sato; Yukio Osaki; Akihisa Ishikawa; Hisaaki Miyoshi; Michiie Sakamoto; Masayoshi Kage; Osamu Nakashima; Akiko Tonomura
    ONCOLOGY 87 63 - 72 2014年 [査読有り]
     
    Objective: Although liver biopsy is the gold standard for viral liver disease management, it is invasive and the sampling error rate is problematic. Real-time tissue elastography (RTE), a recently developed method of ultrasound elastography, can be used to assess liver fibrosis noninvasively but the overlap between fibrosis stages limits its ability to assess liver fibrosis adequately when used alone. Methods: A multicenter collaborative study involving 542 patients with chronic viral hepatitis and cirrhosis who were scheduled to undergo liver biopsy compared the image features obtained from RTE image analysis, the liver fibrosis index (LFI), and pathological diagnosis. RTE and a blood test were performed on the same day as the liver biopsy. Data mining was also performed to construct a decision tree, and its diagnostic performance for assessing liver fibrosis was evaluated. Results: The LFI was higher in patients with chronic hepatitis C (CHC) than in those with chronic hepatitis B (CHB). When a decision tree was constructed by data mining of RTE and serological findings, the diagnostic accuracy was very high for all fibrosis stages, with respective rates at F1, F2, F3, and F4 of 94.4, 54.1, 38.7, and 81.3% for patients with CHC and of 97.1, 50.0, 43.8, and 80.6% for patients with CHB. Conclusions: The variation in LFI values between the different etiologies appears to reflect the difference in the development style of liver fibrosis. The decision tree for assessing liver fibrosis constructed by data mining of both RTE and serological findings had a high diagnostic performance in assessing liver fibrosis and shows promising clinical utility. (C) 2014 S. Karger AG, Basel
  • Kenji Ikeda; Yukio Osaki; Hiroyuki Nakanishi; Akihiro Nasu; Yusuke Kawamura; Koji Jyoko; Takatomo Sano; Hajime Sunagozaka; Koji Uchino; Yasunori Minami; Yu Saito; Kazumasa Nagai; Ryosuke Inokuchi; Shigehiro Kokubu; Masatoshi Kudo
    ONCOLOGY 87 73 - 77 2014年 [査読有り]
     
    In order to attain better ablation and more effective management of hepatocellular carcinoma (HCC), new approaches and devices in radiofrequency ablation (RFA) therapy were presented and discussed in a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. A novel bipolar RFA apparatus was introduced in Japan in January 2013. Hundreds of subjects with HCC were treated with multipolar RFA with varied devices and plans. Among these, no-touch ablation was one of the most useful procedures in the treatment of HCC with the apparatus. In RFA therapy, a few assisting devices and techniques were applied for convenience and improvement of the thermal ablation procedure. Contrast-enhanced ultrasonography and three-dimensional fusion imaging technique using volume data of CT or MRI could improve exact targeting and shorten the treatment time for RFA procedures under ultrasonographic guidance. A more complicated method using a workstation was also reported as being helpful in planning the ablated shape and volume in multineedle RFA. The effective use of sedatives and antianalgesics as well as a novel microwave apparatus with a cooled-tip electrode was also discussed. (C) 2014 S. Karger AG, Basel
  • Koichiro Yamakado; Masatoshi Kudo
    ONCOLOGY 87 78 - 81 2014年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and it shows increasing incidence worldwide. The Barcelona Clinic Liver Cancer (BCLC) staging system has become widely accepted in clinical practice, but in Japan, two clinical practice guidelines have been used for HCC: the Evidence-Based Clinical Practice Guidelines and the Consensus-Based Clinical Practice Guidelines. Although, in Japan, chemoembolization is the first-line treatment of intermediate-stage (stage B) HCC patients in the BCLC staging system, along with chemoembolization, locoregional treatments, such as resection and radiofrequency ablation, and hepatic arterial infusion chemotherapy are incorporated into the treatment algorithm based on the tumor number and size as well as on the liver profile. (C) 2014 S. Karger AG, Basel
  • Kazuhiro Nouso; Norihiro Kokudo; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroki Nishikawa; Hidenori Toyoda; Naoki Oishi; Kenji Kuwaki; Masashi Kusanaga; Takuki Sakaguchi; Zenichi Morise; Satoshi Kitai; Masatoshi Kudo
    ONCOLOGY 87 99 - 103 2014年 [査読有り]
     
    Background: In most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (HCC) with Child-Pugh C cirrhosis (CP-C). However, in Japan, patients were sometimes treated with expectation of benefit. Summary: A workshop was conducted to explore the state of treatments for CP-C HCC in Japan. After the workshop, a questionnaire on therapies was given to the panelists. Clinical data of 769 patients with CP-C HCC from 8 hospitals as well as analyses of data collected by the Liver Cancer Study Group of Japan (LCSGJ) consisting of 1,344 CP-C HCC cases were presented. Patients who underwent liver transplantation were excluded. In total, 424 out of the 769 patients (55.1%) from the 8 hospitals and 537 out of 828 CP-C HCC cases (64.8%) from the LCSGJ data received interventional therapies, such as local ablation and transcatheter arterial chemoembolization. All panelists agreed that there was a subgroup of CP-C patients who benefitted from the locoregional therapies. The major goals for the therapies were to prevent HCC rupture and avoid obstruction of major vessels by tumor growth, which can lead to a sudden deterioration of the patients' condition. Patient liver function and tumor stage are both important factors for the decision to undergo treatment; however, the inclusion criteria for the treatments varied among the centers. Key Message: There exists a subgroup of CP-C patients who benefit from interventions for HCC. (C) 2014 S. Karger AG, Basel
  • Katsuaki Tanaka; Mitsuo Shimada; Masatoshi Kudo
    ONCOLOGY 87 104 - 109 2014年 [査読有り]
     
    Background: Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). Summary: During a consensus workshop at the 50th annual meeting of the Liver Cancer Study Group of Japan held in Kyoto (June 5-6, 2014), experts met to discuss the characteristics of long-term (>3 years) survivors of advanced HCC following sorafenib treatment. A total of 70 long-term survivors following sorafenib treatment at eight institutions were included, and the long-term survival rate (>3 years) at each institution ranged from 2.6 to 6.9% (mean, 4.5). The long-term survival-related factors presented can be categorized as follows: (1) conversion options, including hepatic resection following successful sorafenib treatment, (2) additional salvage options when progressive disease is confirmed, (3) long-term sorafenib treatment, (4) effective post-sorafenib options to prolong postprogression survival, and (5) good pretreatment liver function. Sorafenib monotherapy exceeding 3 years is rare, and most of the patients receiving sorafenib required other treatment modalities in the form of multidisciplinary therapy. Conclusion: The overview obtained from the workshop reflects the pattern of management in practice for long-term survivors following sorafenib treatment for HCC in Japan and may also provide valuable information for other countries. (C) 2014 S. Karger AG, Basel
  • Masahiro Takita; Satoru Hagiwara; Masatoshi Kudo; Masashi Kono; Hirokazu Chishina; Tadaaki Arizumi; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima
    ONCOLOGY 87 110 - 117 2014年 [査読有り]
     
    Background: Telaprevir-based antiviral therapy has been the primary treatment for chronic hepatitis C genotype 1 at a high viral load since November 2011. On the other hand, a number of patients have been reported to require withdrawal from or reduced doses of drugs due to side effects, such as eruptions, anemia, and renal dysfunction. In addition, as hepatitis C patients are growing older, it is imperative to investigate the tolerability of triple combination therapy for elderly patients. Subjects and Methods: The study subjects comprised 35 patients who received telaprevir combination therapy after November 2011. They were divided into group A (age: <65 years; n = 21) and group B (age: >= 65 years; n = 14) in order to compare the treatment completion rate, sustained virological response at week 24 (SVR24), and adverse events between the groups. Results: The treatment completion rate was 82.8% (29/35) in all subjects, 90.4% (19/21) in group A, and 78.5% (11/14) in group B. The rate was lower in group B but without a significant difference between the groups (p = 0.804). The SVR24 rate was 88.5% (31/35) in all subjects, 90.4% (19/21) in group A, and 85.7% (12/14) in group B, without a significant difference between the groups (p = 0.161). Conclusion: Although the incidence of anemia was higher in group B, there was no significant difference in the treatment completion or SVR24 rate between the groups. Telaprevir combination therapy is suggested to be tolerable for elderly hepatitis C patients. (C) 2014 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 87 118 - 123 2014年 [査読有り]
     
    Objective: To investigate the relationship between tissue elasticity before and after antiviral therapy and shear wave as well as strain elastography. Methods: FibroScan and real-time tissue elastography were performed before and after antiviral therapy for chronic hepatitis C, and treatment efficacy and elastographic findings were comparatively analyzed. Elasticity was evaluated by measuring liver stiffness (LS) in kilopascals using FibroScan, and the liver fibrosis index (LFI) was assessed by real-time tissue elastography. Results: LS and LFI correlated well before and after therapy (r = 0.567, p = 0.003 and r = 0.576, p = 0.002, respectively). In the group without a sustained virological response (SVR), LS increased in 4 of 5 patients. Patients with an increase in both LS and LFI were all in the non-SVR group (3/3, 100%). In addition, LS increased in all patients except 1 in the non-SVR group (4/5, 80%). In the SVR group, both LS and LFI decreased in all patients except 1 (18/19, 94.7%). In the patient with an increase in LS despite achieving SVR, LS decreased quickly after alcohol cessation. Conclusions: With a few exceptions, SVR improved LS. All patients with an increase in LFI were in the non-SVR group, even though LFI decreased in 2 patients. Our findings suggest that an LFI increase indicates lack of treatment efficacy with antiviral therapy. LFI may be useful for the assessment of treatment efficacy in patients with worsening of LS despite achieving SVR with antiviral therapy. (C) 2014 S. Karger AG, Basel
  • Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
    LIVER CANCER 3 3-4 458 - 468 2014年 [査読有り]
     
    The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term "lipiodol" from the definition of TACE failure/refractoriness. Copyright (C) 2014 S. Karger AG, Basel
  • 座談会; 肝胆膵腫瘍のバイオインフォマティクス
    工藤正俊; 坂元亨宇; 山下太郎; 三木大樹
    肝胆膵 68 471 - 485 2014年 [査読有り]
  • 肝腫瘍領域の個別化薬物治療の現状. 特集「肝胆膵腫瘍のバイオインフォマティクス」
    上嶋一臣; 工藤正俊
    肝胆膵 68 459 - 463 2014年 [査読有り]
  • 西田直生志; 工藤正俊
    肝胆膵 68 3 353 - 363 (株)アークメディア 2014年 [査読有り]
  • ソラフェニブの最新情報
    上嶋一臣; 工藤正俊
    腫瘍内科 13 637 - 641 2014年 [査読有り]
  • V.肝細胞腺腫の悪性転化. 2）臨床の立場より
    工藤正俊
    肝胆膵 69 795 - 799 2014年 [査読有り]
  • 3.消化器領域の最新動向 2）胆・膵. Ⅰ. 特集「US Today 2014領域別超音波最新動向アプリ＆プローブ、モバイル活用法」
    鎌田 研; 北野雅之; 前川 清; 工藤正俊
    INNERVISION 29 16 - 19 2014年 [査読有り]
  • 欧米と日本の診療ガイドラインの相違を解説する. 特集「肝胆膵診療のNew Horizon」
    工藤正俊
    肝胆膵 69 967 - 976 2014年 [査読有り]
  • Taki H; Taki K; Yamakawa M; Shiina T; Kudo M; Sato T
    Conf Proc IEEE Eng Med Biol Soc 2014 5085 - 5088 2014年 [査読有り]
     
    We have proposed an ultrasound imaging method based on frequency domain interferometry (FDI) with an adaptive beamforming technique to depict real-time high-resolution images of human carotid artery. Our previous study has investigated the performance of the proposed imaging method under an ideal condition with a high signal-to-noise ratio (SNR). In the present study, we propose a technique that has the potential to improve accuracy in estimating echo intensity using the FDI imaging method. We investigated the performance of the proposed technique in a simulation study that two flat interfaces were located at depths of 15.0 and 15.2 mm and white noise was added. Because the -6 dB bandwidth of the signal used in this simulation study is 2.6 MHz, the conventional B-mode imaging method failed to depict the two interfaces. Both the conventional and proposed FDI imaging methods succeeded to depict the two interfaces when the SNR ranged from 15 to 30 dB. However, the average error of the estimated echo intensity at the interfaces using the conventional FDI imaging method ranged from 7.2 to 10.5 dB. In contrast, that using the FDI imaging method with the proposed technique ranged from 2.0 to 2.2 dB. The present study demonstrates the potential of the FDI imaging method in depicting robust and high-range-resolution ultrasound images of arterial wall, indicating the possibility to improve the diagnosis of atherosclerosis in early stages.
  • 食道疣状扁平上皮癌
    松井繁長; 樫田博史; 工藤正俊
    消化器内視鏡 26 10 1606 - 1607 2014年 [査読有り]
  • 松井繁長; 樫田博史; 高山政樹; 峯 宏昌; 足立哲平; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 工藤正俊; 筑後孝章
    胃と腸 49 3 377 - 384 2014年 [査読有り]
  • 発赤調で粘液の付着を伴う胃粘膜下腫瘍様病変
    松井繁長; 樫田博史; 工藤正俊
    消化器内視鏡 26 7 1009 - 1010 2014年 [査読有り]
  • 慢性膵炎の経消化管的治療
    宮田 剛; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    胆と膵 35 5 455 - 461 2014年 [査読有り]
  • 造影ハーモニックEUSによる胆・膵疾患の診断 - 造影CTとの違いは?
    宮田 剛; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    胆と膵 35 8 707 - 713 2014年 [査読有り]
  • 宮田 剛; 北野雅之; 工藤正俊
    膵・胆道癌FRONTIER 4 2 82 - 86 メディカルレビュー社 2014年 [査読有り]
  • Tao Wu; Jie Ren; Shu-zhen Cong; Fan-kun Meng; Hong Yang; Yan Luo; Hong-jun Lin; Yan Sun; Xiu-yan Wang; Shu-Fang Pei; Ying Zheng; Yun He; Yang Chen; Yu Hu; Na Yang; Ping Li; Masatoshi Kudo; Rong-qin Zheng
    DIGESTIVE DISEASES 32 6 791 - 799 2014年 [査読有り]
     
    Background: The prognosis and management of hepatic fibrosis are closely related to the stage of the disease. The limitations of liver biopsy, which is the gold standard for treatment, include its invasiveness and sampling error. Ultrasound elasticity might be the most promising imaging technology for the noninvasive and accurate assessment of hepatic fibrosis. Real-time tissue elastography (RTE) measures the relative stiffness of the tissue in the region of interest caused by the heartbeat. Many studies have verified that RTE is useful for the diagnosis of hepatic fibrosis in patients with chronic hepatitis C (CHC). Purpose: To determine the formula of the liver fibrosis index for chronic hepatitis B (BLFI) and to validate the diagnostic accuracy of the BLFI for hepatic fibrosis compared with the liver fibrosis index (LFI). Materials and Methods: RTE was performed in 747 prospectively enrolled patients with chronic hepatitis B (CHB) or cirrhosis from 8 centers in China; 375 patients were analyzed as the training set, and 372 patients were evaluated as the validation set. The fibrosis stage was diagnosed from pathological specimens obtained by ultrasound-guided liver biopsy. Nine image features were measured from strain images, and the new formula for the BLFI was obtained by combining the nine imaging features of the RTE images using multiple regression analysis of the training set. The BLFI and LFI were compared with the pathological fibrosis stage at diagnosis, and the diagnostic performances of the indexes were compared. Results: The Spearman correlation coefficient between the BLFI and hepatic fibrosis stages was significantly positive (r = 0.711, p < 0.001), and significant differences were present between all disease stages. The areas under the receiver-operating characteristic (AUROC) curves of the BLFI and LFI for predicting significant fibrosis (S0-S1 vs. S2-S4) were 0.858 and 0.858, respectively. For cirrhosis (S0-S3 vs. S4), the AUROC curves of the BLFI and LFI were 0.868 and 0.862, respectively. Conclusion: The results of this large, multicenter study confirmed that RTE is valuable for the diagnosis of hepatic fibrosis in patients with CHB. However, the diagnostic efficiencies of the new BLFI and the original LFI, which were based on CHC, for the assessment of CHB hepatic fibrosis were similar; thus, the LFI has the potential to be used to directly evaluate the extent of hepatic fibrosis in patients with CHB. (C) 2014 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 786 - 790 2014年 [査読有り]
     
    Hepatitis virus infections can be accompanied by extrahepatic manifestations that may be caused by the host's immune reaction to the viral infection. Vascular involvement is one of these manifestations and is occasionally associated with life-threatening conditions due to systemic organ failure. The unique profile of hepatitis-related vascular involvement is associated with infection by different types of hepatitis viruses. For example, polyarteritis nodosa is more frequently reported in patients with chronic hepatitis B than those with chronic hepatitis C. Similarly, membranous nephropathy is a notable manifestation among hepatitis B virus-positive patients. In contrast, patients infected with hepatitis C virus are at risk for cryoglobulinemia and membranoproliferative glomerulonephritis. Antiviral therapy is necessary to control these kinds of vasculitis related to hepatitis virus infections; however, imnnunosuppressive agents may be required to treat severe cases. New antiviral drugs for viral hepatitis could improve the prognosis of vascular and renal involvement. (C) 2014 S. Karger AG, Basel
  • Naoshi Nishida; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 740 - 746 2014年 [査読有り]
     
    Objectives: DNA methylation-dependent transcriptional inactivation of tumor suppressor genes (TSGs) is critical for the pathogenesis of hepatocellular carcinoma (HCC). This study identifies potential TSGs in HCCs using methylation profiling and pharmacological unmasking of methylated TSGs. Methods: Methylation profiling was performed on 22 pairs of HCCs and their corresponding noncancerous liver tissues using the Infinium HumanMethylation27 BeadChip. We also determined the gene reexpression after treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) and trichostatin A (TSA) in 5 HCC cell lines. Results: We selected CpGs that exhibited a significant increase in methylation in HCC tissues compared with that of the noncancerous control group. Two hundred and thirteen CpGs on different gene promoters with a mean difference in the beta value >= 0.15 and a value of p < 0.05 were selected. Of the 213 genes, 45 genes were upregulated in 3 or more HCC cell lines with multiplier value of differences after 5-Aza-dC and TSA treatment. Conclusions: We identified several potential TSGs that participate in transcription inactivation through epigenetic interactions in HCC. The results of this study are important for the understanding of functionally important epigenetic alterations in HCC. (C) 2014 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 733 - 739 2014年 [査読有り]
     
    Background: Sorafenib is a multikinase inhibitor targeting Raf and protein tyrosine kinases, which are involved in cell growth and tumor angiogenesis. Sorafenib administration induces temporary inhibition of tumor growth and a decrease in arterial blood flow in a considerable number of hepatocellular carcinoma (HCC) patients. We retrospectively evaluated the association between decreased blood flow and the overall survival (OS) of HCC patients after the initiation of sorafenib therapy. Patients and Methods: Therapeutic responses of 158 advanced HCC patients with hypervascular tumors who had received sorafenib for more than 1 month were analyzed. To assess their therapeutic response, patients underwent radiological evaluation before and every 4-6 weeks after the initiation of sorafenib treatment. After the classification of patients into three groups based on the change in arterial enhancement during treatment (no change, decrease and disappearance), the OS of each group was compared using the Kaplan-Meier method. Results:Statistically significant differences in OS were observed among the three groups (p < 0.001). A decrease or disappearance of arterial enhancement was significantly associated with improved OS compared to patients with no change in arterial enhancement; the median OS was 19.9 months (95% confidence interval, CI, 16.4-24.5 months) and 6.0 months (95% CI, 4.0-8.8 months), respectively (p < 0.001). However, there was no difference in OS between the decrease and disappearance groups (p = 0.88). Conclusion: We conclude that decreased arterial enhancement during sorafenib treatment was associated with the longest OS and could therefore reflect an effective response. (C) 2014 S. Karger AG, Basel
  • Satoshi Kitai; Masatoshi Kudo; Namiki Izumi; Shuichi Kaneko; Yonson Ku; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Masumi Kadoya; Yutaka Matsuyama; Takashi Matsunaga
    DIGESTIVE DISEASES 32 6 717 - 724 2014年 [査読有り]
     
    Objective: Clinical staging is very important for optimal therapeutic strategy and prognostic prediction in patients with hepatocellular carcinoma (HCC). The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used and best-validated method for HCC. Similarly, the conventional Japan Integrated Staging (c-JIS) score and the biomarker-combined JIS (bm-JIS) score have also been reported to effectively stratify HCC patients. The aim of this study was to evaluate the performance of these three staging systems for prognostic prediction. Methods: A total of 4,649 HCC patients were included in this study. A multivariate analysis identified the independent risk factors associated with overall survival. The stratification ability and the suitability as a prognostic model of the three staging systems were compared. Results: Multivariate analysis revealed that male sex, higher Child-Pugh score, tumor size >2.0 cm, multiple tumors, vascular invasion, higher alpha-fetoprotein (AFP) level, higher des-gamma-carboxyprothrombin level, higher Lens culinaris agglutinin-reactive AFP level, and a performance status of 3-4 were independent risk factors in HCC. The independent homogenizing ability and stratification value of the bm-JIS score were higher than those of the c-JIS score and the BCLC system (X-2 = 972.7581, 758.1041 and 679.6832, respectively). Moreover, the bm-JIS score had the lowest Akaike Information Criteria value, followed by the c-JIS score and the BCLC system (9,844.278, 10,054.93 and 10,131.35, respectively). Conclusions: Our results suggest that the bm-JIS score offers good stratification ability and is a better prognostic predictor than the c-JIS score and the BCLC system. (C) 2014 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshirna; Hirokazu Chishina; Masashi Kono; Mashiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 705 - 710 2014年 [査読有り]
     
    Background: Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC). Although tumor dormancy, characterized by stable tumor status or stable disease (SD) without tumor regression, is a unique feature of sorafenib treatment, the contribution of SD to OS remains debatable. This study aimed to clarify the correlation between SD periods and OS in patients with HCC treated with sorafenib. Methods: From May 2009 to January 2013, 269 patients with advanced-stage HCC were treated with sorafenib at the Kinki University Hospital. The antitumor response of sorafenib was evaluated in 158 patients using the modified Response Evaluation Criteria in Solid Tumors, and patients with SD were divided into two subgroups according to the median duration of SD: short SD (<3 months) and long SD (>= 3 months). The relationship between the duration of SD and OS was analyzed among patients with complete (CR) and partial response (PR), and long and short SD using the Kaplan-Meier method. Results:The median OS was 5.7 months in the short SD, 20.8 months in the long SD and 17.9 months in the CR + PR group. Although the duration of OS was significantly longer in the long SD group than the short SD group, no difference in OS was detected between the patients with CR + PR and patients with long SD. The impact of long SD on OS could be as strong as that of CR + PR. Conclusion: Achievement of long SD is one of the important goals for improving survival in patients with HCC treated with sorafenib. (C) 2014 S. Karger AG, Basel
  • Yasunori Minami; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 690 - 695 2014年 [査読有り]
     
    With advances in technology, imaging techniques that entail fusion of sonography and CT or MRI have been introduced in clinical practice. Ultrasound fusion imaging provides CT or MRI cross-sectional multiplanar images that correspond to the sonographic images, and fusion imaging of B-mode sonography and CT or MRI can be displayed simultaneously and in real time according to the angle of the transducer. Ultrasound fusion imaging helps us understand the three-dimensional relationship between the liver vasculature and tumors, and can detect small liver tumors with poor conspicuity. This fusion imaging is attracting the attention of operators who perform radiofrequency ablation (RFA) for the treatment of hepatic malignancies because this real-time, multimodality comparison can increase monitoring and targeting confidence during the procedure. When RFA with fusion imaging was performed on small hepatocellular carcinomas (HCCs) with poor conspicuity, it was reported that the rates of technical success and local tumor progression were 94.4-100% and 0-8.3%. However, there have been no studies comparing fusion imaging guidance and contrast-enhanced sonography, CT or MRI guidance in ablation. Fusion imaging-guided RFA has proved to be effective for HCCs that are poorly defined on not only conventional B-mode sonography but also contrast-enhanced sonography. In addition, fusion imaging could be useful to assess the treatment response of RFA because of three-dimensional information. Here, we give an overview of the current status of ultrasound fusion imaging for clinical application in the liver. (C) 2014 S. Karger AG, Basel
  • Masashi Kono; Tatsuo Inoue; Masatoshi Kudo; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuorni Ueshima; Naoshi Nishida; Takamichi Murakami
    DIGESTIVE DISEASES 32 6 670 - 677 2014年 [査読有り]
     
    Objective:The purpose of this study was to evaluate the risk factors for local recurrence with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) measuring <= 2 cm. Methods: This study involved 234 patients with 274 HCCs measuring cm who had undergone RFA as the initial treatment. The mean tumor diameter was 1.478 cm. The median follow-up period was 829 days. We evaluated the post-RFA cumulative local recurrence rate and analyzed the risk factors contributing to clinical outcomes. Results: Cumulative local recurrence rates were 9, 19 and 19% at 1,2 and 3 years, respectively. Among the 145 cases with a complete safety margin (SM) after RFA, only 4 developed local tumor recurrence and the cumulative rates of local tumor recurrence at 1, 2 and 3 years were 2, 3 and 3%, respectively. Among the 129 cases with incomplete SM, local tumor recurrence developed in 34 and the cumulative rates of local tumor progression at 1, 2 and 3 years were 14, 36 and 36%, respectively. In multivariate analysis, significant risk factors were tumor location (liver surface), irregular gross type and SM <5 mm. Conclusion: Even with HCC measuring cm, location and gross type of tumor should be carefully evaluated before RFA is performed. (C) 2014 S. Karger AG, Basel
  • Naoshi Nishida; Takafumi Nishimura; Takuya Nakai; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 658 - 663 2014年 [査読有り]
     
    Objective: To clarify the progression pattern of abnormal DNA methylation during the development of hepatocellular carcinoma (HCC) using a comprehensive methylation assay. Methods: We used an Infinium HumanMethylation450 BeadChip array that can analyze >485,000 CpG sites distributed throughout the genome for a comprehensive methylation study of 117 liver tissues consisting of 59 HCC and 58 noncancerous livers. Altered DNA nnethylation patterns during tumor progression were also analyzed. Results: We identified 38,330 CpG sites with significant differences in methylation levels between HCCs and noncancerous livers (DM-CpGs) using strict criteria. Of the DM-CpGs, 92% were hypomethylated and only 3,051 CpGs (8%) were hypermethylated in HCC. The DM-CpGs were more prevalent within intergenic regions with isolated CpGs. In contrast, DM-CpGs that were hypermethylated in HCC were predominantly located within promoter regions and CpG islands (p < 0.0001). The association between methylation profiles of DM-CpGs and tumor size was statistically significant, especially in hepatitis C virus (HCV)-positive cases (p = 0.0001). Conclusions: We clarified the unique characteristics of DM-CpGs in human HCCs. The stepwise progression of alterations in DNA methylation was a common feature of HCV-related hepatocarcinogenesis. (C) 2014 S. Karger AG, Basel
  • Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 655 - 657 2014年 [査読有り][招待有り]
  • IPMN診療におけるEUSの有用性. 特集「膵管内乳頭粘液性腫瘍（IPMN）の診療の現況」
    鎌田 研; 北野雅之; 工藤正俊; 山雄健太郎; 今井 元; 坂本洋城
    臨床消化器内科 29 1709 - 1716 2014年 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo
    LIVER CANCER 3 3-4 417 - 427 2014年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is a common cancer worldwide and develops against a background of chronic liver damage. A variety of HCC-related genes are known to be altered by genetic and epigenetic mechanisms. Therefore, information regarding alteration of the genetic and epigenetic profiles in HCC is essential for understanding the biology of this type of tumor. Methylation at CpG sites in gene promoters is known to affect the transcription of the corresponding genes. Abnormal regional hypermethylation is observed in the 5' region of several tumor suppressor genes (TSGs) in HCC, and this hypermethylation may promote carcinogenesis through the transcriptional inactivation of downstream TSGs. The DNA damage induced by oxidation is a trigger of abnormal DNA methylation and inactivation of TSGs through recruitment of the polycomb repressive complex to the promoter sequence. Thus, oxidative stress may be responsible for the emergence of HCC from chronic hepatitis and liver cirrhosis through the epigenetic alteration of TSGs. There have been several attempts to apply epigenetic information to the diagnosis and treatment of HCC. The predictive value of selected methylation events on survival in HCC patients has been reported, and the methylation profile of background liver could be associated with recurrence-free survival of HCC patients who have undergone hepatectomy. Another study detected methylated DNA from HCC cells in serum, and the circulating tumor DNA was regarded as a potential tumor marker. In addition, several trials of HCC therapy have targeted the epigenetic machinery and were based upon comprehensive analyses of DNA methylation of this type of tumor. Here, we present an overview of research regarding DNA methylation status in human HCC and describe the clinical application of epigenetic information to HCC. Copyright (C) 2014 S. Karger AG, Basel
  • M. Kudo
    LIVER CANCER 3 3-4 399 - 404 2014年 [査読有り]
  • 悪性中下部胆道狭窄に対するステンティング. 特集「悪性胆道狭窄に対する診断・治療の進歩」
    北野雅之; 今井 元; 工藤正俊
    臨床消化器内科 29 1231 - 1240 2014年 [査読有り]
  • 膵腫瘍性病変診断における造影ハーモニックEUS検査の有用性
    山雄健太郎; 北野雅之; 工藤正俊
    超音波TECHNO 26 76 - 78 2014年 [査読有り]
  • Takahashi H; Okada M; Kagawa Y; Hyodo T; Hidaka S; Kudo M; Ishii K; Tomiyama N; Murakami T
    Eur J Radiol. 83 4 684 - 691 Elsevier 2013年12月 [査読有り]
  • Josep M. Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T. Poon; Morris Sherman; Jean-Frederic Blanc; Richard S. Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
    JOURNAL OF CLINICAL ONCOLOGY 31 28 3509 - + 2013年10月 
    Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results Median OS was 9.4 months for brivanib and 8.2 months for placebo (hazard ratio [HR], 0.89; 95.8% CI, 0.69 to 1.15; P = .3307). Adjusting treatment effect for baseline prognostic factors yielded an OS HR of 0.81 (95% CI, 0.63 to 1.04; P = .1044). Exploratory analyses showed a median time to progression of 4.2 months for brivanib and 2.7 months for placebo (HR, 0.56; 95% CI, 0.42 to 0.76; P < .001), and an mRECIST ORR of 10% for brivanib and 2% for placebo (odds ratio, 5.72). Study discontinuation due to treatment-related adverse events (AEs) occurred in 61 brivanib patients (23%) and nine placebo patients (7%). The most frequent treatment-related grade 3 to 4 AEs for brivanib included hypertension (17%), fatigue (13%), hyponatremia (11%), and decreased appetite (10%). Conclusion In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS. The observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.
  • Chishina Hirokazu; Takayama Masaki; Adachi Teppei; Mine Hiromasa; Nagai Tomoyuki; Nagata Yoshiaki; Kawasaki Masanori; Asakuma Yutaka; Sakurai Toshiharu; Matsui Shigenaga; Kashida Hiroshi; Kudo Masatoshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 28 533 - 533 2013年10月 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Takeshi Nagasaka; Ajay Goel
    HEPATOLOGY 58 1065A - 1066A 2013年10月 [査読有り]
  • Kagawa Y; Okada M; Yagyu Y; Kumano S; Kanematsu M; Kudo M; Murakami T
    Acta radiologica (Stockholm, Sweden : 1987) 54 8 843 - 850 2013年10月 [査読有り]
  • Philip J. Johnson; Shukui Qin; Joong-Won Park; Ronnie T. P. Poon; Jean-Luc Raoul; Philip A. Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Avina; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
    JOURNAL OF CLINICAL ONCOLOGY 31 28 3517 - + 2013年10月 [査読有り]
     
    Purpose Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC. Patients and Methods Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive sorafenib 400 mg twice daily orally (n = 578) or brivanib 800 mg once daily orally (n = 577). Primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), disease control rate (DCR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), and safety. Results The primary end point of OS noninferiority for brivanib versus sorafenib in the per-protocol population (n = 1,150) was not met (hazard ratio [HR], 1.06; 95.8% CI, 0.93 to 1.22), based on the prespecified margin (upper CI limit for HR <= 1.08). Median OS was 9.9 months for sorafenib and 9.5 months for brivanib. TTP, ORR, and DCR were similar between the study arms. Most frequent grade 3/4 adverse events for sorafenib and brivanib were hyponatremia (9% and 23%, respectively), AST elevation (17% and 14%), fatigue (7% and 15%), hand-foot-skin reaction (15% and 2%), and hypertension (5% and 13%). Discontinuation as a result of adverse events was 33% for sorafenib and 43% for brivanib; rates for dose reduction were 50% and 49%, respectively. Conclusion Our study did not meet its primary end point of OS noninferiority for brivanib versus sorafenib. However, both agents had similar antitumor activity, based on secondary efficacy end points. Brivanib had an acceptable safety profile, but was less well-tolerated than sorafenib.
  • Josep M. Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T. Poon; Morris Sherman; Jean-Frederic Blanc; Richard S. Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
    JOURNAL OF CLINICAL ONCOLOGY 31 28 3509 - + 2013年10月 [査読有り]
     
    Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results Median OS was 9.4 months for brivanib and 8.2 months for placebo (hazard ratio [HR], 0.89; 95.8% CI, 0.69 to 1.15; P = .3307). Adjusting treatment effect for baseline prognostic factors yielded an OS HR of 0.81 (95% CI, 0.63 to 1.04; P = .1044). Exploratory analyses showed a median time to progression of 4.2 months for brivanib and 2.7 months for placebo (HR, 0.56; 95% CI, 0.42 to 0.76; P < .001), and an mRECIST ORR of 10% for brivanib and 2% for placebo (odds ratio, 5.72). Study discontinuation due to treatment-related adverse events (AEs) occurred in 61 brivanib patients (23%) and nine placebo patients (7%). The most frequent treatment-related grade 3 to 4 AEs for brivanib included hypertension (17%), fatigue (13%), hyponatremia (11%), and decreased appetite (10%). Conclusion In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS. The observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.
  • Masatoshi Kudo; Tsuyoshi Shiina; Fuminori Moriyasu; Hiroko Iijima; Ryosuke Tateishi; Norihisa Yada; Kenji Fujimoto; Hiroyasu Morikawa; Masashi Hirooka; Yasukiyo Sumino; Takashi Kumada
    JOURNAL OF MEDICAL ULTRASONICS 40 4 325 - 357 2013年10月 [査読有り]
     
    In diffuse liver disease, it is extremely important to make an accurate diagnosis of liver fibrosis prior to determining indications for therapy or predicting treatment outcome and malignant potential. Although liver biopsy has long been the gold standard in the diagnosis of liver fibrosis, it is still an invasive method. In addition, the sampling error is an intrinsic problem of liver biopsy. Non-invasive serological methods for the diagnosis of liver fibrosis can be affected by factors unrelated to the liver. Recently, after the introduction of FibroScan, it became possible to measure liver fibrosis directly and non-invasively by elastography, which has attracted attention as a non-invasive imaging diagnostic tool for liver fibrosis. In addition, real-time tissue elastography is currently being used to conduct clinical trials at many institutions. Moreover, virtual touch quantification enables the observation of liver stiffness at any location by simply observing B-mode images. Furthermore, the recently developed ShearWave elastography visualizes liver stiffness on a color map. Elastography is thought to be useful for all types of diffuse liver diseases. Because of its association with portal hypertension and liver carcinogenesis, elastography is expected to function as a novel prognostic tool for liver disease. Although various elastographic devices have been developed by multiple companies, each device has its own measurement principle, method, and outcome, creating confusion in clinical settings. Therefore, it is extremely important to understand the characteristics of each device in advance. The objective of this guideline, which describes the characteristics of each device based on the latest knowledge, is for all users to be able to make the correct diagnosis of hepatic fibrosis by ultrasound elastography.
  • 機能性ディスペプシア 診断と治療の現況を巡って 機能性ディスペプシアに早期慢性膵炎が存在する可能性について
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 110 臨増大会 A771 - A771 (一財)日本消化器病学会 2013年09月
  • 膵癌による閉塞性黄疸に対する乳頭括約筋切開術未施行のカバー付金属ステント留置術の成績
    千品 寛和; 門阪 薫平; 田中 梨絵; 大本 俊介; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 55 Suppl.2 2929 - 2929 (一社)日本消化器内視鏡学会 2013年09月
  • 消化器癌に対する分子標的薬 最近の動向 肝細胞癌に対する分子標的治療 現状と問題点
    工藤 正俊; 上嶋 一臣
    日本消化器病学会雑誌 110 臨増大会 A624 - A624 (一財)日本消化器病学会 2013年09月
  • Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
    Journal of Hepatology 59 3 641  2013年09月 [査読有り]
  • Yoshitaka Inaba; Fumihiko Kanai; Takeshi Aramaki; Takanobu Yamamoto; Toshihiro Tanaka; Koichiro Yamakado; Shuichi Kaneko; Masatoshi Kudo; Kazuho Imanaka; Shinichi Kora; Norifumi Nishida; Nobuyuki Kawai; Hiroshi Seki; Osamu Matsui; Hitoshi Arioka; Yasuaki Arai
    EUROPEAN JOURNAL OF CANCER 49 13 2832 - 2840 2013年09月 [査読有り]
     
    Background: TSU-68 is an antitumour drug that acts by inhibiting angiogenesis. We evaluated the efficacy and safety of TSU-68 in combination with transarterial chemoembolisation (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). Patients and Methods: In this multicenter, open-label phase II study, we randomised patients with HCC who had been treated with a single session of TACE to receive either 200 mg TSU-68 twice daily or no medication. The primary end-point was progression-free survival (PFS). Results: A total of 103 patients were enrolled. Median PFS was 157.0 days (95% confidence interval [CI], 124.0-230.0 days) in the TSU-68 group and 122.0 days (95% CI, 73.0-170.0 days) in the control group. The hazard ratio was 0.699 (95% CI, 0.450-1.088). Fatigue, elevated aspartate aminotransferase (AST), elevated alkaline phosphatase, oedema and anorexia were more frequent in the TSU-68 group than in the control group. The most frequent grade 3/4 adverse events were AST elevation (46% of patients in the TSU-68 group and 12% of controls) and alanine aminotransferase elevation (26% of patients in the TSU-68 group and 8% of controls). Two deaths, grade 5 hepatic failure and melena were noted in the TSU-68 group. Conclusion: This exploratory study shows a trend towards prolonged PFS with TSU-68 treatment after a single session of TACE, but this observation was not statistically significant. The two deaths were related to the study treatment. These results suggest that further examination of the study design is necessary to determine whether TSU-68 has any clinical benefits when combined with TACE. (C) 2013 Elsevier Ltd. All rights reserved.
  • Yoshitaka Inaba; Fumihiko Kanai; Takeshi Aramaki; Takanobu Yamamoto; Toshihiro Tanaka; Koichiro Yamakado; Shuichi Kaneko; Masatoshi Kudo; Kazuho Imanaka; Shinichi Kora; Norifumi Nishida; Nobuyuki Kawai; Hiroshi Seki; Osamu Matsui; Hitoshi Arioka; Yasuaki Arai
    EUROPEAN JOURNAL OF CANCER 49 13 2832 - 2840 2013年09月 [査読有り]
     
    Background: TSU-68 is an antitumour drug that acts by inhibiting angiogenesis. We evaluated the efficacy and safety of TSU-68 in combination with transarterial chemoembolisation (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). Patients and Methods: In this multicenter, open-label phase II study, we randomised patients with HCC who had been treated with a single session of TACE to receive either 200 mg TSU-68 twice daily or no medication. The primary end-point was progression-free survival (PFS). Results: A total of 103 patients were enrolled. Median PFS was 157.0 days (95% confidence interval [CI], 124.0-230.0 days) in the TSU-68 group and 122.0 days (95% CI, 73.0-170.0 days) in the control group. The hazard ratio was 0.699 (95% CI, 0.450-1.088). Fatigue, elevated aspartate aminotransferase (AST), elevated alkaline phosphatase, oedema and anorexia were more frequent in the TSU-68 group than in the control group. The most frequent grade 3/4 adverse events were AST elevation (46% of patients in the TSU-68 group and 12% of controls) and alanine aminotransferase elevation (26% of patients in the TSU-68 group and 8% of controls). Two deaths, grade 5 hepatic failure and melena were noted in the TSU-68 group. Conclusion: This exploratory study shows a trend towards prolonged PFS with TSU-68 treatment after a single session of TACE, but this observation was not statistically significant. The two deaths were related to the study treatment. These results suggest that further examination of the study design is necessary to determine whether TSU-68 has any clinical benefits when combined with TACE. (C) 2013 Elsevier Ltd. All rights reserved.
  • 門阪 薫平; 北野 雅之; 工藤 正俊
    胆道 27 3 519 - 519 (一社)日本胆道学会 2013年08月
  • 大本 俊介; 北野 雅之; 工藤 正俊; 中居 卓也; 竹山 宜典
    胆道 27 3 600 - 600 日本胆道学会 2013年08月
  • 山雄 健太郎; 坂本 洋城; 北野 雅之; 工藤 正俊
    胆道 27 3 443 - 443 日本胆道学会 2013年08月
  • Kazuomi Ueshima; Masatoshi Kudo
    Japanese Journal of Cancer and Chemotherapy 40 8 995 - 997 2013年08月 [査読有り]
     
    The patients with chronic viral hepatitis or cirrhosis are a high-risk group for hepatocellular carcinoma. Thus, those who should be screened for detecting HCC can be specified easily. Early detection of HCC leads to performing the curative therapy. However, HCC is easy to recur because of the underlying viral hepatitis and intrahepatic metastasis. After radical therapy, strict surveillance should be performed and if HCC recurs, strategy of treatment should follow the treatment algorithm of Japanese Clinical Practice Guidelines for hepatocellular carcinoma.
  • Kunal Das; Masatoshi Kudo; Masayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Tadayuki Takagi; Kenji Yamao
    JOURNAL OF MEDICAL ULTRASONICS 40 3 211 - 218 2013年07月 [査読有り]
     
    Ultrasound using microbubble-based contrast agents is useful for vascular imaging. Directional eFLOW (D-eFLOW) is a novel technology for vascular assessment that provides high spatial and temporal resolution. The purpose of this study was to investigate the utility of endoscopic ultrasound (EUS)-guided D-eFlow before and after administration of an ultrasound contrast agent (USCA) for assessing the vascularity of solid pancreatic lesions. D-eFlow was compared to power Doppler EUS (PD-EUS) or color Doppler EUS (CD-EUS) before and after USCA injection. We also evaluated the Visual Vascular Assessment (ViVA) scale for the estimation of vascularity and investigated its reliability using the interclass correlation coefficient (ICC). From January 2007 to March 2007, 35 patients (mean age, 64.5 years old; age range, 28-81 years) underwent EUS followed by D-eFLOW EUS, PD-EUS, and CD-EUS before and after administration of USCA. The pancreatic parenchymal ViVA score, pancreatic vascular pattern, and ICC were evaluated for all lesions. Concerning the sensitivity for detection of the hypovascular pattern in pancreatic adenocarcinoma, D-eFLOW (before and after USCA) had similar sensitivity to PD-EUS (before and after USCA) and CD-EUS (before and after USCA). D-eFLOW after contrast showed the highest accuracy (82.3 %) and negative predictive value (53.8 %) among all the modalities investigated. There was a good correlation among the ViVA scores for D-eFLOW before contrast, those for D-eFLOW EUS, and those for PD-EUS and CD-EUS. The reliability of the ViVA scale was excellent with an ICC of 0.81. In conclusion, D-eFLOW EUS is a sensitive, reliable, and highly accurate method of assessment of pancreatic vascularity. D-eFLOW EUS with contrast was more sensitive than PD-EUS and CD-EUS for assessment of pancreatic vascularity.
  • 上嶋 一臣; 工藤 正俊
    消化器外科Nursing 18 7 603 - 611 (株)メディカ出版 2013年07月
  • ミニオーラル105：肝 その他2 P-105-2 本邦における多発肝嚢胞症治療の実態
    小川光一; 福永 潔; 竹内朋代; 川岸直樹; 乳原善文; 工藤正俊; 大河内,信弘
    第68回日本消化外科学会総会抄録集 2013年07月
  • Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    DIGESTIVE ENDOSCOPY 25 4 468 - 469 2013年07月 [査読有り]
  • 門阪 薫平; 北野 雅之; 工藤 正俊
    膵臓 28 3 346 - 346 (一社)日本膵臓学会 2013年06月
  • 鎌田 研; 北野 雅之; 工藤 正俊; 大本 俊介; 門阪 薫平; 今井 元; 坂本 洋城; 竹山 宜典
    膵臓 28 3 322 - 322 (一社)日本膵臓学会 2013年06月
  • Takashi Katsube; Masahiro Okada; Seishi Kumano; Izumi Imaoka; Yuki Kagawa; Masatoshi Hori; Kazunari Ishii; Noboru Tanigawa; Yasuharu Imai; Masatoshi Kudo; Takamichi Murakami
    European Journal of Radiology 82 6 1039  2013年06月 [査読有り]
  • Satoru Hagiwara; Masatoshi Kudo; Yukio Osaki; Hiroo Matsuo; Tadashi Inuzuka; Akihiro Matsumoto; Eiji Tanaka; Toshiharu Sakurai; Kazuomi Ueshima; Tatsuo Inoue; Norihisa Yada; Naoshi Nishida
    Journal of Medical Virology 85 6 987 - 995 2013年06月 [査読有り]
     
    The ideal approach to treat chronic hepatitis B remains controversial. This pilot study aimed to evaluate the effectiveness of peginterferon (PEG-IFN) α-2b and entecavir hydrate (ETV) as a combination therapy for patients with chronic hepatitis B, particularly in the context of virological response and the reduction of intrahepatic covalently closed circular DNA (cccDNA). A total of 17 patients with hepatitis B virus (HBV) genotype C were enrolled in this study. All subjects were treated with this combination therapy for 48 weeks and observed for an additional 24 weeks. All patients underwent liver biopsy before and after the therapy period. Changes in cccDNA levels and liver histology were monitored between biopsies. Among the 11 patients who exhibited pre-therapy hepatitis B e antigen (HBeAg), 8 (73%) showed evidence of HBeAg seroconversion by the end of the follow-up period. Serum HBV DNA levels decreased by 5.2 and 3.3log copies/ml (mean) by the end of the therapy and follow-up periods, respectively. In addition, intrahepatic cccDNA decreased significantly to 1.4logcopies/μg (mean) by the end of the therapy period. Among the 11 patients who did not experience viral relapse, only 2 (18%) exhibited high levels of cccDNA (> 4.5logcopies/μg) by the end of the treatment period. In contrast, all relapsed subjects exhibited significantly higher levels of cccDNA than subjects who did not relapse (P=0.027). The combination regimen is a promising approach to treat chronic hepatitis B and may achieve significant reduction in serum HBV DNA and intrahepatic cccDNA. © 2013 Wiley Periodicals, Inc.
  • Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    GASTROENTEROLOGY 144 5 S1041 - S1041 2013年05月 [査読有り]
     
    0
  • Yoshiaki Nagata; Toshiharu Sakurai; Masaki Takayama; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Satoru Hagiwara; Naoshi Nishida; Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 144 5 S883 - S883 2013年05月 [査読有り]
     
    0
  • 生活習慣病と内視鏡 早期慢性膵炎と糖尿病の関連について
    門阪 薫平; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 55 Suppl.1 951 - 951 (一社)日本消化器内視鏡学会 2013年04月
  • 慢性膵炎に対する内視鏡治療の現状 当院における膵仮性嚢胞に対するTherapeuticEUSの工夫と成績
    大本 俊介; 工藤 正俊; 北野 雅之
    Gastroenterological Endoscopy 55 Suppl.1 946 - 946 (一社)日本消化器内視鏡学会 2013年04月
  • <診療に活かす>膵腫瘍の診断に最も有用な画像診断法は? 画像診断の現状とピットフォール 膵疾患に対する造影超音波検査
    今井 元; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 工藤 正俊
    超音波医学 40 Suppl. S291 - S291 (公社)日本超音波医学会 2013年04月
  • TACE施行回数からみたソラフェニブ投与時におけるTACE不応の判断
    上嶋 一臣; 有住 忠晃; 工藤 正俊
    肝臓 54 Suppl.1 A286 - A286 (一社)日本肝臓学会 2013年04月
  • Masayuki Kitano; Masatoshi Kudo
    Journal of Japanese Society of Gastroenterology 110 4 557 - 567 2013年04月 [査読有り]
  • 超音波内視鏡下胆嚢ドレナージ術の有用性
    今井 元; 北野 雅之; 工藤 正俊; 門坂 薫平; 大本 俊介; 鎌田 研; 宮田 剛; 坂本 洋城
    日本消化器病学会雑誌 110 臨増総会 A208 - A208 (一財)日本消化器病学会 2013年02月
  • M. Claudon; C. F. Dietrich; B. I. Choi; D. O. Cosgrove; M. Kudo; C. P. Nolsoe; F. Piscaglia; S. R. Wilson; R. G. Barr; M. C. Chammas; N. G. Chaubal; M. -H. Chen; D. A. Clevert; J. M. Correas; H. Ding; F. Forsberg; J. B. Fowlkes; R. N. Gibson; B. B. Goldberg; N. Lassau; E. L. S. Leen; R. F. Mattrey; F. Moriyasu; L. Solbiati; H. -P. Weskott; H. -X. Xu
    ULTRASCHALL IN DER MEDIZIN 34 1 11 - 29 2013年02月 [査読有り]
     
    Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide.
  • Michel Claudon; Christoph F. Dietrich; Byung Ihn Choi; David O. Cosgrove; Masatoshi Kudo; Christian P. Nolsoe; Fabio Piscaglia; Stephanie R. Wilson; Richard G. Barr; Maria C. Chammas; Nitin G. Chaubal; Min-Hua Chen; Dirk Andre Clevert; Jean Michel Correas; Hong Ding; Flemming Forsberg; J. Brian Fowlkes; Robert N. Gibson; Barry B. Goldberg; Nathalie Lassau; Edward L. S. Leen; Robert F. Mattrey; Fuminori Moriyasu; Luigi Solbiati; Hans-Peter Weskott; Hui-Xiong Xu
    ULTRASOUND IN MEDICINE AND BIOLOGY 39 2 187 - 210 2013年02月 [査読有り]
     
    Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide. (E-mail: Christoph.dietrich@ckbm.de) (C) 2013 World Federation for Ultrasound in Medicine & Biology.
  • Tomoko Hyodo; Takamichi Murakami; Yasuharu Imai; Masahiro Okada; Masatoshi Hori; Yuki Kagawa; Sachiyo Kogita; Seishi Kumano; Masatoshi Kudo; Teruhito Mochizuki
    RADIOLOGY 266 2 480 - 490 2013年02月 [査読有り]
     
    Purpose: To identify patient characteristics and magnetic resonance (MR) imaging findings associated with subsequent hypervascularization in hypovascular nodules that show hypointensity on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with chronic liver diseases. Materials and Methods: Institutional review board approval was obtained, and informed consent was waived. At multiple follow-up gadoxetic acid-enhanced MR imaging examinations of 68 patients, 160 hypovascular nodules were retrospectively reviewed. A Cox regression model for hypervascularization was developed to explore the association of baseline characteristics, including patient factors (Child-Pugh classification, etiology of liver disease, history of local therapy for hepatocellular carcinoma [HCC], and coexistence of hypervascular HCC) and MR imaging findings (fat content, signal intensity on T2-weighted images, and nodule size). In addition, the growth rate was calculated as the reciprocal of tumor volume doubling time to investigate its relationship with subsequent hypervascularization by using receiver operating characteristic and Kaplan-Meier analyses. Results: The prevalence of subsequent hypervascularization was 31% (50 of 160 nodules). Independent Cox multivariable predictors of increased risk of hypervascularization were hyperintensity on T2-weighted images (hazard ratio [HR] = 8.7; 95% confidence interval [CI]: 3.6, 20.8), previous local therapy for hypervascular HCC (HR = 5.0; 95% CI: 1.8, 13.6), Child-Pugh B cirrhosis (HR = 3.6; 95% CI: 1.4, 9.5) and coexistence of hypervascular HCC (HR = 2.0; 95% CI: 1.0, 3.8). The mean growth rate was significantly higher in nodules that showed subsequent hypervascularization than in those without hypervascularization. Kaplan-Meier analysis based on the receiver operating characteristic cutoff level (1.8 x 10(-3)/day [tumor volume doubling time, 542 days]) showed that nodules with a higher growth rate had a significantly higher incidence of hypervascularization (P = 5.2 x 10(-8), log-rank test). Conclusion: Hyperintensity on T2-weighted images is an independent and strong risk factor at baseline for subsequent hypervascularization in hypovascular nodules in patients with chronic liver disease. Tumor volume doubling time of less than 542 days was associated with a high rate of subsequent hypervascularization. (C)RSNA, 2013
  • Unique association between global DNA hypomethylation and hromosomal alterations in human hepatocellular carcinoma
    Nishida N; Kudo M; Nishimura T; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Yokomichi N; Nagasaka T; Goel A
    Plos One 8 e72312  2013年 [査読有り]
  • 消化器領域の超音波最新技術と臨床への展開 造影ハーモニックEUS(CH-EUS)を用いた腹部リンパ節の良悪性診断の試み
    大本 俊介; 坂本 洋城; 宮田 剛; 北野 雅之; 工藤 正俊
    超音波医学 40 1 54 - 55 (公社)日本超音波医学会 2013年01月
  • M. Kudo
    LIVER CANCER 2 3-4 151 - 152 2013年 [査読有り]
  • Taki H; Sakamoto T; Taki K; Yamakawa M; Shiina T; Kudo M; Sato T
    Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 2013 1398 - 1401 2013年 [査読有り]
     
    We have proposed a high-range-resolution ultrasound imaging method for human carotid artery using an adaptive beamforming technique based on frequency domain interferometry (FDI). The method assumes that the received signal consists of multiple echoes of targets and noise, where the waveform of each echo is similar to that of the reference signal. In this study, we examine the dependence of the echo waveform on the target depth, and investigate the proper measurement-range for the FDI imaging method using a reference signal. Furthermore, we propose a ROI-division process, where each sub-ROI has a proper measurement-range for the application of the FDI imaging method. Simulation and experimental results show the efficiency of the ROI-division process in improving the image quality of human carotid artery acquired using the FDI imaging method. We believe that the modified FDI imaging method with the ROI-division process has the potential to facilitate significant progress in the detection of vessel stenosis and in the assessment of cardiovascular disease risk.
  • Sakurai T; Kudo M; Umemura A; He G; Elsharkawy AM; Seki E; Karin M
    Cancer research 73 1 215 - 224 2013年01月 [査読有り]
     
    Most hepatocellular carcinomas (HCC) develop in the context of severe liver fibrosis and cirrhosis caused by chronic liver inflammation, which also results in accumulation of reactive oxygen species (ROS). In this study, we examined whether the stress-activated protein kinase p38 alpha (Mapk14) controls ROS metabolism and development of fibrosis and cancer in mice given thioacetamide to induce chronic liver injury. Liver-specific p38 alpha ablation was found to enhance ROS accumulation, which appears to be exerted through the reduced expression of antioxidant protein HSP25 (Hspb1), a mouse homolog of HSP27. Its reexpression in p38 alpha-deficient liver prevents ROS accumulation and thioacetamide-induced fibrosis. p38 alpha deficiency increased expression of SOX2, a marker for cancer stem cells and the liver oncoproteins c-Jun (Jun) and Gankyrin (Psmd10) and led to enhanced thioacetamide-induced hepatocarcinogenesis. The upregulation of SOX2 and c-Jun was prevented by administration of the antioxidant butylated hydroxyanisole. Intriguingly, the risk of human HCC recurrence is positively correlated with ROS accumulation in liver. Thus, p38 alpha and its target HSP25/HSP27 appear to play a conserved and critical hepatoprotective function by curtailing ROS accumulation in liver parenchymal cells engaged in oxidative metabolism of exogenous chemicals. Augmented oxidative stress of liver parenchymal cells may explain the close relationship between liver fibrosis and hepatocarcinogenesis. Cancer Res; 73(1); 215-24. (C) 2012 AACR.
  • Nishida N; Kudo M; Nishimura T; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Yokomichi N; Nagasaka T; Goel A
    PloS one 8 9 e72312  2013年 [査読有り]
     
    Global DNA hypomethylation is a characteristic feature of cancer cells that closely associates with chromosomal instability (CIN). However, the association between these characteristics during hepatocarcinogenesis remains unclear. Herein, we determined the relationship between hypomethylation and CIN in human hepatocellular carcinoma (HCC) by analyzing 179 HCCs, 178 matched non-tumor livers and 23 normal liver tissues. Hypomethylation at three different repetitive DNA (rDNA) sequences and hypermethylation of 12 CpG loci, including 11 tumor suppressor gene (TSG) promoters, were quantified using MethyLight or combined bisulfite restriction analysis. Fractional allelic loss (FAL) was used as a marker for CIN, calculated by analyzing 400 microsatellite markers. Gains and losses at each chromosome were also determined using semi-quantitative microsatellite analysis. The associations between rDNA hypomethylation and FAL, as well as between TSG hypermethylation and FAL were investigated. Significantly more hypomethylation was observed in HCC tissues than in normal liver samples. Progression of hypomethylation during carcinogenesis was more prominent in hepatitis C virus (HCV)-negative cases, which was in contrast to our previous reports of significantly increased TSG methylation levels in HCV-positive tumors. Absence of liver cirrhosis and higher FAL scores were identified as independent contributors to significant hypomethylation of rDNA in HCC. Among the chromosomal alterations frequently observed in HCC, loss of 8p, which was unique in the earliest stages of hepatocarcinogenesis, was significantly associated with hypomethylation of rDNA by multivariable analysis (p=0.0153). rDNA hypomethylation was also associated with a high FAL score regardless of tumor differentiation (p=0.0011, well-differentiated; p=0.0089, moderately/poorly-differentiated HCCs). We conclude that DNA hypomethylation is an important cause of CIN in the earliest step of HCC, especially in a background of non-cirrhotic liver.
  • Masatoshi Kudo
    DIGESTIVE DISEASES 31 5-6 405 - 407 2013年 [査読有り]
  • Kayo Sugimoto; Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Haruma Fujioka; Ke Ih Kim; Yasuhito Tanaka; Yoshihiko Yano; Soo Ki Kim; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Takashi Hatae; Hak Hotta; Yoshitake Hayashi; Masatoshi Kudo
    DIGESTIVE DISEASES 31 5-6 434 - 439 2013年 [査読有り]
     
    Objectives: We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy. Methods: A total of 40 patients infected with HCV-1b whose HCV virus had not been eradicated by previous PEG-IFN/RBV therapy were enrolled for treatment by DFPP plus IFN/RBV. Rapid virological response (RVR) and SVR were assessed, and pretreatment factors associated with SVR the interleukin (IL)28B gene, the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR) were analyzed. Results: Of the 40 patients, 9 (23%) achieved RVR and 10 (25%) achieved SVR. The significant factors associated with SVR were IL28B major and RVR, as assessed by multivariate analysis (p = 0.0182, p = 0.0005). Conclusion: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR. (C) 2013 S. Karger AG, Basel
  • Tatsuo Inoue; Tomoko Hyodo; Takamichi Murakami; Yukihisa Takayama; Akihiro Nishie; Atsushi Higaki; Keiko Korenaga; Azusa Sakamoto; Yukio Osaki; Hiroshi Aikata; Kazuaki Chayama; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Kazushi Numata; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Yasuharu Imai; Masatoshi Kudo
    Digestive Diseases 31 5-6 472 - 479 2013年 [査読有り]
     
    Objective: We aimed to investigate the natural outcome of nonhypervascular lesions detected in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI by performing a longitudinal study retrospectively enrolled in a nationwide manner. Methods: Between February 2008 and March 2011, 224 patients with 504 nodules that were diagnosed as nonhypervascular by imaging were recruited from institutions that participated in the present study. We examined the natural outcome of nonhypervascular lesions and evaluated the risk factors. Results: Of the 504 nodules, 173 (34.3%) showed hypervascular transformation. The overall cumulative incidence of hypervascular transformation was 14.9% at 12 months and 45.8% at 24 months. Multivariate analysis using the Cox regression model revealed previous treatment history for hepatocellular carcinoma (HCC relative risk = 1.498 p = 0.036, 95% CI 1.03-2.19) and hyperintensity on T2-weighted images (relative risk = 1.724 p = 0.015, 95% CI 1.11-2.67) were identified as independent factors for hypervascular transformation. Conclusions: Patients who have a previous treatment history for HCC and with hypointense nodules showing hyperintensity on T2-weighted images need careful follow-up because of the high incidence of hypervascular transformation.
  • Yasunori Minanni; Sosuke Hayaishi; Masatoshi Kudo
    DIGESTIVE DISEASES 31 5-6 480 - 484 2013年 [査読有り]
     
    Objective: To evaluate whether iatrogenic hemorrhage can be prevented by intrahepatic tract ablation following radiofrequency ablation (RFA) therapy for hepatic malignancies. Methods: A retrospective cohort study analyzing a prospective database in a single institution was conducted. The incidence of postprocedural complications was compared in two groups: one with cauterization of the needle tracts after RFA and the other without. Results: The complication rates of intraperitoneal hemorrhage were 1.05% (4/380) and 0.92% (6/652) in the nonablation group and the ablation group, respectively (p = 0.90). All of these 10 patients with iatrogenic bleeding were classified as Child-Pugh grade A. Among the 15 hemodialysis patients in this study, hemorrhage was seen in 2 (13.3%), compared with 8 (0.79%) of the nonhemodialysis patients (p = 0.0002). There were no statistically significant differences in the incidence of other complications including pleural effusion, serous ascites, pneumothorax, hemothorax, hepatic infarction, bile duct injury and pericardial effusion between the two groups. Gastrointestinal perforation, peritonitis or tumor seeding were not observed. Conclusion: Our study found a high incidence of bleeding after RFA among hemodialysis patients. Irrespective of tract ablation being after RFA, iatrogenic hemorrhage appeared to be equivalent in this population. (C) 2013 S. Karger AG, Basel
  • Yuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Masatoshi Hori; Masatoshi Kudo; Takamichi Murakami
    DIGESTIVE DISEASES 31 5-6 485 - 489 2013年 [査読有り]
     
    Objectives: We developed a novel technique of the extracted-overlay function in CT/MR-ultrasonography (US) fusion imaging for radiofrequency ablation (RFA), in which only a tumor extracted from CT/MR images with a virtual ablative margin of arbitrary thickness is overlaid on US. The usefulness of this function is investigated in this preliminary report. Methods: The volume data of the extracted tumor with a virtual ablative margin were created on an image-processing workstation, and transported into a US unit equipped with a CT/MR-US fusion imaging system. After the positional registration of US and transported images, the extracted tumor with an ablative margin could be overlaid on US. In RFA, using this function, an electrode was inserted targeting the overlaid tumor with an ablative safety margin of 5 mm on US, and the treatment effect was evaluated by dynamic CT. Treatment results of 23 consecutive hepatocellular carcinomas (HCCs) that underwent RFA using this function were retrospectively analyzed. Results: Complete tumor ablation was achieved in 22 (95.7%) and 1 (4.3%) HCCs in 1 and 2 treatment sessions, respectively. Conclusions: Due to the visualization of an extracted tumor with an ablative safety margin on a US image, even during and after ablation, this function is useful for treatment planning and guidance of RFA. (C) 2013 S. Karger AG, Basel
  • Toshiharu Sakurai; Masatoshi Kudo
    LIVER CANCER 2 3-4 365 - 366 2013年 [査読有り]
  • ソラフェニブ 商品名: ネクサバール®
    上嶋一臣; 工藤正俊
    消化器外科ナーシング 18 603 - 611 2013年 [査読有り]
  • SILIUS第I相試験とその解釈
    上嶋一臣; 工藤正俊
    The Liver Cancer Journal 5 24 - 31 2013年 [査読有り]
  • 再発肝細胞癌
    上嶋一臣; 工藤正俊
    癌と化学療法 40 995 - 997 2013年 [査読有り]
  • 肝癌診療のEast/Westでの相違とグローバルにおけるコンセンサスの方向性. 特集「肝癌診療のこれまでと今後-アジアをリードする日本の役割」
    工藤正俊
    クリニシアン 613 1009 - 1014 2013年 [査読有り]
  • 自己免疫性肝炎とIgG4関連病態, 特集「IgG4と肝胆膵」
    矢田典久; 工藤正俊; 鄭 浩柄; 渡邉智裕
    肝胆膵 67 381 - 387 2013年 [査読有り]
  • ADL不良の急性胆嚢炎および胆管炎に対するEUS下ドレナージ術. 特集II「後期高齢者に対する胆石症の治療戦略」
    門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本洋城; 工藤正俊
    消化器内科 56 663 - 666 2013年 [査読有り]
  • 上嶋 一臣; 工藤 正俊
    肝・胆・膵 65 6 1302 - 1306 (株)アークメディア 2012年12月
  • Teppei Adachi; Shigenaga Matsui; Masaki Takayama; Masanori Kawasaki; Yutaka Yutaka; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 425 - 426 2012年12月 [査読有り]
  • Masaki Takayama; Shigenaga Matsui; Masanori Kawasaki; Yutaka Asakuma; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 419 - 419 2012年12月 [査読有り]
  • Tomoyuki Nagai; Teppei Adachi; Masaki Takayama; Hiromasa Mine; Yoshiaki Nagata; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Matsui; Mikio Shiomi; Hiroshi Kashida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 409 - 409 2012年12月 [査読有り]
  • Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Masanori Kawasaki; Yoshiaki Nagata; Tomoyuki Nagai; Masaki Takayama; Hiromasa Mine; Teppei Adachi; Shigenaga Matsui; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 202 - 202 2012年12月 [査読有り]
  • Shigenaga Matsui; Hiroshi Kashida; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 392 - 392 2012年12月 [査読有り]
  • Tomoyuki Nagai; Ueshima Kazuomi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 225 - 225 2012年12月 [査読有り]
  • 上嶋 一臣; 工藤 正俊
    日本臨床 70 増刊8 分子標的薬 457 - 462 (株)日本臨床社 2012年11月
  • Masatoshi Kudo
    CURRENT CANCER DRUG TARGETS 12 9 1062 - 1072 2012年11月 [査読有り]
     
    May 2007, sorafenib (Nexavar (R)) was approved for "unresectable hepatocellular carcinoma (HCC)", and was the first molecular targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent, whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has now been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are now ongoing. Phase III clinical trials of several targeted agents comparing them with placebo as second-line treatment agents for patients who failed or was intolerable to sorafenib are also ongoing. In addition, combination of sorafenib with standard treatment such as resection, ablation, transarterial chemoembolization, and hepatic arterial infusion chemotherapy are ongoing. This review outlines the clinical utility of sorafenib in the treatment algorithm of HCC. Furthermore, it also reviews the current status of clinical trials of new agents or combination therapy with sorafenib and standard treatment. Finally, further prospect of the paradigm shift of the HCC treatment is also discussed.
  • Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 18 42 6005 - 6017 2012年11月 [査読有り]
     
    Advances in molecular cell biology over the last decade have clarified the mechanisms involved in cancer growth, invasion, and metastasis, and enabled the development of molecular-targeted agents. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin-like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other components of the signal transduction pathways. In addition, the combination of sorafenib with standard treatment, such as resection, ablation, transarterial embolization, and hepatic arterial infusion chemotherapy are ongoing. This review outlines the main pathways involved in the development and progression of hepatocellular carcinoma and the new agents that target these pathways. Finally, the current statuses of clinical trials of new agents or combination therapy with sorafenib and standard treatment will also be discussed. (C) 2012 Baishideng. All rights reserved.
  • Ueshima K; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 70 Suppl 8 457 - 462 2012年11月 [査読有り]
  • 症例(肝がん) HBV陽性Vp4肝細胞癌の一例
    上嶋 一臣; 田北 雅弘; 工藤 正俊
    日本癌治療学会誌 47 3 799 - 799 (一社)日本癌治療学会 2012年10月
  • Takuji Okusaka; Hiroshi Kasugai; Hiroshi Ishii; Masatoshi Kudo; Michio Sata; Katsuaki Tanaka; Yasukazu Shioyama; Kazuaki Chayama; Hiromitsu Kumada; Masaharu Yoshikawa; Toshihito Seki; Hidetugu Saito; Naoaki Hayashi; Keiko Shiratori; Kiwamu Okita; Isao Sakaida; Masao Honda; Yukio Kusumoto; Takuya Tsutsumi; Kenji Sakata
    INVESTIGATIONAL NEW DRUGS 30 5 2015 - 2025 2012年10月 [査読有り]
     
    Background SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We conducted a multicenter phase II trial in patients with HCC to evaluate the efficacy and safety of SM-11355, using a Zinostatin stimalamer suspension in iodized oil as a reference. Methods Patients with unresectable HCC were randomized 2:1 to receive administration of the SM-11355 or Zinostatin stimalamer suspension into the hepatic artery. A second injection was given 4-12 weeks later. Efficacy was evaluated by CT 3 months after treatment and categorized as therapeutic effect (TE) V to I, where TE V was defined as disappearance or 100% necrosis of all treated tumors. Results A total of 122 patients were evaluated for efficacy and toxicity (SM-11355, n = 83; Zinostatin stimalamer, n = 39). Baseline characteristics were similar in the two groups. The TE V rates were 26.5% (22/83) and 17.9% (7/39) in the SM-11355 and Zinostatin stimalamer groups, respectively. In the SM-11355 group,the most frequent drug-related adverse events (AEs) of a parts per thousand yenaEuro parts per thousand grade 3 were elevated AST, elevated ALT, thrombocytopenia, and hyperbilirubinemia. The AEs with the largest difference between the two groups (SM-11355 vs. Zinostatin stimalamer) were hepatic vascular injury (0 vs. 48.4%) and eosinophilia (84.3 vs. 41.0%). The 2-year and 3-year survival rates were 75.9% vs. 70.3% and 58.4% vs. 48.7%, respectively. Conclusions The results suggest that SM-11355 in iodized oil has similar efficacy to Zinostatin stimalamer and that repeated dosing of SM-11355 is possible without hepatic vascular injury in cases of relapse.
  • Hiroki Sakamoto; Masayuki Kitano; Ken Kamata; Takeshi Miyata; Kunpei Kadosaka; Hajime Imai; Yoshifumi Takeyama; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 76 4 892 - 899 2012年10月 [査読有り]
  • 75歳以上の後期高齢者に対する胆石症の治療戦略 ADL不良の急性胆嚢炎および胆管炎例に対するEUS下ドレナージ術
    門阪 薫平; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 54 Suppl.2 2718 - 2718 (一社)日本消化器内視鏡学会 2012年09月
  • 兵頭 朋子; 岡田 真広; 矢田 典久; 前西 修; 香川 祐毅; 任 誠雲; 柏木 伸夫; 柳生 行伸; 今岡 いずみ; 松木 充; 足利 竜一朗; 石井 一成; 工藤 正俊; 村上 卓道
    近畿大学医学雑誌 37 3-4 18A - 18A 近畿大学医学会 2012年09月
  • Tatsuo Inoue; Masatoshi Kudo; Mina Komuta; Sosuke Hayaishi; Taisuke Ueda; Masahiro Takita; Satoshi Kitai; Kinuyo Hatanaka; Norihisa Yada; Satoru Hagiwara; Hobyung Chung; Toshiharu Sakurai; Kazuomi Ueshima; Michiie Sakamoto; Osamu Maenishi; Tomoko Hyodo; Masahiro Okada; Seishi Kumano; Takamichi Murakami
    JOURNAL OF GASTROENTEROLOGY 47 9 1036 - 1047 2012年09月 [査読有り]
     
    We aimed to evaluate gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for the detection of hepatocellular carcinomas (HCCs) and dysplastic nodules (DNs) compared with dynamic multi-detector row computed tomography (MDCT), and to discriminate between HCCs and DNs. Eighty-six nodules diagnosed as HCC or DNs were retrospectively investigated. Gd-EOB-DTPA-enhanced MRI and dynamic MDCT were compared with respect to their diagnostic ability for hypervascular HCCs and detection sensitivity for hypovascular tumors. The ability of hepatobiliary images of Gd-EOB-DTPA-enhanced MRI to discriminate between these nodules was assessed. We also calculated the EOB enhancement ratio of the tumors. For hypervascular HCCs, the diagnostic ability of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of MDCT for tumors less than 2 cm (p = 0.048). There was no difference in the detection of hypervascular HCCs between hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI (43/45: 96%) and dynamic MDCT (40/45: 89%), whereas the detection sensitivity of hypovascular tumors by Gd-EOB-DTPA-enhanced MRI was significantly higher than that by dynamic MDCT (39/41: 95% vs. 25/41: 61%, p = 0.001). EOB enhancement ratios were decreased in parallel with the degree of differentiation in DNs and HCCs, although there was no difference between DNs and hypovascular well-differentiated HCCs. The diagnostic ability of Gd-EOB-DTPA-enhanced MRI for hypervascular HCCs less than 2 cm was significantly higher than that of MDCT. For hypovascular tumors, the detection sensitivity of hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of dynamic Gd-EOB-DTPA-enhanced MRI and dynamic MDCT. It was difficult to distinguish between DNs and hypovascular well-differentiated HCCs based on the EOB enhancement ratio.
  • 工藤 正俊
    日本消化器病學會雜誌 = The Japanese journal of gastro-enterology 109 8 1327 - 1334 2012年08月
  • 【ウイルス肝炎・肝癌制圧の分子基盤】肝癌制圧への治療の開発状況
    上嶋 一臣; 工藤 正俊
    BIO Clinica 27 8 748 - 751 (株)北隆館 2012年08月 
    2009年5月にソラフェニブが切除不能肝細胞癌に対して適応を取得し、それまで局所治療に頼ってきた肝細胞癌治療に全身化学療法という選択肢が加わった。しかしながら、本剤による治療においては、副作用による不耐例・薬剤無効例そして、いったん奏効したもののその後効果が認められなくなる耐性例があり、これを克服する新規分子標的薬の登場が待ち望まれている。また、分子標的薬と従来の治療方法との組み合わせによる予後延長効果が期待されており、多数の臨床試験が行われている。(著者抄録)
  • Takashi Katsube; Masahiro Okada; Seishi Kumano; Izumi Imaoka; Yuki Kagawa; Masatoshi Hori; Kazunari Ishii; Noboru Tanigawa; Yasuharu Imai; Masatoshi Kudo; Takamichi Murakami
    EUROPEAN JOURNAL OF RADIOLOGY 81 7 1460 - 1464 2012年07月 [査読有り]
     
    Purpose: To investigate the usefulness of T2* mapping of liver on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI for estimating liver function. Materials and methods: 33 patients were classified into 3 groups as follows: normal liver function (NLF) (n = 7); mild liver damage (MLD) (n = 16) with Child-Pugh A; severe liver damage (SLD) (n = 10) with Child-Pugh B. T2*-weighted gradient-echo (T2* W-GRE) and T1-weighted gradient-echo (T1W-GRE) images were obtained before and after Gd-EOB-DTPA administration (3, 8, 13, and 18 min; 5, 10,15, and 20 min; respectively). T2* mapping of liver was calculated from T2* W-GRE, then T2* values of liver and T2* reduction rates of T2* value between pre-and post-contrast enhancement were measured. The increase rates of liver-to-muscle signal intensity (LMS) ratio on T1W-GRE between pre-and post-contrast enhancement were calculated. Results: T2* values on pre-and post-contrast showed no significant differences among three groups. Significant differences in T2* reduction rates were found among groups, and those of LCB were lower than those of other groups (NLF: MLD: SLD, 3.8: 6.0: 0.6% at 3 min, 8.2: 10.3: 1.0% at 8 min, 10.7: 11.5: 1.2% at 13 min, and 16.1: 13.2: 3.5% at 18 min, respectively) (P < 0.05). Significant differences in increase rates of LMS ratio on T1W-GRE were identified (NLF: MLD: SLD, 1.53: 1.46: 1.35 at 5 min, 1.68: 1.64: 1.37 at 10 min, 1.79: 1.76: 1.44 at 15 min, and 1.89: 1.78: 1.49 at 20 min, respectively). Conclusion: T2* reduction rate and increase rate of LMS ratio on T1W-GRE may allow us estimation of liver function according to Child-Pugh score. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
  • 有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    肝臓 53 6 348 - 350 (一社)日本肝臓学会 2012年06月 
    分子標的薬ソラフェニブを投与した進行肝細胞癌患者81例を対象に、mRECIST基準による治療効果判定でCR・PR・SD例を抽出し、SDの持続期間とMedian overall survival(OS)との関係について検討した。mRECISTによる効果判定はCR:2例、PR:16例、SD:36例、PD:27例であった。SDの持続期間の中央値は3.3ヵ月であり、SDの持続期間3ヵ月未満をShort SD群(14例)、3ヵ月以上をLong SD群(22例)に分類し、CR+PR群(18例)とのOSを比較した。3群間では性別のみ有意差を認め、他の因子に有意差はなかった。生存曲線の比較では、OSの中央値はShort SD群6.2ヵ月、Long SD群17.6ヵ月、CR+PR群19.1ヵ月とShort SD群で他2群に比べ有意に短く、Long SD群とCR+PR群の間に有意差はなかった。Short SD群ではソラフェニブと因果関係のある有害事象で投与中止が6例(PS低下、食欲低下各1例、肝機能低下、下痢各2例)あり、他2群では副作用による中止は認めなかった。
  • 有住 忠晃; 上嶋 一臣; 竹田 治彦; 大崎 往夫; 萩原 智; 井上 達夫; 北井 聡; 矢田 典久; 櫻井 俊治; 西田 直生志; 工藤 正俊
    肝臓 53 6 344 - 347 (一社)日本肝臓学会 2012年06月 
    分子標的薬ソラフェニブを投与した進行肝細胞癌患者176例(男性132例、女性44例、平均71.5歳)を対象に、3種の治療効果判定基準(RECIST1.1、mRECIST、RECICL)で効果判定を行い、生存率を比較した。画像評価できた142例で解析し、30日以上内服できた128例の効果判定(CR/PR/SD/PD)は、RECIST1.1で1例/10例/62例/55例、奏効率(RR:CR+PRの割合)8.6%、病勢制御率(DCR:CR+PR+SDの割合)57.0%、mRECISTで2例/22例/54例/50例、RR:18.8%、DCR:60.9%、RECICLで2例/21例/52例/53例、RR:18.0%、DCR:58.6%であった。生存曲線ではmRECISTとRECICLで層別化され、RECICLで有意差が認められた。同様に60日以上内服できた97例の効果判定は、RECIST1.1では1例/9例/49例/38例、RR:10.3%、DCR:60.8%、mRECISTでは2例/18例/42例/35例、RR:20.6%、DCR:63.9%、RECICLでは2例/18例/41例/36例、RR:20.6%、DCR:62.9%であった。生存曲線はRECICLでのみ有意差が認められた。
  • M. Kudo
    LIVER CANCER 1 1 1 - 1 2012年06月 [査読有り]
  • Ah-Mee Park; Masatoshi Kudo; Satoru Hagiwara; Masaki Tabuchi; Tomohiro Watanabe; Hiroshi Munakata; Toshiharu Sakurai
    FREE RADICAL BIOLOGY AND MEDICINE 52 11-12 2284 - 2291 2012年06月 [査読有り]
     
    Mitogen-activated protein kinases (MAPKs) are ubiquitous proteins that function in both normal and stress-related pathophysiological states of the cell. This study aimed to analyze the importance of p38MAPK in pancreatic injury using WBN/Kob rats with spontaneous chronic pancreatitis. Male WBN/Kob rats were injected with the p38MAPK inhibitor SB203580, starting at the age of 4 weeks, and sacrificed 6 weeks later. Compared with vehicle-treated rats, p38 inhibitor-treated rats exhibited a significant increase in pancreatic cell death and inflammation as assessed by histologic examination and myeloperoxidase activity, respectively. p38 inhibition decreased the expression of heat shock protein 27 (HSP27), an antioxidant protein, and enhanced accumulation of reactive oxygen species (ROS). In addition, the proapoptotic protein BAD was increased in the pancreas of rats treated with p38 inhibitor. In a pancreatic cell line (PANC-1), HSP27 knockdown augmented reactive oxygen species accumulation and cell death induced by tumor necrosis factor-alpha plus actinomycin D. In conclusion, p38MAPK suppresses chronic pancreatitis by upregulating HSP27 expression and downregulating BAD expression. (C) 2012 Elsevier Inc. All rights reserved.
  • Shuichi Kaneko; Junji Furuse; Masatoshi Kudo; Kenji Ikeda; Masao Honda; Yasunari Nakamoto; Morikazu Onchi; Goshi Shiota; Osamu Yokosuka; Isao Sakaida; Tetsuo Takehara; Yoshiyuki Ueno; Kazumasa Hiroishi; Shuhei Nishiguchi; Hisataka Moriwaki; Kazuhide Yamamoto; Michio Sata; Shuntaro Obi; Shiro Miyayama; Yukinori Imai
    HEPATOLOGY RESEARCH 42 6 523 - 542 2012年06月 [査読有り]
     
    The Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma was prepared by the Study Group on New Liver Cancer Therapies established by the Research Project on Emergency Measures to Overcome Hepatitis under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using sorafenib and in 535 patients with advanced HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as well as referring to the published studies, academic presentations, and reports from the private sector. The aim of this Guideline is to facilitate understanding and current thinking regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms of the format, the Guideline presents clinical questions on issues pertaining to medical care, makes recommendations on diagnosis and treatment in response to each of these clinical questions, and provides a rationale for these recommendations in the form of scientific statements.
  • Masahiro Okada; Kazunari Ishii; Kazushi Numata; Tomoko Hyodo; Seishi Kumano; Masayuki Kitano; Masatoshi Kudo; Takamichi Murakami
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL 11 3 307 - 313 2012年06月 [査読有り]
     
    BACKGROUND: Excretion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) in the bile may be related to liver function, because of elimination from the liver after preferential uptake by hepatocytes. The purpose of this study was to investigate the relation between liver and biliary enhancement in patients with or without liver dysfunction, and to compare the tumor-to-liver contrast in these patients. METHODS: Forty patients [group 1: normal liver and Child-Pugh class A in 20 patients, group 2: Child-Pugh class B in 18 patients and Child-Pugh C in 2] were evaluated. All patients underwent MR imaging of the liver using a 1.5-Tesla system. T1-weighted 3D images were obtained at 5, 10, 15 and 20 minutes after Gd-EOB-DTPA injection. The relation between group 3 (total bilirubin <1.8 mg/dL) and group 4 (total bilirubin >= 1.8 mg/dL) was investigated at 20 minutes. Liver and biliary signals were measured, and compared between groups 1 and 2 or groups 3 and 4. Tumor-to-liver ratio was also evaluated between groups 1 and 2. Scheffes post-hoc test after two-way repeated-measures ANOVA and Pearson's correlation test were used for statistical analysis. RESULTS: Liver enhancement showed significant difference at all time points between groups 1 and 2. Biliary enhancement did not show a significant difference between groups 1 and 2 at 5 minutes, but did at 10, 15 and 20 minutes. At 20 minutes, significant differences between groups 3 and 4 were seen for liver and biliary enhancement. At all time points, liver enhancement correlated with biliary enhancement in both groups. At 5 minutes and 20 minutes, statistical differences between groups 1 and 2 were seen for tumor-to-liver ratio. CONCLUSIONS: The degree of biliary enhancement has a close correlation to that of liver enhancement. It is especially important that insufficient liver enhancement causes lower tumor-to-liver contrast in the hepatobiliary phase of Gd-EOB-DTPA.
  • 門阪 薫平; 北野 雅之; 竹山 宜典; 工藤 正俊
    膵臓 27 3 422 - 422 (一社)日本膵臓学会 2012年05月
  • 上嶋 一臣; 工藤 正俊
    肝・胆・膵 64 5 669 - 675 (株)アークメディア 2012年05月
  • 上嶋 一臣; 工藤 正俊
    肝・胆・膵 64 5 697 - 700 (株)アークメディア 2012年05月
  • Brivanib
    上嶋 一臣; 工藤 正俊
    肝胆膵 64 5 669 - 675 2012年05月
  • Yasunori Minami; Kinuyo Hatanaka; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    GASTROENTEROLOGY 142 5 S1002 - S1002 2012年05月 [査読有り]
  • Tatsuo Inoue; Tadaaki Arizumi; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    GASTROENTEROLOGY 142 5 S1002 - S1002 2012年05月 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Takeshi Nagasaka; Ajay Goel
    GASTROENTEROLOGY 142 5 S910 - S911 2012年05月 [査読有り]
  • Toshiharu Sakurai; Satoru Hagiwara; Tatsuo Inoue; Kazuomi Ueshima; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 142 5 S452 - S452 2012年05月 [査読有り]
  • 早期慢性膵炎におけるEUS画像の臨床的意義
    門阪 薫平; 北野 雅之; 工藤 正俊
    超音波医学 39 Suppl. S325 - S325 (公社)日本超音波医学会 2012年04月
  • 慢性膵炎の内視鏡診断と治療 EUSによる早期慢性膵炎の画像所見と臨床症状との関連性の検討
    門阪 薫平; 北野 雅之; 工藤 正俊
    Gastroenterological Endoscopy 54 Suppl.1 1004 - 1004 (一社)日本消化器内視鏡学会 2012年04月
  • 肝癌診療ガイドラインの活用と改訂への提案 肝癌診療ガイドラインにおける治療アルゴリズムの妥当性 実臨床への展開とその問題点
    上嶋 一臣; 南 康範; 工藤 正俊
    肝臓 53 Suppl.1 A109 - A109 (一社)日本肝臓学会 2012年04月
  • 進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    肝臓 53 Suppl.1 A398 - A398 (一社)日本肝臓学会 2012年04月
  • Shigenaga Matsui; Masatoshi Kudo; Hiroshi Kashida; Yutaka Asakuma; Toshiharu Sakurai; Masanori Kawasaki
    GASTROINTESTINAL ENDOSCOPY 75 4 237 - 237 2012年04月 [査読有り]
  • 兵頭朋子; 岡田真広; 香川祐毅; 今井康陽; 望月輝一; 工藤正俊; 村上卓道
    肝胆膵画像 14 4 365 - 368 2012年04月 [査読有り]
  • Satoru Hagiwara; Masatoshi Kudo; Hobyung Chung; Kazuomi Ueshima; Tatsuo Inoue; Seiji Haji; Tomohiro Watanabe; Ah-Mee Park; Hiroshi Munakata; Toshiharu Sakurai
    HEPATOLOGY RESEARCH 42 4 394 - 400 2012年04月 [査読有り]
     
    Aim: Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer deaths worldwide. Hepatic resection is the mainstay of curative treatment for early stage HCC. Although c-Jun N-terminal kinase (JNK) activation contributes to hepatocyte proliferation and HCC development in mice, the extent of involvement of JNK in human HCC development is unknown. The aim of this study is to assess the predictive value of JNK for postoperative recurrence in HCC. Methods: From April 2005 to March 2008, 159 patients underwent curative resection for HCC. From the 159 patients, 20 patients each matched for age, gender and etiology were registered as three groups: (i) without recurrence (no recurrence group), (ii) with recurrence within one year after surgery (early recurrence group), and (iii) with recurrence at one year or more after surgery (late recurrence group) (a cross- sectional control study). We investigated factors contributing to postoperative early and late phase recurrence. Results: Multivariate analysis using a Logistic regression model showed that JNK activity in non- cancerous liver tissue was correlated with postoperative late recurrence. (P = 0.02, odds ratio; 5.79, 95% confidence interval [CI]; 1.33- 25.36). Conclusions: JNK activity in non- cancerous liver tissue is considered as a reliable predictive biomarker for postoperative recurrence in HCC.
  • 生活習慣と肝・胆・膵疾患 EUSによる早期慢性膵炎の各画像所見と臨床症状の検討
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器病学会雑誌 109 臨増総会 A162 - A162 (一財)日本消化器病学会 2012年03月
  • 経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討
    早石 宗右; 南 康範; 足立 哲平; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 鄭 浩柄
    日本消化器病学会雑誌 109 臨増総会 A282 - A282 (一財)日本消化器病学会 2012年03月
  • 造影超音波 肝癌に対するラジオ波焼灼療法の治療効果判定造影USと造影CTの比較検討
    井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    超音波医学 39 2 191 - 191 (公社)日本超音波医学会 2012年03月
  • 組織弾性イメージング 肝エラストグラフィ 各モダリティーにおける測定原理と結果の解釈
    矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    超音波医学 39 2 193 - 193 (公社)日本超音波医学会 2012年03月
  • 非上皮性肝腫瘤2例の造影超音波像について
    横川 美加; 辻 裕美子; 桑口 愛; 前野 知子; 前川 清; 井上 達夫; 南 康範; 上嶋 一臣; 樫田 博史; 工藤 正俊
    超音波医学 39 2 198 - 198 (公社)日本超音波医学会 2012年03月
  • 体外式超音波穿刺用コンベックスプローブEUP-B715の使用経験
    矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    超音波医学 39 2 201 - 201 (公社)日本超音波医学会 2012年03月
  • Tomohiro Watanabe; Kouhei Yamashita; Saori Fujikawa; Toshiharu Sakurai; Masatoshi Kudo; Masahiro Shiokawa; Yuzo Kodama; Kazushige Uchida; Kazuichi Okazaki; Tsutomu Chiba
    ARTHRITIS AND RHEUMATISM 64 3 914 - 924 2012年03月 [査読有り]
     
    Objective IgG4-related disease is a recently recognized entity affecting multiple organs, including the pancreas, biliary tracts, and salivary glands. Although IgG4-related disease is characterized by systemic IgG4 antibody responses and by infiltration of IgG4-expressing plasma cells, the innate immune responses leading to adaptive IgG4 antibody responses are poorly understood. The aim of this study was to clarify the innate immune responses leading to IgG4 antibody production. Methods. IgG4 and cytokine responses to various nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) and Toll-like receptor (TLR) ligands were examined using peripheral blood mononuclear cells (PBMCs) from healthy control subjects and patients with IgG4-related autoimmune pancreatitis. Results. Activation of NOD-2 in monocytes from healthy control subjects induced IgG4 production by B cells in a BAFF-dependent and T cell-independent manner. In addition, PBMCs from patients with IgG4-related disease produced a large amount of IgG4 upon stimulation with NLR and TLR ligands; this enhanced IgG4 production was associated with the induction of BAFF by NLR and TLR ligands. Monocytes from patients with IgG4-related disease induced IgG4 production by B cells from healthy control subjects upon stimulation with NLR and TLR ligands. Conclusion. The results of these studies suggest that abnormal innate immune responses against microbial antigens may underlie the immunopathogenesis of IgG4-related disease.
  • HCCのカテーテル治療の最前線 分子標的薬とTACE・動注化学療法の併用療法の現状
    上嶋 一臣; 工藤 正俊
    日本医学放射線学会学術集会抄録集 71回 S84 - S84 (公社)日本医学放射線学会 2012年02月
  • Dual energy CTを用いた肝脂肪の定量評価 ファントム実験と初期臨床経験
    兵頭 朋子; 岡田 真広; 矢田 典久; 工藤 正幸; 香川 祐毅; 熊野 正士; 石井 一成; 工藤 正俊; 村上 卓道
    日本医学放射線学会学術集会抄録集 71回 S272 - S272 (公社)日本医学放射線学会 2012年02月
  • ASIRを用いた低電圧肝Dynamic-CTによる被曝低減と造影剤量低減に関する報告
    日高 正二朗; 高橋 洋人; 岡田 真広; 兵頭 朋子; 香川 祐毅; 今岡 いずみ; 石井 一成; 足利 竜一朗; 工藤 正俊; 村上 卓道
    日本医学放射線学会学術集会抄録集 71回 S273 - S273 (公社)日本医学放射線学会 2012年02月
  • Hirofumi Taki; Kousuke Taki; Takuya Sakamoto; Makoto Yamakawa; Tsuyoshi Shiina; Motoi Kudo; Toru Sato
    IEEE TRANSACTIONS ON MEDICAL IMAGING 31 2 417 - 429 2012年02月 [査読有り]
     
    For high range resolution ultrasonographic vascular imaging, we apply frequency domain interferometry with the Capon method to a single frame of in-phase and quadrature (IQ) data acquired using a commercial ultrasonographic device with a 7.5 MHz linear array probe. In order to tailor the adaptive beamforming algorithm for ultrasonography we employ four techniques: frequency averaging, whitening, radio-frequency data oversampling, and the moving average. The proposed method had a range resolution of 0.05 mm in an ideal condition, and experimentally detected the boundary couple 0.17 mm apart, where the boundary couple was indistinguishable from a single boundary utilizing a B-mode image. Further, this algorithm could depict a swine femoral artery with a range beam width of 0.054 mm and an estimation error for the vessel wall thickness of 0.009 mm, whereas using a conventional method the range beam width and estimation error were 0.182 and 0.021 mm, respectively. The proposed method requires 7.7 s on a mobile PC with a single CPU for a 1 x 3 cm region of interest. These findings indicate the potential of the proposed method for the improvement of range resolution in ultrasonography without deterioration in temporal resolution, resulting in enhanced detection of vessel stenosis.
  • 犬塚 義; 大崎 往夫; 松田 史博; 坂本 梓; 幡丸 景一; 邉見 慎一郎; 石川 哲朗; 齋藤 澄夫; 西川 浩樹; 喜多 竜一; 岡部 純弘; 木村 達; 若狭 朋子; 萩原 智; 工藤 正俊
    肝臓 53 1 42 - 47 一般社団法人 日本肝臓学会 2012年01月 
    症例は65歳の日本人男性．2008年12月にB型慢性肝炎（Genotype C）指摘され，2009年12月よりエンテカビル（0.5 mg/日）とペグインターフェロンα-2b（80 μg/週）の48週間併用治療を開始．その後ウイルス量・HBe抗原価・HBs抗原価の減少を認めた．開始後44週時点でウイルス量は検出感度以下になるとともに，HBeセロコンバージョン・HBs抗原の消失，48週治療後半年以上経過した現在はHBsセロコンバージョンを維持している．HBs抗原自然消失例の報告は散見されるが，本症例は治療により引き起こされたHBs抗原消失例であり，そのような報告は少ない．また，本症例は治療前後の肝組織のcovalently closed circular DNA量や血清HBコア関連抗原量やHBc抗原の免疫染色を治療前後で比較できた点で，貴重な1例と考えられたため報告した．
  • Yasunori Minami; Masatoshi Kudo
    Biotargets of Cancer in Current Clinical Practice 273 - 287 2012年01月 [査読有り]
  • Akira Sugawara; Akira Uruno; Ken Matsuda; Takako Saito-Ito; Tadao Funato; Akiko Saito-Hakoda; Masataka Kudo; Sadayoshi Ito
    Current Molecular Pharmacology 5 2 248 - 254 2012年 [査読有り]
     
    Peroxisome proliferator-activated receptor (PPAR)γ, a nuclear hormone receptor, is activated by its agonists including anti-diabetic thiazolidinediones, and has recently been reported to exert beneficial effects in the vasculature independently of its anti-diabetic effects. We here discuss our recent findings on the beneficial pleiotropic effects of PPARγ agonists. PPARγ agonists have been shown to lower blood pressure in both animals and humans, which may possibly be mediated via the PPARγ agonist-mediated inhibition of the renin-angiotensin-aldosterone system (RAAS) including the suppression of angiotensin (Ang) II type 1 receptor expression/Ang II-mediated signaling pathways and Ang II-induced adrenal aldosterone synthesis/secretion. PPARγ agonists also inhibited the progression of atherosclerosis in both animals and humans. PPARγ agonist-mediated inhibition of the RAAS and the thromboxane A2 system as well as endothelial protection may possibly be involved in the inhibitory effects on blood pressure and atherosclerosis. Furthermore, PPARγ agonists were demonstrated to have reno-protective effects, especially in reducing proteinuria in diabetic nephropathy in both animals and humans. The reno-protective effects of PPARγ agonists were also observed in non-diabetic renal dysfunctions. The effects may possibly be mediated via the PPARγ agonist-mediated blood pressure lowering, endothelial protection, and vasodilation of the glomerular efferent arterioles. Additionally, anti-neoplastic effects of PPARγ agonists have recently received much attention. PPARγ agonists, may therefore, be useful and effective against lifestyle-related diseases. © 2012 Bentham Science Publishers.
  • IL28B型との関連からみたResponse-guided therpy. C型肝炎-新時代の治療戦略
    萩原 智; 工藤正俊
    消化器の臨床 15 2012年 [査読有り]
  • M. Kudo
    LIVER CANCER 1 3-4 141 - 143 2012年 [査読有り]
  • Yasunori Minami; Naoya Okumura; Norio Yamamoto; Naoko Tsuji; Yuko Kono; Masatoshi Kudo
    JOURNAL OF MEDICAL ULTRASONICS 39 1 15 - 19 2012年01月 [査読有り]
     
    Many contrast-enhanced ultrasound (CE-US) studies have been conducted by qualitative analysis of blood flow, such as classification of enhancement pattern. We evaluated early response of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) by quantitative analysis of intratumoral vascularity with CE-US in three patients. Three patients (one man, two women) with HCCs were treated in July 2009. CE-US with perfluorocarbon microbubbles (Sonazoid) and CT were performed serially before and 5 days after TACE. Post-processing enhancement intensity on US was analyzed to determine mean transit time (s), time to peak (s), enhancement peak intensity (dB), and "A" (scaling factor) by ultrasound quantification software after the data were fitted to a gamma variate curve. Mean transit time was prolonged by TACE in all three patients. Mean transit time rates on CE-US were 64.3, 33.8, and 65.6%, respectively, whereas the avascular rates on CT were 59.07, 31.71, and 62.25%, respectively. Mean transit time rates on CE-US approximated avascular rates on CT. Mean transit time rate may quantitatively indicate the early response of HCC to TACE.
  • Masatoshi Kudo; Ryosuke Tateishi; Tatsuya Yamashita; Masafumi Ikeda; Junji Furuse; Kenji Ikeda; Norihiro Kokudo; Namiki Izumi; Osamu Matsui
    CLINICAL DRUG INVESTIGATION 32 37 - 51 2012年 [査読有り]
     
    The Toward Integrated Treatment of Advanced Hepatocellular Carcinoma with Nexavar (TiTAN) Symposium was held in August 2010 in Tokyo, Japan, during which the position of sorafenib (Nexavar) in the treatment of HCC in Japan (for which it received approval in 2009) was discussed by a panel of eight expert hepatologists in a session chaired by Dr Kudo. The following article focuses on the discussion that went on during this session, including question and answer sessions regarding the experiences of the 350 conference attendees in treating patients with HCC, as well as some of the more challenging disease management issues. Since 2008, when the phase III Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial demonstrated an increase in the median overall survival (OS) for patients with unresectable HCC treated with sorafenib compared with placebo, international and Japanese guidelines recommend sorafenib as a first-line option for patients with advanced HCC Child-Pugh liver function class A who have extrahepatic metastasis. Sorafenib is also recommended for patients unresponsive to transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). Importantly, if HCC is judged to be unresponsive to TACE, treatment should be switched to sorafenib in a timely manner. Almost half of the conference attendees said that they used both the Japan Society of Hepatology clinical practice guidelines and the clinical practice guidelines for HCC when determining treatment strategies for individual HCC patients. Sorafenib should currently not be used as adjuvant therapy or in combination with TACE or HAIC until evidence from ongoing clinical trials shows that it is beneficial in these settings.
  • Ken Takahashi; Hiroshi Kashida; Masatoshi Kudo
    INTERNAL MEDICINE 51 19 2753 - 2755 2012年 [査読有り]
     
    Splanchnic arteriovenous malformation (AVM) is a rare condition in which patients present with portal hypertension, which thus causes bleeding varices and ascites. However, to our knowledge, hepatic nodules associated with splanchnic AVM have not yet been described. We herein first report the case of a 78-year-old man with inferior mesenteric AVM presenting with portal hypertension and multiple hepatic nodules dominantly supplied by the portal vein. This unique case not only extends the spectrum of hepatic nodules resulting from abnormal hepatic circulation, but also provides clues for better understanding the etiology of hepatic nodules.
  • Masatoshi Kudo
    DIGESTIVE DISEASES 30 6 539 - 540 2012年 [査読有り]
  • Ueda T; Tsuchiya K; Hashimoto S; Inoue T; Enomoto N; Inao M; Tanaka A; Kaito M; Imazeki F; Nishiguchi S; Mochida S; Yokosuka O; Yatsuhashi H; Izumi N; Kudo M; RETRY Study Group
    Digestive diseases (Basel, Switzerland) 30 6 554 - 560 2012年 [査読有り]
     
    Background/Aims: Peginterferon (PEG-IFN) + ribavirin (RBV) combination therapy is the current standard of care for chronic hepatitis C. However, more than half of the patients cannot achieve sustained viral response (SVR). In Japan, the clinical benefit of retreatment with PEG-IFN + RBV combination retreatment is still unknown. Methods: We collected clinical data in 106 chronic hepatitis C patients who failed to achieve SVR with PEG-IFN alpha-2b + RBV combination therapy and were retreated with PEG-IFN alpha-2a + RBV. This retrospective study examined the efficacy of retreatment with PEG-IFN alpha-2a + RBV by evaluating the time to eradication of hepatitis C virus RNA, early virological response (EVR), and SVR. We compared the results of the previous therapy and retreatment in terms of efficacy and analyzed the factors influencing SVR. Results: The SVR rates in the non-responders and relapsers were 11 and 53%, respectively. EVR and prolonged treatment duration were associated with SVR. We also found that a prior response to PEG-IFN + RBV therapy was more important than the Interleukin-28B genotype for predicting the response to retreatment. Conclusions: Retreatment with PEG-IFN alpha-2a + RBV should be considered for relapsers and partial responders. Our results suggest that prolonged administration is also favorable for EVR cases to attain a higher SVR. Copyright (C) 2012 S. Karger AG, Basel
  • Hagiwara S; Sakurai T; Takita M; Ueshima K; Minami Y; Inoue T; Yada N; Kitai S; Nagai T; Hayaishi S; Arizumi T; Nishida N; Kudo M
    Digestive diseases (Basel, Switzerland) 30 6 561 - 567 2012年 [査読有り]
     
    Objective: Increasing evidence suggests the efficacy of maintenance therapy with interferon (IFN) for chronic hepatitis C (CHC) in reducing the risk of hepatocellular carcinoma (HCC). The aim of this study was to determine clinical characteristics on the risk of occurrence of HCC in CHC patients receiving maintenance IFN therapy. Methods: A total of 55 patients were treated in a single center with PEG-IFN alpha-2a monotherapy for CHC and evaluated for variables predictive of the occurrence of HCC. Results: The cumulative incidences of HCC were 0.092, 0.117 and 0.161 at 3, 5 and 7 years, respectively. Serum ALT level (>40 IU/l) in the 6th month after commencement of IFN therapy and BMI >25 were associated with shorter time-to-HCC emergence using multivariate analysis (relative risk 16.034, p = 0.01 for ALT >40 IU/I; relative risk 6.020, p = 0.026 for BMI >25, respectively). The IL28B SNP was extracted as a significant factor for the occurrence of HCC. Conclusions: Maintenance therapy with the use of long-term low-dose PEG-IFN alpha-2a is effective for preventing HCC occurrence irrespective of the IL28B SNP, at least for a subset of CHC patients. The initial response of serum ALT levels and BMI provides a prognostic value for determining the risk of developing HCC later in life. Copyright (C) 2012 S. Karger AG, Basel
  • Yasunori Minami; Masatoshi Kudo
    DIGESTIVE DISEASES 30 6 592 - 597 2012年 [査読有り]
     
    Among patients with later stage hepatocellular carcinoma (HCC), only 1-12% manifest obstructive jaundice as the initial complaint. Endoscopic retrograde binary drainage (ERBD) and percutaneous transhepatic biliary drainage (PTBD) are the two main non-surgical treatment options for obstructive jaundice in patients with HCC. ERBD is usually the first-line treatment because of its low hemorrhage risk. Some have reported that the successful drainage rate ranges from 72 to 100%. Mean stent patency time and mean survival range from 1.0 to 15.9 and 2.8 to 12.3 months, respectively. PTBD is often an important second-line treatment when ERBD is impossible. With regard to materials, metallic stents offer the benefit of longer patency than plastic stents. The dominant effect of biliary drainage suggests that successful jaundice therapy could enhance anti-cancer treatment by increasing life expectancy, decreasing mortality, or both. We present an overview of the efficacy of endoscopic and percutaneous drainage for obstructive jaundice in patients with HCC who are not candidates for surgical resection and summarize the current indications and outcomes of reported clinical use. Copyright (C) 2012 S. Karger AG, Basel
  • 肝臓がん
    上嶋一臣; 工藤正俊
    日本臨牀 70 457 - 462 2012年 [査読有り]
  • 新規薬剤の治療開発: 現状と展望（SORとの比較試験、SOR耐性後の試験など）
    上嶋一臣; 工藤正俊
    腫瘍内科 9 651 - 658 2012年 [査読有り]
  • 工藤正俊
    肝胆膵画像 14 369 - 370 2012年 [査読有り]
  • 早期慢性膵炎のEUS所見と生活習慣病について. 特集「生活習慣病と胆・膵疾患」
    門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本洋城; 工藤正俊
    胆と膵 33 1247 - 1251 2012年 [査読有り]
  • EUSによる膵線維化診断.特集「肝胆膵の線維化/研究と診療の最近の進歩」
    門阪薫平; 北野雅之; 山田光成; 大本俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本洋城; 工藤正俊
    肝胆膵 65 371 - 376 2012年 [査読有り]
  • 有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 工藤 正俊
    新薬と臨牀 60 12 2516 - 2516 (株)医薬情報研究所 2011年12月
  • 有住 忠晃; 上嶋 一臣; 工藤 正俊
    The Liver Cancer Journal 3 4 320 - 321 (株)メディカルレビュー社 2011年12月
  • 上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 工藤 正俊
    The Liver Cancer Journal 3 4 336 - 337 (株)メディカルレビュー社 2011年12月
  • 兵頭 朋子; 岡田 真広; 香川 祐毅; 熊野 正士; 任 誠雲; 柏木 伸夫; 柳生 行伸; 今岡 いずみ; 足利 竜一朗; 石井 一成; 工藤 正俊; 村上 卓道
    近畿大学医学雑誌 36 3-4 13A - 13A 近畿大学医学会 2011年12月
  • 上嶋 一臣; 工藤 正俊
    臨床外科 66 11 183 - 189 (株)医学書院 2011年10月
  • Naoshi Nishida; Masatoshi Kudo; Takeshi Nagasaka; Ajay Goel
    HEPATOLOGY 54 462A - 462A 2011年10月 [査読有り]
  • 肝血管肉腫の2例
    有住 忠晃; 萩原 智; 大本 俊介; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    肝臓 52 Suppl.2 A680 - A680 (一社)日本肝臓学会 2011年09月
  • Masatoshi Kudo
    Digestive Diseases 29 3 289 - 302 2011年08月 [査読有り]
     
    In recent years, molecular-targeted agents have been used clinically to treat various malignant tumors. In May 2009, sorafenib (Nexavar®) was approved in Japan for 'unresectable hepatocellular carcinoma (HCC)', and was the first molecular-targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has now been approved worldwide. Phase III clinical trials of other molecular-targeted agents comparing them with sorafenib as first-line treatment agents are now ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin-like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other components of the signal transduction pathways. This review outlines the main pathways involved in the development and progression of HCC and the agents that target these pathways. Finally, current status and future perspective will also be discussed. Copyright © 2011 S. Karger AG, Basel.
  • 櫻井 俊治; 萩原 智; 上嶋 一臣; 工藤 正俊
    The Liver Cancer Journal 3 2 150 - 151 (株)メディカルレビュー社 2011年06月
  • 超音波定量診断技術の新展開 Real-time Tissue Elastographyの肝疾患テクスチャ解析
    外村 明子; 元木 満; 三竹 毅; 藤本 研治; 加藤 道夫; 辰巳 千栄; 矢田 典久; 上嶋 一臣; 工藤 正俊; 椎名 毅
    超音波医学 38 3 306 - 306 (公社)日本超音波医学会 2011年05月
  • Toshiharu Sakurai; Masatoshi Kudo; Kazuomi Ueshima; Shigenaga Matsui; Hiroshi Kashida; Michael Karin
    GASTROENTEROLOGY 140 5 S927 - S927 2011年05月 [査読有り]
  • Masanori Kawasaki; Yutaka Asakuma; Shigenaga Matsui; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 140 5 S312 - S312 2011年05月 [査読有り]
  • Yutaka Asakuma; Shigenaga Matsui; Masanori Kawasaki; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 140 5 S235 - S235 2011年05月 [査読有り]
  • Ueda T; Chung H; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 69 Suppl 4 319 - 324 日本臨床社 2011年05月 [査読有り]
  • Hagiwara S; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 69 Suppl 4 546 - 550 日本臨床社 2011年05月 [査読有り]
  • 【最新・消化器がん化学療法と有害事象へのかかわり方】肝臓がん
    上嶋 一臣; 工藤 正俊
    消化器肝胆膵ケア 16 1 20 - 25 日総研出版 2011年04月
  • 分子標的治療におけるPIVKA-II評価のポイント
    上嶋 一臣; 工藤 正俊
    クリニシアン 58 4 464 - 469 エーザイ(株) 2011年04月
  • C型肝炎治療におけるReal-time Tissue Elastographyを用いた肝線維化の非侵襲的評価法
    藤本 研治; 石田 哲士; 矢田 典久; 上嶋 一臣; 外村 明子; 三竹 毅; 椎名 毅; 工藤 正俊; 加藤 道夫
    超音波医学 38 Suppl. S209 - S209 (公社)日本超音波医学会 2011年04月
  • B型慢性肝炎に対するPEG-IFNα2bとエンテカビル48週併用療法の有効性について
    萩原 智; 峯 宏昌; 有住 忠晃; 早石 宗右; 上田 泰輔; 田北 雅弘; 畑中 絹世; 北井 聡; 矢田 典久; 井上 達夫; 鄭 浩柄; 櫻井 俊治; 上嶋 一臣; 工藤 正俊; 犬塚 義; 大崎 往夫
    日本消化器病学会雑誌 108 臨増総会 A251 - A251 (一財)日本消化器病学会 2011年03月
  • Kanae Kudo; Tokuzo Arao; Kaoru Tanaka; Tomoyuki Nagai; Kazuyuki Furuta; Kazuko Sakai; Hiroyasu Kaneda; Kazuko Matsumoto; Daisuke Tamura; Keiichi Aomatsu; Marco A. De Velasco; Yoshihiko Fujita; Nagahiro Saijo; Masatoshi Kudo; Kazuto Nishio
    CLINICAL CANCER RESEARCH 17 6 1373 - 1381 2011年03月 [査読有り]
     
    Purpose: BIBF 1120 is a potent, orally available triple angiokinase inhibitor that inhibits VEGF receptors (VEGFR) 1, 2, and 3, fibroblast growth factor receptors, and platelet-derived growth factor receptors. This study examined the antitumor effects of BIBF 1120 on hepatocellular carcinoma (HCC) and attempted to identify a pharmacodynamic biomarker for use in early clinical trials. Experimental Design: We evaluated the antitumor and antiangiogenic effects of BIBF 1120 against HCC cell line both in vitro and in vivo. For the pharmacodynamic study, the phosphorylation levels of VEGFR2 in VEGF-stimulated peripheral blood leukocytes (PBL) were evaluated in mice inoculated with HCC cells and treated with BIBF 1120. Results: BIBF 1120 (0.01 mu mol/L) clearly inhibited the VEGFR2 signaling in vitro. The direct growth inhibitory effects of BIBF 1120 on four HCC cell lines were relatively mild in vitro (IC50 values: 2-5 mu mol/L); however, the oral administration of BIBF 1120 (50 or 100 mg/kg/d) significantly inhibited the tumor growth and angiogenesis in a HepG2 xenograft model. A flow cytometric analysis revealed that BIBF 1120 significantly decreased the phosphotyrosine (pTyr) levels of VEGFR2(+)CD45(dim) PBLs and the percentage of VEGFR2(+)pTyr(+) PBLs in vivo; the latter parameter seemed to be a more feasible pharmacodynamic biomarker. Conclusions: We found that BIBF 1120 exhibited potent antitumor and antiangiogenic activity against HCC and identified VEGFR2(+)pTyr(+) PBLs as a feasible and noninvasive pharmacodynamic biomarker in vivo. Clin Cancer Res; 17(6); 1373-81. (C)2010 AACR.
  • Gd-EOB-DTPA造影MRI肝細胞相で検出された慢性障害肝の乏血性結節 多血化の危険因子
    兵頭 朋子; 岡田 真広; 香川 祐毅; 熊野 正士; 堀 雅敏; 石井 一成; 今井 康陽; 望月 輝一; 工藤 正俊; 村上 卓道
    日本医学放射線学会学術集会抄録集 70回 S342 - S343 (公社)日本医学放射線学会 2011年02月
  • Hiroki Sakamoto; Masayuki Kitano; Shigenaga Matsui; Ken Kamata; Takamitsu Komaki; Hajime Imai; Kensaku Dote; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 73 2 227 - 237 2011年02月 [査読有り]
     
    Background: Contrast-enhanced harmonic EUS (CEH-EUS) is a new sonographic technique that uses US contrast agents and depicts intratumoral vessels in real time. Objective: To evaluate whether assessment of tumor vascularity by CEH-EUS can predict the preoperative malignancy risk of GI stromal tumors (GISTs). Design: Prospective study to observe GIST vascularity.. Setting: Kinki University School of Medicine. Patients: Between June 2007 and September 2009, 76 consecutive patients suspected of having subepithelial lesions underwent CEH-EUS. Intervention: CEH-EUS was performed by using a prototype echoendoscope in an extended pure harmonic detection mode. Main Outcome Measurements: Resected GIST specimens in 29 patients who underwent surgical resection were divided into high-grade (n = 16) and low-grade (n = 13) malignancy groups based on mitotic activity. The abilities of EUS-guided FNA and CEH-EUS to diagnose the malignant potential were compared. The sensitivities with which contrast-enhanced multidetector CT, power-Doppler EUS, and CEH-EUS detected intratumoral vessels in high-grade malignancy GISTs also were compared. Results: CEH-EUS identified irregular vessels and thereby predicted GIST malignancies with a sensitivity, specificity, and accuracy of 100%, 63%, and 83%, respectively. Diagnosis of high-grade malignancy GISTs by EUS-guided FNA had a sensitivity, specificity, and accuracy of 63%, 92%, and 81%, respectively. Contrast-enhanced multidetector CT, power-Doppler EUS, and CEH-EUS detected intratumoral vessels in high-grade malignancy GISTs with sensitivities of 31%, 63%, and 100%, respectively (P < .05). Limitations: A single center was involved in this study. Conclusions: CEH-EUS successfully visualized intratumoral vessels and may play an important role in predicting the malignancy risk of GISTs. (Gastrointest Endosc 2011;73:227-37.)
  • Masatoshi Kudo; Kinuyo Hatanaka; Takashi Kumada; Hidenori Toyoda; Toshifumi Tada
    AMERICAN JOURNAL OF GASTROENTEROLOGY 106 2 368 - 370 2011年02月 [査読有り]
  • Osamu Yokosuka; Masayuki Kurosaki; Fumio Imazeki; Yasuji Arase; Yasuhito Tanaka; Kazuaki Chayama; Eiji Tanaka; Hiromitsu Kumada; Namiki Izumi; Masashi Mizokami; Masatoshi Kudo
    HEPATOLOGY RESEARCH 41 1 1 - 21 2011年01月 [査読有り]
     
    Recently, much progress has been made in the field of hepatitis B, such as natural history of the disease in relation to the amount of hepatitis B virus (HBV) DNA, genotypes of HBV influencing the natural course and treatment effects, mutations of HBV influencing the severity of the disease and development of hepatocellular carcinoma, and antiviral treatment such as nucleos(t)ide analogues and pegylated interferon. To make the consensus for the diagnosis, management and treatment of hepatitis B, a meeting was held during 45th annual meeting of Japan Society of Hepatology (JSH) in June 2009. In the meeting, recommendations and informative statements were discussed on the following subjects: (i) natural history of HBV infection; (ii) clinical implication of HBV genotypes; (iii) HBV mutations and their potential impact on pathogenesis of HBV infection; (iv) indications for antiviral treatment of chronic hepatitis B; (v) nucleos(t)ide analogues for chronic hepatitis B; and (vi) interferon therapy for chronic hepatitis B. The presenters reviewed the data on these subjects and proposed the consensus statements and recommendations. These statements were discussed among the organizers and presenters, and were approved by the participants of the meeting. In the current report, the relevant data were reviewed and the 12 consensus statements and nine recommendations on chronic hepatitis B were described.
  • Masatoshi Kudo; Kenji Yamao; Tooru Shimosegawa
    Pancreatology 11 2 1 - 2 2011年 [査読有り]
  • Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Takamitsu Komaki
    PANCREATOLOGY 11 28 - 33 2011年 [査読有り]
     
    Endoscopic ultrasonography (EUS) is superior to all other imaging modalities in detecting small pancreatic cancers. However, its ability to characterize hypoechoic pancreatic masses is limited: most carcinomas, neuroendocrine tumors, and inflammatory pseudotumors are simply depicted as hypoechoic masses. Contrast enhancement helps EUS to characterize such hypoechoic masses. Intravenous ultrasound (US) agents increase the signal from the blood and, thus, act as amplifiers and improve visualization of blood flow in small vessels using Doppler US. Contrast-enhanced Doppler EUS can differentiate small pancreatic carcinomas that cannot be detected by other imaging modalities. The development of second-generation US contrast agents and an EUS system with a broad-band transducer enabled the visualization of microvessels and the parenchymal perfusion in the pancreas. This contrast-enhanced harmonic EUS has shown that most pancreatic cancers exhibit hypovascular heterogeneous enhancement with irregular network-like microvessels. Moreover, it can diagnose pancreatic cancers with a high sensitivity (89-92%). Copyright (C) 2011 S. Karger AG, Basel and IAP
  • Ueshima K; Kudo M; Takita M; Nagai T; Tatsumi C; Ueda T; Kitai S; Ishikawa E; Yada N; Inoue T; Hagiwara S; Minami Y; Chung H; Sakurai T
    Digestive diseases (Basel, Switzerland) 29 3 321 - 325 2011年 [査読有り]
     
    Objective: The purpose of this study was to evaluate the role of des-gamma-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC treated with sorafenib were retrospectively evaluated, focusing on DCP levels and clinical characteristics. Results: 50 patients with advanced HCC were treated with sorafenib alone. In 25 of these patients, the serum levels of DCP were evaluated twice (pretreatment and within 2 weeks after starting therapy). The time to progression was significantly longer in patients in whom the DCP level at 2 weeks after starting sorafenib was 6 2-fold higher than the pretreatment levels, as compared with patients without an increase in DCP (p = 0.0296). Conclusions: The serum level of DCP is a surrogate marker for tissue hypoxia and can be a predictive marker to assess the tumor response to sorafenib therapy. Copyright (C) 2011 S. Karger AG, Basel
  • Sosuke Hayaishi; Hobyung Chung; Masatoshi Kudo; Emi Ishikawa; Masahiro Takita; Taisuke Ueda; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima
    DIGESTIVE DISEASES 29 3 326 - 332 2011年 [査読有り]
     
    Background: It has been reported that branched-chain amino acid (BCAA) supplementation can improve nutritional status and prevent liver-related complications in patients with decompensated cirrhosis. We investigated the effects of oral BCAA supplementation on the incidence of hepatocellular carcinoma (HCC) and liver-related events in patients with compensated and decompensated cirrhosis. Methods: We enrolled 211 patients with cirrhosis including 152 patients with Child-Pugh A cirrhosis, but no history of HCC. Of these, 56 received oral administration of 12 g/day BCAA for 6 6 months (BCAA group), and 155 were followed-up without BCAA treatment (control group). The HCC occurrence and event-free survival rates were compared between the two groups. We used a propensity score analysis to overcome selection bias of this retrospective analysis. Results: The HCC occurrence rate was significantly lower and event-free survival rate was significantly higher in the BCAA group than in the control group. Multivariate analyses showed BCAA supplementation was significantly associated with reduced incidence of HCC (hazard ratio (HR) 0.416, 95% confidence interval (CI) 0.216-0.800, p = 0.0085). BCAA supplementation also reduced the incidence of liver-related events in patients with Child-Pugh A cirrhosis, although the difference did not reach statistical significance (HR 0.585, 95% CI 0.336-1.017, p = 0.0575). Conclusions: Oral BCAA supplementation is associated with reduced incidence of HCC in patients with cirrhosis and seems to prevent liver-related events in patients with Child-Pugh A cirrhosis. Copyright (C) 2011 S. Karger AG, Basel
  • Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
    DIGESTIVE DISEASES 29 3 339 - 364 2011年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but also worldwide. Clinical practice guidelines for HCC were first published in 2001 by the European Society of Study of the Liver (EASL) followed by the American Association for the Study of Liver Disease (AASLD) published in 2005 and updated in 2010. However, these guidelines have proven to be somewhat unsuitable for Japanese patients. In 2005, supported by the Japanese Ministry of Health, Labour and Welfare, evidence-based clinical practice guidelines for HCC were compiled in Japan. In 2009, a revised version of evidence-based guidelines was published. Based on both 'evidence-based' guidelines and the consensus of an expert panel on HCC, the Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007 and updated in 2010. In this article, the 2010 updated version of this manual, especially issues on prevention, surveillance, pathology, diagnosis, staging, and treatment algorithm are summarized. Copyright (C) 2011 S. Karger AG, Basel
  • Masatoshi Kudo
    ONCOLOGY 81 50 - 55 2011年 [査読有り]
     
    It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%. This recurrence rate is also known to be similar after various curative treatments including resection, percutaneous ethanol injection therapy, and radiofrequency ablation. Generally, in treating patients with HCC associated with hepatitis C or liver cirrhosis, aggressive efforts to prevent secondary carcinogenesis are necessary rather than simply observing the clinical course after treatment. Presently, a combination of peg-interferon and ribavirin is known to be highly effective in patients with difficult-to-treat hepatitis C with a high viral load and genotype I virus. Therefore, indications of these treatments must be considered to prevent secondary carcinogenesis in patients with hepatitis C. Recently, long-term follow-up of low-dose, long-term maintenance therapy using pegylated interferon-alpha 2a for cirrhotic patients clearly showed a preventive effect on HCC occurrence and recurrence. Preventing secondary carcinogenesis by suppressing inflammation employing the same treatment as that against primary carcinogenesis is also important. The molecular targeted agent sorafenib markedly suppresses the serine/threonine kinases of Raf in the MAP kinase cascade and inhibits the tyrosine kinases of angiogenesis factor receptors such as vascular endothelial growth factor and platelet-derived growth factor receptors. It thus simultaneously prevents the proliferation of tumors and inhibits angiogenesis. A clinical trial to examine the recurrence-preventing effect of sorafenib by administration of it after curative treatment such as resection or ablation is in progress (STORM trial: http://clinicaltrials.gov.com, NCT00692770). Treatments to prevent recurrence (including intrahepatic metastasis and multicentric carcinogenesis) as well as early detection and early curative treatment are extremely important to improve the prognosis of patients with HCC. Thus, further research on this issue should be carried out, especially in relation to molecular targeted therapy. Copyright (C) 2011 S. Karger AG, Basel
  • Masatoshi Kudo
    ONCOLOGY 81 73 - 85 2011年 [査読有り]
     
    The diagnostic imaging of hepatocellular carcinoma (HCC) has recently undergone marked progress. The advent of the ultrasound (US) contrast agent Sonazoid, approved in January 2007, and magnetic resonance imaging (MRI) with the liver-specific MRI contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA-MRI), approved in January 2008, are of particular significance. Sonazoid contrast-enhanced US (Sonazoid-CEUS) is useful not only for the diagnosis of HCC, but also for guiding treatment and assessing treatment response. Sonazoid-CEUS has proven to be particularly effective for screening and staging, which used to be considered impossible with CEUS, through the introduction of the newly developed diagnostic technique of defect reperfusion imaging. It is still not possible if other vascular agents such as SonoVue and Definity are used. In particular, Gd-EOB-DTPA-MRI has been suggested to be much more reliable in the differentiation of early HCC from precancerous dysplastic nodules than any other modalities such as multidetector raw computed tomography, dynamic MRI, and superparamagnetic iron oxide-MRI. A decrease in contrast uptake in the hepatocyte phase observed on EOB-MRI is strongly suggestive of cancer, and the absence of early staining in the arterial phase suggests early HCC. The differential diagnostic capacity of Gd-EOB-DTPA-MRI is considered to far exceed that of what were previously the most useful imaging techniques, computed tomography (CT) during hepatic arteriography or CT during arterial portography, and to be comparable to that of the pathological diagnosis by pathologists specialized in liver. Copyright (C) 2011 S. Karger AG, Basel
  • 混合型肝癌の疫学: 全国集計を中心に. 特集「混合型肝癌および胆管形質を示す肝細胞癌: 肝ステム細胞のインパクト」
    北井 聡; 工藤正俊
    肝胆膵 63 559 - 563 2011年 [査読有り]
  • 上嶋 一臣; 土師 誠二; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 鄭 浩柄; 櫻井 俊治; 工藤 正俊
    新薬と臨牀 59 12 2409 - 2410 (株)医薬情報研究所 2010年12月
  • K. Kamata; M. Kitano; M. Kudo; H. Imai; H. Sakamoto; T. Komaki
    ENDOSCOPY 42 E331 - E332 2010年12月 [査読有り]
  • Nakamura A; Osonoi T; Terauchi Y
    Journal of diabetes investigation 1 5 208 - 211 2010年10月 [査読有り]
  • Arao T; Kudo M; Nishio K
    Gan to kagaku ryoho. Cancer & chemotherapy 37 10 1879 - 1882 2010年10月 [査読有り]
  • 非閉塞性腸管虚血を発症した悪性リンパ腫の一例
    宮田 剛; 井上 達夫; 有住 忠晃; 早石 宗右; 上田 泰輔; 辰巳 千栄; 田北 雅弘; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    日本消化器病学会雑誌 107 臨増大会 A828 - A828 (一財)日本消化器病学会 2010年09月
  • 造影エコーによる肝細胞癌の診断能、Gd-EOB-MRI、Dynamic CTとの比較検討
    井上 達夫; 畑中 絹世; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    肝臓 51 Suppl.2 A564 - A564 (一社)日本肝臓学会 2010年09月
  • 線維化進行C型肝炎患者における脾摘後のインターフェロン導入における問題点 好中球数の変化について
    鄭 浩柄; 上田 泰輔; 早石 宗右; 田北 雅弘; 北井 聡; 畑中 絹代; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 土師 誠二
    肝臓 51 Suppl.2 A600 - A600 (一社)日本肝臓学会 2010年09月
  • Masatoshi Kudo; Kwang Hyub Han; Norihiro Kokudo; Ann-Lii Cheng; Byung Ihn Choi; Junji Furuse; Namiki Izumi; Joong-Won Park; Ronnie T. Poon; Michiie Sakamoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40 i19 - i27 2010年09月 [査読有り]
     
    Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation.
  • Hobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Tsutomu Chiba
    JOURNAL OF INFECTIOUS DISEASES 202 6 853 - 861 2010年09月 [査読有り]
     
    Background. Hepatitis C virus (HCV) activates host innate immune responses mediated by retinoic acid inducing gene-I (RIG-I) and Toll-like receptors (TLRs). Although the nonstructural protein 3/4A (NS3/4A) of HCV disrupts interferon responses by inhibiting RIG-I signaling, the effects of TLR activation by HCV-associated proteins on host innate immune responses are poorly understood. Methods. Proinflammatory cytokine responses to various TLR ligands in human antigen-presenting cells (APCs) were examined either with or without prestimulation by HCV core protein. Results. TLR2 activation by the HCV core protein leads to a decrease in interleukin 6 (IL-6) production by human APCs after subsequent stimulation with TLR2 (homotolerance) ligands and TLR4 (cross-tolerance) ligands. This hyporesponsiveness induced by preexposure to the HCV core protein was partially mediated by the negative regulation of nuclear factor-kappa B activation by the induction of IRAK-M. TLR ligand-induced IL-6 production was significantly reduced in peripheral blood monocytes isolated from HCV-infected patients, compared with those of healthy control subjects. Alloantigen presentation by monocytes isolated from HCV-infected patients results in impaired production of interleukin 17 by naive CD4(+) T cells in the presence of TLR ligands. Conclusions. Chronic stimulation of APCs with HCV core protein is associated with hyporesponsiveness in TLR-mediated innate immunity.
  • Estimation of Liver Function Using T1 Mapping on Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid-enhanced Magnetic Resonance Imaging.
    Katsube T; Okada M; Kumano S; Hori M; Imaoka I; Ishii K; Kudo M; Kitagaki H; Murakami T
    Invest Radiol 46 277 - 283 Lippincott Williams & Wilkins 2010年08月 [査読有り]
  • Sakamoto H; Kitano M; Kudo M
    World journal of radiology 2 8 289 - 297 2010年08月 [査読有り]
  • Umehara Y; Kudo M; Kawasaki M
    Endoscopy 42 E173 - E174 2010年07月 [査読有り]
  • Masatoshi Kudo
    Oncology 78 1 1 - 6 2010年07月 [査読有り]
     
    Hepatocellular carcinoma is a malignant tumor responsible for approximately 600,000-700,000 deaths worldwide, and is becoming more prevalent not only in South-East Asia and Africa, but also in Western countries therefore, interest in hepatocellular carcinoma has mounted in recent years in the West, where little or no interest was evident 10-20 years ago. Copyright © 2010 S. Karger AG.
  • Masatoshi Kudo; Shouji Kubo; Kenichi Takayasu; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Kenji Nakamura; Masatoshi Makuuchi
    HEPATOLOGY RESEARCH 40 7 686 - 692 2010年07月 [査読有り]
     
    The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to assess the direct effects of treatment on the hepatocellular carcinoma (HCC) by locoreginal therapies such as radio-frequency ablation (RFA) and transcatheter arterial chemo-embolization (TACE). Therefore, establishment of response evaluation criteria solely devoted for HCC is needed urgently in the clinical practice as well as in the clinical trials of HCC treatment, such as molecular targeted therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2009 by Liver Cancer Study Group of Japan based on the 2004 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2009 is to provide TE4a (Complete response with enough ablative margin) and TE4b (complete response without enough ablative margin) for local ablation therapy. Second revised point is that setting the timing at which the overall treatment effects are assessed. Third point is that emergence of new lesion in the liver is regarded as progressive disease, different from 2004 version. Finally, 3 tumor markers including alpha-fetoprotein (AFP) and AFP-L3 and des-gamma-carboxy protein (DCP) were also added for the overall treatment response. We hope this new treatment response criteria, RECICL, proposed by Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of the daily clinical practice and clinical trials as well not only in Japan, but also internationally.
  • 肝細胞癌の分子標的探索と臨床応用 HCCに対するソラフェニブの治療効果予測について
    上嶋 一臣; 工藤 正俊
    肝臓 51 Suppl.1 A32 - A32 (一社)日本肝臓学会 2010年04月
  • Real-time Tissue Elastographyによる非侵襲的肝線維化評価法は炎症の影響を受けない
    藤本 研治; 外村 明子; 辰巳 千栄; 石田 哲士; 上嶋 一臣; 三竹 毅; 山本 佳司; 椎名 毅; 工藤 正俊; 加藤 道夫
    肝臓 51 Suppl.1 A346 - A346 (一社)日本肝臓学会 2010年04月
  • 組織エラストグラフィーの現況と展望 慢性肝疾患におけるReal-time Tissue Elastographyの精度の検討
    藤本 研治; 外村 明子; 辰巳 千栄; 石田 哲士; 上嶋 一臣; 三竹 毅; 椎名 毅; 工藤 正俊; 加藤 道夫
    超音波医学 37 Suppl. S168 - S168 (公社)日本超音波医学会 2010年04月
  • びまん性肝疾患のUltrasound Functional Imaging C型慢性肝疾患患者に対する非侵襲的肝線維化評価の有用性に関する検討
    矢田 典久; 辰巳 千栄; 上嶋 一臣; 藤本 研治; 加藤 道夫; 椎名 毅; 外村 明子; 三竹 毅; 工藤 正俊
    超音波医学 37 Suppl. S280 - S280 (公社)日本超音波医学会 2010年04月
  • Kenichi Takayasu; Shigeki Arii; Iwao Ikai; Masatoshi Kudo; Yutaka Matsuyama; Masamichi Kojiro; Masatoshi Makuuchi
    AMERICAN JOURNAL OF ROENTGENOLOGY 194 3 830 - 837 2010年03月 [査読有り]
     
    OBJECTIVE. Although iodized oil transarterial chemoembolization (TACE) has been found to have survival benefit in the care of patients with unresectable hepatocellular carcinoma, iodized oil infusion chemotherapy without embolization has not been clearly found inferior to or equal to TACE. The purpose of this study was to determine whether one of these therapies is superior to the other or the two are equal in survival benefit and whether embolization with gelatin sponge particles is indispensable to prolonging survival. SUBJECTS AND METHODS. A prospective nonrandomized observational cohort study was conducted over 8 years. Among 11,030 patients with unresectable hepatocellular carcinoma, 8,507 underwent TACE, and 2,523 underwent transarterial infusion therapy with an emulsion of iodized oil and an anticancer agent as initial treatment. Patients with extrahepatic metastasis or any previous treatment were excluded. The primary end point was all-cause mortality. To minimize selection bias, propensity score analysis was used to compare the two groups. RESULTS. During the follow-up period, 5,044 patients (46%) died. In the analysis of all patients, TACE was associated with a significantly higher survival rate than infusion therapy without embolization (hazard ratio, 0.60; 95% CI, 0.56-0.64; p = 0.0001). The propensity score analysis showed that the hazard ratio for death in the TACE group (n = 1,699 patients) compared with the group who underwent infusion therapy without embolization (n = 1,699) was 0.70 (95% CI, 0.63-0.76; p = 0.0001). The median survival time of the TACE group was 2.74 years, and the 1-, 3-, and 5-year survival rates were 81%, 46%, and 25%. The corresponding values for the group who underwent transarterial infusion therapy without embolization were 1.98 years and 71%, 33%, and 16%. CONCLUSION. Propensity score analysis showed that in the treatment of patients with unresectable hepatocellular carcinoma, TACE was associated with significantly better overall survival rates than was transarterial infusion therapy without embolization. TACE can be recommended as initial treatment of these patients.
  • 【消化器がん化学療法看護完全マスターBOOK 分子標的薬と従来型抗がん剤のケア 副作用 治療のしくみがやさしくわかる!】こう変わった!こう変わる!肝がん化学療法
    上嶋 一臣; 工藤 正俊
    消化器外科Nursing 2010臨時増刊 128 - 129 (株)メディカ出版 2010年02月
  • MRIおよびCTを用いた画像的肝機能評価
    岡田 真広; 熊野 正士; 勝部 敬; 香川 祐毅; 栗生 明博; 今岡 いずみ; 石井 一成; 今井 康陽; 工藤 正俊; 村上 卓道
    日本医学放射線学会学術集会抄録集 69回 S134 - S134 (公社)日本医学放射線学会 2010年02月
  • Hobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Osamu Maenishi; Yoshio Wakatsuki; Tsutomu Chiba
    LIVER INTERNATIONAL 30 2 222 - 231 2010年02月 [査読有り]
     
    Background Autoimmune hepatitis (AIH) and autoimmune pancreatitis (AIP) share clinical and pathological features such as high serum levels of immunoglobulin (Ig) G and autoantibodies, and lymphoplasmacytic infiltration, suggesting the presence of common immunological abnormalities. However, little is known about the possible involvement of IgG4, a hallmark of AIP, in AIH. Aims In this study, we examined whether the IgG4 response contributes to the histopathological and clinical findings in AIH. Methods Liver sections from 26 patients with AIH, 10 patients with primary biliary cirrhosis (PBC), three patients with primary sclerosing cholangitis (PSC) and 20 chronic hepatitis patients with hepatitis C virus (HCV) infection were immunostained for IgG4. We investigated the relationship among the histopathology, the responses to steroid therapy and the IgG4 staining. Results Nine of the 26 liver specimens from patients with AIH showed positive staining for IgG4 whereas none of the 10 samples from patients with PBC, the three samples from patients with PSC or the 20 samples from patients with HCV hepatitis were positive. Patients with IgG4-positive AIH also showed increased serum levels of IgG. The numbers of T cells, B cells and plasma cells were significantly increased in the livers of patients with IgG4-positive AIH as compared with those patients with IgG4-negative AIH. Patients with IgG4-positive AIH also showed a marked response to prednisolone therapy. Conclusions AIH may be classified into either an IgG4-associated type or an IgG4 non-associated type with the former showing a marked response to prednisolone treatment.
  • Kinuyo Hatanaka; Hobyung Chung; Masatoshi Kudo; Seiji Haji; Yasunori Minami; Kiyoshi Maekawa; Sousuke Hayaishi; Tomoyuki Nagai; Masahiro Takita; Kanae Kudo; Taisuke Ueda; Chie Tatsumi; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima
    ONCOLOGY 78 53 - 59 2010年 [査読有り]
     
    Objective: The purpose of this study was to assess the usefulness of post-vascular phase (PVP) images of contrast-enhanced ultrasonography (CE-US) in the evaluation of the gross types of hepatocellular carcinoma (HCC) that is closely related to the malignant potential of the tumor. Methods: A total of 29 patients with 40 HCCs of <5 cm in diameter, who underwent hepatic resection, were enrolled. The gross type of the tumor was evaluated using real-time scanning during the PVP of CE-US with Sonazoid prior to surgery. The tumors were classified into three types based on the macroscopic classification of the Liver Cancer Study Group of Japan: single nodular (SN) type, single nodular with extranodular growth (SNEG) type, and confluent multinodular (CMN) type. The ability of CE-US to correctly depict the gross type of HCC was evaluated. Results: 26 tumors were macroscopically diagnosed as the SN type, 11 tumors as the SNEG type, and 3 tumors as the CMN type. The sensitivity, specificity and accuracy of CE-US were 96, 80 and 90%, respectively. Conclusion: The PVP image of CE-US with Sonazoid is a useful tool in the evaluation of the gross type of HCC and is considered essential in deciding treatment strategy. Copyright (C) 2010 S. Karger AG, Basel
  • Hobyung Chung; Taisuke Ueda; Masatoshi Kudo
    INTERVIROLOGY 53 1 39 - 43 2010年 [査読有り]
     
    In Japan, hepatocellular carcinoma (HCC) is the fourth leading cause of death in males and the fifth in females. Hepatitis C virus (HCV) is a major cause of HCC in Japan, with 70% of cases being HCV related. HCV genotype 1b, the most prevalent subtype in Japan, started to spread in the 1930s among injecting drug users (IDUs) during and after World War II or through medical procedures such as blood transfusion and use of contaminated syringes. The prevalence of HCV infection is much lower in the current younger generation compared with that in the older generation, particularly those aged 1 55 years (0.1-0.2% vs. >= 2%). Therefore, the total number of patients with HCV infection is estimated to decrease, even though sporadic HCV transmission is mainly seen among young IDUs. Of note, HCV genotype 2 seems to be spreading among IDUs, but the response to antiviral therapy in these patients seems to be better than that in older patients, irrespective of the genotype. Although the number of patients who die because of HCC has steadily increased over the last 50 years, the incidence of HCC is now decreasing, mainly because of the decreased prevalence of HCV-related HCC. Copyright (C) 2010 S. Karger AG, Basel
  • Soo Ryang Kim; Susumu Imoto; Masatoshi Kudo; Keiji Mita; Miyuki Taniguchi; Ke Ih Kim; Noriko Sasase; Ikuo Shoji; Motoko Nagano-Fujii; Ahmed El-Shamy; Hak Hotta; Tomoyuki Nagai; Yoshiaki Nagata; Yoshitake Hayashi
    INTERVIROLOGY 53 1 44 - 48 2010年 [査読有り]
     
    Double-filtration plasmapheresis (DFPP) was approved in Japan in April 2008 for the retreatment of chronic hepatitis C patients with genotype 1b and high viral loads, whose hepatitis C virus was not eradicated by earlier IFN therapy or by pegylated IFN plus ribavirin (PEG-IFN/RBV) combination therapy. In this study, we assessed the early viral dynamics of 9 patients with non-sustained virological response to the combination therapy. The overall viral dynamics of DFPP plus IFN treatment with or without RBV for 4 weeks showed a reduction of 6 1 log in the viral load in 22% (2 of 9 patients), 55.6% (5/9), 77.8% (7/9) and 77.8% (7/9) at 24 h, 1, 2 and 4 weeks after the start of treatment. By contrast, DFPP plus consecutive intravenous IFN-beta for 4 weeks reduced the viral load by >= 1 log in 33% (2/6), 50% (3/6), 83.3% (5/6) and 83.3% (5/6) at 24 h, 1, 2 and 4 weeks. The viral load declined by >= 2 log in 50% (3/6) at 4 weeks after the start of treatment. DFPP plus consecutive intravenous IFN-beta for 4 weeks is a promising treatment for non-sustained virolgical response patients. Copyright (C) 2010 S. Karger AG, Basel
  • Noriko Sasase; Soo Ryang Kim; Masatoshi Kudo; Ke Ih Kim; Miyuki Taniguchi; Susumu Imoto; Keiji Mita; Yoshitake Hayashi; Ikuo Shoji; Ahmed El-Shamy; Hak Hotta
    INTERVIROLOGY 53 1 49 - 54 2010年 [査読有り]
     
    We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). The first RI (RI-1st; the viral load at week 1 divided by the viral load at 24 h) and the second RI (RI-2nd; the viral load at week 2 divided by the viral load at 24 h) were calculated. The subject patients were divided into 3 groups based on RI-1st and RI-2nd: an RI-A group (RI-1st <= 1.0), an RI-B group (RI-1st > 1.0 and RI-2nd <0.7) and an RI-C group (RI-1st > 1.0 and RI-2nd >= 0.7). The SVR rate was 71.4% (10/14) in the RI-A group, 46.2% (6/13) in the RI-B group and 20.0% (3/15) in the RI-C group (p = 0.005 between the RI-A group and the RI-C group). In IRRDR >= 6 and IRRDR <= 5 the SVR rate was 81.3% (13/16) and 23.1% (6/26) (p = 0.0002), respectively. By combining RI and IRRDR as a predicting factor, the SVR rate was 87.5% (7/8) in the RI-A group (>= 6 mutations in the IRRDR) and 7.7% (1/13) in the RI-C group (<= 5 IRRDR mutations) (p = 0.0003). Copyright (C) 2010 S. Karger AG, Basel
  • Norihisa Yada; Masatoshi Kudo; Hobyung Chung; Sosuke Hayaishi; Masahiro Takita; Taisuke Ueda; Chie Tatsumi; Kinuyo Hatanaka; Satoshi Kitai; Emi Ishikawa; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima
    INTERVIROLOGY 53 1 60 - 65 2010年 [査読有り]
     
    Objectives: We investigated the significance of serum ferritin levels in pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy for chronic hepatitis C (CHC) and examined its correlation with serum alanine aminotransferase (ALT) levels during therapy and response to the therapy. Methods: A total of 175 patients with CHC received the combination therapy. Correlations between serum ferritin levels and serum ALT levels at 12 and 24 weeks of therapy were examined. Differences in serum ferritin levels during therapy between patients with sustained viral response (SVR) and non-SVR were also examined. Results: Only 24 (13.7%) and 20 (11.4%) patients showed elevated serum ALT levels (6 70 IU/l) at 12 and 24 weeks of therapy, respectively. There was no correlation between serum ferritin levels and ALT levels. Ninety-five (54.3%) of 175 patients achieved SVR. Serum ferritin levels increased dramatically in both SVR and non-SVR groups after starting the therapy and were significantly higher in the SVR group throughout the therapy. Conclusions: Serum ferritin level increases during PEG-IFN and RBV combination therapy; however, it did not correlate with either serum ALT level or the total dose of RBV. Higher serum ferritin levels during combination therapy appear to be associated with favorable therapeutic response. Copyright (C) 2010 S. Karger AG, Basel
  • Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Sousuke Hayaishi; Taisuke Ueda; Chie Tatsumi; Masahiro Takita; Satoshi Kitai; Kinuyo Hatanaka; Emi Ishikawa; Norihisa Yada; Satoru Hagiwara; Kazuomi Ueshima; Masatoshi Kudo
    ONCOLOGY 78 94 - 101 2010年 [査読有り]
     
    Purpose: To confirm the safety and effectiveness of techniques to assist radiofrequency ablation (RFA) for difficult cases, we retrospectively evaluated successful treatment rates, early complications and local tumor progressions. Patients and Methods: Between June 1999 and April 2009, a total of 341 patients with 535 nodules were treated as difficult cases. Artificial pleural effusion assisted ablation was performed on 64 patients with 82 nodules. Artificial ascites-assisted ablation was performed on 11 patients with 13 nodules. Cooling by endoscopic nasobiliary drainage (ENBD) tube-assisted ablation was performed on 6 patients with 8 nodules. When the tumors were not well visualized with conventional B-mode ultrasonography (US), contrast-enhanced US-assisted ablation with Levovist (R) or Sonazoid (R) or virtual CT sonography-assisted ablation was performed. Contrast-enhanced US-assisted ablation was performed on 139 patients with 224 nodules and virtual CT sonography-assisted ablation was performed on 121 patients with 209 nodules. Results: In total, complete ablation was achieved in 514 of 535 (96%) nodules in difficult cases. For RFA with artificial pleural effusion, artificial ascites and ENBD, complete response was confirmed in all cases. For contrast-enhanced US-and CT sonography-assisted ablation, complete response was 95%. Early complications were recognized in 24 cases (4.5%). All cases recovered with no invasive treatment. Local tumor recurrence was investigated in 377 nodules of 245 patients, and 69 (18%) nodules were positive. Tumor recurrences in each assisted technique were 14.7% in artificial pleural effusion cases, 7% in artificial ascites, 12.5% in ENBD tube cases, 31% in virtual CT sonography, and 8.5% in contrast-enhanced US. Conclusion: Although local tumor progression needs to be carefully monitored, assisted techniques of RFA for difficult cases are well tolerated and expand the indications of RFA. Copyright (C) 2010 S. Karger AG, Basel
  • Masatoshi Kudo; Kazuomi Ueshima
    ONCOLOGY 78 154 - 166 2010年 [査読有り]
     
    Sorafenib, a molecular-targeted agent that inhibits tumor cell proliferation and angiogenesis by inhibiting RAF serine-threonine kinase and VEGF, PDGF, Flt-3, c-Kit receptor tyrosine kinase, was approved in Europe and North America in 2007 and in Japan on May 20, 2009. In the 10 months since its approval, sorafenib has been prescribed for more than 3,700 patients with advanced hepatocellular carcinoma (HCC), and its efficacy has been confirmed in many cases. According to the consensus statements of the Japan Society of Hepatology in 2010, sorafenib is recommended for advanced HCC with extrahepatic spread or major vascular invasion such as invasion of the 1st branch of the portal vein or the main portal branch of the portal vein in patients with Child-Pugh A liver function. In addition to that, transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) refractory HCC patients with Child-Pugh A liver function are also candidates of sorafenib monotherapy as a second-line treatment option. To date, 15 cases with complete remission (CR) to sorafenib in metastatic advanced HCC patients have been reported in Japan, an event that is rarely reported in other countries. Of the 90 cases treated by ourselves, 2 achieved CR. Factors indicating systemic cancer spread, including multiple liver lesions, lymph node metastases, adrenal metastases, lung metastases and vascular invasion, were completely absent in both cases of CR by 2 and 1 year, respectively. Similarly, three tumor markers (AFP, PIVKA-II, and AFP-L3) completely returned to normal values. Although cases of CR are rare, it seems that there might be racial differences in terms of gene mutations. Clinical trials for other molecular-targeted agents, including sunitinib, brivanib, or linifanib, are ongoing and their outcomes are eagerly awaited. According to a subanalysis of the SHARP study, it is expected that sorafenib in combination with resection, ablation, TACE or HAIC will markedly prolong the overall survival in early-, intermediate- and advanced-stage HCCs. Copyright (C) 2010 S. Karger AG, Basel
  • ペグインターフェロンα-2b/リバビリン併用療法の無効・再燃例に対するペグインターフェロンα-2a/リバビリン併用療法の再治療. 増刊号「C型肝炎の臨床最前線」
    工藤正俊; 上田泰輔; 土谷 薫; 橋元 悟; 井上泰輔; 稲生実枝; 田中 篤; 垣内雅彦; 今関文夫; 西口修平
    肝胆膵 61 127 - 133 2010年 [査読有り]
  • Takuji Okusaka; Hiroshi Kasugai; Yasukazu Shioyama; Katsuaki Tanaka; Masatoshi Kudo; Hiromitsu Saisho; Yukio Osaki; Michio Sata; Shigetoshi Fujiyama; Takashi Kumada; Keiko Sato; Seiichiro Yamamoto; Shiro Hinotsu; Tosiya Sato
    JOURNAL OF HEPATOLOGY 51 6 1030 - 1036 2009年12月 [査読有り]
     
    Background/Aims: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. Methods: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. Results: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679 days in the TAI group (p = 0.383). Conclusions: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • Minami Y; Kudo M
    World journal of radiology 1 1 86 - 91 2009年12月 [査読有り]
  • Hiroki Sakamoto; Masayuki Kitano; Takamitsu Komaki; Hajime Imai; Ken Kamata; Masatomo Kimura; Yoshifumi Takeyama; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 15 43 5489 - 5492 2009年11月 [査読有り]
     
    Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass. This report describes a case of small adenocarcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasm (IPMN) in which investigation by EUS took place every 6 mo and diagnosis was made accurately by additional CEH-EUS during the follow-up of the branch duct IPMN. A 68-year-old female was admitted to our hospital because of a branch duct IPMN in the pancreatic body. She had been followed-up by EUS every 6 mo. However, after 2 years EUS demonstrated a low echoic area distinct from the branch duct IPMN which was; vaguely discernible by EUS, and accurate sizing and differential diagnosis were considered difficult on the EUS imaging. CH-EUS with Sonazoid revealed a hypovascular tumor and we suspected small pancreatic carcinoma. The histopathological diagnosis was adenocarcinoma (10 mm) in the pancreatic tail, distinct from the branch duct IPMN of the pancreatic body. EUS and CEH-EUS may play an important role in the correct diagnosis of small pancreatic tumors, including synchronous and metachronous occurrence of IPMN and ductal adenocarcinoma of the pancreas. (C) 2009 The WJG Press and Baishideng. All rights reserved.
  • Soo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Keiji Mita; Katsumi Fukuda; Ryo Nishikawa; Yu-Ichiro Koma; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi
    Case reports in gastroenterology 3 2 187 - 192 2009年07月 [査読有り]
     
    We describe an 8-mm hepatocellular carcinoma (HCC) with hepatitis C virus-related cirrhosis in a 74-year-old woman. Ultrasound (US) revealed an 8-mm hyperechoic nodule in segment 6 of the liver. Contrast-enhanced computed tomography (CT) and US revealed no hypervascularity in the early phase and no washout in the late phase and the Kupffer phase, respectively. CT during arteriography revealed no hypervascularity and CT during arterial portography disclosed no perfusion defect. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) revealed no hypervascularity in the early phase, but disclosed a defect in the hepatobiliary phase. Histologically, the nodule was diagnosed as well-differentiated HCC characterized by more than two-fold the cellularity of the non-tumorous area, with a high nuclear:cytoplasmic ratio, increased cytoplasmic eosinophilia, fatty change, and slight cell atypia with an irregular thin trabecular pattern. Our case demonstrates the utility of Gd-EOB-DTPA-enhanced MRI in the diagnosis of small HCC.
  • Kanae Kudo; Tokuzo Arao; Kaoru Tanaka; Hiroyasu Kaneda; Mari Maegawa; Kazuko Matsumoto; Daisuke Tamura; Keiichi Aomatsu; Yoshihiko Fujita; Masatoshi Kudo; Kazuto Nishio
    CANCER RESEARCH 69 2009年05月 [査読有り]
  • びまん性肝疾患の超音波による評価 肝疾患におけるReal-time Tissue Elastography(第4報)
    藤本 研治; 辰巳 千栄; 上嶋 一臣; 外村 明子; 三竹 毅; 金 栄浩; 山本 佳司; 椎名 毅; 工藤 正俊; 加藤 道夫
    超音波医学 36 Suppl. S204 - S204 (公社)日本超音波医学会 2009年04月
  • 分枝鎖アミノ酸顆粒製剤による肝硬変患者の予後に与える影響に関する検討
    早石 宗右; 石川 恵美; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    肝臓 50 Suppl.1 A206 - A206 (一社)日本肝臓学会 2009年04月
  • 進行肝細胞癌に対するS-1、ペグインターフェロン併用療法の有用性
    矢田 典久; 上嶋 一臣; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊
    肝臓 50 Suppl.1 A275 - A275 (一社)日本肝臓学会 2009年04月
  • 特異な経過をたどったアルコール性肝硬変に合併した肝細胞癌の一例
    早石 宗右; 鄭 浩柄; 辰巳 千栄; 永井 知行; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    肝臓 50 Suppl.1 A292 - A292 (一社)日本肝臓学会 2009年04月
  • 進行肝細胞癌に対するソラフェニブの有効性に関する検討
    上嶋 一臣; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊
    肝臓 50 Suppl.1 A359 - A359 (一社)日本肝臓学会 2009年04月
  • Gd-EOB MRIによる肝細胞癌の診断能 造影超音波検査、Dynamic CTとの比較検討
    井上 達夫; 畑中 絹世; 早石 宗右; 永井 知行; 田北 雅弘; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    肝臓 50 Suppl.1 A368 - A368 (一社)日本肝臓学会 2009年04月
  • Tatsuo Inoue; Masatoshi Kudo; Osamu Maenishi; Mina Komuta; Osamu Nakashima; Masamichi Kojiro; Kiyoshi Maekawa
    AMERICAN JOURNAL OF ROENTGENOLOGY 192 3 698 - 705 2009年03月 [査読有り]
     
    OBJECTIVE. The objective of our study was to investigate whether liver parenchymal phase contrast-enhanced sonography can provide additional information for assessing histologic grades of hepatocellular carcinoma (HCC). SUBJECTS AND METHODS. Contrast-enhanced sonography using Levovist of 50 hepatic nodules was performed. The vascular and liver parenchymal perfusion patterns were evaluated. The sensitivity, specificity, and accuracy of the histologic diagnosis of the tumors using vascular phase imaging only and systematically combined vascular phase imaging with liver parenchymal phase imaging were calculated. We also performed histologic examination and immunostaining for the detection of Kupffer cells and calculated the Kupffer cell count in the tumorous tissue relative to that in the nontumorous tissue (Kupffer cell ratio) and quantitatively evaluated the relationship between the Kupffer cell ratio and the perfusion patterns seen on liver parenchymal phase imaging. RESULTS. The specificity and accuracy of contrast-enhanced sonography in the diagnosis of dysplastic nodules and of moderately and poorly differentiated HCCs were improved by adding liver parenchymal phase imaging (dysplastic nodules, 74% and 78% vs 83% and 86%, respectively; moderately and poorly differentiated HCCs, 74% and 86% vs 85% and 92%). The diagnostic accuracy of contrast-enhanced sonography for dysplastic nodules showed a trend of improvement with the addition of liver parenchymal phase imaging (p = 0.07). Kupffer cell ratios for tumors that showed hypoperfusion during the liver parenchymal phase were significantly lower than those for tumors showing isoperfusion (p < 0.05). CONCLUSION. Adding liver parenchymal phase imaging to contrast-enhanced sonography protocols may yield additional information that can be used to assess histologic grades of tumor and that leads to an improvement in the differential diagnosis of nodular lesions associated with the cirrhotic liver. Further case studies are required in larger numbers of patients for a longer follow-up period.
  • Tatsuo Inoue; Masatoshi Kudo
    Japanese Journal of Cancer and Chemotherapy 36 8 1253 - 1255 2009年 [査読有り]
     
    Radiofrequency ablation (RFA) is widely used as a therapeutic method for hepatocellular carcinoma. It led to more favorable therapeutic results than percutaneous ethanol injection (PEI), which is currently in use. RFA has been used as a new therapeutic tool for metastatic liver cancer. We describe the present situation in our institution regarding RFA therapy for metastatic liver cancer originating from colorectal carcinoma.
  • Masatoshi Kudo
    Oncology 75 1 1 - 12 2008年12月 [査読有り]
     
    Hepatocellular carcinoma (HCC) is a malignant tumor which is becoming more prevalent worldwide. Patients at high risk of developing HCC, namely hepatitis B- and C-related liver cirrhosis patients, should be entered into surveillance programs, which should be performed using both ultrasonography and 3 tumor markers (AFP, PIVKA-II, AFP-L3). The surveillance interval needs to be shortened for patients at higher risk of HCC. Therefore, super-high-risk patients should be screened at 3- to 4-month intervals based on their risk of developing HCC. Sonazoid-enhanced US is extremely useful to characterize hepatic tumors when compared with multidetector-row computed tomography (MDCT). Moreover, Sonazoid-enhanced US with defect reperfusion imaging is a breakthrough approach in the treatment of HCC. This technique will markedly change the therapeutic strategy for liver cancer. Furthermore, diagnostic capability using the new imaging technique Gd-EOB-DTPA MRI is promising. A reduced uptake (low intensity) in the hepatobiliary phase of Gd-EOB-DTPA MRI strongly suggests HCC (including early-stage HCC) or a high-grade dysplastic nodule with high malignant potential. Empirically, intrahepatic arterial infusion chemotherapy using implanted reservoir port is known to be effective for advanced HCC with vascular invasion however, no randomized study exists to prove its efficacy. Further controlled study is necessary to establish this treatment option as a standard of care in a treatment algorithm for HCC. In contrast, sorafenib was established as the first choice of treatment as a standard of care in advanced HCC patients with preserved liver function and vascular invasion/extrahepatic spread. Furthermore, global clinical trials are now ongoing using sorafenib as an adjuvant setting after resection, ablation or TACE. Efficacy of combined use of sorafenib with TACE or intra-arterial infusion chemotherapy is not clear. In order to clarify this issue a randomized clinical trial for intermediate and advanced HCC comparing sorafenib alone versus sorafenib combined with maintenance TACE/intra-arterial infusion chemotherapy and/or intra-arterial infusion chemotherapy is scheduled to be initiated in Japan in 2009. If positive results are obtained by these trials, its impact on treatment strategy for HCC will be drastically changed. Copyright © 2008 S. Karger AG.
  • Soo Ryang Kim; Masatoshi Kudo; Okio Hino; Kwang Hyub Han; Young Hwa Chung; Hyo Suk Lee
    Oncology 75 1 13 - 16 2008年12月 [査読有り]
     
    The worldwide burden of liver cancer has been estimated at 671,000 new cases for the year 2005. Hepatocellular carcinoma (HCC) accounts for between 85 and 90% of primary liver cancer and is one of the most frequent malignancies in Asia. In both Japan and Korea, the incidence exceeds 25 cases/100,000/year and ranks third in cancer deaths after stomach and lung cancer. In Korea the number of deaths from liver cancer increased from approximately 5,789 in 1983 to 9,966 in 1994, and then remained steady at 9,500/100,000 in 2003. In Japan the number of deaths from HCC increased until 2002, and then decreased to 34,089 in 2003, up to 15% of HCC cases are caused by hepatitis B virus (HBV) and ∼80% by hepatitis C virus (HCV) infection the corresponding figures in Korea are ∼70 and ∼20%. Recent clinical data have shown that interferon and lamivudine treatment is effective in preventing the occurrence of HCC attributed to HCV and HBV infection, respectively, and that an aggressive vaccination program against the latter reduces the incidence of HCC. With the enormous efforts of researchers devoted to basic and clinical studies, the incidence of HCC is expected, in the near future, to gradually decline in both countries. Copyright © 2008 S. Karger AG.
  • Masatoshi Kudo
    Oncology 75 1 30 - 41 2008年12月 [査読有り]
     
    Primary and secondary prevention of hepatocellular carcinoma (HCC) which has become endemic worldwide in recent years are the most important issues in reducing mortality of HCC patients. Among several compounds previously reported for secondary prevention, treatment with interferon (IFN) is widely applied and shows encouraging results. To date, there have been 8 published randomized control trials (RCTs) and 6 published non-RCTs on IFN therapy after curative treatment of HCCs. Positive results were shown in 6 of 8 RCTs and in all of 6 non-RCT cohort studies regarding either recurrence rate or patient survival. The impact of IFN therapy after curative treatment of HCC can be summarized as follows: (1) HCC incidence of recurrence is reduced through viral clearance or long-term IFN treatment, even though HCV is not cleared. (2) Low-dose, long-term IFN (maintenance) therapy may suppress HCC recurrence through direct action of IFN on tumor cells. (3) Patient survival is improved through growth inhibition of recurrent tumors, as well as preservation of liver function. (4) According to the above 3 points, there is more chance to receive curative treatment in the IFN than the non-IFN group. (5) Pegylated IFN (PEG-IFN) may be more beneficial than non-PEG-IFN products since IFN concentration is maintained in the body at a high level, which is favorable for its action as a direct anticancer agent. (6) It may be concluded that IFN treatment after curative treatment of HCC is beneficial at least in HCV-related HCC, since it lowers recurrence and improves survival. Copyright © 2008 S. Karger AG.
  • Kinuyo Hatanaka; Masatoshi Kudo; Yasunori Minami; Kiyoshi Maekawa
    Oncology 75 1 42 - 47 2008年12月 [査読有り]
     
    Objective: The purpose of this study was to assess the usefulness of Sonazoid-enhanced ultrasonography (US) in the diagnosis of hepatic malignancies in comparison with contrast-enhanced CT findings. Methods: A total of 74 patients with 113 hepatic tumors having or highly suspected of having malignancies were enrolled. These hepatic nodules were diagnosed by typical findings of imaging such as contrast-enhanced CT, dynamic MRI or Sonazoid-enhanced US, tumor markers and histological examinations after surgical resection or biopsy. Results: 108 nodules were diagnosed as malignant tumors (hepatocellular carcinoma: n = 90 metastasis: n = 16 intrahepatic cholangiocarcinoma: n = 2) and the remaining five tumors were diagnosed as benign tumors (dysplastic nodules: n = 5). Sonazoid-enhanced US correctly depicted the presence or absence of tumors in 74 patients, with a sensitivity of 95.4%, an accuracy of 94.7%, and a positive predictive rate of 99%. Contrast-enhanced CT depicted the malignancies with a sensitivity of 85.2%, an accuracy of 82.3%, and a positive predictive rate of 95.8%. There were significant differences between Sonazoid-enhanced US and contrast-enhanced CT for sensitivity and accuracy (both p < 0.05). Conclusion: Sonazoid-enhanced US has a higher sensitivity and accuracy for the diagnosis of hepatic malignancies than contrast-enhanced CT. Copyright © 2008 S. Karger AG.
  • Tatsuo Inoue; Masatoshi Kudo; Kinuyo Hatanaka; Syunsuke Takahashi; Satoshi Kitai; Taisuke Ueda; Emi Ishikawa; Satoru Hagiwara; Yasunori Minami; Hobyung Chung; Kazuomi Ueshima; Kiyoshi Maekawa
    Oncology 75 1 48 - 54 2008年12月 [査読有り]
     
    Purpose: To evaluate the usefulness of vascular phase images of contrast-enhanced ultrasonography (CE-US) with Sonazoid for hepatocellular carcinomas (HCCs), a retrospective, comparative study was conducted of images of HCCs obtained by CE-US and superparamagnetic iron oxide (SPIO) magnetic resonance imaging (MRI) and evaluated qualitatively and quantitatively. Methods: Seventy-seven patients with 88 HCCs who received CE-US and SPIO-MRI were reviewed. The ratio of the echogenicity of the tumor and nontumor areas was calculated with postvascular phase CE-US (postvascular phase ratio). The ratio of the intensity of the nontumor to tumor areas on SPIO-enhanced MRI (SPIO intensity index) was also calculated. The Pearson correlations were calculated for all values between the postvascular phase ratio and SPIO intensity index for quantitative comparison. These images were also compared qualitatively for the detection rate of the tumors. Results: The sensitivities of CE-US and SPIO-MRI in detecting tumors were 98 and 95%, respectively (nonsignificant, χ2 test). The postvascular phase ratio correlated with the SPIO intensity index for HCCs (Pearson r = 0.803, p < 0.05). The image conformity of the result from the liver parenchymal phase CE-US and SPIO-MRI was 92%. Dedifferentiation spots of nodule-in-nodule HCCs were detected in 4 (80%) of 5 on postvascular phase images of CE-US, and in 2 (40%) of 5 on SPIO-MRI (nonsignificant, χ2 test). Conclusions: Postvascular phase images of CE-US with Sonazoid appear promising as an alternative to SPIO-enhanced MRI. Further study cases are needed to confirm the usefulness of postvascular phase images of CE-US compared to SPIO-MRI for the detection of dedifferentiation foci in hepatic tumors. Copyright © 2008 S. Karger AG.
  • Masatoshi Kudo; Hitoshi Tochio
    Oncology 75 1 55 - 64 2008年12月 [査読有り]
     
    This study was carried out to investigate whether intranodular blood supply in histologically proven well-differentiated hepatocellular carcinomas (HCCs) correlates with tumor growth rates. A total of 52 well-differentiated HCCs were enrolled in this study. Ultrasound angiography with intra-arterial CO 2 microbubble injection was performed in all 52 HCCs and computed tomography during arterial portography was performed in 21 of the 52 HCCs. Tumor volume doubling time (TVDT) was measured in all 52 nodules by B-mode ultrasonography performed at 2- to 3-month intervals for a follow-up period of at least 6 months (range: 6 months to 8 years) with respect to arterial vascularity. In the hypervascular (n = 27), isovascular (n = 9), and hypovascular nodules (n = 16), the mean values of TVDT (mean ± SD) were 79 ± 131, 98 ± 227, and 782 ± 324 days, respectively (rs = 0.722, p < 0.0001). Concerning portal blood supply, the mean TVDT in nodules in which the portal supply was reduced (n = 5) was 178 ± 78 days compared with 592 ± 211 days in nodules in which the portal supply was preserved (n = 11), with a significant difference (p < 0.01). Five nodules in which the portal supply was preserved did not enlarge during the follow-up period of 3-5 years. There was a significant correlation among the three groups (rs = 0.804, p < 0.05). In conclusion, intranodular blood flow dynamics in patients with well-differentiated HCC reflect the biological malignancy or cancer progression in the process of multistep hepatocarcinogenesis, suggesting the importance of this parameter in deciding on a treatment strategy. In other words, nodules in which arterial vascularity is present and those in which the portal blood flow is reduced should be treated for reasons such as a short doubling time and the risk of rapid progression to artery-dominant classical HCC. Copyright © 2008 S. Karger AG.
  • Satoshi Kitai; Masatoshi Kudo; Yasunori Minami; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
    Oncology 75 1 83 - 90 2008年12月 [査読有り]
     
    Objectives: The conventional Japan Integrated Staging (c-JIS) score has been reported to effectively stratify patients with hepatocellular carcinoma (HCC). Recently, two new staging systems, the biomarker-combined JIS (bm-JIS) score and the BALAD score, have been proposed. Both staging systems include three tumor markers: α-fetoprotein (AFP), lens culinaris agglutinin-reactive AFP and des-γ-carboxy prothrombin specific for HCC. The aim of this study is to evaluate the performance of these three staging systems. Methods: A total of 1,173 HCC patients were included in this study. The stratification ability and prognostic predictive power were compared between these three staging systems. Results: These three staging systems effectively predicted the patient survival. When accounting for the best prognostic subgroup of each staging systems (i.e. score of 0), there were significant differences between the bm-JIS score and the BALAD score and, likewise, between the c-JIS score and the BALAD score. The likelihood ratio χ2 test showed the highest value and the Akaike information criterion value was lowest in the bm-JIS score. Conclusions: The bm-JIS score showed good stratification ability and was thus demonstrated to be a better predictor of the prognosis than the c-JIS score and the BALAD score, especially for the patients with a good prognosis. Copyright © 2008 S. Karger AG.
  • Shunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Chie Tatsumi; Taisuke Ueda; Tomoyuki Nagai; Yasunori Minami; Kazuomi Ueshima
    Oncology 75 1 91 - 98 2008年12月 [査読有り]
     
    Objective: This study was undertaken to assess the prognostic predictor in patients with hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA). Methods: This study retrospectively evaluated clinical outcomes in a cohort of 179 Child-Pugh stage A cirrhotic patients who received curative RFA for naive HCC within Milan criteria. The median follow-up period was 40.5 months. Results: The cumulative survival rate was significantly lower in patients with prothrombin induced by vitamin K absence or antagonist II (PIVKA-II) ≥100 mAU/ml compared with PIVKA-II < 100 mAU/ml (58.0 vs. 84.0% at 5 years p < 0.001). The cumulative recurrence-free survival rates were significantly lower in patients with PIVKA-II ≥100 mAU/ml compared with PIVKA-II < 100 mAU/ml (12.1 vs. 16.9% at 5 years p < 0.032). The cumulative rate of maintaining period within Milan criteria was significantly lower in patients with PIVKA-II ≥100 mAU/ml compared with PIVKA-II < 100 mAU/ml (34.1 vs. 55.6% at 5 years p < 0.001). Cox regression analysis showed that low serum albumin (< 3.5 g/dl p = 0.002, RR 3.75, CI 1.64-8.56), a high level of PIVKA-II (≥100 mAU/ml p = 0.04, RR 3.15, CI 1.45-6.87), and multiple nodules (p = 0.021, RR 2.61, CI 1.15-5.91) were independently significant mortality risk factors. Conclusion: In patients with Child-Pugh stage A HCC, the PIVKA-II level is the best prognostic predictor after curative RFA. Copyright © 2008 S. Karger AG.
  • Yu Xia; Masatoshi Kudo; Yasunori Minami; Kinuyo Hatanaka; Kazuomi Ueshima; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Shunsuke Takahashi; Chie Tatsumi; Taisuke Ueda; Sosuke Hayaishi; Kiyoshi Maekawa
    Oncology 75 1 99 - 105 2008年12月 [査読有り]
     
    Background: The purpose of this study was to investigate if Sonazoid-enhanced harmonic ultrasonography (US) could be used to evaluate the responses of hepatocellular carcinomas (HCCs) to treatment with transcatheter arterial chemoembolization (TACE). Patients and Methods: Forty-three HCCs that had been treated by TACE were evaluated by Sonazoid-enhanced harmonic US and dynamic computed tomography (CT) approximately 1 week after their treatment. The detection rates of residual tumor blood supply using the two modalities were compared. Two months after chemoembolization, 16 of the 43 HCCs, which had no additional local treatment, were followed up with dynamic CT. The results of contrast-enhanced harmonic US and dynamic CT 1 week after chemoembolization were analyzed and compared with follow-up dynamic CT results. Results: The detection rates of positive enhancement with Sonazoid-enhanced harmonic US and dynamic CT 1 week after TACE were 25 (58.1%) of 43 lesions and 17 (39.5%) of 43 lesions, respectively. Sonazoid-enhanced harmonic US was significantly more sensitive than dynamic CT in depicting the residual tumor blood supply to HCCs 1 week after TACE (p < 0.01 χ2 test). The Sonazoid-enhanced harmonic US results of the 16 lesions 1 week after chemoembolization were consistent with the follow-up results of dynamic CT 2 months after chemoembolization. Conclusions: Sonazoid-enhanced harmonic US appears to be a highly sensitive and accurate modality for evaluating responses of HCCs shortly after TACE. Copyright © 2008 S. Karger AG.
  • Kazuomi Ueshima; Masatoshi Kudo; Tomoyuki Nagai; Chie Tatsumi; Taisuke Ueda; Shunsuke Takahashi; Kinuyo Hatanaka; Satoshi Kitai; Emi Ishikawa; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Hobyung Chung
    Oncology 75 1 106 - 113 2008年12月 [査読有り]
     
    Purpose: There are currently no effective treatments for patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or extrahepatic metastases. We evaluated the efficacy and safety of combination therapy with S-1 and pegylated interferon (PEG-IFN)-α for advanced HCC. Methods: A total of 22 patients received combination therapy with S-1 and PEG-IFN. One cycle of the combination therapy consists of oral S-1 (80 mg/m2) administration and subcutaneous PEG-IFN injection (PEG-IFN-α-2a 90 μg weekly or PEG-IFN-α-2b 50 μg weekly) for 4 weeks with 1- to 2-week intervals. Results: One patient was evaluated as complete response, 6 as partial response, 8 as stable disease, and 6 as progressive disease. One patient was not evaluable because therapy had to be discontinued as a result of jaundice. The median survival time was 15.3 months (95% CI: 4.4-26.2 months). The 1- and 2-year survival rates were 54.9 and 36.6%, respectively. The overall response rate was 31.8% and the disease control rate was 68.2%. Grade 3 neutropenia (18.2%), leukopenia (9.1%), anemia (9.1%), and thrombocytopenia (18.2%) were observed. Grade 4 toxicities were not observed. Conclusion: Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC. Copyright © 2008 S. Karger AG.
  • 肝癌の分子標的治療 進行肝細胞癌に対するソラフェニブの使用経験
    上嶋 一臣; 南 康範; 工藤 正俊
    肝臓 49 Suppl.2 A424 - A424 (一社)日本肝臓学会 2008年09月
  • 慢性肝炎staging評価のための低周波Real-time Tissue Elastographyの有用性
    藤本 研治; 辰巳 千栄; 上嶋 一臣; 葛下 典由; 三田 英治; 外村 明子; 三竹 毅; 金 栄浩; 岡本 幸春; 椎名 毅; 工藤 正俊; 加藤 道夫
    肝臓 49 Suppl.2 A522 - A522 (一社)日本肝臓学会 2008年09月
  • ソナゾイド造影超音波検査におけるpostvascular phase imagingとSPIO-MRIとの比較検討
    井上 達夫; 畑中 絹世; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 石川 恵美; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 横川 美加; 前野 知子; 市島 真由美; 前川 清
    肝臓 49 Suppl.2 A575 - A575 (一社)日本肝臓学会 2008年09月
  • 進行肝細胞癌に対するS-1・ペグインターフェロン併用療法
    上嶋 一臣; 早石 宗右; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊
    日本消化器病学会雑誌 105 臨増大会 A841 - A841 (一財)日本消化器病学会 2008年09月
  • Yoichiro Suetomi; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kiyoshi Maekawa
    HEPATO-GASTROENTEROLOGY 55 86-87 1785 - 1788 2008年09月 [査読有り]
     
    Background/Aims: Due to the development of contrast-enhanced harmonic imaging, ultrasound can reveal more precise hemodynamic information than conventional angiography. In this study, the value of contrast-enhanced harmonic imaging was studied in the evaluation of response in treatment of pancreatic cancer. Methodology: Thirteen pancreatic cancer patients treated with gemcitabine were enrolled in this study. Contrast-enhanced harmonic ultrasonography was performed to evaluate the treatment response during every period of treatment. After intravenously injecting the contrast agent, pancreatic tumors were observed in a real-time and subsequently in an intermittent fashion. Findings obtained by contrast-enhanced harmonic imaging were compared with dynamic CT findings and serum tumor marker levels. Results: Tumor markers were reduced by at least 50% in 6 patients. We could not evaluate tumor size reduction rates on the B-mode US because the tumor margin was unclear. On the other hand, the hypovascular area was clearly depicted on the perfusion image of contrast-enhanced harmonic imaging in all patients throughout the observation period, and changes in tumor size could be easily evaluated. The tumor size reduction rates in these 6 cases were 13.1 +/- 5.5% by dynamic CT and 21.1 +/- 1.41% by contrast-enhanced harmonic imaging. Conclusions: Contrast-enhanced harmonic imaging is useful for evaluating treatment response for pancreatic cancer.
  • Kudo M
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 97 7 1681 - 1689 2008年07月 [査読有り]
  • Tomohiro Watanabe; Masatoshi Kudo; Tsutomu Chiba; Yoshio Wakatsuki
    HEPATOLOGY RESEARCH 38 5 441 - 449 2008年05月 [査読有り]
     
    The liver has been considered as a tolerogenic organ in the sense that favors the induction of peripheral tolerance. The administration of antigens (Ags) via the portal vein causes tolerance, which is termed portal vein tolerance and can explain the occurrence of tolerogenic responses in the liver. Here we discuss the fundamental mechanisms accounting for portal vein tolerance. Antigen-presenting cells (APCs) in the liver, especially dendritic cells and sinusoidal endothelial cells, have limited the ability to produce pro-inflammatory cytokines upon stimulation with endotoxin, an effect that could be due to the continuous exposure to bacterial Ags derived from intestinal microflora. Ag presentation by liver APCs results in T cell tolerance through clonal deletion and selection of regulatory T cells. Thus, APCs with immunosuppressive functions are associated with the achievement of portal vein tolerance via the induction of clonal deletion and generation of regulatory T cells.
  • Shigenaga Matsui; Masatoshi Kudo; Tsutomu Ichikawa; Mumon Okada; Yoshio Miyabe
    HEPATO-GASTROENTEROLOGY 55 84 959 - 962 2008年05月 [査読有り]
     
    Background/Aims: This study investigated the clinical characteristics, endoscopic appearances, usefulness of endoscopic treatments, and survival of patients kith duodenal varices. Methodology: Twelve patients were evaluated in whom endoscopy confirmed duodenal varices (13 lesions), and patient data was retrospectively analyzed regarding underlying diseases, hepatic function, endoscopic appearance, previous treatment for other complicated varices, endoscopic treatment for hemorrhage from duodenal varices, and survival. Results: Underlying diseases consisted of liver cirrhosis in 8 patients, and pancreatic cancer-related pylemphraxis in 4 patients. Endoscopic appearances of hemorrhage from duodenal varices revealed negative red color (RC) signs in all 6 lesions, and 5 of 6 lesions were F3 lesions Three of 5 patients with hemorrhagic duodenal varices had received treatment for esophageal varices. Successful. hemostasis and complete eradication by endoscopic treatments was achieved in all 5 patients (6 lesions). The 1, 3, and year cumulative survival rates were 66.7%, 48.6%, and 36.5% in the patients With duodenal varices. Conclusions: The hemorrhagic factor of duodenal varices. is F factor, but not RC sign. Changes of blood flow in the collateral circulatory pathway after treatment for esophageal varices may increase the risk of hemorrhage from duodenal varices. Endoscopic treatment is useful for hemorrhagic duodenal varices.
  • 上嶋 一臣; 工藤 正俊
    綜合臨床 57 増刊 1050 - 1052 (株)永井書店 2008年04月
  • Defect Re-injection imagingの有用性について
    畑中 絹世; 南 康範; 北井 聡; 辰巳 千栄; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    超音波医学 35 Suppl. S626 - S626 (公社)日本超音波医学会 2008年04月
  • 肝画像診断の進歩 肝線維化評価における非侵襲的測定法(Real-time tissue elastography)の有用性に関する検討
    辰巳 千栄; 上嶋 一臣; 今井 元; 上田 泰輔; 川崎 正憲; 北井 聡; 萩原 智; 井上 達夫; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊
    肝臓 49 Suppl.1 A55 - A55 (一社)日本肝臓学会 2008年04月
  • 進行肝細胞癌に対するS-1、ペグインターフェロン併用療法
    上嶋 一臣; 早石 宗右; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊
    肝臓 49 Suppl.1 A278 - A278 (一社)日本肝臓学会 2008年04月
  • Shigenaga Matsui; Masatoshi Kudo; Mumon Okada; Yutaka Asakuma; Tsutomu Ichikawa; Masanori Kawasaki
    GASTROENTEROLOGY 134 4 A240 - A240 2008年04月 [査読有り]
  • Susumu Eguchi; Takashi Kanematsu; Shigeki Arii; Masatoshi Okazaki; Kiwarnu Okita; Masao Omata; Iwao Ikai; Masatoshi Kudo; Masamichi Kojiro; Masatoshi Makuuchi; Morito Monden; Yutaka Matsuyama; Yasuni Nakanuma; Kenichi Takayasu
    SURGERY 143 4 469 - 475 2008年04月 [査読有り]
     
    Background. Although a surgical resection is an important modality for the treatment of hepatocellular carcinoma (HCC), the impact of the operative method on both the patient survival and disease-free survival (DTS) still remains controversial. Methods. Using a nationwide Japanese database, 72,744 patients with HCC who underwent a curative liver resection between 1994 and 2001 were divided into two groups based on whether an anatomical subsegmentectomy (AS) or a non-anatomical minor hepatectomy (MH) was performed. A total of 5, 781 patients with single HCCs were selected for the study and divided into 3 subgroups based on the size of the HCCs (less than 2cm, 2 to 5 cm, and greater than 5 cm in diameter). An AS was performed for 2,267 patients while an MH was performed for 3,514 patients. Results. The overall DTS was significantly better after an AS (P = .0089). When the patients were stratified according to the size of the HCC, a better DES was seen in the patients with HCC from 2 to 5 cm after an AS (P < .0005). Further stratification according to liver damage did not show any significant differences between an AS and an MH. Conclusion. An AS is therefore recommended, especially when the size of HCC ranges from 2 to 5 cm.
  • Miyuki Taniguchi; Soo Ryang Kim; Susumu Imoto; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Noriko Sasase; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi
    WORLD JOURNAL OF GASTROENTEROLOGY 14 13 1997 - 2002 2008年04月 [査読有り]
     
    AIM: To evaluate long-term follow-up of minimum-sized hepatocellular carcinoma (HCC) treated with percutaneous ethanol injection (PEI). METHODS: PEI was applied to 42 lesions in 31 patients (23 male and eight female) with HCC < 15 mm in diameter, over the past 15 years. RESULTS: Overall survival rate was 74.1% at 3 years, 49.9% at 5 years, 27.2% at 7 years and 14.5% at 10 years. These results are superior to, or at least the same as those for hepatic resection and radiofrequency ablation. Survival was affected only by liver function, but not by sex, age, etiology of Hepatitis B virus or Hepatitis C virus, a-fetoprotein levels, arterial and portal blood flow, histological characteristics, and tumor multiplicity or size. Patients in Child-Pugh class A and B had 5-, 7- and 10-years survival rates of 76.0%, 42.2% and 15.8%, and 17.1%, 8.6% and 0%, respectively (P = 0.025). CONCLUSION: Treatment with PEI is best indicated for patients with HCC < 15 mm in Child-Pugh class A. (c) 2008 WJG. All rights reserved.
  • Defect Re-injection Testの有用性について
    畑中 絹世; 北井 聡; 上田 泰輔; 辰巳 千恵; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 前川 清; 工藤 正俊
    日本消化器病学会雑誌 105 臨増総会 A218 - A218 (一財)日本消化器病学会 2008年03月
  • 難治性C型慢性肝炎(1型高ウイルス量)に対するPEG-IFNα2b/Ribavirin併用療法の長期投与成績と安全性について
    石川 恵美; 南 康範; 上嶋 一臣; 鄭 浩柄; 早石 宗介; 井上 達夫; 工藤 正俊
    日本消化器病学会雑誌 105 臨増総会 A308 - A308 (一財)日本消化器病学会 2008年03月
  • Hobyung Chung; Masatoshi Kudo; Shunsuke Takahashi; Satoru Hagiwara; Yasuhiro Sakaguchi; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toyokazu Fukunaga; Takashi Matsunaga
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 23 3 445 - 452 2008年03月 [査読有り]
     
    Background and Aim: Although various staging systems for hepatocellular carcinoma (HCC) have been developed in recent years, there is no worldwide consensus which staging system is best. The aim of the present study was to compare the performance of the currently developed three staging systems: the Japan integrated staging (JIS) score, new Barcelona Clinic Liver Cancer (BCLC) staging classification, and the Tokyo score. Methods: A total of 290 consecutive patients with HCC before initial treatment at Kinki University between January 1999 and December 2001 were included. The patients were stratified according to the three staging systems, and the performance of the staging systems was compared using survival time as the only outcome measure. Results: There were significant differences between all stages in the JIS score, while no significant difference was found between stages C and D in the BCLC staging classification and between all the scores, except between scores 0 and 1 and 2 and 3 in the Tokyo score. For all patients (n = 290), the radical treatment group (n = 208) and the non-radical treatment group (n = 82), the likelihood ratio chi(2)-test showed the highest value, and the Akaike information criterion value was lowest in the JIS score. Conclusion: The JIS score provided the best prognostic stratification in a Japanese cohort of HCC patients who were mainly diagnosed at early stages and treated with radical therapies.
  • Shunsuke Takahashi; Hobyung Chung; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo
    LIVER INTERNATIONAL 28 3 414 - 415 2008年03月 [査読有り]
  • Tatsuya Nakatani; Eiko Honda; Sumio Hayakawa; Mayumi Sato; Ken Satoh; Masatoshi Kudo; Hiroshi Munakata
    MOLECULAR AND CELLULAR BIOCHEMISTRY 308 1-2 201 - 207 2008年01月 [査読有り]
     
    Myofibroblasts are metabolically and morphologically distinctive fibroblasts expressing alpha-smooth muscle actin (alpha-SMA), and their activation plays a key role in development of the fibrotic response. In an activated state, myofibroblasts cease to proliferate and start to synthesize large amounts of extracellular component proteins. The expression of alpha-SMA correlates with the activation of myofibroblasts. Decorin, a member of the small leucine-rich proteoglycan gene family, has been implicated in the negative control of cell proliferation primarily by upregulating the expression of p21, a potent inhibitor of cyclin-dependent kinase. In order to examine the effect of decorin on myofibroblast cell growth, we rendered a human lung myofibroblast cell line, MRC-5, quiescent by either cell-cell contact or serum starvation, and examined the relationship between decorin and alpha-SMA expression in these cells. The expression of decorin in cells made quiescent by serum starvation was lower than that in cells made quiescent by cell-cell contact. In contrast, the expression of alpha-SMA in cells made quiescent by cell-cell contact was lower than that in cells made quiescent by serum starvation. Furthermore, forced expression of decorin was accompanied by a suppression of alpha-SMA expression, whereas knocking down of decorin expression by RNA interference increased the expression of alpha-SMA.
  • Masatoshi Kudo; Rong Qin Zheng; Soo Ryang Kim; Yoshihiro Okabe; Yukio Osaki; Hiroko Iijima; Toshinao Itani; Hiroshi Kasugai; Masayuki Kanematsu; Katsuyoshi Ito; Norio Usuki; Kazuhide Shimamatsu; Masayoshi Kage; Masamichi Kojiro
    INTERVIROLOGY 51 17 - 26 2008年 [査読有り]
     
    Objective: To evaluate the diagnostic accuracy of liver cirrhosis by imaging modalities, including CT, MRI and US, compared to results obtained from histopathological diagnoses of resected specimens. Materials and Methods: CT, MRI and US examinations of 142 patients with chronic liver disease who underwent surgery for complicated hepatocellular carcinoma (< 3 cm in diameter) in 10 institutions were blindly reviewed in a multicenter study by three radiologists experienced in CT, MRI and US. The images were evaluated for five imaging parameters ( irregular or nodular liver surface, blunt liver edge, liver parenchymal abnormalities, liver morphological changes and manifestations of portal hypertension) using a severity scale. The diagnostic imaging impression score was also calculated. Patients were histologically classified into chronic hepatitis ( CH; n = 54), liver cirrhosis ( LC; n = 71) and pre- cirrhosis ( P- LC; n = 17) by three pathologists, independently, who reviewed the resected liver specimens. The results of the three imaging methods were compared to those from histological diagnoses, and a multivariate analysis ( stepwise forward logistic regression analysis) was performed to identify independent predictive signs of cirrhosis. The diagnostic efficacies for LC and early cirrhosis were also compared among CT, MRI and US using a receiver- operating characteristic ( ROC) curve analysis. Results: The differences in the five imaging parameters evaluated by CT, MRI and US between LC and CH were statistically significant ( p < 0.001) except for the manifestations of portal hypertension on US. Irregular or nodular surface, blunt edge or morphological changes in the liver were selected as the best predictive signs for cirrhosis on US whereas liver parenchymal abnormalities, manifestations of portal hypertension and morphological changes in the liver were the best predictive signs on MRI and CT by multivariate analysis. The predictive diagnostic accuracy, sensitivity and specificity in discriminating LC from CH based on the best predictive signs were 71.9, 77.1 and 67.6% by CT; 67.9, 67.5 and 68.3% by MRI, and 66.0, 38.4 ( lower than CT and MRI, p = 0.001) and 88.8% ( higher than CT and MRI, p = 0.001) by US. According to the imaging impression scoring system, diagnostic accuracy, sensitivity and specificity were 67.0, 84.3 and 52.9% by CT; 70.3, 86.7 and 53.9% by MRI, and 64.0, 52.4 ( lower than CT and MRI, p = 0.0001) and 73.5% ( higher than CT and MRI, p < 0.003) by US. ROC analysis showed that MRI and CT were slightly superior to US in the diagnosis of LC but no statistically significant difference was found between them. For the pathological diagnosis of P- LC, cirrhosis was diagnosed in 59.5, 46.7 and 41.7% of the P- LC cases by US, CT and MRI, respectively, with no significant difference among these methods. Conclusion: US, CT and MRI had different independent predictive signs for the diagnosis of LC. MRI and CT were slightly superior to US in predicting cirrhosis, especially regarding sensitivity. Noninvasive imaging techniques play an important role in the diagnosis of cirrhosis, especially in the evaluation of P- LC. Copyright (c) 2008 S. Karger AG, Basel.
  • Chie Tatsumi; Masatoshi Kudo; Kazuomi Ueshima; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Kiyoshi Maekawa; Kenji Fujimoto; Tonomura Akiko; Mitake Takeshi
    INTERVIROLOGY 51 27 - 33 2008年 [査読有り]
     
    Objective: The aim of this study was to investigate the accuracy of noninvasive tests, e. g. serum fibrotic markers, transient elastography and real-time tissue elastography, in the diagnosis of hepatic fibrosis, and to determine whether they can replace liver biopsy. Methods: 119 patients with chronic liver disease were included in this study. Serum fibrotic markers including hyaluronic acid, type IV collagen, type IV collagen 7S domain and type III procollagen-N-peptide were measured. Aspartate aminotransferase (AST) and platelet counts were also measured to calculate the AST to platelet ratio index ( APRI). Liver stiffness was measured using FibroScan and real-time tissue elastography. Results: The fibrotic stage, determined by histopathological diagnosis of a liver biopsy sample, did not correlate as well with serum fibrotic markers although it was useful to diagnose liver cirrhosis. However, the stage of hepatic fibrosis correlated well with liver stiffness measured by FibroScan. FibroScan was also a much better predictor of liver cirrhosis than APRI. Furthermore, the levels of liver strain measured by real-time tissue elastography correlated well with liver stiffness ( p < 0.05). Conclusion: Serum fibrotic markers and FibroScan are useful for distinguishing liver cirrhosis ( F 4) from chronic hepatitis (F(1)-F(3)). In addition, real- time tissue elastography is a novel and promising method to determine the stage of hepatic fibrosis. Copyright (c) 2008 S. Karger AG, Basel.
  • Noriko Sasase; Soo Ryang Kim; Ke Ih Kim; Miyuki Taniguchi; Susumu Imoto; Keiji Mita; Hak Hotta; Ikuo Shouji; Ahmed El-Shamy; Norifumi Kawada; Masatoshi Kudo; Yoshitake Hayashi
    INTERVIROLOGY 51 70 - 75 2008年 [査読有り]
     
    We investigated the clinical usefulness of a new immunoradiometric ( IRM) assay of hepatitis C virus ( HCV) core antigen in predicting virological response during pegylated interferon plus ribavirin ( PEG-IFN/RBV) combination therapy for chronic hepatitis with high viral loads of serum HCV RNA genotype 1b. Thirty-nine patients received a regimen of PEG- IFN alpha - 2b ( 1.5 mu g/ kg/ week s. c.) in combination with RBV ( 600 - 1,000 mg/ day). Of the 39 patients, 18 ( 46.2%) achieved sustained virological response ( SVR), 11 ( 28.2%) attained partial response ( PR) and 10 ( 25.6%) showed no response (NR). Four weeks after the start of therapy, 1- and 2-log reductions in the amount of HCV core antigen were observed in 20 (2/10) and 0% (0/10) showing NR, 91 (10/11) and 63.6% 7/ 11) with PRs, and 88.9 (16/18) and 55.6% (10/18) of patients with SVR, respectively. The 1- and 2-log reductions 4 weeks after the start of therapy were not a defining condition for PR and SVR. The amount of HCV core antigen was significantly different between SVR and PR patients on days 1 and 7, and between patients with NR and SVR at all points of time. In conclusion, this new IRM assay is useful in predicting virological response during PEG-IFN/RBV therapy. Copyright (c) 2008 S. Karger AG, Basel.
  • Tatsuo Inoue; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Toyokazu Fukunaga; Toshihiko Kawasaki
    LIVER INTERNATIONAL 27 10 1428 - 1430 2007年12月 [査読有り]
  • Yasunori Minami; Toshihiko Kawasaki; Masatoshi Kudo; Seiji Haji; Osamu Shiraishi; Takashi Kawabe; Chikao Yasuda; Takuya Nakai; Yoshihumi Takeyama; Hitoshi Shiozaki
    HEPATO-GASTROENTEROLOGY 54 80 2358 - 2360 2007年12月 [査読有り]
     
    Background/Aims: Patients with hepatic malignancies are often poor candidates for resection because of the lack of hepatic reserve as a result of coexisting cirrhosis or the presence of multiple tumors. The purpose of this study was to determine the safety and efficacy of open intraoperative radiofrequency ablation of unresectable hepatic malignancies with size larger than 4cm in diameter and/or more than three in number. Methodology: Between May 2000 and September 2003, 30 patients (24 men, 6 women; age range, 5972 years; mean age, 63 years) with 51 hepatic malignancies. The maximal diameter of all tumors ranged from 1.0 to 10cm (mean +/- SD, 3.2 +/- 1.8). Results: All tumors achieved necrosis completely in a. single session. The mean follow-up from the initial ablation in this study was 18.9 +/- 10.1 months (range, 0-41). The 1-, 2 and 3-year overall survival rates were 86.1%, 71.6% and 71.6%, respectively. The 1-, 2 and 3-year disease-free survival rates were 70.9%, 37.6% and 25.1%, respectively. Conclusions: Open radiofrequency ablation is a safety and efficient approach for hepatic malignancies sized more than 4cm in diameter and/or located more than three in number.
  • 進行肝細胞癌に対するS-1、ペグインターフェロン併用療法
    南 康範; 上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 工藤 正俊
    肝臓 48 Suppl.2 A467 - A467 (一社)日本肝臓学会 2007年09月
  • 乏血性肝腫瘍の診療アルゴリズム 転移性肝腫瘍・肝内胆管癌の画像診断 超音波診断を中心に
    上嶋 一臣; 前川 清; 工藤 正俊
    日本消化器病学会雑誌 104 臨増大会 A473 - A473 (一財)日本消化器病学会 2007年09月
  • Iwao Ikai; Shigeki Arii; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Morito Monden; Masatoshi Kudo
    HEPATOLOGY RESEARCH 37 9 676 - 691 2007年09月 [査読有り]
     
    In the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, 18 213 individuals were newly registered as patients with primary liver cancer at 645 medical institutions over a period of 2 years (from 1 January 2002 to 31 December 2003). Of these patients, 94.2% had hepatocellular carcinoma (HCC) and 4.1% had intrahepatic cholangiocarcinoma (ICC). In addition, 24 705 follow-up patients were registered in the survey. Epidemiological and clinicopathological factors, diagnosis and treatment were investigated in the newly registered patients, and the cumulative survival rates of newly registered patients in the 12th to 17th follow-up surveys conducted between 1992 and 2003 were calculated for each histological type (HCC, ICC, and combined HCC and ICC) and stratified by background factors and treatment. The data obtained in this follow-up survey should contribute to future research and medical practice for primary liver cancer.
  • Hidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Masatoshi Kudo
    HEPATOLOGY RESEARCH 37 S166 - S171 2007年09月 [査読有り]
     
    The efficacies of tumor markers, alfa-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of alfa-fetoprotein (AFP-L3), and des-gamma-carboxy prothrombin (DCP) were evaluated for assessment of progression of hepatocellular carcinoma (HCC) and patient prognosis. The prevalence of elevated levels of each tumor marker increased with progression of tumor stage for all three markers among patients with HCC. Survival was poorer among patients with elevated levels of tumor markers than among those without elevated levels. Evaluation of tumor progression with tumor markers was based only on the results of laboratory tests. The tests are objective, simple to perform, and easy to repeat, and therefore, may be useful to supplement conventional tumor staging for the evaluation of tumor progression and prediction of patient outcome.
  • Masatoshi Kudo
    HEPATOLOGY RESEARCH 37 S216 - S222 2007年09月 [査読有り]
     
    Treatment outcomes were compared among several countries based on different staging systems. Data were collected from published data. Treatment outcomes based on Cancer of the Liver Italian Program (CLIP) scores 0-3 were best in Japan when compared among several countries. Furthermore, treatment outcomes in Japan based on Japan Integrated Staging (JIS) scores 0-3 were much better than in the USA. However, Barcelona Clinic Liver Cancer (BCLC) staging was not useful forinternational comparison, suggesting that BCLC staging is not helpful for prognostic staging but for treatment allocation staging. This is an extremely important point, which should be kept in mind.
  • Masatoshi Kudo
    HEPATOLOGY RESEARCH 37 S83 - S87 2007年09月 [査読有り]
  • 高度進行肝細胞癌に対するS-1、ペグインターフェロン併用療法の有用性
    上嶋 一臣; 南 康範; 工藤 正俊
    肝臓 48 Suppl.1 A106 - A106 (一社)日本肝臓学会 2007年04月
  • Hobyung Chung; Masatoshi Kudo; Yasunori Minami; Toshihiko Kawasaki
    HEPATO-GASTROENTEROLOGY 54 75 701 - 704 2007年04月 [査読有り]
     
    Background/Aims: We evaluated the effectiveness of radiofrequency (RF) ablation combined with transarterial embolization using Lipiodol and gelatin sponge. Methodology: A total of 18 normal pig liver lobes were randomly assigned to the following three different RF ablation groups, 1) combined with TAE using Lipiodol and gelatin sponge as "LpTAE group"; 2) combined with TAE using gelatin sponge only as "TAE group"; 3) ablation alone as "control group". Ablations were performed under open laparotomy using an RF generator and a 2-cm expandable needle. The diameter of coagulation and the ablation time were compared among the three groups. Results: The characteristic shape of coagulated area differed among the three groups. The long-axis diameter showed no significant difference among the three groups (27.5mm, 27.5mm, 26.7mm; respectively), while the short-axis diameter was significantly larger in the LpTAE group compared with the control groups (25.2min vs. 20.5mm; p < 0.05). The total ablation time was significantly shorter in the LpTAE and TAE groups compared with the control group (166, 204 seconds vs. 309 seconds; p=0.001, p=0.01). Conclusions: RF ablation combined. with LpTAE produced larger and more spherical areas of coagulation in a shorter ablation time. Such an advantage could potentially enhance the clinical effectiveness of RF ablation.
  • 上嶋 一臣; 工藤 正俊
    薬局 58 4 1751 - 1758 (株)南山堂 2007年03月
  • 上嶋 一臣; 辰巳 千栄; 工藤 正俊
    日本消化器病学会雑誌 104 臨増総会 A16 - A16 (一財)日本消化器病学会 2007年03月
  • 南 康範; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和; 工藤 正俊
    日本消化器病学会雑誌 104 臨増総会 A155 - A155 (一財)日本消化器病学会 2007年03月
  • Soo Ryang Kim; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Michiie Sakamoto; Yoshihiro Kanbara; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi
    WORLD JOURNAL OF GASTROENTEROLOGY 13 8 1271 - 1274 2007年02月 [査読有り]
     
    We describe a rare case of the transformation of a dysplastic nodule into well-differentiated hepatocellular carcinoma (HCC) in a 56-year-old man with alcohol related liver cirrhosis. Ultrasound (US) disclosed a 10 mm hypoechoic nodule and contrast enhanced US revealed a hypovascular nodule, both in segment seven. US-guided biopsy revealed a high-grade dysplastic nodule characterized by enhanced cellularity with a high N/C ratio, increased cytoplasmic eosinophilia, and slight cell atypia. One year later, the US pattern of the nodule changed from hypoechoic to hyperechoic without any change in size or hypovascularity. US-guided biopsy revealed well-differentiated HCC of the same features as shown in the first biopsy, but with additional pseudoglandular formation and moderate cell atypia. Moreover, immunohistochemical staining of cyclase-associated protein 2, a new molecular marker of well-differentiated HCC, turned positive. This is the first case of multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated HCC within one year in alcohol-related liver cirrhosis. (C) 2007 The WJG Press. All rights reserved.
  • Yasunori Minami; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Shunsuke Takahashi; Kinuyo Hatanaka; Taisuke Ueda; Hitoshi Hagiwara; Satoshi Kitai; Kuzuomi Ueshima; Toyokazu Fukunaga; Hitoshi Shiozaki
    Oncology 72 Suppl 1 111 - 6 2007年 
    OBJECTIVE: The purpose of this study was to evaluate the safety and feasibility of a real-time integrated system with computed tomography (CT) and sonographic images for radiofrequency (RF) ablation of hepatic malignancies poorly defined on B-mode sonography, and to clarify the suitable phase of CT images for using this virtual sonography. METHODS: Between September 2004 and December 2004, 12 patients with 16 hepatocellular carcinomas and two metastatic lesions arising from colorectal adenocarcinoma (n = 1) and rectal carcinoid (n = 1) were treated. The maximum diameter of nodules ranged from 1.0 to 2.5 cm (mean +/- SD; 1.5 +/- 0.6 cm) on CT images. RESULTS: Complete tumor necrosis was achieved in a single session in 19 lesions (90%), while a second session was required for the remaining two lesions (10%). Portal phase multi-planar reconstruction images were displayed under a suitable position corresponding to the ultrasound images in 9 patients (HCC = 7, metastasis = 2), and arterial phase multi-planar reconstruction images were displayed in the 3 remaining patients with hepatocellular carcinoma. CONCLUSION: Percutaneous RF ablation guidance using virtual sonography is an effective treatment for patients with hepatic malignancies. The portal phase of CT images may be the most suitable to indicate the 3-dimensional relationship between the liver vasculature and tumors on virtual sonography.
  • Kinuyo Hatanaka; Masatoshi Kudo; Toyokazu Fukunaga; Kazuomi Ueshima; Hobyung Chung; Yasunori Minami; Yasuhiro Sakaguchi; Satoshi Hagiwara; Akio Orino; Yukio Osaki
    INTERVIROLOGY 50 1 24 - 31 2007年 [査読有り]
     
    Objective: To clarify the frequency and trends of both HBsAg and HCVAb negative hepatocellular carcinoma (NonBNonC-HCC) in all HCC, to clarify the etiology of NonBNonC-HCC, and to elucidate the clinical characteristics of NonBNonC-HCC compared with those of HBsAg-positive HCC (B-HCC) and HCVAb-positive HCC (C-HCC). Methods: A total of 2,542 patients with HCC examined at three institutions between 1991 and 2004 were categorized based on their serum viral antigen/antibody positivities, and compared between groups for the etiology, annual trend of the incidence, and clinical characteristics. Results: For the etiology, C-HCC was most prevalent, followed by B-HCC, NonBNonC-HCC, and both HBsAg and HCVAb-positive HCC (BC-HCC) in order. For survival, C-HCC had the most favorable prognosis, followed by NonBNonC-HCC, and B-HCC patients had the poorest prognosis in the three groups (C-HCC, B-HCC, and NonBNonC-HCC). In tumor-node metastasis (TNM) stages I+II, however, NonBNonC-HCC patients took the most favorable clinical course. The incidence of NonB-NonC-HCC in all HCC was 5 - 8% from 1991 to 1998, and has increased to 10 - 12% since 1999. Additionally, the incidence of HBcAb-positive HCC in NonBNonC-HCC declined each year. Among NonBNonC-HCC patients, the morbidity of diabetic complications was significantly higher in HBcAb-negative patients than in HBcAb-positive patients. Conclusion: Although the incidence of NonBNonC-HCC among all HCC has an increasing trend recently, the incidence of HBcAb-positive HCC in NonBNonC-HCC has a tendency of decreasing. This fact suggest its etiology might be changing from occult HBV related HCC to unknown etiology such as nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) related HCC. The prognosis of NonBNonC-HCC was fairly good if the HCC was found in its early stage.
  • Shunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Miki Nagashima; Satoshi Kitai; Tatsumi Chie; Minami Yasunori; Ueshima Kazuomi; Fukunaga Toyokazu; Seiji Haji
    DIGESTIVE DISEASES 25 4 303 - 309 2007年 [査読有り]
     
    Background: This study was undertaken to assess the outcome of potentially curative therapy for early-stage hepatocellular carcinoma (HCC) in patients with Child-Pugh stage A cirrhosis as well as to investigate the impact of low-dose interferon (IFN) therapy after curative therapy on survival. Methods: This study retrospectively evaluated clinical outcomes in a cohort of 224 Child-Pugh stage A cirrhotic patients who received either resection ( 53 cases) or radiofrequency ablation ( RFA: 171 cases) for HCC within Milan criteria. Thirty patients were treated with low-dose maintenance IFN therapy after initial curative therapy. The median follow- up period was 36.7 months. Results: The 5-year survival rate of all patients was 74.9%, with similar rates for the resection and RFA groups (70.4 vs. 76.8%; p = 0.561). The 5-year HCC recurrence rate was higher in the RFA group than the resection group (85.3 vs. 73.2%; p = 0.012). The maintenance IFN-treated group maintained their liver function within Child-Pugh stage A for a significantly longer time (median time 36.9 vs. 32.2 months; p = 0.0025). Conclusion: The 5-year outcomes of resection and RFA in patients with Child-Pugh stage A cirrhosis and early stage HCC were comparable with liver transplantation. Low-dose, long-term maintenance IFN therapy after curative therapy was significantly beneficial on survival.
  • Masatoshi Kudo; Takeshi Okanoue
    ONCOLOGY 72 2 - 15 2007年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but worldwide. Clinical Practice Guidelines for HCC were published in 2001 by the European Society of Study of the Liver (EASL) and in 2005 by the American Association for the Study of Liver Disease (AASLD). However, these guidelines have proven to be somewhat unsuitable for Japanese patients. In 2005, supported by the Japanese Ministry of Health, Labor and Welfare, Evidence-Based Clinical Practice Guidelines for HCC were compiled. Based on 'evidence-based' guidelines and the consensus of an expert panel on HCC, the Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007. In this article, the content of this manual, especially issues on surveillance, diagnosis, staging, and treatment, is summarized.
  • Soo Ryang Kim; Kenji Ando; Keiji Mita; Shuichi Fuki; Hirotsugu Ikawa; Yoshihiro Kanbara; Susumu Imoto; Toshiyuki Matsuoka; Yoshitake Hayashi; Masatoshi Kudo
    ONCOLOGY 72 58 - 66 2007年 [査読有り]
     
    To evaluate the effectiveness of computed tomography (CT) arterioportal angiography in the diagnosis of hepatocellular carcinoma (HCC) in nodules smaller than 2 cm, we compared the findings of CT during arteriography (CTA) and CT during arterial portography (CTAP) with those of enhanced CT and enhanced magnetic resonance imaging (MRI). Sixty-eight nodules smaller than 2 cm in 53 patients with liver cirrhosis were classified into three groups of CTA and CTAP: (group 1) hyperattenuation on CTA, and hypoattenuation on CTAP (56 nodules, 41 patients); (group 2) hypoattenuation on CTA, and hypoattenuation on CTAP (10 nodules, 10 patients); (group 3) hypoattenuation on CTA, and hyperattenuation on CTAP (2 nodules, 2 patients). Histologically, 96% (54/56), 80% (8/10), and 100% (2/2) of the nodules in groups 1, 2 and 3, respectively, were diagnosed as HCC. In group 1, enhanced CT or enhanced MRI confirmed hypervascularity in only 77% (30/39) and venous washout in 21% (8/39). In groups 2 and 3, enhanced CT or enhanced MRI on 7 and 2 nodules, respectively, revealed no hypervascularity (0%). The results suggested that CT arterioportal angiography is superior to enhanced CT and MRI in nodules smaller than 2 cm for diagnosing HCC (p < 0.01 group 1, p < 0.01 group 2).
  • Shunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Chie Tatsumi; Taisuke Ueda; Yasunori Minami; Kazuomi Ueshima; Seiji Haji
    ONCOLOGY 72 98 - 103 2007年 [査読有り]
     
    Objective: This study was undertaken to assess the outcome of potentially curative radiofrequency ablation (RFA) therapy for early-stage hepatocellular carcinoma (HCC) in patients with Child-Pugh stage A cirrhosis. Methods: This study retrospectively evaluated clinical outcomes in a cohort of 171 Child-Pugh stage A cirrhotic patients who received RFA for naive HCC within the Milan criteria. The median follow-up period was 36.7 months. Results: Cumulative survival rates estimated by the Kaplan-Meier method for all patients were 98.8, 91.1 and 76.8% at 1, 3 and 5 years, respectively. Cumulative probabilities of local tumor recurrence at 1, 2 and 3 years were 9.0, 14.1 and 17.7%, respectively. Cumulative survival rates in patients without local tumor recurrence were 96.6, 94.6 and 84.4% at 1, 3 and 5 years, respectively, compared with patients with local tumor recurrence (96.6, 74.8 and 42.1% at 1, 3 and 5 years, respectively; p = 0.0002). Cox regression analysis showed that low serum albumin (p = 0.009, RR 3.04, CI 1.32-6.98), high range of PIVKA-II ( prothrombin induced by vitamin K absence or agonist II) (p = 0.025, RR 2.57, CI 1.13-5.89), with multiple (less than 3) nodules (p = 0.021, RR 2.61, CI 1.15-5.91), and with local tumor recurrence (p = 0.004, RR 3.62, CI 1.51-8.69) were significant risk factors for death. Conclusion: Initial complete response of curative RFA therapy in patients with Child-Pugh stage A cirrhosis and early-stage HCC is associated with improved survival. Therefore, clinicians should aim to achieve complete ablation of all detectable HCC nodules with adequate safety margins.
  • Miki Nagashima; Masatoshi Kudo; Hobyung Chung; Emi Ishikawa; Satoru Hagiwara; Tatsuya Nakatani; Kensaku Dote
    HEPATOLOGY RESEARCH 36 4 288 - 293 2006年12月 [査読有り]
     
    Background/Aims: Elevated serum ferritin and hepatic iron concentrations are frequently observed in chronic hepatitis C (CHC), which may be related to hepcidin. Because the role of hepcidin in CHC patients remains unknown, we aimed in this study to generate some information about hepcidin in CHC. Methods: To determine whether serum hepcidin correlates with markers of iron status in patients with viral hepatitis, we measured serum prohepcidin levels in patients with hepatitis C virus (HCV) and hepatitis B virus (HBV) infection and in healthy controls. Results: Serum prohepcidin and ferritin levels were negatively correlated (r = -0.182, P = 0.037) in HCV patients and positively correlated in HBV patients and in healthy controls. The total iron scores in liver specimens from HCV patients were also negatively correlated ( r = -0.403, P = 0.013). Serum prohepcidin levels in patients with liver cirrhosis (LC) were significantly lower than in patients with chronic hepatitis (CH). In both CH and LC patients, serum prohepcidin levels were significantly lower in HCV patients than in HBV patients. Conclusion: Failure of homeostatic regulation of serum prohepcidin concentrations may be induced by HCV infection, resulting in elevation of serum ferritin levels, which leads to the progression of liver injury by iron overload in CHC patients. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
  • 自然経過が観察し得たアルコール性過形成病変の1例
    前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    超音波医学 33 6 708 - 708 (公社)日本超音波医学会 2006年11月
  • 肝細胞癌への経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性
    南 康範; 高橋 俊介; 坂口 康浩; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    日本消化器病学会雑誌 103 臨増大会 A968 - A968 (一財)日本消化器病学会 2006年09月
  • 原発性肝癌 手術か非手術的治療か適応を探る 肝細胞癌に対する経皮的ラジオ波焼灼療法の現況
    鄭 浩柄; 高橋 俊介; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊
    日本癌治療学会誌 41 2 348 - 348 (一社)日本癌治療学会 2006年09月
  • 腹部臓器に発生した神経原性腫瘍のレボビスト造影超音波について
    市島 真由美; 前野 知子; 橋本 三紀恵; 前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    超音波医学 33 Suppl. S413 - S413 (公社)日本超音波医学会 2006年04月
  • レボビスト造影超音波の後血管相から見た肝機能評価について
    前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    超音波医学 33 Suppl. S440 - S440 (公社)日本超音波医学会 2006年04月
  • 肝癌の経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性について
    南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和; 上嶋 一臣; 萩原 智; 坂口 康浩; 高橋 俊介; 畑中 絹代; 井上 達夫
    日本消化器病学会雑誌 103 臨増総会 A144 - A144 (一財)日本消化器病学会 2006年03月
  • T Watanabe; S Tomita; H Shirane; Y Okabe; A Orino; A Todo; T Chiba; M Kudo
    JOURNAL OF ULTRASOUND IN MEDICINE 25 3 393 - 396 2006年03月 [査読有り]
     
    Ischemic colitis is a vascular disorder of the colon that causes rectal bleeding and abdominal pain in elderly patients.(1,2) It is classified into gangrenous and nongangrenous forms. Nongangrenous colonic ischemia usually requires only medical treatment and is associated with a good prognosis. In contrast, urgent surgical intervention is required for the treatment of gangrenous colonic ischemia, which is associated with high mortality.(3) Thus, in patients with ischemic colitis, it is especially important to determine whether colonic ischemia is the gangrenous or nongangrenous type. Endoscopic assessment of the colon is the most sensitive and reliable method of evaluating the ischemic colon mucosa(4); however, it is not always possible to perform a colonoscopic examination in patients with gangrenous ischemic colitis because of the severe general condition of these patients. Therefore, a noninvasive and rapid examination procedure is necessary for the diagnosis of gangrenous ischemic colitis. In this regard, a sonographic examination may be useful because it can be easily performed even in patients with shock status. In fact, several studies have reported that bowel wall thickening and decreased arterial flow in the affected colon are characteristic findings of patients with nongangrenous ischemic colitis(5-8); however, few articles have addressed the sonographic findings of gangrenous colonic ischemia. In this report, we describe the case of a patient with cecal necrosis due to ischemic colitis and discuss its unique sonographic findings.
  • M Kudo
    JOURNAL OF GASTROENTEROLOGY 41 3 290 - 291 2006年03月 [査読有り]
  • 純動脈相超音波造影法(PAP-US)と画像表示に用いる測定時相について
    前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    超音波医学 33 1 105 - 105 (公社)日本超音波医学会 2006年01月
  • H Sakamoto; M Kitano; Y Suetomi; Y Takeyama; H Ohyanagi; T Nakai; C Yasuda; M Kudo
    JOURNAL OF GASTROENTEROLOGY 41 1 70 - 76 2006年01月 [査読有り]
     
    Background. A prospective, randomized study was performed to determine whether gemcitabine infusion at a low dose (250mg/m(2)) is comparable or superior to the standard-dose infusion (1000mg/m(2)) in terms of the survival period, clinical benefit, and frequency of adverse effects in patients with advanced pancreatic adenocarcinoma. Methods. Twenty-five patients who were histologically proven to have locally advanced pancreatic cancer or pancreatic cancer with distant metastases were initially enrolled in the present study. They were treated with gemcitabine infusion at either a dose of 1000mg/m(2) over 30 min (the standard regimen) on days 1, 8, and 15 of every 4-week cycle or at a dose of 250mg/ m(2) over 30 min every week. Survival time, response rate, time to treatment failure, clinical benefit response, and adverse effects were compared between the two groups. Results. Twenty-one patients received gemcitabine for more than 1 month. The median survival period was 7.2 months for patients who received the low-dose infusion regimen, in contrast to 5.2 months for patients administered the standard-dose infusion regimen. The time to treatment failure was 5.6 months for patients in the low-dose infusion regimen, in contrast to 3.4 months for patients in the standard-dose infusion regimen. There were no significant differences in either survival time to time to treatment failure or clinical benefits between the two groups, but the incidence of adverse reactions in patients administered the low-dose therapy was significantly lower than that in patients receiving the standard-dose therapy (P < 0.05). In particular, patients in the standard infusion regimen group experienced more hematologic toxicity than those in the low-dose regimen. Conclusions. These findings suggest that the low-dose gemcitabine infusion regimen can be continuously administered to patients with locally advanced and systemically spreading pancreatic cancer because of its reduced toxicity, resulting in better quality of life and an improved safety profile as compared to the standard infusion treatment regimen.
  • Rong Qin Zheng; Masatoshi Kudo; Emi Ishikawa; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Yasuhiro Sakaguchi; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa
    Journal of Medical Ultrasonics 32 4 191 - 195 2005年12月 [査読有り]
     
    Two cases of hepatic angiomyolipoma were studied by contrast-enhanced harmonic sonography. The special tumor hemodynamics, namely the efferent blood flow of the hepatic angiomyolipoma draining into the hepatic vein, were clearly shown on harmonic imaging, and they corresponded well with those seen on angiography and computed tomography during angiography. Benign hepatic tumors were diagnosed preoperatively in both cases according to the hemodynamic findings. Hepatic angiomyolipoma was finally identified histologically. The special tumor hemodynamics might be one of the important characteristics of hepatic angiomyolipoma. Contrast-enhanced harmonic sonography is useful for the detection of special tumor hemodynamics and may facilitate the differential diagnosis from other hepatic tumors, especially malignant liver tumors. © The Japan Society of Ultrasonics in Medicine 2005.
  • Yasuhiro Sakaguchi; Masatoshi Kudo; Rong Qin Zheng; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa
    Journal of Medical Ultrasonics 32 4 197 - 204 2005年12月 [査読有り]
     
    To investigate whether observing the morphology of the peripheral hepatic vasculature and the hemodynamics of microbubble arrival time in these vessels can provide useful information for the diagnosis of liver disease, Five normal volunteers and 16 patients were studied by contrast-enhanced coded phase-inversion harmonic sonography. Vessel images of the peripheral vessels were observed in real time after intravenous injection of Levovist. The time when the microbubbles appeared in the peripheral vessels was measured. Three patterns of morphologic change of the peripheral hepatic vasculature were seen, marked, slight, and no abnormal changes. The microbubble arrival times at the peripheral vessels were all shorter in patients with cirrhosis than chronic hepatitis or normal subjects. Marked, slight, and no abnormal morphologic changes of the peripheral hepatic vasculature in patients with liver cirrhosis were found in five, one and zero of the six patients, respectively. Those patients with chronic hepatitis, were found in one, six and three of the ten patients, respectively. There was a significant difference among the different groups (P < 0.001). Evaluating the hemodynamics and morphology by contrast-enhanced coded pulse-inversion harmonic sonography may offer useful information in the diagnosis of liver disease. © The Japan Society of Ultrasonics in Medicine 2005.
  • M Nomura; T Hata; S Naitoh; H Kuwao; K Moriyama; M Fukuoka; M Kudo; Y Tohda
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 125 12 997 - 1004 2005年12月 [査読有り]
     
    The safety of pharmaceuticals has become increasingly important not only in daily medical treatment but also in clinical trials. Although clinical laboratory data are more objective than clinical symptoms, the determination as to whether they indicate abnormal variations depends largely upon the clinical judgment of physicians. The process of determination has not been sufficiently objectified. The present study investigated the indices of criteria for variations in clinical laboratory data obtained in clinical trials. Then, detection rates of abnormal variations were compared between our determination method that employs the reference change value (RCV) expressing the width of biological variation for each test component and conventional determination methods. The study also demonstrated that by combining standard values and the RCV for determination, abnormal variations were found at a rate greater than 50%. The method we propose was applied to the safety evaluation of pharmaceuticals. In clinical trials on the antiviral drug ribavirin administered alone, components of laboratory tests were selected that should be noted in studies on its effects. Expect for decreases in red blood cell counts and hemoglobin values, which are closely associated with anemic symptoms and well known to hepatologists, the increasing trend in platelet counts and decreasing trend in albumin were found to be laboratory test components that should be paid attention to, even though they may not be obvious.
  • T Inoue; M Kudo; R Watai; Z Pei; T Kawasaki; Y Minami; H Chung; T Fukunaga; K Awai; O Maenishi
    JOURNAL OF GASTROENTEROLOGY 40 12 1139 - 1147 2005年12月 [査読有り]
     
    Background. We investigated the diagnostic utility of post-vascular phase contrast-enhanced ultrasonography (US) and superparamagnetic iron oxide (SPIO)enhanced magnetic resonance imaging (MRI) as compared to the histological diagnosis of differential grades of hepatocellular carcinomas (HCCs). Methods. Forty-nine patients with histologically characterized liver nodules (well-differentiated HCC, n = 20; moderately differentiated HCC, n = 19; poorly differentiated HCC, n = 1; dysplastic nodule, n = 9) received contrast-enhanced US and SPIO-MRI. Subsequently, we quantitatively evaluated the relationships between the images of the nodules and their histological diagnosis and differential grades. Results. The ratio of the echogenicity of the tumorous area to that of the nontumorous area with post-vascular phase contrast-enhanced US (post-vascular phase ratio) decreased as nodules became less differentiated (P < 0.05; Kruskal-Wallis test). The ratio of the intensity of the nontumorous area to that of the tumorous area on SPIO-enhanced MR images (SPIO intensity index) also decreased as nodules became less differentiated (P < 0.01). The post-vascular phase ratio correlated with the SPIO intensity index for HCCs and dysplastic nodules (r = 0.76). The conformity of the result from the post-vascular phase contrast-enhanced US and SPIO-MRI was 96%. Conclusions. Contrast-enhanced US is a valuable method for predicting the histological grade of HCCs in cirrhotic patients, and may be a good alternative to SPIO-enhanced MRI.
  • Rong-Qin Zheng; Bo Zhang; Masatoshi Kudo; Yasuhiro Sakaguchi
    WORLD JOURNAL OF GASTROENTEROLOGY 11 40 6348 - 6353 2005年10月 [査読有り]
     
    AIM: To provide the useful information for the diagnosis of liver cirrhosis by observing the morphology of peripheral hepatic vessels and the hemodynamics of microbubble arrival time in these vessels. METHODS: Twenty-one subjects including 5 normal volunteers and 16 patients (liver cirrhosis, n=10; chronic hepatitis, n=6) were studied by contrast-enhanced coded phase inversion harmonic sonography (GE LOGIQ 9 series) using a 6-8 MHz convex-arrayed wide-band transducer. The images of peripheral hepatic artery, portal and hepatic vein were observed in real-time for about 2 min after intravenous injection of Levovist. The time when microbubbles appeared in the peripheral vessels (microbubble arrival time) was also recorded. The morphologic changes of peripheral hepatic vasculature were classified as marked, slight, and no changes based on the regularity in caliber, course, ramification, and the delineation of vessels compared to normal subjects. RESULTS: The microbubble arrival time at peripheral artery, portal, and hepatic vein was shorter in cirrhotic patients than in chronic hepatitis patients and normal subjects. The marked, slight and no morphologic changes of peripheral hepatic vasculature found in 5 (5/6, 83.3%), 1 (1/6, 16.7%), and 0 (0/6, 0%) liver cirrhosis patients, respectively, and in 1 (1/10, 10%), 6 (6/10, 60%), and 3 (3/10, 30%) chronic hepatitis patients, respectively. There was a significant difference between the two groups (P < 0.001). CONCLUSION: Evaluation of the hemodynamics and morphology of peripheral hepatic vasculature by contrast-enhanced coded pulse inversion harmonic sonography can provide useful information for the diagnosis of liver cirrhosis. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
  • Rong-Qin Zheng; Bo Zhang; Masatoshi Kudo; Hirokazu Onda; Tatsuo Inoue
    WORLD JOURNAL OF GASTROENTEROLOGY 11 40 6354 - 6359 2005年10月 [査読有り]
     
    AIM: To evaluate the imaging findings of biliary hamartomas (von Meyenburg complexes, VMCs) and discuss the differential diagnosis with other related diseases. METHODS: Imaging findings of biliary hamartomas on ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), MR cholangiopancreatography (MRCP) and hepatobiliary scintigraphy were retrospectively analyzed in six patients. RESULTS: On ultrasound images, five of the six cases showed multiple small hyper-and hypo-echoic lesions with comet-tail echoes, especially when magnified by us with the usage of zoom function. In all the six cases, multiple tiny hypodense lesions less than 10 mm in diameter were revealed as scattered throughout the liver with no enhancement on CT. These tiny lesions were demonstrated to be hyper-and hypo-intensity on T2- and TI-weighed images, respectively, in three patients who underwent MRI examinations. MRCP was performed in two patients, and clearly showed multiple tiny irregular-and round-shaped hyper-intensity lesions. MRCP and hepatobiliary scintigraphy showed normal appearances of intra-and extra-hepatic bile ducts in two and one patients, respectively. CONCLUSION: Imaging modalities are useful in the diagnosis and differential diagnosis of VMCs. A correct diagnosis might be obtained when typical imaging findings are present even without a histological confirmation. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
  • 進行肝癌の治療最前線 進行肝癌に対するリザーバー動注化学療法の新たな展開
    上嶋 一臣; 工藤 正俊; 坂口 康浩
    肝臓 46 Suppl.2 A352 - A352 (一社)日本肝臓学会 2005年09月
  • 進行肝癌の治療最前線 進行肝癌に対するリザーバー動注化学療法の新たな展開
    上嶋 一臣; 工藤 正俊; 坂口 康浩
    日本消化器病学会雑誌 102 臨増大会 A538 - A538 (一財)日本消化器病学会 2005年09月
  • Kim, SR; KI Kim; Y Maekawa; S Imoto; T Ninomiya; K Mita; K Ando; K Fukuda; S Fuki; M Kudo; T Matsuoka; N Sasase; M Taniguchi; Y Hayashi
    HEPATO-GASTROENTEROLOGY 52 65 1559 - 1562 2005年09月 [査読有り]
     
    A rare case of well-differentiated minute hepatocellular carcinoma (HCC) with hepatitis C virus-related cirrhosis, with unusual radiologic features, is presented, A 10-mm hypoechoic nodule disclosed by ultrasound in segment six showed hypoattenuation on computed tomography hepatic arteriography and hyperattenuation on computed tomography during arterial portography, indicating that the portal vein may have been the dominant vascularity of the nodule. Contrast-enhanced ultrasound revealed hypovascularity in the early arterial phase, isovascularity in the late vascular phase, and the same perfusion as that surrounding the liver parenchyma in the post-vascular phase, with the same pattern observed on the two imaging techniques. These findings were considered not compatible with those of well-differentiated HCC. Ultrasound-guided biopsy showed histological features of well-differentiated HCC with over two-fold the cellularity of the non-tumorous area with a high nuclear/cytoplasmic ratio, increased cytoplasmic eosinophilia, slight atypia and fatty change with an irregular thin trabecular pattern. Further studies may provide insights into the correlation between tumor neovascularity in multistep hepatocarcinogenesis and dual hemodynamics, including the artery and the portal vein.
  • Hisashi Abe; Takamichi Murakami; Masaru Kubota; Tonsok Kim; Masatoshi Hori; Masayuki Kudo; Kazuhiko Hashimoto; Shoji Nakamori; Keizo Dono; Kaname Tomoda; Morito Monden; Hironobu Nakamura
    Radiation Medicine - Medical Imaging and Radiation Oncology 23 5 364 - 370 2005年08月 [査読有り]
     
    Purpose: There has been one report that tissue blood flow (TBF) quantification with xenon CT was effective in predicting the therapeutic response to an anticancer drug in pancreatic cancer. The purpose of this study was to evaluate the correlation between the TBF of pancreatic tumors calculated with xenon CT and those with perfusion CT, in order to evaluate whether perfusion CT could replace xenon CT. Materials and Methods: Nine patients with pathologically proved pancreatic tumors who underwent both xenon CT and perfusion CT were included. Results: Quantitative TBF of pancreatic tumors measured by perfusion CT ranged from 22.1 to 196.2 ml/min/100 g (mean±SD, 52.6±54.8 ml/min/100 g). In contrast, those obtained by xenon CT ranged from 10.3 to 173.6 ml/min/100 g (mean±SD, 47.9±49.4 ml/min/100 g). There was a good linear correlation between xenon CT and perfusion CT (y=0.8537x+2.48, R2=0.895: p< 0.05). Conclusion: The TBF of pancreatic tumors measured by xenon CT and perfusion CT techniques showed a close linear correlation. We can expect that perfusion CT based on the deconvolution algorithm may replace xenon CT to predict the effect of pancreatic tumor treatment with anticancer drugs.
  • M Kitano; M Bernsand; Y Kishimoto; P Norlen; R Hakanson; Y Haenuki; M Kudo; J Hasegawa
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 288 5 G1084 - G1090 2005年05月 [査読有り]
     
    Microdialysis was used to study how ischemia-evoked gastric mucosal injury affects rat stomach histamine, which resides in enterochromaffin-like (ECL) cells and mast cells. A microdialysis probe was inserted into the gastric submucosa, and the celiac artery was clamped (30 min), followed by removal of the clamp. Microdialysate histamine was determined by enzyme-linked immunosorbent assay. In addition, we studied the long-term effects of ischemia on the oxyntic mucosal histidine decarboxylase activity in omeprazole-treated rats. Gastric mucosal lesions induced by the ischemia were enlarged on removal of the clamp. The microdialysate histamine concentration increased immediately on clamping (50-fold rise within 30 min) and declined promptly after the clamp was removed. In contrast, histidine decarboxylase activity of the ECL cells was lowered by the ischemia and returned to preischemic values 9 days later. Mast cell-deficient rats responded to ischemia-reperfusion much like wild-type rats with respect to histamine mobilization. Pretreatment with the irreversible inhibitor of histidine decarboxylase, alpha-fluoromethylhistidine, which is known to eliminate histamine from ECL cells, prevented the rise in microdialysate histamine. Pharmacological blockade of acid secretion (cimetidine or omeprazole) prevented the lesions induced by ischemia-reperfusion insult but not the mobilization of histamine. In conclusion, ischemia of the celiac artery mobilizes large amounts of histamine from ECL cells, which occurs independently of the gross mucosal lesions. The prompt reduction of the mucosal histidine decarboxylase activity in response to ischemia probably reflects ECL cell damage. The lesions develop not because of mobilization of histamine per se but because of ischemia plus reperfusion plus gastric acid.
  • 南 康範; 鄭 浩柄; 畑中 絹代; 井上 達夫; 坂口 康浩; 萩原 智; 上嶋 一臣; 福永 豊和; 工藤 正俊; 土師 誠二; 中居 卓也; 大柳 治正
    胆と膵 26 3 279 - 283 医学図書出版(株) 2005年03月 
    ラジオ波焼灼術(RFA)は高い局所制御能から肝細胞癌の局所治療として用いられており,外科治療と共に根治性の高い治療法として位置づけられている.しかし,全ての肝細胞癌がRFAで治療可能である訳ではない.肝細胞癌治療には外科切除,RFA,経カテーテル的治療など複数の選択肢があり,治療法選択には病期や肝予備能に基づいて内科・外科・放射線科など各科を横断したトータル・マネージメントが必要である.基本的に内科より外科治療が考慮される症例として, 1)外科治療の根治性がより高い場合, 2)経皮的RFAが困難な場合, 3)合併症が危惧される場合が挙げられるが,臨床の場で大切なことは内科と外科との意見交換からコンセンサスを築くことである(著者抄録)
  • N Fukuta; M Kitano; K Maekawa; T Chikugo; M Kudo
    JOURNAL OF GASTROENTEROLOGY 40 3 247 - 255 2005年03月 [査読有り]
     
    Background. Recently. contrast agents for ultrasonography (US) such as Levovist have been introduced for routine clinical use. The contrast-enhanced US with Levovist permits evaluation of the intratumoral vascularity of hepatic and pancreatic tumors and is useful for their differential diagnosis. The purpose of the present study was to assess tumor vessels and the parenchymal flow of oastrointestinal stromal tumors (GISTs) by contrast-enhanced coded phase-inversion harmonic US and to evaluate whether vascularity is related to the malignant grade of the GISTs. Methods. Thirteen patients with GISTs were included in the present study. Tumors were observed in a real-time fashion of contrast-enhanced coded phase-inversion harmonic US after the injection of Levovist (400 mg/ml). The Vascular patterns were compared with tumor size, histological diagnosis. KIT mutations, and clinical findings such as metastasis. Results. The contrast-enhanced US images of the GISTs were classified into two types according to the blood flow area of the tumors as seen by real-time continuous imaging of the tumor vessels. The image pattern "Poor" represented vessels flowing only in the peripheral part of the tumor, and "Rich" represented abundant vessels flowing from the periphery to the central part of the tumor. According to the contrast-enhanced US images, five GISTs were classified as "Poor" and the others as "Rich." Based on the final diagnosis, all tumors with "Poor" images were determined to be benign GISTs. and the rest tumors except one with "Rich" images were determined to be malignant GISTs. Conclusions. Contrast-enhanced US image is more closely correlated with the final diagnosis than the histological findings.
  • Kudo M
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 94 3 464 - 472 2005年03月 [査読有り]
  • Kim, SR; S Imoto; M Taniguchi; KI Kim; N Sasase; T Matsuoka; Y Maekawa; T Ninomiya; K Ando; K Mita; S Fuki; T Koterazawa; K Fukuda; M Kudo; H Sakamoto; Y Hayashi
    INTERVIROLOGY 48 4 268 - 272 2005年 [査読有り]
     
    Two cases of primary sclerosing cholangitis with hepatic C virus infection in a 62-year-old man and a 60-year-old woman are presented. The infection in the man was eradicated with interferon therapy in 1992. Seven years thereafter, endoscopic retrograde cholangiography revealed a diffuse 2.5-cm-long stenotic lesion in the common bile duct which was consequently resected. Histological examination of the resected specimen revealed proliferation of epithelial cells, plasma cell infiltration, and fibrosis in the submucosal layer of the common bile duct. The human leukocyte antigen DR loci were 2 and 9. In the woman, a 6-month course of interferon therapy in 1992 failed to eradicate the infection. Cholangiography in 1999 revealed multiple narrowings and dilatations of intra- and extrahepatic bile ducts. Ultrasound guided biopsy of the liver in 1992 had revealed onionskin lesions around the bile duct epithelium in the portal tract. The human leukocyte antigen DR locus was 2. From these findings, the 2 cases were diagnosed as primary sclerosing cholangitis. Further studies may provide insights into the relation between the pathogenesis of the disease and the infection. Copyright (C) 2005 S. Karger AG, Basel.
  • M Kudo; HY Chung; S Haji; Y Osaki; H Oka; T Seki; H Kasugai; Y Sasaki; T Matsunaga
    HEPATOLOGY 40 6 1396 - 1405 2004年12月 [査読有り]
     
    The Japan Integrated Staging score (JIS score), which combines the Child-Turcotte-Pugh classification and tumor-node-metastasis staging, has been proposed as a better prognostic staging system for hepatocellular carcinoma (HCC) than the Cancer of the Liver Italian Program (CLIP) scoring system. In this study, validation was performed among a larger patient population. A total of 4,525 consecutive patients with HCC who had been diagnosed at five institutions were included. Stratification ability, prognostic predictive power, and reproducibility were analyzed and compared with results from the CLIP scoring system. Only 45% (1,951 of 4,525) of all patients were categorized as early stage HCC according to JIS score (0 or 1), whereas 63% (2,878 of 4,525) of the patients were categorized as having a CLIP score of 0 or 1. Significant differences in survival curves were not observed among CLIP scores 3 to 6. In contrast, survival curves showed significant differences among all the JIS scores. The same JIS scoring subgroups showed a similar prognosis, and good internal reproducibility was observed in each of the institutions. Multivariate analysis of the prognosis in all 4,525 patients proved the JIS score to be the best prognostic factor. Furthermore, the Akaike information criteria proved that the JIS scoring system was statistically a better model for predicting outcome than the CLIP scoring system. In conclusion, the stratification ability and prognostic predictive power of the JIS score were much better than that of the CLIP score and were simple to obtain and remember.
  • Kudo M; Chung H; Osaki Y; Kasugai H; Oka H; Seki T
    Gan to kagaku ryoho. Cancer & chemotherapy 31 13 2100 - 2104 2004年12月 [査読有り]
  • M Shiomi; T Kamisako; Yutani, I; R Yoshimoto; M Kudo; R Fujii
    GASTROINTESTINAL ENDOSCOPY 60 5 854 - 856 2004年11月 [査読有り]
  • T Kawasaki; M Kudo; H Chung; Y Minami
    JOURNAL OF GASTROENTEROLOGY 39 10 1015 - 1016 2004年10月 [査読有り]
  • Kim, SR; Y Maekawa; S Imoto; M Sugano; M Kudo
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 28 8 174S - 180S 2004年08月 [査読有り]
     
    Background: Three cases of hypervascular nodules in the liver, without hepatitis B or C virus infection and with a history of alcohol abuse (120 ml/day for 15 to 30 years), are presented. Results: Ultrasound examination revealed hypoechoic nodules in segment 6 (2 cm in diameter, case 1), in the right and left lobes (1-2 cm multiple type, case 2), and in segment 4 (4 cm, case 3). Hepatic angiography and computed tomography during arteriography revealed hypervascular nodules in the three cases. First, hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, hemangioendothelioma, inflammatory pseudotumor, and pseudolymphoma were diagnostically differentiated. Histologically, there was no evidence of hepatocellular carcinoma or of any of the pathologies considered in the differential diagnosis by imaging studies. In case 1, the lesion was composed of an irregular, thin, trabecular-pattemed hepatic acinus with slighter hypercellularity than in the nonnodular area. In cases 2 and 3, the lesions were composed mainly of fibrosis without hyperplasia, showing stellate scar-like fibrosis septa dividing the nodule. Marked pericellular fibrosis, neutrophilic infiltration, and Mallory bodies in the cytoplasm were also observed. In cases 1 and 2, small unpaired arteries explaining the hypervascularity of the nodules were observed. Conclusion: These hypervascular nodules were classified as regenerative, not neoplastic, nodules according to the classification of the International Working Party.
  • Chung H; Kudo M
    Nihon rinsho. Japanese journal of clinical medicine 62 Suppl 7 Pt 1 315 - 318 2004年07月 [査読有り]
  • M. Kudo; T. Asao; S. Hashimoto; H. Kuwano
    International Journal of Hyperthermia 20 4 441 - 450 2004年06月 [査読有り]
     
    An original model of closed continuous hyperthermic peritoneal perfusion (CHPP) in mice is presented and was found to support the efficacy of intraperitoneal hyperthermia. Closed CHPP was performed after intraperitoneal inoculation of transplantable colon 26 cells into a mouse. Colon 26 cells (5 × 104) were injected into 18 mice. The mice were then allocated to six groups of three each and subjected to peritoneal perfusion over time. Peritoneal washings from each mouse were sampled and counted by the cytosmear method. On day 10 after inoculation, colonies of the disseminated tumour were seen on the mesentery by staining with 0.1% methylene blue for 5 min. The number of tumour nodules on the mesentery was counted. The number of washed-out tumour cells decreased the most at 24 h after inoculation, and 76% of the inoculated cells did not wash out during the peritoneal perfusion procedure. CHPP was performed after 24 h when colon 26 cells were injected into the peritoneal cavity because this status may represent micrometastasis. The total number of nodules on the mesentery in the CHPP group was significantly smaller than that in the control (p < 0.02). In conclusion, because this treatment model is similar to the clinical CHPP, the biostaining model might be useful for the evaluation of peritoneal dissemination and it was unique and valuable in demonstrating an effective treatment for the prevention of peritoneal dissemination. © 2004 Taylor & Francis Ltd.
  • Y Minami; M Kudo; T Kawasaki; H Chung; C Ogawa; H Shiozaki
    AMERICAN JOURNAL OF ROENTGENOLOGY 182 5 1224 - 1226 2004年05月 [査読有り]
  • YL Wen; M Kudo; RG Zheng; H Ding; P Zhou; Y Minami; HY Chung; M Kitano; T Kawasaki; K Maekawa
    AMERICAN JOURNAL OF ROENTGENOLOGY 182 4 1019 - 1026 2004年04月 [査読有り]
     
    Objective. Our purpose was to evaluate the value of contrast-enhanced. coded phase-inversion harmonic imaging in showing the characteristic intranodular hemodynamics of hepatic tumors. Subjects and Methods. Using a microbubble contrast agent we performed coded harmonic angio in 163 patients with 192 hepatic tumor nodules: 153 hepatocellular carcinomas, 13 metastases, 14 hemangiomas, eight dysplastic nodules, and four focal nodular hyperplasias. After injecting Levovist, we performed real-time scanning, interval-delay fast low-angle shot imaging, and sweep scanning in the early arterial phase, late vascular phase, and postvascular phase, respectively. Results. On contrast-enhanced coded harmonic angio, the typical hemodynamic pattern of hepatocellular carcinomas was shown as abundant tumor vessels supplied from the periphery to the center of the tumor and dense parenchymal tumor staining with fast washout (sensitivity, 92.8%; specificity, 92.3%). The characteristic hemodynamic pattern of metastases was peripheral tumor vessels with a rim parenchymal stain in the vascular phase followed by a perfusion defect in the postvascular phase (sensitivity, 69.2%; specificity, 100%). Hemangiomas were hypovascular in the early arterial phase with gradual spotty or cotton-wool pooling continuing to the late vascular phase (sensitivity, 92.9%; specificity, 100%). Dysplastic nodules were shown as having no early arterial supply with isovascularity in the late vascular phase (sensitivity, 75%; specificity, 100%). Focal nodular hyperplasias were shown to have a spoked wheel pattern of blood vessels accompanied by dense staining in interval-delay scanning (sensitivity, 100%; specificity, 100%). Conclusion. Contrast-enhanced coded harmonic angio is a promising method to provide useful information for the differential diagnosis of hepatic tumors.
  • S Matsui; M Kudo; R Nakaoka; M Shiomi; T Kawasaki
    JOURNAL OF GASTROENTEROLOGY 39 4 397 - 399 2004年04月 [査読有り]
  • M Kudo
    JOURNAL OF GASTROENTEROLOGY 39 4 409 - 411 2004年04月 [査読有り]
  • Hitoshi Tochio; Shin-Ichi Nishiuma; Yoshihiro Okabe; Akio Orino; Masatoshi Kudo
    Journal of Medical Ultrasonics 31 1 21 - 28 2004年03月 [査読有り]
     
    Purpose. The aim of this study was to investigate the possibility of diagnosing acute cholecystitis in patients with liver cirrhosis using color Doppler imaging to demonstrate the hemodynamics. Methods. Color Doppler imaging was used to analyze the waveform of the cystic artery in 28 cirrhotic subjects with thickened gallbladder walls and 56 normal controls. The cirrhotic group was further divided into the cholecystitis group, containing 6 cirrhotic patients with acute cholecystitis, and the liver cirrhosis group, containing 22 cirrhotic patients without acute cholecystitis. Results. Maximum velocity (Vmax) was significantly higher in the cholecystitis group (31.6 ± 23.0cm/s) than in the normal controls (16.1 ± 5.9cm/s) (P < 0.01). The resistance index (RI) was higher in the liver cirrhosis group (0.84 ± 0.04) than in either the normal controls (0.70 ± 0.06) (P < 0.01) or the cholecystitis group (0.72 ± 0.09) (P < 0.01). Sensitivity and specificity were 100% when the diagnostic criteria of acute cholecystitis were a maximum velocity of more than 40cm/s, a resistance index of more than 0.75, or both. Conclusion. A pulsatile signal with a maximum velocity of more than 40cm/s, a resistance index lower than 0.75, or both indicated the presence of acute cholecystitis in patients with liver cirrhosis and a thickened gallbladder wall. © The Japan Society of Ultrasonics in Medicine 2004.
  • M Kudo
    JOURNAL OF GASTROENTEROLOGY 39 3 205 - 214 2004年03月 [査読有り]
  • 肝癌治療直接効果判定基準 2004年改訂版
    日本肝癌研究会肝癌集学的治療効果判定基準作成委員会; 有井滋樹; 江原正明; 岡崎正敏; 岡田周一; 沖田極; 工藤正俊; 久保正二; 坂本亨宇; 佐藤守男; 椎名秀一郎; 関寿人; 高安賢一; 田中正俊; 田伏克惇; 辻井博彦; 中島収; 中沼安二; 松井修; 山岡義生; 山崎晋; 山田龍作
    肝臓 45 7 380-385  2004年 [査読有り]
  • H Tochio; M Kudo
    INTERVIROLOGY 47 3-5 144 - 153 2004年 [査読有り]
     
    Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma (HCC) were analyzed using color Doppler imaging. With afferent blood flow, constant waveform signals reflecting portal inflow are a characteristic finding in dysplastic nodules and early well-differentiated HCC. Among advanced HCCs lacking portal blood flow, inflow of arterial pulsatile blood flow signals is characteristic for advanced HCC with increased arterial vascularity. Efferent blood flow enters the hepatic vein of the lowest pressure system in dysplastic nodules and early well-differentiated HCC with afferent portal blood flow. Analysis of waveforms of efferent blood flow signals in advanced HCC detects in the opposite direction adjacent to an accompanying afferent arterial pulsatile blood flow signal. In conclusion, during multistep human hepatocarcinogenesis hemodynamics show characteristic changes; the state of afferent portal blood with low arterial vascularity loses the portal blood flow, and arterial vascularity gradually increases. The efferent blood flow pathway also changes with the pathological multistep development process. Copyright (C) 2004 S. Karger AG, Basel.
  • YL Wen; P Zhou; M Kudo
    INTERVIROLOGY 47 3-5 169 - 178 2004年 [査読有り]
     
    Objective: To investigate the value of contrast-enhanced coded phase inversion harmonic imaging (PIHI) in the depiction of intratumoral vascularity in small hepatocellular carcinoma (HCC). Methods: Eighty-five patients with 106 HCCs less than or equal to3 cm in diameter were evaluated with coded harmonic angio (CHA), a coded PIHI, with use of an intravenous contrast medium, Levovist. Intratumoral vessels were detected in the early arterial phase, and tumor parenchymal stain was demonstrated in the late vascular phase. The detectability of intratumoral vascularity on contrast-enhanced CHA was compared with that on dynamic computed tomography (CT) and digital subtraction angiography (DSA). Results: With a combination of both vessel images and parenchymal flow images demonstrated by contrast-enhanced CHA, 98 of 106 small HCCs were evaluated as being hypervascular or isovascular. Using the results on dynamic CT as a gold standard, the sensitivity, specificity and accuracy were 95.1, 100 and 95.3%, respectively. The detection rate of intratumoral vascularity by contrast-enhanced CHA was 92.5% (98/106), compared with 97.2% (103/106) on dynamic CT (p=0.14) and 88.9% (40/45) on DSA (p=0.53). Conclusions: Contrast-enhanced coded PIHI is a sensitive tool for depicting intratumoral vascularity of small HCC. Copyright (C) 2004 S. Karger AG, Basel.
  • RQ Zheng; M Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 18 8 994 - 994 2003年08月 [査読有り]
  • WP Wang; H Ding; Q Qi; F Mao; ZZ Xu; M Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 9 8 1667 - 1674 2003年08月 [査読有り]
     
    AIM: To characterize enhancement patterns of focal hepatic lesions using C-cube gray scale sonography with a microbubble contrast agent and to evaluate its usefulness in differential diagnosis of hepatic lesions. METHODS: Fifty-four patients with 58 focal hepatic lesions were examined with Levovist-enhanced C-cube gray scale sonography. The final diagnosis of hepatic lesions was 29 primary liver cancers, 4 metastases, 8 hemangiomas, 12 focal nodular hyperplasias, 2 inflammatory pseudotumors of the liver and 3 angiomyolipomas. The initiation time of enhancement in various lesions and enhancement duration after administration of contrast agent were compared. Vascular findings in lesions were classified as peripheral enhancement, homogenous enhancement, mosaic enhancement and no enhancement depending on microbubble signals in the lesion relative to the liver parenchyma. RESULTS: The initiation time of enhancement in hemangioma (48+/-12 s) was significantly later compared to other lesions (P<0.05). The enhancement duration of malignancies (69+/-33 s in primary liver cancer, 61+/-23 s in metastasis) was significantly shorter compared to benign lesions (P<0.05). Intranodular enhancement appearing at arterial phase and decreasing at portal venous phase was considered characteristic for malignancy. Intranodular enhancement did not appear earlier than the liver parenchyma, and peripheral enhancement pattern was regarded as positive findings for hemangioma. Intranodular enhancement appeared in the arterial phase, and homogenous enhancement pattern sustained in the whole portal venous phase were regarded as positive findings for focal nodular hyperplasia. No microbubble signals appeared in two inflammatory pseudotumors of the liver. CONCLUSION: C-cube gray scale sonography can demonstrate dynamic intranodular enhancement in various focal hepatic lesions. The information provided by this methodology may be useful in the differential diagnosis of hepatic lesions.
  • YL Wen; M Kudo; RQ Zheng; Y Minami; H Chung; Y Suetomi; H Onda; M Kitano; T Kawasaki; K Maekawa
    AMERICAN JOURNAL OF ROENTGENOLOGY 181 1 57 - 63 2003年07月 [査読有り]
     
    OBJECTIVE. This study was performed to evaluate the usefulness of contrast-enhanced coded phase-inversion harmonic sonography in assessing the therapeutic response of percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. SUBJECTS AND METHODS. Sixty-seven patients with a total of 107 examinations on 91 hepatocellular carcinoma nodules underwent coded harmonic angio, a technique of coded phase-inversion harmonic sonography, using the IV microbubble contrast agent Levovist before and after percutaneous radiofrequency ablation. The intratumoral blood vessels and tumor parenchymal stain were detected in the early arterial phase and the late vascular phase, respectively. The results of contrast-enhanced imaging with coded harmonic angio were compared with those of three-phase dynamic CT. RESULTS. Before treatment, all examined 107 hepatocellular carcinoma nodules were found to be hypervascular on contrast-enhanced imaging with coded harmonic angio. After radiofrequency ablation, contrast-enhanced coded harmonic angio detected persistent signal enhancement in 41 examined nodules (38.3%), whereas this technique showed no intratumoral enhancement in the remaining 66 (61.7%) examined nodules. Compared with dynamic CT, the sensitivity, specificity, and diagnostic accuracy of contrast-enhanced coded harmonic angio were 95.3%, 100%, and 98.1%, respectively. With contrast-enhanced coded harmonic angio, we found that it was difficult to identify the safety margin that can be detected on dynamic CT. CONCLUSION. Contrast-enhanced imaging with coded harmonic angio may provide an alternative approach that has high diagnostic agreement with dynamic CT in assessing the therapeutic effect of radiofrequency ablation in hypervascular hepatocellular carcinomas, in spite of having limitations in identifying the safety margin.
  • HY Chung; M Kudo; T Kawasaki; M Kitano; Y Minami; Y Suetomi; H Onda
    HEPATOLOGY RESEARCH 26 3 254 - 258 2003年07月 [査読有り]
     
    We describe one case of hepatocellular carcinoma (HCC) arising in secondary haemochromatosis in a non-cirrhotic liver. The patient was a 40-year-old male. He had severe pancytopenia due to myelodysplastic syndrome (MDS) and developed secondary haemochromatosis as a result of a large amount of erythrocyte transfusion. Multiple nodules of the liver appeared about 6 years after the diagnosis of MDS. Needle biopsy of the nodules histologically confirmed them to be moderately differentiated HCCs. The liver parenchyma was shown to be non-cirrhotic and a deposit of hemosiderin was also identified, consistent with a finding of haemochromatosis of the liver. Transarterial chemoembolization was performed to treat multiple HCCs. There are a number of reports describing HCC occurrence in non-cirrhotic patients with hereditary haemochromatosis. However, HCC in secondary haemochromatosis without cirrhosis is extremely rare. (C) 2003 Elsevier Science B.V. All rights reserved.
  • Yan Ling Wen; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa
    Journal of Medical Ultrasonics 30 SUMMER 77 - 84 2003年06月 [査読有り]
     
    Purpose: To investigate the usefulness of contrast-enhanced Agent Detection Imaging in assessing intratumoral vasculature in hepatocellular carcinoma. Materials and Methods: Fourteen hepatocellular carcinoma nodules in 11 patients were studied with contrast-enhanced Agent Detection Imaging, a wide-band color Doppler imaging method, employing Levovistℛ, a microbubble contrast agent. High acoustic power was used with contrast-enhanced Agent Detection Imaging. Intermittent transmission of Agent Detection Imaging was performed at intervals of 200, 500, and 350 milliseconds in the early arterial phase (10 to 40 seconds), late vascular phase (1 to 3 minutes) and postvascular phase (5 to 7 minutes), respectively. The results were compared with those of three-phase dynamic CT. Results: Intratumoral blood vessels in the early arterial phase and tumor parenchymal stain in the late vascular phase were depicted in 12 (88%) of the 14 hepatocellular carcinoma nodules, while all nodules were demonstrated as perfusion defect in the postvascular phase on contrast-enhanced Agent Detection Imaging. The results of Agent Detection Imaging, that were compared with those of dynamic CT, were all 100% : diagnostic sensitivity (12/12), specificity (2/2), and accuracy (14/14). Conclusion: Contrast-enhanced Agent Detection Imaging is a promising method for depicting intratumoral vascularity in hepatocellular carcinoma.
  • RQ Zheng; M Kudo; Y Minami; K Inui; HY Chung
    JOURNAL OF GASTROENTEROLOGY 38 4 406 - 409 2003年04月 [査読有り]
  • Wen YL; Kudo M; Minami Y; Chung H; Suetomi Y; Onda H; Kitano M; Kawasaki T; Maekawa K
    Journal of medical ultrasonics (2001) 30 1 31 - 38 2003年03月 [査読有り]
  • M Kudo; HB Chung; Y Osaki
    JOURNAL OF GASTROENTEROLOGY 38 3 207 - 215 2003年03月 [査読有り]
     
    A clinical staging system for cancer patients provides guidance for patient assessment and making therapeutic decisions. It is useful in deciding whether to treat a patient aggressively, and in avoiding the overtreatment of patients who would not tolerate the treatment or patients whose life expectancy rules out any chance of treatment. Clinical staging is also an essential tool for comparison between groups in therapeutic trials and for comparison between different studies. The current classifications most commonly used for hepatocellular carcinoma (HCC) are the Okuda stages, the Child-Pugh staging system, tumor node metastasis (TNM) staging, and the Cancer of the Liver Italian Program (CLIP) score. Among these, the CLIP score is currently the most commonly used integrated staging score, including both tumor stage and liver disease stage. Although the CLIP score has been well validated by many authors in terms of its prognostic value in HCC patients, this score has some problems and limitations when applied to currently diagnosed HCC patients, who are diagnosed in the early stage of disease. First, the CLIP score can discriminate score 0- to 3-patient populations, but it is not able to discriminate score 4- to 6-patient groups. Second, the definition of tumor morphology in the best prognostic group is too advanced, i.e., uninodular and a tumor extent of less than 50% of the liver. As a result, the prognosis of the CLIP system best prognostic group is not so good. In other words, this system cannot identify the best prognostic group who would benefit from curative and aggressive treatment. Third, nearly 80% of the patient population is classified as having a CLIP score of 0-2, as confirmed by many studies, which shows poor stratification ability. In contrast, a new staging system based on the Liver Cancer Study Group of Japan (LCSGJ), the Japan Integrated Staging (JIS) score is currently proposed in Japan. This staging system combines Child-Pugh grade (grade A, score 0; grade B, score 1; grade C, score 2) and TNM staging by the LCSGJ criteria (stage 1, score 0; stage 11, score 1; stage 111, score 2; stage IV, score 3). The stratification ability of the JIS scoring system is much better than that of the CLIP scoring system. The JIS scoring system also performed better than the CLIP scoring system in selecting the best prognostic patient group. The cumulative 10-year survival rates of the best prognostic groups in the CLIP staging system (CLIP score 0) and JIS staging system (JIS score 0) were 23% and 65%, respectively (P < 0.01). All scoring systems arise as a compromise between simplicity and discriminatory ability. We confirmed that the JIS score increases predictive efficacy, while remaining simple compared with the CLIP score. Because the JIS score is quite easily obtained and is objective, we strongly propose it for widespread use as a prognostic staging system for HCC in clinical practice.
  • T Kawasaki; M Kudo; K Inui; C Ogawa; H Chung; Y Minami
    HEPATOLOGY RESEARCH 25 2 202 - 212 2003年02月 [査読有り]
     
    A 73-year-old man with chronic hepatitis due to hepatitis C virus was referred to our hospital for close examination of hepatic nodule. An abdominal ultrasonography revealed a mosaic pattern nodule with 3.7 cm in diameter. Arterial phase of dynamic CT revealed the small caudal part and marginal area of cranial part of the tumor were enhanced. The enhancement of marginal area of cranial part of the tumor continued up to portal phase and equilibrium phase and enhanced area was gradually filling in to the central area. On the other hand, the caudal part of the tumor was less enhanced compared with surrounding normal hepatic area in portal phase and equilibrium phase. An abdominal angiography revealed spotty tumor staining mimicking cotton-wool appearance, which is a typical finding for cavernous hemangioma. Contrast enhanced harmonic ultrasonography also showed hemangioma like finding (peripheral globular enhancing pattern). Because of these discrepancies on imagings, it was difficult to make final diagnosis of this tumor to be hepatocellular carcinoma since cavernous hemangioma cannot be completely ruled out. The pathological study of the specimen taken by US-guided percutaneous needle biopsy finally confirmed this nodule as hepatocellular carcinoma. In conclusion, we must keep in mind that some hepatocellular carcinomas could mimic hemangioma due to peliotic change or large acinar formation, therefore, needle liver biopsy may be essential for correct diagnosis if there is a discrepancy in several imaging findings. (C) 2002 Elsevier Science B.V. All rights reserved.
  • 造影超音波法が診断に有用であった門脈肝静脈短絡症に伴うFNHの1例
    坂口 康浩; 豊澤 昌子; 中尾 隆美; 石川 恵美; 坂本 洋城; 鄭 永琴; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅彦; 川崎 俊彦; 汐見 幹夫; 工藤 正俊; 前川 清
    超音波医学 30 1 J58 - J58 (公社)日本超音波医学会 2003年01月
  • T Watanabe; M Kondo; M Hirasa; H Shirane; Y Okabe; Y Ibuki; S Tomita; A Orino; A Todo; Y Wakatsuki; T Chiba; M Kudo
    JOURNAL OF GASTROENTEROLOGY 38 7 695 - 699 2003年 [査読有り]
     
    We report the case of a 25-year-old woman with fulminant hepatic failure (FHF). Liver scintigraphy using Tc-99m-galactosyl human serum albumin (GSA) and Tc-99m-phytate produced interesting findings; regenerative nodules appeared as nodules of increased accumulation of Tc-99m-GSA, whereas these nodules were expressed as defects of accumulation of Tc-99m-phytate. These scintigraphic findings suggested that the functions of hepatocytes in regenerative nodules were maintained, whereas those of Kupffer cells were impaired. Although Tc-99m-GSA scintigraphy indicated hepatic functional reserve enough to survive, she died despite intensive therapy including plasma exchange. Based on this case. it is recommended that not only Tc-99m-GSA scintigraphy but also 99mTc-phytate scintigraphy is required to evaluate the prognosis of patients with FHF.
  • H Chung; M Kudo; T Kumada; S Katsushima; A Okano; T Nakamura; Y Osaki; K Kohigashi; Y Yamashita; H Komori; S Nishiuma
    JOURNAL OF GASTROENTEROLOGY 38 9 877 - 879 2003年 [査読有り]
     
    Background We carried out this study to assess the risk of hepatitis C virus (HCV) transmission after needlestick injuries in medical personnel, and to evaluate the efficacy of short-duration interferon administration to prevent HCV transmission. Methods. A total of 684 personnel who had been occupationally exposed to an anti-HCV-positive source and followed for more than 3 months were retrospectively examined. Results. Of the 684 subjects, 279 (41%) were treated with 1 to 3 days of interferon either just after or 1 to 12 days after the injury. One case of HCV infection was found in each of the treated (1/279; 0.4%) and nontreated (1/405; 0.2%) groups. There was no significant difference in the transmission of HCV between the two groups. Both infected patients were treated with interferon after developing acute hepatitis, and HCV was subsequently cleared. Conclusions. There is a lower risk of HCV transmission after needlestick accident than previously reported, and short-duration interferon administration at an early stage after the needlestick injury, to prevent HCV transmission, is unnecessary.
  • Wen YL; Kudo M; Maekawa K; Minami Y; Chung H; Suetomi Y; Onda H; Kitano M; Kawasaki T
    Journal of medical ultrasonics (2001) 29 4 195 - 204 2002年12月 [査読有り]
  • J Hayashi; K Kajino; T Umeda; S Takano; Y Arakawa; M Kudo; O Hino
    INTERNATIONAL JOURNAL OF ONCOLOGY 21 4 847 - 850 2002年10月 [査読有り]
     
    Human DNA-binding protein (dbpA) is a member of a Y-box binding protein family containing a cold shock domain. The increased expression of Y box binding proteins in somatic cells is associated with cell proliferation and transformation. Recently, we isolated a splicing variant of dbpA as a candidate for the cellular recombinogenic protein that leads to genomic instability and inflammation-mediated hepatocarcinogenesis. The expression of dbpA is enhanced in proliferating cells, but the manner in which it regulates transcription is largely unknown. In this study, we analyzed the transcriptional regulatory region of dbpA, and searched for the mutation in this region by a direct sequence method. In 3 of 55 human hepatocellular carcinoma (HCC) cases, we identified one nucleotide replacement (T-->G transversion) in nucleotide position -6 of the promoter region. Among 3 cases showing this transversion, one HCC case was due to a somatic mutation and the other two were due to single nucleotide polymorphism (SNP). By luciferase assay, we showed that the transcriptional activity of the promoter region with the transversion was significantly higher than that of the wildtype. Using the Southwestern blotting, we also confirmed the existence of a cellular proteins (about 25 and 50 kDa) that specifically bind to the sequence with this transversion. Our results suggested the biological significance of the transversion of dbpA's promoter region as one of the factors accelerating hepatocarcinogenesis.
  • Kim, SR; Y Maekawa; T Matsuoka; S Imoto; K Ando; K Mita; HB Kim; T Nakajima; KS Ku; T Koterazawa; K Fukuda; Y Yano; M Nakaji; M Kudo; KI Kim; M Hirai; Y Hayashi
    HEPATOLOGY RESEARCH 23 4 306 - 314 2002年08月 [査読有り]
     
    A case of eosinophilic pseudotumor of the liver due to Ascaris (A) suum is described in a 34-year-old-man with a high serum level of immunoglobulin E and hypereosinophilia ascribed to a history of atopic dermatitis since childhood. Multiple hepatic hypoechoic nodules detected by ultrasound were confirmed as low-density nodules on computed tomography (CT), and as low and high signal intensity lesions on T1- and T2-weighted magnetic resonance imaging (MRI), respectively. CT during arteriography (CTA) and arterial portography revealed multiple nodules with ring-shaped enhancement and perfusion defect, respectively. Biopsied liver tissue specimens did not contain tumor cells or atypical cells; instead, they showed marked infiltration of eosinophils with necrosis and Charcot-Leyden crystals in the portal tracts and hepatic sinusoides, suggesting parasitic infection, although neither larvae nor eggs were detected. The diagnosis of visceral larva migrans (VLM) due to A. suum was based on immunoserological tests. The patient was a habitual consumer of raw bovine liver, which may explain the A. suum infection. After drug therapy with albendazole, the hypoechoic nodules disappeared. Differential diagnoses and the possible transfection route of A. suum are discussed. (C) 2002 Elsevier Science B.V. All rights reserved.
  • Kim, SR; T Matsuoka; Y Maekawa; Y Yano; S Imoto; M Kudo; S Shintani; K Ando; K Mita; K Fukuda; T Koterazawa; M Nakaji; H Ikawa; T Ninomiya; KI Kim; M Hirai; Y Hayashi
    JOURNAL OF GASTROENTEROLOGY 37 8 663 - 668 2002年08月 [査読有り]
     
    We report a case of multicentric hepatocellular carcinoma that developed in a 74-year-old man 3 and 6 years after interferon (IFN) treatment for chronic hepatitis C, despite sustained virologic, biochemical, and histological improvement. Initially, serum hepatitis C virus RNA was positive and the patients' serum level of alanine aminotransferase (ALT; 82IU/ml) was abnormal. Hepatitis B virus (HBV) in the serum was negative for surface antigen, surface antibody, core antibody, and DNA. The patient was started on 10 x 10(6) international units (IU) of IFNalpha, 3 days a week for a total of 24 weeks. After the IFN therapy, the patient demonstrated a normal serum ALT level, and was continuously negative for HCV-RNA, and histology improved from chronic active hepatitis to chronic persistent hepatitis. Follow-up studies with ultrasonography (US) every 3 months and computed tomography (CT) every 6 months revealed no space-occupying lesion (SOL) for 3 years after IFN treatment. US-guided biopsies of two 15-mm hypoechoic SOLs in segments eight (S8) and seven (S7) 34 and 74 months, respectively, after IFN treatment showed well-differentiated hepatocellular carcinoma (HCC). Clinical data, imaging studies, and histologic examinations showed that both tumors were multicentric HCC. Further studies may provide insights into the possible role of HCV in hepatocarcinogenesis in patients demonstrating HCV eradication by IFN treatment.
  • Y Minami; M Kudo; T Kawasaki; HB Chung; S Matsui; M Kitano; Y Suetomi; H Ondo; S Funai; K Kou; M Yasutomi
    HEPATOLOGY RESEARCH 23 2 145 - 151 2002年06月 [査読有り]
     
    Hepatocellular. adenoma sometimes causes intraperitoneal hemorrhage. It is, however, rare for small hepatocellular adenoma to cause intrahepatic huge hemorrhage without intraperitoneal bleeding. Here we describe such a rare case of hepatocellular adenoma with huge intrahepatic hemorrhage in a 25-year-old female, who had taken oral contraceptives for the last 2 weeks. She was admitted to our hospital with a sudden onset of right-upper-quadrant abdominal pain and temporally fell in shock state. Plain CT depicted low density area measuring more than 13 cm in diameter in the right lobe of the liver. Huge tumor was also suggested by abdominal ultrasound, contrast enhanced CT, magnetic resonance imaging (MRI) and angiography. The patient was diagnosed as intrahepatic rupture of hepatic tumor. Because of the risk of re-hemorrhage and malignancy, she underwent right hepatic lobectomy. Histopathologial examination of the resected specimen showed a typical small hepatocellular adenoma with the surrounding huge hematoma in the liver. The case presented here is very rare but seems to be suggestive to the natural course and management of hepatocellular adenoma. (C) 2002 Elsevier Science B.V. All rights reserved.
  • Kim, SR; S Imoto; Y Maekawa; T Matsuoka; Y Hayashi; K Ando; K Mita; S Shintani; HB Kim; K Ku; T Koterazawa; K Fukuda; Y Yano; M Nakaji; H Ikawa; T Ninomiya; M Kudo; KH Kim; M Hirai
    HEPATOLOGY RESEARCH 22 4 313 - 321 2002年04月 [査読有り]
     
    Imaging studies of a hepatic tumor in a 53-year-old woman with elevated serum levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and 5-hydroxyindole acetic acid (5HIAA) revealed a hypervascular tumor in the right lobe. Grossly, the brownish tumor was measured 13.5 x 12 cm with four daughter nodules. Microscopically, the majority of these columnar and round tumor cells had ribbon-or rosette-like patterns with the expression of neuroendocrine marker proteins, such as Grimelius, NSE, chromogranin A, and synaptophysin, and moderate expression of CEA but without the expression of cytokeratin nos 7,8,14,18,19 and OV-6; the minority had glandular patterns with a strong expression of CEA but without the expression of cytokeratin nos 7,8,14,18,19 and OV-6. Ultrastructurally, most tumor cells contained populations of electron-dense core granules ranging between 100 and 200 nm in diameter. After hepatectomy, serum CEA, NSE, and 5HIAA reverted to normal ranges and persisted for 19 months. These findings suggested that the diagnosis of primary hepatic carcinoid was tenable and that the tumor might derive from hepatic stem cells which acquired the additional nature of producing CEA without cytokeratins characteristic of hepatocytes or bile duct cells. Some molecular based approaches have attributed unique biological behavior and histogenesis to this carcinoid tumor. (C) 2002 Elsevier Science B.V. All rights reserved.
  • Tochio H; Iwasaki N; Nakamura H; Nakayama K; Soga T; Nishiuma S; Fukunaga T; Okabe Y; Kashida H; Hirasa M; Ibuki Y; Fujimoto T; Morimoto Y; Kudo M; Tomita S; Konishi Y; Orino A
    Journal of medical ultrasonics (2001) 29 1 11 - 17 2002年03月 [査読有り]
  • M Kudo
    ONCOLOGY 62 48 - 56 2002年 [査読有り]
     
    Since a close relationship exists between intranodular hemodynamics and the grade of biological/pathological malignancy of a nodule occurring in the cirrhotic liver, an accurate evaluation of intranodular hemodynamics is highly essential. Intranodular hemodynamics in hepatocellular carcinoma (HCC) and borderline lesions can be evaluated correctly by invasive and noninvasive techniques. Invasive techniques such as ultrasound (US) angiography, computed tomographies during arteriography or arterial portography are sensitive in the detection of intranodular arterial and portal supplies, for accurate diagnosis of tumors and assessing grades of biologically malignant potential. However, these approaches require an angiographic procedure, which is not always available. Recently, perfusion imaging techniques under US, including contrast-enhanced harmonic imaging or real-time gray-scale harmonic imaging, have become available for routine clinical use. With these techniques, all the five roles of imaging in the management of HCC, i.e., detection, confirmation, staging, evaluation of malignancy grade, and postoperative follow-up, have become much simpler. Perfusion imaging techniques have reduced the requirement for dynamic CT or MRI and may replace some of their roles in the clinical setting. Since viable cancer cells are accurately imaged on US monitoring with sensitive perfusion imaging techniques, the contrast-enhanced harmonic imaging will be of great advantage in US-guided treatment of HCC. With the advent of rapid and remarkable advances in US harmonic imaging techniques, the diagnostic and therapeutic strategies for HCC are changing drastically. Copyright (C) 2002 S. Karger AG, Basel.
  • H Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M Tanaka
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 16 12 1378 - 1383 2001年12月 [査読有り]
     
    Background and Aim: The Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) has been reported to be a highly useful marker for hepatocellular carcinoma (HCC) compared with a conventional serum AFP concentration, which allows earlier detection of HCC compared with using other imaging modalities and predicting prognosis after therapy. A collaborative prospective study involving nine Japanese hospitals was conducted to analyze the relationships between the tumor characteristics of a HCC patient and the percentage of AFP-L3/AFP total at the initial detection. Methods: Between 1 October 1996 and 30 September 1997, a total of 388 patients with newly diagnosed HCC were registered. Results: The cut-off level of the percentage of AFP-L3 was altered from 15 to 10%. The AFP-L3-positive HCC patients demonstrated the characteristics of having an advanced tumor, such as the number of tumors, maximum diameter, tumor spread, portal vein invasion, tumor stage, and tumor classification. With the conventional cut-off level of 15% of the percentage of AFP-L3, the malignant characteristics were more definite than that of 10%. However, no significant differences of serum AFP concentration were observed for malignant characteristics such as maximum diameter and histopathological grading. Conclusion: Serum AFP concentration does not reveal a malignancy of HCC, however, the AFP-L3-positive HCC has biologically malignant characteristics, especially portal vein invasion and lower tumor classification, and is an advanced tumor regardless of small tumor size and lower serum AFP concentration. As AFP-L3 shows the tumor characteristics, its presence should be an important factor in the determination of therapy and prognosis of patients. (C) 2001 Blackwell Science Asia Pty Ltd.
  • H Tochio; M Kudo; S Nishiuma; Y Okabe
    AMERICAN JOURNAL OF ROENTGENOLOGY 177 5 1109 - 1112 2001年11月 [査読有り]
     
    OBJECTIVE. The purpose of our study was to assess whether intrahepatic spontaneous retrograde portal flow in patients with cirrhosis of the liver can be reversed to a normal portal venous flow by food intake. CONCLUSION. Of the 18 cirrhotic patients with intrahepatic spontaneous retrograde portal flow, 16 (89%) showed a marked change in portal flow direction after food intake. This evidence strongly suggests that intrahepatic spontaneous retrograde portal flow may be reversible. Furthermore, this finding implies that regular food intake may be important in the maintenance of effective hepatic blood flow in cirrhotic patients.
  • H Ding; M Kudo; H Onda; H Nomura; S Haji
    JOURNAL OF CLINICAL ULTRASOUND 29 7 411 - 416 2001年09月 [査読有り]
     
    We describe a case of nonfunctioning islet cell tumor of the pancreas diagnosed preoperatively by intermittent harmonic power Doppler imaging and digital subtraction gray-scale harmonic imaging and the use of the contrast agent SH U 508A (Levovist). Hypervascularity and tumor perfusion were clearly demonstrated with both harmonic imaging techniques in the early arterial phase. Sonographic findings were confirmed by other modalities and by histopathologic examination. (C) 2001 John Wiley & Sons, Inc.
  • YL Wen; M Kudo; T Kawasaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 16 7 821 - + 2001年07月 [査読有り]
  • Kim, SR; T Matsuoka; Y Maekawa; Y Yano; Y Hayashi; M Kudo; K Kim; S Imoto; KB Song; K Ando; S Shintani; T Koterazawa; K Fukuda; K Mita; M Taniguchi
    HEPATOLOGY RESEARCH 20 2 244 - 254 2001年06月 [査読有り]
     
    A case of disseminated extrahepatic hepatocellular carcinoma (HCC) occurring after ultrasound (US)-guided biopsy and percutaneous ethanol injection therapy is presented. A 72-year-old man with hepatitis-C-virus-related cirrhosis underwent percutanous ethanol injection therapy (PEIT) two times with complete remission: the first for moderately-differentiated HCC in segment six (S6), and the second for well-differentiated HCC in another part of S6. Imaging studies including carbon dioxide (CO2)-US angiography, incremental computed tomography, and dynamic magnet resonance imaging showed that both HCCs were hypovascular. Twenty-one months after the first PEIT and 7 months after the second, a 5.5 x 4.5 cm extrahepatic mass interfaced with S6 of the liver was detected by imaging studies. The patient underwent surgery for extrahepatic HCC. Grossly, the main tumor was 5.5 x 4.5 cm with capsule and septum; the disseminated tumors were detected on the surface of the liver, including the right diaphragm and the fair ligamentosa. Histologically, it was moderately- to poorly-differentiated HCC, which, although not attributed to direct track seeding, was suspected of being induced by the percutaneous US-guided biopsy procedure or by PEIT, irrespective of a hypovascular tumor. Further studies may provide insight into the risk factor engendered by these procedures. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
  • M Shiomi; T Kamisako; Yutani, I; M Kudo; H Shigeoka; A Tanaka; K Okuno; M Yasutomi
    TUMORI 87 3 191 - 195 2001年05月 [査読有り]
     
    We report two cases of early gastric cancer with distant metastases (stage IV). At our institute 1428 cases of primary gastric cancer were resected between 1980 and 1997; 536 were diagnosed as early gastric cancer based on the resected specimens (304 cases of mucosal cancer, Tis - TNM classification - and 232 of submucosal cancer, T1), 528 of these 536 cases were classified as histological stage I, six as stage II, none as stage III and two as stage IV. The incidence of stage IV early gastric cancer was 0.14% of all gastric cancers and 0.37% of the early gastric cancers,The two patients with stage IV early gastric cancer were women. Both tumors were defined as early cancer because they were confined to the submucosa, One was a type 0 IIc + III early cancer, histologically classifiable as a small, moderately differentiated adenocarcinoma (tub2 according to the Japanese Classification of Gastric Carcinoma(1,2), G2; TNM classification: ICD-O C16), size 10 x 8 mm; the other was a surface spreading type 0 lie, classifiable as a signet-ring cell carcinoma (sig, G3), size 50 x 35 mm. Stage IV factors were N3 in the first and ovarian metastasis (Krukenberg tumor) in the second case.
  • T Murakami; T Kim; M Takamura; M Hori; S Takahashi; MP Federle; K Tsuda; K Osuga; S Kawata; H Nakamura; M Kudo
    RADIOLOGY 218 3 763 - 767 2001年03月 
    PURPOSE: To assess whether double arterial phase imaging with multi-detector row helical computed tomography improves detection of hypervascular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Fifty-one patients with 96 hypervascular HCCs underwent double arterial phase imaging of the entire liver. At measured delay after intravenous administration of 2 mL/kg of contrast medium at a rate of 5 mL/sec, the early and late arterial phase images were obtained serially during a single breath hold with interscan delay of 5.0 seconds. Detector row configuration of 2.5 x 4 mm, pitch of 6, and scanning time of 10.5 seconds for each phase were used. Forty 5-mm-thick reconstruction images were obtained for each phase. Each image set was interpreted separately by three observers, who were unaware of tumor burden in the liver, to detect hypervascular HCC. Sensitivity, positive predictive value, and area below the receiver operating characteristic curve (A(z)) for early and late arterial phases separately and together were calculated. RESULTS: Mean sensitivity and positive predictive value for hypervascular HCC were 54% and 85% for the early arterial phase, 78% and 83% for the late arterial phase, and 86% and 92% for the double arterial phase, respectively. Double arterial phase imaging showed significantly superior sensitivity compared with early or late arterial phase imaging alone for detecting HCC (P < .05). The mean A(z) value for double arterial phase was significantly higher than that for early or late arterial phase imaging alone (P < .05). Double arterial phase imaging showed the lowest number of false-positive lesions. CONCLUSION: Double arterial phase imaging is recommended to improve detection of hypervascular HCCs and reduce false-positive lesions.
  • T Kawasaki; T Ueo; T Itani; M Shibatohge; J Mimura; H Komori; A Todo; M Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 16 2 149 - 153 2001年02月 [査読有り]
     
    Background: We investigated the vascularity of advanced gastric adenocarcinomas by using percutaneous power Doppler imaging. Methods: Seventeen patients with gastric cancer and 10 without a gastric tumor, but with a slightly thick gastric wall in the B-mode ultrasound, were investigated with the use of power Doppler imaging. The color signals of the gastric lesion were graded as follows: 1, no color signals or the same as the surroundings; 2, color signals were slightly increasing; and 3, color signals were obviously increasing. Results: The color signals of three patients were graded 1, those of eight patients were graded 2 and those of six patients were graded 3 in the gastric cancer group. The color signals of all 10 patients without a gastric tumor were grade 1. This difference was statistically significant (P = 0.0002). Conclusions: Power Doppler imaging showed vascularity of gastric cancer increasing in the majority of patients (14 of 17: 82%). Thus, power Doppler imaging might be a good screening examination method for gastric cancer. (C) 2001 Blackwell Science Asia Pty Ltd.
  • M Kitano; P Norlen; Y Kishimoto; J Hasegawa; H Kawasaki; M Kudo; T Itoh; R Hakanson
    HISTAMINE RESEARCH IN THE NEW MILLENNIUM 1224 299 - 304 2001年 [査読有り]
  • Kim, SR; Y Hayashi; M Kudo; S Imoto; KB Song; K Ando; S Shintani; T Koterazawa; KI Kim; M Taniguchi
    INTERVIROLOGY 43 1 13 - 15 2000年01月 [査読有り]
     
    The prevalence of TT virus (TTV) and its rate of transmission through transfusion were investigated to determine its possible hepatocarcinogenic role in non-B, non-C hepatocellular carcinoma (HCC) as compared with that in hepatitis B virus (HBV)- and hepatitis C virus (HCV)-positive HCC. Its transfection route in TTV-positive cases was also studied. Serum was positive for TTV in 77.8% (7/9) of HBV-positive, 36.4% (12/33) of HCV-positive, and 63.6% (7/11) of non-B, non-C cases of HCC. The rate of transmission through transfusion was 52.4% (11/21) in HBV-positive, 40.1% (61/152) in HCV-positive, 33.3% (2/6) in HBV+HCV-positive, and 40% (8/20) in non-B, non-C HCCs, while it was 48.3% (14/29) in TTV-positive and 39.3% (11/28) in TTV-negative cases. The association between TTV and HCC was limited, and the main route of infection of TTV was not th rough transfusion. Copyright (C) 2000 S. Karger AG, Basel.
  • T Watanabe; M Kudo; H Shirane; H Kashida; S Tomita; A Orino; A Todo; T Chiba
    GASTROINTESTINAL ENDOSCOPY 50 5 688 - 691 1999年11月 [査読有り]
  • Kim, SR; Y Hayashi; M Kudo; T Matsuoka; S Imoto; K Sasaki; S Shintani; KB Song; SY Park; JH Kim; K Ando; T Koterazawa; KI Kim; T Ninomiya
    PATHOLOGY INTERNATIONAL 49 8 726 - 730 1999年08月 [査読有り]
     
    A case of an inflammatory pseudotumor of the liver in a 75-year-old female with chronic hepatitis C whose radiologic features simulated that of hepatocellular carcinoma (HCC) is presented. On imaging studies, hypervascularity by CO2 ultrasound (US) angiography, enhancement at an early phase and isodensity at a late phase by incremental dynamic computed tomography (CT), perfusion defect by CT during arteriography (CTAP), and clinical background of hepatitis C virus (HCV) infection strongly suggested HCC. A US-guided needle biopsy revealed a mainly diffuse and polyclonal proliferation of lymphocytes positive for leukocyte common antigen (pan-lymphocyte cells), L-26 (B cell lymphocytes), and UCHL-1 (T cell lymphocytes), negative for both x and lambda light chains and sparsely distributed neutrophils and histiocytes. No lymphoid follicles were observed. The liver tissue around this tumor showed chronic hepatitis with mild activity and mild fibrosis. These histopathologic findings suggested that the diagnosis of inflammatory pseudotumor of the liver was tenable. As it is difficult to differentiate between inflammatory pseudotumor of the liver and HCC by imaging studies alone, supplemental biopsy, where possible, should be obtained when diagnostic imaging of tumors suggesting HCC is carried out. We emphasize that histopathology is a true gold standard in the diagnosis of this disease.
  • H Marusawa; Y Osaki; T Kimura; K Ito; Y Yamashita; T Eguchi; M Kudo; Y Yamamoto; H Kojima; H Seno; F Moriyasu; T Chiba
    GUT 45 2 284 - 288 1999年08月 [査読有り]
     
    Background/Aims-Evidence is accumulating that hepatitis B virus (HBV) is present in patients who are hepatitis B surface antigen negative but have antibody to hepatitis B core antigen (anti-HBc). Furthermore, recent studies have shown that patients with hepatocellular carcinoma who have antibody to hepatitis C virus (HCV) often possess HBV related serological markers. Data on the seroprevalence of HBV infection in patients with HCV related chronic liver disease were collected to evaluate the significance of the presence of antibodies to HBV. Methods-The prevalence of HBV related serological markers was analysed in a total of 2014 Japanese patients with HCV infection. The control group comprised 352 subjects without Liver disorder. Results-A large number of patients (49.9%) with HCV related chronic liver disease including hepatocellular carcinoma were positive for anti-HBc. In addition, the prevalence of anti-HBc closely correlated with the clinical stage of the liver disease. There was no relation between a past history of blood transfusion and the prevalence of anti-HBc. Notably, anti-HBc was the only serological marker for HBV infection in a significant number of patients with HCV related chronic liver disease (24.1%). Conclusions-Our data provide further evidence for the high prevalence of anti-HBc in patients with HCV related chronic liver disease, particularly those with hepatocellular carcinoma, suggesting that HBV infection, probably including latent infection, may play an important role in carcinogenesis in these patients.
  • T Watanabe; M Kudo; M Kayaba; H Shirane; S Tomita; A Orino; A Todo; T Chiba
    JOURNAL OF GASTROENTEROLOGY 34 4 525 - 529 1999年08月 [査読有り]
     
    A patient with massive rectal bleeding due to ileal tuberculosis is reported. Technetium-99m labelled red blood cell scintigraphy indicated hemorrhage from the ileum, and laparotomy was then carried out. A 70cm segment of ileum containing ulcers and erosions was resected, and epitheloid granuloma with Langhans-type giant cell was found in the resected specimen. Massive rectal bleeding is considered a rare presenting symptom of intestinal tuberculosis. Intestinal tuberculosis, including small intestinal tuberculosis, although uncommon, should be taken into consideration as a cause of rectal bleeding.
  • T Yamamoto; K Kajino; M Kudo; Y Sasaki; Y Arakawa; O Hino
    HEPATOLOGY 29 5 1446 - 1452 1999年05月 [査読有り]
     
    The poor prognosis of hepatocellular carcinoma (HCC) is partly the result of the high rate of recurrence that is caused either by intrahepatic metastasis (IM) or independent multicentric occurrence (MO), For convenience, discrimination of IM and MO is based on pathological findings, but reliable parameters are not sufficiently established. In the case of hepatitis B virus (HBV)-associated HCC, molecular discrimination of IM from MO can be achieved by comparison of integrated HBV DNAs. However, Southern blotting cannot be used for this purpose when one tumor is saved in frozen form and the other is in paraffin-embedded form. To solve this problem, we employed polymerase chain reaction (PCR) assays to confirm the clonality of primary and recurrent tumors. From the frozen tissue, we determined the junction between the integrated HBV and flanking genomic DNA by molecular cloning, and checked the existence of an identical junction in the DNA of paraffin-embedded tissue by PCR, Using this method, as well as Southern blotting, we proved in 6 of 8 patients that two nodular HCC lesions resected metachronously or simultaneously were caused by MO, while the remaining 2 cases were caused by IM, In 1 IM case, band patterns between two HCCs detected by Southern blotting were not identical.
  • T Watanabe; S Tomita; M Kudo; M Kurokawa; A Orino; A Todo; T Chiba
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 33 11 1140 - 1143 1998年11月 [査読有り]
     
    Background: Detection of Helicobacter pylori is usually performed by culture, polymerase chain reaction (PCR), histology, or urease test on gastric biopsy samples. Although methods based on feces are noninvasive, their sensitivity has been relatively low. In this study, to improve its sensitivity, immunomagnetic separation (LMS) was used as a pre-PCR step for direct detection of H. pylori in feces. Methods: Fresh fecal samples were taken from 72 patients attending for endoscopy. Of these, 57 patients had a positive H. pylori status according to the results of culture, histology, and PCR on gastric biopsy samples. Anti-H. pylori antibody-sensitized immunomagnetic beads were used to concentrate the bacteria. PCR was then performed to detect the H. pylori urease A-encoding gene. Results: Of the 57 H. pylori-positive patients, 35 (61.4%) had positive fecal samples by IMS-based PCR method. None of the 15 H. pylori-negative patients had positive fecal samples. The sensitivity of this method was 61.4%, and the specificity 100.0%. Conclusions: This study confirms that non-invasive diagnosis of H. pylori infection could be made from feces by using IMS-based PCR.
  • Toshiki Yamamoto; Kazunori Kajino; Masahiro Ogawa; Iori Gotoh; Shunichi Matsuoka; Kazutomo Suzuki; Mitsuhiko Moriyama; Hitoshi Okubo; Masatoshi Kudo; Yasuyuki Arakawa; Okio Hino
    Biochemical and Biophysical Research Communications 251 1 339 - 343 1998年10月 [査読有り]
     
    A novel DNA virus designated TT virus (TTV) was cloned from a patient with posttransfusion hepatitis and is thought to be a new hepatitis virus. At present, hepatitis B virus (HBV) and hepatitis C virus (HCV) are known to induce hepatocellular carcinoma (HCC). But, actually, in Japan approximately 5 to 10% of HCCs are in HBV-negative and HCV-negative (NBNC) patients. In order to study the possible role of TTV in hepatocarcinogenesis, we investigated the frequency of the TTV genome in liver tissue of 20 HCC patients. As a result, 3 of 8 NBNC HCC patients and 5 of 12 HBV-or HCV-associated HCC patients were TTV positive, and TTV was shown not to be specific for NBNC HCC. For all TTV-positive patients, we also confirmed that the TTV genome was not integrated into host hepatocyte DNA.
  • Kim, SR; Y Hayashi; T Matsuoka; SY Park; S Shintani; K Sasaki; J Asano; JH Kim; KIH Kim; S Imoto; H Itoh; M Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 13 9 892 - 896 1998年09月 [査読有り]
     
    A rare case of well-differentiated minute hepatocellular carcinoma (HCC) metastasizing to distant sites in a 77-year-old man with hepatitis C virus (HCV)-related cirrhosis is presented. Ultrasonography (US) disclosed a 9 mm hypoechoic lesion in segment seven (S-7) Of the liver, although computed tomography (CT), magnetic resonance imaging (MRI) and angiography did not reveal any space-occupying lesion. Ultrasound-guided biopsy showed the histological features of well-differentiated HCC. A plain film of the abdomen and CT revealed osteolytic changes in the sacrum and the lumbar vertebra. Ultrasound-guided biopsy of the sacrum revealed well-to-moderately differentiated HCC metastasizing from the liver. Percutaneous ethanol injection therapy (PEIT) effected complete response and completely eliminated the abnormal findings on US. Three months after PEIT, metastasis to the thoracic vertebra was revealed by CT, despite negative alpha-fetoprotein-mRNA in serum. This is the first report describing a well-differentiated HCC with metastatic potential. Further studies may provide insights into metastasis of well-differentiated HCC.
  • T Yamamoto; K Kajino; M Kudo; Y Sasaki; Y Arakawa; O Hino
    HEPATOLOGY 26 4 2009 - 2009 1997年10月 [査読有り]
  • Sang Kil Ha-Kawa; Yoshimasa Tanaka; Shin Hasebe; Yoshio Kuniyasu; Kiyoshi Koizumi; Yasushi Ishii; Kazutaka Yamamoto; Toru Kashiwagi; Akihiko Ito; Masatoshi Kudo; Katsuji Ikekubo; Takaharu Tsuda; Kenya Murase
    European Journal of Nuclear Medicine 24 2 130 - 137 1997年 [査読有り]
     
    A multicentre study on multicompartmental analysis of hepatic scintigraphy using technetium-99m labelled galactosyl serum albumin (GSA), which binds to the asialoglycoprotein receptor, was carried out at seven institutions in Japan. Seventy-four patients with liver disease received 3 mg (185 MBq) of 99mTc-GSA by intravenous injection. Sequential scanning was performed 30 min after injection to obtain anterior images of the heart and liver, followed by single-photon emission tomography (SPET). The indices included in this analysis were hepatic blood flow (Q) and maximal receptor binding rate (R(max)), which showed a good correlation with semiquantitative ratio indices for 99mTc-GSA, namely the retention rate in blood (HH15) and the hepatic uptake rate (LHL15). Q and R(max) also showed a significant correlation with other measures of hepatic function. When patients were grouped according to the severity of chronic liver damage (hepatocellular functional damage), Q was reduced in the moderate and severe groups, while R(max) was reduced in proportion to the functional stage. Both parameters showed no inter-institution difference using analysis of co-variance with the functional stage as a co-variant. With regard to the hepatic uptake rate, anterior planar images and SPET im ages gave similar results for Q and R(max). Acquisition times of 15 or 30 min provided the same results. The multicompartmental model analysis permitted comparable results to be obtained at institutions using different gamma cameras, and is therefore considered a universally applicable method. These results indicate that Q and R(max) are useful general indices for evaluating the functional reserve capacity of the liver.
  • カラ−ドプラ法による慢性肝疾患に見られる小結節の良悪性診断−流入する定常性血流シグナルについて−
    杤尾人司; 冨田周介; 工藤正俊; 岡部純弘; 岩崎信広; 蓑輪和士; 曽我登志子; 田村周二; 森本義人; 渡邉智裕; 福永豊和; 近藤雅彦; 樫田博史; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男
    Clinical Information 9 1 - 13 1997年 [査読有り]
  • パワードプラ法の臨床応用─肝腫瘤の血流動態からみた質的診断─
    杤尾人司; 樫田博史; 冨田周介; 岩崎信広; 簑輪和士; 田村周二; 曽我登志子; 森本義人; 渡辺智裕; 福永豊和; 岡部純弘; 平佐昌弘; 伊吹康良; 工藤正俊; 織野彬雄; 藤堂彰男
    臨床成人病 27 1075 - 1082 1997年 [査読有り]
  • 脂肪肝に伴う胆嚢床のSpared Areaと肝内胆嚢流出血流との関連: カラードプラ法による検討
    杤尾人司; 岡部純弘; 冨田周介; 工藤正俊; 樫田博史; 岩崎信広; 蓑輪和士; 田村周二; 曽我登志子; 森本義人; 渡邉智裕; 福永豊和; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男
    ＪMed Ultrasonics 24 1651 - 1661 1997年 [査読有り]
  • カラ−ドプラ法にて特徴的な血流動態を観察し得た右胃静脈と考えられる還流異常に伴う肝内過形成結節の１例
    杤尾人司; 岡部純弘; 冨田周介; 織野彬雄; 岩崎信広; 蓑輪和士; 曽我登志子; 田村周二; 森本義人; 渡邉智裕; 福永豊和; 近藤雅彦; 樫田博史; 平佐昌弘; 伊吹康良; 工藤正俊; 藤堂彰男
    J Med Ultrasonics 787 - 794 1997年 [査読有り]
  • H. Kashida; M. Kondo; T. Fukunaga; Y. Terai; K. Yamamoto; T. Itani; M. Hirasa; Y. Ibuki; M. Kudo; S. Tomita; A. Orino; A. Todo
    Japanese Journal of Gastroenterology 93 2 96 - 103 1996年 [査読有り]
     
    Obliteration of portal systemic shunts surgically or by interventional radiological techniques is fairly effective in reversing intractable portal- systemic encephalopathy (PSE), but is often associated with ascites accumulation and/or formation of esophageal varices. This study reports four patients with incapacitating PSE who were treated by interventional radiological techniques via percutaneous transhepatic route. One case had the shunt embolized directly. In the other three the blockage was placed on the proximal part of the splenic vein, whereby disconnecting the mesenteric- portal blood flow from the systemic circulation while preserving the shunt. The patient of shunt closure showed transient correction of encephalopathy, but developed massive ascites and esophageal varices, encephalopathy recurred, resulting in death from hepatic failure two months after the procedure. In the cases of shunt preserving disconnection of portal and systemic circulation (SPDPS) immediate and permanent clearing of encephalopathy was achieved without manifestation of ascites or esophageal varices during the follow-up period of 10 to 31 months. The difference of portal pressure between before and after the procedure was 18mmHg in the shunt closed patient and 3 mmHg in SPDPS group. We conclude from this limited experience that SPDPS can be an effective and safe method in treating PSE in adequately selected patients.
  • 十二指腸潰瘍患者におけるHelicobacter pylori除菌療法について
    冨田周介; 渡邉智裕; 近藤雅彦; 福永豊和; 岡部純弘; 樫田博史; 平佐昌弘; 伊吹康良; 工藤正俊; 織野彬雄; 藤堂彰男; 三木寛二; 大西伸策; 黒川 学
    神戸市立病院紀要 35 19 - 23 1995年 [査読有り]
  • Hitoshi Tochio; Syusuke Tomita; Masatoshi Kudo; Yoshihiro Okabe; Hiroshi Kashida; Michio Hamada; Kenji Yamamoto; Yuji Terai; Tomonao Itani; Jun Mimura; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio Todo
    Kanzo 35 5 333 - 346 1994年 [査読有り]
     
    The outcome of 45 small hepatic nodules diagnosed as hypovascular by US angiography were studied with clinical and ultrasonic follow-up carried out more than 1 years. Out of 45 nodules, 23 nodules were performed biopsy under US guidance at first detection, and hypercellularities and/or increasing in N/C ratio were observed in all 23 nodules. Enlargement of the nodule size was observed in 7 (16%) of 45 nodules, while the size has not changed in 20 (44%) nodules. Eighteen nodules (40%) become undetectable with US. Six nodules out of 7 enlarged cases developed into advanced HCCs. Four out of these malignant change group showed “vascular spot” on US angiography and/or perfusion defects on CTAP at the first detect. The remaining two cases also acquired such vascular findings at the later stage when they have enlarged. In this study, the twos of development and extension of HCCs were proved: (1) advanced HCC appear as a hypervascular spot in a benign hypovascular nodule, (2) portal perfusion in the tumor as a whole decreases and arterial vascularity increases in stead in the process of cancer development. It is concluded that, if the nodules which show “vascular spot” on US angiography and/or perfusion defect on CTAP exclude from the subject, only 5% (2/40) of the hypovascular nodules develop into advanced HCC. © 1994, The Japan Society of Hepatology. All rights reserved.
  • Hiroshi Kashida; Toshinao Itani; Jun Mimura; Yoshihiro Okabe; Masahiro Hirasa; Yasuyoshi Ibuki; Masatoshi Kudo; Shusuke Tomita; Hideshi Komori; Akio Orino; Akio Todo
    Nippon Shokakibyo Gakkai Zasshi 91 3 293 - 302 1994年 [査読有り]
     
    Ultrasound angiography (USAG), sonographic imaging of the blood flow in an organ or tissue obtained by carbon dioxide infusion into the supplying artery, was performed on 28 pancreatic nodular lesions less than 3 cm in diameter. The hemodynamics of tumors observed with USAG were divided into three groups : hypovascular, isovascular, and hypervascular, compared with the adjacent pancreatic tissue. Most of hypovascular nodules were duct cell carcinoma (sensitivity 94.1%, specificity 90.4%), while isovascular lesion was the characteristic of inflammatory masses (sensitivity 100%, specificity 95.8%). Hypervascular cases included all of the mucin producing tumors and islet cell tumors but only one case of duct cell carcinoma. So you can almost exclude duct cell carcinoma as an diagnosis in vascular rich tumors (negative predictive value 83.3%). These results were compared with those on conventional x-ray angiograms and incremental CT scans. Ultrasound angiography enabled us to detect more slight differences of tumor vascularity than the other modalities. Thus we conclude that USAG can be a useful diagnostic aid in small mass lesions of the pancreas. © 1994, The Japanese Society of Gastroenterology. All rights reserved.
  • Masatoshi Kudo; David R. Vera; Robert C. Stadalnik; Carlos O. Esquivel; Walter L. Trudeau; Katsuji Ikekubo; Akio Todo
    Digestive Diseases and Sciences 38 12 2183 - 2188 1993年12月 [査読有り]
     
    Technetium-99m-galactosyl-neoglycoalbumin (TcNGA) is a synthetic radiolabeled ligand specific for hepatic binding protein (HBP), a receptor that resides exclusively on hepatocytes. In vivo measurement of receptor concentration was obtained via kinetic analysis of liver and blood time-activity data obtained during the hepatic clearance of intravenously administered TcNGA. The purpose of this study was to assess receptor concentration as a measure of the functioning hepatocyte mass. Therefore, TcNGA and dualinjection indocyanine green maximal removal rate (ICG Rmax) studies were performed on nine patients with hepatic cirrhosis associated or not with hepatocellular carcinoma. Receptor concentration was compared with ICG Rmax, which is a validated method for the estimation of the functioning hepatocyte mass. The correlation coefficient was 0.76 (P=0.017). It is concluded that HBP concentration ([HPB]o) as measured by functional imaging is a measure of functioning hepatocyte mass. This implies that measurement of an individual's receptor concentration by using nuclear medicine techniques provides an objective index of hepatic functional mass and supports attempts to rigorously evaluate [HBP]o for its clinical efficacy. © 1993 Plenum Publishing Corporation.
  • M KUDO; S TOMITA; H TOCHIO; K MINOWA; A TODO
    AMERICAN JOURNAL OF GASTROENTEROLOGY 88 5 723 - 729 1993年05月 [査読有り]
     
    Intrahepatic portosystemic venous shunt is a rare clinical entity; only 33 such cases have been reported. It may be congenital, or secondary to portal hypertension. Five patients with this disorder are presented, each of whom was diagnosed by color Doppler imaging, including waveform spectral analysis. One patient with clinical evidence of cirrhosis and portal hypertension had episodes of hepatic encephalopathy and elevated blood levels of ammonia. This patient had a large tubular shunt between the posterior branch of the portal vein and the inferior vena cava. Shunts of this type are considered to be collateral pathways which develop in the hepatic parenchyma as a result Of portal hypertension. The other four patients had no evidence of liver disease, and all four evidenced an aneurysmal portohepatic venous shunt within the liver parenchyma. Shunts of this type are considered congenital. The diagnosis of intrahepatic portosystemic venous shunts was established by color Doppler imaging, which demonstrated a direct communication of color flow signals between the portal vein and hepatic vein, in addition to the characterization of the Doppler spectrum at each sampling point from a continuous waveform signal (portal vein) to a turbulent signal (aneurysmal cavity), and finally, to a biphasic waveform signal (hepatic vein). As demonstrated by the rive patients, color Doppler imaging is useful in the diagnosis of an intrahepatic portosystemic hepatic venous shunt, and the measurement of shunt ratio may be useful in the follow-up and determining the therapeutic option.
  • Hitoshi Tochio; Syusuke Tomita; Masatoshi Kudo; Yoshihiro Okabe; Kazushi Minowa; Hiroshi Kashida; Jun Mimura; Michio Hamada; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio Todo
    Kanzo 34 8 597 - 605 1993年 [査読有り]
     
    It is considered that retrograde portal flow is an evidence for the existence of arterio-portal (A-P) shunt. Fifteen patients with hepatocellular carcinoma (HCC), in whom retrograde portal flow was detected by color Doppler flow imaging, were studied. The correspondence between existence of A-P shunt on angiogram and retrograde portal flow identified by spectral analysis with pulsed Doppler was evaluated. A-P shunt was observed in all 4 cases with pulsatile retrograde portal flow. Out of 11 cases with continuous retrograde portal flow, A-P shunt was observed in 5 cases (45%). In 11 cases with continuous retrograde portal flow, case with A-P shunt showed Mean ± SD of maximum velocity of 10.6 ± 5.3cm/sec, which is significantly higher than that of in cases without A-P shunt. A-P shunt was observed in all cases with maximum velocity of retrograde portal flow more than 10cm/sec. We concluded that pulsatile retrograde portal flow or continuous retrograde portal flow faster than 10cm/sec in velocity is diagnostic of the existence of A-P shunt relating to HCC. © 1993, The Japan Society of Hepatology. All rights reserved.
  • Masatoshi Kudo; Akio Todo; Katsuji Ikekubo; Kazutaka Yamamoto; David R. Vera; Robert C. Stadalnik
    Hepatology 17 5 814 - 819 1993年 [査読有り]
     
    Technetium 99m diethylenetriaminepentaacetic acid–galactosyl human serum albumin is a newly developed analog ligand to asialoglycoprotein receptor, which is a hepatic cell surface receptor specific for galactose‐terminated glycoproteins. Hepatic functional imaging, which yields estimates of asialoglycoprotein receptor concentration, was performed after intravenous injection of 3 mg technetium 99m diethylenetriaminepentaacetic acid–galactosyl human serum albumin. A total of 75 human subjects were studied: 6 controls without liver diseases, 51 patients with chronic liver diseases and 18 patients with acute liver diseases. In chronic liver disease the asialoglycoprotein receptor concentration significantly correlated with the clinical severity based on the criteria of the Liver Cancer Study Group of Japan (rs = −0.890, p = 0.0001). Good correlations between the asialoglycoprotein receptor concentration and conventional liver function tests were also observed. In acute liver disease the asialoglycoprotein receptor concentration correlated well with the normotest (r = 0.796, p = 0.0001), prothrombin time (r = 0.701, p = 0.0002) and total serum bilirubin (r = −0.642, p = 0.0007). We conclude that the parameter, asialoglycoprotein receptor concentration, obtained from the kinetic analysis of technetium 99m diethylenetriaminepentaacetic acid–galactosyl human serum albumin time‐activity data, is a sensitive measure of functioning hepatocyte mass in acute and chronic liver disease. (HEPATOLOGY 1993 17:814–819.) Copyright © 1993 American Association for the Study of Liver Diseases
  • M KUDO; Y TAKAMINE; K NAKAMURA; H SHIRANE; H UCHIDA; S KASAKURA; T KAJIWARA; Y IBUKI; M HIRASA; S TOMITA; A TODO
    AMERICAN JOURNAL OF GASTROENTEROLOGY 87 12 1859 - 1862 1992年12月 [査読有り]
     
    We describe the case of a 56-yr-old man with primary gastric adenocarcinoma, who had an extremely high plasma level of des-gamma-carboxy prothrombin (2.45 AU/ml) and of serum alpha-fetoprotein (2810 ng/ml). Histopathologically, the gastric cancer was a IIc type of early cancer which consisted of a combination of a poorly differentiated adenocarcinoma and a well-differentiated tubular adenocarcinoma. The association of a hepatic tumor including hepatocellular carcinoma or liver metastasis was ruled out by ultrasonography, computed tomography, radiocolloid liver scan, magnetic resonance imaging, and angiography. Foci strongly resembling hepatocellular carcinoma (hepatoid differentiation) were noted in the gastric tumor. Localization of des-gamma-carboxy prothrombin and alpha-fetoprotein within the tumor cells, especially within the hepatoid differentiated foci, was demonstrated by the immunohistochemical staining of tissue obtained at biopsy and the resected specimen. This case seems to be the first case reported in which des-gamma-carboxy prothrombin was produced by the gastric cancer. This finding supports the theory of hepatoid differentiation of a gastric cancer.
  • M KUDO; A TODO; K IKEKUBO; M HINO
    AMERICAN JOURNAL OF GASTROENTEROLOGY 87 7 865 - 870 1992年07月 [査読有り]
     
    Galactosyl human serum albumin is a newly developed receptor-binding agent, specific for the asialoglycoprotein receptor, which resides exclusively on the plasma membrane of mammalian hepatocytes. The receptor-binding agent was synthesized by the covalent coupling of carbohydrate units to human serum albumin. The clinical utility of technetium-99m-labeled galactosyl human serum albumin was evaluated in six control subjects with normal livers and in 50 patients with chronic liver disease. The parameter, receptor index, was derived from liver and heart time-activity data and is the ratio of radioactivity of the liver over the radioactivity of the liver plus the heart at 15 min after the intravenous injection of 3 mg of labeled ligand. Values for the receptor index in the control subjects and in patients with mild, moderate, and severe liver disease were 0.936 +/- 0.015, 0.909 +/- 0.034, 0.848 +/-0.070, and 0.669 +/- 0.085, respectively. Good correlations were obtained between the receptor index and conventional liver function tests, such as the Child-Turcotte criteria score (r(s) = -0.776, p = 0.0001), prothrombin time (r = 0.736, p = 0.0001), and the plasma disappearance rate of indocyanine green (r = 0.805, p = 0.000 1). These significantly high correlations of the receptor index with classical indicators of hepatic functional reserve suggest that the receptor index is a potentially practical and reliable diagnostic method for estimating the functioning hepatocyte mass and for assessing liver function.
  • Y IBUKI; M KUDO; A TODO
    GASTROINTESTINAL ENDOSCOPY 38 2 178 - 180 1992年03月 [査読有り]
  • 伊吹 康良; 三村 純; 岡部 純弘; 樫田 博史; 平佐 昌弘; 工藤 正俊; 冨田 周介; 小森 英司; 織野 彬雄; 藤堂 彰男
    日本消化機病學會雜誌. 乙 89 9 2078 - 2078 The Japanese Society of Gastroenterology 1992年
  • M. Kudo; S. Tomita; K. Minowa; H. Tochio; K. Shimada; J. Mimura; Y. Okabe; H. Kashida; M. Hirasa; A. Todo
    Journal of Ultrasound in Medicine 11 10 553 - 557 1992年 [査読有り]
  • Masatoshi Kudo; Shusuke Tomita; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Hideji Komori; Akio Orino; Akio Todo
    Kanzo 33 7 556 - 564 1992年 [査読有り]
     
    Presented two cases in this report are 36-year-old man and 78-year-old man with asymptomatic intrahepatic portal-hepatic venous shunt, diagnosed by color Doppler imaging. The patients were admitted for further evaluation of intrahepatic aneurysmal cystic lesion detected by screening ultrasonography. Liver biopsy and laboratory tests showed no abnormality in the liver, and case 1 had no episode of hepatic encephalopathy. Case 2 had an episode of slight encephalopathy. The color signals were obtained in the aneurysmal lesion, which communicates with the portal vein branch and the hepatic vein, on color Doppler imaging. Continuous waveform signals were detected in the aneusysm, the shunt orifice, and the adjacent region in the hepatic vein with the Doppler spectral analysis. The diagnosis was made as intrahepatic portal-hepatic shunt with aneurysmal dilatation by these findings with color Doppler imaging. Color Doppler imaging using pulsed Doppler analysis was also useful in the measurement of shunt ratio, which was calculated by deviding blood flow rate at the shunt orifice by total portal blood flow rate. We conclude that color Doppler imaging is extremely useful in the diagnosis, follow-up, and the determination of the therapeutic indication of the intrahepatic portal-hepatic venous shunt. © 1992, The Japan Society of Hepatology. All rights reserved.
  • Masatoshi Kudo; Shusuke Tomita; Jun Mlmura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio Todo
    Kanzo 33 4 283 - 291 1992年 [査読有り]
     
    Hemodynamic characteristics were studied by using in vivo vascular imaging techniques in 17 resected early stage hepatocellular carcinoma (e-HCC) by comparing them with 49 resected advanced HCCs (ad-HCC) less than 3 cm in diameter. In this study, e-HCC was defined as the nodule being uniformly composed of well-differentiated HCC or adenomatous hyperplastic nodule containing well-differentiated HCC foci within the nodule. In vivo vascular imaging techniques are as follows US angiography with intraarterial CO2 microbubbles were performed to assess the tumor arterial vascularity, and CT during arterial portography (CTAP) was performed to assess the portal perfusion within the nodule. of 17 e-HCC nodules 5 were hypervascular, 5 were isovascular, 4 were hypovascular, and 3 were vascular spot in hypovascular pattern in contrast to 49 ad-HCC nodules, 43 of which were hypervascular and 6 were isovascular. of 14 e-HCCs, 9 nodules showed perfusion defect and 5 did not on CTAP, whereas all 37 ad-HCCs on which CTAP was performed, showed perfusion defect. Forty-one percent (7/17) of e-HCC showed fatty metamorphosis in contrast to 8% (4/49) of ad-HCC. In conclusion, hemodynamic characteristics of e-HCC are summarized as follows. (1) Arterial tumor neovascularization is relatively low. (2) Portal perfusion is present in some of e-HCC cases. (3) Hypoperfusion state both from arterial and portal supply is present in some of e-HCC cases. (4) Vascular spot in hypovascular pattern is characteristic arterial pattern in AH containing HCC foci. (5) Fatty metamorphosis may be related with hypoperfusion state of the nodule in e-HCC. © 1992, The Japan Society of Hepatology. All rights reserved.
  • Masatoshi Kudo; Akio Todo; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Shusuke Tomita; Hideshi Komori; Akio Orino
    Nippon Shokakibyo Gakkai Zasshi 89 6 1349 - 1359 1992年 [査読有り]
     
    Technetium-99m diethylene triamine pentaacetic acid-galactosyl human serum albumin (TcGSA) is a newly developed receptor-binding radiopharmaceutical, specific for the asialogycoprotein receptor, which resides exclusively on the plasma membrane of hepatocytes. Clinical utility of TcGSA was evaluated in 3 control subjects with normal livers and in 54 patients with various liver diseases. The parameter, Receptor Index, was derived from liver and heart time-activity data and is the ratio of radioactivity of the liver over the radioactivity of the liver plus heart at 15 min after the intravenous injection of 3 mg of TcGSA. Receptor concentration ([R]0) was obtained by kinetic analysis of liver and heart time-activity data using pharmacokinetic nonlinear modeling. Values for the Receptor Index and [R]0 were statistically different in the control subjects and in patients with mild, moderate, and severe liver diseases. Good correlations were obtained between the Receptor Index, [R]G and conventional liver function tests, such as Child-Turcotte criteria score, prothrombin time, and indocyanine green test. Receptor Index and [R]G were properly estimated even in patients with obstructive jaundice or remarkable portocaval shunt. These data suggest that the receptor imaging as well as its parameters, Receptor Index and [R]G, is a potentially practical and reliable diagnostic method for estimating the functioning hepatocyte mass and for assessing liver function. © 1992, The Japanese Society of Gastroenterology. All rights reserved.
  • Masatoshi Kudo; Akio Todo; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Shusuke Tomita; Hideshi Komori; Akio Orino
    Nippon Shokakibyo Gakkai Zasshi 89 3 616 - 626 1992年 [査読有り]
     
    Technetium-99m galactosyl human serum albumin (TcGSA) is a synthesized radiolabeled analog ligand to asialoglycoprotein receptor, which resides only at a mammalian hepatocyte. TcGSA studies were performed on 16 patients with various acute liver disease and 3 controls with normal livers. Dynamic data were obtained by a gamma camera during 35 minutes after an intravenous injection of 3 mg (185 MBq) of TcGSA. The parameters of TcGSA timeactivity curves were obtained by dividing radioactivity of the liver by that of the liver plus heart at 15 min (Receptor Index), and by dividing radioactivity of the liver at 15 min by that at 3 min post injection (Clearance Index). The two parameters correlated well with prothrombin time, clinically estimated staging, and severity of acute liver disease. We have concluded that liver function study by the newly developed receptor imaging with TcGSA can be a sensitive and promising tool in estimating the severity and prognosis of acute liver disease. © 1992, The Japanese Society of Gastroenterology. All rights reserved.
  • Ryo Hosotani; Hirohito Momoi; Hiroya Uchida; Yoshihiro Okabe; Masatoshi Kudo; Akio Todo; Toshiaki Ishikawa
    The American Journal of Gastroenterology 87 12 1863 - 1865 1992年 [査読有り]
     
    Splenic tumors are uncommon. Described is a 58‐yr‐old man with multiple hemangiopericytomas of the spleen. Hemangiopericytoma is categorized as a benign vascular tumor, but has a relatively high malignant potential. A review of the literature shows that the case we present is only the second ever reported of a tumor originating from the spleen. Radiological findings and the treatment of the tumor are discussed. Copyright © 1992, Wiley Blackwell. All rights reserved
  • Hitoshi Tocmo; Syusuke Tomita; Masatoshi Kudo; Jun Mimura; Michio Hamada; Kazushi Minowa; Hiroshi Kashida; Yoshihiro Okabe; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio Todo
    Kanzo 33 10 758 - 765 1992年 [査読有り]
     
    Relationship between arterial vascularity and tumor growth speed was evaluated in 41 hepatocellular carcinomas (HCC). Arterial vascularity of HCCs was classified into 3 patients with US angiography during intraarterial carbon dioxide microbubbles: hypervascular (n=25), isovascular (n=7), and hypovascular (n=9) HCCs. Tumor growth speed was determined by the tumor volume doubling time (TVDT) with measuring by US. The logarithmic mean of the doubling time in hypervascular HCCs was statisticaly more rapid than that in isovascular or hypovascular HCCs (p< 0.05, p< 0.001) respectively. Furthermore, the logarithmic mean of TVDT in isovascular HCCs was more rapid than that in hypovascular HCCs (p< 0.05). We concluded that positive correlation between tumor vascularity and the tumor growth speed was observed, i.e., the more vascular the tumor is, the more rapid the growth speed becomes. © 1992, The Japan Society of Hepatology. All rights reserved.
  • M KUDO; S TOMITA; H TOCHIO; J MIMURA; Y OKABE; H KASHIDA; M HIRASA; Y IBUKI; A TODO
    RADIOLOGY 182 1 155 - 160 1992年01月 [査読有り]
     
    Ultrasonographic (US) angiography enhanced with intraarterial CO2 microbubbles, a contrast material used in US imaging, was performed of 103 histologically proved hepatocellular carcinomas (HCCs) smaller than 3 cm in diameter in 95 patients. The detection rate for hypervascular HCC with US angiography was compared with the rate of detection with conventional angiography, digital subtraction angiography (DSA), and computed tomography (CT) after intraarterial injection of iodized oil. Sensitivity in detection of hypervascular HCCs with US angiography was 86% (89 of 103 HCCs), compared with 63% (44 of 70 HCCs) detected with conventional angiography, 70% (23 of 33 HCCs) with DSA, and 82% (75 of 91 HCCs) with CT with iodized oil. US angiography depicted small hypervascular HCCs, especially those less than 1 cm in diameter, and helped clarify vascularity as isovascular or hypovascular in angiographically undetectable HCCs. Findings at US angiography assisted the choice of a therapeutic strategy for treatment of HCC, such as transarterial therapy, percutaneous ethanol injection therapy, or resection.
  • M KUDO; S TOMITA; H TOCHIO; J MIMURA; Y OKABE; H KASHIDA; M HIRASA; Y IBUKI; A TODO
    AMERICAN JOURNAL OF ROENTGENOLOGY 158 1 65 - 74 1992年01月 [査読有り]
     
    Differential diagnosis of small liver tumors is important, but is not always possible, even with angiography. To solve this problem, we introduced sonographic angiography, which combines sonography and angiography. The vascular pattern of a variety of hepatic nodules was evaluated with sonographic angiography, and the results were compared with those of conventional angiography. Sonographic angiography (sonography performed during intraarterial infusion of carbon dioxide microbubbles) was performed in 184 patients with a total of 222 hepatic nodules: 139 hepatocellular carcinomas, nine adenomatous hyperplasias, seven regenerative nodules, 21 hemangiomas, 33 metastases, seven lymphomas, one granuloma, and five focal nodular hyperplasias. Sonographic angiography detected a hypervascular pattern with peripheral blood supply in cases of hepatocellular carcinoma (sensitivity, 90%; specificity, 89%). Typical vascular patterns of adenomatous hyperplasia, hemangioma, metastasis, and focal nodular hyperplasia on sonographic angiography were hypovascularity (sensitivity, 100%; specificity, 91%), spotty pooling (sensitivity, 100%; specificity, 100%), peripheral hypervascularity (sensitivity, 64%; specificity, 100%), and a central arterial supply (sensitivity, 100%; specificity, 100%), respectively. The detectability of hypervascularity was greater with sonographic angiography than with conventional angiography in hepatocellular carcinoma, metastasis, and hemangioma. Our experience indicates that sonographic angiography depicts characteristic vascular features that reflect the vascular anatomy of specific types of hepatic tumors, and thus is useful in the differential diagnosis of these lesions.
  • Masatoshi Kudo; Akio Todo; Katsuji Ikekubo; Megumu Hino; Yoshiharu Yonekura; Kazutaka Yamamoto; Kanji Torizuka
    Gastroenterologia Japonica 26 6 734 - 741 1991年12月 [査読有り]
     
    Asialoglycoprotein receptor (ASGP-R) is a hepatic cell surface receptor specific for galactose-terminated glycoproteins. Technetium-99m diethylenetriaminepentaacetic acid-galactosyl human serum albumin (TcGSA) is a newly developed analog ligand to ASGP-R. Fourteen human subjects were studied: three normal volunteers, one with chronic hepatitis, 6 with liver cirrhosis, and 4 with hepatocellular carcinoma associated with liver cirrhosis. The receptor index parameter (LHL15), was obtained from the liver and heart time-activity data as the ratio of radioactivity of the liver over that of the liver plus heart at 15 min after intravenous injection of 1 mg of TcGSA. Means±standard deviations of LHL15 in normal volunteers (3 cases), patients with mild (4 cases), moderate (2 cases), and severe liver damage (5 cases) were 0.933±0.006, 0.789±0.045, 0.723±0.033, and 0.488±0.094, respectively. The difference between the mean values of each group was statistically significant (P< 0.05). LHL15 correlated well with classical indicators for hepatic functional capacity such as serum albumin level, serum bilirubin level, prothrombin time, ICG R15 or Child-Turcotte criteria score. Our preliminary experiences of high correlations of TcGSA functional imaging data with clinical data suggest that the dynamic data using this receptor-binding radiopharmaceutical provides invaluable information with regard to liver function, and thus, the TcGSA study is potentially a noninvasive practical tool to measure functioning hepatocyte mass. © 1991 The Japanese Society of Gastroenterology.
  • M KUDO; S TOMITA; H TOCHIO; H KASHIDA; M HIRASA; A TODO
    RADIOLOGY 179 2 377 - 382 1991年05月 [査読有り]
     
    Dynamic contrast material-enhanced ultrasonography (US) with intraarterial infusion of carbon dioxide microbubbles was performed for four cases of histologically proved focal nodular hyperplasia (FNH) in four patients and for 167 cases of various hepatic nodules in 144 patients. No complications due to dynamic US were observed in any of the 148 patients. All FNH nodules were less than 3 cm in diameter. Consistent specific findings of FNH were not obtained with US, computed tomography, magnetic resonance imaging, radiocolloid scanning, or angiography in the four cases of FNH. In contrast, the characteristic vascular pattern (ie, early central hypervascular supply with centrifugal filling to the periphery at the arterial phase and a uniform or lobulated dense stain at the capillary phase) was observed in all four cases of FNH with dynamic US. This vascular pattern demonstrated in FNH with dynamic US was not seen in any of the 167 hepatic nodules, including 44 small hepatocellular carcinomas less than 3 cm in diameter. Therefore, the newly developed, dynamic contrast-enhanced US technique seems to be extremely sensitive and specific for diagnosing FNH and is useful in the differentiation of FNH from other hepatic tumors, especially hepatocellular carcinoma.
  • Yasuyoshi Ibuki; Masahiro Hirasa; Masatoshi Kudo; Akio Orino; Akio Todo
    GASTROENTEROLOGICAL ENDOSCOPY 33 11 2394 - 2401 1991年 [査読有り]
     
    We reviewed 142 endoscopic sphincterotomies (EST). The indications (Table 1) included common bile duct stones (78.9%), placing catheters or endoprostheses in patients with malingant stricture of the bile duct (13.4%), papillary stenosis, chronic pancreatitis, and miscellaneous (biopsy, and peroral choledocho-pancreatoscopy). Early complications (Table 2) occurred in 13 patients (9.2%) : hemorrhage in 7, pancreatitis in 4, perforation in 1 and pneumoretroperitoneum in 1. No patients died. Two patients (1.4%) required operation for complications. All patients with hemorrhage following EST (Table 3) were elderly (age > 70, mean 82.7) including 3 patients with no symptoms. All the patients were treated conservatively. Their hemoglobin values reached the bottom 6 to 14 (mean 8.5) days after EST. Five patients did not bleed during EST but bled later. These findings suggest that late bleeding or continuous hemorrhage can occur after EST. Therefore, periodical follow-up of hemoglobin values are important for early detectin of late or continuous bleeding following EST. Perforation of the common bile duct occurred in 1 patient who required surgery, although some reports have suggested that most perforations can be managed conservatively with providing drainage of the bile duct by ensuring adequate sphincterotomy, inserting a pernasal catheter or a biliary stent where appropriate. Precut papillotomy was performed in 6 patients. Two patients developed pancreatitis (Table 4) and three developed hyperamylasemia. The incidences of pancreatitis and hyperamylasemia in patients with precut procedure were much higher than those in patients without percut procedure. Therefore it was concluded that precut procedure should be avoided whenever possible. © 1991, Japan Gastroenterological Endoscopy Society. All rights reserved.
  • Masatoshi Kudo; Shusuke Tomita; Hitoshi TocfflO; Mitsuo Hamada; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio Todo
    Kanzo 32 11 1008 - 1016 1991年 [査読有り]
     
    In this report the arterial vascularity within the nodule in small hepatocellular carcinoma (HCC) was evaluated in comparison with histopathological study. For this goal, dynamic contrast-enhanced ultrasonography with intraarterial CO2 microbubbles infusion (US angiography) was performed on 39 patients with surgically resected 44 small HCCs smaller than 3 cm in diameter. The results are as follows: 1) Out of 44 HCCs, 35 were demonstrated as hypervascular, 5 as isovascular, 3 as vascular spot in hypovascular, and 1 as hypovascular. 2) Out of 11 HCCs, which were pathologically classified into Grade I on Edmondson-Steiner scale, 4 were demonstrated as isovascular, 6 were demonstrated as hypervascular, and 1 were demonstrated as hypovascular. 3) Almost all Grade II-III HCCs (29/30) were demonstrated as hypervascular. 4) Out of 13 angiographically undetected HCCs, 4 were isovascular nodules, 3 were hypovascular nodules including vascular lesions, 5 were hypervascular nodules, and 1 was hypovascular nodule. 5) Out of 13 angiographically undetected HCCs, 9 nodules including 2 hypervascular nodules were nonencapusulated HCCs on pathological study of the resected specimen. 6) Sensitivity in demonstrating hypervascularity of the HCC improved to 80% (35/44) by the use of US angiography, compared to 70% (31/44) with conventional angiography or 73% (30/41) with Lipiodol CT. Moreover, sensitivity in evaluating tumor vascularity with US angiography was 100% (44/44). Our conclusions based on these results are as follow: 1) All HCCs except one have arterial vascularity within the tumor. 2) Half of well-differentiated HCC exhibited isovascualr or hypovascular, suggesting immature neovascularization within the tumor. 3) Tumors undetected with angiography or Lipiodol CT are isovascular, non-encapsulated, or considerably small HCCs. 4) US angiography is sensitive in the detection of arterial vascularity within the HCC nodules, and hence, contributory to the diagnosis of small HCCs. © 1991, The Japan Society of Hepatology. All rights reserved.
  • Masatoshi Kudo; Akio Todo
    Nippon Shokakibyo Gakkai Zasshi 88 1 40 - 50 1991年 [査読有り]
     
    [Tc-99m] Galactosyl-neoglycoalbumin (TcNGA) is a synthetic radiolabeled ligand specific to the hepatocyte receptor, hepatic binding protein (HBP), a specific receptor to serum asialoglycoprotein. A TcNGA study was performed on 34 humans: normal volunteers (7), chronic hepatitis (6), hepatic cirrhosis (8), and hepatocellular carcinoma superimposed on cirrhosis (13). Heart and liver time activity curves were obtained following intravenous injection of TcNGA (5 mCi, 1.82 × 10–9 mol/kg). HBP concentration ([HBP]) was calculated by curve-fitting techniques using the nonlinear three compartment model, which includes bimolecular reaction between HBP and TcNGA. [HBP] values were compared with conventional liver function tests. [HBP] had a good correlation with prothrombin time (n=34, r=0.694, p=0.0001) thrombotest (n=34, r=0.692, p=0.0001), hepaplastin test (n=26, r=0.787, p=0.0001), albumin (n=34, r=0.712, p=0.0001), cholinesterase (n=34, r=0.801, p=0.0001), ICGR15 (n=33, r=—0.761, p=0.0001), KICG (n=30, r=0.709, p=0.0001), ICG Rmax (n=12, r=0.735, p=0.0064) and Child-Turcotte classification score (n=34, r=—0.819, p=0.0001). We concluded that excellent correlations of [HBP] to conventional liver function tests suggest that in vivo receptor measurement via TcNGA kinetic analysis is a sensitive and promissing method in the estimation of hepatic functional reserve in patients with chronic liver disease. © 1991, The Japanese Society of Gastroenterology. All rights reserved.
  • Masatoshi Kudo; Shusuke Tomita; Hiroshi Kashida; Jun Mimura; Yoshihiro Okabe; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio Todo
    Nippon Shokakibyo Gakkai Zasshi 88 8 1554 - 1565 1991年 [査読有り]
     
    Tumor hemodynamics including arterial vascularity (AV) and portal perfusion (PP) were evaluated in histologically confirmed 55 hepatic nodules associated with cirrhosis using ultrasonographic (US) angiography during intraaterial carbon dioxide microbubbles injection and CT during arterial portography. Tumor hemodynamic patterns were classified into 6 types as follows: Type I (n=10): PP (+), AV (hypo) Type I' (n=2): PP (+), AV (iso) Type II (n=5): PP (-), AV (hypo) Type III (n=8): PP (-), AV (iso) Type IV (n=25): PP (-), AV (hyper), Type V (n=5): PP (partially +), AV (vascular spot in hypovascular). Eight nodules of Type I were diagnosed as benign nodules histologically including adenomatous hyperplasia (AH) (n=6) and regenerative nodule (n=2). Hundred percent (5/5) of Type II and 88% (7/8) of Type III nodules were well-differentiated HCC, in contrast to 8% (2/25) of Type IV nodules, typical HCCs. Fatty metamorphosis was observed in 75% (6/8) of Type III nodules, in contrast to 16% (4/25) of typical (classical) HCC nodules (Type IV). We concluded that at the malignant transformation from AH to HCC, reduction of portal blood flow in the nodule precedes the initiation of the increase of the arterial tumor vessel. Moreover, early stage HCC could exhibit hypovascular (Type I, II), isovascular (Type III), or vascular spot in hypovascular pattern (Type V) compared with a typical HCC (Type IV). It was also suggested that the more mature as a neoplams the HCC becomes, the more the arterial tumor vessel in the nodule increases and fatty metamorphosis of well-differentiated HCC is highly related with tumor hemodynamic condition, i.e., hypoperfusion state from both arterial and portal vessel. © 1991, The Japanese Society of Gastroenterology. All rights reserved.
  • Masatoshi Kudo; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Shusuke Tomita; Hideshi Komori; Akio Orino; Akio Todo; Hiroshi Takakuwa; Tomohiko Tani; Toshitaka Okuno; Tatehiro Kajiwara; Hirobumi Shirane
    Kanzo 31 12 1439 - 1445 1990年 [査読有り]
     
    A 72-year-old female was admitted to our hospital with complaints of general malaise, appetite loss, nausea, and vomiting in January, 1984. CT showed large tumor in the right lobe. Ultrasound revealed large tumor in the right lobe, tumor thrombi in the right main branch of the portal vein, and ascites. A sign of mild hepatic encephalopathy was also observed. Serum α-fetoprotein level was 25118 ng/ml. Angiography revealed multiple small hypervascular nodules in the right lobe and extremely extended arterio-portal shunting (A-P shunt), which is consistent with the diagnosis of hepatocellular carcinoma (HCC). The tumor and A-P shunt drastically disappeared on US, CT, colloid liver scan, and angiography a few months after the injection of 10 mg of mitomycine C through the common hepatic artery. Five years and 9 months after one shot arterial infusion chemotherapy, the recurred HCC, measuring 1.9 cm in size was treated with the second arterial infusion chemotherapy combined with lipiodol followed by a right lobectomy. The histopathology showed total necrosis of HCC, multiple organization and fibrosis in the right lobe, and thickened organized lesion with fibrosis within the portal vein. This case is considered to be rare since stage IV HCC responded extremely well to the single arterial infusion chemotherapy as well as the scars of HCC lesion and tumor thrombi in the portal vein were recognized pathologically more than 5 years later. © 1990, The Japan Society of Hepatology. All rights reserved.
  • Tatehiro Kajiwara; Masatoshi Kudo; Shusuke Tomita; Hiroshi Kashida; Jun Mimura; Yoshihiro Okabe; Masahiro Hirasa; Akio Todo; Tomohiko Tani
    Nippon Shokakibyo Gakkai Zasshi 87 12 2691  1990年 [査読有り]
  • Masatoshi Kudo; David R. Vera; Robert C. Stadalnik; Walter L. Trudeau; Katsuji Ikekubo; Akio Todo
    The American Journal of Gastroenterology 85 9 1142 - 1148 1990年 [査読有り]
     
    Hepatic binding protein (HBP) is a hepatic cell surface receptor specific for asialoglycoprotein. In vivo estimates of HBP concentration (IHBPJ) were compared to classical indicators for hepatic functional reserve to clarify the validity of ([HBP]) in estimating the hepatic functional reserve in 30 humans. Estimates of [HBP] were obtained based on kinetic analysis of liver and blood time‐activity data resulting from the hepatic clearance of a single injection of technetium–99m galactosyl‐neoglycoalbumin, which is a synthetic analog radioligand specific to HBP. Estimates of [HBP] ranged 0.054 to 0.720 μM. Estimates of [HBP] in normal volunteers were 0.668 ± 0.050 MM, whereas that in liver cirrhosis were 0.188 ± 0.112 μM. The difference between the mean values of |HBP] estimates was statistically significant (p ‐ 0.0001). Good correlations were observed between [HBP] and prothrombin time (r = 0.625, p ‐ 0.0002), serum albumin level (r = 0.687, p = 0.0001). serum cholinesterase level (r = 0.764, p = 0.0001), indocyanine green plasma disappearance rate (r = 0.602, p = 0.0024), and Child‐Turcotte classification score (Pugh's modification) (r =–0.797, p = 0.0001). We concluded that excellent correlations of |HBP| with classical indicators for hepatic functional reserve suggest potential value of [HBP] as a sensitive measure of functioning hepatocyte mass. Copyright © 1990, Wiley Blackwell. All rights reserved
  • M KUDO; K IKEKUBO; K YAMAMOTO; M HINO; Y IBUKI; S TOMITA; H KOMORI; A ORINO; A TODO
    AMERICAN JOURNAL OF GASTROENTEROLOGY 84 8 948 - 952 1989年08月 [査読有り]
  • M KUDO; K IKEKUBO; K YAMAMOTO; Y IBUKI; M HINO; S TOMITA; H KOMORI; A ORINO; A TODO
    AMERICAN JOURNAL OF ROENTGENOLOGY 152 5 977 - 983 1989年05月 [査読有り]
  • Yasuyoshi Ibuki; Yoshihiro Okabe; Toshihiko Fukui; Hiroshi Kashida; Masahiro Hirasa; Masatoshi Kudo; Katsuhiko Fujimi; Shusuke Tomita; Hideshi Komori; Akio Orino; Akio Toro
    GASTROENTEROLOGICAL ENDOSCOPY 30 1 94 - 1 1988年 [査読有り]
     
    Using the relaxing effect of nitrate on the smooth muscle of the Oddi's sphincter, we were able to eliminate stones in four patients with common bile duct stones without endoscopic sphincterotomy (EST). This method employs intravenous injections of nitrate and uses a basket catheter endoscopically inserted into the bile duct to grasp the stone. Removal of the stone can also be accomplished by endoscopically inserting a balloon catheter into the bile duct and pulling out the stone with the catheter. There was no evidence of adverse side effects such as lowered blood pressure excessively. This method was used on a small stone in the bile duct, but is especially useful in cases where EST is contraindicated or inappropriate. The application of this method is also beneficial when catheter insertion is difficult due to strong tension of the Oddi's sphincter during ERCP or EST. © 1988, Japan Gastroenterological Endoscopy Society. All rights reserved.
  • M. Kudo; Y. Ibuki; K. Fujimi; S. Tomita; H. Komori; A. Orino; A. Todo; M. Hino; K. Ikekubo
    Japanese Journal of Clinical Radiology 32 8 901 - 908 1987年 [査読有り]
     
    Clinical necessity of liver scintigram in diagnosing hepatocellular carcinomas (HCCs) were evaluated in 383 patients with HCCs including 40 patients with a total of 50 small HCCs (less than 5 cm in diameter). Liver scintigram including SPECT is considered to be absolutely necessary in 2% (6/383) of patients with HCC and relatively necessary in 7% (25/383) of patients with HCC. The cases categorized into these 2 groups had 2 specific features of HCC one which showed macroscopically infiltrative type and another which were located in the subdiaphragmatic portion of the liver. In conclusion, liver scintigram is still necessary especially in these cases for the diagnosis of HCC.
  • Masatoshi Kudo; Akio Todo; Toshihiko Fukui; Hiroshi Kashida; Yasuyoshi Ibuki; Katsuhiko Fujimi; Shusuke Tomita; Hideshi Komori; Akio Orino; Katsuji Ikekubo; David R. Vera; Robert C. Stadalnik
    Kanzo 28 10 1277 - 1286 1987年 [査読有り]
     
    Asialoglycoprortecien pto(rA SGPR)r esideast t hec elslu rfacoef h epatocytewsh,e rei tr ecognizes and binds galactose-terminatgeldy coproteinAs.f ter binding,t he ligand-receptcoor mplex is transported to hepaticl ysozomesw here the ligandi s catabolizedA.l terationo f ASGPR binding has been demonstrated in variousp athologicc onditionso f the liver. Tc-99m-Galactosyl-Neoglycoalbum(iTnc -99m-NGA) is a newly developeda nalog ligando f galactose-terminategdl ycoproteinsW.e evaluatedc linicault ilitoyf Tc-99m-NGA in estimatingh epatic functionalr eServei n 23 clinicacla ses. NGA ReceptorI ndex,w hich isg iven by the radioactivitoyf the liverd ividedb y that of the liver plush earta t 30 min afteri ntravenousi njectioonf Tc-99m-NGA, was decidedt o be a preliminariy ndex of liverf unctionp rovidedb y NGA studiesi n thisr eport-Apositivceo rrelatiowna s observedb etween NGA ReceptorI ndex and CholinesteraseH,e paplastint est,T hrombotest,P rothrombin time and KICG. A negativec orrelatiowna s observed between NGA Receptor Index and ICG R15 and Child- Turcotte CriteriaS core. Analysis of the NGA dynamic curye is a promising method for the estimation of the heaptic functionalr eserve,a s the dynamic curves correlatteo the Asialogycoproteirne ceptorc oncentration. © 1987, The Japan Society of Hepatology. All rights reserved.
  • M KUDO; M HIRASA; H TAKAKUWA; Y IBUKI; K FUJIMI; M MIYAMURA; S TOMITA; H KOMORI; A TODO; Y KITAURA; K IKEKUBO; K TORIZUKA
    RADIOLOGY 159 3 697 - 703 1986年06月 [査読有り]
  • Masatoshi Kudo; Masahiro Hirasa; Hiroshi Takakuwa; Yasuyoshi Ibuki; Katsuhiko Fujimi; Masami Miyamura; Shusuke Tomita; Hideshi Komori; Akio Todo
    GASTROENTEROLOGICAL ENDOSCOPY 28 2 318 - 325 1986年 [査読有り]
     
    A 76-year-old male was admitted to our hospital complaining of dysphagia. A barium swallow examination of the esophagus showed a smooth surfaced, soft, 2cm-sized protruded lesion in the upper portion of the esophagus (Figure 1). Esophagoscopy with a fiberoptic endoscope revealed a blue-red colored, pedunculated submucosal tumor 20cm from the incisers (Figure 3 and 4). When pushed with biopsy forceps, the tumor easily indented, suggesting a vascular lesion. Dynamic CT scan with bolus infusion of contrast medium also suggested a vascular tumor in the esophagus (Figure 6). Endoscopic polypectomy was successfully performed following injection of 3.4 ml of ethanol into the stalk of the tumor in order to prevent massive bleeding. No bleeding was observed and the excised specimen measured 2.2X1.2X0.9 cm (Figure 9 and 10). Histologically, the tumor was a capillary hemangioma, which is very rare (Figure 11). Twenty-five cases of esophageal hemangioma have so far been reported in Japan and endoscopic polypectomy was performed in only 4 (including our case) of 25 cases. © 1986, Japan Gastroenterological Endoscopy Society. All rights reserved.
  • Hideshi Komori; Masahiro Hirasa; Hiroshi Takakuwa; Yasuyoshi Ibuki; Masatoshi Kudo; Katsuhiko Fujimi; Masami Miyamura; Shusuke Tomita; Akio Todo
    The American Journal of Gastroenterology 81 7 544 - 549 1986年 [査読有り]
     
    Serial medical diagnostic imagings were performed on 15 patients with acute hepatic failure to compare liver size and clinical picture. In patients showing hepatatrophy at the onset of coma, the interval between the onsets of disease and coma was long, ascites and edema supervened, high total bilirubin and low glutamic pyrubic transaminase levels tended to he found, and prothrombin time did not respond to treatment. All of these patients died. Based on liver size changes in patients who survived acute hepatic failure, acute hepatic failure was assumed to he classified into swelling, reduction, and recovery stages. The shorter the interval between the onsets of disease and coma, the earlier coma and prolonged prothrombin time occurred before hepatatrophy. In acute hepatic failure, signs of hepatic failure develop with various histological pictures and it is very important to institute the treatment before the liver is atrophied. Copyright © 1986, Wiley Blackwell. All rights reserved
  • 伊吹 康良; 平佐 昌弘; 高鍬 博; 工藤 正俊; 藤見 勝彦; 上田 俊二; 宮村 正美; 冨田 周介; 小森 英司; 藤堂 彰男; 北浦 保智
    日本消化機病學會雜誌. 乙 82 5 1406 - 1411 The Japanese Society of Gastroenterology 1985年
  • M. Senda; N. Tamaki; K. Torizuka; Y. Fujiwara; M. Kudo; H. Tochio; H. Ito; H. Yamaguchi; Y. Saiki; K. Ikekubo
    Clinical Nuclear Medicine 10 1 9 - 12 1985年 [査読有り]
  • Yasuyoshi Ibuki; Masahiro Hirasa; Hiroshi Takakuwa; Masatoshi Kudo; Katsuhiko Fujimi; Shunji Ueda; Masami Miyamura; Shusuke Tomita; Hideshi Komori; Akio Todo; Yasutomo Kitaura
    GASTROENTEROLOGICAL ENDOSCOPY 27 4 474 - 487 1985年 [査読有り]
     
    In order to evaluate the effect and limitation of endoscopic hemostatic treatments, 422 patients with hemorrhagic gastric and duodenal ulcers admitted to our hospital before (Jan. 1978∼Jul. 1981) and after (Aug. 1981∼Jun. 1984) adopting these treatments were studied. Endoscopic treatments including bipolar electrocoagulation, local injection of hypertonic saline epinephrine solution and local injection of pure ethanol were applied to 68 patients with arterial bleeding or with exposed vessels. 1) Severe hemorrhage was more frequent in those with exposed vessels than in those without exposed vessels (Figure 1, 2, 3). 2) In hemorrhagic gastric and duodenal ulcers with exposed vessels the effective rates of H2-receptor antagonist were 51.1% and 75.0%, respectively. Endoscopic treatments were effective in 91.5% and 100%, respectively (Figure 4). 3) In hemorrhagic gastric and duodenal ulcers without exposed vessels the effective rates of H2-receptor antagonist were 96.7% and 98.5%, respectively. 4) The rates of emergency operation decreased after adopting endoscopic treatments. In hemorrhagic gastric ulcer the rate of emergency operation significantly decreased from 23.7% to 3.7%. In hemorrhagic duodenal ulcer it decreased from 7.4% to 2.4% (Figure 5). 5) Endoscopic treatments were also applied to patients with critical complications who had no operative indication. The re-bleeding rate for these patients was higher than those without serious complications. © 1985, Japan Gastroenterological Endoscopy Society. All rights reserved.
  • Masatoshi Kudo; Masahiro Hirasa; Hiroshi Takakuwa; Yasushi Ibuki; Katsuhiko FujiMi; Shunji Ueda; Shuhsuke Tomita; Hideshi Komori; Akio Todo; Yasutomo Kitaura; Mamoru Sato; Hiroya Uchida
    Kanzo 25 12 1605 - 1611 1984年 [査読有り]
     
    A 71-year-old male was admitted with complaints of subcutaneous purpura and right hypochondrial pain. He had an episode of being injected with Thorotrast for his war wound in 1939. Intraperitoneal bleeding and disseminated intravascular coagulopathy (DIC) were seen on admission. Abdominal ultrasonography (US), computed tomography (CT), liver scintigraphy and right heaptic arteriography revealed two tumors in the liver, one is in the right lobe and the other is in the medial segment of the left lobe. The finding of US shows a mesh-like or honeycomb-like pattern and the angiogram shows a cotton wool like appearance in the capillary phase, which is consistent with cavernous hemangioma. A right hepatectomy was performed and the histological findings of the resected tumor found it to be hemangiosarcoma of the liver, which is very rare. Our reported case is considered to be the first case in Japan, in which Kasabach-Merritt syndrome occurred based on hemangiosarcoma of the liver. © 1984, The Japan Society of Hepatology. All rights reserved.
  • Hideshi Komori; Masahiro Hirasa; Yasuyoshi Ibuki; Hiroshi Takakuwa; Masatoshi Kudo; Katsuhiko Fujimi; Shunji Ueda; Shusuke Tomita; Akio Todo; Yasutomo Kitaura
    GASTROENTEROLOGICAL ENDOSCOPY 26 5 711 - 720 1984年 [査読有り]
     
    Liver scintigraphy, computed tomography (CT) and ultrasonography were performed in 70 patients with acute hepatitis of acute phase, and these findings were compared with the clinical severity and laparoscopic findings in recovered stage. Cases with severe necrotic lesions of the liver on laparoscopy showed severe clinical courses, however, not vice versa. The low-uptake of the liver on scintigraphy were seen in 3 cases and was related to clinical severity and massive hepatic necrosis. The heterogenous RI distribution of the liver and splenomegaly were showen in most cases of A-type and were related to rapid clinical deterioration. Two cases with the finding of a localized low density area of the liver in CT and irregular echo pattern in sonography showed severe massive necrotic lesions on laparoscopy. Scintigraphy, computed tomography and sonography are valuable in the evaluation of acute hepatic failure in patients with acute hepatitis. © 1984, Japan Gastroenterological Endoscopy Society. All rights reserved.
  • 小森 英司; 平佐 昌弘; 伊吹 康良; 工藤 正俊; 藤見 勝彦; 上田 俊二; 冨田 周介; 沖本 芳春; 藤堂 彰男; 北浦 保智
    肝臓 24 8 860 - 869 The Japan Society of Hepatology 1983年 
    重症肝炎の画像診断とその経過観察より以下の結果を得た.肝シンチでは肝のRI集積の低下,脾,骨髄像の出現が肝不全に関連したが,急性肝不全の肝シンチ所見は様々であり,生存例の経過観察では一旦縮小した後に腫大した.慢性肝炎の劇症化例では,その半数に左葉腫大を認めた.CTにて限局性低吸収域を認めるのは亜急性肝炎であり,急性肝不全ではDIC合併例においてのみ出現し,前者の低吸収域は組織学的に広汎な壊死に相当した.これらの例では超音波検査にても不均一ないし斑状肝実質エコーパターンを呈した.重症肝炎の超音波検査にて全例に肝静脈の狭少化ないし不明瞭化を認め,生存例ではその回復が認められた.重症肝炎のCT所見での低吸収域は肝静脈周辺を中心として出現するが,肝壊死の進展に二次的肝虚血が関与していると考えられる.
  • Hideshi Komori; Masatoshi Kudo; Katsuhiko Fujimi; Shusuke Tomita; Yoshihiko Endo; Okimoto Yoshiharu; Akio Todo; Yasutomo Kitaura; Hiroya Uchida
    Nippon Shokakibyo Gakkai Zasshi 78 12 2384 - 2394 1981年 [査読有り]
     
    In 4 of 6 patients survived from acute hepatic failure showed histological findings similar to chronic hepatitis. One of these 4 patients was considered to be acute hepatic failure based on chronic hepatitis. The re-rise of transminase activities was recognized on recovering stage in the remaining 3 cases. These 3 patients were supposedly developed post transfusion hepatitis following blood exchange transfusion for the treatment of acute hepatic failure. According to the survey of literature in the last five years, 44% of 76 patients survived from acute hepatic failure showed histological findings of portal inflammation and 51% of the cases revealed re-rise of serum transaminase during the long term follow up studies. When histological findings similar to chronic hepatitis are seen in the case recovering from acute hepatic failure, we must take into consideration of possibilities that acute hepatic failure based on chronic hepatitis, post transfusion hepatitis following blood exchange transfusion for the treatment of acute hepatic failure or residual histological reaction in recovering stage of acute hepatic failure. © 1981, The Japanese Society of Gastroenterology. All rights reserved.
  • A Randomised Phase 3 Trial of Lenvatinib vs. Sorafenib in First-line Treatment of Patients With Unresectable Hepatocellular Carcinoma
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron AD; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
    Lancet in press [査読有り]

書籍

  • アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療
    小川 力; 福家和諭; 真鍋卓嗣; 柴峠光成; 工藤正俊 (担当:分担執筆範囲:Wnt/βカテニン変異の症例に対するアテゾリズマブ・ベバシズマブ併用療法の使用経験)アークメディア 2021年09月
  • アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療
    工藤正俊 (担当:分担執筆範囲:アテゾリズマブ・ベバシズマブ併用療法の登場による肝細胞癌治療の今後の展開)アークメディア 2021年09月
  • アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療
    青木智子; 上嶋一臣; 工藤正俊 (担当:分担執筆範囲:アテゾリズマブ・ベバシズマブ併用療法のpatient reported outcomes)アークメディア 2021年09月
  • アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療
    工藤正俊 (担当:分担執筆範囲:抗VEGF抗体の役割.)アークメディア 2021年09月
  • アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療
    工藤正俊; 池田公史; 森口理久; 小笠原定久; 光冨徹哉; 平岡 淳 (担当:分担執筆範囲:特別座談会; アテゾリズマブ・ベバシズマブ併用療法により肝癌治療はどう変わるのか.)アークメディア 2021年09月
  • アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療
    工藤正俊 (担当:監修範囲:)アークメディア 2021年09月
  • ラムシルマブによる肝細胞癌治療
    小川 力, 筒井朱美, 永野拓也, 高口浩一, 谷 丈二, 森下朝洋, 正木 勉, 守屋昭男, 出口章広,工藤正俊 (担当:範囲:香川県下におけるラムシルマブの初期使用経験、pp211-215)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    上嶋一臣,工藤正俊 (担当:範囲:肝細胞癌におけるラムシルマブの有害事象とその対策、pp124-129)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    小川 力,工藤正俊 (担当:範囲:レンバチニブの二次治療としてラムシルマブは効果が期待できるか、pp119-123)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    工藤正俊 (担当:範囲:TKIと抗体薬の作用機序の違いはラムシルマブ治療においてどのようなインパクトが期待できるか、pp101-110)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    工藤正俊 (担当:範囲:AFPは予後予測因子か予後規定因子か、pp95-100, 2020)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    南 康範,工藤正俊 (担当:範囲:日本人に対するラムシルマブの有効性と安全性, pp78-81)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    青木智子, 上嶋一臣, 工藤正俊 (担当:範囲:REACH (AFP >400ng/mL)とREACH-2のデータの違いの解釈, pp64-70)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    工藤正俊 (担当:監修範囲:)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    工藤正俊, 室 圭, 池田公史, 森口理久, 上嶋一臣, 小笠原定久 (担当:範囲:特別座談会; 肝細胞癌治療の新たな選択肢ラムシルマブを徹底解剖する)アークメディア, 東京 2020年
  • ラムシルマブによる肝細胞癌治療
    工藤正俊 (担当:共著範囲:序文)アークメディア, 東京 2020年
  • 大腸癌に対するレゴラフェニブ治療
    工藤正俊; 山口研成; 吉野孝之; 沖 英次; 室 圭 (担当:共著範囲:特別座談会「レゴラフェニブの軌跡（奇跡）」)アークメディア, 東京 2019年03月 pp11-29
  • 消化器疾患 最新の治療2019-2020
    工藤正俊 (担当:共著範囲:肝細胞癌に対する分子標的治療 pp29-34)南江堂 2019年03月
  • 総監修: レンバチニブによる肝細胞癌治療
    工藤正俊 アークメディア, 東京 2019年
  • 工藤, 正俊 医学書院 2018年11月 ISBN: 9784260035972 xvii, 461p
  • 工藤, 正俊 アークメディア 2017年12月 ISBN: 9784875832287 215p
  • 矢崎, 義雄; 赤司, 浩一(大学教員); 渥美, 達也; 伊藤, 裕; 稲垣, 暢也; 神田, 隆; 木下, 芳一; 工藤, 正俊; 小室, 一成; 須永, 真司; 南学, 正臣; 長谷川, 好規; 松本, 哲哉; 楽木, 宏実 朝倉書店 2017年03月 ISBN: 9784254322705 46, 2385, 36, 61p
  • ソラフェニブ・レゴラフェニブsequential療法の可能性
    工藤正俊 肝細胞癌に対するレゴラフェニブ治療, アークメディア, 東京 2017年 100-107
  • レゴラフェニブの第III相試験の経験症例からわかること-市販後経験例も含めて-
    上嶋一臣; 工藤正俊 肝細胞癌に対するレゴラフェニブ治療, アークメディア, 東京 2017年 77-85
  • 特別座談会「レゴラフェニブの登場により肝細胞癌治療のパラダイムはどう変わるのか」
    工藤正俊; 吉野孝之; 黒崎雅之; 山下竜也; 森口理久 (担当:範囲:序文)肝細胞癌に対するレゴラフェニブ治療, アークメディア, 東京 2017年 15-40
  • 監修: 肝細胞癌に対するレゴラフェニブ治療
    工藤正俊 アークメディア, 東京 2017年
  • IgG4-related disease and innate immunity. In “IgG4-Related Disease”, Curr Top Microbiol Immunol, Okazaki K, ed
    Watanabe T; Yamashita K; Kudo M (担当:共著範囲:Vol. 401, pp115-128)Springer 2017年
  • 異所性静脈瘤の診断と内視鏡治療
    松井繁長; 工藤正俊 (担当:範囲:門脈圧亢進症診療マニュアル)日本門脈圧亢進症学会編集, 南江堂, 東京 2015年11月 177 87-92
  • 工藤, 正俊 最新医学社 2015年04月 194p
  • 肝膿瘍・肝嚢胞
    工藤正俊 内科学第11版, 朝倉書店 2015年 1120-1122
  • 肝腫瘍
    工藤正俊 内科学第11版, 朝倉書店 2015年 1108-1119
  • 肝癌診療Q&A, 進行肝癌治療： Q67ソラフェニブの効果が期待できる肝細胞癌を事前に把握できますか？
    上嶋 一臣; 工藤 正俊 (担当:共著範囲:)中外医学社 2013年10月
  • 専門医のための消化器病学（第2版）, 膵管非癒合
    井上 達夫; 工藤 正俊 (担当:共著範囲:)2013年10月
  • 検査診断学への展望―臨床検査指針: 測定データ判読のポイント―, 肝癌のエコー検査の進め方と判読時のポイント. 「生理検査領域」
    井上 達夫; 工藤 正俊 (担当:共著範囲:)南江堂, 東京 2013年06月 
    監修 第62回日本医学検査学会記念誌編集委員会, 編集 野村 努, 正田孝明, 横田浩充, 香川県臨床検査技師会編集委員会
  • 工藤, 正俊; 國分, 茂博 医学書院 2013年06月 ISBN: 9784260017343 xxi, 338p
  • 今日の治療指針2011年版-私はこう治療している 医学書院, 東京, 原発性・転移性肝腫瘍（内科）.
    工藤 正俊 (担当:共著範囲:)2011年
  • 血管新生阻害薬のベストマネジメント 癌治療と副作用対策, 肝細胞癌（hepatocellular carcinoma）.
    上嶋 一臣; 工藤 正俊 (担当:共著範囲:)金原出版, 東京 2011年
  • 新時代のウイルス性肝炎学, B型肝癌根治後の再発抑制治療と有用性.
    萩原 智; 工藤 正俊 (担当:共著範囲:)日本臨牀, 大阪 2011年
  • 新時代のウイルス性肝炎学, C型肝癌根治後の再発抑制治療と有用性.
    上田 泰輔; 鄭 浩柄; 工藤 正俊 (担当:共著範囲:)日本臨牀, 大阪 2011年
  • 臨床薬理学第3版, 肝がん治療薬.
    工藤 正俊 (担当:共著範囲:)医学書院, 東京 2011年
  • 臨床薬理学第3版, 肝不全治療薬.
    工藤 正俊 (担当:共著範囲:)医学書院, 東京 2011年
  • 臨床薬理学第3版, 肝炎治療薬.
    工藤 正俊 (担当:共著範囲:)医学書院, 東京 2011年
  • Plvs vltre ESD!さらなる挑戦 消化管ESDの課題と展望, 胃ESD後の後出血例の臨床的特徴と予防対策.
    朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊 (担当:共著範囲:)診断と治療社, 東京 2011年
  • ガイドライン/ガイダンス-こう診る・こう考える慢性肝炎, 肝癌診療サーベイランスアルゴリズムについて.
    工藤 正俊 (担当:共著範囲:)日本医事新報社, 東京 2011年
  • 工藤, 正俊; 山雄, 健次 羊土社 2010年10月 ISBN: 9784758110426 286p
  • 幕内, 雅敏; 菅野, 健太郎; 工藤, 正俊 医学書院 2010年03月 ISBN: 9784260007986 24, 1050p
  • 肝疾患Review 2010～2011 日本メディカルセンター, 東京, 肝細胞癌の画像診断の最新の進歩. 第1部 Overview 肝癌の診断・治療
    工藤 正俊 (担当:共著範囲:)2010年
  • 肝疾患Review 2010～2011 日本メディカルセンター, 東京, 日本の肝細胞癌診療: コンセンサスミーティングの結果をふまえた最新の話題. 第1部 Overview 肝癌の診断・治療
    工藤 正俊 (担当:共著範囲:)2010年
  • 肝疾患Review 2010～2011 日本メディカルセンター, 東京, 肝細胞癌に対する分子標的治療. 第1部 Overview 肝癌の診断・治療
    工藤 正俊 (担当:共著範囲:)2010年
  • 肝疾患Review 2010～2011 日本メディカルセンター, 東京, ソラフェニブによる進行肝癌の治療. 第2部 トピックス 肝癌の診断・治療
    上嶋 一臣; 工藤 正俊 (担当:共著範囲:)2010年
  • 見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス, 早期肝細胞癌.
    井上 達夫; 工藤 正俊 (担当:共著範囲:)羊土社, 東京 2010年
  • 見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス, 肝癌.
    工藤 正俊 (担当:単著範囲:)羊土社, 東京 2010年
  • 見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス, 序.
    工藤 正俊 (担当:単著範囲:)羊土社, 東京 2010年
  • WHO Classification of Tumours of the Digestive System (Blue Book), Hepatocellular carcinoma.
    Neil D. THEISE; 工藤 正俊; Maria-Paula CURADO; Silvia FRANCESCHI; Prodromos HYTIROGLOU; Young Nyun PARK; 坂元 亨宇; Michael TORBENSON; Aileen WEE (担当:共著範囲:)WHO Press World Health Organization, Geneva, Switzerland 2010年
  • 肝細胞癌の分子標的治療, ソラフェニブによりCRとなった進行肝細胞癌の2症例.
    上嶋 一臣; 工藤 正俊 (担当:共著範囲:)アークメディア, 東京 2010年
  • 肝細胞癌の分子標的治療, 第1回日本肝がん分子標的治療研究会を振り返って.
    工藤 正俊 (担当:単著範囲:)アークメディア, 東京 2010年
  • 肝細胞癌の分子標的治療, 肝細胞癌のシグナル伝達系と分子標的治療.
    工藤 正俊 (担当:単著範囲:)アークメディア, 東京 2010年
  • 肝細胞癌の分子標的治療, ソラフェニブによる進行肝癌の治療: その有効性・副作用対策と将来展望.
    工藤 正俊 (担当:単著範囲:)アークメディア, 東京 2010年
  • 肝細胞癌の分子標的治療, 特別座談会 肝細胞癌の分子標的治療.
    工藤 正俊; 池田 公史; 古瀬 純司; 沖田 極; 有井 滋樹 (担当:共著範囲:)アークメディア, 東京 2010年
  • 肝細胞癌の分子標的治療, 序説.
    工藤 正俊 (担当:単著範囲:)アークメディア, 東京 2010年
  • 症例から学ぶウイルス肝炎の治療戦略, C型肝炎 肝癌治癒後にインターフェロン投与行ったが肝癌の再発が認めた症例.
    上田 泰輔; 鄭 浩柄; 工藤 正俊 (担当:共著範囲:)診断と治療社, 東京 2010年
  • 症例から学ぶウイルス肝炎の治療戦略, B型肝炎 ペグインターフェロンとエンテカビル投与によって薬剤フリーが得られているB型肝炎症例.
    萩原 智; 工藤 正俊 (担当:共著範囲:)診断と治療社, 東京 2010年
  • 症例から学ぶウイルス肝炎の治療戦略, B型肝炎 Child-Pugh Cの非代償性肝硬変で核酸アナログ投与によって肝機能が改善した症例.
    鄭 浩柄; 工藤 正俊 (担当:共著範囲:)診断と治療社, 東京 2010年
  • 症例から学ぶウイルス肝炎の治療戦略, 序文.
    工藤 正俊; 泉 並木 (担当:共著範囲:)診断と治療社, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌治療後のフォローアップの仕方 肝癌根治的治療後の再発の早期発見.
    工藤 正俊; 泉 並木 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌治療後のフォローアップの仕方 肝癌根治後の再発抑制治療.
    工藤 正俊 (担当:単著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌治療のアルゴリズム 肝癌全体の治療アルゴリズム.
    工藤 正俊; 幕内 雅敏; 國土 典宏; 田中 正俊; 川崎 誠治; 高安 賢一; 松井 修; 泉 並木; 大崎 往夫 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌治療のアルゴリズム 肝動注化学療法と分子標的治療薬をどう使い分けるか.
    工藤 正俊 (担当:単著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌治療のアルゴリズム TACE不応例に対する治療指針
    工藤 正俊 (担当:単著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の治療 肝癌治療の実際 全身化学療法と分子標的治療
    工藤 正俊 (担当:単著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の治療 肝癌治療の実際 内科的局所治療 ラジオ波焼灼療法 RFAの適応と除外基準 造影超音波下RFA.
    南 康範; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の治療 肝癌診療のためのステージングシステム.
    工藤 正俊 (担当:単著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の診断 肝癌診断のアルゴリズム 乏血性肝細胞性結節（境界病変, 異型結節, 早期肝癌）はどのような場合に治療すべきか
    工藤 正俊; 泉 並木; 松井 修 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の診断 肝癌診断のアルゴリズム 多血性肝細胞癌の診断アルゴリズム.
    泉 並木; 工藤 正俊; 松井 修 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の診断 画像診断 早期肝癌の画像的特徴.
    松井 修; 工藤 正俊; 高安 賢一; 神代 正道 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の診断 画像診断 どのようなときに造影超音波を行うか.
    工藤 正俊 (担当:単著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌の診断 画像診断 どのようなときにGd-EOB-MRIを行うか.
    工藤 正俊; 井上 達夫; 村上 卓道 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝癌診療マニュアル 第2版, 肝癌早期発見のためのスクリーニング法.
    建石 良介; 工藤 正俊; 泉 並木; 金子 周一 (担当:共著範囲:)医学書院, 東京 2010年
  • 肝疾患Review, 非侵襲的肝線維化測定法-Real-time Tissue ElastographyとFibroscanはどちらが優るか.
    辰巳 千栄; 工藤 正俊; 上嶋 一臣 (担当:共著範囲:)日本メディカルセンター, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 膵癌の診断と治療方針・疼痛対策.
    北野 雅之; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の診断指針 第6版, 肝悪性腫瘍.
    工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 科学的根拠に基づく肝癌診療ガイドライン.
    南 康範; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 腫瘤形成性膵炎.
    坂本 洋城; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 肝結核.
    井上 達夫; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 肝細胞癌の治療方針.
    上嶋 一臣; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 肝細胞癌のスクリーニングと診断.
    井上 達夫; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 造影エコー検査.
    畑中 絹世; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 緊急内視鏡.
    松井 繁長; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 今日の消化器疾患治療指針 第3版, 大腸内視鏡検査.
    梅原 泰; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2010年
  • 講義録 腫瘍学 メジカルビュー社, 東京, 画像検査.
    南 康範; 工藤 正俊 (担当:共著範囲:)2009年
  • 肝細胞癌治療における局所再発の抑制とsafety/surgical marginの必要性-画像による解析-, 肝細胞癌治療における局所再発の抑制とsafety marginの必要性.
    工藤 正俊 (担当:共著範囲:)メディカルトリビューン, 東京 2009年
  • 内科「肝癌撲滅最前線」, 造影剤エコーによる肝癌診療最前線.
    畑中 絹世; 工藤 正俊 (担当:共著範囲:)南江堂, 東京 2009年
  • 消化器研修ノート, 腹部超音波（エコー）検査.
    上嶋 一臣; 工藤 正俊 (担当:共著範囲:)診断と治療社, 東京 2009年
  • 消化器病学の進歩-原点から未来への情報発信-, 造影ハーモニックEUSによる胆膵疾患の診断.
    北野 雅之; 坂本 洋城; 工藤 正俊 (担当:共著範囲:)医学書院 2009年
  • 胆膵内視鏡診療の実際ー標準的検査法と手技のコツー, 造影EUSによる膵疾患診断.
    北野 雅之; 坂本 洋城; 工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2009年
  • 肝臓病診療: こんなときどうするQ&A, 肝臓病診断における造影超音波の有用性はどこまでわかっているのか？
    畑中 絹世; 工藤 正俊 (担当:共著範囲:)中外医学社, 東京 2009年
  • 肝臓病診療: こんなときどうするQ&A, 肝癌診療のためのステージングシステムはどうなっているのか？
    鄭 浩柄; 工藤 正俊 (担当:共著範囲:)中外医学社, 東京 2009年
  • 新臨床内科学 第9版, 医学書院, 肝癌.
    工藤 正俊 (担当:共著範囲:)2009年
  • 肝疾患Review 2008～2009, 乏血性結節の診断・治療アルゴリズム.
    今井 康陽; 工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2008年
  • ハイパーサーミアがん温熱療法ガイドブック, 肝臓がん（ラジオ波焼灼療法）-原発性肝がんに対するラジオ波焼灼療法-.
    鄭 浩柄; 井上 達夫; 工藤 正俊 (担当:共著範囲:)神陵文庫, 兵庫 2008年
  • 肝疾患Review 2008～2009, 日米欧の肝癌へのアプローチの違い.
    工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2008年
  • 肝疾患Review 2008～2009, 肝癌治療アルゴリズムをめぐる話題ーEvidence-basedとConsensus (Experience)- basedの溝をどう埋めるか.
    工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2008年
  • 肝疾患Review 2008～2009 日本メディカルセンター, 東京, 肝癌根治後の再発抑制治療ーOverview.
    工藤 正俊 (担当:共著範囲:)2008年
  • 肝疾患Review 2008～2009, ソナゾイドは肝癌診療をどう変えるか？
    工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2008年
  • 動画で学ぶ 肝癌ラジオ波凝固療法の実践テクニック, 造影超音波下RFA.
    南 康範; 畑中 絹世; 工藤 正俊 (担当:共著範囲:)中山書店, 東京 2008年
  • 動画で学ぶ 肝癌ラジオ波凝固療法の実践テクニック, 治療アルゴリズムにおけるRFAの位置と今後の展望.
    工藤 正俊 (担当:共著範囲:)中山書店, 東京 2008年
  • “Textbook of Practical Ultrasound.” Ahuja B ed, USCON Academic Press, New Delhi, India, 2008, Pancreatic Ultrasound with esmphasis on EUS
    工藤 正俊 (担当:単著範囲:)2008年
  • “Textbook of Practical Ultrasound.“ Ahuja B ed, USCON Academic Press, New Delhi, India, 2008, Ultrasonography of diffuse liver diseases
    工藤 正俊 (担当:単著範囲:)2008年
  • これだけは知っておきたい外科Q&A－研修医からの質問528., 超音波の適応と読み方.
    南 康範; 福永 豊和; 工藤 正俊 (担当:共著範囲:)2007年
  • 肝癌診療マニュアル, 肝癌根治後の再発抑制治療.
    工藤 正俊 (担当:単著範囲:)日本肝臓学会編集, 医学書院 2007年
  • 肝癌診療マニュアル, 肝癌全体の治療アルゴリズム.
    工藤 正俊; 幕内 雅敏; 國土 典宏; 田中 正俊; 川崎 誠治; 高安 賢一; 松井 修; 泉 並木; 大崎 往夫 (担当:共著範囲:)日本肝臓学会編集, 医学書院 2007年
  • 肝癌診療マニュアル, 造影エコー下RFA.
    南 康範; 鄭 浩柄; 工藤 正俊 (担当:共著範囲:)日本肝臓学会編集, 医学書院 2007年
  • 肝癌診療マニュアル, 肝癌診療のためのステージングシステム.
    工藤 正俊 (担当:単著範囲:)日本肝臓学会編集, 医学書院 2007年
  • 肝癌診療マニュアル, 乏血性肝細胞性結節（境界病変, 過形成結節, 早期肝癌）はどのような場合に治療すべきか.
    工藤 正俊; 泉 並木 (担当:共著範囲:)日本肝臓学会編集, 医学書院 2007年
  • 肝癌診療マニュアル, 多血性肝細胞癌の診断アルゴリズム.
    泉 並木; 工藤 正俊; 松井 修 (担当:共著範囲:)日本肝臓学会編集, 医学書院 2007年
  • 肝癌診療マニュアル, どのようなときに造影エコーを行うか.
    工藤 正俊 (担当:単著範囲:)日本肝臓学会編集, 医学書院 2007年
  • ガイドライン外来診療2006, 外来ガイドライン診療―診断、管理・治療―「肝癌」
    工藤 正俊 (担当:共著範囲:)日経メディカル 2006年03月
  • 消化器疾患の診断基準病型分類重症度の用い方 編集 棟方昭博, 小池和彦, 田尻久雄, 肝細胞癌の病型分類（肝癌取扱い規約）と予後予測（JISスコア）.
    工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2006年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, 肝シンチグラムのポイント
    工藤 正俊 (担当:共著範囲:)2006年
  • 工藤, 正俊 へるす出版 2004年12月 ISBN: 4892694886 179p
  • 肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸, （3）肝癌の診断・治療の進歩 （2）造影ハーモニック法による肝癌の診断と治療
    南 康範; 工藤 正俊; 川崎 俊彦 (担当:共著範囲:)日本メディカルセンター, 東京 2004年
  • 肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸, （4）肝癌の治療の進歩ー治療法の現状・進歩からStaging systemまでー
    工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2004年
  • 肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸, （3） 肝癌の診断の進歩ー肝癌の画像診断・腫瘍マーカー・造影剤の進歩ー
    工藤 正俊 (担当:共著範囲:)日本メディカルセンター, 東京 2004年
  • 消化器病診療－良きインフォームドコンセントに向けて－ 財団法人日本消化器病学会 監修, 検査手技「腹部超音波検査」
    井上 達夫; 工藤 正俊 (担当:共著範囲:)医学書院, 東京 2004年
  • Postgraqduate Course & Current Reviews in HEPATOLOGY. Clinico-patho-radiological Correlation., Newer imaging modality of hepatocellular carcinoma: role of contrast-enhanced coded phase inversion harmonics
    工藤 正俊 (担当:共著範囲:)CBS Publishers & Distributors, New Dehli, India 2004年
  • 松井, 修; 工藤, 正俊 南江堂 2003年05月 ISBN: 4524235949 xiii, 216p
  • 消化器内視鏡臨床手技シリーズ5. 超音波内視鏡up date. 村田洋子, 峯 徹哉, 編集, 膵「炎症と癌の鑑別におけるパワードプラの有用性」
    北野 雅之; 工藤 正俊 (担当:共著範囲:)メディカルビュー社, 東京 2003年
  • 消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集, 人工胸水下造影エコー併用RFAの有用性
    南 康範; 工藤 正俊; 川崎 俊彦 (担当:共著範囲:)南江堂, 東京 2003年
  • 消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集, GIMTの造影エコー検査：体表式造影ハーモニックイメージングおよび超音波内視鏡下造影エコーの意義
    福田 信宏; 工藤 正俊; 北野 雅之 (担当:共著範囲:)南江堂, 東京 2003年
  • 消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集, 造影エコー法の現状と今後の展望
    工藤 正俊 (担当:共著範囲:)南江堂, 東京 2003年
  • 超音波造影ガイドブック－すぐに役立つ基礎から臨床まで－, 森安史典, 別府慎太郎, 久 直史, 編, 超音波造影の装置ならびに映像条件（腹部）
    工藤 正俊 (担当:共著範囲:)金原出版, 東京 2003年
  • 内科学, 杉本恒明, 小俣政男, 水野美邦, 編, 肝膿瘍・肝嚢胞
    工藤 正俊 (担当:共著範囲:)朝倉書店, 東京 2003年
  • Annual Review 消化器, 肝の画像診断
    工藤 正俊 (担当:共著範囲:)中外医学社, 東京 2003年
  • 超音波造影ガイドブック－わかりやすい基礎知識と臨床応用－, 森安史典, 別府慎太郎, 久 直史, 編, 超音波造影の装置ならびに映像条件（腹部）
    工藤 正俊 (担当:共著範囲:)金原出版, 東京 2003年
  • Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors
    工藤 正俊 (担当:共著範囲:)Springer Verlag, Tokyo 2003年
  • Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors
    工藤 正俊 (担当:単著範囲:)Springer Verlag, Tokyo 2003年
  • Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors
    工藤 正俊 (担当:単著範囲:)Springer Verlag 2003年
  • Gastroenterology Navigator, 滝川 一編集, MRIとその応用
    臼杵則朗; 工藤 正俊 (担当:共著範囲:)メディカルレビュー社 2002年
  • 肝臓フォーラム'02記録集, 肝画像診断の進歩
    工藤 正俊 (担当:共著範囲:)医事出版社, 東京 2002年
  • 犬山シンポジウム記録集, B型肝炎急性増悪に対するラミブジンの効果
    工藤 正俊; 鄭 浩柄; 大崎 往夫 (担当:共著範囲:)アークメディア, 東京 2002年
  • 今日の診断指針・第5版, 亀山正邦, 高久史磨, 編集, 腹部の超音波診断
    工藤 正俊 (担当:共著範囲:)医学書院, 東京 2002年
  • 第22回犬山シンポジウム（第II部）記録集, 肝細胞癌の課題: 画像診断の立場から
    工藤 正俊 (担当:共著範囲:)アークメディア, 東京 2002年
  • 「肝疾患診療のコツと落とし穴」, 井廻道夫編, 造影エコー法の肝癌治療への応用
    工藤 正俊 (担当:共著範囲:)中山書店 2002年
  • 「肝疾患診療のコツと落とし穴」, 井廻道夫編, 造影ハーモニックイメージングのコツとpitfall
    工藤 正俊 (担当:共著範囲:)中山書店 2002年
  • 図説消化器病シリーズ3「肝・胆・膵の画像診断」, 肝・胆・膵疾患の超音波診断
    工藤 正俊 (担当:共著範囲:)メディカルレビュー社, 東京 2002年
  • 工藤, 正俊 (担当:単著範囲:)医学書院 2001年05月 ISBN: 4260138790 xiv,208p
  • 特別シンポジウム記録集, 大阪肝穿刺生検治療研究会編, RTCシステムによる肝細胞癌に対する熱凝固療法.肝癌に対するラジオ波熱凝固療法(RFA).
    工藤 正俊; 遠田弘一; 南 康範; 鄭 浩柄; 末冨 洋一郎; 川崎 俊彦; 前川 清 (担当:共著範囲:)大阪 2001年
  • 工藤 正俊 (担当:共著範囲:)（財）放射線利用振興協会, 科学技術庁, 編 2001年
  • 看護のための最新医学講座, 検査の目的と検査結果の読み方ー「肝胆膵疾患」画像診断（超音波検査）
    山本健二; 工藤 正俊 (担当:共著範囲:)中山書店 2001年
  • 看護のための最新医学講座, 検査の目的と検査結果の読み方ー「肝胆膵疾患」画像診断（単純X線）
    山本健二; 工藤 正俊 (担当:共著範囲:)中山書店 2001年
  • 消化器病セミナー82, コントラストエコーを用いた癌診断（特集「肝細胞癌治療法の新たな展開」）
    工藤 正俊 (担当:共著範囲:)へるす出版 2001年
  • 「ミレニアム消化器2000」, 多施設共同研究からみた肝硬変の画像診断の限界と役割
    工藤 正俊; 福永 豊和; 川崎 俊彦; 山本健二; 岡部純弘; 井谷智尚; 大崎征夫; 飯島尋子; 加地 到; 春日井博志; 兼松雅之; 伊東克能; 臼杵則朗; 島松一秀; 鹿毛政義; 神代正道 (担当:共著範囲:)日本メディカルセンター 2001年
  • カラードプラによる肝腫瘍の流出血流動態の描出. 「巨視的レベルよりみた肝微小循環動態と腫瘍血流の流出動態.」
    工藤 正俊 (担当:共著範囲:)メディカルトリビューン 2000年
  • プラクティカル内科シリーズNo.9「肝硬変・肝細胞癌」, 肝細胞癌の超音波診断
    工藤 正俊 (担当:共著範囲:)2000年
  • 肝癌に関する最近の話題. 「門脈血流を有する高分化型肝癌の治療 ー治療は必要でないとする立場よりー」
    工藤 正俊; 福永 豊和; 杤尾人司 (担当:共著範囲:)日本アクセルシュプリンガー出版 2000年
  • カラードプラによる肝腫瘍の流出血流動態の描出. 「巨視的レベルよりみた肝微小循環動態と腫瘍血流の流出動態.」
    工藤 正俊 (担当:共著範囲:)メディカルトリビューン 2000年
  • プラクティカル内科シリーズNo.9「肝硬変・肝細胞癌」, 肝細胞癌の超音波診断
    工藤 正俊 (担当:共著範囲:)南江堂 2000年
  • 血流動態からみた肝癌の肉眼型（辺縁と内部構造）と組織の推定は可能か？: US, US angio, カラードプラ
    福永 豊和; 工藤 正俊 (担当:共著範囲:)日本アクセルシュプリンガー出版 2000年
  • 肝硬変の血流動態: 超音波（US-angio、カラードプラ、パワードプラ、3次元画像）
    工藤 正俊 (担当:共著範囲:)日本アクセルシュプリンガー出版 2000年
  • 急性腹症. 新超音波医学「（2）消化器」
    工藤 正俊 (担当:共著範囲:)医学書院 2000年
  • 図説消化器病シリーズ「肝腫瘍」, 造影エコー法: 動注および静注法
    工藤 正俊 (担当:共著範囲:)メデイカルビュー 2000年
  • In Dynamic Study of Efferent Tumor Blood Fow, Itai Y, Miura Y, eds, Color Doppler observation of efferent blood flow in liver tumors
    工藤 正俊; 杤尾人司 (担当:共著範囲:)BRACCO, Italy 2000年
  • "Hepatology in the 21st Century: Diagnosis and Therapy." Tanikawa K, Kojiro M, Gollan J, eds, Advances in diagnostic imaging of hepatocellular carcinoma
    工藤 正俊 (担当:共著範囲:)IASL, APASL, and JSH JOINT POST GRADUATE TEXTBOOK, IASL Publ, Fukuoka 2000年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, 血管造影のポイント
    工藤 正俊 (担当:共著範囲:)1999年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, MRI診断のポイント
    工藤 正俊 (担当:共著範囲:)1999年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, アンギオCT診断のポイント
    工藤 正俊 (担当:共著範囲:)1999年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, CT診断のポイント
    工藤 正俊 (担当:共著範囲:)1999年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, エコー診断のポイント
    工藤 正俊 (担当:共著範囲:)1999年
  • 肝疾患診療マニュアル（日本医師会雑誌特別号）, 画像診断の読み方とチェックポイント
    工藤 正俊 (担当:共著範囲:)1999年
  • 診断と治療社, 肝内胆管癌の画像診断ーUSー, 肝胆膵フロンティア・胆管細胞癌
    岡部 純弘; 工藤 正俊 (担当:共著範囲:)1999年
  • 1. 肝細胞癌の流出静脈は門脈か肝静脈か？板井悠二, 工藤正俊, 監修, その両方とする立場よりーカラードプラ所見を中心にー肝癌に関する最近の話題
    工藤 正俊; 杤尾人司 (担当:共著範囲:)1999年
  • わかりやすい内科学 井村裕夫 編, 腹部腫瘤
    工藤 正俊 (担当:共著範囲:)文光堂, 東京 1999年
  • わかりやすい内科学 井村裕夫 編, 腹部膨満
    工藤 正俊 (担当:共著範囲:)文光堂, 東京 1999年
  • 今日の治療指針1999年版, 多賀須幸男, 尾形悦郎, 編, 原発性・転移性肝癌（内科）
    工藤 正俊 (担当:共著範囲:)医学書院, 東京 1999年
  • 各施設での治療選択の実際,肝癌の Bed side ノ－ト, 小俣政男 監修, 肝細胞癌の治療法─どのよう治療法を選択するか
    福永 豊和; 工藤 正俊 (担当:共著範囲:)現代医療社, 東京 1999年
  • 工藤 正俊 (担当:共著範囲:)Medic-Online, Euromultimedia S.A., Luxembourg 1999年
  • 消化器疾患最新の治療 1999-2000, 戸田剛太郎, 杉町圭蔵, 中村孝司 編, 肝細胞癌の超音波診断－最近の進歩
    工藤 正俊 (担当:共著範囲:)南江堂, 東京 1998年
  • 肝癌診断の最新動向. 小俣政男編, 超音波診断の現状とその展望
    工藤 正俊 (担当:共著範囲:)協和企画通信 1998年
  • 臨床放射線増刊号. 宮本幸夫, 多田信平 編, CO2 アンジオグラフイ－ －スクリ－ニングから精査の時代へ－超音波診断 update
    工藤 正俊 (担当:共著範囲:)金原出版, 東京 1998年
  • 「血流動態よりみた肝細胞癌の基礎と臨床」 監修: 板井悠二, カラードプラよりみた流出静脈
    工藤 正俊; 福永 豊和; 杤尾人司; 冨田周介; 岡部純弘; 岩崎信広; 中村仁美; 曽我登志子; 田村周二; 森本義人; 樫田博史; 渡辺智裕; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男 (担当:共著範囲:)日本アクセル・シュプリンガー出版, 東京 1998年
  • 癌治療Q&A－肝癌－,田口鐵男 監修,今岡真義 編, CO2注入超音波検査による診断とは？
    工藤 正俊 (担当:共著範囲:)医薬ジャ－ナル, 大阪 1998年
  • 「肝癌ー診断と治療ー」, 沖田 極, 市田隆文編, 増感剤を用いた静注US
    工藤 正俊 (担当:共著範囲:)日本メデイカルセンター 1997年
  • 腹部疾患の画像診断, 中村仁信, 松井 修, 高安賢一 編, 肝腫瘍性病変―超音波診断
    工藤 正俊 (担当:共著範囲:)最新医学社 1997年
  • 消化器病 UP TO DATE-Consensus & Controversies, 小林絢三 編, 肝癌の早期診断と治療: 血流動態からみた肝癌の脱分化と進展
    工藤 正俊 (担当:共著範囲:)永井書店, 大阪 1997年
  • "Diagnosis and Treatment of Hepatocellular Carcinoma", Livraghi T, Makuuchi M, Buscarini, eds, Scintigraphy
    工藤 正俊 (担当:共著範囲:)Greenwich Medical Media Limited, London, UK 1997年
  • Liver Cancer, Okuda K and Tabor E, eds, Ultrasound Diagnosis
    工藤 正俊 (担当:共著範囲:)Churchill Livingstone, London 1997年
  • 2.5 “Gastrointestinal Malignancies”; 2.5.3 Hepatocellular carcinoma. In “ESMO Handbook of Immuno-Oncology”, Haanen J, Lugowska I, Garassino MC, Califano R, ed., 2018, pp191-202.
    Harding JJ; Watanabe T; El-Dika I; Nishida N; Abou-Alfa GK; Kudo M 

講演・口頭発表等

  • 特別講演「肝細胞癌の薬物治療における最新トピックス～免疫複合療法とTACEによる新たな治療戦略を考える～」  [招待講演]
    工藤正俊
    ABC TACEセミナー 2024年03月 中外製薬株式会社大崎オフィス, 東京
  • 免疫療法時代におけるレンバチニブの位置付け－LEN-TACE療法のポテンシャルを考える－  [招待講演]
    工藤正俊
    LEN-TACE Academy in 栃木 2024年03月 口頭発表（招待・特別） ライトキューブ宇都宮, 栃木
  • 特別講演「免疫療法時代におけるレンバチニブの位置付け―LEN-TACE療法のポテンシャルを考える―」  [招待講演]
    工藤正俊
    第10回東北のHCC治療を考える会 2024年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌の薬物治療における最新トピックス～免疫複合療法とTACEによる新たな治療戦略を考える～」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Expert Meeting in埼玉東部 2024年03月 口頭発表（招待・特別）
  • Atezolizumab plus Bevacisumab versus lenvatinib for BCLC-B stage patients with hepatocellular carcinoma : a large real life worldwide population
    Vitiello F; Rimini M; Persano M; Tada T; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Masi G; Yoo C; Leonardi S; Rossari F; Amadeo E; Suda G; Gardini AC
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • α-FAtE: a new predictive score of response to atezolizumab plus evacizumab for unresectable hepatocellular carcinoma incorporating α-Fetoprotein, Alkaline phosphatase and Eosinophil count
    Rossari F; Tada T; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Amadeo E; Vitiello F; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Rimini M; Giardini AC
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • The prognostic impact of viral and non-viral etiologies on advanced hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
    Rossari F; Tada T; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Amadeo E; Vitiello F; Persano M; Foti S; Stefanini B; Scartozzi M; Cascinu S; Rimini M; Giardini AC
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
    Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Foti S; Camera S; Cornara N; Vitiello F; Amadeo E; Rossari F; Cascinu S; Scartozzi M; Gardini AC
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
    Persano M; Rimini M; Tada T; Suda G; Shigeo S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Foti S; Camera S; Cornara N; Vitiello F; Amadeo E; Rossari F; Cascinu S; Scartozzi M; Gardini AC
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
    Manfredi GF; Fulgenzi C; D'Alessio A; Celsa C; Stefanini B; Cheon J; Ang C; Marron TU; Saeed A; Wietharn B; Pressiani T; Pinter M; Scheiner B; Huang YH; Phen S; Naqash AR; Piscaglia F; Lin PO; Lin CY; Dalbeni A; Vivaldi C; Masi G; Thimme R; Vogel A; Schoenlein M; von Felden J; Schulze K; Wege H; Galle P; Kudo M; Rimassa L; Singal A; Sharma R; Cortellini A; Chon HJ; Burlone M; Pirisi M; Pinato DJ
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Impact of body mass index on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
    Cornara N; Stefanini B; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Finkelmeier F; Yoo C; Presa J; Amadeo E; Iavarone M; Marra F; Foschio F; Tamburini E; Rossari F; Vitiello F; Lonardi S; Siletta M; Persano M; Camera S; Cascinu S; Casadei-Gardini A; Piscaglia F
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
    Celsa C; Cabibbo G; Fulgenzi C; Scheiner B; D'Alessio A; Manfredi G; Marron TU; Saeed A; Pinter M; Huang YH; Pillai A; Schoenlein M; von Felden J; Galle P; Kudo M; Rimassa L; Singal A; Chon HJ; Hsu WF; Stefanini B; Vogel A; Brunetti L; Pinto C; Bersanelli M; Camma C; Cortellini A; Pinato DJ
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Safety and efficacy of lenvatinib in very elderly patients with unresectable hepatocellular carcinoma
    Camera S; Rimini M; Rossari F; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Salani F; Marseglia M; Amadeo E; Vitiello F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Iavarone M; Cabibbo G; Montes M; Foschi FG; Vivaldi C; Lonardi S; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Hiraoka A; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Gardini AC
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
    Amadeo E; Rossari F; Rimini M; Vitiello F; Foti MMS; Kudo M; Tada T; Suda G; Shimose S; Leonardi S; Salani F; Finkelmeier F; Antouzzo L; Marra F; Lavorane M; Cabibbo G; Foschio F; Scartozzi M; Camera S; Persano M; Kumada T; Iwamoto H; Hiraoka A; Scartozzi M; Aldrighetti L; Cascinu S; Gardini AC; Presa J
    EASL Liver Cancer Summit 2024 2024年02月 ポスター発表 Rotterdam, Netherlands
  • mRECIST outcomes in EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
    Sangro B; Kudo M; Erinjeri J; Qin SD; Ren Z; Chan S; Arai Y; Heo J; Mai A; Escobar J; Chuken YAL; Yoon JH; Tak WY; Suttichaimongkol T; Bouattour M; Lin SM; Żotkiewicz M; Ali S; Cohen G; Lencioni R
    EASL Liver Cancer Summit 2024 2024年02月 口頭発表（一般） Rotterdam, Netherlands
  • Keynote Lecture “Achievement of curative conversion with combination/sequential therapy of resection/locoregional therapy and immunotherapy in TACE unsuitable intermediate-stage HCC”  [招待講演]
    Masatoshi Kudo
    Ecological System of Gastgrointestinal & Hepatobiliary Cancer Treatment Forum 2024年02月 口頭発表（基調） Shanghai Marriott Hotel, China
  • 工藤正俊  [招待講演]
    特別講演; Intermediate Stage肝細胞癌の治療戦略-ABC conversion therapy-」
    第27回日本肝がん分子標的治療研究会 2024年01月 公開講演，セミナー，チュートリアル，講習，講義等 大阪国際会議場, 大阪
  • 特別講演「STRIDEレジメンを含めた当院での進行肝細胞癌の診断と治療」  [招待講演]
    工藤正俊
    中四国IO Expert Seminar 2023年12月 口頭発表（招待・特別） JRホテルクラメント高松, 香川
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    北信医療圏における肝がん薬物療法を考える会 2023年12月 口頭発表（招待・特別） シャトレーゼホテル長野, 長野
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Expert Meeting 2023年12月 口頭発表（招待・特別） グランドハイアット福岡, 福岡
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Meet the Expert on Hepatocellular Carcinoma 2023年12月 口頭発表（招待・特別） 野村コンファレンスプラザ新宿, 東京
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Seminar in OKAYAMA 2023年12月 口頭発表（招待・特別） 岡山コンベンションセンター, 岡山
  • 座長; 特別講演「最新の肝癌治療と合併症対策について」  [招待講演]
    工藤正俊
    肝癌治療と合併症を考える会 2023年12月 その他 フェニーチェ堺, 大阪
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Gunma HCC Expert Meeting 2023年12月 口頭発表（招待・特別） 群馬ロイヤルホテル, 群馬
  • 切除不能HCCに対するABC conversion療法とclinical CRの現状. ワークショップ「肝がん局所治療の多様性とその到達点」
    青木智子; 西田直生志; 工藤正俊
    第45回日本肝臓学会西部会 2023年12月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • Invited Lecture “Optimized Management in Intermediate-stage HCC”  [招待講演]
    Masatoshi Kudo
    APDW 2023 2023年12月 口頭発表（招待・特別） Bangkok
  • 特別講演「Cancer free with drug freeを目指すためのABC」  [招待講演]
    工藤正俊
    肝細胞癌の集学的治療 2023年12月 口頭発表（招待・特別） FUKUI SENKYO bldg, 福井
  • SIERRA: A Phase 3b, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
    Chan SL; Sangro B; Kudo M; Dane A; Emery C; Paskow MJ; Makowsky M; Nguyen B; Rimassa L
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
    Yamashita T; Inaba Y; Ikeda M; Sone M; Yamakado K; Nioshiofuku H; Tsuchiya K; Tada T; Sato Y; Kodama T; Kuzuya T; Ogasawara S; Ueno M; Iwamoto H; Moriguchi M; Ueshima K; Kodama Y; Takehara T; Hamano T; Kudo M
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
    Izumi N; Kudo M; Motomura K; Inaba Y; Katamura Y; Kondo Y; Yabushita K; Motoyoshi K; Furuse J
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
    Rimini M; Amadeo E; Vitiello F; Foti S; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Piscaglia F; Masi G; Yoo C; Lonardi S; Rassari F; Camera S; Casadei-Gardini A; Presa J
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
    Rossari F; Tada T; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Amadeo E; Vitiello F; Foti S; Persano M; Piscaglia F; Scartozzi M; Cascinu S; Rimini M; Casadei-Gardini A
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
    Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Cascinu S; Scartozzi M; Casadei-Gardini A
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
    Ueshima K; Nishida N; Hagiwara S; Minami Y; Ida H; Takita M; Chishina M; Morita M; Aoki T; Kudo M
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
    Vitiello F; Rimini M; Persano M; Suda G; Shimose S; Finkelmeier F; Masi G; Rossari F; Amadeo E; Casadei-Gardini A; Tada T; Kudo M; Cheon J; Lim HY; Yoo C
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
    Amadeo E; Persano M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Rassari F; Vitiello F; Casadei-Gardini A; Rimini M
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
    Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Cascinu S; Scartozzi M; Casadei-Gardini A
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • IMbrave150: Exploratory analyses for investigating associations between Last update: 22-11-2023 12:00:52pm Final Programme overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Kudo M; Yamashita T; Finn RS; Galle P; Ducreux M; Cheng AL; Tsuchiya K; Sakamoto N; Hige S; Take R; Yamada K; Asakawa T; Nakagawa Y; Ikeda M
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
    Kuzuya T; Yamashita T; Takehara T; Aikata H; Kato N; Hiasa Y; Nakamura S; Morimoto N; Moriguchi M; Ikeda M; Inoue J; Tani J; Ueno Y; Chayama K; Tateishi R; Kawamura Y; Furuse J; Kudo M; Yamamoto K; Kokudo N
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Chan SL; Sangro B; Kelly RK; Lau G; Kudo M; Sukeepaisarnjaroen W; De Toni E; Furuse J; Kang YK; Galle P; Rimassa L; Heurgue A; Tam V; Dao T; Thungappa SC; Breder V; Ostapenko Y; Monzon MER; Gupta C; Abou-Alfa G
    ESMO-Asia 2023 2023年12月 ポスター発表 Singapore
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Bunkyo HCC Seminar 2023年11月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    信州肝がん薬物療法セミナー 2023年11月 口頭発表（招待・特別） ホテルブエナビスタ, 長野
  • Invited Lecture “The Practice in Japan: Insights into Gold Standard HCC Surveillance and Management”  [招待講演]
    Masatoshi Kudo
    APAC HCC Expert Meeting 2023 2023年11月 口頭発表（招待・特別） Bangkok
  • 大腸ポリープの3クラス分類問題に対するResidual Networkを用いたAI自動診断. シンポジウム2「先進的な大腸内視鏡検査法の実用化に向けて」
    玉井龍成; 米田頼晃; 印牧奨真; 樫田博史; 半田久志; 工藤正俊
    第41回日本大腸検査学会総会 2023年11月 シンポジウム・ワークショップパネル（公募） ベルサール九段, 東京
  • 大腸ESDにおける抗血栓内服者に対する後出血の検討. パネルディスカッション「下部消化管出血の現状と問題点」
    米田頼晃; 樫田博史; 河野匡志; 工藤正俊
    第78回日本大腸肛門病学会 2023年11月 シンポジウム・ワークショップパネル（公募） 熊本城ホール, 熊本
  • 消化管真菌叢はパーキンソン病感受性遺伝子LRRK2の活性化を介して, 膵炎を重症化させる. ワークショップ21 「腸内微生物叢からみた消化器疾患の病態解明」
    大塚康生; 三長孝輔; 渡邉智裕
    第31回日本消化器関連学会週間JDDW 2023（第65回日本消化器病学会大会, 第27回日本肝臓学会大会, 第106回日本消化器内視鏡学会総会） 2023年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • ランチョンセミナー「肝細胞癌の薬物治療における最新のトピックス～複合免疫療法時代の最適な治療戦略を考える～」  [招待講演]
    工藤正俊
    第27回日本肝臓学会大会 2023年11月 口頭発表（招待・特別） 神戸コンベンションセンター, 兵庫
  • 高脂肪食による肥満は自己免疫性膵炎の危険因子である. 統合プログラム1 (S) 「肥満関連消化器疾患治療の現状と課題」
    瀬海郁衣; 三長孝輔; 渡邉智裕
    第31回日本消化器関連学会週間JDDW 2023（第65回日本消化器病学会大会, 第27回日本肝臓学会大会, 第106回日本消化器内視鏡学会総会） 2023年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • Intermediate stage HCCに対する集学的治療とclinical CR & drug-free strategy. パネルディスカッション「肝細胞癌Intermediate stageに対する治療戦略」
    青木智子; 上嶋一臣; 工藤正俊
    第27回日本肝臓学会大会 2023年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • 司会; ランチョンセミナー33「原発性肝がんのがんゲノム診断と治療―今、消化器医に求められるものー」  [招待講演]
    工藤正俊
    第27回日本肝臓学会大会 2023年11月 その他 神戸コンベンションセンター, 兵庫
  • 特別講演「肝癌治療の進化と深化」  [招待講演]
    工藤正俊
    第27回日本肝臓学会大会 2023年11月 口頭発表（招待・特別） 神戸コンベンションセンター, 兵庫
  • Special Lecture “All stages of HCC patient benefit from systemic therapy combined with locoregional therapy”  [招待講演]
    Masatoshi Kudo
    Asian Pacific Association for the Study of the Liver (APASL Oncology 2023) 2023年10月 口頭発表（招待・特別） Hotel Metropolitan Sendai, Miyagi
  • IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablation
    Yopp A; Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin S
    American College of Surgeons Clinical Congress 2023 2023年10月 口頭発表（一般） Boston, USA
  • Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
    Fulgenzi CAM; Huang YH; Saeed A; Rimassa L; Schoenlein M; Piscaglia A; Kaseb A; Vogel A; Bettinger D; Silletta M; Kudo M; Vivaldi C; Scheiner B; Ulahannan S; Galle PR; Hsu WF; Chon HJ; Pinato DJ; Ang C
    The European Society for Medical Oncology (ESMO Congress 2023) 2023年10月 ポスター発表 Madrid, Spain
  • 講演「切除不能肝癌の一次治療におけるティスレリズマブ: RATIONALE-301の日本人集団解析」
    工藤正俊
    第61回日本癌治療学会学術集会 2023年10月 口頭発表（一般） パシフィコ横浜, 神奈川
  • 司会; 臓器別シンポジウム1「肝細胞癌における集学的治療の課題と展望: “Sequntial”から”Conversion“まで」  [招待講演]
    工藤正俊
    第61回日本癌治療学会学術集会 2023年10月 その他 パシフィコ横浜, 神奈川
  • Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma (HCC): RATIONALE-301 Japanese subpopulation
    Kudo M; Hiraoka A; Takayama T; Takikawa Y; Li S; Abdrashitov R; Chen Y; Boisserie F; Ohkawa K; Satoh T
    The 61st Annual Meeting of Japan Society of Clinical Oncology (JSCO 2023) 2023年10月 ポスター発表 Yokohama, Japan
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    城北HCCセミナー 2023年10月 口頭発表（招待・特別） ステーションコンファレンス池袋, 東京
  • 特別講演;複合免疫療法時代における最適な治療戦略を考える  [招待講演]
    工藤正俊
    CHCS2023 AUTUMN 2023年10月 口頭発表（招待・特別） 札幌グランドホテル, 北海道
  • IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablation
    Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin S
    The 20th Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO 2023) 2023年10月 ポスター発表 Tempe, Arizona, USA
  • 特別講演「肝細胞癌に対する薬物療法の新しい潮流」  [招待講演]
    工藤正俊
    肝細胞癌治療の現在と未来を考える会 2023年10月 口頭発表（招待・特別）
  • NOD2の活性化によるI型IFN経路の制御機能が炎症性腸疾患の病態に果たす役割. シンポジウム2 「炎症性腸疾患: 臨床を深める病態研究の最前線」
    益田康弘; 三長孝輔; 鎌田研; 大塚康生; 本庶元; 正木翔; 瀬海郁衣; 栗本真之; 大丸直哉; 原 茜; 岡井夏輝; 新井康之; 山下浩平; 工藤正俊; 渡邉智裕
    第60回日本消化器免疫学会総会 2023年10月 シンポジウム・ワークショップパネル（公募） ホテルイースト21東京, 東京
  • 腸内真菌叢はパーキンソン病感受性蛋白LRRK2を介し, 急性膵炎の重症化に関与する. シンポジウム1 「臓器関連から診る消化器免疫疾患の病態と治療」
    大塚康生; 三長孝輔; 栗本真之; 瀬海郁衣; 原 茜; 鎌田 研; 渡邉智裕; 工藤正俊
    第60回日本消化器免疫学会総会 2023年10月 シンポジウム・ワークショップパネル（公募） ホテルイースト21東京, 東京
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    HCC Meet the Expert 2023年10月 口頭発表（招待・特別）
  • 心窩部痛を契機に診断・治療し得た傍神経筋腫の一例
    中 貴史; 吉田晃浩; 竹中 完; 田中秀和; 福永朋洋; 山﨑友裕; 大本俊介; 三長孝輔; 鎌田 研; 工藤正俊; 松本逸平; 筑後孝章
    日本消化器病学会近畿支部第119回例会 2023年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • カボザンチニブ投与による腫瘍の著名な縮小、腫瘍マーカーの低下を認めたMET遺伝子増幅を伴う肝細胞癌の1例
    八田寛朗; 萩原 智; 上嶋一臣; 大丸直哉; 松原卓哉; 盛田真弘; 千品寛和; 田北雅弘; 南 康範; 依田 広; 渡邉智裕; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第119回例会 2023年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 術前診断が困難であった肝限局性過形成（FNH）の一例
    藤原大輔; 野村健司; 川崎俊彦; 福西香栄; 加藤弘樹; 河野辰哉; 橋本有人; 木下大輔; 水野成人; 福田泰也; 若狭朋子; 工藤正俊
    日本消化器病学会近畿支部第119回例会 2023年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • リザーバー留置後に胃よりカテーテルの逸脱を認めた一例
    栗本真之; 田北雅弘; 大丸直哉; 松原卓哉; 盛田真弘; 千品寛和; 青木智子; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊; 鶴崎正勝
    日本消化器病学会近畿支部第119回例会 2023年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 新型コロナワクチン接種後にIgA血管炎を発症し、コロナ感染を契機に再燃を繰り返した1例
    勝部滉平; 永井知行; 駒谷 真; 有山武尊; 栗本真之; 岡井夏輝; 吉田早希; 半田康平; 正木 翔; 河野匡志; 米田頼晃; 本庶 元; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第119回例会 2023年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 司会; がんゲノム医療の現状と課題  [招待講演]
    工藤正俊
    日本消化器病学会近畿支部第73回教育講演会 2023年09月 その他 大阪国際交流センター, 大阪
  • A phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, plus lenvatinib in patients with advanced hepatocellular carcinoma (HCC)
    Ikeda M; Kato N; Kondo S; Inaba Y; Ueshima K; Sasaki M; Kanzaki H; Ida H; Imaoka H; Minami Y; Mitsunaga S; Nishida N; Ogasawara S; Watanabe K; Sahara T; Hayata N; Yamamuro S; Kimura T; Tamai T; Ma C; Kudo M
    New Zealand Society for Oncology (NZSO 2023) 2023年09月 ポスター発表 Napier, New Zealand
  • Chairs: ILCA Radiology Session  [招待講演]
    Masatoshi Kudo
    ILCA 2023 2023年09月 その他 Amsterdam, The Netherlands
  • Efficacy and safety analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study
    Kudo M; Ueshima K; Tsuchiya K; Kato N; Yamashita T; Shimose S; Numata K; Kodama Y; Tanaka Y; Kuroda H; Itoh S; Aikata H; Hiraoka A; Moriguchi M; Wada Y; Nakao K; Tateishi R; Ogasawara S; Yamamoto K; Ikeda M
    ILCA 2023 2023年09月 口頭発表（一般） Amsterdam, The Netherlands
  • GAAD and GALAD algorithmic scores demonstrate equivalent clinical performance for detection of early stage hepatocellular carcinoma (HCC) in prospective multicenter biomarker studies
    Hou J; Berg T; Vogel A; Piratvisuth T; Trojan J; De Toni EN; Kudo M; Malinowsky K; Findeisen P; Hegel JK; Schoning W; Madin K; Kroeniger K; Chan HLY; Sharma A
    ILCA 2023 2023年09月 口頭発表（一般） Amsterdam, The Netherlands
  • IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
    Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Qin S; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Yopp A
    ILCA 2023 2023年09月 ポスター発表 Amsterdam, The Netherlands
  • Achievement of cancer and drug-free status by atezolizumab plus bevacizumab followed by curative conversion in patients with TACE-unsuitable, intermediate-stage HCC: a multicenter proof-of-concept study
    Kudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Chishina H; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan SL; Kurosaki M; Izumi N
    ILCA 2023 2023年09月 ポスター発表 Amsterdam, The Netherlands
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    第17回肝癌治療ナビゲーション研究会アフタヌーンセミナー 2023年08月 口頭発表（招待・特別） 京都産業会館ホール, 京都
  • Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in rationale-301 population  [通常講演]
    Finn RS; Qin S; Kudo M; Meyer T; Boisserie F; Li S; Chen Y; Abdrashitov R; Zhu AX; Vogel A
    Asia-Pacific Gastroenterology Cancer Summit 2023年08月 ポスター発表 Academia, Singapore
  • Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)  [通常講演]
    Kudo M; Finn RS; Meyer T; Boisserie F; Li S; Chen Y; Abdrashitov R; Zhu AX; Vogel A; Qin S
    Asia-Pacific Gastroenterology Cancer Summit 2023年08月 ポスター発表 Academia, Singapore
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    久留米肝がんセミナー 2023年08月 口頭発表（招待・特別） 萃香園ホテル, 九州
  • Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population
    Finn R; Qin S; Kudo M; Meyer T; Boisserie F; Li S; Chen Y; Barnes G; Abdrashitov R; Zhu A; Vogel A
    ASCO Breakthrough 2023 2023年08月 ポスター発表 Yokohama, Japan
  • Keynote Lecture “Combination Immunotherapy in early and intermediate stage HCC”  [招待講演]
    Kudo M
    Joint International Conference of Taiwan Liver Cancer Association (TLCA) and Taiwan Academy of Tumor Ablation (TATA) 2023 2023年07月 口頭発表（招待・特別） Taipei
  • 免疫環境変化によりRechallenge療法にてCRが得られたと考えられたABC conversion、drug freeの一例
    二宮七海; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿広; 玉置敬之; 柴峠光成; 工藤正俊
    第59回日本肝癌研究会 2023年07月 口頭発表（一般） 大阪国際会議場, 大阪
  • 全国原発性肝癌追跡調査データによる分子標的治療支援AIアルゴリズム開発. ワークショップ4「肝腫瘍診療におけるAI/ITの可能性」
    國土貴嗣; 山田康秀; 建石良介; 浅岡良成; 壁谷佳典; 吉田澄人; 鎌田亜美; 中村悠馬; 先崎心音; 正木 勉; 山下竜也; 飯島尋子; 坂元亨宇; 工藤正俊; 國土典宏
    第59回日本肝癌研究会 2023年07月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 超音波診断を支援する人工知能モデルによる肝内胆管癌の鑑別. ワークショップ4「肝腫瘍診療におけるAI/ITの可能性」
    西田直生志; 工藤正俊
    第59回日本肝癌研究会 2023年07月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 実臨床におけるアテゾリズマブ・ベバシズマブ併用療法の使用状況－HERITAGE試験から‐. シンポジウム「肝細胞癌に対する免疫チェックポイント阻害剤: 現状と課題」
    浅岡良成; 建石良介; 山田康秀; 長谷川 潔; 飯島尋子; 加藤直也; 島田光生; 波多野悦朗; 福本 巧; 村上卓道; 矢野博久; 吉満賢吾; 黒崎雅之; 坂元亨宇; 松山 裕; 工藤正俊; 國土典宏
    第59回日本肝癌研究会 2023年07月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 座長; ランチョンセミナー「分子標的薬・重粒子・TACE/RFAによる肝癌・胆管癌のハイブリッド治療—この症例をどうする？-」  [招待講演]
    工藤正俊; 藤元治朗
    第59回日本肝癌研究会 2023年07月 その他 大阪国際会議場, 大阪
  • 右下横隔膜動脈からのfeederを造影USで指摘しABC convresion、drug freeを達成したHCCの一例
    堤 千沙; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿広; 玉置敬之; 柴峠光成; 工藤正俊
    第59回日本肝癌研究会 2023年07月 口頭発表（一般） 大阪国際会議場, 大阪
  • Intermediate stage肝癌における初回アテゾリズマブ＋ベバシズマブとレンバチニブの比較・検討
    多田俊史; 熊田 卓; 豊田秀徳; 平岡 淳; 能祖一裕; 工藤正俊
    第59回日本肝癌研究会 2023年07月 口頭発表（一般） 大阪国際会議場, 大阪
  • IMbrave050: 肝細胞癌における切除・焼灼後のAtezo+Bev療法の有用性を検証する多施設共同第III相臨床試験. ワークショップ1「肝細胞癌のコンビネーション治療－術前・術後治療－」
    工藤正俊; Nakamura S; Numata K; Chen M; Cheng AL; Chow P; Kaseb A; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Uguen T; Hsiehchen D; Hack S; Lian Q; Spahn J; Qin S
    第59回日本肝癌研究会 2023年07月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 胆管癌におけるゲノム・エピゲノム変化と腫瘍免疫微小環境. シンポジウム「肝内胆管癌薬物療法の進歩」
    西田直生志; 青木智子; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 南 康範; 上嶋一臣; 工藤正俊
    第59回日本肝癌研究会 2023年07月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • Wnt/β-catenin変異を有するヒト肝細胞癌における免疫微小環境の不均一性に関する検討. シンポジウム「肝癌腫瘍微小環境」
    青木智子; 西田直生志; 紅林 泰; 坂井和子; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 南 康範; 鶴崎正勝; 中居卓也; 坂元亨宇; 西尾和人; 工藤正俊
    第59回日本肝癌研究会 2023年07月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 特別講演「肝細胞癌に対する薬物療法の新しい潮流」  [招待講演]
    工藤正俊
    第22回関西肝血流動態・機能イメージ研究会 2023年07月 口頭発表（招待・特別） エーザイ株式会社大阪コミュニケーションオフィス, 大阪
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    岩手肝癌治療を考える会～BCLC-Bの治療戦略を中心に～ 2023年07月 口頭発表（招待・特別）
  • Keynote Lecture “Insights into Japan’s gold standard in hepatocellular carcinoma surveillance and management”  [招待講演]
    Kudo M
    White Paper Launch Webinar 2023年07月 口頭発表（招待・特別）
  • 特別講演「イミフィンジ・イジュドがもたらす免疫療法の新たな潮流」  [招待講演]
    工藤正俊
    HCC Semiar in Niigata 2023 2023年07月 口頭発表（招待・特別） ホテルイタリア幹新潟, 新潟
  • Invited Lecture “The potential role of systemic therapy in intermediate-stage HCC: A paradigm shift?”.  [招待講演]
    Kudo M
    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) 2023年07月 口頭発表（招待・特別） Seoul, Korea
  • Session 3 “New Trends in Management of Intermediate-Stage HCC”  [招待講演]
    Kudo M
    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) 2023年07月 その他 Seoul, Korea
  • Comparison of background characteristics of patients receiving lenvatinib vs atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
    Itoh S; Ikeda M; Onozuka D; Tateishi R; Yamashita T; Okusaka T; Kato N; Furuse J; Kudo M
    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) 2023年07月 ポスター発表 Seoul Korea
  • Four-year overall survival (OS) update from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Sangro B; Chan SL; Kelly RK; Lau G; Kudo M; Sukeepaisarnjaroen W; De Toni EN; Furuse J; Kang YK; Galle PR; Rimassa L; Heurgue A; Tom VC; Dao TV; Thungappa SC; Breder V; Ostapenko Y; Reig M; Makowsky M; Gupta C; Negro A; Abou-Alfa GK
    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) 2023年07月 ポスター発表 Seoul Korea
  • IMbrave050: Adjuvant atezolizumab + bevacizumab vs active surveillance in hepatocellular carcinoma patients at high risk of disease recurrence following resection or ablation.
    Lee HC; Cheng AL; Chow P; Kaseb A; Kudo M; Qin S; Yopp A; Becker L; Hernandez S; Kovic B; Lian Q; Ma N; Wu C; Chen M
    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) 2023年07月 ポスター発表 Seoul Korea
  • Chair: Session 4 “From APPLE academy into the future”  [招待講演]
    Kudo M
    The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) 2023年07月 その他 Seoul, Korea
  • Randomized, Phase 3 study of tislelizumab vs sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE 301 aged ≥65 years subgroup
    Vogel A; Kudo M; Qin S; Chen Y; Li S; Boisserie F; Abdrashitov R; Finn RS; Meyer T; Zhu AX
    25th ESMO World Congress on Gastrointestinal Cancer (WCGI) 2023年06月 ポスター発表 Barcelona, Spain
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    HCC Expert Meeting 2023年06月 口頭発表（招待・特別） ANAクラウンプラザホテル富山, 富山
  • Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy
    Fulgenzi C; D’Alessio A; Scheiner B; Ang C; Wietharn B; Pinter M; Nishida N; Parisi A; Huang Y; Bettinger D; Vogel A; Silletta M; Schonlein M; Galle P; Kudo M; Singal A; Cortellini A; Chon H; Stefanini B; Giannini E; Pinato D
    25th ESMO World Congress on Gastrointestinal Cancer 2023年06月 ポスター発表 Barcelona, Spain
  • Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
    Persano M; Rimini M; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Piscaglia F; Lavarone M; Marra F; Tamburini E; Cabibbo G; Scartozzi M; Casadei-Gardini A
    25th ESMO World Congress on Gastrointestinal Cancer 2023年06月 ポスター発表 Barcelona, Spain
  • A positive cytokine/chemokine feedback loop establishes plasmacytoid dendritic cell-driven autoimmune pancreatitis in IgG4-related disease
    Hara A; Otsuka Y; Minaga K; Watanabe T; Kudo M
    55th EPC meeting in cooperation with the JPS 2023年06月 口頭発表（一般） Alpbach, Tyrol, Austria
  • IPMNの壁在結節におけるDetective flow imaging（DFI）の有用性について. シンポジウム2「膵疾患に対する内視鏡診療の現況と展望」
    大本俊介; 竹中 完; 工藤正俊
    第110回日本消化器内視鏡学会近畿支部例会 2023年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 選択的胆管挿管に対する新規構造色彩強調機能（Texture and color enhancement Imaging: TXI）の有用性評価. ワークショップ1「胆道内視鏡の現況と展望」
    田中秀和; 竹中 完; 工藤正俊
    第110回日本消化器内視鏡学会近畿支部例会 2023年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 内視鏡治療できた小腸良性腫瘍症例. ビデオシンポジウム「Best of Endoscopist in Kinkiを目指せ～診断・治療困難例へのアプローチ～」
    岡井夏輝; 正木 翔; 米田頼晃; 樫田博史; 工藤正俊
    第110回日本消化器内視鏡学会近畿支部例会 2023年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 当院における潰瘍性大腸炎患者に対するLRGの活用性の検討. ワークショップ3「炎症性腸疾患診療における内視鏡検査の現況と展望」
    河野匡志; 米田頼晃; 工藤正俊
    第110回日本消化器内視鏡学会近畿支部例会 2023年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 造影USにて右下横隔膜動脈からのfeederを指摘しABC conversion、drug freeを達成したHCCの一例
    竹内沙織; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第28回日本肝がん分子標的治療研究会 2023年06月 ポスター発表 京王プラザホテル札幌, 北海道
  • 初回AB療法はPDも、Rechallenge療法にてCRが得られたABC conversion、drug freeの一例  [通常講演]
    近藤由奈; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 小森淳二; 神野真理; 石川雅士; 居村 暁; 熊谷久次郎; 工藤正俊
    第28回日本肝がん分子標的治療研究会 2023年06月 ポスター発表 京王プラザホテル札幌, 北海道
  • プレナリーセッション2-4「Intermediate stage肝癌における初回アテゾリズマブ+ベバシズマブとレンバチニブの比較・検討」  [招待講演]
    多田俊史; 熊田 卓; 平岡 淳; 谷 丈二; 厚川正則; 高口浩一; 糸林 詠; 辻 邦彦; 田尻和人; 小川 力; 畑中 健; 柿崎 暁; 能祖一裕; 豊田秀徳; 的野智光; 越智裕紀; 海堀昌樹; 黒田英克; 日浅陽一; 工藤正俊
    第28回日本肝がん分子標的治療研究会 2023年06月 公開講演，セミナー，チュートリアル，講習，講義等 京王プラザホテル札幌, 北海道
  • プレナリーセッション2-2「PRISM試験に登録された初期1,000例のアテゾリズマブ＋ベバシズマブとレンバチニブの初回薬物療法例の患者背景の比較」  [招待講演]
    池田公史; 伊藤心二; 小野塚大介; 建石良介; 山下竜也; 奥坂拓志; 加藤直也; 古瀬純司; 工藤正俊
    第28回日本肝がん分子標的治療研究会 2023年06月 公開講演，セミナー，チュートリアル，講習，講義等 京王プラザホテル札幌, 北海道
  • スポンサードセッション「肝細胞癌の薬物治療における最新トピックス～複合免疫療法時代の最適な治療戦略を考える～」  [招待講演]
    工藤正俊
    第28回日本肝がん分子標的治療研究会 2023年06月 口頭発表（招待・特別） 京王プラザホテル札幌, 北海道
  • Impact of baseline liver function on overall survival (OS) and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab: Results from the RATIONALE-301 study
    Kudo M; Vogel A; Meyer T; Boisserie F; Li S; Abdrashitov R; Chen Y; Zhu AX; Qin S; Finn RS
    EASL Congress 2023 2023年06月 ポスター発表 Vienna, Austria
  • 座長  [招待講演]
    工藤正俊
    イジュド発売記念講演会in大阪 2023年06月 その他 スイスホテル南海大阪, 大阪
  • 高アンモニア血症に対するレボカルニチン自体の効果について
    萩原 智; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第59回日本肝臓学会総会 2023年06月 口頭発表（一般） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • B型慢性肝炎患者に対するTAFの効果および安全性の検討
    萩原 智; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第59回日本肝臓学会総会 2023年06月 口頭発表（一般） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • 非アルコール性脂肪肝疾患におけるDNAメチル化に関連する臨床的・病理学的特徴. ワークショップ10「NASH/ASHの病態解明とTransrational Research」
    萩原 智; 西田直生志; 工藤正俊
    第59回日本肝臓学会総会 2023年06月 シンポジウム・ワークショップパネル（公募） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • 進行性肝細胞癌患者に対するレンバチニブとペムブロリズマブ併用療法をレンバチニブ単独療法と比較する第III相試験（LEAP-002）: 日本人集団の結果. ワークショップ5「肝癌における薬物療法の最前線」  [招待講演]
    工藤正俊; 金子周一; 熊田博光
    第59回日本肝臓学会総会 2023年06月 シンポジウム・ワークショップパネル（指名） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • Erythropoietic porphyria（EPP）関連肝障害における瀉血治療の有効性. パネルディスカッション5「遺伝・代謝性肝疾患の未来予想図（現状と課題）」
    萩原 智; 西田直生志; 工藤正俊
    第59回日本肝臓学会総会 2023年06月 シンポジウム・ワークショップパネル（公募） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • 免疫チェックポイント阻害剤投与に伴うHBV再活性化および抗ウイルス効果についての検討. シンポジウム3「B型肝炎診療の未来予想図（現状と課題）」
    萩原 智; 西田直生志; 工藤正俊
    第59回日本肝臓学会総会 2023年06月 シンポジウム・ワークショップパネル（公募） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • ランチョンセミナー「複合免疫療法時代におけるレンバチニブの位置づけ」  [招待講演]
    工藤正俊
    第59回日本肝臓学会総会 2023年06月 公開講演，セミナー，チュートリアル，講習，講義等 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • 非硬変肝から発生したFontan術後HCCの1例
    有山武尊; 萩原 智; 西田直生志; 工藤正俊
    第59回日本肝臓学会総会 2023年06月 口頭発表（一般） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良
  • 基調講演「根治を見据えた近未来の肝細胞癌治療戦略」  [招待講演]
    工藤正俊
    第59回日本肝臓学会総会 2023年06月 口頭発表（基調） 奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良.
  • 特別講演「Cancer Free with Drug Freeを目指すためのABC」  [招待講演]
    工藤正俊
    Mee The Expert on Hepatocellular Carcinoma 2023年06月 口頭発表（招待・特別）
  • Finn R, Qin S, Kudo M, Meyer T, Boisserie F, Li S, Chen Y, Barnes G, Abdrashitov R, Zhu A, Vogel A
    Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma; Impact on health-related quality of; life in; RATIONALE; population
    Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023 2023年06月 ポスター発表 Chicago, USA
  • Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Lau G; Cheng AL; Sangro B; Kudo M; Kelley RK; Tak WY; Gasbarrini A; Reig M; Lim HY; Tougeron D; De Toni EN; Tam VC; Mody K; Gong J; McCoy CL; Gupta C; Makowsky M; Negro A; Abou-Alfa GK
    Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023 2023年06月 口頭発表（一般） Chicago, USA
  • A phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, plus lenvatinib in patients with advanced hepatocellular carcinoma (HCC)
    Ikeda M; Kato N; Kondo S; Inaba Y; Ueshima K; Sasaki M; Kanzaki H; Ida H; Imaoka H; Minami Y; Mitsunaga S; Nishida N; Ogasawara S; Watanabe K; Sahara T; Hayata N; Yamamuro S; Kimura T; Tamai T; Ma C; Kudo M
    Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023 2023年06月 ポスター発表 Chicago, USA
  • Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study
    Ueshima K; Kudo M; Tsuchiya K; Kato N; Yamashita T; Shimose S; Numata K; Kodama Y; Tanaka Y; Kuroda H; Itoh S; Aikata H; Hiraoka A; Moriguchi M; Wada Y; Nakao K; Tateishi R; Ogasawara S; Yamamoto K; Ikeda M
    Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023 2023年06月 ポスター発表 Chicago, USA
  • Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
    Kudo M; Chen M; Chow PKH; Kaseb AO; Lee HC; Yopp AC; Becker L; Painter SH; Kovic B; Lian Q; Ma N; Wu C; Qin S; Cheng AL
    Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023 2023年06月 口頭発表（一般） Chicago, USA
  • Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
    Kudo M; Finn RS; Meyer T; Boisserie F; Li S; Chen Y; Abdrashitov R; Zhu AX; Vogel A; Qin S
    Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023 2023年06月 ポスター発表 Chicago, USA
  • Invited Lecture “Systemic therapies for HCC in cirrhosis: Expanding and redefining treatment approaches”  [招待講演]
    Masatoshi Kudo
    The Asian Pacific Association for the Study of the Liver (APASL STC 2023) 2023年05月 口頭発表（招待・特別） Manila, Philippines
  • 司会; ランチョンセミナー「肝疾患における造影超音波診断最前線」  [招待講演]
    工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 その他 ソニックシティ・パレスホテル大宮, 埼玉
  • 造影USが有用であったABC conversion therapyに成功したHCCの２例
    元木史佳; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 真鍋卓嗣; 柴峠光成; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 口頭発表（一般） ソニックシティ・パレスホテル大宮, 埼玉
  • 切除不能HCCに対するABC conversion療法と造影超音波によるclinical CRの補助診断
    青木智子; 南 康範; 依田 広; 千品寛和; 田北雅弘; 萩原 智; 上嶋一臣; 鶴崎正勝; 西田直生志; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 口頭発表（一般） ソニックシティ・パレスホテル大宮, 埼玉
  • 膵・胆管合流異常の診断におけるEUS・造影ハーモニックEUSの意義の検討. シンポジウム消化器3「診断の鍵となる所見」  [通常講演]
    山﨑友裕; 鎌田 研; 高島耕太; 田中秀和; 福永朋洋; 吉田晃浩; 大本俊介; 三長孝輔; 竹中 完; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 シンポジウム・ワークショップパネル（公募） ソニックシティ・パレスホテル大宮
  • 造影USにて右下横隔膜動脈からのfeederが指摘できたHCCの一例
    谷 丈二; 小川 力; 福家和諭; 戸田拓也; 真鍋卓嗣; 正木 勉; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 ポスター発表 ソニックシティ・パレスホテル大宮, 埼玉
  • 致死率の高いClostridium perfringens肝膿瘍に造影USが有用であった一例
    堤 千沙, 小川 力, 福家和諭, 戸田拓也, 松浦賢史, 真鍋卓嗣, 柴峠光成, 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 ポスター発表 ソニックシティ・パレスホテル大宮, 埼玉
  • 胆管病変に対するDetective flow imaging (DFI)の有用性について
    大本俊介; 竹中 完; 吉田晃浩; 福永朋洋; 田中秀和; 高島耕太; 山﨑友裕; 三長孝輔; 鎌田 研; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 口頭発表（一般） ソニックシティ・パレスホテル大宮, 埼玉
  • 橈骨動脈穿刺による腹部血管造影検査における術前血管USの有用性  [通常講演]
    福家和諭; 小川 力; 戸田拓也; 真鍋卓嗣; 柴峠光成; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 口頭発表（一般） ソニックシティ・パレスホテル大宮, 埼玉
  • 膵腫瘍の造影ハーモニックEUS診断. パネルディスカッション消化器6「膵腫瘍（嚢胞性疾患も）の超音波およびEUS診断」  [通常講演]
    鎌田 研; 大塚康生; 田中秀和; 中井 敦; 山﨑友裕; 大本俊介; 三長孝輔; 竹中 完; 北野雅之; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 シンポジウム・ワークショップパネル（公募） ソニックシティ・パレスホテル大宮, 埼玉
  • 当院におけるスキルス胃癌および下部消化管粘膜下腫瘍に対するEUS精査症例の検討. パネルディスカッション消化器2「消化管がんに対する超音波診断（EUS含む）」  [通常講演]
    田中秀和; 鎌田 研; 高田隆太郎; 三長孝輔; 竹中 完; 松井繁長; 樫田博史; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 シンポジウム・ワークショップパネル（公募） ソニックシティ・パレスホテル大宮
  • 消化管がんに対する体外式消化管超音波検査の有用性について. パネルディスカッション消化器2「消化管がんに対する超音波診断（EUS含む）」  [通常講演]
    南 雅人; 中村祐香; 江口香織; 片岡久紗; 横川美香; 市島真由美; 塩見香織; 南 康範; 樫田博史; 工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 シンポジウム・ワークショップパネル（公募） ソニックシティ・パレスホテル大宮
  • 特別講演「肝腫瘍の超音波人工知能診断の社会実装に向けて: 日本超音波医学会の取り組み」  [招待講演]
    工藤正俊
    日本超音波医学会第96回学術集会 2023年05月 口頭発表（招待・特別） ソニックシティ・パレスホテル大宮, 埼玉
  • 弾性線維性仮性黄色腫に合併する消化管病変の内視鏡所見. ワークショップ5 「希少疾患の内視鏡診断」
    三長孝輔; 山下幸孝; 工藤正俊
    第105回日本消化器内視鏡学会総会 2023年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪 国際館パミール, 東京
  • カプセル小腸内視鏡で得られた大量検査画像からEfficient GANによる小腸病変の高速検出. ワークショップ4「小腸内視鏡による診断、治療の最前線（下部）」
    印牧奨真; 米田頼晃; 工藤正俊
    第105回日本消化器内視鏡学会総会 2023年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪国際館パミール, 東京
  • 潰瘍性大腸炎治療中に腸管症型T細胞リンパ腫を発症した症例. ワークショップ5「希少疾患の内視鏡診断」
    米田頼晃; 樫田博史; 工藤正俊
    第105回日本消化器内視鏡学会総会 2023年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪国際館パミール, 東京
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    肝細胞癌Webカンファレンス 2023年05月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    HIMEJI Hepatocellular Carcinoma Expert Meeting 2023年05月 口頭発表（招待・特別）
  • 特別講演「切除不能肝細胞がんにおけるSTRIDEレジメンが果たす役割」  [招待講演]
    工藤正俊
    北海道HCCセミナー 2023年05月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Expert Meeting in 城東 2023年05月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    肝細胞がん薬物治療を考える会2023 in WAKAYAMA 2023年05月 口頭発表（招待・特別） ダイワロイネットホテル和歌山, 和歌山
  • 特別講演;複合免疫療法時代における最適な治療戦略を考える  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Expert Meeting in Hiroshima 2023 2023年05月 口頭発表（招待・特別） ホテルグランビア広島, 広島
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    肝細胞癌セミナーin神奈川 2023年05月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Chugai Hepatocellular Carcinoma Seminar in SHIGA 2023年05月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    HCCの未来を考える会in山形 2023年05月 口頭発表（招待・特別） ホテルメトロポリタン山形, 山形
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    第3回肝がん治療の最前線～in両毛 2023年05月 口頭発表（招待・特別）
  • A multicenter prospective validation study on selective endoscopic resection of sessile serrated lesions using magnifying colonoscopy in clinical practice
    Hirata D; Kashida H; Matsumoto T; Ebisutani C; Teramoto A; Iwatate M; Hattori S; Fujita M; Sano W; Komeda Y; Sano Y; Murakami Y; Kudo M
    Digestive Disease Week 2023 (DDW 2023) 2023年05月 口頭発表（一般） Chicago, USA
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    第4回県央・県北HCC Webセミナー 2023年04月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    中外e-seminar on Hepatocellular Carcinoma 2023年04月 口頭発表（招待・特別）
  • 座長「造影超音波その先へ」  [招待講演]
    工藤正俊
    第36回日本腹部造影エコー・ドプラ診断研究会 2023年04月 その他
  • 造影USにて右下横隔膜動脈からのfeederが指摘できたHCCの一例
    小川 力; 元木史佳; 戸田拓也; 福家和諭; 真鍋卓嗣; 柴峠光成; 工藤正俊
    第36回日本腹部造影エコー・ドプラ診断研究会 2023年04月 口頭発表（一般） ホテルアバローム紀の国, 和歌山
  • 胆管病変に対するDetective flow imaging (DFI)の有用性について.
    大本俊介; 竹中 完; 工藤正俊
    第36回日本腹部造影エコー・ドプラ診断研究会 2023年04月 口頭発表（一般） ホテルアバローム紀の国, 和歌山
  • IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation  [通常講演]
    Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin S
    EASL Liver Cancer Summit 2023 2023年04月 口頭発表（一般） Estoril, Portugal
  • Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments.
    Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Iavarone M; Di Castanzo G; Marra F; Tamburini E; Cabibbo G; Foschi F; Siletta M; Cascinu S; Scartozzi M; Casadei-Gardini A
    EASL Liver Cancer Summit 2023 2023年04月 ポスター発表 Estoril, Portugal
  • Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction
    Fulgenzi AM; D’Alessio A; Scheiner B; Nishida N; Ang C; Marron T; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Pinter M; Sharma R; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Napolitano A; Vivaldi C; Salani F; Masi G; Bettinger D; Thimme R; Vogel A; Schoenlein M; von Felden J; Schulze K; Wege H; Galle P; Pirisi M; Park JW; Kudo M; Rimassa L; Singal A; Cortellini A; Chon HJ; Ghittoni G; Camma C; Stefanini B; Trevisani F; Giannini EG; Pinato DJ
    EASL Liver Cancer Summit 2023 2023年04月 ポスター発表 Estoril, Portugal
  • Real World Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma: how does the adherence to the IMbrave150 trial inclusion criteria impact prognosis?
    Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Gheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Scartozzi M; Cascinu S; Casadei-Gardini A
    EASL Liver Cancer Summit 2023 2023年04月 ポスター発表 Estoril, Portugal
  • The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
    D’Alessio A; Fulgenzi AM; Scheiner B; Korolewicz J; Cheon J; Nishida N; Ang C; Marron T; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Pinter M; Balcar L; Huang YH; Mehan A; Phen S; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schoenlein M; von Felden J; Schulze K; Wege H; Samson A; Galle P; Kudo M; Cortellini A; Singal A; Rimassa L; Sharma R; Chon HJ; Pinato DJ
    EASL Liver Cancer Summit 2023 2023年04月 ポスター発表 Estoril, Portugal
  • Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
    Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Gheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Lonardi S; Piscaglia F; Chon HJ; Scartozzi M; Schirripa M; Cascinu S; Casadei-Gardini A
    EASL Liver Cancer Summit 2023 2023年04月 ポスター発表 Estoril, Portugal
  • Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice: Final analysis of the prospective, observational REFINE study in the sorafenib-intolerant patient subgroup
    Finn RS; Merle P; Ikeda M; klümpen HJ; Masi G; Granito A; Lim HY; Kudo M; Qin S; Gerolami R; Huang YH; Kim DY; Pinter M; Kato N; Kurosaki M; Numata K; Khan J; Awan M; Qzgurdal K; Kim YJ
    EASL Liver Cancer Summit 2023 2023年04月 ポスター発表 Estoril, Portugal
  • IMbrave050: Identification of Atezolizumab plus Bevacizumab prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma: the ABE index
    Persano M; Rimini M; Tada T; Suda G; Shigeo S; Kudo M; Cheon J; Finkelmeier F; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; De Cobelli F; Aldrighetti L; Rimassa L; Cascinu S; Scartozzi M; Gardini AC
    EASL Liver Cancer Summit 2023 2023年04月 口頭発表（一般） Estoril, Portugal
  • IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
    Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin S
    American Association for Cancer Research Annual Meeting 2023 (AACR A 2023) 2023年04月 口頭発表（一般） Orlando, USA
  • 免疫複合療法時代における切除不能肝細胞癌へのcancer-free strategy. シンポジウム14「進行肝癌の治療戦略」  [通常講演]
    回日本消化器病学会総会
    青木智子, 西田直生志, 工藤正俊 2023年04月 シンポジウム・ワークショップパネル（公募） 出島メッセ長崎, 長崎
  • B-mode超音波検査による肝腫瘤診断を支援する人工知能の開発. シンポジウム3「消化器診療におけるAIの現状と展望」  [通常講演]
    西田直生志; 工藤正俊
    第109回日本消化器病学会総会 2023年04月 シンポジウム・ワークショップパネル（公募） 出島メッセ長崎, 長崎
  • ランチョンセミナー「肝細胞癌の薬物治療における最新トピックス～複合免疫療法時代の最適な治療戦略を考える～」  [招待講演]
    工藤正俊
    第109回日本消化器病学会総会 2023年04月 口頭発表（招待・特別） 出島メッセ長崎, 長崎
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    肝細胞癌診療Up to date meeting in 川越 2023年03月 口頭発表（招待・特別）
  • 特別講演「レンバチニブがもたらした肝細胞癌の治療変革」  [招待講演]
    工藤正俊
    HCC Expert Meeting in 愛媛 2023年03月 口頭発表（招待・特別） ANAクラウンプラザホテル松山, 愛媛
  • 特別講演「レンバチニブがもたらした肝細胞癌の治療変革」  [招待講演]
    工藤正俊
    LENVIMA-HCC適応追加5周年記念Web Seminar 2023年03月 口頭発表（招待・特別）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Meet the Expert on Hepatocellular Carcinoma 2023年03月 口頭発表（招待・特別）
  • First-line lenvatinib plus pembrolizumab for advanced hepatocellular carcinoma: LEAP-002 Asian subgroup analysis  [通常講演]
    Qin S; Ikeda M; Xu R; Ryoo BY; Ren Z; Cheng AL; Kim JH; Kaneko S; Kumada H; Lim HY; Pan H; Dechaphunkul A; Wang A; Mody K; Dubrovsky L; Siegel AB; Kudo M
    The Japanese Society of Medical Oncology Annual Meeting (JSMO 2023) 2023年03月 口頭発表（一般） Fukuoka, Japan
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    山陰HCC Academy 2023年03月 口頭発表（招待・特別） 松江エクセルホテル東急, 島根
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    鹿児島肝癌フォーラム 2023年03月 口頭発表（招待・特別） TKPガーデンシティ鹿児島, 鹿児島
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    城北HCC webセミナー 2023年03月 口頭発表（招待・特別）
  • State-of-the-Art Lecture “Nobel treatment strategy in intermediate-stage HCC”  [招待講演]
    Kudp M
    The Asian Pacific Association for the Study of the Liver (APASL 2023) 2023年02月 口頭発表（招待・特別） Taiwan, Taiwan
  • Systemic therapy in intermediate-stage HCC  [招待講演]
    Kudo M
    The Asian Pacific Association for the Study of the Liver (APASL Taipei) 2023年02月 口頭発表（招待・特別） Taiwan, Taiwan
  • 司会; スペシャルシンポジウムパート1/パート2「薬物療法とアブレーション」  [招待講演]
    工藤正俊
    第1回日本アブレーション研究会 2023年02月 その他 東京大学伊藤国際学術研究センター, 東京
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    城北HCC webセミナー 2023年02月 口頭発表（招待・特別）
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～TACE+TKI併用治療の新時代の幕開け～ 2023年01月 口頭発表（招待・特別）
  • 座長; シンポジウム「肝癌薬物治療による画像変化と病理」  [招待講演]
    工藤正俊
    第29回肝血流動態・機能イメージ研究会 2023年01月 その他
  • BCLC stage A/Bの切除不能肝細胞癌に対するABC conversion療法と造影超音波によるcancer-freeの補助診断  [招待講演]
    青木智子; 依田 広; 千品寛和; 田北雅弘; 萩原 智; 上嶋一臣; 南 康範; 鶴崎正勝; 西田直生志; 工藤正俊
    第29回肝血流動態・機能イメージ研究会 2023年01月 口頭発表（一般）
  • 特別講演「複合免疫療法時代における最適な治療戦略を考える」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Expert Meeting 2023年01月 口頭発表（招待・特別） オリエンタルホテル福岡, 福岡
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～TACE+TKI併用治療の新時代の幕開け～ 2023年01月 口頭発表（招待・特別）
  • IL-6応答亢進を伴う潰瘍性大腸炎関連脊椎関節炎の一例. Young Investigator Session 6「大腸1」.
    藤田峻輔; 本庶 元; 高田隆太郎; 原 茜; 益田康弘; 半田康平; 三長康輔; 渡邉智裕; 工藤正俊; 辻 成佳
    日本消化器病学会近畿支部第118回例会 2023年01月 口頭発表（一般） 京都市勧業館みやこめっせ, 京都
  • Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Cheng AL; Galle P; Kaneko S; Kumada H; Kamble S; Norquist J; Mody K; Dubrovsky L; Siegel A; Finn R
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study
    Finn R; Merle P; Ikeda M; Klümpen HJ; Masi G; Granito A; Lim HY; Kudo M; Qin S; Gerolami R; Huang YH; Kim DY; Pinter M; Kato N; Kurosaki M; Numata K; Khan J; Ozgurdal K; Kim YJ
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev)
    Wu L; Fulgenzi C; D’Alessio A; Chon HJ; Kudo M; Schönlein M; Felden J; Wietharn B; Phen S; Scheiner B; Balcar L; Huang YH; Pressiani T; Masi G; Naqash AR; Bettinger D; Vogel A; Galle P; Gaillard V; Ang C
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT)
    Nara S; Ioka T; Ogawa G; Kataoka T; Sano Y; Esaki M; Nagano H; Kudo M; Ikeda M; Kanai M; Yasuda I; Yamazaki K; Shirakawa H; Kobayashi S; Ozaka M; Gotohda N; Hatano E; Furuse J; Okusaka T; Ueno M
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population
    Rimini M; Casadei-Gardini A; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Rimassa L; Presa J; Masi G; Yoo C; Lonardi S; Scatozzi M; Burgio V; Cascinu S; Cucchetti A; Tovoli F
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study
    Asaoka Y; Tateishi R; Yamada Y; Iijima H; Kato N; Shimada M; Hatano E; Fukumoto T; Murakami T; Yano H; Yoshimitsu K; Kurosaki M; Sakamoto M; Matsuyama Y; Kudo M; Kokudo N
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC)
    Sangro B; Yau T; Harding J; Rivera MA; Numata K; El-Khoueiry A; Cruz-Correa M; Perez-Callejo D; McLean S; Sparks J; Neely J; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
    Finn R; Qin S; Kudo M; Meyer T; Boisserie F; Li S; Chen Y; Barnes G; Abdrashitov R; Zhu A; Vogel A
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study
    Ikeda M; Itoh S; Tateishi R; Yamashita T; Okusaka T; Kato N; Furuse J; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-­stage hepatocellular carcinoma: A multicenter cohort study
    Kudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan S; Kurosaki M; Izumi N
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study
    Kudo M; Tsuchiya K; Shao YY; Finn RS; Galle PR; Ducreux M; Cheng AL; Yamashita T; Koga H; Aoki K; Yamada K; Asakawa T; Nakagawa Y; Ikeda M
    Gastrointestinal Cancers Symposium (ASCO-GI 2023) 2023年01月 ポスター発表 San Francisco, USA
  • 肝予備能が良好なレンバチニブ投与例における新規inflammation and liver function-based scoreの有用性  [通常講演]
    村上詩歩; 多田俊史; 熊田 卓; 平岡 淳; 谷 丈二; 福西新弥; 厚; 辻 邦彦; 石川 達; 高口浩一; 糸林 詠; 田尻和人; 島田紀朋; 柴田啓志; 川田一仁; 豊田秀徳; 能祖一裕; 越智裕紀; 日浅陽一; 工藤正俊
    第27回日本肝がん分子標的治療研究会 2023年01月 口頭発表（一般） 大阪国際会議場, 大阪
  • Child-Pugh B患者の切除不能肝細胞癌に対するAtezolizumab+BevacizumabとLenvatinibの治療比較  [通常講演]
    大濱日出子; 多田俊史; 谷 丈二; 厚川正則; 高口浩一; 糸林 詠; 辻 邦彦; 石川 達; 越智裕紀; 豊田秀徳; 畑中 健; 柿崎 曉; 川田一仁; 的野智充; 能祖一裕; 飯島尋子; 海堀昌樹; 日浅陽一; 工藤正俊; 熊田 卓
    第27回日本肝がん分子標的治療研究会 2023年01月 口頭発表（一般） 大阪国際会議場, 大阪
  • ランチョンセミナー「肝細胞癌薬物療法の最新知見」  [招待講演]
    工藤正俊
    第27回日本肝がん分子標的治療研究会 2023年01月 公開講演，セミナー，チュートリアル，講習，講義等 大阪国際会議場, 大阪
  • プレナリーセッション1「切除不能肝細胞癌における薬物療法に関する前向き観察研究（PRISM試験）」  [通常講演]
    伊藤心二; 池田公史; 建石良介; 山下竜也; 奥坂拓志; 加藤直也; 古瀬純司; 工藤正俊
    第27回日本肝がん分子標的治療研究会 2023年01月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • スポンサードセッション3「Intermediate stage肝細胞癌の治療戦略-ABC conversion therapy-」  [招待講演]
    工藤正俊
    第27回日本肝がん分子標的治療研究会 2023年01月 口頭発表（招待・特別） 大阪国際会議場, 大阪
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    LEN-TACE Academy in香川 2022年12月 口頭発表（招待・特別）
  • Invited Lecture “Anti-PD-1/PD-L1 plus anti-VEGF combination immunotherapy for unresectable HCC: Japanese clinical experience”  [招待講演]
    Masatoshi Kudo
    Cancer Salon: IO+Bev for HCC 2022年12月 口頭発表（招待・特別）
  • Invited Lecture “The value and significance of using sonazoid in the whole course of diagnosis and treatment of liver cancer”  [招待講演]
    Masatoshi Kudo
    Liver Cancer Diagnosis and Treatment Summit Forum 2022年12月 口頭発表（招待・特別）
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～TACE+TKI併用治療の新時代の幕開け～（Web) 2022年12月 口頭発表（招待・特別）
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～TACE+TKI併用治療の新時代の幕開け～ 2022年12月 口頭発表（招待・特別）
  • 座長;「肝細胞癌薬物療法におけるClinical decision marking process～カボザンチニブの役割と可能性～」  [招待講演]
    工藤正俊
    HCC Expert Web Seminar 2022年12月 その他
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～TACE+TKI併用治療の新時代の幕開け～ 2022年12月 口頭発表（招待・特別）
  • 特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～TACE+TKI併用治療の新時代の幕開け～ 2022年12月 口頭発表（招待・特別）
  • ランチョンセミナー「BCLC-B, C肝細胞癌に対するLEN-TACE治療」  [招待講演]
    工藤正俊
    第118回日本消化器病学会中国支部例会, 第129回日本消化器内視鏡学会中国支部例会 2022年12月 公開講演，セミナー，チュートリアル，講習，講義等 KDDI維新ホール, 山口
  • irAE腸炎による消化管穿孔に対してステロイド前のinfliximab選考投与により救命できた1例
    萩原 智; 西田直生志; 工藤正俊
    第44回日本肝臓学会東部会 2022年11月 口頭発表（一般） 仙台国際センター, 宮城
  • NAFLD関連肝癌における背景肝のエピゲノム変異の蓄積. シンポジウム1「代謝性肝疾患の標準治療確立のためのエビデンス構築」
    萩原 智; 西田直生志; 工藤正俊
    第44回日本肝臓学会東部会 2022年11月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • ランチョンセミナー「肝細胞癌の複合免疫療法－最新の話題を含めて－」  [招待講演]
    工藤正俊
    第44回日本肝臓学会東部会 2022年11月 公開講演，セミナー，チュートリアル，講習，講義等 仙台国際センター, 宮城県
  • 座長「がん免疫療法に関する非臨床育薬研究～Mechanism in Non-inflamed Tumor」  [招待講演]
    工藤正俊
    Chugai Cancer Immunotherapy Forum 2022 2022年11月 その他 品川プリンスホテル, 東京
  • 座長「肝疾患栄養代謝マネジメント～アンモニア代謝異常潜在期（LAM）における代謝ドミノと亜鉛～」  [招待講演]
    工藤正俊
    肝疾患の栄養代謝マネジメント 2022年11月 その他
  • Invited Lecture “The trends of development in treatment of advanced liver cancer in Japan”  [招待講演]
    工藤正俊
    National Launch Conference (web) 2022年11月 口頭発表（招待・特別）
  • 当院におけるEUS-BD事前準備の工夫. シンポジウム2「胆管ドレナージの現状と課題」  [通常講演]
    福永朋洋; 大本俊介; 山崎友裕; 竹中 完; 工藤正俊
    第109回日本消化器内視鏡学会近畿支部例会 2022年11月 シンポジウム・ワークショップパネル（公募） 京都リサーチバーク, 京都
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    肝細胞癌セミナー～ABC conversionを中心に～ 2022年10月 口頭発表（招待・特別） 札幌グランドホテル, 北海道
  • 腹部超音波動画からの肝腫瘍検出AIシステムの開発. 統合プログラム6「AI研究の実装化に向けた課題」
    目加田慶人; 西田直生志; 工藤正俊
    第30回日本消化器関連学会週間JDDW 2022（第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同） 2022年10月 口頭発表（一般） 福岡サンパレス, 九州
  • 肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果. 統合プログラム5「消化器癌に対する免疫療法の実態」
    西田直生志; 上嶋一臣; 工藤正俊
    第30回日本消化器関連学会週間JDDW 2022（第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同） 2022年10月 口頭発表（一般） 福岡サンパレス, 九州
  • 切除不能肝細胞癌におけるhyper progressive disease (HPD)の頻度と有効な後治療. ワークショップ8「進行肝癌の薬物治療の課題と展望」
    青木智子; 西田直生志; 工藤正俊
    第30回日本消化器関連学会週間JDDW 2022（第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同） 2022年10月 シンポジウム・ワークショップパネル（公募） 福岡サンパレス, 九州
  • 当院における潰瘍性大腸炎患者に対するベドリズマブの治療成績と有効症例の検討.  [通常講演]
    河野匡志; 米田頼晃; 工藤正俊
    第30回日本消化器関連学会週間JDDW 2022（第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同） 2022年10月 ポスター発表 福岡サンパレス, 九州
  • 基調講演「Intermediate stage肝細胞癌の治療戦略」  [招待講演]
    工藤正俊
    第30回日本消化器関連学会週間JDDW 2022（第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同） 2022年10月 口頭発表（基調） マリンメッセ福岡, 九州
  • 座長: パネルディスカッション6「肝癌intermediate stageの治療戦略」  [招待講演]
    工藤正俊
    第30回日本消化器関連学会週間JDDW 2022（第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同） 2022年10月 その他 マリンメッセ福岡, 九州
  • ランチョンセミナー「肝内病変に着目した肝細胞癌治療戦略」  [招待講演]
    工藤正俊
    第26回日本肝臓学会大会(JDDW 2022 Fukuoka) 2022年10月 公開講演，セミナー，チュートリアル，講習，講義等 福岡サンパレス, 九州
  • Invited Lecture “New stage of treatment strategies for HCC-focusing on intrahepatic tumors”  [招待講演]
    Masatoshi Kudo
    The 2022 CJLCA Summit Forum 2022年10月 口頭発表（招待・特別）
  • 特別講演「Intermediate stage肝癌の治療戦略～ABC Conversion Therapy～」  [招待講演]
    工藤正俊
    CHUGAI Web講演会 2022年10月 口頭発表（招待・特別）
  • Invited Lecture “Multidisciplinary management of intermediate stage HCC”  [招待講演]
    Masatoshi Kudo
    Asian Pacific Association for the Study of the Liver 2022 (APASL 2022) 2022年10月 口頭発表（招待・特別）
  • 膵性胸水に対して内視鏡的膵管ドレナージが奏功した1例
    山本智輝; 橋本有人; 森下剛至; 上中大地; 河野辰哉; 木下大輔; 川崎俊彦; 水野成人; 工藤正俊
    日本消化器病学会近畿支部第117回例会 2022年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 空腸濾胞性リンパ腫から形質転換した腹部Double Expressor Lymphoma（DEL）の1例
    高田隆太郎; 三長孝輔; 渡邉智裕; 工藤正俊
    日本消化器病学会近畿支部第117回例会 2022年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • COVID-19ワクチン接種後のI型インターフェロン反応を特徴とする潰瘍性大腸炎再発の一例.
    益田康弘; 三長孝輔; 渡邉智裕; 工藤正俊
    日本消化器病学会近畿支部第117回例会 2022年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 診断に難渋した肝限局性脂肪沈着の一例. Young Investigator Session 13「肝3」
    森下剛至; 川崎俊彦; 山本智輝; 上中大地; 河野辰哉; 橋本有人; 木下大輔; 水野成人; 石川 原; 若狭朋子; 工藤正俊
    日本消化器病学会近畿支部第117回例会 2022年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 急激な経過を辿ったClostridium perfringens肝膿瘍・多臓器ガス壊疽の1例. Young Investigator Session 11「肝2」
    原 茜; 大塚康生; 三長孝輔; 渡邉智裕; 工藤正俊; 梶山 博
    日本消化器病学会近畿支部第117回例会 2022年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 複合免疫療法時代における切除不能肝細胞癌に対するconversion療法. シンポジウム2「消化器癌に対する薬物療法」.
    青木智子; 上嶋一臣; 工藤正俊
    日本消化器病学会近畿支部第117回例会 2022年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    テセントリク/アバスチン-肝細胞癌-適正使用カンファレンス 2022年10月 口頭発表（招待・特別） レンブラントホテル, 大分
  • 特別講演「Intermediate stage肝癌の治療戦略～ABC Conversion Therapy～」  [招待講演]
    工藤正俊
    Mikawa HCC Clinical Conference 2022年09月 口頭発表（招待・特別）
  • 特別講演「BCLC-B, C肝細胞癌に対するLEN-TACE治療」  [招待講演]
    工藤正俊
    HCC Expert Meeting in 愛媛 2022年09月 口頭発表（招待・特別） ホテルマイステイズ松山, 愛媛
  • Invited Lecture “Combination and harmonization of systemic therapy and TACE in intermediate stage HCC”  [招待講演]
    工藤正俊
    Lenvima-HCC International Exchange Web Seminar 2022年09月 口頭発表（招待・特別）
  • Invited Lecture “Current best option of systemic therapy in HCC”  [招待講演]
    工藤正俊
    Taiwan Digestive Disease Week 2022 (TDDW 2022) 2022年09月 シンポジウム・ワークショップパネル（指名）
  • Invited Lecture “New stage of treatment strategies for HCC -Focusing on intrahepatic tumor”  [招待講演]
    工藤正俊
    The 6th Northeast Provices Summit Forum on Tumor Interventional and Minimally Invasive Treatment and the 4th Tumor Minimally Invasive Treatment Forum in Dalian 2022年09月 口頭発表（招待・特別）
  • Invited Lecture “New paradigm of treatment strategy for patients in BCLC B HCC”  [招待講演]
    工藤正俊
    The 4th Hubei Provincial Symposium on Precise and Minimally Invasive Comprehensive Diagnosis and Treatment of Hepatobiliary and Pancreatic Tumors 2022年09月 口頭発表（招待・特別）
  • Luncheon Seminar “Early detection of HCC using HCC biomarkers and GALAD score”  [招待講演]
    Masatoshi Kudo
    TDDW 2022 2022年09月 公開講演，セミナー，チュートリアル，講習，講義等
  • リザーバー留置後に胃よりカテーテルの逸脱を認めた一例  [通常講演]
    大丸直哉; 田北雅弘; 浦瀬篤史; 千品寛和; 青木智子; 萩原 智; 依田 広; 上嶋一臣; 鶴崎正勝; 西田直生志; 工藤正俊
    第46回リザーバー&ポート研究会 2022年09月 口頭発表（一般） 久留米シティプラザ, 九州
  • ランチョンセミナー「肝細胞癌に対する分子標的薬・免疫療法ならびに新規治療法の開発」  [招待講演]
    工藤正俊
    第46回リザーバー＆ポート研究会 2022年09月 公開講演，セミナー，チュートリアル，講習，講義等 久留米シティプラザ, 九州
  • Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
    Qin S; Kudo M; Meyer T; Finn R; Vogel A; Bai Y; Guo Y; Meng Z; Zhang T; Satho T; Hiraoka A; Marino D; Assenat E; Wyrwicz L; Calvo Campos M; Hsing-Tao K; Boisserie F; Li S; Chen Y; Zhu A
    ESMO Congress 2022 2022年09月 口頭発表（一般） Paris, France
  • Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)  [通常講演]
    Finn R; Kudo M; Merle P; Meyer T; Qin M; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Cheng AL; Galle P; Kaneko S; Kumada H; Wang A; Mody K; Dubrovsky L; Siegel A; Llovet J
    ESMO Congress 2022 2022年09月 口頭発表（一般） Paris, France
  • ランチョンセミナー「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    第29回日本門脈圧亢進症学会総会 2022年09月 公開講演，セミナー，チュートリアル，講習，講義等 グランキューブ大阪, 大阪
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    横浜南西部肝細胞がん診療セミナー 2022年09月 口頭発表（招待・特別）
  • Selection of anti-PD-1 antibody effective group using tumor immunological microenvironment. Workshop 15 “Biomarker research on liver cancer for clinical applications including HCC, CCC and metastatic liver cancer”
    Morita M; Nishida N; Kudo M
    APASL Oncology 2022 Takamatsu 2022年09月 シンポジウム・ワークショップパネル（公募） Takamatsu, Japan
  • Transition of treatment selection for primary liver cancer and eecompensated cirrhosis in multiple admissions: Analysis of a nationwide registry for advanced liver diseases (REAL). Workshop 14 “Treatment strategies for liver cirrhosis”
    Okushin K; Tateishi R; Takahashi A; Uchino K; Nakagomi R; Nakatsuka T; Minami T; Sato M; Fujishiro M; Hasegawa K; Eguchi Y; Kanto T; Kubo S; Yoshiji H; Miyata H; Izumi N; Kudo M; Koike K
    APASL Oncology 2022 Takamatsu 2022年09月 シンポジウム・ワークショップパネル（公募） Takamatsu, Japan
  • Keynote Lecture “Treatment of Intermediate-stage Hepatocellular Carcinoma”  [招待講演]
    Masatoshi Kudo
    APASL Oncology 2022 Takamatsu 2022年09月 口頭発表（招待・特別）
  • Chair; Workshop 19 “Treatment of Intermediate-stage Hepatocellular Carcinoma”  [招待講演]
    Masatoshi Kudo
    APASL Oncology 2022 Takamatsu 2022年09月 その他
  • Examination of NASH-related liver carcinogenesis from non-developed fibrosis. Workshop 9 “Molecular mechanisms of liver cancer (including HCC, CCC and metastatic liver cancer)
    Hagiwara S; Nishida N; Kudo M
    APASL Oncology 2022 Takamatsu 2022年09月 シンポジウム・ワークショップパネル（公募） Takamatsu, Japan
  • State-of-the Art Lecture “Sequential therapy for HCC after failure of atezolizumab plus bevacizumab”  [招待講演]
    Masatoshi Kudo
    The 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022) 2022年08月 口頭発表（招待・特別）
  • Chair; Topic 2 “The evolution of systemic treatment for HCC”  [招待講演]
    Masatoshi Kudo
    The 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022) 2022年08月 その他
  • 司会: 肝臓領域の最近の話題と肝臓学会の将来～C型肝炎治療の残された話題、肝癌治療の今後、B型肝炎・NASHの新規治験も含めて～  [招待講演]
    工藤正俊
    南大阪肝疾患フォーラム 2022年07月 その他 スイスホテル南海大阪, 大阪
  • Invited Lecture “New stage of treatment strategies for HCC -Focusing on intrahepatic tumor”  [招待講演]
    Masatoshi Kudo
    Hepatocellular Carcinoma Masterclass 2022 2022年07月 口頭発表（招待・特別） Island Shangri-La, Hong Kong
  • 司会; 特別講演「B型肝炎創薬研究の現状と臨床応用への展開」  [招待講演]
    工藤正俊
    第6回関西肝疾患フォーラム 2022年07月 その他 シェラトン都ホテル大阪, 大阪
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Web Seminar in Aomori 2022年07月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    日本消化器病学会関東支部第370回例会 2022年07月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌の複合免疫療法～最新の話題を含めて～」  [招待講演]
    工藤正俊
    第3回県央・県北HCC Webセミナー 2022年07月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    SMUO Hepatology 2022-肝細胞がん治療の新たなステージ- 2022年07月 口頭発表（招待・特別）
  • 教育講演「肝細胞癌の薬物療法: 最新の話題」  [招待講演]
    工藤正俊
    第66回生涯教育講演会 2022年07月 口頭発表（招待・特別） 日本都市センター, 東京
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    第45回岐阜肝臓病勉強会 2022年07月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    テセントリク・アバスチン適正使用セミナー on Hepatocellular Carcinoma 2022年07月 口頭発表（招待・特別）
  • 特別講演「肝細胞がん治療の現状」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Summit 2022 2022年07月 口頭発表（招待・特別）
  • 特別講演「Intermediate stage肝癌の治療戦略～ABC Conversionを含めて～」  [招待講演]
    工藤正俊
    HCC Expert Meeting 2022 2022年06月 口頭発表（招待・特別） オークスカナルパークホテル富山, 富山
  • ランチョンセミナー「進行肝細胞癌の薬物治療における最新知見～Molecular Markerを含めて～」  [招待講演]
    工藤正俊
    第26回日本肝がん分子標的治療研究会 2022年06月 口頭発表（招待・特別） 軽井沢プリンスホテルウエスト, 長野県
  • ABC LEN-TACE Sandwich療法にてcancer free, drug freeが得られたPET陽性肝癌の1例  [招待講演]
    萩原 智; 大丸直哉; 松原卓哉; 千品寛和; 盛田真弘; 青木智子; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第68回大阪肝穿刺生検治療研究会 2022年06月 口頭発表（一般）
  • 特別講演「新たなステージを迎えた肝細胞癌治療戦略」  [招待講演]
    工藤正俊
    第7回東北のHCC治療を考える会 (Web) 2022年06月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    茨城県南肝がん薬物療法セミナー 2022年06月 口頭発表（招待・特別）
  • 非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例
    加藤弘樹; 松井繁長; 田北雅弘; 上中大地; 今村瑞貴; 原 茜; 野村健司; 瀬海郁衣; 高田隆太郎; 河野匡志; 正木 翔; 永井知行; 本庶 元; 米田頼晃; 上嶋一臣; 渡邉智裕; 西田直生志; 辻 直子; 樫田博史; 工藤正俊
    第108回日本消化器内視鏡学会近畿支部例会 2022年06月 口頭発表（一般） メルパルク京都, 京都
  • 安全に内視鏡治療できた小腸pyogenic granuloma（化膿性肉芽腫）の一例, Young Endoscopist Session 4「小腸1」  [通常講演]
    有山武尊; 米田頼晃; 加藤弘樹; 瀬海郁衣; 原 茜; 野村健司; 高田隆太郎; 正木 翔; 河野匡志; 永井知行; 本庶 元; 松井繁長; 辻 直子; 樫田博史; 工藤正俊
    第108回日本消化器内視鏡学会近畿支部例会 2022年06月 口頭発表（一般） メルパルク京都, 京都
  • 胆嚢結石を合併した総胆管結石に対する内視鏡治療戦略の検討—術前にとるか術後にとるか—, シンポジウム2「胆膵内視鏡治療の工夫とリスクマネージメント」  [通常講演]
    高島耕太; 三長孝輔; 鎌田 研; 竹中 完; 工藤正俊
    第108回日本消化器内視鏡学会近畿支部例会 2022年06月 シンポジウム・ワークショップパネル（公募） メルパルク京都, 京都
  • カプセル内視鏡検査を用いた小腸病変の検出におけるEfficientGANを用いた検出時間の短縮. ワークショップ2「小腸内視鏡診療の現況と課題」  [通常講演]
    印牧奨真; 半田久志; 羽鳥祥平; 米田頼晃; 工藤正俊
    第108回日本消化器内視鏡学会近畿支部例会 2022年06月 シンポジウム・ワークショップパネル（公募） メルパルク京都, 京都
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    第4回岩手肝癌セミナー 2022年06月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法～特にABC Conversionについて～」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Expert Meeting 2022年06月 口頭発表（招待・特別）
  • 開会/閉会の辞  [招待講演]
    工藤正俊
    第19回大阪消化器化学療法懇話会(Web) 2022年05月 その他
  • Invited Lecture “Treatment of Intermediate-stage HCC”  [招待講演]
    工藤正俊
    Society of Interventional Radiology (SIR), USA 2022年05月 口頭発表（招待・特別）
  • 特別講演;新たなステージを迎えたintermediate;stage HC;治療戦略  [招待講演]
    工藤正俊
    HCC Expert Meeting in 愛媛～次世代のIntermediate Stage治療アルゴリズム～ 2022年04月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    Meet the Expert in Hepatocellular Carcinoma (2022 Spring) 2022年04月 口頭発表（招待・特別）
  • 線維化非進展例からの NASH 関連肝癌発症様式の検討. ワークショップ10「肝疾患の遺伝子解析による病態解明と臨床展開」
    萩原 智; 西田直生志; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 肝癌診療ガイドラインにおける肝動注化学療法の立ち位置と今後の展開. シンポジウム13「病態からみた肝癌治療アルゴリズムの今後」
    上嶋一臣; 田北雅弘; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 門脈腫瘍栓合併肝細胞癌に対する肝切除・ソラフェニブ治療成績の検討. シンポジウム13「病態からみた肝癌治療アルゴリズムの今後」
    小松昇平; 工藤正俊; 福本 巧
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • クローン病疾患感受性遺伝子 NOD2 の欠損は T 細胞依存性腸炎の発症を抑制する. ワークショップ7「消化管疾患の遺伝子解析による病態解明・臨床展開」
    高田隆太郎; 渡邉智裕; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 自己免疫性膵炎の発症に関わるサイトカイン・ケモカインネットワークの解明と新規バイオマーカーの同定. ワークショップ4「自己免疫性肝胆膵疾患の新展開」
    原 茜; 渡邉智裕; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 肝細胞癌における腫瘍微小免疫環境と免疫チェックポイント阻害剤の効果. シンポジウム5「消化器癌における免疫治療と分子標的治療の基礎研究と臨床」  [通常講演]
    西田直生志; 上嶋一臣; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 学術賞受賞講演「肝細胞癌に対する分子標的薬・免疫療法ならびに新規治療法の開発」  [招待講演]
    工藤正俊
    第108回日本消化器病学会総会 2022年04月 口頭発表（招待・特別） 京王プラザホテル, 東京
  • イブニングセミナー「進行肝細胞癌に対する二次薬物療法～肝予備能維持を踏まえた治療シークエンス～」  [招待講演]
    工藤正俊
    第108回日本消化器病学会総会 2022年04月 公開講演，セミナー，チュートリアル，講習，講義等 京王プラザホテル, 東京
  • 地域連携システムを用いた膵癌早期診断―MAGURO プロジェクトの成績と地域医療機関への意識調査―. ワークショップ15「膵癌の早期診断を目指した病態解明と診療戦略」
    山雄健太郎; 竹中 完; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 腸管バリアの破壊に伴い，膵臓に定着する Staphylococcus sciuri が自己免疫性膵炎の発症に果たす役割. ワークショップ1「マイクロバイオーム解析による消化器疾患の病態解明と応用」
    吉川智恵; 渡邉智裕; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 総括; パネルディスカッション7「：進行肝癌の病態解明と治療の展開」  [招待講演]
    工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（指名） 京王プラザ, 東京
  • 非ウイルス性切除不能肝癌に対する全身薬物療法：レンバチニブの治療成績. パネルディスカッション7「進行肝癌の病態解明と治療の展開」
    平岡 淳; 熊田 卓; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 急性膵炎に潜む膵癌症例の検討-MRCP, EUSの早期積極的介入は微小膵癌発見および膵癌予後改善に寄与する-. パネルディスカッション13「胆膵診療ガイドラインの未解決問題に対する病態解明と戦略」
    吉田晃浩; 山雄健太郎; 竹中 完; 工藤正俊
    第108回日本消化器病学会総会 2022年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • Invited Lecture “ABC Conversion for Intermediate-stage HCC”  [招待講演]
    工藤正俊
    Sino-Japan HCC Webinar 2022年04月 口頭発表（招待・特別）
  • Educational Lecture “Treatment of HCC”  [招待講演]
    工藤正俊
    Society of International Digestive Disease (SIDD) 2022年04月 口頭発表（招待・特別）
  • 教育講演「肝細胞癌の全身化学療法」  [招待講演]
    工藤正俊
    第81回日本医学放射線学会総会 2022年04月 口頭発表（基調） パシフィコ横浜, 神奈川
  • Pembrolizumab (pembro) for previously treated advanced hepatocellular carcinoma (aHCC): meta-analysis of the phase 3 KEYNOTE-240 and KEYNOTE-394 studies  [通常講演]
    Finn RS; Gu K; Chen X; Merle P; Lee KH; Bouattour M; Cao P; Wang W; Cheng AL; Zhu L; Lim HY; Kudo M; Pan Y; Chang TT; Edeline J; Li W; Yang P; Li C; Li, J; Siegel AB; Qin S
    American Association for Cancer Research Annual Meeting (AACR 2022) 2022年04月 ポスター発表 New Orleans, Louisiana, USA
  • 特別講演「肝細胞癌薬物療法2022 up date」  [招待講演]
    工藤正俊
    第1回大阪消化器・肝臓フォーラム 2022年04月 口頭発表（招待・特別） アゴーラリージェンシー大阪堺, 大阪
  • Luncheon Seminar “ABC Conversion Therapy for HCC”  [招待講演]
    工藤正俊
    31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) 2022年04月 公開講演，セミナー，チュートリアル，講習，講義等
  • Invited Lecture “LEN-TACE Sequential Therapy for Intermediate-stage HCC”  [招待講演]
    工藤正俊
    China Doctors Association 2022年03月 口頭発表（招待・特別）
  • 診断に難渋した髄膜腫の既往を持つ症例に発生した膵多発腫瘍の一例
    吉田晃浩; 山雄健太郎; 竹中 完; 工藤正俊; 松本逸平; 鶴崎正勝; 筑後孝章; 天野良亮
    第75回消化器画像診断研究会 2022年03月 ポスター発表 さいたま新都心ホテルブリランテ武蔵野, 東京
  • ランチョンセミナー「肝細胞癌治療のパラダイムチェンジ～ABC conversionを含めて～」  [招待講演]
    工藤正俊
    第130回日本消化器病学会北海道支部例会, 第124回日本消化器内視鏡学会北海道支部例会ランチョンセミナー 2022年03月 公開講演，セミナー，チュートリアル，講習，講義等
  • Invited Lecture “Treatment strategy of intermediate stage HCC”  [招待講演]
    工藤正俊
    Indian Association of Cancer Research 2022年03月 口頭発表（招待・特別）
  • Invited Lecture “Hepatocellular Carcinoma Masterclass”  [招待講演]
    工藤正俊
    China Japan Liver Cancer Association 2022年02月 口頭発表（招待・特別）
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    肝癌診療を考える会～免疫療法時代における薬物治療を考える～ 2022年02月 口頭発表（招待・特別）
  • Chair; Medical Seminar 18「Latest treatment strategy on advanced HCC at the ERA of cancer immunotherapy」  [招待講演]
    Masatoshi Kudo
    2022 the Japanese Society of Medical Oncology Annual Meeting 2022年02月 その他 Kyoto International Conference Center, Kyoto
  • Invited Lecture “Atezolizumab plus Bevacizumab in Advanced HCC”  [招待講演]
    工藤正俊
    Roche E Seminar 2022年02月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ～ABC conversionを含めて～」  [招待講演]
    工藤正俊
    Meet the Expert webセミナー 2022年02月 口頭発表（招待・特別）
  • 制御性T細胞に依存しない寛解導入が得られたCollagenous Colitisの一例, Young Investigator Session 15「大腸2」  [通常講演]
    瀬海郁衣; 本庶 元; 今村瑞貴; 松原卓哉; 河野匡志; 原 茜; 栗本真之; 吉川馨介; 益田康弘; 大塚康生; 高田隆太郎; 吉川智恵; 鎌田; 三長孝輔; 松井繁長; 木村雅友; 渡邉智裕; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 口頭発表（一般） 日本消化器病学会近畿支部第116回例会
  • EUS-FNAにより診断が可能であった、後腹膜DLBCLの1例, Young Investigator Session 12「その他」  [通常講演]
    大丸直哉; 松原卓哉; 今村瑞貴; 田中秀和; 半田康平; 河野辰哉; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 大谷知之; 山田 薫; 花本 仁; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 口頭発表（一般） 大阪国際会議場, 大阪
  • 浸潤性膵管癌、腺扁平上皮癌が重複膵管に同時発生した1例, Young Investigator Session 10「膵1」  [通常講演]
    加藤弘樹; 大本俊介; 原 茜; 大塚康生; 益田康弘; 高島耕太; 吉田晃浩; 福永朋洋; 岡本彩那; 山崎友裕; 鎌田 研; 三長孝輔; 竹中 完; 筑後孝章; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 口頭発表（一般） 大阪国際会議場, 大阪
  • 腸内細菌に対する炎症性サイトカイン応答の増強を示すクローン病関連脊椎関節炎の1例, Young Investigator Session 8「小腸1」  [通常講演]
    福西香栄; 本庶 元; 岡井夏輝; 河野匡志; 鎌田 研; 三長孝輔; 米田頼晃; 辻 成佳; 渡邉智裕; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 口頭発表（一般） 大阪国際会議場, 大阪
  • 肝細胞癌根治後に出現したため、肝細胞癌との鑑別診断が困難であった限局性結節性過形成の1例, Young Investigator Session 1「肝1」  [通常講演]
    松原卓哉; 河野辰哉; 今村瑞貴; 大丸直哉; 田中秀和; 半田康平; 橋本有人; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 口頭発表（一般） 大阪国際会議場, 大阪
  • 上・下腸管膜動静脈奇形に伴う門脈圧亢進から難治性腹水及び循環血液量低下に伴う血圧低下に対し血管内治療（IVR）にて改善しえた1例, Freshman Session 4「大腸」  [通常講演]
    上原広樹; 田北雅弘; 杉森啓伸; 岡井夏輝; 野村健司; 盛田真弘; 千品寛和; 青木智子; 萩原 智; 依田 広; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 口頭発表（一般） 大阪国際会議場, 大阪
  • 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討, ワークショップ2「免疫チェックポイント阻害剤をめぐる諸問題」  [通常講演]
    萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • ICI投与とHBVフォローにおける問題点, ワークショップ1「肝炎ウイルスコントロール下における課題へのアプローチ」  [通常講演]
    盛田真弘; 萩原 智; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 地域連携システムを用いた膵癌早期診断—MAGURO projectの成績—, シンポジウム「膵癌診療の進歩と今後の展望」  [通常講演]
    益田康弘; 山雄健太郎; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第116回例会 2022年02月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Expert Meeting;免疫療法時代における薬物治療を考える 2022年02月 口頭発表（招待・特別）
  • Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study  [通常講演]
    Finn RS; Kudo M; Kim YJ; Lim HY; Merle P; Ikeda M; Masi G; Frenette CT; Klümpen HJ; Gerolami R; Kurosaki M; Numata K; Pisarenko J; Khan J; Ozgurdal K; Qin S
    EASL Liver Cancer Summit 2022 2022年02月 口頭発表（一般）
  • Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study  [通常講演]
    Talbot T; D’Alessio A; Pinter M; Balcar L; Scheiner B; Marron TU; Jun T; Dharmapuri S; Ang C; Saeed A; Hildebrand H; Muzaffar M; Fulgenzi CAM; Amara S; Naqash AR; Gampa A; Pillai A; Wang Y; Khan U; Lee PC; Huang YH; Bengsch B; Bettinger D; Abugabal YI; Kaseb A; Pressiani T; Personeni N; Rimassa L; Nishida N; Kudo M; Weinmann A; Galle PR; Muhammed A; Cortellini A; Vogel A; Pinato DJ
    EASL Liver Cancer Summit 2022 2022年02月 ポスター発表
  • 特別講演「腫瘍免疫微小環境におけるAtezolizumab+Bevacizumab併用療法の意義」  [招待講演]
    工藤正俊
    中外Eセミナー 2022年02月 口頭発表（招待・特別）
  • Wnt/β-cateninおよびHFN4α変異を有する肝細胞癌における免疫チェックポイント阻害薬  [招待講演]
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 祖父江慶太郎; 西田直生志; 工藤正俊
    第28回肝血流動態・機能イメージ研究会 2022年01月 口頭発表（一般）
  • Invited Lecture “Treatment strategy of intermediate stage HCC”  [招待講演]
    工藤正俊
    HCC Connect 2022年01月 口頭発表（招待・特別）
  • 特別講演「腹部エコーによる、多発性嚢胞腎のスクリーニング」  [招待講演]
    工藤正俊
    肝腎連携の会 2022年01月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    山口消化器癌セミナー 2022年01月 口頭発表（招待・特別） ANAクラウンプラザホテル宇部, 山口
  • Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis  [通常講演]
    Kudo M; Ueshima K; Nakahira S; Nishida N; Ida H; Minami Y; Nakai T; Wada H; Kubo S; Ohkawa K; Morishita A; Nomi T; Ishida K; Kobayashi S; Umeda M; Tsurusaki M; Chiba Y; Yoshimura K; Sakai K; Nishio K
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) ポスター発表
  • Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348)  [通常講演]
    Lim HY; Heo J; Kim TY; Meng W; Tai D; Kang YK; Lau G; Kudo M; Tak WY; Watras M; Ali SK; Negro A; Abou-Alfa GK; Kelley RK
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) 2022年01月 ポスター発表
  • Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma (uHCC): HIMALAYA  [通常講演]
    Abou-Alfa GK; Chan SL; Kudo M; Lau G; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Tu DV; De Toni EN; Rimassa L; Breder VV; Vasilyev A; Heurgue A; Tam V; Mody K; Thungappa SC; He P; Negro A; Sangro B
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) 2022年01月 口頭発表（一般）
  • Transcatheter arterial chemoembolization therapy in combination strategy with lenvatnib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis  [通常講演]
    Ueshima K; Ishikawa T; Saeki I; Morimoto N; Aikata H; Tanabe N; Inaba Y; Wada Y; Kondo Y; Tsuda M; Nakao K; Ikeda M; Moriguchi M; Ito T; Kobayashi M; Koga H; Hino K; Suzuki Y; Yoshimura K; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) 2022年01月 ポスター発表
  • Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study  [通常講演]
    Finn RS; Kudo M; Klumpen HJ; Lim HY; Merle P; Ikeda M; Masi G; Frenette CT; Kim YJ; Gerolami R; Kurosaki M; Numata K; Pisarenko J; Ozgurdal K; Qin S
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) 2022年01月 ポスター発表
  • LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment  [通常講演]
    El-Khoueiry AB; Llovet J; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) 2022年01月 ポスター発表
  • TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma  [通常講演]
    Kudo M; Guo Y; Hua Y; Zhao M; Xing W; Zhang Y; Liu R; Ren Z; Gu S; Lin Z; Lv W; Wang Y; Dong J
    Gastrointestinal Cancers Symposium (ASCO-GI 2022) 2022年01月 ポスター発表
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    岡山肝癌Expert Seminar 2022年01月 口頭発表（招待・特別） ホテルグランヴィア岡山, 岡山
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting in 九州 2022年01月 口頭発表（招待・特別）
  • 特別講演「私と肝細胞癌診療～若手医師への提言も含めて～」  [招待講演]
    工藤正俊
    広島腫瘍セミナー2022 2022年01月 口頭発表（招待・特別）
  • 共催シンポジウム「進行肝細胞癌の薬物治療における最新知見～Molecular Markerを含めて～」  [招待講演]
    工藤正俊
    第25回日本肝がん分子標的治療研究会 2022年01月 シンポジウム・ワークショップパネル（指名） ホテル日航福岡, 九州
  • 共催シンポジウム「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    第25回日本肝がん分子標的治療研究会 2022年01月 シンポジウム・ワークショップパネル（指名） ホテル日航福岡, 九州
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting in 北海道 2021年12月 口頭発表（招待・特別）
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting ～新時代のTKI+TACE戦略を考える～ 2021年12月 口頭発表（招待・特別）
  • Invited Lecture “Second line or further therapy in unresectable HCC”  [招待講演]
    Masatoshi Kudo
    Taiwan Association for the Study of the Liver (TASL 2021) 2021年12月 口頭発表（招待・特別）
  • Chair; Luncheon Seminar 1  [招待講演]
    Masatoshi Kudo
    The Asian Pacific Association for the Study of the Liver (APASL) Oncology 2021 on “Your Gateway to Oncology in Asia-Pacific Region” 2021年12月 その他 The Prince Park Tower Tokyo
  • 特別講演「肝癌診療ガイドライン2021に基づいた最新治療」  [招待講演]
    工藤正俊
    ライブ配信講演会 2021年12月 口頭発表（招待・特別）
  • 小腸ポリープからの出血によると思われる黒色便の1例. Young Endoscopist Session 7「YS7」
    大丸直哉; 松原卓哉; 今村瑞貴; 河野辰哉; 半田康平; 田中秀和; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 大谷知之; 工藤正俊
    第107回日本消化器内視鏡学会近畿支部例会 2021年12月 口頭発表（一般） 神戸国際会議場, 兵庫
  • 当院における胆管ステント迷入に対する経乳頭的re-interventionへの取り組み. ビデオワークショップ1「胆膵内視鏡 治療困難症例を克服するための工夫」
    大塚康生; 山雄健太郎; 竹中 完; 工藤正俊
    第107回日本消化器内視鏡学会近畿支部例会 2021年12月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 兵庫
  • 膵上皮内癌および良性膵管狭窄症例に特徴的なEUS所見の検討—多施設共同後ろ向き研究—. シンポジウム1「難治性胆膵疾患に対する内視鏡診療の取り組み」
    山雄健太郎; 竹中 完; 工藤正俊; 南 竜城; 大花正也
    第107回日本消化器内視鏡学会近畿支部例会 2021年12月 シンポジウム・ワークショップパネル（公募）
  • ランチョンセミナー「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    第44回日本肝臓学会西部会 2021年12月 公開講演，セミナー，チュートリアル，講習，講義等 岡山コンベンションセンター, 岡山
  • A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: Study 116 follow-up analysis  [通常講演]
    Kudo M; Finn RS; Zhu AX; Sung MW; Baron AD; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Meyer T; Nagao S; Saito K; Mody K; Dubrovsky L; Llovet JM
    ESMO Immuno-Oncology Congress 2021 2021年12月 ポスター発表
  • 特別講演「新たなステージを迎えたIntermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～新時代のTKI+TACE戦略を考える～ 2021年12月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    第2回Chugai HCC Seminar 2021年12月 口頭発表（招待・特別）
  • 教育講演「肝細胞癌の最新治療」  [招待講演]
    工藤正俊
    第65回四国支部主催生涯教育講演会 2021年12月 口頭発表（招待・特別）
  • Invited Lecture “Overview of NAFLD/NASH in HCC”  [招待講演]
    Masatoshi Kudo
    HCC Eastern Pioneers Meeting 2021年12月
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    東北のHCC治療を考える会 2021年12月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法の最先端」  [招待講演]
    工藤正俊
    第2回埼玉県東部肝がんセミナー 2021年12月 口頭発表（招待・特別）
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～新時代のTKI+TACE戦略を考える～ 2021年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ～ABC conversionを含めて～」  [招待講演]
    工藤正俊
    第24回北九州肝癌治療研究会 2021年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ～ABC conversionを含めて～」  [招待講演]
    工藤正俊
    肝細胞がんExpert Meeting in Okinawa 2021年11月 口頭発表（招待・特別）
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～新時代のTKI+TACE戦略を考える～ 2021年11月 口頭発表（招待・特別）
  • 特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [招待講演]
    工藤正俊
    HCC Pioneers Meeting～新時代のTKI+TACE戦略を考える～ 2021年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ～ABC conversionを含めて～」  [招待講演]
    工藤正俊
    第4回東海肝癌フォーラム 2021年11月 口頭発表（招待・特別）
  • Industry-sponsored satellite symposium “An envolving landscape: treatment for intermediate-stage HCC”  [招待講演]
    Masatoshi Kudo
    ESMO Asia Virtual Oncology Week 2021年11月 シンポジウム・ワークショップパネル（指名）
  • Education Lecture “Management of HCC: East vs West”
    Masatoshi Kudo
    Meet-the-Expert Networking Session, AASLD 2021年11月 口頭発表（基調）
  • 肝細胞癌におけるWnt/βカテニン経路活性化と腫瘍免疫環境. シンポジウム8「がん微小環境を標的とした消化器がん治療の新展望」  [通常講演]
    盛田真弘; 西田直生志; 工藤正俊
    第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021) 2021年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • B-mode超音波検査による肝腫瘍検出・診断を支援するAIモデルの開発  [招待講演]
    西田直生志; 工藤正俊
    第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021) 2021年11月 口頭発表（一般） 神戸コンベンションセンター, 兵庫
  • Keynote Lecture “The state-of-art lecture on the treatment of liver cancer”  [招待講演]
    Masatoshi Kudo
    Japan Digestive Disease Week (JDDW 2021) 2021年11月 口頭発表（基調） Kobe Convention Center, Hyogo
  • Chair: International Session Symposium 3「Advances in the treatment of the liver cancer: the stage-of-the-art researches to provide the precision medicine and improve the prognosis」  [招待講演]
    Masatoshi Kudo
    第29回日本消化器関連学会週間JDDW 2021（第63回日本消化器病学会大会, 第25回日本肝臓学会大会, 第102回日本消化器内視鏡学会総会） 2021年11月 その他 神戸コンベンションセンター, 兵庫.
  • Gd-EOB-DTPA-enhanced MRI肝細胞相で高信号の肝細胞癌は、PD-1/PD-L1療法への一次耐性を反映し予後不良である
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎正勝; 西田直生志; 工藤正俊
    第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021) 2021年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討. ワークショップ3「薬物性肝障害の実態」
    萩原 智; 西田直生志; 工藤正俊
    第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021) 2021年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • 司会; ランチョンセミナー36「肝細胞癌治療の最新の話題」  [招待講演]
    工藤正俊
    第29回日本消化器関連学会週間JDDW 2021（第63回日本消化器病学会大会, 第25回日本肝臓学会大会, 第102回日本消化器内視鏡学会総会） 2021年11月 その他 神戸コンベンションセンター, 兵庫
  • ランチョンセミナー;肝細胞癌治療の最新の話題  [招待講演]
    工藤正俊
    JDDW 2021 Kobe 2021年11月 公開講演，セミナー，チュートリアル，講習，講義等 神戸国際展示場, 兵庫
  • 開会の挨拶  [招待講演]
    工藤正俊
    第41回南大阪肝疾患研究会 2021年10月 その他
  • 特別講演「肝細胞癌に対する免疫療法時代の夜明け—ABC conversion therapyを含めて-」  [招待講演]
    工藤正俊
    第3回Nagasaki HCC Web Seminar new era 2021年10月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療における肝予備能維持の重要性」  [招待講演]
    工藤正俊
    中外Eセミナー 2021年10月 口頭発表（招待・特別）
  • Invited Lecture “New stage of treatment strategies for intermediate stage HCC”  [招待講演]
    Masatoshi Kudo
    China-Japan Liver Cancer Alliance Online and Offline Redional Meeting in Wuhan 2021年10月 口頭発表（招待・特別）
  • 教育講演「アテゾリズマブ＋ベバシズマブ併用療法による肝細胞癌治療の新しいパラダイム」, 教育シンポジウム「免疫チェックポイント阻害薬の併用療法」  [招待講演]
    工藤正俊
    第59回日本癌治療学会学術集会 2021年10月 シンポジウム・ワークショップパネル（指名）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ～ABC conversionを含めて～」  [招待講演]
    工藤正俊
    肝細胞がんExpert Meeting in Miyazaki 2021年10月 口頭発表（招待・特別） ニューウェルシティ宮崎, 九州
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    テセントリク/アバスチンHCC適応拡大1周年記念講演会 in 会津若松 2021年10月 口頭発表（招待・特別）
  • Invited Lecture “Overview of NAFLD/NASH in HCC”  [招待講演]
    Masatoshi Kudo
    HCC Eastern Pioneers Meeting 2021年10月 口頭発表（招待・特別）
  • Chair: Luncheon Seminar IV  [招待講演]
    Masatoshi Kudo
    JSH International Liver Conference 2021 2021年10月 その他 博多国際展示場&カンファレンスセンター, 福岡
  • 特別講演「TACEとレンバチニブによる新時代の治療戦略」  [招待講演]
    工藤正俊
    LENVIMA-HCC Web Seminar－新展開を迎えたIVR治療とレンバチニブの共存 2021年09月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞癌治療戦略2021」  [招待講演]
    工藤正俊
    HCC Expert Meeting in Saitama～免疫療法時代における最良の治療を考える～ 2021年09月 口頭発表（招待・特別）
  • Detective flow imaging (DFI)にて特徴的な血流血管を観察し得たIntraductal papillary neoplasm of bile duct (IPNB)の2例. Young Investigator Session 14「胆道」
    上中大地; 岡本彩那; 大本俊介; 原 茜; 大塚康生; 益田康弘; 高島耕太; 吉田晃浩; 山﨑友裕; 三長孝輔; 鎌田 研; 山雄健太郎; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 口頭発表（一般）
  • 肝細胞癌に対してアテゾリズマブ＋ベバシズマブ療法を行いirAEと思える髄膜炎をきたした1例. Young Investigator Session 13「肝2」
    松原卓哉; 今村瑞貴; 大丸直哉; 河野辰也; 半田康平; 田中秀和; 橋本有人; 木下大輔; 川崎俊彦; 水野成人; 塩山実章; 工藤正俊
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 口頭発表（一般）
  • インフリキシマブが有効であった腸型Bechet病のサイトカイン反応の解析. Young Investigator Session 7「大腸1」
    吉川馨介; 渡邉智裕; 瀬海郁衣; 高田隆太郎; 原 茜; 栗本真之; 益田康弘; 大塚康夫; 吉川智恵; 正木 翔; 鎌田 研; 三長孝輔; 米田頼晃; 工藤正俊; 筑後孝章
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 口頭発表（一般）
  • TNF-αおよびIL-6の関与が考えられた好酸球性胃腸炎の一例. Young Investigator Session 2「胃・十二指腸1」
    瀬海郁衣; 吉川馨介; 高田隆太郎; 原 茜; 吉川智恵; 鎌田 研; 三長孝輔; 渡邉智裕; 工藤正俊
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 口頭発表（一般）
  • EUS-FNAにて術前診断できた食道schwannomaの一例、Young Investigator Session 1「食道、
    福西香栄; 松井繁長; 杉森啓伸; 高田隆太郎; 正木 翔; 河野匡志; 永井知行; 米田頼晃; 山﨑友裕; 山雄健太郎; 竹中 完; 本庶 元; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊; 白石 治; 安田卓司
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 口頭発表（一般）
  • ウステキヌマブの潰瘍性大腸炎への有効性と安全性の検討. シンポジウム5「炎症性腸疾患治療の最前線」
    永井知行; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 シンポジウム・ワークショップパネル（公募）
  • 急性膵炎からアプローチする膵癌早期診断. シンポジウム4「胆膵腫瘍の診断と治療up to date」
    山雄健太郎; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第115回例会（Web） 2021年09月 シンポジウム・ワークショップパネル（公募）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    肝がん治療最前線in熊本—根治をゴールとした治療戦略— 2021年09月 口頭発表（招待・特別）
  • Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD  [通常講演]
    Ikeda M; Yamashita T; Ogasawara S; Kudo M; Inaba Y; Morimoto M; Tsuchiya K; Shimizu S; Kojima Y; Hiraoka A; Nouso K; Aikata H; Numata K; Sato T; Okusaka T; Furuse J
    Europian Society for Medical Oncology (ESMO) congress 2021年09月 ポスター発表
  • 特別講演「肝腫瘍のAI診断up-date: screening動画像からの検出と診断能」  [招待講演]
    工藤正俊
    日本超音波医学会第42回中部地方会 2021年09月 口頭発表（招待・特別）
  • ランチョンセミナー「肝細胞癌に対する治療戦略—内科的治療のsimulation/navigationも含めて－」  [招待講演]
    工藤正俊
    第15回肝癌治療ナビゲーション研究会 2021年09月 口頭発表（招待・特別） JRホテルクレメント徳島, 徳島
  • Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON  [通常講演]
    Kudo M; Lencionia R; Ozgurdal K; Peck-Radosavljevic M
    The International Liver Cancer Association (ILCA 2021) 2021年09月 ポスター発表
  • IMbrave150: Albumin-bilirubin grade analyses in a phase III study of atezolizumab + bevacizumab versus sorafenib in patiens with unresectable hepatocellular carcinoma  [通常講演]
    Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle P; Gaillard VE; Nicholas A; Vogel A
    The International Liver Cancer Association (ILCA 2021) 2021年09月 口頭発表（一般）
  • Nivolumab (NIVO) in sorafenib (SOR)-naive and -experienced patients with advanced hepatocellular carcinoma (aHCC): 5-year follow-up from CheckMate 040 cohorts 1 and 2  [通常講演]
    Trojan J; Meyer T; Yau T; Melero I; Kudo M; Hsu C; Kim TY; Choo SP; Kang YK; Yeo W; Chopra A; Soleymani S; Yao J; Neely J; Tschaika M; Welling III TH; Sangro B; El-Khoueiry A
    The International Liver Cancer Association (ILCA 2021) 2021年09月 口頭発表（一般）
  • Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Updated interim analysis of the prospective observational REFINE study  [通常講演]
    Lim HY; Merle P; Ikeda M; Masi G; Finn RS; Frenette C; Klümpen HJ; Kim YJ; Gerolami R; Kurosaki M; Numata K; Zebger-Gong H; Fiala-Buskies S; Ozgurdal K; Kudo M; Qin S
    The International Liver Cancer Association (ILCA 2021) 2021年09月 口頭発表（一般）
  • Invited Lecture “Multidisciplinary management of intermediate stage HCC”  [招待講演]
    Masatoshi Kudo
    Taiwan Association for the Study of the Liver (TASL 2021) 2021年08月 口頭発表（招待・特別）
  • 司会; ランチョンセミナー「高齢化するHCC患者の実情—これからの個別化治療戦略—」  [招待講演]
    工藤正俊
    第24回日本肝がん分子標的治療研究会 2021年08月 その他 富山国際会議場, 富山
  • プレナリーセッション「切除不能肝細胞癌に対する肝動脈化学塞栓療法（TACE）とLenvatinibの併用療法第II相臨床試験（TACTICS-L）: 中間解析結果」  [招待講演]
    石川 達; 上嶋一臣; 佐伯一成; 森本直樹; 相方 浩; 田邊暢一; 稲葉吉隆; 和田幸之; 近藤泰輝; 津田政広; 中尾一彦; 池田公史; 森口理久; 葛谷貞二; 小林正宏; 古賀浩徳; 日野啓輔; 鈴木義之; 吉村健一; 工藤正俊
    第24回日本肝がん分子標的治療研究会 2021年08月 シンポジウム・ワークショップパネル（指名） 富山国際会議場, 富山
  • Plenary Session “Prognositc and predictive factors with ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: two Phase III trials”  [招待講演]
    Kudo M; Llovet JM; Singal AG; Villanueva A; Finn RS; Galle PR; Wang C; Widau RC; Gonzalez GE; Zhu AX
    The 24th Japan Society for Molecular Targeted Therapy for HCC 2021年08月 シンポジウム・ワークショップパネル（指名） Toyama
  • 司会; スポンサードシンポジウム「肝癌に対する分子標的薬治療の最前線」  [招待講演]
    沖田 極; 工藤正俊
    第24回日本肝がん分子標的治療研究会 2021年08月 その他 富山国際会議場, 富山
  • 基調講演「Earlyからintermediate stageにおける肝細胞癌薬物療法の最前線」, スポンサードシンポジウム「肝癌に対する分子標的薬治療の最前線」  [招待講演]
    工藤正俊
    第24回日本肝がん分子標的治療研究会 2021年08月 口頭発表（基調） 富山国際会議場, 富山
  • 開会の辞  [招待講演]
    工藤正俊
    第24回日本肝がん分子標的治療研究会 2021年08月 その他 富山国際会議場, 富山
  • Chairs: Session 10 “Systemic Therapy for Advanced HCC”  [招待講演]
    Kudo M
    The 11th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2021) 2021年08月 その他
  • Invited Lecture “Role of systemic therapy in early HCC patients hepatologist perspectives.  [招待講演]
    Kudo M
    11th Asian Pacific Association for the Study of the Liver 2021 (APASL 2021) 2021年08月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌に対する免疫療法時代の夜明け—ABC conversion therapyを含めて－」  [招待講演]
    工藤正俊
    中四国肝細胞薬物療法セミナー 2021年08月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC Webカンファランスin静岡 2021年08月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    Intermediate Stage HC治療戦略を考える会 2021年08月 口頭発表（招待・特別）
  • 特別講演「Intermediate Stage肝細胞癌の治療戦略—ABC conversion therapy—」  [招待講演]
    工藤正俊
    中外Eセミナー 2021年08月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    肝細胞がんExpert Meeting in Okinawa 2021年07月 口頭発表（招待・特別）
  • Invited Lecture “CEUS in small focal liver lesions”  [招待講演]
    Masatoshi Kudo
    Euroson School-Shanghai 2021 2021年07月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC Expert Meeting in愛媛 2021年07月 口頭発表（招待・特別）
  • 肝癌研究会追跡調査よりみたHCV肝炎関連肝内胆管癌の肝切除後長期成績の検討. ワークショップ4「肝内胆管癌の診断・治療の最前線」  [通常講演]
    海堀昌樹; 吉井健悟; 柏原康佑; 國土貴嗣; 長谷川 潔; 泉 並木; 村上卓道; 工藤正俊; 椎名秀一朗; 坂元亨宇; 中島 収; 松山 裕; 江口 晋; 山下竜也; 高山忠利; 國土典宏; 久保正二
    第57回日本肝癌研究会 2021年07月 シンポジウム・ワークショップパネル（公募） 城山ホテル鹿児島, 鹿児島
  • 肝細胞癌の腫瘍径・腫瘍個数による手術、TACE、焼灼療法の生存予測（日本肝癌研究会追跡調査）. パネルディスカッション2「IT・AIを活用した肝癌診療、病理・画像診断の現状と展望」  [通常講演]
    河口義邦; 長谷川 潔; De Bellis Mario; Famularo Simone; Panettieri Elena; 松山 裕; 建石良介; 市川智章; 國土貴嗣; 泉 並木; 久保正二; 坂元亨宇; 椎名秀一朗; 高山忠利; 中島 収; 村上卓道; Vauthey Jean-Nicolas; 工藤正俊; 國土典宏
    第57回日本肝癌研究会 2021年07月 シンポジウム・ワークショップパネル（公募） 城山ホテル鹿児島, 鹿児島
  • Intermediate stage肝細胞癌における分子標的薬の役割. シンポジウム4「Intermediate stage HCCの治療戦略」  [通常講演]
    上嶋一臣; 青木智子; 工藤正俊
    第57回日本肝癌研究会 2021年07月 シンポジウム・ワークショップパネル（公募） 城山ホテル鹿児島, 鹿児島
  • EOT造影MRIをbiomarkerとした肝細胞癌のWNT/beta-catenin mutation/activationの評価と治療効果予測. ワークショップ1「肝癌薬物治療の効果予測の新しい試み」  [通常講演]
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 南 康範; 萩原 智; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊
    第57回日本肝癌研究会 2021年07月 シンポジウム・ワークショップパネル（公募） 城山ホテル鹿児島, 鹿児島
  • SURF trial RCT: 全生存の報告、早期肝細胞癌に対する手術vs. RFA. シンポジウム2「早期肝癌の精度診断・治療」  [通常講演]
    居村 暁; 島田光生; 長谷川 潔; 河口義邦; 高山忠利; 泉 並木; 山中若樹; 工藤正俊; 猪股雅史; 金子周一; 馬場秀夫; 小池和彦; 小俣政男; 幕内雅敏; 松山 裕; 國土典宏; SURF Trialグループ
    第57回日本肝癌研究会 2021年07月 シンポジウム・ワークショップパネル（公募） 城山ホテル鹿児島, 鹿児島
  • 二次治療以降におけるアテゾリズマブ・ベバシズマブの臨床成績. シンポジウム1「複合免疫療法時代を迎えた新たな進行肝癌治療」  [通常講演]
    上嶋一臣; 青木智子; 工藤正俊
    第57回日本肝癌研究会 2021年07月 シンポジウム・ワークショップパネル（公募） 城山ホテル鹿児島, 鹿児島
  • 司会: ランチョンセミナー「肝内胆管癌における新たな個別化治療のアプローチ」  [招待講演]
    工藤正俊
    第57回日本肝癌研究会 2021年07月 その他 城山ホテル鹿児島, 鹿児島
  • 司会; スポンサードシンポジウム「消化器癌におけるがんゲノム診断と分子標的治療」  [招待講演]
    工藤正俊
    第57回日本肝癌研究会 2021年07月 その他 城山ホテル鹿児島, 鹿児島
  • 座長: イブニングセミナー1  [招待講演]
    工藤正俊
    第57回日本肝癌研究会 2021年07月 その他 城山ホテル鹿児島, 鹿児島
  • ランチョンセミナー「肝細胞癌薬物療法新時代における新たな選択肢 ～カボザンチニブの役割～」  [招待講演]
    工藤正俊
    第57回日本肝癌研究会 2021年07月 公開講演，セミナー，チュートリアル，講習，講義等
  • 座長「がん免疫療法に関する育薬研究」  [招待講演]
    工藤正俊
    Chugai Cancer Immunotherapy Forum 2021 2021年07月 口頭発表（招待・特別）
  • Invited Lecture “Sequential treatment for advanced HCC based on real-world data”  [招待講演]
    Masatoshi Kudo
    IASL annual conference 2021 2021年07月 口頭発表（招待・特別）
  • Invited Web Lecture “Sequential treatment for advanced HCC based on real-world-data”  [招待講演]
    Masatoshi Kudo
    International Association for the Study of the Liver (IASL) Annual Conference 2021年07月 口頭発表（招待・特別）
  • EUS-FNAにて診断可能であった、肝限局性結節性過形成の一例. Young Endoscopist Session 7「肝胆膵1」
    今村瑞貴; 福永朋洋; 野村健司; 河野辰也; 半田康平; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊
    第106回日本消化器内視鏡学会近畿支部例会 2021年07月 口頭発表（一般） リーガロイヤルホテル大阪, 大阪
  • 胆道Plastic stentドレナージのre-interventionにおけるsnare over the guidewire法の有用性. ワークショップ2「胆膵内視鏡のトラブルマネジメント」
    吉田晃浩; 竹中 完; 山雄健太郎; 樫田博史; 工藤正俊
    第106回日本消化器内視鏡学会近畿支部例会 2021年07月 シンポジウム・ワークショップパネル（公募） リーガロイヤルホテル大阪, 大阪
  • 膵上皮内癌におけるEUS所見の検討. パネルディスカッション1「胆膵疾患に対する内視鏡診断・治療の工夫」
    山雄健太郎; 竹中 完; 樫田博史; 工藤正俊
    第106回日本消化器内視鏡学会近畿支部例会 2021年07月 シンポジウム・ワークショップパネル（公募） リーガロイヤルホテル大阪, 大阪
  • カプセルおよびバルーン小腸内視鏡で比較的早期に発見し根治手術を行った原発性小腸癌の一例. Young Endoscopist Session 5「消化管5」
    吉田早希; 米田頼晃; 原 茜; 益田康弘; 高田隆太郎; 正木 翔; 河野匡志; 永井知行; 本庶 元; 松井繁長; 櫻井俊治; 辻 直子; 樫田博史; 工藤正俊
    第106回日本消化器内視鏡学会近畿支部例会 2021年07月 口頭発表（一般） リーガロイヤルホテル大阪, 大阪
  • 内視鏡で保存的に回収できた胃石の一例. Young Endoscopist Session 4「消化管4」
    杉本啓伸; 本庶 元; 原 茜; 益田康弘; 吉田早希; 高田隆太郎; 河野匡志; 正木 翔; 永井知行; 米田頼晃; 櫻井俊治; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊
    第106回日本消化器内視鏡学会近畿支部例会 2021年07月 口頭発表（一般） リーガロイヤルホテル大阪, 大阪
  • アザシチジン投与が有効であったMDS関連腸管潰瘍. シンポジウム2「炎症性腸疾患診断・治療における内視鏡検査の現状と課題」
    河野匡志; 永井知行; 米田頼晃; 櫻井俊治; 工藤正俊
    第106回日本消化器内視鏡学会近畿支部例会 2021年07月 シンポジウム・ワークショップパネル（公募） リーガロイヤルホテル大阪, 大阪
  • Invited Lecture “Recent advances in treatment of intermediate stage HCC”  [招待講演]
    Masatoshi Kudo
    Meet the Expert 2021年07月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    第67回大阪肝穿刺生検治療研究会 2021年07月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC Meet the Expert in TAMA 2021年07月 口頭発表（招待・特別）
  • Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073  [通常講演]
    Sangro B; Numata K; Huang Y; Gomez-Martin C; Hiraoka A; Moriguchi M; Shen Y; Horvath A; Feely W; Young T; Neely J; Kudo M
    ESMO World Congress on Gastrointestinal Cancer 2021 (ESMO-GI 2021) 2021年07月 ポスター発表
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    カボメディクスWeb Seminar 2021年07月 口頭発表（招待・特別）
  • Invited Lecture “Emerging role of Lenvatinib in the new era of treatment stragety in HCC”  [招待講演]
    Masatoshi Kudo
    Eisai Oncology Liver Webinar~Optimizing the role of MKIs in the new era of HCC treatment~ 2021年07月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    肝がんクラスター講演会2021 2021年06月 口頭発表（招待・特別）
  • Pembrolizumab/Quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress  [通常講演]
    Li D; Cheng AL; Lim HY; Llovet JM; Zhu Y; Hatogai K; Siegel AB; Kudo M
    ESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2021) 2021年06月 ポスター発表
  • Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON.
    Peck-Radosavljevic M; Lencionia R; Ozgurdal K; Kudo M
    23rd World Congress on Gastrointestinal Cancer (WCGI 2021) 2021年06月 ポスター発表
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC-Expert Meeting～免疫療法時代における薬物治療を考える～ 2021年06月 口頭発表（招待・特別）
  • CheckMate 040: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma: associations between baseline biomarker analyses and outcomes  [通常講演]
    Matilla A; Sangro B; El-Khoueiry AB; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; De Costanzo F; Crysler O; Reig M; Shen Y; Yao J; Neely J; Tschaika M; Kudo M
    The International Liver Congress 2021 (EASL 2021) 2021年06月 口頭発表（一般）
  • Invited Web Lecture “Advanced HCC: Advances in Targeted and Immune-Therapies”  [招待講演]
    Masatoshi Kudo
    ISVHLD GHS 2021 Conference 2021年06月 口頭発表（招待・特別）
  • Invited Web Lecture “TKIs still have roles for advanced HCC”  [招待講演]
    Masatoshi Kudo
    Asian Pacific Association for the Study of the Liver (APASL 2021) 2021年06月 口頭発表（招待・特別）
  • ランチョンセミナー「肝細胞癌領域におけるがん免疫療法の最新Topics」  [招待講演]
    工藤正俊
    第57回日本肝臓学会総会 2021年06月 公開講演，セミナー，チュートリアル，講習，講義等
  • Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L+P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC)  [通常講演]
    Zhu AX; Llovet JM; Kobayashi M; Ikeda M; Gerolami R; Pracht M; Sung MW; Baron AD; Kudo M; Meyer T; Okusaka T; Kumada H; Kaneko S; Hoshi T; Saito K; Li SD; Funahashi Y; Minoshima Y; Dubrovsky L; Finn RS
    American Society of Clinical Oncology (ASCO 2021) 2021年06月 ポスター発表
  • Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): phase 2 KEYNOTE-224 study  [通常講演]
    Laethem JLV; Borbath I; Karwal M; Verslype C; Vlierberghe HV; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline S; Cattan S; Kudo M; Cheng AL; Ogasawara S; Siegel AB; Chisamore MJ; Wang A; Zhu AX
    American Society of Clinical Oncology (ASCO 2021) 2021年06月 ポスター発表
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC Meet the Expert in Tokyo (Web) 2021年06月 口頭発表（招待・特別）
  • Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): results from two Phase III trials.  [通常講演]
    Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Wang C; Widau RC; Gugel EG; Zhu AX
    American Society of Clinical Oncology (ASCO 2021) 2021年06月 ポスター発表
  • Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single arm trial and exploratory biomarker analysis  [通常講演]
    Kudo M; Ueshima K; Nakahira S; Nishida N; Ida H; Minami Y; Kobayashi S; Umeda M; Tsurusaki M; Chiba Y; Yoshimura K; Sakai K; Nishio K
    American Society of Clinical Oncology (ASCO 2021) 2021年06月 ポスター発表
  • A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): analysis of overall survival  [通常講演]
    Kudo M; Hasegawa K; Kawaguchi Y; Takayama T; Izumi N; Yamanaka N; Shimada M; Inomata M; Kaneko S; Baba H; Koike K; Omata M; Makuuchi M; Matsuyama Y; Kokudo N
    American Society of Clinical Oncology (ASCO 2021) 2021年06月 ポスター発表
  • GPSマーカーを用いた安全なRFA治療の工夫, ミニワークショップ「消化器」
    小川 力; 工藤正俊
    日本超音波医学会第94回学術集会 2021年05月 シンポジウム・ワークショップパネル（公募） 神戸ポートピアホテル, 兵庫
  • 胆嚢病変に対するDetective flow imaging (DFI)の有用性について, パネルディスカッション消化器4「胆嚢壁肥厚の鑑別診断」
    竹中 完; 大本俊介; 工藤正俊
    日本超音波医学会第94回学術集会 2021年05月 シンポジウム・ワークショップパネル（公募） 神戸ポートピアホテル, 兵庫
  • ラジオ波焼灼術の治療ガイド: US-US overlay fusionの使い方, パネルディスカッション消化器1「最新の超音波技術を用いた肝癌治療支援」
    南 康範; 工藤正俊
    日本超音波医学会第94回学術集会 2021年05月 シンポジウム・ワークショップパネル（公募） 神戸ポートピアホテル, 兵庫
  • 基調講演「CEUS LI-RADSを知る」, シンポジウム消化器2「超音波による肝腫瘍病変の鑑別診断～造影、各種血流評価方法、硬度測定などの技術を用いて～」
    南 康範; 工藤正俊
    日本超音波医学会第94回学術集会 2021年05月 シンポジウム・ワークショップパネル（公募） 神戸ポートピアホテル, 兵庫
  • Walled-off necrosisに対するEUS-guided cyst drainageにおける造影EUSの有用性. シンポジウム消化器1「胆膵領域における超音波内視鏡の最前線」  [通常講演]
    竹中 完; 工藤正俊
    日本超音波医学会第94回学術集会 2021年05月 シンポジウム・ワークショップパネル（公募） 神戸ポートピアホテル, 兵庫
  • Invited Web Lecture “Cyramza: A new treatment option reach to hepatocellular carcinoma”  [招待講演]
    Masatoshi Kudo
    Cyramza HCC Launch Meeting - Kaohsiung (Web) 2021年05月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC-Expert Meeting～免疫療法時代における薬物治療を考える～ 2021年05月 口頭発表（招待・特別）
  • 特別講演「B型肝炎に対する今後の核酸アナログ製剤の選択は？」  [招待講演]
    工藤正俊
    第5回関西肝疾患フォーラム 2021年05月 口頭発表（招待・特別）
  • Invited Web Lecture “Cyramza: A new treatment option reach to hepatocellular carcinoma”  [招待講演]
    Masatoshi Kudo
    Cyramza HCC Launch Meeting (Web) 2021年04月 口頭発表（招待・特別）
  • Invited Web Lecture “Combination immunotherapy for HCC”  [招待講演]
    Masatoshi Kudo
    State Key Laboratory of Liver Research (SKLLR) 2021年04月 口頭発表（招待・特別）
  • IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)  [通常講演]
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Lim HY; Breder VV; Merle P; Kaseb AO, Li D; Feng YH; Verret W; Nicholas A; Li L; Ma N; Zhu AX; Cheng AL
    American Association for Cancer Research Annual Meeting (AACR 2021) 2021年04月 口頭発表（一般）
  • Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study  [通常講演]
    Fessas P; Naeem M; Marron TU; Szafron D; Sharon E; Saeed A; Jun T; Dharmapuri S; Naqash AR; Peeraphatdit T; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee CJ; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; Nishida N; Kudo M; Kaseb A; Huang YH; Ang C; Pillai A; Rimassa L; Pinato DJ
    American Association for Cancer Research Annual Meeting (AACR 2021) 2021年04月 ポスター発表
  • Invited Lecture “Multidisplinary approch for better outcomes in intermediate stage HCC”  [招待講演]
    Masatoshi Kudo
    APASL-TLW Symposium 06 (Multidisciplinary Approach for Achieving Complete Remission), 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) 2021年04月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    肝癌治療Meet the Expert (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    肝疾患Webセミナー 2021年03月 口頭発表（招待・特別）
  • ラジオ波焼灼術後の焼灼高エコー域を壊死部とみなしてよいか？  [通常講演]
    南 康範; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第34回日本腹部造影エコー・ドプラ診断研究会 2021年03月 口頭発表（一般）
  • 造影USでの早期の治療効果が有効であったHCCに対するAtezolizumab+Bevacizumab療法の一例  [通常講演]
    福家和諭; 小川 力; 工藤正俊
    第34回日本腹部造影エコー・ドプラ診断研究会 2021年03月 口頭発表（一般）
  • 特別講演「肝腫瘍の超音波診断のこれまでと今後: 造影エコーの役割とAI診断開発の現状」  [招待講演]
    工藤正俊
    第34回日本腹部造影エコー・ドプラ診断研究会 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物治療新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    カボメティクスWebセミナー 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    HCC Web Conference (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    第3回Saitama HCC Web Conference～肝がん薬物治療を再考する～(Web) 2021年03月 口頭発表（招待・特別）
  • KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Vogel A; Zhu AX; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo M
    SIR 2021 congress 2021年03月 ポスター発表
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    HCC Web Conference (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    HCC Expert Web Seminar (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    Lenvatinib HCC Meet the Expert in豊能 (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    東北のHCC治療を考える会 (Web) 2021年03月 口頭発表（招待・特別）
  • Invited Web Lecture “Role lf systemic therapy in intermediate-stage hepatocellular carcinoma”  [招待講演]
    Masatoshi Kudo
    The Liver Week 2021 2021年03月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    Lenvatinib Meet the Experts in香川 (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    Hokkaido Hepatology Conference Webセミナー (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療におけるAtezo+Bevのエビデンス」  [招待講演]
    工藤正俊
    Chugai Hepatocellular Carcinoma Symposium (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    本郷Liver Cancer Forum (Web) 2021年03月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    HCC Experts Seminar in Hokusetsu (Web) 2021年03月 口頭発表（招待・特別）
  • 内視鏡治療により診断に至った大腸平滑筋肉腫の一例  [通常講演]
    櫻根寛之; 木下大輔; 友岡瑞貴; 野村健司; 福永朋洋; 河野辰哉; 半田康平; 川崎俊彦; 水野成人; 太田善夫; 若狭朋子; 工藤正俊
    日本消化器病学会近畿支部第114回例会 (Web) 2021年02月 口頭発表（一般）
  • 肝外胆管癌のT-stagingに対する造影ハーモニックEUSと造影CTの比較検討. シンポジウム「胆道癌の早期診断と治療における現状と展望」  [通常講演]
    大塚康生; 鎌田 研; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第114回例会 2021年02月 シンポジウム・ワークショップパネル（公募）
  • ランチョンセミナー「肝細胞癌治療における免疫療法時代の到来」  [招待講演]
    工藤正俊
    日本消化器病学会近畿支部第114回例会 (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    香川肝癌Expert Meeting (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    埼玉県適応拡大記念講演会 on HCC (Web) 2021年02月 口頭発表（招待・特別）
  • Invited Web Lecture “Treatment strategy of intermediate/advanced stage HCC”  [招待講演]
    Masatoshi Kudo
    China Medicine Education Association Online Meeting (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    Lenvima-HCC Web Seminar (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [招待講演]
    工藤正俊
    HCC Expert Meeting 三重 (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    第25回岡山肝癌研究会 (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物治療の新展開～免疫療法時代におけるラムシルマブの役割～」  [招待講演]
    工藤正俊
    Lilly HCC Web Conference 2021年02月 口頭発表（招待・特別）
  • Phase 3 KEYNOTE-937 trial: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Vogel A; Zhu A; Kudo M; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Cheng AL
    European Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021 2021年02月 ポスター発表
  • IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label Phase 3 study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder VV; Merle P; Kaseb AO; Li D; Verret W; Shao H; Liu J; Li L; Zhu AX; Cheng AL
    European Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021 2021年02月 口頭発表（一般）
  • Invited Web Lecture “Goals and targets for personalized therapies in hepatocellular carcinoma”  [招待講演]
    Masatoshi Kudo
    30th Annual Conference Asian Pacific Association for the Study of the Liver (APASL 2021) (Web) 2021年02月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療における免疫療法時代の到来」  [招待講演]
    工藤正俊
    日本消化器病学会東北支部第210回例会 2021年02月 口頭発表（招待・特別）
  • Invited Web Lecture “Combination Immunotherapy for HCC”  [招待講演]
    Masatoshi Kudo
    Society of Interventional Oncology (Web) 2021年02月 口頭発表（招待・特別）
  • Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study.
    Masi G; Ikeda M; Finn RS; Merle P; Lim HY; Kudo M; Klümpen HJ; Frenette C; Kim YJ; Gerolami R; Kurosaki M; Numata K; Zebger-Gong H; Fiala-Buskies S; Ozgurdal K; Qin S
    European Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021 2021年02月 ポスター発表
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma Seminar in Mie 2021年02月 口頭発表（招待・特別）
  • IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in unresectable hepatocellular carcinoma
    Ikeda M; Lim HY; Kim TY; Qin S; Finn RS; Galle PR; Ducreux M; Breder V; Merle P; Kaseb A; Li D; Zhu AX; Verret W; Shao H; Liu J; Li L; Cheng AL; Kudo M
    30th Annual Conference Asian Pacific Association for the Study of the Liver (APASL 2021) 2021年02月 口頭発表（一般）
  • A multicenter observational study of lenvatinib for unresectable hepatocellular carcinoma in Japan -Interim analysis
    Izumi N; Motoyoshi K; Kudo M; Motomura K; Inaba Y; Katamura Y; Kondo Y; Yabushita K; Furuse J
    30th Annual Conference Asian Pacific Association for the Study of the Liver (APASL 2021) 2021年02月 ポスター発表
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    Chugai HCC Expert Meeting (Web) 2021年02月 口頭発表（招待・特別）
  • KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation  [通常講演]
    Uppot RN; Kudo M; Zhu AX; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Vogel A
    SIO 2021 congress 2021年02月 ポスター発表
  • 切除不能な肝細胞癌患者に対するレンバチニブの多施設観察研究—中間報告—
    本村健太; 工藤正俊; 泉 並木; 籔下和久; 稲葉吉隆; 片村嘉男; 近藤泰輝; 元吉克明; 古瀬純司
    第23回日本肝がん分子標的治療研究会 2021年01月 ポスター発表
  • Plenary Session ”Novel regimen tremelimumab (T) + durvalumab (D) for patients (pts) with unresectable hepatocellular carcinoma (uHCC): efficacy and safety”
    Kudo M; Okusaka T; Ikeda M; Kelly RK; Sangro B; Harris W; Kang YK; Qin S; Tai DWM; Lim HY; Yau TCC; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; He P; Negro A; Abou-Alfa GK
    The 23rd Japan Society for Molecular Targeted Therapy for Liver Cancer 2021年01月
  • プレナリーセッション「切除不能肝細胞癌におけるアテゾリズマブ（Atezo）+ベバシズマブ（Bev）療法に関する日本人集団の検討—IMbrave 150部分集団解析—」  [招待講演]
    池田公史; 古賀浩徳; 山下竜也; 河上怜恵; 中川雄貴; 工藤正俊
    第23回日本肝がん分子標的治療研究会 2021年01月
  • ランチョンセミナー「肝細胞癌治療における免疫療法時代の到来」  [招待講演]
    工藤正俊
    第23回日本肝がん分子標的治療研究会 (Web) 2021年01月 口頭発表（招待・特別）
  • 開会の辞: 工藤正俊  [招待講演]
    工藤正俊
    第23回日本肝がん分子標的治療研究会 2021年01月 その他
  • Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040
    El-Khoueiry A; Yau T; Kang YK; Kim TY; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox TJ; He AR; El-Rayes BF; Acosta-Rivera M; Lim HY; Memaj A; Sama AR; Hsu C
    Gastrointestinal Cancers Symposium (ASCO-GI 2021) 2021年01月 口頭発表（一般）
  • A Phase 3, double-blind, randomized study of Nivolumab and Ipilimumab, nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma  [通常講演]
    Sangro B; Harding JJ; Johnson M; Palmer D; Edeline J; Abou-Alfa G; Cheng AL; Decaens T; El-Khoueiry AB; Finn R; Galle P; Park JW; Yau T; Begic D; Shen Y; Neely J; Sama A; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2021) 2021年01月 ポスター発表
  • Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study  [通常講演]
    Edeline J; Cattan S; Merle P; Daniele B; Chan SL; Yau T; Bouattour M; Lim HY; Chao Y; Knox J; Ogasawara S; Garrido M; Cheng AL; Zhu AX; Finn RS; Siegel AB; Rahman A; Liu CC; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2021) (Virtual) 2021年01月 ポスター発表
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    カボメティクス全国WEB講演会 2021年01月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌の治療戦略2021」  [招待講演]
    工藤正俊
    Abbvie Web-Seminar 2020年12月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [招待講演]
    工藤正俊
    カボメティクス全国WEB講演会 2020年12月 口頭発表（招待・特別）
  • 分子標的治療をつないで生存利益を得られる切除不能肝癌症例の特徴. パネルディスカッション「肝炎ウイルス制御後の肝癌治療」
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊
    第56回日本肝癌研究会 2020年12月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 切除不能肝細胞癌に対するLenvatinib併用TACE療法の初期経験.パネルディスカッション2「TACEにおける進歩と個別化」
    鶴崎正勝; 上嶋一臣; 青木智子; 沼本勲男; 小田晃義; 柳生行伸; 盛田真弘; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 石井一成; 工藤正俊
    第56回日本肝癌研究会 2020年12月 シンポジウム・ワークショップパネル（公募）
  • 鑑別診断において造影超音波が有用であった多血性の肝内胆管癌の1例  [通常講演]
    盛田真弘; 南 康範; 青木智子; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第56回日本肝癌研究会 2020年12月 ポスター発表
  • CQ解説CQ1 有効なスクリーニング法はあるか？CQ2診断に有用な臨床検査は何か？ シンポジウム4「肝内胆管癌診療ガイドラインについて」  [招待講演]
    南 康範; 工藤正俊; 杉本勝俊; 糸井隆夫; 藤永康成; 角谷眞澄; 村上卓道
    第56回日本肝癌研究会 2020年12月 シンポジウム・ワークショップパネル（公募）
  • 座長; ランチョンセミナー「肝癌におけるサポーティブケア」  [招待講演]
    工藤正俊
    第56回日本肝癌研究会 2020年12月 その他
  • Sponsored Symposium “How to put molecular targeting agents into your practice of hepatocellular carcinoma systemic therapy?: Current state and future perspective.”  [招待講演]
    Masatoshi Kudo
    The 56th Annual Meeting of Liver Cancer Study Group of Japan 2020年12月 シンポジウム・ワークショップパネル（指名）
  • 座長; スポンサードシンポジウム「How to put molecular targeting agents into your practice of hepatocellular carcinoma systemic therapy?: Current state and future perspective」  [招待講演]
    工藤正俊
    第56回日本肝癌研究会 2020年12月 その他
  • 座長; モーニングセミナー「New LOGIQ E10 Seriesが応える！これからの肝腫瘤性病変の超音波診断と治療」  [招待講演]
    工藤正俊
    第56回日本肝癌研究会（Web) 2020年12月 その他
  • BCLC stage B2肝細胞癌に対するLenvatinib先行投与は標準治療となり得るか. シンポジウム「Intermediate stage 肝癌診療の多様性と個別化」
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 小川 力; 和田幸之; 池田公史; 石井 浩; 泉 並木; 工藤正俊
    第56回日本肝癌研究会 2020年12月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 肝細胞癌の遺伝子異常による分類と微小免疫環境. ワークショップ3「肝細胞癌の亜分類」  [招待講演]
    西田直生志; 盛田真弘; 青木智子; 田北雅弘; 萩原 智; 依田 広; 南 康範; 上嶋一臣; 工藤正俊
    第56回日本肝癌研究会 2020年12月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • Invited Web Lecture “Treatment strategy of Intermediate Stage HCC.  [招待講演]
    Masatoshi Kudo
    China Medicine Education Association (CMEA) 2020年12月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療戦略2020」  [招待講演]
    工藤正俊
    HCC Meet the Expert 2020年12月 口頭発表（招待・特別） 仙台厚生病院, Web
  • Special Web Lecture “Novel treatments for advanced HCC”  [招待講演]
    Masatoshi Kudo
    TASL 2020 Annual Meeting & The 2nd TASL-AASLD Joint Symposium & The 2nd TASL-KASL-JSH Joint Symposium 2020年12月 口頭発表（招待・特別）
  • 特別講演「肝がん」  [招待講演]
    工藤正俊
    ウイルス肝炎研究財団主催市民公開講座「専門医に聞く肝臓のお話」 2020年12月 口頭発表（招待・特別） 沖縄県率博物館・美術館 (Web)
  • Invited Web Lecture “REFLECT trial and subsequent study results.”  [招待講演]
    Masatoshi Kudo
    China Medical Education Association (CMEA) (China) 2020年12月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療におけるパラダイムチェンジ」  [招待講演]
    工藤正俊
    テセントリク適応拡大記念講演会（Web) 2020年12月 口頭発表（招待・特別）
  • Invited Web Lecture “Surveillance of HCC in high risk patients: role of PIVKA-II and AFP-L3.”  [招待講演]
    Masatoshi Kudo
    Japan-Thailand HCC Tumor Marker Project 2020年12月 口頭発表（招待・特別）
  • Invited Web Lecture “Treatment strategy of unresecable HCC.”  [招待講演]
    Masatoshi Kudo
    International HPB Congress (Malaysia) 2020年12月 口頭発表（招待・特別）
  • Invited Web Lecture “Treatment strategy of Intermediate Stage HCC.”  [招待講演]
    Masatoshi Kudo
    China Medicine Education Association (CMEA) 2020年12月 口頭発表（招待・特別）
  • Invited Lecture “Paradigm change in the treatment strategy of intermediate/advanced stage.”  [招待講演]
    Masatoshi Kudo
    27th Annual Scientific Meeting of the Indian National Association for the Study of the Liver (INASL) 2020年12月 口頭発表（招待・特別）
  • 難治性腹水に対するデンバーシャント術の試み
    家村郁衣; 青木智子; 田北雅弘; 盛田真弘; 千品寛和; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 鶴崎正勝; 工藤正俊
    第43回日本肝臓学会東部会 2020年12月 ポスター発表 アイーナ, 岩手
  • 進歩する化学療法時代に注意すべき肝細胞癌の遠隔転移
    吉田早希; 青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎正勝; 西田直生志; 工藤正俊
    第43回日本肝臓学会東部会 2020年12月 ポスター発表 アイーナ, 岩手
  • 特別講演「肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    北河内Lenvatinib Meeting (Web) 2020年12月 口頭発表（招待・特別）
  • 進行肝癌に対する免疫チェックポイント阻害薬後レンバチニブ療法の画像評価
    青木智子; 依田 広; 盛田真弘; 南 知宏; 田北雅弘; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊
    日本超音波医学会第93回学術集会 2020年12月 ポスター発表 仙台国際センター, 岩手
  • 特別講演「Intermediate Stage HCCの症例共有」  [招待講演]
    工藤正俊
    LENVIMA Web Seminar (Web) 2020年11月 口頭発表（招待・特別）
  • Invited Web Lecture “Treatment strategies for intermediate stage HCC.”  [招待講演]
    Masatoshi Kudo
    Asia Area Oncology Day 2020年11月 口頭発表（招待・特別） Hilton Taipei Sinban (web)
  • 座長; 特別講演「複合免疫療法時代をむかえた進行肝細胞癌治療」  [招待講演]
    工藤正俊
    第40回南大阪肝疾患研究会 2020年11月 その他
  • 特別講演「肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    LENVIMA Web Seminar 2020年11月 口頭発表（招待・特別）
  • Invited Web Lecture “The changing paradigm for systemic therapy in unresectable HCC  [招待講演]
    Masatoshi Kudo
    Gastroenterological Society of Australia (GESA) Satellite Supported Symposium of Australian Gastroenterology Week (AGW) 2020 2020年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療戦略2020」  [招待講演]
    工藤正俊
    Meet The Expert Forum首都圏連携を考える会-肝癌診療マニュアル第4版に準じた実臨床を考える- 2020年11月 口頭発表（招待・特別）
  • Invited Web Lecture “Results of REFLECT study and subsequent studies.”  [招待講演]
    Masatoshi Kudo
    China Medicine Education Association (CMEA) 2020年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療における免疫療法時代の到来」  [招待講演]
    工藤正俊
    信州肝がん薬物療法Webセミナー 2020年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    Chugai Hepatocellular Carcinoma Symposium 2020年11月 口頭発表（招待・特別） アゴーラリージェンシー堺, 大阪
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    肝細胞癌WEB講演会in広島 2020年11月 口頭発表（招待・特別）
  • 司会; 肝がん分子標的治療研究会共催シンポジウム「レンバチニブの新たな可能性を考える」  [招待講演]
    工藤正俊
    第22回日本肝がん分子標的治療研究会 2020年11月 その他 金沢歌劇座, 石川
  • Plenary Session; Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2)  [招待講演]
    Kudo M; Finn RS; Morimoto M; Rau KM; Ikeda M; Yen CJ; Galle PR; Llovet JM; Daniele B; Lim HY; Liang K; Shinozaki K; Wang C; Yoshikawa R; Abada P; Widau RC; Zhu AX
    The 22nd Japan Society for Molecular Targeted Therapy for Liver Cancer 2020年11月 シンポジウム・ワークショップパネル（指名） Ishikawa, Japan
  • 開会/閉会の挨拶  [招待講演]
    工藤正俊
    第22回日本肝がん分子標的治療研究会 2020年11月 その他 金沢歌劇座, 石川
  • 共催セミナー「HCC全身薬物治療: これまでとこれからの10年」  [招待講演]
    工藤正俊
    第22回日本肝がん分子標的治療研究会 2020年11月 公開講演，セミナー，チュートリアル，講習，講義等 金沢歌劇座, 石川
  • プレナリーセッション「免疫チェックポイント阻害薬登場後のレンバチニブの位置づけ」
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊
    第22回日本肝がん分子標的治療研究会 2020年11月 シンポジウム・ワークショップパネル（公募） 金沢歌劇場, 金沢
  • LEAP-012 trial in progress: pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatment
    Vogel A; Llovet JM; El-Khoueiry A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
    American Association for the Study of Liver Diseases (AASLD 2020) 2020年11月 ポスター発表 Boston, USA
  • KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Vogel A; Zhu A; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo M
    American Association for the Study of Liver Diseases (AASLD 2020) 2020年11月 ポスター発表 Boston, USA
  • 特別講演「肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    LENVIMA-HCC Meet The Expert 2020年11月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌治療に関する最新情報」  [招待講演]
    工藤正俊
    奈良県消化器癌講演会 2020年11月 口頭発表（招待・特別） The Kashihara, 奈良
  • 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異. シンポジウム3「肝癌診療の現状と未来」
    西田直生志; 盛田真弘; 工藤正俊
    第28回日本消化器関連学会週間 2020年11月 シンポジウム・ワークショップパネル（公募）
  • 切除不能肝細胞癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ二次療法
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊
    第28回日本消化器病関連学会週間（JDDW2020） 2020年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • 全身化学療法により生存利益を得られる切除不能C型肝細胞癌の特徴  [通常講演]
    青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊
    第28回日本消化器病関連学会週間（JDDW2020） 2020年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • 特別講演「肝細胞癌治療のパラダイムチェンジ」  [招待講演]
    工藤正俊
    Chugai Hepatocellular Carcinoma Seminar in Hokkaido 2020年10月 口頭発表（招待・特別） センチュリーロイヤルホテル, 札幌
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    肝癌Expert Meeting—New Paradigm of Treatment Strategy 2020年10月 口頭発表（招待・特別）
  • Invited Web Lecture “Results of REFLECT study and subsequent studies.”  [招待講演]
    Masatoshi Kudo
    China Medicine Education Association (CMEA) 2020年10月 口頭発表（招待・特別）
  • 特別講演「肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    LENVIMA-HCC Web Seminar in 高槻 2020年10月 口頭発表（招待・特別）
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    HCC Expert Meeting—新時代における薬物療法を考える 2020年10月 口頭発表（招待・特別）
  • Invited Lecture “Treatment strategy of Intermediate Stage HCC.”  [招待講演]
    Masatoshi Kudo
    The Fifth International Conference on Cancer Precision Medicine Seminar (中国対象 Web) 2020年10月 口頭発表（招待・特別）
  • Invited Lecture “AI-aided detection and diagnosis of liver tumors.”  [招待講演]
    Masatoshi Kudo
    2nd Asia Pacific International Symposium on Advances in Medical Ultrasound (APISAMU) 2020年10月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌薬物治療の新たな選択肢—テセントリク、アバスチン併用療法—」  [招待講演]
    工藤正俊
    中外Eセミナーon Hepatocellular Carcinoma 2020年10月 口頭発表（招待・特別） ホテル・アゴーラリージェンシー堺, 大阪
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    肝癌Expert Meeting—New Paradigm of Treatment Strategy—10 (Web) 2020年10月 口頭発表（招待・特別）
  • 特別講演「超音波デジタル画像のナショナルデータベース構築と超音波AI診断の開発」  [招待講演]
    工藤正俊
    第30回四国地方会学術集会 2020年10月 口頭発表（招待・特別） 愛媛大学, 四国
  • Invited Lecture “Treatment strategy of Intermediate Stage HCC.”  [招待講演]
    Masatoshi Kudo
    China Medicine Education Association (CMEA) 2020年10月 口頭発表（招待・特別）
  • Invited Lecture “New Paradigm of Treatment Strategy for Patients in BCLC B HCC.”  [招待講演]
    Masatoshi Kudo
    India Webinar HCC Expert Meeting (インド対象 Web） 2020年10月 口頭発表（招待・特別）
  • 鑑別診断に造影超音波が有用であった多血性の肝内胆管癌の1例
    吉田早希; 南 康範; 盛田真弘; 青木智子; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • Detective flow imaging (DFI)にて特徴的な腫瘍内血流を観察し得たIntraductal papillary neoplasm of the bile duct (IPNB)の1例
    尼崎雅也; 大本俊介; 吉田晃浩; 田中秀和; 石川 嶺; 岡本彩那; 山崎友裕; 中井敦史; 三長孝輔; 鎌田 研; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • 膵神経内分泌腫瘍治癒切除後の肝転移再発を認め切除された一例
    杉崎俊亮; 川崎俊彦; 福永朋洋; 野村健司; 米澤真衣; 半田康平; 河野辰哉; 橋本有人; 木下大輔; 水野成人; 若狭朋子; 太田善夫; 辻本智之; 橋本和彦; 石川 原; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • Bouveret症候群に対して電気水圧結石破砕術（EHL）が有効であった1症例
    山岡諭史; 半田康平; 野村健司; 米澤真衣; 河野辰哉; 福永朋洋; 橋本有人; 木下大輔; 川崎俊彦; 水野成人; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • 切除不能進行肝癌に対する免疫チェックポイント阻害薬不応後の二次治療を見据えて. シンポジウム「消化管癌化学療法の進歩と課題」
    青木智子; 萩原 智; 上嶋一臣; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 早期胃胎児消化管上皮類似癌の1例
    岡井夏輝; 松井繁長; 正木 翔; 栗本真之; 大丸直哉; 友岡瑞貴; 益田康弘; 高田隆太郎; 高島耕太; 河野匡志; 永井知行; 米田頼晃; 本庶 元; 櫻井俊治; 辻 直子; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • 当院における新規胆管ステント留置術. ワークショップ「胆膵領域における内視鏡手技の進歩」
    田中秀和; 中井敦史; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 膵腫瘤性病変におけるDetective flow imaging (DFI)の有用性について. パネルディスカッション「胆膵領域癌に対する診断の取り組み」
    田中隆光; 大本俊介; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • JAK阻害薬を用いた潰瘍性大腸炎の治療戦略. パネルディスカッション「炎症性腸疾患の現状と課題」
    友岡瑞貴; 櫻井俊治; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • ヒマシ油ブースターによる大腸カプセル内視鏡検査の新しい前処置軽減の試み（前向き観察研究）. ワークショップ「消化管腫瘍の診断と治療における工夫」  [通常講演]
    高島耕太; 米田頼晃; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 胃底腺型胃癌の内視鏡診断と治療. ワークショップ「消化管腫瘍の診断と治療における工夫」  [通常講演]
    益田康弘; 松井繁長; 櫻井俊治; 工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 司会; ランチョンセミナー「腹腔内感染症の治療戦略」  [招待講演]
    工藤正俊
    日本消化器病学会近畿支部第113回例会 2020年10月 その他 大阪国際会議場, 大阪
  • 特別講演「肝細胞癌治療における免疫療法時代の到来」  [招待講演]
    工藤正俊
    中外Eセミナーon Hepatocellular Carcinoma 2020年10月 口頭発表（招待・特別） ホテル・アゴーラリージェンシー堺, 大阪
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    HCC-Expert Meeting～新時代における薬物療法を考える～（Web） 2020年09月 口頭発表（招待・特別）
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    HCC Expert Meeting in 熊本 2020年09月 口頭発表（招待・特別）
  • LEAP-012 trial in progress: pembrolizumab plus Lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet JM; El-Khoueiry AB; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
    Europian Society for Medical Oncology (ESMO) congress 2020年09月 ポスター発表 Madrid, Spain
  • KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Vogel A; Zhu A; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo M
    Europian Society for Medical Oncology (ESMO) congress 2020年09月 ポスター発表 Madrid, Spain
  • Baseline liver function and outcomes in patients with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240
    Vogel A; Merle P; Verslype C; Finn RS; Zhu AX; Cheng AL; Chan SL; Yau T; Ryoo BY; Wei Z; Holynskyj A; Siegel AB; Kudo M
    Europian Society for Medical Oncology (ESMO) congress 2020年09月 ポスター発表 Madrid, Spain
  • Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
    Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
    Europian Society for Medical Oncology (ESMO) congress 2020年09月 ポスター発表
  • The novel regimen of tremelimumab (T) plus durvalumab (D) in patients (Pts) with unresectable hepatocellular carcinoma (uHCC) by viral etiology
    Qin S; Kelley K; Kudo M; Harris W; Ikeda M; Okusaka T; Kang YK; Tai DWM; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; He P; Negro A; Sangro B; Abou-Alfa G
    23rd Annual Meeting of Chinese Society of Clinical Oncology (CSCO 2020) 2020年09月 Xiamen, China
  • Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 (KN224) and KEYNOTE-240 (KN240)
    Chan SL; Zhu AX; Finn RS; Edeline J; Ogasawara S; Knox JJ; Daniele B; Ryoo BY; Merle P; Bouattour M; Lim HY; Chao Y; Yau T; Haber BA; Malhotra U; Liu CC; Kudo M; Cheng AL
    23rd Annual Meeting of Chinese Society of Clinical Oncology (CSCO 2020) 2020年09月 Xiamen, China
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    HCC Expert Meeting (近畿) 2020年09月 口頭発表（招待・特別）
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    肝癌Expert Meeting （九州） 2020年09月 口頭発表（招待・特別）
  • Invited Lecture “Treatment strategy of BCLC B HCC.”  [招待講演]
    Masatoshi Kudo
    Eisai Malaysia Virtual Advisory Board Meeting（マレーシア対象 Web） 2020年09月 口頭発表（招待・特別）
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    第16回広島肝胆膵Web研究会 2020年09月 口頭発表（招待・特別）
  • IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma
    Ikeda M; Zhu AX; Qin S; Kim TY; Lim HY; Kudo M; Breder V; Merle A; Kaseb A; Li D; Ma N; Villalobos M; Stanzel S; Gaillard VE; Xu DZ; Hernandez S; Cheng AL; Finn RS; Galle PR; Ducreux M
    Europian Society for Medical Oncology (ESMO) congress 2020年09月 ポスター発表
  • Leap-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with Intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Finn RS; Ogasawara S; Llovet JM; El-Khoueiry AB; Vogel A; Madoff DC; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
    14th Annual Conference International Liver Cancer Association (ILCA 2020) 2020年09月 ポスター発表
  • Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Vogel A; Zhu A; Kudo M; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Cheng AL
    14th Annual Conference International Liver Cancer Association (ILCA 2020) 2020年09月 ポスター発表
  • Effect of pembrolizumab (pembro) on hepatitis B viral (Hbv) load and aminotransferase (Alt) levels in patients (Pts) with advanced hepatocellular carcinoma (Ahcc) in Keynote-224 and Keynote-240
    Merle P; Chan SL; Zhu AX; Finn RS; Edeline J; Ogasawara S; Knox JJ; Daniele B; Ryoo BY; Merle P; Bouattour M; Lim HY; Chao Y; Yau T; Haber BA; Malhotra U; Liu CC; Kudo M; Cheng AL
    14th Annual Conference International Liver Cancer Association (ILCA 2020) 2020年09月 ポスター発表
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    肝癌Expert Meeting—New Paradigm of Treatment Strategy— 2020年09月 口頭発表（招待・特別）
  • Chair: Sponsored Symporium 4 “Role of the liver tumor board in early- and intermediate-stage HCC”  [招待講演]
    Masatoshi Kudo
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2020年08月 その他 Royton Sapporo, Hokkaido
  • B型慢性肝炎患者に対するETVとTAAFの前向き比較観察研究
    萩原 智; 盛田真弘; 青木智子; 田北真弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第56回日本肝臓学会総会 2020年08月 口頭発表（一般） 大阪国際会議場, 大阪
  • 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援. ワークショップ「画像診断の新展開」
    西田直生志; 工藤正俊
    第56回日本肝臓学会総会 2020年08月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 進行肝癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ療法の有効性の検討. パネルディスカッション2「肝癌に対する分子標的治療および免疫治療」
    青木智子; 上嶋一臣; 盛田真弘; 南 知宏; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 工藤正俊
    第56回日本肝臓学会総会 2020年08月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • ランチョンセミナー「レンバチニブのすべて」  [招待講演]
    工藤正俊
    第56回日本肝臓学会総会 2020年08月 口頭発表（招待・特別）
  • Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study
    Ducreux M; Zhu AX; Qin S; Ikeda M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Verret W; Xu D; Hernandez S; Liu J; Shao H; Huang C; Cheng AL; Finn RS; Galle PR
    EASL Digital International Liver Congress (EASL-ILC 2020) 2020年08月 口頭発表（一般）
  • 特別講演「肝細胞癌治療戦略2020」  [招待講演]
    工藤正俊
    Lenvima-HCC Web Seminar 2020年08月 口頭発表（招待・特別）
  • Invited Lecture “Lenvatinib 1L treatment for intermediate to advanced stage patients in uHCC.”  [招待講演]
    Masatoshi Kudo
    Eisai Oncology Liver Webinar (アジア対象 Web) 2020年08月 口頭発表（招待・特別）
  • チロシンキナーゼ阻害薬時代に注意すべき肝細胞癌の遠隔転移
    大塚康生; 青木智子; 南 知宏; 田北雅弘; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第106回日本消化器病学会総会 2020年08月 口頭発表（一般） リーガロイヤルホテル広島, 広島
  • TACE不適Intermediate-stage肝細胞癌に対するLenvatinib先行投与の有用性～up-to-7 criteria outを対象として～. シンポジウム7「肝癌薬物療法の最前線」
    青木智子; 上嶋一臣; 工藤正俊
    第106回日本消化器病学会総会 2020年08月 シンポジウム・ワークショップパネル（公募） リーガロイヤルホテル広島, 広島
  • 特別講演「肝細胞癌薬物治療の新展開～二次治療としてのラムシルマブへの期待～」  [招待講演]
    工藤正俊
    CYRAMZA HCC Treatment Seminar in Kansai 2020年08月 口頭発表（招待・特別） ヒルトン大阪, 大阪
  • 特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [招待講演]
    工藤正俊
    LENVIMA Meet the Expert (Web) 2020年07月 口頭発表（招待・特別）
  • 特別講演「新薬上市を見据えた肝細胞癌治療戦略2020」  [招待講演]
    工藤正俊
    肝癌Expert Meeting—New Paradigm of Treatment Strategy— 2020年07月 口頭発表（招待・特別）
  • 特別講演「新薬上市を見据えた肝細胞癌治療戦略2020」  [招待講演]
    工藤正俊
    肝癌Expert Meeting—New Paradigm of Treatment Strategy— 2020年07月 口頭発表（招待・特別）
  • LEAP-012 trial in progress: pembrolizumab plus Lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet JM; El-Khoueiry AB; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
    ESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2020) 2020年07月 ポスター発表
  • Efficacy and safety of Nivolumab + Ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study
    Yau T; Hsu C; Kang YK; Kim TY; Hou MM; Lim HY; Chao Y; Kim YH; Ikeda M; Choo SP; Neely J; Shen Y; Tschaika M; Kudo M
    ESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2020) 2020年07月 口頭発表（一般）
  • Atezolizumab + bevacizumab versus sorafenib for unresectable hepatocellular carcinoma (HCC): results from older patients enrolled in IMbrave150
    Li D; Toh HC; Merle P; Kudo M; Tsuchiya K; Hernandez S; Shao H; Mulla S; Ding B
    ESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2020) 2020年07月 口頭発表（一般）
  • Invited Lecture “Systemic therapy for HCC”  [招待講演]
    Masatoshi Kudo
    The Asian Pacific Association for the Study of the Liver (APASL) Hepatology Webinar 2020年06月 口頭発表（招待・特別）
  • 特別講演「BCLC-Bにおける治療方針の考え方の変化」  [招待講演]
    工藤正俊
    LENVIMA-HCC WEB Seminar 画像による肉眼分類・腫瘍分化度の臨床判断 2020年06月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌セカンドライン スチバーガの役割と今後の展望~クリニカルクエスチョンに応えて～」  [招待講演]
    工藤正俊
    バイエル薬品株式会社HCC Webカンファレンス～スチバーガ®錠 肝細胞癌発売3周年記念Webカンファレンス～ 2020年06月 口頭発表（招待・特別）
  • 特別講演「BCLC-Bにおける治療方針の考え方の変化」  [招待講演]
    工藤正俊
    LENVIMA-HCC WEB Seminar 画像による肉眼分類・腫瘍分化度の臨床判断 2020年06月 口頭発表（招待・特別）
  • Invited Lecture “Lenvatinib use in TACE ineligible patients”  [招待講演]
    Masatoshi Kudo
    ASCO Virtual Eisai Canada National HCC Advisory Board 2020年06月 口頭発表（招待・特別）
  • Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in IMbrave150: a phase III clinical trial for unresectable hepatocellular carcinoma (HCC)
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Lim HY; Breder VV; Merle P; Kaseb AO, Li D; Feng YH; Verret W; Xu DZ; Hernandez S; Ding B; Zhu AX; Cheng AL
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表
  • A phase 1b study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)
    Zhu AX; Finn RS; Ikeda M; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Mody K; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Llovet JM
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表
  • A multicenter non-randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF Cohort trial)
    Tateishi R; Hasegawa K; Kawaguchi Y; Takayama T; Izumi N; Yamanaka N; Kudo M; Shimada M; Inomata M; Kaneko S; Koike K; Omata M; Makuuchi M; Matsuyama Y; Kokudo N
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表
  • An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib
    Sharma R; Hajiev S; Aval LM; Bettinger D; Arizumi T; Pirisi M; Rimassa L; Personeni N; Pressiani T; Giordano L; Kudo M; Thimme R; Park JW; Taddei TH; Kaplan DE; Ramaswami R; Pinato DJ; Allara E
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表
  • Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites
    Zhu AX; Ikeda M; Galle P; Yamashita T; Llovet J; Liang K; Wang C; Sakaguchi S; Abada P; Widau RC; Kudo M
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表
  • Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study
    Merle P; Lim HY; Finn RS; Ikeda M; Kudo M; Frenette C; Masi G; Kim YJ; Gerolami R; Kurosaki M; Numata K; Klümpen HJ; Zebger-Gong H; Fiala-Buskies S; Ozgurdal K; Qin S; on behalf of; the; REFINE investigators
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表
  • Efficacy and tolerability of tremelimumab (T) and durvalumab (D) in combination or as monotherapy for patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Kelly K; Sangro B; Harris WP; Ikeda M; Okusaka T; Kang YK; Qin S; Tai D; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Braud FGD; Bruix J; Borad MJ; He P; Negro A; Kudo M; Abou-Alfa GK
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 口頭発表（一般）
  • Effect of pembrolizumab on hepatitis B viral load and transaminase levels in patients with advanced hepatocellular carcinoma in KEYNOTE-224 and KEYNOTE-240  [通常講演]
    Chan SL, Zhu AX, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber BA, Malhotra U, Liu CC, Kudo M, Cheng AL:
    American Society of Clinical Oncology (ASCO 2020) 2020年05月 ポスター発表 Chicago, USA
  • 特別講演「COVID-19環境下における肝細胞癌治療～各ガイダンスと、いま我々が考えるべき治療戦略～」  [招待講演]
    工藤正俊
    Lenvatinib-HCC Web Seminar 2020年05月 口頭発表（招待・特別）
  • 特別講演「COVID-19環境下における肝細胞癌治療～各ガイダンスと、いま我々が考えるべき治療戦略～」  [招待講演]
    工藤正俊
    Lenvatinib-HCC Web Seminar 2020年05月 口頭発表（招待・特別）
  • 特別講演「肝がん分子標的治療薬10年の軌跡と今後の展望～ネクサバール発売10年目を迎えて～」  [招待講演]
    工藤正俊
    バイエル薬品株式会社HCC Webカンファレンス～肝がん分子標的治療薬 今後の展望～ 2020年05月 口頭発表（招待・特別）
  • Invited Lecture “Treatment strategy of BCLC B HCC”  [招待講演]
    Masatoshi Kudo
    Liver Cancer Intervention Community (LCIC) Kick-off Meeting (Web) (Observer 17,484 people) 2020年05月 公開講演，セミナー，チュートリアル，講習，講義等
  • Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Vogel A; Zhu A; Kudo M; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Cheng AL
    American Association for Cancer Research Annual Meeting (AACR 2020) 2020年04月 ポスター発表
  • Invited Lecture “Treatment strategy of BCLC B HCC”  [招待講演]
    Masatoshi Kudo
    China-Japan Intervention Web seminar (Observer 16,000 people) 2020年04月 公開講演，セミナー，チュートリアル，講習，講義等
  • 特別講演「肝細胞癌における治療方針の考え方の変化」  [招待講演]
    工藤正俊
    肝細胞癌の画像による肉眼分類・腫瘍分化度の臨床判断座談会 2020年03月 口頭発表（招待・特別）
  • LEAP-012 trial in progress: Pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatment  [通常講演]
    Maddoff DC; Llovet JM; El-Khoueiry AB; Kudo M; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Vogel A
    SIR 2021 congress 2020年03月 口頭発表（一般）
  • 深層学習を用いた超音波肝腫瘤像のAI診断システム開発
    椎名 毅; 山川 誠; 西田直生志; 工藤正俊
    日本音響学会2020年春季研究発表会 2020年03月 口頭発表（招待・特別）
  • Invited Lecture “LENVIMA for first-line treatment for patients with unresectable hepatocellular carcinoma(uHCC): A case-based approach”  [招待講演]
    Masatoshi Kudo
    Lenvima HCC National Broadocast 2020年03月 口頭発表（招待・特別）
  • Invited Lecture “LENVIMA for first-line treatment for patients with unresectable hepatocellular carcinoma(uHCC): A case-based approach”  [招待講演]
    Masatoshi Kudo
    Lenvima HCC National Broadocast 2020年03月 口頭発表（招待・特別）
  • 術前診断が困難であった肝多血性腫瘍の1例
    大丸直哉, 川崎俊彦, 高田隆太郎, 福永朋洋, 橋本有人, 秦 康倫, 木下大輔, 水野成人, 橋本和彦, 石川 原, 若狭朋子, 太田善夫, 工藤正俊
    日本消化器病学会近畿支部第112回例会 2020年02月 口頭発表（一般） 京都テルサ, 京都
  • 急性膵炎の発症を契機に診断し得た膵IPMCの一例
    福永朋洋, 高田隆太郎, 橋本有人, 秦 康倫, 木下大輔, 川崎俊彦, 工藤正俊, 石川 原, 若狭朋子, 太田善夫, 水野成人
    日本消化器病学会近畿支部第112回例会 2020年02月 口頭発表（一般） 京都テルサ, 京都
  • チロシンキナーゼ阻害薬による抗腫瘍効果と肝予備能
    青木智子, 上嶋一臣, 南 知宏, 田北雅弘, 萩原 智, 南 康範, 依田 広, 西田直生志, 鶴崎正勝, 工藤正俊
    第26回肝血流動態機能イメージ研究会 2020年02月 口頭発表（一般） 石川県立音楽堂
  • Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation.  [通常講演]
    Zhu AX, Kudo M, Vogel A, Yau T, Zhou J, Kim E, Malhotra U, Siegel AB, Cheng AL
    Therapeutic Agents for Hepatocellular Carcinoma (HCC-TAG Conference 2020) 2020年02月 ポスター発表 Park City, Utah, USA
  • 急激な発熱、腹痛を契機に発見された単純性潰瘍の一例  [通常講演]
    立野沙織; 奥田英之; 秦 康倫; 木下大輔; 高山政樹; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器病学会近畿支部第110回例会 2020年02月 口頭発表（一般） 京都テルサ, 京都
  • 特別講演「Intermediate Stage肝癌の治療戦略」  [招待講演]
    工藤正俊
    Lenvatinib Meet The Expert in Shiga 2020年02月 クサツエストピアホテル, 滋賀
  • Invited Lecture “Changing paradigm of treatment strategy in unresectable HCC”  [招待講演]
    Masatoshi Kudo
    MGLS-IASL Joint Symposium Yangon 2020年02月 Yangon, Myanmar
  • Invited Lecture “New systemic therapies”  [招待講演]
    Masatoshi Kudo
    The 24th International Symposium of Yonsei Institute of Gastroenterology 2020年02月 Yonsei University Health System, Seoul, Korea
  • 特別講演「造影超音波検査の現状と超音波AI診断の開発」  [招待講演]
    工藤正俊
    第29回日本乳癌画像研究会 2020年02月 大阪国際会議場, 大阪
  • 膵頭十二指腸切除後に針状の胆管結石を反復する1例
    橋本有人, 福永朋洋, 高田隆太郎, 木下大輔, 秦 康倫, 川崎俊彦, 水野成人, 石川 原, 井上雅智, 工藤正俊
    第103回日本消化器内視鏡学会 2020年01月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 食道、胃、小腸に病変が確認できた好酸球性胃腸症の1例
    秦 康倫, 高田隆太郎, 福永朋洋, 橋本有人, 木下大輔, 川崎俊彦, 水野成人, 阿部洋介, 若狭朋子, 太田善夫, 河野匡志, 工藤正俊
    第103回日本消化器内視鏡学会 2020年01月 口頭発表（一般） 大阪国際交流センター, 大阪
  • von Recklinghausen病に合併した多発十二指腸性GISTの1例
    野村健司, 松井繁長, 吉川馨介, 高島耕太, 山田光成, 正木 翔, 永井知行, 米田頼晃, 本庶 元, 櫻井俊治, 辻 直子, 樫田博史, 工藤正俊, 吉田雄太, 松本逸平, 竹山宜典
    第103回日本消化器内視鏡学会 2020年01月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 特別講演「肝細胞癌治療のパラダイムシフト」  [招待講演]
    工藤正俊
    HCC Expert Seminar in Niigata 2020年01月 口頭発表（招待・特別） ホテルオークラ新潟, 新潟
  • 切除不能肝癌に対するレンバチニブを含むMTA sequential治療成績と予後因子  [通常講演]
    糸永 詠, 平岡 淳, 熊田 卓, 厚川正則, 広岡昌史, 辻 邦彦, 石川 達, 高口浩一, 狩山和也, 田尻和人, 島田紀朋, 柴田啓志, 越智裕紀, 多田俊史, 豊田秀徳, 能祖一裕, 田中弘教, 玉井 努, 工藤正俊
    第21回日本肝がん分子標的治療研究会 2020年01月 ポスター発表 国立がん研究センター, 東京
  • プレナリーセッション2「ソラフェニブ前治療後のAFP高値進行肝細胞癌に対するラムシルマブによるALBIスコアへの影響: REACH試験及びREACH-2試験の日本人部分集団の併合解析」  [通常講演]
    池田公史, Zhu AX, 奥坂拓志, 本村健太, 森本 学, 瀬尾 智, 和田幸之, 佐藤新平, 山下竜也, 古川正幸, 新槇 剛, Wang C, Widau R, 篠崎健太, 吉川麗月, 工藤正俊
    第21回日本肝がん分子標的治療研究会 2020年01月 シンポジウム・ワークショップパネル（公募） 国立がん研究センター, 東京
  • 10周年特別企画ランチョンセミナー「HCC分子標的薬 10年の軌跡と今後の展望」  [招待講演]
    工藤正俊
    第21回日本肝がん分子標的治療研究会 2020年01月 口頭発表（招待・特別） 国立がん研究センター, 東京
  • 開会の辞  [招待講演]
    工藤正俊
    第21回日本肝がん分子標的治療研究会 2020年01月 その他 国立がん研究センター, 東京
  • 特別講演「肝細胞癌治療のパラダイムシフト」  [招待講演]
    工藤正俊
    第1回Kobe Liver Conference 2020年01月 口頭発表（招待・特別） ホテルオークラ神戸, 兵庫
  • A study on liver tumor detection from an ultrasound image using deep learning.
    Nakashima T; Tsutsui I; Takami H; Doman K; Mekata Y; Nishida N; Kudo M
    International Workshop on Advanced Image Technology (IWAIT 2020) 2020年01月
  • Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial
    Kudo M; Ueshima K; Ogawa C; Chiba Y
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 ポスター発表 San Francisco, USA
  • Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2)
    Kudo M; Finn RS; Morimoto M; Rau KM; Ikeda M; Yen CJ; Galle PR; Llovet JM; Daniele B; Lim HY; Liang K; Shinozaki K; Wang C; Yoshikawa R; Abada P; Widau RC; Zhu AX
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 ポスター発表 San Francisco, USA
  • Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trials
    Kudo M; Chiba Y; Meyer T; Lencioni R; Llovet JM
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 ポスター発表 San Francisco, USA
  • Subsequent anticancer procedures following first-line Lenvatinib (LEN): A post hoc analysis from the Phase 3 REFLECT study in unresectable hepatocellular carcinoma (uHCC)
    Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; Lopéz CL; Daniele B; Blanc JF; Ren M; Baldwin RL; Izumi N; Qin S; Finn RS
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 San Francisco, USA
  • RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro)  [通常講演]
    Edeline J; Karwal M; Zhu AX; Finn RS; Cattan S; Ogasawara S; Verslype C; Zagonel V; Fartoux L; Vogel A; Rosmorduc O; Verset G; Chan SL; Knox J; Daniele B; Cheng AL; Goldmacher G; Jensen E; Siegel AB; Kudo M
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 ポスター発表 San Francisco, USA
  • A phase 1b study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) (Study 117)  [通常講演]
    Kudo M; Ikeda M; Motomura K; Okusaka T; Kato N; Dutcus CE; Hisai T; Suzuki M; Ikezawa H; Iwata T; Kumada H; Kobayashi M
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 ポスター発表 San Francisco, USA
  • Phase 3 study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup  [通常講演]
    Kudo M; Lim HY; Cheng AL; Chao Y; Yau T; Ogasawara S; Kurosaki M; Morimoto N; Ohkawa K; Yamashita T; Lee DW; Chen E; Siegel A; Ryoo BY
    2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020) 2020年01月 ポスター発表 San Francisco, USA
  • 座長; 特別講演「最新C型慢性肝疾患治療について」  [招待講演]
    工藤正俊
    South Osaka Liver Summit 2019年12月 その他 ホテルモントレグラスミア大阪, 大阪
  • Invited Lecture “Updates of targeted therapies for HCC  [招待講演]
    工藤正俊
    Taiwan Association for the Study of the Liver (TASL 2019) 2019年12月 口頭発表（招待・特別） Taipei, Taiwan
  • Roche Symposium “Recent advances on cancer immunotherapy combination for advanced HCC”  [招待講演]
    工藤正俊
    Taiwan Association for the Study of the Liver (TASL 2019) 2019年12月 口頭発表（招待・特別） Taipei, Taiwan
  • モーニングセミナー「肝細胞癌薬物治療の新展開～2次治療としてのラムシルマブへの期待～」  [招待講演]
    工藤正俊
    第43回日本肝臓学会西部会 2019年12月 口頭発表（招待・特別） 海峡メッセ下関, 山口
  • 座長: イブニングセミナー「免疫チェックポイント阻害剤の作用機序と免疫関連有害事象について」  [招待講演]
    工藤正俊
    第43回日本肝臓学会西部会 2019年12月 その他 海峡メッセ下関, 山口
  • 総括; シンポジウム3「肝癌診療の現状と展開」  [招待講演]
    工藤正俊
    第43回日本肝臓学会西部会 2019年12月 その他 海峡メッセ下関, 山口
  • Keynote Lecture “Changing Paradigm of Treatment Strategy in Intermediate-stage HCC”  [招待講演]
    工藤正俊
    17th National Liver Cancer Conference 2019年12月 口頭発表（基調） Shanghai, China
  • 特別講演「超音波領域におけるAI開発の現状と展望」  [招待講演]
    工藤正俊
    同志社大学ハリス理化学研究所研究発表会 2019年11月 口頭発表（招待・特別） ホテルグランヴィア京都, 京都
  • 胆道閉塞に対するantegrade long plastic stent留置術の有用性  [通常講演]
    中井敦史; 竹中 完; 工藤正俊
    第27回日本消化器関連学会週間JDDW 2019（第61回日本消化器病学会大会, 第23回日本肝臓学会大会, 第98回日本消化器内視鏡学会総会） 2019年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • EUS施行時のプロポフォール持続注入による鎮静の有用性の検討  [通常講演]
    岡本彩那; 鎌田 研; 竹中 完; 吉川智恵; 石川 嶺; 山﨑友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 工藤正俊
    第27回日本消化器関連学会週間JDDW 2019（第61回日本消化器病学会大会, 第23回日本肝臓学会大会, 第98回日本消化器内視鏡学会総会） 2019年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • PPI長期投与の有無からみた胃底腺ポリープの臨床病理学的検討  [通常講演]
    松村まり子; 辻 直子; 梅原康湖; 正木 翔; 岡元寿樹; 山田光成; 永井知行; 米田頼晃; 櫻井俊治; 松井繁長; 渡邉智裕; 樫田博史; 工藤正俊
    第27回日本消化器関連学会週間JDDW 2019（第61回日本消化器病学会大会, 第23回日本肝臓学会大会, 第98回日本消化器内視鏡学会総会) 2019年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • 膵癌診断のための新たなアプローチ性の提案—3D. シンポジウム5「膵癌/胆道癌における早期診断の進歩」  [通常講演]
    山雄健太郎; 竹中 完; 工藤正俊
    第61回日本消化器病学会大会 2019年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み.  [通常講演]
    西田直生志; 工藤正俊
    第23回日本肝臓学会大会 2019年11月 口頭発表（一般） 神戸コンベンションセンター, 兵庫
  • 司会; サテライトシンポジウム89「肝細胞がんにおける薬物療法: 最近の動向」  [招待講演]
    工藤正俊
    第23回日本肝臓学会大会 2019年11月 その他 神戸コンベンションセンター, 兵庫
  • 司会; 招待講演「Recent advances in clinical research of HBV and HCC」  [招待講演]
    工藤正俊
    第23回日本肝臓学会大会 2019年11月 その他 神戸コンベンションセンター, 兵庫
  • 司会; サテライトシンポジウム76「切除不能な肝細胞癌の最前線」  [招待講演]
    工藤正俊
    第23回日本肝臓学会大会 2019年11月 その他 神戸コンベンションセンター, 兵庫
  • Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: a multicenter propensity-score matched study  [通常講演]
    Kudo M; Ueshima K; Chan SL; Minami T; Chishina H; Aoki T; Takita M; Hagiwara S; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Wada Y; Ikeda M; Ishii H; Izumi N; Nishida N
    American Association for the Study of Liver Diseases (AASLD 2019) 2019年11月 口頭発表（一般） Boston, USA
  • Checkmate 040: efficacy, hepatic safety, and biomarkers of Nivolumab + Ipilimumab combination therapy in patients with advanced hepatocellular carcinoma  [通常講演]
    Sangro B; Hsu C; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; He AR; El-Rayes B; Acosta-Rivera M; Lim HY; Neely J; Zhao H; Anderson J; Yau T
    American Association for the Study of Liver Diseases (AASLD 2019) 2019年11月 口頭発表（一般） Boston
  • Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
    Kudo M; Zhu AX; Vogel A; Yau T; Zhou J; Chen E; Malhotra U; Siegel AB; Cheng AL
    34th Annual Meeting & Pre-Conference Programs (SITC 2019) 2019年11月 ポスター発表 Gaylord National Hotel & Convention Center, Maryland, USA
  • Development of AI-aided us diagnosis system of liver tumor using deep neural network.  [通常講演]
    Nshida N; Yamakawa M; Shiina T; Kudo M
    American Association for the Study of Liver Diseases (AASLD 2019) 2019年11月 ポスター発表 Boston, USA
  • Clinical significance of tumor markers in surveillance for hepatocellular carcinoma in cirrhostic patients: a multicenter prospective cohort study in Japan.  [通常講演]
    Ucnino K; Tateishi R; Fujiwara N; Moriyama M; Eguchi Y; Toyoda H; Ida Y; Karino Y; Kudo M; Chuma M; Takuma Y; Kaneko S; Kato N; Chayama K; Izumi N; Itoi T; Sakaida I; Komeda H; Umemura T; Ishikawa T; Nakamuta M; Takaki A; Terai S; Ido A; Enomoto N; Yoshida H; Baba T; Torimura T; Hiasa Y; Ogawa C; Takehara T; Kumada T; Koike K
    American Association for the Study of Liver Diseases (AASLD 2019) 2019年11月 ポスター発表 Boston, USA
  • Objective response by mrecist is a prognostic factor for overall survival in unresectable hepatocellular carcinoma treated with systemic therapy: a systematic review and metaanalysis of randomized controlled trials.  [通常講演]
    Kudo M; Ueshima K; Nishida N
    American Association for the Study of Liver Diseases (AASLD 2019) 2019年11月 ポスター発表 Boston, USA
  • Lenvatinib for unresectable hepatocellular carcinoma in real-world practice: a multicenter analysis of prognostic factors.  [通常講演]
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Ishikawa T; Tsuji K; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M
    American Association for the Study of Liver Diseases (AASLD 2019) 2019年11月 ポスター発表 Boston, USA
  • 特別講演「急激に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    第6回北摂津肝疾患連携セミナー 2019年10月 口頭発表（招待・特別） 千里阪急ホテル, 大阪
  • 特別講演「肝細胞癌治療のパラダイムシフト」  [招待講演]
    工藤正俊
    Asahikawa Hepatocellular Carcinoma Conference 2019年10月 口頭発表（招待・特別） 星野リゾート OMO7 旭川, 北海道
  • 特別講演「超音波診断におけるAI開発の現状と課題」  [招待講演]
    工藤正俊
    シンポジウム「人工知能時代の放射線画像診断・病理診断と専門医のあり方」 2019年10月 口頭発表（招待・特別） 日本学術会議講堂, 東京
  • 膵癌の門脈浸潤に対する造影ハーモニックEUSの有用性. シンポジウム2「新しい超音波法で腹部を診る（腹部疾患への超音波診断の新たな展開）」  [通常講演]
    中井敦史; 鎌田 研; 竹中 完; 筑後孝章; 兵頭朋子; 工藤正俊
    日本超音波医学会第46回関西地方会学術集会 2019年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 特別企画「超音波デジタル画像のナショナルデータ構築とAI診断—日本超音波医学会のミッション—」  [招待講演]
    工藤正俊
    日本超音波医学会第46回関西地方会学術集会 2019年10月 口頭発表（招待・特別） 大阪国際会議場, 大阪
  • 胆のう: 胆のう疾患診療における超音波の役割
    青木智子; 山雄健太郎; 工藤正俊
    本超音波医学会第46回関西地方会学術集会 2019年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • Safety and efficacy of Lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT  [通常講演]
    Okusaka T; Ikeda K; Kudo M; Finn RS; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019) 2019年10月 ポスター発表 Manitoba, Canada
  • Association between overall survival and adverse events with Lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)  [通常講演]
    Sung M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Kudo M; Tateishi R; Ikeda M; Breder V; Rau KM; Ma YT; Alsina A; Ryoo BY; Ren Z; Mody K; Dutcus C; Tamai T; Saito K; Piscaflia F
    31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019) 2019年10月 ポスター発表 Winnipeg, Manitoba
  • Invited Lecture “Construction of big database of US digital image; Platform for creating artificial intelligence-aided US: Work in progress”  [招待講演]
    工藤正俊
    The 1st Asia Pacific International Symposium on Advances in Medical Ultrasound 2019年10月 口頭発表（招待・特別） Taipei, Taiwan
  • Subsequent anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma
    Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; Lopez C; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RS
    2019 Annual Meeting of the DGHO 2019年10月 Berlin
  • Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT  [通常講演]
    Vogel A; Kudo M; Cheng AL; Sung MW; Finn RS; Lin AY; Abou-Alfa GK; Alsina A; Breder V; Tebbutt N; Osterlund P; Yen CJ; Ren M; Misir S; Dutcus CE; Palmer D; Merle P; Pinter M; Evans TRJ
    2019 Annual Meeting of the DGHO 2019年10月 Berlin
  • 特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [招待講演]
    工藤正俊
    Sys-Loco therapy Meeting in 東海 2019年10月 名古屋マリオットアソシアホテル, 愛知
  • 特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [招待講演]
    工藤正俊
    Sys-Loco therapyを考える 2019年10月 口頭発表（招待・特別） ステーションコンファレンス東京, 東京
  • 血清IFN-α/IL-33が治療効果判定に有用と考えられた自己免疫性膵炎/IgG4関連疾患の1例  [通常講演]
    原 茜; 三長孝輔; 岡本彩那; 石川 嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 竹中 完; 渡邉智裕; 工藤正俊; 安川 覚
    日本消化器病学会近畿支部第111回例会 2019年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 肝細胞腺腫の1例  [通常講演]
    山根雅智; 秦 泰倫; 松村まり子; 福永朋洋; 高田龍太郎; 河野匡志; 木下大輔; 奥田英之; 川崎俊彦; 水野成人; 日向 聖; 石川 原; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器病学会近畿支部第111回例会 2019年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 自己免疫性胃炎に合併した胃型腺腫の1例  [通常講演]
    吉川馨介; 松井繁長; 野村健司; 橋本有人; 山田光成; 高島耕太; 正木 翔; 永井知行; 米田頼晃; 本庶 元; 櫻井俊治; 辻 直子; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第111回例会 2019年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • DLBCLに発症したリンパ管拡張症に対してステロイド投与、食事療法が奏効した1症例  [通常講演]
    大塚康生; 米田頼晃; 正木 翔; 吉川馨介; 高島耕太; 橋本有人; 山田光成; 本庶 元; 永井知行; 櫻井俊治; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊; 筑後孝章
    日本消化器病学会近畿支部第111回例会 2019年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 難症例に対するSOクリップ使用による大腸ESD、SOUTENを使用した大腸hybrid ESDの検討. シンポジウム2「下部消化管腫瘍に対する低侵襲治療の最前線」  [通常講演]
    正木 翔; 米田頼晃; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第111回例会 2019年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 急性胆嚢炎治療における内視鏡的経乳頭胆嚢ドレナージ（ENGBD）の位置づけ. ワークショップ2「急性胆嚢炎に対する治療戦略」  [通常講演]
    武部敦志; 竹山宜典; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第111回例会 2019年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 特別講演「急速に変貌するIntermediate stage肝癌の治療戦略」  [招待講演]
    工藤正俊
    第44回リザーバー研究会 2019年10月 口頭発表（招待・特別） 都メッセ, 京都
  • The interim report of B-RTO using candis system
    Aoki T; Oda T; Minami T; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Tsurusaki M; Kudo M
    International Liver Conference 2019年10月 Osaka International Convention Center
  • Clinicopathological and immunohistochemical study of the mechanism of sporadic fundic gland polyp proliferation and enlargement in long-term PPI-users  [通常講演]
    Matsumura M; Tsuji N; Yoshida S; Tomooka M; Umehara Y; Kudo M
    United European Gastroenterology (UEGW 2019) 2019年10月 ポスター発表 Barcelona, Spain
  • Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein: an exposure-response analysis  [通常講演]
    Llovet JM; Kudo M; Kang YK; Yen CJ; Finn RS; Gale PR; Assenat E; Motomura K; Okusaka T; Berg T; Hsu CH; Ikeda M; Hsu Y; Liang K; Widau R; Schelman W; O’Braian L; Gao L; Zhu AX
    European Society for Medical Oncology (ESMO 2019) 2019年09月 ポスター発表 Barcelona, Spain
  • Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240  [通常講演]
    Merle P; Kulkarni AS; Ryoo BY; Cheng AL; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Daniele B; Norquist J; Chen E; Siegel AB; Zhu AX; Finn RS
    European Society for Medical Oncology (ESMO 2019) 2019年09月 ポスター発表 Barcelona, Spain
  • 難治性腹水に対して行われたデンバーシャント術の報告
    青木智子; 田北雅弘; 大塚康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 鶴崎正勝; 工藤正俊
    第26回日本門脈圧亢進症学会総会 2019年09月 口頭発表（一般） 海峡メッセ下関, 山口
  • 特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [招待講演]
    工藤正俊
    Sys-Loco therapyを考える 2019年09月 口頭発表（招待・特別） ストリングスホテル東京インターコンチネンタル, 東京
  • 特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [招待講演]
    工藤正俊
    Sys-Loco therapyを考えるin 関西 2019年09月 口頭発表（招待・特別） ホテルグランヴィア大阪, 大阪
  • 特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [招待講演]
    工藤正俊
    Sys-Loco therapy Meeting in中国 2019年09月 口頭発表（招待・特別） ホテルグランヴィア広島, 広島
  • Efficacy and safety of ramucirumab for advanced hepatocellular carcinoma with elevated alpha-fetoprotein following sorafenib across age subgroups in two global Phase 3 trials (REACH, REACH-2)
    Kudo M; Galle PF; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomasek J; Borg C; Zagonel V; Morimoto M; Pracht M; Finn RS; Llovet J; Homma G; Jen MH; Shinozaki K; Yoshikawa R; Zhu AX
    European Society for Medical Oncology (ESMO 2019) 2019年09月 Barcelona, Spain
  • Ramucirumab (RAM) effect on albumin-bilirubin (ALBI) grade during treatment of Japanese patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib from two randomized phase 3 studies (REACH, REACH-2)  [通常講演]
    Kudo M; Okusaka T; Motomura K; Ikeda M; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Hirota S; Homma G; Chunxiao W; Shinozaki K; Yoshikawa R; Zhu AX
    European Society for Medical Oncology (ESMO 2019) 2019年09月 Barcelona, Spain
  • LEAP-002: Phase 3 Study of First-Line Lenvatinib (len) Plus Pembrolizumab (pembro) for patients with advanced hepatocellular carcinoma (HCC)  [通常講演]
    Llovet JM; Kudo M; Cheng AL; Finn RS; Galle PR; Kaneko S; Meyer T; Qin S; Dutcus CE; Chen E; Dubrovsky L; Siegel AB; Zhu AX
    European Society for Medical Oncology (ESMO 2019) 2019年09月 Barcelona, Spain
  • Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial  [通常講演]
    Bruix J; Reig M; Merle P; Kudo M; Meinhardt G; Zhang M; Ozgurdal K
    European Society for Medical Oncology (ESMO 2019) 2019年09月 Barcelona, Spain
  • Safety profile of Nivolumab (NIVO) plus Ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study  [通常講演]
    El-Khoueiry AB; Hsu C; Kang YK; Kim TY; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; He AR; El-Rayes B; Acosta-Rivera M; Neely J; Shen Y; Baccan C; Yau T
    13th Annual Conference International Liver Cancer Association (ILCA) 2019年09月 Chicago, USA
  • CheckMate 040: Health-related quality of life (HRQoL) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B status treated with nivolumab (NIVO)  [通常講演]
    Sangro B; Matilla A; Santoro A; Cubillo A; El-Khoueiry AB; El-Rayes B; Numata K; Itoh Y; Taylor F; Thompson G; Blum S; Wisniewski T; Baccan C; Kudo M
    13th Annual Conference International Liver Cancer Association (ILCA) 2019年09月 Chicago, USA
  • A Phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC): EMERALD-1  [通常講演]
    Sangro B; Kudo M; Qin S; Ren Z; Chan S; Erinjeri J; Arai Y; Mann H; Morgan S; Cohen G; Vlahovic G; Lencioni R
    13th Annual Conference International Liver Cancer Association (ILCA) 2019年09月 Chicago, USA
  • A post hoc analysis of neutrophil-lymphocyte ratios (NLR) in the REFLECT study: First-line lenvatinib (LEN) or sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC)  [通常講演]
    Evans TRJ; Kudo M; Cheng AL; Gomez-Martin C; Daniele B; Izumi N; Yamashita T; Tateishi R; Lim HJ; Chan SL; Rau KM; Alsina A; Misir S; Dutcus C; Sung MW
    13th Annual Conference International Liver Cancer Association (ILCA) 2019年09月 Chicago, USA
  • Pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) and complete radiological response following surgical resection or local ablation: Phase 3 KEYNOTE-937 trial  [通常講演]
    Zhu AX; Cheng AL; Vogel A; Yau T; Zhou J; Chen E; Malhotra U; Siegel AB; Kudo M
    13th Annual Conference International Liver Cancer Association (ILCA) 2019年09月 ポスター発表 Chicago, USA
  • First-line combination therapy with lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma: Phase 3 Leap-002 study  [通常講演]
    Llovet JM; Kudo M; Cheng AL; Finn RS; Galle PR; Kaneko S; Meyer T; Qin S; Dutcus CE; Chen E; Dubrovsky L; Zhu AX
    13th Annual Conference International Liver Cancer Association (ILCA) 2019年09月 ポスター発表 Chicago, USA
  • Chair ; Cheng AL; minar 6 “A combined approach for advanced HCC checkpoint inhibitor plus VEGF blockade”  [招待講演]
    工藤正俊
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 その他 Royton Sapporo, Hokkaido
  • A phase 3 study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab in patients with locoregional HCC: EMERALD-1  [通常講演]
    Kudo M; Sangro B; Qin S; Ren Z; Chan S; Erinjeri J; Arai Y; Mann H; Morgan S; Cohen G; Vlahovic G; Lencioni R
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 ポスター発表 Royton Sapporo, Hokkaido
  • Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies  [通常講演]
    Okusaka T; Kang YK; Kudo M; Lim HY; Hsu CH; Vogel A; Brandi G; Cheng R; Carton I; Abada P; Hsu Y; Zhu A; Yen CJ
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Subsequent anticancer medication following first-line lenvatinib: Post Hoc responder analysis from the Phase 3 REFLECT study in unresectable hepatocellular carcinoma  [通常講演]
    Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; Lopez C; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RS
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)  [通常講演]
    Sung M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Kudo M; Tateishi R; Ikeda M; Breder V; Rau KM; Ma YT; Alsina A; Ryoo BY; Ren Z; Mody K; Dutcus C; Tamai T; Saito K; Piscaglia F
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Nivolumab in patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh (CP) B status: Japanese subanalysis from the CheckMate 040 study  [通常講演]
    Kudo M; Matilla A; Santoro A; Melero I; Gracian AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Takahashi H; Shen Y; Neely J; Anderson J; Sangro B
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Safety and efficacy of lenvatinib by starting dose based on bodyweight in patients with unresectable hepatocellular carcinoma (uHCC) in REFLECT  [通常講演]
    Okusaka T; Ikeda K; Kudo M; Finn RS; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Role of the liver tumor board in early- and intermediate-stage HCC. Sponsored Symposium 4  [招待講演]
    Kudo M; Han KH; Chan SL; Chow P
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 シンポジウム・ワークショップパネル（指名） Royton Sapporo, Hokkaido
  • Challenging Precise Ablation: CEUS Guidance & Fusion Imaging Guidance. Symposium 7 “Ablation therapy for hepatocellular carcinoma in Asia”  [通常講演]
    Minami Y; Kudo M
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 シンポジウム・ワークショップパネル（公募） Royton Sapporo, Hokkaido
  • Changing paradigm of treatment strategy for intermediate stage HCC: APPLE expert consensus  [通常講演]
    Ikeda M; Han KH; Miyayama S; Lin HM; Choo SP; Huang YH; Chan S; Kudo M; Wang CK
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a Phase 3 study of lenvatinib (REFLECT)  [通常講演]
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Ueshima K; Aikata H; Vogel A; Lopez C; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Dutcus C; Tamai T; Saito K; Lencioni R
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Luncheon Seminar “Real-world experience with lenvatinib in patients with uHCC from Japan”  [招待講演]
    工藤正俊
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（招待・特別） Royton Sapporo, Hokkaido
  • Current and future treatment strategy for TACE failure or refractoriness. Morning Workshop 3  [招待講演]
    工藤正俊
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 シンポジウム・ワークショップパネル（指名） Royton Sapporo, Hokkaido
  • Association between tumor response by mRECIST and overall survival in patients with poorly differentiated hepatocellular carcinoma (HCC) in REFLECT study  [通常講演]
    Kudo M; Ueshima K; Aikata H; Tamai T; Saito K; Ikeda K
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • Using workstation for diagnosis and treatment of hepatocellular carcinoma  [通常講演]
    Ogawa C; Kudo M
    The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) 2019年08月 口頭発表（一般） Royton Sapporo, Hokkaido
  • 特別講演「肝細胞癌二次治療の新時代～REACH試験/REACH-2試験を紐解く～」  [招待講演]
    工藤正俊
    中四国肝細胞癌薬物療法セミナー 2019年08月 口頭発表（招待・特別） JRホテルクレメント高松, 香川
  • 特別講演「肝細胞癌二次治療の新時代～REACH試験/REACH-2試験を紐解く～」  [招待講演]
    工藤正俊
    北海道肝細胞癌薬物療法セミナー 2019年07月 口頭発表（招待・特別） 札幌グランドホテル, 北海道
  • ランチョンセミナー「肝癌診療ガイドライン 改訂のポイント」  [招待講演]
    工藤正俊
    第19回臨床消化器病研究会 2019年07月 口頭発表（招待・特別） ベルサール高田馬場, 東京
  • 教育講演「肝癌薬物治療のup-to-date」  [招待講演]
    工藤正俊
    日本内科学会北海道支部主催第61回生涯教育講演会 2019年07月 口頭発表（招待・特別） 北海道大学医学部, 北海道
  • 腫瘤性膵炎の再発に対してステロイド投与が著効した一例  [通常講演]
    鎌田 研; 田中秀和; 橋本有人; 石川 嶺; 吉川智恵; 岡本彩那; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 竹中 完; 工藤正俊
    第102回日本消化器内視鏡学会近畿支部例会 2019年07月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 胆道閉塞に対するantegrade long plastic stent留置術の有用性. ワークショップ「胆膵疾患の内視鏡診断・治療up date」  [通常講演]
    中井敦史; 竹中 完; 工藤正俊
    第102回日本消化器内視鏡学会近畿支部例会 2019年07月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • T1直腸癌の内視鏡治療後の経過観察例の検討. シンポジウム2「下部消化管腫瘍の内視鏡診断・治療up date」  [通常講演]
    高島耕太; 米田頼晃; 櫻井俊治; 樫田博史; 工藤正俊
    第102回日本消化器内視鏡学会近畿支部例会 2019年07月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • CMV腸炎を合併した紫斑のない成人IgA血管炎の一例  [通常講演]
    松村まり子; 米田頼晃; 大塚康生; 河野辰哉; 高島耕太; 正木 翔; 岡元寿樹; 山田光成; 永井知行; 櫻井俊治; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊; 榎木英介
    第102回日本消化器内視鏡学会近畿支部例会 2019年07月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 超音波内視鏡ガイド下ラジオ波焼灼術の開発  [通常講演]
    前島秀哉; 井田良幸; 清水 遼; 川路祐輝; 田村 崇; 幡丸景一; 奴田絢也; 糸永昌弘; 工藤正俊; 北野雅之
    第55回日本肝癌研究会 2019年07月 口頭発表（一般） ホテル椿山荘, 東京
  • OPTIMIS国際共同前向き観察研究: 初回TACE施行後の肝予備能の検討―日本人サブ解析―. パネルディスカッション「再発肝癌の治療選択」  [通常講演]
    工藤正俊; 泉 並木; 小笠原定久; 中尾一彦; 沼田和司; 平岡 淳; 武冨紹信; 大崎往夫; 池田公史; 和田幸之
    第55回日本肝癌研究会 2019年07月 シンポジウム・ワークショップパネル（公募） ホテル椿山荘, 東京
  • ランチョンセミナー「レンバチニブのすべて」  [招待講演]
    工藤正俊
    第55回日本肝癌研究会 2019年07月 公開講演，セミナー，チュートリアル，講習，講義等 ホテル椿山荘, 東京
  • Internation Symposium “Lenvatinib as an initial treatment in patiens with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A Multicentre propensity-score matched study.  [招待講演]
    工藤正俊
    The 55th Annual Meeting of Liver Cancer Study Group of Japan 2019年07月 シンポジウム・ワークショップパネル（指名） Hotel Chinzanso Tokyo
  • レンバチニブの第III相試験 (REFLECT試験)における肝細胞癌患者の生存期間と奏効の解析  [通常講演]
    上嶋一臣; 工藤正俊; Finn RS; Qin S; Han KH; 池田健次; Cheng AL; Piscaglia F; 相方 浩; Vogel A; Lopez C; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Dutcus C; 玉井俊行; 齋藤健一; Lencioni R
    第55回日本肝癌研究会 2019年07月 口頭発表（一般） ホテル椿山荘, 東京
  • 肝細胞癌切除における幕内基準の検証: 日本肝癌研究会全国集計データ解析結果より  [通常講演]
    荒牧 修; 高山忠利; 松山 裕; 久保正二; 國土典宏; 泉 並木; 村上卓道; 椎名秀一朗; 工藤正俊; 坂元亨宇; 中島 収
    第55回日本肝癌研究会 2019年07月 口頭発表（一般） ホテル椿山荘, 東京
  • ソラフェニブ不耐のAFP高値肝細胞癌患者に対するラムシルマブ治療: 無作為化第III相試験におけるサブ解析  [通常講演]
    森本 学; Josep Llovet; Yen CJ; Finn R; Kang YK; Galle P; Assenat E; Godinot N; Wang C; Hsu Y; Schelman W; Zhu A; 工藤正俊
    第55回日本肝癌研究会 2019年07月 口頭発表（一般） ホテル椿山荘, 東京
  • Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)  [通常講演]
    Meyer T; Finn R; Kudo M; Kang YK; Yen CJ; Galle P; Llovet J; Assenat E; Brandi G; Motomura K; Okusaka T; Hubner R; Karwal M; Baron A; Ikeda M; Liang K; Wang C; Widau R; Schelman W; Zhu A
    ESMO 21th World Congress on Gastrointestinal Cancer 2019 (ESMO-WCGC 2019) 2019年07月 口頭発表（一般） Barcelona, Spain
  • レンバチニブに対しPD判定となった後も継続投与によってPRが得られた一例  [通常講演]
    盛田真弘; 小川 力; 工藤正俊
    第20回日本肝がん分子標的治療研究会 2019年06月 ポスター発表 ANAクラウンプラザホテル長崎グラバーヒル, 長崎
  • 司会; プレナリーセッション2  [招待講演]
    工藤正俊
    第20回日本肝がん分子標的治療研究会 2019年06月 その他 ANAクラウンプラザホテル長崎グラバーヒル, 長崎
  • プレナリーセッション「ソラフェニブ後のAFP高値進行肝細胞癌に対するラムシルマブ: 2つの国際共同無作為化第3相試験の併合解析における日本人患者の有効性と安全性」  [招待講演]
    池田公史; 工藤正俊; 奥坂拓志; 本村健太; 大野 泉; 森本 学; 瀬尾 智; 和田幸之; 佐藤新平; 山下竜也; 古川正幸; 新槇 剛; 瀬野成人; 大川和良; 藤井博文; 工藤敏啓; 古瀬純司; 高井弘基; 本間剛介; 吉川麗月; Zhu AX
    第20回日本肝がん分子標的治療研究会 2019年06月 その他 ANAクラウンプラザホテル長崎グラバーヒル, 長崎
  • 開会/閉会の辞  [招待講演]
    工藤正俊
    第20回日本肝がん分子標的治療研究会 2019年06月 その他 ANAクラウンプラザホテル長崎グラバーヒル, 長崎
  • 特別講演「肝細胞治療のパラダイムシフト」  [招待講演]
    工藤正俊
    第10回中国ウイルス肝炎研究会 2019年06月 口頭発表（招待・特別） リーガロイヤルホテル広島, 広島
  • Invited Lecture “Recent trends of treatment for intermediate stage HCC: Japanese experience”  [招待講演]
    工藤正俊
    The Liver Week 2019 2019年06月 口頭発表（招待・特別） BEXCO, Busan, South Korea
  • 特別講演「肝細胞治療における最新の知見」  [招待講演]
    工藤正俊
    第15回倉敷肝疾患研究会 2019年06月 口頭発表（招待・特別） 倉敷アイビースクエア, 岡山
  • 特別講演「最新データから読み解くレンバチニブの導入タイミング」  [招待講演]
    工藤正俊
    Lenvima-HCC Web Seminar 2019年06月 口頭発表（招待・特別） 木村情報技術東京第一スタジオ, 東京
  • 特別講演「肝細胞癌診療の最近の進歩」  [招待講演]
    工藤正俊
    北海道消化器癌懇話会 2019年06月 口頭発表（招待・特別） 札幌プリンスホテル, 北海道
  • Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).  [通常講演]
    Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder VV; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox JJ; Daniele B; Ebbinghaus S; Chen E; Siegel AB; Zhu AX; Cheng AL; for the KEYNOT; Investigators
    American Society of Clinical Oncology Annual Meeting (ASCO 2019) 2019年06月 口頭発表（一般） Chicago, USA
  • A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma (SURF trial)  [通常講演]
    Izumi N; Hasegawa K; Nishioka Y; Takayama T; Yamanaka N; Kudo M; Shimada M; Inomata M; Kaneko S; Baba H; Koike K; Omata M; Makuuchi M; Matsuyama Y; Kokudo N
    American Society of Clinical Oncology Annual Meeting (ASCO 2019) 2019年06月 口頭発表（一般） Chicago, USA
  • Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): outcomes from two randomized phase 3 studies (REACH, REACH2)  [通常講演]
    Llovet JM; Yen CJ; Finn RS; Kang YK; Kudo M; Galle PR; Assenat E; Pracht M; Lim Y; Rau KM; Borg C; Hiriart JB; Daniele B; Berg T; Chung HC; Godinot N; Wang C; Hsu Y; Schelman WR; Zhu AX
    American Society of Clinical Oncology Annual Meeting (ASCO 2019) 2019年06月 ポスター発表 Chicago, USA
  • Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040  [通常講演]
    Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox J; He AR; El-Rayes B; Acosta-Rivera M; Neely J; Shen Y; Baccan C; Dela Cruz C; Hsu C
    American Society of Clinical Oncology Annual Meeting (ASCO 2019) 2019年06月 ポスター発表 Chicago, USA
  • First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100)  [通常講演]
    Kudo M; Motomura K; Wada Y; Inaba Y; Sakamoto Y; Kurosaki M; Umeyama Y; Kamei Y; Yoshimitsu J; Fujii Y; Aizawa M; Robbins PB; Furuse J
    American Society of Clinical Oncology Annual Meeting (ASCO 2019) 2019年06月 ポスター発表 Chicago, USA
  • Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies  [通常講演]
    Borbath I; Kudo M; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Peck-Radosavljevic M; Girvan A; Gable J; Bowman L; Abada P; Hsu Y; Zhu AX; Lee SY
    Osterreichische Gesellschaft fur Gastroenterologie und Hepatologie (OGGH 2019) 2019年06月 Austria
  • 汎用ワークステーションを用いた大腰筋の体積の測定とサルコペニアの診断への応用  [通常講演]
    小川 力; 柴峠光成; 工藤正俊
    第55回日本肝臓学会総会 2019年05月 ポスター発表 京王プラザホテル, 東京
  • 高AFP肝細胞癌（HCC）患者に対する二次治療ラムシルマブ（RAM）の第3相REACH-2試験におけるAFP動態分析  [通常講演]
    本村健太; Finn RS; 工藤正俊; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; 大野 泉; Daniele B; Shin D; Gerken G; Abada P; Hsu Y; Zhu AX
    第55回日本肝臓学会総会 2019年05月 口頭発表（一般） 京王プラザホテル, 東京
  • 超音波内視鏡ガイド下ラジオ波焼灼術の開発  [通常講演]
    前島秀哉; 井田良幸; 清水 遼; 川路佑輝; 田村 崇; 奴田絢也; 幡丸景一; 糸永昌弘; 工藤正俊; 北野雅之
    第55回日本肝臓学会総会 2019年05月 口頭発表（一般） 京王プラザホテル, 東京
  • 司会; ランチョンセミナー10「知らないと損をする肝硬変診療up-to-date」  [招待講演]
    工藤正俊
    第55回日本肝臓学会総会 2019年05月 その他 京王プラザホテル, 東京
  • 司会; シンポジウム3「進行肝癌の治療: 分子標的薬の位置づけ」  [招待講演]
    工藤正俊
    第55回日本肝臓学会総会 2019年05月 その他 京王プラザホテル, 東京
  • 特別企画「肝細胞癌治療における免疫チェックポイント阻害薬の開発状況」  [招待講演]
    工藤正俊
    第55回日本肝臓学会総会 2019年05月 口頭発表（招待・特別） 京王プラザホテル, 東京
  • 司会: 招待講演4「Management of sarcopenia in liver cirrhosis」  [招待講演]
    工藤正俊
    第55回日本肝臓学会総会 2019年05月 その他 京王プラザホテル, 東京
  • 超音波検査が診断に有用であった消化管疾患の検討. ワークショップ 消化器2「超音波検査が診断に有用であった消化管疾患の検討」  [通常講演]
    南 雅人; 横川美加; 桑口 愛; 市島真由美; 塩見香織; 前川 清; 南 康範; 樫田博史; 工藤
    日本超音波医学会第92回学術集会 2019年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • State-of-the-Art Lecture “IO in liver cancer therapy now and future.”  [招待講演]
    工藤正俊
    2019 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation: Precision medicine in HCC: research and treatment 2019年05月 口頭発表（招待・特別） Taiwan
  • Keynote Lecture “When is the best time for TKI (LEN) be used in BCLC B & C HCC patients."  [招待講演]
    工藤正俊
    Expert Round Table Meeting for Unresectable Hepatocellular Carcinoma 2019年05月 口頭発表（基調） Fullon Hotel, Taiwan
  • レンバチニブ著効症例の残存病変評価に造影エコーが有用であった一例  [通常講演]
    盛田真弘; 小川 力; 重福亜紀奈; 野田晃世; 久保敦司; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 口頭発表（一般） グランドプリンスホテル新高輪, 東京
  • Attenuation coefficient（ATT）による肝脂肪化定量化の検討. パネルディスカッション 消化器5「肝脂肪と超音波:基礎から臨床、そして未来へ」  [通常講演]
    玉城信治; 小泉洋平; 廣岡昌史; 矢田典久; 中島 収; 工藤正俊; 日浅陽一; 泉 並木
    日本超音波医学会第92回学術集会 2019年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • 南 康範, 依田 広, 工藤正俊: Monopolarラジオ波熱凝固療法の実際とその治療効果判定. パネルディスカッション 消化器3「肝癌診療と超音波: 最新の治療支援と効果判定テクニック」  [通常講演]
    南 康範; 依田 広; 工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • 座長; シンポジウム 消化器1「臨床に活かす超音波検査」  [招待講演]
    工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 その他 グランドプリンスホテル新高輪, 東京
  • 超音波画像データベース構築の推進と展望. シンポジウム 領域横断3「AI: 超音波診断の近未来」  [通常講演]
    西田直生志; 工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • 座長; シンポジウム 領域横断3「AI: 超音波診断の近未来」  [招待講演]
    工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 その他 グランドプリンスホテル新高輪, 東京.
  • AMED事業: AI利活用を見据えた超音波画像データベース構築. シンポジウム 領域横断3「AI: 超音波診断の近未来」  [招待講演]
    工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 シンポジウム・ワークショップパネル（指名） グランドプリンスホテル新高輪, 東京
  • Histological Diagnosis of pancreatic neuroendocrine tumor using 25G FNA needle with core trap: Multicenter prospective study  [通常講演]
    Ashida R; Kamata K; Yasukawa S; Chiba Y; Fukutake N; Nebiki H; Kurita A; Takaoka M; Ogura T; Shiomi H; Asada M; Yasuda H; Shigekawa M; Yanagisawa A; Kudo M; Kitano M
    Digestive Disease Week 2019 (DDW 2019) 2019年05月 ポスター発表 San Diego, USA
  • Value of the bispectral index monitor during endoscopic ultraosonography under sedation with propofol and midazolam  [通常講演]
    Okamoto A; Kamata K; Takenaka M; Yoshikawa T; Ishikawa R; Yamazaki T; Nakai A; Omoto S; Minaga K; Yamao K; Kudo M
    Digestive Disease Week 2019 (DDW 2019) 2019年05月 ポスター発表 San Diego, USA
  • Computer-aided diagnosis based on convolutional neural network system using artificial intelligence for colorectal polyp classification  [通常講演]
    Komeda K; Handa H; Matsui R; Sakurai T; Watanabe T; Kashida S; Kudo M
    Digestive Disease Week 2019 (DDW 2019) 2019年05月 ポスター発表 San Diego, USA
  • Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: a prospective mylticenter study  [通常講演]
    Itonaga M; Kitano M; Hatamaru K; Tamura T; Nuta1 J; Kawaji Y; Takenaka M; Minaga K; Kudo M; Ogura T; Higuchi K; Chiba Y
    Digestive Disease Week 2019 (DDW 2019) 2019年05月 ポスター発表 San Diego, USA
  • 座長: 特別講演「C型肝炎DAAの選択と不成功例・非代謝肝硬変の治療」  [招待講演]
    工藤正俊
    第4回関西肝疾患フォーラム 2019年05月 その他 帝国ホテル大阪, 大阪
  • Invited Lecture “Value of Primovist in HCC screening  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） National University Hospital, Singapore
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） National University Hospital, Singapore
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Inperial Treasure Super Pekin Duck, Singapore
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Inperial Treasure Super Pekin Duck, Singapore
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Changi General Hospital, Singapore
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Changi General Hospital, Singapore
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Tan Tock Seng Hospital, Singapore
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Tan Tock Seng Hospital, Singapore
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Seng Kang General Hospital, Singapore
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Seng Kang General Hospital, Singapore
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Singapore General Hospital, Singapore
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Singapore General Hospital, Singapore
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Taipei Veteran General Hospital, Taiwan
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Taipei Veteran General Hospital, Taiwan
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Sheraton Hotel Taipei, Taiwan
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”.  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Sheraton Hotel Taipei, Taiwan
  • Invited Lecture “Value of Primovist in HCC screening”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Chang-Gung Memorial Hospital, Taiwan
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Chang-Gung Memorial Hospital, Taiwan
  • Invited Lecture “Value of Primovist in HCC screening”.  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） China Medical University, Taiwan
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） China Medical University, Taiwan
  • Invited Lecture “Value of Primovist in HCC screening”.  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Taiwan
  • Invited Lecture “Primovist benefit for HCC treatment particulary in RFA”.  [招待講演]
    Masatoshi Kudo
    Role of EOB-MRI in HCC management 2019年05月 口頭発表（招待・特別） Taiwan
  • 術前診断に難渋した膵頭部・尾部同時性多発癌の一例  [通常講演]
    岡本彩那; 三長孝輔; 竹中 完; 吉川智恵; 石川 嶺; 山﨑友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 松本逸平; 大谷知之; 工藤正俊
    第105回日本消化器病学会総会 2019年05月 ポスター発表 ホテル日航金沢, 石川
  • Interventional EUSのトラブルシューティング: 超音波造影剤の併用. ワークショップ14「ERCP・EUS関連手技のトラブルシューティング」  [通常講演]
    三長孝輔; 竹中 完; 工藤正俊
    第105回日本消化器病学会総会 2019年05月 シンポジウム・ワークショップパネル（公募） ホテル日航金沢, 石川
  • 司会; シンポジウム9「進行肝癌に対する新たな治療戦略」  [招待講演]
    工藤正俊
    第105回日本消化器病学会総会 2019年05月 その他 石川県立音楽堂, 石川
  • 腸内細菌叢からみた膵酵素補充療法の慢性膵炎に対する炎症抑制機序の解明. ワークショップ2「消化器領域における腸内細菌研究と臨床応用」  [通常講演]
    三長孝輔; 渡邉智裕; 工藤正俊
    第105回日本消化器病学会総会 2019年05月 シンポジウム・ワークショップパネル（公募） ANAクラウンプラザホテル金沢, 石川
  • Invited Lecture “Evolving roles of targeted therapy in HCC”  [招待講演]
    工藤正俊
    the 3rd Symposium of the Singapore Liver Cancer Consortium (SLCC) 2019年05月 口頭発表（招待・特別） Singapore
  • Lenvatinib (lenva) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study  [通常講演]
    Llovet J; Kudo M; Cheng AL; Finn R; Galle P; Kaneko S; Meyer T; Qin S; Dutcus C; Chen E; Dubrovsky L; Zhu A
    American Society of Clinical Oncology Annual Meeting (ASCO 2019) 2019年05月 ポスター発表 Chicago, USA
  • 座長; 男女共同参画委員会企画「医療者のためのアンガーマネジメント入門」  [招待講演]
    工藤正俊
    日本超音波医学会第92回学術集会 2019年05月 その他 グランドプリンスホテル新高輪, 東京
  • Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis  [通常講演]
    Peck-Radosavljevic M; Lee HC; Kudo M; Nakajima K; Bayh I; Cheng AL; Raoul JL
    The International Iiver Congress (EASL 2019) 2019年04月 ポスター発表 Vienna, Austria
  • A phase 1b trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results.  [通常講演]
    Ikeda M; Sung MW; Kudo M; Kobayashi M; Baron AD; Finn RS; Kaneko S; Zhu AX; Kubota T; Kraljevic S; Ikezawa H; Dubrovsky L; Siegel AB; Kumada H; Okusaka T
    American Association for Cancer Research Annual Meeting (AACR 2019) 2019年04月 ポスター発表 Atlanta, Georgia, USA
  • Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis.  [通常講演]
    Hiraoka A; Kumada T; Takaguchi K; Kariyama K; Tsuji K; Itobayashi E; Ochi H; Tajiri K; Hirooka M; Shimada N; Ishikawa T; Tsutsui A; Shibata H; Tada T; Toyoda H; Nouso K; Itokawa N; Joko K; Atsukawa M; Imai M; Michitaka K; Hiasa Y; Kudo M
    The International Iiver Congress (EASL 2019) 2019年04月 Vienna, Austria
  • Efficacy and hepatic safety of Nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040  [通常講演]
    Sangro B; Matilla A; Santoro A; Melero I; Gracian AC; Acosta MR; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; dela Cruz C; Baccan C; Kudo M
    The International Iiver Congress (EASL 2019) 2019年04月 Vienna, Austria
  • 司会; 特別講演「C型肝炎の治療薬選択と経過観察留意点」  [招待講演]
    工藤正俊
    第15回Kinki Liver Club 2019年03月 その他 ホテルモントレグラスミア大阪, 大阪
  • 開会の辞: 工藤正俊  [招待講演]
    工藤正俊
    第15回Kinki Liver Club 2019年03月 その他 ホテルモントレグラスミア大阪, 大阪
  • 特別講演「肝細胞癌に対する薬物療法の最新の進歩～支持療法の重要性を含めて～」  [招待講演]
    工藤正俊
    Otsuka Web Seminar 2019年03月 公開講演，セミナー，チュートリアル，講習，講義等
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    Liver Cancer Forum in Fukuoka 2019年03月 口頭発表（招待・特別） ホテルオークラ福岡, 九州
  • 特別講演「新たなステージに入った肝細胞癌治療」  [招待講演]
    工藤正俊
    肝細胞がん治療の新時代を考える会 in 八王子」 2019年02月 口頭発表（招待・特別） 京王プラザホテル八王子, 東京
  • 肝予備能からみたレンバチニブの有効性と安全性の検討. シンポジウム2「進行肝細胞癌治療の現状と課題」  [通常講演]
    萩原 智; 上嶋一臣; 工藤正俊
    日本消化器病学会近畿支部第110回例会 2019年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • 膵神経内分泌腫瘍の悪性度評価における造影ハーモニックEUSの有用性. ワークショップ2「胆膵腫瘍診断・治療の進歩と課題」  [通常講演]
    石川 嶺; 鎌田 研; 竹中 完; 工藤正俊
    日本消化器病学会近畿支部第110回例会 2019年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • 胃底腺型胃癌の臨床的特徴の検討. シンポジウム1「ピロリ陰性時代の上部消化管診療」  [通常講演]
    河野辰哉; 松井繁長; 櫻井俊治; 工藤正俊
    日本消化器病学会近畿支部第110回例会 2019年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • PPI長期投与例の胃底腺ポリープの特徴. シンポジウム1「ピロリ陰性時代の上部消化管診療」  [通常講演]
    松村まり子; 辻 直子; 梅原康湖; 工藤正俊
    日本消化器病学会近畿支部第110回例会 2019年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験. パネルディスカッション「炎症性腸疾患治療の最前線」  [通常講演]
    河野匡志; 櫻井俊治; 工藤正俊
    日本消化器病学会近畿支部第110回例会 2019年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • Efficacy, safety, and patient-reported outcomes in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies  [通常講演]
    Borbath I; Kudo M; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Peck-Radosavljevic M; Girvan A; Gable J; Bowman L; Abada P; Hsu Y; Zhu AX
    Belgian Week of Gastroenterology 2019年02月 口頭発表（一般） Antwerp, Belgium
  • 座長: シンポジウム2「肝癌治療の画像的効果判定—分子標的治療薬を中心に—」  [招待講演]
    工藤正俊
    第25回肝血流動態・機能イメージ研究会 2019年02月 その他 笹川記念会館, 東京
  • conventional TACEのヨード密度画像による治療効果判定. シンポジウム2「肝癌治療の画像的効果判定—分子標的治療薬を中心に—」  [通常講演]
    兵頭朋子; 柳生行伸; 河野雄輝; 沼本 勲; 鶴﨑正勝; 上嶋一臣; 工藤正俊; 石井一成
    第25回肝血流動態・機能イメージ研究会 2019年02月 シンポジウム・ワークショップパネル（公募） 笹川記念会館, 東京
  • US-US overlay fusionを用いたPrecision RFAと早期治療効果判定. シンポジウム1「肝癌治療の画像シミュレーションとナビゲーション」  [通常講演]
    南 康範; 工藤正俊
    第25回肝血流動態・機能イメージ研究会 2019年02月 シンポジウム・ワークショップパネル（公募） 笹川記念会館, 東京
  • ラジオ波焼灼術における画像解析ソフトを用いた治療シミュレーションと治療効果判定. シンポジウム1「肝癌治療の画像シミュレーションとナビゲーション」  [通常講演]
    小川 力; 盛田真弘; 工藤正俊
    第25回肝血流動態・機能イメージ研究会 2019年02月 シンポジウム・ワークショップパネル（公募） 笹川記念会館, 東京
  • Practice patterns, response rates, and deterioration of liver function after transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC): Final analysis of OPTIMIS in China  [通常講演]
    Shan H; Lee HC; Raoul JL; Peck-Radosavljevic M; Kudo M; Nakajima K; Bayh I; Yang Y; Wang W; Cheng AL
    The 28th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2019) 2019年02月 ポスター発表 Manila, Philippines
  • Invited Lecture “Ongoing trials in systemic therapies for HCC”  [招待講演]
    工藤正俊
    Asian Pacific Association for the Study of the Liver (APASL 2019) 2019年02月 口頭発表（招待・特別） Manila, Philippines
  • Invited Lecture “Role of the hepatologist”  [招待講演]
    工藤正俊
    Asian Pacific Association for the Study of the Liver (APASL 2019) 2019年02月 口頭発表（招待・特別） Manila, Philippines
  • Ramucirumab for patients with hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib treatment: exploratory analysis of REACH-2 trial results by albumin-bilirubin grade and Child-Pugh score  [通常講演]
    Brandi G; Kudo M; Kang Y; Yen C; Finn R; Galle P; Llovet J; Assenat E; Merle P; Jean-Baptiste H; Chan SL; Palmer D; Wang C; Widau R; Hsu Y; Abada PB; Zhu A
    EASL HCC Summit 2019 2019年02月 Lisbon, Portugal
  • 教育講演「肝癌治療のこれから～来たるべきパラダイムシフトへの期待～」  [招待講演]
    工藤正俊
    第19回日本肝がん分子標的治療研究会 2019年01月 口頭発表（招待・特別） ベルサール九段, 東京
  • 開会/閉会の挨拶  [招待講演]
    工藤正俊
    第19回日本肝がん分子標的治療研究会 2019年01月 その他 ベルサール九段, 東京
  • 特別講演「肝細胞癌治療のパラダイム－最新データを紐解く－」  [招待講演]
    工藤正俊
    LENVIMA-HCC Web Seminar 2019年01月 口頭発表（招待・特別）
  • Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): an analysis of AFP kinetics in the phase 3 REACH-2 study.  [通常講演]
    Finn RS; Kudo M; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; Motomura K; Ohno I; Daniele B; Shin D; Gerken G; Abada P; Hsu Y; Zhu AX
    American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study  [通常講演]
    Ogasawara S; Ueshima K; Ikeda M; Yasui Y; Terashima T; Yamashita T; Obi S; Sato S; Aikata H; Ohmura T; Kuroda H; Ohki T; Nagashima K; Kurosaki M; Chayama K; Kaneko S; Izumi N; Kato N; Kudo M; Omata M
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • CheckMate-040: Nivolumab (NIVO) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status  [通常講演]
    Kudo M; Matilla A; Santoro A; Melero I; Gracian A; Acosta MR; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; dela Cruz C; Baccan C; Sangro B
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase 3 study of lenvatinib (REFLECT)  [通常講演]
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Ueshima K; Aikata H; Vogel A; Lopez C; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Dutcus C; Tamai T; Saito K; Lencioni R
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 口頭発表（一般） San Francisco, USA
  • Subsequent anticancer medication following first-line lenvatinib: a posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma  [通常講演]
    Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TJ; Lopez CL; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RS
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • Safety and efficacy of lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT  [通常講演]
    Okusaka T; Ikeda K; Kudo M; Finn RS; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrxicz L; Yoon JH; Ren Z; Stepan D; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)  [通常講演]
    Sung M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Kudo M; Tateishi R; Ikeda M; Breder V; Rau KM; Ma YT; Alsina A; Ryoo BY; Ren Z; Mody K; Dutcus C; Tamai T; Saito K; Piscaglia F
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studi  [通常講演]
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019) 2019年01月 ポスター発表 San Francisco, USA
  • Invited Lecture “HCC and cholangiocarcinoma”  [招待講演]
    工藤正俊
    Hot Topics at AASLD 2018 2018年12月 口頭発表（招待・特別） Hyderabad, India
  • Invited Lecture “Newer diagnostic algorithm for a solid tumor <3 cm in a cirrhotic”  [招待講演]
    工藤正俊
    Hot Topics at AASLD 2018 2018年12月 口頭発表（招待・特別） Hyderabad, India
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    LENVIMA-Meet the Expert 効能・効果追加記念講演会 2018年12月 口頭発表（招待・特別） 札幌プリンスホテル, 北海道
  • 特別講演「新たなステージに入った肝細胞癌治療－薬物療法のもたらす新たなパラダイム」  [招待講演]
    工藤正俊
    富山LENVIMA-HCC Expert 治療最前線‐臨床へどう反映すべきか－ 2018年12月 口頭発表（招待・特別） 富山大学附属病院, 富山
  • 開会/閉会の挨拶  [招待講演]
    工藤正俊
    第17回大阪消化器化学療法懇話会 2018年12月 その他 ホテルモントレグラスミア大阪, 大阪
  • 特別講演「新たなステージに入った肝細胞癌治療‐薬物療法のもたらす新たなパラダイム」  [招待講演]
    工藤正俊
    LENVIMA-Meet the Expert 2018年11月 口頭発表（招待・特別） JRタワー名古屋, 愛知
  • 特別講演「新たなステージに入った肝細胞癌治療‐薬物療法のもたらす新たなパラダイム」  [招待講演]
    工藤正俊
    LENVIMA HCC Seminar 2018年11月 口頭発表（招待・特別） ホテルグランヴィア和歌山, 和歌山
  • Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions  [通常講演]
    Heo J; Cheng AL; Raoul JL; Peck-Radosavljevic M; Kudo M; Nakajima K; Bayh I; Lin SM; Lee HC
    European Society for Medical Oncology Congress (ESMO-Asia 2018) 2018年11月 ポスター発表 Singapore
  • Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies  [通常講演]
    Kang YK; Kudo M; Lim HY; Hsu CH; Vogel A; Brandi G; Cheng R; Carton I; Abada P; Hsu Y; Zhu A; Yen CJ
    European Society for Medical Oncology Congress (ESMO-Asia 2018) 2018年11月 ポスター発表 Singapore
  • M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype  [通常講演]
    Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
    European Society for Medical Oncology Congress (ESMO-Asia 2018) 2018年11月 口頭発表（一般） Singapore
  • Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)  [通常講演]
    Chan SL; Finn RS; Zhu AX; Knox J; Cheng AL; Siegel AB; Bautista O; Kudo M
    European Society for Medical Oncology (ESMO)-ASIA 2017 2018年11月 ポスター発表 Singapore
  • Clinical efficacy and safety of EUS-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study in Japan  [通常講演]
    工藤正俊
    Asian Pacific Digestive Week (APDW 2018) 2018年11月 口頭発表（一般） Seoul, Korea
  • Nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma (aHCC) in the CheckMate-040 study  [通常講演]
    Kudo M; Matilla A; Santoro A; Melero I; Gracian AC; Acosta MR; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; dela Cruz C; Baccan C; Sangro B
    American Association for the study of liver diseases (AASLD 2018) 2018年11月 口頭発表（一般） San Francisco
  • New diagnostic method for hepatic steatosis using attenuation measurement by ultrasound B mode: comparison with controlled attenuation parameter  [通常講演]
    Koizumi Y; Hirooka M; Yada N; Tamaki N; Izumi N; Kudo M; Hiasa Y
    American Association for the study of liver diseases (AASLD 2018) 2018年11月 ポスター発表 San Francisco
  • Stem cell feature and immune-suppressive microenvironment in human hepatocellular carcinoma  [通常講演]
    Nishida N; Kudo M
    American Association for the study of liver diseases (AASLD 2018) 2018年11月 ポスター発表 San Francisco
  • Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis  [通常講演]
    Peck-Radosavljevic; Kudo M; Raoul JL; Lee HC; Decaens T; Heo J; Lin SM; Shan H; Yang Y; Bayh I; Nakajima K; Cheng AL
    American Association for the study of liver diseases (AASLD 2018) 2018年11月 口頭発表（一般） San Francisco
  • Ramucirumab as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib: pooled results from two global phase 3 studies (REACH-2 and REACH)  [通常講演]
    Llovet JM; Kudo M; Finn R; Galle PR; Blanc JF; Okusaka T; Chau I; Abada PB; Hsu Y; Zhu AX
    American Association for the study of liver diseases (AASLD 2018) 2018年11月 口頭発表（一般） San Francisco, USA
  • IPMN切除例からみた新ガイドラインの検証と、造影ハーモニックEUSの有用性について  [通常講演]
    山崎友裕; 大本俊介; 竹中 完; 吉川智恵; 岡本彩那; 石川 嶺; 中井敦史; 鎌田 研; 三長孝輔; 山雄健太郎; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 胆管損傷後のBiloma内でランデブー法にて胆管ステントを留置し得た一例  [通常講演]
    岡本彩那; 三長孝輔; 竹中 完; 吉川智恵; 石川 嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 工藤正俊; 岩崎寿光; 松本逸平; 鶴崎正勝
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 若年性ポリポーシスにより胃切除を施行した2症例  [通常講演]
    河野辰哉; 松井繁長; 工藤正俊; 樫田博史; 渡邉智裕; 米田頼晃; 山田光成; 河野匡志; 櫻井俊治; 永井知行; 辻 直子; 安田卓司; 白石 治; 木村 豊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 表在型食道神経内分泌癌の一例  [通常講演]
    高島耕太; 松井繁長; 岡元寿樹; 山田光成; 正木 翔; 河野匡志; 米田頼晃; 永井知行; 櫻井俊治; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 急性膵炎を発症した肺腺癌膵転移の一例  [通常講演]
    久家沙希那; 大本俊介; 竹中 完; 石川 嶺; 岡本彩那; 中井敦史; 鎌田 研; 三長孝輔; 山雄健太郎; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • Russell body gastritisの一例  [通常講演]
    秦 康倫; 木下大輔; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 工藤正俊; 渡辺敏彦; 若狭朋子; 岩渕三哉
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • クラリスロマイシン耐性とH. pylori除菌法の選択  [通常講演]
    辻 直子; 梅原康湖; 谷池聡子; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 肝外胆管癌のT-stagingにおける造影ハーモニックEUSと造影CT検査の有用性についての検討. パネルディスカッション2「膵胆道癌早期診断への内視鏡的アプローチ」  [通常講演]
    大塚康生; 鎌田 研; 竹中 完; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 当院におけるソナゾイド造影下interventional EUSの検討. シンポジウム1「胆膵内視鏡治療の工夫」  [通常講演]
    吉川智恵; 三長孝輔; 竹中 完; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • EUSガイド下膵管ドレナージのトラブルシューティングにおいてRe-puncture techniqueが有用であった一例. シンポジウム1「胆膵内視鏡治療の工夫」  [通常講演]
    大本俊介; 竹中 完; 工藤正俊
    第101回日本消化器内視鏡学会近畿支部例会 2018年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: multicenter analysis  [通常講演]
    Hiraoka A; Kumada T; Tsuji K; Takaguchi K; Itobayashi E; Kariyama K; Ochi H; Tajiri K; Hirooka M; Shimada N; Ishikawa T; Tachi Y; Tada T; Toyoda H; Nouso K; Joko K; Hiasa Y; Michitaka K; Kudo M
    American Association for the study of liver diseases (AASLD 2018) 2018年11月 ポスター発表 San Francisco
  • 司会; サテライトシンポジウム97「がん免疫療法の現状」  [招待講演]
    工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 その他 神戸コンベンションセンター, 兵庫
  • 術前水平方向進展度診断にSpyGlass DSが有用であった遠位胆管癌の2例  [通常講演]
    東原久美; 三長孝輔; 岡本彩那; 榎木英介; 石川 嶺; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 竹中 完; 工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • Cap polyposisにおける腸内細菌叢の解析  [通常講演]
    岡元寿樹; 渡邉智裕; 工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • EUS施行時の鎮静に対するBISモニターの有用性の検討  [通常講演]
    岡本彩那; 鎌田 研; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • 膵癌の門脈浸潤診断における造影ハーモニックEUSと造影CTの診断能の比較検討  [通常講演]
    中井敦史; 鎌田 研; 竹中 完; 石川 嶺; 岡本彩那; 大本俊介; 三長孝輔; 山雄健太郎; 兵頭朋子; 松本逸平; 竹山宜典; 工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • 腸内細菌叢からみたIgG4関連疾患の発症機序の解明. ワークショップ21「胆膵領域におけるIgG4関連疾患の研究と診療の進歩」  [通常講演]
    鎌田 研; 渡邉智裕; 工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • 当院でのirAE大腸炎の臨床的特徴  [通常講演]
    櫻井俊治; 川上尚人; 工藤正俊
    第26回日本消化器関連学会週刊JDDW 2018（第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会） 2018年11月 口頭発表（一般） 神戸コンベンションセンター, 兵庫
  • 良性胆道狭窄（慢性膵炎）に対するfully covered metallic stentの有用性. ワークショップ14「Innovative therapeutic endoscopy良性胆管・膵管狭窄に対する内視鏡治療」  [通常講演]
    竹中 完; 山雄健太郎; 工藤正俊
    第26回日本消化器関連学会週間JDDW 2018（第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会, 第60回日本消化器病学会大会） 2018年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib (REACH-2): efficacy, safety, and patient-reported outcome results  [通常講演]
    Zhu A; Finn R; Galle P; Llovet J; Nipp R; Cella D; Girvan A; Gable J; Bowman L; Abada P; Hsu Y; Kudo M
    Gastrointestinal Oncology Conference 2018 (ISGIO) 2018年11月 口頭発表（一般） Arlington, VA, USA
  • ランチョンセミナー38「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    第26回日本消化器関連学会週間JDDW 2018（第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会, 第60回日本消化器病学会大会） 2018年11月 口頭発表（招待・特別） 神戸コンベンションセンター, 兵庫
  • Independent imaging review analysis of REFLECT trial of lenvatinib in HCC. ワークショップ5「生存期間延長を目指す分子機構に立脚した肝癌診療の基礎と臨床」  [通常講演]
    相方 浩; 工藤正俊; 池田健次
    第26回日本消化器関連学会週間JDDW 2018（第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会, 第60回日本消化器病学会大会） 2018年11月 シンポジウム・ワークショップパネル（公募） 戸コンベンションセンター, 兵庫
  • Special Remarks, International Session (Symposium) 2 “Hepatitis towards the control of HCC-the remaining issues and future directions in Japan and the world”  [招待講演]
    工藤正俊
    Japan Digestive Disease Week 2018 (JDDW 2018)（the 60th Annual Meeting of the Japanese Society of Gastroenterology, the 96th Congress of the Japan Gastroenterological Endoscopy Society, the 22nd General Meeting of the Japan Society of Hepatology） 2018年11月 その他 Kobe Convention Center, Hyogo
  • Independent imaging review analysis of REFLECT trial of lenvatinib in HCC  [通常講演]
    工藤正俊
    Japan Digestive Disease Week (JDDW 2018)(The 60th Annual Meeting of the Japanese Society of Gastroenterolgy, the 22nd General Meeting of the Japan Society of Hepatology, the 96th Congress of the Japan Gastroenterological Endoscopy Society) 2018年11月 シンポジウム・ワークショップパネル（公募） Kobe Convention Center, Hyogo
  • Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study  [通常講演]
    Ladron de; Guevara L; Dagher L; Miguel Viana; Arruda V; Nakajima K; Kudo M
    Mexican Society of Oncology 36th National Congress 2018 (SMEO 2018) 2018年11月 ポスター発表 Guardalajara, Mexico
  • 特別講演「急速に変貌する肝細胞癌の薬物療法—ESMOの最新情報を含めて－」  [招待講演]
    工藤正俊
    NEXT Web Conference 2018年10月 口頭発表（招待・特別）
  • 司会; 特別シンポジウム「超音波デジタル画像のナショナルデータベース構築とAI診断開発」  [招待講演]
    工藤正俊
    第30回関東甲信越地方会学術集会 2018年10月 その他 都市センターホテル, 東京
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    The HCC Summit in Shizuoka 2018年10月 口頭発表（招待・特別） ホテルセンチュリー静岡, 静岡
  • 特別講演「肝細胞癌の薬物治療が大きく変わる」  [招待講演]
    工藤正俊
    LENVIMA適応追加講演会 2018年10月 口頭発表（招待・特別） ホテル日航姫路, 兵庫
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    LENVIMA適応追加講演会 日本で生まれた新薬・レンビマの登場 2018年10月 口頭発表（招待・特別） ホテル東日本宇都宮, 栃木
  • Global phase 3 study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress  [通常講演]
    Qin S; Finn R; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla T; Tomasello G; Boisserie F; Hou J; Li C; Song J; Zhu A
    European Society for Medical Oncology (ESMO 2018) 2018年10月 ポスター発表 Munich, Germany
  • Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada  [通常講演]
    Raoul JL; Decaens T; Burak K; Koskinas J; Villadsen GE; Heurgue-Berlot A; Bayh I; Cheng AL; Kudo M; Lee HC; Nakajima K; Peck-Radosavljevic M
    European Society for Medical Oncology (ESMO 2018) 2018年10月 ポスター発表 Munich, Germany
  • A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma  [通常講演]
    Cheng AL; Yen CJ; Okusaka T; Ikeda M; Hsu CH; Wu SY; Morizane C; Hashimoto Y; Ueshima K; Ohtomo T; Tanaka T; Kudo M
    European Society for Medical Oncology (ESMO 2018) 2018年10月 ポスター発表 Munich, Germany
  • Invited Lecture “HCC Meet the Expert”  [招待講演]
    工藤正俊
    European Society for Medical Oncology (ESMO 2018) 2018年10月 口頭発表（招待・特別） Munich, Germany
  • Final analysis of serum biomarkers in patients (pts) from the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]  [通常講演]
    Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan R; Blanc JF; Baron A; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus C; Funahashi Y; Evans TRJ
    European Society for Medical Oncology (ESMO 2018) 2018年10月 ポスター発表 Munich, Germany
  • 膵癌の門脈浸潤に対する造影ハーモニックEUS (CH-EUS)と造影multidetector CT (MDCT)の診断能の比較検討  [通常講演]
    中井敦史; 鎌田 研; 竹中 完; 松本逸平; 竹山宜典; 兵頭朋子; 筑後孝章; 工藤正俊
    日本超音波医学会第45回関西地方会学術集会 2018年10月 口頭発表（一般） 神戸国際会議場, 兵庫
  • 診断に難渋したNeurilemmomaの一例  [通常講演]
    横川美加; 南 雅人; 桑口 愛; 市島真由美; 塩見香織; 前川 清; 南 康範; 依田 広; 樫田博史; 工藤正俊
    日本超音波医学会第45回関西地方会学術集会 2018年10月 口頭発表（一般） 神戸国際会議場, 兵庫
  • 膵神経内分泌腫瘍における超音波内視鏡下ソナゾイド造影による悪性度診断の有用性  [通常講演]
    石川 嶺; 鎌田 研; 竹中 完; 大本俊介; 筑後孝章; 松本逸平; 竹山宜典; 工藤正俊
    日本超音波医学会第45回関西地方会学術集会 2018年10月 口頭発表（一般） 神戸国際会議場, 兵庫
  • 肝癌に対するラジオ波焼灼術の支援画像: US-US overlay fusionの有用性. シンポジウム2「Interventional US」  [通常講演]
    南 康範; 依田 広; 工藤正俊
    日本超音波医学会第45回関西地方会学術集会 2018年10月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 兵庫
  • Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)  [通常講演]
    Zhu AX; Finn R; Galle P; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Girvan A; Gable J; Bowman L; Hsu Y; Abada P; Kudo M
    European Society for Medical Oncology (ESMO 2018) 2018年10月 ポスター発表 Munich, Germany
  • 司会: 臓器別シンポジウム6「肝細胞癌: 診断・治療の新たな展開」  [招待講演]
    工藤正俊
    第56回日本癌治療学会学術集会 2018年10月 その他 パシフィコ横浜, 神奈川
  • Invited Lecture “The Role of CEUS in the Detection and Diagnosis of FLL”  [招待講演]
    工藤正俊
    The 2018 Convention of Taiwan Society of Ultrasound in Medicine (TSUM) 2018年10月 口頭発表（招待・特別） Taipei, Taiwan
  • 特別講演「肝細胞癌治療のブレークスルー～薬物療法が変わる～」  [招待講演]
    工藤正俊
    第45回青森県肝胆膵研究会 2018年10月 弘前大学医学部コミュニケーションセンター, 青森
  • 特別講演「新たなステージに入った肝細胞癌治療－薬物療法が変わる－」  [招待講演]
    工藤正俊
    第100回北九州肝腫瘍研究会特別記念講演会 2018年10月 口頭発表（招待・特別） ホテルクラウンパレス小倉,福岡
  • 特別講演「新たなステージに入った肝細胞癌治療～薬物療法が変わる～」  [招待講演]
    工藤正俊
    首都圏肝臓交流セミナー 2018年10月 口頭発表（招待・特別） 八芳園, 東京
  • M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial  [通常講演]
    Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
    European Society for Medical Oncology (ESMO 2018) 2018年10月 ポスター発表 Munich, Germany
  • セルブロック法を用いた内視鏡的経鼻胆嚢ドレナージチューブ下細胞診にて診断し得たIntracystic papillary neoplasmの一例  [通常講演]
    原 茜; 石川 嶺; 鎌田 研; 大塚康生; 吉川智恵; 山崎友裕; 高田龍太郎; 岡本彩那; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 竹中 完; 工藤正俊; 筑後孝章; 木村雅友; 吉田雄太; 中居卓也; 竹山宜典
    日本消化器病学会近畿支部第109回例会 2018年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 胃、十二指腸への転移を来した悪性中皮腫の一例  [通常講演]
    永谷奈央; 木下大輔; 秦 康倫; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 明石雄策; 田村孝雄; 工藤正俊
    日本消化器病学会近畿支部第109回例会 2018年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • FNH類似の造影エコー像を示した肝細胞癌の一切除例  [通常講演]
    大丸直哉; 永谷奈央; 秦 康倫; 木下大輔; 奥田英之; 高山政樹; 川崎俊彦; 水野成人; 眞鍋弘暢; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊; 大谷知之
    日本消化器病学会近畿支部第109回例会 2018年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 術前診断が困難であった膵頭部、尾部重複癌の一例  [通常講演]
    岡本彩那; 三長孝輔; 大塚康生; 高田龍太郎; 吉川智恵; 石川 嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 竹中 完; 工藤正俊; 大谷知之
    日本消化器病学会近畿支部第109回例会 2018年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 慢性偽性腸閉塞に対し、胃瘻造設が有効であった一例  [通常講演]
    田中秀和; 永井知行; 櫻井俊治; 河野辰哉; 高島耕太; 正木 翔; 岡元寿樹; 河野匡志; 山田光成; 米田頼晃; 渡邉智裕; 松井繁長; 辻 直子; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第109回例会 2018年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 進行肝細胞癌に対するレゴラフェニブの治療成績. パネルディスカッション「消化器癌治療の現状と未来」  [通常講演]
    萩原 智; 上嶋一臣; 工藤正俊
    日本消化器病学会近畿支部第109回例会 2018年09月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • シミュレーションからナビゲーション: 放射線科領域での技術の到達点と今後の展望. シンポジウム3「シミュレーションからナビゲーションへ 放射線科領域」  [通常講演]
    鶴﨑正勝; 工藤正俊; 村上卓道
    第13回肝癌治療シミュレーション研究会 2018年09月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 肝癌に対するラジオ波焼灼術の支援画像: US-US overlay fusionの有用性  [通常講演]
    南 康範; 依田 広; 工藤正俊
    第13回肝癌治療シミュレーション研究会 2018年09月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • Stress response protein RBM3 promotes the development of colitis-associated cancer  [招待講演]
    Sakurai T; Kudo M
    The 77th Annual Meeting of the Japanese Cancer Association 2018年09月 口頭発表（一般） Osaka International Convention Center, Osaka
  • 特別講演「肝細胞癌治療のブレークスルー～薬物療法が変わる～」  [招待講演]
    工藤正俊
    第33回岐阜肝画像研究会 2018年09月 口頭発表（招待・特別） じゅうろくプラザ, 岐阜
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    肝胆膵の分子標的治療セミナー 2018年09月 口頭発表（招待・特別） ラグナヴェールプレミア, 大阪
  • Systemic therapy for hepatocellular carcinoma: current status and future perspective. Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment”  [招待講演]
    工藤正俊
    The 77th Annual Meeting of the Japanese Cancer Association 2018年09月 シンポジウム・ワークショップパネル（指名） Osaka International Convention Center, Osaka
  • Chair: Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment”  [招待講演]
    工藤正俊
    The 77th Annual Meeting of the Japanese Cancer Association 2018年09月 その他 Osaka International Convention Center, Osaka
  • 肝外胆管癌における造影ハーモニックEUSの有用性についての検討  [通常講演]
    大塚康生; 鎌田 研; 竹中 完; 石川 嶺; 岡本彩那; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 筑後孝章; 兵頭朋子; 中居卓也; 竹山宜典; 工藤正俊
    第54回日本胆道学会学術集会 2018年09月 口頭発表（一般） 幕張メッセ, 千葉
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    第38回奈良消化器代謝セミナー 2018年09月 口頭発表（招待・特別） 奈良ホテル, 奈良
  • 内視鏡治療後の再発十二指腸静脈瘤に対するEUSの有用性  [通常講演]
    松井繁長; 樫田博史; 工藤正俊
    第25回日本門脈圧亢進症学会総会, 第20回肝不全治療研究会, 第21回B-RTO研究会 2018年09月 口頭発表（一般） グランキューブ大阪, 大阪
  • 特別講演「新たなステージに入った肝細胞癌診療‐薬物療法が変わる‐」  [招待講演]
    工藤正俊
    レンバチニブ適応追加講演会 2018年09月 口頭発表（招待・特別） オークラフロンティアホテルつくば, 茨城
  • Hand-foot syndrome as a predictor of survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study  [通常講演]
    Ogawa C; Shibatoge M; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kudo M
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • Urine protein: creatinine ratio (UPCR) vs 24-h urine protein for the management of proteinuria: results from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in hepatocellular carcinoma (HCC)  [通常講演]
    Evans TR; Kudo M; Finn RS; Han KH; Cheng AL; Kraljevic S; Ren M; Dutcus CE; Piscaglia F; Sung MW
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • Acute and chronic deterioration in liver function after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): the final analysis of OPTIMIS  [通常講演]
    Cheng AL; Raoul JL; Lee HC; Bayh I; Nakajima K; Peck-Radosavljevic M; Kudo M
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • Newly proposed tools for assessment of hepatic function for hepatocellular carcinoma staging and treatment planning-usefulness of modified ALBI grade  [通常講演]
    Izumoto H; Hiraoka A; Kumada T; Hirooka M; Tsuji K; Itobayashi E; Kariyama K; Ishikawa T; Tajiri K; Ochi H; Tada T; Toyoda H; Nouso K; Joko K; Hiasa Y; Ninomiya T; Michitaka K; Kudo M
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (PTS) with unresectable hepatocellular carcinoma (UHCC)  [通常講演]
    Lencioni R; Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Han G; Ikeda M; Simon K; Komov D; OuYang X; Evans TR; Sung M; Binder T; Damon A; Kraljevic S; Ren M; Ryoo BY
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • Overall survival (OS) update: 2-year follow-up from the phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) progressing on sorafenib  [通常講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Houmand I; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on; behalf of the; RESORCE Investigators
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 口頭発表（一般） London, United Kingdom
  • A cost-effectiveness analysis of Lenvatinib compared with sorafenib in unresectable hepatocellular carcinoma allowing for AFP adjustment in overall survival in Japan from the reflect phase 3 clinical trial  [通常講演]
    Kudo M; Izumi N; Kaneko S; Kobayashi M; Azuma MK; Copher R; Meier G; Ishii M; Ikeda S
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 口頭発表（一般） London, United Kingdom
  • Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial  [通常講演]
    Ueshima K; Kudo M; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Arai Y; TACTICS study group
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 口頭発表（一般） London, United Kingdom
  • Outcomes of patients (PTS) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global optimis final analysis  [通常講演]
    Peck-Radosavljevic M; Kudo M; Raoul JL; Lee HC; Decaens T; Heo J; Lin SM; Shan H; Yang Y; Bayh I; Nakajima K; Cheng AL
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 口頭発表（一般） London, United Kingdom
  • Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2): a phase 3, randomized, double-blind, placebo-controlled trial  [通常講演]
    Galle PR; Kudo M; Kang YK; Yen CJ; Finn R; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; Motomura K; Ohno I; Daniele B; Shin DB; Gerken G; Abada P; Hsu Y; Zhu AX
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 口頭発表（一般） London, United Kingdom
  • Chair: General Session 3 “Epidemiology, Diagnosis, Staging”  [招待講演]
    工藤正俊
    Interntional Liver Cancer Association (ILCA) Annual Conference 2018年09月 その他 London, United Kingdom
  • Efficacy and safety of Tislelizumab, an anti-PD-1 antibody, versus sorafenib as a potential first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, multicenter study: A Trial-in-Progress  [通常講演]
    Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li C; Song J; Zhu AX
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    Lenvima-Meet the Expert効能・効果追加記念講演会 2018年09月 口頭発表（招待・特別） 札幌グランドホテル, 北海道
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    Lenvima適応追加記念講演会in 広島 2018年09月 口頭発表（招待・特別） リーガロイヤルホテル広島, 広島
  • Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study  [通常講演]
    Ladron de; Guevara L; Dagher L; Miguel Viana; Arruda V; Nakajima K; Kudo M
    ALEH 2018 2018年09月 ポスター発表 International Convention Center, Punta Cana, Dominican Republic
  • A prospective, observational study to assess the safety and effectiveness of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice (REFINE)  [通常講演]
    Finn R; Frenette C; Granito A; Ikeda M; Lim HY; Merle P; Ozgurdal K; Kudo M
    12th Annual Conference International Liver Cancer Association (ILCA) 2018年09月 ポスター発表 London, United Kingdom
  • Hand–foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenibfor treatment of hepatocellular carcinoma (HCC) progressing on sorafenib  [通常講演]
    Silva M; Carrilho FJ; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Xu L; Baumhauer A; Meinhardt G; Han G; Bruix J; on behalf of; the; RESORCE Investigators
    ALEH 2018 2018年09月 ポスター発表 International Convention Center, Punta Cana, Dominican Republic
  • 司会; ランチョンセミナー1「EOB-MRIは肝細胞癌の診療をどのように変えたか？」  [招待講演]
    工藤正俊
    第69回日本消化器画像診断研究会 2018年08月 その他 石川県立音楽堂, 石川
  • 特別講演「新たなステージに入った肝細胞癌診療－薬物療法が変わる－」  [招待講演]
    工藤正俊
    LENVIMA適応追加記念講演会 2018年08月 口頭発表（招待・特別） リーガロイヤルホテル大阪, 大阪
  • 特別講演「肝細胞癌診療のブレークスルー－薬物療法が変わる－」  [招待講演]
    工藤正俊
    LENVIMA Meet The Expert南大阪 2018年08月 口頭発表（招待・特別） ホテルアゴーラリージェンシー堺, 大阪
  • 特別講演「肝癌診療のブレイクスルー－薬物療法が変わる－」  [招待講演]
    工藤正俊
    中四国エリアレンビマHCC講演会in香川 2018年08月 口頭発表（招待・特別） JRホテルクレメント高松, 香川
  • 特別講演「肝癌診療のブレイクスルー－薬物療法が変わる－」  [招待講演]
    工藤正俊
    中四国エリアレンビマHCC講演会in香川 2018年08月 口頭発表（招待・特別） JRホテルクレメント高松, 香川
  • Invited Lecture “Eastern perspective”  [招待講演]
    工藤正俊
    Hepatocellular Carcinoma (HCC) Scientific Input Engagement 2018年08月 口頭発表（招待・特別） Hoboken, New Jersey
  • 特別講演「新たなステージに入った肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    LENVIMA適応追加記念講演会 日本で生まれた新薬・レンビマの登場 2018年08月 口頭発表（招待・特別） ホテルメトロポリタン山形, 山形
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    HCC Meet the Expert in AKITA LENVIMA「肝細胞癌」適応追加記念講演会 2018年08月 口頭発表（招待・特別） ホテルメトロポリタン秋田, 秋田
  • 特別講演「急速に変貌する肝細胞癌の薬物療法」  [招待講演]
    工藤正俊
    第171回東北腹部画像診断検討会 2018年08月 口頭発表（招待・特別） 江陽グランドホテル, 宮城
  • 特別講演「新たなステージに入った肝細胞癌治療－薬物療法が変わる－」  [招待講演]
    工藤正俊
    肝細胞癌Meet The Experts in 岩手 2018年08月 口頭発表（招待・特別） ホテルメトロポリタン盛岡, 岩手
  • 特別講演「肝癌診療のブレイクスルー薬物療法が変わる」  [招待講演]
    工藤正俊
    LENVIMA-HCC埼玉適応追加記念講演会 2018年07月 口頭発表（招待・特別） パレスホテル大宮, 埼玉
  • 特別講演「新たなステージに入った肝細胞癌診療－薬物療法が変わる－」  [招待講演]
    工藤正俊
    第1回千葉肝がんフォーラム～適応追加記念講演会～ 2018年07月 口頭発表（招待・特別） 京成ホテルミラマーレ, 千葉
  • 特別講演「新たなステージに入った肝細胞癌診療－薬物療法が変わる－」  [招待講演]
    工藤正俊
    LENVIMA-HCC適応拡大記念講演会 2018年07月 口頭発表（招待・特別） 深志神社, 長野
  • 特別講演「肝細胞癌診療のブレイクスルー」  [招待講演]
    工藤正俊
    第18回関西肝血流動態・機能イメージ研究会 2018年07月 口頭発表（招待・特別） エーザイ株式会社大阪コミュニケーションオフィス33階, 大阪
  • テノホビルアラフェナミドの初期使用経験について  [通常講演]
    萩原 智; 西田直生志; 工藤正俊
    第60回京都肝疾患懇話会 2018年07月 口頭発表（一般） 京都ホテルオークラ, 京都
  • Educational Lecture “Phase 3 study of ramucirumab versus placebo in 2nd-line advanced HCC patients with high baseline AFP (REACH-2)”  [通常講演]
    工藤正俊
    16th Annual Meeting of the Japanese Society of Medical Oncology 2018年07月 口頭発表（招待・特別） Kobe Convention Center/Kobe Portopia hotel
  • PD-L1陽性肝癌の特徴と腫瘍免疫環境に関する解析. プレナリーセッション2  [通常講演]
    西田直生志; 工藤正俊
    第18回日本肝がん分子標的治療研究会 2018年07月 口頭発表（一般） 東京大学伊藤国際学術研究センター, 東京
  • 肝予備能良好なBCLC-B肝細胞癌に対するTACE予後予測・腫瘍マーカースコアの有用性; 肝癌研究会データベース解析  [通常講演]
    平岡 淳; 道堯浩二郎; 熊田 卓; 泉 並木; 角谷眞澄; 國土典宏; 久保正二; 松山 裕; 中島 収; 坂元亨宇; 高山忠利; 國土貴嗣; 柏原康佑; 江口 晋; 山下達也; 工藤正俊
    第18回日本肝がん分子標的治療研究会 2018年07月 口頭発表（一般） 東京大学伊藤国際学術研究センター, 東京
  • 司会: プレナリーセッション1  [招待講演]
    工藤正俊
    第18回日本肝がん分子標的治療研究会 2018年07月 その他 東京大学伊藤国際学術研究センター, 東京
  • 開会/閉会の辞  [招待講演]
    工藤正俊
    第18回日本肝がん分子標的治療研究会 2018年07月 その他 東京大学伊藤国際学術研究センター, 東京
  • Chair: Oral Poster Presentation “Treatment: clinical trials”  [招待講演]
    工藤正俊
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 その他 Grand Hyatt Seoul, South Korea
  • Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE): final analysis of OPTIMIS in Asian regions  [通常講演]
    工藤正俊
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 ポスター発表 Grand Hyatt Seoul, South Korea
  • Invited Lecture “TKI-Based combination therapy: the more the better?”  [招待講演]
    工藤正俊
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 口頭発表（招待・特別） Grand Hyatt Seoul, South Korea
  • Invited Lecture “TACE refractoriness: definition and treatment options”  [招待講演]
    工藤正俊
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 口頭発表（招待・特別） Grand Hyatt Seoul, South Korea
  • Invited Lecture “Role of contrast-enhanced ultrasound in diagnosis of early-stage HCC”  [招待講演]
    工藤正俊
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 口頭発表（招待・特別） Grand Hyatt Seoul, South Korea
  • Chair: Session 1 “Update of HCC guidelines”  [招待講演]
    工藤正俊
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 その他 Grand Hyatt Seoul, South Korea
  • US-US overlay image fusionを用いたラジオ波焼灼術の有用性：従来治療との比較. ワークショップ4「肝癌治療におけるナビゲーションの有用性と将来性」  [通常講演]
    南 康範; 工藤正俊
    第53回日本肝癌研究会 2018年07月 シンポジウム・ワークショップパネル（公募）
  • 特別講演「新たなステージに入った肝細胞癌治療～薬物療法が変わる～」  [招待講演]
    工藤正俊
    HCC Sorafenib-Regorafenib講演会 2018年07月 口頭発表（招待・特別） 大阪マリオット都ホテル, 大阪
  • Safety and Effectiveness of Regorafenib in Patients with Unresectable Hepatocellular Carcinoma in Routine Clinical Practice: REFINE, a Prospective, Observational Study  [通常講演]
    Lim HY; Finn RS; Frenette C; Granito A; Ikeda M; Merle P; Ozgurdal K; Kudo M
    The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2018年07月 ポスター発表 Grand Hyatt Seoul, South Korea
  • 教育講演「肝細胞癌の薬物療法: 最近の進歩と将来展望」  [招待講演]
    工藤正俊
    日本内科学会第58回近畿支部生涯教育講演会 2018年07月 口頭発表（招待・特別） 大阪国際交流センター, 大阪
  • 造影ハーモニックEUSは膵癌の術前治療の効果判定に有用か？  [通常講演]
    田中秀和; 鎌田 研; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 三長孝輔; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    第49回日本膵臓学会大会 2018年06月 口頭発表（一般） 和歌山県民文化会館, ホテルアバローム紀の国, 和歌山
  • 肝癌研究会追跡調査よりみた高齢肝細胞癌に対する至適治療法の検討, ワークショップ7「高齢化時代の肝癌診療」  [通常講演]
    海堀昌樹; 吉井健悟; 長谷川 潔; 小川朝生; 久保正二; 建石良介; 泉 並木; 角谷眞澄; 工藤正俊; 熊田 卓; 坂元亨宇; 中島 収; 松山 裕; 高山忠利; 國土典宏
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • 腫瘍マーカースコアによる肝予備能良好なBCLC-B肝細胞癌に対するTACE予後予測: 肝癌研究会データベース解析, ワークショップ6「診断技術（画像、腫瘍マーカー、ゲノム解析など）のイノベーション」  [通常講演]
    平岡 淳; 道蕘浩二郎; 熊田 卓; 泉 並木; 角谷眞澄; 國土典宏; 久保正二; 松山 裕; 中島 収; 坂元亨宇; 高山忠利; 國土貴嗣; 柏原康佑; 工藤正俊
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • TACE施行後のソラフェニブ投与の有無ならびに開始時期が予後へ与える影響を検討した国際共同観察研究, シンポジウム1「肝癌における分子標的薬の新たな治療展開」  [通常講演]
    工藤正俊; 中島圭子
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • 肝内胆管癌: 臨床診断, パネルディスカッション5「肝内胆管癌の診断と治療」  [通常講演]
    工藤正俊; 角谷眞澄; 村上卓道; 糸井隆夫; 海野倫明
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • 司会; 教育講演「Management of hepatocellular carcinoma and molecularly targeted therapy」  [招待講演]
    工藤正俊
    第54回日本肝癌研究会 2018年06月 その他 久留米シティプラザ, 福岡
  • 重症急性膵炎の予後不良予測因子および被包化壊死（WON）合併予測因子の検討  [通常講演]
    大本俊介; 竹中 完; 松本逸平; 竹山宜典; 工藤正俊
    第49回日本膵臓学会大会 2018年06月 口頭発表（一般） 和歌山県民文化会館, ホテルアバローム紀の国, 和歌山
  • 術後膵液廔（POPF）に対するEUSドレナージの有用性  [通常講演]
    中井敦史; 竹中 完; 山雄健太郎; 松本逸平; 竹山宜典; 工藤正俊
    第49回日本膵臓学会大会 2018年06月 口頭発表（一般） 和歌山県民文化会館, ホテルアバローム紀の国, 和歌山
  • 造影ハーモニックEUSによる膵神経内分泌腫瘍の悪性度評価. ワークショップ1「膵NETの最新の画像診断と治療」  [通常講演]
    石川 嶺; 鎌田 研; 竹中 完; 田中秀和; 中井敦史; 大本俊介; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 工藤正俊
    第49回日本膵臓学会大会 2018年06月 シンポジウム・ワークショップパネル（公募） 和歌山県民文化会館, ホテルアバローム紀の国, 和歌山
  • ランチョンセミナー7「レンビマによる肝癌治療のブレークスルー」  [招待講演]
    工藤正俊
    第54回日本肝癌研究会 2018年06月 口頭発表（招待・特別） 久留米シティプラザ, 福岡
  • 司会: 演者: 豊田秀徳「SVR後肝発癌を見逃さないために～一歩先を見るプリモビストMRIを用いたサーベイランスの工夫」  [招待講演]
    工藤正俊
    第54回日本肝癌研究会 2018年06月 その他 久留米シティプラザ, 福岡
  • 汎用型Workstationを用いたTACE治療とその問題点, ワークショップ3「TACE治療の新たな進歩」  [通常講演]
    盛田真弘; 小川 力; 大村亜紀奈; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • 汎用型Workstationを用いたHCCの診断、治療の試み. ワークショップ5-13「医用工学の肝癌治療への応用」  [通常講演]
    小川 力; 盛田真弘; 大村亜紀奈; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • 切除不能肝細胞癌に対する肝動脈化学塞栓療法とソラフェニブの併用療法第2相臨床試験（TACTICS）.シンポジウム1-3「肝癌における分子標的薬の新たな治療展開」  [通常講演]
    上嶋一臣; 池田公史; 工藤正俊
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • シンポジウム「TACE施行後のソラフェニブ投与の有無ならびに開始時期が予後へ与える影響を検討した国際共同観察研究」  [招待講演]
    工藤正俊
    第54回日本肝癌研究会 2018年06月 口頭発表（招待・特別） 久留米シティプラザ, 福岡
  • ラジオ波焼灼術の早期治療効果判定: US-US image overlay fusionの有用性. ワークショップ5-10「医用工学の肝癌治療への応用」  [通常講演]
    南 康範; 工藤正俊
    第54回日本肝癌研究会 2018年06月 シンポジウム・ワークショップパネル（公募） 久留米シティプラザ, 福岡
  • 司会: シンポジウム1「肝癌における分子標的治療薬の新たな治療展開」  [招待講演]
    工藤正俊
    第54回日本肝癌研究会 2018年06月 その他 久留米シティプラザ, 福岡
  • 基調講演「Keynote Lecture」  [招待講演]
    工藤正俊
    第54回日本肝癌研究会 2018年06月 口頭発表（基調） 久留米シティプラザ, 福岡
  • 特別講演「新たなステージに入った肝癌の薬物治療」  [招待講演]
    工藤正俊
    第49回京都肝癌セミナー 2018年06月 口頭発表（招待・特別） 京都ホテルオークラ, 京都
  • 特別講演「肝細胞癌診療のブレークスルー～薬物療法が変わる～」  [招待講演]
    工藤正俊
    第2回山口県肝臓癌セミナー, レンビマ®効能・効果追加記念講演会 2018年06月 口頭発表（招待・特別） ANAクラウンプラザホテル, 山口
  • 特別講演「肝細胞癌の薬物治療が大きく変わる」  [招待講演]
    工藤正俊
    Lenvatinib-Meet the Expert in 三重 2018年06月 口頭発表（招待・特別） 三重県総合文化センター, 三重
  • 慢性C型肝炎のDAA投与例におけるSVR後のAFP、ALT異常及び肝発癌に関する検討, ワークショップ11「肝炎ウイルスの制御が肝癌診療に及ぼす影響」  [通常講演]
    河野匡志; 西田直生志; 工藤正俊
    第54回日本肝臓学会総会 2018年06月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • RFA治療の効果判定: Hepatic Guideの有用性, パネルディスカッション5「画像診断の新展開」  [通常講演]
    南 知宏; 村上卓道; 工藤正俊
    第54回日本肝臓学会総会 2018年06月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 特別講演「肝細胞癌の治療アルゴリズム－穿刺局所療法・TACE・化学療法」, 特別企画5「日本肝臓学会ガイドラインup to date」  [招待講演]
    工藤正俊
    第54回日本肝臓学会総会 2018年06月 口頭発表（招待・特別） 大阪国際会議場, 大阪
  • 特別講演「これからの肝細胞癌診療」, 特別企画2「肝臓研究の過去から未来への潮流②」  [招待講演]
    工藤正俊
    第54回日本肝臓学会総会 2018年06月 口頭発表（招待・特別） 大阪国際会議場, 大阪
  • 司会: Jordi Bruix “Understanding current treatment options for HCC and exploring novel approaches”  [招待講演]
    工藤正俊
    第54回日本肝臓学会総会 2018年06月 その他 大阪国際会議場, 大阪
  • 遺伝子変化に基づいた肝細胞癌の分子スコアリングと転移再発, シンポジウム1「肝癌治療の新展開」  [通常講演]
    西田直生志; 海道利実; 工藤正俊
    第54回日本肝臓学会総会 2018年06月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 切除不能肝細胞癌に対する肝動脈化学塞栓療法（TACE）とソラフェニブの併用療法第II相臨床試験TACTICS Trial, シンポジウム1「肝癌治療の新展開」  [通常講演]
    上嶋一臣; 池田公史; 工藤正俊
    第54回日本肝臓学会総会 2018年06月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 総合司会  [招待講演]
    工藤正俊
    Lenvima-HCC Web Seminar 2018年06月 その他 近畿大学医学部消化器内科第3研究室, 大阪
  • Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”  [招待講演]
    工藤正俊
    Next Symposium 2018年06月 口頭発表（招待・特別） Ho Chi Minh, Vietnam
  • 肝膿瘍の視認性に関する低音圧造影tissue harmonic imagingの有用性. シンポジウム消化器7「肝臓 診断 肝腫瘤の診療ガイドラインを考える」  [通常講演]
    南 康範; 河野匡志; 工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 神戸ポートピアホテル, 兵庫
  • 新しい造影法導入後の問題点. シンポジウム消化器7「肝臓 診断 肝腫瘤の診療ガイドラインを考える」  [通常講演]
    小川 力; 盛田真弘; 野田晃世; 大村亜紀奈; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 神戸ポートピアホテル, 兵庫
  • 肝膿瘍治療指針におけるソナゾイド造影の有用性. シンポジウム消化器6「肝臓 診断 肝膿瘍の悪性度診断～Bモード・エラスト・Sonazoid造影～」  [通常講演]
    盛田真弘; 小川 力; 大村亜紀奈; 野田晃世; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 大西宏明; 工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 神戸ポートピアホテル, 兵庫
  • 座長: 男女共同参画委員会企画「キャリア継続およびキャリア支援に関する企業での取り組み」  [招待講演]
    工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 その他 神戸ポートピアホテル, 兵庫
  • US-US image overlay fusionを用いたラジオ波焼灼術の有用性: 従来治療との比較. パネルディスカッション消化器3「肝臓 治療 安全かつ確実なRFA治療を目指した超音波技術の工夫」  [通常講演]
    南 康範; 南 知宏; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 神戸ポートピアホテル, 兵庫
  • 超音波エラストグラフィ併用による肝線維化・炎症評価. シンポジウム消化器5「肝臓 エラスト エラストグラフィは何を見ている？」  [通常講演]
    玉城信治; 泉 並木; 小泉洋平; 廣岡昌史; 日浅陽一; 中島 収; 矢田典久; 工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 神戸ポートピアホテル, 兵庫
  • 座長: 会長講演「画像診断の未来」  [招待講演]
    工藤正俊
    日本超音波医学会第91回学術集会 2018年06月 その他 神戸国際会議場, 兵庫
  • Similar efficacy and safety of endoscopic ultrasound-guided biliary drainage via hepaticogastrostomy and choledochoduodenostomy approaches for malignant distal obstruction: a multicenter, prospective randomized trial. Topic Forum “Exploring Newer Indicati  [通常講演]
    Minaga K; Kitano M; Ogura, T; Shiomi H; Hoki N; Nishikiori H; Yamashita Y; Hisa Takeshi; Kato H; Kamada H; Takenaka, M; Higuchi, K; Chiba Y; Kudo M
    Digestive Disease Week (DDW 2018) 2018年06月 口頭発表（一般） Washington DC, USA
  • REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe  [通常講演]
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; Motomura K; Ohno I; Daniele B; Shin D; Gerken G; Abada P; Hsu Y; Kudo M
    American Society of Clinical Oncology Annual Meeting (ASCO 2018) 2018年06月 口頭発表（一般） Chicago, USA
  • A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma  [通常講演]
    Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Mercade TM; Tomasello G; Boisserie F; Hou J; Li C; Song J; Zhu AX
    American Society of Clinical Oncology Annual Meeting (ASCO 2018) 2018年06月 ポスター発表 Chicago, USA
  • Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial  [通常講演]
    Kudo M; Ueshima K; Torimura T; Tanabe N; Ikeda M; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Isoda N; Yasui K; Kuzuya T; Okusaka T; Furuse J; Kokudo N; Okita K; Yoshimura K; Arai Y; TACTICS Trial Group
    American Society of Clinical Oncology Annual Meeting (ASCO 2018) 2018年06月 ポスター発表 Chicago, USA
  • Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis  [通常講演]
    Peck-Radosavljevic M; Kudo M; Raoul JL; Lee HC; Decaens T; Heo J; Lin SM; Shan H; Yang Y; Bayh I; Nakajima K; Cheng AL
    American Society of Clinical Oncology Annual Meeting (ASCO 2018) 2018年06月 ポスター発表 Chicago, USA
  • A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)  [通常講演]
    Ikeda M; Sung MW; Kudo M; Kobayashi M; Baron AD; Finn RS; Kaneko S; Zhu AX; Kubota T; Kraljevic S; Ishikawa K; Siegel AB; Kumada H; Okusaka T
    American Society of Clinical Oncology Annual Meeting (ASCO 2018) 2018年06月 ポスター発表 Chicago, USA
  • 経口デジタル胆道鏡(SpyGlass DS)が胆管癌の進展度診断に有用であった一例. 一般演題「肝胆膵」  [通常講演]
    岡本彩那; 三長孝輔; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊; 木村雅友
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 口頭発表（一般） 大阪国際交流センター 藤原靖弘
  • ビガトランによる薬剤性食道潰瘍の検討. Young Endoscopist Session 3 食道  [通常講演]
    益田康弘; 松井繁長; 河野匡志; 岡元寿樹; 山田光成; 米田頼晃; 永井知行; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター 藤原靖弘
  • 閉塞性黄疸が診断の契機となった低分化型食道胃接合部癌の1例. Fresh Endoscopist Session 2 食道・十二指腸  [通常講演]
    東原久美; 三長孝輔; 岡本彩那; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 工藤正俊; 榎木英介
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター 藤原靖弘
  • Chasing methodを用いた安全なEUSスクリーニングの標準化、教育の取り組み. ビデオワークショップ「胆膵内視鏡診療におけるdo and don’t」  [通常講演]
    大本俊介; 竹中 完; 工藤正俊
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター 藤原靖弘
  • 早期直腸癌に対する治療法の選択. パネルディスカッション「アンメットメディカルニーズに対する内視鏡の役割-下部消化管疾患の診断・治療-」  [通常講演]
    米田頼晃; 樫田博史; 櫻井俊治; 工藤正俊; 奥野清隆
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター 藤原靖弘
  • 経乳頭的re-intervention困難例の悪性肝門部胆道閉塞に対するEUS下胆道ドレナージの有用性. シンポジウム 1「アンメットメディカルニーズに対する内視鏡の役割-胆膵疾患の診断・治療-」  [通常講演]
    三長孝輔; 竹中 完; 鎌田 研; 山雄健太郎; 工藤正俊
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター 藤原靖弘
  • “Small HCCs”, Hot Issues: ACUCI “CEUS: how to maker it clear”  [招待講演]
    工藤正俊
    The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018) 2018年05月 口頭発表（招待・特別） Seoul, Korea
  • 迷入膵が原因と思われる胃壁内膿瘍の1例. Fresh Endoscopist Session 1 胃  [通常講演]
    辻本智之; 秦 康倫; 木下大輔; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 工藤正俊
    第100回日本消化器内視鏡学会近畿支部例会 2018年05月 大阪国際交流センター 藤原靖弘
  • Expansion of color fusion outside the liver  [通常講演]
    Ogawa C; Morita M; Shibatoge M; Kudo M
    The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018) 2018年05月 口頭発表（一般） Seoul, Korea
  • Chair; Consensus Meeting “Guidelines for contrast-enhanced harmonic endoscopic ultrasonography”  [招待講演]
    工藤正俊
    The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018) 2018年05月 その他 Seoul, Korea
  • Hand-foot syndrome as predictor of survival in advanced HCC treated with sorafenib  [通常講演]
    Ogawa C; Morita M; Shibatoge M; Takaguchi K; Tani J; Masaki T; Moriya A; Deguchi A; Kudo M
    Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference 2018年05月 口頭発表（一般） Yokohama, Japan
  • Keynote-224: Pembrolizumab in patients with advanced HCC previously treated with sorafenib  [通常講演]
    Kudo M; Zhu AX; Finn RS; Cattan S; Edeline J; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan S; Knox J; Daniele B
    Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference 2018年05月 口頭発表（一般） Yokohama, Japan
  • Invited Lecture “Molecular targeted therapy”, Symposium 6 “Aging society and HCC: up to what age do we consider treating patients with HCC in general?”  [招待講演]
    工藤正俊
    Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference 2018年05月 シンポジウム・ワークショップパネル（指名） Yokohama, Japan
  • Studies on AFP, ALT abnormalities and hepatocarcinogenesis after SVR in chronic hepatitis C patients treated with direct acting antivirals  [通常講演]
    Kono M; Nishida N; Kudo M
    Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference 2018年05月 口頭発表（一般） Yokohama, Japan
  • Chair: Symposium 3 “HCC with vascular invasion: HAIC, radioembolization, radiation therapy, surgery, or systemic therapy?”  [招待講演]
    工藤正俊
    Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference 2018年05月 その他 Yokohama, Japan
  • Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”  [招待講演]
    工藤正俊
    Next Symposium 2018年05月 口頭発表（招待・特別） Bach Mai Hospital, Vietnam
  • Keynote Lecture “The role of TKI in HCC in an immunotherapy world”  [招待講演]
    工藤正俊
    5th Asia-Pacific Gastroenterology Cancer Summit 2018 2018年05月 口頭発表（基調） Singapore
  • Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”  [招待講演]
    工藤正俊
    Next Symposium 2018年04月 口頭発表（招待・特別） National Cancer Hospital, Vietnam
  • 肝細胞癌診療と造影エコー法. ランチョンセミナー  [通常講演]
    工藤正俊
    第31回日本腹部造影エコー・ドプラ診断研究会 2018年03月 公開講演，セミナー，チュートリアル，講習，講義等 ホテルアバローム紀の国, 和歌山
  • 興味深いEUS像を呈した膵多発Myeloif Sarcomaの1例. Freshman Session 11 膵臓  [通常講演]
    吉田早希; 三長孝輔; 竹中 完; 石川 嶺; 岡本彩那; 中井敦史; 大本俊介; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 工藤正俊; 井上宏昭; 松村 到; 清水重喜; 佐藤隆夫
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ 安藤 朗
  • mFOLFOX6+Cetuximab併用療法により画像的にComplete Responseが得られた切除不能肝転移を伴うS状結腸癌の1例  [通常講演]
    塚康生; 永井知行; 櫻井俊治; 福永明洋; 半田康平; 高田隆太郎; 岡元寿樹; 木下 淳; 河野匡志; 山田光成; 米田頼晃; 松井繁長; 渡邉智裕; 汐見幹夫; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ 安藤 朗
  • 動注リザーバーシステム留置時に腫瘍の広範な壊死を呈した進行肝細胞癌の一例. Freshman Session 1 肝臓(1)  [通常講演]
    藤井佳奈子; 岡本彩名; 半田康平; 高田隆太郎; 福永朋洋; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ 安藤 朗
  • TACE治療時にEmboGuideが有用であった肝細胞癌の1例. Freshman Session 1 肝臓(1)  [通常講演]
    伊藤智彦; 奥田英之; 秦 康倫; 木下大輔; 高山政樹; 川崎正憲; 岡崎能久; 川崎俊彦; 水野成人; 朝戸信行; 工藤正俊
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ 安藤 朗
  • ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験. シンポジウム1「生物学的製剤時代におけるIBD治療の現状と課題」  [通常講演]
    河野匡志; 櫻井俊治; 工藤正俊; 樫田博史
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ 安藤 朗
  • セツキシマブを含む抗がん剤にて肺胞出血を来した一例. Young Investigator Session 6 大腸(1)  [通常講演]
    福永朋洋; 岡元寿樹; 櫻井俊治; 半田康平; 高田隆太郎; 木下 淳; 石川 嶺; 河野匡志; 山田光成; 永井知行; 米田頼晃; 松井繁長; 渡邉智裕; 汐見幹夫; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ 安藤 朗
  • mFOLFIRINOX療法に対するPegfilgrastim 2次予防療法の安全性・有効性の検討. ワークショップ3「外科手術、化学療法を含めた膵癌治療の最前線」  [通常講演]
    山雄健太郎; 竹中 完; 工藤正俊; 竹山宜典
    日本消化器病学会近畿支部第108回例会 2018年03月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都 安藤 朗
  • 開会の辞  [招待講演]
    工藤正俊
    第14回臨床消化器病フォーラム 2018年03月 その他
  • Invited Lecture “Novel management of advanced HCC”  [招待講演]
    工藤正俊
    5th Myanmar GI & Liver, International Scientific Meeting and ASEAN Perspective in Liver Diseases (APLD) 2018年02月 口頭発表（招待・特別） Yangon, Myanmar
  • Invited Lecture “Systemic therapy for hepatocellular carcinoma: 2018 update”  [招待講演]
    工藤正俊
    The 33rd Nagoya International Cancer Treatment Symposium 2018年02月 口頭発表（招待・特別） Aichi Cancer Center
  • RFA治療の効果判定: Hepatic Guideの有用性  [通常講演]
    南 知宏; 南 康範; 工藤正俊; 鶴﨑正勝; 村上卓道
    第24回肝血流動態・機能イメージ研究会 2018年02月 口頭発表（一般） 都久志会館, 福岡
  • Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib  [通常講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder VV; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Xu L; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE Investigators
    Gastrointestinal Cancers Symposium (ASCO-GI 2018) 2018年01月 ポスター発表 San Francisco, USA
  • Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)  [通常講演]
    Lencioni R; Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Han G; Ikeda M; Simon K; Komov D; OuYang X; Evans TRJ; Sung MW; Binder TA; Damon A; Kraljevic S; Ren M; Ryoo BY
    Gastrointestinal Cancers Symposium (ASCO-GI 2018) 2018年01月 ポスター発表 San Francisco, USA
  • KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib  [通常講演]
    Zhu AX; Finn RS; Cattan S; Edeline J; Ogasawara S; Palmer DH; Verslype C; Zagonel V; Rosmorduc O; Vogel A; Sarker D; Verset G; Chan SL; Knox JJ; Daniele B; Ebbinghaus S; Ma J; Siegel AB; Cheng AL; Kudo M
    Gastrointestinal Cancers Symposium (ASCO-GI 2018) 2018年01月 口頭発表（一般） San Francisco, USA
  • Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2)  [通常講演]
    Zhu AX; Galle PR; Kudo M; Finn RS; Qin S; Xu Y; Abada P; Llovet J
    Gastrointestinal Cancers Symposium (ASCO-GI 2018 2018年01月 ポスター発表 San Francisco, USA
  • Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040  [通常講演]
    El-Khoueiry AB; Merero I; Yau TC; Crocenzi TS; Kudo M; Hsu C; Choo S; Trojan J; Welling T; Meyer T; Kang YK; Yeo W; Chopra A; Zhao H; Baakili A; dela Cruz CM; Sangro B
    Gastrointestinal Cancers Symposium (ASCO-GI 2018) 2018年01月 ポスター発表 San Francisco, USA
  • Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial  [通常講演]
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Arai Y; for the TACTICS Trial Group
    Gastrointestinal Cancers Symposium (ASCO-GI 2018) 2018年01月 口頭発表（一般） San Francisco, USA
  • Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS－An international observational study assessing the use of sorafenib after TACE  [通常講演]
    Kudo M; Raoul JL; Lee HC; Cheng AL; Nakajima K; Peck-Radosavljevic M
    Gastrointestinal Cancers Symposium (ASCO-GI 2018) 2018年01月 ポスター発表 San Francisco, USA
  • 司会: 特別講演「肝細胞がんに対する新たな分子標的治療薬や免疫チェックポイント阻害剤の開発の最前線」  [招待講演]
    工藤正俊
    第17回日本肝がん分子標的治療研究会 2018年01月 その他 パシフィコ横浜, 神奈川
  • 急激に変貌する肝癌の薬物療法：免疫療法を含めて. 講演II  [通常講演]
    工藤正俊
    中・四国肝疾患研究会 2017年12月 公開講演，セミナー，チュートリアル，講習，講義等 JRホテルクレメント高松, 香川
  • 座長; ランチョンセミナー4「肝細胞癌における治療戦略～分子標的薬治療の新たなステージへ～」  [招待講演]
    工藤正俊
    第42回日本肝臓学会西部会 2017年11月 その他 ヒルトン福岡シーホーク, 福岡
  • 腹壁静脈瘤破裂に対し直接穿刺にて硬化療法を施行した２例. 若手医師症例報告奨励賞  [通常講演]
    半田康平; 萩原 智; 福永朋洋; 高田隆太郎; 岡本彩那; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第42回日本肝臓学会西部会 2017年11月 口頭発表（招待・特別） ヒルトン福岡シーホーク, 福岡
  • 真性多血症にBudd-Chiari症候群を伴った1例. 若手医師症例報告奨励賞  [通常講演]
    高田隆太郎; 萩原 智; 福永朋洋; 半田康平; 岡本彩那; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第42回日本肝臓学会西部会 2017年11月 口頭発表（招待・特別） ヒルトン福岡シーホーク, 福岡
  • 胃への遠隔転移を認めた肝細胞癌の一例. 若手医師症例報告奨励賞  [通常講演]
    福永朋洋; 萩原 智; 半田康平; 高田隆太郎; 岡本彩那; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    第42回日本肝臓学会西部会 2017年11月 口頭発表（招待・特別） ヒルトン福岡シーホーク, 福岡
  • DAA投与におけるSVR後のAFP異常値と関連する臨床背景の検討. 一般演題  [通常講演]
    河野匡志; 西田直生志; 千品寛和; 南 知宏; 有住忠晃; 田北雅弘; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊
    第42回日本肝臓学会西部会 2017年11月 口頭発表（一般） ヒルトン福岡シーホーク, 福岡
  • 開会/閉会の挨拶  [招待講演]
    工藤正俊
    第16回大阪消化器化学療法懇話会 2017年11月 その他
  • 空腸穿通魚骨を小腸内視鏡にて除去し得た一例. Young Endoscopist Session 9「小腸・その他」  [通常講演]
    福永朋洋; 永井知行; 櫻井俊治; 岡元寿樹; 岡本彩那; 河野匡志; 山田光成; 米田頼晃; 松井繁長; 渡邊智裕; 樫田博史; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • 大網裂孔ヘルニアによるレイウスの1例. Fresh Endoscopist Session 5「十二指腸・小腸」  [通常講演]
    吉川馨介; 木下 淳; 櫻井俊治; 高島耕太; 河野辰哉; 石川 嶺; 岡本彩那; 河野匡志; 岡元寿樹; 山田光成; 永井知行; 米田頼晃; 松井繁長; 渡邊智裕; 樫田博史; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • 止血に難渋した十二指腸静脈瘤出欠の1例. Fresh Endoscopist Session 5「十二指腸・小腸」  [通常講演]
    中野省吾; 松井繁長; 高島耕太; 河野辰哉; 石川 嶺; 岡元寿樹; 山田光成; 河野匡志; 木下 淳; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 渡邊智裕; 樫田博史; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • 術前診断が困難であり経口膵管鏡による直接生検で診断しえた膵神経内分泌癌の1例. Young Endoscopist Session 6「膵臓」  [通常講演]
    工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • 糞便移植を実施した潰瘍性大腸炎患者の2症例. パネルディスカッション2「下部消化管炎症性疾患の診断と治療」  [通常講演]
    永井知行; 櫻井俊治; 樫田博史; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • 超音波内視鏡下吸引細胞診（EUS-FNA）にて診断に至ったスキルス胃癌の1例. Fresh Endoscopist Session 2「胃  [通常講演]
    山田信広; 米田頼晃; 三長孝輔; 河野辰哉; 高島耕太; 木下 淳; 石川 嶺; 岡本彩那; 岡元寿樹; 山田光成; 河野匡志; 永井知行; 櫻井俊治; 松井繁長; 渡邊智裕; 樫田博史; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • Stage 0, I膵癌の発見におけるEUSの役割. ワークショップ2「胆膵癌の早期発見における内視鏡の役割」  [通常講演]
    山雄健太郎; 竹中 完; 樫田博史; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • リザーバー留置後に十二指腸よりカテーテルの逸脱を認めた一例. 一般演題「十二指腸・小腸」  [通常講演]
    岡本彩那; 田北雅弘; 半田康平; 高田隆太郎; 福永朋洋; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 南 康範; 依田 広; 櫻井俊治; 上嶋一臣; 西田直生志; 工藤正俊
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 口頭発表（一般）
  • ESDにより切除しえた、巨大直腸腫瘍の1例. 一般演題「大腸2」  [通常講演]
    木下大輔; 秦 康倫; 岡崎能久; 高山政樹; 奥田英之; 川崎正憲; 水野成人; 川崎俊彦; 若狭朋子; 太田善夫; 工藤正俊; 森田圭紀
    第99回日本消化器内視鏡学会近畿支部例会 2017年11月 口頭発表（一般）
  • 司会；Session1「肝疾患とサルコペニア」  [招待講演]
    工藤正俊
    OTSUKA Liver Forum 2017 2017年11月 その他
  • 開会の挨拶  [招待講演]
    工藤正俊
    第37回南大阪肝疾患研究会 2017年11月 その他
  • 特別講演「肝細胞癌薬物治療のブレイクスルー」  [通常講演]
    工藤正俊
    第168回群馬肝癌検討会特別講演会 2017年11月 口頭発表（招待・特別）
  • 胃前庭部たこいぼびらんとH. pyloriの関連. 一般演題口演74 胃－HP関連  [通常講演]
    辻直子; 川崎正憲; 梅原康湖; 松本望; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年11月 口頭発表（一般）
  • 早期直腸癌に対する内視鏡治療について．ﾊﾟﾈﾙﾃﾞｨｽｶｯｼｮﾝ「早期直腸がんに対する治療戦略」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    第72回日本大腸肛門病学会学術集会 2017年11月 シンポジウム・ワークショップパネル（公募） 福岡
  • 早期直腸がんに対する治療戦略（肛門温存）, パネルディスカッション2  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    第72回日本大腸肛門病学会学術集会 2017年11月 シンポジウム・ワークショップパネル（公募）
  • losing remarks  [招待講演]
    工藤正俊
    大阪和歌山消化器疾患カンファレン 2017年11月 その他
  • Endoscopic ultrasonography-guided biliary drainage without dilation device using a thin delivery-system stent: A preclinical study  [通常講演]
    Itonaga M; Kitano M; Kawaji Y; Abe H; Takashi T; Nuta J; Hatamaru K; Omoto S; Minaga K; Kamata K; Miyata T; Yamao K; Imai H; Takenaka M; Kudo M
    25th UEG Week 2017 2017年10月 ポスター発表
  • Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment  [通常講演]
    Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross P; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Schlief S; Fiala-Buskes S; Meinhardt G; Bruix J on; ehalf; of; h; ESORCE Investigators
    American Association for the study of liver diseases (AASLD 2017) 2017年10月 口頭発表（一般） Washington DC, USA
  • 特別講演II「肝細胞癌診療のブレークスルー－薬物療法が変わる－」  [招待講演]
    工藤正俊
    第18回岡山肝がん研究会 2017年10月 口頭発表（招待・特別）
  • Significance of surgical margin in patients with single hepatocellular carcinoma undergoing curative hepatic resection: an analysis using nationwide survey data in Japan  [通常講演]
    Aoki T; Kubota K; Matsumoto T; Izumi N; Kadoya M; Kubo S; Kumada T; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Matsuyama Y; Kudo M; for the Liver; Cancer Study; Group of Japan
    AASLD 2017 2017年10月 ポスター発表 Washington DC, USA
  • Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)  [通常講演]
    Vogel A; Qin S; Kudo M; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; Lopez C; Sung M; Dutcus C; Kraljevic S; Tamai T; Grunow N; Meier G; Breder V
    AASLD 2017 2017年10月 ポスター発表 Washington DC, USA
  • Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment  [通常講演]
    Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Shukui Qin; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Sarah Schlief; Sabine Fiala-Buskies; Gerold Meinhardt; Jordi Bruix; on behalf of; the; RESORCE Investigators
    AASLD 2017 2017年10月 シンポジウム・ワークショップパネル（公募） Geneva, Switzerland,
  • Sonazoid-enhaunced US in the Management of HCC.  [招待講演]
    工藤正俊
    2017年日中笹川医学協力プロジェクト超音波実用技術研修 2017年10月 口頭発表（招待・特別）
  • Special Lecture “CEUS for Pancreatobiliary Diseases.”  [通常講演]
    工藤正俊
    The 9th Asian Conference on Ultrasound Contrast Imaging (ACUCI) 2017 2017年10月 口頭発表（招待・特別）
  • Special Lecture “US-US Overlay Fusion Imaging in the Evaluation of Treatment Response After RFA.”  [招待講演]
    工藤正俊
    The 9th Asian Conference on Ultrasound Contrast Imaging (ACUCI) 2017 2017年10月 口頭発表（招待・特別）
  • CEUS in the Diagnosis and Treatment for Malignant Liver Tumors.  [招待講演]
    工藤正俊
    The 16th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2017 2017年10月 口頭発表（一般）
  • A new strategy to personalize surveillance program for colitis-associated cancer. International Session (Symposium)9 (JGES・JSGE・JSGS) “Surveillance colonoscopy for ulcerative colitis; Up-to-date procedure and therapeutic strategy”  [招待講演]
    akurai T; Kashida H; Kudo M
    Japan Digestive Disease Week (JDDW) 2017 Fukuoka 2017年10月 シンポジウム・ワークショップパネル（公募） 福岡
  • 抗血栓薬内服での大腸 ESD における検討  [通常講演]
    岡元寿樹; 米田頼晃; 樫田博史; 岡本彩那; 河野匡志; 永井知行; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊
    第59回日本消化器病学会大会 Japanese Digestive Disease Week (JDDW) 2017 Fukuoka 2017年10月 口頭発表（一般） 福岡
  • 抗血栓薬服用者に対する胃病変の ESD/EMR の安全性評価検討．  [通常講演]
    永井知行; 松井繁長; 岡本彩那; 岡元寿樹; 河野匡志; 山田光成; 米田頼晃; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊
    第94回日本消化器内視鏡学会総会 Japanese Digestive Disease Week (JDDW) 2017 Fukuoka 2017年10月 口頭発表（一般） 福岡
  • 特別講演「急激に変貌する肝細胞癌の薬物治療  [招待講演]
    工藤正俊
    第17回肝癌治療研究会 2017年10月 口頭発表（招待・特別）
  • 特別講演「肝細胞癌診療のブレークスルー～薬物療法が変わる～」  [通常講演]
    工藤正俊
    スチバーガ錠HCC承認記念講演会in京都 2017年10月 口頭発表（招待・特別）
  • How to Improve Survival Outcome and Use Molecular Targeted Agent in HCC Patients? Symposium (XI) ”Innovation and New Approaches in Hepatocellular Carcinoma.”  [招待講演]
    工藤正俊
    Taiwan Digestive Disease Week 2017 (TDDW) 2017年09月 シンポジウム・ワークショップパネル（指名）
  • Special Lecture (V) “Impact of Surveillance and Diagnosis on Survival in HCC Patients”, Taiwan Digestive Disease Week 2017 (TDDW)  [招待講演]
    工藤正俊
    Taiwan Digestive Disease Week 2017 (TDDW) 2017年09月 口頭発表（招待・特別）
  • 十二指腸ステント留置下の胆道ドレナージの成績の検討, シンポジウム8「悪性胆管狭窄に対するドレナージ」  [通常講演]
    山雄健太郎; 竹中 完; 工藤正俊
    第53回日本胆道学会学術集会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 造影ハーモニックEUS による胆嚢病変の良悪性鑑別～Vessel image とPerfusion image の比較～, シンポジウム6「了せ胆嚢疾患ー胆嚢癌との鑑別困難例に対する診断・治療戦略ー」  [通常講演]
    鎌田 研; 竹中 完; 工藤正俊
    第53回日本胆道学会学術集会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 経乳頭処置困難総胆管結石症例に対するEUS下rendezvous technique の有用性, シンポジウム5「高難度胆管結石治療の極意を求めて」  [通常講演]
    竹中完; 山雄健太郎; 工藤正俊
    第53回日本胆道学会学術集会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • Roux-en-Y 再建後の輸入脚狭窄に対してショートタイプシングルバルーン内視鏡を用いて消化管ステント留置術を行った1例．Yung Investigator Session10 胃・十二指腸3  [通常講演]
    田中秀和; 鎌田 研; 三長孝輔; 竹中 完; 中井敦史; 大本俊介; 宮田 剛; 山尾健太郎; 今井 元; 櫻井俊治; 西田直生志; 渡邉智裕; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第107回例会 2017年09月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • FNHのLMI-THI造影の検討.一般演題9「消化器3（造影）」  [通常講演]
    横川 美香; 前野 知子; 市島真由美; 塩見 香織; 前川 清; 依田 広; 南 康範; 工藤 正俊
    日本超音波医学会 第44回関西地方会学術集会,第21回関西地方講習会 2017年09月 口頭発表（一般）
  • カテーテルアブレーション後に急性胃拡張を来した2例. Freshman Session 6 胃・十二指腸1  [通常講演]
    久家沙希那; 永井知行; 松井繁長; 河野辰哉; 高島耕大; 木下 淳; 岡本彩那; 岡元寿樹; 石川 嶺; 山田光成; 河野匡志; 米田頼晃; 櫻井俊治; 渡邊智裕; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第107回例会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 食道癌、肺癌、膵臓癌の異時性3重複癌の1例. Freshman Session 3 膵  [通常講演]
    大賀智行; 宮田 剛; 竹中 完; 中井敦史; 三長孝輔; 鎌田 研; 山雄健太郎; 今井 元; 工藤正俊
    日本消化器病学会近畿支部第107回例会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 肝原発MCNと鑑別が困難であった腸間膜神経鞘腫の一例. Young Investigator Session 3 肝2  [通常講演]
    吉田晃浩; 山雄健太郎; 中井敦史; 大本俊介; 鎌田 研; 三長孝輔; 宮田 剛; 今井 元; 竹中 完; 樫田博史; 工藤正俊; 里井俊平; 松本逸平; 竹中宜典; 前西 修
    日本消化器病学会近畿支部第107回例会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 膵胆道腫瘍のリンパ節転移診断における造影ハーモニックEUSの有用性. パネルディスカッション「胆膵疾患診療の最前線」  [通常講演]
    中井敦史; 竹中 完; 宮田 剛; 工藤正俊
    日本消化器病学会近畿支部第107回例会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 開会、閉会挨拶  [招待講演]
    工藤正俊
    第2回南大阪肝疾患診療連携セミナー 2017年09月 その他
  • 特別講演「Total SVR時代の肝炎診療」  [招待講演]
    工藤正俊
    第2回南大阪肝疾患診療連携セミナー 2017年09月 口頭発表（招待・特別）
  • 術前に肝原発嚢胞性病変が疑われた腸間膜由来神経鞘腫の1例. 口演20 肝・その他  [通常講演]
    竹中 完; 山雄健太郎; 鎌田 研; 三長孝輔; 宮田 剛; 今井 元; 松本逸平; 竹山宜典; 前西 修; 工藤正俊
    第67回日本消化器画像診断研究会 2017年09月 口頭発表（一般）
  • 巨木型食道静脈瘤に対するmodified EISL. ビデオワークショップ4「EIS―私はこうしている―」  [通常講演]
    松井繁長; 樫田博史; 工藤正俊
    第24回日本門脈圧亢進症学会総会 2017年09月 シンポジウム・ワークショップパネル（公募）
  • KEYNOTE-240: Phase 3, Randomized Study of  [通常講演]
    R.S. Finn; S.L. Chan; A.X. Zhu; J. Knox; A.-L. Cheng; A.B. Siegel; O. Bautista; M. Kudo
    ESMO 2017 2017年09月 シンポジウム・ワークショップパネル（公募）
  • 特別講演「肝癌の薬物療法が変わる」  [招待講演]
    工藤正俊
    近畿・中国四国肝疾患研究会 2017年08月 口頭発表（招待・特別）
  • 司会：シンポジウム26「これからの進行肝細胞がん治療」  [招待講演]
    工藤正俊
    第15回日本臨床腫瘍学会 2017年07月 シンポジウム・ワークショップパネル（指名）
  • Treatment of advanced hepatocellular carcinoma: Future perspective. シンポジウム26「これからの進行肝細胞がん治療」  [招待講演]
    工藤正俊
    第15回日本臨床腫瘍学会学術集会 2017年07月 シンポジウム・ワークショップパネル（指名）
  • Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): An Exploratory Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib after TACE  [通常講演]
    Han Chu Lee; Ann-Lii Cheng; Jean-Luc Raoul; Masatoshi Kudo; Keiko Nakajima; Markus Peck-Radosavljevic
    ILCA 2017 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 慢性膵炎に対する径乳頭的金属ステント留置,短期間抜去の有用性. ミニワークショップ3-1「肝疾患診療におけるERCPの役割を見直す」  [通常講演]
    竹中 完; 大本俊介; 三長孝輔; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    48回日本膵臓学会大会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 当院におけるWONに対するstep-up approachの検討. パネルディスカッション3「急性膵炎の後期合併症に対する手術・インターベンション治療の現状と課題」  [通常講演]
    竹中 完; 大本俊介; 三長孝輔; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    第48回日本膵臓学会大会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 早期慢性膵炎のEUS所見の妥当性, 早期治療介入の意義について. パネルディスカッション1「慢性膵炎の進展予防を目的とした治療－その適応と限界－」  [通常講演]
    竹中 完; 大本俊介; 三長孝輔; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    第48回日本膵臓学会大会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • EUSガイド下神経ブロックの成績と治療効果予測因子の検討.ビデオシンポジウム12「超音波内視鏡を用いた膵疾患診療ー基本から応用までー」  [通常講演]
    三長孝輔; 竹中 完; 宮田 剛; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 今井 元; 渡邉智裕; 工藤正俊
    第48回日本膵臓学会大会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 肝細胞癌に対する肝切除における、surgical marginの意義の検討：追跡調査データを用いた解析. 一般演題「肝切除(1)」  [通常講演]
    青木 琢; 窪田敬一; 松本尊嗣; 泉 並木; 角谷眞澄; 久保正二; 熊田 卓; 國土典宏; 坂元亨宇; 高山忠利; 中島 収; 松山裕; 工藤正俊
    第53回日本肝癌研究会 2017年07月 口頭発表（一般）
  • レンバチニブ (Lenvatinib)  [招待講演]
    工藤正俊
    第53回日本肝癌研究会 2017年07月 口頭発表（招待・特別）
  • 司会：シンポジウム4「肝癌診療ガイドライン第4版公聴会：エビデンスとコンセンサス」  [招待講演]
    工藤正俊; 國土典宏
    第53回日本肝癌研究会 2017年07月 その他
  • 肝静脈腫瘍栓合併肝細胞癌に対する外科的切除の意義の検討―肝癌研究会追跡調査より.パネルディスカッション4「高度進行肝細胞癌(Vp3以上、Vv2以上)に対する集学的治療：エビデンスとコンセンサス」  [通常講演]
    國土貴嗣; 長谷川潔; 高山忠利; 泉 並木; 角谷眞澄; 工藤正俊; 久保正二; 坂元亨宇; 中島 収; 熊田 卓; 國土典宏
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 肝癌研究会追跡調査よりみた高齢肝細胞癌に対する外科的切除の意義. パネルディスカッション7「超高齢者肝癌の治療(切除か非切除か)」  [通常講演]
    海堀昌樹; 吉井健悟; 横田 勲; 長谷川潔; 高山忠利; 久保正二; 權 雅憲; 長島文夫; 泉 並木; 角谷眞澄; 工藤正俊; 熊田 卓; 坂元亨宇; 中島 収; 松山 裕; 國土典宏
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 第4版改訂のコンセプト. シンポジウム4「肝癌診療ガイドライン第4版公聴会：エビデンスとコンセンサス」  [招待講演]
    國土典宏; 工藤正俊; 長谷川潔
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • Intermediate stage HCCの新しい亜分類と治療方針－全国原発性肝癌追跡調査46997例の解析から－. パネルディスカッション1「Intermediate stage肝癌の標準治療はなにか？：エビデンスとコンセンサス」  [通常講演]
    上嶋一臣; 工藤正俊; 泉 並木; 角谷眞澄; 久保正二; 熊田 卓; 國土典宏; 高山忠利; 坂元亨宇; 中島 収; 松山 裕
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • 鎮静下RFAにおける3D-GPS markerの使用経験と課題. ワークショップ4「肝癌治療におけるナビゲーションの有用性と将来性」  [通常講演]
    小川 力; 盛田真弘; 大村亜紀奈; 野田晃世; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • TheCurrent Situations and Future Perspectives of the Japanese Nationwide Survey of Patients with Primary Liver Cancer. 国際シンポジウム3「肝悪性腫瘍のRegistry」  [通常講演]
    Hasegawa K; Kudo M; Izumi N; Kadoya M; Kubo S; Kumada T; Sakamoto M; Takayama T; Nakajima O; Matsuyama Y; Kokudo
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. 国際シンポジウム2「肝細胞癌のStaging」  [通常講演]
    Ueshima K; Kudo M; Izumi N; Kadoya M; Kubo M; Kumada T; Kokudo N; Takayama T; Sakamoto M; Nakashima O; Matsuyama Y
    第53回日本肝癌研究会 2017年07月 シンポジウム・ワークショップパネル（公募）
  • HCC treatnebt landscape-the Asian perspective- HCC treatment guidelines, Asian perspective- Experience sharing from Japan.  [招待講演]
    工藤正俊
    Necavar 10-years Anniversary 2017年07月 口頭発表（一般）
  • 特別講演I「肝細胞癌に対する薬物治療の新たな展開～ASCO2017の最新発表を踏まえて～」  [招待講演]
    工藤正俊
    肝疾患学術講演会 2017年06月 口頭発表（招待・特別）
  • Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment  [招待講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE Investigators
    19th ESMO World Congress on Gastrointestinal Cancer 2017 (ESMO-GI 2017) 2017年06月 口頭発表（一般） Barcelona, Spain
  • Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: a sub-analysis of the CheckMate 040 study  [通常講演]
    Melero I; El-Khoueiry AB; Yau T; Hsu C; Kudo M; Crocenzi T; Kim TY; Choo SP; Trojan J; Willing TH; Kang YK; Yeo W; Chopra A; Baakili A; dela Cruz C; Lang L; Sangro B; Meyer T
    19th ESMO World Congress on Gastrointestinal Cancer 2017 (ESMO-GI 2017) 2017年06月 口頭発表（一般） Barcelona, Spain
  • 特別講演「肝細胞癌の分子標的治療：現状と今後の展望」  [通常講演]
    工藤正俊
    第16回日本肝癌分子標的治療研究会 2017年06月 その他
  • STAT3制御分子に注目した肝細胞癌のソラフェニブ治療効果予測の可能性. プレナリーセッション1.  [通常講演]
    櫻井俊治; 工藤正俊; 有住忠明; 田北雅弘; 矢田典久; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志
    第16回日本肝がん分子標的治療研究会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • Speaker/ Chairperson: Master Class: Workshop: Master Class for Hepatocellular Carcinoma.  [招待講演]
    工藤正俊
    24th Asia Pacific Cancer Conference (APCC) 2017年06月 口頭発表（一般）
  • 特別講演2「肝細胞癌の分子標的治療：最新の話題」  [招待講演]
    工藤正俊
    第6回香川肝がん分子標的治療研究会 2017年06月 口頭発表（招待・特別）
  • 急性膵炎の経過中に来たした肝障害の原因精査に超音波内視鏡が有用であった一例. Fresh Endoscopist Session 4「胆膵」  [通常講演]
    大塚康生; 鎌田 研; 竹中 完; 山雄健太郎; 三長孝輔; 宮田 剛; 大本俊介; 今井 元; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 胃全摘後の総胆管結石性胆管炎に対して超音波内視鏡下管内胆管空腸吻合術が有用であった一例. Fresh Endoscopist Session 4「胆膵」  [通常講演]
    鎌田 研; 竹中 完; 山雄健太郎; 三長孝輔; 宮田 剛; 大本俊介; 今井 元; 工藤正俊
    98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • SpyGlassTM DSを用いた電気水圧衝撃波結石破砕術（EHL）が有用であった巨大総胆管結石の一例. Young Endoscopist Session 8「胆道」  [通常講演]
    中井敦史; 宮田 剛; 竹中 完; 大本俊介; 鎌田 研; 三長孝輔; 山雄健太郎; 樫田博史; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 大腸早期印環細胞癌の一例. Young Endoscopist Session 7「小腸・大腸」  [通常講演]
    高島耕大; 樫田博史; 朝隈 豊; 岡本彩那; 岡元寿樹; 河野匡志; 山田光成; 足立哲平; 米田頼晃; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • ESDを施行した胃低腺型胃癌の検討. Young Endoscopist Session 3 「胃」  [通常講演]
    河野辰哉; 松井繁長; 岡本彩那; 岡元寿樹; 河野匡志; 足立哲平; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 内視鏡的粘膜下層剥離術にて切除した胃底腺胃癌の1例. Fresh Endoscopist Session 1 消化管1  [通常講演]
    今村修三; 秦 康倫; 岡崎典久; 木下大輔; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 工藤正俊; 若狭朋子; 太田善夫; 盛田圭紀; 石黒信吾; 橋本恵介
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 当院におけるself-expandable metallic stent留置の工夫～BONASTENTの使用経験を添えて～. ビデオワークショップ「安全で確実なERCP関連処置を目指して―手技のコツからトラブルシューティングまで―」  [通常講演]
    山雄健太郎; 竹中 完; 樫田博史; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 径乳頭処置困難総胆管結石症例に対するEUSガイド下治療の成績. ワークショップ1「Interventional EUSによる胆膵診療の現状と新たな展開」  [通常講演]
    三長孝輔; 竹中 完; 宮田 剛; 樫田博史; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 大腸ESDにおける抗血栓薬の影響に関する検討. シンポジウム2「下部消化器内視鏡治療の現状と課題」  [通常講演]
    岡元寿樹; 米田頼晃; 朝隈 豊; 樫田博史; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 抗血栓薬服用者の胃病変に対する内視鏡的治療の安全の評価検討. シンポジウム1「上部消化管内視鏡治療の現状と課題」  [通常講演]
    永井知行; 松井繁長; 樫田博史; 工藤正俊
    第98日本消化器内視鏡学会近畿支部例会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • Systemic Therapy for Hepatocellular Carcinoma: current Status and Future Perspective. KEYNOTE LECTURE II (KL-2-1)  [招待講演]
    工藤正俊
    APASL Single Topic Conference 2017 Mongolia, 6th HCV Conference on HCV and CO-INFECTIONS 2017年06月 口頭発表（一般）
  • 特別講演「肝細胞癌に対する分子標的治療：現況と今後の展望」  [招待講演]
    工藤正俊
    」, Specific MoleculeAntiviral tRestment Tokyo HepatitisC (SMART C) 2017年06月 その他
  • 肝細胞癌の治療アルゴリズム―穿刺局所療法・TACE・化学療法―. 特別企画2「日本肝臓学会ガイドラインup to date」B型肝炎治療ガイドライン  [通常講演]
    工藤正俊
    第53回日本肝臓学会総会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • 肝癌診療ガイドライン. 特別企画2「日本肝臓学会ガイドラインup to date」  [通常講演]
    工藤正俊
    第53回日本肝臓学会総会 2017年06月 シンポジウム・ワークショップパネル（公募）
  • An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS interim analysis  [通常講演]
    Cheng AL; Raoul JL; Lee HC; Kudo M; Nakajima K; Peck-Radosavljevic M on; behalf of the; OPTIMIS Investigators
    World Conference on Interventional Oncology (WCIO 2017) 2017年06月 ポスター発表 Boston, USA
  • 司会：ランチョンセミナー13「DAA選択時代の課題と今後の展望」  [招待講演]
    工藤正俊
    第53回日本肝臓学会総会 2017年06月 その他
  • US-US overlay image fusionを用いたラジオ波焼灼術の有用性：従来法との比較.セッション(一般公演)  [通常講演]
    南康範; 西田直生志; 工藤正俊
    第53回日本肝臓学会総会 2017年06月 口頭発表（一般）
  • DAA投与におけるSVR後のAFP及びALT異常値と関連する臨床背景の検討.セッション（一般公演）  [通常講演]
    河野匡志; 西田直生志; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 依田 広; 矢田典久; 南 康範; 萩原 智; 上嶋一臣; 工藤正俊
    第53回日本肝臓学会総会 2017年06月 口頭発表（一般）
  • 散発性急性C型肝炎例に於ける血清type-1 IFNｓ及びtype-3 IFNｓ値の動態とその臨床的意義.セッション（一般公演）  [通常講演]
    井本 勉; 天野恵介; 飯尾悦子; 勝島慎二; 米田俊貴; 福永豊和; 堀江 裕; 鄭 浩柄; 國立裕之; 金 秀基; 金 守良; 工藤正俊; 田中靖人
    第53回日本肝臓学会総会 2017年06月 口頭発表（一般）
  • 司会:ランチョンセミナー7「進行性肝癌に対する治療戦略－BCAAの意義について－  [招待講演]
    工藤正俊
    第53回日本肝臓学会総会 2017年06月 その他 広島
  • Invited Lecture “Molecular Targeted Therapy for HCC: Current Status and Future Perspective.” Luncheon Seminor 18 “Diagnosis and Treatment od Liver Cancer.”  [招待講演]
    工藤正俊
    第6回アジア太平洋肝胆膵学会(6th A-PHPBA),第29回日本肝胆膵外科学会学術集会(29th JSHBPS) 2017年06月 口頭発表（招待・特別） Pacifico Yokohama, Kanagawa
  • Treatment Strategy of Intermediate Stage HCC. Symposium 43 (Keynote) ”Strategy for Intermediate Stage of HCC”  [招待講演]
    工藤正俊
    第6回アジア太平洋肝胆膵学会(6th A-PHPBA),第29回日本肝胆膵外科学会学術集会(29th JSHBPS) 2017年06月 シンポジウム・ワークショップパネル（指名）
  • Phase 3 randomized study of pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: KEYNOTR-240  [通常講演]
    Finn RS; Chan SL; Zhu AX; Knox J; Cheng AL; Siegel AB; Bautista O; Kudo M
    Annual Meeting of American Society of Clinical Oncology (ASCO 2017) 2017年06月 口頭発表（基調）
  • Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patien（pts) with unresectable hepatocellular carcinoma (uHCC).  [通常講演]
    Cheng AL; Finn RS; Qin F; Han KH; Ikeda K; Piscaglia F; Baron AD; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez-Lopez C; Dutcus CE; Ren M; Kraljevic S; Tamai T; Kudo M
    Annual Meeting of American Society of Clinical Oncology (ASCO 2017) 2017年06月 口頭発表（一般）
  • Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.  [通常講演]
    Crocenzi TS; El-Khoueiry AB; Yau TC; Melero I; Sangro B; Kudo M; Hsu C; Trojan J; Kim TY; Choo SP; Meyer T; Kang YK; Yeo W; Chopra A; Baakili A; Dela Cruz CM; Lang L; Neely J; Welling T
    Annual Meeting of American Society of Clinical Oncology (ASCO 2017) 2017年06月 口頭発表（一般）
  • ラジオ波焼灼術後のバブルによる高エコー域を壊死部とみなして良いか？ワークショップ 消化器1 肝臓「肝腫瘤に対する穿刺・治療の進歩」  [通常講演]
    南 康範; 工藤正俊
    日本超音波医学会第90回学術集会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 早期慢性膵炎EUS所見の臨床的意義について. パネルディスカッション 消化器1 膵臓「慢性膵炎診断における超音波の役割」  [通常講演]
    竹中 完; 大本俊介; 三長孝輔; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 樫田博史; 工藤正俊
    日本超音波医学会第90回学術集会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 種超音波エラストグラフィデバイスの進歩とその有用性. シンポジウム 消化器2 消化器横断領域「消化器領域における超音波最新技術」  [通常講演]
    矢田典久; 依田 広; 工藤正俊
    日本超音波医学会第90回学術集会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • ディスカッサー： 男女共同参画委員会企画「日本超音波医学会が取り組むキャリア支援」  [招待講演]
    工藤正俊; 長谷川雄一; 小川眞広
    日本超音波医学会第90回学術 2017年05月 その他
  • 座長：特別講演（海外招待講演2）Special Lecture (Overeas Invited Lecture 2)  [通常講演]
    工藤正俊
    日本超音波医学会第90回学術集会 2017年05月 その他
  • 座長：シンポジウム 消化器2 消化器横断領域「消化器領域における超音波最新技術」  [招待講演]
    工藤正俊; 森安史典
    日本超音波医学会第90回学術集会 2017年05月 その他
  • 造影ハーモニックEUSによる上部消化管粘膜下腫瘍の鑑別診断～EUS-FNA診断との併用～. 奨励賞演題「消化器 奨励賞」  [通常講演]
    鎌田 研; 竹中 完; 大本俊介; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 筑後孝章; 安田卓司; 工藤正俊
    日本超音波医学会第90回学術集会 2017年05月 口頭発表（一般）
  • Speaker/ Chairperson: Latest Advances in Using Molecular Targeted Therapy in Advanced HCC Patients. Concurrent Session 3 “Hepatocellular Cancer”  [招待講演]
    工藤正俊
    Hong Kong International Oncology Forum 2017 2017年05月 口頭発表（一般）
  • 広範囲食道表在癌ESD 後の狭窄に対する治療成績の検討. 一般演題口演36 食道－狭窄2  [通常講演]
    岡元寿樹; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 口頭発表（一般）
  • 当院における小児上部消化管内視鏡検査の現状. 一般演題講演92 胃-その他2  [通常講演]
    奥田英之; 高山政樹; 木下大輔; 秦 康倫; 岡崎能久; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 口頭発表（一般）
  • 硬化性胆管炎と診断された膵癌、閉塞性黄疸の1例. 一般演題ポスター12 膵-症例  [通常講演]
    中井敦史; 山雄健太郎; 大本俊介; 鎌田研; 三長孝輔; 宮田剛; 今井元; 竹中 完; 松本逸平; 竹山宜典; 筑後孝章; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 口頭発表（一般）
  • 当院におけるERCP 教育の工夫(drawing pictures method/CD method). パネルディスカッション14「胆膵内視鏡における安全かつ効果的な教育法」  [通常講演]
    竹中 完; 東 健; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 経乳頭的re-intervention 困難例の悪性肝門部胆道閉塞に対するEUS 下胆道ドレナージの有用性. パネルディスカッション11「EUS 下胆道ドレナージ（戦略と安全な手技）」  [通常講演]
    三長孝輔; 竹中 完; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 当院主催のESD/EMR・大腸内視鏡挿入法のハンズオンセミナーの検証. パネルディスカッション10「ハンズオンセミナーを検証する」  [通常講演]
    永井知行; 樫田博史; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • The Japan NBI Expert Team(JNET)分類Type 2B 病変の取り扱い. パネルディスカッション05「大腸拡大JNET 分類の有用性と今後の課題」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 経乳頭処置困難総胆管結石症例に対するEUS ガイド下治療の意義. ワークショップ04「治療に難渋する胆管結石の治療ストラテジー」  [通常講演]
    宮田 剛; 竹中 完; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月
  • 切除不能悪性胃十二指腸狭窄症例に対する胃十二指腸ステント留置の予後予測因子の検討. ワークショップ01「緩和医療における内視鏡の役割」  [通常講演]
    山雄健太郎; 竹中 完; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 噴門部静脈瘤合併巨木型食道静脈瘤にはEISL. シンポジウム4「決定版！これが今の食道胃静脈瘤治療だ！」  [通常講演]
    松井繁長; 樫田博史; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • 胃粘膜下腫瘍における造影ハーモニックEUSによる悪性抽出能の検討. パネルディスカッション07「上部消化管粘膜下腫瘍のマネージメントー経験とエビデンスに基づく食道・胃粘膜下腫瘍の診断と治療指針ー」  [通常講演]
    鎌田 研; 竹中 完; 工藤正俊
    第93回日本消化器内視鏡学会総会 2017年05月 シンポジウム・ワークショップパネル（公募）
  • Follow-up examination of the recurrence after endoscopic treatment of colorectal tumors.  [通常講演]
    Komeda Y; Kashida H; Sakurai T; Asakuma Y; Nagai T; Matsui S; Watanabe T; Kudo M
    Digestive Disease Week (DDW 2017) 2017年05月 口頭発表（一般）
  • Diagnosis of localized colorectal lesions with magnifying narrow band imaging (NBI) using Japan NBI Expert Team (JNET) classification: a cross sectional study.  [通常講演]
    Komeda Y; Kashida H; Sakurai T; Asakuma Y; Nagai T; Matsui S; Watanabe T; Kudo M
    Digestive Disease Week (DDW 2017) 2017年05月 口頭発表（一般）
  • Outcomes of biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter retrospective study in west japan.  [通常講演]
    Yamao K; Kitano M; Takenaka M; Kayahara T; Ishida E; Yamamoto H; Yoshiawa T; Minaga K; Yamashita Y; Asada M; Okabe Y; Osaki Y; Ikemoto J; Hanada K; Kudo M
    Digestive Disease Week (DDW 2017), 2017年05月 ポスター発表
  • 座長：モーニングセミナー2「肝炎・肝硬変診療におけるさらなる挑戦慢性肝疾患・残された多くの課題―掻痒症も含めて―」  [通常講演]
    工藤正俊
    第103回日本消化器病学会総会 2017年04月 その他
  • 早期慢性肝炎EUS所見の臨床的意義について. ワークショップ13「早期慢性肝炎をめぐる諸問題」  [通常講演]
    竹中 完; 山雄健太郎; 工藤正俊
    第103回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • 汎用型ワークステーションを用いた新しいTACE治療の試み. ワークショップ12「肝画像診断の進歩」  [通常講演]
    小川 力; 柴峠光成; 工藤正俊
    第103回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • US-US image fusionを用いた肝細胞癌へのラジオ派焼灼術の有用性. ワークショップ12「肝画像診断の進歩」  [通常講演]
    南 康範; 西田直生志; 工藤正俊
    第130回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • Strain imaging によるC 型慢性肝疾患の肝発癌リスク予測. ワークショップ12「肝画像診断の進歩」  [通常講演]
    矢田典久; 櫻井俊治; 工藤正俊
    第103回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • 司会：ワークショップ12「肝画像診断の進歩」  [招待講演]
    工藤正俊; 泉 並木
    第103回日本消化器病学会総会 2017年04月 その他
  • STAT3 に注目した分子標的薬の治療効果予測.ワークショップ7「進行大腸がん治療のup to date」  [通常講演]
    櫻井俊治; 樫田博史; 工藤正俊
    第103回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル.シンポジウム8「肝発癌メカニズムのパラダイムシフトとこれからの展望」  [通常講演]
    西田直生志; 工藤正俊
    第103回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • EUSによるIPMN併存膵癌の早期発見と問題点. パネルディスカッション「IPMNの診断と治療の進歩」  [通常講演]
    鎌田 研; 竹中 完; 工藤正俊
    第103回日本消化器病学会総会 2017年04月 シンポジウム・ワークショップパネル（公募）
  • Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study.  [通常講演]
    Sangro B; Yau T; Hsu C; Kudo M; Crocenzi TS; Choo SP; Meyer T; Welling TH; Yeo W; Chopra A; Baakili A; dela Cruz C; Lang L; Neely J; Melero I; El-Khoueiry AB; Trojan J
    The International Liver Congress 2017 (EASL 2017) 2017年04月 口頭発表（一般）
  • Molecular Targeted Therapy for Hepatocellular Carcinoma: Current Status and Future Perspective. シンポジウム4「肝細胞癌の治療戦略」  [通常講演]
    工藤正俊
    第76回日本医学放射線学会総会 2017年04月 シンポジウム・ワークショップパネル（指名）
  • New HCC Diagnosis. Session5“HCC-2”  [招待講演]
    工藤正俊
    The Asian Pacific Association for the Study of the Liver (APASL STC 2017) 2017年04月 口頭発表（一般）
  • コンパニオン診断時代における造影USの役割とその啓蒙.  [通常講演]
    小川 力; 川井伸彦; 三野 智; 盛田真弘; 野田晃世; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 紫峠光成; 村川佳子; 日野賢志; 西田知紗; 横井靖世; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊
    第30回日本腹部造影エコー・ドプラ診断研究会 2017年04月 口頭発表（一般） 米子コンベンションセンター, 鳥取.
  • 造影USにて診断した虚血性鼠径ヘルニアの一例.  [通常講演]
    川井伸彦; 小川 力; 三野 智; 盛田真弘; 野田晃世; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 紫峠光成; 村川佳子; 日野賢志; 西田知紗; 横井靖世; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊
    第30回日本腹部造影エコー・ドプラ診断研究会 2017年04月 口頭発表（一般） 米子コンベンションセンター, 鳥取.
  • 造影USにて破裂性肝膿瘍が予測できた一例.  [通常講演]
    盛田真弘; 小川 力; 川井伸彦; 三野 智; 野田晃世; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 紫峠光成; 村川佳子; 日野賢志; 西田知紗; 横井靖世; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊
    第30回日本腹部造影エコー・ドプラ診断研究会 2017年04月 口頭発表（一般） 米子コンベンションセンター, 鳥取.
  • 開会の挨拶  [招待講演]
    工藤正俊
    第30回日本腹部造影エコー・ドプラ診断研究会 2017年04月 その他 米子コンベンションセンター, 鳥取.
  • 座長; 「C型肝炎の最新治療と今度の課題」  [招待講演]
    工藤正俊
    第13回Kinki Liver Club 2017年03月 その他 スイスホテル南海大阪, 大阪.
  • 開会/閉会の辞  [招待講演]
    工藤正俊
    第13回Kinki Liver Club 2017年03月 その他 スイスホテル南海大阪, 大阪.
  • Prospective risk analysis of hepatocellular carcinoma in patients with chronic hepatitis C by ultrasound strain imaging  [通常講演]
    Yada N; Sakurai T; Kudo M
    American Institute of Ultrasound in Medicine (AIUM) 2017年03月 ポスター発表 Florida, USA
  • 開会の辞  [招待講演]
    工藤正俊
    第13回臨床消化器病フォーラム 2017年03月 その他 ホテルグランヴィア大阪, 大阪.
  • シンポジスト; 総合討論・症例提示  [招待講演]
    工藤正俊
    Radiology Update in Gifu 2017年03月 口頭発表（一般） 岐阜グランドホテル, 岐阜
  • 特別講演「内科医からみた肝画像診断の役割」  [招待講演]
    工藤正俊
    Radiology Update in Gifu 2017年03月 口頭発表（招待・特別） 岐阜グランドホテル, 岐阜
  • 膵炎を繰り返す膵頭部癌に対して超音波内視鏡下膵管ドレナージ術を施行した一例. Freshman Session 11「膵臓・その他」  [通常講演]
    中野省吾; 鎌田 研; 竹中 完; 大本俊介; 宮田 剛; 三長孝輔; 山雄健太郎; 工藤正俊
    第106回日本消化器病学会近畿支部例会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • 主膵管狭窄を厳重に経過観察することで診断し得た膵上皮内癌の1例. Freshman Session 10「膵臓」  [通常講演]
    神山真紀子; 山雄健太郎; 大本俊介; 鎌田 研; 三長孝輔; 宮田 剛; 今井 元; 竹中 完; 工藤正俊; 松本逸平; 竹山宜典; 筑後孝章
    第106回日本消化器病学会近畿支部例会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • 緊急EUS-guided choledochoduodenostomyが有効であった総胆管結石性胆管炎の一例. Freshman Session 9「胆道」  [通常講演]
    和田祐太郎; 三長孝輔; 竹中 完; 大本俊介; 鎌田研; 宮田 剛; 山雄健太郎; 樫田博史; 工藤正俊
    第106回日本消化器病学会近畿支部例会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • 発する多血性肝腫瘍を認めた若年女性の1例. Freshman Session 8「肝臓(4)」  [通常講演]
    森本真衣; 奥田英之; 秦 康倫; 木下大輔; 高山政樹; 岡崎典久; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊
    第106回日本消化器病学会近畿支部例会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • PPIによる胃低腺ポリープの変化についての検討. Young Investigator Session1「直動・胃・十二指腸」  [通常講演]
    岩西美奈; 辻 直子; 川崎正憲; 松本 望; 尾崎信人; 米田 円; 谷池聡子; 井上達夫; 梅原康湖; 富田崇文; 前倉俊治; 落合 健; 工藤正俊
    第106回日本消化器病学会近畿支部例会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • ERCP後膵炎早期発見におけるERCP直後CT撮影の有用性. ワークショップ2「胆膵領域における診断と治療の新たな展開」  [通常講演]
    宮田 剛; 竹中 完; 工藤正俊
    第106回日本消化器病学会近畿支部例会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • 座長; 「C型肝炎治療－これまで、これから－」  [招待講演]
    工藤正俊
    エレルサ®・グラジナ®発売記念講演会in南大阪 2017年02月 その他 シェラトン都ホテル大阪, 大阪.
  • 開会の辞  [招待講演]
    工藤正俊
    エレルサ®・グラジナ®発売記念講演会in南大阪 2017年02月 その他 シェラトン都ホテル大阪, 大阪.
  • 司会; ランチョンセミナー13「腸内細菌制御と炎症性腸疾患」  [招待講演]
    工藤正俊
    第13回日本消化管学会総会学術集会 2017年02月 その他 名古屋国際会議場, 愛知
  • Regional use of sorafenib after transarterial chemoembolization (TACE) in Chinese patients with hepatocellular carcinoma (HCC): results from the second interim analysis of OPTIMIS  [通常講演]
    Hong S; Cheng AL; Raoul JL; Lee HC; Kudo M; Nakajima K; Peck-Radosavljevic M; on behalf of the; OPTIMIS Investigators
    The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2017年02月 口頭発表（一般） Shanghai, China
  • Analysis of overall survival (OS) by pattern of progression of hepatocellular carcinoma (HCC) during prior sorafenib treatment in the randomized phase 3 RESORCE trial comparing regorafenib with placebo  [通常講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; LeBerre MA; Meinhardt G; Han G; on behalf of; the; RESORCE Investigators
    The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2017年02月 口頭発表（一般） Shanghai, China
  • Invited Lecture “TACE”  [招待講演]
    工藤正俊
    the 26th Conference of Asian Pacific Association for the Study of the Liver (APASL 2017) 2017年02月 口頭発表（招待・特別） Shanghai, China
  • 特別講演「肝がんの薬剤治療の現況と薬剤の開発状況」  [招待講演]
    工藤正俊
    社内サテライト研修 2017年02月 口頭発表（招待・特別） エーザイ大阪コミュニケーションオフィス, 大阪
  • 大腸腫瘍内視鏡治療後の局所再発に対するサーベイランスについて. ワークショップ7「大腸腫瘍の診断とサーベイランス法の最前線」  [通常講演]
    米田頼晃; 樫田博史; 橋本有人; 岡元寿樹; 河野匡志; 山田光成; 足立哲平; 峯宏昌; 永井知行; 朝隈 豊; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊
    第13回日本消化管学会総会学術集会 2017年02月 シンポジウム・ワークショップパネル（公募）
  • Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study.  [通常講演]
    Yen C; Sharma R; Rimassa L; Arizumi T; Bettinger D; Evans J; Pressiani T; Burlone ME; Pirisi M; Giordano L; Howell J; Kudo M; Thimme R; Park JW; Pinato DJ
    The International Liver Congress 2017 (EASL 2017) 2017年02月 ポスター発表
  • Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment.  [通常講演]
    Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross P; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Schlief S; Fiala-Buskes S; Meinhardt G; Bruix J on; ehalf; of; h; ESORCE Investigators
    EASL HCC Summit 2017 2017年02月 口頭発表（一般）
  • Chair: Hepatocellular Carcinoma Symposium “Multidisciplinary Therapy for HCC”  [招待講演]
    工藤正俊
    2nd Eastern & Western Association Liver Tumors 2017年01月 その他 Seiryo Auditorium, Tohoku University
  • Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.  [通常講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Gerolami R; Masi G; Ross PF; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Le Berre MA; Beinhardt G; Han G; on behalf of; RESORCE investigators
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017) 2017年01月 ポスター発表 San Francisco, USA
  • Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.  [通常講演]
    工藤正俊
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017) 2017年01月 ポスター発表 San Francisco, USA
  • Subgroup analyses of a phase 2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)  [通常講演]
    Ikeda M; Ikeda K; Kudo M; Osaki Y; Okusaka T; Tamai T; Suzuki T; Hisai T; Miyagishi H; Okita K; Kumada H
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017) 2017年01月 ポスター発表 San Francisco, USA
  • Randomized phase 3 study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma  [通常講演]
    工藤正俊
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017) 2017年01月 ポスター発表 San Francisco, USA
  • Phase 2 study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.  [通常講演]
    Zhu AX; Knox J; Kudo M; Chan S; Finn R; Siegel A; Ma J; Cheng AL
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017) 2017年01月 ポスター発表 San Francisco, USA
  • Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study  [通常講演]
    Melero I; Sangro B; Yau T; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Welling TH; Yeo W; Chopra A; Anderson J; dela Cruz C; Lang L; Neely J; Tang H; El-Khoueiry AB
    American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017) 2017年01月 口頭発表（一般） San Francisco, USA
  • Efficacy and safety of regorafnib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial  [招待講演]
    Kudo M; Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE Investigators
    15th Japan Association of Molecular Targeted Therapy for HCC 2017年01月 口頭発表（一般） Iino hall & Conference Center, Tokyo
  • Locked Nucleic Acidsを用いた血清中マイクロRNA定量とソラフェニブ治療に対する反応予測  [通常講演]
    西田直生志; 岩西美奈; 南 知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 矢田典久; 依田 広; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊
    第15回日本肝がん分子標的治療研究会 2017年01月 口頭発表（一般） イイノホール＆カンファレンスセンター, 東京
  • 司会: 優秀演題2  [招待講演]
    工藤正俊
    第15回日本肝がん分子標的治療研究会 2017年01月 その他 イイノホール＆カンファレンスセンター, 東京
  • 癌遺伝子ガンキリンは炎症細胞でのSTAT3を活性化することで大腸発癌を促進する  [通常講演]
    櫻井俊治; 工藤正俊; 渡邊智裕; 樫田博史; 西田直生志; 米田頼晃; 永井知行; 萩原 智
    第2回G-PLUS 2016年12月 口頭発表（一般） ホテルイースト21東京, 東京
  • Invited Lecture “Recent trends of TACE”  [招待講演]
    工藤正俊
    57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016) 2016年12月 口頭発表（招待・特別） New Delhi, India
  • Invited Lecture “Classification and management algorithm of HCC”  [招待講演]
    工藤正俊
    57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016) 2016年12月 口頭発表（招待・特別） New Delhi, India
  • Invited Lecture “Detection of early HCC-advance in diagnosis”  [招待講演]
    工藤正俊
    57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016) 2016年12月 口頭発表（招待・特別） New Delhi, India
  • 胆道出血を契機に発見された胆嚢管癌の1例  [通常講演]
    奥田英之; 秦 康倫; 木下大輔; 高山政樹; 岡崎能久; 川崎俊彦; 辻江正徳; 石川 原; 水野成人; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • 当院における小児上部消化管内視鏡検査の状況  [通常講演]
    水野成人; 奥田英之; 高山政樹; 木下大輔; 秦 康倫; 岡崎能久; 川崎俊彦; 工藤正俊; 一木美穂; 近藤宏樹; 虫明総太朗; 若狭朋子; 太田善夫
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • EUS-HGSステント閉塞に対しtrough the mesh法でreinterventionしえた1例  [通常講演]
    上田泰大; 宮田 剛; 竹中 完; 三長孝輔; 大本俊介; 松田友彦; 鎌田 研; 山雄健太郎; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • 胆管合流異常症に合併した拡張胆管内隆起病への1例  [通常講演]
    吉川和也; 大本俊介; 竹中 完; 宮田 剛; 鎌田 研; 三長孝輔; 山雄健太郎; 工藤正俊; 松本逸平; 竹山宜典; 筑後孝章
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • 自己免疫性膵炎に対するステロイド投与の影響を造影ハーモニックEUSで評価しえた症例  [通常講演]
    岩津友大; 鎌田 研; 竹中 完; 大本俊介; 三長孝輔; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • 主膵管狭窄を2年間経過観察し得た膵上皮内癌の1例  [通常講演]
    橋本有人; 山雄健太郎; 竹中 完; 大本俊介; 鎌田 研; 宮田 剛; 三長孝輔; 樫田博史; 工藤正俊; 松本逸平; 竹山宜典; 筑後孝章
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • ョートシングルバルーン内視鏡を用いた金属ステント留意が有用であった十二指腸癌術後再発による挙上空腸狭窄の1例  [通常講演]
    國田裕貴; 三長孝輔; 竹中 完; 大本俊介; 松田友彦; 宮田 剛; 鎌田 研; 山雄健太郎; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • PTP誤嚥による食道気管支廔に対しOTSCによる閉鎖が奏功した一例  [通常講演]
    石村香織; 朝隈 豊; 岡元寿樹; 河野匡志; 足立哲平; 峯 宏昌; 永井知行; 米田頼晃; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 口頭発表（一般） 京都テルサ, 京都
  • 膵頭十二指腸切除術胃膵部吻合部狭窄に対するEUS-PDの検討. ワークショップ1「膵がんにおけるEUS-FNA関連手技の現状と問題点」  [通常講演]
    竹中 完; 三長孝輔; 山雄健太郎; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • 大腸腫瘍内視鏡治療後の局所再発に対するサーベイランスについて. パネルディスカッション2「大腸腫瘍内視鏡治療後のfollow upの課題」  [通常講演]
    米田頼晃; 樫田博史; 櫻井俊治; 朝隈 豊; 工藤正俊
    日本消化器内視鏡学会近畿支部第97回支部例会 2016年11月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • Invited Lecture “Immune checkpoint blockade in hepatocellular carcinoma”, Symposium 3 “Emerging Issues in the Management of Advanced Liver Disease”  [招待講演]
    工藤正俊
    Seoul International Digestive Disease Symposium (SIDDS 2016) 2016年11月 口頭発表（招待・特別） Grand Hilton Seoul Hotel, Seoul, Korea
  • 閉会の辞: 工藤正俊  [招待講演]
    工藤正俊
    第15回大阪消化器化学療法懇話会 2016年11月 その他 ホテル日航大阪, 大阪
  • 座長; 特別講演「大腸癌薬物療法の最新情報」  [招待講演]
    工藤正俊
    第15回大阪消化器化学療法懇話会 2016年11月 その他 ホテル日航大阪, 大阪
  • Invited Lecture “Contrast-enhanced EUS for pancreatobiliary disease”  [招待講演]
    工藤正俊
    The Westlake International Forum on Ultrasound in Medicine and Biology (WIFUMB 2016) in conjunction with the International Contrast Ultrasound Society (ICUS) meeting 2016年11月 口頭発表（招待・特別） Hongzhou, China
  • Invited Lecture “Fusion imaging for the treatment of liver cancer”.  [招待講演]
    工藤正俊
    The Westlake International Forum on Ultrasound in Medicine and Biology (WIFUMB 2016) in conjunction with the International Contrast Ultrasound Society (ICUS) meeting 2016年11月 口頭発表（招待・特別） Hongzhou, China
  • Invited Lecture “HCC clinical practice and ongoing trials in Japan”  [招待講演]
    工藤正俊
    Asia Advisory Board Meeting on GI Tumors 2016年11月 口頭発表（招待・特別） Beijing, China
  • Nivolumab (Nivo) in patients (Pts) with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study.  [通常講演]
    Melero I; Sangro B; Yau T; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Welling TH; Yeo W; Chopra A; Anderson J; dela Cruz C; Lang L; Neely J; Tang H; El-Khoueiry AB
    American Association for the Study of Liver Diseases (AASLD 2016) 2016年11月 口頭発表（一般）
  • 形質細胞様樹状細胞が産生するIL-33がIgG4関連疾患の状態に果たす役割. ワークショップ16「消化器領域におけるIgG4関連疾患の病態」  [通常講演]
    渡邉智裕; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: long-term outcomes after removal of a self-expandable metal stent  [通常講演]
    Kamata K; Takenaka M; Kudo M
    Asian Pacific Digestive Week (APDW 2016) 2016年11月 ポスター発表 Kobe Convention Center, Hyogo
  • EUSガイド下胆道ドレナージ困難例に対する治療ルート変更の有用性  [通常講演]
    三長孝輔; 北野雅之; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016) 2016年11月 口頭発表（一般） 神戸コンベンションセンター, 兵庫
  • IPMN併存膵癌の臨床像と早期発見におけるEUSの有用性. ワークショップ10「IPMN併存膵癌における諸問題と対策」  [通常講演]
    鎌田 研; 北野雅之; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016) 2016年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • 司会; ワークショップ12「肝癌分子標的薬導入のタイミング」  [招待講演]
    工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 その他 ポートピアホテル, 兵庫
  • エンテカビルとPEG-IFNα2a/2b 48週併用療法の効果および治療効果予測因子の検討. ワークショップ9「B型肝炎治療のアップデート」  [通常講演]
    萩原 智; 西田直生志; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • 膵癌の癌性疼痛に対するEUSガイド下神経叢融解術の治療効果予測因子の検討  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 口頭発表（一般） 神戸コンベンションセンター, 兵庫
  • 司会; ブレックファーストセミナー2「肝細胞癌の診断と治療の進歩」  [招待講演]
    工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016) 2016年11月 その他 ポートピアホテル, 兵庫
  • Chair; Liver-S2 “Current therapeutic strategy for HCC”  [招待講演]
    工藤正俊
    Asian Pacific Digestive Week (APDW 2016) 2016年11月 その他 Kobe Convention Center, Hyogo
  • Estimation of EUS findings of early chronic pancreatitis in comparison with clinical symptoms. International Session (Workshop) 1“Recent progress in chronic pancreatitis”  [通常講演]
    Takenaka M; Kitano M; Kudo M
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 シンポジウム・ワークショップパネル（公募） ポートピアホテル, 兵庫
  • pTis/pT1a膵癌の診断における内視鏡の役割. パネルディスカッション5「膵・胆道癌の早期発見における内視鏡の役割」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016) 2016年11月 シンポジウム・ワークショップパネル（公募） 神戸コンベンションセンター, 兵庫
  • US-US image fusionを用いた肝細胞癌へのラジオ波焼灼術と治療効果判定  [通常講演]
    南 康範; 工藤正俊
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 ポスター発表 神戸コンベンションセンター, 兵庫
  • Identification of fetal liver-type hepatocellular carcinoma based on a methylome analysis and its associations with genetic alterations. International Session (Symposium) 1 “Genomics of hepatocellular carcinoma: hepatitis virus infection and hepatocarcino  [通常講演]
    Nishida N; Kudo M
    第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016) 2016年11月 シンポジウム・ワークショップパネル（公募） ポートピアホテル, 兵庫
  • US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [通常講演]
    Minami Y; Kudo M
    the 3rd Asian Conference on Tumor Ablation (ACTA) 2016年10月 口頭発表（一般） Asan Medical Center, Seoul, Korea
  • 造影超音波を施行した膵NET肝転移の一例  [通常講演]
    横川美加; 前野知子; 市島真由美; 塩見香織; 前川 清; 矢田典久; 依田 広; 南 康範; 工藤正俊
    第43回日本超音波医学会関西地方会 2016年10月 口頭発表（一般） 大阪国際会議場, 大阪
  • 画像解析ソフトを用いた超音波診療の教育システム. シンポジウム1「腹部超音波検査の進歩と新たな展開」  [通常講演]
    小川 力; 盛田真弘; 野田晃世; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊
    第43回日本超音波医学会関西地方会 2016年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 肝病態診断におけるエラストグラフィの有用性. シンポジウム1「腹部超音波検査の進歩と新たな展開」  [通常講演]
    矢田典久; 工藤正俊
    第43回日本超音波医学会関西地方会 2016年10月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 理事長特別講演「超音波がもたらすイノベーション」  [招待講演]
    工藤正俊
    第43回日本超音波医学会関西地方会 2016年10月 口頭発表（招待・特別） 大阪国際会議場, 大阪
  • Moderator; ACTA meets WCIO I: Challenges and solutions in ablation  [招待講演]
    工藤正俊
    The 3rd Asian Conference on Tumor Ablation 2016年10月 その他 Asan Medical Center, Seoul, Korea
  • Invited Lecture “CE-US guided RFA for HCC”, Luncheon Symposium I  [招待講演]
    工藤正俊
    the 3rd Asian Conference on Tumor Ablation (ACTA) 2016年10月 口頭発表（招待・特別） Asan Medical Center, Seoul, Korea
  • Invited Lecture “CEUS in the evaluation of RFA treatment efficacy”  [招待講演]
    工藤正俊
    2016 Annual Convention of Taiwan Society of Ultrasound in Medicine (TSUM) 2016年10月 口頭発表（招待・特別） Taipei International Convention Center, Taiwan
  • Invited Lecture “Value of EOB in clinical perspective: Japan”  [招待講演]
    工藤正俊
    Asia Pacific Liver Imaging Symposium (APLIS 2016) 2016年10月 口頭発表（招待・特別） Conrad Beijing, China
  • 司会: Session 1「本邦における肝疾患とサルコペア」  [招待講演]
    工藤正俊
    OTSUKA Liver Forum 2016 2016年10月 その他 ホテルニューオータニ東京, 東京
  • 特別講演「肝細胞癌診療の最近のtopics」  [招待講演]
    工藤正俊
    第2回肝疾患Up to Date研究会 2016年10月 口頭発表（招待・特別） ANAクラウンプラザホテル新潟, 新潟
  • Combination therapy with peginterferon and entecavir for persistent viral suppression in patients with chronic hepatitis B  [通常講演]
    Hagiwara S; Nishida N; Kudo M
    23rd International Symposium on Hepatitis C Virus and Related Viruses (HCV2016) 2016年10月 ポスター発表 Kyoto International Conference Center, Kyoto, Japan
  • Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study  [通常講演]
    Melero I; Sangro B; Yau T; Hsu C; Kudo M; Crocenzi T; Kim TY; Choo SP; Trojan J; Meyer T; Willing T; Yeo W; Chopra A; Anderson J; dela Cruz CX; Lang L; Neely J; El-Khoueiry A
    ESMO 2016 2016年10月 口頭発表（一般） Copenhagen, Denmark
  • Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study  [通常講演]
    Zhu A; Knox J; Kudo M; Chan S; Finn R; Siegel A; Ma J; Watson P; Cheng AL
    ESMO 2016 2016年10月 ポスター発表 Copenhagen, Denmark
  • Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study  [通常講演]
    Finn R; Chan S; Zhu A; Knox J; Cheng AL; Siegel A; Bautista O; Watson P; Kudo M
    ESMO 2016 2016年10月 ポスター発表 Copenhagen, Denmark
  • A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [通常講演]
    Zhu A; Galle P; Kudo M; Finn R; Yang L; Abada P; Llovet J
    ESMO 2016 2016年10月 ポスター発表 Copenhagen, Denmark
  • Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial  [通常講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Isabelle Ollivier-Hourmang; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G
    ESMO 2016 2016年10月 ポスター発表 Copenhagen, Denmark
  • 特別講演「肝胆膵領域の超音波診療: 最近の動向」  [招待講演]
    工藤正俊
    日本超音波医学会第26回四国地方会学術集会 2016年10月 口頭発表（招待・特別） 愛媛大学医学部40周年記念講堂, 愛媛
  • The oncoprotein gankyrin promotes the development of colitis-associated cancer by mediating STAT3 and ERK activation  [通常講演]
    Sakurai T; Nagai T; Kashida H; Kudo M
    The 75th Annual Meeting of the Japanese Cancer Association 2016年10月 acifico Yokohama, Kanagawa
  • Chair: English Oral Sessions “Hepato-biliary-pancreatic cancer: translational research”  [招待講演]
    工藤正俊
    The 75th Annual Meeting of the Japanese Cancer Association 2016年10月 その他 Pacifico Yokohama, Kanagawa
  • 慢性膵炎合併良性胆道狭窄に対するfully covered metallic stentの有用性  [通常講演]
    竹中 完; 北野雅之; 工藤正俊
    第52回日本胆道学会学術集会 2016年09月 口頭発表（一般） 新横浜プリンスホテル, 神奈川
  • 経乳頭的、経皮的治療抵抗性の切除不能肝門部悪性胆道狭窄に対するEUS-guided biliary drainage (EUS-BD)の有用性, ビデオワークショップ「胆道内視鏡のトラブルシューティング」  [通常講演]
    竹中 完; 北野雅之; 工藤正俊
    第52回日本胆道学会学術集会 2016年09月 シンポジウム・ワークショップパネル（公募） 新横浜プリンスホテル, 神奈川
  • 急性胆嚢炎に対するEUSガイド下胆嚢ドレナージの長期成績～長期成績からみたSEMS早期抜去の有用性～, ワークショップ2「胆道疾患に対する超音波内視鏡の有用性」  [通常講演]
    鎌田 研; 北野雅之; 工藤正俊
    第52回日本胆道学会学術集会 2016年09月 シンポジウム・ワークショップパネル（公募） 新横浜プリンスホテル, 神奈川
  • 胆嚢病変の治療方針決定における造影ハーモニックEUSの有用性  [通常講演]
    鎌田 研; 北野雅之; 工藤正俊
    第52回日本胆道学会学術集会 2016年09月 口頭発表（一般） 新横浜プリンスホテル, 神奈川
  • Chair; Luncheon Seminar 3 “Significance of anti-viral therapy in patients with HCV-related HCC”  [招待講演]
    工藤正俊
    12th JSH Single Topic Conference 2016年09月 口頭発表（招待・特別） Hotel Nikko Kanazawa, Kanazawa
  • chair; The position of molecular target therapy in HCC, now and future  [招待講演]
    工藤正俊
    12th Japan Society of Hepatology 2016年09月 その他 Hotel Nikko Kanazawa
  • US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [通常講演]
    Minami Y; Nishida N; Kudo M
    The 12th JSH Single Topic Conference 2016年09月 ポスター発表 Hotel Nikko Kanazawa, Kanazawa
  • Invited Lecture “New subclassification and treatment strategy for intermediate stage HCC”  [招待講演]
    工藤正俊
    the 12th JSH Single Topic Conference 2016年09月 口頭発表（招待・特別） Hotel Nikko Kanazawa, Kanazawa
  • Treatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)  [通常講演]
    Ye SL; Lencioni R; Marrero JA; Venook AP; Nakajima K; Kudo M
    The 19th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) 2016年09月 その他
  • 主膵管の著名な拡張を呈したIPMNの一例  [通常講演]
    森本真衣; 高山政樹; 岡崎能久; 秦 康倫; 木下大輔; 奥田英之; 川崎俊彦; 水野成人; 古形修平; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器病学会近畿支部第105回例会 2016年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 透析患者の胃粘膜組織から炭酸ランタン沈着を証明できた一例  [通常講演]
    橋本有人; 松井繁長; 岡本寿樹; 河野匡志; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 永井知行; 米田頼晃; 朝隈 豊; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊; 榎木英介; 木村雅友
    日本消化器病学会近畿支部第105回例会 2016年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 急性胆嚢炎に対する超音波内視鏡下胆嚢ドレナージ術, ワークショップ2「胆膵疾患診断および治療の最近の進歩」  [通常講演]
    鎌田 研; 竹中 完; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第105回例会 2016年09月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 肝細胞癌治療アルゴリズムの検討. パネルディスカッション「肝細胞癌の治療アルゴリズムをめぐる諸問題」  [通常講演]
    有住忠晃; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第105回例会 2016年09月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 大腸潰瘍の治療法選択におけるJNET分類の診断能に関する検討. シンポジウム2「大腸腫瘍の診断・治療における戦略と展望」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第105回例会 2016年09月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 開会/閉会の挨拶  [招待講演]
    工藤正俊
    南大阪肝疾患診療連携セミナー 2016年09月 その他 スイスホテル南海大阪, 大阪
  • 座長: 特別講演「世界初の核酸型"チェインターミネーター"100%駆除を目指して」  [招待講演]
    工藤正俊
    南大阪肝疾患診療連携セミナー 2016年09月 その他 スイスホテル南海大阪, 大阪
  • Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma  [通常講演]
    Kudo M; Ueshima K; Yokosuka O; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Arai Y; Kanai F; Akazawa K
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 口頭発表（一般） Vancouver, Canada
  • Patients benefit from treatment with sorafenib for more than 28 weeks: analysis from the GIDEON study according to duration of treatment  [通常講演]
    Ye SL; Lencioni R; Nakajima K; Kudo M
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 ポスター発表 Vancouver, Canada
  • Validation of a proposed substaging system for patients with intermediate hepatocellular carcinoma  [通常講演]
    Arizumi T; Ueshima K; Kudo M
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 ポスター発表 Vancouver, Canada
  • New technology to detect of tumor-feeding branches and simulate embolization area of hepatocellular carcinoma with SYNAPSE VINCENT durint transcatheter arterial chemoembolization  [通常講演]
    Ogawa C; Shibatoge M; Kudo M
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 ポスター発表 Vancouver, Canada
  • A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [通常講演]
    Zhu AX; Galle PR; Kudo M; Finn RF; Yang L; Abada PB; Llovet JM
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 ポスター発表 Vancouver, Canada
  • An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS interim analysis  [通常講演]
    Cheng AL; Raoul JL; Lee HC; Kudo M; Nakajima K; Peck-Radosavljevic M on; behalf of the; OPTIMIS Investigators
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 ポスター発表 Vancouver, Canada
  • A propensity score analysis on survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion using nationwide survey data in Japan  [通常講演]
    Kokudo N; Kokudo T; Hasegawa K; Matsuyama Y; Takayama T; Kadoya M; Kudo M; Ku Y; Sakamoto M; Nakashima O; Kaneko S; Izumi N
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 口頭発表（一般） Vancouver, Canada
  • Safety and antitumour activity of Nivolumab (Nivo) in patients with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 checkmate-040 study  [通常講演]
    Sangro B; Melero I; Yau T; Hsu C; Kudo M; Crocenzi T; Kim TY; Choo SP; Trojan J; Meyer T; Kang YK; Anderson J; dela Cruz C; Lang L; Neely J; El-Khoueiry A
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 口頭発表（一般） Vancouver, Canada
  • New subclassification of intermediate stage HCC: Analysis of 46,997 Japanese HCC patients from a nationwide survey of the Liver Cancer Study Group of Japan  [通常講演]
    Ueshima K; Kudo M; Izumi N; Kadoya M; Kaneko S; Ku Y; Kokudo N; Takayama T; Sakamoto M; Nakashima O; Matsuyama Y
    10th Annual Conference International Liver Cancer Association (ILCA) 2016年09月 口頭発表（一般） Vancouver, Canada
  • Chair: ILCA Symposium 2 “Controversies in Liver Cancer”  [招待講演]
    工藤正俊
    ILCA 10th Annual Conference 2016 2016年09月 その他 Fairmont Hotel Vancouver, Canada
  • ラジオ出演「C型肝炎について」  [招待講演]
    工藤正俊
    ラジオ大阪(番組名: 高岡美樹のべっぴんラジオ) 2016年08月 メディア報道等
  • 特別講演「Intermediate Stage 肝癌の多様性と治療戦略」  [招待講演]
    工藤正俊
    TACE Refractory Focus Expert Meeting 2016年08月 口頭発表（招待・特別） JRクレメントホテル高松, 香川
  • 座長: 特別講演  [招待講演]
    工藤正俊
    第58回京都肝疾患懇話会 2016年07月 その他 京都ホテルオークラ, 京都
  • Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma”  [招待講演]
    工藤正俊
    14th Annual Meeting of the Japanese Society of Medical Oncology 2016年07月 口頭発表（招待・特別） Kobe International Exhibition Hall/Kobe International Conference Center
  • Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma”  [招待講演]
    工藤正俊
    14th Annual Meeting of the Japanese Society of Medical Oncology 2016年07月 口頭発表（招待・特別） Kobe International Exhibition Hall/Kobe International Conference Center
  • Chair; Poster Session “Hepatoma/HCC, Biliary Tract Cancer”  [招待講演]
    工藤正俊
    14th Annual Meeting of the Japanese Society of Medical Oncology 2016年07月 その他 Kobe International Exhibition Hall/Kobe International Conference Center
  • 画像コメンテーター: 肝「炎症を伴う肝腫瘤性病変（非腫瘍性・腫瘍性を含む）」  [招待講演]
    工藤正俊
    第17回臨床消化器病研究会 2016年07月 その他 東京ビッグサイト, 東京
  • Special Lecture “Role of EOB-MRI in the management of HCC”  [招待講演]
    工藤正俊
    Bayer Sponsored Meeting From Diagnosis to Treatment, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 口頭発表（招待・特別） Crowne Plaza Hong Kong Kowloon East
  • Chair; Session 17: State-of-the Art Lecture “Systemic Therapy for HCC – The Future and Beyond”  [招待講演]
    工藤正俊
    The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 その他 Crowne Plaza Hong Kong Kowloon East, Hong Kong
  • A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line Sorafenib (REACH-2)  [通常講演]
    Zhu AX; Galle PR; Kudo M; Finn RS; Yang L; Abada PB; Llovet JM
    7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 ポスター発表 Crowne Plaza Hong Kong Kowloon East
  • Chair; Session 14: Debate Session  [招待講演]
    工藤正俊
    The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 Crowne Plaza Hong Kong Kowloon East, Hong Kong
  • Chair; Consensus Workshop2 “Role of Chemotherapy in HCC”  [招待講演]
    工藤正俊
    The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 その他 Crowne Plaza Hong Kong Kowloon East
  • Easy detection of tumor-feeding branches of hepatocellular carcinoma with SYNAPSE VINCENT during transcatheter arterial chemoembolization  [通常講演]
    Ogawa C; Shibatoge M; Kudo M
    7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 ポスター発表 Crowne Plaza Hong Kong Kowloon East
  • Safety and antitumor activity of Nivolumab (Nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the Phase 1/2 CheckMate-040 study  [通常講演]
    Sangro B; Melero I; Yau T; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Kang YK; Anderson J; dela Cruz C; Lang L; Neely J; El-Khoueiry AB
    7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 口頭発表（一般） Crowne Plaza Hong Kong Kowloon East
  • State-of-the Art Lecture “Recent Advancement in HCC Treatment”  [招待講演]
    工藤正俊
    7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 口頭発表（招待・特別） Crowne Plaza Hong Kong Kowloon East
  • Chair; Consensus Workshop2 “Role of Chemotherapy in HCC”  [招待講演]
    工藤正俊
    The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2016年07月 その他 Crowne Plaza Hong Kong Kowloon East
  • NASH関連肝発癌における線維化進展と遺伝子変化. ワークショップ2「非ウイルス性肝細胞癌の病態と分類」  [通常講演]
    萩原 智; 西田直生志; 工藤正俊
    第52回日本肝癌研究会 2016年07月 シンポジウム・ワークショップパネル（公募） 虎ノ門ヒルズフォーラム, 東京
  • 門脈腫瘍栓合併肝細胞癌に対する外科的切除の意義の検討-肝癌研究会追跡調査より. パネルディスカッション3「進行肝細胞癌の治療: 切除、動注、放射線科、分子標的治療薬の役割」  [通常講演]
    國土貴嗣; 長谷川 潔; 松山 裕; 高山忠利; 泉 並木; 角谷眞澄; 工藤正俊; 具 英成; 坂元亨宇; 中島 収; 金子周一; 國土典宏
    第52回日本肝癌研究会 2016年07月 シンポジウム・ワークショップパネル（公募） 虎ノ門ヒルズフォーラム, 東京
  • 予測塞栓領域を考慮したTACE治療の試み. ビデオセッション3「肝癌・背景肝の画像評」  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊
    第52回日本肝癌研究会 2016年07月 その他 虎ノ門ヒルズフォーラム, 東京
  • ゲノム・エピゲノム・染色体情報に基づいた肝癌の亜分類と転移再発予測. パネルディスカッション2「肝細胞癌の新たなサブクラス分類と治療ストラテジー」  [通常講演]
    西田直生志; 海道利実; 工藤正俊
    第52回日本肝癌研究会 2016年07月 シンポジウム・ワークショップパネル（公募） 虎ノ門ヒルズフォーラム, 東京
  • “Proposal of new BCLC stage B subclassification”, Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC”  [招待講演]
    工藤正俊
    52nd Annual Meeting of Liver Cancer Study Group of Japan 2016年07月 シンポジウム・ワークショップパネル（指名） 虎ノ門ヒルズフォーラム
  • Chair: Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC”  [招待講演]
    工藤正俊
    第52回日本肝癌研究会 2016年07月 その他 虎ノ門ヒルズフォーラム, 東京
  • 司会: ランチョンセミナー7「肝がん合併肝硬変の治療戦略」  [招待講演]
    工藤正俊
    第52回日本肝癌研究会 2016年07月 その他 虎ノ門ヒルズフォーラム, 東京
  • Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, randomized phase 3 RESORCE trial  [通常講演]
    Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Boucher E; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross P; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE investigators
    ESMO 18th World Congress on Gastrointestinal Cancer 2016 2016年06月 口頭発表（一般） Barcelona, Spain
  • 予測塞栓領域を考慮したTACE治療の試み  [通常講演]
    小川 力; 野田晃世; 盛田真弘; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊
    第16回関西肝血流動態・機能イメージ研究会 2016年06月 口頭発表（一般） オーバルホール, 大阪
  • 当院におけるDrug eluting bead (DEB)-TACEの現況  [通常講演]
    田北雅弘; 南 知宏; 千品寛和; 有住忠晃; 矢田典久; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 任 誠雲; 柳生行伸; 松木 充; 鶴崎正勝; 村上卓道; 工藤正俊
    第16回関西肝血流動態・機能イメージ研究会 2016年06月 口頭発表（一般） オーバルホール, 大阪
  • 教育講演「免疫チェックポイント阻害剤による肝細胞癌治療への期待」  [招待講演]
    工藤正俊
    第16回関西肝血流動態・機能イメージ研究会 2016年06月 口頭発表（招待・特別） オーバルホール, 大阪
  • ネクサバールでCRが5年間持続後にSOF+RBVを行いSVR12が得られている症例  [通常講演]
    小川 力; 野田晃世; 出田雅子; 久保敦司; 石川哲郎; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊
    第14回日本肝がん分子標的治療研究会 2016年06月 ポスター発表 スペース36, 大阪
  • ソラフェニブ国際共同非介入試験GIDEON最終解析～日本における肝癌治療の実際～, シンポジウム2「進行肝癌に対するカテーテル治療」  [通常講演]
    角谷眞澄; 池田公史; 高山忠利; 沼田和司; 泉 並木; 國土典宏; 古瀬純司; 奥坂拓志; 山下哲史; 奥村正文; 工藤正俊
    第14回日本肝がん分子標的治療研究会 2016年06月 シンポジウム・ワークショップパネル（公募） スペース36, 大阪
  • 司会: シンポジウム2「進行肝癌に対するカテーテル治療」  [招待講演]
    工藤正俊
    第14回日本肝がん分子標的治療研究会 2016年06月 その他 スペース36, 大阪
  • Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)  [通常講演]
    Abou-Alfa GK; Sangro B; Morse M; Zhu AX; Kim RD; Cheng AL; Kudo M; Kang YK; Chan SL; Antal J; Boice J; Xiao F; Morris SR; Bendell J; Study Group
    52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016) 2016年06月 ポスター発表 Chicago, Illinois
  • Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey  [通常講演]
    Kokudo T; Hasegawa K; Matsuyama Y; Takayama T; Izumi N; Kadoya M; Kudo M; Ku Y; Sakamoto M; Nakashima O; Kaneko S; Kokudo N
    52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016) 2016年06月 ポスター発表 Chicago, Illinois
  • A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [通常講演]
    Zhu AX; Galle PR; Kudo M; Finn RS; Yang L; Abada P; Llovet JM
    52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016) 2016年06月 ポスター発表 Chicago, Illinois
  • Safety and antitumor activity of Nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study  [通常講演]
    Sangro B; Melero I; Yau TC; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Kang YK; Anderson J; Dela Cruz C; Lang L; Neely J; El-Khoueiry AB
    52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016) 2016年06月 ポスター発表 Chicago, Illinois
  • Usefulness of contrast-ehnaced ultrasonography with sonazoid in the preperative evaluation of histological differentiation and gross types of hepatocellular carcinoma  [通常講演]
    Ogawa C; Minami Y; Kudo M
    8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201 2016年05月 口頭発表（一般） Kyoto International Conference Center, Kyoto
  • 造影ハーモニックEUSの定量的血流評価による膵腫瘍診断, シンポジウム 消化器3「胆膵疾患の造影エコー診断up-to-date」  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（公募） 国際京都国際会館, 京都
  • 転移性肝癌に対するUS-US fusionを用いたラジオ波焼灼術. シンポジウム領域横断2「Image Fusionは診断能・治療成績をどの様に向上させたか？」  [通常講演]
    南 知宏; 南 康範; 工藤正俊
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（公募） 国際京都国際会館, 京都
  • シミュレーション機能を用いた超音波検査の教育体制. シンポジウム領域横断2「Image Fusionは診断能・治療成績をどの様に向上させたか？」  [通常講演]
    小川 力; 荒澤壮一; 芝峠光成; 西田知紗; 村上佳子; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（公募） 国際京都国際会館, 京都
  • 超音波で観察し得た小児における腸重責症の検討  [通常講演]
    前野知子; 横川美加; 市島真由美; 塩見香織; 前川 清; 南 康範; 樫田博史; 工藤正俊; 八木 誠
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 口頭発表（一般） 国際京都国際会館, 京都
  • 低音圧Tissue Harmonic Imagingによる造影超音波の検討  [通常講演]
    横川美加; 前野知子; 塩見香織; 前川 清; 矢田典久; 依田 広; 南 康範; 樫田博史; 工藤正俊
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 口頭発表（一般） 国際京都国際会館, 京都
  • EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」  [通常講演]
    Minaga K; Kitano M; Imai H; Yamao K; Kamata K; Miyata T; Matsuda T; Omoto S; Kadosaka K; Kudo M
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（公募） 国際京都国際会館, 京都
  • Utility of endoscopic ultrasonography for follow-up of IPMN. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」  [通常講演]
    Kamata K; Kitano M; Kudo M
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（公募） 国際京都国際会館, 京都
  • Shear wave imagingによる非アルコール性脂肪性肝疾患の病態診断, シンポジウム 消化器2「消化器領域におけるエラストグラフィーの最先端」  [通常講演]
    矢田典久; 工藤正俊
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（公募） 国際京都国際会館, 京都
  • 日本超音波医学会理事長としてキャリア支援を考える. 医師の立場から, パネルディスカッション領域横断3「日本超音波医学会が取り組むキャリア支援（JSUM男女共同参画委員会共同企画）  [招待講演]
    工藤正俊
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（指名） 国際京都国際会館, 京都
  • 日本超音波医学会男女共同参画委員会 アンケート調査報告. パネルディスカッション領域横断3「日本超音波医学会が取り組むキャリア支援（JSUM男女共同参画委員会共同企画）  [招待講演]
    赤坂和美; 工藤正俊; 飯島尋子; 上原麻理子; 斎藤明子; 椎名 毅; 高野真澄; 谷口信行; 畠 二郎; 平井都始子; 古川まどか; 山口 匡
    日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会（AFSUMB）, アジア造影超音波会議第8回学術集会（ACUCI）(Ultrasonic Week 2016) 2016年05月 シンポジウム・ワークショップパネル（指名） 国際京都国際会館, 京都
  • US-US image fusion in radiofrequency ablation therapy for hepatocellular carcinoma  [招待講演]
    Minami Y; Minami T; Kudo M
    8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201 2016年05月 口頭発表（招待・特別） Kyoto International Conference Center
  • New US technology using 3D volume analyzer synapse VINCENT  [招待講演]
    Ogawa C; Minami Y; Kudo M
    8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201 2016年05月 口頭発表（招待・特別） Kyoto International Conference Center, Kyoto, Japan
  • Contrast-enhanced harmonic EUS for pancreatic diseases  [招待講演]
    Kitano M; Kamata K; Omoto S; Minaga K; Yamao K; Imai H; Takenaka M; Kudo M
    8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201 2016年05月 口頭発表（招待・特別） Kyoto International Conference Center, Kyoto, Japan
  • カラー表示RVSを用いた小HCCの診断、およびRFAの治療効果判定  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 口頭発表（一般） 京王プラザホテル, 東京
  • トルバプタンにおける初期、および遅発性効果予測因子の検討  [通常講演]
    萩原 智; 千品寛和; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 口頭発表（一般） 日本消化器病学会総会, 平成28年4月21-23日,
  • US-US fusionを用いた肝細胞癌へのラジオ波焼灼術と治療効果判定, ワークショップ9「新規技術を用いた肝疾患診療の未来～診断から治療へ」  [通常講演]
    南 康範; 南 知宏; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル  [通常講演]
    西田直生志; 工藤正俊
    第103回日本消化器病学会総会 2016年04月 シンポジウム・ワークショップパネル（公募）
  • 座長; ランチョンセミナー12「C型肝炎治療におけるDAAの選択基準」  [招待講演]
    工藤正俊
    第102回日本消化器病学会総会 2016年04月 その他 京王プラザホテル, 東京
  • 既存治療の効果予測の可能性, プレナリーセッション「IBD 臨床」  [通常講演]
    櫻井俊治; 樫田博史; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 その他 京王プラザホテル, 東京
  • BCLC Bの細分類と治療選択. パネルディスカッション9: Intermediateから進行肝細胞癌治療の最前線」  [通常講演]
    有住忠晃; 上嶋一臣; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 司会: パネルディスカッション9: Intermediateから進行肝細胞癌治療の最前線  [招待講演]
    工藤正俊
    2016年04月 その他 京王プラザホテル, 東京
  • 大腸腫瘍診断・治療におけるJNET分類の試用結果. パネルディスカッション8「大腸腫瘍の治療法選択としての画像強調観察の意義」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 術後胃に発生した胃石症の特徴と治療  [通常講演]
    岡元寿樹; 松井繁長; 田中梨絵; 山田光成; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 樫田博史; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 ポスター発表 京王プラザホテル, 東京
  • An objective model to optimize treatment decisions in advanced hepatocellular carcinoma after sorafenib failure: the SORFA score  [通常講演]
    Pinato DJ; Yen C; Arizumi T; Giarda P; Howell J; Ramaswami R; Burlone ME; Kudo M; Pirisi M; Sharma R
    The International Liver Congress 2016 2016年04月 ポスター発表 Barcelona, Spain
  • Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH patients by albumin-bilirubin (ALBI) grade  [通常講演]
    Blanc JF; Chan SL; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Baran A; Pfiffer T; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Abada P; Chang SC; Yang L; Zhu A
    The International Liver Congress 2016 2016年04月 ポスター発表 Barcelona, Spain
  • Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatine/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma  [通常講演]
    Kudo M; Ueshima K; Yokosuka O; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Arai Y; Kanai F; Akazawa K; SILIUS Study Group
    The International Liver Congress 2016 2016年04月 口頭発表（一般） Barcelona, Spain
  • 特別講演「Intermediate Stage肝癌の細分類と免疫チェックポイント阻害剤への期待」  [招待講演]
    工藤正俊
    第4回奈良消化器病セミナー 2016年04月 口頭発表（招待・特別） 橿原ロイヤルホテル, 奈良
  • 座長: 特別講演「DAAで広がるC型肝炎治療～治療困難例への取り組み～」  [招待講演]
    工藤正俊
    南大阪HCV治療セミナー 2016年04月 その他 ホテルモントレグラスミア大阪, 大阪
  • 膵神経内分泌腫瘍診断における造影ハーモニックEUSの有用性  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    第29回日本腹部造影エコー・ドプラ診断研究会 2016年04月 口頭発表（一般） 宮崎市エムアールティ・ミック, 北九州
  • 病変の視認性に着目した肝腫瘍に対する低音圧造影tissue harmonic imaging (low MI CE-THI)の検討  [通常講演]
    河野匡志; 南 康範; 工藤正俊
    第29回日本腹部造影エコー・ドプラ診断研究会 2016年04月 口頭発表（一般） 宮崎市エムアールティ・ミック, 北九州
  • ラジオ波焼灼術後のバブルによる高エコー域を壊死部とみなして良いか？  [通常講演]
    南 康範; 岩西美奈; 南 知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第29回日本腹部造影エコー・ドプラ診断研究会 2016年04月 口頭発表（一般） 宮崎市エムアールティ・ミック, 北九州
  • 特別講演「肝細胞癌に対する新規分子標的薬の開発動向と免疫チェックポイント阻害薬への期待」  [招待講演]
    工藤正俊
    第18回北九州肝癌治療研究会 2016年03月 口頭発表（招待・特別） リーガロイヤルホテル小倉, 北九州
  • 座長: C型肝炎の新たな治療選択～ヴィキラックスを含めた今後のDAAs治療戦略～  [招待講演]
    工藤正俊
    アッヴィ肝炎フォーラム 2016年03月 その他 スイスホテル南海大阪, 大阪
  • Invited Lecture “Hepatocellular cancer drug development”  [招待講演]
    工藤正俊
    8th Annual Asian Oncology Summit (AOS 2016) 2016年03月 口頭発表（招待・特別） Kyoto International Community House, Kyoto, Japan
  • Practice patterns, sorafenib dosing and safety in Asian hepatocellular carcinoma patients in GIDEON  [通常講演]
    Kudo M; Venook A; Lencioni R; Ye SL; Nakajima K; Marrero J
    25th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2016年02月 口頭発表（一般） International Convention Center Pamir, Tokyo, Japan
  • Regional differences in practice patterns among countries, Luncheon Symposium “New light on the integration of evidence into practice”  [招待講演]
    工藤正俊
    25th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2016年02月 シンポジウム・ワークショップパネル（指名） International Convention Center Pamir, Tokyo, Japan
  • Biomarker and Imaging Diagnosis of HCC. Symposium 11 “Update of HCC Treatment”  [通常講演]
    工藤正俊
    25th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2016年02月 シンポジウム・ワークショップパネル（公募） International Convention Center Pamir, Tokyo, Japan
  • Invited Lecture “Non-Curative Treatment (TACE/Sorafenib) of HCC”  [招待講演]
    工藤正俊
    25th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2016年02月 口頭発表（招待・特別） International Convention Center Pamir, Tokyo, Japan
  • Regional Differences in the Use of Transarterial Chemoembolization (TACE) in HCC: Interim Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib After TACE  [通常講演]
    Lee HC; Cheng AL; Raoul JL; Peck-Radosavljevic M; Nakajima K; Kudo M; on behalf of the; OPTIMIS Investigators
    25th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2016年02月 口頭発表（一般） International Convention Center Pamir, Tokyo, Japan
  • Invited Lecture “Immuno-oncology for HCC: Beyond the target therapy”  [招待講演]
    工藤正俊
    the 1st anniversary International Symposium of Yonsei Liver Center 2016年02月 口頭発表（招待・特別） Newilhan Memorial Hall, Avision BioMedical Research Center, Korea
  • 開会の挨拶  [通常講演]
    工藤正俊
    日本肝臓学会主催平成27年度「肝がん撲滅運動」 2016年02月 その他 堺商工会議所, 大阪
  • 司会  [招待講演]
    工藤正俊
    第4回ディーシービーズ検討会～DEB-TACEの可能性を探る～ 2016年02月 その他 東京ビッグサイト, 東京
  • 特別講演「Intermediate Stageの細分類」  [招待講演]
    工藤正俊
    第4回ディーシービーズ検討会～DEB-TACEの可能性を探る～ 2016年02月 口頭発表（招待・特別） 東京ビッグサイト, 東京
  • 当院でのダクラタスビル/アスナプレビル併用療法の検討  [通常講演]
    千品寛和; 萩原 智; 岩西美奈; 南 知宏; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 依田 広; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 造影ハーモニックEUS画像と病理組織像の対比・検討を行った胆嚢癌の一例  [通常講演]
    吉川智恵; 鎌田 研; 北野雅之; 大本俊介; 門阪薫平; 松田友彦; 三長孝輔; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊; 榎木英介; 木村雅友
    日本消化器病学会近畿支部第104回例会 2016年02月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 術前診断が困難であった腸間膜悪性リンパ腫の一例  [通常講演]
    秦 康倫; 木下大輔; 奥田英之; 高山政樹; 末吉功冶; 岸谷 譲; 川崎俊彦; 水野成人; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 漢方薬服用者に見られた突発性腸間膜静脈硬化症の2例  [通常講演]
    岡元寿樹; 樫田博史; 米田頼晃; 河野匡志; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 永井知行; 岡崎能久; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 自己免疫性溶血性貧血を合併した自己免疫性肝炎の一例  [通常講演]
    岩西美奈; 依田 広; 高島耕太; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊; 平瀬主税; 前西 修; 筑後孝章
    日本消化器病学会近畿支部第104回例会 2016年02月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 若年男性に発症した肝細胞腺腫の悪性転化の一例  [通常講演]
    南 知宏; 萩原 智; 岩西美奈; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 潰瘍性大腸炎症例における重症度別の栄養指標と術後経過の検討. ワークショップ2「消化器疾患の栄養療法」  [通常講演]
    峯 宏昌; 松井繁長; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 周在性の大きな食材表在癌に対する内視鏡治療の有用性. ワークショップ1「消化器腫瘍に対する低侵襲治療」  [通常講演]
    朝隈 豊; 松井繁長; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 膵神経内分泌腫瘍診断におけるEUSの有用性. シンポジウム1「神経内分泌腫瘍の診断と治療」  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第104回例会 2016年02月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 直腸NETの内視鏡治療. シンポジウム1「神経内分泌腫瘍の診断と治療」  [通常講演]
    山田光成; 樫田博史; 米田頼晃; 工藤正俊
    本消化器病学会近畿支部第104回例会 2016年02月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • USが肝細胞癌との鑑別に有用と思われたリンパ増殖性疾患が疑われた肝腫瘍の一例  [通常講演]
    出田雅子; 小川 力; 三野 智; 野田晃世; 荒澤壮一; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 隈部 力; 中島 収; 工藤正俊
    第22回肝血流動態・機能イメージ研究会 2016年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • 次世代型Shear wave imaging測定値の信憑性を表す指標VsNの有用性について  [通常講演]
    矢田典久; 工藤正俊
    第22回肝血流動態・機能イメージ研究会 2016年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • Color RVSを用いたRFAの治療効果判定  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第22回肝血流動態・機能イメージ研究会 2016年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • 座長: 画像による病態解明・造影技術  [招待講演]
    工藤正俊
    第22回肝血流動態・機能イメージ研究会 2016年02月 その他 東京ビッグサイト, 東京
  • 高齢者の進行肝細胞癌に対する当院でのソラフェニブ治療の成績  [招待講演]
    有住忠晃; 上嶋一臣; 南 知宏; 千品寛和; 河野匡志; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 櫻井俊治; 西田直生志; 工藤正俊
    第11回日本肝がん分子標的治療研究会 2016年01月 ポスター発表 海運クラブ, 東京
  • 司会"肝細胞癌の臨床試験はなぜ上手くいかないのか"  [招待講演]
    工藤正俊
    第11回日本肝がん分子標的治療研究会 2016年01月 その他 海運クラブ, 東京
  • 開会の挨拶  [招待講演]
    工藤正俊
    第11回日本肝がん分子標的治療研究会 2016年01月 その他 海運クラブ, 東京
  • 特別講演「Intermediate肝癌の細分類と新しい分子標的薬への期待」  [招待講演]
    工藤正俊
    第12回九州C型肝炎研究会 2016年01月 口頭発表（招待・特別） ホテル日航福岡, 九州
  • 開会の挨拶  [招待講演]
    工藤正俊
    第34回南大阪肝疾患研究会 2016年01月 その他 ホテル・アゴーラリージェンシー堺, 大阪
  • 座長: 特別講演「肝細胞がんサーベイランスにおける血清マーカーの役割」  [招待講演]
    工藤正俊
    第1回大阪がんフォーラム 2016年01月 その他 ウェスティンホテル大阪, 大阪
  • Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC)  [通常講演]
    工藤正俊
    American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016) 2016年01月 ポスター発表 San Francisco, USA
  • Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial  [通常講演]
    Kudo M; Okusaka T; Kaneko S; Furuse J; Takeuchi M; Fang X; Date Y; Takeuchi M
    American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016) 2016年01月 ポスター発表 San Francisco, USA
  • A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [通常講演]
    Zhu A; Galle PR; Kudo M; Finn RS; Yang L; Abada P; Chang SC; Llovet JM
    American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016) 2016年01月 ポスター発表 San Francisco, USA
  • Usefulness of serum procalcitonin for diagnosis of acute pancreatitis  [通常講演]
    Omoto S; Kitano M; Sakamoto H; Imai H; Yamao K; Kamata K; Miyata T; Minaga K; Kadosaka K; Kudo M
    Asian Pacific Digestive Week (APDW 2016) 2015年12月 ポスター発表 Taipei, Taiwan
  • The analysis of three cases that gastrointestinal bezoars have history of gastrointestinal surgery  [通常講演]
    Okamoto K; Matsui S; Tanaka R; Yamada M; Adachi T; Takayama M; Mine H; Nagai T; Okazaki Y; Komeda Y; Asakuma Y; Sakurai T; Kashida H; Kudo M
    Asian Pacific Digestive Week (APDW 2016) 2015年12月 ポスター発表 Taipei, Taiwan
  • Treatment of colorectal LST: focus on EMR techniques  [通常講演]
    Komeda Y; Kashida H; Sakurai T; Asakuma Y; Okazaki Y; Nagai T; Mine H; Adachi T; Tanaka R; Yamada M; Kono M; Okamoto K; Matsui S; Kudo M
    Asian Pacific Digestive Week (APDW 2016) 2015年12月 ポスター発表 Taipei, Taiwan
  • A case of endoscopic mucosal resection for gastric perineurioma  [通常講演]
    Kono M; Matsui S; Okamoto K; Yamada M; Tanaka R; Adachi T; Mine H; Nagai T; Okazaki Y; Komeda Y; Asakuma Y; Sakurai T; Kashida H; Kudo M
    Asian Pacific Digestive Week (APDW 2016) 2015年12月 ポスター発表 Taipei, Taiwan
  • Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR (EMR)  [通常講演]
    Yamada M; Kashida H; Komeda Y; Okamoto K; Kono M; Tanaka R; Adachi T; Mine H; Nagai T; Okazaki Y; Asakuma Y; Sakurai T; Matsui S; Kudo M
    Asian Pacific Digestive Week (APDW 2016) 2015年12月 口頭発表（一般） Taipei, Taiwan
  • 特別講演「肝癌診療のBreakthroughはあるか？」  [招待講演]
    工藤正俊
    第130回宮城肝癌治療研究会 2015年11月 口頭発表（招待・特別） ホテルメトロポリタン仙台, 宮城
  • Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinoma  [通常講演]
    Nishida N; Kaido T; Kudo M
    66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015) 2015年11月 ポスター発表 San Francisco, USA
  • 当院における上皮内癌および小膵癌の診断  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊; 今井 元; 鎌田 研; 宮田 剛; 大本俊介; 門阪薫平; 三長孝輔; 松田友彦; 亀井敬子; 松本逸平; 竹山宜典
    第64回近畿膵疾患談話会 2015年11月 口頭発表（一般） エーザイ株式会社大阪コミュニケーションオフィス, 大阪
  • PALBI-an objective score based on platelets, albumin & Bilirubin Stratifies HCC patients undergoing resection & ablation better than Child’s classification  [通常講演]
    Roayaie S; Jibara G; Berhane S; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Kudo M; Roberts LR; Sherman M; Johnson P
    66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015) 2015年11月 ポスター発表 San Francisco, USA
  • 粘膜下腫瘍様形態を呈した胃perineuriomaの一例  [通常講演]
    河野匡志; 松井繁長; 樫田博史; 永井知行; 峯 宏昌; 米田頼晃; 朝隈 豊; 櫻井俊治; 工藤正俊; 筑後孝章
    日本消化器内視鏡学会近畿支部第95回支部例会 2015年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 粘膜下腫瘍様の形態を呈したhamartomatous inverted polypの一例  [通常講演]
    田中梨絵; 山田光成; 河野匡志; 足立哲平; 峯 宏昌; 永井知行; 朝隈 豊; 米田頼晃; 岡崎能久; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第95回支部例会 2015年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 腎癌術後18年で発見された転移性胃腫瘍の1例  [通常講演]
    奥田英之; 秦 康倫; 木下大輔; 高山政樹; 岸谷 譲; 川崎友彦; 水野成人; 平山暁秀; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器内視鏡学会近畿支部第95回支部例会 2015年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 腸重積を来したが、内視鏡的に整復、切除し得た巨大大腸脂肪腫  [通常講演]
    橋本有人; 樫田博史; 米田頼晃; 河野匡志; 岡元寿樹; 山田光成; 田中梨絵; 足立哲平; 峯 宏昌; 永井知行; 岡崎能久; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊; 高山政樹; 川崎正憲; 榎本英介; 木村雅友; 佐藤隆夫
    日本消化器内視鏡学会近畿支部第95回支部例会 2015年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 食道疣状扁平上皮癌の一例. ワークショップ2「希少消化器疾患の内視鏡像」  [通常講演]
    岡元寿樹; 松井繁長; 工藤正俊
    日本消化器内視鏡学会近畿支部第95回支部例会 2015年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 造影ハーモニックEUSによる膵疾患の診断. シンポジウム2「胆膵腫瘍性疾患の診断と治療における工夫」  [通常講演]
    松田友彦; 北野雅之; 工藤正俊
    日本消化器内視鏡学会近畿支部第95回支部例会 2015年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 特別講演「Intermediate stage肝癌の再分類と新しい分子標的薬への期待」  [招待講演]
    工藤正俊
    第30回岐阜肝画像研究会 2015年10月 口頭発表（招待・特別） 岐阜
  • 進行肝細胞癌に対するソラフェニブとシスプラチン肝動注療法のランダム化第II相試験.ワークショップ9「肝臓3: 進行肝細胞がんの集学的治療(1)」  [通常講演]
    小島康志; 池田公史; 清水 怜; 佐藤俊哉; 森本 学; 稲葉吉隆; 萩原淳司; 萩原敦司; 工藤正俊; 中森正二; 金子周一; 杉本理恵; 佐藤恵子; 石井 浩; 古瀬純司; 奥坂拓志
    第53回日本癌治療学会学術集会 2015年10月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, グランドプリンス京都, 京都
  • 固形がんに対する化学療法施行時のB型肝炎ウイルス再活性化に関する多施設共同前向き観察研究. ワークショップ12「基礎研究: 基礎研究の臨床応用」  [通常講演]
    灘野成人; 池田公史; 近藤俊輔; 工藤正俊; 古瀬純司; 大﨑往夫; 熊田 卓; 大川和良; 伊藤清顕; 楠本 茂; 溝上雅史
    第53回日本癌治療学会学術集会 2015年10月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, グランドプリンス京都, 京都
  • Predictive factors for outcomes of through-the-scope gastroduodenal stenting in patients with gastric outlet obstruction; a large multicenter retrospective study in West Japan  [通常講演]
    Yamao K; Kitano M; Kayahara T; Ishida E; Minaga K; Yamashita Y; Nakajima J; Asada M; Okabe S; Chiba Y; Imai H; Kudo M
    23rd United European Gastroenterology Week (UEGW 2015) 2015年10月 ポスター発表 Barcelona, Spain
  • Evaluation of anti-migration properties of biliary covered self-expandable metal stents  [通常講演]
    Minaga K; Kitano M; Harwani Y; Imai H; Kamata K; Miyata T; Yamao K; Kadosaka K; Omoto S; Kudo M
    23rd United European Gastroenterology Week (UEGW 2015) 2015年10月 ポスター発表 Barcelona, Spain
  • Invited Lecture “Ultrasound fusion imaging of liver tumor: recent progress and clinical relevance”  [招待講演]
    工藤正俊
    IEEE International Ultrasonics Symposium 2015年10月 口頭発表（招待・特別） Taipei International Convention Center, Taiwan
  • 食道癌深達度診断における食道学会分類の検証. ワークショップ13「（JSES Core Session ）上部消化管におけるadvanced diagnostic endoscopy (ADE)エビデンスと新たな展開」  [通常講演]
    朝隈 豊; 松井繁長; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル高輪, 東京
  • EUS guided biliary drainage for treatment of biliary obstruction. International Session (Panel Discussion) 2 “Strategy of treatment for biliary stenosis”  [通常講演]
    Imai H; Kitano M; Kudo M
    第90回日本消化器内視鏡学会総会 2015年10月 シンポジウム・ワークショップパネル（指名） グランドプリンスホテル高輪, 東京
  • 座長: ブレックファーストセミナー14「肝細胞癌の診断と治療UP-TO-DATE」  [招待講演]
    工藤正俊
    第19回日本肝臓学会大会 2015年10月 その他 グランドプリンスホテル高輪, 東京
  • 司会: パネルディスカッション13「肝疾患の診断・治療に伴う侵襲はどこまで減らせるか」  [通常講演]
    工藤正俊
    第19回日本肝臓学会大会 2015年10月 その他 グランドプリンスホテル高輪, 東京
  • SSA/Pの内視鏡診断  [通常講演]
    岡崎能久; 樫田博史; 櫻井俊治; 朝隈 豊; 米田頼晃; 高山政樹; 峯 宏昌; 足立哲平; 田中梨絵; 山田光成; 岡元寿樹; 榎本英介; 前西 修; 筑後孝章; 木村雅友; 佐藤隆夫; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 ポスター発表 グランドプリンスホテル高輪, 東京
  • 大腸拡大NBI観察におけるJNET分類の有効性に関する検討. ワークショップ6「（JSES Core Session ）下部消化管におけるadvanced diagnostic endoscopy (ADE)エビデンスと新たな展開」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル高輪, 東京
  • 経乳頭治療困難悪性胆管狭窄に対するEUS下hepaticogastrostomyとantegrade stenting併用の有用性の検討. ワークショップ9「（JSES Core Session ）Interventional EUS: エビデンスと新たな展開」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル高輪, 東京
  • 機能性ディスペプシアに早期慢性膵炎が含まれている.ワークショップ7「機能性上部消化管疾患の病態と新規治療」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル高輪, 東京
  • 当院において直腸神経内分泌腫瘍に対してEMR-C (EMR using a cap), EMR-L (EMR with a ligation device)を中心とした内視鏡的切除の検討  [通常講演]
    山田光成; 樫田博史; 岡元寿樹; 田中梨絵; 足立哲平; 峯 宏昌; 高山政樹; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊
    第57回日本消化器病学会大会 2015年10月 ポスター発表 グランドプリンスホテル高輪, 東京
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第57回日本消化器病学会大会 2015年10月 ポスター発表 グランドプリンスホテル高輪, 東京
  • プロポフォールを用いた上部消化管内視鏡検査で出現する不随意運動の検討  [通常講演]
    梅原康湖; 辻 直子; 尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 谷池聡子; 森村正嗣; 山田 哲; 米田 円; 工藤正俊
    第57回日本消化器病学会大会 2015年10月 ポスター発表 グランドプリンスホテル高輪, 東京
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品博和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第19回日本肝臓学会大会 2015年10月 ポスター発表 グランドプリンスホテル高輪, 東京
  • Discussant, International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”  [招待講演]
    工藤正俊
    第19回日本肝臓学会大会 2015年10月 その他 グランドプリンスホテル高輪, 東京
  • Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma. International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”  [通常講演]
    Nishida N; Kudo M
    第19回日本肝臓学会大会 2015年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル高輪, 東京
  • 壊死性膵炎後のwalled-off necrosisに対するInterventional EUSの有用性. 統合プログラム1「壊死性膵炎後のwalled-off necrosisに対するベストアプローチ法は？」  [通常講演]
    三長孝輔; 北野雅之; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 口頭発表（一般） グランドプリンスホテル高輪, 東京
  • 膵癌早期診断におけるEUSの有用性の検討. パネルディスカッション7「膵がんのスクリーニングと事後管理」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第90回日本消化器内視鏡学会総会 2015年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル高輪, 東京
  • 超音波検査が鑑別にもっとも有用であったと考えられた肝原発Castleman病の1例  [通常講演]
    三野 智; 小川 力; 柴峠光成; 西田知紗; 村川佳子; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊
    日本超音波医学会第25回四国地方会学術集会, 第14回四国地方会講習会 2015年10月 口頭発表（一般） かがわ国際会議場, 香川
  • カラーRVSを用いた新しいsegment領域の教育方法  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    日本超音波医学会第25回四国地方会学術集会, 第14回四国地方会講習会 2015年10月 シンポジウム・ワークショップパネル（公募） かがわ国際会議場, 香川
  • 特別講演「消化器疾患の診断と治療における超音波の役割」  [通常講演]
    工藤正俊
    日本超音波医学会第25回四国地方会学術集会, 第14回四国地方会講習会 2015年10月 口頭発表（招待・特別） かがわ国際会議場, 香川
  • 特別講演「最新の肝癌診療―診断、治療、予後―」  [招待講演]
    工藤正俊
    HIV Specialist Forum in Tokyo 2015年10月 口頭発表（招待・特別） 野村コンファレンスプラザ日本橋, 東京
  • 肝臓解析を用いたTACEの塞栓領邦予測の試み～放射線技師との協力～  [通常講演]
    須和大輔; 坂東 誠; 槇殿元誉; 中川真吾; 西村悟郎; 吉崎康則; 安部一成; 小川 力; 工藤正俊
    第10回肝癌治療シミュレーション研究会 2015年09月 口頭発表（一般） ホテル椿山荘, 東京
  • DICOM dataの統合法によるカラー表示RVSを用いたRFA治療  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第10回肝癌治療シミュレーション研究会 2015年09月 口頭発表（一般） ホテル椿山荘, 東京
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術. セミナーシンポジウム「Navigationによる肝癌局所療法の最先端」  [通常講演]
    南 康範; 工藤正俊
    第10回肝癌治療シミュレーション研究会 2015年09月 シンポジウム・ワークショップパネル（公募） ホテル椿山荘, 東京
  • 非特異的な臨床・画像経過を呈した膵退形成癌（多形細胞型）の一例  [通常講演]
    松田友彦; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 造影ハーモニックEUSが病勢診断に有用であった自己免疫性膵炎の一例  [通常講演]
    高島耕太; 大本俊介; 門阪薫平; 鎌田 研; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 複数回のENPD下膵液細胞診により診断し得た膵上皮内癌の一例  [通常講演]
    加藤 寛; 宮田 剛; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 著明な肝機能障害を呈した骨髄性ポルフィリン症の一例  [通常講演]
    青山真吾; 萩原 智; 岩西美奈; 南 知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 依田 広; 上嶋一臣; 櫻井俊治; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • Hemosuccus pancreaticusによる出血に対し血管塞栓術にて止血しえた一例  [通常講演]
    岡元寿樹; 高山政樹; 山雄健太郎; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 松井繁長; 北野雅之; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 正常乳頭に近い状態であったため、診断に難渋した十二指腸乳頭部癌の一例  [通常講演]
    丹正幸祐; 木下大輔; 秦 康倫; 末吉功治; 奥田英之; 高山正樹; 岸谷 譲; 川崎俊彦; 水野成人; 加藤寛章; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 当院におけるPancreatic fluid collectionに対する予後予測の検討  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 閉塞性黄疸を契機に発見された先天性胆道拡張症の一例  [通常講演]
    高場雄久; 尾崎信人; 松本 望; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 慢性下痢を主訴としたC型慢性肝炎関連クリオグロブリン血症の一例  [通常講演]
    足立哲平; 岡元寿樹; 河野匡志; 田中梨絵; 山田光成; 峯 宏昌; 永井知行; 朝隈 豊; 米田頼晃; 岡崎能久; 萩原 智; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊; 野崎祐史; 松村 到; 石井道治
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • トルバプタンの治療効果における予測因子の検討  [通常講演]
    千品寛和; 萩原 智; 岩西美奈; 南 知宏; 河野匡志; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 転移性肝癌に対するUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 岩西美奈; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 当院における超音波内視鏡ガイド下腹腔神経叢ブロック術の検討. シンポジウム2「消化器腫瘍に対する内視鏡的アプローチの現況と問題点」  [通常講演]
    三長孝輔; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第103回例会 2015年09月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • Invited Lecture “Hepatologists’ perspectives on EOB-MRI: Pre-& post-operative evaluation in malignant lesions”  [招待講演]
    工藤正俊
    Asila Pacific Liver Imaging Symposium (APLIS) 2015年09月 口頭発表（招待・特別） Seoul, Korea
  • Invited Lecture; Luncheon Satellite Symposium “Treatment strategies to optimize outcome and experience of patients with HCC”  [招待講演]
    工藤正俊
    The Liver Week 2015 2015年09月 口頭発表（招待・特別） BEXCO, Busan, Korea
  • KLCSG & LCSGJ Joint Symposium “HCC nationwide surveillance and out come in Japan”  [招待講演]
    工藤正俊
    The Liver Week 2015 2015年09月 口頭発表（招待・特別） BEXCO, Busan, Korea
  • Invited Lecture “HCC nationwide surveillance and outcome in Japan”  [招待講演]
    工藤正俊
    The Liver Week 2015 2015年09月 口頭発表（招待・特別） BEXCO, Busan, Korea
  • Chairs: “KLCSG & JLCSG Joint Symposium”  [招待講演]
    工藤正俊
    The Liver Week 2015 2015年09月 その他 BEXCO, Busan, Korea
  • Special Lecture 2”The evolution of HCC treatment”  [招待講演]
    工藤正俊
    The Liver Week 2015 2015年09月 口頭発表（招待・特別） BEXCO, Busan, Korea
  • Invited Lecture “The evolution of HCC treatment”  [招待講演]
    工藤正俊
    The Liver Week 2015 2015年09月 口頭発表（招待・特別） BEXCO, Busan, Korea
  • A randomized phase 2 trial of sorafenib plus intraarterial cisplatin versus sorafenib alone for advanced hepatocellular carcinoma  [通常講演]
    Morimoto M; Ikeda M; Shimizu S; Inaba Y; Kojima Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 口頭発表（一般） Paris, France
  • Objective response by mRECIST predicts survival in hepatocellular carcinoma: a multivariate, time-dependent analysis from the phase 3 BRISK-PS study  [通常講演]
    Lencioni R; Park JW; Torres F; Decaens T; Boucher E; Raoul JL; Kudo M; Chang C; Boige V; Assenat E; Kang YK; Lim HY; Walters I; Llovet JM
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 口頭発表（一般） Paris, France
  • Platelet count improves prognostic value of A-L-B-I grade: introducting a new P-A-L-B-I score  [通常講演]
    Roayaie S; Jibara G; Berhane S; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Roberts L; Kudo M; Sherman M; Johnson P
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 口頭発表（一般） Paris, France
  • Evaluation of detection rate of liver tumor existing deep location from the surface using second generation agent, sorafenib  [通常講演]
    Izuta M; Ogawa C; Shibatoge M; Kudo M
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 ポスター発表 Paris, France
  • A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [通常講演]
    Zhu AX; Galle PR; Kudo M; Finn RS; Yang L; Abada P; Chang SC; Llovet JM
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 ポスター発表 Paris, France
  • An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patiens with hepatocellular carcinoma (HCC): OPTIMIS interim analysis  [通常講演]
    Peck-Radosavljivic M; Raoul JL; Lee HC; Kudo M; Nakajima K; Cheng AL; on behalf of the; OPTIMIS Investigators
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 ポスター発表 Paris, France
  • Survival benefit of locoregional therapy for hepatocellular carcinoma with Child-Pugh C liver function: a multicenter nation-wide study  [通常講演]
    Kudo M; Kitai S; Nishida N; Izumi N; Sakamoto M; Matsuyama Y; Ichida T; Nakashima O; Matsui O; Ku Y; Kokudo N; Makuuchi M; for the Liver; Cancer Study; Group of Japan
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 ポスター発表 Paris, France
  • US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [通常講演]
    Minami Y; Minami T; Kudo M
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 ポスター発表 Paris, France
  • Chair: General Session 2 “Molecular Pathogenesis of Liver Cancer II”  [招待講演]
    工藤正俊
    International Liver Cancer Association 9th Annual Conference (ILCA) 2015 2015年09月 その他 Paris, France
  • Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized Phase III REACH study: analysis ofα-fetoprotein (AFP) kinetics during treatment  [通常講演]
    Chau I; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Kudo M; Eduardo T; Pfiffer F; Hatano E; Chung HC; Kubackova K; Phelip JM; Brandi G; Ohkawa S; Li CP; Okusaka T; Yang L; Abada PB; Zhu AX
    European Cancer Congress 2015 (18th ECCO-40th ESMO) 2015年09月 ポスター発表 Vienna, Austria
  • Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the phase III REACH trial.  [通常講演]
    Kudo M; Hatano E; Okusaka T; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Arai K; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Asou H; Abada PB; Yang L; Zhu AX
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 口頭発表（一般） Paris, France
  • Invited Lecture “Assessing treatment effect and treatment failure: when to stop LRTs”  [招待講演]
    工藤正俊
    9th Annual Conference International Liver Cancer Association (ILCA) 2015年09月 口頭発表（招待・特別） September 4-6, 2015.
  • State of Art Lecture “Benefit of early diagnosis of liver cancer with changed therapeutic paradigm in HCC”  [招待講演]
    工藤正俊
    23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD) 2015年08月 Manekshaw Center, New Delhi, India
  • Invited Lecture “Imaging in early HCC-MR advances”  [招待講演]
    工藤正俊
    23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD) 2015年08月 口頭発表（招待・特別） Manekshaw Center, New Delhi, India
  • Invited Lecture“HCC: early diagnosis impacts prognosis”  [招待講演]
    工藤正俊
    23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD) 2015年07月 Max Hospital, New Delhi, India
  • Invited Lecture“Molecular targeted therapy for HCC: current status and future perspectives”  [招待講演]
    工藤正俊
    23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD) 2015年07月 Amity University, New Delhi, India
  • 総括発言「DEB-TACEのポジショニング～cTACEとの使い分けはいかにすべきか～」  [招待講演]
    工藤正俊
    第3回ディーシービーズ症例検討会 2015年07月 口頭発表（基調） 東京コンファレンスセンター, 東京
  • 仮想超音波のDICOM dataを用いたカラー表示USでの造影US、RFA治療方法  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第51回日本肝癌研究会 2015年07月 口頭発表（一般） 神戸国際会議場, 兵庫
  • 司会: シンポジウム4「肝癌に対する国内外の診療ガイドラインの問題点」  [招待講演]
    工藤正俊
    第51回日本肝癌研究会 2015年07月 その他 神戸国際会議場, 兵庫
  • 司会: ランチョンセミナー  [招待講演]
    工藤正俊
    第51回日本肝癌研究会 2015年07月 その他 神戸国際会議場, 兵庫
  • 原発性肝癌追跡調査症例の解析結果から検討した肝内胆管癌の病期分類について. パネルディスカッション3「肝内胆管癌の病態と最新の治療戦略」  [通常講演]
    阪本良弘; 國土典宏; 松山 裕; 坂元亨宇; 泉 並木; 角谷真澄; 金子周一; 具 英成; 工藤正俊; 高山忠利; 中島 収
    第51回日本肝癌研究会 2015年07月 シンポジウム・ワークショップパネル（公募） 神戸国際会議場, 兵庫
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 康範; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第51回日本肝癌研究会 2015年07月 口頭発表（一般） 神戸国際会議場, 兵庫
  • Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial  [通常講演]
    Ohkawa S; Okusaka T; Kudo M; Hatano E; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Arai K; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Asou H; Abada PB; Yang L; Zhu AX
    The 13th Annual Meeting of Japanese Soceity of Medical Oncology 2015年07月 口頭発表（一般） Hotel Sapporo Geibunkan, Sapporo
  • Activin signal in pancreatic cancer  [通常講演]
    Togashi Y; Sakamoto H; Kogita A; de Velasco M; Sakai K; Fujita Y; Tomida S; Kitano M; Kudo M; Nishio K
    The 13th Annual Meeting of Japanese Soceity of Medical Oncology 2015年07月 口頭発表（一般） Hotel Sapporo Geibunkan, Sapporo
  • Chair "Poster Session: Biliary Tract and Pancreatic Cancer 2 FOLFIRINOX(2)"  [招待講演]
    工藤正俊
    The 13th Annual Meeting of Japanese Society of Medical Oncology 2015年07月 その他 Sapporo Education and Culture Hall in Sapporo
  • Moderator and Commentator “Non-surgical treatment of HCC: achievement from Taiwan over the past quarter century”  [招待講演]
    工藤正俊
    Taiwan Association for the Study of the Liver 2015 (TASL) 2015年07月 口頭発表（招待・特別） Westin Taipei, Taipei, Taiwan
  • Moderator and Commentator “Androgen pathway in the mechanisms of liver carcinogenesis and targets for future therapy”  [招待講演]
    工藤正俊
    Taiwan Association for the Study of the Liver 2015 (TASL) 2015年07月 口頭発表（招待・特別） Westin Taipei, Taipei, Taiwan
  • 開会の辞  [招待講演]
    工藤正俊
    第33回南大阪肝疾患研究会 2015年07月 その他 ホテル・アゴーラリージェンシー堺, 大阪
  • 座長: Special Lectur: 坂本長逸「抗血栓薬と消化管傷害、現状とリスクマネジメント」  [招待講演]
    工藤正俊
    Scientific Exchange Meeting 2015 in Osaka 2015年07月 その他 ホテルグランヴィア大阪, 大阪
  • Opening Remarks  [招待講演]
    工藤正俊
    Scientific Exchange Meeting 2015 in Osaka 2015年07月 その他 ホテルグランヴィア大阪, 大阪
  • 特別講演「肝癌に対する分子標的治療: 現状と今後の展望」  [通常講演]
    工藤正俊
    第12回消化器癌研究会 2015年07月 口頭発表（招待・特別） 甲府富士屋ホテル, 山梨
  • Invited Lecture “Subclassification of intermediate stage HCC and treatment strategy”, APPLE Consensus Workshop “Searching consensus for controversies”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2015年07月 口頭発表（招待・特別） Hyatt Regency Osaka
  • Chair; State-of-the-Art Lecture III “Cholangiocarcinoma: new trends and emerging targets”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Chair; State-of-the-Art Lecture II “Design of clinical trial in advanced HCC: trial enrichment and stratification”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Chair; The BCLC B Stage: Debate  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Chair; Memorial Award Ceremony “Prof. Ichio Honjo Award Lecture”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Chair; Luncheon Seminar “Efficacy & Safety of Lipiodol for Improved Overall Survival in HCC”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Invited Lecture “Management of intermediate/advanced HCC in Japan”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2015年07月 口頭発表（招待・特別） Hyatt Regency Osaka
  • US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [通常講演]
    Minami Y; Minami T; Kudo M
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2015年07月 ポスター発表 Hyatt Regency Osaka
  • Epigenetics in HCC pathogenesis  [招待講演]
    Nishida N; Kudo M
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2015年07月 口頭発表（一般） Hyatt Regency Osaka
  • Chair; New Aspects of Locoregional/Surgical Therapy  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Chair; State-of-the-Art Lecture I  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka
  • Chari: Sponsored Seminar“Diagnostic Imaging with EOB-MRI for Malignancy Grade of HCC”  [招待講演]
    工藤正俊
    The 6th Asia-Pacific Primary Liver Cancer Expert Meeting 2015年07月 その他 Hyatt Regency Osaka, Japan
  • 自己免疫性膵炎のステロイド治療における再燃リスクの検討. ミニパネルディスカッション1「自己免疫性膵炎治療の現状と課題」  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    第46回日本膵臓学会大会 2015年06月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 愛知
  • 難治性下痢を主訴とし著明な腸管浸潤を認めた成人T細胞白血病の1例  [通常講演]
    岡崎能久; 樫田博史; 米田頼晃; 櫻井俊治; 朝隈 豊; 高山政樹; 峯 宏昌; 足立哲平; 田中梨絵; 山田光成; 岡元寿樹; 工藤正俊; 筑後孝章; 大山泰世
    日本消化器内視鏡学会近畿支部第94回支部例会 2015年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 下部消化管内視鏡で切除しえた盲腸顆粒細胞腫の一例  [通常講演]
    尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊
    日本消化器内視鏡学会近畿支部第94回支部例会 2015年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 胃噴門部粘膜下腫瘍に対してLECSを施行した1症例  [通常講演]
    安部美希子; 木下大輔; 秦 康倫; 貫戸幸星; 奥田英之; 岸谷 譲; 川崎俊彦; 加藤寛章; 井上雅智; 藤原由規; 永井知行; 太田善夫; 若狭朋子; 工藤正俊
    日本消化器内視鏡学会近畿支部第94回支部例会 2015年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 術後胃に発生した胃石症3例の検討  [通常講演]
    岡元寿樹; 松井繁長; 田中梨絵; 山田光成; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第94回支部例会 2015年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • Helicobacter pylori除菌後の内視鏡所見の変化. シンポジウム「ヘリコバクター胃炎除菌時代を迎えて-変わるもの、残るもの-」  [通常講演]
    松本 望; 辻 直子; 工藤正俊
    日本消化器内視鏡学会近畿支部第94回支部例会 2015年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 大腸LSTの治療方針. パネルディスカッション「大腸LST治療の最前線-内視鏡医・内視鏡外科医の立場から-」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第94回支部例会 2015年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 胃十二指腸ステントおよびステント留置下胆道ドレナージ術の治療成績の検討. パネルディスカッション2「切除不能膵癌の治療選択」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊; 中島 潤; 岡部純弘; 大﨑往夫; 萱原隆久; 石田悦嗣; 山本 博; 三長孝輔; 山下幸孝
    第46回日本膵臓学会大会 2015年06月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 愛知
  • 進行膵癌の癌性疼痛に対するEUS神経叢・神経節ブロック術の有用性の検討. ビデオシンポジウム1「内視鏡的手技 膵疾患に対するInterventional Endoscopy」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第46回日本膵臓学会大会 2015年06月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 愛知
  • 閉会挨拶  [招待講演]
    工藤正俊
    第17回関西B型肝炎研究会 2015年06月 その他 ホテルモントレグラスミア, 大阪
  • 座長: 特別講演「これからの肝臓病学」  [招待講演]
    工藤正俊
    第59回大阪肝穿刺生検治療研究会 2015年06月 その他 ホテルグランヴィア大阪, 大阪
  • 開会・閉会の辞  [招待講演]
    工藤正俊
    第59回大阪肝穿刺生検治療研究会 2015年06月 その他 ホテルグランヴィア大阪, 大阪
  • Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score  [通常講演]
    Zhu AX; Baron AD; Malfertheiner P; Kudo M; Kawazoe S; Pezet D; Weissinger F; Brandi G; Barone C; Okusaka T; Wada Y; Park J; Ryoo B; Cho JY; Chung HC; Li C; Yen C; Lee K; Yang L; Chau I
    Annual Meeting of American Society of Clinical Oncology (ASCO 2015) 2015年06月 ポスター発表 Chicago, USA
  • Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study  [通常講演]
    工藤正俊
    Annual Meeting of American Society of Clinical Oncology (ASCO 2015) 2015年06月 ポスター発表 Chicago, USA
  • Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study  [通常講演]
    Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz J; Park J; Ryoo B; Yen C; Kudo M; Poon RT; Pastorelli D; Blanc J; Chung H; Baron AD; Okusaka T; Cui ZL; Girvan AC; Abada P; Yang L; Zhu AX
    Annual Meeting of American Society of Clinical Oncology (ASCO 2015) 2015年06月 ポスター発表 Chicago, USA
  • Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial  [通常講演]
    Ikeda M; Shimizu S; Sato T; Morimoto M; Inaba Y; Kojima Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    Annual Meeting of American Society of Clinical Oncology (ASCO 2015) 2015年06月 ポスター発表 Chicago, USA
  • Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan  [通常講演]
    Sakamoto Y; Kokudo N; Matsuyama Y; Sakamoto M; Kadoya M; Kaneko S; Ku Y; Kudo M; Takayama T; Nakashima O; The Liver Cancer Study; Group of Japan
    Annual Meeting of American Society of Clinical Oncology (ASCO 2015) 2015年06月 ポスター発表 Chicago, USA
  • A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib refractory advanced hepatocellular carcinoma (S-CUBE)  [通常講演]
    Kudo M; Moriguchi M; Numata K; Hidaka H; Tanaka H; Ikeda M; Kawazoe S; Ohkawa S; Sato Y; Okusaka T
    Annual Meeting of American Society of Clinical Oncology (ASCO 2015) 2015年06月 ポスター発表 Chicago, USA
  • 膵胆道腫瘍のリンパ節転移診断における造影ハーモニックEUSの有用性.ワークショップ13「膵胆道疾患における超音波内視鏡診断の新展開」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • EUS検査時のミダゾラムとプロポフォールによる鎮静に対するBISモニター（Bis-pectral index monitoring）の有用性の検討.パネルディスカッション1「内視鏡診療における鎮静に関するガイドラインを検証する」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • 大腸鋸歯状病変の内視鏡診断について  [通常講演]
    岡崎能久; 樫田博史; 櫻井俊治; 朝隈 豊; 米田頼晃; 高山政樹; 峯 宏昌; 足立哲平; 田中梨絵; 山田光成; 岡元寿樹; 榎本英介; 前西 修; 筑後孝章; 木村雅友; 佐藤隆夫; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 口頭発表（一般） 名古屋国際会議場, 名古屋
  • 十二指腸静脈瘤の病態と治療方針. ビデオワークショップ1「消化管静脈瘤の診断・治療の現状と将来展望-異所性静脈瘤も含む-」  [通常講演]
    松井繁長; 樫田博史; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • 自己免疫性膵炎の診断および治療におけるEUSの役割.ワークショップ14「IgG4関連膵胆管病変における内視鏡の役割」  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • EUS下胆道ドレナージ術の有用性. JGES Core Session 3-パネルディスカッション「胆膵におけるInterventional EUS: 超音波内視鏡下瘻孔形成術の現状と問題点」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • 早期慢性膵炎が機能性ディスペプシアとして診断される可能性について.ワークショップ4「消化管機能異常に対する内視鏡の役割」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • 大腸T1癌の治療適応決定における内視鏡診断に関する検討.パネルディスカッション6「大腸T1(SM)癌に対する内視鏡治療の課題と将来展望」  [通常講演]
    櫻井俊治; 樫田博史; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • Contrast-enhanced harmonic EUS for differential diagnosis of pancreatic tumors. International Video Session 2 “Advances and education of endoscopic diagnosis and treatment-biliary tract, pancreas-“  [通常講演]
    Kamata K; Kitano M; Kudo M
    第89回日本消化器内視鏡学会総会 2015年05月 その他 名古屋国際会議場, 名古屋
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術. シンポジウム 消化器3「消化器疾患における新技術」  [通常講演]
    南 康範; 工藤正俊
    JUSM2015 日本超音波医学会第88回学術集会 2015年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • 深部病変におけるソナゾイド®造影超音波検査の検出率についての検討  [通常講演]
    出田雅子; 小川 力; 荒澤壮一; 柴峠光成; 西田知紗; 村川佳子; 河合直之; 丸山哲夫; 木太秀行; 工藤正俊
    JUSM2015 日本超音波医学会第88回学術集会 2015年05月 口頭発表（一般） グランドプリンスホテル新高輪, 東京
  • 簡便な小肝腫瘍の検出方法～初心者を対象とした仮想超音波の併用～  [通常講演]
    小川 力; 荒澤壮一; 出田雅子; 柴峠光成; 西田知紗; 村川佳子; 河合直之; 丸山哲夫; 木太秀行; 工藤正俊
    JUSM2015 日本超音波医学会第88回学術集会 2015年05月 口頭発表（一般） グランドプリンスホテル新高輪, 東京
  • Real-time tissue elastography. ワークショップ 消化器4「肝臓の硬さ診断: その精度と使途」  [通常講演]
    矢田典久; 工藤正俊
    JUSM2015 日本超音波医学会第88回学術集会 2015年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • Stage I膵癌診断における超音波検査の役割. ワークショップ 消化器3「腹部悪性腫瘍の早期診断の限界と見逃してはいけない所見」  [通常講演]
    北野雅之; 宮田 剛; 工藤正俊
    JUSM2015 日本超音波医学会第88回学術集会 2015年05月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪, 東京
  • ソナゾイド®造影超音波検査が虚血の診断に有用であった鼠径ヘルニアの1例  [通常講演]
    村上佳子; 小川 力; 荒澤壮一; 出田雅子; 柴峠光成; 西田知紗; 河合直之; 丸山哲夫; 木太秀行; 工藤正俊
    JUSM2015 日本超音波医学会第88回学術集会 2015年05月 口頭発表（一般） グランドプリンスホテル新高輪, 東京
  • 司会; ランチョンセミナー「進行肝癌に対する肝動注および塞栓療法について」  [招待講演]
    工藤正俊
    第51回日本肝臓学会総会 2015年05月 その他 鶴屋ホール, 熊本
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 康範; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 ポスター発表 鶴屋東館, 熊本
  • Fusion機能を用いたカラー表示US、および仮想超音波を用いた肝腫瘍の検出と治療  [通常講演]
    小川 力; 森岡弓子; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 ポスター発表 鶴屋東館, 熊本
  • 司会: ランチョンセミナー「マイクロスフィアを用いた塞栓療法について」  [通常講演]
    工藤正俊
    第51回日本肝臓学会総会 2015年05月 その他 ホテル日航熊本・熊本ホテルキャッスル・鶴屋ホール, 熊本
  • Shear Wave Measurementによる肝硬変測定  [通常講演]
    矢田典久; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 ポスター発表 鶴屋東館, 熊本
  • intermediate stageの肝細胞癌に対してTACE不応後のTACE継続とソラフェニブの検討  [通常講演]
    有住忠晃; 上嶋一臣; 南 知宏; 千品寛和; 河野匡志; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 櫻井俊治; 西田直生志; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 ポスター発表 鶴屋東館, 熊本
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 口頭発表（一般） 鶴屋東館, 熊本
  • ストレス応答蛋白の肝発癌リスク予測における可能性. ミニワークショップ4「肝病態を反映する新たなバイオマーカーの探索」  [通常講演]
    櫻井俊治; 矢田典久; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 鶴屋東館, 熊本
  • 変異型HBx遺伝子の肝発癌促進における分子機序の解明. ワークショップ4「肝病態を反映する新たなバイオマーカーの探索」  [通常講演]
    萩原 智; 西田直生志; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） 熊本ホテルキャッスル, 熊本
  • 血清中マイクロRNAプロファイルとソラフェニブに対する肝細胞癌の反応性予測. ワークショップ1「肝細胞癌の亜分類と個別化医療」  [通常講演]
    西田直生志; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 シンポジウム・ワークショップパネル（公募） ホテル日航熊本, 熊本
  • 司会: ワークショップ1「肝細胞癌の亜分類と個別化医療」  [招待講演]
    工藤正俊
    第51回日本肝臓学会総会 2015年05月 その他 ホテル日航熊本, 熊本
  • 分子生物学的特徴に基づいた肝癌のマネージメント. シンポジウム1「肝発癌研究と臨床への展開」  [通常講演]
    西田直生志; 海道利実; 工藤正俊
    第51回日本肝臓学会総会 2015年05月 シンポジウム・ワークショップパネル（指名） ホテル日航熊本, 熊本
  • 乳頭括約筋切開術を行わないTrans-catheter biliary endoscopyの有用性の検討. ビデオワークショップ3「胆道・膵疾患の内視鏡診断・治療における進歩」  [通常講演]
    河野匡志; 北野雅之; 工藤正俊
    第89回日本消化器内視鏡学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 名古屋国際会議場, 名古屋
  • 全国原発性肝癌追跡調査のNational Clinical Databaceへの移行. シンポジウム15「日本の診断データベース構築へ向けて今、何をすべきか？」  [通常講演]
    建石良介; 工藤正俊; 小池和彦
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • EUS下胆道・膵管ドレナージ術の適応と成績. ワークショップ9「膵・胆道内視鏡治療の最先端」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • Invited Lecture “Surveillance, treatment and outcome of HCC in Japan”  [招待講演]
    工藤正俊
    Joint Workshop EASL-JSH, 50th International Liver Congress of the European Association for the Study of the Liver (EASL) 2015年04月 口頭発表（招待・特別） Vienna, Austria
  • インターフェロン治療前後の状態から考えるShear wave elastographyとStrain elastographyによる複合診断の有用性  [通常講演]
    矢田典久; 櫻井俊治; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 口頭発表（一般） 仙台国際センター, 宮城
  • IPMNの経過観察におけるEUSおよび造影ハーモニックEUSの有用性. パネルディスカッション10「国際診療ガイドラインに基づいたIPMN/MCN診療の課題と対策」  [通常講演]
    鎌田 研; 北野雅之; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • 大腸LSTにおける腫瘍の性格に応じた治療方針. パネルディスカッション4「大腸LSTの病態生理と診断・治療戦略」  [通常講演]
    米田頼晃; 樫田博史; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • 当院におけるPancreatic fluid collectionに対する治療成績. シンポジウム10「壊死性膵炎の予後改善を目指した治療の新展開」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS  [通常講演]
    Peck-Radosavljevic M; Raoul JL; Lee HC; Kudo M; Nakajima K; Cheng AL
    50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015) 2015年04月 ポスター発表 Vienna, Austria
  • Combined sequential use of HAP and ART scores to predict transarterial chemoembolization failure in hepatocellular carcinoma: a multicenter comparative study  [通常講演]
    Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah P; Smirne C; Grossi G; Pirisi M; Kudo M; Sharma R
    50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015) 2015年04月 ポスター発表 Vienna, Austria
  • GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib): A retrospective analysis of prognostic factors for survival  [通常講演]
    Bronowicki JP; Kudo M; Lencioni R; Chen XP; Dagher L; Furuse J; Geschwind JFH; de Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Ye SL; Marrero JA
    50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015) 2015年04月 ポスター発表 Vienna, Austria
  • 肝細胞癌に対してUS-US Fusionを用いたラジオ波焼灼術. ワークショップ7「Navitationに基づいた肝細胞癌IVR治療の最前線」  [通常講演]
    南 康範; 西田直生志; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • VINCENTのvirtual sonographyとAWを用いたRFA前の安全なNavigation方法. ワークショップ7「Navitationに基づいた肝細胞癌IVR治療の最前線」  [通常講演]
    小川 力; 柴峠光成; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • 司会: ワークショップ7「Navitationに基づいた肝細胞癌IVR治療の最前線」  [招待講演]
    工藤正俊
    第101回日本消化器病学会総会 2015年04月 その他 仙台国際センター, 宮城
  • ワークショップ7 基調講演「Navigationに基づいた肝細胞癌IVR治療」  [招待講演]
    工藤正俊
    第101回日本消化器病学会総会 2015年04月 口頭発表（基調） 仙台国際センター, 宮城
  • 機能性ディスペプシア患者における早期慢性膵炎所見について. ワークショップ2「機能性ディスペプシア診療の現状と将来」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • 早期慢性膵炎の診断基準と臨床的意義. パネルディスカッション11「早期慢性膵炎の病態と予後」  [通常講演]
    北野雅之; 門阪薫平; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 シンポジウム・ワークショップパネル（公募） 仙台国際センター, 宮城
  • Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer  [通常講演]
    Togashi Y; Kogita A; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Kitano M; Kudo M; Nishio K
    American Association for Cancer Research Annual Meeting (AACR 2015) 2015年04月 ポスター発表 Philadelphia, USA
  • Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer  [通常講演]
    Kang YK; Seery TE; Kato M; Chakrabarti D; Valota O; Chen Y; Jie T; Pithavala Y; Kudo M
    American Association for Cancer Research Annual Meeting (AACR 2015) 2015年04月 ポスター発表 Philadelphia, USA
  • 座長  [招待講演]
    工藤正俊
    第12回Kinki Liver Clubバニプレビル学術講演会 2015年04月 その他 スイスホテル南海大阪, 大阪
  • 開会・閉会の辞  [招待講演]
    工藤正俊
    第12回Kinki Liver Clubバニプレビル学術講演会 2015年04月 その他 スイスホテル南海大阪, 大阪
  • ポスターセッション座長  [通常講演]
    工藤正俊
    第112回日本内科学会総会 2015年04月 その他 みやこめっせ, 京都
  • 座長: 医学生研修医ポスターセッション  [通常講演]
    工藤正俊
    第112回日本内科学会総会 2015年04月 その他 みやこめっせ, 京都
  • Time intensity curve (TIC)を用いた造影ハーモニックEUSによる膵腫瘍血流評価の検討  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    第28回日本腹部造影エコー・ドプラ診断研究会 2015年04月 口頭発表（一般） 札幌医科大学, 北海道
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第28回日本腹部造影エコー・ドプラ診断研究会 2015年04月 口頭発表（一般） 札幌医科大学, 北海道
  • A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (Orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma  [通常講演]
    Park JW; Cheng AL; Kudo M; Park JH; Liang PC; Hidaka H; Izumi N; Heo J; Lee YJ; Sheen IS; Chiu CF; Arioka H; Morita S; Arai Y
    50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015) 2015年04月 口頭発表（一般） Vienna, Austria
  • 特別講演「肝細胞癌に対する新規分子標的薬の開発動向と免疫チェックポイント阻害薬への期待」  [招待講演]
    工藤正俊
    第18回北九州肝癌治療研究会 2015年03月 口頭発表（招待・特別） リーガロイヤルホテル小倉, 九州
  • Invited Lecture “WFUMB Guidelines”  [招待講演]
    工藤正俊
    American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015) 2015年03月 口頭発表（招待・特別） Florida, USA
  • Invited Lecture “Liver strain”  [招待講演]
    Masatoshi Kudo
    American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015) 2015年03月 口頭発表（招待・特別） Florida, USA
  • 特別講演「透析患者におけるC型肝炎治療」  [招待講演]
    工藤正俊
    南大阪透析患者の肝炎治療を考える会 2015年03月 口頭発表（招待・特別） SAYAKAホール, 大阪
  • Multicenter Observational Study of Reactivation of Hepatitis B Virus Caused by Chemotherapy with Sorafenib  [通常講演]
    Furuse J; Ikeda M; Kondo S; Kudo M; Nadano S; Osaki Y; Kumada T; Ohkawa K; Mizokami M
    24th Conference of APASL 2015年03月 ポスター発表 Istanbul
  • Multicenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors  [通常講演]
    Furuse J; Ikeda M; Kondo S; Kudo M; Nadano S; Osaki Y; Kumada T; Ohkawa K; Mizokami M
    24th Conference of APASL 2015年03月 ポスター発表 Istanbul
  • Plain cone-beam CTによる肝動脈塞栓術の早期治療効果予測  [通常講演]
    南 康範; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊; 柳生行伸; 鶴崎正勝; 村上卓道
    第17回関西肝癌局所療法研究会 2015年03月 口頭発表（一般） 阪急電鉄本社ビル, 大阪
  • Invited Lecture “Recent advances in therapy for advanced hepatocellular carcinoma”  [招待講演]
    工藤正俊
    The 24th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL) 2015年03月 口頭発表（招待・特別） Istanbul, Turkiye
  • 開会の辞  [招待講演]
    工藤正俊
    第11回臨床消化器病フォーラム 2015年03月 その他 ホテルグランヴィア大阪, 大阪
  • 座長: 初心者から中級者に対する超音波検査の新しい取り組み～肝疾患を中心に～  [招待講演]
    工藤正俊
    第9回Kinki GUT Club 2015年02月 その他 帝国ホテル大阪, 大阪
  • 慢性リンパ性白血病の発症を契機にB型肝炎の再活性化から急性肝不全を来し急速な転帰を辿った一例  [通常講演]
    渡部由佳子; 萩原 智; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 櫻井俊治; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第102回例会 2015年02月 口頭発表（一般） 京都テルサ, 京都
  • ストレス応答蛋白を指標とするサーベイランス最適化の可能性. パネルディスカッション2「炎症性腸疾患関連腫瘍のサーベイランス」  [通常講演]
    櫻井俊治; 足立哲平; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第102回例会 2015年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • 当院においてシングルバルーン小腸内視鏡検査を施行した高齢者OGIB症例の臨床的検討. シンポジウム2「消化管出血に対する診療」  [通常講演]
    田中梨絵; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第102回例会 2015年02月 シンポジウム・ワークショップパネル（公募） 京都テルサ, 京都
  • 食道表在癌の日本食道学会拡大内視鏡分類による深達度の検討. ワークショップ10「食道扁平上皮（表在）癌に対する新規拡大内視鏡分類（食道学会分類）の検証」  [通常講演]
    朝隈 豊; 松井繁長; 山田光成; 田中梨絵; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 川崎正憲; 岡崎能久; 米田頼晃; 櫻井俊治; 樫田博史; 工藤正俊
    第11回日本消化管学会総会学術集会 2015年02月 シンポジウム・ワークショップパネル（公募） 京王プラザホテル, 東京
  • 大腸ESD施行時の抗血栓薬の取り扱いの検討  [通常講演]
    足立哲平; 樫田博史; 工藤正俊
    第11回日本消化管学会総会学術集会 2015年02月 口頭発表（一般） 京王プラザホテル, 東京
  • 司会: シンポジウム1「肝動脈塞栓下での血行動態の変化-B-TACEから得られる所見-」  [通常講演]
    工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 その他 東京ビッグサイト「国際会議場」, 東京
  • FNH様の異常門脈域などの示唆に富む病理所見を認めたHCCの一例  [通常講演]
    荒澤壮一; 小川 力; 野田晃世; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 南 貴人; 北村好史; 西平友彦; 石川 亮; 荻野哲朗; 近藤福雄; 工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • 座長: セッション4「画像による病態解析」  [通常講演]
    工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 その他 東京ビッグサイト「国際会議場」, 東京
  • plain cone-beam CTによる肝動脈塞栓術の早期治療効果予測（第2報）  [通常講演]
    南 康範; 村上卓道; 工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • RFA術前のシミュレーションに向けた教育システム. 当院における肝細胞癌に対するディーシービーズ®を用いたDEB-TACEの治療成績  [通常講演]
    小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • 当院における肝細胞癌に対するディーシービーズ®を用いたDEB-TACEの治療成績  [通常講演]
    渡口真史; 鶴崎正勝; 柳生行伸; 沼本勲男; 朝戸信行; 山川美帆; 任 誠雲; 松木 充; 村上卓道; 井上達夫; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • 門脈血栓, 肝内胆管拡張に, 流体の変化を伴い安全にB-TACEを行えた一例  [通常講演]
    出田雅子; 小川 力; 野田晃世; 荒澤壮一; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 石川 亮; 荻野哲朗; 工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • C型慢性肝炎のインターフェロン治療効果から考えるStrain elastographyおよびShear wave elastography同時観察による肝の病態把握の可能性  [通常講演]
    矢田典久; 工藤正俊
    第21回肝血流動態・機能イメージ研究会 2015年02月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • 特別講演「肝がんの分子標的治療～現状と今後の展望～」  [通常講演]
    工藤正俊
    肝疾患学術講演会 2015年01月 口頭発表（招待・特別） ホテルアバローム紀の国2F, 和歌山
  • 特別講演「肝細胞癌診療: 最近の進歩」  [通常講演]
    工藤正俊
    第15回兵庫県肝がん撲滅研究会 2015年01月 口頭発表（招待・特別） ANAクラウンプラザホテル神戸, 兵庫
  • Invited Lecture “The Eastern point of view”  [招待講演]
    工藤正俊
    Eastern & Western Association Liver Tumors (1st ewalt) 2015年01月 Milan, Italy
  • Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC)  [通常講演]
    Cheng AL, Thongprasert S; Lim HY; Sukeepaisarnjaroen, W; Yang TS; Wu CC; Chao Y; Chang L; Kudo M; Ikeda M; Kang Y; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
    2015 Gastrointeritinal Cancers Symposium (ASCO-GI 2015) 2015年01月 ポスター発表 San Francisco, California, USA
  • 特別発言  [招待講演]
    工藤正俊
    TACE Meet the Expert 2015年01月 口頭発表（招待・特別） ホテルモントレグラスミア大阪, 大阪
  • 司会: パネルディスカッション  [招待講演]
    工藤正俊
    TACE Meet the Expert 2015年01月 その他 ホテルモントレグラスミア大阪, 大阪
  • 特別講演「肝癌に対する分子標的治療：現状と今後の展望」  [招待講演]
    工藤正俊
    第1回東北肝癌分子標的治療セミナー 2014年12月 口頭発表（招待・特別） TKP仙台カンファレンスセンター3F, 仙台, 宮城
  • Invited Lecture “Molecular targeted therapy for HCC: Past, present and future perspective”  [招待講演]
    工藤正俊
    24th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO 2014) 2014年12月 Vienna, Austria
  • Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR  [通常講演]
    Yamada M; Kashida H; Tanaka R; Adachi T; Mine H; Takayama M; Okazaki Y; Nagata Y; Nagai T; Kawasaki M; Komeda N; Asakuma Y; Sakurai T; Matsui S; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 ポスター発表 Bali, Indonesia
  • Small-intestinal mucosal injury induced by non-steroidal anti-inflammatory drugs or antiplatelet agents in our hospital  [通常講演]
    Nagai T; Tanaka R; Yamada M; Adachi T; Takayama M; Mine H; Okazaki Y; Komeda Y; Asakuma Y; Sakurai T; Matsui S; Kashida H; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 ポスター発表 Bali, Indonesia
  • The clinical characteristics and treatment of eosinophilic esophagitis  [通常講演]
    Matsui S; Kashida H; Kawasaki M; Asakuma Y; Sakurai T; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 ポスター発表 Bali, Indonesia
  • Two cases of gastric amyloidosis  [通常講演]
    Matsui S; Kashida H; Okamoto K; Asakuma Y; Sakurai T; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 ポスター発表 Bali, Indonesia
  • Colorectal endoscopic submucosal dissection is useful and safe  [通常講演]
    Kashida H; Adachi T; Komeda Y; Sakurai T; Asakuma Y; Takayama M; Mine H; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 口頭発表（一般） Bali, Indonesia
  • Comparison of Japanese primary and secondary regimen of Helicobacter pylori eradication  [通常講演]
    Adachi T; Tanaka R; Yamada M; Takayama M; Mine H; Nagai T; Kawasaki M; Asakuma Y; Okazaki Y; Komeda Y; Sakurai T; Matsui S; Kashida H; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 口頭発表（一般） Bali, Indonesia
  • The usefulness of single-balloon endoscopy for the small bowel lesions  [通常講演]
    Adachi T; Tanaka R; Yamada M; Takayama M; Mine H; Nagai T; Kawasaki M; Asakuma Y; Okazaki Y; Komeda Y; Sakurai T; Matsui S; Kashida H; Kudo M
    Asian Pacific Digetive Week (APDW 2014) 2014年11月 口頭発表（一般） Bali, Indonesia
  • 司会: 特別講演「肝硬変の治療マネジメントup-to date 2014」  [招待講演]
    工藤正俊
    OTSUKA Liver Forum 2014 2014年11月 その他 ホテルニューオータニ東京, 東京
  • 特別講演「びまん性肝疾患診療におけるReal-time Tissue Elastographyの役割」  [招待講演]
    工藤正俊
    日本超音波医学会第41回関西地方会学術集会 2014年11月 口頭発表（招待・特別） ホテルグランヴィア京都, 京都
  • 低音圧Tissue Harmonic Imagingによる造影下穿刺治療画面の提案  [通常講演]
    前川 清; 横川美加; 前野知子; 塩見香織; 井上達夫; 南 康範; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 特別講演「Liver」  [招待講演]
    工藤正俊
    日本超音波医学会第41回関西地方会学術集会 2014年11月 口頭発表（招待・特別） ホテルグランヴィア京都, 京都
  • 座長: 特別企画「Elastography診断のデファクトスタンダードに向けて」  [招待講演]
    工藤正俊
    日本超音波医学会第41回関西地方会学術集会 2014年11月 その他 ホテルグランヴィア京都, 京都
  • Chair "Session 5: Hepatocellular carcinoma, basic and therapy"  [招待講演]
    工藤正俊
    The 11th JSH Single Topic Conference 2014年11月 その他 Hotel Granvia Hiroshima, Hiroshima
  • Walled-off necrosisに対してリタリックステントを用いたEUS下ドレナージ術が有用であった1例  [通常講演]
    古川健太郎; 北野雅之; 大本俊介; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 腸結核の4例  [通常講演]
    中尾剛幸; 樫田博史; 米田頼晃; 山田光成; 田中梨絵; 足立哲平; 峯 宏昌; 高山政樹; 岡崎能久; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊; 佐野博幸; 前西 修; 佐藤隆夫
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • ステロイドが奏効したCronkhite-Canada症候群の1例  [通常講演]
    長原 大; 奥田英之; 秦 康倫; 木下大輔; 永井知行; 岸谷 譲; 川崎俊彦; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • ESDにて切除しえた胃底腺型胃癌の一例  [通常講演]
    高場雄久; 尾崎信人; 松本 望; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 肝硬変を合併した限局性強皮症における難治性上部消化管出血にアルゴンプラズマ凝固法が有効であった一例  [通常講演]
    南 康範; 大本俊介; 松井繁長; 北野雅之; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 高齢者または手術不能の急性胆嚢炎に対するEUS下胆嚢ドレナージ術. ワークショップ1「緊急内視鏡の現状とマネージメント」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 小腸内視鏡から見たovertOGIBの特徴.ワークショップ2「カプセル内視鏡とバルーン内視鏡の現状と展望」  [通常講演]
    岡﨑能久; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 当院におけるEUS-BDの成績. パネルディスカッション2「胆膵疾患における診断と治療」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 司会: 特別講演「消化器内視鏡医学の最新動向と今後求められる方向性」  [招待講演]
    工藤正俊
    2014年11月 その他 大阪国際交流センター, 大阪
  • 大腸ESD施行時の出血のリスクについての検討. パネルディスカッション1「内視鏡治療における偶発症の予防と対処法」  [通常講演]
    足立哲平; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第93回支部例会 2014年11月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 開会の挨拶  [招待講演]
    工藤正俊
    第32回南大阪肝疾患研究会 2014年11月 その他 ホテル第一堺, 大阪
  • Involvement of stress response protein crip in refractory inflammatory bowel diseases and colitis-associated cancer. Symposium 1 “Cancer prevention and early diagnosis”  [通常講演]
    Sakurai T; Kashida H; Kudo M
    The 25th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 2014年11月 シンポジウム・ワークショップパネル（公募） ホテル日航福岡
  • How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained?  [通常講演]
    Roayaie S; Jibara G; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Johnson P; Kudo M; Roberts LR; Sherman M
    65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014) 2014年11月 ポスター発表 Boston, USA
  • Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT  [通常講演]
    Minami Y; Kudo M
    65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014) 2014年11月 ポスター発表 Boston, USA
  • Pathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in nonalcoholic fatty liver disease  [通常講演]
    Nishida N; Yada N; Chishina H; Arizumi T; Takita M; Kitai S; Inoue T; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kudo M
    65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014) 2014年11月 ポスター発表 Boston, USA
  • Invited Lecture “Interventaional and contrast EUS for pancreatobiliary disease”  [招待講演]
    工藤正俊
    The 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014) 2014年10月 口頭発表（招待・特別） Kuala Lumpur, Malaysia
  • Invited Lecture “Fusion imaging for treatment guidance of hepatic tumours”  [招待講演]
    工藤正俊
    The 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014) 2014年10月 口頭発表（招待・特別） Kuala Lumpur, Malaysia
  • H. Pylori陰性C-0胃症例のたこいぼびらんに認めた腸上皮化生についての検討  [通常講演]
    辻 直子; 尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 梅原康湖; 谷池聡子; 森村正嗣; 米田 円; 山田 哲; 落合 健; 前倉俊治; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 経乳頭処置困難総胆管結石に対するrendezvous法の手技と成績. ワークショップ21「胆管結石治療困難例への戦略《ビデオ》」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • EUSガイド下胆道ドレナージ術における金属ステントの有用性. パネルディスカッション17「悪性消化管・胆管閉塞に対する内視鏡的金属ステント治療の進歩」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • Kitano M; Sakamoto H; Kudo M
    Japan Digestive Disease Week 2014 (JDDW) 2014年10月 口頭発表（一般） Kobe
  • PPI内服による胃底腺ポリープの変化  [通常講演]
    河野 匡; 梅原康湖; 辻 直子; 尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 森村正嗣; 山田 哲; 米田 円; 落合 健; 前倉俊治; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 腫瘍径1cm以内の膵癌の特徴と診断ストラテジー. ワークショップ15「微小膵癌発見のための検査・診断法」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 早期慢性膵炎におけるEUS画像所見と臨床的意義の検討. ワークショップ14「慢性膵炎とその進展予防」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 胆膵良性疾患の救命救急におけるEUS下ドレナージ術の位置づけ. ワークショップ13「Life saving endoscopy」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 西田直生志; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 鎌田 研; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 口頭発表（一般） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 当院における食道表在癌の日本食道学会拡大内視鏡分類による深達度診断の検討  [通常講演]
    朝隈 豊; 松井繁長; 南 知行; 山田光成; 田中梨絵; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 櫻井俊治; 樫田博史; 工藤正俊; 白石 治; 安田卓司
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • ピロリ菌感染に対する胃粘膜防御機構. ワークショップ4「胃/十二指腸粘膜防御とその破綻-revisited」  [通常講演]
    櫻井俊治; 樫田博史; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 背景肝によるReal-time Tissue Elastography画像の違い-HBVとHCVとの比較-. パネルディスカッション8「画像診断を駆使した肝疾患治療の最前線」  [通常講演]
    矢田典久; 河田則文; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 その他 神戸国際展示場, 兵庫
  • 座長: ランチョンセミナー34「HCCの診断と治療UP TO DATE」  [通常講演]
    工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 その他 ポートピアホテル, 兵庫
  • 当院におけるヘリコバクターピロリ除菌の治療成績の検討  [通常講演]
    足立哲平; 南 知行; 田中梨絵; 山田光成; 高山政樹; 峯 宏昌; 永井知行; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 腸粘膜防御機構におけるストレス応答蛋白の役割. ワークショップ1「腸粘膜防御機構の維持と再生をめざして」  [通常講演]
    櫻井俊治; 足立哲平; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 当院における肝転移に対する経皮的ラジオ波焼灼術  [通常講演]
    南 康範; 中居卓也; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • VINCENTの仮想超音波システムとGE社のワークステーションAWを用いたRFA前のシミュレーション.  [通常講演]
    小川 力; 森岡弓子; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • B-modeで描出困難な肝癌に対するFusion imaging+造影USガイドでのラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 井上達夫; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 ポスター発表 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 櫻井俊治; 樫田博史; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • 大本俊介; 北野雅之; 工藤正俊
    第22回日本消化器関連学会週間JDDW2014（第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会） 2014年10月 シンポジウム・ワークショップパネル（公募） 神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫
  • Prospective multicenter randomized controlled trial of histological diagnostic yield comparing 25G EUG-FNA needles with and without a core trap in solid pancreatic masses: analysis of factors affecting tissue acquisition and diagnostic accuracy  [通常講演]
    Nebiki H; Yanagisawa A; Yasukawa S; Kamata K; Kudo M; Ogura T; Higuchi K; Fukutake N; Ashida R; Yamasaki T; Hirose S; Hoki N; Asada M; Yazumi S; Takaoka M; Okazaki K; Matsuda F; Okabe Y; Kitano M
    United European Gastroenterology Week (UEGW 2014) 2014年10月 ポスター発表 Vienna, Austria
  • Validation of staging systems for hepatocellular carcinoma: a comparison of the BM-JIS score, the JIS score and the BCLC staging  [通常講演]
    Kitai S; Kudo M; Nishida N; Izumi N; Sakamoto M; Matsuyama Y; Ichida T; Nakashima O; Matsui O; Ku Y; Kokudo N; Makuuchi M; Liver Cancer Study; Group of Japan
    United European Gastroenterology Week (UEGW 2014) 2014年10月 ポスター発表 Vienna, Austria
  • 悪性消化管、胆道狭窄に対する治療戦略～EUS下胆道ドレナージと消化管ステントによるdouble stentingの有用性～  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    第63回近畿膵疾患談話会 2014年10月 口頭発表（一般） エーザイ株式会社大阪コミュニケーションオフィス, 大阪
  • 甲状腺クリーゼを契機に急性肝不全を発症した1例  [通常講演]
    山本貴子; 萩原 智; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 北井 聡; 井上達夫; 矢田典久; 南 康範; 櫻井俊治; 上嶋一臣; 西田直生志; 工藤正俊; 庭野史丸; 池上博司
    日本消化器病学会近畿支部第101回例会 2014年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 肝左葉切除後の肝門部胆管閉塞に対し超音波内視鏡下胆管胃吻合術（EUS-HGS）が奏効した一例  [通常講演]
    加藤 寛; 宮田 剛; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    日本消化器病学会近畿支部第101回例会 2014年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • EUS-FNAにて診断可能であった、腎癌膵転移の1例  [通常講演]
    濱田隆介; 木下大輔; 秦 康倫; 奥田英之; 永井知行; 岸谷 譲; 川崎俊彦; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器病学会近畿支部第101回例会 2014年10月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 大腸表在癌・腺腫に対する大腸ESDの現況について. ワークショップ1「消化管表在癌に対する内視鏡的治療の現況と位置づけ」  [通常講演]
    米田頼晃; 樫田博史; 櫻井俊治; 工藤正俊
    日本消化器病学会近畿支部第101回例会 2014年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 潰瘍性大腸炎における腸管感染症の合併. ワークショップ3「急性消化管感染症の臨床」  [通常講演]
    田中梨絵; 櫻井俊治; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第101回例会 2014年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • EUS下胆嚢ドレナージ術の有用性. ワークショップ2「肝胆膵疾患の診断と治療の進歩」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    日本消化器病学会近畿支部第101回例会 2014年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 当院におけるNSAIDs/LDAによる小腸粘膜傷害の現況. シンポジウム1「NSAIDs/LDAによる薬剤性消化管障害」  [通常講演]
    永井知行; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第101回例会 2014年10月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • An International observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS  [通常講演]
    Raoul JL; Peck-Radosavljevic M; Lee HC; Kudo M; Nakajima K; Cheng AL; on behalf of the; OPTIMIS investigators
    European Society for Medical Oncology Congress (ESMO 2014) 2014年09月 ポスター発表 Madrid, Spain
  • Randomised study of axitinib (Axi) plus best supportive care (BSC) versus placebo (Pbo) plus BSC in patients with advanced hepatocellular carcinoma (HCC) following prior antiangiogenic therapy  [通常講演]
    Kang YK; Yau T; Park JW; Boucher E; Lim HY; Poon RTP; Lee TY; Obi S; Chan SL; Qin SK; Kim RD; Tang J; Valota O; Chakrabarti D; Kudo M
    European Society for Medical Oncology Congress (ESMO 2014) 2014年09月 ポスター発表 Madrid, Spain
  • Ramucirumab (RAM; IMC-1121B) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib: Results from the Randomized Phase III REACH Study  [招待講演]
    Zhu A; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung H; Baron A; Pfiffer T; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada P; Yang L; Schwartz J; Park J
    European Society for Medical Oncology Congress (ESMO 2014) 2014年09月 口頭発表（招待・特別） Madrid, Spain
  • Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer  [通常講演]
    Sakurai T; Kudo M; Nishida N; Fujita J; Kashida H
    The 73rd Annual Meeting of the Japanese Cancer Association 2014年09月 口頭発表（一般） Pacifico Yokohama
  • VINCENTの仮想超音波とAWを併用した経皮的RFAのシミュレーション. シンポジウム2「経皮的治療もしくはInterventional Radiologyにおけるシミュレーション・ナビゲーション技術の最近の工夫」  [通常講演]
    小川 力; 荒澤壮一; 出田雅子; 柴峠光成; 工藤正俊
    第9回肝癌治療シミュレーション研究会 2014年09月 シンポジウム・ワークショップパネル（公募） 大阪国際会議場, 大阪
  • 座長"症例検討会"  [招待講演]
    工藤正俊
    第9回肝癌治療シミュレーション研究会 2014年09月 その他 大阪国際会議場, 大阪
  • 招待講演「造影超音波の新しい展開: 肝癌スクリーニングと肉眼形態診断への応用」  [招待講演]
    工藤正俊
    日本超音波医学会第24回九州地方会学術集会 2014年09月 口頭発表（招待・特別） 福岡国際会議場, 福岡
  • 座長: 肝細胞癌のサブクラス分類-Molecular Classificationと病理からの視点-  [招待講演]
    工藤正俊
    第9回大阪肝臓ミーティング 2014年09月 その他 ANAクラウンプラザホテル大阪, 大阪
  • 座長: C型肝炎に対するDAAs治療-当院の使用経験も含めて-  [招待講演]
    工藤正俊
    大阪C型肝疾患DAAs治療セミナー 2014年09月 その他 スイスホテル南海大阪, 大阪
  • B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial (Nct01507168)  [通常講演]
    Kudo M; Ueshima K; Osaki Y; Hirooka M; Imai Y; Aso K; Numata K; Ichinose M; Kumada T; Izumi N; Sumino Y; Akazawa K
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 口頭発表（一般） Kyoto, Japan
  • Chair “e-poster viewing tour and networking break”  [招待講演]
    工藤正俊
    8th ILCA Annual Conference 2014年09月 その他 Hotel Granvia Kyoto, Kyoto
  • STORM: A phase III, randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma  [通常講演]
    Llovet JM; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roaayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Le Berre MA; Meinhardt G; Bruix J; on behalf of the; STORM investigators
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 口頭発表（一般） Hotel Granvia Kyoto
  • Newly simulated virtual ultrasound sonography software before RFA  [通常講演]
    Ogawa C; Kudo M
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 ポスター発表 Hotel Granvia Kyoto
  • Proposals for improvement of the AJCC/UICC and Japanese staging systems for intrahepatic cholangiocarcinoma in review of the Japanese nationwide database  [通常講演]
    Sakamoto Y; Kokudo N; Matsuyama Y; Izumi N; Ichida T; Ku Y; Kudo M; Sakamoto M; Takayama T; Nakashima O; Matsui O
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 口頭発表（一般） Hotel Granvia Kyoto, Japan
  • Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT  [通常講演]
    Minami Y; Murakami T; Kudo M
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 ポスター発表 Hotel Granvia Kyoto, Japan
  • How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained? Answers from the Bridge database  [通常講演]
    Roayaie S; Jibara G; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Johnson P; Kudo M; Roberts LR; Sherman M
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 ポスター発表 Hotel Granvia Kyoto, Japan
  • Tumor response to transarterial chemoembolization in unresectable hepatocellular carcinoma patients in clinical practice: findings from the GIDEON database  [通常講演]
    Kudo M; Marrero J; Lencioni R; Nakajima K; Ye SL
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 ポスター発表 Hotel Granvia Kyoto, Japan
  • Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC) (NCT01507168)  [通常講演]
    Kudo M; Yen CJ; Daniele B; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Rutman O; Chen YC; Lee R; Abou-Alfa GK
    8th Annual Conference, International Liver Cancer Association (ILCA 2014) 2014年09月 ポスター発表 Hotel Granvia Kyoto, Japan
  • 工藤正俊
    The 8th Annual Conference, International Liver Cancer Association (ILCA) 2014年09月 口頭発表（招待・特別） Hotel Granvia Kyoto, Japan
  • 特別講演「肝細胞癌の分子標的治療: 現状と今後の課題」  [招待講演]
    工藤正俊
    TACE Refractory Focus Expert Meeting 2014年08月 口頭発表（招待・特別） JRクレメントホテル高松, 香川
  • 座長"新たなTACE不応の定義をめぐって"  [通常講演]
    工藤正俊
    Nexavar HCC Web Conference 2014年07月 その他
  • Chair "Symposium 2 “Treatment strategy for advanced stage hepatocellular carcinoma after approval of sorafenib”  [招待講演]
    工藤正俊
    The 12th Annual Meeting of Japanese Society of Medical Oncology 2014年07月 その他 Fukuoka International Congress Center, Fukuoka
  • Chair "Session 10 “APPLE consensus workshop: searching consensus for controversies”  [招待講演]
    工藤正俊
    The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2014年07月 その他 The Grand Hotel, Taipei, Taiwan
  • Chair "Session 5 “Prof. Juei-Low Sung Award Lecture”  [招待講演]
    工藤正俊
    The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2014年07月 その他 The Grand Hotel, Taipei, Taiwan
  • 当院におけるStage 0/I膵癌の特徴～膵癌早期診断ストラテジーの標準化にむけて～, パネルディスカッション2「膵癌早期診断を目指して」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊; 竹山宜典
    第45回日本膵臓学会大会 2014年07月 シンポジウム・ワークショップパネル（公募） 北九州国際会議場, 北九州
  • 膵癌早期診断におけるEUSの位置づけ  [通常講演]
    北野雅之; 鎌田 研; 工藤正俊
    第45回日本膵臓学会大会 2014年07月 口頭発表（一般） 北九州国際会議場, 北九州
  • Invited Lecture “Lessons from the TACE trials”  [招待講演]
    工藤正俊
    The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2014年07月 口頭発表（招待・特別） The Grand Hotel, Taipei, Taiwan
  • Chair "Session 6 “Future treatment for HCC”  [招待講演]
    工藤正俊
    The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2014年07月 その他 The Grand Hotel, Taipei, Taiwan
  • Kudo M
    The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2014年07月 その他 The Grand Hotel, Taipei, Taiwan
  • Treatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib)  [通常講演]
    Ye SL; Lencioni R; Marrero JA; Venook AP; Nakajima K; Kudo M
    The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2014年07月 ポスター発表 Taipei, Taiwan
  • Value of semi-annual follow-up of EUS in patients with IPMN. International Teleconference 2 “Intraductal papillary mucinous neoplasm of the pancreas: clinical experiences in Asian countries”  [通常講演]
    Kamata K; Kitano M; Kudo M
    the 45th Annual Meeting of the Japan Pancreas Society 2014年07月 口頭発表（一般） Kitakyushu International Conference Center, Japan
  • 膵液瘻に対するEUS下ドレナージ術の有用性. ミニシンポジウム3「膵空腸吻合の工夫と術後管理」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊; 竹山宜典
    第45回日本膵臓学会大会 2014年07月 シンポジウム・ワークショップパネル（公募） 北九州国際会議場, 北九州
  • 自己免疫性膵炎の診断, 治療におけるEUSの役割  [通常講演]
    大本俊介; 北野雅之; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    第45回日本膵臓学会大会 2014年07月 口頭発表（一般） 北九州国際会議場, 北九州
  • 早期慢性膵炎画像所見と臨床症状との関係. ワークショップ1「早期慢性膵炎の現状」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第45回日本膵臓学会大会 2014年07月 シンポジウム・ワークショップパネル（公募） 北九州国際会議場, 北九州
  • 膵神経内分泌腫瘍に対するEUSの有用性の検討. パネルディスカッション1「PNET診療ガイドラインをめぐって」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第45回日本膵臓学会大会 2014年07月 シンポジウム・ワークショップパネル（公募） 北九州国際会議場, 北九州
  • 非切除膵癌の癌性疼痛に対するEUS下腹腔内神経叢融解術の治療戦略. シンポジウム2「膵癌に対する新たな治療戦略-非切除膵癌」  [通常講演]
    坂本洋城; 北野雅之; 工藤正俊
    第45回日本膵臓学会大会 2014年07月 シンポジウム・ワークショップパネル（公募） 北九州国際会議場, 北九州
  • 工藤正俊
    Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) 2014年07月 口頭発表（招待・特別） Grand Hotel Taipei, Taiwan
  • Invited Lecture “HCC guidelines in the region: an update-Japan”  [招待講演]
    Masatoshi Kudo
    Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) 2014年07月 口頭発表（招待・特別） Grand Hotel Taipei, Taiwan
  • B-modeで描出困難な肝細胞癌に対するFusion-imaging+造影USガイドでのラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 工藤正俊
    第14回肝血流動態・機能イメージ研究会 2014年07月 口頭発表（一般） オーバルホール, 大阪
  • 当院における肝細胞癌に対するディーシービーズ®を用いたTACEの初期経験  [通常講演]
    渡口真史; 鶴﨑正勝; 柳生行伸; 沼本勲男; 朝戸信行; 山川美帆; 任 誠雲; 松木 充; 村上卓道; 井上達夫; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊
    第14回肝血流動態・機能イメージ研究会 2014年07月 口頭発表（一般） オーバルホール, 大阪
  • 当院におけるマイクロバルーン閉塞下肝動脈化学塞栓療法（B-TACE）導入後の検討  [通常講演]
    千品寛和; 田北雅弘; 有住忠晃; 北井 聡; 井上達夫; 矢田典久; 南 康範; 萩原 智; 上嶋一臣; 西田直生志; 朝戸信行; 任 誠雲; 柳生行伸; 松木 充; 鶴﨑正勝; 村上卓道; 工藤正俊
    第14回肝血流動態・機能イメージ研究会 2014年07月 口頭発表（一般） オーバルホール, 大阪
  • 司会"Debates Session “大腸がん肝転移の治療戦略を如何に組み立てるか？"  [通常講演]
    工藤正俊
    第14回関西肝血流動態・機能イメージ研究会 2014年07月 その他 オーバルホール, 大阪
  • Early response prediction of hepatocellular carcinoma to transcatheter therapies using intraprocedual plain cone-beam CT.  [通常講演]
    Minami Y; Kudo M; Yagyu Y; Murakami T
    Computer Assisted Radiology and Surgery (CARS 2014), 28th International Congress and Exhibition 2014年06月 口頭発表（一般） Fukuoka, Japan
  • 術前診断が可能であった胆管原発悪性リンパ腫の1例  [通常講演]
    秦 康倫; 木下大輔; 奥田英之; 永田嘉昭; 岸谷 譲; 川崎俊彦; 原 譲次; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊
    日本消化器内視鏡学会近畿支部第92回支部例会 2014年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 急性壊死性食道炎の1例  [通常講演]
    池田 守; 足立哲平; 南 知宏; 田中梨絵; 山田光成; 高山政樹; 峯 宏昌; 永井知行; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第92回支部例会 2014年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • プロトンポンプ阻害剤長期投与により胃底腺ポリープが増大したと思われる1例  [通常講演]
    尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊
    日本消化器内視鏡学会近畿支部第92回支部例会 2014年06月 口頭発表（一般） 大阪国際交流センター, 大阪
  • 当院で内視鏡治療を施行した表在型バレット食道腺癌の検討. シンポジウム「GERD～バレット食道癌の現状」  [通常講演]
    高山政樹; 松井繁長; 工藤正俊
    日本消化器内視鏡学会近畿支部第92回支部例会 2014年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 大腸ESD後潰瘍の縫縮における小切開法の導入, ビデオワークショップ1「ESDの工夫―安全性と効率の両立を目指して」  [通常講演]
    足立哲平; 樫田博史; 工藤正俊
    日本消化器内視鏡学会近畿支部第92回支部例会 2014年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • 当院におけるEUS下胆道ドレナージの工夫と成績. ビデオワークショップ2「閉塞性黄疸の治療戦略」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    日本消化器内視鏡学会近畿支部第92回支部例会 2014年06月 シンポジウム・ワークショップパネル（公募） 大阪国際交流センター, 大阪
  • ソラフェニブ投与にてPD判定であった進行肝細胞癌患者の検討  [通常講演]
    有住忠晃; 上嶋一臣; 千品寛和; 田北雅弘; 北井 聡; 井上達夫; 矢田典久; 萩原 智; 南 康範; 櫻井俊治; 西田直生志; 工藤正俊
    第10回日本肝がん分子標的治療研究会 2014年06月 ポスター発表 淡路夢舞台国際会議場, 兵庫
  • 香川県下におけるソラフェニブの使用経験～開始容量, 肝機能, 副作用の検討～. ワークショップ「分子標的薬に関する多施設共同研究から得られた知見」  [通常講演]
    小川 力; 荒澤壮一; 柴峠光成; 馬場伸介; 妹尾知典; 永野拓也; 高口浩一; 谷 丈二; 三好久昭; 米山弘人; 正木 勉; 守屋昭男; 安東正晴; 出口章広; 國土泰孝; 工藤正俊
    第10回日本肝がん分子標的治療研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 淡路夢舞台国際会議場, 兵庫
  • 総括発言「新規分子標的薬剤の動向と展望」  [招待講演]
    工藤正俊
    第10回肝がん分子標的治療研究会 2014年06月 シンポジウム・ワークショップパネル（指名） 淡路夢舞台国際会議場, 兵庫
  • Special Lecture “LCSGJ consensus”  [通常講演]
    Masatoshi Kudo
    The 4th International Kyoto Liver Cancer Symposium (IKLS) 2014年06月 口頭発表（招待・特別） Kyoto International Conference Center, Kyoto
  • Special Lecture “GIDEON final analysis data: regional difference”  [通常講演]
    Masatoshi Kudo
    The 4th International Kyoto Liver Cancer Symposium (IKLS) 2014年06月 口頭発表（招待・特別） Kyoto International Conference Center, Kyoto
  • Special Lecture “Emerging role of CEUS”  [通常講演]
    Masatoshi Kudo
    The 4th International Kyoto Liver Cancer Symposium (IKLS) 2014年06月 口頭発表（招待・特別） Kyoto International Conference Center, Kyoto
  • Chair "Luncheon Seminar II“Current challenges to manage HCC”  [通常講演]
    Masatoshi Kudo
    The 4th International Kyoto Liver Cancer Symposium (IKLS) 2014年06月 その他 Kyoto International Conference Center, Kyoto
  • Chair "Luncheon Seminar I“Current challenge to chronic hepatitis C”  [通常講演]
    Masatoshi Kudo
    The 4th International Kyoto Liver Cancer Symposium (IKLS) 2014年06月 その他 Kyoto International Conference Center, Kyoto
  • Chair "Session II “Diagnosis of pathological early HCC”  [通常講演]
    Masatoshi Kudo
    The 4th International Kyoto Liver Cancer Symposium (IKLS) 2014年06月 その他 Kyoto International Conference Center, Kyoto
  • 現行のTACE不応基準の妥当性の検証. コンセンサスミーティング2「TACE不応の定義をめぐって」  [通常講演]
    上嶋一臣; 有住忠晃; 工藤正俊
    第50回日本肝癌研究会 2014年06月 口頭発表（一般） 国立京都国際会館, 京都
  • 全国原発性肝癌追跡調査データからみた第5版取扱規約における肝内胆管癌の病期分類の問題点について. ワークショップ5「肝内胆管癌に対する治療戦略」  [通常講演]
    阪本良弘; 國土典宏; 松山 裕; 泉 並木; 市田隆文; 具 英成; 工藤正俊; 坂元亨宇; 高山忠利; 中島 収; 松井 修
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • ソラフェニブ開始後3年以上の長期生存例の臨床的特徴に関する検討. ワークショップ4「進行肝細胞癌に対する分子標的治療開始後の長期生存例（3年以上）」  [通常講演]
    上嶋一臣; 有住忠晃; 工藤正俊
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • 肝細胞癌(HCC)合併の非代償性肝硬変患者に対する局所治療の有用性についての検討. ワークショップ1「Child-Pugh C肝癌に対する治療」  [通常講演]
    北井 聡; 工藤正俊; 西田直生志; 泉 並木; 坂元亨宇; 松山 裕; 市田隆文; 中島 収; 松井 修; 具 英成; 國土典宏; 幕内雅敏
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • 進行肝細胞癌を対象としたソラフェニブとシスプラチン肝動注の併用療法. パネルディスカッション3「肝癌における分子標的治療の近未来展望」  [通常講演]
    清水 怜; 池田公史; 森本 学; 加藤弥菜; 河田則文; 工藤正俊; 中森正二; 金子周一; 杉本理恵; 古瀬純司; 奥坂拓志
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • 進行肝細胞癌に対するソラフェニブ+TACE併用療法. パネルディスカッション3「肝癌における分子標的治療の近未来展望」  [通常講演]
    有住忠晃; 上嶋一臣; 工藤正俊
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • ヒト肝発癌における酸化ストレスとエピゲノム変異の関連. パネルディスカッション2「ゲノム・エピゲノム解析に基づく肝癌診療の将来展望」  [通常講演]
    萩原 智; 西田直生志; 工藤正俊
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • Dual-energy CTを用いた肝脂肪定量. パネルディスカッション1「肝画像診断のイノベーション」  [通常講演]
    兵頭朋子; 矢田典久; 前西 修; 工藤正幸; 朝戸信行; 柳生行伸; 鶴崎正勝; 松木 充; 足利竜一朗; 石井一成; 工藤正俊; 村上卓道
    第50回日本肝癌研究会 2014年06月 シンポジウム・ワークショップパネル（公募） 国立京都国際会館, 京都
  • Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC) (NCT01507168)  [通常講演]
    Yen CJ; Daniele B; Kudo M; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Rutman O; Chen YC; Lee R; Abou-Alfa GK
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 ポスター発表 Chicago, USA
  • OPTIMIS: an International observational study to assess the use of sorafenib after transarterial chemoembolization in patients with hepatocellular carcinoma  [通常講演]
    Peck-Radosavljevic M; Raoul JL; Lee HC; Kudo M; Nakajima K; Cheng AL; on behalf of the; OPTIMIS Investigators
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 ポスター発表 Chicago, USA
  • Regorafenib in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: an ongoing randomized, double-blind, phase III trial  [通常講演]
    Bruix J; Finn RS; Kudo M; Llovet JM; Qin S; Le Berre MA; Wagner A; Cheng AL
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 ポスター発表 Chicago, USA
  • STORM: a phase III, randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma  [通常講演]
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Le Berree MA; Meinhardt G; Llovet JM on; behalf of the; STORM Investigators
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 口頭発表（一般） Chicago, USA
  • Multicenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors  [通常講演]
    Kondo S; Ikeda M; Kudo M; Nadano S; Furuse J; Osaki Y; Kumada T; Ohkawa K; Mizokami M
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 ポスター発表 Chicago, USA
  • A multicenter, open-label, phase 3 trial to compare the efficacy and safety of Lenvatinib (E7080) versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma  [通常講演]
    Finn RS; Cheng AL; Ikeda K; Kudo M; Tamai T; Dutcus C; Younger S; Han KH; Qin S; Raymond E
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 ポスター発表 Chicago, USA
  • Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.  [通常講演]
    Vergote I; Ball D; Kudo M; Sachdev P; Matijevic M; Kadowaki T; Funahashi Y; Flaherty K
    American Society of Clinical Oncology (ASCO) 50th Annual Meeting 2014年06月 ポスター発表 Chicago, USA
  • plain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測. ワークショップ13「肝癌に対する肝動脈塞栓療法の新展開」  [通常講演]
    南 康範; 村上卓道; 工藤正俊
    第50回日本肝臓学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） ホテルニューオータニ, 東京
  • VINCENTの仮想超音波システムを用いた簡便な腫瘍, 走行血管の描出と安全な穿刺ラインの同定方法  [通常講演]
    小川 力; 柴峠光成; 工藤正俊
    第50回日本肝臓学会総会 2014年05月 ポスター発表 ホテルニューオータニ, 東京
  • 高齢者Genotype 1b高ウイルス量のC型慢性肝炎患者における治療効果と安全性～ReGIT-J試験の層別解析～  [通常講演]
    西川浩樹; 榎本平之; 斎藤正紀; 絵澤信弘; 津田泰宏; 樋口和秀; 岡崎和一; 関 寿人; 金 守良; 本合 泰; 城村尚登; 西田直生志; 工藤正俊; 大﨑往夫; 西口修平
    第50回日本肝臓学会総会 2014年05月 口頭発表（一般） ホテルニューオータニ, 東京
  • 肝外再発例の肝癌DNAメチル化プロファイルを用いた治癒切除後の早期再発予測  [通常講演]
    西田直生志; 中居卓也; 工藤正俊
    第50回日本肝臓学会総会 2014年05月 口頭発表（一般） ホテルニューオータニ, 東京
  • 超音波エラストグラフィによる肝線維化・炎症の評価. ワークショップ8「肝臓病理に画像診断はどこまで迫れたか」  [通常講演]
    矢田典久; 工藤正俊
    第50回日本肝臓学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） ホテルニューオータニ, 東京
  • 特別講演「今後の展望」  [通常講演]
    工藤正俊
    第50回日本肝臓学会総会 2014年05月 口頭発表（招待・特別） ホテルニューオータニ, 東京
  • 悪性胃十二指腸狭窄に対する治療戦略～胆道狭窄合併例に対するEUS下胆道ドレナージ術も含めて～, ワークショップ16「消化管狭窄の内視鏡治療上部」  [通常講演]
    山雄健太郎; 北野雅之; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） 福岡国際会議場, 福岡
  • 胃アミロイドーシスの2例  [通常講演]
    岡元寿樹; 高山政樹; 峯 宏昌; 山田光成; 足立哲平; 永井知行; 川崎正憲; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 ポスター発表 福岡国際会議場, 福岡
  • 当院における超高齢者（85歳以上）の下部内視鏡検査・治療の現況  [通常講演]
    永井知行; 樫田博史; 工藤正俊; 南 知宏; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 高山政樹; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長
    第87回日本消化器内視鏡学会総会 2014年05月 ポスター発表 福岡国際会議場, 福岡
  • 膵神経内分泌腫瘍に対するEUSの有用性  [通常講演]
    今井 元; 北野雅之; 工藤正俊; 大本俊介; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 坂本洋城
    第87回日本消化器内視鏡学会総会 2014年05月 口頭発表（一般） 福岡国際会議場, 福岡
  • EUSを主としたIPMNの診断および経過観察の成績～IPMN国際診療ガイドライン2012年度版の妥当性の検証～. シンポジウム6「分枝型膵IPMNの診断・悪性度の評価における内視鏡の役割」  [通常講演]
    鎌田 研; 北野雅之; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） 福岡国際会議場, 福岡
  • 当院におけるEUS-FNAのラーニングカーブについての検討: EUS-FNAの診断率. ワークショップ8「胆膵内視鏡における質の高い技術習得を目指した指導法の工夫」  [通常講演]
    坂本洋城; 北野雅之; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） 福岡国際会議場
  • 当院における直腸内分泌腫瘍（NET）の診断と治療成績  [通常講演]
    山田光成; 樫田博史; 南 知宏; 田中梨絵; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 口頭発表（一般） 福岡国際会議場, 福岡
  • 急性胆嚢炎および胆管炎例に対するEUS下胆嚢ドレナージ術の有用性  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 口頭発表（一般） 福岡国際会議場, 福岡
  • EUSガイド下胆道ドレナージ術におけるコツとトラブルシューティング. パネルディスカッション3「胆膵インターベンショナルEUSの偶発症とその対策」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） 福岡国際会議場, 福岡
  • EUS下腹腔内神経叢融解術の偶発症とその対策, パネルディスカッション3「胆膵インターベンショナルEUSの偶発症とその対策」  [通常講演]
    坂本洋城; 北野雅之; 工藤正俊
    第87回日本消化器内視鏡学会総会 2014年05月 シンポジウム・ワークショップパネル（公募） 福岡国際会議場, 福岡
  • 特別講演「ソナゾイド造影超音波の新たな展開～肝癌スクリーニングと肉眼形態診断への応用～」  [招待講演]
    工藤正俊
    北信消化器画像セミナー 2014年05月 口頭発表（招待・特別） 長野 第一三共株式会社
  • ランチョンセミナー17「ソナゾイド造影超音波の新たな展開～肝癌スクリーニングと肉眼形態診断への応用～」  [通常講演]
    工藤正俊
    日本超音波医学会第87回学術集会 2014年05月 口頭発表（招待・特別） パシフィコ横浜
  • 超音波検査で観察し得た新生児chest wall hamartomaの一例  [通常講演]
    前野知子; 横川美加; 辻 裕美子; 塩見香織; 前川 清; 工藤正俊; 八木 誠; 上杉忠雄; 筑後孝章; 佐藤隆夫
    日本超音波医学会第87回学術集会 2014年05月 口頭発表（一般） パシフィコ横浜
  • 座長: Guideline of CEUS  [招待講演]
    工藤正俊
    第6回アジア造影超音波会議（ACUCI 2014） 2014年05月 その他 パシフィコ横浜
  • 胆膵疾患における超音波内視鏡による造影超音波診断  [通常講演]
    北野雅之; 工藤正俊
    第6回アジア造影超音波会議 2014年05月 口頭発表（一般） パシフィコ横浜
  • 造影ハーモニックEUS（CH-EUS）における膵腫瘍の血流評価の有用性について  [通常講演]
    大本俊介; 田中梨絵; 門阪薫平; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 坂本洋城; 北野雅之; 工藤正俊
    日本超音波医学会第87回学術集会 2014年05月 口頭発表（一般） パシフィコ横浜
  • ランチョンセミナー3「肝線維化診断におけるReal-time Tissue Elastographyの有用性」  [招待講演]
    工藤正俊
    日本超音波医学会第87回学術集会 2014年05月 口頭発表（招待・特別） パシフィコ横浜
  • エラストグラフィと肝血清マーカーを用いた肝線維化診断-臨床応用に向けて-  [通常講演]
    矢田典久; 工藤正俊
    日本超音波医学会第87回学術集会 2014年05月 口頭発表（一般） パシフィコ横浜
  • 組織弾性評価手法の世界的動向と消化器領域への展開, シンポジウム領域横断2「組織弾性評価手法の現状と将来動向」  [招待講演]
    工藤正俊
    日本超音波医学会第87回学術集会 2014年05月 口頭発表（招待・特別） パシフィコ横浜
  • EUS下膵管ドレナージ術.  [招待講演]
    北野雅之; 工藤正俊
    日本消化器内視鏡学会附置研究会超音波内視鏡下治療研究会共同企画「消化器領域におけるEUS-FNAの現在とこれから」, 日本超音波医学会第87回学術集会 2014年05月 口頭発表（招待・特別） パシフィコ横浜
  • 座長: シンポジウム領域横断2「組織弾性評価手法の現状と将来動向」  [招待講演]
    工藤正俊
    日本超音波医学会第87回学術集会 2014年05月 その他 パシフィコ横浜
  • Moderator: Local ablation for hepatic tumors- Part Ⅰ  [招待講演]
    Masatoshi Kudo
    Australian Council of TESOL Assciatins (ACTA) International Conference 2014 2014年05月 シンポジウム・ワークショップパネル（公募） Taipei, Taiwan
  • 超音波エラストグラフィによる非アルコール性脂肪性肝疾患患者の意識改革  [通常講演]
    矢田典久; 萩原 智; 工藤正俊
    第100回日本消化器病学会総会 2014年04月 ポスター発表 東京国際フォーラム
  • 当院におけるNSAIDs・抗血小板薬起因性の小腸粘膜傷害の検討  [通常講演]
    永井知行; 高山政樹; 岡元寿樹; 千品寛和; 山田光成; 足立哲平; 峯 宏昌; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    第100回日本消化器病学会総会 2014年04月 ポスター発表 東京国際フォーラム
  • 当院における好酸球性食道炎の検討  [通常講演]
    松井繁長; 樫田博史; 工藤正俊; 川崎正憲; 朝隈 豊; 永井知行; 櫻井俊治
    第100回日本消化器病学会総会 2014年04月 ポスター発表 東京国際フォーラム
  • Plain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測  [通常講演]
    南 康範; 南 知宏; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 井上達夫; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊; 柳生行伸; 村上卓道
    第100回日本消化器病学会総会 2014年04月 口頭発表（一般） 東京国際フォーラム
  • 癌性疼痛に対するEUS下腹腔内神経叢融解術の有用性とその適応, シンポジウム9「膵胆道疾患におけるInterventional EUSの有用性と問題点」  [通常講演]
    坂本洋城; 北野雅之; 工藤正俊
    第100回日本消化器病学会総会 2014年04月 シンポジウム・ワークショップパネル（公募） 東京国際フォーラム
  • 分枝型IPMNの経過観察例からみた2012年国際診療ガイドラインの妥当性の検証. パネルディスカッション11「IPMNの経過観察, 治療のタイミングと予後」  [通常講演]
    鎌田 研; 北野雅之; 工藤正俊
    第100回日本消化器病学会総会 2014年04月 シンポジウム・ワークショップパネル（公募） 東京国際フォーラム
  • 機能性ディスペプシアと早期慢性膵炎との関係性について. パネルディスカッション4「FDの亜分類と治療選択」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第100回日本消化器病学会総会 2014年04月 シンポジウム・ワークショップパネル（公募） 東京国際フォーラム
  • 司会: シンポジウム7「早期肝臓癌画像診断の到達点と治療選択」  [通常講演]
    工藤正俊
    第100回日本消化器病学会総会 2014年04月 その他 東京国際フォーラム, 東京
  • EOB-MRIと造影超音波検査による乏血性結節の多血化因子の検討  [通常講演]
    井上達夫; 兵頭朋子; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 村上卓道; 工藤正俊
    第27回日本腹部造影エコー・ドプラ診断研究会 2014年04月 口頭発表（一般） はまぎんホールヴィアマーレ, 横浜
  • 肝炎に続発した肝内多発輪状結節の1例  [通常講演]
    横川美加; 前野知子; 前川 清; 北井 聡; 井上達夫; 南 康範; 工藤正俊; 川崎俊彦
    第27回日本腹部造影エコー・ドプラ診断研究会 2014年04月 口頭発表（一般） はまぎんホールヴィアマーレ, 横浜
  • B-modeで描出困難な肝癌に対するFusion image+造影USガイドでのラジオ波焼灼術の有用性  [通常講演]
    南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 井上達夫; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊
    第27回日本腹部造影エコー・ドプラ診断研究会 2014年04月 口頭発表（一般） はまぎんホールヴィアマーレ, 横浜
  • Final analysis of GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma [HCC] and of its treatment with sorafenib): factors influencing treatment duration and outcomes  [通常講演]
    Bronowicki JP; 工藤 正俊; Venook A; Marrero J; Ye SL; Nakajima K; Lencion R
    49th Annual Meeting of the European Association for the Sudy of the Liver (EASL) 2014年04月 London, United Kingdom 49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • Once-daily oral lusutrombopag, alternative to platelet transfusion inthrombocytopenic patients with chronic liver disease undergoingradiofrequency ablation: results from a phase 2B, randomized, double-blind study.  [通常講演]
    Izumi N; 工藤 正俊; Tateishi R; Seike M; Tamai H; Kawazoe S; Tanaka K; Kurokawa M; Osaki Y; Yamamoto K; Imawari M
    49th Annual Meeting of the European Association for the Sudy of the Liver (EASL) 2014年04月 London, United Kingdom 49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • Final analysis of GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): treatment practices, safety and outcomes by race  [通常講演]
    Furuse J; 工藤 正俊; Ye SL; Marrero J; Lencioni R; Venook A; Nakajima K
    Asian Pacific Association for the Study of the Liver (APASL 2014) 2014年03月 Brisbane, Australia Asian Pacific Association for the Study of the Liver (APASL 2014)
  • Invited Lecture “Current evidence and future perspective of molecular targeted therapies in HCC”  [通常講演]
    工藤 正俊
    The 11th World Congress of the International Hepato-Pancreato-Biliary Association 2014年03月 Seoul, Korea The 11th World Congress of the International Hepato-Pancreato-Biliary Association
  • Invited Lecture “Contrast enhanced ultrasound of gastrointestinal disorders”  [招待講演]
    工藤正俊
    12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop 2014年03月 口頭発表（招待・特別） Kathmandu, Nepal
  • Contrast-enhanced ultrasound of hepatic tumours with Sonazoid  [招待講演]
    工藤正俊
    12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop 2014年03月 口頭発表（招待・特別） Kathmandu, Nepal
  • Invited Lecture “Interventional EUS for pancreatobiliary tumours”  [招待講演]
    工藤正俊
    12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop 2014年02月 口頭発表（招待・特別） Kathmandu, Nepal
  • Invited Lecture “Ultrasound evaluation of diffuse liver diseases”  [招待講演]
    工藤正俊
    12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop 2014年02月 口頭発表（招待・特別） Kathmandu, Nepal
  • 上行結腸動静脈奇形の１例  [通常講演]
    千品寛和; 峯 宏昌; 南 知宏; 田中梨絵; 山田光成; 足立哲平; 高山政樹; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊; 杉浦史哲; 上田和毅; 奥野清隆; 筑後孝章; 佐藤隆夫
    日本消化器病学会近畿支部第100回例会 2014年02月 口頭発表（一般）
  • Time intensity curve (TIC) を用いた造影ハーモニックEUSによる膵腫瘍血流評価の検討  [通常講演]
    大本俊介; 北野雅之; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    日本消化器病学会近畿支部第100回例会 2014年02月 口頭発表（一般）
  • 診断に難渋した十二指腸隆起性潰瘍性病変の一例  [通常講演]
    岡元寿樹; 永井知行; 山田光成; 足立哲平; 高山政樹; 峯 宏昌; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊; 田中裕美子; 石川 原; 竹山宜典
    日本消化器病学会近畿支部第100回例会 2014年02月 口頭発表（一般）
  • 機能性ディスペプシアと早期慢性膵炎の鑑別について  [通常講演]
    門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    日本消化器病学会近畿支部第100回例会 2014年02月 口頭発表（一般）
  • TS-1+ Interferon併用療法が奏効した巨大な肝細胞癌の一例  [通常講演]
    南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 井上達夫; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊
    日本消化器病学会近畿支部第100回例会 2014年02月 口頭発表（一般）
  • 分岐型IPMNに対する造影EUSのフォローによりIPMN由来癌を早期診断した１例  [通常講演]
    伊藤貴嶺; 北野雅之; 門阪薫平; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊
    日本消化器病学会近畿支部第100回例会 2014年02月 口頭発表（一般）
  • 潰瘍性大腸炎の手術適応におけるインフリキシマブの位置づけ. パネルディスカッション2「炎症性腸疾患の内科・外科境界領域」  [通常講演]
    田中梨絵; 櫻井俊治; 樫田博史; 工藤正俊
    日本消化器病学会近畿支部第100回例会 2014年02月 シンポジウム・ワークショップパネル（公募）
  • Moderator "Keynote session"  [通常講演]
    工藤正俊
    3rd Investigators Meeting for ORIENTAL 2014年02月 Taipei, Taiwan
  • 興味のある経過を示した胃アミロイドーシスの1例  [通常講演]
    岡本寿樹; 高山政樹; 峯 宏昌; 山田光成; 足立哲平; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    第10回日本消化管学会総会学術集会 2014年02月 ポスター発表 クラッセふくしま, 福島
  • 当院においてOGIBと診断され、シングルバルーン小腸内視鏡検査を施工した高齢者症例の臨床的検討  [通常講演]
    高山政樹; 足立哲平; 峯 宏昌; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    第10回日本消化管学会総会学術集会 2014年02月 口頭発表（一般） ホテル福島グリーンパレス, 福島
  • NST介入患者における胃瘻と半固形栄養剤の有用性について  [通常講演]
    峯 宏昌; 足立哲平; 高山政樹; 永井知行; 川崎正憲; 朝隈 豊; 松井繁長; 樫田博史; 工藤正俊
    第10回日本消化管学会総会学術集会 2014年02月 口頭発表（一般） ホテル福島グリーンパレス, 福島
  • Invited Lecture “Recent trends of management of HCC”  [招待講演]
    工藤正俊
    The 22nd International Seoul Radiology Symposium (ISRS 2015) 2014年02月 口頭発表（招待・特別） Seoul National University Hospital Beiomedical Research Institute Auditorium, Korea
  • Dual energy CTを用いたdynamicCTによる肝線維化の評価  [通常講演]
    朝戸 信行; 村上 卓道; 鶴﨑 正勝; 兵頭 朋子; 福井 秀行; 任 誠雲; 栁生 行伸; 岡田 真広; 今岡 いずみ; 松木 充; 足利 竜一朗; 矢田 典久; 前西 修; 工藤 正俊; 工藤 正幸
    第20回肝血流動態・機能イメージ研究会 2014年02月 大阪 第20回肝血流動態・機能イメージ研究会
  • Invited Lecture “Lessons from other TKI trials combined with TACE (tentative)”  [通常講演]
    工藤 正俊
    3rd Investigators Meeting for ORIENTAL 2014年02月 Taipei, Taiwan 3rd Investigators Meeting for ORIENTAL
  • 慢性胃炎性変化の乏しいC-0症例のたこいぼびらんに見られる腸上皮化生についての検討  [通常講演]
    辻 直子; 丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 本庶 元; 工藤 正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2014年 グランドプリンスホテル新高輪, 東京 第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013）
  • TACE不応の進行肝細胞癌に対するソラフェニブ開始時期の検討.  [通常講演]
    有住 忠晃; 上嶋 一臣; 千品 寛和; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第9回日本肝がん分子標的治療研究会 2014年01月 海運クラブ, 東京 第9回日本肝がん分子標的治療研究会
  • 司会：教育講演：治療アルゴリズムにおける分子標的薬の取扱い～エビデンスvs.コンセンサス～  [通常講演]
    工藤 正俊
    第9回日本肝がん分子標的治療研究会 2014年01月 海運クラブ, 東京 第9回日本肝がん分子標的治療研究会
  • 司会"血液検査"  [通常講演]
    工藤正俊
    平成25年度日本肝臓学会後期教育講演会 2013年12月 その他 長良川国際会議場, 岐阜
  • 司会"肝細胞癌"  [通常講演]
    工藤正俊
    平成25年度日本肝臓学会後期教育講演会 2013年12月 その他 長良川国際会議場, 岐阜
  • Invited Lecture “Ongoing trial with Sonazoid in Japan”  [通常講演]
    工藤 正俊
    Workshop for a Clinical Trial of HCC Screening with Sonazoid 2013年12月 Seoul, Korea Workshop for a Clinical Trial of HCC Screening with Sonazoid
  • Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): regional trends, safety, and outcomes in patients receiving concomitant transarterial chemoembolization.  [通常講演]
    Geschwind JF; 工藤 正俊; Marrero J; Venook A; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lencioni R
    99th Scientific Assembly and Annual Meeting (RSNA 2013) 2013年12月 Chicago, USA 99th Scientific Assembly and Annual Meeting (RSNA 2013)
  • 急速な増大を認めた後腹膜嚢胞性腫瘤の一例  [通常講演]
    前野 知子; 横川 美加; 辻 裕美子; 市島 真由美; 塩見 香織; 前川 清; 樫田 博史; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • Fly thruによる胆嚢（胆石・ポリープ）の描出について  [通常講演]
    辻 裕美子; 横川 美加; 前野 知子; 市島 真由美; 塩見 香織; 前川 清; 井上 達夫; 南 康範; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • 造影ハーモニックEUSにおける消化器系疾患の鑑別および悪性度診断  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • ソナゾイド造影を施行した小腸腫瘍の1例  [通常講演]
    横川 美加; 辻 裕美子; 前野 知子; 市島 真由美; 塩見 香織; 前川 清; 南 康範; 樫田 博史; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • Fly thruによるPV Shuntの描出  [通常講演]
    前川 清; 横川 美加; 辻 裕美子; 前野 知子; 市島 真由美; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • Acoustic structure quantificationによるfocal spared areaの描出の試み  [通常講演]
    前川 清; 横川 美加; 辻 裕美子; 前野 知子; 市島 真由美; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊; 矢野 雅彦
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • 造影ハーモニックEUS（CH-EUS）における膵腫瘍の血流評価の有用性について  [通常講演]
    大本 俊介; 田中 梨絵; 門阪 薫平; 鎌田 研; 宮田 剛; 山雄 健太郎; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • 当院におけるEUS下胆道および膵管ドレナージの工夫と成績. シンポジウム1「消化器領域超音波の最前線-診断からインターベンションまで」  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • 特別講演「超音波診断の最新動向: 腹部領域を中心に」  [通常講演]
    工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • 特別講演「超音波診断の最新動向: 腹部領域を中心に」  [通常講演]
    工藤 正俊
    日本超音波医学会第40回関西地方会学術集会 2013年11月 大阪国際会議場, 大阪 日本超音波医学会第40回関西地方会学術集会
  • HBs抗原消失を目指したエンテカビルとPEG-IFN48週併用療法の効果について  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    第15回葵肝臓研究会 2013年11月 メルパルク京都 第15回葵肝臓研究会
  • 造影ハーモニックEUS（CH-EUS）による膵腫瘤性病変の血流の定量化の試み  [通常講演]
    大本 俊介; 北野 雅之; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 坂本 洋城; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 消化管病変を合併したHenoch-Schonlein紫斑病（HSP）の一例  [通常講演]
    南 知宏; 松井 繁長; 岡元 寿樹; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 潰瘍性大腸炎の加療中に壊疽性膿皮症および下肢深部静脈血栓症を合併した1例  [通常講演]
    松本 望; 尾崎 信人; 河野 匡志; 丸山 康典; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 遠藤 英樹; 落合 健; 前倉 俊治; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 陥凹を伴ったSessile serrated adenoma/polyp（SSA/P）の1例  [通常講演]
    千品 寛和; 朝隈 豊; 南 知宏; 岡元 寿樹; 山田 光成; 田中 梨絵; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • コーラ溶解法と結石粉砕術で内視鏡的摘出した胃十二指腸動脈瘤の一例  [通常講演]
    田中 梨絵; 永井 知行; 千品 寛和; 山田 光成; 足立 哲平; 高山 政樹; 峯 宏昌; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 胃Inverted hamartomatous polypの一例  [通常講演]
    尾崎 信人; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 食欲不振を契機に発見された巨大脾腫瘍の一例  [通常講演]
    吉川 恵輔; 奥田 英之; 秦 康倫; 木下 大輔; 清水 昌子; 岸谷 讓; 永田 嘉昭; 川崎 俊彦; 太田 善夫; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • walled-off necrosisの術前の管理においてメタリックステントによるドレナージが有用であった  [通常講演]
    中田 有紀; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 坂本 洋城; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 潰瘍性大腸炎に膵胆管合流異常症を合併した1例  [通常講演]
    東 千尋; 山雄 健太郎; 田中 梨絵; 大本 俊介; 門阪 薫平; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 血便を契機に発見された上行結腸非上皮性巨大腫瘤の2例  [通常講演]
    沼本 勲男; 朝隈 豊; 岡元 寿樹; 山田 光成; 千品 寛和; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 当院におけるEUS下ドレナージ術の成績. ワークショップ1「内視鏡ステント治療の現状と問題点（胆膵）」  [通常講演]
    山雄 健太郎; 北野 雅之; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • （追加発言3）当院における高齢患者のEMR治療成績と問題点. シンポジウム2「高齢者における内視鏡診療の問題点と対策（消化管）」  [通常講演]
    永井 知行; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 高齢者における大腸ポリペクトミーの安全性と予後. シンポジウム2「高齢者における内視鏡診療の問題点と対策（消化管）」  [通常講演]
    高場 雄久; 辻 直子; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 高齢者またはADL不良の急性胆嚢炎および胆管炎例に対するEUS下胆嚢ドレナージ術. シンポジウム1「高齢者における内視鏡診療の問題点と対策（胆膵）」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器内視鏡学会近畿支部第91回支部例会 2013年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第91回支部例会
  • 座長： 特別講演：西口修平「C型肝炎治療の今後の展開」  [通常講演]
    工藤 正俊
    C型肝炎学術講演会 2013年11月 ホテルグランヴィア大阪, 大阪 C型肝炎学術講演会
  • B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial  [通常講演]
    工藤 正俊; 上嶋 一臣; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masao Ichinose; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Kouhei Akazawa
    The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) 2013年11月 Washington D.C., USA The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • Role of oxidative stress and epigenetic alteration on chronic hepatitis C-related human hepatocarcinogenesis  [通常講演]
    西田 直生志; 工藤 正俊; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; Takeshi Nagasaka; Ajay Goel
    The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) 2013年11月 Washington D.C. The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • Safety and outcomes by disease etiology in sorafenib-treated uHCC patients in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)  [通常講演]
    Sanyal AJ; 工藤 正俊; Lencioni R; Ye SL; Venook A; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Guevara LL; Papandreou C; Takayama T; Yoon SK; Nakajima K; Marrero J
    The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) 2013年11月 Washington D.C., USA The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 膵癌による閉塞性黄疸に対する乳頭括約筋切開術未施行のカバー付金属ステント留置術の成績  [通常講演]
    千品寛和; 門阪薫平; 田中梨絵; 大本俊介; 宮田 剛; 鎌田 研; 今井 元; 坂本洋城; 北野雅之; 工藤正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 ポスター発表 品川プリンスホテル, 東京
  • EUSにおけるミタゾラムとプロポフォールによる鎮静に対するBISモニター（Bispectral index monitoring）の有用性の検討. ワークショップ25「プロフォールを活用する」  [通常講演]
    宮田 剛; 北野雅之; 工藤正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 シンポジウム・ワークショップパネル（公募） 品川プリンスホテル, 東京
  • プロポフォールを用いた外来内視鏡検査の安全性・有用性と患者満足度の検討. ワークショップ25「プロフォールを活用する」  [通常講演]
    梅原康湖; 辻 直子; 工藤正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 シンポジウム・ワークショップパネル（公募） 品川プリンスホテル, 東京
  • EUSガイド下胆管ドレナージ術における工夫とトラブルシューティング. ワークショップ23「胆膵内視鏡のトラブルシューティング《ビデオ》」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第86回日本消化器内視鏡学会総会 2013年10月 シンポジウム・ワークショップパネル（公募） 品川プリンスホテル, 東京
  • Predictive factors for pain relief after endscopicultrasound-guided plexus neurolysis  [通常講演]
    Sakamoto H; Kitano M; Kudo M
    Japan Digestive Disease Week 2013 (JDDW) 2013年10月 口頭発表（一般） Tokyo, Japan
  • Usefulness of single-balloon endscopy for the small bowel lesions  [通常講演]
    Adachi T; Matsui S; Kashida H
    Japan Digestive Disease Week 2013 (JDDW) 2013年10月 口頭発表（一般） Tokyo, Japan
  • Clostridium difficile感染症例の検討  [通常講演]
    奥村直己; 工藤正俊; 辻 直子; 高場雄久; 松本 望; 谷池聡子; 河野匡志; 丸山康典; 山田 哲; 森村正嗣; 米田 円; 梅原康湖; 富田崇文
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 ポスター発表 品川プリンスホテル, 東京
  • 大腸発癌における幹細胞の制御機構  [通常講演]
    峯 宏昌; 櫻井俊治; 工藤正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 ポスター発表 品川プリンスホテル, 東京
  • 肝発癌および治療抵抗性獲得における幹細胞の役割. ワークショップ16「消化器癌に対する幹細胞研究の現状と展望」  [通常講演]
    櫻井俊治; 樫田博史; 工藤正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 シンポジウム・ワークショップパネル（公募） 品川プリンスホテル, 東京
  • 切除不能胆道狭窄でのEUS下胆道ドレナージの位置づけ. ワークショップ14「胆道癌の胆管ドレナージの標準化-手術症例と非手術症例」  [通常講演]
    今井 元; 北野雅之; 工藤正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪国際パミール, 東京
  • 機能性ディスペプシアの早期慢性膵炎が存在する可能性について. ワークショップ12「機能性ディスペプシア-診断と治療の現況を巡って-」  [通常講演]
    門阪薫平; 北野雅之; 工藤正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 シンポジウム・ワークショップパネル（公募） グランドプリンスホテル新高輪国際パミール, 東京
  • 肝細胞癌に対する分子標的治療: 現状と問題点. シンポジウム15「消化器癌に対する分子標的薬-最近の動向」  [通常講演]
    工藤正俊; 上嶋一臣
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 シンポジウム・ワークショップパネル（指名） グランドプリンスホテル新高輪国際パミール, 東京
  • 司会: シンポジウム15「消化器癌に対する分子標的薬-最近の動向」  [招待講演]
    工藤正俊
    第21回日本消化器関連学会週間JDDW 2013（第55回日本消化器病学会大会, 第17回日本肝臓学会大会） 2013年10月 その他 グランドプリンスホテル新高輪, 東京
  • 司会: サテライトシンポジウム82「肝癌診療は新たな時代へ」  [通常講演]
    工藤正俊
    第21回日本消化器関連学会週間JDDW 2013（第17回日本肝臓学会大会, 第17回日本肝臓学会大会） 2013年10月 その他 グランドプリンスホテル高輪, 東京
  • 当院においてOGIBと診断されシングルバルーン小腸内視鏡検査を施行した高齢者症例の臨床的検討.  [通常講演]
    高山政樹; 足立哲平; 峯 宏昌; 永田嘉昭; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 ポスター発表 グランドプリンスホテル新高輪, 東京
  • 座長： ランチョンセミナー29「HCCにおける診断から治療に関する最新の話題」  [通常講演]
    工藤正俊
    第21回日本消化器関連学会週間JDDW 2013（第17回日本肝臓学会大会, 第17回日本肝臓学会大会） 2013年10月 その他 グランドプリンスホテル新高輪, 東京
  • プロポフォール投与下内視鏡検査における飲酒患者, 睡眠薬・精神安定剤内服患者への注意点  [通常講演]
    梅原 康湖; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 谷池 聡子; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 辻 直子; 工藤 正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪, 東京 第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013）
  • プロポフォール投与下内視鏡検査で生じる不随意運動の検討  [通常講演]
    梅原 康湖; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 谷池 聡子; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 辻 直子; 工藤 正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪, 東京 第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013）
  • 上部消化管内視鏡検査前スクリーニングとして実施した胸部X-rayおよび心電図より得られた所見についての検討  [通常講演]
    谷池 聡子; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪, 東京 86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013）
  • Chair: Treatment of advanced HCC with macro-vascular invasion (Surgery vs Sorafenib). JDDW International debte session (featured lecture) 1-2 (JDDW)  [通常講演]
    工藤 正俊
    Japan Digestive Disease Week 2013 (JDDW) 2013年10月 Tokyo, Japan Japan Digestive Disease Week 2013 (JDDW)
  • EUS-guided hepaticogastrostomy for treatment of obstructive jaundice in patients with malignant hilar biliary stricture after transpillary drainage is ineffective or unsuccessful  [通常講演]
    北野 雅之; 今井 元; 工藤 正俊
    Japan Digestive Disease Week 2013 (JDDW) 2013年10月 Tokyo, Japan Japan Digestive Disease Week 2013 (JDDW)
  • The role of EUS in diagnosis and treatment of autoimmune pancreatitis  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    Japan Digestive Disease Week 2013 (JDDW) 2013年10月 Tokyo, Japan Japan Digestive Disease Week 2013 (JDDW)
  • 乳頭括約筋切除術を行わないTrans-catheter biliary endoscopyの有用性の検討. ワークショップ6「胆道疾患の診断・治療に有用な画像診断-内視鏡診断から三次元画像診断」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪国際パミール, 東京 第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013）
  • 造影ハーモニックEUSのよる胆嚢病変の鑑別診断. ワークショップ6「胆道疾患の診断・治療に有用な画像診断-内視鏡診断から三次元画像診断」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪国際パミール, 東京 第86回日本消化器内視鏡学会総会（第21回日本消化器関連学会週間JDDW2013）
  • IPMN国際診療ガイドライン2012年度版の検証～EUSの位置づけはどこにあるか？～. パネルディスカッション7「IPMN新コンセンサス診療ガイドラインの検証」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪国際パミール, 東京 第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013）
  • 肝のう胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北 雅弘; 有住 忠晃; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第17回日本肝臓学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪, 東京 第17回日本肝臓学会大会（第21回日本消化器関連学会週間JDDW2013）
  • C型肝炎に対する3剤併用療法の高齢者における認容性の検討  [通常講演]
    田北 雅弘; 萩原 智; 工藤 正俊
    第17回日本肝臓学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 グランドプリンスホテル新高輪, 東京 第17回日本肝臓学会大会（第21回日本消化器関連学会週間JDDW2013）
  • 当院における大腸癌肝転移の治療ストラテジー  [通常講演]
    南 康範; 工藤 正俊; 中居 卓也
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 品川プリンスホテル, 東京 第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013）
  • Gd-EOB-DTPA MRI肝細胞相で低信号に描出される結節の多血化因子の検討多施設共同retrospective study  [通常講演]
    井上 達夫; 工藤 正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 品川プリンスホテル, 東京 第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013）
  • 各種超音波エラストグラフィによる肝線維化診断. パネルディスカッション5「非侵襲的肝病態評価法の適応と限界」  [通常講演]
    矢田 典久; 萩原 智; 工藤 正俊
    第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013） 2013年10月 品川プリンスホテル, 東京 第55回日本消化器病学会大会（第21回日本消化器関連学会週間JDDW2013）
  • The usefulness of the epoch method “Defect re-perfusion imaging”to diagnose HCC using new agent sonazoid  [通常講演]
    Ogawa C; 工藤 正俊; Shibatouge M
    The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI 2013) 2013年10月 Taipei, Taiwan The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI 2013)
  • The learning curve of endoscopic submucosal dissection in the colorectum  [通常講演]
    樫田 博史; 足立 哲平; 櫻井 俊治; 朝隈 豊; 川崎 正憲; 永井 知行; 峯 宏昌; 高山 政樹; 松井 繁長; 工藤 正俊
    21th United European Gastroenterology Week (UEGW) 2013年10月 Berlin, Germany 21th United European Gastroenterology Week (UEGW)
  • Invited Lecture “Diagnosis of Gross Pathological Classification of HCC by Kupffer phase CEUS”  [通常講演]
    工藤 正俊
    The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI) 2013年10月 Taipei, Taiwan The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)
  • Invited Lecture “Contrast-enhanced EUS of GI disorders”  [通常講演]
    工藤 正俊
    The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI) 2013年10月 Taipei, Taiwan The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)
  • 肝臓がんの集学的治療. 腫瘍別シンポジウム「消化器がん研究の進歩と今後の展望」  [通常講演]
    工藤 正俊
    第72回日本癌学会学術集会 2013年10月 パシフィコ横浜, 神奈川 第72回日本癌学会学術集会
  • Special Lecture “Management of Hepatocellular Carcinoma: Recent Progress” “Special Lecture (III)”  [通常講演]
    工藤 正俊
    Taiwan Digestive Disease Week 2013 (TDDW) 2013年10月 Taipei, Taiwan Taiwan Digestive Disease Week 2013 (TDDW)
  • Predictive factors for pain relief after endoscopic ultrasound-guided upper plexus neurolysis.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    21th United European Gastroenterology Week (UEGW) 2013年10月 Berlin, Germany 21th United European Gastroenterology Week (UEGW)
  • Differential diagnosis of SMT and evaluation of malignant potential GISTS by contrast enhanced harmonic EUS  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    21th United European Gastroenterology Week (UEGW) 2013年10月 Berlin, Germany 21th United European Gastroenterology Week (UEGW)
  • Lecture “Diagnosis of diffuse liver diseases.”  [通常講演]
    工藤 正俊
    Medical ultrasound society, Singapore 11th Annual Seminar in conjunction with AFSUMB Workshop 2013 2013年09月 Singapore Medical ultrasound society, Singapore 11th Annual Seminar in conjunction with AFSUMB Workshop 2013
  • 十二指腸静脈瘤の病態と治療方針. 要望演題11「異所性静脈瘤の病態と治療1」  [通常講演]
    松井 繁長; 樫田 博史; 朝隈 豊; 川崎 正憲; 工藤 正俊
    第20回日本民脈圧亢進症学会総会 2013年09月 名古屋国際会議場, 愛知 第20回日本民脈圧亢進症学会総会
  • 胆管癌として切除された良性胆管病変の4例  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊; 中居 卓也; 竹山 宜典
    第49回日本胆道学会学術集会 2013年09月 ヒルトン東京ベイ, 千葉 第49回日本胆道学会学術集会
  • 切除不能胆道癌に対する集学的治療における胆道マネジメントの重要性  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第49回日本胆道学会学術集会 2013年09月 ヒルトン東京ベイ, 千葉 第49回日本胆道学会学術集会
  • ERCP不能な悪性胆道狭窄における急性胆嚢炎および胆管炎例に対するEUS下ドレナージ術の有用性について  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第49回日本胆道学会学術集会 2013年09月 ヒルトン東京ベイ, 千葉 第49回日本胆道学会学術集会
  • 非EST症例に対する経カテーテル胆道内視鏡（Trans-catheter endoscopy; TCE）のコツとピットフォール  [通常講演]
    山雄 健太郎; 坂本 洋城; 北野 雅之; 工藤 正俊
    第49回日本胆道学会学術集会 2013年09月 第49回日本胆道学会学術集会
  • EUS下胆道ドレナージ術の可能性. シンポジウム1「胆道ドレナージの現状と新たな展開」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第49回日本胆道学会学術集会 2013年09月 ヒルトン東京ベイ, 千葉 第49回日本胆道学会学術集会
  • 座長: 企業セミナー  [通常講演]
    工藤 正俊
    第8回肝癌診療シミュレーション研究会 2013年09月 ホテル椿山荘東京, 東京 第8回肝癌診療シミュレーション研究会
  • Final analysis of GIDEON (Global Investigation of therapeutic DE-cisions in hepatocellular carcinoma and Of its treatment with sorafeNib) in>3000 sorafenib-treated patients: prognostic value of baseline characteristics and staging systems  [通常講演]
    工藤 正俊; ※Bronowicki JP; Lencioni R; Ye SL; Papandreou C; Nakajima K; Venook A; Marrero J
    Poster presented at the European Cancer Congress 2013 (EC-CO-ESMO-ESTRO) 2013年09月 Amsterdam, Netherlands Poster presented at the European Cancer Congress 2013 (EC-CO-ESMO-ESTRO)
  • Sorafenib treatment for non-hypervascular hepatocellular carcinoma  [通常講演]
    有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 Washington D.C. Seventh Annual Conference International Liver Cancer Association (ILCA)
  • The factors related to the vascularization of border line lesions detected as low intensity on hepatobiliary phase image of GD-EOB-DTPA MRI  [通常講演]
    井上 達夫; 有住 忠晃; 上嶋 一臣; 西田 直生志; 工藤 正俊
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 Washington D.C. Seventh Annual Conference International Liver Cancer Association (ILCA)
  • Updated results from phase1/2 trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, and biomarker correlative analyses in patients (Pts) with advanced hepatocellular carcinoma (HCC).  [通常講演]
    工藤 正俊; Kumada H; Ikeda K; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Kadowaki T; Funahashi Y; O’Brien JP; Okita K
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Association (ILCA)
  • Effects on survival prognosis by peretinoin, an acyclic retinoid: five-year follow-up of phase 2/3 randomized placebo-controlled trial.  [通常講演]
    Okita K; 工藤 正俊; Kumada H
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Association (ILCA)
  • Invited Lecture“Resection vs. ablation in very early HCC”  [通常講演]
    工藤 正俊
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Association (ILCA)
  • A randomized, double-blind, multicenter phase 3 study of Brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization (TACE)in patients with unresectable hepatocellular carcinoma (HCC): Initial results.  [通常講演]
    工藤 正俊; Finn R; Poon RT; Blanc JF; Han G; Yan L; Yang J; Lu L; Tak WY; Yu X; Lee JH; Lin SM; Wu C; Tanwandee T; Shao G; Walters I; Dela Cruz C; Poulart V; Wang JH
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Association (ILCA)
  • 特別講演「超音波診断の最新動向: 腹部領域を中心に」  [通常講演]
    工藤 正俊
    第31回日本乳腺甲状腺超音波医学会学術集会 2013年09月 神戸国際会議場, 兵庫 第31回日本乳腺甲状腺超音波医学会学術集会
  • 慢性C型肝炎に対するテラプレビル3剤併用療法中に結核性リンパ節炎を発症した1例  [通常講演]
    千品 寛和; 井上 達夫; 南 知宏; 岡元 寿樹; 山田 光成; 田中 梨絵; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • Walled off necrosisに対してEUS下内外瘻術を施行後に再発を認めた一例  [通常講演]
    古川 健太郎; 北野 雅之; 田中 梨絵; 大本 俊介; 門阪 薫平; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 急激な肝機能低下をきたしたBudd-Chiari症候群の1例  [通常講演]
    鍵岡 賛典; 萩原 智; 岩西 美奈; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 急性発症型自己免疫性肝炎の一例  [通常講演]
    岩西 美奈; 萩原 智; 鍵岡 賛典; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 南 康範; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 転移性腫瘍との鑑別を要した肝腫瘤を合併した十二指腸乳頭部癌の1例.  [通常講演]
    谷池 聡子; 尾崎 信人; 丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森本 正嗣; 米田 円; 山田 哲; 辻 直子; 船井 貞往; 落合 健; 前倉 俊治; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 当院におけるOGIB症例の検討. シンポジウム2「原因不明消化管出血の診断と治療の最前線」  [通常講演]
    高山 政樹; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 進行膵癌に対するGemcitabine（GEM）/Erlotinib併用療法の二次化学療法の治療成績. パネルディスカッション2「根治治療不能進行消化器癌に対する治療選択」  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • TACE不応の進行肝細胞癌患者に対するソラフェニブ開始時期の検討. パネルディスカッション2「根治治療不能進行消化器癌に対する治療選択」  [通常講演]
    有住忠晃; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • HBs抗原消失を目指したエンテカビルとPEG-IFNα2b 48週併用療法の効果について. シンポジウム「ウイルス性肝炎治療の最前線」  [通常講演]
    萩原 智; 工藤 正俊; 大﨑往夫
    日本消化器病学会近畿支部第99回例会 2013年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 特別講演 肝臓領域「ソノグラファーへの望む！肝臓エコー」  [通常講演]
    工藤 正俊
    JSS第20回地方会学術集会 2013年09月 神戸国際会議場, 兵庫 JSS第20回地方会学術集会
  • 大腸発癌における幹細胞の制御機能. シンポジウム2「発がんとがん予防の科学と実践」  [通常講演]
    櫻井 俊治; 峯 宏昌; 樫田 博史; 工藤 正俊
    第24回日本消化器癌発生学会総会 2013年09月 石川県立音楽堂, 石川 第24回日本消化器癌発生学会総会
  • Validation of staging systems for hepatocellular carcinoma: a comparison of the Bm-Jis score, the Jis score and the Bclc staging  [通常講演]
    北井 聡; 工藤 正俊; Izumi N; Sakamoto M; Matsuyama Y; Ichida T; Nakashima O; Matsui O; Ku Y; Kokudo N; Matsunaga T; Makuuchi M
    Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
  • Regional differences in treatment history, practices and outcomes: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)  [通常講演]
    工藤 正俊; Lencioni R; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Venook A; Nakajima K; Marrero J
    Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
  • Unique association between global dna hypomethylation and chromosomal alterations in human hepatocellular carcinoma.  [通常講演]
    西田 直生志; 工藤 正俊; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; Yokomichi N; Nagasaka T; Goel A
    Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA) 2013年09月 Washington D.C., USA Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
  • 司会： Colorectal Cancer, Supportive Care and QOL/ 大腸がん 支持療法、QOL  [通常講演]
    工藤 正俊
    第11回日本臨床腫瘍学会学術集会 2013年08月 仙台国際センター, 東北大学百周年記念会館川内萩ホール 第11回日本臨床腫瘍学会学術集会
  • 特別講演「肝炎, 肝癌治療の最近の話題」  [通常講演]
    工藤 正俊
    東四国ベアネットカンファレンス 2013年08月 JRホテルクレメント高松, 香川 東四国ベアネットカンファレンス
  • 肝原発神経内分泌腫瘍の1例  [通常講演]
    田中梨絵; 井上達夫; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊; 兵頭朋子; 村上卓道
    第13回関西肝血流動態イメージ研究会 2013年07月 口頭発表（一般） オーバルホール, 大阪
  • EOB造影MRIとSonazoid造影USによる乏血性肝細胞癌の診断  [通常講演]
    小来田幸世; 村上 卓道; 兵頭 朋子; 岡田 真広; 工藤 正俊; 今井康陽; 井倉; 技; 澤井良之; 福田和人; 中島 収; 関 康; 坂元亭宇
    第49回日本肝癌研究会 2013年07月 東京 第49回日本肝癌研究会
  • Estimation of EUS features of choronic pancreatitis in comparison with clinical symptoms  [通常講演]
    北野 雅之; 門阪 薫平; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 大本 俊介; 山雄 健太郎; 工藤 正俊
    International Pancreatic Research Forum 2013 (IPRF) 2013年07月 Sendai, Japan International Pancreatic Research Forum 2013 (IPRF)
  • 経乳頭的治療不能悪性胆道狭窄に対するAntegrade drainage併用治療の有用性  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第44回日本膵臓学会大会 2013年07月 仙台国際センター, 宮城 第44回日本膵臓学会大会
  • 早期慢性膵炎EUS画像所見と糖尿病の関連について. パネルディスカッション2「膵内外分泌相関の新しい展開」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第44回日本膵臓学会大会 2013年07月 仙台国際センター, 宮城 第44回日本膵臓学会大会
  • 急性・慢性膵炎の治療におけるInterventional EUSの有用性. 特別企画2ビデオシンポジウム「急性膵炎・慢性膵炎に対する内視鏡・腹腔鏡治療の最前線」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第44回日本膵臓学会大会 2013年07月 仙台国際センター, 宮城 第44回日本膵臓学会大会
  • IPMN経過観察におけるEUSの有用性～造影EUSによる診断も含めて～. 特別企画1ディベート「分枝型IPMNの診療: 内科vs外科vs病理」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 大本 俊介; 門阪 薫平; 今井 元; 坂本 洋城; 竹山 宜典
    第44回日本膵臓学会大会 2013年07月 仙台国際センター, 宮城 第44回日本膵臓学会大会
  • Invited Lecture “Interventional and contrast-enhanced EUS for pancreatobiliary diseases.”  [通常講演]
    工藤 正俊
    Program of WFUMB COE Launching Workshop 2013年07月 Ulaanbaatar, Mongolia Program of WFUMB COE Launching Workshop
  • Invited Lecture “Ultrasound elastography for non-invasive diagnosis of liver fibrosis.”  [通常講演]
    工藤 正俊
    Program of WFUMB COE Launching Workshop 2013年07月 Ulaanbaatar, Mongolia Program of WFUMB COE Launching Workshop
  • 経皮的ラジオ波焼灼術後の穿刺経路焼灼は必要か？: 後出血予防の検討  [通常講演]
    南 康範; 早石 宗右; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊; 鄭 浩柄
    第49回日本肝癌研究会 2013年07月 京王プラザホテル, 東京 第49回日本肝癌研究会
  • ソラフェニブ治療例の生存期間からみた画像診断法による効果判定規準の問題点と再評価. シンポジウム2「肝細胞癌における画像診断法の最前線」  [通常講演]
    有住 忠晃; 工藤 正俊; 大﨑 往夫
    第49回日本肝癌研究会 2013年07月 京王プラザホテル, 東京 第49回日本肝癌研究会
  • 座長: シンポジウム2「肝細胞癌における画像診断の最前線」  [通常講演]
    工藤 正俊
    第49回日本肝癌研究会 2013年07月 京王プラザホテル, 東京 第49回日本肝癌研究会
  • 近畿大学病院における大腸癌肝転移の治療ストラテジー. パネルディスカッション2「転移性肝癌治療のアルゴリズム」  [通常講演]
    南 康範; 工藤 正俊; 中居 卓也
    第49回日本肝癌研究会 2013年07月 京王プラザホテル, 東京 第49回日本肝癌研究会
  • TACEと動注化学療法: 分子標的薬との併用. ワークショップ3「肝細胞癌に対するTACE・肝動注化学療法・放射線療法の適応と治療成績」  [通常講演]
    工藤 正俊
    第49回日本肝癌研究会 2013年07月 京王プラザホテル, 東京 第49回日本肝癌研究会
  • TACEまたは肝動注化学療法とソラフェニブの併用療法の重要性. シンポジウム1「肝癌における分子標的治療の最前線」  [通常講演]
    上嶋 一臣; 有住 忠晃; 工藤 正俊
    第49回日本肝癌研究会 2013年07月 京王プラザホテル, 東京 第49回日本肝癌研究会
  • 司会： Debates Session「TACEはどこまで続けるか？」  [通常講演]
    工藤 正俊
    第13回関西肝血流動態イメージ研究会 2013年07月 オーバルホール, 大阪 第13回関西肝血流動態イメージ研究会
  • エピゲノム変異からみたヒト肝発癌における喫煙の影響とGST遺伝子多型に関する研究  [通常講演]
    西田 直生志; 工藤 正俊
    第28回喫煙科学研究財団助成研究発表会 2013年07月 京王プラザホテル 第28回喫煙科学研究財団助成研究発表会
  • 特別講演「肝発癌の予測と分子標的治療」, 固形がんの基礎と臨床-インフォメーションからコミュニケーションへ-  [通常講演]
    工藤 正俊
    第2回三重先端がんフォーラム 2013年07月 三重大学医学部 第2回三重先端がんフォーラム
  • Invited Lecture “Imaging assessment of tumor response” “Controversial issues in early HCC”  [通常講演]
    工藤 正俊
    The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2013年07月 Busan, Korea The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Invited Lecture “What is TACE failure/refractory? Literature update and arriving at consensus” “EPOIHCC”  [通常講演]
    工藤 正俊
    The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2013年07月 Busan, Korea The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Invited Lecture “Treatment strategy for early stage of HCC” “APPLE Consensus Workshop”  [通常講演]
    工藤 正俊
    The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2013年07月 Busan, Korea The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Invited Lecture “Sorafenib in patients with liver dysfunction:Final analysis of GIDEON” “Unresolved Issues for Advanced HCC ”  [通常講演]
    工藤 正俊
    The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2013年07月 Busan, Korea The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Invited Lecture “How to evaluate treatment response in HCC: a mRESIST criterion enough?” “Unresolved Issues for Advanced HCC ”  [通常講演]
    工藤 正俊
    The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2013年07月 Busan, Korea The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Invited Lecture “New druggable targets in HCC” “Early Morning Work Shop 1 II. Hepatocellular Carcinoma: Genomics, Pathways & Targets”  [通常講演]
    工藤 正俊
    The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2013年07月 Busan, Korea The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • 十二指腸水平部過形成性ポリープをスネアポリペクトミーした1例  [通常講演]
    丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器内視鏡学会近畿支部第90回例会 2013年06月 日本消化器内視鏡学会近畿支部第90回例会
  • Role of contrast-enhanced harmonic EUS in differentiating malignant from benign lymphadenopathy  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013) 2013年06月 Ito International Research Center, Japan Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)
  • The role of EUS in diagnosis and treatment of autoimmune pancreatitis  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013) 2013年06月 Ito International Research Center, Japan Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)
  • 早期慢性膵炎EUS画像所見と糖尿病との関連  [通常講演]
    門阪 薫平; 北野 雅之; 大本 俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 工藤 正俊
    日本消化器内視鏡学会近畿支部第90回支部例会 2013年06月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第90回支部例会
  • 経乳頭的治療不能悪性胆道狭窄に対するEUS下胆道ドレナージ術の有用性. ワークショップ「超音波内視鏡を用いた胆膵疾患の診断と治療の現況」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本消化器内視鏡学会近畿支部第90回支部例会 2013年06月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第90回支部例会
  • 肝がん化学療法からみた肝動注リザーバーの生き残る道～SILIUS Phase Ⅲ trialの重要性～. シンポジウム1「肝細胞癌に対する肝動注療法の生き残る道」  [通常講演]
    上嶋 一臣; 有住 忠晃; 工藤 正俊
    第38回リザーバー研究会 2013年06月 かがわ国際会議場, 香川 第38回リザーバー研究会
  • 座長： 共催シンポジウム「明日に向かって撃て」  [通常講演]
    工藤 正俊
    第8回日本肝がん分子標的治療研究会 2013年06月 和倉温泉「加賀屋」, 石川 第8回日本肝がん分子標的治療研究会
  • 進行肝細胞癌のソラフェニブ治療における腫瘍血流と治療効果との関連. ワークショップ1「分子標的薬の効果予後予測因子から治療法対象を考える」  [通常講演]
    有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第8回日本肝がん分子標的治療研究会 2013年06月 和倉温泉「加賀屋」, 石川 第8回日本肝がん分子標的治療研究会
  • 座長： 診断・治療支援の部  [通常講演]
    工藤 正俊
    腹部造影超音波フォーラム2013 2013年06月 TKPガーデンシティ品川, 東京 腹部造影超音波フォーラム2013
  • 特別講演「肝細胞癌治療の現状」  [通常講演]
    工藤 正俊
    第3回札幌肝疾患フォーラム 2013年06月 ニューオータニイン札幌, 北海道 第3回札幌肝疾患フォーラム
  • Quantitative assessment of liver fat with dual energy CT: comparison with MR spectroscopy  [通常講演]
    兵頭 朋子; 村上 卓道; 工藤 正俊; 岡田 真広; 矢田 典久; 前西 修; 石井 一成
    Computer Assisted Radiology and Surgery, 27th Intemational Congress and Exhibition 2013年06月 ドイツ Computer Assisted Radiology and Surgery, 27th Intemational Congress and Exhibition
  • Regoranib in patients with hepatocellular carcinoma (HCC) progressing following Sorafenib: an ongoing randomized, double-blind, phase Ⅲ trial  [通常講演]
    Cheng AL; Finn R; Kudo M; Llovet JM; Qin S; Berre ML; Krissel H; Bruix J
    American Society of Clinical Oncology (ASCO) 49th Annual Meeting 2013年05月
  • Special Lecture “a) Liver (Strain)” “Elastography”  [通常講演]
    工藤 正俊
    14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013 2013年05月 Sao Paulo, Brazil 14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013
  • Coordinator: Elastography  [通常講演]
    工藤 正俊
    14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013 2013年05月 Sao Paulo, Brazil 14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013
  • Real-time tissue quantification (VTTQ)による自己免疫性肝炎の治療評価  [通常講演]
    矢田 典久; 萩原 智; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • 消化器診断の立場から. パネルディスカッション24「Real-time Tissue Elasstography～10年の歩み～」  [通常講演]
    工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • 肝血管筋脂肪腫の3例  [通常講演]
    田中 梨絵; 南 康範; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • 超音波を施行した0歳児の嘔吐症例の検討  [通常講演]
    前野 知子; 横川 美加; 辻 裕美子; 塩見香織; 前川 清; 井上 達夫; 南 康範; 西田 直生志; 八木 誠; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • Defect re-purfusion imagingによる新しいHCCの診断方法とその教育システム  [通常講演]
    小川 力; 工藤 正俊; 野田晃世; 村川佳子; 河合直之; 木太秀行; 嶋田俊秀; 廣瀬哲朗; 西平
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • VINCENTを用いた超音波検査指導の有用性  [通常講演]
    野田晃世; 工藤 正俊; 小川 力; 森岡弓; 柴峠光成; 村川佳子; 河合直之; 木太秀行; 嶋田俊秀
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • Diagnostic performance of liver fibrosis with real-time tissue elastography in chronic viral hepatitis C. International Symposium“Elastography of the liver in Asia”  [通常講演]
    矢田 典久; 工藤 正俊
    The 86th Annual Scientific Meeting of the Japan Society of Ultrasonics in Medicine 2013年05月 Osaka The 86th Annual Scientific Meeting of the Japan Society of Ultrasonics in Medicine
  • 膵疾患に対する造影超音波検査. パネルディスカッション27「膵腫瘍の診断に最も有用な画像診断法は？: 画像診断の現状とピットフォール」  [通常講演]
    今井 元; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • 膵疾患診断における造影ハーモニックEUS検査の有用性. パネルディスカッション26「消化器疾患診断に造影超音波は必要か？」  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • EUS-FNAと造影ハーモニックEUSによるステージⅠ膵癌の検討. パネルディスカッション17「小膵癌: 超音波検査を用いたステージⅠへのアプローチ」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • 超音波内視鏡（EUS）による膵疾患の診断と治療. シンポジウム17「体腔内超音波の現状と展望」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • 司会： パネルディスカッション7「進行肝細胞癌に対する化学療法の治療戦略」  [通常講演]
    工藤 正俊; 金子 周一
    第99回日本消化器病学会総会 2013年05月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • EUS下膵管・胆道ドレナージ術の方法と成績. VTRシンポジウム2「Interventional EUSの進歩」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第85回日本消化器内視鏡学会総会 2013年05月 国立京都国際会館, 京都 第85回日本消化器内視鏡学会総会
  • 胃粘膜下腫瘍のEUS-FNAの成績と造影ハーモニックEUSによる鑑別診断の試み  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第85回日本消化器内視鏡学会総会 2013年05月 国立京都国際会館, 京都 第85回日本消化器内視鏡学会総会
  • 早期慢性膵炎と糖尿病の関連について  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第85回日本消化器内視鏡学会総会 2013年05月 国立京都国際会館, 京都 第85回日本消化器内視鏡学会総会
  • 当院における膵仮性嚢胞に対するTherapeuticEUSの工夫と成績  [通常講演]
    大本 俊介; 工藤 正俊; 北野 雅之
    第85回日本消化器内視鏡学会総会 2013年05月 国立京都国際会館, 京都 第85回日本消化器内視鏡学会総会
  • Time trends for helicobactor pylori eradication rate of the first-line and second-line Japanese regimens and clarithromycin resistance.  [通常講演]
    辻 直子; 奥村 直己; 谷池 聡子; 高場 雄久; 松本 望; 河野 匡志; 丸山 康典; 工藤 正俊
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • Verrucous antral gastritis is not related to H. pylori-positive chronic gastritis, but is related to a high BMI and barrett's esophagus.  [通常講演]
    辻 直子; 奥村 直己; 谷池 聡子; 高場 雄久; 松本 望; 河野 匡志; 丸山 康典; 工藤 正俊
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • Role of contrast-enhanced harmonic EUS in differentiating malignant from benign lymphadenopathy.  [通常講演]
    宮田 剛; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 門阪 薫平; 大本 俊介; 工藤 正俊
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • EUS-guided drainage for treatment of postoperative complications after pancreatic surgery.  [通常講演]
    北野 雅之; 竹山 宜典; 宮田 剛; 鎌田 研; 坂本 洋城; 今井 元; 門阪 薫平; 大本 俊介; 工藤 正俊
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • The clinical characteristics and endoscopic treatment of hemorrhagic duodenal varices.  [通常講演]
    松井 繁長; 工藤 正俊; 樫田 博史; 朝隈 豊; 川崎 正憲; 櫻井 俊治
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • Heat shock protein 27 expression is inversely correlated with intraepithelial neoplasia and positively correlated with poor differentiation of gastris cancer.  [通常講演]
    永田 嘉昭; 櫻井 俊治; 高山 政樹; 永井 知行; 川崎 正憲; 朝隈 豊; 萩原 智; 西田 直生志; 松井 繁長; 樫田 博史; 工藤 正俊
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • Noninvasive assessment of liver fibrosis by measurement of LF index in patients with chronic viral hepatitis.  [通常講演]
    矢田 典久; 萩原 智; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    Digestive Disease Week(DDW) 2013 2013年05月 Orlando, USA Digestive Disease Week(DDW) 2013
  • 特別講演「肝細胞癌診療の新しいパラダイム」  [通常講演]
    工藤正俊
    第10回臨床消化器病フォーラム 2013年04月 口頭発表（招待・特別） ウインクあいち，愛知
  • 造影ハーモニックEUS(CH-EUS)における膵腫瘍血流評価の検討  [通常講演]
    大本俊介; 北野雅之; 工藤正俊
    第26回日本腹部造影エコーー・ドプラ診断研究会 2013年04月 口頭発表（一般） ウインクあいち, 愛知
  • 造影を行なった小腸良性腫瘍の１例  [通常講演]
    横川美加; 辻裕美子; 前野知子; 塩見香織; 前川 清; 樫田博史; 工藤正俊
    第26回日本腹部造影エコーー・ドプラ診断研究会 2013年04月 口頭発表（一般） ウインクあいち, 愛知
  • 肝原発神経内分泌腫瘍の１例  [通常講演]
    田中梨絵; 井上達夫; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 樫田博史; 工藤正俊
    第26回日本腹部造影エコーー・ドプラ診断研究会 2013年04月 口頭発表（一般） ウインクあいち, 愛知
  • 特別講演「肝細胞癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第10回臨床消化器病フォーラム 2013年04月 第10回臨床消化器病フォーラム
  • 座長： ランチョンセミナー1「C型慢性肝炎の3剤併用療法－埼玉県のAG＆RGTトライアル－」  [通常講演]
    工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 胃粘膜上皮のHSP27発現は上皮内癌の発生リスクと負の相関を示す  [通常講演]
    永田 嘉昭; 櫻井 俊治; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 慢性膵炎におけるp38MAPK, HSP27の役割  [通常講演]
    櫻井 俊治; 樫田 博史; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 肝血管筋脂肪腫の3例  [通常講演]
    田中 梨絵; 上嶋 一臣; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 膵仮性嚢胞に対するInterventional EUS  [通常講演]
    大本 俊介; 北野 雅之; 山田 光成; 門阪 薫平; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 超音波内視鏡下胆嚢ドレナージ術の有用性  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊; 門阪 薫平; 大本 俊介; 鎌田 研; 宮田 剛; 坂本 洋城
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 十二指腸静脈瘤の病態と治療. ワークショップ7「異所性静脈瘤・胃静脈瘤の病態と治療」  [通常講演]
    松井 繁長; 樫田 博史; 工藤 正俊
    第49回日本腹部救急医学会総会 2013年03月 福岡国際会議場, 福岡 第49回日本腹部救急医学会総会
  • 胃粘膜上皮のHSP27発現は上皮内癌の発生リスクと負の相関を示す  [通常講演]
    永田 嘉昭; 櫻井 俊治; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 慢性膵炎におけるp38MAPK, HSP27の役割  [通常講演]
    櫻井 俊治; 樫田 博史; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 当院のヘリコバクターピロリ除菌治療におけるPPI別検討  [通常講演]
    足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • EUS下腹腔内神経叢融解術の成績とその適応. ワークショップ「胆膵疾患に対するinterventional EUSの現状」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • EUS下胆道ドレナージ術の有用性. シンポジウム「非切除胆膵癌に対する内視鏡的interventionの進歩」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 城山観光ホテル, かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 腸重積を契機に発見された回腸癌の1例  [通常講演]
    八木澤朋弘; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊; 大東 弘治; 吉岡 康多; 上田 和毅; 筑後 孝章
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 同時多発早期胃癌11病変に対し内視鏡治療を施行した1例  [通常講演]
    南 知宏; 朝隈 豊; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 胃粘膜下腫瘍様形態を呈した膵扁平上皮癌の1例  [通常講演]
    木下 大輔; 川崎 俊彦; 岸谷 讓; 清水 昌子; 宮部 欽生; 茂山 朋広; 奥田 英之; 秦 康倫; 工藤 正俊; 太田 善夫
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 肝細胞癌に合併した膵solid-pseudopapillary neoplasmの1例  [通常講演]
    茂山 朋広; 秦 康倫; 木下 大輔; 奥田 英之; 宮部 欽生; 清水 昌子; 岸谷 讓; 川崎 俊彦; 佐藤 克明; 辻江 正徳; 井上 雅智; 太田 善夫; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 腫瘍内出血を呈した肉腫様肝癌の1例  [通常講演]
    千品 寛和; 井上 達夫; 田中 梨絵; 山田 光成; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 閉塞黄疸を合併した黄色肉芽腫性胆嚢炎の一例  [通常講演]
    河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 船井 貞往; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 膵腫瘍に対する造影ハーモニックEUS（CH-EUS）の有用性について. シンポジウム1「消化器診療におけるイノベーション」  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • 閉塞性黄疸を合併した黄色肉芽腫性胆のう炎の1例  [通常講演]
    河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 船井 貞往; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 日本消化器病学会近畿支部第98回例会
  • Chair "Luncheon Seminar; Jordi Bruix “Recent progress of chemotherapy for HCC”  [招待講演]
    工藤正俊
    The 8th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences 2013年02月 その他 Ito International Research Center
  • CTHAと比較したソナゾイドUSによるnodule in noduleのHCCの診断とその問題点. シンポジム2「肝血流・機能イメージのバイオマーカー的意義を探る」  [通常講演]
    小川 力; 森岡弓子; 野田晃世; 上田祐也; 宮本由貴子; 野上明子; 吉岡正博; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 河合直之; 山岡竜也; 石川順英; 廣瀬哲朗; 西平友彦; 嶋田俊秀; 荻野哲朗; 工藤正俊
    第19回肝血流動態イメージ研究会 2013年01月 シンポジウム・ワークショップパネル（公募） 東京ビッグサイト「国際会議場」, 東京
  • 司会"シンポジウム「肝血流・機能イメージのバイオマーカー的意義を探る」"  [通常講演]
    工藤正俊
    第19回肝血流動態イメージ研究会 2013年01月 その他 東京ビッグサイト「国際会議場」, 東京
  • 腫瘍内出血を認めた肉腫様肝癌の１例  [通常講演]
    千品寛和; 井上達夫; 田中梨絵; 山田光成; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊; 隈部 力; 中島 収
    第19回肝血流動態イメージ研究会 2013年01月 口頭発表（一般） 東京ビッグサイト「国際会議場」, 東京
  • First-line Brivanib (BRIV) Versus Sorafenib (SOR) in Unresectable, Advanced Hepatocellular Carcinoma (HCC): Asia/Non-Asia Survival Results in Phase 3 BRISK-FL Study  [通常講演]
    Cheng AL; 工藤 正俊; Qin S; Park JW; Poon R; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Avina JR; Liu D Ezzeddine R Walters I; Johnson P
    Asian Pacific Association for the Study of the Liver (APASL) 2013 2013年 Singapore Asian Pacific Association for the Study of the Liver (APASL) 2013
  • 当院におけるヘリコバクターピロリ除菌治療成績の検討  [通常講演]
    足立 哲平; 松井 繁長; 樫田 博史; 工藤 正俊
    第9回日本消化管学会総会学術集会 2013年01月 京王プラザホテル, 東京 第9回日本消化管学会総会学術集会
  • ソラフェニブ治療後の後治療についての検討. シンポジウム「進行肝細胞癌に対してネクサバールを含んだ治療を、どう生命予後改善につなげるか？」  [通常講演]
    上嶋 一臣; 有住 忠晃; 工藤 正俊
    第7回日本肝がん分子標的治療研究会 2013年01月 じゅうろくプラザ, 岐阜 第7回日本肝がん分子標的治療研究会
  • ソラフェニブ治療におけるJNK活性の重要性-CD133との関連も含めて-  [通常講演]
    萩原 智; 櫻井 俊治; 工藤 正俊
    第7回日本肝がん分子標的治療研究会 2013年01月 じゅうろくプラザ, 岐阜 第7回日本肝がん分子標的治療研究会
  • 特別講演「What we learned from the Negative studies.」  [通常講演]
    工藤 正俊
    TACE Refractory Focus Expert Meeting 2012年12月 JRクレメントホテル高松, 高松 TACE Refractory Focus Expert Meeting
  • Comparison of different proton pump inhibitors (PPI)in helicobacter pylori eradication.  [通常講演]
    足立 哲平; 松井 繁長; 高山 政樹; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • A prospective randomized controlled study of a rebamipid monotherapy in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers.  [通常講演]
    高山 政樹; 松井 繁長; 川崎 正憲; 朝隈 豊; 樫田 博史; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • Albumin levels can be a predictive factor for the short-term complications after percutaneous endoscopic gastrostomy in retrospective study.  [通常講演]
    永井 知行; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 汐見 幹夫; 樫田 博史; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • The clinical characteristics and endscopic treatment of duodenal varices.  [通常講演]
    松井 繁長; 樫田 博史; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • The retrospective study of novel anticancer agent, miriplatin in TACE and TAI for unresectable hepatocellular carcinoma in Japan.  [通常講演]
    永井 知行; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • Utility of EUS-guided gallbladder drainage for rescue treatment of malignant biliary obstruction.  [通常講演]
    今井 元; 北野 雅之; 門阪 薫平; 鎌田 研; 宮田 剛; 坂本 洋城; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • Endoscopic submucosal dissection for the colorectum: usefulness and feasibility.  [通常講演]
    樫田 博史; 櫻井 俊治; 朝隈 豊; 川崎 正憲; 永田 嘉昭; 永井 知行; 高山 政樹; 峯 宏昌; 足立 哲平; 松井 繁長; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • Trans-catheter endoscopy for pancreaticobiliary duct diseases.  [通常講演]
    坂本 洋城; 北野 雅之; 今井 元; 宮田 剛; 鎌田 研; 門阪 薫平; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • A prospective feasibility study on EUS guided broad plexus neurolysis in combination with celiac ganglion neurolysis.  [通常講演]
    坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • Diffrential diagnosis of SMT and evaluation of malignant potentioal gists by contrast enhanced harmonic EUS.  [通常講演]
    坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • 特別講演「肝細胞がん診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第7回JULIET 2012年12月 野村コンファレンスプラザ日本橋 第7回JULIET
  • Invited Lecture “Interventional and contrast EUS for pancreatobiliary tumors.”  [通常講演]
    工藤 正俊
    The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2012年11月 Bali, Indonesia The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • Invited Lecture “Sonazoid-enhanced US in the management of HCC.”  [通常講演]
    工藤 正俊
    The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2012年11月 Bali, Indonesia The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • Invited Lecture “Double contrast US for surveillance of HCC.”  [通常講演]
    工藤 正俊
    The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2012年11月 Bali, Indonesia The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • Invited Lecture “Interventional US for liver tumors.”  [通常講演]
    工藤 正俊
    The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2012年11月 Bali, Indonesia The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • HCC challenges: Definition on TACE failure and refractoriness.  [通常講演]
    工藤 正俊
    HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management- 2012年11月 Taipei, Taiwan HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management-
  • Chairs: Session 5: Diagnosis and treatment of HCV-associated HCC  [通常講演]
    工藤 正俊
    The 10th JSH Single Topic Conference”Hepatitis C: Best practice based on science.” 2012年11月 Keio Plaza Hotel Tokyo, Tokyo, Japan The 10th JSH Single Topic Conference”Hepatitis C: Best practice based on science.”
  • 吐血を契機に発見した妊婦の特発性食道粘膜下血腫の一例  [通常講演]
    南 知宏; 朝隈 豊; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • Inflammatory fibroid polypの一例  [通常講演]
    木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 宮部 欽生; 清水 昌子; 岸谷 讓; 川崎 俊彦; 太田 善夫; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • リンパ管侵襲を伴う胃粘膜内癌の一例  [通常講演]
    峯 宏昌; 朝隈 豊; 足立 哲平; 高山 政樹; 永田 嘉昭; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • 慢性腎不全合併十二指腸静脈瘤に対して内視鏡的硬化療法治療が奏効した一例  [通常講演]
    千品 寛和; 松井 繁長; 田北 雅弘; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • 腸重積で発見された炎症性線維性ポリープの1例  [通常講演]
    足立 哲平; 松井 繁長; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊; 大東 弘治; 上田 和毅; 奥野 清隆
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • 生検で消失したバレット腺癌の一例  [通常講演]
    丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • 診断確定に造影ハーモニックEUSが有用であった膵腫瘍の検討  [通常講演]
    大本 俊介; 北野 雅之; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • 当院でのEMRの工夫. ビデオワークショップ2「下部消化管: 大腸内視鏡挿入法とEMRの基本と工夫」  [通常講演]
    永井 知行; 樫田 博史; 工藤 正俊
    日本消化器内視鏡学会近畿支部第89回支部例会 2012年11月 大阪国際交流センター, 大阪 日本消化器内視鏡学会近畿支部第89回支部例会
  • GIDEON (Global Investigation of therapeutic DEcisions in he-patocellular carcinoma and Of its treatment with SoraeNib) second interim analysis: subgoup analysis by disease aetiology.  [通常講演]
    Bronowicki JP; 工藤 正俊; Ye SL; Marrero J; Venook A; Nakajima K; Lencioni R
    The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) 2012年11月 Boston, USA The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • Invited Lecture “The potential of surveillance -the Japanese experience.”  [通常講演]
    工藤 正俊
    Falk Symposium 186 2012年10月 Mainz, Germany Falk Symposium 186
  • Comparison of four different proton pump inhibitors in helicobacter pylori eradication treatment.  [通常講演]
    足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    20th United European Gastroenterology Week (UEGW) 2012年10月 Amsterdam, The Netherlands 20th United European Gastroenterology Week (UEGW)
  • Usefulness of rebamipide for endoscopic submucosal dissection (ESD) -induces ulcer in early gastric cancer: prospective randomized study.  [通常講演]
    高山 政樹; 松井 繁長; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    20th United European Gastroenterology Week (UEGW) 2012年10月 Amsterdam, The Netherlands 20th United European Gastroenterology Week (UEGW)
  • 肝がんディベートセッション2 特別講演 ラジオ波の適応と優位性「原発性肝がんに対する治療方針 外科vs RF治療」  [通常講演]
    工藤 正俊
    第50回日本癌治療学会学術集会 2012年10月 パシフィコ横浜, 神奈川. 第50回日本癌治療学会学術集会
  • ランチョンセミナー「肝胆膵疾患における造影超音波の役割」  [通常講演]
    工藤 正俊
    超音波分科会（日本超音波医学会第42回北海道地方会学術集会） 2012年10月 札幌医科大学臨床教育研究棟講堂記念ホール, 札幌 超音波分科会（日本超音波医学会第42回北海道地方会学術集会）
  • 司会： ブレックファーストセミナー9「肝細胞癌の早期診断と分子標的薬治療の進歩」  [通常講演]
    工藤 正俊
    第20回日本消化器関連学会週間JDDW 2012 2012年10月 ポートピアホテル, 兵庫 第20回日本消化器関連学会週間JDDW 2012
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性の検討～造影CTとの比較～  [通常講演]
    井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012
  • 肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北 雅弘; 井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012
  • Support Vector Machineを用いたReal-time Tissue ElastograhyによるF Stage推定値. ワークショップ11「低侵襲な肝疾患診断法の進歩」  [通常講演]
    矢田 典久; 工藤 正俊; 藤本 研治
    第20回日本消化器関連学会週間JDDW2012 2012年10月 ポートピアホテル, 兵庫 第20回日本消化器関連学会週間JDDW2012
  • 肝癌の遺伝子変化および背景肝組織の男女差に関する検討. ワークショップ7「消化器疾患と性差」  [通常講演]
    西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際会議場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 肝発癌における酸化ストレスとエピゲノム変異. パネルディスカッション5「消化器癌と酸化ストレス」  [通常講演]
    西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 ポートピアホテル, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • シンポジウム1・特別発言「分子標的治療の限界を超える新しい肝癌治療法の開発」  [通常講演]
    工藤 正俊
    第54回日本消化器病学会大会 2012年10月 神戸国際展示場, 兵庫 第54回日本消化器病学会大会
  • 基調講演 シンポジウム1「分子標的治療の限界を超える新しい肝癌治療法の開発」  [通常講演]
    工藤 正俊
    第54回日本消化器病学会大会 2012年10月 神戸国際展示場, 兵庫 第54回日本消化器病学会大会
  • 司会：シンポジウム1「分子標的治療の限界を超える新しい肝癌治療法の開発」  [通常講演]
    工藤 正俊
    第20回日本消化器関連学会週間JDDW 2012（第54回日本消化器病学会大会） 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW 2012（第54回日本消化器病学会大会）
  • 当院におけるH.pylori除菌の年次変化（2001年～2010年）  [通常講演]
    丸山 康典; 辻 直子; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 南 康範; 工藤 正俊; 本庶 元
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 腸管重複症に対しSBナイフJrを用いて内視鏡的隔壁切除を施行した1例  [通常講演]
    宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 清水 昌子; 岸谷 讓; 川崎 俊彦; 米倉 竹夫; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • ランソプラゾールによるcollagenous colitisの4症例  [通常講演]
    秦 康倫; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 清水 昌子; 岸谷 讓; 川崎 俊彦; 太田 善夫; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学
  • シングルバルーン小腸内視鏡検査（SBE）にて診断し得た小腸癌について  [通常講演]
    高山 政樹; 樫田 博史; 足立 哲平; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊; 竹山 宜典; 筑後 孝章
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 大腸ESD導入時の治療成績に関する検討.  [通常講演]
    足立 哲平; 樫田 博史; 大本 俊介; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 経皮内視鏡的胃？造設術（PEG）の患者背景と早期合併症  [通常講演]
    永井 知行; 大本 俊介; 高山 政樹; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 汐見 幹夫; 樫田 博史; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 当院における胃ESD症例での多発例の検討  [通常講演]
    朝隈 豊; 松井 繁長; 足立 哲平; 大本 俊介; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • プロトンポンプ阻害薬（PPI）内服中GERD患者に対するGerdQによる治療実態の検討  [通常講演]
    大本 俊介; 松井 繁長; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 当院におけるH.pylori CAM耐性の年次変化（2001年～2010年）  [通常講演]
    河野 匡志; 辻 直子; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 南 康範; 工藤 正俊; 本庶 元
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • Helicobacter pylori除菌前後の内視鏡所見の比較検討  [通常講演]
    奥村 直己; 辻 直子; 工藤 正俊; 山本 典雄; 高場 雄久; 松本 望; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 南 康範; 丸山 康典; 河野 匡志; 梅原 康湖
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • EUS下胆管ドレナージ術の穿刺ルートおよびステント留置法の使い分けと成績  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • ADL不良の急性胆嚢炎および胆管炎例に対するEUSドレナージ術. パネルディスカッション26「75歳以上における腹腔鏡下胆嚢摘出術の安全性の検討」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際会議場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • StageO/I膵癌の臨床的特徴. パネルディスカッション4「膵癌早期発見に向けた取組み」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 ポートピアホテル南館, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 膵癌診断ストラテジーと各画像検査の比較検討. パネルディスカッション2「超音波検査発見胆膵病変の精密検査のストラテジー」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 癌性疼痛に対するEUS下腹腔内神経叢/節ブロック術のストラテジー. シンポジウム16「胆膵疾患に対するtherapeutic EUSの現状（EUS-FNAを除く）」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際会議場, 兵庫 第20回日本消化器関連学会週間JDDW2012（第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 肝胆膵疾患の造影超音波診断  [通常講演]
    工藤 正俊
    日本超音波医学会第22回四国地方会学術集会 2012年10月 松山市総合コミュニティーセンター, 愛媛 日本超音波医学会第22回四国地方会学術集会
  • 1年以上の下痢，下血で受診した腸重積合併1型S状結腸がんの1例  [通常講演]
    河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 亀井 敬子; 田中 晃; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部大97会例会 2012年09月 京都市 日本消化器病学会近畿支部大97会例会
  • GIDEON (Global Investigation of therapeutic DEcisions in he-patocellular carcinoma and of its treatment with soraeNib) second interim analysis: subgoup analysis by disease aetiology.  [通常講演]
    Bronowicki JP; 工藤 正俊; Ye SL; Marrero J; Venook A; Nakajima K; Lencioni R
    ESMO 2012 2012年09月 Vienna, Austria ESMO 2012
  • Final results of a randomized Phase II study of TSU-68 after transarterial chemoembolisation in Japanese patients with unresectable hepatocellular carcinoma. Chemoembolization.  [通常講演]
    Kaneko S; 工藤 正俊; Unaba Y; Kanai F; Aramaki T; Yamamoto T; Tanaka K; Yamakado K; Imanaka K; Arai Y
    ESMO 2012 2012年09月 Vienna, Austria ESMO 2012
  • EUS下胆道ドレナージ術の工夫. ビデオワークショップ「胆道疾患内視鏡治療困難例に対する手技の工夫」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第48回日本胆道学会学術集会 2012年09月 京王プラザホテル, 東京 第48回日本胆道学会学術集会
  • 司会： 教育セミナー6「門脈圧亢進症と超音波診断」  [通常講演]
    工藤 正俊
    第19回日本門脈圧亢進症学会総会 2012年09月 椿山荘, 東京. 第19回日本門脈圧亢進症学会総会
  • Phase I/II trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)  [通常講演]
    Ikeda K; 工藤 正俊; Kumada H; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Suzuki T; O'Brien JP; Okita K
    ESMO 2012 2012年09月 Vienna, Austria ESMO 2012
  • 巨大胆石が十二指腸球部に穿通し胆石イレウスを起こした一例  [通常講演]
    宮内 正晴; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 上部胆管癌との鑑別を要したIgG4関連胆管炎  [通常講演]
    田中 寛樹; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 著明な蛋白漏出性胃腸症を呈し、ステロイドが奏効したCronkhite-Canada症候群の一例  [通常講演]
    南 康範; 松井 繁長; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    著明な蛋白漏出性胃腸症を呈し、ステロイドが奏効したCronkhite-Canada症候群の一例 2012年09月 京都テルサ, 京都 著明な蛋白漏出性胃腸症を呈し、ステロイドが奏効したCronkhite-Canada症候群の一例
  • 1年以上の下痢、下血で受診した腸重積合併1型S状結腸癌による成人型腸重積の1例  [通常講演]
    河野匡志; 南 康範; 工藤 正俊; 丸山康典; 松本; 望; 高場雄久; 奥村直己; 冨田崇文; 梅原康湖; 谷池聡子; 森村正嗣; 辻; 直子; 米田; 円; 山田 哲; 亀井敬子; 田中; 落合 健; 前倉俊治
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 無症候性膵内分泌腫瘍の1例  [通常講演]
    秦 康倫; 工藤 正俊; 木下大輔; 奥田英之; 茂山朋広; 宮部欽生; 清水昌子; 岸谷 譲; 川崎俊彦; 辻江正徳; 太田善夫
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 造影ハーモニックEUS（CH-EUS）によってのみ存在診断および境界診断が可能であった膵癌の2例  [通常講演]
    大本 俊介; 北野 雅之; 山田 光成; 門阪 薫平; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 早期慢性膵炎のEUS所見とその臨床所見について  [通常講演]
    門阪 薫平; 北野 雅之; 山田 光成; 大本 俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 当院におけるPPI別ヘリコバクターピロリ菌除菌治療成績の検討  [通常講演]
    足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 当院における進行膵癌の癌性疼痛に対する治療戦略. シンポジウム2「進行膵癌に対する治療戦略の現状と展望」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 胆管胆汁細胞診にて診断し得た胆嚢癌の1例  [通常講演]
    山田 光成; 北野 雅之; 宮田 剛; 坂本 洋城; 門阪 薫平; 鎌田 研; 今井 元; 工藤 正俊
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • 上腹部痛で発見された低分化型肝癌の一例  [通常講演]
    高橋一肇; 工藤 正俊; 奥田英之; 秦; 康倫; 木下大輔; 茂山朋広; 宮部欽生; 清水昌子; 岸谷 讓; 川崎俊彦; 太田善夫
    日本消化器病学会近畿支部第97回例会 2012年09月 京都テルサ, 京都 日本消化器病学会近畿支部第97回例会
  • Invited Lecture "Liver biopsy: Is it useful for staging?"  [通常講演]
    工藤 正俊
    Sixth Annual Conference International Liver Cancer Association(ILCA) 2012年09月 Berlin, Germany Sixth Annual Conference International Liver Cancer Association(ILCA)
  • Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: global comprison of outcomes by staging system.  [通常講演]
    Morris Sherman; 工藤 正俊; Colombo M; Roberts L; Schwartz M; Degos F; Chen PJ; Chen M; Park JW; Johnson P; Huang B; Wagner S; Orsini LS
    Sixth Annual Conference International Liver Cancer Association(ILCA) 2012年09月 Berlin, Germany Sixth Annual Conference International Liver Cancer Association(ILCA)
  • Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: assessment of baseline and on-treatment alpha-fetoprotein levels in the phase III Brisk-Ps study.  [通常講演]
    Raoul JL; 工藤 正俊; Decaens T; Boucher E; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; David Liu; Walters I; Park JW; Llovet JM
    Sixth Annual Conference International Liver Cancer Association(ILCA) 2012年09月 Berlin, Germany Sixth Annual Conference International Liver Cancer Association(ILCA)
  • The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma.  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    Sixth Annual Conference International Liver Cancer Association(ILCA) 2012年09月 Berlin, Germany Sixth Annual Conference International Liver Cancer Association(ILCA)
  • Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase III Brisk-Ps Study.  [通常講演]
    Llovet JM; 工藤 正俊; Service d'Hepato-gastro-enterologie; Hopital Henri Mondor; Creteil Cedex; Service d'Oncologie Medicale; Institut Paoli Calmette; Marseille; Service d'Oncologie Medicale; Central Eugene Marquis; Rennes Cedex; France, Liver; Cancer Program; Division of Liver Diseases; Mount Sinai; School of Medicine; New York; United States; Department of Oncology; Asan Medical Center; Seoul, Korea; Service d'Hepato-gastro-enterologie; Hopital Saint Eloi; Montpellier Cedex; France; Division of Hematology-Oncology; Samsung Medical Center; Seoul, Korea; Service de Gastroenterologie; Institut; Gustave Roussy; Villejuif; Service des Maladies de; l'Appareil Digestif; Hopital Claude Huriez; Lille Cedex; Service Hepatologie; Hopital Saint Antoine; Paris, France; Liver Research Unit; Chang Gung Memorial Hospital; Taipei, Taiwan; Liver Unit; Hospital Clinic; University of Barcelona; Barcelona, Spain; Department of Hepatobiliary; Pancreatic Surgery; University of Hong Kong; Hong Kong; Hong Kong; China; Department of Medicine; Toronto General Hospital; Toronto, Canada; Department of Surgery; Saint-Andre Hospital; Bordeaux; France; Department of Medicine; Hematology/Oncology; University of California; Los Angeles; United States; Department of Internal Medicine; Kyungpook National; University Hospital; Daegu, Korea; Department of Medicine; Taipei Veterans General Hospital; Taipei, Taiwan; Bristol-Myers Squibb; Wallingford; United States; Bristol-Myers Squibb, Wallingford; United States; Bristol-Myers Squibb, Wallingford; United States; Center for Liver Cancer; National Cancer Center; Goyang, Korea
    Sixth Annual Conference International Liver Cancer Association(ILCA) 2012年09月 Berlin, Germany Sixth Annual Conference International Liver Cancer Association(ILCA)
  • Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE Study: An interim analysis of HCC burden of illness in the Asia-Pacific (AP) cohort.  [通常講演]
    Lucinda S. Orsini; 工藤 正俊; Joong-Won Park; Pei-Jer Chen; Minshan Chen
    International Society for Pharmaco-economics and Outsomes Research (ISPOR) 5th Asia-Pacific Conferen 2012年09月 Taipei, Taiwan International Society for Pharmaco-economics and Outsomes Research (ISPOR) 5th Asia-Pacific Conferen
  • Invited Lecture “Controversies on the role of TACE” “Intermediate HCC”  [通常講演]
    工藤 正俊
    Advances in HCC management in Asia 2012年08月 Ho Chi Minh , Vietnam Advances in HCC management in Asia
  • Invited Lecture “Real life experience with Nexavar: GIDEON 2nd IA” “Advanced HCC: rich evidence for Nexavar”  [通常講演]
    工藤 正俊
    Advances in HCC management in Asia 2012年08月 Ho Chi Minh , Vietnam Advances in HCC management in Asia
  • ソラフェニブの上皮間葉移行阻害効果  [通常講演]
    永井 知行; 木村 英晴; 荒尾 徳三; 松本 和子; 藤田 至彦; 吉田 修平; 林 秀敏; 工藤 正俊; 西尾 和人
    第10回日本臨床腫瘍学会学術集会 2012年07月 大阪国際会議場,大阪. 第10回日本臨床腫瘍学会学術集会
  • Chairs：International Session 1: Hepato-biliary-pancreatic  [通常講演]
    工藤 正俊
    The 10th Annual Meeting of Japanese Society of Medical Oncology 2012年07月 Osaka International Convention Center, Osaka, Japan. The 10th Annual Meeting of Japanese Society of Medical Oncology
  • シンポジウム6 肝細胞癌に対する新しい治療戦略, 総括発言「肝癌治療のアルゴリズムを含めて」  [通常講演]
    工藤 正俊
    第10回日本臨床腫瘍学会学術集会 2012年07月 大阪国際会議場, 大阪 第10回日本臨床腫瘍学会学術集会
  • 基調講演：ワークショップ1「肝癌のバイオマーカー（分子・血液・画像）による悪性度診断・治療効果判定」  [通常講演]
    工藤 正俊
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 座長：ワークショップ1「肝癌のバイオマーカー（分子・血液・画像）による悪性診断・治療効果判定」  [通常講演]
    工藤 正俊; 高安 賢一
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 座長：シンポジウム1「肝癌診療におけるGd-EOB-DTPA造影MRIの役割」  [通常講演]
    工藤 正俊; 松井 修
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性  [通常講演]
    南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • ソナゾイドUSによるnodule in nodule patternのHCCの診断  [通常講演]
    小川 力; 工藤 正俊; 森岡 弓子; 野田; 晃世; 上田; 祐也; 宮本; 由貴子; 野上; 明子; 吉岡; 正博; 石川; 哲朗; 松中; 寿浩; 玉置; 敬之; 芝峠 光成
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討  [通常講演]
    有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性～造影CTとの比較～  [通常講演]
    井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 肝細胞癌に対する肝切除と経皮的局所法の長期成績: 全国データに基づく比較検討  [通常講演]
    長谷川 潔; 工藤 正俊; 國土 典宏; 幕内 雅敏; 泉 並木; 市田 隆文; 具 英成; 坂本 亨宇; 中島 收; 松井 修; 松山 裕
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 多発性の限局性結節性過形成（FNH）およびFNH様結節に関する検討. ワークショップ2「肝癌類似病変診断の新しい展開: 肝細胞腺腫とFNHを中心に」  [通常講演]
    喜多 竜一; 工藤 正俊; 西田 直生志; 那須 章洋; 木村; 達; 大﨑; 往夫; 依田 広; 恵荘; 裕嗣; 千葉 勉
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • Sorafenib国際試験GIDEONの中間解析:TACE施行歴による層別解析. パネルディスカッション4「肝細胞癌分子標的治療: 現状と問題点」  [通常講演]
    高山 忠利; 工藤 正俊; 池田 公史; 沼田 和司; 泉 並木; 國土 典宏; 古瀬 純司; 奥坂 拓志; 角谷 眞澄; 伊藤 雄一郎
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 肝血行動態解析によるソラフェニブ治療効果の早期予測-CT perfusionを用いて  [通常講演]
    兵頭 朋子; 村上 卓道; 岡田 真広; 香川 祐毅; 日高 正二朗; 任 誠雲; 栁生 行伸; 上嶋 一臣; 矢田 典久; 石井 一成; 工藤 正俊; 工藤 正幸
    第48回日本肝癌研究会 2012年07月 石川 第48回日本肝癌研究会
  • High risk noduleの自然経過と多血化因子  [通常講演]
    今井 康陽; 村上 卓道; 兵頭 朋子; 岡田 真広; 工藤 正俊; 小来田 幸世
    第48回日本肝癌研究会 2012年07月 石川 第48回日本肝癌研究会
  • Dual energy CTを用いた肝脂肪の定量評価：ファントム実験と初期臨床経験  [通常講演]
    兵頭 朋子; 岡田 真広; 矢田 典久; 前西 修; 香川 祐毅; 任 誠雲; 柏木 伸夫; 栁生 行伸; 今岡 いずみ; 松木 充; 足利 竜一朗; 石井 一成; 工藤 正俊; 村上 卓道
    第71回近畿大学医学会学術講演会 2012年07月 大阪 第71回近畿大学医学会学術講演会
  • Invited Lecture "Japanese treatment algorithm." Session XII "Algorithm Consensus Discussion"  [通常講演]
    工藤 正俊
    The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2012年07月 Shanghai, China The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Chair: Session XII: Algorithm Consensus Discussion  [通常講演]
    工藤 正俊
    The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2012年07月 Shanghai, China The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Chair: Session XI: Novel Therapy ＆ Ongoing Trials  [通常講演]
    工藤 正俊
    The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2012年07月 Shanghai, China The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Chair: Management of TACE Failure  [通常講演]
    工藤 正俊
    Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC) 2012年07月 Shanghai, China Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC)
  • Chair: Evening Symposium: Recent Observations in the mangement of HCC  [通常講演]
    工藤 正俊
    The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2012年07月 Shanghai, China The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Invited Lecture "Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: an analysis of the Asian cohort." Evening Symposium "Recent observation in the management of HCC"  [通常講演]
    工藤 正俊
    The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2012年07月 Shanghai, China The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • 膵神経内分泌腫瘍診断におけるEUSの有用性  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 安田 武生; 竹山 宜典
    第43回日本膵臓学会大会 2012年06月 ホテルメトロポリタン山形, 山形 第43回日本膵臓学会大会
  • 早期慢性膵炎のEUS画像と臨床所見の比較検討  [通常講演]
    門阪 薫平; 北野 雅之; 竹山 宜典; 工藤 正俊
    第43回日本膵臓学会大会 2012年06月 ホテルメトロポリタン山形, 山形 第43回日本膵臓学会大会
  • 膵切除後合併症に対するEUSガイド下治療の有用性. シンポジウム5「膵切除の合併症とその対処法」  [通常講演]
    宮田 剛; 北野 雅之; 竹山 宜典; 工藤 正俊
    第43回日本膵臓学会大会 2012年06月 ホテルメトロポリタン山形 第43回日本膵臓学会大会
  • 膵上皮内癌とStageⅠ膵癌の臨床的および病理学的特徴. シンポジウム6「膵癌の早期診断と病理」  [通常講演]
    坂本 洋城; 北野 雅之; 竹山 宜典; 安田 武生; 中居 卓也; 工藤 正俊
    第43回日本膵臓学会大会 2012年06月 ホテルメトロポリタン山形, 山形 第43回日本膵臓学会大会
  • CT perfusionによる肝血行動態解析：sorafenib投与による背景肝血流の変化と肝細胞癌治療効果  [通常講演]
    兵頭 朋子; 村上 卓道; 岡田 真広; 香川 祐毅; 日高 正二朗; 栁生 行伸; 上嶋 一臣; 矢田 典久; 松木 充; 石井 一成; 工藤 正俊
    第12回関西肝血流動態イメージ研究会 2012年06月 大阪 第12回関西肝血流動態イメージ研究会
  • 特別講演「ネクサバール発売後3年間の治療成績」  [通常講演]
    工藤 正俊
    沖縄肝癌治療セミナー 2012年06月 沖縄県医師会館, 沖縄 沖縄肝癌治療セミナー
  • 司会: ランチョンセミナー  [通常講演]
    工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • IL28BとPEG-IFN/RBV併用療法をうけたHCVジェノタイプ1型高ウイルス量患者の効果との関連について  [通常講演]
    田北 雅弘; 萩原 智; 有住 忠晃; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊; 鄭 浩柄
    第48回日本肝臓学会総会 2012年06月 JR金沢駅前もてなしドーム, 金沢 第48回日本肝臓学会総会
  • Interventional radiologyにおける新しい支援画像「FlightPlan」の有用性  [通常講演]
    南 康範; 工藤 正俊
    第48回日本肝臓学会総会 2012年06月 JR金沢駅前もてなしドーム, 金沢 第48回日本肝臓学会総会
  • 外科切除標本からの2cm以下のHCCに対するCE-US, 動注CT, EOB-MRIの術前診断の比較, 検討  [通常講演]
    小川 力; 工藤 正俊; 柴峠 光成
    第48回日本肝臓学会総会 2012年06月 JR金沢駅前もてなしドーム, 金沢 第48回日本肝臓学会総会
  • 経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討.  [通常講演]
    早石 宗右; 南 康範; 工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • 進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討.  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • Drug freeを目指したエンテカビルとPEG-IFNα2b 48週併用療法の効果について. ワークショップ22「B型慢性肝炎に対する抗ウイルス療法の継続と終了をめぐって」  [通常講演]
    萩原 智; 工藤 正俊; 大﨑 往夫
    第48回日本肝臓学会総会 2012年06月 ポルテ金沢, 金沢 第48回日本肝臓学会総会
  • 国際共同非介入試験GEDEON第2回中間解析における日本人集団解析結果ならびに投与開始時AFP値での層別解析の検討. ワークショップ13「肝細胞癌に対する分子標的薬開発の基礎から臨床」  [通常講演]
    奥坂 拓志; 工藤 正俊; 池田 公史; 高山 忠利; 沼田 和司; 泉 並木; 國土 典宏; 古瀬 純司; 角谷 眞済; 木村 丹香子
    第48回日本肝臓学会総会 2012年06月 ANAクラウンプラザホテル金沢, 金沢 第48回日本肝臓学会総会
  • 肝癌診療ガイドラインにおける治療アルゴリズムの妥当性～実臨床への展開とその問題点～. ワークショップ12「肝癌診療ガイドラインの活用と改訂への提案」  [通常講演]
    上嶋 一臣; 南 康範; 工藤 正俊
    第48回日本肝臓学会総会 2012年06月 ANAクラウンプラザホテル金沢, 金沢 第48回日本肝臓学会総会
  • Real-time Tissue Elastographyによる非アルコール性脂肪性肝炎の囲い込み. ワークショップ2「肝疾患における画像診断の課題と新たな展開」  [通常講演]
    矢田 典久; 工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • 司会, パネルディスカッション「肝細胞癌画像診断の進歩」  [通常講演]
    工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • 造影エコーによる肝癌肉眼分類の有用性について. パネルディスカッション「肝細胞癌画像診断の進歩」  [通常講演]
    早石 宗右; 南 康範; 工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • 肝細胞癌の化学療法. シンポジウム3「肝細胞癌の治療戦略」  [通常講演]
    工藤 正俊
    第48回日本肝臓学会総会 2012年06月 石川県立音楽堂, 金沢 第48回日本肝臓学会総会
  • 組織弾性法の領域別臨床応用  [通常講演]
    工藤 正俊
    第37回日本超音波検査学会ランチョンセミナーIII 2012年06月 札幌コンベンションセンター, 北海道 第37回日本超音波検査学会ランチョンセミナーIII
  • 座長: ランチョンセミナーIII「組織弾性法の領域別臨床応用」  [通常講演]
    工藤 正俊
    第37回日本超音波検査学会 2012年06月 札幌コンベンションセンター 第37回日本超音波検査学会
  • 当院における肝細胞癌分子標的治療の現状. パネルディスカッション「ソラフェニブ治療の実践－多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す―」  [通常講演]
    上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第6回日本肝がん分子標的治療研究会 2012年06月 ザ・プリンス箱根, 神奈川 第6回日本肝がん分子標的治療研究会
  • Phase 1b dose-escalation study of a phase 2 randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).  [通常講演]
    Ann-Lii Cheng; 工藤 正俊; Yoon-Koo Kang; Baek-Yeol Ryoo; Chia-Jui Yen; Ho Yeong Lim; Do-Youn Oh
    ASCO 2012 Annual Meeting 2012年06月 Chicago, USA ASCO 2012 Annual Meeting
  • Effect of rebamipide for endoscopic submucosal dissection (ESD)-induced ulcer in early gastric cancer: a randomized controlled trial.  [通常講演]
    松井 繁長; 工藤 正俊; 樫田 博史; 朝隈 豊; 櫻井 俊治; 川崎 正憲
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • A prospective feasibility study on EUS guided broad plexus in combination of celiac ganglion neurolysis in pancreatic cancer pain  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • Usefulness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: comparison with contrast-enhanced CT  [通常講演]
    井上 達夫; 有住 忠晃; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced sonography using perfluorocarbon microbubbles (sonazoid)  [通常講演]
    南 康範; 畑中 絹世; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • Activation of JNK in the Non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma  [通常講演]
    櫻井 俊治; 萩原 智; 井上 達夫; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • Percutaneous endoscopic gastrostomy with gastropexy greatly reduces the risk of peristomal infection and eases pain after the operation.  [通常講演]
    奥村 直己; 辻 直子; 工藤 正俊
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • Detection of small concomitant carcinomas distinct from intraductal papillary mucinous neoplasms under surveillance of the whole pancreas using EUS  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 坂本 洋城
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • Novel association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma  [通常講演]
    西田 直生志; 工藤 正俊; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 櫻井 俊治
    Digestive Disease Week(DDW) 2012 2012年05月 San Diego, USA Digestive Disease Week(DDW) 2012
  • 特別講演「肝細胞癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第9回城北消化器病研究会 2012年05月 ホテルメトロポリタン池袋, 東京 第9回城北消化器病研究会
  • 特別講演「肝疾患に対する超音波診断の新展開-Real-time Tissue Elastographyを用いて-」  [通常講演]
    工藤 正俊
    日本超音波医学会第85回学術集会ランチョンセミナー12 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会ランチョンセミナー12
  • ソナゾイド造影超音波におけるAP Shuntの診断について  [通常講演]
    前川 清; 横川 美加; 辻 裕美子; 前野 知子; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • ソナゾイド造影超音波による肝血管腫の診断についての検討  [通常講演]
    前野 知子; 横川 美加; 辻 裕美子; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • 当院におけるEUS下胆道ドレナージ術の有用性.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • 早期慢性膵炎におけるEUS画像の臨床的意義  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    日本超音波医学会第85回学術集 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集
  • 超音波エラストグラフィーによる非アルコール性脂肪性肝炎診断. ワークショップ6「消化器疾患診療における超音波Elastographyの有用性」  [通常講演]
    矢田 典久; 工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • 造影ハーモニックEUS (CH-EUS)を用いた腹部リンパ節の良悪性診断の試み. ワークショップ1「超音波内視鏡の進歩-診断と治療への応用-」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • シンポジウム7「肝腫瘍造影超音波過去5年の総括と今後の展望」, 座長: 森安史典, 工藤正俊  [通常講演]
    工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪 日本超音波医学会第85回学術集会
  • 下肢静脈超音波検査における仰臥位での下腿深部静脈血栓症診断の検討. ワークショップ14「静脈エコーで何処まで観るか？: 目的別にみた検査法の工夫」  [通常講演]
    小谷 敦志; 谷口 京子; 河野 ふみえ; 前川 清; 中江 健市; 保田 知生; 工藤 正俊; 久保田 義則
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • 肝領域における組織弾性評価法: 「硬さ」と「粗さ」の違い. シンポジウム6「組織弾性評価の手法と用語の標準化に向けて」  [通常講演]
    矢田 典久; 工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • パネリスト, シンポジウム「今後の超音波医学の発展のために」  [通常講演]
    工藤 正俊
    日本超音波医学会第85回学術集会 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会
  • Invited Lecture "CEUS as a screening tool of HCC in cirrhotic liver."  [通常講演]
    工藤 正俊
    ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging 2012年05月 Korea ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging
  • Invited Lecture "CEUS in the pancreatobiliary intervention."  [通常講演]
    工藤 正俊
    ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging 2012年05月 Korea ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging
  • 特別講演「ソナゾイド発売5年」  [通常講演]
    工藤 正俊
    日本超音波医学会第85回学術集会ランチョンセミナー2 2012年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第85回学術集会ランチョンセミナー2
  • Role of contrast-enhanced harmonic EUS in differentiating malignant from benigh lymphadenopathy.  [通常講演]
    宮田 剛; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 門阪 薫平; 工藤 正俊
    The 83rd Congress of the Japan Gastroenterological Endoscopy Society 2012年05月 Tokyo The 83rd Congress of the Japan Gastroenterological Endoscopy Society
  • IPMNの診断・フォローアップにおけるEUSの役割. ワークショップ9「IPMNの診断・治療における内視鏡の役割」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • 十二指腸静脈瘤の臨床的特徴と治療指針. ワークショップ3「異所性静脈瘤の病態と治療指針」  [通常講演]
    松井 繁長; 川崎 正憲; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • 当院でのEUS下胆管ドレナージ術の安全性の検討. VTRシンポジウム6「安全かつ効果的な胆道Stentingを求めて」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • EUSガイド下治療におけるトラブルシューティング. VTRシンポジウム1「内視鏡治療に伴う偶発症の対処法-胆膵病変-」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • 噴門部静脈瘤合併巨大型食道静脈瘤の内視鏡的治療の工夫. シンポジウム11「危ない静脈瘤出血の病態と治療」  [通常講演]
    松井 繁長; 朝隈 豊; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • 胆石性膵炎の診断・治療におけるEUSの役割. シンポジウム1「胆・膵疾患の救急医療の現状と治療戦略」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • 当院におけるEUS下複合神経叢融解術の適応と限界. シンポジウム4「EUSガイド下治療の適応と限界」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • 造影ハーモニックEUSによるSMTの鑑別診断およびGISTの悪性度評価. ワークショップ6「上部消化管粘膜下腫瘍の内視鏡による診断と治療」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • EUS-guided drainage for biliary obstruction after unsuccessful ERCP. International Symposium “EUS-FNA: Current status and new developments”  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    Tokyo 2012年05月 The 83rd Congress of the Japan Gastroenterological Endoscopy Society Tokyo
  • A prospective study feasibility combination of EUS guided broad plexus-neuro lysis and celiac ganglion neurolysis. International Symposium “EUS-FNA: Current status and new developments”  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    The 83rd Congress of the Japan Gastroenterological Endoscopy Society 2012年05月 Tokyo The 83rd Congress of the Japan Gastroenterological Endoscopy Society
  • 造影ハーモニックEUSによるSMTの鑑別診断およびGISTの悪性度評価. ワークショップ「上部消化管粘膜下腫瘍の内視鏡による診断と治療」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • A prospective study feasibility combination of EUS guided broad plexus-neuro lysis and celiac ganglion neurolysis. Symposium “EUS-FNA: Current status and new developments”  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年05月 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • Dual energy CTを用いた肝脂肪の定量評価：ファントム実験と初期臨床経験  [通常講演]
    兵頭 朋子; 岡田 真広; 村上 卓道; 工藤 正俊; 矢田 典久; 工藤 正幸
    第71回日本医学放射線学会学術集会 2012年04月 横浜 第71回日本医学放射線学会学術集会
  • Invited Lecture "Endoscopic ultrasound in the differential diagnosis of cystic pancreatic lesions: do we always need it?"  [通常講演]
    工藤 正俊
    EFSUMB Annual Meeting EUROSON 2012 2012年04月 Madrid, Spain EFSUMB Annual Meeting EUROSON 2012
  • 経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討.  [通常講演]
    早石 宗右; 南 康範; 足立 哲平; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 鄭 浩柄
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • 非上皮性肝悪性腫瘍の3例.  [通常講演]
    足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • プロトンポンプ阻害薬（PPI）内服中GERD患者に対するGerdQによる治療効果の評価.  [通常講演]
    大本 俊介; 松井 繁長; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • 限局性腫瘤を形成した自己免疫性膵炎におけるEUS所見の検討. ワークショップ10「IgG4関連肝胆膵疾患の診断と治療-非典型例へのアプローチ」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • 超音波エラストグラフィーによる非アルコール性脂肪性肝炎診断. シンポジウム8「臓器線維化（肝・膵を中心）研究・診療の最前線」  [通常講演]
    矢田 典久; 萩原 智; 工藤 正俊
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • 当院におけるStage I膵癌の特徴. シンポジウム5「膵胆道癌の早期診断」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • Invited Lecture "The role of TACE & Nexavar in HCC treatment."  [通常講演]
    工藤 正俊
    HCC Expert Symposium on Tumor Therapy 2012年04月 Seoul, Korea HCC Expert Symposium on Tumor Therapy
  • Invited Lecture "Management of hepatocellular carcinoma.  [通常講演]
    工藤 正俊
    2012年04月 Yonsei University, Korea
  • 司会: シンポジウム4「肝細胞癌集学的治療の現況と再発予防」  [通常講演]
    工藤 正俊
    第98回日本消化器病学会総会 2012年04月 京王プラザ 第98回日本消化器病学会総会
  • The management of HCC in Japan. The role of TACE in management of HCC: Korea and Japan  [通常講演]
    工藤 正俊
    2012 BESTT symposium 2012年04月 Seoul, Korea 2012 BESTT symposium
  • Observed patterns of systemic therapy use in hepatocellular carcinoma (HCC) patients from the multinational HCC BRIDGE Study: Results of a second interim analysis.  [通常講演]
    Massimo Colombo; 工藤 正俊; Lewis Roberts; Myron Schwartz; Francoise Degos; Morris Sherman; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson; Baisong Huang
    47th Annual Meeting of the European Association for the Sudy of the Liver (EASL) 2012年04月 Barcelona, Spain 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with SoraenibB) Second interim analysis: Clinical findings in Child-pugh B score subgourps.  [通常講演]
    Jean-Pierre Bronowicki; 工藤 正俊; Sheng-Long Ye; Jorge Marrero; Lucy Dagher; Junji Furuse; Jeff F. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Seung Kew Yoon; Riccardo Lencioni
    47th Annual Meeting of the European Association for the Sudy of the Liver (EASL) 2012年04月 Barcelona, Spain 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • Opening Lectures “Contrast-enhanced EUS of pancreatic tumors”  [通常講演]
    工藤 正俊
    EFSUMB Annual Meeting EUROSON 2012 2012年04月 Madrid, Spain EFSUMB Annual Meeting EUROSON 2012
  • 座長: 工藤正俊  [通常講演]
    工藤 正俊
    第8回Kinki Liver Club 2012年03月 スイスホテル南海大阪, 大阪 第8回Kinki Liver Club
  • Management of hepatocellular carcinoma: Recent progress.  [通常講演]
    工藤 正俊
    the 42nd Annual Meeting of GEST and The 21st Annual Meeting of DEST 2012年03月 Taipei, Taiwan the 42nd Annual Meeting of GEST and The 21st Annual Meeting of DEST
  • From JSH treatment guideline to combination therapy.  [通常講演]
    工藤 正俊
    HCC Expert Meeting ?New Advances in HCC Management 2012年03月 Taipei, Taiwan HCC Expert Meeting ?New Advances in HCC Management
  • 特別講演「肝硬変・肝癌の治療のガイドラインと発癌抑制」  [通常講演]
    工藤 正俊
    リーバクト配合顆粒発売15周年記念講演会 2012年03月 ホテルオークラ札幌, 北海道 リーバクト配合顆粒発売15周年記念講演会
  • Lemmel症候群の1例. Young Endoscopist Session  [通常講演]
    木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • シングルバルーン小腸内視鏡検査（SBE）にて診断された小腸血管性病変の検討. Young Endoscopist Session  [通常講演]
    大本 俊介; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • 難治性潰瘍性大腸炎に対してIFXが奏功した症例. Fresh Endoscopist Session  [通常講演]
    田中 梨絵; 峯 宏昌; 大本 俊介; 足立 哲平; 高山 政樹; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • 貧血を契機に発見された腸間膜静脈硬化症の一例. Fresh Endoscopist Session  [通常講演]
    一木 美穂; 奥田 英之; 宮部 欽生; 茂山 朋広; 豊澤 昌子; 秦 康倫; 木下 大輔; 川崎 俊彦; 太田 善夫; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • リセドロネートによると考えられた十二指腸潰瘍の一例. Fresh Endoscopist Session  [通常講演]
    高場 雄久; 松本 望; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 南 康範; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • 当院におけるEUS下複合神経叢溶解術の適応と限界. ワークショップ「EUSによる消化器疾患の診断と治療の進歩」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • 内視鏡治療における高齢者の特殊性. シンポジウム「高齢者における内視鏡治療の適応と限界（消化管）」  [通常講演]
    櫻井 俊治; 松井 繁長; 工藤 正俊
    第88回日本消化器内視鏡学会近畿地方会 2012年03月 大阪国際交流センター, 大阪 第88回日本消化器内視鏡学会近畿地方会
  • Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma.  [通常講演]
    永井 知行; 荒尾 徳三; 松本 和子; 藤田 至彦; 林 秀敏; 木村 英晴; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人
    AACR 103rd Annual Meeting 2011 2012年03月 Chicago, USA AACR 103rd Annual Meeting 2011
  • Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): second interim analysis [1500 patients] of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study.  [通常講演]
    JF Geschwind; 工藤 正俊; R Lencioni; J Marrero; A Venook; S-L Ye
    SIR 2012 2012年03月 San Francisco, USA SIR 2012
  • アダリムマブにて蛋白尿が改善したCrohn病関連二次性アミロイドーシスの１例  [通常講演]
    辻 直子; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 南 康範; 工藤 正俊
    第８回日本消化管学会総会 2012年02月 仙台市 第８回日本消化管学会総会
  • シングルバルーン小腸内視鏡検査にて診断された小腸血管性病変の検討.  [通常講演]
    高山 政樹; 川崎 正憲; 峯 宏昌; 永田 嘉昭; 永井 知行; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    第8回日本消化管学会総会学術集会 2012年02月 仙台国際センター, 宮城 第8回日本消化管学会総会学術集会
  • Real life experience with Sorafenib: GIDEON, the largest prospective global study in HCC. Satellite symposium Advances in HCC management : from diagnosis to treatment  [通常講演]
    工藤 正俊
    The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012) 2012年02月 Taipei, Taiwan The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
  • Hepatocellular carcinoma. APASL-AASLD symposium-When east meets west: Management of the complications of cirrhosis  [通常講演]
    工藤 正俊
    The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012) 2012年02月 Taipei, Taiwan The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
  • Evolving strategies on the treatment of HCC: Physician’s perspective.  [通常講演]
    工藤 正俊
    The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012) 2012年02月 Taipei, Taiwan The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
  • CEUS, EOB-MRI, targeted therapy and Japanese HCC guideline.  [通常講演]
    工藤 正俊
    Cancer Genomics: a way to personalized medicine 2012年02月 Taipei, Taiwan Cancer Genomics: a way to personalized medicine
  • 特別講演「Sonazoidは肝癌診療をどう変えたか？」  [通常講演]
    工藤 正俊
    第17回鈴鹿肝胆膵画像研究会 2012年02月 ホテルグリーンパーク鈴鹿, 三重 第17回鈴鹿肝胆膵画像研究会
  • Observations of hepatocellular carcinoma (HCC) management ptterns from the Global HCC BRIDGE Study: An interim analysis of the Asia-Pacific (AP) Cohort.  [通常講演]
    Pei-Jer Chen; 工藤 正俊; Joon-Won Park; Minshan Chen; Morris Sherman; Phillip Johnson; Massimo Colombo; Lewis Roberts; Baisong Huang
    Asian Pacific Association for the Study of the Liver (APASL) 2012 2012年02月 Taipei, Taiwan Asian Pacific Association for the Study of the Liver (APASL) 2012
  • GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its Treatment with sorafeNib) second interim analysis (IA): subgroup analysis by race.  [通常講演]
    Junji Furuse; 工藤 正俊; Sheng-Long Ye; Jorge Marrero; Riccardo Lencioni; Alan Venook
    Asian Pacific Association for the Study of the Liver (APASL) 2012 2012年02月 Taipei, Taiwan Asian Pacific Association for the Study of the Liver (APASL) 2012
  • 特別講演「肝細胞癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第3回中四国肝臓病研究会 2012年02月 ホテルグランヴィア岡山, 岡山 第3回中四国肝臓病研究会
  • Invited Lecture "Intravascular treatment (TACE, HAIC)"  [通常講演]
    工藤 正俊
    10th International Conference ofthe Asian Clinical Oncology Society (ACOS) 2012年 Seoul, Korea 10th International Conference ofthe Asian Clinical Oncology Society (ACOS)
  • 当院における表在型パレット食道腺癌に対する内視鏡的診断と治療の検討.  [通常講演]
    朝隈 豊; 松井 繁長; 足立 哲平; 大本 俊介; 高山 政樹; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • Estination of EUS features of chronic pancreatitis in comparison with clinical symptoms  [通常講演]
    門阪 薫平; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 工藤 正俊
    The 83rd Congress of the Japan Gastroenterological Endoscopy Society 2012年 Tokyo The 83rd Congress of the Japan Gastroenterological Endoscopy Society
  • EUSによる早期慢性膵炎の画像所見と臨床症状との関連性の検討. パネルディスカッション5「慢性膵炎の内視鏡診断と治療」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第83回日本消化器内視鏡学会総会 2012年 グランドプリンスホテル新高輪, 東京 第83回日本消化器内視鏡学会総会
  • EUSによる早期慢性膵炎の各画像所見と臨床症状の検討. ワークショップ5「生活習慣と肝・胆・膵疾患」  [通常講演]
    門阪 薫平; 北野 雅之; 工藤 正俊
    第98回日本消化器病学会総会 2012年 京王プラザ 第98回日本消化器病学会総会
  • Observations of Hepatocellular Carcinoma (HCC) Management Patterns from the Global HCC BRIDGE Study: First Characterization of the Full Study Population.  [通常講演]
    Joong-Won Park; 工藤 正俊; Morris Sherman; Massimo Colombo; Lewis Roberts Terry Therneau; Myron Schwartz; Francoise Degos; Pei-Jer Chen; Minshan Chen; Phillip Johnson; Baisong Huang
    ASCO 2012 Annual Meeting 2012年 Chicago, USA ASCO 2012 Annual Meeting
  • Percutaneous endoscopic gastrostomy with gastropexy greatly reduces the risk of peristomal infection.  [通常講演]
    辻 直子; 奥村 直己; 山本 典雄; 高場 雄久; 松本 望; 工藤 正俊
    Clinical Nutrition Week 2012 2012年01月 Florida, USA Clinical Nutrition Week 2012
  • Interventional radiology における新しい支援画像「FightPlan」の初期臨床経験  [通常講演]
    南 康範; 有住 忠晃; 早石 宗右; 工藤 正俊; 柳生 行伸; 村上 卓道
    第18回肝血流動態イメージ研究会 2012年01月 神戸 第18回肝血流動態イメージ研究会
  • CE-US、CT-Angio、EOB-MRIと病理の比較～術前診断が2cm以下の肝切除症例～.  [通常講演]
    小川 力; 工藤 正俊; 大原 芳章; 宮本; 由貴子; 柴峠; 光成; 山岡; 竜也; 廣瀬; 哲朗; 西平; 友彦; 嶋田; 俊秀; 荻野; 哲朗; 河合 直之
    第18回肝血流動態イメージ研究会 2012年01月 神戸ポートピアホテル, 兵庫 第18回肝血流動態イメージ研究会
  • 進行肝細胞癌患者に対する分子標的薬（ソラフェニブ）投与における治療効果判定基準の比較.  [通常講演]
    有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊; 竹田 治彦; 大﨑
    第18回肝血流動態イメージ研究会 2012年01月 神戸ポートピアホテル, 兵庫 第18回肝血流動態イメージ研究会
  • 超音波エラストグラフィーによる非アルコール性脂肪性肝炎診断.  [通常講演]
    矢田 典久; 萩原 智; 工藤 正俊
    第18回肝血流動態イメージ研究会 2012年01月 神戸ポートピアホテル, 兵庫 第18回肝血流動態イメージ研究会
  • 造影エコーによる肝癌肉眼分類の有用性について.  [通常講演]
    早石 宗右; 南 康範; 畑中 絹世; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第18回肝血流動態イメージ研究会 2012年01月 神戸ポートピアホテル, 兵庫 第18回肝血流動態イメージ研究会
  • Interventional radiologyにおける新しい支援画像「FlightPlan」の初期臨床経験.  [通常講演]
    南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 柳生 行伸; 村上 卓道
    第18回肝血流動態イメージ研究会 2012年01月 神戸ポートピアホテル, 兵庫 第18回肝血流動態イメージ研究会
  • Percutaneous Endoscopic Gastrostomy with Gastropexy Greatly Reduces the Risk of Peristomal Infection  [通常講演]
    辻 直子; 奥村 直己; 山本 典雄; 高場 雄久; 松本 望; 工藤 正俊
    CNW2012 (Clinical Nutrition Week) (ASPEN) 2012年01月 Orland CNW2012 (Clinical Nutrition Week) (ASPEN)
  • 脾仮性動脈瘤の胃内穿破に対してIVRによる止血が有用であった一例. Freshman Session「肝胆膵」  [通常講演]
    平木 洋子; 早石 宗右; 川崎 正憲; 朝隈 豊; 南 康範; 松井 繁長; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • 糖尿病に対しインスリン導入後早期に発症した腫瘤形成性膵炎の1例. Freshman Session「肝胆膵」  [通常講演]
    安達 融; 谷浦 允厚; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 野口 周也; 大野 恭裕; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • 微小膵癌との鑑別を要した自己免疫性膵炎の1例. Freshman Session「肝胆膵」  [通常講演]
    和田 翔太; 宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • 虫垂粘液嚢胞腺腫の1例. Freshman Session「消化管」  [通常講演]
    玉田 博之; 秦 康倫; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊; 佐藤 克明; 木谷 光太郎; 井上 雅智; 太田 善夫
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • 成人腸重積で発症した盲腸癌の1例. Freshman Session「消化管」  [通常講演]
    谷浦 允厚; 安達 融; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 亀井 敬子; 北野 義徳; 田中 晃; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • 当院における悪性胃十二指腸狭窄に対する消化管ステントの成績. シンポジウム「手術不能進行癌に対する集学的治療の現況と新たな展開（消化管）」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • プロトンポンプ阻害薬内服中GERD患者におけるGerdQの有用性. Young Investigator Session「食道」  [通常講演]
    大本 俊介; 松井 繁長; 足立 哲平; 川崎 正憲; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • PEG-IFN α2a/RBV併用療法におけるResponse-Guided TherapyとIL28B多型との関連性の検討: ReGIT-J study. ワークショップ「ウイルス肝炎治療の新たな展開」  [通常講演]
    津田 泰宏; 工藤 正俊; 樋口 和秀; 西口 修平
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • ペグインターフェロンα-2b・エンテカビル48週間併用療法の治療成績. ワークショップ「ウイルス肝炎治療の新たな展開」  [通常講演]
    犬塚 義; 工藤 正俊; 木村 達; 大﨑
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • 造影エコーによる肝癌肉眼分類の有用性について.  [通常講演]
    早石 宗右; 南 康範; 畑中 絹世; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): second interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study.  [通常講演]
    Jeff Geschwind; 工藤 正俊; Riccardo Lencioni; Jorge Marrero; Alan Venook; Sheng-Long Ye
    2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012) 2012年01月 San Francisco, USA 2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)
  • Second interim analysis of GIDEON (Global Investigation of therapeutic DEcisions in unresectable hepatocellular carcinoma and Of its treatment with sorafeNib): differences in adverse-event reporting across physician specialties.  [通常講演]
    Alan Venook; 工藤 正俊; Riccardo Lencioni; Jorge Marrero; Sheng-Long Ye
    2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012) 2012年01月 San Francisco, USA 2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)
  • 講演「肝臓がんの内科的治療」  [通常講演]
    工藤 正俊
    近畿大学医学部附属病院がんセンター第35回ともに生きる会 2012年01月 近畿大学医学部附属病院PET棟3階 大会議室, 大阪 近畿大学医学部附属病院がんセンター第35回ともに生きる会
  • 特別講演「肝疾患最近の話題」  [通常講演]
    工藤 正俊
    東四国ベアネットカンファレンス 2011年12月 全日空ホテルクレメント高松, 香川 東四国ベアネットカンファレンス
  • Diagnosis of gross pathology of HCC: Value of Kupffer phase of Sonazoid-enhanced US.  [通常講演]
    工藤 正俊
    3rd Asia-Pacific Conference on Ultrasound Contrast Imaging, 13th International Symposium on Ultrasou 2011年12月 Kunming, China 3rd Asia-Pacific Conference on Ultrasound Contrast Imaging, 13th International Symposium on Ultrasou
  • Molecular targeting therapy.  [通常講演]
    工藤 正俊
    Session “HCV and HCC I”, The 7th APASL single topic conference 2011年12月 Chiba, Japan Session “HCV and HCC I”, The 7th APASL single topic conference
  • 糞線虫症の２例  [通常講演]
    橋本 知江美; 河野 匡史; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 辻 直子; 浦瀬 文明; 梅原 泰; 工藤 正俊
    第196回 日本内科学会近畿地方会 2011年12月 京都市 第196回 日本内科学会近畿地方会
  • 尋常性乾癬に対してインフリキシマブを投与中に発症した抗ミトコンドリアＭ2抗体陽性肝障害の１例  [通常講演]
    河野 匡史; 橋本 知江美; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 辻 直子; 南 康範; 工藤 正俊
    第196回 日本内科学会近畿地方会 2011年12月 京都市 第196回 日本内科学会近畿地方会
  • 基調講演「肝癌治療アルゴリズムと治療法の選択」  [通常講演]
    工藤 正俊
    第39回日本肝臓学会西部会 2011年12月 岡山コンベンションセンター, 岡山 第39回日本肝臓学会西部会
  • Clinical staging systems for HCC. Symposium “HCC staging and response assessment”  [通常講演]
    工藤 正俊
    APASL 2nd Hepatocellular catcinmoma conference (APASL STC) 2011年12月 Jeju, Korea APASL 2nd Hepatocellular catcinmoma conference (APASL STC)
  • Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: An interim analysis from a South Korean Referral Center.  [通常講演]
    Joong-Won Park; 工藤 正俊; Hwi Young Kim; Pei-Jer Chen; Minshan Chen; Phillip Johnson; Morris Sherman; Massimo Colombo; Lewis Roberts
    APASL 2nd Hepatocellular catcinmoma conference (APASL STC) 2011年12月 Jeju, Korea APASL 2nd Hepatocellular catcinmoma conference (APASL STC)
  • How to Use Liver Imaging Reporting and Data System (LI-RADS) in Patients with Hepatocellular Carcinoma (HCC)  [通常講演]
    岡田 真広; 村上 卓道; 工藤 正俊; 横浜市立大学付属市民総合医療センター消化器病センター; ミュンヘン大学放射線科; 大船中央病院病理科
    RSNA - Educational Poster Session 2011年11月 Chicago RSNA - Educational Poster Session
  • Analysis of Elasticity Image of Chronic Hepatitis Based on Dynamic Model of Fibrosis Progression.  [通常講演]
    牧 智紀; 工藤 正俊; 椎名 毅; 山川; 藤本 研治
    The 32nd Symposium on Ultrasonic Electronics (USE 2011) 2011年11月 Kyoto, Japan The 32nd Symposium on Ultrasonic Electronics (USE 2011)
  • 超音波エラストグラフィーは、肝生検の代替になりうるか.  [通常講演]
    矢田 典久; 萩原 智; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第53回大阪肝穿刺生検治療研究会 2011年11月 ホテルグランヴィア大阪, 大阪 第53回大阪肝穿刺生検治療研究会
  • 特別講演「分子機序に基づく癌治療戦略」  [通常講演]
    工藤 正俊
    第53回大阪肝穿刺生検治療研究会 2011年11月 ホテルグランヴィア大阪, 大阪 第53回大阪肝穿刺生検治療研究会
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    腹部超音波オープンカンファレンス特別講演会 2011年11月 神戸市立医療センター中央市民病院, 兵庫 腹部超音波オープンカンファレンス特別講演会
  • Lecture “Sonazoid-enhanced US in the management of HCC.”  [通常講演]
    工藤 正俊
    9th ABDA teaching course in conjuction with AFSIMB Workshop 2011年11月 Bali, Indonesia 9th ABDA teaching course in conjuction with AFSIMB Workshop
  • Lecture “Interventional EUS for pancreatobiliary tumors.”  [通常講演]
    工藤 正俊
    9th ABDA teaching course in conjuction with AFSIMB Workshop 2011年11月 Bali, Indonesia 9th ABDA teaching course in conjuction with AFSIMB Workshop
  • Second interim analysis of GIDEON (Global investigation of therapeutic decisions in unresectable HCC [UHCC] and of its treatment with Sorafenib): subgroup analysis by initial sorafenib (Sor) dose.  [通常講演]
    Jorge A. Marrero; 工藤 正俊; Alan Venook; Sheng-Long Ye; Riccardo Lencioni
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Second interim analysis of GIDEON (Global investigation of ther-apeutic decisions in unresectable HCC [UHCC] and of its treatment with Sorafenib): multiregional variation in patient (pt) characteristics, previous treatment history, and sorafenib (Sor) use  [通常講演]
    工藤 正俊; Sheng-Long Ye; Alan Venook; Jorge A. Marrero; Riccardo Lencioni
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Assessment of hepatobiliary phase Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection ability versus MDCT.  [通常講演]
    井上 達夫; 工藤 正俊; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 岡田 真広; 兵頭 朋子; 村上 卓道
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Impact on aberrant methylation of an unique subset of tumor suppressor genes on the initial steps of human hepatocarcinogenesis.  [通常講演]
    西田 直生志; 工藤 正俊; Takeshi Nagasaka; Ajay Goel
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • 特別講演「造影超音波は肝癌診療をどう変えたか？」  [通常講演]
    工藤 正俊
    第11回北海道腹部造影エコー・ドプラ診断研究会 2011年11月 第一三共株式会社札幌支店, 北海道 第11回北海道腹部造影エコー・ドプラ診断研究会
  • 膵仮性嚢胞に伴った膵仮性動脈瘤の1例.  [通常講演]
    前野 知子; 横川 美加; 辻 裕美子; 桑口 愛; 前川 清; 今井 元; 井上 達夫; 南 康範; 樫田 博史; 工藤 正俊
    日本超音波医学会第38回関西地方会学術集会 2011年11月 大阪国際会議場, 大阪 日本超音波医学会第38回関西地方会学術集会
  • 体外式超音波穿刺用コンベックスプローブEUP-B715の使用経験.  [通常講演]
    矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    日本超音波医学会第38回関西地方会学術集会 2011年11月 大阪国際会議場, 大阪 日本超音波医学会第38回関西地方会学術集会
  • 非上皮性肝腫瘤2例の造影超音波像について.  [通常講演]
    横川 美加; 辻 裕美子; 桑口 愛; 前野 知子; 前川 清; 井上 達夫; 南 康範; 上嶋 一臣; 樫田 博史; 工藤 正俊
    日本超音波医学会第38回関西地方会学術集会 2011年11月 大阪国際会議場, 大阪 日本超音波医学会第38回関西地方会学術集会
  • 造影エコーによる肝癌肉眼分類の有用性について.  [通常講演]
    早石 宗右; 南 康範; 畑中 絹世; 井上 達夫; 工藤 正俊
    日本超音波医学会第38回関西地方会学術集会 2011年11月 大阪国際会議場, 大阪 日本超音波医学会第38回関西地方会学術集会
  • 肝エラストグラフィ ?各モダリティ―における測定原理と結果の解釈-. ワークショップ「組織弾性イメージング」  [通常講演]
    矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    日本超音波医学会第38回関西地方会学術集会 2011年11月 大阪国際会議場, 大阪 日本超音波医学会第38回関西地方会学術集会
  • 肝癌に対するラジオ波焼灼療法の治療効果判定 造影USと造影CTの比較検討. パネルディスカッション「造影超音波」  [通常講演]
    井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    日本超音波医学会第38回関西地方会学術集会 2011年11月 大阪国際会議場, 大阪 日本超音波医学会第38回関西地方会学術集会
  • Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit.  [通常講演]
    北井 聡; 工藤 正俊; 泉 並木; 坂本 穣; 松山 裕; 市田 隆文; 中島 收; 松井 修; 具 英成; 國土 典宏; 幕内 雅敏
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Phase I study of Sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy.  [通常講演]
    上嶋 一臣; 工藤 正俊; 鄭 浩柄; 萩原 智; 井上 達夫; 矢田 典久; 南 康範; 櫻井 俊治; 田中 正俊; 熊田 卓
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Efficacy and safety of sorafenib for hepatocellular carcinoma: a multicenter retrospective study in Japan.  [通常講演]
    金子 周一; 工藤 正俊; 古瀬 純司; 池田 健次
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Drastic improvement of survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients.  [通常講演]
    工藤 正俊; 泉 並木; 坂元 享宇; 松山 裕; 市田 隆文; 中島 收; 松井 修; 具 英成; 國土 典宏; 幕内 雅敏
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: Comparion with multidetector row CT.  [通常講演]
    井上 達夫; 工藤 正俊; 畑中 絹世; 南 康範; 上嶋 一臣; 有住 忠晃; 田北 雅弘; 北井 聡
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Updated Liver Function Imaging by MRI and CT: Quantification Analysis for Hepatic Steatosis, Fibrosis, and Siderosis.  [通常講演]
    岡田 真広; 工藤 正俊; 村上 卓道; 工藤 正幸
    RSNA - Educational Poster Session 2011年11月 Chicago RSNA - Educational Poster Session
  • Advanced CT Evaluation for Liver Imaging: Perfusion CT, Ultrafast Arterial Scanning of Whole Liver and Dual-Energy CT.  [通常講演]
    山田 浩司; 岡田 真広; 工藤 正俊; 矢田 典久; 村上 卓道; 工藤 正幸
    RSNA - Educational Poster Session 2011年11月 Chicago RSNA - Educational Poster Session
  • Atypical Imaging of Liver Hemangioma: Pictorial Review by Gd-EOB-DTPA-enhanced MRI, Dynamic CT and Sonography.  [通常講演]
    岡田 真広; 兵頭 朋子; 香川 祐毅; 工藤 正俊; 村上 卓道; 沼田 和司
    RSNA - Scientific Poster Session 2011年11月 Chicago RSNA - Scientific Poster Session
  • Hepatocellular Carcinoma: Pictorial Review for the Planning of Therapy and the Evaluation after Therapy.  [通常講演]
    岡田 真広; 兵頭 朋子; 香川 祐毅; 工藤 正俊; 村上 卓道; 沼田 和司
    RSNA - Educational Poster Session 2011年11月 Chicago RSNA - Educational Poster Session
  • Evaluation of Angiogenesis after Antiangiogenic Therapy Using Liver CT Perfusion: Additional Detailed Capillary-level Hemodynamics in Patients with Advanced Hepatocellular Carcinoma.  [通常講演]
    岡田 真広; 工藤 正俊; 矢田 典久; 上嶋 一臣; 村上 卓道; 工藤 正幸
    RSNA - Scientific Poster Session 2011年11月 Chicago RSNA - Scientific Poster Session
  • Evaluation of Degree of Hepatic Fibrosis: Comparison T1 Mapping Technique of Gd-EOB-DTPA Enhanced MRI with US Elastography.  [通常講演]
    岡田 真広; 熊野 正士; 工藤 正俊; 矢田 典久; 小野田 農; 村上 卓道
    RSNA - Scientific Poster Session 2011年11月 Chicago RSNA - Scientific Poster Session
  • Mechanical model analysis for quantitative evaluation of liver fibrosis based on real-time tissue elastography.  [通常講演]
    Tsuyoshi Shiina; 工藤 正俊; Makoto Yamakawa
    The 10th International Tissue Elasticity Conference 2011年10月 Texas, USA The 10th International Tissue Elasticity Conference
  • ステロイド依存性の潰瘍性大腸炎に対する白血球除去療法の有用性と問題点の検討．  [通常講演]
    大本 俊介; 峯 宏昌; 櫻井 俊治; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会）
  • “Establishing treatment algorithms for hepatocellular carcinoma: What tests do we need?” , Symposium “When East meets West: Management of hepatocellular carcinoma”,  [通常講演]
    工藤 正俊
    19th United European Gastroenterology Week (UEGW) 2011年10月 Stockholm, Sweden 19th United European Gastroenterology Week (UEGW)
  • Verrucous antral gastritis is not related to H. pylori-positive chronic gastritis, but is related to a high BMI.  [通常講演]
    辻 直子; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 南 康範; 工藤 正俊
    APDW2011 2011年10月 Singapore APDW2011
  • Malignant gastric outlet obstruction (MGOO)に対するステント留置術と胃空腸吻合術の比較検討  [通常講演]
    山本 典雄; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 南 康範; 工藤 正俊
    第５３回日本消化器病学会大会 2011年10月 福岡市 第５３回日本消化器病学会大会
  • 内視鏡的胃液胆汁色の臨床的意義と評価  [通常講演]
    松本 望; 辻 直子; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊; 本庶 元
    第５３回日本消化器病学会大会 2011年10月 福岡市 第５３回日本消化器病学会大会
  • 本邦における多発肝嚢胞症の実態調査.  [通常講演]
    小川 光一; 工藤 正俊; 福永 潔; 大河内; 信弘; 竹内 朋代; 川岸 直樹
    第19回日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会）
  • Diagnostic utility of contrast enhanced harmonic EUS imaging in patients with submucosal tumor of gastrointersinal tract.  [通常講演]
    坂本 洋城; 北野 雅之; 今井 元; 小牧 孝充; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊
    19th United European Gastroenterology Week (UEGW) 2011年10月 Stockholm, Sweden 19th United European Gastroenterology Week (UEGW)
  • Long duration of stable disease may improve the overall survival in the patients with advanced hepa-tocellular carcinoma treated with Soraenib.  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    United European Gastroenterology Week (UEGW) 2011年10月 Stockholm, Sweden United European Gastroenterology Week (UEGW)
  • Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma; comparion eith MDCT.  [通常講演]
    井上 達夫; 工藤 正俊; 畑中 絹世; 南 康範; 上嶋 一臣; 北井 聡
    19th United European Gastroenterology Week (UEGW) 2011年10月 Stockholm, Sweden 19th United European Gastroenterology Week (UEGW)
  • Endoscopic ultrasonograph (EUS)-guided choledochoduo-denostomy and hepatogastrostomy for treatment of biliary obstruction.  [通常講演]
    今井 元; 北野 雅之; 坂本 洋城; 鎌田 研; 小牧 孝充; 宮田 剛; 門阪 薫平; 工藤 正俊
    19th United European Gastroenterology Week (UEGW) 2011年10月 Stockholm, Sweden 19th United European Gastroenterology Week (UEGW)
  • 特別講演「造影超音波は肝癌診療をどう変えたか？」  [通常講演]
    工藤 正俊
    肝炎・肝硬変治療レクチャーミーティング 2011年10月 川崎日航ホテル, 神奈川 肝炎・肝硬変治療レクチャーミーティング
  • Hepatocellular carcinoma: Recent development of molecular targeted agent.  [通常講演]
    工藤 正俊
    JSCO university “Hepatobiliary and pancreas cancers”, 第49回日本癌治療学会学術集会 2011年10月 名古屋国際会議場, 愛知 JSCO university “Hepatobiliary and pancreas cancers”, 第49回日本癌治療学会学術集会
  • 肝血管肉腫の2例.  [通常講演]
    有住 忠晃; 萩原 智; 大本 俊介; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会）
  • シングルバルーン小腸内視鏡の有用性について.  [通常講演]
    川崎 正憲; 峯 宏昌; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会）
  • 胃たこいぼびらんの臨床的内視鏡的検討.  [通常講演]
    辻 直子; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊; 本庶 元
    第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会）
  • 難治性食道カンジタ症に合併した食道乳頭腫の1例.  [通常講演]
    永田 嘉昭; 松井 繁長; 峯 宏昌; 高山 政樹; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会）
  • Barrett食道に発生した表在未分化癌の一例.  [通常講演]
    朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会） 2011年10月 福岡国際会議場, 福岡 第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会）
  • PEG-IFN α（もしくはIFN）/RBV併用療法でSVRが得られなかったGenotype 2型C型慢性肝炎に対するPEG-IFNα2a/RBV併用療法の有効性および安全性の検討（中間報告）  [通常講演]
    八橋 弘; 工藤 正俊; 泉 並木
    日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会） 2011年10月 福岡国際センター, 福岡 日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会）
  • IPMNの悪性度評価およびフォローアップにおける造影法を含めたEUSの有用性. ワークショップ「嚢胞性膵腫瘍の病態からみた治療」  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第9回日本消化器外科学会大会・第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会合同） 2011年10月 福岡国際センター, 福岡 第19回日本消化器関連学会週間JDDW 2011（第9回日本消化器外科学会大会・第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会合同）
  • 膵癌の早期診断のストラテジー. パネルディスカッション「膵管癌の危険因子と早期診断」  [通常講演]
    宮田 剛; 北野 雅之; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会・第9回日本消化器外科学会大会・第49回日本消化器がん検診学会大会合同） 2011年10月 福岡国際センター, 福岡 第19回日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会・第9回日本消化器外科学会大会・第49回日本消化器がん検診学会大会合同）
  • 経乳頭的胆管ドレナージ困難例に対するEUS下胆道ドレナージ術の有用性. パネルディスカッション「EUS-FNA関連の手技と工夫《ビデオ》」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会・第53回日本消化器病学会大会・第9回日本消化器外科学会大会合同） 2011年10月 福岡国際センター, 福岡 第19回日本消化器関連学会週間JDDW 2011（第82回日本消化器内視鏡学会総会・第53回日本消化器病学会大会・第9回日本消化器外科学会大会合同）
  • 分岐鎖アミノ酸による肝細胞癌へのNutrigenomics: 肝細胞癌合併肝硬変例に対する癌細胞内シグナル伝達制御. シンポジウム「消化器疾患における栄養マネージメント」  [通常講演]
    土師 誠二; 工藤 正俊; 荒尾 徳三
    第19回日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会・第15回日本肝臓学会大会・第9回日本消化器外科学会大会・第42回日本消化吸収学会総会合同） 2011年10月 福岡国際センター, 福岡 第19回日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会・第15回日本肝臓学会大会・第9回日本消化器外科学会大会・第42回日本消化吸収学会総会合同）
  • PEG-IFNα2a/RBV併用療法におけるResponse-Guided TherapyとIL28B多型との関連性の検討: ReGIT-J Study. シンポジウム「C型肝炎個別化医療のための宿主因子・ウイルス因子」  [通常講演]
    工藤 正俊; 樋口 和秀; 西口 修平
    第19回日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会・第53回日本消化器病学会大会合同） 2011年10月 福岡国際センター, 福岡 第19回日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会・第53回日本消化器病学会大会合同）
  • 癌性疼痛における超音波内視鏡下広範囲腹腔神経叢融解術（EUS-BPN）の有用性.  [通常講演]
    坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊
    第60回近畿膵疾患談話会 2011年10月 エーザイ株式会社大阪コミュニケーションオフィス, 大阪 第60回近畿膵疾患談話会
  • Does wire guided cannulation reduce the risk of pancreatic disorder?  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 門阪 薫平; 宮田 剛; 坂本 洋城; 今井 元; 小牧 孝充
    Asian Pacific Digestive Week (APDW) 2011 2011年10月 Singapore Asian Pacific Digestive Week (APDW) 2011
  • Endoscopic ultrasonography (EUS)-guided biliary drainage for treatment of biliary obstruction.  [通常講演]
    今井 元; 北野 雅之; 鎌田 研; 門阪 薫平; 宮田 剛; 坂本 洋城; 小牧 孝充; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2011 2011年10月 Singapore Asian Pacific Digestive Week (APDW) 2011
  • EG-IFN α/RBV併用療法でSVRが得られなかったGenotype 1型C型慢性肝炎に対するPEG-IFNα2a/RBV併用による再治療の有効性および安全性の検討（中間報告）  [通常講演]
    泉 並木; 工藤 正俊; 八橋 弘
    日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会） 2011年10月 福岡国際センター, 福岡 日本消化器関連学会週間JDDW 2011（第53回日本消化器病学会大会）
  • PEG-IFN α2b/RBV併用療法の無効・再燃例に対するPEG-IFN α2a/RBV併用療法の再治療の検討-多施設共同研究RETRY study-.  [通常講演]
    上田 泰輔; 工藤 正俊; 土谷 薫 泉; 並木; 橋元 悟; 井上 泰輔; 稲生 実枝; 田中 篤; 垣内 雅彦; 今関 文夫; 西口 修平; 八橋 弘
    日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会） 2011年10月 福岡国際センター, 福岡 日本消化器関連学会週間JDDW 2011（第15回日本肝臓学会大会）
  • S状結腸穿孔による手術標本により診断されたアレルギー性肉芽腫性血管炎の一例.  [通常講演]
    峯 宏昌; 大本 俊介; 高山 政樹; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊; 杉浦 史哲; 上田 和毅; 市橋 秀夫
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 下行結腸狭窄をきたしたCrohn病に対して内視鏡的拡張術とInfliximab投与により寛解維持を得た1症例.  [通常講演]
    永田 嘉昭; 樫田 博史; 大本 俊介; 高山 政樹; 峯 宏昌; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • Collagenous colitisの1症例.  [通常講演]
    秦 康倫; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 造影ハーモニックEUSを用いた腹部リンパ節の良悪性診断の試み.  [通常講演]
    宮田 剛; 坂本 洋城; 北野 雅之; 鎌田 研; 今井 元; 小牧 孝充; 門阪 薫平; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 腹水と下痢を契機に発見された好酸球性胃腸炎の一例.  [通常講演]
    山本 典雄; 辻 直子; 米田 円; 山田 哲; 森村 正嗣; 梅原 康湖; 冨田 崇文; 奥村 直己; 高場 雄久; 松本 望; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 肝膿瘍を契機に診断されたcholedochoceleの1例.  [通常講演]
    宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 膵領域診断における造影ハーモニックEUSの有用性の検討. シンポジウム「胆膵領域における内視鏡診断と治療-その基本と工夫」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 当院でのESDトレーニングシステム. パネルディスカッション「効率的なESDの技術習得に向けて（Animal Modelを用いたHands-on Training. を含む）」  [通常講演]
    川崎 正憲; 松井 繁長; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 当院におけるESDデバイスの使い分けについて. シンポジウム「ESDデバイスの使い分け（Animal Modelを用いたLive Demo. を含む）」  [通常講演]
    朝隈 豊; 松井 繁長; 工藤 正俊
    第87回日本消化器内視鏡学会近畿地方会 2011年10月 神戸ポートピアホテル, 兵庫 第87回日本消化器内視鏡学会近畿地方会
  • 特別講演「C型慢性肝炎の最新の治療」  [通常講演]
    工藤 正俊
    C型肝炎治療学術講演会 2011年10月 ホテルグランヴィア大阪, 大阪 C型肝炎治療学術講演会
  • PEG-IFNα（IFN）/RBV併用療法でSVRが得られなかったGenotype 1型C型慢性肝炎に対するPRG-IFNα2a/RBV併用による再治療の有効性及び安全性の検討（中間報告）.  [通常講演]
    泉 並木; 工藤 正俊; 八橋 弘
    第19回日本消化器関連学会週間 2011年10月 福岡国際センター, 福岡 第19回日本消化器関連学会週間
  • Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma.  [通常講演]
    永井 知行; 荒尾 徳三; 松本 和子; 工藤 可苗; 木村 英晴; 藤田 至彦; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人
    70th Annual Meeting of the Japanese Cancer Association 2011年10月 Nagoya, Japan 70th Annual Meeting of the Japanese Cancer Association
  • 当院におけるEUS-FNAのラーニングカーブについての検討.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第16回日本外科病理学会学術集会 2011年09月 大阪ガーデンパレス, 大阪 第16回日本外科病理学会学術集会
  • Second interim results of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its Treatment with sorafeNib) study: Barcelona-Clinic Liver Cancer (BCLC) stage subgroup analysis.  [通常講演]
    工藤 正俊; Riccardo Lencioni; Alan Venook; Jorge Marrero; Sheng-Long Ye
    16th ECCO-36th ESMO Multidisciplinary cancer congress 2011年09月 Stockholm, Sweden 16th ECCO-36th ESMO Multidisciplinary cancer congress
  • Observations of hepatocellular carcinoma (HCC) management patterns from the HCC BRIDGE Study: An interim analysis of the European cohort.  [通常講演]
    Massimo Colombo; 工藤 正俊; Robert Lewis Terry Therneau; Myron Schwartz; Fran?oise Degos; Morris Sherman; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson
    16th ECCO-36th ESMO Multidisciplinary cancer congress 2011年09月 Stockholm, Sweden 16th ECCO-36th ESMO Multidisciplinary cancer congress
  • Preferred strategies for inclusion in comprehensive liver cancer control in Asia.  [通常講演]
    J. F. Bridges; 工藤 正俊; G. Gallego; KH Han; SL Ye; B. M. Blauvelt
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Long duration of stable disease may improve the overall survival in the patients with advanced hepatocellular carcinoma treated with Sorafenib.  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • 特別講演「肝硬変・肝癌の治療ガイドラインと発癌抑制」  [通常講演]
    工藤 正俊
    リーバクト配合顆粒発売15周年講演会 2011年09月 城西館, 高知 リーバクト配合顆粒発売15周年講演会
  • Phase I study of Sorafenib in combination with low-dose cisplatin and flurouracil intra-arterilal infusion chemotherapy.  [通常講演]
    上嶋 一臣; 工藤 正俊; 櫻井 俊治; 鄭 浩柄; 南 康範; 萩原 智; 井上 達夫; 矢田 典久; 北井 聡; 有住 忠晃; 早石 宗右; 田中 正俊; 熊田 卓
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Assessment of hepatobiliary phase Gd-EOB-DTPA-Enhanced MRI for HCC and dysplastic nodules and comparison of detection ability versus MDCT.  [通常講演]
    井上 達夫; 工藤 正俊; 北井 聡; 有住 忠晃; 南 康範; 上嶋 一臣; 岡田 真広; 村上 卓道
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit.  [通常講演]
    北井 聡; 工藤 正俊; 有井 滋樹; 市田 隆文; 小俣 政男; 坂元 亨宇; 高安 賢一; 中島 收; 幕内 雅敏; 松山 裕; 門田 守人
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Second interim analysis of GIDEON (Global investigation of therapeutic decisions in HCC and of its treatment with Sorafenib): Regional variation in patient characteristics and treatment history.  [通常講演]
    工藤 正俊; R. Lencioni; A. Venook; J. Marrero; SL. Ye
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Benefit and nonsense in oncologic follow-up imaging and the role of US.  [通常講演]
    工藤 正俊
    13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011 2011年09月 Vienna, Austria 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
  • 特別講演「肝癌治療の現状と今後の展開」  [通常講演]
    工藤 正俊
    第7回西濃がん診療研究会学術講演会 2011年09月 大垣フォーラムホテル, 岐阜 第7回西濃がん診療研究会学術講演会
  • 胆嚢疾患の鑑別における造影ハーモニックEUSの有用性.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充
    第47回日本胆道学会学術集会 2011年09月 ワールドコンベンションセンターサミット, 宮崎 第47回日本胆道学会学術集会
  • EUSによる肝外胆管癌の進展度診断.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊; 中居 卓也; 竹山 宜典
    第47回日本胆道学会学術集会 2011年09月 ワールドコンベンションセンターサミット, 宮崎 第47回日本胆道学会学術集会
  • 当院でのEUS下胆道ドレナージ術の成績.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第47回日本胆道学会学術集会 2011年09月 ワールドコンベンションセンターサミット, 宮崎 第47回日本胆道学会学術集会
  • Wire Guided Cannulation法はERCP後膵障害のリスクを減少させるか.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充
    第47回日本胆道学会学術集会 2011年09月 ワールドコンベンションセンターサミット, 宮崎 第47回日本胆道学会学術集会
  • CT Perfusionによる肝細胞癌の分子標的薬治療効果予測  [通常講演]
    兵頭 朋子; 香川 祐毅; 岡田 真広; 日高 正二朗; 柳生 行伸; 熊野 正士; 柏木 伸夫; 小塚 健倫; 今岡 いずみ; 足利 竜一朗; 石井 一成; 工藤 正俊; 北野 雅之; 上嶋 一臣; 井上 達夫; 矢田 典久; 村上 卓道; 工藤 正幸
    第2回大阪消化器画像・IVR研究会 2011年09月 大阪 第2回大阪消化器画像・IVR研究会
  • A randomized, double-blind, placebo-controlled phase III study (EVOLVE-1) evaluating the efficacy and safety of everolimus in advanced HCC after failure of sorafenib treatment.  [通常講演]
    Andrew X. Zhu; 工藤 正俊; Dalila Sellami Oezlem Anak; Li-Tzong Chen
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Observed Patterns of Systemic Therapy Use in Hepatocellular Carcinoma (HCC) Patients From the Multinational HCC BRIDGE Study: An Initial Overall Analysis  [通常講演]
    Lewis Roberts; 工藤 正俊; Massimo Colombo; Myron Schwartz; Fran?oise Degos; Morris Sherman; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson; Terry Therneau; Baisong Huang
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Observations of Hepatocellular Carcinoma (HCC) Management Patterns From the Multinational HCC BRIDGE Study: An Interim Overall Analysis  [通常講演]
    Morris Sherman; 工藤 正俊; Massimo Colombo; Lewis Roberts Terry Therneau; Myron Schwartz; Fran?oise Degos; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson; Baisong Huang
    International Liver Cancer Association Fifth Annual Conference (ILCA) 2011 2011年09月 Hong Kong, China International Liver Cancer Association Fifth Annual Conference (ILCA) 2011
  • Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib).  [通常講演]
    Jean-Pierre Bronowicki; 工藤 正俊; Ho Yeong Lim; Per St?l; Jorge A. Marrero; Alan Venook; Sheng-Long Ye
    66th Annual Meeting of the German Society for Digestive and Metabolic Diseases 2011年09月 Leipzig, Germany 66th Annual Meeting of the German Society for Digestive and Metabolic Diseases
  • Future prospectcs of ultrasound diagnosis for diffuse liver disease. Symposium“Hitachi Aloka Medical Ltd.: The next generation in high-resolution imaging technology and elastography”  [通常講演]
    工藤 正俊
    13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011 2011年08月 Vienna, Austria 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
  • US-guided ablation of HCC. “US-guided tumor theraphy”  [通常講演]
    工藤 正俊
    13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011 2011年08月 Vienna, Austria 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
  • Lecture “Future prospects of ultrasound diagnosis for diffuse liver disease."  [通常講演]
    工藤 正俊
    The next generation in high-resolution imaging technology and elastgraphy 2011年08月 Vienna, Austria The next generation in high-resolution imaging technology and elastgraphy
  • 特別講演「肝疾患最近の話題」  [通常講演]
    工藤 正俊
    香川ベアネットカンファレンス 2011年08月 全日空ホテルクレメント高松, 香川 香川ベアネットカンファレンス
  • Interventional EUS for pancreatic tumours.  [通常講演]
    工藤 正俊
    13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011 2011年08月 Vienna, Austria 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
  • Cirrhotic liver.  [通常講演]
    工藤 正俊; F. Piscaglia
    13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011 2011年08月 Vienna, Austria 13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011
  • インフリキシマブが有効であった難治性潰瘍性大腸炎の1例.  [通常講演]
    高山 政樹; 大本 俊介; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊; 山本 典雄; 辻 直子; 船井 貞往; 富田 尚裕; 池内
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 難治性潰瘍性大腸炎に対する白血球除去療法の有用性と問題点の検討.  [通常講演]
    峯 宏昌; 櫻井 俊治; 大本 俊介; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • Predicting length of stay in patients admitted with acute upper gastrointestinal bleeding using Rockall score.  [通常講演]
    Hasmoni Hadzri; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • Interventional radiologyにおける新しい支援画像「FlightPlan」の初期臨床経験.  [通常講演]
    南 康範; 足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 村上 卓道; 柳生 行伸
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討.  [通常講演]
    早石 宗右; 南 康範; 足立 哲平; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 鄭 浩柄
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定～造影超音波検査と造影CTの比較検討～.  [通常講演]
    井上 達夫; 畑中 絹世; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 術前診断が困難であった肝血管肉腫の一例.  [通常講演]
    足立 哲平; 早石 宗右; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊; 土師 誠二; 武本 昌子; 鄭 浩柄
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 膵尾部腫瘤を形成した自己免疫性膵炎（IgG4関連疾患）の一例.  [通常講演]
    松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 胃腫瘍ESDにおける後出血例の検討と対策. ワークショップ「上部消化器及び小腸出血における最近の動向」  [通常講演]
    朝隈 豊; 松井 繁長; 大本 俊介; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 潰瘍性大腸炎合併colitic cancerに対し大腸全摘及び内肛門括約筋切除術を施行した一例.  [通常講演]
    千品 寛和; 櫻井 俊治; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊; 肥田 仁一
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 進行胃癌にgastric emphysemaを合併した1例.  [通常講演]
    細本 宜志; 宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 小膵癌におけるUS, MDCT, EUS(CH-EUS)の診断能の比較検討. ワークショップ「膵腫瘍性病変の診断と治療」  [通常講演]
    宮田 剛; 坂本 洋城; 門阪 薫平; 鎌田 研; 今井 元; 小牧 孝充; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 進行肝細胞癌に対する分子標的治療を先行した肝切除の妥当性. シンポジウム「進行肝細胞癌に対する治療戦略」  [通常講演]
    土師 誠二; 竹山 宜典; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 進行肝細胞癌に対するソラフェニブ投与例におけるSDの持続期間と生存期間の検討. シンポジウム「進行肝細胞癌に対する治療戦略」  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 診断に苦慮した後腹膜腫瘍の1例.  [通常講演]
    花田 宗一郎; 奥田 英之; 秦 康倫; 木下 大輔; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 瀉血療法が著効したNASHの1例.  [通常講演]
    木下 大輔; 川崎 俊彦; 茂山 朋広; 秦 康倫; 奥田 英之; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • 保存的治療で軽快した外傷性肝損傷の1例.  [通常講演]
    秦 康倫; 豊澤 昌子; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 岸谷 讓; 川崎 俊彦; 工藤 正俊
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • Comparative study between EUS-guided celiac plezus neurolysis and EUS-guided broad neurolysis. VTRシンポジウム「Interventional EUSの最前線」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第81回日本消化器内視鏡学会総会 2011年08月 名古屋国際会議場, 愛知 第81回日本消化器内視鏡学会総会
  • 特徴的な画像所見を呈し、肝転移巣からのEUS-FNAにより退形成癌と診断された1例.  [通常講演]
    大西 佐代子; 北野 雅之; 工藤 正俊; 門阪 薫平; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 小牧 孝充
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • FDP-PETにて治療経過を観察しえた腫瘤形成型膵炎像を呈した自己免疫性膵炎の一例.  [通常講演]
    門阪 薫平; 坂本 洋城; 北野 雅之; 小牧 孝充; 今井 元; 鎌田 研; 宮田 剛; 工藤 正俊; 筑後 孝章; 土手 健作; 廣岡 知臣; 高柳
    日本消化器病学会近畿支部第95回例会 2011年08月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第95回例会
  • Special Lecture “Design and conduct of clinical trials for the design and rational of clinical tirals for the combination of hepatic arterial infusion chemotherapy with molecular targeted agents.”  [通常講演]
    工藤 正俊
    The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2011年07月 Osaka, Japan The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Special Lecture “Current situation of HCC management in Japan.”  [通常講演]
    工藤 正俊
    The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2011年07月 Osaka, Japan The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Special Lecture “EVOLVE-1 trial.”  [通常講演]
    工藤 正俊
    The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2011年07月 Osaka, Japan The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • Special Lecture “RECICL.”  [通常講演]
    工藤 正俊
    The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2011年07月 Osaka, Japan The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • 特別講演「肝癌に対する分子標的治療の現状とOngoing Trial」  [通常講演]
    工藤 正俊
    肝細胞癌ソラフェニブ治療研究会 2011年07月 名古屋東急ホテル, 愛知 肝細胞癌ソラフェニブ治療研究会
  • CT perfusionを用いた肝細胞癌に対するソラフェニブの効果判定の検討  [通常講演]
    村上 卓道; 香川 祐毅; 岡田 真広; 兵頭 朋子; 日高 正二朗; 柳生 行伸; 熊野 正士; 柏木 伸夫; 小塚 健倫; 今岡 いずみ; 足利 竜一朗; 石井 一成; 工藤 正俊; 北野 雅之; 上嶋 一臣; 井上 達夫; 矢田 典久; 工藤 正幸
    第11回関西肝血流動態イメージ研究会 2011年07月 第11回関西肝血流動態イメージ研究会
  • Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性. シンポジウム「超音波を用いた肝細胞癌治療の更なる進歩」  [通常講演]
    南 康範; 工藤 正俊
    第47回日本肝癌研究会 2011年07月 静岡県コンベンションアーツセンター, 静岡 第47回日本肝癌研究会
  • 進行肝細胞癌に対するソラフェニブ投与例におけるSDの持続期間と生存期間の検討.  [通常講演]
    有住 忠晃; 上嶋 一臣; 工藤 正俊
    第47回日本肝癌研究会 2011年07月 静岡県コンベンションアーツセンター, 静岡 第47回日本肝癌研究会
  • ソラフェニブによりCRとなった進行肝細胞癌2症例の臨床的特徴について. ワークショップ「ソラフェニブによりRECISTにてCR例の集積から特徴を掴む」  [通常講演]
    上嶋 一臣; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 井上 達夫; 南 康範; 櫻井 俊治; 工藤 正俊
    第47回日本肝癌研究会 2011年07月 静岡県コンベンションアーツセンター, 静岡 第47回日本肝癌研究会
  • 肝細胞癌治療におけるJNK活性の重要性-ソラフェニブ治療効果との関連も含めて-. シンポジウム「肝細胞癌に対する分子標的治療の基礎と臨床」  [通常講演]
    萩原 智; 櫻井 俊治; 工藤 正俊
    第47回日本肝癌研究会 2011年07月 静岡県コンベンションアーツセンター, 静岡 第47回日本肝癌研究会
  • シンポジウム・特別発言「超音波を用いた肝細胞癌治療の更なる進歩」  [通常講演]
    工藤 正俊
    第47回日本肝癌研究会 2011年07月 静岡県コンベンションアーツセンター, 静岡 第47回日本肝癌研究会
  • 金属ステントが有用であった良性胆道狭窄の2例.  [通常講演]
    宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 小牧 孝充; 北野 雅之; 工藤 正俊
    第42回日本膵臓学会大会 2011年07月 ホテルニューキャッスル, 青森 第42回日本膵臓学会大会
  • IPMNおよび併存膵癌の診断におけるEUSの役割.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充; 安田 武生; 竹山 宜典
    第42回日本膵臓学会大会 2011年07月 ホテルニューキャッスル, 青森 第42回日本膵臓学会大会
  • 当院におけるEUS下膵仮性嚢胞ドレナージ術の成績.  [通常講演]
    今井 元; 北野 雅之; 鎌田 研; 宮田 剛; 門阪 薫平; 坂本 洋城; 小牧 孝充; 工藤 正俊; 竹山 宜典
    第42回日本膵臓学会大会 2011年07月 ホテルニューキャッスル, 青森 第42回日本膵臓学会大会
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第28回烏城消化器カンファレンス 2011年07月 岡山プラザホテル, 岡山 第28回烏城消化器カンファレンス
  • 肝臓癌におけるmTOR阻害剤開発の現状. シンポジウム「PI3K/Akt/mTOR経路阻害剤の基礎と臨床」  [通常講演]
    工藤 正俊
    第9回日本臨床腫瘍学会学術集会 2011年07月 パシフィコ横浜, 神奈川 第9回日本臨床腫瘍学会学術集会
  • Phase I/II study of Sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy. International Session “Hepato-biliary-pancreatic Cancer”  [通常講演]
    上嶋 一臣; 工藤 正俊; 南 康範; 田中 正俊; 熊田 卓
    The 9th Annual Meeting of Japanese Society of Medical Ocology 2011年07月 Yokohama, Japan The 9th Annual Meeting of Japanese Society of Medical Ocology
  • 膵臓癌の血漿中血管新生関連分子の検討.  [通常講演]
    木村 英晴; 荒尾 徳三; 松本 和子; 古田 一行; 工藤 可苗; 永井 知行; 坂本 洋城; 北野 雅之; 工藤 正俊; 西尾 和人
    日本がん分子標的治療学会第15回学術集会 2011年06月 ホテル日航東京, 東京 日本がん分子標的治療学会第15回学術集会
  • ソラフェニブは肝細胞癌株のHGF誘導性上皮間葉移行を阻害する.  [通常講演]
    永井 知行; 荒尾 徳三; 古田 一行; 金田 裕靖; 工藤 可苗; 青松 圭一; 田村 大介; 坂井 和子; 木村 英晴; 藤田 至彦; 松本 和子; 工藤 正俊; 西條 長宏; 西尾 和人
    日本がん分子標的治療学会第15回学術集会 2011年06月 ホテル日航東京, 東京 日本がん分子標的治療学会第15回学術集会
  • 噴門部静脈瘤合併巨木型食道静脈瘤の内視鏡的治療.  [通常講演]
    松井 繁長; 峯 宏昌; 高山 政樹; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第20回近畿食道・胃静脈瘤研究会 2011年06月 大阪薬業年金会館, 大阪 第20回近畿食道・胃静脈瘤研究会
  • C型代償性肝硬変患者に対するペグインターフェロンα-2a/リバビリン併用療法の有効性及び安全性の検討.  [通常講演]
    泉 並木; 工藤 正俊; 金子 周一; 西口 修平; 佐田 通夫; 小俣 政男
    第47回日本肝臓学会総会 2011年06月 ホテルグランパシフィック LE DAIBA, 東京 第47回日本肝臓学会総会
  • PEG-IFN α-2a/RBV併用療法におけるResponse-Guided Therapyの有用性: IL28B多型との関連性を踏まえて.  [通常講演]
    岩井 孝史; 工藤 正俊; 西口 修平; 樋口 和秀; 城村 尚登; 大崎 往夫; 岡崎 和一; 關 壽人; 金 守良
    第47回日本肝臓学会総会 2011年06月 ホテルグランパシフィック LE DAIBA, 東京 第47回日本肝臓学会総会
  • 慢性肝疾患においてEOB-MRI肝細胞相で低信号を示す乏血性結節の多血化に関与する因子の検討.  [通常講演]
    小来田 幸世; 兵頭 朋子; 岡田 真広; 香川 祐毅; 熊野 正士; 工藤 正俊; 村上 卓道; 今井 康陽; 澤井; 良之; 井倉; 枝; 福田 和人; 堀 雅敏
    第47回日本肝臓学会総会 ワークショップ「肝癌画像診断の進歩」 2011年06月 ホテルグランパシフィック LE DAIBA, 東京 第47回日本肝臓学会総会 ワークショップ「肝癌画像診断の進歩」
     
    1541. 2011 小来田幸世, 今井康陽, 兵頭朋子, 岡田真広, 香川祐毅, 澤井良之, 井倉 枝, 福田和人, 熊野正士, 堀 雅敏, 工藤正俊, 村上卓道: , , 平成23年6月2-3日, .
  • 肝細胞癌治療におけるJNK活性の重要性-ソラフェニブ治療効果との関連も含めて-.  [通常講演]
    萩原 智; 櫻井 俊治; 工藤 正俊
    第47回日本肝臓学会総会 シンポジウム「テーラーメイド医療時代へ向けた肝癌治療」 2011年06月 ホテルグランパシフィック LE DAIBA, 東京 第47回日本肝臓学会総会 シンポジウム「テーラーメイド医療時代へ向けた肝癌治療」
  • 肝膿瘍の治療経過の中で直腸癌が見つかった1例  [通常講演]
    丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 南 康範; 辻 直子; 落合 健; 工藤 正俊
    第194回 日本内科学会近畿地方会 2011年06月 奈良市 第194回 日本内科学会近畿地方会
  • Special Invited Lecture “Sonazoid-enhanced US in the management of HCC”  [通常講演]
    工藤 正俊
    XV Congress of the Latin American Federation for Ultrasound in Medicine and Biology (FLAUS) 2011年06月 Asuncion, Paraguay XV Congress of the Latin American Federation for Ultrasound in Medicine and Biology (FLAUS)
  • Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients.  [通常講演]
    工藤 正俊; 泉 並木; 坂元 亨宇; 松山 裕; 市田 隆文; 中島 收; 松井 修; 具 英成; 國土 典宏; 幕内 雅敏
    American Society of Clinical Oncology (ASCO) 2011 Annual Meeting 2011年06月 Chicago, USA American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
  • GIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma [HCC] And Of Its Treatment With Sorafenib) 2nd interim analysis in >1500 patients: clinical findings in patients with liver dysfunction.  [通常講演]
    Jorge Marrero; 工藤 正俊; Riccardo Lencioni; Sheng-Long Ye; Alan Venook
    American Society of Clinical Oncology (ASCO) 2011 Annual Meeting 2011年06月 Chicago, USA American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
  • Phase 3 trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).  [通常講演]
    Ann-Lii Cheng; 工藤 正俊; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Shukui Qin; Masao Omata; Eric Raymond
    American Society of Clinical Oncology (ASCO) 2011 Annual Meeting 2011年06月 Chicago, USA American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
  • Randomized trial of axitinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) following failure of one prior antiangiogenic therapy.  [通常講演]
    Ann-Li Cheng; 工藤 正俊; Yoon-Koo Kang; Shukui Qin; Eric Raymond
    American Society of Clinical Oncology (ASCO) 2011 Annual Meeting 2011年06月 Chicago, USA American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
  • 特別講演「肝癌の造影超音波」 お昼の勉強会「Aplioが創る超音波の新潮流」  [通常講演]
    工藤 正俊
    第84回日本超音波医学会総会 2011年05月 グランドプリンスホテル新高輪, 東京 第84回日本超音波医学会総会
  • Luncheon “Hepatocellular carcinoma: prevention and treatment by interferon.”  [通常講演]
    工藤 正俊
    The Japanese Society for Interferon and Cytokine Research-The Japanese Society for Macrophage Molecu 2011年05月 Osaka, Japan The Japanese Society for Interferon and Cytokine Research-The Japanese Society for Macrophage Molecu
  • 胆膵領域おけるEUSガイド下ドレナージ術の当院での治療成績.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    日本超音波医学会第84回学術集会 特別企画「消化器インターベンションと超音波」 2011年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第84回学術集会 特別企画「消化器インターベンションと超音波」
  • C型肝炎治療におけるReal-time Tissue Elastographyを用いた肝線維化の非侵襲的評価法.  [通常講演]
    藤本 研治; 矢田 典久; 上嶋 一臣; 工藤 正俊; 石田 哲士; 椎名 毅; 加藤 道夫
    日本超音波医学会第84回学術集会 特別企画「びまん性肝疾患2011（組織性状・コントラスト・硬さ評価）」 2011年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第84回学術集会 特別企画「びまん性肝疾患2011（組織性状・コントラスト・硬さ評価）」
  • 内視鏡医の立場からみた消化管超音波検査.  [通常講演]
    樫田 博史; 前川 清; 工藤 正俊
    日本超音波医学会第84回学術集会 特別企画「消化管超音波検査を普及させるには？」 2011年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第84回学術集会 特別企画「消化管超音波検査を普及させるには？」
  • 日本超音波医学会と消化器関連学会と連携: 問題点は何か？  [通常講演]
    工藤 正俊
    日本超音波医学会第84回学術集会 特別企画「日本超音波医学会の役目は何か？（他の超音波関連学会との連携）」 2011年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第84回学術集会 特別企画「日本超音波医学会の役目は何か？（他の超音波関連学会との連携）」
  • 肝疾患診断と硬さ計測-各モダリティーにおける測定原理と結果の解釈.  [通常講演]
    矢田 典久; 工藤 正俊
    日本超音波医学会第84回学術集会 特別企画「硬さの基礎 硬さを測る方法を整理して理解する」 2011年05月 グランドプリンスホテル新高輪, 東京 日本超音波医学会第84回学術集会 特別企画「硬さの基礎 硬さを測る方法を整理して理解する」
  • Special Invited Lecture “Sonazoid-enhanced US in the management of HCC”  [通常講演]
    工藤 正俊
    The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM) 2011年05月 Seoul, Korea The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)
  • 特別講演「コンセンサスに基づく肝細胞癌診断アルゴリズム」  [通常講演]
    工藤 正俊
    第15回TCEL MR meeting 2011年05月 東京コンファレンスセンター, 東京 第15回TCEL MR meeting
  • EUSによる自己免疫性膵炎の検討.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊
    第97回日本消化器病学会総会 ミニシンポジウム 2011年05月 京王プラザホテル, 東京 第97回日本消化器病学会総会 ミニシンポジウム
  • B型慢性肝炎に対するPRG-IFNa2bとエンテカビル48週併用療法の有効性について.  [通常講演]
    萩原 智; 峯 宏昌; 有住 忠晃; 早石 宗右; 上田 泰輔; 田北 雅弘; 畑中 絹世; 北井 聡; 矢田 典久; 井上 達夫; 鄭 浩柄; 櫻井 俊治; 上嶋 一臣; 工藤 正俊; 犬塚 義; 大﨑
    第97回日本消化器病学会総会 2011年05月 京王プラザホテル, 東京 第97回日本消化器病学会総会
  • 当院における早期慢性膵炎症例.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    第97回日本消化器病学会総会 パネルディスカッション「慢性膵炎早期診断への新たなアプローチ～概念、機能、画像診断～ 2011年05月 京王プラザホテル, 東京 第97回日本消化器病学会総会 パネルディスカッション「慢性膵炎早期診断への新たなアプローチ～概念、機能、画像診断～
  • Role of EUS in detection and follow-up of intraductal papillary mucinous neoplasms and concomitant invasive carcinomas.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 小牧 孝充; 坂本 洋城
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • Dynamic imaging of gallbladder diseases by contrast-enahanced harmonic EUS.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 小牧 孝充; 坂本 洋城
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • EUS-guided gallbladder drainage as an alternative treatment for malignant biliary obstruction after unsuccessful ERCP: Outcomes of long term follow-up.  [通常講演]
    北野 雅之; 今井 元; 鎌田 研; 小牧 孝充; 坂本 洋城; 工藤 正俊
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • P38alpha inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.  [通常講演]
    櫻井 俊治; 工藤 正俊; 上嶋 一臣; 松井 繁長; 樫田 博史
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • Assessment of hepatobilliary phase Gd-EOB-DTPA-Enhanced MRI for HCC and borderline lesions and comparison of detection ability versus MDCT.  [通常講演]
    井上 達夫; 工藤 正俊; 岡田 真広; 村上 卓道; 小無田; 美菜; 坂元; 亨
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • The usefulness of helicobacter pylori eradication therapy for the healing artifical gastric ulcer after endoscopic submucosal dissection for early gastric cancer.  [通常講演]
    川崎 正憲; 朝隈 豊; 松井 繁長; 櫻井 俊治; 樫田 博史; 工藤 正俊
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • Evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS.  [通常講演]
    松井 繁長; 工藤 正俊; 岡田 無文; 朝隈 豊; 川崎 正憲; 櫻井 俊治; 樫田 博史
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • Prevention of delayed bleeding after endoscopic submucosal dissection (ESD) for gastric tumors.  [通常講演]
    朝隈 豊; 松井 繁長; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • Peginterferon alfa-2a (40KD) plus ribavirin for the treatment of patients with chronic hepatitis C and compensated liver cirrhosis in Japan.  [通常講演]
    泉 並木; 工藤 正俊; 金子 周一; 西口 修平; 佐田 通夫; 小俣 政男
    Digestive Disease Week (DDW) 2011Chicago, USA 2011年05月 Digestive Disease Week (DDW) 2011Chicago, USA
  • Special Focus Session “Update on endoscopic USG: hoe much for imaging, needling, or therapy?”  [通常講演]
    工藤 正俊
    The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM) 2011年05月 Seoul, Korea The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)
  • Contrast enhanced harmonic EUS imaging of submucosal tumor of gastrointestinal tract.  [通常講演]
    坂本 洋城; 北野 雅之; 鎌田 研; 松井 繁長; 朝隈 豊; 工藤 正俊
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • EUS-guided broad plexus-neurolysis over the superior mesenteric artery.  [通常講演]
    坂本 洋城; 北野 雅之; 鎌田 研; 工藤 正俊
    Digestive Disease Week (DDW) 2011 2011年05月 Chicago, USA Digestive Disease Week (DDW) 2011
  • 胃十二指腸静脈瘤出血に対する内視鏡的止血術.  [通常講演]
    松井 繁長; 樫田 博史; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 工藤 正俊
    第3回集学的静脈瘤治療研究会 2011年04月 青森文化会館, 青森 第3回集学的静脈瘤治療研究会
  • 切除不能悪性中下部胆道狭窄に対する胆管ステンティングの検討.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊; 鎌田 研; 坂本 洋城; 小牧 孝充; 宮田 剛
    第81回日本消化器内視鏡学会総会 2011年04月 ホテル青森, 青森 第81回日本消化器内視鏡学会総会
  • コンベックス型EUSによる胆膵領域のスクリーニング. パネルディスカッション 胆膵内視鏡の基本  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第81回日本消化器内視鏡学会総会 2011年04月 ホテル青森, 青森 第81回日本消化器内視鏡学会総会
  • 造影ハーモニックEUSシステムの開発と臨床応用. パネルディスカッション 内視鏡関連機器の進歩と課題  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第81回日本消化器内視鏡学会総会 2011年04月 ホテル青森, 青森 第81回日本消化器内視鏡学会総会
  • 経乳頭的治療困難例におけるEUSガイド下胆道ドレナージ術.  [通常講演]
    宮田 剛; 鎌田 研; 今井 元; 小牧 孝充; 坂本 洋城; 北野 雅之; 工藤 正俊
    第81回日本消化器内視鏡学会総会 2011年04月 ホテル青森, 青森 第81回日本消化器内視鏡学会総会
  • 悪性胃十二指腸狭窄に対するself-expandable-metal-stentの有用性について.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊; 鎌田 研; 坂本 洋城; 小牧 孝充
    第81回日本消化器内視鏡学会総会 2011年04月 ホテル青森, 青森 第81回日本消化器内視鏡学会総会
  • シンポジウム 超音波医療の最前線「消化器領域の超音波診療最前線」  [通常講演]
    工藤 正俊
    第28回日本医学総会 2011年04月 東京国際フォーラム, 東京 第28回日本医学総会
  • Expression levels of EMT-related genes in hepatocellular carcinoma.  [通常講演]
    永井 知行; 荒尾 徳三; 松本 和子; 工藤 可苗; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人
    AACR 102th Annual Meeting 2011 2011年04月 Florida, USA AACR 102th Annual Meeting 2011
  • Serum concentrations of Angiogenesis-related molecules in Patients with Pancreatic Cancer.  [通常講演]
    木村 英晴; 坂本 洋城; 永井 知行; 工藤 可苗; 古田 一行; 荒尾 徳三; 北野 雅之; 工藤 正俊; 西尾 和人
    AACR 102th Annual Meeting 2011 2011年04月 Florida, USA AACR 102th Annual Meeting 2011
  • GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study first interim results, Sorafenib dosing across regions and disease subgroups.  [通常講演]
    Jean-Pierre Bronowicki; 工藤 正俊; Riccardo Lencioni; Alan Venook; Jorge Marrero; Sheng-Long Ye
    46th Annual Meeting of the European Association for the Sudy of the Liver (EASL) 2011年03月 Berlin, Germany 46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • Stakeholder involvement in priority setting of strategies to improve liver cancer control policy in Asia.  [通常講演]
    John FP Bridges; 工藤 正俊; Gisselle Gallego; BPharm; Kiwamu Okita; Kwang-Hyub Han; Sheng-Long Ye; Barri M Blauvelt
    46th Annual Meeting of the European Association for the Sudy of the Liver (EASL) 2011年03月 Berlin, Germany 46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • Special lecture “Treatment guideline of hepatocellular carcinoma: Asian perspective.”  [通常講演]
    工藤 正俊
    Asan Liver Center Opening Symposium 2011年03月 Seoul, Korea Asan Liver Center Opening Symposium
  • 早期胃癌と十二指腸MALTリンパ腫を併発した1例.  [通常講演]
    峯 宏昌; 松井 繁長; 朝隈 豊; 川崎 正憲; 永田 嘉昭; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第86回日本消化器内視鏡学会近畿地方会 2011年03月 京都テルサ, 京都 第86回日本消化器内視鏡学会近畿地方会
  • 食道小細胞癌の1例.  [通常講演]
    奥田 英之; 秦 康倫; 宮部 欽生; 茂山 朋広; 豊澤 昌子; 岸谷 譲; 川崎 俊彦; 池田 光憲; 工藤 正俊
    第86回日本消化器内視鏡学会近畿地方会 2011年03月 京都テルサ, 京都 第86回日本消化器内視鏡学会近畿地方会
  • 当院におけるEUS下interventionの成績. シンポジウム「超音波内視鏡下穿刺術の意義と今後の展望」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第86回日本消化器内視鏡学会近畿地方会 2011年03月 京都テルサ, 京都 第86回日本消化器内視鏡学会近畿地方会
  • 当院における悪性胃十二指腸狭窄に対する消化管ステントの成績.パネルディスカッション「消化管ステント留置の苦痛と限界  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第86回日本消化器内視鏡学会近畿地方会 2011年03月 京都テルサ, 京都 第86回日本消化器内視鏡学会近畿地方会
  • Malignant gastric outlet obstruction (MGOO)に対するステント留置術と胃空腸吻合術の比較検討.パネルディスカッション「消化管ステント留置の苦痛と限界  [通常講演]
    山本 典雄; 辻 直子; 工藤 正俊
    第86回日本消化器内視鏡学会近畿地方会 2011年03月 京都テルサ, 京都 第86回日本消化器内視鏡学会近畿地方会
  • Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): first interim analysis of the Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib (GIDEON) study.  [通常講演]
    JF Geschwind; 工藤 正俊; R Lencioni; J Marrero; A Venook; S-L Ye
    SIR 36th Annual Scientific 2011 Meeting 2011年03月 Chicago, USA SIR 36th Annual Scientific 2011 Meeting
  • 腫瘤形成性膵炎と膵癌との鑑別診断に苦慮した一例.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊; 筑後 孝章; 竹山 宜典
    第54回日本消化器画像診断研究会 2011年02月 昭和女子大学, 東京 第54回日本消化器画像診断研究会
  • Endoscopic ultrasound (EUS)-guided transluminal endoscopic removal of gallstones.  [通常講演]
    鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充; 北野 雅之; 工藤 正俊
    第9回FNA-Club Japan 2011年02月 東京医科大学, 東京 第9回FNA-Club Japan
  • Special lecture “Interventional US for pancreatic malignancy.”  [通常講演]
    工藤 正俊
    Innovative Practive in Ultrasound With Live Demonstration 2011年02月 Bangkok, Thailand Innovative Practive in Ultrasound With Live Demonstration
  • Special lecture “Diagnosis of pancreatic tumors by EUS-FNA and CE-EUS.”  [通常講演]
    工藤 正俊
    Innovative Practive in Ultrasound With Live Demonstration 2011年02月 Bangkok, Thailand Innovative Practive in Ultrasound With Live Demonstration
  • Special lecture “Sonazoid enhanced US for the management of liver cancer.”  [通常講演]
    工藤 正俊
    Innovative Practive in Ultrasound With Live Demonstration 2011年02月 Bangkok, Thailand Innovative Practive in Ultrasound With Live Demonstration
  • Special lecture "Double contrast US for surveillance of hepatoma.”  [通常講演]
    工藤 正俊
    Innovative Practive in Ultrasound With Live Demonstration 2011年02月 Bangkok, Thailand Innovative Practive in Ultrasound With Live Demonstration
  • GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) interim results: Child-Pugh status subgroup analysis.  [通常講演]
    Si-Hyun Bae; 工藤 正俊; S-L Ye; J Marrero; R Lencioni; A Venook
    The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2011年02月 Bangkok, Thailand The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL)
  • 胃ESD後の後出血例の検討と対策.  [通常講演]
    朝隈 豊; 松井 繁長; 川崎 正憲; 永田 嘉昭; 櫻井 俊治; 樫田 博史; 工藤 正俊
    第7回日本消化管学会総会学術集会 2011年02月 国立京都国際会館, 京都 第7回日本消化管学会総会学術集会
  • Special lecture “Contrast enhanced endoscopic ultrasound value in the diagnosis of small pancreatic cancer.”  [通常講演]
    工藤 正俊
    World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop 2011年02月 Jakarta, Indonesia World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop
  • Special lecture “Sonazoid-enhanced US for hepatoma: Value of defect re-perfusion of imaging.”  [通常講演]
    工藤 正俊
    World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop 2011年02月 Jakarta, Indonesia World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop
  • Special lecture “Double contrast US for surveillance of hepatoma.”  [通常講演]
    工藤 正俊
    World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop 2011年02月 Jakarta, Indonesia World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop
  • 特別講演「肝細胞癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    ウイルス肝炎講習会 2011年02月 岐阜県医師会館, 岐阜 ウイルス肝炎講習会
  • 特別講演「ウイルス性肝炎」  [通常講演]
    工藤 正俊
    平成22年度「肝がん撲滅運動」 2011年02月 大阪狭山市さやかホール, 大阪 平成22年度「肝がん撲滅運動」
  • 特別講演「肝癌診療ガイドラインと最新治療: 分子標的治療の位置付けを中心に」  [通常講演]
    工藤 正俊
    第164回滋賀肝・胆・膵勉強会 2011年02月 京都センチュリーホテル, 京都 第164回滋賀肝・胆・膵勉強会
  • 肝機能障害精査でHIV感染症が判明した一例.  [通常講演]
    松本 望; 田村 瑠衣; 高場 雄久; 奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 工藤 正俊
    日本消化器病学会近畿支部第94回例会 Freshman Session「肝」 2011年02月 大阪国際会議場, 大阪 日本消化器病学会近畿支部第94回例会 Freshman Session「肝」
  • 破壊性甲状腺炎と二次性アミロイドーシスを合併したCrohn病の1例.  [通常講演]
    田村 瑠衣; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 工藤 正俊
    日本消化器病学会近畿支部第94回例会 Freshman Session「消化管」 2011年02月 大阪国際会議場, 大阪 日本消化器病学会近畿支部第94回例会 Freshman Session「消化管」
  • 潰瘍性大腸炎に対する免疫調節剤の有用性と問題点の検討.  [通常講演]
    櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第94回例会 2011年02月 大阪国際会議場, 大阪 日本消化器病学会近畿支部第94回例会
  • HTLV-1関連脊髄症（HAM）に合併した難治性食道カンジタ症の1例.  [通常講演]
    永田 嘉昭; 松井 繁長; 峯 宏昌; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第94回例会 2011年02月 大阪国際会議場, 大阪 日本消化器病学会近畿支部第94回例会
  • 造影ハーモニックEUSによるMSTの鑑別およびGISTの悪性度評価の試み.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第94回例会 シンポジウム「新しいイメージングテクノロジーによる消化器病診療の進歩」 2011年02月 大阪国際会議場, 大阪 日本消化器病学会近畿支部第94回例会 シンポジウム「新しいイメージングテクノロジーによる消化器病診療の進歩」
  • First interim results of the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma (HCC) and Of its treatment with sorafeNib (GIDEON) study: Oncologists and non-oncologists appear to use sorafenib (Sor) differently in the management of  [通常講演]
    A.Venook; 工藤 正俊; R. Lencioni; J.A. Marrero; S.L. Ye
    2011 Gastrointeritinal Cancers Symposium (ASCO-GI 2011) 2011年01月 San Francisco, USA 2011 Gastrointeritinal Cancers Symposium (ASCO-GI 2011)
  • 肝機能障害で紹介されたAIDSの1例  [通常講演]
    松本 望; 沖本 奈美; 高場 雄久; 奥村 直己; 山本 典雄; 南 康範; 辻 直子; 上田 宏次; 浦瀬 文明; 工藤 正俊
    日本内科学会近畿支部主催 第193回近畿地方回 2010年12月 神戸市 日本内科学会近畿支部主催 第193回近畿地方回
  • α-グルコシダーゼ阻害剤（アカルボース）が原因と考えられた腸管嚢胞様気腫症の1例  [通常講演]
    沖本 奈美; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 辻 直子; 工藤 正俊
    日本内科学会近畿支部主催 第193回 近畿地方会 2010年12月 神戸市 日本内科学会近畿支部主催 第193回 近畿地方会
  • Special lecture “On going trial and future role of molecular targeted agent in HCC.”  [通常講演]
    工藤 正俊
    All India Institute of Medical Science (AIIMS) 2010年11月 New Delhi, India All India Institute of Medical Science (AIIMS)
  • Special lecture “Current role of sorafenib in the management of HCC.”  [通常講演]
    工藤 正俊
    All India Institute of Medical Science (AIIMS) 2010年11月 New Delhi, India All India Institute of Medical Science (AIIMS)
  • Special lecture “Interventional US for GI & pancreatico biliary disease.”  [通常講演]
    工藤 正俊
    9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology 2010年11月 New Delhi, India 9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology
  • Special lecture “Endoscopic CEUS for pancreatic lesions.”  [通常講演]
    工藤 正俊
    9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology 2010年11月 New Delhi, India 9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology
  • Special lecture “Sonazoid-enhanced US in the management of HCC.”  [通常講演]
    工藤 正俊
    Medanta University Hospital 2010年11月 India Medanta University Hospital
  • Special lecture “Imaging diagnosis of early-stage HCC: Role of EOB-MRI.”  [通常講演]
    工藤 正俊
    Medanta University Hospital 2010年11月 India Medanta University Hospital
  • Special lecture “Molecular targeted therapy for HCC: Current situation and future prospective.”  [通常講演]
    工藤 正俊
    Medanta University Hospital 2010年11月 India Medanta University Hospital
  • 特別講演「肝癌診療の新しいパラダイム」,  [通常講演]
    工藤 正俊
    阪神肝臓病治療研究会 第三回学術講演会 2010年11月 ホテル阪急インターナショナル, 大阪 阪神肝臓病治療研究会 第三回学術講演会
  • 特別講演「ウイルス性肝炎の治療」  [通常講演]
    工藤 正俊
    肝がん撲滅の為の肝臓病市民公開講座 2010年11月 堺市民会館, 大阪 肝がん撲滅の為の肝臓病市民公開講座
  • 特別講演「肝細胞癌診療の最新の話題～IFN治療から分子標的治療まで～」  [通常講演]
    工藤 正俊
    第3回渋谷消化器病ゼミナール 2010年11月 セルリアンタワー東急ホテル, 東京 第3回渋谷消化器病ゼミナール
  • 特別講演「B型慢性肝疾患治療の最近の話題～肝がん抑止を目指して～」  [通常講演]
    工藤 正俊
    OSAKA HBV SEMINAR ～de novo HEPATITIS & Latest CHB treatment, For Hepatologist and Hematologist～ 2010年11月 リーガロイヤルホテル堺, 大阪 OSAKA HBV SEMINAR ～de novo HEPATITIS & Latest CHB treatment, For Hepatologist and Hematologist～
  • 腹部超音波検査で特発性腸間膜静脈硬化症が疑われた1例 ．  [通常講演]
    横川 美加; 桑口 愛; 前野 知子; 前川 清; 鄭 浩柄; 樫田 博史; 工藤 正俊
    日本超音波医学会第37回関西地方会学術集会 2010年10月 神戸, 兵庫 日本超音波医学会第37回関西地方会学術集会
  • Percutaneous endoscopic gastrosotmy with Funada-style gastropexy, an easy and safe technique, greatly reduce the risk of peristomal infection (Travel Grant)  [通常講演]
    奥村 直己; 辻 直子; 高場 雄久; 山本 典雄; 南 康範; 工藤 正俊
    UEGW 2010 2010年10月 バルセロナ UEGW 2010
  • Colonoscopic polypectomy in the very elderly, is it safe?  [通常講演]
    山本 典雄; 辻 直子; 高場 雄久; 奥村 直己; 南 康範; 工藤 正俊
    UEGW 2010 2010年10月 バルセロナ UEGW 2010
  • 特別講演「ウイルス性肝炎の治療」  [通常講演]
    工藤 正俊
    肝がん撲滅の為の肝臓病市民公開講座 2010年10月 羽曳野市市民会館, 大阪 肝がん撲滅の為の肝臓病市民公開講座
  • Special lecture “Imaging diagnosis of early HCC.”  [通常講演]
    工藤 正俊
    4th International Forum for Liver MRI 2010年10月 Seoul Korea 4th International Forum for Liver MRI
  • First Interim Results of The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) Study.  [通常講演]
    Riccardo Lencioni; 工藤 正俊; HoYeong Lim; Per St?l; Jorge Marrero; Alan Venook; Keiko Nakajima; Sheng-Long Ye
    Europian Society for Medical Oncology (ESMO) congress 2010年10月 Milan, Italy Europian Society for Medical Oncology (ESMO) congress
  • Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib).  [通常講演]
    Jorge Marrero; 工藤 正俊; HoYeong Lim; Per St?l; Riccardo Lencioni; Alan Venook; Keiko Nakajima; Sheng-Long Ye
    American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010 2010年10月 Massachusetts, USA American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010
  • 悪性胆道狭窄に対するEUS下胆道ドレナージ術の有用性.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第85回日本消化器内視鏡学会近畿地方会, ビデオワークショップ「胆膵疾患における治療の進歩と今後の展開」 2010年10月 大阪国際交流センター, 大阪 第85回日本消化器内視鏡学会近畿地方会, ビデオワークショップ「胆膵疾患における治療の進歩と今後の展開」
  • 特別講演「肝細胞癌診療の最新の話題: 発癌抑制から分子標的治療まで」  [通常講演]
    工藤 正俊
    西神奈川肝炎学術講演会 2010年10月 ロワジールホテル厚木, 神奈川 西神奈川肝炎学術講演会
  • Examination of factors of delayed bleeding after endoscopic submucosal dissection (ESD) for gastric tumors.  [通常講演]
    朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 北井 聡; 坂本 洋城; 井上 達夫; 櫻井 俊治; 樫田 博史; 工藤 正俊
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • The efficacy of helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection early gastric cancer: Prospective randomized study.  [通常講演]
    朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 北井 聡; 坂本 洋城; 井上 達夫; 櫻井 俊治; 樫田 博史; 工藤 正俊
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • Is the combination therapy of ecabet sodium and proton pump inhibitor (PPI) useful for treating the artificial ulcer after endoscopic submucosal dissection (ESD) treatment of early gastric cancer? : Prospective randomized study.  [通常講演]
    朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 北井 聡; 坂本 洋城; 井上 達夫; 櫻井 俊治; 樫田 博史; 工藤 正俊
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • 特別講演「コンセンサスに基づく肝細胞癌診断アルゴリズム」  [通常講演]
    工藤 正俊
    第4回肝癌の診断・治療に関する病診連携セミナー 2010年10月 ソニックシティ, 埼玉 第4回肝癌の診断・治療に関する病診連携セミナー
  • 造影超音波による血流定量化の試み-肝細胞癌に対するTACEの早期治療効果判定-.  [通常講演]
    南 康範; 奥村 直己; 山本 典雄; 辻 直子; 工藤 正俊
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第14回日本肝臓学会大会）
  • 肝細胞癌治療における術中造影エコーの有用性.  [通常講演]
    土師 誠二; 畑中 絹世; 竹山 宜典; 工藤 正俊
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第14回日本肝臓学会大会）
  • 線維化進行C型肝炎患者における脾摘後のインターフェロン導入における問題点-好中球数の変化について-.  [通常講演]
    鄭 浩柄; 上田 泰輔; 早石 宗右; 田北 雅弘; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第14回日本肝臓学会大会）
  • 造影エコーによる肝細胞癌の診断能、Gd-EOB-MRI、Dynamic CTとの比較検討.  [通常講演]
    井上 達夫; 畑中 絹世; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第14回日本肝臓学会大会）
  • PEG-IFN α2b/RBV併用療法の無効・再燃例に対するPEG-IFN α2a/RBV併用療法の再治療の検討-他施設共同研究 RETRY study.  [通常講演]
    上田 泰輔; 工藤 正俊; 土谷 薫; 橋元 悟; 今関 文夫; 垣内 雅彦
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第14回日本肝臓学会大会）
  • 胆管挿入困難例に対するEUS下ドレナージ術の位置づけ.  [通常講演]
    今井 元; 北野 雅之; 小牧 孝充; 鎌田 研; 坂本 洋城; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • 高齢者の外来下部消化管内視鏡検査におけるプロポフォール至適導入量の検討.  [通常講演]
    梅原 康湖; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • 胃壁固定併用の経皮内視鏡的胃瘻増設術（PEG）におけるquli法とdirect法の比較検討.  [通常講演]
    高場 雄久; 辻 直子; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 工藤 正俊; 本庶 元
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • 経皮内視鏡的胃瘻増設術（PEG）における胃壁固定の有用性と問題点.  [通常講演]
    奥村 直己; 辻 直子; 高場 雄久; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 工藤 正俊; 本庶 元
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • 治療成績からみら胃腫瘍に対するESDの検討.  [通常講演]
    永田 嘉昭; 松井 繁長; 朝隈 豊; 川崎 正憲; 岡田 無文; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • 消化管悪性リンパ腫の初回内視鏡診断と病理診断の問題点.  [通常講演]
    山本 典雄; 辻 直子; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 藤田 純也; 浦瀬 文明; 前倉 俊治; 工藤 正俊; 本庶 元
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • ヘリコバクターピロリ陽性早期胃癌における除菌治療がESD後人工潰瘍治癒過程に及ぼす影響の検討.  [通常講演]
    川崎 正憲; 松井 繁長; 峯 宏昌; 永田 嘉昭; 朝隈 豊; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）
  • 非閉塞性腸管虚血を発症した悪性リンパ腫の一例.  [通常講演]
    宮田 剛; 井上 達夫; 有住 忠晃; 早石 宗右; 上田 泰輔; 辰巳 千栄; 田北 雅弘; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第18回日本消化器関連学会週間（第52回日本消化器病学会）, 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第52回日本消化器病学会）,
  • EUSガイド下治療のコツと工夫.  [通常講演]
    北野 雅之; 小牧 孝充; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）, ワークショップ「胆膵内視鏡治療のエキスパートテクニック＜ビデオ＞」 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会）, ワークショップ「胆膵内視鏡治療のエキスパートテクニック＜ビデオ＞」
  • 癌性疼痛における超音波内視鏡下広範囲腹腔神経叢融解術（EUS-BPN）の有用性.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同）シンポジウム「胆道・膵臓癌に対するInterventional oncology-現在そして将来を展 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同）シンポジウム「胆道・膵臓癌に対するInterventional oncology-現在そして将来を展
  • 造影ハーモニックEUSによるGISTの悪性度評価.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第18回日本消化器関連学会週間（第52回日本消化器病学会・第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同）ワークショップ「GISTの基礎と臨床」 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第52回日本消化器病学会・第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同）ワークショップ「GISTの基礎と臨床」
  • EUSを主としたIPMN、IPNBの診療ストラテジー.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会・第52回日本消化器病学会・第8回日本消化器外科学会大会合同）ワークショップ「肝胆膵での上皮内腫瘍: 病態解明と治療戦略」 2010年10月 第18回日本消化器関連学会週間（第14回日本肝臓学会大会・第52回日本消化器病学会・第8回日本消化器外科学会大会合同）ワークショップ「肝胆膵での上皮内腫瘍: 病態解明と治療戦略」
  • 肝細胞癌の肉眼分類評価におけるソナゾイド造影超音波の有用性-造影dynamic CTとの比較.  [通常講演]
    畑中 絹世; 工藤 正俊; 熊野 正士
    第18回日本消化器関連学会週間（第52回日本消化器病学会大会・第14回日本肝臓学会大会合同）ワークショップ「肝細胞癌に対する画像診断の進歩と新たな治療戦略」 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第52回日本消化器病学会大会・第14回日本肝臓学会大会合同）ワークショップ「肝細胞癌に対する画像診断の進歩と新たな治療戦略」
  • PEG-IFNα/RBV併用療法における血清フェリチン値とSVRとの関係.  [通常講演]
    矢田 典久; 鄭 浩柄; 工藤 正俊
    第18回日本消化器関連学会週間（第14回日本肝臓学会大会・第52回日本消化器病学会大会合同）パネルディスカッション「代謝異常（金属代謝を含む）からみたC型肝炎の病態解析」 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第14回日本肝臓学会大会・第52回日本消化器病学会大会合同）パネルディスカッション「代謝異常（金属代謝を含む）からみたC型肝炎の病態解析」
  • 胆膵疾患に対するEUSガイド下ドレナージ術.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会・第52回日本消化器病学会大会合同）シンポジウム「Interventional EUSの評価」 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第80回日本消化器内視鏡学会総会・第52回日本消化器病学会大会合同）シンポジウム「Interventional EUSの評価」
  • 教育講演「消化器癌の治療戦略-海外との比較も含めて-」  [通常講演]
    工藤 正俊
    第18回日本消化器関連学会週間（第28回日本医学会総会共催） 2010年10月 パシフィコ横浜, 神奈川 第18回日本消化器関連学会週間（第28回日本医学会総会共催）
  • Estimation of malignant potential gist by contrast-enhanced harmonic endoscopic ultrasonography.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 鎌田 研; 今井 元; 工藤 正俊
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • Can Gd-EOB-DTPA-enhanced MRI discriminate between dysplastic nodules and early-to- well-differentiated HCC?  [通常講演]
    井上 達夫; 工藤 正俊; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 畑中 絹世; 矢田 典久; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 岡田 真広; 熊野 正士; 村上 卓道; 坂元 亨宇
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • Usefulness of hepatocyte phase imaging of Gd-EOB-DTPA-MRI in detecting borderline lesions which are difficult to detect other imaging modalities.  [通常講演]
    井上 達夫; 工藤 正俊; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • Characterization of small pancreatic neoplasms by contrast-enhanced harmonic EUS.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊; 高木 忠之; 山雄
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • Utility of evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS using Sonazoid.  [通常講演]
    松井 繁長; 工藤 正俊; 岡田 無文; 朝隈 豊; 川崎 正憲; 永田 嘉昭; 樫田 博史
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit.  [通常講演]
    北井 聡; 工藤 正俊; 有井 滋樹; 市田 隆文; 小俣 政男; 坂元 亨宇; 高安 賢一; 中島 収; 幕内 雅敏; 松山 裕; 門田 守人
    18th United European Gastroenterology Week (UEGW) 2010 2010年10月 Barcelona, Spain 18th United European Gastroenterology Week (UEGW) 2010
  • The usefulness of the post-vascular phase of contrast-enhanced ultrasonography with Sonazoid in the evaluation of gross type of hepatocellular carcinoma.  [通常講演]
    畑中 絹世; 鄭 浩柄; 工藤 正俊; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣
    American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010 2010年10月 Massachusetts, USA American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010
  • Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. ソラフェニブは肝細胞癌株において、HGF起因の上皮間葉移行（Epithelial mesenchymal transition）を阻害する.  [通常講演]
    永井 知行; 荒尾 徳三; 坂井 和子; 工藤 可苗; 金田 裕靖; 田村 大介; 青松 圭一; 木村 英晴; 藤田 至彦; 松本 和子; 西條 長宏; 工藤 正俊; 西尾 和人
    第69回日本癌学会学術総会 2010年09月 大阪国際会議場, 大阪 第69回日本癌学会学術総会
  • 特発性腸間膜静脈硬化症の1例.  [通常講演]
    宮田 剛; 樫田 博史; 峯 宏昌; 川崎 正憲; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊
    日本消化器病学会近畿支部第93回例会 2010年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第93回例会
  • 自己免疫性膵炎の検討: EUSによる膵実質所見.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊; 坂本 洋城
    日本消化器病学会近畿支部第93回例会 2010年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第93回例会
  • 発熱、及び軽度の肝機能障害に発症した肝サルコイドーシスの1例.  [通常講演]
    有住 忠晃; 萩原 智; 早石 宗右; 田北 雅弘; 上田 泰輔; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 樫田 博史; 工藤 正俊
    日本消化器病学会近畿支部第93回例会 2010年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第93回例会
  • 十二指腸狭窄を契機に診断された十二指腸悪性リンパ腫の一例.  [通常講演]
    奥村 直己; 高場 雄久; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    日本消化器病学会近畿支部第93回例会 2010年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第93回例会
  • 十二指腸狭窄を契機に診断された十二指腸悪性リンパ腫の一例  [通常講演]
    奥村 直己; 高場 雄久; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    日本消化器病学会近畿支部 第93回例会 2010年09月 大阪市 日本消化器病学会近畿支部 第93回例会
  • Luncheon workshop “Novel concepts in HCC staging.”  [通常講演]
    工藤 正俊
    4th Annual Conference International Liver Cancer Association (ILCA) 2010年09月 Montral, Canada 4th Annual Conference International Liver Cancer Association (ILCA)
  • Special Lecture “Management and outcome of HCC in Japan: Analysis of 51,430 HCC cases registerd in nationwide survey program of Liver Cancer Study Group of Japan.”  [通常講演]
    工藤 正俊
    4th Annual Conference International Liver Cancer Association (ILCA) 2010年09月 Montral, Canada 4th Annual Conference International Liver Cancer Association (ILCA)
  • EUS-FNA穿刺針の使い分けとコツ.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊
    第8回FNA-Club Japan, 特別企画講演「先端施設における膵のEUS-FNA」 2010年09月 三井ガーデンホテル広島, 広島 第8回FNA-Club Japan, 特別企画講演「先端施設における膵のEUS-FNA」
  • 特別講演「肝細胞癌治療に対する分子標的治療の現状と今後の展望」  [通常講演]
    工藤 正俊
    第1回鹿児島肝細胞がん分子標的治療研究会 2010年09月 城山観光ホテル, 鹿児島 第1回鹿児島肝細胞がん分子標的治療研究会
  • 特別講演「肝細胞癌に対する分子標的治療の現状と今後の展望」  [通常講演]
    工藤 正俊
    兵庫HCC分子標的治療セミナー 2010年09月 神戸ポートピアホテル, 兵庫 兵庫HCC分子標的治療セミナー
  • 特別講演「肝癌治療の新しいパラダイム」  [通常講演]
    工藤 正俊
    H22 八尾徳洲会医療連携の会 2010年09月 リーガロイヤルホテル大阪, 大阪 H22 八尾徳洲会医療連携の会
  • 特別講演「肝細胞癌診療における新しいパラダイム」  [通常講演]
    工藤 正俊
    高知肝癌診断治療セミナー 2010年09月 高知新阪急ホテル, 高知 高知肝癌診断治療セミナー
  • Sonazoidを用いた造影EUSによる胆嚢病変の診断.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 小牧 孝充; 坂本 洋城
    第46回日本胆道学会学術集会 2010年09月 リーガロイヤルホテル広島, 広島 第46回日本胆道学会学術集会
  • EUSによる肝外胆管癌の進展度診断.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊; 中居 卓也; 竹山 宜典
    第46回日本胆道学会学術集会 2010年09月 リーガロイヤルホテル広島, 広島 第46回日本胆道学会学術集会
  • 経乳頭的アプローチ困難例に対するEUS下胆道ドレナージの有用性.ビデオワークショップ「私が薦める胆道内視鏡のコツ～安全性を目指して～」  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第46回日本胆道学会学術集会 2010年09月 リーガロイヤルホテル広島, 広島 第46回日本胆道学会学術集会
  • The usefulness of helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection for early gastric cancer.  [通常講演]
    川崎 正憲; 朝隈 豊; 峯 宏昌; 永田 嘉昭; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊
    Asian Pacific Digestive Week (APDW) 2010 2010年09月 Kuala Lumpur, Malaysia Asian Pacific Digestive Week (APDW) 2010
  • 特別講演「造影超音波は肝癌診療をどう変えたか？」  [通常講演]
    工藤 正俊
    第52回いわき肝疾患研究会 2010年08月 いわきワシントンホテル, 福島 第52回いわき肝疾患研究会
  • Special lecture “Ultrasound diagnosis of pancreatic tumors.”  [通常講演]
    工藤 正俊
    8 AFSUMB Workshop: 2010 2010年08月 Ulaanbaatar, Mogolia 8 AFSUMB Workshop: 2010
  • 特別講演「肝細胞癌の最新の話題」  [通常講演]
    工藤 正俊
    KBNCの会 2010年08月 全日空ホテルクレメント高松, 香川 KBNCの会
  • 進行型肝細胞癌に対するSorafenib治療効果判定における肝CT Perfusion検査  [通常講演]
    岡田 真広; 熊野 正士; 香川祐毅; 上嶋 一臣; 矢田 典久; 井上 達夫; 工藤 正俊; 村上 卓道
    第10回関西肝血流動態イメージ研究会 2010年07月 オーバルホール，大阪 第10回関西肝血流動態イメージ研究会
  • 特別講演「肝癌診療ガイドライン2009年版 改訂のポイント」  [通常講演]
    工藤 正俊
    第11回臨床消化器病研究会 2010年07月 グランドプリンスホテル新高輪, 東京 第11回臨床消化器病研究会
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第21回北海道肝がん研究会 2010年07月 ホテルニューオータニ札幌, 北海道 第21回北海道肝がん研究会
  • 特別講演「肝細胞癌に対する分子標的治療の現状と今後の展望」  [通常講演]
    工藤 正俊
    日本医師会生涯教育講座 第34回肝臓を診る会 2010年07月 旭川グランドホテル, 北海道 日本医師会生涯教育講座 第34回肝臓を診る会
  • 特別講演「進行性肝細胞癌に対するソラフェニブの使用経験」  [通常講演]
    工藤 正俊
    広島ネクサバール承認1周年記念セミナー 2010年07月 リーガロイヤルホテル広島, 広島 広島ネクサバール承認1周年記念セミナー
  • Branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma in patients with liver cirrhosis.  [通常講演]
    早石 宗右; 鄭 浩柄; 工藤 正俊
    The 7th Japan-Korea Liver Symposium 2010年07月 Kyoto, Japan The 7th Japan-Korea Liver Symposium
  • 特別講演「ペグインターフェロン・リバビリン併用療法無効・再燃例に対するペグインターフェロン・リバビリン併用療法による再治療」  [通常講演]
    工藤 正俊
    第8回肝臓病研究会シンポジウム 2010年07月 六本木アカデミーヒルズ49, 東京 第8回肝臓病研究会シンポジウム
  • 特別講演「肝癌診療の最新の話題」  [通常講演]
    工藤 正俊
    OK7KK（岡山市中基幹7病院肝疾患研究会） 2010年07月 ホテルグランヴィア岡山, 岡山 OK7KK（岡山市中基幹7病院肝疾患研究会）
  • 教育セミナー「肝細胞癌 内科の立場から-肝癌の内科治療の将来展望-」  [通常講演]
    工藤 正俊
    第13回日本高齢消化器病学会 2010年07月 六本木アカデミーヒルズ, 東京 第13回日本高齢消化器病学会
  • ランチョンセミナー「コンセンサスに基づく肝細胞癌診断アルゴリズム」  [通常講演]
    工藤 正俊
    第46回日本肝癌研究会 2010年07月 大阪国際会議場, 大阪 第46回日本肝癌研究会
  • EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 今井 元; 鎌田 研; 竹山 宜典; 中居 卓也; 安田 武生; 亀井 敬子; 工藤 正俊
    Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010 2010年07月 Fukuoka, Japan Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
  • Management of IPMNs by endoscopic ultrasonography.  [通常講演]
    鎌田 研; 北野 雅之; 今井 元; 小牧 孝充; 坂本 洋城; 竹山 宜典; 工藤 正俊
    Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010 2010年07月 Fukuoka, Japan Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
  • Endoscopic ultrasound-guided drainage for pancreatic diseases. JPS Video Symposium 1 “Cutting edge endoscopic procedures for diagnosis and treatment of panvreatic diseases”  [通常講演]
    鎌田 研; 北野 雅之; 小牧 孝充; 今井 元; 坂本 洋城; 竹山 宜典; 工藤 正俊
    Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010 2010年07月 Fukuoka, Japan Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
  • Contrast-enhanced harmonic endosonography in diagnosing pancreatic diseases. JPS Symposium 1 “Recent advances in the imaging studies of pancreatic diseases”  [通常講演]
    北野 雅之; 小牧 孝充; 今井 元; 坂本 洋城; 竹山 宜典; 工藤 正俊
    Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010 2010年07月 Fukuoka, Japan Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010
  • HCCに対するソラフェニブを用いた血管新生抑制治療の効果予測因子としてのPIVKA-IIの有用性に関する検討.  [通常講演]
    上嶋 一臣; 工藤 正俊
    第10回関西肝血流動態イメージ研究会 2010年07月 オーバルホール, 大阪 第10回関西肝血流動態イメージ研究会
  • 造影超音波による血流定量化の試み-肝細胞癌に対する TACEの早期治療効果判定- Early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: Quantification of tumor vascularity with contrast-enhanced sonography.  [通常講演]
    南 康範; 奥村 直己; 山本 典雄; 辻 直子; 工藤 正俊; Yuko Kono
    第10回関西肝血流動態イメージ研究会 2010年07月 オーバルホール, 大阪 第10回関西肝血流動態イメージ研究会
  • Workshop “Treatment algorithm for intermediate and advanced stage of HCC: Japan.”  [通常講演]
    工藤 正俊
    The 1st Asia-Pacific Primary Liver Cancer Expert Meeting 2010年07月 Incheon, Korea The 1st Asia-Pacific Primary Liver Cancer Expert Meeting
  • Workshop “Report from working group.”  [通常講演]
    工藤 正俊
    The 1st Asia-Pacific Primary Liver Cancer Expert Meeting 2010年07月 Incheon, Korea The 1st Asia-Pacific Primary Liver Cancer Expert Meeting
  • 特別講演「肝細胞癌の分子標的治療」  [通常講演]
    工藤 正俊
    伊丹市医師会内科医会 第7回消化器勉強会 2010年07月 伊丹シティホテル, 兵庫 伊丹市医師会内科医会 第7回消化器勉強会
  • 進行型肝細胞癌症例に対するSorafenib治療前後の肝CT prefusion検査  [通常講演]
    岡田 真広; 熊野 正士; 香川祐毅; 塚部明大; 上嶋 一臣; 矢田 典久; 井上 達夫; 工藤 正俊; 村上 卓道
    第2回日本肝がん分子標的治療研究会 2010年06月 大手町サンケイプラザ，東京 第2回日本肝がん分子標的治療研究会
  • Special lecture “Clinical classification in Asia.”  [通常講演]
    工藤 正俊
    Europian Association for the Study of the Liver 2010年06月 Dubrovnik, Croatia Europian Association for the Study of the Liver
  • Sorafenibは肝細胞がんの上皮間葉移行を阻害する.  [通常講演]
    永井 知行; 荒尾 徳三; 工藤 可苗; 工藤 正俊; 西尾 和人
    第2回日本肝がん分子標的治療研究会 2010年06月 大手町サンケイプラザ, 東京 第2回日本肝がん分子標的治療研究会
  • 分子標的薬によるがん幹細胞マーカーCD133の発現制御.  [通常講演]
    荒尾 徳三; 松本 和子; 工藤 可苗; 永井 知行; 工藤 正俊; 西尾 和人
    第2回日本肝がん分子標的治療研究会 2010年06月 大手町サンケイプラザ, 東京 第2回日本肝がん分子標的治療研究会
  • 発癌分子機序に基づく新しい肝がん治療薬の可能性.  [通常講演]
    櫻井 俊治; 萩原 智; 矢田 典久; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第2回日本肝がん分子標的治療研究会 2010年06月 大手町サンケイプラザ, 東京 第2回日本肝がん分子標的治療研究会
  • ランチョンセミナー「造影超音波は肝癌診療をどう変えたか？」  [通常講演]
    工藤 正俊
    日本消化器病学会中国支部例会 第12回教育講演会 2010年06月 山口県国際総合センター, 山口 日本消化器病学会中国支部例会 第12回教育講演会
  • 特別講演「肝癌に対する分子標的治療への期待と今後の展望」  [通常講演]
    工藤 正俊
    肝細胞癌ソラフェニブ治療研究会 2010年06月 名古屋マリオットアソシアホテル, 愛知 肝細胞癌ソラフェニブ治療研究会
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第4回消化器疾患地域連携フォーラム 2010年06月 ホテルオークラ神戸, 兵庫 第4回消化器疾患地域連携フォーラム
  • Special lecture “Defect re-perfusion imaging for HCC.”  [通常講演]
    工藤 正俊
    Korean Society of Ultrasound in Medicine 2010 Open 2010年05月 Seoul, Korea Korean Society of Ultrasound in Medicine 2010 Open
  • Special lecture “Sonazoid-enhanced US as a treatment-guidance for HCC.”  [通常講演]
    工藤 正俊
    Korean Society of Ultrasound in Medicine 2010 Open 2010年05月 Seoul, Korea Korean Society of Ultrasound in Medicine 2010 Open
  • Real-time Tissue Elastographyによる非侵襲的肝線維化評価法は炎症の影響を受けない.  [通常講演]
    藤本 研治; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 石田 哲士; 山本 佳司; 椎名 毅; 加藤 道夫
    第46回日本肝臓学会総会 2010年05月 ホテルメトロポリタン山形, 山形 第46回日本肝臓学会総会
  • 肝細胞癌根治後C型肝癌に対するインターフェロン少量長期維持療法の生命予後改善効果に関する検討.  [通常講演]
    上田 泰輔; 鄭 浩柄; 工藤 正俊
    第46回日本肝臓学会総会 2010年05月 ホテルメトロポリタン山形, 山形 第46回日本肝臓学会総会
  • 根治的治療不能の肝細胞癌に対して肝動脈塞栓化学療法（TACE）を施行した患者を対象としたソラフェニブの日韓共同第III相臨床試験.  [通常講演]
    工藤 正俊; 今中 和穂; 千田 信之; 仲地 耕平; 高山 忠利; 金子 周一; 坪内 博仁; 林 紀夫; 熊田 博光; 沖田 極
    2010年05月
  • HCCに対するソラフェニブの治療効果予測について.  [通常講演]
    上嶋 一臣; 工藤 正俊
    第46回日本肝臓学会総会, シンポジウム「肝細胞癌の分子標的探索と臨床応用」 2010年05月 ホテルメトロポリタン山形, 山形 第46回日本肝臓学会総会, シンポジウム「肝細胞癌の分子標的探索と臨床応用」
  • 特別企画「肝細胞癌の画像診断up-to-date」  [通常講演]
    工藤 正俊
    第46回日本肝臓学会総会 2010年05月 ホテルメトロポリタン山形, 山形 第46回日本肝臓学会総会
  • 特別講演「肝細胞癌診療の最新の話題」  [通常講演]
    工藤 正俊
    第42回生涯教育講演会 2010年05月 岡山コンベンションセンター, 岡山 第42回生涯教育講演会
  • Special lecture “Imaging diagnosis of very early stage HCC.”  [通常講演]
    工藤 正俊
    Seoul Laennec meeting 2010 2010年05月 Seoul, Korea Seoul Laennec meeting 2010
  • Special lecture “Management of HCC in Japan.”  [通常講演]
    工藤 正俊
    Global HCC investigator’s meeting in Taiwan 2010年05月 Taipei, Taiwan Global HCC investigator’s meeting in Taiwan
  • 膵腫瘍に対する腹部超音波, 超音波内視鏡, MDCTの部位別検出率の比較検討.  [通常講演]
    今井 元; 北野 雅之; 鎌田 研; 小牧 孝充; 坂本 洋城; 工藤 正俊
    日本超音波医学会 第83回学術集会 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会
  • 造影超音波検査による肝細胞癌の診断能-Gd-EOB-MRI, Dynamic CTとの比較検討-.  [通常講演]
    井上 達夫; 畑中 絹世; 前川 清; 工藤 正俊
    日本超音波医学会 第83回学術集会 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会
  • 造影ハーモニックEUSによる上部消化管粘膜下腫瘍の鑑別の試み.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊
    日本超音波医学会 第83回学術集会 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会
  • 造影エコー撮像法の工夫 ?Defect Re-perfusion imaging-.  [通常講演]
    南 康範; 畑中 絹世; 工藤 正俊
    日本超音波医学会 第83回学術集会, 特別企画「肝腫瘍の超音波診断基準の検証」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, 特別企画「肝腫瘍の超音波診断基準の検証」
  • C型慢性肝疾患患者に対する非侵襲的肝線維化評価の有用性に関する検討.  [通常講演]
    矢田 典久; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 藤本 研治; 加藤 道夫; 椎名 毅
    日本超音波医学会 第83回学術集会, ワークショップ「びまん性肝疾患のUltrasound Functional Imaging」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, ワークショップ「びまん性肝疾患のUltrasound Functional Imaging」
  • 造影ハーモニックEUSによるGISTの悪性度評価の試み.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    日本超音波医学会 第83回学術集会, ワークショップ「胆・膵・消化管疾患による造影エコー法の位置づけ」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, ワークショップ「胆・膵・消化管疾患による造影エコー法の位置づけ」
  • 膵疾患に対する超音波内視鏡ガイド下ドレナージ術.  [通常講演]
    北野 雅之; 小牧 孝充; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊
    日本超音波医学会 第83回学術集会, ワークショップ「消化器疾患におけるInterventional Sonography」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, ワークショップ「消化器疾患におけるInterventional Sonography」
  • Sonazoidを用いた造影EUS検査による膵腫瘍性病変の診断.  [通常講演]
    小牧 孝充; 北野 雅之; 今井 元; 鎌田 研; 工藤 正俊
    日本超音波医学会 第83回学術集会, パネルディスカッション「超音波内視鏡の新展開」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, パネルディスカッション「超音波内視鏡の新展開」
  • EUSを用いたIPMN診療.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊; 坂本 洋城; 小牧 孝充; 今井 元
    日本超音波医学会 第83回学術集会, シンポジウム「膵疾患の超音波診断」 2010年05月 都国際会議場, 京都 日本超音波医学会 第83回学術集会, シンポジウム「膵疾患の超音波診断」
  • 慢性肝疾患におけるReal-time Tissue Elastographyの精度の検討.  [通常講演]
    藤本 研治; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 石田 哲士; 椎名 毅; 加藤 道夫
    日本超音波医学会 第83回学術集会, シンポジウム「組織エラストグラフィーの現況と展望」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, シンポジウム「組織エラストグラフィーの現況と展望」
  • 造影EUS検査による進行胃癌の化学療法効果判定.  [通常講演]
    岡田 無文; 松井 繁長; 工藤 正俊
    日本超音波医学会 第83回学術集会, シンポジウム「消化管疾患における超音波診断」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, シンポジウム「消化管疾患における超音波診断」
  • 肝細胞癌の肉眼敬体とSonazoid造影超音波におけるdefect像の比較.  [通常講演]
    畑中 絹世; 鄭 浩柄; 工藤 正俊; 土師 誠二; 熊野 正士; 岡田 真広
    日本超音波医学会 第83回学術集会, シンポジウム「肝腫瘍の造影エコーの最先端（術中超音波含む）」 2010年05月 京都国際会議場, 京都 日本超音波医学会 第83回学術集会, シンポジウム「肝腫瘍の造影エコーの最先端（術中超音波含む）」
  • Contrast-enhanced harmonic EUS for diagnosis of pancreatic tumors.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第79回日本内視鏡学会総会, Symposium “Therapeutic and diagnostic EUS for pancreatobiliary diseases ?Current pra 2010年05月 グランドプリンスホテル新高輪, 東京 第79回日本内視鏡学会総会, Symposium “Therapeutic and diagnostic EUS for pancreatobiliary diseases ?Current pra
  • 経乳頭的アプローチ困難例に対するEUS下胆道ドレナージ術の有用性.  [通常講演]
    鎌田 研; 北野 雅之; 今井 元; 小牧 孝充; 坂本 洋城; 末冨 洋一郎; 工藤 正俊
    第79回日本消化器内視鏡学会総会 2010年05月 グランドプリンスホテル新高輪, 東京 第79回日本消化器内視鏡学会総会
  • EUSを用いたIPMNの診断～診断ハーモニック法を含めて～.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第79回日本消化器内視鏡学会総会, ワークショップ「国際診療ガイドラインを踏まえたIPMNの内視鏡診断の現状と問題点」 2010年05月 グランドプリンスホテル新高輪, 東京 第79回日本消化器内視鏡学会総会, ワークショップ「国際診療ガイドラインを踏まえたIPMNの内視鏡診断の現状と問題点」
  • 造影ハーモニックEUSによるSMTの鑑別およびGISTの悪性度評価の試み.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第79回日本消化器内視鏡学会総会, シンポジウム「上部消化管SMTのマネージメント-GISTとの鑑別と取り扱い」 2010年05月 グランドプリンスホテル新高輪, 東京 第79回日本消化器内視鏡学会総会, シンポジウム「上部消化管SMTのマネージメント-GISTとの鑑別と取り扱い」
  • 切除不能悪性胆道狭窄に対する胆管ステンティングの検討②.  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」 2010年05月 グランドプリンスホテル新高輪, 東京 第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」
  • 切除不能悪性胆道狭窄に対する胆管ステンティングの検討①  [通常講演]
    今井 元; 北野 雅之; 工藤 正俊
    第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」 2010年05月 グランドプリンスホテル新高輪, 東京 第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」
  • 特別講演「肝細胞癌治療における分子標的治療への期待と課題」  [通常講演]
    工藤 正俊
    大阪外科HCC分子標的治療セミナー 2010年05月 ホテル阪急インターナショナル, 大阪 大阪外科HCC分子標的治療セミナー
  • 特別講演「肝癌の最新の治療: RFA治療困難例対策から分子標的治療まで」  [通常講演]
    工藤 正俊
    第9回神奈川肝炎若手の会 2010年05月 横浜ベイシェラトンホテル, 神奈川 第9回神奈川肝炎若手の会
  • EUS-guided choledochoduodenostomy followed by endoscopic antegrade biliary stenting via the fistula for treatment of obstructive jaundice with duodenal stenosis.  [通常講演]
    北野 雅之; 小牧 孝充; 坂本 洋城; 鎌田 研; 今井 元; 工藤 正俊
    2010 Digestive Disease Week 2010年05月 Louisiana, USA 2010 Digestive Disease Week
  • EUS-guided gallbladder drainage for treatment of acute cholecystitis and obstructive jaundice.  [通常講演]
    北野 雅之; 今井 元; 小牧 孝充; 鎌田 研; 坂本 洋城; 工藤 正俊
    2010 Digestive Disease Week 2010年05月 Louisiana, USA 2010 Digestive Disease Week
  • 癌性疼痛におけるEUS下広範囲腹腔神経叢融解術の有用性の検討: preliminary study.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    ワークショップ「消化器疾患におけるInterventional sonography」, 日本超音波医学会 第83会学術集会 2010年05月 京都国際会議場, 京都 ワークショップ「消化器疾患におけるInterventional sonography」, 日本超音波医学会 第83会学術集会
  • Special lecture “Imaging diagnosis of every stage HCC.”  [通常講演]
    工藤 正俊
    Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo 2010年04月 Sao Paulo, Brazil Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo
  • Special lecture “Molecular targeted therapy for hepatocellular carcinoma.”  [通常講演]
    工藤 正俊
    Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo 2010年04月 Sao Paulo, Brazil Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo
  • Special lecture “Advanced in US techniques for treatment guidance for liver tumours.”  [通常講演]
    工藤 正俊
    JPR 2010 2010年04月 Sao Paulo, Brazil JPR 2010
  • Special lecture “Enhanced sonography of hepatic nodules.”  [通常講演]
    工藤 正俊
    JPR 2010 2010年04月 Sao Paulo, Brazil JPR 2010
  • 当院における根治手術不能な膵小細胞癌の治療成績.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊; 末冨 洋一郎; 今井 元; 鎌田 研
    第96回日本消化器病学会総会 2010年04月 新潟市民プラザ, 新潟 第96回日本消化器病学会総会
  • 難治性胆管炎を伴った胆管癌に対する低容量ジェムザール治療.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊; 末冨 洋一郎; 今井 元; 鎌田 研
    第96回日本消化器病学会総会 2010年04月 新潟市民プラザ, 新潟 第96回日本消化器病学会総会
  • Sonazoidを用いた造影EUS検査による膵腫瘍性病変の診断.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    第96回日本消化器病学会総会, ワークショップ「胆膵画像診断の進歩」 2010年04月 新潟市民プラザ, 新潟 第96回日本消化器病学会総会, ワークショップ「胆膵画像診断の進歩」
  • 胆膵疾患に対するEUSガイド下ステント治療の成績.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第96回日本消化器病学会総会, パネルディスカッション「消化器ステント治療の進歩と現状」 2010年04月 新潟市民プラザ, 新潟 第96回日本消化器病学会総会, パネルディスカッション「消化器ステント治療の進歩と現状」
  • EUSを用いたIPMNの診断とフォローアップ.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第96回日本消化器病学会総会, シンポジウム「膵IPMNの手術適応の見直し」 2010年04月 新潟市民プラザ, 新潟. 第96回日本消化器病学会総会, シンポジウム「膵IPMNの手術適応の見直し」
  • ポストグラデュエイトコース「肝腫瘍の診断」  [通常講演]
    工藤 正俊
    第96回日本消化器病学会総会 2010年04月 新潟市民プラザ, 新潟 第96回日本消化器病学会総会
  • 特別講演「肝癌診療ガイドラインをめぐる最新の話題」  [通常講演]
    工藤 正俊
    肝癌診療の最前線～ミリプラ新発売記念講演会～ 2010年04月 リーガロイヤルホテル堺, 大阪 肝癌診療の最前線～ミリプラ新発売記念講演会～
  • Special Lecture “Contrast-enhanced US: its role in the management of HCC.”  [通常講演]
    工藤 正俊
    26th International Congress of Radiology 2010年04月 Shanghai, China 26th International Congress of Radiology
  • 特別講演「本当は怖いB型慢性肝疾患」  [通常講演]
    工藤 正俊
    第11回府中臨床セミナー 2010年04月 府中病院, 大阪 第11回府中臨床セミナー
  • 特別講演「ウイルス性肝炎の治療」  [通常講演]
    工藤 正俊
    肝がん撲滅の為の肝臓病市民公開講座 2010年04月 松原市民文化会館, 大阪 肝がん撲滅の為の肝臓病市民公開講座
  • 閉塞性黄疸で発見された悪性リンパ腫の一例.  [通常講演]
    山本 典雄; 奥村 直己; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊; 村上 晴郎; 浦瀬 文明
    第84回日本消化器内視鏡学会近畿地方会 2010年03月 大阪国際交流センター, 大阪 第84回日本消化器内視鏡学会近畿地方会
  • EUSを主としたIPMNの診断とフォローアップ方法.  [通常講演]
    鎌田 研; 北野 雅之; 工藤 正俊
    第84回日本消化器内視鏡学会近畿地方会, ワークショップ「？胞性膵疾患の鑑別診断と治療法の選択」 2010年03月 大阪国際交流センター, 大阪 第84回日本消化器内視鏡学会近畿地方会, ワークショップ「？胞性膵疾患の鑑別診断と治療法の選択」
  • Special Lecture “The use of TACE in the treatment of hepatocellular carcinoma.”  [通常講演]
    工藤 正俊
    The 8th ASIA PACIFIC ONCOLOGY SUMMIT 2010年03月 Tokyo, Japan The 8th ASIA PACIFIC ONCOLOGY SUMMIT
  • 特別講演「肝細胞癌の治療」  [通常講演]
    工藤 正俊
    第8回日本臨床腫瘍学会学術集会 2010年03月 東京ビッグサイト, 東京 第8回日本臨床腫瘍学会学術集会
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第12回長崎肝癌研究会学術講演会 2010年03月 長崎全日空ホテルグラバーヒル, 長崎 第12回長崎肝癌研究会学術講演会
  • 特別講演「肝がん診療ガイドラインの現状と問題点」  [通常講演]
    工藤 正俊
    第2回肝疾患地域連携の会総会「肝疾患診療ネットワーク」 2010年03月 筑波大学附属病院, 茨城 第2回肝疾患地域連携の会総会「肝疾患診療ネットワーク」
  • 特別講演「肝癌の分子標的治療: Up date」  [通常講演]
    工藤 正俊
    第12回関西肝癌局所療法研究会 2010年03月 阪急電鉄本社ビル, 大阪 第12回関西肝癌局所療法研究会
  • 肝細胞癌外科治療における術中造影エコーの意義.  [通常講演]
    土師 誠二; 山崎 満夫; 北口 博士; 中多 靖幸; 亀井 敬子; 安田 武生; 石川 原; 中居 卓也; 竹山 宜典; 畑中 絹世; 工藤 正俊
    第12回関西肝癌局所療法研究会 2010年03月 阪急電鉄本社ビル, 大阪 第12回関西肝癌局所療法研究会
  • 造影超音波による血流定量化の試み-肝細胞癌に対するTACEの早期治療効果判定-.  [通常講演]
    南 康範; 奥村 直己; 山本 典雄; 辻 直子; 工藤 正俊
    第12回関西肝癌局所療法研究会 2010年03月 阪急電鉄本社ビル, 大阪 第12回関西肝癌局所療法研究会
  • 特別講演「HCC治療における分子標的治療への期待と課題」  [通常講演]
    工藤 正俊
    群馬県HCC分子標的治療セミナー 2010年03月 前橋マーキュリーホテル, 群馬 群馬県HCC分子標的治療セミナー
  • 特別講演「肝癌治療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第12回久留米消化器癌セミナー 2010年02月 久留米大学筑水会館, 福岡 第12回久留米消化器癌セミナー
  • 特別講演「肝癌診療ガイドラインと最新治療: 分子標的治療の位置付けも含めて」  [通常講演]
    工藤 正俊
    第22回県北DSC 2010年02月 ホテルリソル佐世保, 長崎 第22回県北DSC
  • 遊走脾の捻転により脾梗塞をきたした一例.  [通常講演]
    宮田 剛; 鄭 浩柄; 有住 忠晃; 早石 宗右; 田北 雅弘; 上田 泰輔; 辰巳 千栄; 北井 聡; 畑中 絹世; 石川 恵美; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 土師 誠二; 山崎 満夫
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • サイトメガロウイルス検査が陰性を示したガンシクロビル投与により軽快した潰瘍性大腸炎の一例.  [通常講演]
    林 道友; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 潰瘍性大腸炎経過中に発症したClostridium difficile関連腸病変の一例.  [通常講演]
    奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 癌性疼痛に対しEUS下腹腔神経叢ブロックが有用であった1症例.  [通常講演]
    湯本 妙子; 今井 元; 鎌田 研; 坂本 洋城; 末冨 洋一郎; 小牧 孝充; 北野 雅之; 工藤 正俊
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 肝機能障害を認めたエルシニア腸炎の一例.  [通常講演]
    足立 哲平; 萩原 智; 有住 忠晃; 峯 宏昌; 宮田 剛; 早石 宗右; 辰巳 千栄; 上田 泰輔; 田北 雅弘; 畑中 絹世; 北井 聡; 石川 恵美; 矢田 典久; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 梅原 泰
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • C型慢性肝炎SVR後に悪性リンパ腫を発症した一例.  [通常講演]
    高場 雄久; 宮田 剛; 峯 宏昌; 鎌田 研; 有住 忠晃; 田北 雅弘; 早石 宗右; 永井 知行; 上田 泰輔; 辰巳 千栄; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 石川 恵美; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 慢性C型肝炎に対してPEG-IFN+Ribavirin併用療法中にITPを発症した1例.  [通常講演]
    有住 忠晃; 石川 恵美; 宮田 剛; 峯 宏昌; 早石 宗右; 田北 雅弘; 上田 泰輔; 辰巳 千栄; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 金井 良高
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 癌幹細胞のマーカーであるCD133は進行肝細胞癌に対するS1+PEG-IFNalpha2b治療における効果予測因子である. シンポジウム「消化器癌化学療法の適応と限界-肝胆膵領域-」  [通常講演]
    萩原 智; 上嶋 一臣; 鄭 浩柄; 工藤 正俊
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 十二指腸ステント留置後にEUS下胆嚢ドレナージ術を行った閉塞性黄疸の一例.  [通常講演]
    今井 元; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 鎌田 研; 坂本 洋城; 工藤 正俊
    日本消化器病学会近畿支部第92回例会 2010年02月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第92回例会
  • 特別講演「肝細胞癌に対する最新の話題: ネクサバールの有用性とその位置づけ」  [通常講演]
    工藤 正俊
    学術講演会 2010年02月 メルキュールホテル横須賀, 神奈川 学術講演会
  • 特別講演「肝癌治療アルゴリズムにおける分子標的治療の位置づけ」  [通常講演]
    工藤 正俊
    第24回冬季札幌がんセミナー 2010年02月 北海道 第24回冬季札幌がんセミナー
  • Special Lecture “Imaging diagnosis of early HCC: Recent advance.”  [通常講演]
    工藤 正俊
    Choshu International Liver Smposium 2010 2010年02月 Yamaguchi, Japan Choshu International Liver Smposium 2010
  • 特別講演「世界から見た日本の肝癌治療の現状」  [通常講演]
    工藤 正俊
    KBNCの会 2010年 全日空ホテルクレメント高松, 香川 KBNCの会
  • Special lecture “Earlier HCC diagnosis: US, CT and MRI aspects ?anatomopathological correlation―US aspects-.”  [通常講演]
    工藤 正俊
    JPR 2010 2010年 Sao Paulo, Brazil JPR 2010
  • 特別講演「肝細胞癌に対するネクサバール治療: 副作用対策の成功が治療の成功」  [通常講演]
    工藤 正俊
    名古屋肝癌セミナー 2010年01月 愛知 名古屋肝癌セミナー
  • 特別講演「異型結節・早期肝癌の診断、多血性腫瘍への移行 US」  [通常講演]
    工藤 正俊
    第16回肝血流動態イメージ研究会 シンポジウム「肝細胞癌多段階発癌の診断: 慢性肝炎、異型結節、進行肝癌の個別化診断に向けて」 2010年01月 神戸ポートピアホテル, 兵庫 第16回肝血流動態イメージ研究会 シンポジウム「肝細胞癌多段階発癌の診断: 慢性肝炎、異型結節、進行肝癌の個別化診断に向けて」
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第70回倉敷肝臓臨床談話会 2010年01月 岡山 第70回倉敷肝臓臨床談話会
  • 特別講演「Sonazoid造影エコー法の新しい展開」  [通常講演]
    工藤 正俊
    日本超音波医学会第29回中部地方会学術集会 2010年01月 石川 日本超音波医学会第29回中部地方会学術集会
  • 肝細胞癌に対してラジオ波焼灼療法（RFA）を施行したCAPDの1例.  [通常講演]
    中野 志仁; 鮫島 謙一; 木下 浩二; 有馬 秀二; 船内 正憲; 鄭 浩柄; 工藤 正俊; 岩本 一郎
    第23回大阪CAPD研究会 2009年12月 大阪市立大学, 大阪 第23回大阪CAPD研究会
  • Malignancy grading of primary hepatocellular carcinoma by liver-specific contrast agent and hemodynamic alteration  [通常講演]
    岡田 真広; 熊野 正士; 工藤 正俊; 村上 卓道
    Radiological Society of North America 2009 95th Scientific Assembly and Annual Meeting(RSNA) 2009年12月 Chicago,USA Radiological Society of North America 2009 95th Scientific Assembly and Annual Meeting(RSNA)
  • Contrast-enhanced harmonic endosonography in pancreatobiliary diseases.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊
    11th International Symposium on Ultrasound Contrast Imaging 2009年12月 Kunming, China 11th International Symposium on Ultrasound Contrast Imaging
  • Special Lecture “RF Ablation of HCC under CEUS guideline.”  [通常講演]
    工藤 正俊
    11th International Symposium on Ultrasound Contrast Imaging 2009年12月 Kunming, China 11th International Symposium on Ultrasound Contrast Imaging
  • Special Lecture “Defect-Re-perfusion imaging for liver tumors and CEUS in the diagnosis of macroscopic classification of HCC.”  [通常講演]
    工藤 正俊
    11th International Symposium on Ultrasound Contrast Imaging 2009年12月 Kunming, China 11th International Symposium on Ultrasound Contrast Imaging
  • Special Lecture “EOB-MRI in liver tumors: Its role in differentiation berween early HCC and dysplastic nodule.”  [通常講演]
    工藤 正俊
    All India Institute of Medical Science (AIIMS) 2009年12月 New Delhi, India All India Institute of Medical Science (AIIMS)
  • Special Lecture and Live Demonstration“Contrast-enhanced US of liver tumors.”  [通常講演]
    工藤 正俊
    Institute of Hepatobiliary and Pancreatic Science 2009年12月 New Delhi, India Institute of Hepatobiliary and Pancreatic Science
  • Special Lecture “Management of HCC: Recent advances.”  [通常講演]
    工藤 正俊
    Indian Society of Gastroenterology 2009年12月 Colcutta, India Indian Society of Gastroenterology
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    KNBCの会 2009年12月 高松 KNBCの会
  • PEG-IFN療法施行中に、ALTおよびフェリチンの上昇をきたしたC型慢性肝炎の3例と、うち瀉血療法が奏効した1例  [通常講演]
    宮田 央; 工藤 正俊; 宮田 学
    第38回日本肝臓学会西部会 2009年12月 米子コンベンションセンター, 鳥取. 第38回日本肝臓学会西部会
  • Special Lecture “Recent advances in the imaging of HCC.”  [通常講演]
    工藤 正俊
    9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue 2009年12月 Department of Hepatology Pgimer, Chandigarh & Department of Gastroenterology AIIMS, New Delhi, India 9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue
  • Special Lecture “Management of HCC: Role of molecular targeted agents. "  [通常講演]
    工藤 正俊
    9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue 2009年12月 Department of Hepatology Pgimer, Chandigarh & Department of Gastroenterology AIIMS, New Delhi, India 9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue
  • 特別講演「ネクサバール錠副作用対策」  [通常講演]
    工藤 正俊
    第2回山形分子標的治療講演会 2009年12月 山形メトロポリタンホテル, 山形 第2回山形分子標的治療講演会
  • 特別講演「肝癌診療の新しいパラダイム」  [通常講演]
    工藤 正俊
    第4回北里肝臓フォーラム 2009年12月 小田急ホテルセンチュリー相模大野, 神奈川 第4回北里肝臓フォーラム
  • Estimation of the malignant potential of gastrointestinal stromal tumors: for a precise management of SMT by CHE-EUS.  [通常講演]
    坂本 洋城; 北野 雅之; 鎌田 研; 小牧 孝充; 今井 元; 筑後 孝章; 竹山 宜典; 工藤 正俊
    UEGW 2009年11月 London, UK UEGW
  • Detection rates of pancreatic tumors according to location by contrast-enhanced ultrasonography, endosonography and multidetector row CT.  [通常講演]
    今井 元; 北野 雅之; 末冨 洋一郎; 坂本 洋城; 小牧 孝充; 野田 佳寿; 鎌田 研; 竹山 宜典; 工藤 正俊
    East Meets West 40th Anniversary 2009年11月 Honolulu, USA East Meets West 40th Anniversary
  • Pancreas by EUS-guided in vivo microdialysis.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊
    East Meets West 40th Anniversary 2009年11月 Honolulu, USA East Meets West 40th Anniversary
  • EUS-assisted drainage of pancreatic duct for obstructive pancreatitis.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 竹山 宜典; 工藤 正俊
    East Meets West 40th Anniversary 2009年11月 Honolulu, USA East Meets West 40th Anniversary
  • Special Lecture “Hepatocellular Carcinoma in Japan: Epidemiology, Diagnosis and RF Ablatiom.”  [通常講演]
    工藤 正俊
    “HBV Now in Asia” The 8th JSH Single Topic Conference by The Japan Society of Hepatolog (JSH) 2009年11月 Tokyo, Japan “HBV Now in Asia” The 8th JSH Single Topic Conference by The Japan Society of Hepatolog (JSH)
  • Special Lecture “Defect re-perfusion imaging for HCC.”  [通常講演]
    工藤 正俊
    Italian Society of Ultrasound in Medicine (ISUM) 2009年11月 Rome, Italy Italian Society of Ultrasound in Medicine (ISUM)
  • Special Lecture “Consensus statement of management of HCC in Asia.”  [通常講演]
    工藤 正俊
    20th Asia Pacific Cancer Conference (APCC) 2009 2009年11月 Tsukuba, Japan 20th Asia Pacific Cancer Conference (APCC) 2009
  • Special Lecture “Ultrasound diagnosis of pancreatic tumors.”  [通常講演]
    工藤 正俊
    7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB) 2009年11月 Jakarta, Indonesia 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)
  • Special Lecture “Color doppler imaging of liver tumors.”  [通常講演]
    工藤 正俊
    7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB) 2009年11月 Jakarta, Indonesia 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)
  • Special Lecture “Sonazoid-enhanced US of Liver Tumors.”  [通常講演]
    工藤 正俊
    7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB) 2009年11月 Jakarta, Indonesia 7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)
  • Special Lecture “Radiological diagnosisi of very early-stage HCC.”  [通常講演]
    工藤 正俊
    Mini-Symposium “Very-Early HCC”, American Association of Study of the liver Disease (AASLD) 2009年11月 Boston, USA Mini-Symposium “Very-Early HCC”, American Association of Study of the liver Disease (AASLD)
  • 特別講演「BCAA顆粒製剤の今後の展望（コホート研究結果を踏まえて）」  [通常講演]
    工藤 正俊
    肝臓疾患フォーラム2009 BCAA顆粒製剤の新たな知見「肝癌抑制メカニズムと臨床的意義」 2009年11月 品川プリンスホテル, 東京 肝臓疾患フォーラム2009 BCAA顆粒製剤の新たな知見「肝癌抑制メカニズムと臨床的意義」
  • 特別講演「肝癌治療の現状と展望」  [通常講演]
    工藤 正俊
    北九州肝癌最先端治療講演会 2009年11月 ステーションホテル小倉, 福岡 北九州肝癌最先端治療講演会
  • EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle. Awarded as a (Best submit abstract)  [通常講演]
    坂本 洋城; 北野 雅之; 鎌田 研; 小牧 孝充; 今井 元; 筑後 孝章; 竹山 宜典; 工藤 正俊
    UEGW 2009年11月 London, UK UEGW
  • Estimation of the malignant potential of gastrointestinal stromal tumors: imaging  [通常講演]
    坂本 洋城; 北野 雅之; 鎌田 研; 小牧 孝充; 今井 元; 筑後 孝章; 竹山 宜典; 工藤 正俊
    UEGW 2009年11月 London, UK UEGW
  • 特別講演「ネクサバールの使用経験とポジショニングについて」  [通常講演]
    工藤 正俊
    佐賀県肝癌治療研究会 2009年11月 マリトピア, 佐賀 佐賀県肝癌治療研究会
  • 特別講演「肝癌診療における画像診断の最新の話題」  [通常講演]
    工藤 正俊
    第8回会津肝胆膵画像研究会 2009年11月 会津ワシントンホテル, 福島 第8回会津肝胆膵画像研究会
  • 特別講演「肝細胞癌診療の最新の話題; EOB-MRIと分子標的治療への期待」  [通常講演]
    工藤 正俊
    第9回Hyogo Liver Conference 2009年11月 神戸ベイシェラトンホテル＆タワーズ, 兵庫 第9回Hyogo Liver Conference
  • 特別講演「肝細胞癌の最新治療～ネクサバールの有効性と安全性について」  [通常講演]
    工藤 正俊
    第1回栃木肝細胞癌セミナー 2009年11月 ホテル東日本宇都宮, 栃木 第1回栃木肝細胞癌セミナー
  • The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+PEG-IFN α-2b therapy against advanced hepatocellular carcinoma  [通常講演]
    萩原 智; 工藤 正俊; 上嶋 一臣; 鄭 浩柄; 井上 達夫; 矢田 典久; 北井 聡; 田北 雅弘; 永井 知行; 土師 誠二; 木村 雅友; Ah-Mee Park; 宗像 浩
    The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD) 2009年11月 Boston, USA The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)
  • Usefulness of hepatocyte phase imaging of Gd-EOB-DTPA-MRI in detecting HCCs which are difficult to detect other imaging modalities.  [通常講演]
    井上 達夫; 工藤 正俊
    The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2009年11月 Boston, USA The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • シンポジウム・特別発言「肝細胞癌の生命予後改善のための挑戦（再発予防を中心に）」  [通常講演]
    工藤 正俊
    第13回日本肝臓学会大会・第51回日本消化器病学会大会 2009年10月 グランドプリンスホテル京都, 京都 第13回日本肝臓学会大会・第51回日本消化器病学会大会
  • 新規血管新生阻害剤BIBF1120の肝細胞癌に対する有用性.  [通常講演]
    工藤 可苗; 荒尾 徳三; 坂井 和子; 永井 知行; 田村 大介; 青松 圭一; デベラスコマルコ; 金田 裕靖; 藤田 至彦; 松本 和子; 工藤 正俊; 西尾 和人
    第68回日本癌学会学術総会 2009年10月 パシフィコ横浜, 神奈川 第68回日本癌学会学術総会
  • 特別講演「ウイルス性肝炎の治療」  [通常講演]
    工藤 正俊
    平成21年度肝がん撲滅運動 2009年10月 大阪狭山市さやかホール, 大阪 平成21年度肝がん撲滅運動
  • Special Lecture “Current advances in the management of HCC.”  [通常講演]
    工藤 正俊
    HCC Asian Expert Meeting 2009年10月 Taipei, Taiwan HCC Asian Expert Meeting
  • Special Lecture “Concept of early HCC and its imaging finding.”  [通常講演]
    工藤 正俊
    The 3rd International Forum for Liver MRI 2009年10月 Rhome, Italy The 3rd International Forum for Liver MRI
  • 特別講演「肝癌診療の最前線」  [通常講演]
    工藤 正俊
    近畿大学関連病院長会議 2009年10月 大阪狭山, 大阪 近畿大学関連病院長会議
  • 特別講演「肝癌根治後のIFNの役割」  [通常講演]
    工藤 正俊
    Hepatitis C Forum 2009 YAMAGATA 2009年10月 ホテルメトロポリタン山形, 山形 Hepatitis C Forum 2009 YAMAGATA
  • 特別講演「肝発癌進展抑制におけるIFNの役割」  [通常講演]
    工藤 正俊
    城北Hepatologyセミナー 2009年10月 池袋ホテルメトロポリタン, 東京 城北Hepatologyセミナー
  • 特別講演「肝癌診療の最前線」  [通常講演]
    工藤 正俊
    第237回青森市消化器病集談会 2009年10月 ホテル青森, 青森 第237回青森市消化器病集談会
  • HCV陽性肝癌根治後のPEG-IFNα2b/Ribavirin併用療法は再発を抑制できるか. シンポジウム「肝細胞癌の生命予後改善のための挑戦(再発予防を中心に)」  [通常講演]
    齋藤 澄夫; 工藤 正俊; 木村 達; 大崎 往夫
    第13回日本肝臓学会大会 2009年10月 国立京都国際会館・グランドプリンスホテル京都, 京都 第13回日本肝臓学会大会
  • PEG-IFNα2b/RBV併用療法の無効・再燃例に対するPEG-IFNα2a/RBV併用療法の再治療の検討-多施設共同研究 RETRY study-. パネルディスカッション「C型慢性肝炎に対するpeg-IFN+RBV併用無効例に対する方策」  [通常講演]
    上田 泰輔; 工藤 正俊; 橋元 悟; 土谷 薫
    第13回日本肝臓学会大会 2009年10月 国立京都国際会館・グランドプリンスホテル京都, 京都 第13回日本肝臓学会大会
  • Real-time Tissue Elastographyを用いた非侵襲的肝線維化評価法. パネルディスカッション「非侵襲的肝病態評価法の進歩」  [通常講演]
    藤本 研治; 工藤 正俊; 加藤 道夫
    第13回日本肝臓学会大会 2009年10月 国立京都国際会館・グランドプリンスホテル京都, 京都 第13回日本肝臓学会大会
  • 分枝鎖アミノ酸顆粒製剤による肝硬変患者の予後に与える影響に関する検討. シンポジウム「肝炎ウイルス治療ガイドラインの検証」  [通常講演]
    早石 宗右; 石川 恵美; 工藤 正俊; 熊田 博光
    第13回日本肝臓学会大会 2009年10月 国立京都国際会館・グランドプリンスホテル京都, 京都 第13回日本肝臓学会大会
  • PEG-IFNα2a/Ribavirin併用療法のResponse-Guided Therapyを考慮した至適. シンポジウム「肝炎ウイルス治療ガイドラインの検証」  [通常講演]
    西口 修平; 工藤 正俊; 樋口 和秀
    第13回日本肝臓学会大会 2009年10月 国立京都国際会館・グランドプリンスホテル京都, 京都 第13回日本肝臓学会大会
  • Antitumor activity of a novel angiogenesis inhibitor BIBF1120 for hepatocellular carcinoma and a new pharamacodynamic biomaker in blood samples.  [通常講演]
    工藤 正俊; 工藤 可苗; 荒尾 徳三; 西尾 和人
    The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD) 2009年10月 Boston, USA The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)
  • 特別講演「肝細胞癌診療の最新の進歩～Sonazoid造影超音波は中心に～」  [通常講演]
    工藤 正俊
    東北肝疾患病態・治療研究会 2009年10月 盛岡グランドホテル, 岩手 東北肝疾患病態・治療研究会
  • 特別講演「肝癌治療アルゴリズムにおけるネクサバールの位置付け」  [通常講演]
    工藤 正俊
    第1回信州肝癌分子標的治療研究会 2009年10月 ホテルブエナビスタ, 長野 第1回信州肝癌分子標的治療研究会
  • 高齢者に対する大腸ポリペクトミーの安全性と問題点  [通常講演]
    山本 典雄; 辻 直子; 奥村 直己; 酒井 清裕; 加納 友環; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 山田 哲; 今井 元; 工藤 正俊; 本庶 元
    第78回日本消化器内視鏡学会総会(JDDW2009） 2009年10月 京都市 第78回日本消化器内視鏡学会総会(JDDW2009）
  • 大腸ポリペクトミークリニカルパスバリアンス分析からみた大腸LSTの問題点  [通常講演]
    奥村 直己; 辻 直子; 山本 典雄; 加納 友環; 酒井 清裕; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 山田 哲; 今井 元; 工藤 正俊; 本庶 元
    第78回日本消化器内視鏡学会総会（JDDW2009） 2009年10月 京都市 第78回日本消化器内視鏡学会総会（JDDW2009）
  • 患者の安全・満足度から考えるsedation下内視鏡検査、プロポフォール投与下での外来下部消化管内視鏡検査の有用性  [通常講演]
    梅原 康湖; 辻 直子; 工藤 正俊
    第78回日本消化器内視鏡学会総会（JDDW2009） 2009年10月 京都市 第78回日本消化器内視鏡学会総会（JDDW2009）
  • 予後解析からみた大腸ポリペクトミーの意義と問題点  [通常講演]
    辻 直子; 奥村 直己; 山本 典雄; 加納 友環; 酒井 清裕; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 山田 哲; 今井 元; 工藤 正俊; 本庶 元
    第51回日本消化器病学会大会（JDDW2009) 2009年10月 京都市 第51回日本消化器病学会大会（JDDW2009)
  • Utility of contrast-enhanced harmonic EUS on diagnosis of intra-abdominal lesions with undertermined origin.  [通常講演]
    鎌田 研; 北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 末冨 洋一郎; 工藤 正俊
    Asia Pacific Digestive Disease Week (APDW) 2009年09月 Taipei, Taiwan Asia Pacific Digestive Disease Week (APDW)
  • EUS-FNA guided by contrast-enhanced harmonic imaging.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊
    Asia Pacific Digestive Disease Week (APDW) 2009年09月 Taipei, Taiwan Asia Pacific Digestive Disease Week (APDW)
  • EUS-BD後の難治性逆行性胆管炎に対するトラブルシューティング.  [通常講演]
    小牧 孝充; 北野 雅之; 末冨 洋一郎; 今井 元; 鎌田 研; 工藤 正俊
    第6回FNA-Club Japan 2009年09月 東京医科大学, 東京 第6回FNA-Club Japan
  • 経乳頭的アプローチ困難例に対するEUSガイド下胆管ドレナージ術の有用性.  [通常講演]
    鎌田 研; 北野 雅之; 末冨 洋一郎; 坂本 洋城; 小牧 孝充; 今井 元; 工藤 正俊
    第45回日本胆道学会学術集会 2009年09月 千葉県がんセンター, 千葉 第45回日本胆道学会学術集会
  • EUSによる胆管癌の進展度診断.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    ワークショップ「ビデオワークショップ 胆道疾患に対する内視鏡診断の進展」, 第45回日本胆道学会学術集会 2009年09月 千葉県がんセンター, 千葉 ワークショップ「ビデオワークショップ 胆道疾患に対する内視鏡診断の進展」, 第45回日本胆道学会学術集会
  • IPMNに随伴した膵癌の1例.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    第51回日本消化器画像診断研究会 2009年09月 仙台市医師会館, 宮城 第51回日本消化器画像診断研究会
  • 潰瘍性大腸炎として紹介されたClostridium.difficile関連腸病変の一例.  [通常講演]
    奥村 直己; 山本 典雄; 富田 崇文; 梅原 康子; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    第83回日本消化器内視鏡学会近畿地方会 2009年09月 京都テルサ, 京都 第83回日本消化器内視鏡学会近畿地方会
  • Special Lecture “Current topics in HCC: Diagnosis of early HCC and Sonazoid-enhanced US guided ablation.”  [通常講演]
    工藤 正俊
    1st Japan Korea Image guided Tumor Ablation Meeting 2009年09月 Villa Fontaine Shiodome Conference Center, Tokyo, Japan 1st Japan Korea Image guided Tumor Ablation Meeting
  • Special Lecture “Clinical and radiological aspects of preneoplastic liver lesions.”  [通常講演]
    工藤 正俊
    3rd Annual Conference International Liver Cancer Association (ILCA) 2009年09月 Milan, Italy 3rd Annual Conference International Liver Cancer Association (ILCA)
  • 特別講演「肝細胞癌の早期診断と分子標的治療」  [通常講演]
    工藤 正俊
    肝癌診断治療講演会 2009年09月 高松国際ホテル, 香川 肝癌診断治療講演会
  • 特別講演「Future treatment in HCV」  [通常講演]
    工藤 正俊
    Hepatitis C Forum 2009 OSAKA 2009年09月 ホテルニューオータニ大阪, 大阪 Hepatitis C Forum 2009 OSAKA
  • 特別講演「HCC治療における分子標的治療への期待と課題」  [通常講演]
    工藤 正俊
    第1回TOKYO HCC EXPERT MEETING 2009年09月 アルカディア市ヶ谷, 東京 第1回TOKYO HCC EXPERT MEETING
  • 潰瘍性大腸炎として紹介されたClostridium difficile関連腸病変の一例  [通常講演]
    奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊
    第83回日本消化器内視鏡学会近畿地方会 2009年09月 京都市 第83回日本消化器内視鏡学会近畿地方会
  • 肝細胞癌破裂後に肝切除を行ったが腹腔内播種で再発した一例.  [通常講演]
    林 道友; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 村田 賢; 井上 雅智; 工藤 正俊
    日本消化器病学会近畿支部第91回例会 2009年09月 京都テルサ, 京都 日本消化器病学会近畿支部第91回例会
  • 抗アクアポリン4抗体陽性視神経炎に合併した自己免疫性肝炎の一例  [通常講演]
    山本 典雄; 奥村 直己; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊; 小長谷 奈美; 中尾 雄三
    日本消化器病学会近畿支部第91回例会 2009年09月 京都市 日本消化器病学会近畿支部第91回例会
  • Evaluation of liver fibrosis progression using real-time tissue elastography.  [通常講演]
    外村 明子; 辰巳 千栄; 工藤 正俊; 藤本 研治; 三竹 毅; 加藤 道夫; 椎名 毅
    12th World Congress of the World Federation for Ultrasound in Medicine and Biology 2009年09月 Sydney, Australia 12th World Congress of the World Federation for Ultrasound in Medicine and Biology
  • 特別講演「ウイルス性肝炎の治療」  [通常講演]
    工藤 正俊
    肝がん撲滅の為の肝臓病市民公開講座 2009年08月 堺市民会館, 大阪 肝がん撲滅の為の肝臓病市民公開講座
  • 食道静脈瘤上に合併した早期食道癌の1例.  [通常講演]
    松井 繁長; 工藤 正俊
    第18回近畿食道・胃静脈瘤研究会 2009年08月 大阪薬業年金会館, 大阪 第18回近畿食道・胃静脈瘤研究会
  • Special Lecture “Defect Re-perfusion imaging as a treatment guideline for HCC“  [通常講演]
    工藤 正俊
    WFUMB 2009年08月 Sydney, Australia WFUMB
  • Special Lecture “Sonazoid-enhanced US for liver tumors.”  [通常講演]
    工藤 正俊
    WFUMB 2009年08月 Sydney, Australia WFUMB
  • 特別講演「肝癌診療におけるネクサバールの位置づけ」  [通常講演]
    工藤 正俊
    ネクサバール発売記念シンポジウム 肝細胞癌におけるネクサバールの位置づけ 2009年08月 東京 ネクサバール発売記念シンポジウム 肝細胞癌におけるネクサバールの位置づけ
  • パネルディスカッション・特別発言「凝固療法の適応と限界及び合併症ー対策と新工夫ー」  [通常講演]
    工藤 正俊
    第45回日本肝癌研究会 2009年07月 福岡国際会議場, 福岡 第45回日本肝癌研究会
  • 切除不能肝細胞癌に対するSM-11355とジノスタリンストマラマーのランダム化比較試験第II相試験.  [通常講演]
    池田 公史; 工藤 正俊; 奥坂 拓志; 春日井 博志; 石井 浩; 佐田 通夫; 田中 克明; 塩山 靖和; 茶山 一彰; 熊田 博光; 吉川 正治
    第45回日本肝癌研究会 2009年07月 福岡国際会議場, 福岡 第45回日本肝癌研究会
  • Special Lecture “Management of HCC: Current practice guideline.”  [通常講演]
    工藤 正俊
    Yonsei University Liver Cancer Symposium 2009年07月 Seoul, Korea Yonsei University Liver Cancer Symposium
  • Special Lecture “The current assessment algprothm for HCC (EASL, AASL, APASL JSH).”  [通常講演]
    工藤 正俊
    Hepatocellular Cancer (HCC) International Comprehensive Workshop 2009年07月 Freyberg, Germany Hepatocellular Cancer (HCC) International Comprehensive Workshop
  • 特別講演「肝癌再発抑制治療の現状と今後の展望」  [通常講演]
    工藤 正俊
    平成21年度京都医師会肝炎ウイルス研修会 2009年07月 北九州, 福岡 平成21年度京都医師会肝炎ウイルス研修会
  • 造影ハーモニックEUS検査による膵腫瘍性病変診断.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 竹山 宜典; 工藤 正俊; 高木 忠之; 山雄 健次
    第40回日本膵臓学会大会 2009年07月 京王プラザホテル, 東京 第40回日本膵臓学会大会
  • 特別講演「ソナゾイドは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    県北肝疾患研究会 2009年07月 福島ビューホテル, 福島 県北肝疾患研究会
  • 特別講演「診断の進歩と今後の治療アルゴリズム-分子標的治療を含めて-」  [通常講演]
    工藤 正俊
    第7回肝臓病研究会シンポジウム 2009年07月 品川プリンスホテル, 東京 第7回肝臓病研究会シンポジウム
  • The current assessment algorithm for HCC (EASL, AASL, APASL) guidelines.  [通常講演]
    工藤 正俊
    Advanced Hepatocellular Cancer (HCC): Steps Forward 2009年07月 Freyburg, German Advanced Hepatocellular Cancer (HCC): Steps Forward
  • 肝癌患者の治療法別QOL(quality of life)における性差.  [通常講演]
    中山 伸朗; 工藤 正俊; 名越 澄子; 持田 智; 小俣 政男; 熊田 博光; 佐田 通夫; 國土 典宏; 門田 守人; 兼松 隆之; 江川 裕人; 森脇 久隆; 藤原 研司
    第5回消化器病における性差医学・医療研究会 2009年07月 大阪国際会議場, 大阪 第5回消化器病における性差医学・医療研究会
  • 症例4-1  [通常講演]
    井本 勉; 工藤 正俊; 金 守良; 安藤 健治; 三田 敬二; 和田 純子; 有本 明; 若狭 朋子; 林 祥剛; 全 陽; 中沼 安二; 松岡 利幸
    問題症例検討会4「肝癌診断困難症例」, 第45回日本肝癌研究会 2009年07月 福岡国際会議場, 福岡 問題症例検討会4「肝癌診断困難症例」, 第45回日本肝癌研究会
  • 特別講演「肝細胞癌の早期診断と分子標的治療」  [通常講演]
    工藤 正俊
    肝癌診断治療講演会 2009年06月 高松国際ホテル, 香川 肝癌診断治療講演会
  • 新規血管新生阻害剤BIBF1120の肝細胞癌に対する有用性.  [通常講演]
    工藤 可苗; 荒尾 徳三; 田村 大介; 青松 圭一; 金田 裕靖; 田中 薫; 前川 麻里; 松本 和子; 藤田 至彦; 工藤 正俊; 西尾 和人
    第13回日本がん分子標的治療学会 2009年06月 徳島 第13回日本がん分子標的治療学会
  • Special Lecture “Positioning and indication of Sorafenib in the treatment algorithm and real practice setting: Western and Eastern Approach.”  [通常講演]
    工藤 正俊
    3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA) 2009年06月 Kobe, Japan 3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)
  • Luncheon Seminar “The burden of HCC: From the surveillance to molecular targeted therapy.”  [通常講演]
    工藤 正俊
    3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA) 2009年06月 Kobe, Japan 3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)
  • Special Lecture “Imaging of early HCC.”  [通常講演]
    工藤 正俊
    3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA) 2009年06月 Kobe, Japan 3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)
  • Special Lecture “BCLC staging is good as a treatment selection staging similar to Japanese treatment algorithm and different from prognostic staging.”  [通常講演]
    工藤 正俊
    International Symposium “Different Approach to HCC Management Japan, North America and Europe, The 2009年06月 Kobe, Japan International Symposium “Different Approach to HCC Management Japan, North America and Europe, The
  • 特別講演「肝細胞癌治療のパラダイムシフト: 分子標的治療への期待」  [通常講演]
    工藤 正俊
    C型肝炎対策学術講演会 2009年06月 今治国際ホテル, 愛媛 C型肝炎対策学術講演会
  • 特別講演「造影エコーの有用性と将来の展望」  [通常講演]
    工藤 正俊
    第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 特別講演「肝癌診療におけるEOB・プリモビストの役割」  [通常講演]
    工藤 正俊
    第1回多摩エリアEOB・プリモビストセミナー 2009年06月 三鷹産業プラザ, 東京 第1回多摩エリアEOB・プリモビストセミナー
  • Special Lecture “RF Ablation of HCC under CEUS guidance.”  [通常講演]
    工藤 正俊
    World Conference on Interventional Oncology 2009 2009年06月 Beijing International Convention Center, Beijing, China World Conference on Interventional Oncology 2009
  • 血管新生阻害薬のバイオマーカー研究.  [通常講演]
    荒尾 徳三; 工藤 正俊; 西尾 和人
    ワークショップ「肝癌発生・進展の分子機構と臨床への還元」第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 ワークショップ「肝癌発生・進展の分子機構と臨床への還元」第45回日本肝臓学会総会
  • BCLC staging is good as a treatment selection staging similar to Japanese treatment algorithm and different from prognostic staging.  [通常講演]
    工藤 正俊
    シンポジウム「日米欧における肝癌診療の相違をめぐって」第45回日本肝臓学会総会 2009年06月 シンポジウム「日米欧における肝癌診療の相違をめぐって」第45回日本肝臓学会総会
  • Gd-EOB MRIによる肝細胞癌の診断能～造影超音波検査, Dynamic CTとの比較検討.  [通常講演]
    井上 達夫; 畑中 絹世; 早石 宗右; 永井 知行; 田北 雅弘; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 進行肝細胞癌に対するソラフェニブの有効性に関する検討.  [通常講演]
    上嶋 一臣; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊
    第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 特異な経緯をたどったアルコール性肝硬変に合併した肝細胞癌の一例.  [通常講演]
    早石 宗右; 鄭 浩柄; 辰巳 千栄; 永井 知行; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊
    第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 進行肝細胞癌に対するS-1, ペグインターフェロン併用療法の有用性.  [通常講演]
    矢田 典久; 鄭 浩柄; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 井上 達夫; 南 康範; 上嶋 一臣; 工藤 正俊
    第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 慢性C型肝炎における末梢血血小板数減少のメカニズムについてー免疫血液学的検索を中心に.  [通常講演]
    永井 知行; 工藤 正俊; 井本 勉; 金 守良; 三田 敬二; 谷口 美幸; 林 祥剛
    第45回日本肝臓学会総会 2009年06月 戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 分子鎖アミノ酸顆粒製剤による肝硬変患者の予後に与える影響に関する検討.  [通常講演]
    早石 宗右; 石川 恵美; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 第45回日本肝臓学会総会
  • 診断（US）.  [通常講演]
    荒井 邦明; 工藤 正俊; 金子 周一
    特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会
  • 経皮的局所療法.  [通常講演]
    工藤 正俊; 建石 良介
    特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会
  • 特別講演「肝癌治療に与えるネクサバールのインパクト」  [通常講演]
    工藤 正俊
    第40回京都肝癌セミナー 2009年06月 ホテルフジタ京都, 京都 第40回京都肝癌セミナー
  • Dynamic imaging by contrast-enhanced harmonic EUS with long-lasting contrast: Role in diagnosis of pancreatic tumors.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 工藤 正俊
    Digestive Disease Week 2009年06月 Chicago, USA Digestive Disease Week
  • Contrast-enhanced harmonic EUS of intra-abdominal lesions with undertermined origin: initial observation of vascularity depiction.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 工藤 正俊
    Digestive Disease Week 2009年06月 Chicago, USA Digestive Disease Week
  • EUS-guided in vivo microdialysis of pancreas: A novel technique of potential diagnostic and therapeutic application.  [通常講演]
    北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊
    Digestive Disease Week 2009年06月 Chicago, USA Digestive Disease Week
  • Special Lecture “Recent advanced of imaging diagnosis.”  [通常講演]
    工藤 正俊
    The Taiwan Liver Cancer Association (TLCA) 2nd Annual Meeting 2009年06月 Kaohsiung, Taiwan The Taiwan Liver Cancer Association (TLCA) 2nd Annual Meeting
  • 保存的治癒した非代償性肝硬変合併穿孔性十二指腸潰瘍の1例  [通常講演]
    加納 友環; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 米田 円; 辻 直子; 工藤 正俊
    日本内科学会 第188回近畿地方会 2009年06月 大阪市 日本内科学会 第188回近畿地方会
  • 経皮的局所療法.  [通常講演]
    工藤 正俊
    特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会 2009年06月 神戸ポートピアホテル, 兵庫 特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会
  • Special Lecture “Prevention of recurrence after resection and ablation.”  [通常講演]
    工藤 正俊
    5th APASL Single Topic Conference 2009年05月 Istanbul, Turkey 5th APASL Single Topic Conference
  • 特別講演「肝細胞癌の分子標的治療」  [通常講演]
    工藤 正俊
    KBNCの会 2009年05月 全日空ホテルクレメント高松, 香川 KBNCの会
  • 当科における癌性疼痛緩和におけるEUS下腹腔神経叢ブロック術の工夫.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 工藤 正俊
    第77回日本消化器内視鏡学会総会 2009年05月 名古屋国際会議場, 愛知 第77回日本消化器内視鏡学会総会
  • 胆膵疾患に対するTherapeutic EUSの工夫と成績.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 工藤 正俊
    第77回日本消化器内視鏡学会総会 2009年05月 名古屋国際会議場, 愛知 第77回日本消化器内視鏡学会総会
  • EUSガイド下胆管ドレナージ術後の瘻孔部からのAntegrade stenting法.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 工藤 正俊
    第77回日本消化器内視鏡学会総会 2009年05月 名古屋国際会議場, 愛知 第77回日本消化器内視鏡学会総会
  • 膵腫瘍性病変診断における造影ハーモニックEUS検査の有用性.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    シンポジウム「膵癌の診断と治療の新展開」, 第77回日本消化器内視鏡学会総会 2009年05月 名古屋国際会議場, 愛知 シンポジウム「膵癌の診断と治療の新展開」, 第77回日本消化器内視鏡学会総会
  • 慢性膵炎に対するEUSガイド下治療.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    シンポジウム「慢性膵炎に対する最新の治療」, 第77回日本消化器内視鏡学会総会 2009年05月 名古屋国際会議場, 愛知 シンポジウム「慢性膵炎に対する最新の治療」, 第77回日本消化器内視鏡学会総会
  • 肝細胞癌の自然壊死症例でのviability評価における造影超音波検査の有用性.  [通常講演]
    矢田 典久; 前川 清; 畑中 絹世; 高橋 俊介; 鄭 浩柄; 土師 誠二; 工藤 正俊
    日本超音波医学会第82回学術集会 2009年05月 東京国際フォーラム, 東京 日本超音波医学会第82回学術集会
  • 肝細胞癌の肉眼分類とSonazoid造影超音波におけるdefect像の比較.  [通常講演]
    畑中 絹世; 南 康範; 工藤 正俊; 土師 誠二
    日本超音波医学会第82回学術集会 2009年05月 東京国際フォーラム, 東京 日本超音波医学会第82回学術集会
  • ソナゾイド造影超音波による肝癌局所療法の効果判定.  [通常講演]
    前川 清; 工藤 正俊
    ライブセッション「造影超音波検査の治療への応用」, 日本超音波医学会第82回学術集会 2009年05月 東京国際フォーラム, 東京 ライブセッション「造影超音波検査の治療への応用」, 日本超音波医学会第82回学術集会
  • 造影ハーモニックEUS検査.  [通常講演]
    北野 雅之; 鎌田 研; 坂本 洋城; 小牧 孝充; 工藤 正俊
    パネルディスカッション「各領域の造影超音波の新展開」, 日本超音波医学会第82回学術集会 2009年05月 東京国際フォーラム, 東京 パネルディスカッション「各領域の造影超音波の新展開」, 日本超音波医学会第82回学術集会
  • 肝疾患におけるReal-time Tissue Elastography-第4報.  [通常講演]
    藤本 研治; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 金 栄浩; 山本 佳司; 椎名 毅; 加藤 道夫
    パネルディスカッション「びまん性肝疾患の超音波による評価」, 日本超音波医学会第82回学術集会 2009年05月 東京国際フォーラム, 東京 パネルディスカッション「びまん性肝疾患の超音波による評価」, 日本超音波医学会第82回学術集会
  • Defect Re-perfusion Imagingの有用性とRFA治療支援.  [通常講演]
    畑中 絹世; 南 康範; 工藤 正俊
    シンポジウム「肝腫瘍診断における造影超音波の位置づけ」, 日本超音波医学会第82回学術集会 2009年05月 東京国際フォーラム, 東京 シンポジウム「肝腫瘍診断における造影超音波の位置づけ」, 日本超音波医学会第82回学術集会
     
    , 平成21年5月22日-24日, .
  • 「genotype 1b高ウイルス量」以外のC型慢性肝炎症例に対するPEG-IFNα2a response guided therapy.  [通常講演]
    鍋島 紀滋; 林 道友; 奥田 英之; 茂山 朋広; 宮部 欽生; 北口 容子; 豊澤 昌子; 岸谷 讓; 工藤 正俊
    第95回日本消化器病学会総会 2009年05月 北海道厚生年金会館, 北海道 第95回日本消化器病学会総会
  • 粘膜下異所性胃腺を合併した早期胃癌の2例.  [通常講演]
    岡田 無文; 松井 繁長; 朝隈 豊; 川崎 正憲; 梅原 泰; 工藤 正俊; 今本 治彦; 筑後 孝章
    第95回日本消化器病学会総会 2009年05月 北海道厚生年金会館, 北海道 第95回日本消化器病学会総会
  • 診断に難渋した腹部腫瘤における造影ハーモニック超音波内視鏡検査の有用性.  [通常講演]
    今井 元; 北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 鎌田 研; 工藤 正俊
    第95回日本消化器病学会総会 2009年05月 北海道厚生年金会館, 北海道 第95回日本消化器病学会総会
  • IgG4関連自己免疫性肝炎の臨床的特徴象および治療反応性に関する検討.ワークショップ「IgG4関連硬化性疾患ー膵病変と膵外病変をめぐって」  [通常講演]
    鄭 浩柄; 工藤 正俊; 渡邉 智裕
    第95回日本消化器病学会総会 2009年05月 北海道厚生年金会館, 北海道 第95回日本消化器病学会総会
  • Gd-EOB MRIによる肝細胞癌の診断能 造影超音波検査, Dynamic CTとの比較検討.ワークショップ「肝胆膵領域の画像診断の進歩」  [通常講演]
    井上 達夫; 畑中 絹世; 工藤 正俊
    第95回日本消化器病学会総会 2009年05月 北海道厚生年金会館, 北海道 第95回日本消化器病学会総会
  • 進行胃癌に対するソナゾイドを用いた造影EUSの意義.  [通常講演]
    工藤 正俊
    第77回日本消化器内視鏡学会総会 2009年05月 名古屋国際会議場, 愛知 第77回日本消化器内視鏡学会総会
  • Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey.  [通常講演]
    長谷川 潔; 工藤 正俊; 高山 忠利; 國土 典宏; 有井 滋樹; 岡崎 正敏; 沖田 極; 小俣 政男; 神代 正道; 中沼 安二; 高安 賢一; 門田 守人; 松山 裕; 猪飼 伊和夫; 幕内 雅敏
    The 44th Annual Meeting of the European Association for the Study of the liver 2009年04月 Copenhagen, Denmark The 44th Annual Meeting of the European Association for the Study of the liver
  • Antitumor activity of a novel angiogenesis inhibitor BIBF1120 for hepatocellular carcinoma and a new pharmacodynamic biomarker in blood samples.  [通常講演]
    工藤 可苗; 荒尾 徳三; 田中 薫; 金田 裕靖; 前川 麻里; 松本 和子; 田村 大介; 青松 圭一; デベラスコ マルコ アントニオ; 藤田 至彦; 工藤 正俊; 西尾 和人
    AACR 100th Annual Meeting 2009 2009年04月 Denver, USA AACR 100th Annual Meeting 2009
  • 特別講演「ソナゾイドは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    第24回青森県肝疾患研究会 2009年03月 ホテルニューキャッスル, 青森 第24回青森県肝疾患研究会
  • 教育講演「肝癌」  [通常講演]
    工藤 正俊
    第7回日本臨床腫瘍学会学術集会 教育講演会 2009年03月 名古屋, 愛知 第7回日本臨床腫瘍学会学術集会 教育講演会
  • 特別講演「腹部領域における3D, 4D超音波の現状」  [通常講演]
    工藤 正俊
    Phillips 超音波セミナー 2009年03月 東京 Phillips 超音波セミナー
  • 特別講演「C型肝炎治療の重要性と最新の情報」  [通常講演]
    工藤 正俊
    平成20年度「肝がん撲滅運動」市民公開講座 2009年03月 泉佐野市立文化会館泉の森ホール, 大阪 平成20年度「肝がん撲滅運動」市民公開講座
  • 肝細胞癌外科治療におけるソナゾイドを用いた術中造影エコーの有用性.  [通常講演]
    土師 誠二; 安田 武生; 石川 原; 中居 卓也; 竹山 宜典; 大柳 治正; 畑中 絹世; 工藤 正俊
    第11回関西肝癌局所療法研究会 2009年03月 阪急電鉄本社ビル, 大阪 第11回関西肝癌局所療法研究会
  • Special Lecture “Early HCC: Concept and imaging diagnosis.”  [通常講演]
    工藤 正俊
    17th Annual Conference of the Indian National Association for Study of Liver(INASL) 2009年03月 New Delhi, India 17th Annual Conference of the Indian National Association for Study of Liver(INASL)
  • Special Lecture “Molecular targeted therapy for HCC current status and future prospects.”  [通常講演]
    工藤 正俊
    17th Annual Conference of the Indian National Association for Study of Liver(INASL) 2009年03月 New Delhi, India 17th Annual Conference of the Indian National Association for Study of Liver(INASL)
  • 膵頭部癌に伴う下部胆管閉塞に対し超音波内視鏡下胆道ドレナージ術（EUS-BD）が有用であった1例.  [通常講演]
    鎌田 研; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 北野 雅之; 汐見 幹夫; 工藤 正俊
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • IPMNに随伴したTS1膵癌.  [通常講演]
    有住 忠晃; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 北野 雅之; 汐見 幹夫; 工藤 正俊; 新垣 亘; 竹山 宜典
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • OGIBの診断、治療にシングルバルーン小腸内視鏡が有用であったBernard-Soulier症候群の1例.  [通常講演]
    高山 政樹; 松井 繁長; 川崎 正憲; 梅原 泰; 岡田 無文; 朝隈 豊; 工藤 正俊
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • 早期胃癌とキサントーマが同一病巣内に存在した1例.  [通常講演]
    高山 政樹; 松井 繁長; 岡田 無文; 朝隈 豊; 川崎 正憲; 梅原 泰; 工藤 正俊; 筑後 孝章
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • 胃悪性リンパ腫の化学療法後に認めた2cの一例.  [通常講演]
    酒井 清裕; 今井 元; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸郎; 辻 直子; 工藤 正俊; 田中 晃
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • ペグインターフェロンとリバビリン併用医療により著明な胃粘膜障害をきたしたC型慢性肝炎の一例.  [通常講演]
    茂山 朋広; 宮部 欽生; 林 道友; 北口 容子; 豊澤 昌子; 岸谷 譲; 鍋島 紀滋; 工藤 正俊
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • 特別講演「ソナゾイドは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    第24回青森県肝疾患研究会 2009年03月 ホテルニューキャッスル, 青森 第24回青森県肝疾患研究会
  • ステロイド未使用の潰瘍性大腸炎に対するサイクロスポリン持続静注と経口タクロリムスの比較検討.  [通常講演]
    梅原 泰; 高山 政樹; 川崎 正憲; 朝隈 豊; 岡田 無文; 松井 繁長; 早石 宗右; 野田 佳寿; 坂本 洋城; 井上 達夫; 石川 恵美; 矢田 典久; 萩原 智; 末冨 洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 第82回日本消化器内視鏡学会近畿地方会
  • 胃ESD後の後出血に関する検討と対策.  [通常講演]
    岡田 無文; 松井 繁長; 工藤 正俊
    パネルディスカッション「消化管疾患の内視鏡的治療における偶発症と対策」, 第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 パネルディスカッション「消化管疾患の内視鏡的治療における偶発症と対策」, 第82回日本消化器内視鏡学会近畿地方会
  • シングルバルーン小腸内視鏡による小腸疾患の診断と治療.  [通常講演]
    川崎 正憲; 梅原 泰; 工藤 正俊
    シンポジウム「小腸疾患の診断と治療の現況」, 第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 シンポジウム「小腸疾患の診断と治療の現況」, 第82回日本消化器内視鏡学会近畿地方会
  • 経乳頭的アプローチ困難例に対するEUSガイド下胆管ドレナージ術の検討.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    ワークショップ「胆・膵疾患の内視鏡的治療におけるコツと手技」, 第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 ワークショップ「胆・膵疾患の内視鏡的治療におけるコツと手技」, 第82回日本消化器内視鏡学会近畿地方会
  • 胃腫瘍に対するESD治療成績の検討.  [通常講演]
    朝隈 豊; 松井 繁長; 工藤 正俊
    シンポジウム「治療成績からみた消化管腫瘍に対するESDの評価」, 第82回日本消化器内視鏡学会近畿地方会 2009年03月 大阪国際交流センター, 大阪 シンポジウム「治療成績からみた消化管腫瘍に対するESDの評価」, 第82回日本消化器内視鏡学会近畿地方会
  • 胃悪性リンパ腫の化学療法後に認めたＩＩｃの一例  [通常講演]
    酒井 清裕; 今井 元; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 田中 晃; 工藤 正俊
    第82回日本消化器内視鏡学会近畿地方回 2009年03月 大阪市 第82回日本消化器内視鏡学会近畿地方回
  • Special Lecture “Role of molecular targeted therapy in Japan.”  [通常講演]
    工藤 正俊
    “State of the Art in HCC Management: From Diagnosis to Treatment” Annual congress of Asia Pacific A 2009年02月 Hong Kong Convention and Exhibition Centre, Hong Kong, China “State of the Art in HCC Management: From Diagnosis to Treatment” Annual congress of Asia Pacific A
  • Round Table Meeting “The role of molecular targeted agent; Optimizing treatment outcomes.”  [通常講演]
    工藤 正俊
    he 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2009年02月 Hong Kong, China he 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL)
  • Special Lecture “The burden of HCC in Aisa-Pacific.”  [通常講演]
    工藤 正俊
    APASL Hong Kong “State of the Art in HCC Management: From Diagnosis to Treatment” 2009年02月 Hong Kong Convention and Exhibition Centre, Hong Kong, China APASL Hong Kong “State of the Art in HCC Management: From Diagnosis to Treatment”
  • 腸間膜血腫を契機に発見された横行結腸がんの1例  [通常講演]
    今井 元; 奥村 直己; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 由谷 逸朗; 米田 円; 辻 直子; 船井 貞往; 工藤 正俊
    日本消化器病学会近畿支部第90回例会 2009年02月 大阪市 日本消化器病学会近畿支部第90回例会
  • 特別講演「肝細胞癌診療の最新の話題」  [通常講演]
    工藤 正俊
    第7回Sendai Liver Symposium 2009年02月 ホテル仙台プラザ, 宮城 第7回Sendai Liver Symposium
  • 特別講演「ソナゾイドは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    ソナゾイド学術講演会 2009年02月 名鉄トヤマホテル, 富山 ソナゾイド学術講演会
  • 特別講演「C型肝炎治療の重要性と最新の情報」  [通常講演]
    工藤 正俊
    平成20年度「肝がん撲滅運動」市民公開講座 2009年02月 岸和田市立浪切ホール, 大阪 平成20年度「肝がん撲滅運動」市民公開講座
  • 特別講演「肝癌診療の最新のトピックス: 分子標的治療も含めて」  [通常講演]
    工藤 正俊
    第15回北九州肝疾患勉強会 2009年02月 ステーションホテル小倉, 福岡 第15回北九州肝疾患勉強会
  • 特別講演「肝細胞癌治療の新しい展開」  [通常講演]
    工藤 正俊
    肝疾患学術講演会 2009年02月 ホテル日航金沢, 石川 肝疾患学術講演会
  • 特別講演「肝腫瘍の画像診断: 最新のトピックス」  [通常講演]
    工藤 正俊
    第19回三重腹部画像診断・IVR研究会 2009年02月 ホテルグリーンパーク津, 三重 第19回三重腹部画像診断・IVR研究会
  • 特別講演「HCC治療における分子標的治療への期待と課題」  [通常講演]
    工藤 正俊
    第1回TOKYO HCC EXPERT MEETING 2009年 アルカディア市ヶ谷, 東京 第1回TOKYO HCC EXPERT MEETING
  • 胆膵疾患に対するEUSガイド下ドレナージ術の成績. ワークショップ「Interventional EUSのコツ」  [通常講演]
    北野 雅之; 小牧 孝充; 工藤 正俊
    第78回日本消化器内視鏡学会総会 2009年 国立京都国際会館・グランドプリンスホテル京都, 京都 第78回日本消化器内視鏡学会総会
  • 特別講演「safety marginの必要性とそのevidence」  [通常講演]
    工藤 正俊
    第15回肝血流動態イメージ研究会 2009年01月 パシフィコ横浜, 神奈川 第15回肝血流動態イメージ研究会
  • 自然退縮した肝細胞癌症例の画像所見と組織所見との比較.  [通常講演]
    矢田 典久; 前川 清; 高橋 俊介; 鄭 浩柄; 土師 誠二; 工藤 正俊
    第15回肝血流動態イメージ研究会 2009年01月 パシフィコ横浜, 神奈川 第15回肝血流動態イメージ研究会
  • 特別講演「肝細胞癌の診断と治療: Up to date」  [通常講演]
    工藤 正俊
    第3回大塚リバーシンポジウム静岡 2009年01月 ホテルアソシア静岡, 静岡 第3回大塚リバーシンポジウム静岡
  • Gastric Duplication Cyst Mimcking Pancreas pseudocystの一例.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 野田 佳寿; 今井 元; 末冨 洋一郎; 工藤 正俊; 筑後 孝章; 木村 雅友; 竹山 宜典
    第50回日本消化器画像診断研究会 2009年01月 万国津梁館サミットホール, 沖縄 第50回日本消化器画像診断研究会
  • Special Lecture “Diagnostic algorithm”  [通常講演]
    工藤 正俊
    APASL Consensus Development Meeting on Management of Hepatocellular Carcinoma 2008年12月 Grand Hyatt Hotel, Nusa Dua, Bali APASL Consensus Development Meeting on Management of Hepatocellular Carcinoma
  • 肝血管筋脂肪腫の一例.  [通常講演]
    前野 知子; 横川 美加; 市島 真由美; 前川 清; 畑中 絹世; 井上 達夫; 矢田 典久; 鄭 浩柄; 南 康範; 工藤 正俊
    日本超音波医学会第35回関西地方会学術集会 2008年12月 神戸国際会議場, 兵庫. 日本超音波医学会第35回関西地方会学術集会
  • 振幅変調法によるソナゾイド造影超音波撮像法の使用経験.  [通常講演]
    前川 清; 畑中 絹世; 矢田 典久; 南 康範; 鄭 浩柄; 工藤 正俊
    日本超音波医学会第35回関西地方会学術集会 2008年12月 神戸国際会議場, 兵庫. 日本超音波医学会第35回関西地方会学術集会
  • 超音波造影剤Sonazoidを用いた造影ハーモニックEUS. パネルディスカッション「造影エコーの現状と未来 -造影イメージから病態解明へ-」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    日本超音波医学会第35回関西地方会学術集会 2008年12月 神戸国際会議場, 兵庫 日本超音波医学会第35回関西地方会学術集会
  • 各種肝腫瘤のソナゾイド造影超音波による質的診断評価. パネルディスカッション「造影エコーの現状と未来 -造影イメージから病態解明へ-」  [通常講演]
    前川 清; 横川 美加; 前野 知子; 市島 真由美; 畑中 絹世; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊
    日本超音波医学会第35回関西地方会学術集会 2008年12月 神戸国際会議場, 兵庫 日本超音波医学会第35回関西地方会学術集会
  • Contrast-enhanced harmonic endosonography with Sonazoid.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    10th International Symposium on Ultrasound Contrast Imaging 2008年12月 Tokyo, Japan 10th International Symposium on Ultrasound Contrast Imaging
  • Special Lecture “Sonazoid-enhanced US for liver tumors: Present status and future perspective.”  [通常講演]
    工藤 正俊
    10th International Symposium on Ultrasound Contrast Imaging 2008年12月 Tokyo Medical Hospital, Tokyo, Japan 10th International Symposium on Ultrasound Contrast Imaging
  • Special Lecture “Treatment of single HCC in 2-5cm: Debate on gray zone. Non-surgical treatment: Eastern experience.”  [通常講演]
    工藤 正俊
    6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues o 2008年12月 Asian Medical Center, Seoul, Korea 6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues o
  • Special Lecture “Is adjuvant therapy necessary after curative treatment of HCC? Low-dose, long-term maintenance interferon therapy after curative RFA increases survival in patients with hepatitis C-related HCC.”  [通常講演]
    工藤 正俊
    6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues o 2008年12月 Asian Medical Center, Seoul, Korea 6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues o
  • Special Lecture “Ultrasound”  [通常講演]
    工藤 正俊
    APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma 2008年12月 Grand Hyatt Hotel, Nusa Dua, Bali APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma
  • Special Lecture “How to screen”  [通常講演]
    工藤 正俊
    APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma 2008年12月 Grand Hyatt Hotel, Nusa Dua, Bali APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma
  • Rituximab投与後にHBV再活性化劇症肝炎を発症したDLBCLの１例  [通常講演]
    宮武 淳一; 頼 晋也; 金井 良高; 高井 俊輔; 平瀬 主税; 川田 修平; 森田 泰慶; 佐野徹明; 川西 一信; 辰巳 陽一; 芦田 隆司; 前田 裕弘; 金丸 昭久; 早石 宗右; 工藤 正俊
    第9回 大阪リンパ腫研究会 2008年11月 大阪 第9回 大阪リンパ腫研究会
     
    ＜現病歴＞ 平成20年1月に右鼡径部の皮下腫瘤に気付き増大傾向となったため、大阪労災病院皮膚科受診し生検の結果、び慢性大細胞リンパ腫(DLBCL)と診断され紹介となる。PET-CTでは両腋下・右鼡径部にFDGの集積を認めた。骨髄穿刺ではDLBCL細胞の浸潤を認めなかったことよりStage Ⅲと診断した（IPIはH-I）。4月2日からR-THP-COP療法開始し副作用なく終了し2回目より外来治療となる。6月20日に４回目の同療法後、7月4日に肝障害(GOT 131IU/l, GPT 153IU/l, T-bil 0.8mg/dl, ALP 227IU/l,)を認め、7月20日にはGOT 4625IU/l, GPT 1647IU/l, T-bil 9.3mg/dl, D-bil 7.0mg/dl, ALP 283IU/lと著増し黄疸も認められた。腹部CT・超音波所見でも肝腫大・胆嚢壁肥厚あり急性肝炎で入院となる。 ＜入院後経過＞ HBs抗原 98.97IU/ml, HBs抗体陰性、Hbe抗原陰性、HBe抗体 99％、HBc抗体 10.4S/CO、HBV-DNA定量で8.7LGE/mlと上昇しており、平成15年のHBs抗原は陰性で輸血歴もないことより急性B型肝炎の再活性化(reactivation)と診断した。なおDLBCLは寛解状態を持
  • 腸間膜血腫を契機に発見された横行結腸癌の1例  [通常講演]
    奥村 直己; 今井 元; 西尾 健; 冨田 崇文; 梅原 康湖; 由谷 逸朗; 辻 直子; 船井 貞往; 工藤 正俊
    日本内科学会第187回近畿地方会 2008年11月 京都市 日本内科学会第187回近畿地方会
  • 十二指腸静脈瘤の臨床的特徴と診断, 治療.  [通常講演]
    松井 繁長; 工藤 正俊
    ワークショップ「異所性静脈瘤の診断と治療」, 第15回日本門脈圧亢進症学会総会 2008年11月 アクロス福岡, 福岡 ワークショップ「異所性静脈瘤の診断と治療」, 第15回日本門脈圧亢進症学会総会
  • Special Lecture “U/s & EUS in diagnosis of pancreatic tumors”  [通常講演]
    工藤 正俊
    6th AFSUMB Workshop Delhi 2008年11月 New Delhi, India 6th AFSUMB Workshop Delhi
  • 特別講演「肝癌診療の最新の話題」  [通常講演]
    工藤 正俊
    第3回「21世紀の肝疾患を考える会」 2008年11月 京王プラザホテル, 東京 第3回「21世紀の肝疾患を考える会」
  • 特別講演「肝画像診断におけるEOB・プリモビスト注への期待」  [通常講演]
    工藤 正俊
    第3回北陸EOB・プリモビストセミナー 2008年11月 金沢大学医学部類教育棟, 石川 第3回北陸EOB・プリモビストセミナー
  • 特別講演「肝腫瘍における造影エコー法 最前線」  [通常講演]
    工藤 正俊
    第7回山梨Body Imaging 研究会 2008年11月 ベルクラシック甲府, 山梨 第7回山梨Body Imaging 研究会
  • 特別講演「肝臓の画像診断」  [通常講演]
    工藤 正俊
    第15回南大阪臨床消化器病学研究会 2008年11月 天王寺都ホテル, 大阪 第15回南大阪臨床消化器病学研究会
  • Inhibition of phospho-tyrosine in VEGFR2+CD45dim population as a biomarker for VEGFR2 tyrosine kinase inhibitors.  [通常講演]
    工藤 可苗; 荒尾 徳三; 松本 和子; 田中 薫; 金田 裕靖; 藤田 至彦; 工藤 正俊; 西尾 和人
    第67回日本癌学会学術総会 2008年10月 名古屋国際会議場, 愛知 第67回日本癌学会学術総会
  • Inhibitation of phospho-tyrosine in VEGFR2+D45dim population as a biomaker for VEGFR2 tyrosine kinase inhibitors.  [通常講演]
    工藤 可苗; 荒尾 徳三; 田中 薫; 金田 裕靖; 松本 和子; 藤田 至彦; 工藤 正俊; 西尾 和人
    The 67th Annual Meeting of the Japanese Cnacer Association 2008年10月 Nagoya, Japan The 67th Annual Meeting of the Japanese Cnacer Association
  • Mass spectrometric analysis of plasma N-glycan in pancreas cancer.  [通常講演]
    坂本 洋城; 荒尾 徳三; 松本 和子; 北野 雅之; 工藤 正俊; 西尾 和人
    The 67th Annual Meeting of the Japanese Cnacer Association 2008年10月 Nagoya, Japan The 67th Annual Meeting of the Japanese Cnacer Association
  • ランチョンセミナー「Sonazoidは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    第18回日本超音波医学会四国地方会学術集会 2008年10月 松山市立総合コミュニティーセンター, 愛媛 第18回日本超音波医学会四国地方会学術集会
  • 慢性膵炎に対するInterventional EUS.  [通常講演]
    野田 佳寿; 北野 雅之; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • 当院における胆管メタリックステント使用症例の経過解析.  [通常講演]
    末冨 洋一郎; 北野 雅之; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • Value of computed tomography for evaluating the injection site in.  [通常講演]
    坂本 洋城; 荒尾 徳三; 北野 雅之; 工藤 正俊; 西尾 和人
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • 当院におけるHelicobacter pylori(H. pylori)のCAM/AMPC耐成率と除菌治療の年次変化  [通常講演]
    梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元; 工藤 正俊
    JDDW 2008 第76回日本消化器内視鏡学会総会 2008年10月 東京都 JDDW 2008 第76回日本消化器内視鏡学会総会
  • 純型・混合型と患者背景・長期予後からみた早期胃がんの治療方針  [通常講演]
    辻 直子; 西尾 健; 冨田 崇文; 梅原 康湖; 米田 円; 森村 正嗣; 由谷 逸朗; 工藤 正俊; 石黒 信吾; 本庶 元
    JDDW2008 第76回日本消化器内視鏡学会総会 2008年10月 東京都 JDDW2008 第76回日本消化器内視鏡学会総会
  • ESD後胃潰瘍に対するエカベトナトリウムの有用性（Prospective randomized study）.  [通常講演]
    朝隈 豊; 松井 繁長; 岡田 無文; 市川 勉; 川崎 正憲; 梅原 泰; 工藤 正俊
    第50回日本消化器病学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第50回日本消化器病学会大会
  • Sonazoidを用いた造影EUSによる進行胃癌の化学療法効果判定.  [通常講演]
    岡田 無文; 松井 繁長; 工藤 正俊
    シンポジウム「化学療法評価に果たす内視鏡の役割り」, 第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 シンポジウム「化学療法評価に果たす内視鏡の役割り」, 第76回日本消化器内視鏡学会総会
  • Quantitative measurement of whole brain CT perfusion parameters and CT angiography using non-stop detector row CT scanner(MDCT) :initial experience.  [通常講演]
    工藤 正俊; 村上 卓道
    12th Asia Oceania Congress of Radiology 2008年10月 Seoul 12th Asia Oceania Congress of Radiology
  • Evaluation of the effectiveness of radiofrequency ablation for hepatic malignancies: Usefulness of virtual CT Sonography using magnetic navigation.  [通常講演]
    北井 聡; 南 康範; 工藤 正俊; 川崎 正憲; 朝隈 豊
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas.  [通常講演]
    坂本 洋城; 北野 雅之; 末冨 洋一郎; 野田 佳寿; 小牧 孝充; 筑後 孝章; 工藤 正俊
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses.  [通常講演]
    坂本 洋城; 北野 雅之; 野田 佳寿; 小牧 孝充; 筑後 孝章; 工藤 正俊
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • Value of computed tomography for evaluating the injection site in.  [通常講演]
    坂本 洋城; 北野 雅之; 野田 佳寿; 小牧 孝充; 末冨 洋一郎; 工藤 正俊
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • Special Lecture “Impact of primovist on current diagnostic and therapeutic algorithm in HCC”  [通常講演]
    工藤 正俊
    The 2nd International Forum for Liver MRI 2008 2008年10月 Kyoto, Japan The 2nd International Forum for Liver MRI 2008
  • Usefullness of single balloon enteroscopy for diagnosis in small intestinal disease.  [通常講演]
    川崎 正憲; 松井 繁長; 上嶋 一臣; 朝隈 豊; 岡田 無文; 工藤 正俊
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • Combination therapy of ecabet sodium and proton pump inhibitor(PPI) compared with PPI alone for endoscopic submucosal dissection(ESD) ?induced ulcer in early gastric cancers: prospective randomized study.  [通常講演]
    朝隈 豊; 松井 繁長; 岡田 無文; 川崎 正憲; 北井 聡; 坂本 洋城; 井上 達夫; 工藤 正俊
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna Asutria 16th United Europian Gastroenterology Week(UEGW)
  • 当院でのステロイド未使用の潰瘍性大腸炎に対する白血球除去療法の治療成績.  [通常講演]
    梅原 泰; 川崎 正憲; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 今井 元; 野田 佳寿; 坂本 洋城; 石川 恵美; 井上 達夫; 萩原 智; 末冨 洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • 当院におけるシングルバルーン小腸内視鏡検査の有用性.  [通常講演]
    川崎 正憲; 松井 繁長; 梅原 泰; 岡田 無文; 市川 勉; 朝隈 豊; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • 超音波造影剤Sonazoidを用いた造影ハーモニックEUS.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • 当院におけるTherapeutic EUSの現状.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • 1cm以下の早期膵癌診断の為のアプローチ.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第50回日本消化器病学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第50回日本消化器病学会大会
  • 当院におけるTS1膵癌の特徴.  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第76回日本消化器内視鏡学会総会, 2008年10月 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会,
  • Child-Pugh C型肝硬変に合併した肝癌は治療すべきか？その是非と治療法選択に関するRetrospectivee多施設共同研究.  [通常講演]
    大崎 往夫; 工藤 正俊; 松永 隆
    第12回日本肝臓学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第12回日本肝臓学会大会
  • 疼痛緩和により抗癌剤治療が可能となった超音波内視鏡ガイド下腹腔神経叢ブロック術の成績.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    第50回日本消化器病学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第50回日本消化器病学会大会
  • 難治性C型慢性肝炎に対する治療戦略-後期陰性化症例における検討-.  [通常講演]
    上田 泰輔; 鄭 浩柄; 工藤 正俊
    第50回日本消化器病学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第50回日本消化器病学会大会
  • ソナゾイド造影超音波検査におけるpost vascular phase imagingとSPIO-MRIとの比較.  [通常講演]
    井上 達夫; 畑中 絹世; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 石川 恵美; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 横川 美加; 前野 智子; 市島 真由美; 前川 清
    第12回日本肝臓学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第12回日本肝臓学会大会
  • 肝腫瘍の診断におけるDefect Re-perfusion Imagingの有用性について.  [通常講演]
    畑中 絹世; 南 康範; 工藤 正俊
    第12回日本肝臓学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第12回日本肝臓学会大会
  • Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [通常講演]
    南 康範; 畑中 絹世; 工藤 正俊
    第12回日本肝臓学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第12回日本肝臓学会大会
  • 肝予備能良好かつ単発の肝細胞癌患者に対するラジオ波焼灼療法治療成績.  [通常講演]
    鄭 浩柄; 南 康範; 工藤 正俊
    第50回日本消化器病学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第50回日本消化器病学会大会
  • 肝細胞癌根治後C型肝癌に対するIFN少量長期維持療法の生命予後改善効果に関する検討.  [通常講演]
    上田 泰輔; 鄭 浩柄; 工藤 正俊
    第12回日本肝臓学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第12回日本肝臓学会大会
  • 進行肝細胞癌に対するソラフェニブの使用経験.  [通常講演]
    上嶋 一臣; 南 康範; 工藤 正俊
    第12回日本肝臓学会大会 2008年10月 グランドプリンスホテル新高輪, 東京 第12回日本肝臓学会大会
  • 特別講演「肝画像診断におけるEOB・プリモビスト注への期待」  [通常講演]
    工藤 正俊
    第2回関西EOB・プリモビストセミナー 2008年10月 新大阪ワシントンホテルプラザ, 大阪 第2回関西EOB・プリモビストセミナー
  • Experimental and early clinical studies of S-1, a novel oral DPD inhibitor, chemotherapy for advanced hepatocellular carcinoma.  [通常講演]
    山下 竜也; 工藤 正俊; 上嶋 一臣; 金子 周一; 古瀬 純司; 奥坂 拓志; 仲地 耕平; 池田 公史
    The 59th Annual Meeting of the American Association for the Study of Liver Diseases(AASLD) 2008年10月 San Francisco, USA The 59th Annual Meeting of the American Association for the Study of Liver Diseases(AASLD)
  • Value of liver parenchymal phase imaging of contrast-enhanced ultrasonography to diagnose the premalignant/borderline lesions and overt HCC.  [通常講演]
    井上 達夫; 工藤 正俊; 前西 修; 前川 清; 黑木 美奈; 中島 収; 神代 正道
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna, Austria 16th United Europian Gastroenterology Week(UEGW)
  • Qualitative and quantitative analysis of liver-parenchymal phase contrast-enhanced US with Sonazoid in detecting HCC; Comparison with SPIO-MRI.  [通常講演]
    井上 達夫; 工藤 正俊; 畑中絹世; 前川 清; 高橋 俊介; 北井 聡; 上田 泰輔; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣
    16th United Europian Gastroenterology Week(UEGW) 2008年10月 Vienna, Austria 16th United Europian Gastroenterology Week(UEGW)
  • 経乳頭的アプローチ困難例に対するEUSを用いた胆管ドレナージ術の検討.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 工藤 正俊
    第44回日本胆道学会学術集会 2008年09月 名古屋東急ホテル, 愛知 第44回日本胆道学会学術集会
  • 内視鏡的破砕術にて除去した胃石の一例  [通常講演]
    今井 元; 西尾 健; 由谷 逸朗; 辻 直子; 田中 久夫; 工藤 正俊
    第81回 日本消化器内視鏡学会近畿地方会 2008年09月 大阪市 第81回 日本消化器内視鏡学会近畿地方会
  • 当院でのHelocpbacter pyloriのCAM,AMPC耐性率と除菌治療の年次変化(2001～2007年）  [通常講演]
    梅原 康湖; 辻 直子; 工藤 正俊
    第81回日本消化器内視鏡学会近畿地方会 シンポジウム 2008年09月 大阪市 第81回日本消化器内視鏡学会近畿地方会 シンポジウム
  • 特別講演「肝硬変・肝癌診療におけるインターフェロンとソナゾイドの役割」  [通常講演]
    工藤 正俊
    第10回岐阜県肝疾患セミナー 2008年09月 岐阜グランドホテル, 岐阜 第10回岐阜県肝疾患セミナー
  • 肝細胞癌非合併の硬変変症例におけるBCAA製剤投与による生存率への寄与  [通常講演]
    早石 宗右; 石川 恵美; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • 肝細胞癌におけるBiomarker Combined Japan Integrated Staging (bm-JIS) Scoreの有用性  [通常講演]
    北井 聡; 南 康範; 工藤 正俊
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • 原発不明の癌性腹膜炎の1例.  [通常講演]
    茂山 朋広; 林 道友; 宮部 欽生; 北口 容子; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • 肝内胆管癌にTS-1を投与し著効した1例  [通常講演]
    西尾 健; 今井 元; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 杉浦 孝宗; 保田 昇平; 家田 泰浩; 長坂 行雄
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • C型慢性肝炎に対するインターフェロン療法著効後に発症した肝細胞癌破裂の1例  [通常講演]
    峯 宏昌; 萩原 智; 早石 宗右; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 畑中 絹世; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • 悪性リンパ腫治療後にHBVの再活性化をきたした1例.  [通常講演]
    椋棒 圭子; 林 道友; 加藤 玲明; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 北口 容子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • 肝動注用リザーバーのGDAコイルによる難治性十二指腸潰瘍出血を止血し得た1例.  [通常講演]
    早石 宗右; 辰巳 千栄; 上嶋 一臣; 北井 聡; 高橋 俊介; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊
    日本消化器病学会近畿支部第89回例会 2008年09月 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第89回例会
  • Separate analysis of intranodular blood supply in nodular lesions associated with liver cirrhosis: a novel ultrasound technique “pure arterial phase imaging”  [通常講演]
    工藤 正俊; 南 康範
    2nd International Liver Cancer Association(ILCA) 2008 Annual Conference 2008年09月 Chicago, USA 2nd International Liver Cancer Association(ILCA) 2008 Annual Conference
  • A proposal of novel treatment-assist technique in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging.  [通常講演]
    工藤 正俊; 南 康範
    2nd International Liver Cancer Association(ILCA) 2008 Annual Conference 2008年09月 Chicago, USA 2nd International Liver Cancer Association(ILCA) 2008 Annual Conference
  • Phase I/II study of the efficacy and safety of S-1 in patients(PTS) with advanced hepatocellular carcinoma(HCC).  [通常講演]
    工藤 正俊; 上嶋 一臣; 古瀬 純司; 奥坂 拓志; 金子 周一; 仲地 耕平; 池田 公史; 山下 竜也
    2nd International Liver Cancer Association(ILCA) 2008 Annual Conference 2008年09月 Chicago, USA 2nd International Liver Cancer Association(ILCA) 2008 Annual Conference
  • Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses.  [通常講演]
    坂本 洋城; 工藤 正俊
    16th International Symposium on Endoscopic Ultrasound 2008年09月 San Francisco, California. 16th International Symposium on Endoscopic Ultrasound
  • Dynamic imaging of pancreatic tumors by contrast-enhanced harmonic EUS with long-lastiong contrast.  [通常講演]
    北野 雅之; 坂本 洋城; Das Kunal; 小牧 孝充; 野田 佳寿; 工藤 正俊; 高木 忠之; 山雄 健次
    EUS 2008 2008年09月 San San Francisco, California. EUS 2008
  • Invited Lecture “Contrast-enhanced US with new contrast agent, Sonazoid for liver tumors. "  [通常講演]
    工藤 正俊
    Australasian Society for Ultrasound in Medicine 38th Annual Scientific Meeting 2008年09月 New Zealand. Australasian Society for Ultrasound in Medicine 38th Annual Scientific Meeting
  • 特別講演「ソナゾイドは肝癌診療をどう変えるか？」  [通常講演]
    工藤 正俊
    第64回東海総合画像医学研究会 2008年08月 名鉄ニューグランドホテル, 愛知 第64回東海総合画像医学研究会
  • Invited Lecture “Hepatocellular carcinoma: current topics in the diagnosis and treatment”  [通常講演]
    工藤 正俊
    LAENNEC SOCIETY: SUMMER MEETING 2008年07月 Padova, Italy LAENNEC SOCIETY: SUMMER MEETING
  • 膵癌早期診断の為のアプローチ: US, EUSを中心に.  [通常講演]
    坂本 洋城; 北野 雅之; 竹山 宜典; 工藤 正俊
    第39回日本膵臓学会大会 2008年07月 パシフィコ横浜, 神奈川. 第39回日本膵臓学会大会
  • Invited Lecture “Diffuse liver disease”  [通常講演]
    工藤 正俊
    WFUMB 2008 WORKSHOP 2008年07月 Ulaanbaatar, Mongolian. WFUMB 2008 WORKSHOP
  • Invited Lecture “Contrast-enhanced US of hepatic tumors with Sonazoid”  [通常講演]
    工藤 正俊
    WFUMB 2008 WORKSHOP 2008年07月 Ulaanbaatar, Mongolian. WFUMB 2008 WORKSHOP
  • Invited Lecture “Direct Re-perfusion Imaging with Sonazoid in the diagnosis and treatment of hepatic malignancies”  [通常講演]
    工藤 正俊
    WFUMB 2008 WORKSHOP 2008年07月 Ulaanbaatar, Mongolian. WFUMB 2008 WORKSHOP
  • 特別講演「肝胆膵疾患におけるSonazoid造影検査の意義」  [通常講演]
    工藤 正俊
    第17回鳥取県西部腹部超音波研究会 2008年07月 米子全日空ホテル, 鳥取 第17回鳥取県西部腹部超音波研究会
  • 特別講演「日常診療における造影超音波診断」  [通常講演]
    工藤 正俊
    第91回姫路消化器病研究会 2008年07月 姫路市医師会館, 兵庫 第91回姫路消化器病研究会
  • シンポジウム「日本肝癌研究会全国原発性肝癌追跡調査の現状と課題」  [通常講演]
    猪飼伊和夫; 工藤 正俊
    第63回日本消化器外科学会定期学術総会 2008年07月 札幌 第63回日本消化器外科学会定期学術総会
  • 進行肝細胞癌に対するS-1, ペグインターフェロン併用療法.  [通常講演]
    上嶋 一臣; 早石 宗右; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊
    第44回日本肝臓学会総会 2008年06月 愛媛県県民文化会館, 愛媛 第44回日本肝臓学会総会
  • 肝細胞癌バイオマーカー血清TERTmRNAの臨床的有用性の多施設研究.  [通常講演]
    三浦 典正; 永島 美樹; 工藤 正俊; 大崎 往夫; 河野 通盛; 大山 賢治; 庄盛 浩平; 神戸 貴雅; 岸本 幸広; 丸山 茂雄; 野間 英二郎; 堀江 裕; 坂口 正剛; 川崎 寛中; 長谷川 純一; 汐田 剛史
    第44回日本肝臓学会総会 2008年06月 愛媛県県民文化会館, 愛媛 第44回日本肝臓学会総会
  • 特別講演「Sonazoidは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    第21回熊本肝癌研究会 2008年06月 熊本 第21回熊本肝癌研究会
  • ソナゾイド造影超音波による肝腫瘤の質的診断評価.  [通常講演]
    前川 清; 畑中 絹世; 井上 達夫; 横川 美加; 前野 知子; 市島 真由美; 内藤 昭智; 上硲 俊法; 高橋 俊介; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第8回関西肝血流動態イメージ研究会 2008年06月 オーバルホール, 兵庫 第8回関西肝血流動態イメージ研究会
  • VEGFR2阻害剤に対する耐性株とCEC及びCEPの検討.  [通常講演]
    工藤 可苗; 荒尾 徳三; 松本 和子; 金田 裕靖; 田中 篤; 前川 麻里; 藤田 至彦; 工藤 正俊; 西尾 和人
    第12回がん分子標的治療研究会総会 2008年06月 学術総合センター, 東京 第12回がん分子標的治療研究会総会
  • MDCT,MRI画像診断によるHCCのRFA治療効果判定  [通常講演]
    岡田 真広; 熊野 正士; 桑原 雅知; 柳生 行伸; 勝部 敬; 荒木 哲朗; 香川 祐毅; 葉 輝明; 安藤 理奈; 松久保 祐子; 任 誠雲; 米矢 吉宏; 小塚 健倫; 土屋 典生; 下野 太郎; 今岡 いずみ; 足利 竜一朗; 細野 眞; 工藤 正俊; 村上 卓道
    第44回日本肝癌研究会 2008年05月 大阪 第44回日本肝癌研究会
  • 特別講演「Sonazoidは肝癌診療をどう変えるか？」  [通常講演]
    工藤 正俊
    第44回日本肝癌研究会 ランチョンセミナー 2008年05月 大阪国際会議場, 大阪 第44回日本肝癌研究会 ランチョンセミナー
  • 特別講演「肝細胞癌根治後のC型慢性肝炎に対するPEG-IFN少量・長期・維持療法の可能性」  [通常講演]
    工藤 正俊
    第44回日本肝癌研究会 ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」 2008年05月 大阪国際会議場, 大阪 第44回日本肝癌研究会 ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」
  • 特別講演「肝癌に魅せられて30年」  [通常講演]
    工藤 正俊
    定例愛光医会 2008年05月 松山全日空ホテル, 愛媛. 定例愛光医会
  • 膵腫瘍性病変診断におけるTrucut針、25Gおよび22G吸引穿刺針の比較検討.  [通常講演]
    坂本 洋城; 北野 雅之; 野田 佳寿; 小牧 孝充; 今井 元; 工藤 正俊
    第4回超音波内視鏡下生検法の診断制度向上のための研究会 2008年05月 パシフィコ横浜, 神奈川. 第4回超音波内視鏡下生検法の診断制度向上のための研究会
  • 特別講演「肝癌ラジオ波焼灼療法の現状」  [通常講演]
    工藤 正俊
    第2回神鋼病診連携消化器病懇話会 2008年05月 神鋼病院, 兵庫 第2回神鋼病診連携消化器病懇話会
  • 当院での超音波内視鏡下腹腔神経叢ブロックのコツと手技の工夫.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    第75回日本消化器内視鏡学会総会 2008年05月 パシフィコ横浜, 神奈川 第75回日本消化器内視鏡学会総会
  • 胆膵疾患に対するEUSガイド下ドレナージ術.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第75回日本消化器内視鏡学会総会 2008年05月 パシフィコ横浜, 神奈川. 第75回日本消化器内視鏡学会総会
  • 癌性疼痛緩和における超音波内視鏡ガイド下腹腔神経叢ブロック術の成績.  [通常講演]
    小牧 孝充; 北野 雅之; 工藤 正俊
    パネルディスカッション「癌緩和医療における内視鏡の役割」, 第75回日本消化器内視鏡学会総会 2008年05月 パシフィコ横浜, 神奈川 パネルディスカッション「癌緩和医療における内視鏡の役割」, 第75回日本消化器内視鏡学会総会
  • 当院におけるInterventional EUSの現状. シンポジウム「Interventional EUSの進歩」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第75回日本消化器内視鏡学会総会 2008年05月 パシフィコ横浜, 神奈川 第75回日本消化器内視鏡学会総会
  • Defect Re-inection imagingの有用性について.  [通常講演]
    畑中 絹世; 南 康範; 北井 聡; 辰巳 千栄; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    日本超音波医学会第81回学術集会 2008年05月 神戸国際会議場, 兵庫 日本超音波医学会第81回学術集会
  • ソナゾイド造影超音波による肝癌局所療法の効果判定『特にDefect-reinjection-testと支援画像表示』  [通常講演]
    前川 清; 畑中 絹世; 横川 美加; 前野 知子; 市島 真由美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    日本超音波医学会第81回学術集会 2008年05月 神戸国際会議場, 兵庫 日本超音波医学会第81回学術集会
  • Sonazoidを用いた造影ハーモニックEUS検査. シンポジウム「画像診断に与えた造影超音波のインパクト」  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    日本超音波医学会第81回学術集会 2008年05月 神戸国際会議場, 兵庫 日本超音波医学会第81回学術集会
  • 肝臓エラストグラフィの定量化の試みと深部領域の感度の改善. パネルディスカッション「弾性の考え方と診断法: 各領域における見方」  [通常講演]
    藤本研吾; 辰巳 千栄; 上嶋 一臣; 前川 清; 工藤 正俊; 加藤 道夫; 外村 明子; 山川 誠; 椎名 毅
    日本超音波医学会第81回学術集会 2008年05月 神戸国際会議場, 兵庫 日本超音波医学会第81回学術集会
  • 非B非C肝癌の臨床的特徴: B型関連肝癌・C型関連肝癌との比較.  [通常講演]
    畑中 絹世; 南 康範; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第44回日本肝癌研究会 2008年05月 大阪国際会議場, 大阪. 第44回日本肝癌研究会
  • Multistep hepatocecarcinogenesis: Correlation of imaging with pathology.  [通常講演]
    工藤 正俊
    The 94th Annual Meeting of the Japanese Society of Gastroenterology 1st International Forum 2008年05月 Fukuoka, Japan. The 94th Annual Meeting of the Japanese Society of Gastroenterology 1st International Forum
  • Clinicopathological time trends for early gastric cancer and helicobacter pylori infection in Japan.  [通常講演]
    梅原 康湖; 辻 直子; 石黒 信吾; 工藤 正俊
    DDW (Digestive Disease Week) 2008 2008年05月 San Diego, USA. DDW (Digestive Disease Week) 2008
  • Defect Re-injection Testの有用性とRFA治療支援.  [通常講演]
    畑中 絹世; 南 康範; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    シンポジウム「RFA-STATE of ARTS」, 第44回日本肝癌研究会 2008年05月 大阪. シンポジウム「RFA-STATE of ARTS」, 第44回日本肝癌研究会
  • 特別講演「Sonazoidは肝癌診療をどう変えるか？」  [通常講演]
    工藤 正俊
    ランチョンセミナー, 第44回日本肝癌研究会 2008年05月 大阪. ランチョンセミナー, 第44回日本肝癌研究会
  • 特別講演「肝細胞癌根治後のC型慢性肝炎に対するPEG-IFN少量・長期・維持療法の可能性.」  [通常講演]
    工藤 正俊
    ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」, 第44回日本肝癌研究会 2008年05月 大阪. ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」, 第44回日本肝癌研究会
  • Cronkhite-Canada症候群に腸重積を合併した1例.  [通常講演]
    早石 宗右; 石川 恵美; 南 康範; 上田 和毅; 工藤 正俊
    第94回日本消化器病学会総会 2008年05月 福岡. 第94回日本消化器病学会総会
  • 難治性C型慢性肝炎（Ⅰ型高ウイルス量）に対するPEG-IFN α2b/Ribavirin併用療法の長期投与成績と安全性について.  [通常講演]
    石川 恵美; 南 康範; 上嶋 一臣; 鄭 浩柄; 早石 宗右; 井上 達夫; 工藤 正俊
    第94回日本消化器病学会総会, 2008年05月 福岡. 第94回日本消化器病学会総会,
  • Defect Re-injection Testの有用性について.  [通常講演]
    畑中 絹世; 北井 聡; 上田 泰輔; 辰巳 千栄; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 前川 清; 工藤 正俊
    第94回日本消化器病学会総会, 2008年05月 福岡. 第94回日本消化器病学会総会,
  • 進行肝細胞癌に対するS-1、ペグインターフェロン併用療法.  [通常講演]
    上嶋 一臣; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 井上 達夫; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊
    第94回日本消化器病学会総会 2008年05月 福岡. 第94回日本消化器病学会総会
  • 造影ハーモニックEUSによる胆膵疾患の診断.  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    シンポジウム「胆膵画像診断の進歩」, 第94回日本消化器病学会総会 2008年05月 福岡. シンポジウム「胆膵画像診断の進歩」, 第94回日本消化器病学会総会
  • HCV Core抗原、NS3蛋白によるTLR2を介するCross Torelanceの誘導.  [通常講演]
    鄭 浩柄; 工藤 正俊; 渡邉 知裕
    シンポジウム「ウイルス肝炎・肝癌に対する生体防御」, 第94回日本消化器病学会総会 2008年05月 福岡. シンポジウム「ウイルス肝炎・肝癌に対する生体防御」, 第94回日本消化器病学会総会
  • Evaluation of the effectiveness of radiofrequency ablation for hepatic malignancies: Usefulness of virtual CT Sonography using magnetic navigation.  [通常講演]
    北井 聡; 南 康範; 工藤 正俊
    DDW (Digestive Disease Week) 2008 2008年05月 San Diego, America. DDW (Digestive Disease Week) 2008
  • Combination therapy of ecabet sodium and proton pump inhibitor (PPI) compared with PPI alone for endoscopic submucosal dissection (ESD) ?induced ulcer in gastric cancer: Prospective randomized study.  [通常講演]
    松井 繁長; 工藤 正俊; 岡田 無文; 朝隈 豊; 市川 勉; 川崎 正憲
    DDW (Digestive Disease Week) 2008 2008年05月 San Diego, America. DDW (Digestive Disease Week) 2008
  • Contrast enhanced sonography for hepatic malignancies: value of Defect Re-injection Test.  [通常講演]
    畑中 絹世; 南 康範; 工藤 正俊
    DDW (Digestive Disease Week) 2008 2008年05月 San Diego, America. DDW (Digestive Disease Week) 2008
  • 教育講演「第2世代超音波造影剤による内視鏡的超音波検査（CE-EUS）の開発と臨床応用」  [通常講演]
    工藤 正俊
    第75回日本消化器内視鏡学会総会 2008年05月 パシフィコ横浜, 神奈川. 第75回日本消化器内視鏡学会総会
  • Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of the pgase II part.  [通常講演]
    奥坂 拓志; 工藤 正俊; 上嶋 一臣; 古瀬 純司; 金子 周一; 池田 公史; 仲地 耕平; 山下 竜也
    2008 Annual Meeting, AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2008年05月 Chicago, America 2008 Annual Meeting, AMERICAN SOCIETY OF CLINICAL ONCOLOGY
  • Superiority of atrerioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2cm.  [通常講演]
    金 守良; 工藤 正俊; 井本 勉; 猪川 弘嗣; 安藤 健治; 三田 敬二; 婦木 秀一; 笹瀬 典子; 松岡 利幸; 林 祥
    The 43rd Annual Meeting of the Europian Association for the Study of the Liver 2008年04月 Milan, Italy. The 43rd Annual Meeting of the Europian Association for the Study of the Liver
  • Sonazoid造影超音波によるRFA治療の効果判定: 特にDefect-reinjection-test (D-RIT)と支援画像表示.  [通常講演]
    前川 清; 横川 美加; 前野 知子; 市島 真由美; 内藤 昭智; 上硲 俊法; 畑中 絹世; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    ワークショップII 「肝腫瘤性病変のSonazoidr造影超音波「私の工夫」」, 第21回日本腹部造影エコー・ドプラ診断研究会 2008年04月 秋葉原コンベンションホール, 東京. ワークショップII 「肝腫瘤性病変のSonazoidr造影超音波「私の工夫」」, 第21回日本腹部造影エコー・ドプラ診断研究会
  • Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [通常講演]
    南 康範; 今井 元; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第21回日本腹部造影エコー・ドプラ診断研究会 2008年04月 秋葉原コンベンションホール, 東京. 第21回日本腹部造影エコー・ドプラ診断研究会
  • 特別講演「C型肝炎治療の重要性と最新の情報」  [通常講演]
    工藤 正俊
    平成19年度「肝がん撲滅運動」市民公開講座 2008年03月 岸和田市立浪切ホール, 大阪. 平成19年度「肝がん撲滅運動」市民公開講座
  • 特別講演「C型肝炎治療の重要性と最新の情報」  [通常講演]
    工藤 正俊
    平成19年度「肝がん撲滅運動」市民公開講座 2008年03月 泉佐野市立文化会館泉の森ホール, 大阪. 平成19年度「肝がん撲滅運動」市民公開講座
  • 特別講演「肝臓癌」  [通常講演]
    工藤 正俊
    第6回日本臨床腫瘍学会学術集会 2008年03月 福岡国際会議場, 福岡. 第6回日本臨床腫瘍学会学術集会
  • Live Demonstration "Abdominal Ultrasound."  [通常講演]
    工藤 正俊
    The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo 2008年03月 Manila, Phillipine The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo
  • Invited Lecture “Ultrasound of Pancreas including EUS.”  [通常講演]
    工藤 正俊
    6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI) 2008年03月 Manila, Phillipine 6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI)
  • Invited Lecture “Ultrasound Diagnosis of Non-alcoholic Steatoheoatitis (NASH).”  [通常講演]
    工藤 正俊
    6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI) 2008年03月 Manila, Phillipine 6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI)
  • 総括.  [通常講演]
    工藤 正俊
    第3回 Bay Area Gut Club (BAG) 2008年03月 淡路夢舞台国際会議場, 兵庫. 第3回 Bay Area Gut Club (BAG)
  • 進行肝細胞癌に対するS-1・ペグインターフェロン併用療法の有用性.  [通常講演]
    上嶋 一臣; 工藤 正俊
    第3回 Bay Area Gut Club (BAG) 2008年03月 淡路夢舞台国際会議場, 兵庫. 第3回 Bay Area Gut Club (BAG)
  • 造影ハーモニック超音波内視鏡検査の新規開発と臨床応用.  [通常講演]
    北野 雅之; 工藤 正俊
    第3回 Bay Area Gut Club (BAG) 2008年03月 淡路夢舞台国際会議場, 兵庫. 第3回 Bay Area Gut Club (BAG)
  • 当院でのペグインターフェロン+リバビリン併用療法について。LVR及び長期投与の検討.  [通常講演]
    上田 泰輔; 工藤 正俊
    第3回 Bay Area Gut Club (BAG) 2008年03月 淡路夢舞台国際会議場, 兵庫. 第3回 Bay Area Gut Club (BAG)
  • 特別講演「Sonazoid造影エコーは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    第1回腹部画像診断勉強会 2008年03月 大阪. 第1回腹部画像診断勉強会
  • Invited Lecture “Treatment of HCC using Real-time Virtual Sonography and Contrast US”  [通常講演]
    工藤 正俊
    The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo 2008年03月 Manila The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo
  • Invited Lecture “Doppler/Contrast-enhanced US of liver mass”  [通常講演]
    工藤 正俊
    The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo 2008年03月 Manila The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo
  • Invited Lecture “ Application of Sonazoid in the Liver”  [通常講演]
    工藤 正俊
    The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo 2008年03月 Manila The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo
  • ステロイド、免疫調節剤使用歴のないサイトメガロウイルス感染を合併した潰瘍性大腸炎の2例.  [通常講演]
    梅原 泰; 川崎 正憲; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 今井 元; 野田 佳寿; 坂本 洋城; 井上 達夫; 石川 恵美; 萩原 智; 末冨 洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊
    第80回日本消化器内視鏡学会近畿地方会 2008年03月 大阪国際交流センター, 大阪 第80回日本消化器内視鏡学会近畿地方会
  • 下痢を初発症状とし急速に進行した完全型ベーチェット病の一例.  [通常講演]
    冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    第80回日本消化器内視鏡学会近畿地方会 2008年03月 大阪国際交流センター, 大阪 第80回日本消化器内視鏡学会近畿地方会
  • 当院におけるEUS下ドレナージ術の工夫.  [通常講演]
    野田 佳寿; 北野 雅之; 工藤 正俊
    第80回日本消化器内視鏡学会近畿地方会 2008年03月 大阪国際交流センター, 大阪 第80回日本消化器内視鏡学会近畿地方会
  • 十二指腸静脈瘤に対する内視鏡的治療と予後.  [通常講演]
    松井 繁長; 岡田 無文; 工藤 正俊
    第80回日本消化器内視鏡学会近畿地方会 2008年03月 大阪国際交流センター, 大阪 第80回日本消化器内視鏡学会近畿地方会
  • Invited Lecture “Drug development in TACE. What are some important issues to consider in trial design? "  [通常講演]
    工藤 正俊
    AstraZeneca Hepatocellular Carcinoma Advisory Board Meeting 2008年02月 Singapore AstraZeneca Hepatocellular Carcinoma Advisory Board Meeting
  • 肝類上皮性血管内皮腫の一例  [通常講演]
    茂山 朋広; 林 道友; 宮部 欽生; 豊澤 昌子; 加藤 玲明; 岸谷 讓; 鍋島 紀滋; 工藤 正俊
    第88回日本消化器病学会近畿支部例会 2008年02月 大阪 第88回日本消化器病学会近畿支部例会
  • Special Lecture ”Pancreatic ultrasound including EUS”  [通常講演]
    工藤 正俊
    WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound 2008年02月 Agra, India. WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound
  • Special Lecture ”Diffuse Liver Diseases”  [通常講演]
    工藤 正俊
    WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound 2008年02月 Agra, India. WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound
  • Live Demonstration “Color Doppler examination in the adenoma”  [通常講演]
    工藤 正俊
    WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound i 2008年02月 Agra, India. WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound i
  • Invited Lecture ”Recent Advances in Management of HCC.”  [通常講演]
    工藤 正俊
    2008年02月 Fortis Hospital, New Delhi, India.
  • One Day Visitig Professorship “Case Consultation (Session), Ultrtasound Live Demonstration and Ward Round as a Visiting Professor.”  [通常講演]
    工藤 正俊
    2008年02月 Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.
  • Invited Lecture ”Treatment efficacy of TACE for HCC by use of IVR-CT.”  [通常講演]
    工藤 正俊
    2008年02月 Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.
  • Invited Lecture ”Novel ultrasound technique “Pure Arterial Phase Imaging” in the diagnosis of liver tumors.”  [通常講演]
    工藤 正俊
    2008年02月 Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.
  • Invited Lecture ”Sonazoid-enhanced US for the Management of hepatocellular carcinoma.”  [通常講演]
    工藤 正俊
    2008年02月 Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.
  • Invited Lecture ”Real-time virtual sonography for the treatment of hepatocellular carcinoma.”  [通常講演]
    工藤 正俊
    2008年02月 Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.
  • Invited Lecture “Radiofrequency ablation for difficult-to-treat HCC cases: How We Do It?”  [通常講演]
    工藤 正俊
    2008年02月 Delhi University School of Medicene, GB Panda Hospital, New Delhi, India
  • 特別講演「肝細胞癌の超音波診断」  [通常講演]
    工藤 正俊
    日本超音波医学会第26回中部地方会 2008年02月 名古屋国際会議場, 愛知. 日本超音波医学会第26回中部地方会
  • 基礎:造影剤と撮像法の工夫（ワークショップ「超音波フローイメージング」）  [通常講演]
    工藤 正俊
    第27回日本画像医学会 2008年02月 東京コンファレンスセンター・品川, 東京. 第27回日本画像医学会
  • 特別講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    病院連携懇談会 2008年02月 国家公務員共済組合連合京阪奈病院, 大阪. 病院連携懇談会
  • 当院で経験した日本海裂頭条虫症の一例  [通常講演]
    西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 宇仁 茂彦
    第88回日本消化器病学会近畿支部例会 2008年02月 第88回日本消化器病学会近畿支部例会
  • 急速な転帰をとった腸管ベーチェット病の一例  [通常講演]
    梅原 泰; 川崎 正憲; 有住 忠晃; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 北野 雅之; 汐見 幹夫; 工藤 正俊; 石丸 英三郎; 沖 貴士; 上田 和毅; 所 忠男; 奥野 清隆
    第88回日本消化器病学会近畿支部例会 2008年02月 大阪国際交流センター, 大阪 第88回日本消化器病学会近畿支部例会
  • シングルバルーン小腸内視鏡が診断に有用だった縦走潰瘍を呈するNSAID小腸潰瘍の一例  [通常講演]
    川崎 正憲; 梅原 泰; 有住 忠晃; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 汐見 幹夫; 工藤 正俊
    第88回日本消化器病学会近畿支部例会 2008年02月 大阪国際交流センター, 大阪 第88回日本消化器病学会近畿支部例会
  • 高齢発症クローン病に対するTOP-DOWN療法で経時的に粘膜治癒が追えた一例  [通常講演]
    有住 忠晃; 梅原 泰; 川崎 正憲; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 今井 元; 野田 佳寿; 坂本 洋城; 石川 恵美; 井上 達夫; 萩原 智; 末冨洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊
    第88回日本消化器病学会近畿支部例会 2008年02月 大阪国際交流センター, 大阪 第88回日本消化器病学会近畿支部例会
  • Defect Re-injection imagingの有用性について.  [通常講演]
    畑中 絹世; 南 康範; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第88回日本消化器病学会近畿支部例会 2008年02月 大阪国際交流センター, 大阪. 第88回日本消化器病学会近畿支部例会
  • Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [通常講演]
    南 康範; 今井 元; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第88回日本消化器病学会近畿支部例会 2008年02月 大阪国際交流センター, 大阪 第88回日本消化器病学会近畿支部例会
  • 特別講演「ウィルス肝炎の長期予後、肝がん・肝硬変との関係」  [通常講演]
    工藤 正俊
    肝炎肝がん対策講習会 2008年02月 大阪府富田林保健所, 大阪. 肝炎肝がん対策講習会
  • 内視鏡の偶発症対策-術前インフォームド・コンセントと電子カルテ.  [通常講演]
    汐見 幹夫; 末冨 洋一郎; 工藤 正俊
    第76回日本消化器内視鏡学会総会 2008年 グランドプリンスホテル新高輪, 東京 第76回日本消化器内視鏡学会総会
  • 肝腫瘤におけるDefect Re-perfusion Imagingの有用性について.  [通常講演]
    畑中 絹世; 南 康範; 工藤 正俊
    日本超音波医学会第35回関西地方会学術集会 2008年 神戸国際会議場, 兵庫. 日本超音波医学会第35回関西地方会学術集会
  • Special Lecture “Diagnostic algorithm”  [通常講演]
    工藤 正俊
    APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma 2008年 Grand Hyatt Hotel, Nusa Dua, Bali APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma
  • 特別講演「肝細胞癌診療におけるSonazoid造影エコーの役割」  [通常講演]
    工藤 正俊
    学術講演会 2008年01月 ウエディングプラザホテルアピオ, 山梨 学術講演会
  • 特別講演「肝細胞癌の自然経過と画像診断の役割」  [通常講演]
    工藤 正俊
    大阪EOB研究会 2008年01月 大阪. 大阪EOB研究会
  • 特別講演「RFA治療支援におけるSonazoid造影下Defect Re-Perfusion Imagingの有用性」  [通常講演]
    工藤 正俊
    第14回肝血流動態イメージ研究会 2008年01月 パシフィコ横浜, 横浜 第14回肝血流動態イメージ研究会
  • ソナゾイド造影超音波による肝癌局所療法の効果判定―特にdefect-reinjection-testによる判定.  [通常講演]
    前川 清; 横川 美加; 前野 知子; 市島 真由美; 畑中 絹世; 辰巳 千栄; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第14回肝血流動態イメージ研究会 2008年01月 パシフィコ横浜, 横浜 第14回肝血流動態イメージ研究会
  • Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [通常講演]
    南 康範; 今井 元; 上田 泰輔; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 工藤 正俊
    第14回肝血流動態イメージ研究会 2008年01月 パシフィコ横浜, 横浜 第14回肝血流動態イメージ研究会
  • Defect re-injection testの有用性について.  [通常講演]
    畑中 絹世; 南 康範; 鄭 浩柄; 上嶋 一臣; 前川 清; 工藤 正俊
    第14回肝血流動態イメージ研究会 2008年01月 パシフィコ横浜, 横浜 第14回肝血流動態イメージ研究会
  • 特別講演「肝細胞癌の診断と治療 ～最近の話題～」  [通常講演]
    工藤 正俊
    第25回 神戸肝疾患カンファレンス 2008年01月 神戸 第25回 神戸肝疾患カンファレンス
  • C型慢性肝炎例の瀉血施工時における分岐鎖アミノ酸を含む栄養付加効果の検討.  [通常講演]
    川口雅功; 石川 恵美; 南 康範; 工藤 正俊; 土細工利夫; 高松正剛; 中村浩彦; 高瀬光徳
    第37回日本肝臓学会西部会 2007年12月 長崎. 第37回日本肝臓学会西部会
  • 粉末化シスプラチン（アイエーコール）＋リピオドール懸濁液による肝細胞癌の治療  [通常講演]
    林 道友; 鍋島 紀滋; 茂山 朋広; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 宮部 欽生; 工藤 正俊
    第37回日本肝臓学会西部会 2007年12月 長崎 第37回日本肝臓学会西部会
  • 下痢を契機に発症した完全型ベーチェット病の１例  [通常講演]
    安田 宗生; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 野崎 祐史; 工藤 正俊
    第184回日本内科学会近畿地方会 2007年12月 京都市 第184回日本内科学会近畿地方会
  • 筋線維芽細胞の α-smooth muscle actin発現に対するデコリンの効果  [通常講演]
    仲谷 達也; 本田 映子; 佐藤 真弓; 早川 清雄; 工藤 正俊; 宗像 浩; JR仙台病院
    2007年12月
  • 教育セミナー「肝臓癌」  [通常講演]
    工藤 正俊
    特定非営利活動法人日本臨床腫瘍学会 教育セミナー 2007年12月 東京 特定非営利活動法人日本臨床腫瘍学会 教育セミナー
  • 特別講演「肝細胞癌診療におけるSonazoid造影エコーの役割」  [通常講演]
    工藤 正俊
    第49回かもがわ肝臓カンファレンス 2007年12月 京都 第49回かもがわ肝臓カンファレンス
  • 特別講演「明日からできる造影超音波～～入門から応用まで～～」  [通常講演]
    工藤 正俊
    島根腹部超音波研究会 2007年12月 島根 島根腹部超音波研究会
  • 教育講演「肝細胞癌の診断と治療Up To Date」  [通常講演]
    工藤 正俊
    第37回日本内科学四国支部生涯教育講演会 2007年12月 香川 第37回日本内科学四国支部生涯教育講演会
  • 教育講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    第184回日本内科学近畿支部生涯教育講演会 2007年12月 京都 第184回日本内科学近畿支部生涯教育講演会
  • ペグインターフェロンがS-1の抗腫瘍効果を増強したと考えられたHCC肺転移の1例.  [通常講演]
    上嶋 一臣; 今井 元; 辰巳 千栄; 上田 泰輔; 川崎 正憲; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊
    第45回 大阪肝穿刺生検治療研究会 2007年12月 大阪 第45回 大阪肝穿刺生検治療研究会
  • Development of Dynamic Pitch Helical Reconstruction Algorithm for Continuous Helical Shuttle Scan of 64ch MDCT with Advanced Table Control.  [通常講演]
    萩原明; 工藤 正俊; 村上 卓道; 柳生行伸
    93rd Radiological Society of North America 2007年12月 Chicago 93rd Radiological Society of North America
  • 進行膵癌に対してS-1単剤療法が奏効した2例  [通常講演]
    茂山 朋広; 加藤 玲明; 宮部 欽生; 林 道友; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊
    第6回大阪消化器化学療法懇話会 2007年11月 大阪 第6回大阪消化器化学療法懇話会
  • Invited Lecture "Novel ultrasonographic technique for the diagnosis and treatment of hepatocellular carcinoma. "  [通常講演]
    工藤 正俊
    Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan 2007年11月 Bangkok, Thailand. Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan
  • Invited Lecture "Contrast-enhanced ultrasound for liver tumors. "  [通常講演]
    工藤 正俊
    Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan 2007年11月 Bangkok, Thailand. Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan
  • Invited Lecture “Value of real-time virtual sonography in the ablation theraphy for liver malignancies.  [通常講演]
    工藤 正俊
    Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan 2007年11月 Bangkok, Thailand. Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan
  • Contrast enhanced sonography for hepatic malignancies: Value of defect re-injection test.  [通常講演]
    畑中 絹世; 南 康範; 工藤 正俊
    Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thaila 2007年11月 Bangkok, Thailand. Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thaila
  • A proposal of novel treatment-assist technique in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging.  [通常講演]
    工藤 正俊; 畑中 絹世; 南 康範; 鄭 浩柄; 前川 清
    American Association for the Study of liver Diseases (AASLD) 2007年11月 Boston, USA. American Association for the Study of liver Diseases (AASLD)
  • Separate analysis of intranodular blood supply in nodular lesions associated with liver cirrhosis: a novel ultrasound technique “Pure arterial phase imaging”.  [通常講演]
    工藤 正俊; 畑中 絹世; 南 康範; 鄭 浩柄; 前川 清
    American Association for the Study of liver Diseases (AASLD) 2007年11月 Boston, USA. American Association for the Study of liver Diseases (AASLD)
  • 特別講演「肝疾患とインターフェロン治療」  [通常講演]
    工藤 正俊
    お茶の水肝疾患談話会 2007年10月 東京 お茶の水肝疾患談話会
  • Radiofrequency ablation of hepatocellular carcinoma: usefulness of real-time virtual CT sonography.  [通常講演]
    南 康範; 鄭 浩柄; 工藤 正俊; 北井 聡; 高橋 俊介; 井上 達夫; 上嶋 一臣; 福永 豊和; 塩﨑 均
    15th United European Gastroenterology Week (UEGW) 2007年10月 Paris, France 15th United European Gastroenterology Week (UEGW)
  • Expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma. Workshop: Hepatobiliary and pancreatic tuomr(1).  [通常講演]
    辻 直子; 工藤 正俊; 石黒 信吾; 佐々木 洋
    66th Annual Meeting of the Japanese Cancer Association 2007年10月 Kobe 66th Annual Meeting of the Japanese Cancer Association
  • 特別講演「肝腫瘍の造影超音波診断の進歩」  [通常講演]
    工藤 正俊
    京都消化器医会例会 10月度 2007年10月 京都 京都消化器医会例会 10月度
  • 早期胃癌の時代的変遷とH. pyloriの関連  [通常講演]
    辻 直子; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 工藤 正俊; 石黒信吾; 本庶 元
    JDDW2007・第７４回日本消化器内視鏡学会総会 2007年10月 神戸市 JDDW2007・第７４回日本消化器内視鏡学会総会
  • 外来下部消化管内視鏡検査(CS)時のsedationの検討  [通常講演]
    梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    JDDW2007 神戸/第７４回日本消化器内視鏡学会総会 2007年10月 神戸市 JDDW2007 神戸/第７４回日本消化器内視鏡学会総会
  • PEG術後合併症からみたその誘因についての検討  [通常講演]
    冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    JDDW2007/第７４回日本消化器内視鏡学会総会 2007年10月 神戸市 JDDW2007/第７４回日本消化器内視鏡学会総会
  • Special Lecture “Recent advances in management of HCC: Newly developed breakthrough imaging technique and long-term IFN maintenance therapy after RFA.”  [通常講演]
    工藤 正俊
    Asian pacific Digestive Week 2007 2007年10月 Kobe Asian pacific Digestive Week 2007
  • 進行性肝細胞癌に対するS-1、ペグインターフェロン併用療法.  [通常講演]
    南 康範; 上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 工藤 正俊
    第11回日本肝臓学会大会, 2007年10月 神戸 第11回日本肝臓学会大会,
  • 難治性C型慢性肝炎（Ⅰ型高ウイルス量）に対するPEG-IFNα-2b/Ribavirin併用療法の使用成績と安全について.  [通常講演]
    石川 恵美; 上嶋 一臣; 汐見 幹夫; 北野 雅之; 松井 繁長; 福永 豊和; 仲谷 達也; 鄭 浩柄; 南 康範; 末冨 洋一郎; 福田 信宏; 坂本 洋城; 井上 達夫; 梅原 泰; 永島 美樹; 宮部 欽生; 野田 佳寿; 工藤 正俊
    第11回日本肝臓学会大会, 2007年10月 神戸 第11回日本肝臓学会大会,
  • クローン病に対するインフリキシマブ投与の有効性の検討.  [通常講演]
    梅原 泰; 工藤 正俊; 仲谷 達也; 福田 信宏; 永島 美樹; 石川 恵美; 坂本 洋城; 井上 達夫; 坂口 康浩; 萩原 智; 南 康範; 末冨 洋一郎; 小牧 孝充; 鄭 浩柄; 上嶋 一臣; 松井 繁長; 福永 豊和; 北野 雅之; 汐見 幹夫
    第49回日本消化器病学会大会 2007年10月 神戸 第49回日本消化器病学会大会
  • 健常人に発症し、大量消化管出血を来たしたサイトメガロウイルス腸炎の一例.  [通常講演]
    今井 元; 永島 美樹; 渡邊 愛可; 仲谷 達也; 工藤 正俊; 坂本 洋城
    第49回日本消化器病学会大会 2007年10月 神戸 第49回日本消化器病学会大会
  • 当院における無症状酔眼の診断と予後.ワークショップ「検診発見膵・胆道がんの予後 ?早期発見に向けて」  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第49回日本消化器病学会大会 2007年10月 神戸 第49回日本消化器病学会大会
  • DPCにおける効率的診断法 肝悪性腫瘍を中心に. シンポジウム「DPC時代の画像診断はどうあるべきか」  [通常講演]
    井上達夫; 工藤 正俊
    第49回日本消化器病学会大会 2007年10月 神戸 第49回日本消化器病学会大会
  • 転移性肝腫瘍・肝内胆管癌の画像診断～超音波診断を中心に～. ワークショップ「乏血性肝腫瘍の診療アルゴリズム」  [通常講演]
    上嶋 一臣; 前川 清; 工藤 正俊
    第49回日本消化器病学会大会 2007年10月 神戸 第49回日本消化器病学会大会
  • Child-Pugh Aの早期肝細胞癌患者に対するラジオ波焼灼療法治療成績. シンポジウム「肝癌診療ガイドライン改訂に向けて: 切除, ラジオ波, 移植の位置づけ」  [通常講演]
    鄭 浩柄; 井上 達夫; 工藤 正俊
    第49回日本消化器病学会大会 2007年10月 神戸 第49回日本消化器病学会大会
  • 当院におけるEUS下ドレナージ術の成績. ビデオシンポジウム「Interventional EUS」  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第47回日本消化器内視鏡学会総会 2007年10月 神戸 第47回日本消化器内視鏡学会総会
  • 噴門部静脈瘤合併巨木型食道静脈瘤の内視鏡的治療. ワークショップ「食道噴門部静脈瘤に対する治療戦略」  [通常講演]
    松井 繁長; 岡田 無文; 工藤 正俊
    第47回日本消化器内視鏡学会総会 2007年10月 神戸 第47回日本消化器内視鏡学会総会
  • CD34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma  [通常講演]
    辻 直子; 工藤 正俊; 石黒 信吾; 佐々木 洋
    第66回 日本癌学会学術総会 ワークショップ 2007年10月 横浜 第66回 日本癌学会学術総会 ワークショップ
  • 十二指腸血腫による急性膵炎の経過をUSで観察し得た1例.  [通常講演]
    横川 美加; 前野 智子; 市島 真由美; 前川 清; 内藤 昭智; 上硲 俊法; 野上 隆司; 八木 誠; 鄭 浩柄; 工藤 正俊
    日本調音波医学会第34回関西地方学術集会 2007年10月 大阪 日本調音波医学会第34回関西地方学術集会
  • LOGIQ7を用いたソナゾイド造影超音波検査における新しい支援画像表示の試み.  [通常講演]
    前川 清; 上硲俊法; 上嶋 一臣; 工藤 正俊; 橋本 浩
    日本調音波医学会第34回関西地方学術集会 2007年10月 大阪 日本調音波医学会第34回関西地方学術集会
  • 肝腫瘍治療, パネルディスカッション「造影超音波検査、最新の動向-次世代超音波造影剤の果たせる役割」  [通常講演]
    南 康範; 工藤 正俊
    日本調音波医学会第34回関西地方学術集会 2007年10月 大阪 日本調音波医学会第34回関西地方学術集会
  • 腸間膜静脈血栓症で発症した多発性骨髄腫の一例  [通常講演]
    豊澤 昌子; 茂山 朋広; 宮部 欽生; 林 道友; 小川 力; 加藤 玲明; 岸谷 讓; 鍋島 紀滋; 工藤 正俊
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • Educational Lecture “Critical appraisal of the paper and clinical trial design.”  [通常講演]
    工藤 正俊
    Train the Trainers workshop, World Gastroenterology Otganization(WGO) 2007年09月 Chicago. Train the Trainers workshop, World Gastroenterology Otganization(WGO)
  • Train the Trainers workshop "Critical appraisal of the paper and clinical trial design. "  [通常講演]
    工藤 正俊
    World Gastroenterology Otganization(WGO) 2007年09月 Chicago World Gastroenterology Otganization(WGO)
  • B型肝炎ウィルス感染における発癌リスク因子の検討.  [通常講演]
    萩原 智; 工藤 正俊
    第2回大阪肝臓ミーティング-スミフェロン発売20周年記念- 2007年09月 大阪 第2回大阪肝臓ミーティング-スミフェロン発売20周年記念-
  • 異種様に対するESD後の後出血例の検討.  [通常講演]
    岡田 無文; 松井 繁長; 永田 嘉昭; 宮部 欽生; 市川 勉; 畑中 絹世; 工藤 正俊
    第47回日本消化器内視鏡学会総会 2007年09月 神戸 第47回日本消化器内視鏡学会総会
  • アレルギー性紫斑病治療中にサイトメガロウイルス関連消化管病変を認めた１例  [通常講演]
    梅原 康湖; 西尾 健; 冨田 崇文; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 永禮 靖章; 野崎 祐史; 田中 久夫; 浦瀬 文明; 工藤 正俊; 本庶 元
    第７９回日本消化器内視鏡学会近畿地方会 2007年09月 大阪市 第７９回日本消化器内視鏡学会近畿地方会
  • ３型の本固有株による重症Ｅ型肝炎の１例  [通常講演]
    脇本 麻由子; 由谷 逸朗; 安田 宗生; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊; 岡本 宏明
    第87回日本消化器病学会近畿地方会 2007年09月 第87回日本消化器病学会近畿地方会
  • 特別講演「肝細胞癌の診断と治療: Up to date」  [通常講演]
    工藤 正俊
    第1回HCC Forum in TOYAMA 2007年09月 富山 第1回HCC Forum in TOYAMA
  • 腸重積を発症したCrinkhite-Canada症候群も1例.  [通常講演]
    早石 宗右; 石川 恵美; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 上田 和毅
    第79回日本消化器内視鏡学会近畿地方会 2007年09月 大阪 第79回日本消化器内視鏡学会近畿地方会
  • アレルギー性紫斑病治療中にサイトメガロウィルス関連消化管病変を認めた1例.  [通常講演]
    梅原 康湖; 西尾 健; 冨田 崇文; 森村 正嗣; 米田 円; 由谷 逸郎; 辻 直子; 永禮 靖章; 野崎 祐史; 田中 久夫; 浦瀬 文明; 工藤 正俊; 本庶 元
    第79回日本消化器内視鏡学会近畿地方会 2007年09月 大阪 第79回日本消化器内視鏡学会近畿地方会
  • Non-invasive methods for the assessment of liver fibrosis: comparision of transient elastography(Fibroscan), real-time tissue elastography and serum fibrotic markers.  [通常講演]
    辰巳 千栄; 上嶋 一臣; 鄭 浩柄; 南 康範; 工藤 正俊
    The 4th Korea-Japan Liver Synposium 2007年09月 Seoul, Korea The 4th Korea-Japan Liver Synposium
  • Maintenance interpheron therapy after curative RFA improves survival in patients with HCC.  [通常講演]
    工藤 正俊
    17th World Congress of tg\he international association of surgeons, gastroenterologists and oncologi 2007年09月 Bucharest, Rumania. 17th World Congress of tg\he international association of surgeons, gastroenterologists and oncologi
  • 特別講演「LOGIQ7におけるSonazoid造影エコー法 ?特に肝癌治療支援におけるDefect Re-perfusion Imagingの有用性について-」  [通常講演]
    工藤 正俊
    第10回GE Ultrasound Instractional Seminar 2007年09月 大阪 第10回GE Ultrasound Instractional Seminar
  • 重症Ｅ型肝炎の１例  [通常講演]
    脇本 麻由子; 由谷 逸朗; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊; 岡本宏明
    第１８３回日本内科学会近畿地方会 2007年09月 神戸市 第１８３回日本内科学会近畿地方会
  • 膵癌と急性膵炎の鑑別が困難であった1症例.  [通常講演]
    今井 元; 北野 雅之; 坂本 洋城; 前川 清; 筑後 孝章; 工藤 正俊
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • 術前診断が困難であった肝？胞腺癌の一例.  [通常講演]
    生田 研祐; 北井 聡; 南 康範; 工藤 正俊; 石川 原; 中居 卓也
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • 腸間膜静脈血栓症で発症した多発性骨髄腫の一例.  [通常講演]
    豊澤 昌子; 工藤 正俊; 茂山 朋広; 林 道友; 宮部 欽生; 小川 力; 加藤 玲明; 岸谷 譲; 鍋島 紀滋
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • Real-taime Virtual Sonographyを用いたラジオ波焼灼術の治療効果判定.  [通常講演]
    北井 聡; 南 康範; 工藤 正俊
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • 3型日本固有(株)による重症E型肝炎の一例.  [通常講演]
    脇本 麻由子; 工藤 正俊; 由谷 逸郎; 安田 宗生; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 辻 直子; 岡本 宏明
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • 当院でのステロイド未使用の潰瘍性大腸炎に対する白血球除去療法の治療成績.  [通常講演]
    梅原 泰; 工藤 正俊; 福田 信宏
    第87回日本消化器病学会近畿支部例会 2007年09月 大阪 第87回日本消化器病学会近畿支部例会
  • 特別講演「Sonazoidは肝癌診療をどう変えるか？」  [通常講演]
    工藤 正俊
    第50回滋賀肝疾患研究会 2007年09月 クサツエストピアホテル, 滋賀 第50回滋賀肝疾患研究会
  • CEUS of HCC: Up-to-date technology in diagnostic and therapeutic approach.  [通常講演]
    工藤 正俊
    9th International Conference in Interventional Ultrasound and Cntraast-enhanced Ultrasound 2007年08月 China. 9th International Conference in Interventional Ultrasound and Cntraast-enhanced Ultrasound
  • Invited Lecture “Contrast-enhanced US of HCC: Up-to-date technology in the diagnostic and therapeutic approach.”  [通常講演]
    工藤 正俊
    9th International Conference on Interventional Ultrasound and Contrast-enhanced Ultrasound 2007年08月 Beijing. 9th International Conference on Interventional Ultrasound and Contrast-enhanced Ultrasound
  • 特別講演「肝細胞癌の診断と治療: UP-TO-DATE」  [通常講演]
    工藤 正俊
    学術講演会 2007年08月 千葉 学術講演会
  • “Imaging diagnosis of early HCC.”  [通常講演]
    工藤 正俊
    Laennec Liver Pathlogy Society and ICGHN V 2007年07月 Chester Basin Laennec Liver Pathlogy Society and ICGHN V
  • ソナゾイドを用いた造影超音波によるRFAの治療効果判定の検討.  [通常講演]
    北井 聡; 畑中 絹世; 上田 泰輔; 辰巳 千栄; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 前川 清
    第7回関西肝血流動態イメージ研究会 2007年07月 大阪 第7回関西肝血流動態イメージ研究会
  • ソナゾイド造影超音波検査による肝腫瘍の鑑別診断の試み.  [通常講演]
    上嶋 一臣; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 畑中 絹世; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊; 前川 清
    第7回関西肝血流動態イメージ研究会 2007年07月 大阪 第7回関西肝血流動態イメージ研究会
  • ソナゾイド造影超音波検査における新しい支援画像表示の試み 特にPAP時相及びDefect re-injection testの支援画像について.  [通常講演]
    前川 清; 上硲 俊法; 上嶋 一臣; 工藤 正俊; 橋本 浩
    第7回関西肝血流動態イメージ研究会 2007年07月 大阪 第7回関西肝血流動態イメージ研究会
  • B型慢性肝炎ウィルス感染における発癌リスク因子の検討.  [通常講演]
    萩原 智; 高橋 俊介; 北井 聡; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 仲谷 達也; 工藤 正俊
    第18回南大阪肝疾患研究会 2007年07月 大阪 第18回南大阪肝疾患研究会
  • 超音波内視鏡ガイド下で胃膵吻合術を行った一例.  [通常講演]
    坂本 洋城; 北野 雅之; 小牧 孝充; 竹山 宜典; 工藤 正俊
    第38回日本膵臓学会大会 2007年06月 福岡 第38回日本膵臓学会大会
  • 「ソナゾイドは肝癌診療をどう変えるか」  [通常講演]
    工藤 正俊
    第43回日本肝癌研究会ランチョンセミナー6 2007年06月 東京 第43回日本肝癌研究会ランチョンセミナー6
  • 胃動脈瘤出血に対するα-シアノアクリレートによる硬化療法  [通常講演]
    松井 繁長; 市川 勉; 岡田 無文; 川崎 正憲; 工藤 正俊
    第16回近畿食道・胃動脈瘤研究会 2007年06月 大阪 第16回近畿食道・胃動脈瘤研究会
  • 特別講演「肝細胞癌の診断と治療UP TO DATE ?国際比較も含めて- 」  [通常講演]
    工藤 正俊
    第6回KMU肝疾患フォーラム 2007年06月 石川 第6回KMU肝疾患フォーラム
  • 特別講演「肝細胞癌治療の最近の進歩」  [通常講演]
    工藤 正俊
    『肝がん撲滅運動』学術講演会 2007年06月 大阪 『肝がん撲滅運動』学術講演会
  • 診断に苦慮し急速な経過をたどった肉腫様肝癌の一例.  [通常講演]
    井上 達夫; 辰巳 千栄; 北井 聡; 高橋 俊介; 畑中 絹世; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • TAE併用RFA後に炎症性肉芽腫形成を来たし、播種性腫瘍再発との鑑別が困難であった一例.  [通常講演]
    高橋 俊介; 鄭 浩柄; 辰巳 千栄; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊; 土師 誠二
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • 進行肝細胞癌に対するS-1, ペグインターフェロン併用療法の有用性.  [通常講演]
    上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 福永 豊和; 工藤 正俊
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • 肝細胞癌根治治療施行例における治療前腫瘍マーカーの予後におよぼす影響. シンポジウム「術前検査による肝細胞癌の悪性度予測と治療選択」  [通常講演]
    豊田秀徳; 工藤 正俊; 熊田 卓; 大崎往夫; 岡 博子; 浦野文博; 松永 隆
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • 治療前後のAFP-L3分画値から検討した肝細胞癌治療後の予後予測（前向き多施設共同研究）. シンポジウム「術前検査による肝細胞癌の悪性度予測と治療選択」  [通常講演]
    田中正俊; 工藤 正俊; 斉藤明子; 伊東和樹; 熊田 卓; 岡 博子; 関 寿人; 春日井博志; 大崎往夫
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • 肝細胞癌に対する肝動脈塞栓療法と肝動注化学療法の多施設共同ランダム化比較試験. パネルディスカッション「肝細胞癌診療ガイドライン改訂に向けて; TACE, TAI, 肝動注化学療法の適切な選択」  [通常講演]
    春日井博志; 工藤 正俊; 佐藤俊哉; 樋之津史郎; 塩山靖和; 田中克明; 税所宏光; 大崎往夫; 佐田通夫; 奥坂拓志
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • Child-Pugh Aの早期肝細胞癌患者に対するラジオ波焼灼療法治療成績. パネルディスカッション「ガイドライン改訂に向けて; 肝移植, ラジオ波導入時代における肝切除の意義」  [通常講演]
    鄭 浩柄; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊; 土師 誠二
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • 全国データに基づく肝切除と経皮療法の長期比較. パネルディスカッション「ガイドライン改訂に向けて; 肝移植, ラジオ波導入時代における肝切除の意義」  [通常講演]
    長谷川 潔; 工藤 正俊; 幕内雅敏; 高山忠利; 國土典宏; 有井滋樹; 小俣政男; 神代正道; 坂元亨宇; 高安賢一; 林 紀夫; 門田守人; 松山 裕; 猪飼伊和夫
    第43回日本肝癌研究会 2007年06月 東京ドームホテル, 東京 第43回日本肝癌研究会
  • 特別講演「肝細胞癌の治療効果判定と穿刺ガイド-Sonazoidの有用性-」  [通常講演]
    工藤 正俊
    第1回ソナゾイド研究会第2部「診断と治療支援」 2007年06月 東京 第1回ソナゾイド研究会第2部「診断と治療支援」
  • Transarterial infusion chemotherapy alone versus transarterial chemoembolization for the treatment of hepatocellular carcinoma: Results of a multicenter randomized phase Ⅲ traial.  [通常講演]
    奥坂 拓志; 工藤 正俊; 佐藤 俊哉; 樋之津 史郎; 塩山 靖和; 春日井 博志; 田中 克明; 税所 宏光; 大崎 往夫; 佐田 通夫; 藤山 重俊
    American Society of Clinical Oncology 2007年06月 Chicago, USA American Society of Clinical Oncology
  • 特別講演「肝硬変・肝癌の治療におけるインターフェロンの役割」  [通常講演]
    工藤 正俊
    第43回日本肝臓学会総会モーニングセミナー・ランチョンセミナー 2007年06月 ホテルグランパシフィックメリディアン, 東京 第43回日本肝臓学会総会モーニングセミナー・ランチョンセミナー
  • パネルディスカッション「患者さんの疑問にこたえるQ&A」  [通常講演]
    工藤 正俊
    市民公開講座「ウィルス性肝炎疾患 その最新治療を学ぶ」 2007年05月 京都 市民公開講座「ウィルス性肝炎疾患 その最新治療を学ぶ」
  • 特別講演「ソナゾイドによる肝細胞癌診療」  [通常講演]
    工藤 正俊
    日本インターベンショナルラジオロジー学会総会ランチョンセミナー 2007年05月 石川 日本インターベンショナルラジオロジー学会総会ランチョンセミナー
  • 特別講演「肝臓ガンの病態と最新治療」  [通常講演]
    工藤 正俊
    市民公開講座「ウィルス性肝疾患 その最新治療を学ぶ」 2007年05月 京都 市民公開講座「ウィルス性肝疾患 その最新治療を学ぶ」
  • 腸重積を呈した横行結腸脂肪腫の１例  [通常講演]
    旭爪 章統; 梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    第182回日本内科学会近畿地方会 2007年05月 大阪市 第182回日本内科学会近畿地方会
  • 急性膵炎の経過中、腸腰筋膿瘍を合併した１例  [通常講演]
    田中 意浩; 梅原 康湖; 西尾 健; 冨田 崇文; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    第182回日本内科学会近畿地方会 2007年05月 大阪市 第182回日本内科学会近畿地方会
  • 内視鏡的ドレナージ術により軽快した感染性膵嚢胞の１例  [通常講演]
    赤岩 譲; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    第182回日本内科学会近畿地方会 2007年05月 大阪市 第182回日本内科学会近畿地方会
  • 腹膜刺激症状を認めなかった胆嚢穿孔の１例  [通常講演]
    藤田 淳也; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元
    第182回日本内科学会近畿地方会 2007年05月 大阪市 第182回日本内科学会近畿地方会
  • Clinical application of contrast-enhanced harmonic imaging to endosonography.  [通常講演]
    北野 雅之; 坂本 洋城; 前川 清; 工藤 正俊; 松井 宇部; 伊藤 安啓; Tammo von Schrenk
    DDW(Digestive Disease Week) and ASGE 2007年05月 Washington, DC DDW(Digestive Disease Week) and ASGE
  • 特別講演「新しい超音波造影剤は肝癌の診療をどう変えるか？」ランチョンセミナー  [通常講演]
    工藤 正俊
    日本超音波医学会第80会学術集会 2007年05月 鹿児島 日本超音波医学会第80会学術集会
  • 造影ハーモニック超音波内視鏡装置の新規開発と臨床応用.  [通常講演]
    北野 雅之; 坂本 洋城; 前川 清; 工藤 正俊; 松井 宇部; 伊藤 安啓; von Schrenck Tammo
    日本超音波医学会第80回学術集会 2007年05月 鹿児島 日本超音波医学会第80回学術集会
  • Regulatory failure pf serem prohepcidin levels in patients with hepatitis C.  [通常講演]
    永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 萩原 智; 仲谷 達也
    DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA 2007年05月 Washington, DC. DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA
  • Multicentric recurrence of hepatocellular carcinoma and CD-34 expression in background liver.  [通常講演]
    辻 直子; 石黒 信吾; 工藤 正俊
    DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA 2007年05月 Washington, DC. DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA
  • Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonography.  [通常講演]
    井上 達夫; 北野 雅之; 工藤 正俊; 坂本 洋城
    DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA 2007年05月 Washington, DC DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA
  • 新しい超音波造影剤ソナゾイドによる肝腫瘍の造影評価.  [通常講演]
    前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    日本超音波医学会第80回学術集会 2007年05月 鹿児島 日本超音波医学会第80回学術集会
  • 肝疾患におけるTissue Elastography -第2報  [通常講演]
    藤本 研治; 辰巳 千栄; 上嶋 一臣; 前川 清; 工藤 正俊; 外村 明子; 三竹 毅; 山川 誠; 加藤 道夫; 椎名 毅
    日本超音波医学会第80回学術集会 2007年05月 鹿児島 日本超音波医学会第80回学術集会
  • 造影超音波の新しい展開 パネルディスカッション消化器「肝癌診断最近の動向 診断」  [通常講演]
    南 康範; 工藤 正俊
    日本超音波医学会第80回学術集会 2007年05月 鹿児島 日本超音波医学会第80回学術集会
  • 肝膵疾患に対するinterventional EUS シンポジウム消化器「腹部領域におけるInterventional Sonography」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    日本超音波医学会第80回学術集会 2007年05月 鹿児島 日本超音波医学会第80回学術集会
  • Child-Pugh Aの早期肝細胞癌患者に対するラジオ波焼灼療法治療成績. パネルディスカッション「肝癌診療ガイドラインの検証」.  [通常講演]
    鄭 浩柄; 福永 豊和; 工藤 正俊
    第43回日本肝臓学会総会 2007年05月 ホテルグランパシフィックメリディアン, 東京 第43回日本肝臓学会総会
  • 高度進行肝細胞癌に対するS-1, ペグインターフェロン併用療法の有用性.  [通常講演]
    上嶋 一臣; 南 康範; 工藤 正俊
    第43回日本肝臓学会総会 2007年05月 ホテルグランパシフィックメリディアン, 東京 第43回日本肝臓学会総会
  • EUS-FNAが診断に有効であった腹腔内リンパ節結核の一例.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 今井 元; 汐見 幹夫; 工藤 正俊
    第2回超音波内視鏡下生検法の診断精度向上のための研究会 2007年05月 国際館パミール, 東京 第2回超音波内視鏡下生検法の診断精度向上のための研究会
  • 当院における超音波内視鏡ガイド下治療の現状. ワークショップ「EUS-FNAの現状と将来」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第73回日本消化器内視鏡学会総会 2007年05月 グランドプリンスホテル新高輪, 東京 第73回日本消化器内視鏡学会総会
  • 次世代超音波造影剤SonoVueを用いた造影ハーモニック超音波内視鏡検査. シンポジウム「超音波内視鏡（EUシンポジウム）による診断・治療の最前線」  [通常講演]
    北野 雅之; 坂本 洋城; 工藤 正俊
    第73回日本消化器内視鏡学会総会 2007年05月 グランドプリンスホテル新高輪, 東京 第73回日本消化器内視鏡学会総会
  • 特別講演「肝細胞癌の診断と治療：Up-to-date」  [通常講演]
    工藤 正俊
    第146回愛媛消化器疾患懇話会 2007年04月 愛媛 第146回愛媛消化器疾患懇話会
  • 粉末化シスプラチン（アイエーコール）+リピオドール懸濁液による肝細胞癌の治療経験  [通常講演]
    林 道友; 鍋島 紀滋; 小川 力; 水野 成人; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 工藤 正俊
    第93回日本消化器病学会総会 2007年04月 青森市文化会館, 青森 第93回日本消化器病学会総会
  • B型肝炎ウィルス感染における発癌リスク因子の検討  [通常講演]
    萩原 智; 工藤 正俊; 仲谷 達也; 鄭 浩柄; 大阪赤十字病院; 日本赤十字社和歌山医療センター; 岸和田市民病院
    第93回日本消化器病学会総会 2007年04月 青森市文化会館, 青森 第93回日本消化器病学会総会
  • 進行膵癌化学療法効果測定における各腫瘍マーカーの有用性について  [通常講演]
    野田 佳寿; 坂本 洋城; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 工藤 正俊
    第93回日本消化器病学会総会 2007年04月 青森市文化会館, 青森 第93回日本消化器病学会総会
  • 膵癌におけるバイオマーカーとしてのKL-6の有用性.  [通常講演]
    小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 汐見 幹夫; 工藤 正俊
    第93回日本消化器病学会総会 2007年04月 青森市文化会館, 青森 第93回日本消化器病学会総会
  • ステージ4B肝内胆管癌に対するGemcitabine (GEM)をfirst lineとした化学療法と無治療群との比較検討.  [通常講演]
    南 康範; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和; 工藤 正俊
    第93回日本消化器病学会総会 2007年04月 青森市文化会館, 青森 第93回日本消化器病学会総会
  • 進行肝細胞癌に対するCDDP+5FU動注化学療法における5FU投与濃度の意義. シンポジウム「進行肝癌に対する集学的治療」  [通常講演]
    上嶋 一臣; 辰巳 千栄; 工藤 正俊
    第93回日本消化器病学会総会 2007年04月 青森市文化会館, 青森 第93回日本消化器病学会総会
  • 教育講演「肝癌」  [通常講演]
    工藤 正俊
    第93回日本消化器病学会総会ポストグラデュエイトコース 2007年04月 ウェルシティ青森, 青森 第93回日本消化器病学会総会ポストグラデュエイトコース
  • シンポジウム「超音波造影剤ソナゾイド?を使用した造影超音波検査ー最新ソフトおよび臨床画像を含めてー.」  [通常講演]
    工藤 正俊
    第20回日本腹部造影エコー・ドプラ診断研究会 2007年04月 今池ガスビル, 名古屋 第20回日本腹部造影エコー・ドプラ診断研究会
  • 新しい超音波造影剤ソナゾイドによる肝腫瘍の造影評価.  [通常講演]
    前川 清; 井上 達夫; 鄭 浩柄; 南 康範; 上嶋 一臣; 工藤 正俊
    第20回日本腹部造影エコー・ドプラ診断研究会 2007年04月 今池ガスビル, 名古屋 第20回日本腹部造影エコー・ドプラ診断研究会
  • Invited Lecture “Novel Sonographic Technique for the Diagnosis and Treatment of Hepatocellular Carcinoma.”  [通常講演]
    工藤 正俊
    International HCC Symposium 2007年03月 Seoul National University Cancer Institute, Seoul, Korea International HCC Symposium
  • ステージ4B肝内胆管癌に対するGemcitabine(GEM)をfirst lineとした化学療法と無治療群との比較検討.  [通常講演]
    南 康範; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和; 工藤 正俊
    第5回日本臨床腫瘍学会学術集会 2007年03月 札幌コンベンションセンター, 北海道 第5回日本臨床腫瘍学会学術集会
  • Round Table Discussion “Diagnosis and treatment of HCC.”  [通常講演]
    工藤 正俊
    Up-to-date prevention and therapy for hepatocellular carcinoma (HCC) 2007年03月 Kurume, Japan Up-to-date prevention and therapy for hepatocellular carcinoma (HCC)
  • PEGインターフェロン併用療法の経験.  [通常講演]
    上嶋 一臣; 南 康範; 工藤 正俊
    第5回日本臨床腫瘍学会学術集会 2007年03月 札幌コンベンションセンター, 北海道 第5回日本臨床腫瘍学会学術集会
  • Estimation of angiotensin-II and angiotensin-II receptor blocker (TCV-116) on rat pancreatic stellate cells: angiotensin-II type 1 receptor blocker (CV-11974) and angiotensin―converting enzyme inhibitor (perindopril) suppress pancreatitis and fibrosis in  [通常講演]
    福田 信宏; 工藤 正俊
    第2回Bay Area Gut Club 2007年03月 淡路夢舞台, 淡路 第2回Bay Area Gut Club
  • C型肝炎患者における血清プロヘプシジン濃度の調節異常.  [通常講演]
    永島 美樹; 工藤 正俊
    第2回Bay Area Gut Club 2007年03月 淡路夢舞台, 淡路 第2回Bay Area Gut Club
  • 当院における超音波内視鏡ガイド下腹腔神経叢ブロックの成績.  [通常講演]
    坂本 洋城; 工藤 正俊
    第2回Bay Area Gut Club 2007年03月 淡路夢舞台, 淡路 第2回Bay Area Gut Club
  • 早期胃癌治療における術前複数周波数超音波内視鏡検査の有用性.  [通常講演]
    市川 勉; 工藤 正俊
    第2回Bay Area Gut Club 2007年03月 淡路夢舞台, 淡路 第2回Bay Area Gut Club
  • Clinial staging system for hepatocellular carcinoma.  [通常講演]
    鄭 浩柄; 工藤 正俊
    17th APASL Conference 2007年03月 Kyoto 17th APASL Conference
  • Education Lecture “Imaging diagnosis of early-stage HCC.”  [通常講演]
    工藤 正俊
    17th APASL Conference 2007年03月 Kyoto 17th APASL Conference
  • Regulatory failure of serum prohepcidin levels in patients with hepatitis C.  [通常講演]
    永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 萩原 智; 仲谷 達也
    17th APASL Conference 2007年03月 Kyoto 17th APASL Conference
  • Real-time virtual CT sonographic-guided radiofrequency ablation for hepatocellular carcinoma.  [通常講演]
    南 康範; 鄭 浩柄; 井上 達夫; 上嶋 一臣; 福永 豊和; 工藤 正俊
    17th APASL Conference 2007年03月 Kyoto 17th APASL Conference
  • Pegylated interferon therapy increases serum ferritin and ALT levels in chronic hepatitis C patients.  [通常講演]
    永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 仲谷 達也
    17th APASL Conference 2007年03月 Kyoto 17th APASL Conference
  • Impact of pretreatment tumor marker elevations on survival of HCC patients after curative treatment.  [通常講演]
    工藤 正俊; 豊田 秀徳; 熊田 卓; 大崎 往夫; 岡 博子; 浦野 文博
    17th APASL Conference 2007年03月 Kyoto 17th APASL Conference
  • 特別講演「Diagnosis and treatment of early-stage HCC: An Update」  [通常講演]
    工藤 正俊
    久留米大学21世紀COEプログラムアジア肝癌フォーラムーUp-to-Date Prevention and Therapy for Hepatocellular Carcinoma (HCC)ー 2007年03月 久留米大学, 九州 久留米大学21世紀COEプログラムアジア肝癌フォーラムーUp-to-Date Prevention and Therapy for Hepatocellular Carcinoma (HCC)ー
  • Invited Lecture “Long-dose, Long-term IFN therapy improves survival in patients with HCV-related HCC after curative RFA.”  [通常講演]
    工藤 正俊
    Miami Clinical Exchange-Liver Disease in Japan and USA- 2007年03月 Miami, USA Miami Clinical Exchange-Liver Disease in Japan and USA-
  • 教育講演「肝臓癌」  [通常講演]
    工藤 正俊
    日本臨床腫瘍学会第8回教育セミナーBセッション 2007年03月 札幌コンベンションセンター, 北海道 日本臨床腫瘍学会第8回教育セミナーBセッション
  • Invited Lecture “Real-time virtual sonography for liver malignancies.”  [通常講演]
    工藤 正俊
    WFUMB Center of Excellence Workshop 2007年03月 Dhaka, Bangladesh WFUMB Center of Excellence Workshop
  • Invited Lecture “Contrast-enhance ultrasound for liver tumors.”  [通常講演]
    工藤 正俊
    WFUMB Center of Excellence Workshop 2007年03月 Dhaka, Bangladesh WFUMB Center of Excellence Workshop
  • Invited Lecture “Ultrasound diagnosis of pancreatic tumor.”  [通常講演]
    工藤 正俊
    WFUMB Center of Excellence Workshop 2007年03月 Dhaka, Bangladesh WFUMB Center of Excellence Workshop
  • 吻合部狭窄に対し内視鏡的バルーン拡張術を行い著名な体積増加が得られたクローン病の一例.  [通常講演]
    梅原 泰; 工藤 正俊; 中岡 良介; 福田 信宏; 永島 美樹; 石川 恵美; 仲谷 達也; 汐見 幹夫
    第78回日本消化器内視鏡学会近畿地方会 2007年03月 大阪国際交流センター, 大阪 第78回日本消化器内視鏡学会近畿地方会
  • 内視鏡的に止血し得た盲腸Dieurafoy潰瘍の一例.  [通常講演]
    梅原 泰; 工藤 正俊; 福田 信宏; 永島 美樹; 石川 恵美; 汐見 幹夫
    第78回日本消化器内視鏡学会近畿地方会 2007年03月 大阪国際交流センター, 大阪 第78回日本消化器内視鏡学会近畿地方会
  • 腸重責を呈した横行結腸脂肪腫の一例.  [通常講演]
    梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 中村 浩一; 井上 潔彦; 田中 晃; 本庶 元; 工藤 正俊
    第78回日本消化器内視鏡学会近畿地方会 2007年03月 大阪国際交流センター, 大阪 第78回日本消化器内視鏡学会近畿地方会
  • 内視鏡で経時的に変化が追えた難治性潰瘍性大腸炎の一例.  [通常講演]
    梅原 泰; 工藤 正俊; 福田 信宏; 永島 美樹; 石川 恵美; 仲谷 達也; 汐見 幹夫
    第78回日本消化器内視鏡学会近畿地方会 2007年03月 大阪国際交流センター, 大阪 第78回日本消化器内視鏡学会近畿地方会
  • 当院におけるEUSによる膵疾患の診断と治療の現状. パネルディスカッションII「胆膵領域の内視鏡診断・治療の最前線」  [通常講演]
    坂本 洋城; 北野 雅之; 工藤 正俊
    第78回日本消化器内視鏡学会近畿地方会 2007年03月 大阪国際交流センター, 大阪 第78回日本消化器内視鏡学会近畿地方会
  • 粉末化シスプラチン（アイエーコール）＋リピオドール懸濁液による肝細胞癌の治療経験  [通常講演]
    鍋島 紀滋; 小川 力; 林 道友; 水野 成人; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 工藤 正俊
    第48回京都肝疾患懇話会 2007年02月 京都 第48回京都肝疾患懇話会
  • EUS下胃膵吻合術を行った一症例.  [通常講演]
    坂本 洋城; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 野田 佳寿; 工藤 正俊
    1st FNA-Club Conference 2007年02月 新宿, 東京 1st FNA-Club Conference
  • 進行肝細胞癌に対するS-1、ペグインターフェロン併用療法の経験.  [通常講演]
    上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 福永 豊和; 工藤 正俊
    第86回日本消化器病学会近畿支部例会 2007年02月 京都テルサ, 京都 第86回日本消化器病学会近畿支部例会
  • 腹膜刺激症状を認めずERCPにて診断しえた胆嚢穿孔の一例.  [通常講演]
    西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 田中 晃; 川邊 高史; 北口 博士; 工藤 正俊
    第86回日本消化器病学会近畿支部例会 2007年02月 京都テルサ, 京都 第86回日本消化器病学会近畿支部例会
  • C型肝硬変に伴う肝内びまん性動門脈シャントに対して肝動脈塞栓術およびバルン閉塞下逆行性シャント閉塞術が奏功した一例.  [通常講演]
    前川 昌平; 鄭 浩柄; 辰巳 千栄; 北井 聡; 高橋 俊介; 萩原 智; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊; 堀 信一
    第86回日本消化器病学会近畿支部例会 2007年02月 京都テルサ, 京都 第86回日本消化器病学会近畿支部例会
  • 特別講演「肝癌の診断と治療: Up To Date」  [通常講演]
    工藤 正俊
    第3回神奈川肝炎若手の会 2007年02月 横浜ベイシェラトンホテル＆タワーズ, 横浜 第3回神奈川肝炎若手の会
  • ポリウレタン製PEGの長期留置の有用性について.  [通常講演]
    中岡 良介; 末冨 洋一郎; 汐見 幹夫; 工藤 正俊; 川端 一史; 中川 裕隆; 山本 博晟
    第15回クリニカル・ビデオフォーラム（CVF） 2007年02月 大手前サンケイプラザ, 東京 第15回クリニカル・ビデオフォーラム（CVF）
  • リザーバー肝動注化学療法が有効であった乳癌肝転移の一症例.  [通常講演]
    辰巳 千栄; 上嶋 一臣; 上田 泰輔; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 南 康範; 工藤 正俊
    第87回日本消化器病学会近畿支部例会 2007年 大阪 第87回日本消化器病学会近畿支部例会
  • 特別講演「肝細胞癌の治療効果判定と穿刺ガイド ?Sonazoidの有用性-」  [通常講演]
    工藤 正俊
    第56回山口県難治性肝疾患研究会 2007年 山口 第56回山口県難治性肝疾患研究会
  • 特別講演「新しい超音波造影剤は肝癌の診療をどう変えるか？」  [通常講演]
    工藤 正俊
    日本超音波医学会第80会学術集会 ランチョンセミナー 2007年 鹿児島 日本超音波医学会第80会学術集会 ランチョンセミナー
  • レボビスト造影超音波の後血管相における肝と脾臓の輝度評価「特に肝の過形所成結節について」.  [通常講演]
    前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊
    第13回肝血流動態イメージ研究会 2007年01月 パシフィコ横浜 第13回肝血流動態イメージ研究会
  • 特別講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    宇部・小野田地区学術講演会 2007年01月 宇部全日空ホテル, 山口 宇部・小野田地区学術講演会
  • 特別講演「ウイルス肝炎治療の最前線」  [通常講演]
    工藤 正俊
    肝炎肝がん対策研修会 2007年01月 大阪府富田林保健所, 大阪 肝炎肝がん対策研修会
  • Invited Lecture “ Pure arterial phase imaging of liver tumors: an innovative technology in the contrastenhanced ultrasonograhy.”  [通常講演]
    工藤 正俊
    8th International Symposium on Ultrasound Contrast Imaging 2006年12月 Tokyo Medical University Hospital, Tokyo 8th International Symposium on Ultrasound Contrast Imaging
  • Role of computed tomography in evaluating the injection site in endosonography guided celiac plexus neurolysis.  [通常講演]
    北野 雅之; 坂本 洋城; 西尾 健; 竹山 宜典; 保田 知生; 工藤 正俊
    21st International Workshop on Therapeutic Endoscopy 2006年12月 Hong Kong 21st International Workshop on Therapeutic Endoscopy
  • Invited Lecture “Pure arterial phase imaging on liver tumors.”  [通常講演]
    工藤 正俊
    The 4th AFSUMB Ultrasound Workshop 2006年12月 Bangkok, Thailand The 4th AFSUMB Ultrasound Workshop
  • Invited Lecture “Real-time virtual sonography for liver malignancies.”  [通常講演]
    工藤 正俊
    The 4th AFSUMB Ultrasound Workshop 2006年12月 Bangkok, Thailand The 4th AFSUMB Ultrasound Workshop
  • Assessment of 4D MDCT abdominal angiography by using non-stop continuous helical shuttle scan technique.  [通常講演]
    工藤 正俊; 村上 卓道
    92nd Radiological Society of North America. 2006年11月 Chicago. 92nd Radiological Society of North America.
  • Invited Lecture “Diagnosis of early HCC in Japan: value of contrast-enhanced ultrasound.”  [通常講演]
    工藤 正俊
    Symposium on Hepatocellular Carcinoma 2006年11月 University of Leuven, Belgique Symposium on Hepatocellular Carcinoma
  • シンポジウム「肝がん治療について」  [通常講演]
    工藤 正俊
    がん予防キャンペーン大阪2006シンポジウム「がんの最新治療～早く見つけて上手に治す～」 2006年11月 大阪 がん予防キャンペーン大阪2006シンポジウム「がんの最新治療～早く見つけて上手に治す～」
  • 特別講演「肝腫瘍の純動脈相イメージング」  [通常講演]
    工藤 正俊
    第24回TOYエコーフォーラム 2006年11月 京都 第24回TOYエコーフォーラム
  • Non-transplant treatment for hepatocellular carcionoma associated with child-Pugh grade C cirrhosis: a multicenter study on survival benefit.  [通常講演]
    工藤 正俊; 大崎 往夫; 大阪府立成人病センタ; 大阪府立成人病センタ; 大阪市立総合医療センター
    14th United European Gastroenterology Week (UEGW2006 2006年11月 Berlin 14th United European Gastroenterology Week (UEGW2006
  • 特別講演「肝臓がん」  [通常講演]
    工藤 正俊
    第44回日本消化器病学会関東支部市民公開講座「消化器の早期がんのお話」 2006年11月 横浜市教育会館, 横浜 第44回日本消化器病学会関東支部市民公開講座「消化器の早期がんのお話」
  • 特別講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    第42回鹿児島肝疾患懇話会 2006年11月 城山観光ホテル, 鹿児島 第42回鹿児島肝疾患懇話会
  • ランチョンセミナー「原発性肝癌の治療」  [通常講演]
    工藤 正俊
    日本消化器病学会関東支部第9回教育講演会 2006年11月 シェーンバッハ砂防, 東京 日本消化器病学会関東支部第9回教育講演会
  • Value of computed tomography for evaluating the injection site in endoconography-guided celiac plexus neurolysis.  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之; 西尾 健; 竹山 宜典; 保田 知生
    14th United European Gastroenterology Week (UEGW2006) 2006年10月 Berlin 14th United European Gastroenterology Week (UEGW2006)
  • The utility of endoscopic ultrasonography using multiple miniature endoscopic ultrasound probe in the endoscopic submucosal desection of early gastric cancer.  [通常講演]
    市川 勉; 工藤 正俊; 松井 繁長; 北野 雅之; 末冨 洋一郎; 岡田 無文
    14th United European Gastroenterology Week (UEGW2006) 2006年10月 Berlin 14th United European Gastroenterology Week (UEGW2006)
  • Novel perfusion imaging technique of the pancreas, contrast-enhanced harmonic endosonography: the first clinical report.  [通常講演]
    北野 雅之; 工藤 正俊; 坂本 洋城; 松井 繁長; 前川 清
    14th United European Gastroenterology Week (UEGW2006) 2006年10月 Berlin 14th United European Gastroenterology Week (UEGW2006)
  • The novel questionnairee to evaluate health-related quality of life specific for patients with hepatocellular carcinoma.  [通常講演]
    中山 伸朗; 工藤 正俊; 柿沼 徹; 松井 淳; 名越 澄子; 持田 智; 小俣 政男; 熊田 博光; 佐田 通夫; 國土 典宏; 門田 守人; 兼松 隆之; 田中 宏一; 森脇 久隆; 藤原 研司
    The Liver Meeting (AASLD) 2006年10月 Boston The Liver Meeting (AASLD)
  • Non-transplant treatment for hepatocellular carcionoma associated with child-Pugh grade C cirrhosis: a multicenter study on survival benefit.  [通常講演]
    工藤 正俊; 大崎 往夫; 松永 隆; 春日井 博志; 大阪総合医療センタ
    The Liver Meeting (AASLD) 2006年10月 Boston The Liver Meeting (AASLD)
  • 特別講演「消化器・肝臓病学の魅力」  [通常講演]
    工藤 正俊
    内科医をめざす若手医師のための教育セミナー 2006年10月 石川県地場産業振興センター 内科医をめざす若手医師のための教育セミナー
  • 純型・混合型からみた早期胃癌の臨床病理学的検討  [通常講演]
    辻 直子; 工藤 正俊; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 石黒 信吾; 藤井 恭子; 本庶 元
    DDW-Japan 2006 第14回日本消化器関連学会週間 2006年10月 札幌市 DDW-Japan 2006 第14回日本消化器関連学会週間
  • PEG後腸瘻に移行した症例とPEG症例との背景因子についての比較検討  [通常講演]
    冨田 崇文; 工藤 正俊; 落合 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元
    DDW-Japan 2006 第14回日本消化器関連学会週間 2006年10月 札幌市 DDW-Japan 2006 第14回日本消化器関連学会週間
  • 緊急上部消化管内視鏡止血術後の絶食期間の検討  [通常講演]
    梅原 康湖; 工藤 正俊; 辻 直子; 冨田 崇文; 落合 健; 森村 正嗣; 米田 円; 由谷 逸朗; 本庶 元
    DDW-Japan 2006 第14回 日本消化器関連学会週間 2006年10月 札幌市 DDW-Japan 2006 第14回 日本消化器関連学会週間
  • C型慢性肝炎に対するPEG-IFNα-2a製剤投与中の血清ALT値上昇の原因についての検討.  [通常講演]
    永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 仲谷 達也
    第10回日本肝臓学会大会（DDW-Japan） 2006年10月 札幌コンベンションセンター, 道立総合体育センター, 北海道 第10回日本肝臓学会大会（DDW-Japan）
  • 肝細胞癌への経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性.  [通常講演]
    南 康範; 工藤 正俊
    第48回日本消化器病学会大会（DDW-Japan） 2006年10月 札幌コンベンションセンター, 道立総合体育センター, 北海道 第48回日本消化器病学会大会（DDW-Japan）
  • パネルディスカッション「超音波内視鏡ガイド下腹腔神経叢ブロック術におけるCTの役割.  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之
    第72回日本消化器内視鏡学会総会（DDW-Japan） 2006年10月 札幌コンベンションセンター, 道立総合体育センター, 北海道 第72回日本消化器内視鏡学会総会（DDW-Japan）
  • ビデオワークショップ「食道静脈瘤に対する内視鏡的治療の工夫」.  [通常講演]
    松井 繁長; 工藤 正俊; 岡田 無文
    第72回日本消化器内視鏡学会総会（DDW-Japan） 2006年10月 札幌コンベンションセンター, 道立総合体育センター, 北海道 第72回日本消化器内視鏡学会総会（DDW-Japan）
  • 早期胃癌に対してESD術前に複数周波数を用いた超音波内視鏡検査の有用性.  [通常講演]
    市川 勉; 工藤 正俊; 松井 繁長; 岡田 無文; 北野 雅之
    第72回日本消化器内視鏡学会総会（DDW-Japan） 2006年10月 札幌コンベンションセンター, 道立総合体育センター, 北海道 第72回日本消化器内視鏡学会総会（DDW-Japan）
  • 確定診断までに時間を要した早期胃癌の1例  [通常講演]
    加藤 玲明; 石川一樹; 林 道友; 豊澤 昌子; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 井上 雅智; 太田 善夫; 工藤 正俊
    第77回日本消化器内視鏡学会近畿地方会 2006年09月 京都 第77回日本消化器内視鏡学会近畿地方会
  • Gastric submucosal heterotopiの１例  [通常講演]
    西尾 健; 工藤 正俊; 由谷 逸朗; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 本庶 元
    第77会日本消化器内視鏡学会近畿地方会 2006年09月 京都市 第77会日本消化器内視鏡学会近畿地方会
  • レボビスト造影超音波の後血管相における肝と脾臓の輝度評価.  [通常講演]
    前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    第12回関西超音波造影剤研究会 2006年09月 日本シェーリング株式会社本社, 大阪 第12回関西超音波造影剤研究会
  • 肝癌に対するTAE・RFA治療後に遅発性胆管気管支瘻が出現した一例.  [通常講演]
    末冨 洋一郎; 工藤 正俊; 北野 雅之; 坂本 洋城; 西尾 健; 南 康範; 汐見 幹夫
    第42回日本胆道学会学術集会 2006年09月 仙台 第42回日本胆道学会学術集会
  • 胆嚢病変診断における造影超音波検査の有用性.  [通常講演]
    井上 達夫; 工藤 正俊; 坂本 洋城; 北野 雅之; 前川 清
    第42回日本胆道学会学術集会 2006年09月 仙台 第42回日本胆道学会学術集会
  • ERPが診断に有用であった小児膵損傷の1例.  [通常講演]
    小牧 孝充; 工藤 正俊; 北野 雅之; 末冨 洋一郎; 志村 康彦; 坂本 洋城; 野田 佳寿; 汐見 幹夫; 吉田 洋; 吉田 英樹; 八木 誠; 竹山 宜典; 大柳 治正
    第77回日本消化器内視鏡学会近畿地方会 2006年09月 京都テレサ, 京都 第77回日本消化器内視鏡学会近畿地方会
  • 超音波内視鏡下腹水穿刺が治療方針決定に有用であった膵体癌の1例.  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之; 末冨 洋一郎; 梅原 泰; 汐見 幹夫
    第77回日本消化器内視鏡学会近畿地方会 2006年09月 京都テレサ, 京都 第77回日本消化器内視鏡学会近畿地方会
  • Gastric submucosal heterotopiaの1例.  [通常講演]
    西尾 健; 工藤 正俊; 由谷 逸朗; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 本庶 元
    第77回日本消化器内視鏡学会近畿地方会 2006年09月 京都テレサ, 京都 第77回日本消化器内視鏡学会近畿地方会
  • 診断までに時間を要した胃癌の1例.  [通常講演]
    加藤 玲明; 工藤 正俊; 石井 一樹; 林 道友; 豊澤 昌子; 小川 力; 岸谷 譲; 鍋島 紀滋; 水野 成人; 小川 稔; 井上 雅智; 太田 善夫
    第77回日本消化器内視鏡学会近畿地方会 2006年09月 京都テレサ, 京都 第77回日本消化器内視鏡学会近畿地方会
  • 当院でのinterventional EUSの現状.  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之
    第77回日本消化器内視鏡学会近畿地方会 2006年09月 京都テレサ, 京都 第77回日本消化器内視鏡学会近畿地方会
  • 感染性膵嚢胞に対し内視鏡的経胃嚢胞ドレナージ術が有効であった１例  [通常講演]
    冨田 崇文; 工藤 正俊; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元
    第85会日本消化器病学会近畿支部例会 2006年09月 大阪市 第85会日本消化器病学会近畿支部例会
  • 嚥下困難で発症したLong Segment Barrett's Esophagusの１例  [通常講演]
    百谷 起代子; 工藤 正俊; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元
    第180回日本内科学会近畿地方会 2006年09月 市 第180回日本内科学会近畿地方会
  • ヘルペス食道炎の１例  [通常講演]
    矢野 智洋; 工藤 正俊; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元
    第１８０回日本内科学会近畿地方会 2006年09月 京都市 第１８０回日本内科学会近畿地方会
  • 十二指腸静脈瘤の診断、治療と予後.  [通常講演]
    松井 繁長; 工藤 正俊; 市川 勉; 岡田 無文
    第13回日本門脈圧亢進症学会総会 2006年09月 ホテルオークラ東京, 東京 第13回日本門脈圧亢進症学会総会
  • 消化器内視鏡検査、治療後に偽痛風を発症した2例.  [通常講演]
    永田 嘉昭; 工藤 正俊; 松井 繁長; 末冨 洋一郎; 岡田 無文; 宮部 欽生; 石川 恵美; 市川 勉
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • 感染性膵？胞に対し内視鏡的経胃的？胞ドレナージ術が有効であった1例.  [通常講演]
    冨田 崇文; 工藤 正俊; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • 膵癌早期診断のためのアプローチ: US、EUSを中心に.  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之; 竹山 宜典
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • 肝動脈塞栓術併用経皮的ラジオ波焼灼術後に炎症性肉芽腫形成を来たし、播種性腫瘍再発との鑑別が困難であった一例.  [通常講演]
    高橋 俊介; 工藤 正俊; 鄭 浩柄; 北井 聡; 井上 達夫; 坂口 康浩; 南 康範; 上嶋 一臣; 福永 豊和; 土師 誠二
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • S1とペグインターフェロンが奏功したHCC肺転移の1例.  [通常講演]
    高瀬 徹; 工藤 正俊; 上嶋 一臣; 井上 達夫; 坂口 康浩; 南 康範; 鄭 浩柄; 福永 豊和; 北野 雅之
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • PEG-IFNα2bとribavirin併用治療中に1型糖尿病を発症した一例.  [通常講演]
    宮本 武明; 工藤 正俊; 小川 力; 岸谷 譲; 鍋島 紀滋; 水野 成人; 加藤 玲明; 豊澤 昌子; 林 道友; 北井 聡
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • B型肝炎ウイルス感染における発癌リスク因子の検討.  [通常講演]
    萩原 智; 工藤 正俊; 仲谷 達也; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • 成人期の初感染により慢性化したと考えられたB型肝炎の一例.  [通常講演]
    林 道友; 工藤 正俊; 鍋島 紀滋; 小川 力; 水野 成人; 岸谷 譲; 加藤 玲明; 豊澤 昌子; 北井 聡
    第85回日本消化器病学会近畿支部例会 2006年09月 大阪国際交流センター, 大阪 第85回日本消化器病学会近畿支部例会
  • Invited Lecture “Characterization of liver nodules in cirrhosis by ultrasonography.”  [通常講演]
    工藤 正俊
    18th European congress of ultrasound in conjunction with XVIII congresso Nazionale SIUMB 2006年09月 Bologna 18th European congress of ultrasound in conjunction with XVIII congresso Nazionale SIUMB
  • 特別講演「肝がん治療の最前線」  [通常講演]
    工藤 正俊
    日本肝臓学会肝がん撲滅運動市民公開講座～肝臓病で命を失わないために～ 2006年08月 堺市民会館 日本肝臓学会肝がん撲滅運動市民公開講座～肝臓病で命を失わないために～
  • 自然経過が観察し得たアルコール性過形成病変の一例.  [通常講演]
    前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    日本超音波医学会第32回関西地方会学術集会 2006年08月 大阪国際会議場, 大阪 日本超音波医学会第32回関西地方会学術集会
  • 肝領域. シンポジウム「病変を見落とさない超音波診断 私はこうしている」  [通常講演]
    南 康範; 工藤 正俊
    日本超音波医学会第32回関西地方会学術集会 2006年08月 大阪国際会議場, 大阪 日本超音波医学会第32回関西地方会学術集会
  • Invited Lecture “Diagnosis and treatment of HCC.”  [通常講演]
    工藤 正俊
    S.M.S. Hospital & Medical College (Invited by Dr. Ramesh Roop Rai) 2006年08月 Jaipur, India S.M.S. Hospital & Medical College (Invited by Dr. Ramesh Roop Rai)
  • Ward Round as a Visiting Professor.  [通常講演]
    工藤 正俊
    All India Institute of Medical Science 2006年08月 New Delhi, India All India Institute of Medical Science
  • Case Discussion and Consultation as a Visiting Professor.  [通常講演]
    工藤 正俊
    All India Institute of Medical Science 2006年08月 New Delhi, India All India Institute of Medical Science
  • Invited Lecture “Role of contrast enhanced ultrasonography for liver tumors.”  [通常講演]
    工藤 正俊
    All India Institute of Medical Science (Invited by Prof. Acharya) 2006年08月 New Delhi, India All India Institute of Medical Science (Invited by Prof. Acharya)
  • Invited Lecture “Staging system for HCC”  [通常講演]
    工藤 正俊
    All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)” 2006年08月 Delhi, India All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”
  • Invited Lecture “Real-time virtual sonography for liver malignancies.”  [通常講演]
    工藤 正俊
    All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)” 2006年08月 Delhi, India All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”
  • Invited Lecture “FNAC/Biopsy of HCC: Is it required?”  [通常講演]
    工藤 正俊
    All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)” 2006年08月 Delhi, India All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”
  • Ward Round as a Visiting Professor.  [通常講演]
    工藤 正俊
    Post Graduate Institute of Medical Education and Research 2006年07月 Chandigarh, India Post Graduate Institute of Medical Education and Research
  • Case Discussion and Consultation as a Visiting Professor.  [通常講演]
    工藤 正俊
    Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla) 2006年07月 Chandigarh, India Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla)
  • Invited Lecture “Real-time virtual sonography for liver malignancies.”  [通常講演]
    工藤 正俊
    Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla) 2006年07月 Chandigarh, India Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla)
  • 特別講演「肝細胞癌治療の最近の進歩」  [通常講演]
    工藤 正俊
    第21回肝臓を診る会 2006年07月 旭川グランドホテル 第21回肝臓を診る会
  • PEG-IFNα2bとribavirin併用治療中に１型糖尿病を発症した１例  [通常講演]
    宮本 武明; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 加藤 玲明; 豊澤 昌子; 林 道友; 北井 聡; 工藤 正俊
    第47回京都肝疾患懇話会 2006年07月 京都 第47回京都肝疾患懇話会
  • 肝細胞癌への経皮的ラジオ波焼灼術におけるReal-time virtual sonographyの有用性.  [通常講演]
    南 康範; 工藤 正俊; 高橋 俊介; 坂口 康浩; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    第6回関西肝血流動態イメージ研究会 2006年07月 オーバルホール, 大阪 第6回関西肝血流動態イメージ研究会
  • 自然経過が観察し得たアルコール性過形成病変の一例.  [通常講演]
    前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    第6回関西肝血流動態イメージ研究会 2006年07月 オーバルホール, 大阪 第6回関西肝血流動態イメージ研究会
  • 教育講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    日本消化器病学会近畿支部第21回教育講演会 2006年07月 アバローム紀の国 日本消化器病学会近畿支部第21回教育講演会
  • von Gierke disease（糖尿病I型）に肝細胞癌を合併した一症例.  [通常講演]
    鄭 浩柄; 工藤 正俊; 高橋 俊介; 萩原 智; 井上 達夫; 坂口 康浩; 南 康範; 上嶋 一臣; 福永 豊和; 中居 卓也
    第42回日本肝癌研究会 2006年07月 東京ドームホテル, 東京 第42回日本肝癌研究会
  • Child-Pugh C肝硬変に合併した肝癌の治療は？その是非と治療法選択に関するRetrospective多施設共同研究.  [通常講演]
    大崎 往夫; 工藤 正俊; 松永 隆; 春日井博志; 岡 博子; 関 寿人
    第42回日本肝癌研究会 2006年07月 東京ドームホテル, 東京 第42回日本肝癌研究会
  • ステージIVB肝内胆管癌に対するGemcitabine (GEM)をfirst lineとした化学療法と無治療群との比較検討. ワークショップ2「肝内胆管癌の診断と治療ーエビデンスに基づいた次の一手を求めてー」  [通常講演]
    南 康範; 工藤 正俊; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和
    第42回日本肝癌研究会 2006年07月 東京ドームホテル, 東京 第42回日本肝癌研究会
  • 教育講演「肝細胞癌へのアプローチ: 世界のConsensusとControversies」  [通常講演]
    工藤 正俊
    第42回日本肝癌研究会 2006年07月 東京ドームホテル, 東京 第42回日本肝癌研究会
  • ペグインターフェロン（PEG-IFN）と5-FUの併用によるp53を介する肝細胞癌抑制効果.  [通常講演]
    仲谷 達也; 工藤 正俊; 福永 豊和; 上嶋 一臣; 鄭 浩柄; 南 康範; 井上 達夫; 坂口 康浩; 萩原 智
    第47回京都肝疾患懇話会 2006年07月 京都ホテルオークラ, 京都 第47回京都肝疾患懇話会
  • PEG-IFNα2bとribavirin併用治療中に1型糖尿病を発症した1例.  [通常講演]
    宮本 武明; 工藤 正俊; 小川 力; 岸谷 譲; 鍋島 紀滋; 水野 成人; 加藤 玲明; 豊澤 昌子; 林 道友; 北井 聡
    第47回京都肝疾患懇話会 2006年07月 京都ホテルオークラ, 京都 第47回京都肝疾患懇話会
  • 成人期の初感染により慢性化したと考えられたB型肝炎の一例  [通常講演]
    林 道友; 鍋島 紀滋; 小川 力; 水野 成人; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 北井 聡; 工藤 正俊
    第8回関西B型肝炎研究会 2006年06月 大阪 第8回関西B型肝炎研究会
  • Usefulness and limitation of contrast-enhanced power Doppler EUS for diagnosis of pancreatic diseases.  [通常講演]
    北野 雅之; 工藤 正俊; 坂本 洋城; 前川 清; 末冨 洋一郎; 西尾 健; 竹山 宜典; 筑後 孝章
    15th International Symposium on Endoscopic Ultrasonograhy 2006年06月 Amsterdam, Netherland 15th International Symposium on Endoscopic Ultrasonograhy
  • ワークショップ 「転移性肝腫瘍に対する焼灼療法の治療成績」大腸癌肝転移におけるRFA治療の局所制御能  [通常講演]
    中居 卓也; 川邊 高史; 吉藤 竹仁; 上田 和毅; 肥田 仁一; 石丸 英三郎; 奥野 清隆; 塩﨑 均; 大柳 治正; 南 康範; 鄭 浩柄; 工藤 正俊
    第31回日本外科系連合学会 2006年06月 金沢 第31回日本外科系連合学会
     
    大腸癌肝転移にRFAを応用し、肝切除にRFA併用すれば化学療法単独治療より予後は改善していた。RFAの局所制御能を肝細胞癌と比較したところ、腫瘍サイズで両者に差はないが、3cmを超えるものは局所再発率が20%を超え適応外と考えられた。
  • 特別講演「肝細胞癌のステージングと治療選択」  [通常講演]
    工藤 正俊
    第3回肝・消化器・代謝・栄養研究会 2006年06月 ホテルグランヴィア大阪 第3回肝・消化器・代謝・栄養研究会
  • 特別講演「肝細胞癌の診断と治療ー最近の話題」  [通常講演]
    工藤 正俊
    肝がん撲滅運動学術講演会 2006年06月 リーガロイヤルホテル堺, 大阪 肝がん撲滅運動学術講演会
  • Relation of tumor vascularity to effect of gemcitabine in pancreastic carcinomas: Value of contrast-enhanced harmonic ultrasonography.  [通常講演]
    北野 雅之; 工藤 正俊; 坂本 洋城; 末冨 洋一郎; 西尾 健; 竹山 宜典
    42nd Annual Meeting, American Society of Clinical Oncology 2006年06月 Atlanta, Georgia 42nd Annual Meeting, American Society of Clinical Oncology
  • 腹部臓器に発生した神経原性腫瘍のレボビスト造影超音波について.  [通常講演]
    市島 真由美; 工藤 正俊; 前野 知子; 橋本 美紀恵; 前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    日本超音波医学会第79回学術集会 2006年05月 大阪国際会議場 日本超音波医学会第79回学術集会
  • レボビスト造影超音波の後血管相から見た肝機能評価について.  [通常講演]
    前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    日本超音波医学会第79回学術集会 2006年05月 大阪国際会議場 日本超音波医学会第79回学術集会
  • 膵癌早期診断における造影超音波および超音波内視鏡検査の有用性.  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之; 前川 清
    日本超音波医学会第79回学術集会 2006年05月 大阪国際会議場 日本超音波医学会第79回学術集会
  • Percutaneous radiofrequency ablation of liver tumors: feasibility and usefulness of a novel guidance technique with an integrated system of CT and sonographic images.  [通常講演]
    南 康範; 工藤 正俊
    11th Congress of the World Federation for Ultrasound in Medicine and Biology 2006年05月 COEX, Seoul, Korea 11th Congress of the World Federation for Ultrasound in Medicine and Biology
     
    Minami Y, Kudo M: P
  • Evaluation of liver function by contrast enhanced coded phase inversion harmonic ultrasonography with levovist using parenchymal imaging of liver and spleen in the post vascular phase.  [通常講演]
    上嶋 一臣; 工藤 正俊; 前川 清; Chinamnan W; 南 康範; 鄭 浩柄; 福永 豊和
    11th Congress of the World Federation for Ultrasound in Medicine and Biology 2006年05月 COEX, Seoul, Korea 11th Congress of the World Federation for Ultrasound in Medicine and Biology
  • Invited Lecture “Treatment response and treatment guidance of hepatoccellular carcinoma: value of contrast-enhanced harmonic US and RVS.”  [通常講演]
    工藤 正俊
    11th Congress of the World Federation for Ultrasound in Medicine and Biology 2006年05月 COEX, Seoul, Korea 11th Congress of the World Federation for Ultrasound in Medicine and Biology
  • 肝癌局所治療における最近の超音波検査ーProSound α10を用いてー.  [通常講演]
    南 康範; 工藤 正俊
    日本超音波医学会第79回学術集会 2006年05月 大阪国際会議場, 大阪 日本超音波医学会第79回学術集会
  • ランチョンセミナー「肝細胞癌のステージ分類: その重要性と問題点」  [通常講演]
    工藤 正俊
    第42回日本肝臓学会総会 2006年05月 国立京都国際会館, 京都 第42回日本肝臓学会総会
  • EUS-CPN時のエタノール注入部位と疼痛改善度の関連性.  [通常講演]
    西尾 健; 工藤 正俊; 坂本 洋城; 北野 雅之; 坂口 康浩; 末冨洋一郎; 上嶋 一臣; 汐見 幹夫
    第2回超音波内視鏡下生検法の診断精度向上のための研究会 2006年05月 京王プラザホテル 第2回超音波内視鏡下生検法の診断精度向上のための研究会
  • 当院における早期膵癌診断におけるストラテジー.  [通常講演]
    末冨洋一郎; 工藤 正俊; 北野 雅之
    第71回日本消化器内視鏡学会 2006年05月 京王プラザホテル 第71回日本消化器内視鏡学会
  • Mixed Intestinal and Diffuse Type Histology is a Risk Factor for Lymph Node Metastasis of Early Gastric Cancer  [通常講演]
    辻 直子; 工藤 正俊; 石黒 信吾
    Digestive Disease Week 2006 2006年05月 Lon Angeles Digestive Disease Week 2006
  • Peginterferon alpha-2α and 5-fluorouracil suppresses proliferation of human hepatocellular carcinoma in p53-mediated apoptotic response.  [通常講演]
    仲谷 達也; 工藤 正俊; 坂口 康浩; 木村 雅友; 早川 清雄; 宗像 浩
    41th Annual Meeting of the European Association for the Study of the Liver (EASL) 2006年04月 Vienna, Austria 41th Annual Meeting of the European Association for the Study of the Liver (EASL)
  • Carcinogenic risk factors in hepatitis B rivus infection.  [通常講演]
    萩原 智; 工藤 正俊; 仲谷 達也; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 宗像 浩
    41th Annual Meeting of the European Association for the Study of the Liver (EASL) 2006年04月 Vienna, Austria 41th Annual Meeting of the European Association for the Study of the Liver (EASL)
  • Comparison of staging systems for hepatocellular carcinoma in Japanese cohort.  [通常講演]
    鄭 浩柄; 工藤 正俊; 高橋俊介; 南 康範; 井上達夫; 坂口康浩; 萩原 智; 福永 豊和; 上嶋 一臣
    41th Annual Meeting of the European Association for the Study of the Liver (EASL) 2006年04月 Vienn, Austria 41th Annual Meeting of the European Association for the Study of the Liver (EASL)
  • 肝癌の経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性について.  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和; 上嶋 一臣; 萩原 智; 坂口康浩; 高橋俊介; 畑中絹代; 井上達夫
    第92回日本消化器病学会総会 2006年04月 リーガロイヤルホテル小倉, 福岡 第92回日本消化器病学会総会
  • 早期肝細胞癌の造影超音波所見: pure arterial phase imagingおよびpost-vascular phase imagingを中心に.  [通常講演]
    井上達夫; 工藤 正俊; 福永 豊和
    第92回日本消化器病学会総会 2006年04月 リーガロイヤルホテル小倉, 福岡 第92回日本消化器病学会総会
  • Invited Lecture “New Sonographic Techniques for HCC: have they any impact on clinical practice?”  [通常講演]
    工藤 正俊
    Joint Meeting of Cancer Research Institute and Liver Research Institute of Seoul National University 2006年04月 Seoul Joint Meeting of Cancer Research Institute and Liver Research Institute of Seoul National University
  • ランチョンセミナー「肝癌の進展抑制におけるIFNの効果」  [通常講演]
    工藤 正俊
    第92回日本消化器病学会総会 2006年04月 北九州 第92回日本消化器病学会総会
  • 特別講演「肝細胞癌のStagingと治療選択」  [通常講演]
    工藤 正俊
    第48回肝臓クリニカルセミナー 2006年04月 ソラリア西鉄ホテル, 福岡 第48回肝臓クリニカルセミナー
  • 特別講演「腹部造影超音波法の現状と今後の展望」  [通常講演]
    工藤 正俊
    第19回日本造影エコー・ドプラ診断研究会 2006年04月 神戸商工会議所, 神戸 第19回日本造影エコー・ドプラ診断研究会
  • レボビスト造影超音波で得られた後血管相画像の定量化について  [通常講演]
    前川 清; 工藤 正俊; 井上達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    第19回日本造影エコー・ドプラ診断研究会 2006年04月 神戸商工会議所, 神戸 第19回日本造影エコー・ドプラ診断研究会
  • 肝細胞癌局所再発例に対する造影超音波ガイド下ラジオ波焼灼術- Prospective randomized controlled traial-.  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和
    第19回日本造影エコー・ドプラ診断研究会-. 第19回日本造影エコー・ドプラ診断研究会 2006年04月 神戸商工会議所, 神戸 第19回日本造影エコー・ドプラ診断研究会-. 第19回日本造影エコー・ドプラ診断研究会
  • 真性多血症に合併したサイトメガロウイルス腸炎の一例  [通常講演]
    梅原 康湖; 工藤 正俊; 米田 円; 冨田 崇文; 落合 健; 本庶 元; 森村 正嗣; 由谷 逸朗; 辻 直子
    第76回日本消化器内視鏡学会近畿地方会 2006年03月 大阪市 第76回日本消化器内視鏡学会近畿地方会
  • 教育講演「肝細胞癌の治療」  [通常講演]
    工藤 正俊
    臨床腫瘍学会教育講演会 2006年03月 国際会議場, 大阪 臨床腫瘍学会教育講演会
  • レボビストによる純動脈相造影超音波法（PAP-US）の画像評価と腫瘍内の造影剤動態について  [通常講演]
    前川 清; 工藤 正俊; 井上達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    第111回大阪超音波研究会 2006年03月 ホテルグランヴィア大阪, 大阪 第111回大阪超音波研究会
  • 短期間に総胆管への落石と胆嚢炎繰り返し内視鏡的に対処した胆嚢結石症の１例  [通常講演]
    加藤 玲明; 林 道友; 北井 聡; 豊澤 昌子; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 工藤 正俊
    第76回日本消化器内視鏡学会近畿地方会 2006年03月 大阪 第76回日本消化器内視鏡学会近畿地方会
  • 特別講演「Real-time virtual sonographyの臨床的有用性について」  [通常講演]
    工藤 正俊
    超音波診断装置への今後の期待に関するディスカッション 2006年03月 ウェスティンホテル大阪, 大阪 超音波診断装置への今後の期待に関するディスカッション
  • 十二指腸静脈瘤の臨床的特徴と治療  [通常講演]
    松井 繁長; 工藤 正俊; 市川 勉
    第76回日本消化器内視鏡学会近畿地方会 2006年03月 大阪国際交流センター, 大阪 第76回日本消化器内視鏡学会近畿地方会
  • Invited Lecture “Novel Ultrasound techniques & technology”  [通常講演]
    工藤 正俊
    APASL (Asian Pacific Asoociation for the Study of the Liver) 2006年03月 Manila, Philippines APASL (Asian Pacific Asoociation for the Study of the Liver)
  • Peginterferon α-2aと5-FUの併用によるp53を介する肝細胞癌に対する抗腫瘍効果.  [通常講演]
    仲谷 達也; 工藤 正俊
    Bay Area Digestive 2006年03月 淡路夢舞台, 淡路 Bay Area Digestive
  • B型肝炎ウイルスキャリアにおけるgenotypeおよびCP/PC変異測定の臨床的意義.  [通常講演]
    萩原 智; 工藤 正俊
    Bay Area Digestive 2006年03月 淡路夢舞台, 淡路 Bay Area Digestive
  • 肝癌の経皮的ラジオ波焼灼術におけるReal-time virtual sonographyの有用性について.  [通常講演]
    南 康範; 工藤 正俊
    Bay Area Digestive 2006年03月 淡路夢舞台, 淡路 Bay Area Digestive
  • 肝障害度のスコア化による新分類法の提唱.  [通常講演]
    鄭 浩柄; 工藤 正俊
    Bay Area Digestive 2006年03月 淡路夢舞台, 淡路 Bay Area Digestive
  • 真性多血症に合併したサイトメガロウイルス腸炎の一例  [通常講演]
    梅原 康湖; 工藤 正俊; 米田 円; 冨田 崇文; 落合 健; 本庶 元; 森村 正嗣; 由谷 逸朗; 辻 直子
    第76回日本消化器内視鏡学会近畿地方会 2006年03月 大阪国際交流センター 第76回日本消化器内視鏡学会近畿地方会
  • 短期間に総胆管への落石と胆嚢炎を繰り返し内視鏡的に対処した胆嚢結石症の一例.  [通常講演]
    加藤 玲明; 工藤 正俊; 林道 友; 北井 聡; 豊澤昌子; 小川 力; 岸谷 譲; 鍋島紀滋; 水野成人
    第76回日本消化器内視鏡学会近畿地方会 2006年03月 大阪国際交流センター, 大阪 第76回日本消化器内視鏡学会近畿地方会
  • シンポジウム2. 消化管内視鏡up to date胆・膵「超音波内視鏡ガイド下腹腔神経叢ブロック術: CTによる注入部造影の有用性について」  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之
    第76回日本消化器内視鏡学会近畿地方会 2006年03月 大阪国際交流センター, 大阪 第76回日本消化器内視鏡学会近畿地方会
  • 腹腔鏡下腹膜生検にて確診しえた結核性腹膜炎の一例  [通常講演]
    河田奈都子; 鍋島 紀滋; 水野 成人; 岸谷 讓; 加藤 玲明; 小川 力; 豊澤 昌子; 北井 聡; 林 道友; 井上 雅智; 湯川 真生; 岩崎拓也; 太田 善夫; 工藤 正俊
    第84回日本消化器病学会近畿支部例会 2006年02月 神戸 第84回日本消化器病学会近畿支部例会
  • 特別講演「肝細胞癌のStagingと治療戦略」  [通常講演]
    工藤 正俊
    第5回肝胆膵疾患臨床懇話会 2006年02月 スイスホテル南海大阪, 大阪 第5回肝胆膵疾患臨床懇話会
  • 気腫性胆嚢炎の一例.  [通常講演]
    落合 健; 工藤 正俊; 冨田 崇文; 梅原 康湖; 本庶 元; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 船井 貞往
    第84回日本消化器病学会近畿支部例会 2006年02月 神戸国際会議場 第84回日本消化器病学会近畿支部例会
  • TS1膵癌診断における造影超音波および超音波内視鏡検査の有用性  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 西尾 健; 末冨洋一郎; 竹山 宜典; 筑後 孝章
    日本超音波医学会第31回関西地方会学術集会 2006年02月 京都テルサ 日本超音波医学会第31回関西地方会学術集会
  • 特別講演「肝細胞癌の診断と治療選択: 最近のトピックス」  [通常講演]
    工藤 正俊
    第３回佐賀県医師会癌検診会肝癌部会研修会 2006年01月 佐賀県医師会成人病予防センター 第３回佐賀県医師会癌検診会肝癌部会研修会
  • Invited Lecture “Pancreatic ultrasound: is it still useful in 2006?”  [通常講演]
    工藤 正俊
    WFUMB 2006 & Workshop 2006年01月 Jakarta WFUMB 2006 & Workshop
  • Invited Lecture “Ultrasound of malignant liver tumors”  [通常講演]
    工藤 正俊
    WFUMB 2006 & Workshop 2006年01月 Jakarta WFUMB 2006 & Workshop
  • Invited Lecture “Ultrasound of benign liver mass”  [通常講演]
    工藤 正俊
    WFUMB 2006 & Workshop 2006年01月 Jakarta WFUMB 2006 & Workshop
  • Ｃｒｏｈｎ病の経過中に急性出血性大腸炎を合併した１症例  [通常講演]
    冨田 崇文; 工藤 正俊; 米田 円; 落合 健; 梅原 康湖; 森村 正嗣; 由谷 逸朗; 辻 直子
    第５回 南大阪大腸内視鏡研究会 2006年01月 堺市 第５回 南大阪大腸内視鏡研究会
  • AFP-L3 is the most reliable tumor marker after radiofrequency ablation therapy for hepatocellular carcinoma  [通常講演]
    小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 水野 成人; 鍋島 紀滋
    Fourth JSH Single Topic Conference"Hepatocellular carcinoma: international consensus and controversi 2005年12月 Awaji Fourth JSH Single Topic Conference"Hepatocellular carcinoma: international consensus and controversi
  • 食道入口部直下に多発潰瘍を規制したLong Segment Barrett’s Esophagusの一例.  [通常講演]
    冨田 崇文; 落合 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊
    第75回日本消化器内視鏡学会近畿地方会 2005年10月 大阪 第75回日本消化器内視鏡学会近畿地方会
  • Histologic heterogeneity is a risk factor for lymph node metastasis of early gastric cancer  [通常講演]
    辻 直子; 工藤 正俊; 石黒 信吾
    13th United European Gastroenterology Week 2005年10月 Copenhagen, Denmark 13th United European Gastroenterology Week
  • Helicobacter pyloriクラリスロマイシン耐性と患者背景の動向  [通常講演]
    落合 健; 工藤 正俊; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第70回日本消化器内視鏡学会総会 2005年10月 神戸市 第70回日本消化器内視鏡学会総会
  • 食道入口部直下に多発潰瘍を形成したLong Segment Barrett's Esophagusの１例  [通常講演]
    冨田 崇文; 工藤 正俊; 落合 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第75回日本消化器内視鏡学会近畿地方会 2005年10月 大阪市 第75回日本消化器内視鏡学会近畿地方会
  • 著明な大腸狭窄をきたした一例  [通常講演]
    豊澤 昌子; 北井 聡; 林 道友; 加藤 玲明; 小川 力; 鍋島 紀滋; 水野 成人; 太田 善夫; 工藤 正俊
    第75回日本消化器内視鏡学会近畿地方会 2005年10月 大阪 第75回日本消化器内視鏡学会近畿地方会
     
    症例は７０歳代，男性。平成16年2月、吐血にて当院を受診したが、上部消化管に出血源認めず、鼻出血の嚥下が原因と判明し帰宅した。翌朝，意識障害が出現し，当院救命科に搬入された。入院当日下血を認めたため翌日大腸内視鏡施行した。肛門付近を除く直腸からS状結腸まで全周性に粘膜壊死を認めた。CTでは直腸に著明な壁肥厚を認め、S状結腸以深は異常なかった。意識障害も消失し当科に転科した。約１ヶ月後の大腸内視鏡では、直腸下部に正常粘膜を認めたが、その奥に全周性潰瘍の残存を認め、疼痛により深部挿入出来なかった。３月の注腸にて下行結腸に狭窄を認めた。手術予定となるも、総胆管結石による胆管炎をきたし、手術延期となった。５月の大腸内視鏡にて肛門より約１０ｃｍ以深に潰瘍を認め、２０ｃｍ以深は狭窄の為挿入出来なかった。６月に左結腸・Ｓ状結腸切除術を施行した。術中所見では下行結腸からＳ状結腸にかけて狭小化、硬化しており、小腸と
  • HP除菌によって内視鏡的に改善した鳥肌胃炎の一例  [通常講演]
    加藤 玲明; 河田 奈都子; 林 道友; 北井 聡; 豊澤 昌子; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 工藤 正俊
    第27回奈良県胃腸研究会 2005年10月 奈良 第27回奈良県胃腸研究会
  • 急速に増大し得た胃GISTの1手術例  [通常講演]
    吉本 理恵; 工藤 正俊; 汐見 幹夫; 末冨 洋一郎; 中岡 良介; 松井 繁長; 北野 雅之; 保田 知生; 大柳 治正
    第69回日本消化器内視鏡学会近畿地方会 2005年10月 大阪 第69回日本消化器内視鏡学会近畿地方会
  • PEG-IFN ALPHA-2a and 5-fluorouracil suppresses proliferation of human hepatocellular carcinoma in node mice  [通常講演]
    仲谷 達也; 工藤 正俊; 坂口康浩; 木村 雅友; 早川 清雄; 宗像 浩
    13th united European gastroenterology week (UEGW) 2005年10月 Copenhargen 13th united European gastroenterology week (UEGW)
  • 腸腰筋膿瘍を合併した急性膵炎の１例  [通常講演]
    梅原 康湖; 工藤 正俊; 冨田 崇文; 落合 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第83回日本消化器病学会近畿支部例会 2005年09月 大阪市 第83回日本消化器病学会近畿支部例会
  • 純動脈相超音波造影法（PAP-US）と画像表示に用いる測定時相について  [通常講演]
    前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和
    日本超音波医学会第30回関西地方会学術集会 2005年09月 千里ライフサイエンスセンター 日本超音波医学会第30回関西地方会学術集会
  • 肝細胞癌に対する経撓骨動脈アプローチによる血管造影の有用性  [通常講演]
    林 道友; 鍋島 紀滋; 北井 聡; 水野 成人; 小川 力; 加藤 玲明; 豊澤 昌子; 工藤 正俊
    第83回日本消化器病学会近畿支部例会 2005年09月 大阪 第83回日本消化器病学会近畿支部例会
     
    【目的】腹部血管造影において患者の不満が最も多いのは、検査後の長時間の安静臥床である。循環器領域では、近年経撓骨動脈アプローチが主流になっているが、腹部血管造影においてもその有用性が報告されている（日消誌Vol 99, 1450-1454, 2002）。2005年4月から我々の施設でも、この報告を参考に若干の工夫を加えて経撓骨動脈アプローチによる腹部血管造影を行っているので報告する。【方法】肝細胞癌と診断され左撓骨動脈より経動脈的治療（TAE、TAI）を行った20例について、造影および治療の成功率、所要時間、合併症について検討した。2004年4月から2005年3月までに大腿動脈からのアプローチで治療を行った58例を比較対象とした。また、過去に大腿動脈からの検査を受けている15例にはアンケートを行った。検査手技は、左撓骨動脈を22G針で穿刺しSeldinger法にて4Frシースを留置した。4Fr 110cmのKAGAWAカテーテルをガイドワイヤーを先行させながら下行大動脈まで誘導し、上腸間膜動脈
  • 特別講演「肝細胞癌の診断と治療選択」  [通常講演]
    工藤 正俊
    第25回名古屋肝炎セミナー、第108回名古屋肝疾患研究会 2005年09月 名古屋マリオットアソシアホテル 第25回名古屋肝炎セミナー、第108回名古屋肝疾患研究会
  • Usefulness of contrast enhancement for diagnosis of pancreatic desease by transabdominal US and EUS  [通常講演]
    北野 雅之; 工藤 正俊
    World congress of Gastroenterology 2005 2005年09月 Montreal, Canada World congress of Gastroenterology 2005
  • Invited Lecture “Recent progress in imaging of HCC:from ultrasound to PET Scan”  [通常講演]
    工藤 正俊
    Asia Pacific Association of Study of the Liver (APASL) 2005年08月 Bali Asia Pacific Association of Study of the Liver (APASL)
  • Real-time virtual sonography, an integrated system of computer tomography with ultrasound images: value in radiofrequency ablation guidance.  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 井上 達夫; 萩原 智; 畑中 絹代; 坂口 康浩; 上嶋 一臣; 福永 豊和
    15th Asian Pacific Association for the Study of the Liver (APASL) 2005年08月 Bali 15th Asian Pacific Association for the Study of the Liver (APASL)
  • 特別講演「肝細胞癌の診断と治療: 最新情報」  [通常講演]
    工藤 正俊
    日本肝臓学会主催, 平成13年度肝がん撲滅運動市民公開講座 2005年08月 堺市民会館, 堺 日本肝臓学会主催, 平成13年度肝がん撲滅運動市民公開講座
  • Invited Lecture “Color Doppler diagnosis of hepatocellular carcinoma.”  [通常講演]
    工藤 正俊
    Asia Pacific Association of Study of the Liver (APASL) 2005年08月 Bali Asia Pacific Association of Study of the Liver (APASL)
  • Invited Lecture “Diagnosis of hepatocellular carcinoma.”  [通常講演]
    工藤 正俊
    Asia Pacific Association of Study of the Liver (APASL) 2005年08月 Bali Asia Pacific Association of Study of the Liver (APASL)
  • 特別講演「肝細胞癌診療の最近の進歩」  [通常講演]
    工藤 正俊
    和歌山県立医科大学第二内科同門会学術講演会 2005年07月 和歌山 和歌山県立医科大学第二内科同門会学術講演会
  • 特別講演「肝細胞癌の診断と治療: 最近の動向」  [通常講演]
    工藤 正俊
    第15回光生病院臨床談話会 2005年07月 光生病院, 岡山 第15回光生病院臨床談話会
  • 膵癌診断における造影超音波および超音波内視鏡検査の有用性. （ワークショップ「膵画像診断の最前線」）  [通常講演]
    北野 雅之; 工藤 正俊; 坂本洋城
    第36回日本膵臓学会大会 2005年07月 京王プラザホテル, 東京 第36回日本膵臓学会大会
  • 教育講演「肝細胞癌診療の最近のトピックス」  [通常講演]
    工藤 正俊
    日本消化器病学会中国支部例会教育講演会 2005年06月 岡山 日本消化器病学会中国支部例会教育講演会
  • 特別講演「肝細胞癌治療と再発抑制」  [通常講演]
    工藤 正俊
    平成17年度肝がん撲滅運動学術講演会 2005年06月 スイスホテル, 大阪 平成17年度肝がん撲滅運動学術講演会
  • Invited Lecture “Contrast US technology.” EASL Monothematic Conference on HCC.  [通常講演]
    工藤 正俊
    EASL・AASLD・JSH Joint Symposium 2005年06月 Barcelona, Spain EASL・AASLD・JSH Joint Symposium
  • Special Lecture “Imaging human hepatocarcinogenesis.”  [通常講演]
    工藤 正俊
    Laennec Meeting 2005年06月 Bordeaux, France Laennec Meeting
  • Contrast US technology  [通常講演]
    工藤 正俊
    EASL Monothematic Conference 2005年06月 Barcelona EASL Monothematic Conference
  • Usefulness of contrast-enhanced harmonic ultrasonography for the detection of small tumors in pancreas  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之; 前川 清
    Euro-EUS2005 2005年06月 Copenhagen Euro-EUS2005
  • Usefulness of contrast-enhanced power Doppler EUS in differential diagnosis of pancreatic tumors  [通常講演]
    北野 雅之; 工藤 正俊; 坂本洋城; 前川 清
    Euro-EUS2005 2005年06月 Copenhagen Euro-EUS2005
  • ランチョンセミナー「肝細胞癌診療の最近のトピックス」  [通常講演]
    工藤 正俊
    日本消化器病学会中国支部第7回教育講演会 2005年06月 岡山コンベンションセンター, 岡山 日本消化器病学会中国支部第7回教育講演会
  • 日本肝癌研究会 肝障害度のスコア化による新分類法の提唱. ポスター「肝細胞癌の予後解析1」  [通常講演]
    鄭 浩柄; 工藤 正俊; 井上達夫; 坂口康浩; 萩原 智; 南 康範; 上嶋 一臣; 福永 豊和; 大崎往夫; 春日井博志; 関 寿人; 岡 博子
    第41回日本肝癌研究会 2005年06月 幕張メッセ国際会議場, 千葉 第41回日本肝癌研究会
  • 非B非C肝癌の臨床的特徴像  [通常講演]
    畑中絹世; 工藤 正俊; 大崎往夫
    第41回日本肝癌研究会 2005年06月 幕張メッセ国際会議場, 千葉 第41回日本肝癌研究会
  • 肝癌の経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性について. ビデオセッション「経皮的局所療法(II)」  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 井上達夫; 坂口康浩; 萩原 智; 畑中絹世; 上嶋 一臣
    第41回日本肝癌研究会 2005年06月 幕張メッセ国際会議場, 千葉 第41回日本肝癌研究会
  • 造影超音波検査の新しい作画法Accumulation modeを用いた肝腫瘍性病変の血流評価. ビデオセッション「肝癌診断」  [通常講演]
    福永 豊和; 工藤 正俊; 前川 清
    第41回日本肝癌研究会 2005年06月 幕張メッセ国際会議場, 千葉 第41回日本肝癌研究会
  • 当院における肝細胞癌に対する経皮的ラジオ波治療成績と工夫. パネルディスカッション「より安全で効果的なラジオ波焼灼療法」  [通常講演]
    鄭 浩柄; 工藤 正俊; 井上達夫; 坂口康浩; 萩原 智; 南 康範; 上嶋 一臣; 福永 豊和
    第41回日本肝癌研究会 2005年06月 幕張メッセ国際会議場, 千葉 第41回日本肝癌研究会
  • 大腸癌肝転移に対するラジオ波熱凝固療法後の局所再発  [通常講演]
    中居 卓也; 川邊 高史; 奥野 清隆; 大柳 治正; 塩﨑 均; 南 康範; 工藤 正俊
    第106回日本外科学会 2005年05月 名古屋 第106回日本外科学会
     
    大腸癌肝転移に対して肝切除以外にRFAも選択してきた。肝転移に対するRFA治療の局所制御能を肝細胞癌の再発率で比較した。その両者で局所再発率に差はなく、合併症もなかった。
  • にんにく療法とL-NAME吸入を試みた肝肺症候群の一例  [通常講演]
    山藤 緑; 岩永 賢司; 佐藤 隆司; 辻 文生; 宮良 高維; 原口 龍太; 久保 裕一; 東田 有智; 北口 容子; 工藤 正俊
    第176回日本内科学会近畿地方会 2005年05月 大阪 第176回日本内科学会近畿地方会
  • 特別講演「肝細胞癌治療と再発抑制」  [通常講演]
    工藤 正俊
    肝癌再発予防研究会第8回学術講演会 2005年05月 千里ライフサイエンスセンター, 大阪 肝癌再発予防研究会第8回学術講演会
  • 報告講演「次世代超音波造影剤対応造影ハーモニックモードを搭載した超音波内視鏡探触子の開発－消化器疾患の微小循環動態評価による診断－」  [通常講演]
    工藤 正俊
    第78回日本超音波医学会総会 2005年05月 東京国際フォーラム, 東京 第78回日本超音波医学会総会
  • ラジオ出演「肝臓がんの診断と治療（5）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    ABCラジオ（朝日放送） 2005年05月 大阪 ABCラジオ（朝日放送）
  • ラジオ出演「肝臓がんの診断と治療（4）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    ABCラジオ（朝日放送） 2005年05月 大阪 ABCラジオ（朝日放送）
  • ラジオ出演「肝臓がんの診断と治療（3）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    ABCラジオ（朝日放送） 2005年05月 大阪 ABCラジオ（朝日放送）
  • ラジオ出演「肝臓がんの診断と治療（2）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    ABCラジオ（朝日放送） 2005年05月 大阪 ABCラジオ（朝日放送）
  • ラジオ出演「肝臓がんの診断と治療（1）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    ABCラジオ（朝日放送） 2005年05月 大阪 ABCラジオ（朝日放送）
  • 講演「肝臓がんの早期発見・内科的治療と再発予防の最前線」  [通常講演]
    工藤 正俊
    平成17年度日本肝臓学会市民公開講座, 日本肝臓学会 2005年05月 有楽町読売ホール, 東京 平成17年度日本肝臓学会市民公開講座, 日本肝臓学会
  • Clinical characteristics and endoscopic treatment of duodenal varices  [通常講演]
    松井 繁長; 工藤 正俊
    DDW 2005 2005年05月 Chicago DDW 2005
  • Contrast-enhanced harmonic EUS: a method to visualize microcirculation in digestive organs  [通常講演]
    北野 雅之; 工藤 正俊
    DDW 2005 2005年05月 Chicago DDW 2005
  • The utility of endoscopic ultrasonography using 30MHz, 20MHz and 12MHz endoscopic ultrasound probe, endoscopy in the endoscopic submucosal desection of early gastric cancer  [通常講演]
    市川 勉; 工藤 正俊
    DDW 2005 2005年05月 Chicago DDW 2005
  • Real-time virtual sonography, an integrated system of computer tomography with ultrasound images: value in radiofrequency ablation guidance  [通常講演]
    南 康範; 工藤 正俊
    DDW 2005 2005年05月 Chicago DDW 2005
  • ポスター「内視鏡的に切除した単発性胃粘膜下異所性胃腺の2例ー超音波内視鏡所見を含めてー  [通常講演]
    吉本理恵; 工藤 正俊; 汐見 幹夫; 上田泰輔; 末冨洋一郎; 中岡 良介; 筑後 孝章
    第69回日本消化器内視鏡学会総会 2005年05月 ホテルニューオータニ東京, 東京 第69回日本消化器内視鏡学会総会
  • パネルディスカッション「膵癌の確定診断における経乳頭的膵液細胞診とEUS下穿刺生検の使い分けに関する検討」  [通常講演]
    北野 雅之; 工藤 正俊; 坂本洋城
    第69回日本消化器内視鏡学会総会 2005年05月 ホテルニューオータニ東京, 東京 第69回日本消化器内視鏡学会総会
  • パネルディスカッション「十二指腸静脈瘤の内視鏡的診断と治療」  [通常講演]
    松井 繁長; 工藤 正俊; 市川 勉
    第69回日本消化器内視鏡学会総会 2005年05月 ホテルニューオータニ東京, 東京 第69回日本消化器内視鏡学会総会
  • シンポジウム「超音波内視鏡ガイド下腹腔神経叢ブロック術の成績とその適応; 後方接近法との比較」  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之
    第69回日本消化器内視鏡学会総会 2005年05月 ホテルニューオータニ東京, 東京 第69回日本消化器内視鏡学会総会
  • ビデオシンポジウム「超音波内視鏡ガイド下腹腔神経叢ブロック術の標準的描出法とその成績」  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之
    第69回日本消化器内視鏡学会総会 2005年05月 ホテルニューオータニ東京, 東京 第69回日本消化器内視鏡学会総会
  • ワークショップ(2)「肝癌のラジオ波焼灼術のおけるRVSの有用性」  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄
    第78回日本超音波医学会総会 2005年05月 東京国際フォーラム, 東京 第78回日本超音波医学会総会
  • ワークショップ(1)「膵腫瘍性病変診断におけるEUS下穿刺生検の有用性とその工夫」  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之; 前川 清
    第78回日本超音波医学会総 2005年05月 東京国際フォーラム, 東京 第78回日本超音波医学会総
  • パネルディスカッション(3)「超音波内視鏡探触子による消化器系臓器の微小循環動態の観察」  [通常講演]
    北野 雅之; 工藤 正俊; 坂本洋城; 前川 清; 南 康範; 中岡 良介; 仲谷 達也
    第78回日本超音波医学会総会 2005年05月 東京国際フォーラム, 東京 第78回日本超音波医学会総会
  • パネルディスカッション(2)「GISTsの悪制度評価における造影超音波の有用性」  [通常講演]
    福田信宏; 工藤 正俊; 北野 雅之; 前川 清
    第78回日本超音波医学会総会 2005年05月 東京国際フォーラム, 東京 第78回日本超音波医学会総会
  • パネルディスカッション(1)「膵管癌の早期診断と治療効果判定における造影超音波検査の有用性」  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之
    第78回日本超音波医学会総 2005年05月 東京国際フォーラム, 東京 第78回日本超音波医学会総
  • 特別講演「肝細胞の治療と再発抑制」  [通常講演]
    工藤 正俊
    肝疾患治療フォーラム, ヒルトンホテル 2005年04月 大阪 肝疾患治療フォーラム, ヒルトンホテル
  • 教育講演Meet-the-Professor「肝癌の診断と集学的な治療の最前線」  [通常講演]
    工藤 正俊
    第91回日本消化器病学会総会ポストグラデュエイトコース 2005年04月 東京国際フォーラム, 東京 第91回日本消化器病学会総会ポストグラデュエイトコース
  • ラジオ出演「肝臓がんの予防」(番組名: 健やかライフ),  [通常講演]
    工藤 正俊
    ABCラジオ（朝日放送） 2005年04月 大阪 ABCラジオ（朝日放送）
  • Special Lecture “Non-B, non-C HCC-overview.”  [通常講演]
    工藤 正俊
    Japan-Korean Liver Symposium 2005年04月 Teju, Korea Japan-Korean Liver Symposium
  • “Therapy for Early HCC.”  [通常講演]
    工藤 正俊
    JSGE・AGA Joint Meeting 2005年04月 Tokyo Forum, Tokyo JSGE・AGA Joint Meeting
  • Education Lecture "Contrast US of pancreato-biliary tumor."  [通常講演]
    工藤 正俊
    Informal administrative council meeting of AFSUMB 2005年04月 Shanghai, China Informal administrative council meeting of AFSUMB
  • Education Lecture "Treatment of HCC using real-time virtual sonography and contrast US."  [通常講演]
    工藤 正俊
    Informal administrative council meeting of AFSUMB 2005年04月 Shanghai, China Informal administrative council meeting of AFSUMB
  • Education Lecture "Doppler/Contrast-enhanced US of liver mass."  [通常講演]
    工藤 正俊
    Informal administrative council meeting of AFSUMB 2005年04月 Shanghai, China Informal administrative council meeting of AFSUMB
  • Invited Lecture "Diagnosis and treatment of hepatocellular carcinoma up-to-date."  [通常講演]
    工藤 正俊
    The 6th Sino-Japanese symposium on hepato-biliaty-pancreatic deseases 2005年04月 Beijing, China The 6th Sino-Japanese symposium on hepato-biliaty-pancreatic deseases
  • Non-B Non-C HCC in Japan, overview  [通常講演]
    畑中絹世; 工藤 正俊
    The2nd Korea-Japan Liver Symosium(KJLS) 2005 2005年04月 Cheju, Korea The2nd Korea-Japan Liver Symosium(KJLS) 2005
  • Hepatocellular carcinoma up-to date; Diagnosis and treatment of hepatocellular carcinoma up-to date  [通常講演]
    工藤 正俊
    6th Sino-Japan Hepato-pancreato-biliary symposium 2005年04月 China 6th Sino-Japan Hepato-pancreato-biliary symposium
  • パネルディスカッション（８）消化器病診断・治療における造影超音波検査の新しい展開－次世代造影剤を含めて「次世代超音波造影剤を用いた造影ハーモニック超音波検査による微小循環動態の観察」  [通常講演]
    北野 雅之; 工藤 正俊; 坂本洋城
    第91回日本消化器病学会総会 2005年04月 東京国際フォーラム, 東京 第91回日本消化器病学会総会
  • シンポジウム（3）肝細胞癌のラジオ波治療のQualityコントロールと長期予後及び今後の課題「当院における肝細胞癌に対するラジオ波焼灼術治療成績」  [通常講演]
    井上達夫; 工藤 正俊; 鄭 浩柄
    第91回日本消化器病学会総会 2005年04月 東京国際フォーラム, 東京 第91回日本消化器病学会総会
  • Hepatocellular carcinoma ; Therapies for Early HCC.  [通常講演]
    工藤 正俊
    Second joint Meeting of the Japanese Society of Gastroenterology and the American Gastroenterologica 2005年04月 Tokyo Second joint Meeting of the Japanese Society of Gastroenterology and the American Gastroenterologica
  • Hepatocellular carcinoma up-to date; Diagnosis and treatment of hepatocellular carcinoma up-to date.  [通常講演]
    工藤 正俊
    6th Sino-Japan Hepato-pancreato-biliary symposium 2005年04月 China 6th Sino-Japan Hepato-pancreato-biliary symposium
  • 慢性関節リウマチ発病後, 比較的短期間のうちに発症した続発性消化管アミロイドーシスの一例.  [通常講演]
    落合 健; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸郎; 辻 直子; 工藤 正俊
    第74回日本消化器内視鏡学会近畿地方会 2005年03月 大阪国際会議場, 大阪. 第74回日本消化器内視鏡学会近畿地方会
  • 化学療法に一時的に反応した小腸癌の一例  [通常講演]
    加藤 玲明; 水野 成人; 林 道友; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 工藤 正俊; 藤島 正浩; 村田 賢; 井上 雅智
    第74回日本消化器内視鏡学会近畿地方会 2005年03月 大阪 第74回日本消化器内視鏡学会近畿地方会
  • 特別講演「慢性肝疾患治療の最前線」  [通常講演]
    工藤 正俊
    慢性肝疾患セミナー 2005年03月 リーガロイヤルホテル新居浜, 新居浜 慢性肝疾患セミナー
  • 基調講演「肝癌の診療における造影エコーの現状と展望」  [通常講演]
    工藤 正俊
    第30回 肝胆膵治療研究会 2005年03月 エーザイ（株）東海サポートセンター, 名古屋 第30回 肝胆膵治療研究会
  • 当院におけるラジオ波焼灼術の成績と工夫（シンポジウム「安全で確実なラジオ波熱凝固療法施行のために」）  [通常講演]
    鄭 浩柄; 工藤 正俊; 井上達夫; 萩原 智; 南 康範; 上嶋 一臣; 福永 豊和
    第7回関西肝癌局所療法研究会 2005年03月 ホテルグランヴィア大阪, 大阪 第7回関西肝癌局所療法研究会
  • 小腸穿孔の一例  [通常講演]
    林 道友; 水野 成人; 藤島 正浩; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 新崎 亘; 中山 剛之; 井上 雅智; 太田 善夫; 工藤 正俊
    第82回日本消化器病学会近畿支部例会 2005年02月 京都 第82回日本消化器病学会近畿支部例会
  • 非典型的な画像所見を呈したHCCの一例  [通常講演]
    小川 力; 水野 成人; 藤島 正浩; 林 道友; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 北口 博士; 村田 賢; 井上 雅智; 太田 善夫; 工藤 正俊
    第82回日本消化器病学会近畿支部例会 2005年02月 京都 第82回日本消化器病学会近畿支部例会
  • 特別講演「ウイルス性肝炎の最新知識」  [通常講演]
    工藤 正俊
    肝炎肝がん啓発普及講習会 2005年02月 大阪狭山市保健センター, 大阪 肝炎肝がん啓発普及講習会
  • 教育講演「肝細胞癌の診断における最先端の腹部エコー検査法」  [通常講演]
    工藤 正俊
    第40回山口大学医師会・山口大学医学部主催医師教育講座 2005年02月 山口大学, 山口 第40回山口大学医師会・山口大学医学部主催医師教育講座
     
    教育講演「肝細胞癌の診断における最先端の腹部エコー検査法」
  • 教育講演「肝細胞癌の診断と治療：最近の進歩」  [通常講演]
    工藤 正俊
    日本消化器病学会近畿支部第17回教育講演会 2005年02月 京都テルサ, 京都 日本消化器病学会近畿支部第17回教育講演会
  • 特別講演「肝細胞癌の診断と治療：最近のトピックス」  [通常講演]
    工藤 正俊
    第15回大分肝炎研究会 2005年02月 大分東洋ホテル, 大分 第15回大分肝炎研究会
  • 特別講演「肝細胞癌診療の最近の進歩」  [通常講演]
    工藤 正俊
    第2回北九州肝癌治療研究会 2005年02月 リーガロイヤルホテル小倉, 九州 第2回北九州肝癌治療研究会
  • 膵膿瘍を合併した有機リン中毒の一例  [通常講演]
    荻野 公一; 工藤 正俊; 落合 健; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    日本消化器病学会第82回近畿支部例会 2005年02月 京都 日本消化器病学会第82回近畿支部例会
     
    膵膿瘍を合併した有機リン中毒の症例報告を行った。
  • 胆、膵における臨床的有用性について  [通常講演]
    北野 雅之; 工藤 正俊
    GE Ultrasound Advanced Symposium 2003 2005年 GE Ultrasound Advanced Symposium 2003
  • 造影超音波. シンポジウム「早期肝癌ー診断と治療の最前線ー」  [通常講演]
    工藤 正俊
    第39回日本医学放射線学会秋季臨床大会 2005年 神戸 第39回日本医学放射線学会秋季臨床大会
  • 食道静脈瘤に対するELSLの有用性. （ワークショップI 「食道静脈瘤の治療戦略」）  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介
    第67回日本消化器内視鏡学会近畿地方会 2005年 大阪 第67回日本消化器内視鏡学会近畿地方会
  • 特別講演「肝疾患診療の最新情報」  [通常講演]
    工藤 正俊
    ルミパルス学会 2005年01月 ホテルサンルートソプラ神戸, 神戸 ルミパルス学会
  • 特別講演「肝細胞癌治療と再発抑制」  [通常講演]
    工藤 正俊
    Meet-the-Expert Seminar in Yamanashi 2005 2005年01月 甲府, 山梨 Meet-the-Expert Seminar in Yamanashi 2005
  • 側方リンパ節転移を認めた直腸カルチノイドの1例  [通常講演]
    所 忠男; 奥野 清隆; 肥田 仁一; 石丸 英三郎; 内田 寿博; 吉藤 竹仁; 松崎智彦; 安富 正幸; 塩? 均; 南 康範; 工藤 正俊
    第62回大腸癌研究会 2005年01月 第62回大腸癌研究会
  • 特別講演「肝細胞癌の診断と治療：最近のトピックス」  [通常講演]
    工藤 正俊
    ひだ消化器病研究会 2004年12月 高山赤十字病院, 岐阜 ひだ消化器病研究会
  • 特別講演ランチョンセミナー「肝細胞癌の診断と治療：最近のトピックス」  [通常講演]
    工藤 正俊
    第84回日本消化器病学会九州支部例会 2004年12月 福岡国際会議場, 福岡 第84回日本消化器病学会九州支部例会
  • Invited Lecture "Imaging fro parenchymal assessment in chronic liver disease."  [通常講演]
    工藤 正俊
    Asian Pacific Association for the Study of the Liver (APASL) 2004年12月 New delhi, India Asian Pacific Association for the Study of the Liver (APASL)
  • Invited Lecture "Newer imaging modalities for hepatocellular carcinoma."  [通常講演]
    工藤 正俊
    Asian Pacific Association for the Study of the Liver (APASL) 2004年12月 New delhi, India Asian Pacific Association for the Study of the Liver (APASL)
  • Invited Lecture "Screening for HCC: Is it relevant in Asia pacific: How to screen?"  [通常講演]
    工藤 正俊
    Asian Pacific Association for the Study of the Liver (APASL) 2004年12月 New delhi, India Asian Pacific Association for the Study of the Liver (APASL)
  • Invited Lecture "Evaluation of state of lecture in normal and cirrhotic liver."  [通常講演]
    工藤 正俊
    Asian Pacific Association for the Study of the Liver (APASL) 2004年12月 New delhi, India Asian Pacific Association for the Study of the Liver (APASL)
  • TS-１にて長期コントロールされている進行胃癌の１例  [通常講演]
    林 道友; 水野 成人; 加藤 玲明; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 中山 剛之; 井上 雅智; 工藤 正俊; 藤島 正浩
    第3回大阪消化器化学療法懇話会 2004年11月 大阪 第3回大阪消化器化学療法懇話会
  • 肝腫瘍の一例  [通常講演]
    小川 力; 水野 成人; 林 道友; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊
    第8回画像診断・治療研究会 2004年11月 大阪 第8回画像診断・治療研究会
  • 特別講演「肝癌治療と再発予防について」  [通常講演]
    工藤 正俊
    京都肝炎友の会 2004年11月 ラボール京都, 京都 京都肝炎友の会
  • 特別講演「肝細胞がんの早期発見と治療－最近の進歩を含めて－」  [通常講演]
    工藤 正俊
    肝癌撲滅運動記念講演会, 日本肝臓学会 2004年11月 もくせい会館, 静岡 肝癌撲滅運動記念講演会, 日本肝臓学会
  • 特別講演「肝細胞癌診療の最近のトピックス」  [通常講演]
    工藤 正俊
    第9回宮城インターベンション研究会 2004年11月 良陸会館, 仙台 第9回宮城インターベンション研究会
  • 特別講演「肝細胞癌のステージングと治療アルゴリズム」  [通常講演]
    工藤 正俊
    第17回南大阪消化器病懇話会 2004年11月 リーガロイヤルホテル堺, 大阪 第17回南大阪消化器病懇話会
  • 特別講演「RFAによる肝細胞癌根治後のIFN治療による再発抑制効果」  [通常講演]
    工藤 正俊
    自治医科大学大学院特別講義 2004年11月 自治医科大学, 栃木 自治医科大学大学院特別講義
  • 特別講演「消化器領域における造影エコー法の進歩と今後の展望」  [通常講演]
    工藤 正俊
    第 回日本超音波医学会四国地方会 2004年11月 松山 第 回日本超音波医学会四国地方会
  • 特別講演「肝細胞癌の画像診断」  [通常講演]
    工藤 正俊
    第 回神奈川肝癌研究会 2004年11月 横浜 第 回神奈川肝癌研究会
  • 小腸穿孔を来した一例  [通常講演]
    加藤 玲明; 水野 成人; 林 道友; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 太田 善夫; 工藤 正俊; 新崎 亘; 中山 剛之; 井上 雅智
    第26回奈良県胃腸研究会 2004年10月 奈良 第26回奈良県胃腸研究会
  • 肝SOLの１例  [通常講演]
    水野 成人; 小川 力; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊
    第7回関西GEクラブ 2004年10月 大阪 第7回関西GEクラブ
  • 特別講演「IFNによる肝癌のsecondary prevention」  [通常講演]
    工藤 正俊
    イブニングセミナー, DDW2004 2004年10月 福岡 イブニングセミナー, DDW2004
  • 上部消化管内視鏡検査におけるプロポフォールの安全性と有用性  [通常講演]
    米田 円; 工藤 正俊; 安藤 理奈; 落合 健; 田中 陽一; 由谷 逸朗; 森村 正嗣; 辻 直子
    第68回日本消化器内視鏡学会総会 2004年10月 福岡 第68回日本消化器内視鏡学会総会
  • sm分化型胃癌リンパ節転移に関する臨床病理学的検討  [通常講演]
    辻 直子; 工藤 正俊; 落合 健; 田中 陽一; 米田 円; 森村正嗣; 由谷 逸朗; 石黒 信吾
    第46回日本消化器病学会大会 2004年10月 福岡 第46回日本消化器病学会大会
     
    sm分化型胃癌手術症例のリンパ節転移陽性群と陰性群を比較することでリンパ節転移の危険因子について検討した。
  • PEG管理の実情と問題点および安全対策  [通常講演]
    辻 直子; 工藤 正俊; 落合 健; 田中 陽一; 森村正嗣; 米田 円; 由谷 逸朗
    第68回日本消化器内視鏡学会総会 2004年10月 福岡 第68回日本消化器内視鏡学会総会
     
    堺病院におけるPEG管理の実情と問題点および安全対策について発表した。
  • サテライトシンポジウム4「Interventional Hepatology: 癌の治療とウイルス駆除」癌根治的法と二次予防  [通常講演]
    工藤 正俊
    第8回日本肝臓学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第8回日本肝臓学会総会（DDW）
  • パネルディスカッション12・特別発言「肝癌の治療における腹腔鏡の役割」  [通常講演]
    工藤 正俊
    第8回日本肝臓学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第8回日本肝臓学会総会（DDW）
  • プレナリーセッション「造影ハーモニック超音波検査による膵管癌治療効果判定の検討」  [通常講演]
    坂本洋城; 工藤 正俊
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • ワークショップ「食道静脈瘤治療におけるEVLの位置付け」  [通常講演]
    松井 繁長; 工藤 正俊; 市川 勉
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • ワークショップ「造影超音波検査による肝腫瘍のpost vascular phaseにおける悪性度評価-SPIO MRI組織学的所見、免疫染色との比較-」  [通常講演]
    井上達夫; 工藤 正俊; 周 佩
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • ワークショップ「EUS下穿刺検体の取扱いの工夫」  [通常講演]
    中岡 良介; 工藤 正俊; 汐見 幹夫
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • ワークショップ・基調講演「肝細胞癌のステージングシステムの確立とその評価」  [通常講演]
    工藤 正俊
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • パネルディスカッション12・特別発言「肝癌の治療における腹腔鏡の役割」  [通常講演]
    工藤 正俊
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • シンポジウム「肝細胞癌に対する経皮的ラジオ波焼灼療法」  [通常講演]
    鄭 浩柄; 工藤 正俊; 川崎俊彦
    第46回日本消化器病学会総会（DDW） 2004年10月 福岡国際会議場, 福岡 第46回日本消化器病学会総会（DDW）
  • 微小浸潤を認めた分枝型IPMTの一例  [通常講演]
    小川 力; 水野 成人; 林 道友; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 橋本 幸彦; 井上 雅智; 太田 善夫; 工藤 正俊
    第73回日本消化器内視鏡学会近畿地方会 2004年09月 大阪 第73回日本消化器内視鏡学会近畿地方会
  • 経皮的アプローチを併用して治療した総胆管結石の一例  [通常講演]
    加藤 玲明; 水野 成人; 林 道友; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 工藤 正俊; 村田 賢; 井上 雅智
    第73回日本消化器内視鏡学会近畿地方会 2004年09月 大阪 第73回日本消化器内視鏡学会近畿地方会
  • 著明な壁肥厚を認めた慢性胆嚢炎の一例  [通常講演]
    豊澤 昌子; 水野 成人; 小川 力; 加藤 玲明; 渡邉 和彦; 南野 達夫; 中山 剛之; 新崎 亘; 井上 雅智; 工藤 正俊
    第81回日本消化器病学会近畿支部例会 2004年09月 京都 第81回日本消化器病学会近畿支部例会
  • 特別講演「肝細胞癌の診断の進歩」  [通常講演]
    工藤 正俊
    第63回日本癌学会 2004年09月 福岡 第63回日本癌学会
  • 特別講演「肝胆道系の画像診断ー最近のトピックスー」  [通常講演]
    工藤 正俊
    第40回日本胆道系学会ランチョンセミナー 2004年09月 筑波 第40回日本胆道系学会ランチョンセミナー
  • 特別講演「超音波血流画像による肝癌の診断と治療」  [通常講演]
    工藤 正俊
    第16回阪神肝胆膵懇話会 2004年09月 兵庫医科大学 第16回阪神肝胆膵懇話会
  • 教育講演「肝細胞癌診療の最近のトピックス」  [通常講演]
    工藤 正俊
    平成16年度日本内科学会生涯教育講演会Aセッション（第3回） 2004年09月 岡山シンフォニーホール, 岡山 平成16年度日本内科学会生涯教育講演会Aセッション（第3回）
  • 特別講演「肝細胞癌診療の最近の進歩」ー造影エコー法を中心にー.  [通常講演]
    工藤 正俊
    第26回兵庫肝炎研究会 2004年09月 ポートピアホテル, 神戸 第26回兵庫肝炎研究会
  • Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete response by radiofrequency ablation for hepatocellular cracinoma  [通常講演]
    工藤 正俊; 小川 力; 南 康範; 鄭 浩柄; 川崎俊彦
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Validation study of the new prognostic staging, the Japan integrated staging score (JIS score) for hepatocellular carcinoma in 3,934 Japanese patients: a multicenter collaborative study  [通常講演]
    工藤 正俊; 鄭 浩柄; 土師 誠二; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • 健常成人に発症したサイトメガロウイルス（CMV）肝炎の一例  [通常講演]
    落合 健; 米田 円; 田中 陽一; 由谷 逸朗; 辻 直子; 工藤 正俊
    日本消化器病学会第81回近畿支部例会 2004年09月 日本消化器病学会第81回近畿支部例会
  • Usefulness and limitations of the endoscopic argon plasma coagulation treatment for gastric antral vascular ectasia  [通常講演]
    松井 繁長; 工藤 正俊; 市川 勉; 石川恵美; 中岡 良介; 北野 雅之; 汐見幹夫
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US  [通常講演]
    福田信宏; 工藤 正俊; 北野 雅之; 坂本洋城; 汐見幹夫; 梅原 泰
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Usefulness of contrast-enhanced harmonic ultrasonography for the detection of small nodules in pancreas  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 末冨洋一郎
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Evaluation of therapeutic response to gemcitabine in pancreatic cancers: value of contrast-enhanced harmonic ultrasonography  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之; 末冨洋一郎; 福田信弘; 井上達夫; 坂口康浩; 梅原 泰; 萩原 智; 市川 勉; 畑中絹世
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Effect of angiotensin-II and angiotensin-II type 1 receptor blocker on rat pancreatic stellate cells  [通常講演]
    福田信弘; 工藤 正俊; 仲谷 達也; 北野 雅之; 坂本洋城; 宗像 浩
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Uptake of Levovist at the post-vascular phase correlates well with CD-68 staining (Kupffer cells), histology, and SPIO-MRI uptake ratio in hepatocellular carcinoma and its premalignant/borderline lesions  [通常講演]
    工藤 正俊; 井上達夫; 福永 豊和; 前川 清
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Comparison of posttreatment prognosis between ablation and resection for early-stage hepatocellular carcinoma: standardized analysis of 737 patients by stratification method based of JIS scoring system  [通常講演]
    工藤 正俊; 鄭 浩柄
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Prognostic staging system for hepatocellular carcinoma: comparison between JIS score, modified JIS score and CLIP score in 4,525 patients  [通常講演]
    工藤 正俊; 鄭 浩柄; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Low-dose, long-term interferon therapy delays clinical recurrence after curative radiofrequency ablation in patients with hepatitis C related hepatocellular carcinoma  [通常講演]
    工藤 正俊; 坂口康浩
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • Effects of angiotensin II on rat pancreatic stellate cells  [通常講演]
    仲谷 達也; 工藤 正俊; 福田信弘; 石川恵美; 南 康範; 鄭 浩柄; 中岡 良介; 福永 豊和; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫; 宗像 浩
    12th United European Gastroenterology Week (UEGW) 2004年09月 Prague 12th United European Gastroenterology Week (UEGW)
  • 経過観察中に胃腺腫を合併した自己免疫性胃炎（Ａ型胃炎）の一例  [通常講演]
    杉立 紗綾; 工藤 正俊; 落合 健; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第73回日本消化器内視鏡学会近畿地方会 2004年09月 大阪 第73回日本消化器内視鏡学会近畿地方会
     
    経過観察中に胃腺腫を合併した自己免疫性胃炎（Ａ型胃炎）について症例報告を行った。
  • 肝癌および早期病変の画像診断. シンポジウム「肝がんの診断・治療の最先端」  [通常講演]
    工藤 正俊
    第63回日本癌学会学術総会 2004年09月 福岡国際会議場, 福岡 第63回日本癌学会学術総会
  • 肝細胞癌局所再発症例に対する造影超音波ガイド下ラジオ波焼灼術-Prospective randomized controlled study-. シンポジウム「肝腫瘍の局所療法に対する造影超音波の役割」  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和
    第10回関西地方会造影剤研究会 2004年09月 ジブラルタ生命千里ホール 第10回関西地方会造影剤研究会
  • ビデオワークショップ「消化管出血に対する内視鏡治療」上部消化管非静脈瘤出血に対する内視鏡的止血術－高周波電気凝固法を中心に－  [通常講演]
    末冨洋一郎; 工藤 正俊; 汐見 幹夫
    第73回日本消化器内視鏡学会近畿地方会 2004年09月 大阪 第73回日本消化器内視鏡学会近畿地方会
  • ビデオワークショップ「胆膵疾患における新しい内視鏡的診断・治療法－手技の実際と工夫」超音波内視鏡ガイド下腹腔神経叢ブロック術の成績とその適応  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之
    第73回日本消化器内視鏡学会近畿地方会 2004年09月 大阪 第73回日本消化器内視鏡学会近畿地方会
  • 特別講演「肝臓の超音波診断up to date」  [通常講演]
    工藤 正俊
    第47回東部医師会医学セミナー 2004年08月 鳥取県医師会館, 鳥取 第47回東部医師会医学セミナー
  • 特別講演「肝臓と消化器を診るー欧州と日本の消化器エコーー最前線ー」  [通常講演]
    工藤 正俊
    2004アロカ技術フェアー 2004年07月 東京 2004アロカ技術フェアー
  • 特別講演「肝細胞癌の診断と治療ーup to date」  [通常講演]
    工藤 正俊
    東京肝臓疾患勉強会 2004年07月 東京 東京肝臓疾患勉強会
  • 特別講演「肝細胞癌局所療法後の造影CT, 造影MRIによる根治の判定について」  [通常講演]
    工藤 正俊
    E0167 大阪地区検討会 2004年07月 岡山 E0167 大阪地区検討会
  • 特別講演「肝がん撲滅のためのインターフェロン療法」C型慢性肝炎～高齢者のインターフェロン治療～  [通常講演]
    工藤 正俊
    学術講演会 2004年07月 大阪 学術講演会
  • Randomized comparison of dose-intense gemcitabine; standard infusion and low dose infusion in patients with pancreatic adenocarcinoma  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之; 末冨洋一郎
    The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin 2004年07月 Sendai The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin
  • Dynamic imaging of pancreatic disease: Value of contrast-enhanced coded phase-inversion harmonic ultrasonography  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 末冨洋一郎; 中岡 良介; 福田信弘; 川崎俊彦
    The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin 2004年07月 Sendai The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin
  • 生存率および再発率からみた画像的根治RFA後の腫瘍マーカーの推移とその変動の意義  [通常講演]
    小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 川崎俊彦
    第40回日本肝臓学会総会 2004年06月 シェラトングランデトーキョーベイホテル, 千葉 第40回日本肝臓学会総会
  • 非定型的大型高分化型肝癌2切除症例の臨床病理学的検討  [通常講演]
    金 守良; 工藤 正俊; 金 啓二; 岡部 純弘
    第40回日本肝臓学会総会 2004年06月 シェラトングランデトーキョーベイホテル, 千葉 第40回日本肝臓学会総会
  • 肝細胞癌症例における門脈腫瘍栓出現のrisk factorについての検討  [通常講演]
    萩原 智; 工藤 正俊; 石川恵美; 小川 力; 坂口康浩; 井上達夫; 南 康範; 鄭 浩柄; 福永 豊和; 川崎俊彦
    第40回日本肝臓学会総会 2004年06月 シェラトングランデトーキョーベイホテル, 千葉 第40回日本肝臓学会総会
  • 肝細胞癌staging systemの有用性に関する検討  [通常講演]
    鄭 浩柄; 工藤 正俊; 小川 力; 井上達夫; 坂口康浩; 萩原 智; 石川恵美; 南 康範; 福永 豊和; 川崎俊彦; 大崎 征夫
    第40回日本肝臓学会総会 2004年06月 シェラトングランデトーキョーベイホテル, 千葉 第40回日本肝臓学会総会
  • 右横隔膜直下に存在するBモードで同定困難な肝細胞癌に対する治療法: 人工胸水造影超音波下RFAの有用性について  [通常講演]
    南 康範; 工藤 正俊; 川崎俊彦
    第40回日本肝臓学会総会 2004年06月 シェラトングランデトーキョーベイホテル, 千葉 第40回日本肝臓学会総会
  • 膵腫瘍を疑った二例  [通常講演]
    小川 力; 水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊; 北口 博士; 中山 剛之; 小川 稔; 村田 賢; 湯川 真生; 井上 雅智
    第26回奈良県肝胆膵研究会 2004年06月 奈良 第26回奈良県肝胆膵研究会
  • 特別講演「消化器領域における造影超音波の現況と次世代造影剤の動向」  [通常講演]
    工藤 正俊
    第5回東海腹部造影エコー研究会 2004年06月 名古屋 第5回東海腹部造影エコー研究会
  • 教育講演「消化器疾患診療の方向性」  [通常講演]
    工藤 正俊
    日本消化器病学会中国支部第6回教育講演会 2004年06月 岡山 日本消化器病学会中国支部第6回教育講演会
  • Invited Lecture "Staging system for assessment of HCC status."  [通常講演]
    工藤 正俊
    The 12th International Symposium of Yonsei Institute of Gastroenterology 2004年06月 Yonsei, Korea The 12th International Symposium of Yonsei Institute of Gastroenterology
  • Invited Lecture "Contrast-enhanced Harmonic Imaging in the Hepatic Tumors with Special Emphasis on the Application to Its Treatment."  [通常講演]
    工藤 正俊
    Euroson Meeting 2004 2004年06月 Zacreb, Croatia Euroson Meeting 2004
  • ワークショップ「肝細胞癌に対する経皮的ラジオ波焼灼術の長期治療成績」  [通常講演]
    鄭 浩柄; 工藤 正俊; 石川恵美; 井上達夫; 坂口康浩; 小川 力; 萩原 智; 南 康範; 福永 豊和; 川崎俊彦; 土師 誠二; 中居 卓也
    第40回日本肝癌研究会 2004年06月 茨城 第40回日本肝癌研究会
  • ランチョンセミナー「肝腫瘍の治療効果判定において造影超音波はMDCT/ MRIより優れるか？造影超音波の治療ガイドへの応用」  [通常講演]
    南 康範; 工藤 正俊
    第40回日本肝癌研究会 2004年06月 茨城 第40回日本肝癌研究会
  • 超音波内視鏡下穿刺が診断に有用であったparagangliomaの1例.  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之; 末冨洋一郎; 中岡 良介; 朝隈 豊; 北井 聡; 汐見幹夫; 前川 清
    第4回超音波内視鏡下穿刺吸引法（EUS-FNA）の臨床応用に関する研究会 2004年05月 京都 第4回超音波内視鏡下穿刺吸引法（EUS-FNA）の臨床応用に関する研究会
  • 汎用パピロトームによる乳頭プレカットの有用性  [通常講演]
    水野 成人; 工藤 正俊; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫
    第67回日本消化器内視鏡学会総会 2004年05月 京都 第67回日本消化器内視鏡学会総会
  • EUS下造影エコー法による膵腫瘍性病変の診断ー現状と将来の展望ー  [通常講演]
    北野 雅之; 工藤 正俊; 坂本洋城
    第67回日本消化器内視鏡学会総会 2004年05月 京都 第67回日本消化器内視鏡学会総会
  • 当院における平成15年度ERCP症例の検討  [通常講演]
    加藤 玲明; 水野 成人; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 工藤 正俊; 中山 剛之; 小川 稔; 村田 賢; 湯川 真生; 井上 雅智
    第41回奈良県消化器内視鏡研究会 2004年05月 奈良 第41回奈良県消化器内視鏡研究会
  • 汎用パピロトームによる乳頭プレカットの有用性  [通常講演]
    水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊; 吉岡 毅; 本庶
    第67回日本消化器内視鏡学会総会 2004年05月 京都 第67回日本消化器内視鏡学会総会
  • 特別講演「ウイルス性肝炎と肝癌の最新治療の現状」  [通常講演]
    工藤 正俊
    平成16年度肝がん撲滅運動市民公開講座（大阪府） 2004年05月 大阪狭山市SAYAKAホール, 大阪 平成16年度肝がん撲滅運動市民公開講座（大阪府）
  • 特別講演「肝細胞癌は克服できる」  [通常講演]
    工藤 正俊
    平成16年度肝がん撲滅運動市民公開講座 2004年05月 岡山県, 津山市 平成16年度肝がん撲滅運動市民公開講座
  • 教育講演「肝細胞癌診療の最近のトピックス」  [通常講演]
    工藤 正俊
    平成16年度日本内科学会障害教育講演会Aセッション（第2回） 2004年05月 東京国際フォーラム, 東京 平成16年度日本内科学会障害教育講演会Aセッション（第2回）
  • 教育講演「肝細胞癌の統合ステージングと局所治療」  [通常講演]
    工藤 正俊
    第 回日本肝胆膵外科学会 2004年05月 大阪 第 回日本肝胆膵外科学会
  • Invited Lecture "Early detection and characterization of HCC."  [通常講演]
    工藤 正俊
    The 2nd MMRF Meeting on Viral Hepatitis in Asia 2004年05月 Tokyo The 2nd MMRF Meeting on Viral Hepatitis in Asia
  • Radiofrequency ablation for liver tumor: can ablated tumor be delineated from the whole ablated area by B-mode sonography and what is the role of contrast-enhanced sonography?  [通常講演]
    井上達夫; 工藤 正俊; 周 佩; 南 康範; 鄭 浩柄; 福永 豊和; 川崎俊彦; 前川 清
    Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2004年05月 Tochigi Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB
  • Percutaneous ultrasound-guided radiofrequency ablation with the artificial pleural effusion for hepatocellular carcinoma in the hepatic dome  [通常講演]
    南 康範; 工藤 正俊; 川崎俊彦; 鄭 浩柄; 小川 力; 井上達夫; 坂口康浩; 坂本洋城; 塩崎 均
    The American Gastroenterological Association and Digestive Disease Week 2004年05月 New Orleans The American Gastroenterological Association and Digestive Disease Week
  • Survival and recurrence rates after complete radiofrequency ablation for hepatocellular carcinoma; value of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction)  [通常講演]
    小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 川崎俊彦
    The American Gastroenterological Association and Digestive Disease Week 2004年05月 New Orleans The American Gastroenterological Association and Digestive Disease Week
  • Chronic respiratory disease is a risk factor for helicobacter pylori clarithromycin resistance  [通常講演]
    辻 直子; 工藤 正俊
    The American Gastroenterological Association and Digestive Disease Week 2004年05月 New Orleans The American Gastroenterological Association and Digestive Disease Week
  • Fine needle aspiration guided by endoscopic ultrasonography. Usefulness of blood flow evaluation and gene analysis.  [通常講演]
    中岡 良介; 工藤 正俊; 北野 雅之
    Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2004年05月 Tochigi Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB
  • 特別講演「肝細胞癌局所療法後の造影CT, 造影MRIによる根治の判定について」  [通常講演]
    工藤 正俊
    E0167 岡山地区検討会 2004年04月 岡山済生会総合病院, 岡山 E0167 岡山地区検討会
  • Low-dose, long-term interferon alfa 2b delays clinical recurrence after curative radiofrequency ablation patients with hepatitis C related hepatocellular carcinoma  [通常講演]
    工藤 正俊; 坂口康浩
    The 39th Annual Meeting of the European Association for the Study of the Liver 2004年04月 Berlin, Germany The 39th Annual Meeting of the European Association for the Study of the Liver
  • JIS scoring system combined with 3 tumor makers (modified JIS score) is an exellent prognostic staging system for hepatocellular carcinoma (HCC): analysis of 4525 patients with HCC  [通常講演]
    工藤 正俊; 鄭 浩柄; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人
    The 39th Annual Meeting of the European Association for the Study of the Liver 2004年04月 Berlin, Germany The 39th Annual Meeting of the European Association for the Study of the Liver
  • 内視鏡的粘膜切除術（EMR）にて治療しえた十二指腸癌の一例  [通常講演]
    川崎正憲; 工藤 正俊; 松井 繁長; 末冨洋一郎; 市川 勉; 坂本洋城; 井上達夫; 中岡 良介; 石川恵美; 鄭 浩柄; 福永 豊和; 北野 雅之; 川崎俊彦; 汐見幹夫
    第72回日本消化器内視鏡学会近畿支部例会 2004年03月 奈良県新公会堂, 奈良 第72回日本消化器内視鏡学会近畿支部例会
  • IIc型胃カルチノイドの一例  [通常講演]
    守口 将典; 工藤 正俊; 由谷 逸朗; 落合 健; 安藤 理奈; 田中 陽一; 森村 正嗣; 米田 円; 辻 直子
    第72回日本消化器内視鏡学会近畿支部例会 2004年03月 奈良県新公会堂, 奈良 第72回日本消化器内視鏡学会近畿支部例会
  • 診断に苦慮した大腸潰瘍の一例  [通常講演]
    豊澤 昌子; 工藤 正俊; 加藤 玲明; 渡邉 和彦; 水野 成人; 南 康範
    第72回日本消化器内視鏡学会近畿支部例会 2004年03月 奈良県新公会堂, 奈良 第72回日本消化器内視鏡学会近畿支部例会
  • パネルディスカッション「緊急内視鏡検査における問題点とその対策」 内視鏡的止血術の成績向上のための工夫.  [通常講演]
    末冨洋一郎; 工藤 正俊; 汐見幹夫
    第72回日本消化器内視鏡学会近畿支部例会 2004年03月 奈良県新公会堂, 奈良 第72回日本消化器内視鏡学会近畿支部例会
  • パネルディスカッション「肝細胞癌に対するラジオ波焼灼術後のインターフェロン少量・長期・間歇投与の有用性」  [通常講演]
    坂口康浩; 工藤 正俊
    第25回大阪肝炎ミーティング学術講演 2004年03月 全日空ホテル大阪, 大阪 第25回大阪肝炎ミーティング学術講演
  • 特別講演「肝腫瘍に対する造影ハーモニック法－治療への応用も含めて－」  [通常講演]
    工藤 正俊
    第13回肝胆膵疾患治療フォーラム 2004年03月 神戸 第13回肝胆膵疾患治療フォーラム
  • 特別講演「肝細胞癌の診断と治療－最近の話題－」  [通常講演]
    工藤 正俊
    第6回北摂肝臓病研究会 2004年03月 阪急電鉄本社1階「エコルテホール」, 大阪 第6回北摂肝臓病研究会
  • 特別講演「消化器領域における造影エコー法の現況」  [通常講演]
    工藤 正俊
    関西造影エコー研究会 2004年03月 大阪 関西造影エコー研究会
  • シンポジウム造影超音波検査における肝腫瘍のpost-vascular-phaseにおける悪性度評価組織学的所見との比較検討  [通常講演]
    井上達夫; 工藤 正俊; 周 佩; 坂口康浩; 萩原 智; 南 康範; 鄭 浩柄; 福永 豊和; 川崎俊彦
    第9回関西超音波造影剤研究会 2004年03月 大阪 第9回関西超音波造影剤研究会
  • パネルディスカッション「緊急内視鏡検査における問題点とその対策」 内視鏡的止血術の成績向上のための工夫  [通常講演]
    末冨洋一郎; 工藤 正俊; 汐見 幹夫
    第72回日本消化器内視鏡学会近畿支部例会 2004年03月 奈良県新公会堂, 奈良 第72回日本消化器内視鏡学会近畿支部例会
  • パネルディスカッション「肝細胞癌に対するラジオ波焼灼術後のインターフェロン少量・長期・間歇投与の有用性」  [通常講演]
    坂口康浩; 工藤 正俊
    第25回大阪肝炎ミーティング学術講演 2004年03月 全日空ホテル大阪, 大阪 第25回大阪肝炎ミーティング学術講演
     
    【目的】肝細胞癌（以下HCC）に対してラジオ波焼灼術後の根治例に対してインターフェロンの長期少量投与を行うことが再発を抑制するかについて比較検討を行った。 【方法】1999年6月より2003年7月30日まで局所治療の目的で入院となった3cm、3結節以内のHCCの症例は130例であった。この内、患者の同意を得ることができた24例をインターフェロン投与群とし、残りの106例を非投与群とした。インターフェロン投与群にはIFN-α2b 300万単位を週二回の割合で投与（筋肉注射）した。各群の局所再発または他部位再発に関してKaplan-Meier法（Log-rank検定）によって比較検討した。【成績】両群の患者背景を年齢、性別、ウイルスマーカーで比較したところ、有意差はなかった（投与群：男性17例、女性7例、年齢は56歳～72歳、中央値69歳 HCV陽性23例、HBV陽性1例 非投与群：男性76例、女性30例、年齢は47歳～79歳、中央値67歳、HCV陽性102例、HBV陽性4例）。非投与群の他部位再発率は1年9％、2年22％、3
  • ヘリコバクター・ピロリ感染と胃炎（シドニー分類とMST）  [通常講演]
    水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊
    第4回奈良県ヘリコバクター・ピロリ研究会 2004年02月 奈良 第4回奈良県ヘリコバクター・ピロリ研究会
  • 抗生剤感受性試験導入後のヘリコバクター・ピロリ除菌状況  [通常講演]
    水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊
    第4回奈良県ヘリコバクター・ピロリ研究会 2004年02月 奈良 第4回奈良県ヘリコバクター・ピロリ研究会
  • 多発肝転移をきたしカルチノイド症候群を呈した胆嚢原発と考えられる神経内分泌細胞癌の一例  [通常講演]
    田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第14回日本消化器病学会近畿支部例会 2004年02月 大阪国際会議場, 大阪 第14回日本消化器病学会近畿支部例会
  • 成人に発症した腸重積の一例  [通常講演]
    加藤 玲明; 工藤 正俊; 豊澤 昌子; 渡邉 和彦; 水野 成人; 南野 達夫
    第80回日本消化器病学会近畿支部例会 2004年02月 大阪国際会議場, 大阪 第80回日本消化器病学会近畿支部例会
  • 診断に苦慮した肝嚢胞性腫瘍の1例  [通常講演]
    田北雅弘; 工藤 正俊; 福永 豊和; 永島美樹; 石川恵美; 南 康範; 鄭 浩柄; 中岡 良介; 仲谷 達也; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫; 前川 清
    日本超音波医学会第27回関西地方会 2004年02月 大阪 日本超音波医学会第27回関西地方会
  • 小腸平滑筋肉腫肝転移の1例  [通常講演]
    辰巳千栄; 工藤 正俊; 福永 豊和; 田北雅弘; 永島美樹; 石川恵美; 南 康範; 鄭 浩柄; 中岡 良介; 仲谷 達也; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫; 前川 清
    日本超音波医学会第27回関西地方会 2004年02月 大阪 日本超音波医学会第27回関西地方会
  • 造影超音波検査が膵癌の胆管ステント内腫瘍進展の診断に有用であった1例  [通常講演]
    坂本康範; 工藤 正俊; 坂本洋城; 北野 雅之; 萩原 智; 末冨洋一郎; 汐見幹夫; 前川 清
    日本超音波医学会第27回関西地方会 2004年02月 大阪 日本超音波医学会第27回関西地方会
  • 乏血性膵腫瘍の1例  [通常講演]
    坂本洋城; 工藤 正俊; 北野 雅之; 萩原 智; 末冨洋一郎; 汐見幹夫; 前川 清
    日本超音波医学会第27回関西地方会 2004年02月 大阪 日本超音波医学会第27回関西地方会
  • 腹部超音波造影診断ー現状と次世代超音波造影剤の動向ー  [通常講演]
    工藤 正俊
    日本超音波医学会第27回関西地方会, ランチョンセミナー 2004年02月 大阪 日本超音波医学会第27回関西地方会, ランチョンセミナー
  • 特別講演「肝癌の診断」  [通常講演]
    工藤 正俊
    第14回日本消化器病学会近畿支部例会教育講演会 2004年02月 大阪国際会議場, 大阪 第14回日本消化器病学会近畿支部例会教育講演会
  • ランチョンセミナー「消化器領域における造影エコー法の現況」  [通常講演]
    工藤 正俊
    第27回日本超音波医学会関西地方会 2004年02月 大阪国際会議場, 大阪 第27回日本超音波医学会関西地方会
  • 教育講演「肝細胞癌診療の最近のトピックス」  [通常講演]
    工藤 正俊
    平成16年度日本内科学会障害教育講演会Aセッション（第1回） 2004年02月 大阪国際会議場, 大阪 平成16年度日本内科学会障害教育講演会Aセッション（第1回）
  • 特別講演「肝癌診療の最近の話題」  [通常講演]
    工藤 正俊
    第11回肝細胞癌治療研究会（藤原研二先生） 2004年02月 川越プリンスホテル, 埼玉 第11回肝細胞癌治療研究会（藤原研二先生）
     
    特別講演「肝癌診療の最近の話題」
  • Evaluation of microcirculation in dog gastrointestinal tract and pancreas by contrast-enhanced harmonic sonography with EUS probe.  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 坂本 洋城; 末冨 洋一郎; 南 康範; 中岡 良介; 仲谷 達也
    4th International Symposium on Endoscopic Ultrasonography 2004年 Tokyo, Japan 4th International Symposium on Endoscopic Ultrasonography
  • Invited Lecture "Advances in US for pancreatic diseases"  [通常講演]
    工藤 正俊
    2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI) 2004年01月 2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI)
  • Invited Lecture "Contrast-enhanced US of the abdomen"  [通常講演]
    工藤 正俊
    2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI) 2004年01月 2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI)
  • Invited Lecture "Contrast enhanced ultrasound in hepatobiliary and pancreatic tumors"  [通常講演]
    工藤 正俊
    Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB 2004年01月 Quezon, Philippine Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB
  • Invited Lecture "Ultrasound for bowel diseases"  [通常講演]
    工藤 正俊
    Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB 2004年01月 Quezon, Philippine Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB
  • Invited Lecture "Ultrasound for focal liver masses"  [通常講演]
    工藤 正俊
    Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB 2004年01月 Quezon, Philippine Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB
  • Invited Lecture "Ultrasound for pancreatic diseases"  [通常講演]
    工藤 正俊
    Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB 2004年01月 Quezon, Philippine Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB
  • Invited Lecture "Ultrasound diagnosis of acute abdomen"  [通常講演]
    工藤 正俊
    Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB 2004年01月 Quezon, Philippine Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB
  • Invited Lecture "Ultrasound for bowel diseases"  [通常講演]
    工藤 正俊
    Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2004年01月 Karachi, Pakistan Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • Invited Lecture "Role of ultrasound in portal hypertension"  [通常講演]
    工藤 正俊
    Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2004年01月 Karachi, Pakistan Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • Invited Lecture "Focal Masses in the liver"  [通常講演]
    工藤 正俊
    Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) 2004年01月 Karachi, Pakistan Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)
  • Invited Lecture "Low-dose, long-term interferon alpha-2b therapy after curative treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C related hepatocellular carcinoma"  [通常講演]
    工藤 正俊
    Prevention of Occurrence and Recurrence in Human Hepatocarcinogenesis, Japan-Korea Liver Symposium 2004年01月 Kobe Prevention of Occurrence and Recurrence in Human Hepatocarcinogenesis, Japan-Korea Liver Symposium
  • 造影超音波法を中心とした解析. 教育シンポジウム「肝細胞癌ー発癌・血管新生と血流イメージング」  [通常講演]
    福永 豊和; 工藤 正俊
    第10回肝血流動態イメージ研究会 2004年01月 東京 第10回肝血流動態イメージ研究会
  • 特別講演「超音波所見とJIS scoreから見た肝細胞癌局所療法の適応」  [通常講演]
    工藤 正俊
    第22回Hokkaido DD (Digestive Disease) Club 2003年12月 北海道厚生年金会館, 札幌 第22回Hokkaido DD (Digestive Disease) Club
  • 大腸潰瘍の一例  [通常講演]
    豊澤 昌子; 水野 成人; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊
    第25回奈良県胃腸研究会 2003年11月 奈良 第25回奈良県胃腸研究会
  • 特別講演「肝細胞癌の診療と治療ー最近のトピックスー」  [通常講演]
    工藤 正俊
    第9回上町台消化器セミナー 2003年11月 都ホテル大阪, 大阪 第9回上町台消化器セミナー
  • 特別講演「肝腫瘍の造影ハーモニックイメージングー治療への応用も含めてー」  [通常講演]
    工藤 正俊
    第2回山口県総合画像診断研究会 2003年11月 宇部全日空ホテル, 山口 第2回山口県総合画像診断研究会
  • 特別講演「肝腫瘍の造影ハーモニックイメージングー治療への応用も含めてー」  [通常講演]
    工藤 正俊
    第9回栃木県超音波懇話会 2003年11月 ホテル東日本宇都宮, 栃木 第9回栃木県超音波懇話会
  • 特別講演「肝疾患の早期発見と治療」  [通常講演]
    工藤 正俊
    近畿大学薬学部・薬友会平成15年度第3回生涯教育研修会 2003年11月 近畿大学本部11月ホール, 東大阪 近畿大学薬学部・薬友会平成15年度第3回生涯教育研修会
  • 肝脾腫を呈し，病理組織学的にgranulomaの形成が認められた一例  [通常講演]
    米田 円; 工藤 正俊; 安藤 理奈; 落合 健; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子
    第３７回大阪肝穿刺生検治療 2003年11月 大阪 第３７回大阪肝穿刺生検治療
  • Effect of mucosa-fibrosing therapy with argon plasma coagulation on esophageal varices  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介; 北野 雅之; 汐見幹夫; 川崎俊彦
    11th United European Gastroenterology Weeek (UEGW) 2003年11月 Madrid, Spain 11th United European Gastroenterology Weeek (UEGW)
  • Stratification ability of the new prognostic staging system, Japan Integrated Staging score (JIS score) for hepatocellular carcinoma: comprison with CLIP score  [通常講演]
    工藤 正俊; 鄭 浩柄; 土師 誠二; 南 康範; 小川 力; 福永 豊和; 北野 雅之; 大崎往夫
    11th United European Gastroenterology Weeek (UEGW) 2003年11月 Madrid, Spain 11th United European Gastroenterology Weeek (UEGW)
  • Evaluation of microvasculature in dog pancreas and gastrointestinal tract by contrast-enhanced harmonic sonography: a novel technology available for endosonography  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 南 康範; 中岡 良介; 伊藤安啓; 宮; 堀川義人; 藤本
    11th United European Gastroenterology Weeek (UEGW) 2003年11月 Madrid, Spain 11th United European Gastroenterology Weeek (UEGW)
  • Validation study of the new prognostic staging system, the Japan Integrated Staging score (JIS score) for hepatocellular carcinoma in 3,934 Japanese patients: a multicenter collaborative study  [通常講演]
    工藤 正俊; 鄭 浩柄; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人
    11th United European Gastroenterology Weeek (UEGW) 2003年11月 Madrid, Spain 11th United European Gastroenterology Weeek (UEGW)
  • 十二指腸静脈瘤の診断と治療. ワークショップ「食道胃以外の静脈瘤の診断と治療」  [通常講演]
    松井 繁長; 工藤 正俊
    第10回日本門脈圧亢進症学会総会 2003年11月 横浜 第10回日本門脈圧亢進症学会総会
  • 超音波Color Doppler Imaging (CDI) による胃癌原発巣内の血流評価  [通常講演]
    第１４６回大阪腹部超音波研究会 2003年11月 大阪 第１４６回大阪腹部超音波研究会
     
    胃癌など腺癌では、血流は少ないと考えられてきた。今回、進行胃癌64例の原発巣内の血流を対外式超音波にて観察し、病理学的所見とも対比した結果、血流の増加が認められた。
  • 胆道出血を契機に診断した胆嚢癌の1例  [通常講演]
    加藤 玲明; 水野 成人; 澤本 学; 渡邉 和彦; 南野 達夫; 井上 雅智; 工藤 正俊
    第71回日本消化器内視鏡学会近畿地方会 2003年10月 京都 第71回日本消化器内視鏡学会近畿地方会
  • インターネットによる内視鏡情報配信システム  [通常講演]
    水野 成人; 南野 達夫; 工藤 正俊; 大野 崇; 辻本; 隆; 渡邊; 元樹; 上尾; 太郎; 吉岡; 毅; 吉本; 貴宜; 本庶; 元; 光本; 保英; 森; 敬弘; 平山; 哲也; 鹿田; 潮; 富岡; 秀夫; 伊藤; 正; 清水; 誠治; 木本 邦彦
    第66回日本消化器内視鏡学会総会 2003年10月 大阪 第66回日本消化器内視鏡学会総会
  • ランチョンセミナー「消化器領域における造影超音波診断の新たな展開」  [通常講演]
    工藤 正俊
    第7回日本肝臓学会大会 2003年10月 大阪 第7回日本肝臓学会大会
  • 特別講演「肝細胞癌の診断と治療: 最近のトピックス」  [通常講演]
    工藤 正俊
    第5回葵肝臓研究会 2003年10月 京都 第5回葵肝臓研究会
  • Ｈ.pylori菌のｸﾗﾘｽﾛﾏｲｼﾝ耐性に関する患者背景の検討  [通常講演]
    田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 飯森 真幸; 工藤 正俊
    第11回日本消化器関連学会週間 2003年10月 大阪 第11回日本消化器関連学会週間
     
    慢性呼吸器疾患や慢性耳鼻科疾患の合併はＨ.pylori菌のｸﾗﾘｽﾛﾏｲｼﾝ耐性の危険因子であることを報告した。
  • 真性多血症に合併したサイトメガロウイルス腸炎の一例  [通常講演]
    米田 円; 工藤 正俊; 田中 陽一; 森村 正嗣; 由谷 逸朗; 辻 直子
    第19回大腸内視鏡検査法研究会 2003年10月 第19回大腸内視鏡検査法研究会
  • アフタ型クローン病の１例  [通常講演]
    米田 円; 工藤 正俊; 安藤 理奈; 落合 健; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子
    第21回IBD Club Jr. 2003年10月 東京 第21回IBD Club Jr.
  • 被検者の立場からみた上・下部消化管内視鏡検査におけるsedationの必要性  [通常講演]
    米田 円; 工藤 正俊; 安藤 理奈; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子
    第６６回日本消化器内視鏡学会総会 2003年10月 大阪 第６６回日本消化器内視鏡学会総会
  • 食道多発ヨード不染帯の臨床病理学的検討  [通常講演]
    辻 直子; 工藤 正俊; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 石黒 信吾
    第45回日本消化器病学大会 2003年10月 大阪 第45回日本消化器病学大会
  • Special Lecture "Present status of contrast-enahnced ultrasonography in the hepatobiliary and pancreatic diseases"  [通常講演]
    工藤 正俊
    5th International Symposium on Ultrasound Contrast Imaging 2003年10月 Kyoto 5th International Symposium on Ultrasound Contrast Imaging
  • Special Lecture "Characteristics of AFP-L3 % positive HCC in relation to HCC staging"  [通常講演]
    工藤 正俊
    Evening Session, Wako Meeting, 54th AASLD 2003年10月 Sheraton Hotel, Boston Evening Session, Wako Meeting, 54th AASLD
  • Invited Lecture "Prevention of Recumbence after Curative Treatment by RFA for Hepatocellular Carcinoma "  [通常講演]
    工藤 正俊
    2003年10月 University of Miami, Florida
  • Invited Lecture "New Prognostic Staging System for Hepatocellular Carcinoma, JIS Score"  [通常講演]
    工藤 正俊
    2003年10月 University of Miami, Florida
  • アルコール多飲者に発生したヘルペス食道炎の1例  [通常講演]
    落合 健; 安藤 理奈; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊
    第71回日本消化器内視鏡学会近畿地方会 2003年10月 第71回日本消化器内視鏡学会近畿地方会
  • Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete radiofrequency ablation for hepatocellular carcinoma: analysis of 186 patients  [通常講演]
    小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 福永 豊和; 北野 雅之; 川崎俊彦; 汐見幹夫
    The American Association for the Study of Liver Diseases (AASLD) 2003年10月 Boston The American Association for the Study of Liver Diseases (AASLD)
  • Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: analysis of 3,891 ablation in 2,614 patients  [通常講演]
    春日井博志; 工藤 正俊; 大崎往夫; 岡 博子; 関 寿人
    The American Association for the Study of Liver Diseases (AASLD) 2003年10月 Boston The American Association for the Study of Liver Diseases (AASLD)
  • A novel treatment technique for symptomatic huge liver cyst: intracystic injection therapy of monoethanolamine oleate in 12 cases with 15 liver cysts  [通常講演]
    中岡 良介; 工藤 正俊; 石川恵美; 松井 繁長; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 北野 雅之; 川崎俊彦; 汐見幹夫
    The American Association for the Study of Liver Diseases (AASLD) 2003年10月 Boston The American Association for the Study of Liver Diseases (AASLD)
  • Comparison of posttreatment prognosis between ablation and resection for early-stage hepatocellular carcinoma: standardized analysis of 737 patients by stratification method based on JIS scoring system  [通常講演]
    工藤 正俊; 鄭 浩柄
    The American Association for the Study of Liver Diseases (AASLD) 2003年10月 Boston The American Association for the Study of Liver Diseases (AASLD)
  • Validation study of the new prognostic staging system, the Japan integrated staging score (JIS score) for hepatocellular carcinoma in 3,934 Japanese patients: a multicenter collaborative study  [通常講演]
    工藤 正俊; 鄭 浩柄; 土師 誠二; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人
    The American Association for the Study of Liver Diseases (AASLD) 2003年10月 Boston The American Association for the Study of Liver Diseases (AASLD)
  • Stratification abiliaty of the new prognostic staging system, Japan integrated staging score (JIS score) for hepatocellular carcinoma: comparison with CLIP score  [通常講演]
    鄭 浩柄; 工藤 正俊; 土師 誠二; 南 康範; 小川 力; 福永 豊和; 北野 雅之; 川崎俊彦; 大崎往夫
    The American Association for the Study of Liver Diseases (AASLD) 2003年10月 Boston The American Association for the Study of Liver Diseases (AASLD)
  • 超音波内視鏡ガイド下腹腔神経叢ブロックにおける穿刺部位確認の工夫. シンポジウム「超音波内視鏡の高度先進技術ー消化器腫瘍の診断と治療の新しい到達点ー」  [通常講演]
    北野 雅之; 工藤 正俊
    第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会（DDW） 2003年10月 大阪 第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会（DDW）
  • GISTに対する超音波内視鏡下診断の有用性について. シンポジウム「超音波内視鏡の高度先進技術ー消化器腫瘍の診断と治療の新しい到達点ー」  [通常講演]
    中岡 良介; 工藤 正俊; 北野 雅之
    第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会（DDW） 2003年10月 大阪 第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会（DDW）
  • GISTの基礎と臨床. ワークショップ7「Gastrointestinal stromal tumor (GIST)における造影ハーモニックイメージング法の意義および組織学的遺伝子学的診断との比較」  [通常講演]
    福田信宏; 工藤 正俊; 北野 雅之
    第45回日本消化器病学会大会 2003年10月 大阪 第45回日本消化器病学会大会
  • 消化器疾患における造影エコー法の位置づけ. ワークショップ6「高分解能Bモード造影ハーモニック法による肝腫瘍の鑑別診断：肝細胞癌の分化度診断の試み」  [通常講演]
    川崎俊彦; 工藤 正俊; 鄭 浩柄
    第45回日本消化器病学会大会, 第7回日本肝臓学会大会（DDW） 2003年10月 大阪 第45回日本消化器病学会大会, 第7回日本肝臓学会大会（DDW）
  • 肝癌に対する局所療法の長期予後－肝切除との比較－. ワークショップ1「統合Staging systemを用いた肝細胞癌に対する局所療法の長期予後」  [通常講演]
    鄭 浩柄; 工藤 正俊; 大崎往夫
    第45回日本消化器病学会大会, 第7回日本肝臓学会大会（DDW） 2003年10月 大阪 第45回日本消化器病学会大会, 第7回日本肝臓学会大会（DDW）
  • 膵癌性疼痛に対する超音波内視鏡ガイド下腹腔神経叢ブロックの有用性. シンポジウム「消化器病における内視鏡診療の最前線」  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介
    第71回日本消化器内視鏡学会近畿地方 2003年10月 京都 第71回日本消化器内視鏡学会近畿地方
  • ビルロートⅡ法再建後の輸入脚に発生したGISTの１例  [通常講演]
    渡邉 和彦; 水野 成人; 加藤 玲明; 南野 達夫; 小川 稔; 井上 雅智; 太田 善夫; 工藤 正俊
    第79回日本消化器病学会近畿支部例会 2003年09月 奈良 第79回日本消化器病学会近畿支部例会
  • 膵管口からの乳頭プレカットの有用性  [通常講演]
    水野 成人; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊; 吉岡 毅; 木本
    第39回日本胆道学会学術集会 2003年09月 金沢 第39回日本胆道学会学術集会
  • 特別講演「腹部超音波造影診断－現状と次世代超音波造影剤の動向－」  [通常講演]
    工藤 正俊
    第8回関西超音波造影剤研究会 2003年09月 ジブラルタ生命千里ホール, 大阪 第8回関西超音波造影剤研究会
  • 教育講演「消化器領域における造影エコー法：最近の進歩」  [通常講演]
    工藤 正俊
    日本超音波医学会第39回中国治療会第2回中国地方会講習会 2003年09月 ウェルシティ島根, 島根 日本超音波医学会第39回中国治療会第2回中国地方会講習会
  • 特別講演「新しい肝細胞癌の臨床：ステージングシステム」  [通常講演]
    工藤 正俊
    第8回神戸肝臓疾患勉強会 2003年09月 神戸 第8回神戸肝臓疾患勉強会
  • 特発性血小板減少性紫斑病を合併したＢ型肝硬変の一例  [通常講演]
    田中 陽一; 落合 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊
    第79回日本消化器病学会近畿支部例会 2003年09月 奈良 第79回日本消化器病学会近畿支部例会
     
    ステロイドとラミブジンの併用療法でＢ型肝炎の急性増悪を緩解させることが出来た特発性血小板減少性紫斑病合併Ｂ型肝硬変の一例について報告した。
  • 早期肝細胞癌に対する局所療法と肝切除との比較：JISスコアに基づいた層別法による737症例の解析  [通常講演]
    工藤 正俊; 鄭 浩柄
    Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD) 2003年09月 Atlanta Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)
  • 日本における肝細胞癌3934症例に対するJISスコアの成績：多施設共同研究  [通常講演]
    工藤 正俊; 鄭 浩柄
    Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD) 2003年09月 Atlanta Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)
  • 肝細胞癌に対する新しい診断ステージングシステム、JISスコアの層別化能：CLIPスコアとの比較  [通常講演]
    工藤 正俊; 鄭 浩柄
    Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD) 2003年09月 Atlanta Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)
  • 肝細胞癌の外科的病理学と分子生物学  [通常講演]
    林 祥剛; 工藤 正俊
    8th Asia Pacific Association of Societies of Pathologists Congress-2003 2003年09月 Bali 8th Asia Pacific Association of Societies of Pathologists Congress-2003
  • 食道静脈瘤に対するアルゴンプラズマ凝固法による地固め療法の有用性. シンポジウム「エビデンスに基づいたアルゴンプラズマ凝固療法の適応と治療効果」  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介
    第66回日本消化器内視鏡学会総会 2003年09月 大阪 第66回日本消化器内視鏡学会総会
  • HCCに対するRFA治療成績と基礎的検討に基づいた成績向上の試み. シンポジウム「消化器病治療の新たな展開ー基礎から臨床へー」  [通常講演]
    鄭 浩柄; 工藤 正俊; 南 康範
    第79回日本消化器病学会近畿支部例会 2003年09月 奈良 第79回日本消化器病学会近畿支部例会
  • 肝細胞癌に対するラジオ波焼灼術後のインターフェロン長期少量投与の有用性について. シンポジウム「肝炎治療の最前線－肝硬変・肝癌はなくせるか？－」  [通常講演]
    坂口康浩; 工藤 正俊; 川崎俊彦
    第79回日本消化器病学会近畿支部例 2003年09月 奈良 第79回日本消化器病学会近畿支部例
  • 特別講演「肝癌は克服できる－最新情報－」  [通常講演]
    工藤 正俊
    平成15年度日本肝臓学会主催. 肝がん撲滅運動市民公開講座 2003年08月 SAYAKAホール, 大阪狭山市 平成15年度日本肝臓学会主催. 肝がん撲滅運動市民公開講座
  • 特別講演「肝細胞癌の診断と治療ー最近のトピックスー」  [通常講演]
    工藤 正俊
    第3回三重肝癌研究会 2003年08月 ホテルグリーンパーク津, 三重 第3回三重肝癌研究会
  • 特別講演「肝癌治療標準化のためのclinical staging system－その重要性と新しいstaging system (JIS score)の意義－」  [通常講演]
    工藤 正俊
    第8回京都外科侵襲研究会 2003年08月 京都センチュリーホテル, 京都 第8回京都外科侵襲研究会
  • 胆道出血を契機に診断した胆嚢癌の一例  [通常講演]
    水野 成人; 加藤 玲明; 渡邉 和彦; 南野 達夫; 井上 雅智; 工藤 正俊
    第39回奈良県消化器内視鏡研究会 2003年07月 奈良 第39回奈良県消化器内視鏡研究会
  • 特別講演「肝疾患診療の最近の話題」  [通常講演]
    工藤 正俊
    第16回泉南消化器病研究会 2003年07月 貝塚 第16回泉南消化器病研究会
  • 特別講演「造影USの最先端」  [通常講演]
    工藤 正俊
    第11回日本がん検診・診断学会 2003年07月 日本大学会館, 東京 第11回日本がん検診・診断学会
  • 特別講演「肝細胞癌の診断と治療：最近の進歩」  [通常講演]
    工藤 正俊
    第25回奈良県肝・胆・膵研究会 2003年06月 奈良市医師会館 第25回奈良県肝・胆・膵研究会
  • 特別講演「肝炎に対するインターフェロン治療と肝がんのラジオ波治療」  [通常講演]
    工藤 正俊
    2003年06月 富田林市, 富田林内科医会
  • 講演「肝がんで命を落とさないコツ」  [通常講演]
    工藤 正俊
    日本肝臓学会主催 市民公開講座 2003年06月 堺市民会館大ホール 日本肝臓学会主催 市民公開講座
  • Radiofrequency ablation therapy under harmonic imaging guidance for the recurring cancer after local therapy for HCC: a randomized controlled study with RFA under B-mode guidance  [通常講演]
    工藤 正俊; 南 康範
    10th Congress of the World Federation for ultrasound in Medicine and Biology (WFUMB) 2003年06月 Montreal, Canada 10th Congress of the World Federation for ultrasound in Medicine and Biology (WFUMB)
  • HCCに対するRFA併用療法としてのLpTAEの有用性に関する検討. ワークショップ1 「肝細胞癌に対する手術療法、局所ablation療法の治療成績（生存率）ーTAEはどのような寄与をしているのかー」  [通常講演]
    鄭 浩柄; 工藤 正俊; 坂本洋城; 井上達夫; 小川 力; 梅原 泰; 坂口康浩; 福田信宏; 末冨洋一郎; 豊沢昌子; 石川恵美; 南 康範; 福永 豊和; 川崎俊彦
    第39回日本肝癌研究会 2003年06月 金沢 第39回日本肝癌研究会
  • 血流動態より境界病変と考えられる硬変肝内微小結節性病変の予後. シンポジウム「肝硬変に伴う肝細胞性結節性病変の悪性度診断と生物学的予後」  [通常講演]
    福永 豊和; 工藤 正俊; 岡部純弘
    第39回日本肝癌研究会 2003年06月 金沢 第39回日本肝癌研究会
  • 特別企画「示唆に富む肝結節病変の画像と病理」コメンテイター  [通常講演]
    工藤 正俊
    第39回日本肝臓学会総会 2003年05月 福岡 第39回日本肝臓学会総会
  • 肝細胞癌の治療法の客観評価とその標準化ーJIS scoreとAFP-L3分画を用いてー. ランチョンセミナー「我が国のNASHを考えるー疾患概念と治療を中心にー」  [通常講演]
    工藤 正俊
    第39回日本肝臓学会総会 2003年05月 福岡 第39回日本肝臓学会総会
  • ランチョンセミナー「肝細胞癌の血流動態はどこまでわかったか？」  [通常講演]
    工藤 正俊
    第39回日本肝臓学会総会 2003年05月 福岡 第39回日本肝臓学会総会
  • Levovistおよび次世代造影エコー法の現状と展望. ランチョンセミナー「肝腫瘍の診断と治療の最先端ー肝血流評価とコントラストハーモニックエコー」  [通常講演]
    工藤 正俊
    日本超音波医学会第76回学術集会 2003年05月 札幌 日本超音波医学会第76回学術集会
  • Differential diagnosis of pancreatic diseases by contrast-enhanced power Doppler endosonography  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介; 末冨洋一郎; 坂本洋城; 福田信宏; 松井 繁長; 汐見幹夫; 前川 清
    DDW (AASLD) 2003年05月 Orland DDW (AASLD)
  • Radiofrequency ablation therapy for hepatocellular carcinoma located at subphrenic region: value of artificial pleural effusion combined with contrast-harmonic imaging  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 小川 力; 福田信宏; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 末冨洋一郎; 川崎俊彦; 汐見幹夫
    DDW (AASLD) 2003年05月 Orland DDW (AASLD)
  • Radiofrequency ablation therapy under contrast-enhanced harmonic imaging guidance for recurrence after local ablation therapy for hepatocellular carcinoma: a randomized controlled study  [通常講演]
    工藤 正俊; 南 康範; 鄭 浩柄; 小川 力; 福田信宏; 末冨洋一郎; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    DDW (AASLD) 2003年05月 Orland DDW (AASLD)
  • Usefulness of mucosa-fibrosing therapy with argon plasma coagulation for esophageal varices  [通常講演]
    松井 繁長; 工藤 正俊; 北野 雅之; 中岡 良介; 汐見幹夫
    DDW (AASLD) 2003年05月 Orland DDW (AASLD)
  • Esophagus with multiple small lugol's iodine-unstained lesions has high likelihood of developing multicentric esophageal squamous cell carcinoma  [通常講演]
    辻 直子; 工藤 正俊
    DDW (AASLD） 2003年05月 Orland DDW (AASLD）
  • Usefulness of contrast-enhanced coded phase-inversion harmonic ultrasonography for differential diagnosis of pancreatic diseases and evaluation of chemotherapy  [通常講演]
    北野 雅之; 工藤 正俊; 末冨洋一郎; 前川 清; 坂本洋城; 中岡 良介; 川崎俊彦
    DDW (AASLD) 2003年05月 Orland DDW (AASLD)
  • Evaluation of pancreatic microcirculation by contrast-enhanced endosonography in dogs  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 南 康範; 中岡 良介; 宮本 清; 藤本 浩
    DDW (AASLD 2003年05月 Orland DDW (AASLD
  • Validation and limitation of CLIP scoring system in 722 Japanses patients with hepatocellular carcinoma and a proposal of better prognostic staging system, Japan Integrated Staging Score (JIS score)  [通常講演]
    工藤 正俊; 鄭 浩柄; 南 康範; 小川 力; 福田信宏; 末冨洋一郎; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    DDW (AASLD) 2003年05月 Orland DDW (AASLD)
  • Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete response by radiofrequency ablation for hepatocellular carcinoma  [通常講演]
    小川 力; 工藤 正俊; 鄭 浩柄; 南 康範; 福田信宏; 末冨洋一郎; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    DDW (AASLD) (Topic Forum-oral) 2003年05月 Orland DDW (AASLD) (Topic Forum-oral)
  • 統合staging systemによる肝細胞癌の治療法の選択: CLIP scoreとJIS scoreの比較. パネルディスカッション「肝細胞癌の診断・治療の今後の展開」  [通常講演]
    鄭 浩柄; 工藤 正俊
    第39回日本肝臓学会総会 2003年05月 福岡 第39回日本肝臓学会総会
  • Levovistおよび次世代造影エコー法の現状と展望. ランチョンセミナー「肝腫瘍の診断と治療の最先端ー肝血流評価とコントラストハーモニックエコー」  [通常講演]
    工藤 正俊
    日本超音波医学会第76回学術集会 2003年05月 札幌 日本超音波医学会第76回学術集会
  • 肝細胞癌局所再発に対する造影超音波ガイド下ラジオ波焼灼術. シンポジウム「肝癌診療における超音波の新潮流」  [通常講演]
    南 康範; 工藤 正俊
    日本超音波学会 第76回学術集会 2003年05月 札幌 日本超音波学会 第76回学術集会
  • 超音波Color Doppler Imaging (CDI) による胃癌原発巣内の血流評価  [通常講演]
    日本超音波医学会第７６回学術集会 2003年05月 札幌 日本超音波医学会第７６回学術集会
     
    従来、胃癌の原発巣内の血流は低下している例が多いと考えられてきた。今回、進行胃癌64例の原発巣内の血流を対外式超音波にて観察し、病理学的所見とも対比した結果、むしろ血流の増加している症例のほうが多いことが示された。
  • YM454造影剤を用いた肝臓浅部域の造影能評価：実験モデルによる基礎的検討  [通常講演]
    日本超音波医学会第７６回学術集会 2003年05月 札幌 日本超音波医学会第７６回学術集会
     
    新しい造影剤perfluoropropaneを主成分とした低音圧系造影剤YM454を用いて肝臓の表面浅深部領域の造影能評価を小型犬の肝臓を用いて検討し、10～20μl/kgの経静脈的注入で充分な造影像を示し、TICも良好で臨床応用が可能と考え報告した。
  • 造影超音波を用いた各種肝疾患における血流動態の評価  [通常講演]
    坂口 康浩; 工藤 正俊; 豊澤 昌子; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第89回日本消化器病学会総会 2003年04月 埼玉 第89回日本消化器病学会総会
  • CHA (Coded Harmonic Angio)モードを用いた胆嚢隆起性病変の造影ハーモニック像の検討  [通常講演]
    井上 達夫; 工藤 正俊; 小川 力; 坂口 康浩; 坂本 洋城; 福田 信宏; 末冨 洋一郎; 南 康範; 石川 恵美; 中岡 良介; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清
    第89回日本消化器病学会総会 2003年04月 埼玉 第89回日本消化器病学会総会
  • 肝細胞癌に対する新しい統合ステージングシステムの提唱  [通常講演]
    鄭 浩柄; 工藤 正俊
    第8回南大阪肝胆膵懇話会 2003年04月 近畿大学 第8回南大阪肝胆膵懇話会
  • 造影超音波検査による膵癌の血行動態評価ー鑑別およびGemcitabineの治療効果判定における有用性ー  [通常講演]
    坂本 洋城; 工藤 正俊; 北野 雅之; 前川 清; 中岡 良介; 井上 達夫; 福田 信宏; 末冨 洋一郎
    第14回日本腹部造影エコー・ドプラ診断研究会 2003年04月 名古屋 第14回日本腹部造影エコー・ドプラ診断研究会
  • 教育講演「肝細胞癌の治療: EBMに基づいた体系の確立」  [通常講演]
    工藤 正俊
    第89回日本消化器病学会総会 2003年04月 ポストグラデュエイトコース, 埼玉 第89回日本消化器病学会総会
  • 特別講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    神戸大学大学院特別講演 2003年04月 神戸 神戸大学大学院特別講演
  • 特別講演「肝細胞癌の診断と治療: 最近のトピックス」  [通常講演]
    工藤 正俊
    第6回京都消化器セミナー 2003年04月 京都大学 第6回京都消化器セミナー
  • 肝細胞癌の統合Staging systemによる治療法の客観的評価: CLIP scoreとJIS scoreを用いた検討. パネルディスカッション「肝細胞癌の治療：EBMに基づいた体系の確立」  [通常講演]
    鄭 浩柄; 工藤 正俊; 大崎往夫
    第89回日本消化器病学会総会 2003年04月 埼玉 第89回日本消化器病学会総会
  • 超音波血流画像による肝腫瘍の病態評価. シンポジウム「形態と機能の統合」  [通常講演]
    工藤 正俊
    第62回日本医学放射線学会学術発表会 2003年04月 横浜 第62回日本医学放射線学会学術発表会
  • 憩室内乳頭の総胆管再発巨大結石に対して乳頭切開、砕石術にて排石し得た一症例  [通常講演]
    吉本 理恵; 工藤 正俊; 汐見 幹夫; 野田 佳寿; 信夫 清; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 坂口 康浩; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦
    第70回日本消化器内視鏡学会近畿地方会 2003年03月 阿倍野 第70回日本消化器内視鏡学会近畿地方会
  • 超音波内視鏡下穿刺生検が診断に有用であった十二指腸GISTの1症例  [通常講演]
    北井 聡; 工藤 正俊; 石川 恵美; 北野 雅之; 豊澤 昌子; 坂本 洋城; 坂口 康浩; 井上 達夫; 小川 力; 福田 信宏; 末冨 洋一郎; 吉本 理恵; 信夫 清; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 川崎 俊彦; 汐見 幹夫
    第70回日本消化器内視鏡学会近畿地方会 2003年03月 阿倍野 第70回日本消化器内視鏡学会近畿地方会
  • GAVEに対するAPCの検討  [通常講演]
    宮部 欽生; 工藤 正俊; 松井 繁長; 信夫 清; 石川 恵美; 坂本 洋城; 福田 信宏; 末冨 洋一郎; 吉本 理恵; 鄭 浩柄; 中岡 良介; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第70回日本消化器内視鏡学会近畿地方会 2003年03月 阿倍野 第70回日本消化器内視鏡学会近畿地方会
  • 特別講演「YM454の使用経験と今後の展望」  [通常講演]
    工藤 正俊
    第14回超音波ドプラ研究会 2003年03月 野口英世記念会館, 東京 第14回超音波ドプラ研究会
  • Serrated Adenomatous Polyposisの１例  [通常講演]
    安藤 理奈; 工藤 正俊; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第70回日本消化器内視鏡学会近畿地方会 2003年03月 大阪 第70回日本消化器内視鏡学会近畿地方会
  • Invited Lecture "Clinical usefulness of new contrast agent, Definity."  [通常講演]
    工藤 正俊
    International Symposium of New Advances in Mediical Ultrasound 2003年03月 Guang Zhou, China International Symposium of New Advances in Mediical Ultrasound
  • Invited Lecture "Application of contrast harmonic imaging to the treatment of hepatocellular carcinoma."  [通常講演]
    工藤 正俊
    International Symposium of New Advances in Mediical Ultrasound 2003年03月 Guang Zhou, China International Symposium of New Advances in Mediical Ultrasound
  • Invited Lecture "Characterization of hepatic tumors by contrast-enhanced harmonic imaging."  [通常講演]
    工藤 正俊
    International Symposium of New Advances in Mediical Ultrasound 2003年03月 Guang Zhou, China International Symposium of New Advances in Mediical Ultrasound
  • 肝臓における臨床的有用性についてーVascular Phaseを中心にー  [通常講演]
    南 康範; 工藤 正俊
    GE Ultrasound Advanced Symposium 2003 2003年02月 GE Ultrasound Advanced Symposium 2003
  • 早期胆嚢癌を合併した非拡張型膵胆管合流異常症の一例  [通常講演]
    田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第78回日本消化器病学会近畿支部例会 2003年02月 神戸 第78回日本消化器病学会近畿支部例会
  • 2本の太い流出路をもつため、B-RTOが困難であった巨大静脈瘤の一例  [通常講演]
    朝隈 豊; 工藤 正俊; 川崎俊彦; 坂本洋城; 梅原 泰; 小川 力; 野田佳寿; 福田信宏; 末冨洋一郎; 南 康範; 石川恵美; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 汐見幹夫
    第78回日本消化器病学会近畿支部例会 2003年02月 神戸 第78回日本消化器病学会近畿支部例会
  • 超音波検査にて後腹膜神経原性腫瘍が疑われた一症例  [通常講演]
    前野知子; 工藤 正俊; 桑口 愛; 江口真由美; 前川 清; 川崎俊彦
    日本超音波医学会第25回関西地方会 2003年02月 大阪 日本超音波医学会第25回関西地方会
  • 嚢胞内出血を造影エコー法にて診断し得た腎盂腸管瘻合併多発性嚢胞腎の一例  [通常講演]
    冨田崇文; 工藤 正俊; 石川恵美; 汐見幹夫; 川崎俊彦; 北野 雅之; 松井 繁長; 前川 清
    日本超音波医学会第25回関西地方会 2003年02月 大阪 日本超音波医学会第25回関西地方会
  • 超音波内視鏡下穿刺吸引組織診（EUS-FNAB）が診断に有用であった膵ソマトスタチノーマの一例  [通常講演]
    野田佳寿; 工藤 正俊; 末冨洋一郎; 宮部欽生; 前川 清; 南 康範; 中岡 良介; 北野 雅之; 川崎俊彦; 汐見幹夫; 保田 知生; 大柳 治正
    日本超音波医学会第25回関西地方会 2003年02月 大阪 日本超音波医学会第25回関西地方会
  • 特別講演「肝細胞癌診療の最近のトピックス」肝炎セミナー～肝炎・肝癌の現状と今後～  [通常講演]
    工藤 正俊
    2003年02月 岡山
  • 特別講演「治療効果判定と造影ハーモニックガイド下RFA」  [通常講演]
    工藤 正俊
    朝日サイエンスセミナー 2003年02月 京都 朝日サイエンスセミナー
  • 特別講演「肝細胞癌の早期診断」  [通常講演]
    工藤 正俊
    平成14年度厚生労働科学研究費肝炎等克服緊急対策研究公開報告会 2003年02月 経団連会館, 東京 平成14年度厚生労働科学研究費肝炎等克服緊急対策研究公開報告会
  • 特別講演「経皮的ラジオ波焼灼療法（RFA）の現状と展望」  [通常講演]
    工藤 正俊
    朝日サイエンスセミナー 2003年02月 京都 朝日サイエンスセミナー
  • 特別講演「日本における肝癌の早期診断」  [通常講演]
    工藤 正俊
    第1回肝癌撲滅アジアフォーラム 2003年02月 久留米 第1回肝癌撲滅アジアフォーラム
  • 特別講演「肝癌の診断と治療」  [通常講演]
    工藤 正俊
    大阪府医師会医学会平成14年度セミナー形式による研修会 2003年02月 大阪 大阪府医師会医学会平成14年度セミナー形式による研修会
     
    特別講演「肝癌の診断と治療」
  • 特別講演「肝細胞癌の血流動態」  [通常講演]
    工藤 正俊
    第9回肝血流動態イメージ研究会 2003年02月 東商ホール, 東京 第9回肝血流動態イメージ研究会
  • 超音波検査にて後腹膜神経性腫瘍が疑われた一例  [通常講演]
    日本超音波医学会第２５回関西地方会 2003年02月 大阪 日本超音波医学会第２５回関西地方会
     
    良性の後腹膜神経鞘腫の1症例を経験した。超音波BモードとTHIはMRI、T1強調画像と酷似した像を示した。また、レボビスト造影超音波は造影CTとおなじ染影動態を示した。今後、超音波検査が神経鞘腫の鑑別に有用となり得ると考える。
  • 教育講演「肝癌診療の最新情報（画像診断のこつ）」  [通常講演]
    工藤 正俊
    第37回日本成人病（生活習慣病）学会 2003年01月 日本都市センター, 東京 第37回日本成人病（生活習慣病）学会
  • Special Lecture "Diagnosis of early, small hepatocellular carcinoma"  [通常講演]
    工藤 正俊
    U.S. - Japan Cooperative Medical Sciences Program Joint Annual Meeting of the Hepatitis Panel 2003年01月 Diamond Hotel, Tokyo U.S. - Japan Cooperative Medical Sciences Program Joint Annual Meeting of the Hepatitis Panel
  • 難治性C型慢性肝炎（Ib型, 高ウイルス例）に対するIFNα2b+リバビリン併用療法の効果  [通常講演]
    石川恵美; 工藤 正俊; 福田信宏; 末冨洋一郎; 鄭 浩柄; 南 康範; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    第14回南大阪肝胆膵研究会 2002年12月 リーガロイヤル堺 第14回南大阪肝胆膵研究会
  • EISLにて止血し得た十二指腸静脈瘤の１例  [通常講演]
    松井 繁長; 工藤 正俊; 福田信宏; 末冨洋一郎; 鄭 浩柄; 南 康範; 中岡 良介; 北野 雅之; 川崎俊彦; 汐見幹夫
    第5回南大阪肝胆膵懇話会 2002年11月 大阪狭山 第5回南大阪肝胆膵懇話会
  • 当院における経皮的ラジオ波焼灼術の合併症  [通常講演]
    鄭 浩柄; 工藤 正俊; 豊澤 昌子; 石川恵美; 坂本洋城; 小川 力; 坂口康浩; 井上達夫; 福田信宏; 末冨洋一郎; 南 康範; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    第35回大阪肝穿刺生検治療研究会 2002年11月 大阪 第35回大阪肝穿刺生検治療研究会
  • EUSガイド下腹腔神経叢ブロックでコントロールし得た眼精疼痛の1例  [通常講演]
    福田信宏; 工藤 正俊; 末冨洋一郎; 中岡 良介; 前川 清; 坂本洋城; 石川恵美; 小川 力; 南 康範; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    第143回大阪腹部超音波研究会 2002年11月 大阪 第143回大阪腹部超音波研究会
  • EUS-FNAが治療方針決定に有用であった進行性膵悪性腫瘍の1例  [通常講演]
    宮部欽生; 工藤 正俊; 末冨洋一郎; 中岡 良介; 福田信宏; 前川 清; 坂本洋城; 石川恵美; 小川 力; 南 康範; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫
    第143回大阪腹部超音波研究会 2002年11月 大阪 第143回大阪腹部超音波研究会
  • 特別講演「肝細胞癌の診断と治療－最近の進歩－」  [通常講演]
    工藤 正俊
    第97回日本消化器病学科東海支部例会 2002年11月 名古屋 第97回日本消化器病学科東海支部例会
  • 特別講演「消化器疾患診療の最近の話題」  [通常講演]
    工藤 正俊
    第143回青森消化器疾患セミナー 2002年11月 青森 第143回青森消化器疾患セミナー
  • 特別講演「肝細胞癌の診断と治療ー最近の進歩ー」  [通常講演]
    工藤 正俊
    消化器病センターセミナー 2002年11月 昭和大学横浜市北部医療センター, 横浜市 消化器病センターセミナー
  • 当院におけるアンケート結果から省みた前処置対策  [通常講演]
    米田 円; 工藤 正俊; 田中 陽一; 森村 正嗣; 由谷 逸朗; 辻 直子
    第2回南大阪大腸内視鏡研究会 2002年11月 大阪 第2回南大阪大腸内視鏡研究会
  • Special Lecture "Pancreatic Diseases "  [通常講演]
    工藤 正俊
    AFSUMB ULTRSOUND COURSES 2002 2002年11月 Phnom Penh, Cambodia AFSUMB ULTRSOUND COURSES 2002
  • Special Lecture "Malignant Focal Liver Lesions "  [通常講演]
    工藤 正俊
    AFSUMB ULTRSOUND COURSES 2002 2002年11月 Phnom Penh, Cambodia AFSUMB ULTRSOUND COURSES 2002
  • Special Lecture "Diffuse Liver Disease "  [通常講演]
    工藤 正俊
    AFSUMB ULTRSOUND COURSES 2002 2002年11月 Phnom Penh, Cambodia AFSUMB ULTRSOUND COURSES 2002
  • Special Lecture "Benign Focal Liver Lesions "  [通常講演]
    工藤 正俊
    AFSUMB ULTRSOUND COURSES 2002 2002年11月 Phnom Penh, Cambodia AFSUMB ULTRSOUND COURSES 2002
  • Special Lecture "Liver Cancer in Japan; Advances of Imaging Diagnosis"  [通常講演]
    工藤 正俊
    4th Korea-Japan Medical symposium 2002年11月 Kobe International Conference Center, Kobe 4th Korea-Japan Medical symposium
  • Special Lecture "AFP-L3 Fraction in the Evaluation of Treatment Respoce for Hepatocellular Carcinoma"  [通常講演]
    工藤 正俊
    53th American Association of Study of the Liver 2002年11月 Boston, MA, USA 53th American Association of Study of the Liver
  • シンポジウム「US(腫瘍のUSによる治療効果予測・効果判定)」: 肝癌の治療効果判定－ラジオ波治療効果－  [通常講演]
    南 康範; 工藤 正俊
    第31回断層映像研究会 2002年11月 高知 第31回断層映像研究会
  • 肝血管腫の造影超音波  [通常講演]
    第10回画論 2002年11月 東京 第10回画論
     
    肝左葉を占拠する病変に対しレボビストを用いて造影超音波を行った結果、綿花上濃染像が得られ、肝血管腫が同定できた症例を第10回画論にて発表し、超音波検査部門の最優秀賞を受賞した。
  • 超音波内視鏡ガイド下腹腔神経叢ブロックが著効を示した膵癌性疼痛の1例  [通常講演]
    北野 雅之; 工藤 正俊; 末冨洋一郎; 中岡 良介; 福田信宏; 前川 清; 坂本洋城; 石川恵美; 小川 力; 南 康範; 鄭 浩柄; 松井 繁長; 川崎俊彦; 汐見幹夫
    第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会 2002年10月 横浜 第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会
  • 超音波内視鏡下穿刺生検が有用であった進行膵悪性腫瘍の1例  [通常講演]
    中岡 良介; 工藤 正俊; 南 康範; 福田信宏; 末冨洋一郎; 北野 雅之; 汐見幹夫; 白石 治; 中居 卓也; 塩崎 均
    第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会 2002年10月 横浜 第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会
  • B-modeにて同定困難な症例における超音波造影下治療の検討  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 川崎俊彦
    第6回日本肝臓学会大会（DDW-Japan） 2002年10月 横浜 第6回日本肝臓学会大会（DDW-Japan）
  • 肝細胞癌に対するRFA問題点とその対策  [通常講演]
    鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 川崎俊彦
    第6回日本肝臓学会大会（DDW-Japan） 2002年10月 横浜 第6回日本肝臓学会大会（DDW-Japan）
  • 肝細胞癌に対するRFA治療後の再発とAFP-L3分画の相関関係について  [通常講演]
    小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田 無文; 北口 容子; 豊澤 昌子; 石川 恵美; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田 弘一; 松井 繁長; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第6回日本肝臓学会大会（DDW-Japan） 2002年10月 横浜 第6回日本肝臓学会大会（DDW-Japan）
  • 胃幽門部癌性狭窄に対するステント治療とバイパス手術の比較検討  [通常講演]
    田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第64回日本消化器内視鏡学会総会 2002年10月 横浜 第64回日本消化器内視鏡学会総会
  • 食道静脈瘤に対するEISL後の地固め療法の検討ーASとAPCの比較ー  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介; 石川 恵美; 福田 信宏; 末冨 洋一郎; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第64回日本消化器内視鏡学会総会 2002年10月 横浜 第64回日本消化器内視鏡学会総会
  • 造影パワードプラEUSによる膵腫瘍性病変の診断; 体外式造影超音波および造影CT検査との比較  [通常講演]
    北野 雅之; 工藤 正俊; 末冨 洋一郎; 中岡 良介; 福田 信宏; 松井 繁長; 南 康範; 鄭 浩柄; 川崎 俊彦; 汐見 幹夫
    第64回日本消化器内視鏡学会総会 2002年10月 横浜 第64回日本消化器内視鏡学会総会
  • 造影ハーモニックイメージングによる膵癌におけるGemcitabineの治療効果判定ー造影ハーモニックイメージングの意義ー  [通常講演]
    末冨 洋一郎; 工藤 正俊
    第44回日本消化器病学会大会（DDW-Japan） 2002年10月 横浜 第44回日本消化器病学会大会（DDW-Japan）
  • 肝細胞癌に対しLp-TAE後に急性閉塞性化膿性胆管炎を発症した1例  [通常講演]
    坂本 洋城; 工藤 正俊; 鄭 浩柄; 豊澤 昌子; 石川 恵美; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第69回日本消化器内視鏡学会近畿地方会 2002年10月 大阪 第69回日本消化器内視鏡学会近畿地方会
  • 超音波内視鏡ガイド下腹腔内神経叢ブロックが著効を示した膵癌性疼痛の1例  [通常講演]
    福田 信宏; 工藤 正俊; 北野 雅之; 前川 清; 豊澤 昌子; 石川 恵美; 小川 力; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 川崎 俊彦; 汐見 幹夫
    第69回日本消化器内視鏡学会近畿地方会 2002年10月 大阪 第69回日本消化器内視鏡学会近畿地方会
  • 膵腫瘍における造影エコー法の意義  [通常講演]
    北野 雅之; 工藤 正俊
    岡山近畿消化器画像診断研究会 2002年10月 リーガロイヤルホテル堺, 大阪 岡山近畿消化器画像診断研究会
  • 造影ハーモニック法の治療への応用ー治療効果判定と泉誌  [通常講演]
    南 康範; 工藤 正俊
    岡山近畿消化器画像診断研究会 2002年10月 リーガロイヤルホテル堺, 大阪 岡山近畿消化器画像診断研究会
  • Pulse Subtraction法による肝腫瘍の診断  [通常講演]
    鄭 浩柄; 工藤 正俊
    岡山近畿消化器画像診断研究会 2002年10月 リーガロイヤルホテル堺, 大阪 岡山近畿消化器画像診断研究会
  • 特別講演「肝細胞癌の診断と治療－最近の進歩－」  [通常講演]
    工藤 正俊
    第1回肝疾患診療の最前線 2002年10月 大阪, ホテルグランヴィア大阪 第1回肝疾患診療の最前線
  • 特別講演「肝・胆・膵疾患の造影エコー法の進歩」  [通常講演]
    工藤 正俊
    第13回日本腹部造影エコー・ドプラ診断研究会( JACUA), 2002年10月 レ・ルミエール, 大阪 第13回日本腹部造影エコー・ドプラ診断研究会( JACUA),
  • ランチョンセミナー「RFA治療と超音波造影剤による効果判定」  [通常講演]
    工藤 正俊
    第44回日本消化器病学会（DDW-Japan） 2002年10月 横浜 第44回日本消化器病学会（DDW-Japan）
  • ブレックファーストセミナー「RFAによる肝癌治療の今後の展開」  [通常講演]
    工藤 正俊
    第6回日本肝臓学会大会（DDW-Japan） 2002年10月 横浜 第6回日本肝臓学会大会（DDW-Japan）
  • 基調講演「消化器造影エコー診断の現況と展望」  [通常講演]
    工藤 正俊
    第44回日本消化器病学会（DDW-Japan） 2002年10月 横浜 第44回日本消化器病学会（DDW-Japan）
  • ランチョンセミナー「肝腫瘍における超音波造影法の現状と展望」  [通常講演]
    工藤 正俊
    第40回日本癌治療学会総会 2002年10月 東京国際フォーラム, 東京 第40回日本癌治療学会総会
  • 特別講演「肝癌における効率的局所治療のストラテジー -造影超音波併用の与えるインパクト-」  [通常講演]
    工藤 正俊
    腹部造影エコー学術講演会 2002年10月 愛知医科大学 本館3F, 愛知 腹部造影エコー学術講演会
  • ハンズオンレクチャー「造影エコーの基本手技」  [通常講演]
    工藤 正俊
    愛知医科大学 2002年10月 愛知 愛知医科大学
  • 特別講演「発癌の血流と病態」  [通常講演]
    工藤 正俊
    第2回肝臓フォーラム 2002年10月 千里ライフサイエンスセンター, 大阪 第2回肝臓フォーラム
  • 大腸腫瘍における間質反応，特に筋線維芽細胞の形態変化についての病理組織学的検討  [通常講演]
    米田 円; 工藤 正俊; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子
    第４４回日本消化器病学会総会 2002年10月 横浜 第４４回日本消化器病学会総会
  • 接合部腺癌および食道非腺癌における背景粘膜のSSBEと食道胃接合部の病理  [通常講演]
    辻 直子; 工藤 正俊; 石黒 信吾
    第64回日消化器内視鏡学会総会 2002年10月 横浜 第64回日消化器内視鏡学会総会
  • Special Lecture "Contrast harmonic imaging in the characterization of hepatic tumors"  [通常講演]
    工藤 正俊
    Chinese Taipei Society of Ultrasound in Medicine 2002年10月 Taipei, Taiwan Chinese Taipei Society of Ultrasound in Medicine
  • Special Lecture "Radofrequency ablation for HCC under contrast-harmonic imaging guidance"  [通常講演]
    工藤 正俊
    Chinese Taipei Society of Ultrasound in Medicine 2002年10月 Taipei, Taiwan Chinese Taipei Society of Ultrasound in Medicine
  • 胃幽門狭窄に対するステント治療とバイパス手術の比較検討  [通常講演]
    田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊
    第64回日本消化器内視鏡学会総会 2002年10月 横浜 第64回日本消化器内視鏡学会総会
     
    胃幽門部狭窄に対してステント治療とバイパス手術を行い、食事開始時期、在院日数、在宅日数などにつき比較検討を行った。
  • Contrast-enhanced power Doppler endoscopic ultrasound in pancreatic diseases: comparison with contrast-enhanced extracorporal harmonic ultrasound and computed tomography  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介; 末冨洋一郎; 汐見幹夫; 福田信宏; 松井 繁長; 川崎俊彦; 前川 清
    13th International Symposium on Endoscopic Ultrasonography 2002年10月 New York 13th International Symposium on Endoscopic Ultrasonography
  • Gastrointestinal mesenchymal tumor (GIMT)における体表式造影ハーモニックイメージング法および超音波内視鏡下造影法の有用性. （ワークショップ「消化器疾患における造影エコーup to date」）  [通常講演]
    福田信宏; 工藤 正俊; 北野 雅之
    第44回日本消化器病学会大会 2002年10月 横浜 第44回日本消化器病学会大会
  • 人工胸水下造影超併用RFAの有用性. （ワークショップ「消化器疾患における造影エコーup to date」）  [通常講演]
    南 康範; 工藤 正俊; 川崎俊彦
    第44回日本消化器病学会大会 2002年10月 横浜 第44回日本消化器病学会大会
  • シンポジウムII「内視鏡診断・治療における新しい展開（肝胆膵）」膵腫瘍におけるEUS下造影、穿刺生検および穿刺治療の有用性  [通常講演]
    末冨洋一郎; 工藤 正俊; 北野 雅之
    第69回日本消化器内視鏡学会近畿地方会 2002年10月 大阪 第69回日本消化器内視鏡学会近畿地方会
  • シンポジウムI「内視鏡診断・治療における新しい展開（消化管）」食道静脈瘤に対するアルゴンプラズマ凝固法（APC）の有用性  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介
    第69回日本消化器内視鏡学会近畿地方会 2002年10月 大阪 第69回日本消化器内視鏡学会近畿地方会
  • 急性肝炎様症状で発症した肝脾型悪性リンパ腫の一例  [通常講演]
    田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子
    第77回日本消化器病学会近畿支部例会 2002年09月 平成14年9月7日, 京都 第77回日本消化器病学会近畿支部例会
  • 肝内巨大P-Vシャントに合併した肝FNH様病変の一例  [通常講演]
    坂口 康浩; 工藤 正俊; 松井 繁長; 坂本 洋城; 井上 達夫; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 北野 雅之; 石川 恵美; 川崎 俊彦; 汐見 幹夫
    第77回日本消化器病学会近畿支部例会 2002年09月 京都 第77回日本消化器病学会近畿支部例会
  • 超音波内視鏡下穿刺が有用であった膵endocrine cell tumorの一例  [通常講演]
    宮部 鉄生; 工藤 正俊; 中岡 良介; 野田 佳寿; 坂本 洋城; 南 康範; 福田 信宏; 末冨 洋一郎; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 塩崎 均
    第77回日本消化器病学会近畿支部例会 2002年09月 京都 第77回日本消化器病学会近畿支部例会
  • 胆嚢癌との鑑別が困難であった、CA19-9が著明高値を呈した、腹腔内膿瘍を合併した、急性胆嚢炎の一例  [通常講演]
    井上 達夫; 工藤 正俊; 北口 容子; 坂本 洋城; 豊澤 昌子; 中尾 隆美; 石川 恵美; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第77回日本消化器病学会近畿支部例会 2002年09月 京都 第77回日本消化器病学会近畿支部例会
  • 体表式造影超音波法が術前診断に有用であった小腸GISTの2例  [通常講演]
    福田 信宏; 工藤 正俊; 北野 雅之; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 坂口 康浩; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 川崎 俊彦; 汐見 幹夫; 前川 清
    第77回日本消化器病学会近畿支部例会 2002年09月 京都 第77回日本消化器病学会近畿支部例会
  • 腹腔内および右肩に認めた巨大脂肪腫の一例  [通常講演]
    坂本 洋城; 工藤 正俊; 川崎 俊彦; 豊澤 昌子; 石川 恵美; 坂口 康浩; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 汐見 幹夫
    第77回日本消化器病学会近畿支部例会 2002年09月 京都 第77回日本消化器病学会近畿支部例会
  • 特別講演「肝画像診断のトピックスー造影エコーを中心にー」  [通常講演]
    工藤 正俊
    第7回神戸管と肝研究会 2002年09月 生田神社会館, 神戸 第7回神戸管と肝研究会
  • 特別講演「超音波血流画像による肝腫瘍の鑑別と癌局所療法への応用」  [通常講演]
    工藤 正俊
    第13回播州肝・胆・膵・消化器癌勉強会 2002年09月 ホテルサンガーデン姫路, 姫路 第13回播州肝・胆・膵・消化器癌勉強会
  • ランチョンセミナー「肝腫瘍の超音波血流画像と治療への応用」  [通常講演]
    工藤 正俊
    第37回日本消化器画像診断研究会 2002年09月 愛知県がんセンター国際交流センター, 名古屋 第37回日本消化器画像診断研究会
  • 特別講演「肝細胞癌に対するRFA治療と今後の肝癌治療の展望」  [通常講演]
    工藤 正俊
    秋田県肝・胆道癌研究会 2002年09月 秋田 秋田県肝・胆道癌研究会
  • 特別講演「超音波血流画像による肝腫瘍の診断と治療への応用」  [通常講演]
    工藤 正俊
    西神・播磨消化器懇話会 2002年09月 神戸 西神・播磨消化器懇話会
  • B modeで同定困難な肝細胞癌に対する造影超音波ガイドでのRFAの検討（シンポジウム「診断と治療の最前線ー肝細胞癌」）  [通常講演]
    南 康範; 工藤 正俊; 川崎俊彦
    第77回日本消化器病学会近畿支部例会 2002年09月 京都 第77回日本消化器病学会近畿支部例会
  • CHA (Coded Harmonic Angio)モードを用いた造影ハーモニックイメージングによる膵腫瘍性病変の診断  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 末冨 洋一郎; 中岡 良介
    第33回日本膵臓学会大会 2002年08月 仙台 第33回日本膵臓学会大会
  • 興味あるレボビスト造影像を呈した小腸原発悪性リンパ腫の1例  [通常講演]
    石川 恵美; 工藤 正俊; 汐見 幹夫; 川崎 俊彦; 北野 雅之; 松井 繁長; 中岡 良介; 鄭 浩柄; 南 康範; 末冨 洋一郎; 福田 信宏; 小川 力; 前川 清
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
  • 興味ある血行動態を示した転移性肝癌のレボビスト造影  [通常講演]
    小川 力; 工藤 正俊; 豊澤 昌子; 石川 恵美; 坂本 洋城; 井上 達夫; 坂口 康浩; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
  • 体表式造影エコーおよびEUS造影エコーが診断に有用であった膵臓癌の一例  [通常講演]
    井上 達夫; 工藤 正俊; 坂本 洋城; 豊澤 昌子; 石川 恵美; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
  • 興味ある血行動態を示した転移性肝癌のレボビスト造影  [通常講演]
    坂本 洋城; 工藤 正俊; 豊澤 昌子; 石川 恵美; 坂口 康浩; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
  • 造影超音波法が診断に有用であった門脈肝静脈短絡症に伴うFNHの一例  [通常講演]
    坂口 康浩; 工藤 正俊; 豊澤 昌子; 中尾 隆美; 石川 恵美; 坂本 洋城; 鄭 栄琴; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
  • 肝区域からみたCoded Harmonic Angioを用いた肝細胞癌の血流評価  [通常講演]
    前川 清; 工藤 正俊; 前野 知子; 桑口 愛; 江口 真由美; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
  • 嚢胞腎の経過中に発症した腸管腎盂瘻の1例  [通常講演]
    石川 恵美; 工藤 正俊; 坂本 洋城; 鄭 浩柄; 井上 達夫; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 栄琴; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第44回腹部画像診断カンファレンス 2002年08月 大阪 第44回腹部画像診断カンファレンス
  • 肝内P-Vシャントに合併した肝多発性結節性病変の1例  [通常講演]
    松井 繁長; 工藤 正俊
    第3回臨床消化器病研究会 2002年08月 ホテルパシフィック東京, 東京 第3回臨床消化器病研究会
  • 特別講演「肝細胞癌治療におけるAFPレクチン分画の意義」  [通常講演]
    工藤 正俊
    神戸肝疾患勉強会 2002年08月 神戸 神戸肝疾患勉強会
  • 特別講演「肝腫瘍の血流と病態ー造影ハーモニックイメージングの治療への応用ー」  [通常講演]
    工藤 正俊
    第80回東北腹部画像診断検討会 2002年08月 艮陵会「記念ホール」, 仙台 第80回東北腹部画像診断検討会
  • 特別講演「肝癌における効率的局所治療のストラテジー: 造影超音波併用の与えるインパクト」  [通常講演]
    工藤 正俊
    腹部超音波フォーラム 2002年08月 横浜エクセルホテル東急, 横浜 腹部超音波フォーラム
  • Key Note Lecture「レボビストの臨床使用における基礎知識」  [通常講演]
    工藤 正俊
    腹部超音波フォーラム 2002年08月 横浜エクセルホテル東急, 横浜 腹部超音波フォーラム
  • Key Note Lecture「レボビストの臨床使用における基礎知識」  [通常講演]
    工藤 正俊
    腹部超音波フォーラム 2002年08月 横浜エクセルホテル東急, 横浜 腹部超音波フォーラム
  • 肝区域から見たCode Hamonic Angioを用いた肝細胞癌の血流評価  [通常講演]
    日本超音波医学会第24回関西地方会 2002年08月 奈良 日本超音波医学会第24回関西地方会
     
    肝細胞癌の大きさ、深さ及び造影パターンごとに分類した結果、腫瘍径についてはvesselおよびPerfusion imageに差がなく、深部病変でPerfusion imageがvessel image比し染影が優れていた。
  • 消化管以外の臓器におけるFNAの現況と将来  [通常講演]
    中岡 良介; 工藤 正俊
    第7回内視鏡・超音波研究会 2002年07月 大阪 第7回内視鏡・超音波研究会
  • 胃腎シャントのない孤立性胃静脈瘤破裂に対してPTOを施行し長期経過観察しえた1例  [通常講演]
    松井 繁長; 工藤 正俊; 井上 良一; 高幣 和郎
    第11回近畿食道・胃静脈瘤研究会 2002年07月 大阪 第11回近畿食道・胃静脈瘤研究会
  • 門脈流入結節の造影ハーモニック像の検討  [通常講演]
    坂本 洋城; 工藤 正俊; 鄭 浩柄; 石川 恵美; 井上 達夫; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 栄琴; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清
    第2回関西肝血流動態イメージ研究会 2002年07月 大阪 第2回関西肝血流動態イメージ研究会
  • 特別講演「肝腫瘍の超音波血流画像と癌局所治療への応用」  [通常講演]
    工藤 正俊
    第12回府中地区肝臓病研究会 2002年07月 府中市、広島県 第12回府中地区肝臓病研究会
  • 特別講演「肝腫瘍の血流と病態・治療への応用」  [通常講演]
    工藤 正俊
    広島肝疾患ゼミナール 2002年07月 広島 広島肝疾患ゼミナール
  • 特別講演「肝癌における効率的局所治療のストラテジー: 造影超音波併用の与えるインパクト」  [通常講演]
    工藤 正俊
    長崎プリンスホテル 2002年07月 長崎 長崎プリンスホテル
  • ハンズオンレクチャー「腹部超音波の実際」  [通常講演]
    工藤 正俊
    国立長崎医療センター 2002年07月 長崎 国立長崎医療センター
  • 特別講演「肝細胞癌の血流と病態ー造影ハーモニック法も含めてー」  [通常講演]
    工藤 正俊
    県北肝疾患研究会, （佐藤由起夫 福島県立医大教授） 2002年07月 福島ビューホテル, 福島 県北肝疾患研究会, （佐藤由起夫 福島県立医大教授）
  • 客観的臨床能力試験（OSCE）における医療面接の評価法についての検討  [通常講演]
    岩本 一郎; 金丸 昭久; 宮崎 俊夫; 北野 雅之; 村木 正人; 木原 幹洋; 北野 元一; 飯田 仁; 福田 寛二; 工藤 正俊; 松尾 理; 安富 正幸
    第34回日本医学教育学会 2002年07月 東京 第34回日本医学教育学会
     
    本学の客観的臨床能力試験(OSCE)における医療面接の評価は、複数のシナリオを用いて2日間にわたって実施するため、客観性の確保に問題があった。本年度は外部評価者を含む複数の教官で評価したのでその客観性につてい検討し報告した。
  • 造影US. （シンポジウム「肝癌診断における各種画像診断の位置付け」）  [通常講演]
    工藤 正俊
    第37回近畿肝癌談話会 2002年07月 第37回近畿肝癌談話会
  • 経皮内視鏡的胃瘻造設術(PEG)の現況－PEGの現況に関するアンケート集計報告  [通常講演]
    汐見 幹夫; 工藤 正俊
    第8回関西経皮内視鏡的胃瘻造設術研究会 2002年06月 大阪 第8回関西経皮内視鏡的胃瘻造設術研究会
  • C型肝炎針刺し事故直後のIFNの有用性に関する検討  [通常講演]
    鄭 浩柄; 工藤 正俊; 熊田 卓; 勝島 慎二; 岡野 明浩; 中村 武史; 大崎 往夫; 加藤 玲明; 小東 克次; 山下 幸孝; 荻原 智; 小森 英司; 西馬 信一
    第38回日本肝臓学会総会 2002年06月 大阪国際会議場, 大阪 第38回日本肝臓学会総会
  • 肝硬変の超音波診断: 多施設共同研究  [通常講演]
    鄭 栄琴; 工藤 正俊; 川崎 俊彦; 岡部 純弘; 大崎 征夫; 飯島 尋子; 春日井 博志; 兼松 雅之; 伊藤 克能; 神代 正道
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 造影超音波にて肝静脈が流出血流と同定した肝血管筋脂肪腫の2例  [通常講演]
    南 康範; 工藤 正俊; 川崎 俊彦; 鄭 浩柄; 遠田 弘一; 末冨 洋一郎; 小川 力; 桑口 愛; 江口 真由美; 前川 清
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • CHAリサーチ(H7)を用いた肝腫瘍の造影3D像の検討  [通常講演]
    前川 清; 工藤 正俊; 桑口 愛; 江口 真由美; 小川 力; 末冨 洋一郎; 南 康範; 鄭 浩柄; 北野 雅之; 川崎 俊彦
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 「人工胸水下造影超音波併用RFA」の初期臨床経験  [通常講演]
    南 康範; 工藤 正俊; 川崎 俊彦; 鄭 浩柄; 遠田 弘一; 末冨 洋一郎; 小川 力; 桑口 愛; 江口 真由美; 前川 清
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • CHAモードを用いた膵腫瘍性病変の造影超音波像  [通常講演]
    桑口 愛; 工藤 正俊; 江口 真由美; 前川 清; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 北野 雅之; 川崎 俊彦
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 局所治療後遺残肝細胞癌 (HCC) に対する造影超音波下RFAの検討  [通常講演]
    鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 末冨 洋一郎; 北野 雅之; 川崎 俊彦; 桑口 愛; 江口 真由美; 前川 清
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 超音波内視鏡下造影および穿刺生検のよる膵腫瘍性疾患の診断  [通常講演]
    北野 雅之; 工藤 正俊; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 汐見 幹夫; 川崎 俊彦; 小川 力; 石川 恵美; 由谷 逸朗; 前川 清
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 消化器粘膜下腫瘍における造影超音波法およびEUS下穿刺の有用性  [通常講演]
    福田 信宏; 工藤 正俊; 北野 雅之; 前川 清; 末冨 洋一郎; 由谷 逸朗; 中岡 良介; 松井 繁長; 川崎 俊彦; 汐見 幹夫
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 肝腫瘍性病変の特徴: CHAモード造影超音波の有用性  [通常講演]
    文 艶玲; 工藤 正俊; 丁 紅; 南 康範; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 北野 雅之; 川崎 俊彦; 前川 清
    日本超音波医学会第75回学術集会 2002年06月 高松県県民ホール・全日空ホテルクレメント高松, 香川 日本超音波医学会第75回学術集会
  • 特別講演「肝がんは克服できる－最新情報」  [通常講演]
    工藤 正俊
    平成14年度肝がん撲滅運動市民公開講座（日本肝臓学会・大阪府主催） 2002年06月 大阪狭山市文化会館（SAYAKAホール）, 大阪市 平成14年度肝がん撲滅運動市民公開講座（日本肝臓学会・大阪府主催）
  • ランチョンセミナー: 肝がん治療最近の動向「内科的治療とその効果判定」  [通常講演]
    工藤 正俊
    第38回日本肝臓学会総会 2002年06月 大阪国際会議場, 大阪 第38回日本肝臓学会総会
  • ランチョンセミナー「肝細胞癌の効率的RFA治療ー造影超音波併用の与えるimpactー」  [通常講演]
    工藤 正俊
    第38回日本肝臓学会総会 2002年06月 大阪国際会議場, 大阪 第38回日本肝臓学会総会
  • ランチョンセミナー: 肝がん治療最近の動向「内科的治療とその効果判定」  [通常講演]
    工藤 正俊
    第38回日本肝臓学会総会 2002年06月 大阪国際会議場, 大阪 第38回日本肝臓学会総会
     
    ランチョンセミナー: 肝がん治療最近の動向「内科的治療とその効果判定」
  • 教育講演「肝癌局所療法における超音波の役割」  [通常講演]
    工藤 正俊
    日本超音波医学会第75回学術集会 2002年06月 高松, 香川 日本超音波医学会第75回学術集会
  • CHA リサーチモード (H7)を用いた肝腫瘍の造影3D像の検討  [通常講演]
    日本超音波医学会第75回学術集会 2002年06月 香川 日本超音波医学会第75回学術集会
     
    レボビスト造影において早期相のReal time sweep scanによる撮像にて構築し、腫瘍の同定を試み、腫瘍血管3D像は肝臓腫瘍の血管構築を3次元的に理解する上で有用であった。
  • TAE先行RFAの有用性: 生体豚肝による検討  [通常講演]
    鄭 浩柄; 工藤 正俊
    （厚生労働省指定研究「肝細胞がんに対する肝動脈塞栓療法の延命効果に関する研究」班会議） 2002年05月 国立がんセンター, 東京 （厚生労働省指定研究「肝細胞がんに対する肝動脈塞栓療法の延命効果に関する研究」班会議）
  • 人工胸水造影超音波併用RFAの初期臨床経験  [通常講演]
    南 康範; 工藤 正俊; 小川 力; 鄭 浩柄; 川崎 俊彦
    第38回日本肝癌研究会 2002年05月 東京ドームホテル, 東京 第38回日本肝癌研究会
  • 肝細胞癌に対するラジオ波焼灼療法( RFA)後の腫瘍マーカーの変動とその意義  [通常講演]
    小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田 無文; 北口 容子; 豊澤 昌子; 石川 恵美; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田 弘一; 松井 繁長; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第38回日本肝癌研究会 2002年05月 東京ドームホテル, 東京 第38回日本肝癌研究会
  • 肝内PVシャントに合併した肝結節性病変の一例  [通常講演]
    北口 容子; 工藤 正俊; 松井 繁長; 乾 絹世; 市川 勉; 岡田 無文; 豊澤 昌子; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 石川 恵美; 鄭 浩柄; 中岡 良介; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第34回大阪肝穿刺生検治療研究会 2002年05月 大阪大林ビル, 大阪 第34回大阪肝穿刺生検治療研究会
  • ラジオ出演「C型肝炎って治るの？（5）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    2002年05月 ABCラジオ（朝日放送）, 大阪
  • ラジオ出演「C型肝炎って治るの？（4）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    2002年05月 ABCラジオ（朝日放送）, 大阪
  • ラジオ出演「C型肝炎って治るの？（3）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    2002年05月 ABCラジオ（朝日放送）, 大阪
  • ラジオ出演「C型肝炎って治るの？（2）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    2002年05月 ABCラジオ（朝日放送）, 大阪
  • ラジオ出演「C型肝炎って治るの？（1）」(番組名: 健やかライフ)  [通常講演]
    工藤 正俊
    2002年05月 ABCラジオ（朝日放送）, 大阪
  • Special Lecture "Application of Harmonic Imaging to the Treatment of hepatocellular Carcinoma.“  [通常講演]
    工藤 正俊
    The 8th International Symposium on Interventional Radiology and New Vascular Imaging ( 第8回国際IVR/ 血管造 2002年05月 Keio Plaza Hotel, Tokyo, Japan The 8th International Symposium on Interventional Radiology and New Vascular Imaging ( 第8回国際IVR/ 血管造
  • 当院におけるｱﾙｺﾞﾝﾋﾟﾗｽﾞﾏ凝固療法  [通常講演]
    田中 陽一; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊
    近大堺カンファレンス 2002年05月 大阪 近大堺カンファレンス
     
    ｱﾙｺﾞﾝﾋﾟﾗｽﾞﾏ凝固療法の新しい治療方法としての有用性や適応について解説した。
  • Evaluation of treatment response after transcatheter arterial embolization mixed with Lipiodol for hepatocellular carcinoma: utility of coded phase inversion harmonic imaging  [通常講演]
    工藤 正俊; 南 康範; 鄭 浩柄; 小川 力; 末冨洋一郎; 福田信宏; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見 幹夫; 前川 清
    Digestive Disease Week-2002 (AGA) 2002年05月 San Francisco Digestive Disease Week-2002 (AGA)
  • Radofrequency ablation (RFA) therapy under harmonic image guidance for the recurrence after local therapy for HCC  [通常講演]
    工藤 正俊; 南 康範; 鄭 浩柄; 小川 力; 末冨洋一郎; 福田信宏; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見 幹夫; 前川 清
    Digestive Disease Week-2002 (AGA) 2002年05月 San Francisco Digestive Disease Week-2002 (AGA)
  • Ultrasonography in pancreatic diseases by contrast-enhanced phase-inversion harmonics with coded pulse  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 鄭 栄琴; 中岡 良介; 末冨洋一郎; 南 康範; 鄭 浩柄; 川崎俊彦
    Digestive Disease Week-2002 (AGA) 2002年05月 San Francisco Digestive Disease Week-2002 (AGA)
  • 2年間の治療成績からみた、HCCに対するRFAによる治療戦略（シンポジウム）  [通常講演]
    鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 川崎俊彦
    第38回日本肝癌研究会 2002年05月 東京ドームホテル, 東京 第38回日本肝癌研究会
  • 肝細胞癌に対する根治的RFA治療後のAFP-L 3分画の意義  [通常講演]
    小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田 無文; 北口 容子; 豊澤 昌子; 石川 恵美; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田 弘一; 松井 繁長; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第88回日本消化器病学会総会 2002年04月 旭川, 北海道 第88回日本消化器病学会総会
  • 真性多血症による食道静脈瘤破裂の1例  [通常講演]
    松井 繁長; 工藤 正俊; 井上 良一; 中岡 良介; 北野 雅之; 福田 信宏; 末冨 洋一郎; 川崎 俊彦; 汐見 幹夫
    第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」) 2002年04月 甲府 第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」)
  • 食道静脈瘤治療後に出血を来した十二指腸静脈瘤の1例  [通常講演]
    松井 繁長; 工藤 正俊; 井上 良一; 中岡 良介; 福田 信宏; 末冨 洋一郎; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」) 2002年04月 甲府 第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」)
  • 不整胃潰瘍辺縁から陳旧化したアニサキス虫体片を認めた1例  [通常講演]
    木下 理恵; 工藤 正俊; 汐見 幹夫; 石川 恵美; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷 逸朗; 川崎 俊彦
    第63回日本消化器内視鏡学会総会 2002年04月 甲府, 山梨 第63回日本消化器内視鏡学会総会
  • 体表式造影超音波検査および超音波内視鏡下造影法による膵腫瘍性病変の診断  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 岡田 無文; 乾 絹世; 市川 勉; 豊澤 昌子; 北口 容子; 石川 恵美; 小川 力; 福田 信宏; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 川崎 俊彦; 汐見 幹夫
    第12回日本腹部造影エコードプラ診断研究会 2002年04月 広島大学医学部, 広島 第12回日本腹部造影エコードプラ診断研究会
  • 特別講演「肝腫瘍の超音波血流画像と治療への応用」  [通常講演]
    工藤 正俊
    第90回鹿児島超音波医学研究会 2002年04月 鹿児島労働衛生センター, 鹿児島 第90回鹿児島超音波医学研究会
  • 特別講演「ラジオ波による肝癌治療: 根治性ならびに効率性向上の試み」  [通常講演]
    工藤 正俊
    第2回福岡肝癌局所治療研究会 2002年04月 アクロス福岡 第2回福岡肝癌局所治療研究会
  • 特別講演「ラジオ波による肝癌治療: 根治性ならびに効率性向上の試み」  [通常講演]
    工藤 正俊
    第2回福岡肝癌局所治療研究会 2002年04月 アクロス福岡 第2回福岡肝癌局所治療研究会
  • Special Lecture "Imaging diagnosis of small nodular lesions in cirrhoric liver.“  [通常講演]
    工藤 正俊
    International Consensus Meeting on Nodular Lesions in Cirrhoric Liver 2002年04月 Kurume International Consensus Meeting on Nodular Lesions in Cirrhoric Liver
  • Special Lecture "Clinical Characteristics of early HCC: A view point from vasculature"  [通常講演]
    工藤 正俊
    International Consensus Meeting on Small Nodular Lesions in Cirrhotic Liver (Supported by Grant-in A 2002年04月 Kurume University School of Medicine, Kurume, Japan International Consensus Meeting on Small Nodular Lesions in Cirrhotic Liver (Supported by Grant-in A
  • Imaging diagnosis of focal nodular hyperplasia  [通常講演]
    工藤 正俊
    Laennec Liver Pathology Society (Organizer: Iwan Wanless, Toronto) 2002年04月 Karatsu, Japan Laennec Liver Pathology Society (Organizer: Iwan Wanless, Toronto)
  • 体表式造影超音波検査および超音波内視鏡下造影法による膵腫瘍性病変の診断. （ワークショップ「胆管癌、膵癌に対する新しい画像診断と治療体系」）  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介
    第88回日本消化器病学会総会 2002年04月 旭川, 北海道 第88回日本消化器病学会総会
  • 肝細胞癌に対するRFA2年間の成績と今後の展望（シンポジウム「肝癌治療の最先端」）  [通常講演]
    鄭 浩柄; 工藤 正俊; 遠田弘一
    第88回日本消化器病学会総会 2002年04月 旭川, 北海道 第88回日本消化器病学会総会
  • 超音波内視鏡下穿刺の有用性と血流評価・遺伝子解析の意義 (シンポジウム「超音波内視鏡下穿刺ー適応と問題点ー」)  [通常講演]
    中岡 良介; 工藤 正俊; 北野 雅之
    第63回日本消化器内視鏡学会総会 2002年04月 甲府, 山梨 第63回日本消化器内視鏡学会総会
  • 人工胸水下造影超音波併用RFAの初期臨床経験  [通常講演]
    南 康範; 工藤 正俊
    第1回関西肝癌局所治療研究会 2002年03月 大阪 第1回関西肝癌局所治療研究会
  • 食道静脈瘤に対するEVL・EIS(EISL)の有用性の検討  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第99回日本内科学会 2002年03月 名古屋 第99回日本内科学会
  • サイズ、数ともに増加中の多発性肝FNHの1例  [通常講演]
    鄭 浩柄; 工藤 正俊; 汐見 幹夫; 松井 繁長; 中岡 良介; 南 康範; 福田 信宏; 石川 恵美; 川崎 俊彦; 末冨 洋一郎; 小川 力
    第34回大阪肝臓病談話会 2002年03月 大阪 第34回大阪肝臓病談話会
  • 内視鏡的粘膜切除にて治療した胃血管腫の1例  [通常講演]
    石川 恵美; 工藤 正俊; 松井 繁長; 乾 絹世; 市川 勉; 岡田 無文; 北口 容子; 豊澤 昌子; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 汐見 幹夫
    第68回日本消化器内視鏡学会近畿地方会 2002年03月 京都 第68回日本消化器内視鏡学会近畿地方会
  • 術中に内視鏡検査にて出血部位を同定できた小腸毛細血管性血管腫の1例  [通常講演]
    福田 信宏; 工藤 正俊; 松井 繁長; 石川 恵美; 乾 絹世; 市川 勉; 岡田 無文; 北口 容子; 豊澤 昌子; 小川 力; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 保田 知生; 新海 政幸; 十川 佳史; 大柳 治正
    第68回日本消化器内視鏡学会近畿地方会 2002年03月 京都 第68回日本消化器内視鏡学会近畿地方会
  • 特別講演「肝疾患におけるハーモニックイメージングー診断から治療応用までー」  [通常講演]
    工藤 正俊
    メディカル・コア 2002年03月 ホテルB&G, 東京 メディカル・コア
  • 特別講演「Coded Harmonic Angioによる肝腫瘍の診断と治療への応用」  [通常講演]
    工藤 正俊
    GE Clinical Forum 2002年03月 リッツカールトンホテル大阪, 大阪 GE Clinical Forum
  • ハンズオンセミナー「肝腫瘍の造影ハーモニックイメージング」  [通常講演]
    工藤 正俊
    2002年03月 宮崎県立病院, 宮崎
  • 特別講演「肝疾患におけるカラードプラと造影エコー法ー基本から実地臨床への応用までー」  [通常講演]
    工藤 正俊
    宮崎県腹部超音波懇話会 2002年03月 宮崎 宮崎県腹部超音波懇話会
  • 特別講演「肝癌の治療のコンセンサス」  [通常講演]
    工藤 正俊
    神戸消化器病セミナー 2002年03月 神戸 神戸消化器病セミナー
  • 特別講演「超音波血流画像による肝腫瘍の診断と治療」  [通常講演]
    工藤 正俊
    第20回東海超音波研究会 2002年03月 第２豊田ビル, 名古屋 第20回東海超音波研究会
  • 特別講演「肝画像診断の進歩」  [通常講演]
    工藤 正俊
    第14回肝臓フォーラム(西部) 2002年03月 大阪 第14回肝臓フォーラム(西部)
  • Angiocentric ＮＫ/Ｔ細胞リンパ腫の消化管浸潤により下血をきたした一例  [通常講演]
    田中 陽一; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊
    第68回日本消化器内視鏡学界地方会 2002年03月 京都 第68回日本消化器内視鏡学界地方会
     
    Angiocentric ＮＫ/Ｔ細胞リンパ腫に伴う消化管出血は知られているが、内視鏡像の記載は乏しく、今回血管中心性発育によると思われる多発打ち抜き様潰瘍像を内視鏡的にとらえることができたので報告した。
  • 体表式造影超音波検査および超音波内視鏡下造影法による膵腫瘍性病変の診断. シンポジウム「各領域における超音波造影検査の現況ーレボビスト超音波造影検査は従来の画像診断をどう変えたか？－」  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清
    第5回関西超音波造影剤研究会 2002年03月 大阪 第5回関西超音波造影剤研究会
  • 膵疾患の鑑別における超音波内視鏡下造影の有用性. ワークショップ「胆膵疾患における最新の内視鏡的アプローチ」  [通常講演]
    末冨 洋一郎; 工藤 正俊; 北野 雅之
    第68回日本消化器内視鏡学会近畿地方会 2002年03月 京都 第68回日本消化器内視鏡学会近畿地方会
  • 上部消化管出血に対するEndoscopic Band Ligation (EBL) と4端子バイポラー高周波電気凝固法の比較検討. シンポジウム「消化管出血に対する止血法の選択」  [通常講演]
    松井 繁長; 工藤 正俊; 汐見 幹夫
    第68回日本消化器内視鏡学会近畿地方会 2002年03月 京都 第68回日本消化器内視鏡学会近畿地方会
  • 胆管ディスプラジアを合併した肝外胆管限局性狭窄の1例  [通常講演]
    田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 辻 直子
    第76回日本消化器病学会近畿支部例会 2002年02月 大阪 第76回日本消化器病学会近畿支部例会
  • 消化管出血を契機に発見された小腸GISTの1例  [通常講演]
    乾 絹世; 工藤 正俊; 松井 繁長; 福田 信宏; 石川 恵美; 小川 力; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 里井 俊平; 保田 知生; 橋本 直樹; 大柳 治正
    第76回日本消化器病学会近畿支部例会 2002年02月 大阪 第76回日本消化器病学会近畿支部例会
  • 急速に進行する肝不全で死亡した原発性アミロイドーシスの1例  [通常講演]
    岡田 無文; 工藤 正俊; 市川 勉; 乾 絹世; 北口 容子; 豊澤 昌子; 石川 恵美; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田 弘一; 松井 繁長; 北野 雅之; 由谷 逸朗; 川崎 俊彦; 汐見 幹夫
    第76回日本消化器病学会近畿支部例会 2002年02月 大阪 第76回日本消化器病学会近畿支部例会
  • DSMを用いたLp-TAE後に急性化化膿性胆管炎を発症した一例  [通常講演]
    北口容子; 工藤 正俊; 鄭 浩柄; 市川 勉; 乾 絹世; 岡田無文; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 南 康範; 末冨洋一郎; 中岡 良介; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫
    第76回日本消化器病学会近畿支部例会 2002年02月 大阪 第76回日本消化器病学会近畿支部例会
  • 超音波内視鏡下穿刺生検が診断に有用であった直径2cmの平滑筋肉腫の1例  [通常講演]
    市川 勉; 工藤 正俊; 福田信宏; 北野 雅之; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 末冨洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田弘一; 松井 繁長; 由谷逸朗; 川崎俊彦; 汐見幹夫
    第76回日本消化器病学会近畿支部例会 2002年02月 大阪 第76回日本消化器病学会近畿支部例会
  • 特別講演「肝疾患の病態・診断・治療ーコンセンサスミーティングをふまえて」  [通常講演]
    工藤 正俊
    神戸肝疾患談話会 2002年02月 神戸 神戸肝疾患談話会
  • 特別講演「超音波血流画像による肝細胞癌の診断と治療」  [通常講演]
    工藤 正俊
    第15回日医放・放射線科専門医会共催冬期セミナー 2002年02月 千里ライフサイエンスセンター, 大阪 第15回日医放・放射線科専門医会共催冬期セミナー
  • 特別講演「肝細胞癌に対する内科的局所治療ーラジオ波焼灼療法を中心にー」  [通常講演]
    工藤 正俊
    第6回Surgical Forum in Osaka 2002年02月 ホテル阪神, 大阪 第6回Surgical Forum in Osaka
  • 講演「肝細胞癌の診断と治療ー最近の進歩ー」  [通常講演]
    工藤 正俊
    姫路消化器病研究会 2002年02月 姫路市医師会館, 姫路 姫路消化器病研究会
  • 「人工胸水下造影超音波併用RFA」の初期臨床経験. シンポジウム「肝胆膵癌治療の新しい展開」  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄
    第76回日本消化器病学会近畿支部例会 2002年02月 大阪 第76回日本消化器病学会近畿支部例会
  • 腹部血管造影検査にて出血部位を同定できた小腸毛細血管性血管腫の1例  [通常講演]
    石川 恵美; 工藤 正俊; 松井 繁長; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 遠田 弘一; 汐見 幹夫; 保田 知生; 新海 政幸; 十川 佳史; 大柳 治正
    第76回日本消化器病学会近畿支部例会 2002年 大阪 第76回日本消化器病学会近畿支部例会
  • Application of harmonic imaging to the treatment of hepatocellular carcinoma  [通常講演]
    工藤 正俊
    The 8th Internationl Symposium on Interventional Radiology & New Vascular Imaging 2002年 Tokyo The 8th Internationl Symposium on Interventional Radiology & New Vascular Imaging
  • EUS下穿刺が診断に有用であった腫瘤形成性膵炎の1症例  [通常講演]
    乾 絹世; 工藤 正俊; 市川 勉; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 新型軽量EUS専用機の使用経験  [通常講演]
    末冨洋一郎; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 胃粘膜下腫瘍におけるEUS下造影エコー法の有用性  [通常講演]
    北野 雅之; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会, 2002年01月 大阪 日本超音波医学会第23回関西地方会,
  • 体表アプローチによる消化管粘膜下腫瘍の造影エコー法について  [通常講演]
    福田信宏; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 肝癌に対するラジオ波治療後の効果判定における造影エコー法の有用性に関する検討  [通常講演]
    鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 造影エコー法により明瞭なnodule in noduleが示された肝細胞癌の2症例  [通常講演]
    豊澤昌子; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • Coded Harmonic Angio H7 modeにおけるレボビスト造影  [通常講演]
    前川 清; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • Aplio SSA-770を用いた肝腫瘤病変のレボビスト造影ー特にAdvanced Dynamic FlowとPulse subtractionについてー  [通常講演]
    鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • Extended Pure Harmonic Detection (ALOKA SSD-6500)を用いた肝腫瘤病変のレボビスト造影  [通常講演]
    小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 診断に難渋した結核性肝腫瘤の1例  [通常講演]
    石川恵美; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 興味ある造影エコー所見を呈した肝内胆管癌の一例  [通常講演]
    北口容子; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 膵臓「造影ハーモニック法およびEUS下造影による膵疾患の鑑別診断」（シンポジウム「各臓器における超音波血流イメージの現状と展望ー臨床をどうかえたかー」）  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 川崎俊彦
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 特別講演「肝癌の病態・診断と治療 Consensus & Recommendation」  [通常講演]
    工藤 正俊
    第2回東神戸消化器疾患セミナー 2002年01月 神鋼病院, 神戸 第2回東神戸消化器疾患セミナー
  • 特別講演「造影ハーモニック法による肝細胞癌の診断と治療」  [通常講演]
    工藤 正俊
    第128回滋賀肝・胆・膵勉強会 2002年01月 京都センチュリーホテル, 京都 第128回滋賀肝・胆・膵勉強会
  • 特別講演「肝細胞癌の超音波血流画像と治療への応用」  [通常講演]
    工藤 正俊
    沖縄肝胆膵疾患研究会 2002年01月 ザナハテラス, 那覇 沖縄肝胆膵疾患研究会
  • 特別講演「肝細胞癌の診断と治療の最近の進歩ー造影ハーモニック法からラジオ波治療までー」  [通常講演]
    工藤 正俊
    第51回近畿大学医学会学術講演会 2002年01月 近畿大学医学部大講堂, 大阪狭山市 第51回近畿大学医学会学術講演会
  • Code Harmonic Angio H7 modeにおけるレボビスト造影  [通常講演]
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
     
    GE社製LOGIQ700EXPERTに新しく加わったCHA H7モードを使用して肝腫瘍症例を対象にレボビスト造影を 行い、興味ある知見を得たので報告した。
  • 膵臓「造影ハーモニック法およびEUS下造影による膵疾患の鑑別診断」（シンポジウム「各臓器における超音波血流イメージの現状と展望ー臨床をどうかえたかー」）  [通常講演]
    北野 雅之; 工藤 正俊; 前川 清; 川崎俊彦
    日本超音波医学会第23回関西地方会 2002年01月 大阪 日本超音波医学会第23回関西地方会
  • 膵疾患に対するEUS-FNAおよびEUS下造影の有用性  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介; 松井 繁長; 汐見幹夫
    第5回南大阪肝胆膵懇話会 2001年12月 近畿大学医学部附属病院, 大阪狭山市 第5回南大阪肝胆膵懇話会
  • Lp-TAEの早期治療効果判定についてー造影超音波ハーモニックイメージングの有用性  [通常講演]
    南 康範; 工藤 正俊; 小川 力; 鄭 浩柄; 川崎俊彦
    第6回肝動脈塞栓療法研究会 2001年12月 神戸 第6回肝動脈塞栓療法研究会
  • ラジオ出演「ウイルス性肝炎・肝癌の診断と治療」  [通常講演]
    工藤 正俊
    毎日放送「家庭医学」 2001年12月 大阪 毎日放送「家庭医学」
  • ＩＢＤにおけるＮＫＴ細胞の役割  [通常講演]
    八木田 旭邦; 丸山 正二; 助川 寧; 工藤 正俊; 高添正和
    厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成13年度第2回総会 2001年12月 東京 厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成13年度第2回総会
  • 講演「C型慢性肝炎における新しい治療戦略」  [通常講演]
    工藤 正俊
    コンセンサスミーティング 2001年11月 ヒルトンホテル大阪, 大阪 コンセンサスミーティング
  • ラジオ出演「肝癌の早期発見と治療」  [通常講演]
    工藤 正俊
    毎日放送「家庭医学」 2001年11月 大阪 毎日放送「家庭医学」
  • Special Lecture "Has vascular enhancement with Levovist changed diagnosis of liver tumors?"  [通常講演]
    工藤 正俊
    The Third International Kyoto Symposium on Ultrasound Contrast Imaging 2001年11月 Kyoto, Japan The Third International Kyoto Symposium on Ultrasound Contrast Imaging
  • 消化管間葉系腫瘍の術前診断におけるEUS下穿刺を含めた超音波内視鏡診断の有用性  [通常講演]
    中岡 良介; 工藤 正俊; 北野 雅之; 松井 繁長; 汐見幹夫
    第62回日本消化器内視鏡学会総会 2001年10月 京都 第62回日本消化器内視鏡学会総会
  • 食道静脈瘤に対するEIS・EVL併用療法(EISL)の評価  [通常講演]
    松井 繁長; 工藤 正俊; 井上良一; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 由谷逸朗; 北野 雅之; 上硲 俊法; 川崎俊彦; 汐見幹夫
    第62回日本消化器内視鏡学会総会 2001年10月 京都 第62回日本消化器内視鏡学会総会
  • CHA( Coded Harmonic Angio)モードを用いた造影ハーモニックイメージングによる膵・胆道領域腫瘍性病変のdynamic image. (パネルディスカッション「膵・胆道領域腫瘍性病変のdynamic image」)  [通常講演]
    北野 雅之; 工藤 正俊; 川崎俊彦
    第43回日本消化器病学会大会 2001年10月 京都 第43回日本消化器病学会大会
  • サイズ, 数ともに増加傾向を示す多発性肝過形成結節の1例  [通常講演]
    鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 南 康範; 末冨洋一郎; 中岡 良介; 中里 勝; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫
    第7回南大阪肝疾患研究会 2001年10月 リーガロイヤルホテル堺, 大阪 第7回南大阪肝疾患研究会
  • 消化管粘膜下腫瘍に対するEUSを用いた血行動態評価およびFNAの有用性. （ワークショップII「消化管粘膜下腫瘍の診断・治療」）  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介
    第67回日本消化器内視鏡学会近畿地方会 2001年10月 大阪 第67回日本消化器内視鏡学会近畿地方会
  • 食道静脈瘤に対するELSLの有用性. （ワークショップI 「食道静脈瘤の治療戦略」）  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介
    第67回日本消化器内視鏡学会近畿地方会 2001年10月 大阪 第67回日本消化器内視鏡学会近畿地方会
  • 消化管内視鏡検査・治療時のインフォームドコンセント. （シンポジウムII「内視鏡診断・治療のリスクマネージメント」）  [通常講演]
    汐見幹夫; 工藤 正俊; 由谷逸朗
    第67回日本消化器内視鏡学会近畿地方会 2001年10月 大阪 第67回日本消化器内視鏡学会近畿地方会
  • 教育講演「肝細胞癌の画像診断の進歩」  [通常講演]
    工藤 正俊
    第6回日本外科病理学会学術総会 2001年10月 神戸大学医学部 第6回日本外科病理学会学術総会
  • ランチョンセミナー「造影エコー診断の肝癌局所治療への応用：治療効果判定・局在および穿刺ガイド」  [通常講演]
    工藤 正俊
    第20回Microwave Surgery研究会 2001年10月 東京ガーデンパレス 第20回Microwave Surgery研究会
  • 特別講演「C型肝炎と肝がんは克服できる: 最新情報」  [通常講演]
    工藤 正俊
    第5回近畿大学公開講座 2001年10月 さやかホール, 大阪狭山市 第5回近畿大学公開講座
  • Evaluation of treatment response after transcatheter arterial embolization mixed with Lipiodol for hepatocellular carcinoma: Utility of coded phase inversion  [通常講演]
    工藤 正俊; 南 康範; 鄭 浩柄; 末冨洋一郎; 川崎俊彦; 前川 清; 文 艶玲; 北野 雅之
    2001年10月 Kuala Lumpur, Malaysia
  • Characterization of hepatic tumours: Value of coded phase inversion harmonics  [通常講演]
    工藤 正俊; 南 康範; 鄭 浩柄; 末冨洋一郎; 北野 雅之; 川崎俊彦; 前川 清; 文 艶玲
    2001年10月 Kuala Lumpur, Malaysia
  • Radiofrequency ablation (RFA) therapy under harmonic imaging guidance for recurrence of hepatocellular carcinoma (HCC) after local therapy  [通常講演]
    工藤 正俊; 南 康範; 鄭 浩柄; 川崎俊彦; 文 艶玲; 北野 雅之; 前川 清
    2001年10月 Kuala Lumpur, Malaysia
  • CHA (Coded Harmonic Angio)モードを用いた造影ハーモニックイメージングによる膵・胆道領域腫瘍性病変のdynamic image. (パネルディスカッション「膵胆道領域腫瘍性病変のdynamic image」)  [通常講演]
    北野 雅之; 工藤 正俊; 川崎俊彦
    第43回日本消化器病学会大会 2001年10月 京都 第43回日本消化器病学会大会
  • 消化管粘膜下腫瘍に対するEUSを用いた血行動態評価およびFNAの有用性. （ワークショップII「消化管粘膜下腫瘍の診断・治療」）  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介
    第67回日本消化器内視鏡学会近畿地方会 2001年10月 大阪 第67回日本消化器内視鏡学会近畿地方会
  • 消化管内視鏡検査・治療時のインフォームドコンセント. （シンポジウムII「内視鏡診断・治療のリスクマネージメント」）  [通常講演]
    汐見 幹夫; 工藤 正俊; 由谷 逸朗
    第67回日本消化器内視鏡学会近畿地方会 2001年10月 大阪 第67回日本消化器内視鏡学会近畿地方会
  • Levovistを用いた超音波造影撮像法Coded Harmonic Angio (LOGIQ700EXPERT)による肝腫瘍の質的診断  [通常講演]
    前川 清; 工藤 正俊; 文 艶玲; 鄭 浩柄; 末冨洋一郎; 南 康範; 川崎俊彦
    第4回関西超音波造影剤研究会 2001年09月 大阪 第4回関西超音波造影剤研究会
  • 肝脾サルコイドーシスの一例  [通常講演]
    田中 陽一; 工藤 正俊; 米田 円; 辻 直子
    第75回日本消化器病学会近畿支部例会 2001年09月 大阪国際交流センター 第75回日本消化器病学会近畿支部例会
  • 生体豚肝を用いたラジオ波焼灼療法の基礎的検討  [通常講演]
    鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 南 康範; 末冨洋一郎; 中岡 良介; 中里 勝; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫
    第75回日本消化器病学会近畿支部例会 2001年09月 大阪国際交流センター 第75回日本消化器病学会近畿支部例会
  • 肝細胞癌（HCC）に対するラジオ波（RFA）後に十二指腸穿通をきたした一例  [通常講演]
    末冨洋一郎; 工藤 正俊; 松井 繁長; 北口容子; 豊澤昌子; 乾 絹世; 岡田無文; 市川 勉; 石川恵美; 小川 力; 福田信宏; 南 康範; 鄭 浩柄; 中岡 良介; 北野 雅之; 由谷逸朗; 上硲 俊法; 川崎俊彦; 汐見幹夫
    第75回日本消化器病学会近畿支部例会 2001年09月 大阪国際交流センター 第75回日本消化器病学会近畿支部例会
  • 肝血管腫に類似した画像所見を呈した肝細胞癌の1例  [通常講演]
    小川 力; 工藤 正俊; 川崎俊彦; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 乾 可苗; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷逸朗; 汐見幹夫
    第75回日本消化器病学会近畿支部例会 2001年09月 大阪国際交流センター 第75回日本消化器病学会近畿支部例会
  • 部分的脾動脈塞栓術後内視鏡的治療が奏効した十二指腸静脈瘤出血の1例  [通常講演]
    松井 繁長; 工藤 正俊; 井上良一; 中岡 良介; 北野 雅之; 川崎俊彦; 汐見幹夫
    第8回門脈圧亢進症学会総会 2001年09月 金沢 第8回門脈圧亢進症学会総会
  • 教育講演「血流で何が解るか－造影ハーモニックイメージング」  [通常講演]
    南 康範; 工藤 正俊
    日本超音波医学会第22回関西地方会 2001年09月 国立京都国際会館 日本超音波医学会第22回関西地方会
  • Levovist静注Coded Harmonic AngioによるGastro-intestinal stromal tumor (GIST)像の検討  [通常講演]
    福田信宏; 工藤 正俊; 北野 雅之; 文 艶玲; 小川 力; 南 康範; 末冨洋一郎; 鄭 浩柄; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 中里 勝; 松井 繁長; 中岡 良介; 石川恵美; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第22回関西地方会 2001年09月 国立京都国際会館 日本超音波医学会第22回関西地方会
  • 画像診断にて脾血管腫が強く疑われた1症例  [通常講演]
    岡田無文; 工藤 正俊; 川崎俊彦; 文 艶玲; 小川 力; 南 康範; 末冨洋一郎; 鄭 浩柄; 遠田弘一; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 石川恵美; 市川 勉; 乾 絹世; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第22回関西地方会 2001年09月 国立京都国際会館 日本超音波医学会第22回関西地方会
  • 人工胸水併用造影ハーモニックガイド下RFA治療の試み  [通常講演]
    小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 文 艶玲; 末冨洋一郎; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 石川恵美; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第22回関西地方会 2001年09月 国立京都国際会館 日本超音波医学会第22回関西地方会
  • 肝炎症性腫瘤の1例  [通常講演]
    石川恵美; 工藤 正俊; 文 艶玲; 小川 力; 南 康範; 末冨洋一郎; 鄭 浩柄; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第22回関西地方会 2001年09月 国立京都国際会館 日本超音波医学会第22回関西地方会
  • Levovistを用いた超音波造影撮像法 Coded Harmonic Angio (LOGIQ700EXEPERT)による肝腫瘍の質的判断  [通常講演]
    2001年09月 第4回関西超音波造影研究会（大阪） 関西超音波造影研究会
     
    Coded Harmonic Angio(以下CHA、GELOGUQ700EXEPERT)を用いて未治療の肝占拠性病変143症例（肝細胞127例を含む）についてLevovistによる超音波造影を施行し、HCC121例中127例が豊富な血液構築像と早期濃染像を呈し、特徴的なタイプに分類が可能であった。また、転移性肝癌で50％およびAHの75％が特徴的なタイプに分類が可能であった。血行動態パターン分類にて鑑別診断が容易になる可能性について報告した。
  • 特別講演「肝におけるカラー/ パワードプラと経静脈的造影超音波の臨床的意義」  [通常講演]
    工藤 正俊
    北海道腹部造影エコー・ドプラ診断研究会 2001年09月 札幌 北海道腹部造影エコー・ドプラ診断研究会
  • 教育講演「肝癌の局所治療」  [通常講演]
    工藤 正俊
    日本ハイパーサーミア学会第18回大会 2001年09月 東京都文京シビックホール, 東京 日本ハイパーサーミア学会第18回大会
  • 特別講演「造影ハーモニック法による肝細胞癌の診断と治療, 最近の新しい展開」  [通常講演]
    工藤 正俊
    腹部造影超音波セミナー 2001年09月 新潟大学, 新潟 腹部造影超音波セミナー
  • ハンズオンセミナー「肝細胞癌の造影ハーモニックイメージングのコツ」  [通常講演]
    工藤 正俊
    新潟大学病院 2001年09月 新潟 新潟大学病院
  • 特別講演「肝細胞癌の診断と治療の最近の進歩－造影エコーからRFAまで」  [通常講演]
    工藤 正俊
    山梨外科医会 2001年09月 ロイヤルガーデンホテル, 甲府 山梨外科医会
  • ランチョンセミナー「肝細胞癌の発生・進展と血流動態－造影ハーモニック法も含めて－」  [通常講演]
    工藤 正俊
    第12回日本消化器癌発生学会総会 2001年09月 シェーンバッハ・サボー, 東京 第12回日本消化器癌発生学会総会
  • シンポジウム「消化器疾患診断における最先端（消化管）」: EUS下穿刺及び造影併用超音波内視鏡診断の有用性  [通常講演]
    中岡 良介; 工藤 正俊; 北野 雅之
    第75回日本消化器病学会近畿支部例会 2001年09月 大阪国際交流センター 第75回日本消化器病学会近畿支部例会
  • 特別講演「肝細胞癌治療の課題－画像診断の立場から」  [通常講演]
    工藤 正俊
    第22回犬山シンポジウム 2001年08月 名鉄犬山ホテル, 犬山市 第22回犬山シンポジウム
  • 特別講演「造影ハーモニックイメージングの治療への応用」  [通常講演]
    工藤 正俊
    GE Ultrasound Clinical Forum 2001 2001年08月 毎日新聞オーバルホール, 大阪 GE Ultrasound Clinical Forum 2001
  • 長期間ラミブジンを投与中のB型慢性肝炎の1例  [通常講演]
    鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 文 艶玲; 末冨洋一郎; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 石川恵美; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子
    第2回関西B型肝炎研究会 2001年07月 ガーデンシティ－クラブ大阪 第2回関西B型肝炎研究会
  • 特別講演「血流動態からみた肝細胞癌の診断と治療」  [通常講演]
    工藤 正俊
    第79回熊本肝疾患懇話会 2001年07月 熊本市医師会館, 熊本 第79回熊本肝疾患懇話会
  • 特別講演「肝細胞癌の局所治療法：ラジオ波治療を中心に」  [通常講演]
    工藤 正俊
    津山肝疾患研究会 2001年07月 津山鶴山ホテル, 津山市 津山肝疾患研究会
  • 特別講演「肝細胞癌の診断と治療: 最近の新しい展開」  [通常講演]
    工藤 正俊
    腹部超音波造影セミナー「Clinical Forum in Nagoya」 2001年07月 名古屋市吹上ホール, 名古屋 腹部超音波造影セミナー「Clinical Forum in Nagoya」
  • 特別講演「造影ハーモニック法による肝細胞癌の診断と治療」  [通常講演]
    工藤 正俊
    GE Ultrasound Clinical Forum 2001年07月 仙台国際センター, 仙台 GE Ultrasound Clinical Forum
  • 特別講演「造影ハーモニック法による肝細胞癌の診断と治療: 最近の新しい展開」  [通常講演]
    工藤 正俊
    超音波クリニカルフォーラム 2001年07月 野口英世 記念会館, 東京 超音波クリニカルフォーラム
  • 炎症性腸疾患におけるＮＫＴ細胞の役割り  [通常講演]
    八木田 旭邦; 丸山 正二; 若杉慎司; 助川 寧; 工藤 正俊; 高添正和
    厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成１３年度第１回総会 2001年07月 厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成１３年度第１回総会
  • 続発性ヘモクロマトーシスに肝細胞癌(HCC)を合併した1症例  [通常講演]
    鄭 浩柄; 工藤 正俊; 南 康範; 末冨洋一郎; 川崎俊彦; 金丸 昭久
    第37回日本肝癌研究会 2001年06月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • 肝細胞癌に対する経皮経肝高周波焼灼術にて門脈内血栓の形成を認めた1症例  [通常講演]
    末冨洋一郎; 工藤 正俊; 永島美樹; 南 康範; 鄭 浩柄; 川崎俊彦
    第37回日本肝癌研究会 2001年06月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • 肝細胞癌におけるCoded Harmonic Angioを用いた血行動態分類と治療効果判定  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 末冨洋一郎; 遠田弘一; 川崎俊彦; 文 艶玲; 前川 清
    第37回日本肝癌研究会 2001年06月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • 問題症例検討会,「治療を中心に」  [通常講演]
    鄭 浩柄; 工藤 正俊; 南 康範; 末冨洋一郎; 川崎俊彦
    第37回日本肝癌研究会 2001年06月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • 特別講演「肝硬変の血流動態: 超音波血流画像解析と病態」  [通常講演]
    工藤 正俊
    肝疾患病理研究会 2001年06月 東京 肝疾患病理研究会
  • 特別講演「肝細胞癌の診断と治療: 最近の進歩」  [通常講演]
    工藤 正俊
    日本消化器病学会第77回九州支部例会（北野正剛会長） 2001年06月 別府 日本消化器病学会第77回九州支部例会（北野正剛会長）
  • ランチョンセミナー「超音波を用いた肝癌治療のstrategy: 造影超音波の肝癌局所治療への応用」  [通常講演]
    工藤 正俊
    第37回日本肝癌研究会 2001年06月 海峡 メッセ下関, 下関 第37回日本肝癌研究会
  • Invited Lecture "Recent Advances of Imaging Diagnosis and Ablation of Hepatocellular Carcinoma"  [通常講演]
    工藤 正俊
    The 3rd symposium of the Korean Liver Cancer Study Group (KLCSG) 2001年06月 Seoul, Korea The 3rd symposium of the Korean Liver Cancer Study Group (KLCSG)
  • Invited Lecture "Diagnosis and Treatment of Hepatocellular Carcinoma: Recent advances"  [通常講演]
    工藤 正俊
    The 857th Radiology Ground Round 2001年06月 Seoul National University, Seoul, Korea The 857th Radiology Ground Round
  • TAEは肝細胞癌の生存率に寄与するか？ -無治療群を対象としての検討-. (ワークショップ「肝動脈塞栓療法の再評価と今後の展開」)  [通常講演]
    岡 博子; 工藤 正俊; 山崎 修; 真鍋隆夫; 井上 健; 関 寿人; 大崎往夫; 春日井博志
    第37回日本肝癌研究会 2001年06月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • 肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 造影超音波ハーモニック法の有用性について. (ワークショップ「肝動脈塞栓療法の再評価と今後の展開」)  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 遠田弘一; 川崎俊彦; 文 艶玲; 前川 清
    第37回日本肝癌研究会 2001年06月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • オリンパス社製Sonosite 180の画質性能に関する検討  [通常講演]
    文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨洋一郎; 遠田弘一; 川崎俊彦; 江口真由美; 前川 清; 丁 紅
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 肝細胞癌 (HCC)局所治療後の遺残癌に対する造影超音波下RFAの試み  [通常講演]
    鄭 浩柄; 工藤 正俊; 文 艶玲; 南 康範; 末冨洋一郎; 遠田弘一; 川崎俊彦; 江口真由美; 前川 清; 丁 紅
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 造影超音波ハーモニック法の有用性について  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 遠田弘一; 丁 紅; 文 艶玲; 川崎俊彦; 桑口 愛; 前川 清
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • Coded Harmonic Angioによる肝腫瘍の血行動態的パターン分類の試み  [通常講演]
    日本超音波医学会第７４回学術集会（東京） 2001年05月 日本超音波医学会第７４回学術集会（東京）
     
    Coded Harmonic Angio（以下CHA、GE LOGIQ700EXPERT）を用いて未治療の肝占拠性病変８７症例（肝細胞癌５８症例を含む）についてLevovistによる超音波造影を施行し、HCC５８例中４９例の84.5%が豊富な血管構築像と早期濃染像を呈し、特徴的なタイプに分類が可能であった。また、CCCで50％、転移性肝癌で50％およびAHの75％が特徴的なタイプに分類が可能であった。血行分類パターンにて鑑別診断が容易になる可能性が示唆された。
  • 特別講演「肝腫瘤性病変の造影超音波診断」  [通常講演]
    工藤 正俊
    超音波造影剤学術講演会 2001年05月 新大阪シティプラザ 超音波造影剤学術講演会
  • 特別講演「肝細胞診療の最近の進歩: 超音波造影からRFAまで」  [通常講演]
    工藤 正俊
    岡山血管造影・INTERVENTIONAL RADIOLOGY症例検討会(SAIRO) 2001年05月 岡山大学放射線科カンファレンスルーム, 岡山 岡山血管造影・INTERVENTIONAL RADIOLOGY症例検討会(SAIRO)
  • 特別講演「造影エコー法による肝細胞癌の診断と治療」  [通常講演]
    工藤 正俊
    第74回佐賀肝臓懇話会 2001年05月 ホテルニューオータニ佐賀, 佐賀 第74回佐賀肝臓懇話会
  • 特別講演「肝細胞癌診療の最近の進歩: 造影ハーモニック法からRFAまで」  [通常講演]
    工藤 正俊
    第41回山口県肝癌治療検討会 2001年05月 山口 第41回山口県肝癌治療検討会
  • 教育講演「造影エコー診断の治療への応用: 治療効果判定・穿刺ガイド」  [通常講演]
    工藤 正俊
    第19回超音波専門医・検査士セミナー 2001年05月 パシフィコ横浜, 横浜 第19回超音波専門医・検査士セミナー
  • ランチョンセミナー「携帯型超音波の現状と今後の展望」  [通常講演]
    工藤 正俊
    第74回日本超音波医学会学術集会 2001年05月 横浜 第74回日本超音波医学会学術集会
     
    ランチョンセミナー「携帯型超音波の現状と今後の展望」 , ,
  • ランチョンセミナー「肝細胞癌の診断と治療の最近の進歩:造影エコーからRFAまで」  [通常講演]
    工藤 正俊
    第37回日本肝臓学会総会 2001年05月 パシフィコ横浜, 横浜 第37回日本肝臓学会総会
  • 門脈血流流入結節の造影ハーモニック法の検討.  [通常講演]
    鄭 浩柄; 工藤 正俊; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 大谷真由美; 前川 清; 丁 紅; 文 艶玲
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • Levovist造影によるFundamental Power Doppler とHarmonic Power Dopplerの肝腫瘍内血流検出能の比較検討.  [通常講演]
    文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 大谷真由美; 前川 清; 丁 紅
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • FNHにおける造影ハーモニック像の検討.  [通常講演]
    文 艶玲; 工藤 正俊; 丁 紅; 前川 清; 桑口 愛; 南 康範; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 超小型コンベックスアレイを内蔵したEUSの使用経験.  [通常講演]
    末冨 洋一郎; 工藤 正俊; 川崎 俊彦; 南 康範; 文 艶玲; 丁 紅; 遠田 弘一; 鄭 浩柄; 前川 清; 桑口 愛
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • Coded Harmonic Angioによる肝腫瘍の血行動態的パターン分類の試み.  [通常講演]
    前川 清; 工藤 正俊; 大谷真由美; 文 艶玲; 丁 紅; 末冨 洋一郎; 鄭 浩柄; 南 康範; 遠田 弘一; 川崎 俊彦
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • Levovist(R)静注Coded Harmonic Angioによる肝血管腫像の検討.  [通常講演]
    川崎 俊彦; 工藤 正俊; 文 艶玲; 南 康範; 末冨 洋一郎; 鄭 浩柄; 遠田 弘一; 江口真由美; 前川 清; 丁 紅
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 肝細胞癌 (HCC)局所治療後の遺残癌に対する造影超音波下RFAの試み.  [通常講演]
    鄭 浩柄; 工藤 正俊; 遠田 弘一; 川崎 俊彦
    2001年05月
  • 肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 造影超音波ハーモニック法の有用性について.  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 北野 雅之; 遠田 弘一; 川崎 俊彦; 文 艶玲; 前川 清
    第37回日本肝臓学会総会 2001年05月 パシフィコ横浜, 横浜 第37回日本肝臓学会総会
  • 保存的に治療し得た若年膵管内結石症の1例.  [通常講演]
    木下 理恵; 工藤 正俊; 汐見 幹夫; 福田 信宏; 南 康範; 末冨 洋一郎; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦
    第61回日本消化器内視鏡学会総会 2001年05月 神戸 第61回日本消化器内視鏡学会総会
  • 上部消化管疾患に対するアルゴンプラズマ凝固法 (Argon Plasma Coagulation; APC)治療の有用性の検討.  [通常講演]
    中岡 良介; 工藤 正俊; 汐見 幹夫; 末冨 洋一郎; 南 康範; 鄭 浩柄; 松井 繁長; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦
    第61回日本消化器内視鏡学会総会 2001年05月 神戸 第61回日本消化器内視鏡学会総会
  • Role of ECL-cell histamine in acute gastric mucosal damage induced by ischemia-reperfusion  [通常講演]
    北野 雅之; 工藤 正俊
    Digestive Disease Week-2001 2001年05月 Atlanta, Georgi Digestive Disease Week-2001
  • 肝細胞癌(HCC)に対する経皮的ラジオ波熱凝固療法(RFA)の検討. (シンポジウム「ラジオ波焼灼術の適応・効果・合併症」)  [通常講演]
    鄭 浩柄; 工藤 正俊; 遠田弘一; 南 康範; 末冨 洋一郎; 川崎俊彦
    第37回日本肝癌研究会 2001年05月 海峡メッセ下関, 下関 第37回日本肝癌研究会
  • 臓器血流量測定の意義, 臨床測定の意義, 臨床応用, 問題点: 肝血流計測の臨床応用問題点. インターネットディスカッション「血流量計測の臨床応用と問題点」.  [通常講演]
    川崎俊彦; 工藤 正俊
    日本超音波医学会第74回学術集会 2001年05月 日本超音波医学会第74回学術集会
  • 高分解能造影モードによる腫瘍血流の動的・形態的解析 (シンポジウム「肝腫瘍における造影エコー法の応用」)  [通常講演]
    川崎俊彦; 工藤 正俊; 前川 清
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 造影エコーの治療的応用. (シンポジウム「 造影エコー法の理論と実際」)  [通常講演]
    南 康範; 工藤 正俊; 文 艶玲; 末冨 洋一郎; 鄭 浩柄; 遠田弘一; 川崎俊彦
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 肝腫瘍診断におけるHarmonic Imaging法の現況と臨床的有用性. (シンポジウム「Tissue Harmonic Imagingの理論と実際」)  [通常講演]
    鄭 浩柄; 工藤 正俊; 前川 清; 杤尾人司
    日本超音波医学会第74回学術集会 2001年05月 東京ビッグサイト, 東京 日本超音波医学会第74回学術集会
  • 血流動態より境界病変と考えられる硬変肝内微少結節性病変の予後 (パネルディスカッション「肝硬変に生じた小結節性病変の診断と対応」)  [通常講演]
    福永豊和; 工藤 正俊; 織野彬雄
    第37回日本肝臓学会総会 2001年05月 パシフィコ横浜, 横浜 第37回日本肝臓学会総会
  • 肝細胞癌に対するRadiofrequency ablation therapy後の造影CT所見についての検討  [通常講演]
    栁生 行伸; 井上 正昭; 大石 初香; 西村 恭昌; 工藤 正俊; 小野 幸彦
    第60回日本医学放射線学会総会 2001年04月 東京 第60回日本医学放射線学会総会
     
    肝細胞癌に対するRadiofrequency ablation therapy後治療部周囲に生じる造影効果の持続期間、造影効果の範囲について検討した。術直後の造影効果については可逆性であり、熱凝固による血管透過性亢進などが関与していると考えられた
  • 特別講演「造影エコー法による肝細胞癌の診断と治療」  [通常講演]
    工藤 正俊
    第5回MRI検討会 2001年04月 福島テルサ, 福島 第5回MRI検討会
  • TAE治療後にHarmonic Imaging にて血流の残存を認めた肝細胞がん結節の予後. 「肝細胞がんに対する肝動脈塞栓療法の延命効果に関する研究」.  [通常講演]
    南 康範; 工藤 正俊; 川崎 俊彦
    平成13年度第1回厚生省班会議 2001年04月 国立がんセンター, 東京 平成13年度第1回厚生省班会議
  • 肝細胞癌（HCC）に対するLipTAE治療効果判定における造影ハーモニックエコー法（CHA）の有用性.  [通常講演]
    南 康範; 工藤 正俊; 文 艶玲; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 川崎俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清
    日本超音波医学会第21回関西地方会 2001年04月 大阪 日本超音波医学会第21回関西地方会
  • 特別講演「造影エコー法による肝腫瘍の診断と治療」  [通常講演]
    工藤 正俊
    備後肝胆膵研究会 2001年03月 福山 備後肝胆膵研究会
  • 特別講演「肝臓の超音波解剖と超音波診断」  [通常講演]
    工藤 正俊
    全国社会保険協会連合会, 平成12年度 超音波研究会 2001年03月 全社連会館, 東京 全国社会保険協会連合会, 平成12年度 超音波研究会
  • 間歇的に主乳頭からの粘液排泄が見られた粘液産生膵腫瘍の2手術例.  [通常講演]
    福田 信宏; 工藤 正俊; 汐見 幹夫; 木下 理恵; 南 康範; 末冨 洋一郎; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦
    第66回日本消化器内視鏡学会近畿地方会 2001年03月 大阪 第66回日本消化器内視鏡学会近畿地方会
  • 十二指腸静脈瘤出血の1例.  [通常講演]
    永島 美樹; 工藤 正俊; 松井 繁長; 小村 康湖; 乾 可苗; 石川 恵美; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 井上 良一
    第66回日本消化器内視鏡学会近畿地方会 2001年03月 大阪 第66回日本消化器内視鏡学会近畿地方会
  • 超小型コンベックスアレイを内蔵したEUSが診断に有用であった胃粘膜下腫瘍の1症例.  [通常講演]
    北野 雅之; 工藤 正俊; 中岡 良介; 前川 清; 末冨 洋一郎; 南 康範; 鄭 浩柄; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫
    第66回日本消化器内視鏡学会近畿地方会 2001年03月 大阪 第66回日本消化器内視鏡学会近畿地方会
  • ワークショップIII「肝胆膵疾患とステント」悪性胆道閉塞に対するステント治療  [通常講演]
    松井 繁長; 工藤 正俊; 中岡 良介; 汐見 幹夫
    第66回日本消化器内視鏡学会近畿地方会 2001年03月 大阪 第66回日本消化器内視鏡学会近畿地方会
  • 特別講演「肝細胞癌治療におけるAFP-L3分画の役割と意義」OLM（大阪Liver Meeting）  [通常講演]
    工藤 正俊
    大阪大学第一内科消化器グループ関連病院会議 2001年02月 大阪 大阪大学第一内科消化器グループ関連病院会議
  • 特別講演「肝細胞癌に対するラジオ波熱凝固療法(RFA)の現況」  [通常講演]
    工藤 正俊
    第16回神戸消化器病懇話会 2001年02月 神戸 第16回神戸消化器病懇話会
  • 教育講演「肝疾患における造影エコー法の実際」  [通常講演]
    工藤 正俊
    第90回超音波診断法講習会（日本超音波医学会主催） 2001年02月 パシフィコ横浜, 横浜 第90回超音波診断法講習会（日本超音波医学会主催）
  • 特別講演「肝細胞癌の血流と画像」  [通常講演]
    工藤 正俊
    第90回名古屋肝疾患研究会 2001年02月 栄ガスビル, 名古屋 第90回名古屋肝疾患研究会
  • 特別講演「超音波血流画像による肝細胞癌の血流動態の解析」  [通常講演]
    工藤 正俊
    第7回肝血流動態イメージ研究会 2001年02月 東京商工会議所, 東京 第7回肝血流動態イメージ研究会
  • Special Lecture "Diagnosis and Treatment of Hepatocellular Carcinoma: Special Emphasis on Harmonic Imaging"  [通常講演]
    工藤 正俊
    GE Medical Meeting in Milwaukee 2001年02月 Milwaukee GE Medical Meeting in Milwaukee
  • 肝細胞癌に対するLipiodol TAE後の治療効果判定と治療ガイド: Coded Phase-inversion Harmonicsの有用性.  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 中岡 良介; 遠田 弘一; 北野 雅之; 川崎 俊彦
    第36回京都肝疾患懇話会 2001年02月 京都ホテル, 京都 第36回京都肝疾患懇話会
  • 超小型コンベックスアレイを内蔵したEUSの使用経験.  [通常講演]
    末冨 洋一郎; 工藤 正俊; 北野 雅之; 南 康範; 文 艶玲; 遠田 弘一; 鄭 浩柄; 中岡 良介; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 前川 清; 江口真由美; 大谷真由美; 桑口 愛; 川端久美子
    第3回関西超音波造影剤研究会 2001年02月 大阪 第3回関西超音波造影剤研究会
  • 肝細胞癌（HCC）に対する経皮経肝高周波焼灼術（RFA）後に門脈内血栓の形成を認めた1症例.  [通常講演]
    永島 美樹; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 汐見 幹夫; 中岡 良介; 小村 康湖; 石川 恵美; 乾 可苗; 上硲 俊法
    第74回日本消化器病学会近畿支部例会 2001年02月 京都 第74回日本消化器病学会近畿支部例会
  • 動注化学療法及び経皮経肝ラジオ波焼灼術のコンビネーション治療が著効を呈したStage IV-A肝細胞癌の1例.  [通常講演]
    乾 可苗; 工藤 正俊; 小村 康湖; 由谷 逸朗; 川崎 俊彦; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 汐見 幹夫; 上硲 俊法; 北野 雅之; 松井 繁長; 中岡 良介; 永島 美樹; 石川 恵美
    第74回日本消化器病学会近畿支部例会 2001年02月 京都 第74回日本消化器病学会近畿支部例会
  • 興味ある画像所見を呈した硬化型肝細胞癌の1例.  [通常講演]
    小村 康湖; 工藤 正俊; 川崎 俊彦; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 永島 美樹; 石川 恵美; 乾 可苗
    第74回日本消化器病学会近畿支部例会 2001年02月 京都 第74回日本消化器病学会近畿支部例会
  • 続発性ヘモクロマトーシスに肝細胞癌（HCC）を合併した1症例.  [通常講演]
    鄭 浩柄; 工藤 正俊; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 南 康範; 末冨 洋一郎; 中岡 良介; 北野 雅之; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 金丸 昭久
    第74回日本消化器病学会近畿支部例会 2001年02月 京都 第74回日本消化器病学会近畿支部例会
  • OLYMPUS社製Sonosite 180の画像性能に関する検討.  [通常講演]
    文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清
    日本超音波医学会第21回関西地方会 2001年02月 大阪 日本超音波医学会第21回関西地方会
  • レボビスト造影下狙撃生検が有用であった限局性結節性過形成（FNH）の1例.  [通常講演]
    小村 康湖; 工藤 正俊; 中岡 良介; 文 艶玲; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 石川 恵美; 乾 可苗; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清
    日本超音波医学会第21回関西地方会 2001年02月 大阪 日本超音波医学会第21回関西地方会
  • 造影超音波検査にて特徴的な血行動態を把握し得た肝血管筋脂肪腫（AML）の1例.  [通常講演]
    石川 恵美; 工藤 正俊; 南 康範; 文 艶玲; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清
    日本超音波医学会第21回関西地方会 2001年02月 大阪 日本超音波医学会第21回関西地方会
  • 超音波内視鏡 (EUS)下レボビスト造影を施行した胃粘膜下腫瘍の1例.  [通常講演]
    中岡 良介; 工藤 正俊; 北野 雅之; 末冨 洋一郎; 鄭 浩柄; 文 艶玲; 南 康範; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 松井 繁長; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清
    日本超音波医学会第21回関西地方会 2001年02月 大阪 日本超音波医学会第21回関西地方会
  • 肝細胞癌局所治療後の遺残癌に対する造影超音波下RFAの試み.  [通常講演]
    鄭 浩柄; 工藤 正俊; 文 艶玲; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清
    日本超音波医学会第21回関西地方会 2001年02月 大阪 日本超音波医学会第21回関西地方会
  • 肝細胞癌の多段階発育に伴う流出血管の変遷について: 超音波ドプラ法による検討  [通常講演]
    杤尾人司; 工藤 正俊; 佐々木一朗; 岩崎信広; 浜田一美; 中村仁美; 中山圭子; 曽我登志子; 藤本敏明; 森本義人; 岡部純弘; 高橋 健; 西本正興; 西馬信一; 上島一臣; 木本直哉; 岡田明彦; 樫田博史; 平佐昌弘; 伊吹康良; 織野彬雄; 冨田周介
    第7回肝血流動態イメージ研究会 2001年02月 東京 第7回肝血流動態イメージ研究会
  • 超音波ドプラ法で評価した肝動脈の末梢血管抵抗（Resistant Index）と脾腫との関係: 肝硬変に随伴する脾腫大の機序について.  [通常講演]
    杤尾人司; 工藤 正俊; 佐々木一朗; 岩崎信広; 浜田一美; 中村仁美; 中山圭子; 曽我登志子; 藤本敏明; 森本義人; 岡部純弘; 高橋 健; 西本正興; 西馬信一; 上島一臣; 木本直哉; 岡田明彦; 樫田博史; 平佐昌弘; 伊吹康良; 織野彬雄; 冨田周介
    第7回肝血流動態イメージ研究会 2001年02月 東京 第7回肝血流動態イメージ研究会
  • 肝細胞癌（HCC）局所治療後の遺残癌に対する造影超音波下RFAの試み.  [通常講演]
    鄭 浩柄; 工藤 正俊; 南 康範; 遠田弘一; 川崎俊彦; 文 艶玲
    第7回肝血流動態イメージ研究会 2001年02月 東京 第7回肝血流動態イメージ研究会
  • シンポジウム「高齢化社会と超音波医学」高齢者における消化器疾患の臨床像と腹部超音波検査の役割  [通常講演]
    南 康範; 工藤 正俊; 川崎俊彦
    日本超音波医学会第21回関西地方会 2001年02月 大阪 日本超音波医学会第21回関西地方会
  • 肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 超音波harmonic imagingの有用性について.  [通常講演]
    南 康範; 工藤 正俊; 鄭 浩柄; 末富洋一郎; 遠田弘一; 川崎俊彦; 文 艶玲; 前川 清
    第7回肝血流動態イメージ研究会 2001年02月 東京 第7回肝血流動態イメージ研究会
  • B-modeにて同定困難な症例における超音波造影下治療の検討  [通常講演]
    南 康範; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2001年01月 大阪 日本超音波医学会第23回関西地方会
  • 肝静脈が主たる流出血管であることが造影エコー法により示された肝血管筋脂肪腫の2症例  [通常講演]
    鄭 栄琴; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清
    日本超音波医学会第23回関西地方会 2001年01月 大阪 日本超音波医学会第23回関西地方会
  • 特別講演「肝腫瘍の血流と病態」  [通常講演]
    工藤 正俊
    第4回信州肝疾患研究会 2001年01月 信州大学附属病院, 松本 第4回信州肝疾患研究会
  • 特別講演「肝細胞癌の血流と病態・治療」  [通常講演]
    工藤 正俊
    第27回肝臓研究会 2001年01月 経団連会館, 東京 第27回肝臓研究会
  • 肝細胞癌の超音波造影  [通常講演]
    ザ・ベストイメージ2000画論ミレニアム 2000年12月 東京 ザ・ベストイメージ2000画論ミレニアム
     
    高分子および中分化域を有する肝細胞癌についてLevovistを用いた造影超音波検査を行い、腫瘍血管造影効果および実質濃染像より腫瘍の分化度に一致した造影効果が得られたので報告した。
  • 自己免疫性胃炎、悪性貧血を合併した自己免疫性甲状腺疾患の一例  [通常講演]
    北野 元一; 青木 矩彦; 藤本 美香; 矢田 裕人; 宮武 利行; 山内 孝哲; 西村 明芳; 荒井 宏司; 大野 恭裕; 松井 繁長; 工藤 正俊
    第162回日本内科学会近畿地方会 2000年09月 大阪 第162回日本内科学会近畿地方会
  • 超音波検査で壁の血流を詳細に観察し得た胃癌の一例  [通常講演]
    日本超音波医学会第20回関西地方会 2000年09月 大阪 日本超音波医学会第20回関西地方会
     
    GE社製LOGIQ700のリニアﾌﾟﾛｰﾌﾞを用いて、B-mode、THI、CDI、PDI並びにPFDにて、質的診断が可能であった胃癌症例を経験したので報告した。
  • Coded Harmonic Angioによる肝腫瘍の質的診断の試み  [通常講演]
    第20回日本超音波医学会関西地方会 2000年09月 大阪 第20回日本超音波医学会関西地方会
     
    CHAを用いて肝占拠性病変（肝細胞癌35例、肝血管腫8例、転位性肝癌3例）についてLevovistによる超音波造影を施行し、腫瘍の質的診断が可能であったので報告した。
  • 模擬患者、ロールプレイ、OSLEを導入した臨床診断学実習の効果と問題点  [通常講演]
    石川 欽司; 青木 矩彦; 金丸 昭久; 福岡 正博; 高橋 光雄; 工藤 正俊; 花田 雅憲; 安富 正幸; 大柳 治正; 種子田 護; 浜西 千秋; 星合 昊; 松尾 理; 橋本 重夫
    第32回日本医学教育学会 2000年07月 仙台 第32回日本医学教育学会
  • 肝疾患におけるBモ－ド血流表示（B-Fｌｏｗ）の有用性  [通常講演]
    日本超音波医学会第73回学術集会 2000年05月 横浜 日本超音波医学会第73回学術集会
     
    赤血球などの微小な反射信号を画像化するＢモ－ド血流表示を用いて肝内の血流を観察した。Ｂモ－ドで血流を表示するためカラ－ドプラ法に比べ空間分解能やリアルタイム性に優れ、肝疾患における血流動態観察に有用であったため報告した。
  • Levovist静注による肝腫瘍の造影カラードプラ法：間欠送信法による腫瘍perfusion血流の評価  [通常講演]
    日本超音波医学会第73回学術集会 2000年05月 横浜 日本超音波医学会第73回学術集会
     
    新しく開発されたCoded Harmonic Angio法はLevovistを用いた造影において連続送信にて腫瘍の血管構築ならびに腫瘍内血管の描出が注入早期相にて描出され注入後期相では間欠操作によるFlash echoすなわちperfusion imageが得られた肝腫瘍の質的診断に有用な方法として評価し、報告した。
  • 膵芽腫根治術後に非定型的肝限局性結節性過形成（FNH)様病変を呈した1例  [通常講演]
    山内 勝治; 大柳 治正; 窪田昭男; 米倉 竹夫; 臼井規朗; 廣岡慎治; 小角 卓也; 山崎満夫; 工藤 正俊
    第37回日本小児外科学会総会 2000年05月 福岡 第37回日本小児外科学会総会
     
    膵芽腫に対する門脈合併切除幽門輪温存膵頭十二指腸切除後約1年の5歳男児に非定型的肝限局性結節性過形成（FNH)様病変を生じ、増大傾向を示すため凝固療法を施行した症例を報告した。
  • 肝細胞癌のLevovist静注によるIntermittent Color Doppler Imagingの初期臨床経験  [通常講演]
    日本超音波医学会第19回関西地方会 2000年02月 神戸 日本超音波医学会第19回関西地方会
     
    肝細胞癌を対象に超音波造影剤Levovist静注によるFundamental Color Doppler法とともにIntermittent Color Doppler法による血流シグナルの増強効果の評価を行い画像上腫瘍の染影効果が認められたので報告した。

MISC

受賞

  • 2022年04月 日本消化器病学会学術賞受賞
  • 2021年11月 Highly Cited Researchers 2021 受賞(Clarivate Analytics:臨床医学部門）(日本人2名中1名)
  • 2021年05月 日本超音波医学会 学会特別賞
  • 2021年04月 近畿大学学術研究褒賞（学校法人 近畿大学）
  • 2020年12月 インド肝臓学会（INASL）S.R. Naik Memorial Award
  • 2020年11月 Highly Cited Researcher 2020 (Clarivate Analytics:臨床医学部門）(日本人唯一の選出)
  • 2019年11月 Highly Cited Researcher 2019 (Clarivate Analytics:臨床医学部門）(日本人唯一の選出)
  • 2018年12月 Desai Memorial Lecture Award from Education Universe and Care Foundation
  • 2018年12月 SGHがん特別賞
  • 2018年10月 台湾超音波医学会名誉会員賞（TSUM Honorary Member Award）
  • 2018年06月 日本肝臓学会 織田賞受賞
  • 2018年05月 韓国超音波医学会名誉会員賞（KSUM honorary Award）
  • 2014年12月 Lorenzo Capussotti Award受賞（from IASGO）
  • 2012年11月 USE論文賞（応用物理学会論文賞）
  • 2011年11月 Certificate of Merit Award from Radiological Society of North America (RSNA)
  • 2011年06月 Romanian Society of Ultrasound in Medicine and Biology (SRUMB) Honorary Award
  • 2011年06月 日本肝臓学会「日本肝臓学会機関誌 肝臓Highest Citation賞」
  • 2011年05月 韓国超音波医学会名誉会員賞（KSUM honorary Award）
  • 2011年04月 米国超音波医学会名誉会員賞（AIUM Honorary Member Award）
  • 2010年06月 日本肝臓学会「日本肝臓学会機関誌 Highest Citation賞」
  • 2010年05月 JISAN Lecture Award Presented by Korean Society of Ultrasound in Medicine
  • 2009年12月 北米放射線学会 Cum Laude賞受賞（7000編の論文中上位10編に採択）
  • 2009年03月 インド肝臓学会Madangopalan Award
  • 2008年12月 Certificate of Merit Award from Radiological Society of North America (RSNA)
  • 2008年09月 Okuda Award presented by Asian Pacific Gastroenterology Society
  • 2008年03月 フィリピン超音波医学会名誉会員（Honorary Member of PSUCMI）
  • 2006年09月 ボローニャ大学医学部医学会名誉会員賞
  • 2003年06月 AIUM Scientific Exhibit Winner
  • 1993年11月 兵庫県医師会医学研究賞受賞
  • 1993年10月 日本核医学会賞受賞
  • 1992年04月 日本消化器病学会奨励賞受賞
  • 1992年03月 日本対がん協会がん研究助成奨励賞受賞
  • 1990年03月 兵庫県勤務医学会医学研究賞受賞
  • 1989年07月 神戸市長賞(医学研究分野)受賞
  • 1989年06月 米国核医学会 Berson-Yalow Award 受賞

共同研究・競争的資金等の研究課題

  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2022年04月 -2025年03月 
    代表者 : 萩原 智; 工藤 正俊; 西田 直生志
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2022年04月 -2025年03月 
    代表者 : 渡邉 智裕; 工藤 正俊
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2021年04月 -2024年03月 
    代表者 : 工藤 正俊; 西田 直生志
     
    肝細胞癌（肝癌）根治療法後に再発予防目的で免疫チェックポイント阻害剤(ICI)が投与された例を用い、根治療法後の血中のcirculating tumor DNA（ctDNA）が腫瘍再発の予測因子となりうるかを検討した。 ICIをアジュバントで投与された31例を用いた。根治術後血漿よりCAPP-sequenceにてctDNAを検討し、valiantが10 copy/ml以上をminimum residual disease (MRD)陽性とした。さらに、根治術時の腫瘍免疫状態(tumor microenvironment: TME)を解析するため、免疫染色にて腫瘍のCD8、PD-1、PD-L1、Foxp3、β-catenin、glutamine synthetase (GS)陽性細胞を検討した。加えて、Tumor Mutation Load Assayにて肝癌のゲノム解析を行い、遺伝子変異は10 copy以上のvaliant出現を陽性、copy number gain (CNG)は3 copy以上を陽性とした。β-cateninとGSの染色結果より2群(β-catenin経路活性化、非活性化）、TMEの状態により4群（CD8、PD-1、PD-L1とFoxp3染色により、hot型、exhausted型、cold型、Treg型）に分類した。ICI投与による術後無再発生存期間(RFS)はβ-catenin経路非活性化群で活性化群より有意に長く、またhot/exhausted型はcold/Treg型に比較して有意に長かった。β-catenin経路関連遺伝子のCNG陰性例では陽性例と比較し、有意にRFSが延長していた。一方、MRD陰性例は陽性例に比較してRFSが長い傾向にあったが有意ではなかった。MRDの肝癌根治療法後に再発に対する効果の解析にはさらなる検討が必要である。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2020年04月 -2023年03月 
    代表者 : 竹中 完; 細野 眞; 工藤 正俊
     
    本研究は各国の医療に用いられる放射線の使用基準に消化器領域の透視下医療処置の記載がほとんどされていないのは、信頼度の高い実際の被ばく量データが存在しないためであり、各透視下処置における、装置から出力される放射線量、患者・医療従事者の被ばく量を明らかにすることは、現在世に存在しない信頼度の高い情報を得られるのみではなく、「消化器領域のさまざまな透視下処置における被ばく量の基準値を定めDRL設定に繋げる」こと、消化器領域のみならず、透視下医療処置全般に関する被ばく量の基準作りにまで繋がることが可能になると考え立案した。唯一の被ばく国として放射線被ばくに関心の高い本邦において、世界に先駆けて、特に消化器領域の透視下医療処置に関する放射線被ばく量の基準を作成し、世界に発信することを目的に立案した。 「実臨床での透視下手技における患者と医療従事者の被ばく線量集計・解析」については当院における患者への透視下内視鏡手技における被ばく線量測定を行い、その数値は十分に防護対策をとらなければ基準値を容易に超える値であることが判明した。この内容は消化器病学会誌の速報に取り上げられ報告し、日本中の消化器内科医の被ばく防護意識改善に寄与したことが予想される。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2019年04月 -2022年03月 
    代表者 : 渡邉 智裕; 工藤 正俊
     
    RIP2は自然免疫反応受容体であるTLR及びNOD2の下流分子として機能する。我々はマウス腸炎モデルを用いることにより、樹状細胞が腸内細菌を認識することによって、活性化されるTLRs-RIP2経路が実験腸炎の発症に病的な役割を果たすことを見出した。さらに、炎症性腸疾患患者の炎症局所のサンプルを用いることにより、RIP2の活性化が炎症性サイトカインの産生・疾患活動性と強い相関を示すことを明らかにした。以上の結果から、RIP2が炎症性腸疾患の新規治療標的として有望であることが明らかになった。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2020年04月 -2021年03月 
    代表者 : 櫻井 俊治; 西尾 和人; 工藤 正俊
     
    がん免疫療法は多くの癌腫において有効性が示され、がん治療戦略を大きく変化させた。一方で、免疫関連副作用(immune-related adverse event: irAE)と呼ばれる副作用のリスクがあり、大腸炎を呈する消化管 (Gastrointestinal: GI) irAEの分子機序は不明な点が多い。臨床症状および内視鏡所見において、GI irAEと潰瘍性大腸炎(UC)は類似し、GI irAEはUCの1つのサブタイプである可能性がある。大腸粘膜と糞便を採取した。次世代シーケンサー(whole transcriptome, 16S sequencing)を用いて、GI irAEとUCの遺伝子発現プロファイルおよび腸内細菌叢を比較検討した。またinteractome解析によりGI irAEにおける宿主と腸内細菌の相互作用を考察した。コントロールと比べて、T細胞を活性化する働きのあるケモカインCXCL10、CXCL11の発現がGI irAEにおいて亢進していた。一方で、腸上皮の恒常性維持に関わるPDCD6IPの発現がUCにおいて低下していた。炎症粘膜では、遺伝子発現および腸内細菌叢において、GI irAEとUCは類似性を認めた。腸内細菌叢と遺伝子発現プロファイルの統合解析により、７つのclusterに分けられ、更にこれらは２つのmega-clusterに分けられた。機能解析では、免疫チェックポイント阻害薬に対する良好な反応は DNA repair やcell cycleが相関し、逆にinnate immune response、NFAT、IFN signaling pathwaysが負に相関することがわかった。炎症による２次的な腸内細菌叢の変化を除外するため、非炎症粘膜での検討を行い、Fusobacterium sp.の増加ががん免疫療法の治療効果と正の相関を示した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2018年04月 -2021年03月 
    代表者 : 萩原 智; 工藤 正俊
     
    HBx C1485T変異の存在下では活性酸素の産生亢進やJNK経路の活性化が誘導される結果、肝癌の発症が促進されていることを見出した。またHBxC1485T変異の存在下に誘導される腫瘍微小免疫環境を解明では、TAMsやMDSCsの細胞数が抑制されており、抗腫瘍効果の要因の一つであることが証明された。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2018年04月 -2021年03月 
    代表者 : 工藤 正俊; 西田 直生志
     
    肝細胞癌(肝癌）において、癌関連シグナルの変化は腫瘍微小免疫環境に影響する可能性がある。本解析により、PD-L1陽性肝癌は腫瘍浸潤リンパ球(TIL)が多く、PI3K-Akt活性型変異が多いことが確認された。一方、β-カテニン経路の活性型変異を持つ肝癌はPD-L1陰性かつTILに乏しかった。ICI治療を受けた肝癌例では、β-カテニン経路活性化の有無, TIL, PD-L1の状態で治療における予後を層別化できた。PD-L1陽性肝癌はPI3K-Akt活性に介在するチロシンキナーゼ阻害剤の併用が有効である可能性がある。一方、PD-L1陰性肝癌はβ-カテニン阻害剤の影響を検討する余地がある。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2017年04月 -2020年03月 
    代表者 : 櫻井 俊治; 工藤 正俊
     
    慢性炎症に対するストレス応答が大腸および肝発癌を促進する。ストレス応答蛋白Heat shock protein 27 (HSP27) の欠損マウスを用いて、ストレス応答の生体内での役割を解明し、大腸および肝癌の病態解明と新規治療及びバイオマーカーの探索を行った。慢性炎症により発現が亢進するガンキリンは、炎症細胞において抗アポトーシス蛋白の発現を上昇させ、炎症の更なる増幅と発癌を促進する。一方で、小腸上部（空腸）でのガンキリンは大腸での炎症を抑制する働きがある。炎症性腸疾患の病態において、腸内細菌叢を介する小腸大腸コミュニケーションが関与していることを明らかにした。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2016年04月 -2019年03月 
    代表者 : 北野 雅之; 西尾 和人; 工藤 正俊
     
    膵腫瘍性病変に対する造影ハーモニック超音波内視鏡の有用性に関するメタ解析を実施し、統合感度および統合特異度はそれぞれ93%および80%であり、信頼性の高い画像診断と判明した。多施設共同研究により、ERCP不成功悪性胆管閉塞患者に対する超音波内視鏡下胆管ドレナージ術（ランデブー法、Choledochoduodenostomy Hepaticogastrostomy、antegrade stenting）の有効性・安全性を評価した。さらに、超音波内視鏡下胆管ドレナージ術専用のデバイスを開発し、前臨床試験で評価した後、ERCP不成功悪性胆管閉塞患者に対する有効性・安全性を評価した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2015年04月 -2018年03月 
    代表者 : 工藤 正俊; 西田 直生志
     
    血清分泌型microRNA(miR)定量によるソラフェニブ効果予測を試みた。screening、validation cohortにより、対象miR絞り込んだ。3ヶ月以上のdisease control (DC)例とnon-DC例、健常者間で血清中miR-181a-5を定量したところ、non-DC群ではDC群、健常者群と比較して有意にmiR-181a-5量は低値であった。BCLC-stage C例を対象として、多変量解析を行い、血清miR-181a-5量が独立して治療開始後のDC、全生存期間に影響することを確認した。血清中miR-181a-5定量により、病勢制御効果が予測できる可能性がある。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2014年04月 -2017年03月 
    代表者 : 櫻井 俊治; 藤田 潤; 工藤 正俊
     
    プロテアソームの機能を制御するガンキリンは大腸前癌病変において発現が亢進し、大腸発癌に重要な役割を果たしている。これまでガンキリンの機能解析は主に細胞株で行われてきたが、実際の生体では、上皮細胞、間質細胞、幹細胞の細胞間の相互作用が発癌を決定する。本研究ではガンキリンを大腸上皮細胞、炎症細胞、又は幹細胞で欠損させたknock-out mouseを用いて、生体での機能解析を行い、炎症細胞でのガンキリンがSTAT3, ERK, 幹細胞の増幅を制御して大腸癌の発生および治療抵抗性に関わっていることがわかった。ガンキリンは新しい治療およびバイオマーカーの標的分子として有望である。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2013年05月 -2016年03月 
    代表者 : 椎名 毅; 山川 誠; 近藤 健悟; 戸井 雅和; 工藤 正俊
     
    超音波エラストグラフィは、組織の弾性を可視化する方法として実用化したが、歪みを得る静的手法は定性的であり、剪断波を用いる動的手法も音速の不均一によりアーチファクトが生じ易いなどの課題が残されている。また、粘性を独立に測定する方法は未だ実用化していない。本研究は、組織性状の可視化により疾患の診断精度の向上を図るため、静的・動的における励振法を複合化することで、それらの利点である定量性、実時間と高精度を併せ持ち、さらに弾性と粘性をともに画像化できる超音波ビスコエラストグラフィの開発を目指した。そのために各種の要素技術を開発し、また生体組織のファントムを用いた実験により、臨床適用の可能性を示した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2013年04月 -2016年03月 
    代表者 : 北野 雅之; 工藤 正俊; 西尾 和人
     
    造影ハーモニック超音波内視鏡を用いることにより膵嚢胞性病変の良悪性鑑別および膵・胆道癌のリンパ節転移診断が向上することを報告した。膵管内乳頭粘性腫瘍例を超音波内視鏡を用いて経過観察を行うことにより併存小膵癌が7%に認められ、膵癌早期診断に繋がることを提唱した。超音波内視鏡下胆管・胆嚢ドレナージ術が、難治性の閉塞黄疸に有用であることを報告した。胆道金属ステントは、ラジアルフォース、フレアの立ち上がり角度、ステント材質がステント安定性に影響していることが判明した。癌性疼痛に対する超音波内視鏡下神経ブロック術において、広範囲、神経叢と神経節の両方へのエタノール注入が有効な治療となることを提唱した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2012年10月 -2015年03月 
    代表者 : 西尾 和人; 工藤 正俊; 鈴木 俊宏; 荒尾 徳三
     
    肝細胞がんにおいて、ソラフェニブの効果を予測するFGF3、FGF4遺伝子増幅以外の新たなバイオマーカーの探索を多施設臨床研究で実施した。収集した著効例のコピー数変動解析よりFGF19のコピー数変動を見出した。 多施設共同前向き試験として、次世代シーケンサーを用いて肝生検FFPEサンプルを用いた遺伝子解析を実施した。DNAシーケンシングにより、「がん遺伝子の変異の頻度」、RNAシーケンシングによりTGF-αおよびPECAM1が腫瘍縮小効果に関連するバイオマーカーとして、Neuregulin 1遺伝子発現が、無増悪生存期間延長の予測マーカーであることを示した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2011年 -2013年 
    代表者 : 櫻井 俊治; 工藤 正俊; 藤田 潤
     
    多くの肝癌は慢性炎症による組織の線維化を背景に発癌し、この過程において活性酸素種（ROS）の蓄積およびその下流分子JNKが重要な役割を果たしている。癌幹細胞の増殖にはROS依存性と非依存性の経路があり、前者にはc-Jun/JNK, SOX2が、後者にはガンキリンによる血管内皮増殖因子(VEGF), Nanog発現の制御が関与している。ヒト大腸、肝癌において、ガンキリンの発現量は癌幹細胞マーカーであるCD133の発現量と有意な相関を認め、ガンキリンは炎症や幹細胞の制御を介して発癌に関与していると思われる。ROS、ガンキリンを標的とした新しい治療効果予測のバイオマーカーや治療薬の開発が期待できる。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2010年 -2012年 
    代表者 : 工藤 正俊; 井上 達夫
     
    肝細胞癌の多段階発癌は、異型結節から早期肝癌を経て、多血性の中分化型肝炎に至る。その過程における造影超音波クッパ―相の所見と遺伝子発現を検討した。その結果、異型結節ではほぼ全例にOATP8が発現するが、造影超音波クッパ―相で低信号を呈す早期発癌ではほぼ全例においてOATP8の発現を認めなかった。また異型結節ではGlypican3,HSP70,CAP2,GS,Bmi-1の発現を認める例はなかったが、造影超音波クッパ―相で低信号を呈す早期肝癌ではこれらの遺伝子群の発現を認めた。以上より、臨床的には造影超音波クッパ―相で低信号を呈す結節は治療対象とすべき結節であることが確認された。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2010年 -2012年 
    代表者 : 北野 雅之; 工藤 正俊; 西尾 和人
     
    新しく開発した造影ハーモニック超音波内視鏡が、膵腫瘍性病変の鑑別診断、原発不明腹腔内腫瘤の良悪性診断、およびGastrointestinal Stromal Tumors の悪性度評価に有用であり、本法を用いることにより、従来の検査法と比べそれぞれの診断能が向上することを報告した。また、癌性疼痛に対して、超音波内視鏡下広範囲腹腔神経叢ブロック術が従来の腹腔神経叢ブロック術よりも良好な成績が得られることを報告した。さらに、超音波内視鏡下ドレナージ術の機器・手技開発を行い、本法が、経乳頭的・外科的治療不能の胆道・膵管閉塞に対する次のドレナージ治療法となり得ることを報告した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2011年 -2011年 
    代表者 : 西尾 和人; 工藤 正俊
     
    本研究の成果として、肝細胞がんに対するソラフェニブ治療著効例の効果予測因子となる11q13の遺伝子増幅を初めて特定した。動物実験において、FGF4強制発現がん細胞はソラフェニブに奏功することを確認した。臨床的因子としては、肺転移症例および低分化型組織例がソラフェニブ著効例の効果予測因子となることを示した。本研究の成果により、血管新生阻害薬の奏功メカニズムにおいてがん細胞側の効果規定因子があることを初めて示し、臨床的に有効なバイオマーカーを特定した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2006年 -2008年 
    代表者 : 北野 雅之; 工藤 正俊; 竹山 宜典; 筑後 孝章
     
    研究成果の概要:超音波内視鏡下穿刺術とマイクロダイアリシス法を応用して局所における低分子物質量の測定法を開発し、薬物の局所薬物動態評価に成功した。また、超音波内視鏡を用いた膵疾患の局所病態生理を評価する方法として、超音波造影剤による血流評価、超音波内視鏡下穿刺による病理診断があり、その有用性を報告した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2006年 -2008年 
    代表者 : 工藤 正俊; 村上 卓道; 宗像 浩; 福永 豊和
     
    今回われわれはraw data保存を利用して動脈血流と門脈血流を分離評価できる方法を開発した。新規超音波造影剤Sonazoidを用いることにより、そのraw data保存から検査後に腫瘍ならびに腫瘍の外側の動脈や門脈に関心領域(ROI)をおき、その立ち上がりから純粋に動脈のみで栄養される数秒間を装置内でコンピューター解析で同定し、その時間だけのMIP画像を加算してaccumulation画像を作成すると動脈が栄養しているか否かを判定し得ることを明らかにした。また、その後の門脈と動脈の両方が入るmixed phaseにおいては両者の交じり合ったこのphaseで血流が認められれば、それは門脈血流が存在する結節であることが評価できる。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2004年 -2005年 
    代表者 : 工藤 正俊; 宗像 浩; 福永 豊和; 地挽 隆夫
     
    我々は肝細胞癌の発癌進展において動脈血流が上昇する前に門脈血流が低下することを証明してきた。今回の研究では酸化鉄造影剤を用いて網内系の取り込みを検討することによりKuppfer細胞の機能も血流動態と深く関与することも証明した。すなわち、前癌病変であるdysplastic noduleは肝細胞癌の前癌病変においてKuppfer細胞が保たれかつ門脈血流も保たれること並びに動脈血流は低下していることをCTA、CTAP並びに造影ハーモニックイメージングを用いることにより証明した。次に全く新しい概念の血流イメージ法の開発を行った。すなわち、超音波装置の画像記録データを従来のモニター表示の手前のデータを保存することにより動脈と門脈を分離評価することが可能となることを明らかにした。この動脈と門脈の分離評価を単に定性的のみならず定量的に行うことにより肝発癌過程における血流の変化が非侵襲的かつ定量的にとらえることを可能にした。以上より臨床的にはRaw Data保存から数秒間のデータを後処理で呼び出してきて、そのデータのMIP像を加算して表示することにより大きな門脈と動脈が明瞭に表示される。これに関心領域を設定し、動脈の立ち上がりの時間輝度曲線および門脈の時間輝度曲線を設定する。この動脈と門脈の立ち上がりの差が肝動脈由来の血流の時間と門脈由来の血流の時間差として認識が可能となる。これにより結節内の血流が動脈由来であれば動脈だけで栄養される時相(pure arterial phase:純動脈相)のイメージが定性評価可能となる。腺腫様過形成や再生結節などは動脈から栄養されず、むしろ門脈からの血流が多いとされているが、この純動脈相より以降のmixed phase(動脈と門脈が混じり合うphase)の時相を血流表示することによりさらに純粋に門脈血流がどの程度、他の肝実質と比べて流入しているかという解析も可能となった。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2003年 -2005年 
    代表者 : 北野 雅之; 工藤 正俊; 宗像 浩; 仲谷 達也; 宮本 清; 藤本 浩
     
    当研究は、次世代超音波造影剤対応の超音波内視鏡装置を開発し、消化器系臓器の微小循環動態の観察法を確立することを目的とした。平成15年度および平成16年度では、次世代超音波造影剤対応の造影ハーモニックモードを開発した上で、超音波内視鏡用小型探触子を作製し、犬における消化器系臓器の血行動態を観察した。平成17年度は、犬における膵癌の実験的モデルとしてラジオ波にて膵の一部を焼灼することにより乏血性病変を作成し、同部位の血行動態の観察に成功した。即ち膵癌の微小循環動態が観察可能であることが示唆された。また、本研究機関中、機器開発と同時に、造影ハーモニックエコー法の臨床的有用性を検討した。体外式造影ハーモニック超音波検査を用いて膵腫瘍性病変の存在、質的診断および治療効果判定、さらに消化管粘膜下腫瘍の悪性度評価に有用であることを証明した(Gut 2004,53,854-859;J Gastroenterol 2006,41,70-76;J Gastroenterol 2005,40,247-255)。本邦において、次世代造影剤が未だ許可されないため、平成18年1月より、SonoVueの臨床使用が認可されているドイツBethesda総合病院との共同研究を行った。膵・胆道系腫瘍が疑われた患者に対して造影ハーモニ'ック超音波内視鏡検査を行い、造影剤投与後のリアルタイム画像と間欠送信画像を評価した。膵腫瘍性病変および消化管聞葉系腫瘍において、リアルタイム画像では微細な腫瘍内血流が観察され、間欠送信では実質染影像が得られた。このドイツでの臨床研究により、従来の超音波内視鏡では不可能であった造影ハーモニック法の臨床応用が可能であることが証明され、消化器系疾患の診断に有用であることが示唆された。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 2002年 -2003年 
    代表者 : 工藤 正俊; 川崎 俊彦; 地挽 隆夫; 宗像 浩
     
    従来、我々は肝細胞癌の発癌進展において動脈血統が上昇する前に門脈血流が低下することを証明してきた。当該研究期間においても門脈造影下CTおよび動脈造影下CT(CTA)を用いることにより肝発癌の進展に伴い動脈および門脈血流動態が変化することを証明してきた。特に最近の研究では酸化鉄造影剤を用いて網内系の取り込みを検討することによりKuppfer細胞の機能も血流動態と深く関与することも証明してきた。すなわち、前癌病変であるdysplastic noduleは肝細胞癌の前癌病変においてKuppfer細胞が保たれかつ、門脈血流も保たれること並びに動脈血流は低下していることをCTA、CTAP並びに造影ハーモニックイメージングを用いることにより証明した。又、早期肝癌においては動脈も門脈も低下した状態があること、又この時期を境にKuppfer細胞数も減少することをSPIO MRI及びCD68染色を用いてKuppfer細胞を免疫組織染色することにより証明した。通常型の肝細胞癌に進展すればSPIO MRIの取り込みはなくなり、従ってKuppfer細胞も減少すること及び免疫組織学的にCD68陽性細胞も減少することも示してきた。これらの解析においてCoded Harmonic ImagingのPost Vascular Phaseも極めて重要な働きをすることも示してきた。さらに、今年度はまったく新しい画像解析装置と新しい超音波造影剤(Definity, Sonozoid)を用いてビーグル犬の肝臓において微細血流をcoded phase inversionにて観察することに成功した。現在、肝腫瘍においてこれらの血管構築と肝血流動態との関連について検討中である。これらの成果の詳細は幾つかの英文論文並びにSpringer VerlagよりContrast harmonic imaging in the diagnosis and treatment of hepatocelullar carcinoma.に研究成果として発表した。
  • 日本学術振興会：科学研究費助成事業
    研究期間 : 1998年 -2000年 
    代表者 : 工藤 正俊
     
    1.肝細胞癌の発癌進展に伴う血流動態の変化 肝細胞癌の発癌初期には結節は過形成として発癌して発癌するが、動脈血流は低下し門脈血流は保たれることを示した。その後、動脈も門脈も低下する時期を経て動脈性腫瘍血管の新生が誘導されて典型的な動脈優位の肝細胞癌へと発育・進展することをinvivo血流イメージングにより示した。またその変化は病理学的進展、あるいは分子生物学的な血管新生因子の誘導ともよく一致した。 2.血流画像的解析 超音波造影剤を用いてハーモニックイメージを行うことにより、上記の血流動態の推移も容易に把握しうることを示した。

その他のリンク

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.